discontinued_n,started_n,completed_n,rate_vs_trial_start,base_rate,size_factor_log1p_started,recency_decay,evidence_quality,enrollment_count,num_countries,total_sites,reason,period_title,arm_id,search_condition,sponsor_class,actual_target,predicted_target,absolute_error
18.0,787.0,696.0,0.022872,0.022872,6.669498,0.579829,1.0,787.0,16.0,170.0,At the Participant's own Request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08844983,0.08870783609431557,0.0002580060943155743
10.0,787.0,696.0,0.012706,0.012706,6.669498,0.579829,1.0,787.0,16.0,170.0,At the Participant's own Request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04913622,0.049281018426109616,0.0001447984261096144
15.0,787.0,696.0,0.01906,0.01906,6.669498,0.579829,1.0,787.0,16.0,170.0,At the Participant's own Request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07370819,0.07512015794787695,0.0014119679478769437
8.0,787.0,696.0,0.010165,0.010165,6.669498,0.579829,1.0,787.0,16.0,170.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03930975,0.04049742193904761,0.0011876719390476118
6.0,787.0,696.0,0.007624,0.007624,6.669498,0.579829,1.0,787.0,16.0,170.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02948328,0.02978095238065476,0.00029767238065476
9.0,787.0,696.0,0.011436,0.011436,6.669498,0.579829,1.0,787.0,16.0,170.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04422491,0.04421293072402619,1.1979275973808545e-05
0.0,787.0,696.0,0.0,0.0,6.669498,0.579829,1.0,787.0,16.0,170.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,787.0,696.0,0.002541,0.002541,6.669498,0.579829,1.0,787.0,16.0,170.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00982647,0.009895002669226178,6.853266922617757e-05
3.0,787.0,696.0,0.003812,0.003812,6.669498,0.579829,1.0,787.0,16.0,170.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01474164,0.014961600792589291,0.00021996079258929102
1.0,787.0,696.0,0.001271,0.001271,6.669498,0.579829,1.0,787.0,16.0,170.0,Study Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00491517,0.004950623188511927,3.545318851192695e-05
0.0,787.0,696.0,0.0,0.0,6.669498,0.579829,1.0,787.0,16.0,170.0,Study Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,787.0,696.0,0.0,0.0,6.669498,0.579829,1.0,787.0,16.0,170.0,Study Terminated by Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,787.0,696.0,0.005083,0.005083,6.669498,0.579829,1.0,787.0,16.0,170.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01965681,0.01985180711186777,0.00019499711186777083
4.0,787.0,696.0,0.005083,0.005083,6.669498,0.579829,1.0,787.0,16.0,170.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01965681,0.019835229699010623,0.0001784196990106228
1.0,787.0,696.0,0.001271,0.001271,6.669498,0.579829,1.0,787.0,16.0,170.0,Reason not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00491517,0.004956369032440497,4.119903244049691e-05
5.0,787.0,696.0,0.006353,0.006353,6.669498,0.579829,1.0,787.0,16.0,170.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02456811,0.024619396138968276,5.128613896827547e-05
1.0,787.0,696.0,0.001271,0.001271,6.669498,0.579829,1.0,787.0,16.0,170.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00491517,0.004961607770317481,4.643777031748068e-05
4.0,787.0,696.0,0.005083,0.005083,6.669498,0.579829,1.0,787.0,16.0,170.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01965681,0.019829270037522533,0.00017246003752253297
15.0,350.0,308.0,0.042857,0.042857,5.860786,0.384821,1.0,350.0,13.0,83.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09665775,0.09898342055018856,0.0023256705501885633
10.0,350.0,308.0,0.028571,0.028571,5.860786,0.384821,1.0,350.0,13.0,83.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06443775,0.0647113302491766,0.0002735802491765915
0.0,350.0,308.0,0.0,0.0,5.860786,0.384821,1.0,350.0,13.0,83.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,350.0,308.0,0.005714,0.005714,5.860786,0.384821,1.0,350.0,13.0,83.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0128871,0.012901540269394858,1.4440269394858096e-05
1.0,350.0,308.0,0.002857,0.002857,5.860786,0.384821,1.0,350.0,13.0,83.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00644355,0.006590476370574494,0.00014692637057449418
0.0,350.0,308.0,0.0,0.0,5.860786,0.384821,1.0,350.0,13.0,83.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,350.0,308.0,0.014286,0.014286,5.860786,0.384821,1.0,350.0,13.0,83.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03222,0.03217407266192461,4.592733807538829e-05
9.0,350.0,308.0,0.025714,0.025714,5.860786,0.384821,1.0,350.0,13.0,83.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0579942,0.057833851777738136,0.0001603482222618663
5.0,577.0,480.0,0.008666,0.008666,6.359574,0.451053,1.0,577.0,9.0,89.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02485848,0.0249158549541766,5.737495417660124e-05
2.0,577.0,480.0,0.003466,0.003466,6.359574,0.451053,1.0,577.0,9.0,89.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00994224,0.00998993107015783,4.7691070157829946e-05
8.0,577.0,480.0,0.013865,0.013865,6.359574,0.451053,1.0,577.0,9.0,89.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03977185,0.040179638944424584,0.00040778894442458635
6.0,577.0,480.0,0.010399,0.010399,6.359574,0.451053,1.0,577.0,9.0,89.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0298296,0.03075161001300597,0.0009220100130059687
7.0,577.0,480.0,0.012132,0.012132,6.359574,0.451053,1.0,577.0,9.0,89.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03480073,0.03482535486295645,2.4624862956450222e-05
2.0,577.0,480.0,0.003466,0.003466,6.359574,0.451053,1.0,577.0,9.0,89.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00994224,0.009994597764364179,5.2357764364178994e-05
1.0,577.0,480.0,0.001733,0.001733,6.359574,0.451053,1.0,577.0,9.0,89.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00497112,0.004964507428544368,6.612571455631537e-06
2.0,577.0,480.0,0.003466,0.003466,6.359574,0.451053,1.0,577.0,9.0,89.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00994224,0.009992486699086402,5.024669908640193e-05
1.0,577.0,480.0,0.001733,0.001733,6.359574,0.451053,1.0,577.0,9.0,89.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00497112,0.004964527701103892,6.592298896108094e-06
14.0,577.0,480.0,0.024263,0.024263,6.359574,0.451053,1.0,577.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06959858,0.06922570820903948,0.00037287179096051615
17.0,577.0,480.0,0.029463,0.029463,6.359574,0.451053,1.0,577.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08451482,0.08374362410358124,0.000771195896418761
18.0,577.0,480.0,0.031196,0.031196,6.359574,0.451053,1.0,577.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.08948594,0.08852008986718098,0.0009658501328190239
5.0,577.0,480.0,0.008666,0.008666,6.359574,0.451053,1.0,577.0,9.0,89.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02485848,0.024936469224176604,7.79892241766049e-05
2.0,577.0,480.0,0.003466,0.003466,6.359574,0.451053,1.0,577.0,9.0,89.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00994224,0.009991138185157828,4.889818515782865e-05
7.0,577.0,480.0,0.012132,0.012132,6.359574,0.451053,1.0,577.0,9.0,89.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03480073,0.03486585454396836,6.512454396835621e-05
3.0,420.0,367.0,0.007143,0.007143,6.042633,0.256675,1.0,972.0,9.0,89.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01107873,0.011168515997916668,8.978599791666791e-05
0.0,420.0,367.0,0.0,0.0,6.042633,0.256675,1.0,972.0,9.0,89.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,420.0,367.0,0.002381,0.002381,6.042633,0.256675,1.0,972.0,9.0,89.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00369291,0.0037188424065674676,2.5932406567467405e-05
4.0,420.0,367.0,0.009524,0.009524,6.042633,0.256675,1.0,972.0,9.0,89.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01477165,0.014845284319345241,7.363431934524073e-05
3.0,420.0,367.0,0.007143,0.007143,6.042633,0.256675,1.0,972.0,9.0,89.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01107873,0.011144774661785714,6.604466178571425e-05
3.0,420.0,367.0,0.007143,0.007143,6.042633,0.256675,1.0,972.0,9.0,89.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01107873,0.011158752547678572,8.002254767857167e-05
9.0,420.0,367.0,0.021429,0.021429,6.042633,0.256675,1.0,972.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0332362,0.03352923131748018,0.0002930313174801802
8.0,420.0,367.0,0.019048,0.019048,6.042633,0.256675,1.0,972.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02954329,0.02974151148323417,0.00019822148323416985
6.0,420.0,367.0,0.014286,0.014286,6.042633,0.256675,1.0,972.0,9.0,89.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02215747,0.022210310088313503,5.284008831350426e-05
0.0,420.0,367.0,0.0,0.0,6.042633,0.256675,1.0,972.0,9.0,89.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,420.0,367.0,0.002381,0.002381,6.042633,0.256675,1.0,972.0,9.0,89.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00369291,0.0037256310213888955,3.272102138889531e-05
0.0,420.0,367.0,0.0,0.0,6.042633,0.256675,1.0,972.0,9.0,89.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,420.0,367.0,0.009524,0.009524,6.042633,0.256675,1.0,972.0,9.0,89.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01477165,0.014848122643839293,7.647264383929195e-05
2.0,420.0,367.0,0.004762,0.004762,6.042633,0.256675,1.0,972.0,9.0,89.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00738582,0.007928447422857138,0.0005426274228571377
4.0,420.0,367.0,0.009524,0.009524,6.042633,0.256675,1.0,972.0,9.0,89.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01477165,0.014854526678333342,8.287667833334171e-05
3.0,420.0,367.0,0.007143,0.007143,6.042633,0.256675,1.0,972.0,9.0,89.0,"Non-compliance, not met criteria etc.",Overall Study,FG000,diabetes type 2,INDUSTRY,0.01107873,0.011164783389583335,8.605338958333521e-05
2.0,420.0,367.0,0.004762,0.004762,6.042633,0.256675,1.0,972.0,9.0,89.0,"Non-compliance, not met criteria etc.",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00738582,0.007932023850714282,0.0005462038507142815
0.0,420.0,367.0,0.0,0.0,6.042633,0.256675,1.0,972.0,9.0,89.0,"Non-compliance, not met criteria etc.",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,305.0,279.0,0.003279,0.003279,5.723585,0.300923,1.0,306.0,3.0,19.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564761,0.005579725239305559,6.788476069444129e-05
3.0,305.0,279.0,0.009836,0.009836,5.723585,0.300923,1.0,306.0,3.0,19.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01694111,0.016974426135009955,3.331613500995659e-05
0.0,305.0,279.0,0.0,0.0,5.723585,0.300923,1.0,306.0,3.0,19.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,305.0,279.0,0.006557,0.006557,5.723585,0.300923,1.0,306.0,3.0,19.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0112935,0.011310619630942426,1.7119630942426245e-05
2.0,305.0,279.0,0.006557,0.006557,5.723585,0.300923,1.0,306.0,3.0,19.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0112935,0.011308151103323385,1.4651103323385511e-05
0.0,305.0,279.0,0.0,0.0,5.723585,0.300923,1.0,306.0,3.0,19.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,305.0,279.0,0.019672,0.019672,5.723585,0.300923,1.0,306.0,3.0,19.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03388222,0.03375994174690474,0.00012227825309525653
3.0,305.0,279.0,0.009836,0.009836,5.723585,0.300923,1.0,306.0,3.0,19.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01694111,0.016961851087509958,2.0741087509958817e-05
0.0,305.0,279.0,0.0,0.0,5.723585,0.300923,1.0,306.0,3.0,19.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,305.0,279.0,0.009836,0.009836,5.723585,0.300923,1.0,306.0,3.0,19.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01694111,0.016927388289027817,1.3721710972181694e-05
2.0,305.0,279.0,0.006557,0.006557,5.723585,0.300923,1.0,306.0,3.0,19.0,patient's refusal to come,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0112935,0.011302749863501948,9.249863501948133e-06
2.0,305.0,279.0,0.006557,0.006557,5.723585,0.300923,1.0,306.0,3.0,19.0,patient's refusal to come,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0112935,0.011311346240942419,1.7846240942418976e-05
1.0,305.0,279.0,0.003279,0.003279,5.723585,0.300923,1.0,306.0,3.0,19.0,patient's private reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564761,0.005578288969305558,6.932103069444157e-05
1.0,305.0,279.0,0.003279,0.003279,5.723585,0.300923,1.0,306.0,3.0,19.0,patient's private reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00564761,0.005575630429662704,7.197957033729628e-05
0.0,442.0,376.0,0.0,0.0,6.09357,0.220602,1.0,442.0,9.0,56.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,442.0,376.0,0.002262,0.002262,6.09357,0.220602,1.0,442.0,9.0,56.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00304071,0.0030628955819245996,2.218558192459974e-05
1.0,442.0,376.0,0.002262,0.002262,6.09357,0.220602,1.0,442.0,9.0,56.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00304071,0.003067822351200392,2.711235120039226e-05
4.0,442.0,376.0,0.00905,0.00905,6.09357,0.220602,1.0,442.0,9.0,56.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01216552,0.012302044366369018,0.00013652436636901744
5.0,442.0,376.0,0.011312,0.011312,6.09357,0.220602,1.0,442.0,9.0,56.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01520623,0.01516746351732147,3.876648267852993e-05
6.0,442.0,376.0,0.013575,0.013575,6.09357,0.220602,1.0,442.0,9.0,56.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01824828,0.018493508106874997,0.00024522810687499855
3.0,442.0,376.0,0.006787,0.006787,6.09357,0.220602,1.0,442.0,9.0,56.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00912347,0.009170787538541671,4.731753854167117e-05
5.0,442.0,376.0,0.011312,0.011312,6.09357,0.220602,1.0,442.0,9.0,56.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01520623,0.015200498234434581,5.73176556541849e-06
8.0,442.0,376.0,0.0181,0.0181,6.09357,0.220602,1.0,442.0,9.0,56.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02433104,0.02428796309286705,4.307690713295162e-05
5.0,442.0,376.0,0.011312,0.011312,6.09357,0.220602,1.0,442.0,9.0,56.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01520623,0.015206231821101248,1.8211012489666167e-09
13.0,442.0,376.0,0.029412,0.029412,6.09357,0.220602,1.0,442.0,9.0,56.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03953727,0.03958059627559524,4.3326275595237385e-05
14.0,442.0,376.0,0.031674,0.031674,6.09357,0.220602,1.0,442.0,9.0,56.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04257797,0.04229413224143849,0.00028383775856150734
0.0,442.0,376.0,0.0,0.0,6.09357,0.220602,1.0,442.0,9.0,56.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,442.0,376.0,0.002262,0.002262,6.09357,0.220602,1.0,442.0,9.0,56.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00304071,0.003065665336091265,2.4955336091265178e-05
17.0,1029.0,0.0,0.016521,0.016521,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period II,FG000,diabetes type 2,INDUSTRY,0.03138739,0.031289257075119085,9.813292488091568e-05
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
49.0,1029.0,0.0,0.047619,0.047619,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period II,FG004,diabetes type 2,INDUSTRY,0.09046887,0.09061122776292654,0.00014235776292653712
18.0,1029.0,0.0,0.017493,0.017493,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period II,FG000,diabetes type 2,INDUSTRY,0.03323404,0.033475403887837346,0.0002413638878373467
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,1029.0,0.0,0.01069,0.01069,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period II,FG004,diabetes type 2,INDUSTRY,0.02030938,0.020033617203234093,0.00027576279676590557
17.0,1029.0,0.0,0.016521,0.016521,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period II,FG000,diabetes type 2,INDUSTRY,0.03138739,0.03128611449904766,0.00010127550095234
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
23.0,1029.0,0.0,0.022352,0.022352,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period II,FG004,diabetes type 2,INDUSTRY,0.0424654,0.04104494702748013,0.0014204529725198728
2.0,1029.0,0.0,0.001944,0.001944,6.937314,0.273859,1.0,1029.0,14.0,114.0,Death,Period II,FG000,diabetes type 2,INDUSTRY,0.0036933,0.0037154205950198304,2.212059501983032e-05
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Death,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Death,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Death,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1029.0,0.0,0.003887,0.003887,6.937314,0.273859,1.0,1029.0,14.0,114.0,Death,Period II,FG004,diabetes type 2,INDUSTRY,0.00738471,0.007364994841617079,1.971515838292137e-05
11.0,1029.0,0.0,0.01069,0.01069,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period II,FG000,diabetes type 2,INDUSTRY,0.02030938,0.020055966598650762,0.00025341340134923604
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,1029.0,0.0,0.007775,0.007775,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period II,FG004,diabetes type 2,INDUSTRY,0.01477132,0.01477133789498021,1.78949802111944e-08
5.0,1029.0,0.0,0.004859,0.004859,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period II,FG000,diabetes type 2,INDUSTRY,0.00923136,0.00922549245698407,5.867543015928775e-06
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1029.0,0.0,0.004859,0.004859,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period II,FG004,diabetes type 2,INDUSTRY,0.00923136,0.00922620813198407,5.151868015930081e-06
8.0,1029.0,0.0,0.007775,0.007775,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period II,FG000,diabetes type 2,INDUSTRY,0.01477132,0.014760313080277827,1.100691972217259e-05
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1029.0,0.0,0.003887,0.003887,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period II,FG004,diabetes type 2,INDUSTRY,0.00738471,0.0073654467170337435,1.9263282966256595e-05
50.0,1029.0,0.0,0.048591,0.048591,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period II,FG000,diabetes type 2,INDUSTRY,0.09231552,0.09373868128048608,0.001423161280486085
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period II,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period II,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period II,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
70.0,1029.0,0.0,0.068027,0.068027,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period II,FG004,diabetes type 2,INDUSTRY,0.12924096,0.13015617364922621,0.0009152136492262264
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1029.0,0.0,0.004859,0.004859,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period III,FG001,diabetes type 2,INDUSTRY,0.00923136,0.009220604709484067,1.0755290515931937e-05
3.0,1029.0,0.0,0.002915,0.002915,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period III,FG002,diabetes type 2,INDUSTRY,0.00553806,0.005544196837281737,6.136837281737334e-06
8.0,1029.0,0.0,0.007775,0.007775,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period III,FG003,diabetes type 2,INDUSTRY,0.01477132,0.014781440239920684,1.0120239920684629e-05
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Protocol Violation,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1029.0,0.0,0.002915,0.002915,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period III,FG001,diabetes type 2,INDUSTRY,0.00553806,0.005535831876894833,2.228123105166638e-06
4.0,1029.0,0.0,0.003887,0.003887,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period III,FG002,diabetes type 2,INDUSTRY,0.00738471,0.007362248375902792,2.246162409720847e-05
10.0,1029.0,0.0,0.009718,0.009718,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period III,FG003,diabetes type 2,INDUSTRY,0.01846272,0.018244921795327374,0.00021779820467262428
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Adverse Event,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1029.0,0.0,0.004859,0.004859,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period III,FG001,diabetes type 2,INDUSTRY,0.00923136,0.009221319424603112,1.0040575396887477e-05
9.0,1029.0,0.0,0.008746,0.008746,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period III,FG002,diabetes type 2,INDUSTRY,0.01661607,0.016289051087073434,0.00032701891292656604
15.0,1029.0,0.0,0.014577,0.014577,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period III,FG003,diabetes type 2,INDUSTRY,0.02769409,0.02672368987716269,0.0009704001228373095
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Physician Decision,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,1029.0,0.0,0.006803,0.006803,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period III,FG001,diabetes type 2,INDUSTRY,0.01292467,0.012856572071249999,6.809792875000012e-05
5.0,1029.0,0.0,0.004859,0.004859,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period III,FG002,diabetes type 2,INDUSTRY,0.00923136,0.009224676818115014,6.683181884984887e-06
9.0,1029.0,0.0,0.008746,0.008746,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period III,FG003,diabetes type 2,INDUSTRY,0.01661607,0.016308664117430583,0.00030740588256941703
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lack of Efficacy,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1029.0,0.0,0.000972,0.000972,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period III,FG001,diabetes type 2,INDUSTRY,0.00184665,0.001854306492579357,7.65649257935706e-06
1.0,1029.0,0.0,0.000972,0.000972,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period III,FG002,diabetes type 2,INDUSTRY,0.00184665,0.001851446775138882,4.796775138881954e-06
2.0,1029.0,0.0,0.001944,0.001944,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period III,FG003,diabetes type 2,INDUSTRY,0.0036933,0.003713742709186497,2.0442709186497144e-05
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Lost to follow up,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1029.0,0.0,0.000972,0.000972,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period III,FG001,diabetes type 2,INDUSTRY,0.00184665,0.0018537948890079278,7.144889007927764e-06
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period III,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1029.0,0.0,0.000972,0.000972,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period III,FG003,diabetes type 2,INDUSTRY,0.00184665,0.0018536174356745946,6.967435674594576e-06
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Entry Criteria Not Met,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period III,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,1029.0,0.0,0.006803,0.006803,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period III,FG001,diabetes type 2,INDUSTRY,0.01292467,0.012863730414583335,6.0939585416664235e-05
8.0,1029.0,0.0,0.007775,0.007775,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period III,FG002,diabetes type 2,INDUSTRY,0.01477132,0.014787243729623057,1.5923729623057437e-05
20.0,1029.0,0.0,0.019436,0.019436,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period III,FG003,diabetes type 2,INDUSTRY,0.03692545,0.0362390222286508,0.0006864277713491962
0.0,1029.0,0.0,0.0,0.0,6.937314,0.273859,1.0,1029.0,14.0,114.0,Subject Decision,Period III,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
526.0,2274.0,1681.0,0.23131,0.23131,7.729735,0.650733,1.0,2274.0,21.0,210.0,Run-in failure,Run-in Period (12 Weeks),FG000,diabetes type 2,INDUSTRY,1.16348737,1.2471916335295132,0.08370426352951332
0.0,2274.0,1681.0,0.0,0.0,7.729735,0.650733,1.0,2274.0,21.0,210.0,Run-in failure,Run-in Period (12 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2274.0,1681.0,0.0,0.0,7.729735,0.650733,1.0,2274.0,21.0,210.0,Run-in failure,Run-in Period (12 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2274.0,1681.0,0.0,0.0,7.729735,0.650733,1.0,2274.0,21.0,210.0,Withdrawal by Subject,Treatment Period (Week 0 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,2274.0,1681.0,0.004398,0.004398,7.729735,0.650733,1.0,2274.0,21.0,210.0,Withdrawal by Subject,Treatment Period (Week 0 to 52),FG001,diabetes type 2,INDUSTRY,0.0221219,0.022354956989394843,0.00023305698939484268
38.0,2274.0,1681.0,0.016711,0.016711,7.729735,0.650733,1.0,2274.0,21.0,210.0,Withdrawal by Subject,Treatment Period (Week 0 to 52),FG002,diabetes type 2,INDUSTRY,0.08405619,0.08310189038827376,0.0009542996117262448
0.0,2274.0,1681.0,0.0,0.0,7.729735,0.650733,1.0,2274.0,21.0,210.0,Lost to Follow-up,Treatment Period (Week 0 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2274.0,1681.0,0.001319,0.001319,7.729735,0.650733,1.0,2274.0,21.0,210.0,Lost to Follow-up,Treatment Period (Week 0 to 52),FG001,diabetes type 2,INDUSTRY,0.00663456,0.006452522125783724,0.0001820378742162761
4.0,2274.0,1681.0,0.001759,0.001759,7.729735,0.650733,1.0,2274.0,21.0,210.0,Lost to Follow-up,Treatment Period (Week 0 to 52),FG002,diabetes type 2,INDUSTRY,0.00884776,0.008764938518210679,8.282148178932053e-05
0.0,2274.0,1681.0,0.0,0.0,7.729735,0.650733,1.0,2274.0,21.0,210.0,Death,Treatment Period (Week 0 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,2274.0,1681.0,0.004837,0.004837,7.729735,0.650733,1.0,2274.0,21.0,210.0,Death,Treatment Period (Week 0 to 52),FG001,diabetes type 2,INDUSTRY,0.02433007,0.023886748766200405,0.00044332123379959426
1.0,2274.0,1681.0,0.00044,0.00044,7.729735,0.650733,1.0,2274.0,21.0,210.0,Death,Treatment Period (Week 0 to 52),FG002,diabetes type 2,INDUSTRY,0.0022132,0.0022453711831547625,3.217118315476273e-05
4.0,236.0,222.0,0.016949,0.016949,5.46806,0.377941,1.0,323.0,6.0,58.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03502687,0.03671413486128967,0.0016872648612896654
1.0,236.0,222.0,0.004237,0.004237,5.46806,0.377941,1.0,323.0,6.0,58.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0087562,0.008773121963413509,1.6921963413508295e-05
2.0,236.0,222.0,0.008475,0.008475,5.46806,0.377941,1.0,323.0,6.0,58.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01751447,0.017762370300916302,0.0002479003009163011
1.0,236.0,222.0,0.004237,0.004237,5.46806,0.377941,1.0,323.0,6.0,58.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0087562,0.008768756588413508,1.2556588413507527e-05
3.0,236.0,222.0,0.012712,0.012712,5.46806,0.377941,1.0,323.0,6.0,58.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02627067,0.026802507057946404,0.0005318370579464049
1.0,236.0,222.0,0.004237,0.004237,5.46806,0.377941,1.0,323.0,6.0,58.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0087562,0.008766272688413507,1.0072688413506614e-05
0.0,236.0,222.0,0.0,0.0,5.46806,0.377941,1.0,323.0,6.0,58.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,236.0,222.0,0.004237,0.004237,5.46806,0.377941,1.0,323.0,6.0,58.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0087562,0.008771238644663507,1.5038644663506809e-05
0.0,236.0,222.0,0.0,0.0,5.46806,0.377941,1.0,323.0,6.0,58.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,236.0,222.0,0.004237,0.004237,5.46806,0.377941,1.0,323.0,6.0,58.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0087562,0.008768756588413508,1.2556588413507527e-05
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,448.0,430.0,0.002232,0.002232,6.107023,0.511889,1.0,459.0,9.0,112.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0069775,0.007069062932371042,9.156293237104138e-05
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,448.0,430.0,0.004464,0.004464,6.107023,0.511889,1.0,459.0,9.0,112.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.013955,0.013932157534315542,2.2842465684458357e-05
3.0,448.0,430.0,0.006696,0.006696,6.107023,0.511889,1.0,459.0,9.0,112.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0209325,0.02093961761619047,7.117616190471104e-06
4.0,448.0,430.0,0.008929,0.008929,6.107023,0.511889,1.0,459.0,9.0,112.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02791313,0.0272251133567163,0.0006880166432837002
2.0,448.0,430.0,0.004464,0.004464,6.107023,0.511889,1.0,459.0,9.0,112.0,Screen Failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.013955,0.013931096168898878,2.3903831101122416e-05
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Screen Failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Screen Failure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,448.0,430.0,0.002232,0.002232,6.107023,0.511889,1.0,459.0,9.0,112.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0069775,0.007069652482371042,9.21524823710414e-05
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,448.0,430.0,0.004464,0.004464,6.107023,0.511889,1.0,459.0,9.0,112.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.013955,0.01393345587282744,2.1544127172560754e-05
1.0,448.0,430.0,0.002232,0.002232,6.107023,0.511889,1.0,459.0,9.0,112.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0069775,0.007039898116001997,6.239811600199704e-05
1.0,448.0,430.0,0.002232,0.002232,6.107023,0.511889,1.0,459.0,9.0,112.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0069775,0.0070734026561210415,9.590265612104132e-05
1.0,448.0,430.0,0.002232,0.002232,6.107023,0.511889,1.0,459.0,9.0,112.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0069775,0.007069062932371042,9.156293237104138e-05
0.0,448.0,430.0,0.0,0.0,6.107023,0.511889,1.0,459.0,9.0,112.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,241.0,185.0,0.020747,0.020747,5.488938,1.0,1.0,241.0,9.0,52.0,Adverse Event,Up to Interim Analysis (Week 12),FG000,diabetes type 2,INDUSTRY,0.11387899,0.11397396887849229,9.497887849228837e-05
4.0,241.0,185.0,0.016598,0.016598,5.488938,1.0,1.0,241.0,9.0,52.0,Adverse Event,Up to Interim Analysis (Week 12),FG001,diabetes type 2,INDUSTRY,0.09110539,0.09192804529612099,0.0008226552961209943
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Protocol Violation,Up to Interim Analysis (Week 12),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022794051718690485,2.0451718690483317e-05
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Protocol Violation,Up to Interim Analysis (Week 12),FG001,diabetes type 2,INDUSTRY,0.0227736,0.02280583988535713,3.223988535712777e-05
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Withdrawal by Subject,Up to Interim Analysis (Week 12),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022774303899940472,7.038999404705704e-07
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Withdrawal by Subject,Up to Interim Analysis (Week 12),FG001,diabetes type 2,INDUSTRY,0.0227736,0.022788474456607116,1.4874456607114755e-05
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Lack of Efficacy,Up to Interim Analysis (Week 12),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022785673777857136,1.2073777857134205e-05
0.0,241.0,185.0,0.0,0.0,5.488938,1.0,1.0,241.0,9.0,52.0,Lack of Efficacy,Up to Interim Analysis (Week 12),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Other reason not described above,Up to Interim Analysis (Week 12),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022773036994523804,5.630054761979197e-07
2.0,241.0,185.0,0.008299,0.008299,5.488938,1.0,1.0,241.0,9.0,52.0,Other reason not described above,Up to Interim Analysis (Week 12),FG001,diabetes type 2,INDUSTRY,0.04555269,0.04563020682897811,7.751682897810808e-05
17.0,241.0,185.0,0.070539,0.070539,5.488938,1.0,1.0,241.0,9.0,52.0,Adverse Event,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.38718418,0.3772047039500092,0.009979476049990776
10.0,241.0,185.0,0.041494,0.041494,5.488938,1.0,1.0,241.0,9.0,52.0,Adverse Event,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.22775798,0.2210132183914881,0.0067447616085118955
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Lack of Efficacy,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022780343293452368,6.7432934523666e-06
2.0,241.0,185.0,0.008299,0.008299,5.488938,1.0,1.0,241.0,9.0,52.0,Lack of Efficacy,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.04555269,0.04573477984272814,0.0001820898427281406
4.0,241.0,185.0,0.016598,0.016598,5.488938,1.0,1.0,241.0,9.0,52.0,Protocol Violation,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.09110539,0.09145626941487095,0.0003508794148709554
0.0,241.0,185.0,0.0,0.0,5.488938,1.0,1.0,241.0,9.0,52.0,Protocol Violation,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,241.0,185.0,0.008299,0.008299,5.488938,1.0,1.0,241.0,9.0,52.0,Lost to Follow-up,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.04555269,0.04549459156153762,5.8098438462377e-05
0.0,241.0,185.0,0.0,0.0,5.488938,1.0,1.0,241.0,9.0,52.0,Lost to Follow-up,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,241.0,185.0,0.012448,0.012448,5.488938,1.0,1.0,241.0,9.0,52.0,Withdrawal by Subject,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.0683263,0.06863183932693448,0.00030553932693447305
2.0,241.0,185.0,0.008299,0.008299,5.488938,1.0,1.0,241.0,9.0,52.0,Withdrawal by Subject,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.04555269,0.045601828472311444,4.913847231144408e-05
1.0,241.0,185.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,9.0,52.0,Study site excluded from analysis,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.0227736,0.022767706510119036,5.8934898809655245e-06
5.0,241.0,185.0,0.020747,0.020747,5.488938,1.0,1.0,241.0,9.0,52.0,Study site excluded from analysis,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.11387899,0.11405428483908749,0.00017529483908748644
5.0,241.0,185.0,0.020747,0.020747,5.488938,1.0,1.0,241.0,9.0,52.0,Other reason not described above,Up to Final Analysis (Week 52),FG000,diabetes type 2,INDUSTRY,0.11387899,0.11396491997390897,8.592997390896584e-05
4.0,241.0,185.0,0.016598,0.016598,5.488938,1.0,1.0,241.0,9.0,52.0,Other reason not described above,Up to Final Analysis (Week 52),FG001,diabetes type 2,INDUSTRY,0.09110539,0.09129934918588281,0.00019395918588281658
3.0,928.0,880.0,0.003233,0.003233,6.834109,0.853566,1.0,928.0,11.0,113.0,Adverse Event,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01885927,0.018808903630516825,5.03663694831763e-05
3.0,928.0,880.0,0.003233,0.003233,6.834109,0.853566,1.0,928.0,11.0,113.0,Adverse Event,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01885927,0.01882364301748112,3.562698251887916e-05
3.0,928.0,880.0,0.003233,0.003233,6.834109,0.853566,1.0,928.0,11.0,113.0,Assigned treatment by mistake,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01885927,0.01881522355849301,4.4046441506989664e-05
4.0,928.0,880.0,0.00431,0.00431,6.834109,0.853566,1.0,928.0,11.0,113.0,Assigned treatment by mistake,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02514181,0.02595179650624007,0.0008099865062400693
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Death,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00628837,0.00628943463270836,1.064632708359936e-06
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Death,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00628837,0.0062993598952678816,1.0989895267881841e-05
6.0,928.0,880.0,0.006466,0.006466,6.834109,0.853566,1.0,928.0,11.0,113.0,Lost to Follow-up,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03771854,0.03753715943506947,0.00018138056493053473
3.0,928.0,880.0,0.003233,0.003233,6.834109,0.853566,1.0,928.0,11.0,113.0,Lost to Follow-up,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01885927,0.018824111430040626,3.5158569959375247e-05
0.0,928.0,880.0,0.0,0.0,6.834109,0.853566,1.0,928.0,11.0,113.0,Non-compliance with study drug,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Non-compliance with study drug,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00628837,0.0062993598952678816,1.0989895267881841e-05
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Physician Decision,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00628837,0.006289004739851216,6.347398512161068e-07
0.0,928.0,880.0,0.0,0.0,6.834109,0.853566,1.0,928.0,11.0,113.0,Physician Decision,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Protocol deviation,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00628837,0.00628638463895836,1.985361041639648e-06
0.0,928.0,880.0,0.0,0.0,6.834109,0.853566,1.0,928.0,11.0,113.0,Protocol deviation,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,928.0,880.0,0.010776,0.010776,6.834109,0.853566,1.0,928.0,11.0,113.0,Withdrawal by Subject,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.06286035,0.06296466842489355,0.00010431842489355692
11.0,928.0,880.0,0.011853,0.011853,6.834109,0.853566,1.0,928.0,11.0,113.0,Withdrawal by Subject,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.06914288,0.06953440600264157,0.00039152600264157067
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Death,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.00628837,0.006290412722073439,2.042722073439078e-06
0.0,928.0,880.0,0.0,0.0,6.834109,0.853566,1.0,928.0,11.0,113.0,Death,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,928.0,880.0,0.002155,0.002155,6.834109,0.853566,1.0,928.0,11.0,113.0,Lost to Follow-up,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.0125709,0.01268487301109126,0.00011397301109125971
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Lost to Follow-up,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.00628837,0.0063066611992162935,1.8291199216293776e-05
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Protocol deviation,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.00628837,0.006286724503323439,1.645496676560762e-06
1.0,928.0,880.0,0.001078,0.001078,6.834109,0.853566,1.0,928.0,11.0,113.0,Protocol deviation,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.00628837,0.006298208691716294,9.838691716294347e-06
0.0,928.0,880.0,0.0,0.0,6.834109,0.853566,1.0,928.0,11.0,113.0,Withdrawal by Subject,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,928.0,880.0,0.003233,0.003233,6.834109,0.853566,1.0,928.0,11.0,113.0,Withdrawal by Subject,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.01885927,0.01876942536157742,8.984463842258081e-05
9.0,1050.0,914.0,0.008571,0.008571,6.957497,0.218621,1.0,1050.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01303699,0.013101331447430555,6.434144743055516e-05
19.0,1050.0,914.0,0.018095,0.018095,6.957497,0.218621,1.0,1050.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02752355,0.02774592112236109,0.000222371122361089
1.0,1050.0,914.0,0.000952,0.000952,6.957497,0.218621,1.0,1050.0,0.0,0.0,Trial Terminated ( Site Closed),Overall Study,FG000,diabetes type 2,INDUSTRY,0.00144805,0.0014522496048773445,4.199604877344479e-06
0.0,1050.0,914.0,0.0,0.0,6.957497,0.218621,1.0,1050.0,0.0,0.0,Trial Terminated ( Site Closed),Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,1050.0,914.0,0.009524,0.009524,6.957497,0.218621,1.0,1050.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01448656,0.014400533381339281,8.602661866071934e-05
1.0,1050.0,914.0,0.000952,0.000952,6.957497,0.218621,1.0,1050.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00144805,0.00145468089231782,6.630892317819985e-06
9.0,1050.0,914.0,0.008571,0.008571,6.957497,0.218621,1.0,1050.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01303699,0.013050954823382937,1.3964823382936475e-05
14.0,1050.0,914.0,0.013333,0.013333,6.957497,0.218621,1.0,1050.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02028027,0.020523586881904764,0.00024331688190476486
1.0,1050.0,914.0,0.000952,0.000952,6.957497,0.218621,1.0,1050.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00144805,0.0014530471673773445,4.997167377344481e-06
2.0,1050.0,914.0,0.001905,0.001905,6.957497,0.218621,1.0,1050.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00289762,0.002919188241448416,2.156824144841597e-05
14.0,1050.0,914.0,0.013333,0.013333,6.957497,0.218621,1.0,1050.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02028027,0.02051027771678573,0.00023000771678572882
15.0,1050.0,914.0,0.014286,0.014286,6.957497,0.218621,1.0,1050.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02172984,0.02147807617214286,0.0002517638278571391
16.0,1050.0,914.0,0.015238,0.015238,6.957497,0.218621,1.0,1050.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02317788,0.02297722894705359,0.00020065105294641075
23.0,1050.0,914.0,0.021905,0.021905,6.957497,0.218621,1.0,1050.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03331878,0.03327190004464285,4.687995535714723e-05
1.0,1050.0,914.0,0.000952,0.000952,6.957497,0.218621,1.0,1050.0,0.0,0.0,Glycemic discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00144805,0.0014522496048773445,4.199604877344479e-06
1.0,1050.0,914.0,0.000952,0.000952,6.957497,0.218621,1.0,1050.0,0.0,0.0,Glycemic discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00144805,0.0014543371923178203,6.287192317820309e-06
2.0,628.0,550.0,0.003185,0.003185,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Lead-In Period,FG000,diabetes type 2,INDUSTRY,0.01325179,0.013245546787291647,6.243212708352194e-06
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Lead-In Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Lead-In Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,628.0,550.0,0.003185,0.003185,6.444131,0.645655,1.0,628.0,3.0,41.0,Lack of Efficacy,Lead-In Period,FG000,diabetes type 2,INDUSTRY,0.01325179,0.013245452166041649,6.33783395835065e-06
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Lack of Efficacy,Lead-In Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Lack of Efficacy,Lead-In Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,628.0,550.0,0.007962,0.007962,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Lead-In Period,FG000,diabetes type 2,INDUSTRY,0.03312738,0.03315064100836301,2.3261008363015256e-05
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Lead-In Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Lead-In Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,628.0,550.0,0.007962,0.007962,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Lead-In Period,FG000,diabetes type 2,INDUSTRY,0.03312738,0.03311777859139873,9.601408601268846e-06
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Lead-In Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Lead-In Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
19.0,628.0,550.0,0.030255,0.030255,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Lead-In Period,FG000,diabetes type 2,INDUSTRY,0.12588156,0.12494098120191462,0.0009405787980853869
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Lead-In Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Lead-In Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,628.0,550.0,0.001592,0.001592,6.444131,0.645655,1.0,628.0,3.0,41.0,Adverse Event,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00662381,0.006634564122023789,1.0754122023789482e-05
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Lost to Follow-up,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,628.0,550.0,0.003185,0.003185,6.444131,0.645655,1.0,628.0,3.0,41.0,Lost to Follow-up,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01325179,0.013196516925208329,5.52730747916709e-05
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Lost to Follow-up,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,628.0,550.0,0.003185,0.003185,6.444131,0.645655,1.0,628.0,3.0,41.0,Physician Decision,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01325179,0.01323653782758927,1.5252172410730111e-05
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,628.0,550.0,0.001592,0.001592,6.444131,0.645655,1.0,628.0,3.0,41.0,Protocol Violation,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00662381,0.006633431307023788,9.621307023787926e-06
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,628.0,550.0,0.007962,0.007962,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03312738,0.03301548978860113,0.00011189021139886707
26.0,628.0,550.0,0.041401,0.041401,6.444131,0.645655,1.0,628.0,3.0,41.0,Withdrawal by Subject,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.17225657,0.17025761093844433,0.001998959061555672
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Due to COVID 19 restrictions,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,628.0,550.0,0.003185,0.003185,6.444131,0.645655,1.0,628.0,3.0,41.0,Due to COVID 19 restrictions,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01325179,0.013212708931874992,3.908106812500721e-05
5.0,628.0,550.0,0.007962,0.007962,6.444131,0.645655,1.0,628.0,3.0,41.0,Due to COVID 19 restrictions,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.03312738,0.033133335219791595,5.955219791596578e-06
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Participant had taken prohibited concomitant medication,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,628.0,550.0,0.0,0.0,6.444131,0.645655,1.0,628.0,3.0,41.0,Participant had taken prohibited concomitant medication,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,628.0,550.0,0.001592,0.001592,6.444131,0.645655,1.0,628.0,3.0,41.0,Participant had taken prohibited concomitant medication,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00662381,0.006633258444523789,9.44844452378888e-06
7.0,277.0,231.0,0.025271,0.025271,5.627621,0.586334,1.0,277.0,15.0,106.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08338584,0.08390217014011889,0.0005163301401188841
7.0,277.0,231.0,0.025271,0.025271,5.627621,0.586334,1.0,277.0,15.0,106.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08338584,0.08391017508488081,0.0005243350848808115
6.0,277.0,231.0,0.021661,0.021661,5.627621,0.586334,1.0,277.0,15.0,106.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07147405,0.0726247514143949,0.0011507014143948974
2.0,277.0,231.0,0.00722,0.00722,5.627621,0.586334,1.0,277.0,15.0,106.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02382358,0.023848815968720304,2.5235968720303814e-05
2.0,277.0,231.0,0.00722,0.00722,5.627621,0.586334,1.0,277.0,15.0,106.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02382358,0.023899740643898864,7.616064389886351e-05
2.0,277.0,231.0,0.00722,0.00722,5.627621,0.586334,1.0,277.0,15.0,106.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02382358,0.023874933470863162,5.135347086316147e-05
5.0,277.0,231.0,0.018051,0.018051,5.627621,0.586334,1.0,277.0,15.0,106.0,At the Participant's Own Request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05956226,0.06358008438734129,0.004017824387341294
1.0,277.0,231.0,0.00361,0.00361,5.627621,0.586334,1.0,277.0,15.0,106.0,At the Participant's Own Request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01191179,0.011976744549702413,6.495454970241281e-05
4.0,277.0,231.0,0.01444,0.01444,5.627621,0.586334,1.0,277.0,15.0,106.0,At the Participant's Own Request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04764717,0.04811040513991074,0.0004632351399107351
3.0,277.0,231.0,0.01083,0.01083,5.627621,0.586334,1.0,277.0,15.0,106.0,Reason Not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03573538,0.03902739552442461,0.00329201552442461
4.0,277.0,231.0,0.01444,0.01444,5.627621,0.586334,1.0,277.0,15.0,106.0,Reason Not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04764717,0.04804647986979169,0.00039930986979169053
1.0,277.0,231.0,0.00361,0.00361,5.627621,0.586334,1.0,277.0,15.0,106.0,Reason Not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01191179,0.011980535805416703,6.874580541670235e-05
1.0,277.0,231.0,0.00361,0.00361,5.627621,0.586334,1.0,277.0,15.0,106.0,Study Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01191179,0.0119837321354167,7.194213541670061e-05
0.0,277.0,231.0,0.0,0.0,5.627621,0.586334,1.0,277.0,15.0,106.0,Study Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,277.0,231.0,0.00361,0.00361,5.627621,0.586334,1.0,277.0,15.0,106.0,Study Terminated by Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01191179,0.011983631456250038,7.184145625003732e-05
3.0,944.0,880.0,0.003178,0.003178,6.851185,0.323595,1.0,2996.0,16.0,329.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00704565,0.007056800696785687,1.115069678568701e-05
5.0,944.0,880.0,0.005297,0.005297,6.851185,0.323595,1.0,2996.0,16.0,329.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01174349,0.011754063792817482,1.0573792817481636e-05
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00234781,0.0023586818303147424,1.087183031474228e-05
3.0,944.0,880.0,0.003178,0.003178,6.851185,0.323595,1.0,2996.0,16.0,329.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00704565,0.007057905647202351,1.2255647202351685e-05
7.0,944.0,880.0,0.007415,0.007415,6.851185,0.323595,1.0,2996.0,16.0,329.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01643911,0.016657090225963192,0.00021798022596319216
2.0,944.0,880.0,0.002119,0.002119,6.851185,0.323595,1.0,2996.0,16.0,329.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00469784,0.0047379094273948905,4.006942739489053e-05
6.0,944.0,880.0,0.006356,0.006356,6.851185,0.323595,1.0,2996.0,16.0,329.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0140913,0.014293756743571426,0.00020245674357142682
9.0,944.0,880.0,0.009534,0.009534,6.851185,0.323595,1.0,2996.0,16.0,329.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02113695,0.021349485740565482,0.00021253574056548027
6.0,944.0,880.0,0.006356,0.006356,6.851185,0.323595,1.0,2996.0,16.0,329.0,No longer met study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0140913,0.014271460925535707,0.0001801609255357075
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,No longer met study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234781,0.00235363519309252,5.825193092519939e-06
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,No longer met study criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,944.0,880.0,0.005297,0.005297,6.851185,0.323595,1.0,2996.0,16.0,329.0,No longer met study criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01174349,0.011749948668234146,6.458668234145953e-06
5.0,944.0,880.0,0.005297,0.005297,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01174349,0.01173909499649803,4.395003501970335e-06
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234781,0.0023525270910091864,4.717091009186301e-06
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,944.0,880.0,0.002119,0.002119,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00469784,0.004735926060638937,3.8086060638937123e-05
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,944.0,880.0,0.002119,0.002119,6.851185,0.323595,1.0,2996.0,16.0,329.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00469784,0.0047375040131091735,3.966401310917349e-05
3.0,944.0,880.0,0.003178,0.003178,6.851185,0.323595,1.0,2996.0,16.0,329.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00704565,0.007056927043035687,1.1277043035687502e-05
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234781,0.00235363519309252,5.825193092519939e-06
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234781,0.00235363519309252,5.825193092519939e-06
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Administrative reason by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,944.0,880.0,0.001059,0.001059,6.851185,0.323595,1.0,2996.0,16.0,329.0,Administrative reason by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234781,0.00235363519309252,5.825193092519939e-06
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Administrative reason by sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,944.0,880.0,0.0,0.0,6.851185,0.323595,1.0,2996.0,16.0,329.0,Administrative reason by sponsor,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1202.0,657.0,0.00416,0.00416,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00907264,0.008888834537828141,0.0001838054621718585
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1202.0,657.0,0.002496,0.002496,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00544359,0.005389708700009933,5.388129999006706e-05
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00181453,0.0018145623767757827,3.2376775782735553e-08
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00181453,0.0018143835621924492,1.464378075507599e-07
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Entry Criteria Not Met,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00181453,0.0018146201718055443,9.017180554429967e-08
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00181453,0.0018146641191368945,1.3411913689451854e-07
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,1202.0,657.0,0.010815,0.010815,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02358669,0.022915934042599204,0.0006707559574007961
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,1202.0,657.0,0.009151,0.009151,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01995763,0.019850670063502007,0.00010695993649799396
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00181453,0.0018145888984424496,5.88984424496064e-08
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,1202.0,657.0,0.007488,0.007488,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.01633076,0.016238869003849184,9.189099615081534e-05
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lost to Follow-up,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00725811,0.007293626202767848,3.5516202767847845e-05
2.0,1202.0,657.0,0.001664,0.001664,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00362906,0.0036152933363690376,1.3766663630962375e-05
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00181453,0.0018152919101686407,7.619101686407066e-07
18.0,1202.0,657.0,0.014975,0.014975,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03265933,0.031021195448085317,0.0016381345519146835
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
24.0,1202.0,657.0,0.019967,0.019967,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.04354651,0.044033503402990636,0.0004869934029906389
2.0,1202.0,657.0,0.001664,0.001664,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00362906,0.003626630082202369,2.4299177976308366e-06
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
36.0,1202.0,657.0,0.02995,0.02995,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,INDUSTRY,0.06531867,0.06563950890187498,0.0003208389018749813
21.0,1202.0,657.0,0.017471,0.017471,7.092574,0.307494,1.0,1202.0,13.0,99.0,Withdrawal by Subject,Overall Study,FG008,diabetes type 2,INDUSTRY,0.03810292,0.037677216649385795,0.00042570335061420383
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00725811,0.0072882194538988,3.0109453898800008e-05
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00181453,0.0018132972651686407,1.2327348313592723e-06
11.0,1202.0,657.0,0.009151,0.009151,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01995763,0.01986769446159724,8.99355384027592e-05
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,1202.0,657.0,0.007488,0.007488,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG007,diabetes type 2,INDUSTRY,0.01633076,0.01622237663340276,0.00010838336659723877
9.0,1202.0,657.0,0.007488,0.007488,7.092574,0.307494,1.0,1202.0,13.0,99.0,Physician Decision,Overall Study,FG008,diabetes type 2,INDUSTRY,0.01633076,0.01622237663340276,0.00010838336659723877
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00725811,0.0072997582209226065,4.164822092260663e-05
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00725811,0.00729710261377975,3.899261377974996e-05
63.0,1202.0,657.0,0.052413,0.052413,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.11430876,0.11464082882650796,0.0003320688265079641
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00181453,0.001815247971180545,7.179711805449605e-07
64.0,1202.0,657.0,0.053245,0.053245,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.11612329,0.11652522240192459,0.00040193240192458457
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00181453,0.0018149637961805448,4.3379618054487437e-07
65.0,1202.0,657.0,0.054077,0.054077,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.11793782,0.11818772884942463,0.00024990884942463487
39.0,1202.0,657.0,0.032446,0.032446,7.092574,0.307494,1.0,1202.0,13.0,99.0,Adverse Event,Overall Study,FG008,diabetes type 2,INDUSTRY,0.07076225,0.07250909312685519,0.001746843126855191
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00725811,0.0072879257538988,2.9815753898800035e-05
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1202.0,657.0,0.002496,0.002496,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00544359,0.005396621289593268,4.6968710406732235e-05
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1202.0,657.0,0.002496,0.002496,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00544359,0.005396823439593268,4.6766560406731605e-05
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Protocol Violation,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00181453,0.0018154547685317354,9.247685317354502e-07
8.0,1202.0,657.0,0.006656,0.006656,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG000,diabetes type 2,INDUSTRY,0.01451623,0.01442891516607141,8.731483392858917e-05
25.0,1202.0,657.0,0.020799,0.020799,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG001,diabetes type 2,INDUSTRY,0.04536103,0.045093829977963525,0.00026720002203647203
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,1202.0,657.0,0.006656,0.006656,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG003,diabetes type 2,INDUSTRY,0.01451623,0.014452174039821413,6.405596017858631e-05
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
21.0,1202.0,657.0,0.017471,0.017471,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG005,diabetes type 2,INDUSTRY,0.03810292,0.0376862015223223,0.00041671847767769943
23.0,1202.0,657.0,0.019135,0.019135,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG006,diabetes type 2,INDUSTRY,0.04173198,0.040705654410015335,0.0010263255899846668
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,"Sponsor Decision, Arm Discontinued",Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1202.0,657.0,0.001664,0.001664,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00362906,0.0036233803551190356,5.679644880964355e-06
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Sponsor Decision,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00181453,0.0018133666739186406,1.1633260813593855e-06
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1202.0,657.0,0.001664,0.001664,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00362906,0.0036254698526190367,3.5901473809632663e-06
1.0,1202.0,657.0,0.000832,0.000832,7.092574,0.307494,1.0,1202.0,13.0,99.0,Death,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00181453,0.0018144567685317353,7.3231468264651e-08
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00725811,0.00727714939467261,1.9039394672609906e-05
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1202.0,657.0,0.0,0.0,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1202.0,657.0,0.003328,0.003328,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00725811,0.007285821106041659,2.771110604165867e-05
6.0,1202.0,657.0,0.004992,0.004992,7.092574,0.307494,1.0,1202.0,13.0,99.0,Lack of Efficacy,Overall Study,FG008,diabetes type 2,INDUSTRY,0.01088717,0.010407772572896828,0.00047939742710317174
16.0,423.0,334.0,0.037825,0.037825,6.049733,0.274836,1.0,426.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06289108,0.06283470726177583,5.637273822417521e-05
18.0,423.0,334.0,0.042553,0.042553,6.049733,0.274836,1.0,426.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07075226,0.0704369591666171,0.00031530083338289494
2.0,423.0,334.0,0.004728,0.004728,6.049733,0.274836,1.0,426.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00786118,0.0078834029378472,2.2222937847199767e-05
2.0,423.0,334.0,0.004728,0.004728,6.049733,0.274836,1.0,426.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00786118,0.007884085842192435,2.2905842192433995e-05
1.0,423.0,334.0,0.002364,0.002364,6.049733,0.274836,1.0,426.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00393059,0.003961444503016765,3.0854503016764824e-05
0.0,423.0,334.0,0.0,0.0,6.049733,0.274836,1.0,426.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,423.0,334.0,0.002364,0.002364,6.049733,0.274836,1.0,426.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00393059,0.0039692230703381945,3.8633070338194193e-05
6.0,423.0,334.0,0.014184,0.014184,6.049733,0.274836,1.0,426.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02358353,0.02376445745712302,0.00018092745712302086
1.0,423.0,334.0,0.002364,0.002364,6.049733,0.274836,1.0,426.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00393059,0.003965214933016766,3.462493301676587e-05
3.0,423.0,334.0,0.007092,0.007092,6.049733,0.274836,1.0,426.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01179177,0.011814256174404767,2.248617440476705e-05
2.0,423.0,334.0,0.004728,0.004728,6.049733,0.274836,1.0,426.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00786118,0.007896937016388874,3.575701638887374e-05
2.0,423.0,334.0,0.004728,0.004728,6.049733,0.274836,1.0,426.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00786118,0.007898133105109107,3.6953105109106474e-05
24.0,423.0,334.0,0.056738,0.056738,6.049733,0.274836,1.0,426.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09433746,0.0947986111920238,0.0004611511920238065
11.0,423.0,334.0,0.026005,0.026005,6.049733,0.274836,1.0,426.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04323814,0.043043524448174574,0.00019461555182542778
19.0,788.0,739.0,0.024112,0.024112,6.670766,0.534489,1.0,788.0,12.0,119.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0859702,0.08463107431165685,0.001339125688343143
14.0,788.0,739.0,0.017766,0.017766,6.670766,0.534489,1.0,788.0,12.0,119.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06334384,0.062327154594613104,0.001016685405386894
7.0,788.0,739.0,0.008883,0.008883,6.670766,0.534489,1.0,788.0,12.0,119.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03167192,0.03156958675659725,0.0001023332434027524
8.0,788.0,739.0,0.010152,0.010152,6.670766,0.534489,1.0,788.0,12.0,119.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03619648,0.03595391819964286,0.00024256180035714392
1.0,788.0,739.0,0.001269,0.001269,6.670766,0.534489,1.0,788.0,12.0,119.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00452456,0.004519657340327374,4.902659672626625e-06
0.0,788.0,739.0,0.0,0.0,6.670766,0.534489,1.0,788.0,12.0,119.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
19.0,329.0,252.0,0.057751,0.057751,5.799093,0.199291,1.0,329.0,18.0,67.0,Hyperglycemia rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06674308,0.07156179033192453,0.004818710331924533
13.0,329.0,252.0,0.039514,0.039514,5.799093,0.199291,1.0,329.0,18.0,67.0,Hyperglycemia rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0456665,0.04628458957266868,0.0006180895726686786
10.0,329.0,252.0,0.030395,0.030395,5.799093,0.199291,1.0,329.0,18.0,67.0,Hyperglycemia rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03512763,0.03566911685937499,0.0005414868593749886
1.0,329.0,252.0,0.00304,0.00304,5.799093,0.199291,1.0,329.0,18.0,67.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00351334,0.0035218680876785767,8.528087678576473e-06
3.0,329.0,252.0,0.009119,0.009119,5.799093,0.199291,1.0,329.0,18.0,67.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01053887,0.010581946237202385,4.3076237202384e-05
2.0,329.0,252.0,0.006079,0.006079,5.799093,0.199291,1.0,329.0,18.0,67.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00702553,0.007163418839186496,0.00013788883918649554
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,329.0,252.0,0.009119,0.009119,5.799093,0.199291,1.0,329.0,18.0,67.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01053887,0.010582290025773811,4.342002577381078e-05
3.0,329.0,252.0,0.009119,0.009119,5.799093,0.199291,1.0,329.0,18.0,67.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01053887,0.01058844161904762,4.957161904761871e-05
3.0,329.0,252.0,0.009119,0.009119,5.799093,0.199291,1.0,329.0,18.0,67.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01053887,0.010588717494166669,4.984749416666809e-05
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,329.0,252.0,0.006079,0.006079,5.799093,0.199291,1.0,329.0,18.0,67.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00702553,0.0071665314875198295,0.00014100148751982917
1.0,329.0,252.0,0.00304,0.00304,5.799093,0.199291,1.0,329.0,18.0,67.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00351334,0.003525158961428575,1.1818961428574585e-05
1.0,329.0,252.0,0.00304,0.00304,5.799093,0.199291,1.0,329.0,18.0,67.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00351334,0.0035165834803869106,3.2434803869103683e-06
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,329.0,252.0,0.00304,0.00304,5.799093,0.199291,1.0,329.0,18.0,67.0,Participant Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00351334,0.0035235642105952425,1.0224210595242283e-05
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Participant Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Participant Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,329.0,252.0,0.0,0.0,5.799093,0.199291,1.0,329.0,18.0,67.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,329.0,252.0,0.024316,0.024316,5.799093,0.199291,1.0,329.0,18.0,67.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02810211,0.029639695076865098,0.0015375850768650987
7.0,329.0,252.0,0.021277,0.021277,5.799093,0.199291,1.0,329.0,18.0,67.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02458992,0.02535493129616075,0.0007650112961607482
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, Subject wanted HbA1c to be > 7%",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00364128,0.0036438836753273952,2.6036753273950275e-06
0.0,689.0,606.0,0.0,0.0,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, Subject wanted HbA1c to be > 7%",Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, weight gain, hypoglycaemic events",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00364128,0.0036438836753273952,2.6036753273950275e-06
0.0,689.0,606.0,0.0,0.0,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, weight gain, hypoglycaemic events",Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,689.0,606.0,0.0,0.0,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, Subject moved out of the country",Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,"Other, Subject moved out of the country",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00364128,0.0036463275566369167,5.047556636916459e-06
15.0,689.0,606.0,0.021771,0.021771,6.536692,0.383909,1.0,881.0,10.0,144.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05463418,0.05483402928482157,0.00019984928482157105
15.0,689.0,606.0,0.021771,0.021771,6.536692,0.383909,1.0,881.0,10.0,144.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05463418,0.05468683755562515,5.265755562515462e-05
5.0,689.0,606.0,0.007257,0.007257,6.536692,0.383909,1.0,881.0,10.0,144.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01821139,0.017540345716994064,0.0006710442830059372
2.0,689.0,606.0,0.002903,0.002903,6.536692,0.383909,1.0,881.0,10.0,144.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00728506,0.0072481309808856455,3.6929019114354845e-05
0.0,689.0,606.0,0.0,0.0,6.536692,0.383909,1.0,881.0,10.0,144.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00364128,0.0036463275566369167,5.047556636916459e-06
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00364128,0.0036438836753273952,2.6036753273950275e-06
4.0,689.0,606.0,0.005806,0.005806,6.536692,0.383909,1.0,881.0,10.0,144.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01457012,0.014463703971974209,0.00010641602802579156
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00364128,0.003642655880744061,1.3758807440606563e-06
1.0,689.0,606.0,0.001451,0.001451,6.536692,0.383909,1.0,881.0,10.0,144.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00364128,0.0036450997620535823,3.8197620535820875e-06
20.0,689.0,606.0,0.029028,0.029028,6.536692,0.383909,1.0,881.0,10.0,144.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07284558,0.07292431147838736,7.873147838736994e-05
15.0,689.0,606.0,0.021771,0.021771,6.536692,0.383909,1.0,881.0,10.0,144.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05463418,0.05453902706636916,9.515293363084043e-05
1.0,257.0,226.0,0.003891,0.003891,5.55296,0.279906,1.0,257.0,6.0,33.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0060478,0.006078195235753976,3.0395235753976138e-05
3.0,257.0,226.0,0.011673,0.011673,5.55296,0.279906,1.0,257.0,6.0,33.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01814341,0.018530123657867076,0.0003867136578670771
8.0,257.0,226.0,0.031128,0.031128,5.55296,0.279906,1.0,257.0,6.0,33.0,Condition under investigation worsened,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04838244,0.04905423874979433,0.000671798749794332
7.0,257.0,226.0,0.027237,0.027237,5.55296,0.279906,1.0,257.0,6.0,33.0,Condition under investigation worsened,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04233463,0.04232720948465277,7.420515347231205e-06
2.0,257.0,226.0,0.007782,0.007782,5.55296,0.279906,1.0,257.0,6.0,33.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01209561,0.01214207061136903,4.646061136902996e-05
3.0,257.0,226.0,0.011673,0.011673,5.55296,0.279906,1.0,257.0,6.0,33.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01814341,0.01849494287021826,0.0003515328702182602
2.0,257.0,226.0,0.007782,0.007782,5.55296,0.279906,1.0,257.0,6.0,33.0,Incorrect enrolment to study,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01209561,0.012156030319107124,6.042031910712467e-05
1.0,257.0,226.0,0.003891,0.003891,5.55296,0.279906,1.0,257.0,6.0,33.0,Incorrect enrolment to study,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0060478,0.00607736951569445,2.956951569444994e-05
2.0,257.0,226.0,0.007782,0.007782,5.55296,0.279906,1.0,257.0,6.0,33.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01209561,0.012155112660773794,5.950266077379453e-05
0.0,257.0,226.0,0.0,0.0,5.55296,0.279906,1.0,257.0,6.0,33.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,226.0,0.003891,0.003891,5.55296,0.279906,1.0,257.0,6.0,33.0,Developed discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0060478,0.006075947590277784,2.8147590277784185e-05
1.0,257.0,226.0,0.003891,0.003891,5.55296,0.279906,1.0,257.0,6.0,33.0,Developed discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0060478,0.00607736951569445,2.956951569444994e-05
3.0,451.0,411.0,0.006652,0.006652,6.113682,0.286086,1.0,833.0,6.0,88.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0116346,0.011746452797589277,0.0001118527975892767
7.0,451.0,411.0,0.015521,0.015521,6.113682,0.286086,1.0,833.0,6.0,88.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02714683,0.027562582065158735,0.00041575206515873445
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00387762,0.003882688712202362,5.068712202362189e-06
0.0,451.0,411.0,0.0,0.0,6.113682,0.286086,1.0,833.0,6.0,88.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,451.0,411.0,0.028825,0.028825,6.113682,0.286086,1.0,833.0,6.0,88.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05041604,0.051140153148397344,0.0007241131483973415
4.0,451.0,411.0,0.008869,0.008869,6.113682,0.286086,1.0,833.0,6.0,88.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01551222,0.015547127908035717,3.490790803571675e-05
3.0,451.0,411.0,0.006652,0.006652,6.113682,0.286086,1.0,833.0,6.0,88.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0116346,0.011746675541339277,0.0001120755413392769
4.0,451.0,411.0,0.008869,0.008869,6.113682,0.286086,1.0,833.0,6.0,88.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01551222,0.015574389865922623,6.216986592262261e-05
0.0,451.0,411.0,0.0,0.0,6.113682,0.286086,1.0,833.0,6.0,88.0,Poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,Poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00387762,0.0038799143934523626,2.2943934523626114e-06
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,Subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00387762,0.003882688712202362,5.068712202362189e-06
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,Subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00387762,0.0038799143934523626,2.2943934523626114e-06
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,site closing,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00387762,0.003882688712202362,5.068712202362189e-06
0.0,451.0,411.0,0.0,0.0,6.113682,0.286086,1.0,833.0,6.0,88.0,site closing,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,451.0,411.0,0.002217,0.002217,6.113682,0.286086,1.0,833.0,6.0,88.0,lack of efficacy and subject compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00387762,0.003882688712202362,5.068712202362189e-06
0.0,451.0,411.0,0.0,0.0,6.113682,0.286086,1.0,833.0,6.0,88.0,lack of efficacy and subject compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,936.0,663.0,0.00641,0.00641,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01419339,0.014149075796468237,4.431420353176278e-05
8.0,936.0,663.0,0.008547,0.008547,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01892525,0.018859200780912667,6.604921908733366e-05
5.0,936.0,663.0,0.005342,0.005342,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01182856,0.01182082221626985,7.737783730150938e-06
5.0,936.0,663.0,0.005342,0.005342,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01182856,0.011814051544186514,1.4508455813485796e-05
10.0,936.0,663.0,0.010684,0.010684,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02365712,0.023631496444007936,2.5623555992063812e-05
10.0,936.0,663.0,0.010684,0.010684,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02365712,0.023631496444007936,2.5623555992063812e-05
6.0,936.0,663.0,0.00641,0.00641,6.842683,0.323595,1.0,936.0,6.0,132.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01419339,0.014157633442658708,3.5756557341292544e-05
3.0,936.0,663.0,0.003205,0.003205,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00709669,0.007094631055559178,2.0589444408225174e-06
2.0,936.0,663.0,0.002137,0.002137,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00473187,0.0047064300902152105,2.5439909784789536e-05
1.0,936.0,663.0,0.001068,0.001068,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00236483,0.0023705468625270505,5.716862527050445e-06
2.0,936.0,663.0,0.002137,0.002137,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00473187,0.0047111522047390214,2.0717795260978555e-05
1.0,936.0,663.0,0.001068,0.001068,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00236483,0.0023706530833603836,5.823083360383553e-06
2.0,936.0,663.0,0.002137,0.002137,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00473187,0.004712608820572357,1.9261179427643334e-05
0.0,936.0,663.0,0.0,0.0,6.842683,0.323595,1.0,936.0,6.0,132.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,936.0,663.0,0.005342,0.005342,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01182856,0.011809475511894848,1.908448810515259e-05
2.0,936.0,663.0,0.002137,0.002137,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00473187,0.004719084080096159,1.2785919903841002e-05
4.0,936.0,663.0,0.004274,0.004274,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00946373,0.00950104214097218,3.7312140972179525e-05
0.0,936.0,663.0,0.0,0.0,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,936.0,663.0,0.004274,0.004274,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00946373,0.009464095577609093,3.655776090929347e-07
3.0,936.0,663.0,0.003205,0.003205,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00709669,0.00709201245228537,4.677547714630401e-06
3.0,936.0,663.0,0.003205,0.003205,6.842683,0.323595,1.0,936.0,6.0,132.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00709669,0.007096148596868703,5.414031312971773e-07
7.0,936.0,663.0,0.007479,0.007479,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01656043,0.016493291921925494,6.71380780745065e-05
3.0,936.0,663.0,0.003205,0.003205,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00709669,0.007081329538594888,1.5360461405111887e-05
4.0,936.0,663.0,0.004274,0.004274,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00946373,0.00950069738597219,3.696738597219057e-05
3.0,936.0,663.0,0.003205,0.003205,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00709669,0.007092314286392512,4.3757136074882436e-06
2.0,936.0,663.0,0.002137,0.002137,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00473187,0.004709929490602116,2.1940509397883924e-05
6.0,936.0,663.0,0.00641,0.00641,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01419339,0.014176988560297605,1.6401439702395243e-05
5.0,936.0,663.0,0.005342,0.005342,6.842683,0.323595,1.0,936.0,6.0,132.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01182856,0.011796709280436506,3.185071956349379e-05
9.0,936.0,663.0,0.009615,0.009615,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02129008,0.021255960537251987,3.411946274801264e-05
13.0,936.0,663.0,0.013889,0.013889,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03075381,0.0306276396750893,0.00012617032491070088
10.0,936.0,663.0,0.010684,0.010684,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02365712,0.02363879327347221,1.8326726527791853e-05
8.0,936.0,663.0,0.008547,0.008547,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01892525,0.018811901511269807,0.00011334848873019443
7.0,936.0,663.0,0.007479,0.007479,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01656043,0.016431740508711212,0.0001286894912887887
9.0,936.0,663.0,0.009615,0.009615,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02129008,0.021253719509097223,3.636049090277593e-05
10.0,936.0,663.0,0.010684,0.010684,6.842683,0.323595,1.0,936.0,6.0,132.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.02365712,0.0236240777151984,3.304228480159946e-05
15.0,936.0,663.0,0.016026,0.016026,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03548568,0.035244597591170664,0.00024108240882933507
11.0,936.0,663.0,0.011752,0.011752,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02602194,0.02601479974862102,7.140251378979362e-06
17.0,936.0,663.0,0.018162,0.018162,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04021533,0.03938971442096227,0.0008256155790377293
12.0,936.0,663.0,0.012821,0.012821,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02838898,0.028418202779186545,2.9222779186544035e-05
12.0,936.0,663.0,0.012821,0.012821,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02838898,0.02842011312626989,3.113312626988954e-05
15.0,936.0,663.0,0.016026,0.016026,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG005,diabetes type 2,INDUSTRY,0.03548568,0.03527147651617066,0.0002142034838293408
13.0,936.0,663.0,0.013889,0.013889,6.842683,0.323595,1.0,936.0,6.0,132.0,Reasons other than stated above,Overall Study,FG006,diabetes type 2,INDUSTRY,0.03075381,0.030675201604761906,7.86083952380931e-05
1.0,582.0,555.0,0.001718,0.001718,6.368187,0.758938,1.0,582.0,12.0,130.0,Death,Main Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0083032,0.008295002848690449,8.197151309551412e-06
0.0,582.0,555.0,0.0,0.0,6.368187,0.758938,1.0,582.0,12.0,130.0,Death,Main Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,582.0,555.0,0.001718,0.001718,6.368187,0.758938,1.0,582.0,12.0,130.0,Lost to Follow-up,Main Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0083032,0.008311789650565445,8.589650565445084e-06
1.0,582.0,555.0,0.001718,0.001718,6.368187,0.758938,1.0,582.0,12.0,130.0,Lost to Follow-up,Main Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.0083032,0.008298713456577352,4.48654342264862e-06
9.0,582.0,555.0,0.015464,0.015464,6.368187,0.758938,1.0,582.0,12.0,130.0,Withdrawal by Subject,Main Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.07473847,0.07548359284810519,0.0007451228481051841
7.0,582.0,555.0,0.012027,0.012027,6.368187,0.758938,1.0,582.0,12.0,130.0,Withdrawal by Subject,Main Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.05812724,0.05912659643452388,0.000999356434523882
1.0,582.0,555.0,0.001718,0.001718,6.368187,0.758938,1.0,582.0,12.0,130.0,Physician Decision,Extension Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0083032,0.008307122825476165,3.922825476164807e-06
0.0,582.0,555.0,0.0,0.0,6.368187,0.758938,1.0,582.0,12.0,130.0,Physician Decision,Extension Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,582.0,555.0,0.0,0.0,6.368187,0.758938,1.0,582.0,12.0,130.0,Lost to Follow-up,Extension Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,582.0,555.0,0.001718,0.001718,6.368187,0.758938,1.0,582.0,12.0,130.0,Lost to Follow-up,Extension Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.0083032,0.008301304737827355,1.8952621726447266e-06
4.0,582.0,555.0,0.006873,0.006873,6.368187,0.758938,1.0,582.0,12.0,130.0,Withdrawal by Subject,Extension Phase (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.03321764,0.03342721280587297,0.00020957280587297067
2.0,582.0,555.0,0.003436,0.003436,6.368187,0.758938,1.0,582.0,12.0,130.0,Withdrawal by Subject,Extension Phase (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.0166064,0.016539085653998004,6.731434600199676e-05
14.0,6068.0,5853.0,0.002307,0.002307,8.710949,0.384821,1.0,6068.0,49.0,829.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00773343,0.007746899353022185,1.346935302218473e-05
11.0,6068.0,5853.0,0.001813,0.001813,8.710949,0.384821,1.0,6068.0,49.0,829.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00607746,0.006270951733958341,0.00019349173395834078
83.0,6068.0,5853.0,0.013678,0.013678,8.710949,0.384821,1.0,6068.0,49.0,829.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04585082,0.04645276671337756,0.0006019467133775575
88.0,6068.0,5853.0,0.014502,0.014502,8.710949,0.384821,1.0,6068.0,49.0,829.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.048613,0.048264601248670644,0.0003483987513293596
13.0,6068.0,5853.0,0.002142,0.002142,8.710949,0.384821,1.0,6068.0,49.0,829.0,Site termination by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00718032,0.006983439802159087,0.0001968801978409129
5.0,6068.0,5853.0,0.000824,0.000824,8.710949,0.384821,1.0,6068.0,49.0,829.0,Site termination by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00276218,0.0025392622857738096,0.00022291771422619034
0.0,6068.0,5853.0,0.0,0.0,8.710949,0.384821,1.0,6068.0,49.0,829.0,Other than specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,1.9333750000000002e-07,1.9333750000000002e-07
1.0,6068.0,5853.0,0.000165,0.000165,8.710949,0.384821,1.0,6068.0,49.0,829.0,Other than specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00055311,0.0005558549741269841,2.7449741269841e-06
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00497913,0.004974799057619034,4.330942380966103e-06
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00248956,0.002490534687559525,9.746875595248797e-07
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1233.0,1101.0,0.002433,0.002433,7.118016,0.431264,1.0,1233.0,0.0,0.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00746869,0.007432574115178594,3.6115884821406007e-05
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00248956,0.002490413391250001,8.533912500010253e-07
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Participant moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00248956,0.002489509768075398,5.0231924602055916e-08
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Participant moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00248956,0.002489316924920636,2.430750793641981e-07
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Participant moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00248956,0.002484093432450398,5.466567549601911e-06
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Participant moved,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Participant moved,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00497913,0.004980773460595222,1.6434605952216422e-06
7.0,1233.0,1101.0,0.005677,0.005677,7.118016,0.431264,1.0,1233.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01742695,0.01766033691931546,0.00023338691931545918
11.0,1233.0,1101.0,0.008921,0.008921,7.118016,0.431264,1.0,1233.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0273852,0.027471591505753953,8.639150575395424e-05
13.0,1233.0,1101.0,0.010543,0.010543,7.118016,0.431264,1.0,1233.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03236433,0.032315392366894846,4.8937633105150535e-05
9.0,1233.0,1101.0,0.007299,0.007299,7.118016,0.431264,1.0,1233.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02240607,0.02214338853587302,0.0002626814641269806
13.0,1233.0,1101.0,0.010543,0.010543,7.118016,0.431264,1.0,1233.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.03236433,0.03232310695481151,4.122304518848485e-05
3.0,1233.0,1101.0,0.002433,0.002433,7.118016,0.431264,1.0,1233.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00746869,0.007430740628511927,3.794937148807274e-05
5.0,1233.0,1101.0,0.004055,0.004055,7.118016,0.431264,1.0,1233.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01244782,0.012455781058054661,7.96105805466081e-06
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00497913,0.004982737678571415,3.607678571415293e-06
3.0,1233.0,1101.0,0.002433,0.002433,7.118016,0.431264,1.0,1233.0,0.0,0.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00746869,0.0074307098326785925,3.7980167321407556e-05
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00497913,0.0049780910107737955,1.0389892262045036e-06
6.0,1233.0,1101.0,0.004866,0.004866,7.118016,0.431264,1.0,1233.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01493738,0.014958295851736116,2.0915851736115487e-05
12.0,1233.0,1101.0,0.009732,0.009732,7.118016,0.431264,1.0,1233.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02987476,0.030123228607380956,0.00024846860738095625
11.0,1233.0,1101.0,0.008921,0.008921,7.118016,0.431264,1.0,1233.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0273852,0.027550058046051575,0.0001648580460515761
5.0,1233.0,1101.0,0.004055,0.004055,7.118016,0.431264,1.0,1233.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01244782,0.012499277327697522,5.145732769752144e-05
6.0,1233.0,1101.0,0.004866,0.004866,7.118016,0.431264,1.0,1233.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01493738,0.014965162793015876,2.778279301587569e-05
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00248956,0.0024913783757539694,1.818375753969391e-06
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Death,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Screen failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Screen failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Screen failure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Screen failure,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Screen failure,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00248956,0.002488902146666668,6.57853333332209e-07
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00497913,0.004978867149047604,2.6285095239622636e-07
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00248956,0.002488902146666668,6.57853333332209e-07
3.0,1233.0,1101.0,0.002433,0.002433,7.118016,0.431264,1.0,1233.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00746869,0.007425820680178593,4.286931982140727e-05
0.0,1233.0,1101.0,0.0,0.0,7.118016,0.431264,1.0,1233.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00248956,0.002484265211617065,5.294788382935196e-06
2.0,1233.0,1101.0,0.001622,0.001622,7.118016,0.431264,1.0,1233.0,0.0,0.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00497913,0.004982196558928556,3.0665589285557016e-06
1.0,1233.0,1101.0,0.000811,0.000811,7.118016,0.431264,1.0,1233.0,0.0,0.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00248956,0.002489138430000001,4.2156999999903855e-07
1.0,532.0,499.0,0.00188,0.00188,6.278521,0.49457,1.0,532.0,7.0,71.0,Unclassified,Initiation Period (Week 0-26),FG000,diabetes type 2,INDUSTRY,0.00583772,0.005827049229995493,1.0670770004507155e-05
3.0,532.0,499.0,0.005639,0.005639,6.278521,0.49457,1.0,532.0,7.0,71.0,Unclassified,Initiation Period (Week 0-26),FG001,diabetes type 2,INDUSTRY,0.01751004,0.017529755200535756,1.971520053575468e-05
1.0,532.0,499.0,0.00188,0.00188,6.278521,0.49457,1.0,532.0,7.0,71.0,Adverse Event,Initiation Period (Week 0-26),FG000,diabetes type 2,INDUSTRY,0.00583772,0.005822126903442466,1.5593096557534047e-05
0.0,532.0,499.0,0.0,0.0,6.278521,0.49457,1.0,532.0,7.0,71.0,Adverse Event,Initiation Period (Week 0-26),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,532.0,499.0,0.00188,0.00188,6.278521,0.49457,1.0,532.0,7.0,71.0,Lost to Follow-up,Initiation Period (Week 0-26),FG000,diabetes type 2,INDUSTRY,0.00583772,0.005828404932316923,9.315067683077216e-06
4.0,532.0,499.0,0.007519,0.007519,6.278521,0.49457,1.0,532.0,7.0,71.0,Lost to Follow-up,Initiation Period (Week 0-26),FG001,diabetes type 2,INDUSTRY,0.02334776,0.022942603041140867,0.00040515695885913125
3.0,532.0,499.0,0.005639,0.005639,6.278521,0.49457,1.0,532.0,7.0,71.0,Withdrawal by Subject,Initiation Period (Week 0-26),FG000,diabetes type 2,INDUSTRY,0.01751004,0.01757693646255959,6.689646255958817e-05
4.0,532.0,499.0,0.007519,0.007519,6.278521,0.49457,1.0,532.0,7.0,71.0,Withdrawal by Subject,Initiation Period (Week 0-26),FG001,diabetes type 2,INDUSTRY,0.02334776,0.022971071105605156,0.00037668889439484293
3.0,532.0,499.0,0.005639,0.005639,6.278521,0.49457,1.0,532.0,7.0,71.0,Unclassified,Intensification Period (Week 26-38),FG000,diabetes type 2,INDUSTRY,0.01751004,0.017514829580952435,4.789580952433564e-06
2.0,532.0,499.0,0.003759,0.003759,6.278521,0.49457,1.0,532.0,7.0,71.0,Unclassified,Intensification Period (Week 26-38),FG001,diabetes type 2,INDUSTRY,0.01167233,0.011625471414265868,4.685858573413165e-05
0.0,532.0,499.0,0.0,0.0,6.278521,0.49457,1.0,532.0,7.0,71.0,Adverse Event,Intensification Period (Week 26-38),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,532.0,499.0,0.003759,0.003759,6.278521,0.49457,1.0,532.0,7.0,71.0,Adverse Event,Intensification Period (Week 26-38),FG001,diabetes type 2,INDUSTRY,0.01167233,0.011611877058759917,6.045294124008317e-05
3.0,532.0,499.0,0.005639,0.005639,6.278521,0.49457,1.0,532.0,7.0,71.0,Lost to Follow-up,Intensification Period (Week 26-38),FG000,diabetes type 2,INDUSTRY,0.01751004,0.017520727835897493,1.0687835897492393e-05
1.0,532.0,499.0,0.00188,0.00188,6.278521,0.49457,1.0,532.0,7.0,71.0,Lost to Follow-up,Intensification Period (Week 26-38),FG001,diabetes type 2,INDUSTRY,0.00583772,0.005820407916916492,1.7312083083508185e-05
3.0,532.0,499.0,0.005639,0.005639,6.278521,0.49457,1.0,532.0,7.0,71.0,Withdrawal by Subject,Intensification Period (Week 26-38),FG000,diabetes type 2,INDUSTRY,0.01751004,0.017578093661726253,6.805366172625213e-05
2.0,532.0,499.0,0.003759,0.003759,6.278521,0.49457,1.0,532.0,7.0,71.0,Withdrawal by Subject,Intensification Period (Week 26-38),FG001,diabetes type 2,INDUSTRY,0.01167233,0.011627530049801584,4.479995019841636e-05
5.0,601.0,579.0,0.008319,0.008319,6.400257,0.422249,1.0,601.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02248209,0.021746333925287704,0.000735756074712296
9.0,601.0,579.0,0.014975,0.014975,6.400257,0.422249,1.0,601.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04046993,0.039451021873035716,0.0010189081269642852
4.0,601.0,579.0,0.006656,0.006656,6.400257,0.422249,1.0,601.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01798784,0.01746176100030573,0.0005260789996942711
1.0,601.0,579.0,0.001664,0.001664,6.400257,0.422249,1.0,601.0,1.0,43.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00449696,0.004520863811964284,2.39038119642836e-05
0.0,601.0,579.0,0.0,0.0,6.400257,0.422249,1.0,601.0,1.0,43.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,601.0,579.0,0.001664,0.001664,6.400257,0.422249,1.0,601.0,1.0,43.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00449696,0.004518502007103172,2.1542007103171612e-05
0.0,601.0,579.0,0.0,0.0,6.400257,0.422249,1.0,601.0,1.0,43.0,Missing follow-up information,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,601.0,579.0,0.001664,0.001664,6.400257,0.422249,1.0,601.0,1.0,43.0,Missing follow-up information,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00449696,0.004517885543561504,2.092554356150373e-05
1.0,601.0,579.0,0.001664,0.001664,6.400257,0.422249,1.0,601.0,1.0,43.0,Missing follow-up information,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00449696,0.004518963351686505,2.2003351686505045e-05
17.0,517.0,469.0,0.032882,0.032882,6.249975,0.464417,1.0,517.0,10.0,110.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09544315,0.09405407213166668,0.0013890778683333244
4.0,517.0,469.0,0.007737,0.007737,6.249975,0.464417,1.0,517.0,10.0,110.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02245738,0.02243878975416664,1.8590245833359498e-05
9.0,517.0,469.0,0.017408,0.017408,6.249975,0.464417,1.0,517.0,10.0,110.0,Participant did not wish to continue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05052839,0.051504873618768945,0.000976483618768946
4.0,517.0,469.0,0.007737,0.007737,6.249975,0.464417,1.0,517.0,10.0,110.0,Participant did not wish to continue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02245738,0.022410612655297594,4.676734470240515e-05
0.0,517.0,469.0,0.0,0.0,6.249975,0.464417,1.0,517.0,10.0,110.0,Poor compliance to study protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,517.0,469.0,0.003868,0.003868,6.249975,0.464417,1.0,517.0,10.0,110.0,Poor compliance to study protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01122724,0.011221107072503646,6.132927496352997e-06
0.0,517.0,469.0,0.0,0.0,6.249975,0.464417,1.0,517.0,10.0,110.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,517.0,469.0,0.001934,0.001934,6.249975,0.464417,1.0,517.0,10.0,110.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00561362,0.005597851281502528,1.5768718497471794e-05
1.0,517.0,469.0,0.001934,0.001934,6.249975,0.464417,1.0,517.0,10.0,110.0,Randomized but not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00561362,0.005607650139523814,5.96986047618573e-06
2.0,517.0,469.0,0.003868,0.003868,6.249975,0.464417,1.0,517.0,10.0,110.0,Randomized but not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01122724,0.011218703470003649,8.536529996350586e-06
6.0,517.0,469.0,0.011605,0.011605,6.249975,0.464417,1.0,517.0,10.0,110.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03368462,0.0342768101289683,0.0005921901289683007
2.0,517.0,469.0,0.003868,0.003868,6.249975,0.464417,1.0,517.0,10.0,110.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01122724,0.011221107072503646,6.132927496352997e-06
169.0,5380.0,4764.0,0.031413,0.031413,8.59063,0.332945,1.0,5380.0,50.0,908.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08984771,0.09074753422068456,0.0008998242206845614
150.0,5380.0,4764.0,0.027881,0.027881,8.59063,0.332945,1.0,5380.0,50.0,908.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07974546,0.08108543040651782,0.0013399704065178153
0.0,5380.0,4764.0,0.0,0.0,8.59063,0.332945,1.0,5380.0,50.0,908.0,Major Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,1.9333750000000002e-07,1.9333750000000002e-07
1.0,5380.0,4764.0,0.000186,0.000186,8.59063,0.332945,1.0,5380.0,50.0,908.0,Major Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.000532,0.0005478320045436512,1.5832004543651175e-05
19.0,5380.0,4764.0,0.003532,0.003532,8.59063,0.332945,1.0,5380.0,50.0,908.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01010225,0.010348186775863098,0.00024593677586309814
11.0,5380.0,4764.0,0.002045,0.002045,8.59063,0.332945,1.0,5380.0,50.0,908.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00584913,0.005797295582251977,5.183441774802341e-05
104.0,5380.0,4764.0,0.019331,0.019331,8.59063,0.332945,1.0,5380.0,50.0,908.0,Voluntary Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05529068,0.05405695307782734,0.0012337269221726621
101.0,5380.0,4764.0,0.018773,0.018773,8.59063,0.332945,1.0,5380.0,50.0,908.0,Voluntary Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05369468,0.05259507100008924,0.0010996089999107603
0.0,5380.0,4764.0,0.0,0.0,8.59063,0.332945,1.0,5380.0,50.0,908.0,Investigator Discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,1.9333750000000002e-07,1.9333750000000002e-07
1.0,5380.0,4764.0,0.000186,0.000186,8.59063,0.332945,1.0,5380.0,50.0,908.0,Investigator Discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.000532,0.0005478320045436512,1.5832004543651175e-05
26.0,5380.0,4764.0,0.004833,0.004833,8.59063,0.332945,1.0,5380.0,50.0,908.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01382338,0.013595747442916653,0.00022763255708334665
34.0,5380.0,4764.0,0.00632,0.00632,8.59063,0.332945,1.0,5380.0,50.0,908.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01807651,0.01778809820668649,0.00028841179331351094
2.0,388.0,368.0,0.005155,0.005155,5.963579,0.390249,1.0,388.0,3.0,31.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01199712,0.011980668436309563,1.6451563690437e-05
3.0,388.0,368.0,0.007732,0.007732,5.963579,0.390249,1.0,388.0,3.0,31.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01799452,0.018188585653482154,0.00019406565348215402
2.0,388.0,368.0,0.005155,0.005155,5.963579,0.390249,1.0,388.0,3.0,31.0,Protocol required discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01199712,0.011979470348809562,1.7649651190438168e-05
1.0,388.0,368.0,0.002577,0.002577,5.963579,0.390249,1.0,388.0,3.0,31.0,Protocol required discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0059974,0.00603149879175596,3.409879175596004e-05
5.0,388.0,368.0,0.012887,0.012887,5.963579,0.390249,1.0,388.0,3.0,31.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02999165,0.030005573888065466,1.3923888065463935e-05
5.0,388.0,368.0,0.012887,0.012887,5.963579,0.390249,1.0,388.0,3.0,31.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02999165,0.02999540974247024,3.759742470237082e-06
1.0,388.0,368.0,0.002577,0.002577,5.963579,0.390249,1.0,388.0,3.0,31.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0059974,0.006046586243601195,4.918624360119531e-05
0.0,388.0,368.0,0.0,0.0,5.963579,0.390249,1.0,388.0,3.0,31.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,388.0,368.0,0.0,0.0,5.963579,0.390249,1.0,388.0,3.0,31.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,388.0,368.0,0.002577,0.002577,5.963579,0.390249,1.0,388.0,3.0,31.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0059974,0.006024538834672628,2.7138834672628225e-05
34.0,2487.0,1723.0,0.013671,0.013671,7.819234,0.235372,1.0,2487.0,1.0,6.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02516049,0.025148589875783726,1.1900124216274871e-05
21.0,2487.0,1723.0,0.008444,0.008444,7.819234,0.235372,1.0,2487.0,1.0,6.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01554057,0.015455302881438492,8.526711856150782e-05
67.0,2487.0,1723.0,0.02694,0.02694,7.819234,0.235372,1.0,2487.0,1.0,6.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04958112,0.0488128304567163,0.0007682895432837011
132.0,2487.0,1723.0,0.053076,0.053076,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09768254,0.09441159280006936,0.0032709471999306378
44.0,2487.0,1723.0,0.017692,0.017692,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03256085,0.03227370295221228,0.0002871470477877197
78.0,2487.0,1723.0,0.031363,0.031363,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05772133,0.05806611291443448,0.00034478291443448134
151.0,2487.0,1723.0,0.060716,0.060716,7.819234,0.235372,1.0,2487.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11174341,0.1068111903703571,0.004932219629642895
40.0,2487.0,1723.0,0.016084,0.016084,7.819234,0.235372,1.0,2487.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02960144,0.029053699496418662,0.0005477405035813378
83.0,2487.0,1723.0,0.033374,0.033374,7.819234,0.235372,1.0,2487.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06142243,0.06028109299845234,0.001141337001547657
31.0,2487.0,1723.0,0.012465,0.012465,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02294093,0.02319376519842261,0.00025283519842261154
1.0,2487.0,1723.0,0.000402,0.000402,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00073985,0.0007394069627380966,4.430372619034515e-07
3.0,2487.0,1723.0,0.001206,0.001206,7.819234,0.235372,1.0,2487.0,1.0,6.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00221956,0.0021771742591269886,4.238574087301163e-05
0.0,2487.0,1723.0,0.0,0.0,7.819234,0.235372,1.0,2487.0,1.0,6.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2487.0,1723.0,0.000402,0.000402,7.819234,0.235372,1.0,2487.0,1.0,6.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00073985,0.0007401777127380965,3.277127380964598e-07
2.0,2487.0,1723.0,0.000804,0.000804,7.819234,0.235372,1.0,2487.0,1.0,6.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0014797,0.001434944243690477,4.4755756309523094e-05
4.0,2487.0,1723.0,0.001608,0.001608,7.819234,0.235372,1.0,2487.0,1.0,6.0,non compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00295941,0.002923016391587302,3.639360841269784e-05
0.0,2487.0,1723.0,0.0,0.0,7.819234,0.235372,1.0,2487.0,1.0,6.0,non compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,2487.0,1723.0,0.004423,0.004423,7.819234,0.235372,1.0,2487.0,1.0,6.0,non compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00814021,0.007991514678789679,0.00014869532121032127
8.0,2487.0,1723.0,0.003217,0.003217,7.819234,0.235372,1.0,2487.0,1.0,6.0,Requirement for restricted medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00592066,0.005915801638841989,4.858361158011429e-06
7.0,2487.0,1723.0,0.002815,0.002815,7.819234,0.235372,1.0,2487.0,1.0,6.0,Requirement for restricted medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0051808,0.00510726713452381,7.353286547619013e-05
5.0,2487.0,1723.0,0.00201,0.00201,7.819234,0.235372,1.0,2487.0,1.0,6.0,Requirement for restricted medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00369926,0.00362447786283196,7.478213716803975e-05
18.0,2487.0,1723.0,0.007238,0.007238,7.819234,0.235372,1.0,2487.0,1.0,6.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01332102,0.013322224898611101,1.2048986111016374e-06
10.0,2487.0,1723.0,0.004021,0.004021,7.819234,0.235372,1.0,2487.0,1.0,6.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00740036,0.007397341827698411,3.01817230158926e-06
13.0,2487.0,1723.0,0.005227,0.005227,7.819234,0.235372,1.0,2487.0,1.0,6.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00961992,0.009372418806875005,0.00024750119312499583
4.0,222.0,197.0,0.018018,0.018018,5.407172,0.292333,1.0,222.0,4.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02848096,0.02850971986559521,2.875986559520982e-05
3.0,222.0,197.0,0.013514,0.013514,5.407172,0.292333,1.0,222.0,4.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02136151,0.02156504917004964,0.00020353917004964014
5.0,222.0,197.0,0.022523,0.022523,5.407172,0.292333,1.0,222.0,4.0,45.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.035602,0.03599629697794643,0.00039429697794642754
7.0,222.0,197.0,0.031532,0.031532,5.407172,0.292333,1.0,222.0,4.0,45.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04984248,0.050651589905238076,0.0008091099052380743
3.0,222.0,197.0,0.013514,0.013514,5.407172,0.292333,1.0,222.0,4.0,45.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02136151,0.021453855245009944,9.234524500994351e-05
3.0,222.0,197.0,0.013514,0.013514,5.407172,0.292333,1.0,222.0,4.0,45.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02136151,0.021606946252430596,0.00024543625243059544
2.0,1428.0,1304.0,0.001401,0.001401,7.26473,0.753374,1.0,1428.0,16.0,135.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00766776,0.0076535830786309145,1.4176921369085486e-05
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00383114,0.0038401383447023625,8.998344702362653e-06
2.0,1428.0,1304.0,0.001401,0.001401,7.26473,0.753374,1.0,1428.0,16.0,135.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00766776,0.007656215855714251,1.1544144285748764e-05
4.0,1428.0,1304.0,0.002801,0.002801,7.26473,0.753374,1.0,1428.0,16.0,135.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01533004,0.015032613404205468,0.0002974265957945317
3.0,1428.0,1304.0,0.002101,0.002101,7.26473,0.753374,1.0,1428.0,16.0,135.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0114989,0.011525152830505956,2.6252830505956587e-05
3.0,1428.0,1304.0,0.002101,0.002101,7.26473,0.753374,1.0,1428.0,16.0,135.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0114989,0.01146487910747023,3.402089252976977e-05
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00383114,0.0038243116405952144,6.828359404785402e-06
11.0,1428.0,1304.0,0.007703,0.007703,7.26473,0.753374,1.0,1428.0,16.0,135.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04215898,0.042541762232470234,0.0003827822324702357
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00383114,0.0038368063472618854,5.666347261885571e-06
2.0,1428.0,1304.0,0.001401,0.001401,7.26473,0.753374,1.0,1428.0,16.0,135.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00766776,0.007670514583273781,2.754583273780614e-06
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00383114,0.003829972695595213,1.1673044047868023e-06
6.0,1428.0,1304.0,0.004202,0.004202,7.26473,0.753374,1.0,1428.0,16.0,135.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0229978,0.021650021039196443,0.0013477789608035556
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00383114,0.003831250723928552,1.1072392855230109e-07
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1428.0,1304.0,0.001401,0.001401,7.26473,0.753374,1.0,1428.0,16.0,135.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00766776,0.007652356692499968,1.5403307500032153e-05
5.0,1428.0,1304.0,0.003501,0.003501,7.26473,0.753374,1.0,1428.0,16.0,135.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01916118,0.01861742870702831,0.0005437512929716906
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00383114,0.003839715853928552,8.57585392855225e-06
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1428.0,1304.0,0.002801,0.002801,7.26473,0.753374,1.0,1428.0,16.0,135.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01533004,0.01506934365643761,0.00026069634356238984
4.0,1428.0,1304.0,0.002801,0.002801,7.26473,0.753374,1.0,1428.0,16.0,135.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01533004,0.015098577171378086,0.00023146282862191413
4.0,1428.0,1304.0,0.002801,0.002801,7.26473,0.753374,1.0,1428.0,16.0,135.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01533004,0.01508117741584237,0.00024886258415762925
58.0,1428.0,1304.0,0.040616,0.040616,7.26473,0.753374,1.0,1428.0,16.0,135.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.22229379,0.237255028139017,0.014961238139017008
2.0,1428.0,1304.0,0.001401,0.001401,7.26473,0.753374,1.0,1428.0,16.0,135.0,Missed study visits,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00766776,0.007653348659166631,1.4411340833369105e-05
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Missed study visits,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Missed study visits,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1428.0,1304.0,0.002101,0.002101,7.26473,0.753374,1.0,1428.0,16.0,135.0,Missed study visits,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0114989,0.0114596504603869,3.924953961309888e-05
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Sponsor's decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Sponsor's decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Sponsor's decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00383114,0.0038320081180952125,8.681180952126513e-07
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Sponsor's decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00383114,0.003827722912261881,3.41708773811877e-06
1.0,1428.0,1304.0,0.0007,0.0007,7.26473,0.753374,1.0,1428.0,16.0,135.0,Safety reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00383114,0.003839715853928552,8.57585392855225e-06
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Safety reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Safety reasons,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1428.0,1304.0,0.0,0.0,7.26473,0.753374,1.0,1428.0,16.0,135.0,Safety reasons,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,870.0,848.0,0.011494,0.011494,6.769642,0.287447,1.0,870.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02236636,0.022356141668363118,1.021833163688049e-05
4.0,870.0,848.0,0.004598,0.004598,6.769642,0.287447,1.0,870.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00894732,0.008916245428105148,3.1074571894851646e-05
5.0,870.0,848.0,0.005747,0.005747,6.769642,0.287447,1.0,870.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01118318,0.011136563652529756,4.6616347470242875e-05
1.0,870.0,848.0,0.001149,0.001149,6.769642,0.287447,1.0,870.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00223586,0.0022694359463293623,3.357594632936219e-05
2.0,870.0,848.0,0.002299,0.002299,6.769642,0.287447,1.0,870.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00447366,0.004497977895634921,2.4317895634920657e-05
0.0,870.0,848.0,0.0,0.0,6.769642,0.287447,1.0,870.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,912.0,791.0,0.013158,0.013158,6.816736,0.275882,1.0,912.0,21.0,108.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02474513,0.025136101290873025,0.00039097129087302396
25.0,912.0,791.0,0.027412,0.027412,6.816736,0.275882,1.0,912.0,21.0,108.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05155141,0.05140946534794644,0.00014194465205356194
1.0,912.0,791.0,0.001096,0.001096,6.816736,0.275882,1.0,912.0,21.0,108.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00206115,0.002110705258273805,4.955525827380529e-05
0.0,912.0,791.0,0.0,0.0,6.816736,0.275882,1.0,912.0,21.0,108.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,912.0,791.0,0.002193,0.002193,6.816736,0.275882,1.0,912.0,21.0,108.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00412419,0.00430115302970238,0.0001769630297023799
6.0,912.0,791.0,0.006579,0.006579,6.816736,0.275882,1.0,912.0,21.0,108.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01237256,0.012385140509536438,1.2580509536438966e-05
17.0,912.0,791.0,0.01864,0.01864,6.816736,0.275882,1.0,912.0,21.0,108.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03505466,0.03493549939921625,0.00011916060078374924
5.0,912.0,791.0,0.005482,0.005482,6.816736,0.275882,1.0,912.0,21.0,108.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01030953,0.010318302942579344,8.772942579343343e-06
8.0,912.0,791.0,0.008772,0.008772,6.816736,0.275882,1.0,912.0,21.0,108.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01649675,0.01646173381424603,3.501618575397006e-05
18.0,912.0,791.0,0.019737,0.019737,6.816736,0.275882,1.0,912.0,21.0,108.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03711769,0.03718919594259919,7.150594259918569e-05
13.0,912.0,791.0,0.014254,0.014254,6.816736,0.275882,1.0,912.0,21.0,108.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02680628,0.026825075473938486,1.8795473938487683e-05
5.0,912.0,791.0,0.005482,0.005482,6.816736,0.275882,1.0,912.0,21.0,108.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01030953,0.010320878215496012,1.1348215496011227e-05
1.0,912.0,791.0,0.001096,0.001096,6.816736,0.275882,1.0,912.0,21.0,108.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00206115,0.002116775554791663,5.562555479166325e-05
0.0,912.0,791.0,0.0,0.0,6.816736,0.275882,1.0,912.0,21.0,108.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,912.0,791.0,0.007675,0.007675,6.816736,0.275882,1.0,912.0,21.0,108.0,Loss Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01443372,0.014471177162103168,3.7457162103167116e-05
1.0,912.0,791.0,0.001096,0.001096,6.816736,0.275882,1.0,912.0,21.0,108.0,Loss Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00206115,0.002116441000466266,5.5291000466266196e-05
0.0,312.0,296.0,0.0,0.0,5.746203,0.496688,1.0,312.0,4.0,56.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,312.0,296.0,0.003205,0.003205,5.746203,0.496688,1.0,312.0,4.0,56.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00914729,0.009145817625357155,1.4723746428451506e-06
1.0,312.0,296.0,0.003205,0.003205,5.746203,0.496688,1.0,312.0,4.0,56.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00914729,0.009154059183154773,6.769183154772818e-06
4.0,312.0,296.0,0.012821,0.012821,5.746203,0.496688,1.0,312.0,4.0,56.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03659201,0.0364546397255655,0.00013737027443450067
2.0,312.0,296.0,0.00641,0.00641,5.746203,0.496688,1.0,312.0,4.0,56.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01829458,0.018314617295676402,2.0037295676400557e-05
2.0,312.0,296.0,0.00641,0.00641,5.746203,0.496688,1.0,312.0,4.0,56.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01829458,0.01832023859052488,2.5658590524880315e-05
1.0,312.0,296.0,0.003205,0.003205,5.746203,0.496688,1.0,312.0,4.0,56.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00914729,0.009148389602857155,1.0996028571540195e-06
3.0,312.0,296.0,0.009615,0.009615,5.746203,0.496688,1.0,312.0,4.0,56.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02744187,0.027496911861875015,5.504186187501453e-05
0.0,312.0,296.0,0.0,0.0,5.746203,0.496688,1.0,312.0,4.0,56.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,312.0,296.0,0.003205,0.003205,5.746203,0.496688,1.0,312.0,4.0,56.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00914729,0.00913468402494049,1.2605975059511165e-05
1.0,312.0,296.0,0.003205,0.003205,5.746203,0.496688,1.0,312.0,4.0,56.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00914729,0.009141962857857155,5.32714214284552e-06
0.0,312.0,296.0,0.0,0.0,5.746203,0.496688,1.0,312.0,4.0,56.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,821.0,787.0,0.004872,0.004872,6.71174,0.503334,1.0,822.0,12.0,106.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01645883,0.016393061077428252,6.576892257174893e-05
10.0,821.0,787.0,0.01218,0.01218,6.71174,0.503334,1.0,822.0,12.0,106.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04114708,0.04070606037720236,0.0004410196227976407
7.0,821.0,787.0,0.008526,0.008526,6.71174,0.503334,1.0,822.0,12.0,106.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02880296,0.02842102156319443,0.0003819384368055692
12.0,821.0,787.0,0.014616,0.014616,6.71174,0.503334,1.0,822.0,12.0,106.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0493765,0.04817107057720242,0.0012054294227975756
0.0,821.0,787.0,0.0,0.0,6.71174,0.503334,1.0,822.0,12.0,106.0,Died,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,821.0,787.0,0.001218,0.001218,6.71174,0.503334,1.0,822.0,12.0,106.0,Died,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00411471,0.004139656398154753,2.4946398154753607e-05
0.0,703.0,663.0,0.0,0.0,6.556778,0.492695,1.0,703.0,11.0,105.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,703.0,663.0,0.007112,0.007112,6.556778,0.492695,1.0,703.0,11.0,105.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02297526,0.022997478189613143,2.2218189613142092e-05
5.0,703.0,663.0,0.007112,0.007112,6.556778,0.492695,1.0,703.0,11.0,105.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02297526,0.023012385835029816,3.712583502981509e-05
4.0,703.0,663.0,0.00569,0.00569,6.556778,0.492695,1.0,703.0,11.0,105.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0183815,0.01853158163171537,0.0001500816317153708
5.0,703.0,663.0,0.007112,0.007112,6.556778,0.492695,1.0,703.0,11.0,105.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02297526,0.022972820039851224,2.439960148776371e-06
7.0,703.0,663.0,0.009957,0.009957,6.556778,0.492695,1.0,703.0,11.0,105.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03216602,0.03221731482172619,5.129482172619437e-05
5.0,703.0,663.0,0.007112,0.007112,6.556778,0.492695,1.0,703.0,11.0,105.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02297526,0.02300688830366077,3.1628303660768964e-05
2.0,703.0,663.0,0.002845,0.002845,6.556778,0.492695,1.0,703.0,11.0,105.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00919075,0.009200538117708353,9.788117708353639e-06
0.0,703.0,663.0,0.0,0.0,6.556778,0.492695,1.0,703.0,11.0,105.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,703.0,663.0,0.0,0.0,6.556778,0.492695,1.0,703.0,11.0,105.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,703.0,663.0,0.001422,0.001422,6.556778,0.492695,1.0,703.0,11.0,105.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00459376,0.004623326987182517,2.9566987182517122e-05
0.0,703.0,663.0,0.0,0.0,6.556778,0.492695,1.0,703.0,11.0,105.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,703.0,663.0,0.001422,0.001422,6.556778,0.492695,1.0,703.0,11.0,105.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00459376,0.004617847164315453,2.4087164315453498e-05
2.0,703.0,663.0,0.002845,0.002845,6.556778,0.492695,1.0,703.0,11.0,105.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00919075,0.009194587342470258,3.83734247025834e-06
1.0,703.0,663.0,0.001422,0.001422,6.556778,0.492695,1.0,703.0,11.0,105.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00459376,0.004623098383343232,2.9338383343232438e-05
2.0,703.0,663.0,0.002845,0.002845,6.556778,0.492695,1.0,703.0,11.0,105.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00919075,0.009193834645208355,3.084645208355913e-06
3.0,605.0,569.0,0.004959,0.004959,6.40688,0.393038,1.0,819.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01248748,0.012381138431458322,0.0001063415685416784
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.004162460074007912,2.992599208717639e-08
0.0,605.0,569.0,0.0,0.0,6.40688,0.393038,1.0,819.0,0.0,0.0,"Adverse Event, prior to treatment",Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,"Adverse Event, prior to treatment",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.004162460074007912,2.992599208717639e-08
0.0,605.0,569.0,0.0,0.0,6.40688,0.393038,1.0,819.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.004162645011507913,1.5501150791349255e-07
0.0,605.0,569.0,0.0,0.0,6.40688,0.393038,1.0,819.0,0.0,0.0,"Death, prior to treatment",Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,"Death, prior to treatment",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.004162460074007912,2.992599208717639e-08
8.0,605.0,569.0,0.013223,0.013223,6.40688,0.393038,1.0,819.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03329744,0.0336909044471925,0.0003934644471925014
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.004179525503382914,1.703550338291466e-05
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00416249,0.004165746767757913,3.2567677579137602e-06
0.0,605.0,569.0,0.0,0.0,6.40688,0.393038,1.0,819.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,605.0,569.0,0.009917,0.009917,6.40688,0.393038,1.0,819.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02497245,0.024681561238363074,0.0002908887616369267
1.0,605.0,569.0,0.001653,0.001653,6.40688,0.393038,1.0,819.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00416249,0.0041632475427579125,7.575427579129337e-07
6.0,605.0,569.0,0.009917,0.009917,6.40688,0.393038,1.0,819.0,0.0,0.0,Reason not provided,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02497245,0.024695826516101173,0.0002766234838988274
6.0,605.0,569.0,0.009917,0.009917,6.40688,0.393038,1.0,819.0,0.0,0.0,Reason not provided,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02497245,0.024693413432976173,0.00027903656702382706
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.01399739,0.01400071950675603,3.3295067560293323e-06
3.0,222.0,135.0,0.013514,0.013514,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.04198907,0.043603715307152735,0.0016146453071527317
2.0,222.0,135.0,0.009009,0.009009,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.02799168,0.027992863224345226,1.183224345224776e-06
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.01399739,0.014000999805922693,3.6098059226930684e-06
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.01399739,0.014007512510148874,1.0122510148874095e-05
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.01399739,0.014001880224256025,4.490224256024564e-06
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.01399739,0.014002448985089358,5.058985089357801e-06
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Randomized but not treated,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Randomized but not treated,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,222.0,135.0,0.009009,0.009009,5.407172,0.574622,1.0,223.0,0.0,0.0,Randomized but not treated,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.02799168,0.028038270929285708,4.6590929285706545e-05
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Randomized but not treated,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.01399739,0.014007936033898877,1.0546033898876928e-05
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.01399739,0.014006553608065544,9.16360806554363e-06
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.01399739,0.01400272551050603,5.335510506030219e-06
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Consent withdrawn by Parent/Guardian,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,222.0,135.0,0.009009,0.009009,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.02799168,0.027969627344404738,2.2052655595263676e-05
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.01399739,0.01400734876556554,9.958765565540664e-06
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.01399739,0.014004182501339361,6.792501339360907e-06
2.0,222.0,135.0,0.009009,0.009009,5.407172,0.574622,1.0,223.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.02799168,0.027985458705238067,6.2212947619343095e-06
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,222.0,135.0,0.0,0.0,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,135.0,0.004505,0.004505,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.01399739,0.014005062919672693,7.672919672692402e-06
2.0,222.0,135.0,0.009009,0.009009,5.407172,0.574622,1.0,223.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.02799168,0.028007201482916647,1.5521482916645152e-05
10.0,1056.0,984.0,0.00947,0.00947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Adverse Event,Maintenance Period (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.01382961,0.013894204029583327,6.459402958332652e-05
12.0,1056.0,984.0,0.011364,0.011364,6.96319,0.209726,1.0,1056.0,3.0,3.0,Adverse Event,Maintenance Period (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.01659553,0.01641204282614088,0.00018348717385912108
0.0,1056.0,984.0,0.0,0.0,6.96319,0.209726,1.0,1056.0,3.0,3.0,Physician Decision,Maintenance Period (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1056.0,984.0,0.001894,0.001894,6.96319,0.209726,1.0,1056.0,3.0,3.0,Physician Decision,Maintenance Period (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.00276592,0.002803567808333332,3.7647808333332155e-05
8.0,1056.0,984.0,0.007576,0.007576,6.96319,0.209726,1.0,1056.0,3.0,3.0,Withdrawal by Subject,Maintenance Period (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.01106368,0.011015725080257936,4.795491974206312e-05
11.0,1056.0,984.0,0.010417,0.010417,6.96319,0.209726,1.0,1056.0,3.0,3.0,Withdrawal by Subject,Maintenance Period (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.01521257,0.015434281824206347,0.0002217118242063467
5.0,1056.0,984.0,0.004735,0.004735,6.96319,0.209726,1.0,1056.0,3.0,3.0,Lost to Follow-up,Maintenance Period (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.0069148,0.007008766866378967,9.396686637896771e-05
4.0,1056.0,984.0,0.003788,0.003788,6.96319,0.209726,1.0,1056.0,3.0,3.0,Lost to Follow-up,Maintenance Period (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.00553184,0.005582140994613088,5.030099461308859e-05
1.0,1056.0,984.0,0.000947,0.000947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Other,Maintenance Period (26 Weeks),FG000,diabetes type 2,INDUSTRY,0.00138296,0.0013942347915476185,1.1274791547618603e-05
1.0,1056.0,984.0,0.000947,0.000947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Other,Maintenance Period (26 Weeks),FG001,diabetes type 2,INDUSTRY,0.00138296,0.0013935785198809511,1.0618519880951222e-05
3.0,1056.0,984.0,0.002841,0.002841,6.96319,0.209726,1.0,1056.0,3.0,3.0,Adverse Event,Washout Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00414888,0.004197032712188848,4.815271218884792e-05
6.0,1056.0,984.0,0.005682,0.005682,6.96319,0.209726,1.0,1056.0,3.0,3.0,Adverse Event,Washout Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00829776,0.008491874645386905,0.00019411464538690582
2.0,1056.0,984.0,0.001894,0.001894,6.96319,0.209726,1.0,1056.0,3.0,3.0,Withdrawal by Subject,Washout Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00276592,0.002804224638749999,3.830463874999936e-05
4.0,1056.0,984.0,0.003788,0.003788,6.96319,0.209726,1.0,1056.0,3.0,3.0,Withdrawal by Subject,Washout Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00553184,0.005574310863363089,4.2470863363089535e-05
0.0,1056.0,984.0,0.0,0.0,6.96319,0.209726,1.0,1056.0,3.0,3.0,Lost to Follow-up,Washout Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1056.0,984.0,0.000947,0.000947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Lost to Follow-up,Washout Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00138296,0.0013939719271726181,1.1011927172618202e-05
1.0,1056.0,984.0,0.000947,0.000947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Other,Washout Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00138296,0.0013929899036309518,1.0029903630951907e-05
1.0,1056.0,984.0,0.000947,0.000947,6.96319,0.209726,1.0,1056.0,3.0,3.0,Other,Washout Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00138296,0.0013923072944642843,9.34729446428438e-06
44.0,803.0,526.0,0.054795,0.054795,6.689599,0.235372,1.0,803.0,1.0,86.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0862771,0.08619601624698404,8.108375301595083e-05
87.0,803.0,526.0,0.108344,0.108344,6.689599,0.235372,1.0,803.0,1.0,86.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.17059233,0.1681263515426732,0.002465978457326795
13.0,803.0,526.0,0.016189,0.016189,6.689599,0.235372,1.0,803.0,1.0,86.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02549028,0.02501674280426588,0.00047353719573411945
16.0,803.0,526.0,0.019925,0.019925,6.689599,0.235372,1.0,803.0,1.0,86.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03137278,0.03138200936530755,9.229365307547588e-06
25.0,803.0,526.0,0.031133,0.031133,6.689599,0.235372,1.0,803.0,1.0,86.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04902026,0.04901775199218259,2.5080078174116727e-06
20.0,803.0,526.0,0.024907,0.024907,6.689599,0.235372,1.0,803.0,1.0,86.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03921715,0.039330852698174615,0.00011370269817461559
6.0,803.0,526.0,0.007472,0.007472,6.689599,0.235372,1.0,803.0,1.0,86.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01176499,0.011759706458263892,5.283541736107386e-06
2.0,803.0,526.0,0.002491,0.002491,6.689599,0.235372,1.0,803.0,1.0,86.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00392219,0.003925646346557537,3.4563465575367797e-06
25.0,803.0,526.0,0.031133,0.031133,6.689599,0.235372,1.0,803.0,1.0,86.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04902026,0.04890177783134926,0.00011848216865074229
20.0,803.0,526.0,0.024907,0.024907,6.689599,0.235372,1.0,803.0,1.0,86.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03921715,0.03932073477053574,0.00010358477053574316
6.0,803.0,526.0,0.007472,0.007472,6.689599,0.235372,1.0,803.0,1.0,86.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01176499,0.011752695385763892,1.2294614236107657e-05
8.0,803.0,526.0,0.009963,0.009963,6.689599,0.235372,1.0,803.0,1.0,86.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01568718,0.015732591995625003,4.5411995625004725e-05
2.0,803.0,526.0,0.002491,0.002491,6.689599,0.235372,1.0,803.0,1.0,86.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00392219,0.003926574881557537,4.384881557537544e-06
3.0,803.0,526.0,0.003736,0.003736,6.689599,0.235372,1.0,803.0,1.0,86.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00588249,0.0058913659500000005,8.875950000000743e-06
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00279225,0.002791232565833345,1.0174341666551769e-06
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00279225,0.002791921003333345,3.2899666665498276e-07
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Treatment Complications,Enrolled - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,576.0,508.0,0.015625,0.015625,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.02513185,0.024715767603343246,0.00041608239665675423
3.0,576.0,508.0,0.005208,0.005208,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.00837675,0.008325386013194458,5.1363986805542244e-05
4.0,576.0,508.0,0.006944,0.006944,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.01116899,0.011113700326190454,5.5289673809546386e-05
3.0,576.0,508.0,0.005208,0.005208,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.00837675,0.00834528204602184,3.1467953978160657e-05
4.0,576.0,508.0,0.006944,0.006944,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.01116899,0.011112483249523788,5.6506750476211995e-05
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0055845,0.005589366712976218,4.866712976218067e-06
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00279225,0.0027921476920833473,1.0230791665276698e-07
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.00279225,0.00279296481291668,7.148129166799008e-07
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.00279225,0.0027930720129166805,8.220129166804611e-07
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Protocol Violation,Entered - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.0055845,0.0055901283195238325,5.628319523832449e-06
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0055845,0.005584943869523835,4.438695238350235e-07
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0055845,0.005585773385773838,1.2733857738377735e-06
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.00279225,0.002792923978333348,6.739783333480076e-07
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.0055845,0.005586283078690506,1.7830786905063609e-06
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.00279225,0.0027928384658333478,5.884658333477413e-07
5.0,576.0,508.0,0.008681,0.008681,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.01396285,0.013798197081785733,0.00016465291821426802
7.0,576.0,508.0,0.012153,0.012153,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.01954735,0.019679395603436144,0.0001320456034361421
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0055845,0.005586136132500029,1.6361325000293497e-06
3.0,576.0,508.0,0.005208,0.005208,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.00837675,0.008320609975069455,5.614002493054514e-05
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.0055845,0.005585567729583364,1.0677295833637704e-06
2.0,576.0,508.0,0.003472,0.003472,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0055845,0.005586632485833364,2.132485833364166e-06
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.00279225,0.0027931117670833474,8.617670833473666e-07
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.00279225,0.0027930262545833467,7.762545833466666e-07
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,576.0,508.0,0.0,0.0,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,576.0,508.0,0.001736,0.001736,6.357842,0.252985,1.0,576.0,0.0,0.0,Use of Excluded Medications,Entered - Long-Term Extension Study,FG007,diabetes type 2,INDUSTRY,0.00279225,0.0027930262545833467,7.762545833466666e-07
1.0,4401.0,4361.0,0.000227,0.000227,8.389814,0.532337,1.0,4401.0,34.0,575.0,Closed Site,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00101383,0.0010522750274801576,3.844502748015749e-05
1.0,4401.0,4361.0,0.000227,0.000227,8.389814,0.532337,1.0,4401.0,34.0,575.0,Closed Site,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00101383,0.0010556522257242054,4.182222572420534e-05
11.0,4401.0,4361.0,0.002499,0.002499,8.389814,0.532337,1.0,4401.0,34.0,575.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01116105,0.011194919614315487,3.386961431548624e-05
5.0,4401.0,4361.0,0.001136,0.001136,8.389814,0.532337,1.0,4401.0,34.0,575.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00507361,0.005182346080019837,0.00010873608001983701
13.0,4401.0,4361.0,0.002954,0.002954,8.389814,0.532337,1.0,4401.0,34.0,575.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01319317,0.0128872430208135,0.00030592697918650075
9.0,4401.0,4361.0,0.002045,0.002045,8.389814,0.532337,1.0,4401.0,34.0,575.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00913339,0.009285203024107135,0.00015181302410713533
2.0,736.0,691.0,0.002717,0.002717,6.602588,0.39877,1.0,736.0,18.0,236.0,Randomized but not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00715363,0.007244577267338561,9.094726733856109e-05
4.0,736.0,691.0,0.005435,0.005435,6.602588,0.39877,1.0,736.0,18.0,236.0,Randomized but not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0143099,0.014310070676269842,1.7067626984119955e-07
4.0,736.0,691.0,0.005435,0.005435,6.602588,0.39877,1.0,736.0,18.0,236.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0143099,0.014342493974037694,3.2593974037693416e-05
1.0,736.0,691.0,0.001359,0.001359,6.602588,0.39877,1.0,736.0,18.0,236.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00357813,0.0035833322659523698,5.20226595236966e-06
12.0,736.0,691.0,0.016304,0.016304,6.602588,0.39877,1.0,736.0,18.0,236.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04292707,0.04274316393779763,0.00018390606220236583
3.0,736.0,691.0,0.004076,0.004076,6.602588,0.39877,1.0,736.0,18.0,236.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01073177,0.010716565974057542,1.5204025942457816e-05
1.0,736.0,691.0,0.001359,0.001359,6.602588,0.39877,1.0,736.0,18.0,236.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00357813,0.003582826499623005,4.6964996230050744e-06
0.0,736.0,691.0,0.0,0.0,6.602588,0.39877,1.0,736.0,18.0,236.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,736.0,691.0,0.016304,0.016304,6.602588,0.39877,1.0,736.0,18.0,236.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04292707,0.04296364827642857,3.657827642856992e-05
6.0,736.0,691.0,0.008152,0.008152,6.602588,0.39877,1.0,736.0,18.0,236.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02146353,0.02153650059623015,7.297059623014718e-05
3.0,272.0,234.0,0.011029,0.011029,5.609472,0.339489,1.0,272.0,5.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02100314,0.02139916488100734,0.0003960248810073383
2.0,272.0,234.0,0.007353,0.007353,5.609472,0.339489,1.0,272.0,5.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01400273,0.014427455558154747,0.0004247255581547472
18.0,272.0,234.0,0.066176,0.066176,5.609472,0.339489,1.0,272.0,5.0,45.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12602267,0.1258674413457341,0.0001552286542658987
15.0,272.0,234.0,0.055147,0.055147,5.609472,0.339489,1.0,272.0,5.0,45.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10501953,0.10718850637819444,0.002168976378194437
12.0,287.0,229.0,0.041812,0.041812,5.66296,0.222179,1.0,288.0,5.0,102.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05260748,0.05342704050656749,0.0008195605065674932
1.0,287.0,229.0,0.003484,0.003484,5.66296,0.222179,1.0,288.0,5.0,102.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00438354,0.004377121046792044,6.4189532079563655e-06
1.0,287.0,229.0,0.003484,0.003484,5.66296,0.222179,1.0,288.0,5.0,102.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00438354,0.004386162335502362,2.622335502361871e-06
1.0,287.0,229.0,0.003484,0.003484,5.66296,0.222179,1.0,288.0,5.0,102.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00438354,0.00438468771345871,1.1477134587095997e-06
7.0,287.0,229.0,0.02439,0.02439,5.66296,0.222179,1.0,288.0,5.0,102.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03068728,0.031170689496041667,0.0004834094960416667
3.0,287.0,229.0,0.010453,0.010453,5.66296,0.222179,1.0,288.0,5.0,102.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01315187,0.013364624922797615,0.00021275492279761513
6.0,287.0,229.0,0.020906,0.020906,5.66296,0.222179,1.0,288.0,5.0,102.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02630374,0.026459817049811495,0.0001560770498114962
3.0,287.0,229.0,0.010453,0.010453,5.66296,0.222179,1.0,288.0,5.0,102.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01315187,0.013356930114047616,0.0002050601140476168
14.0,287.0,229.0,0.04878,0.04878,5.66296,0.222179,1.0,288.0,5.0,102.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06137456,0.06250513510366071,0.0011305751036607067
10.0,287.0,229.0,0.034843,0.034843,5.66296,0.222179,1.0,288.0,5.0,102.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04383915,0.04459943894136904,0.0007602889413690431
2.0,242.0,222.0,0.008264,0.008264,5.493061,0.235372,1.0,242.0,1.0,65.0,Adverse Event,Period 1,FG000,diabetes type 2,INDUSTRY,0.01068463,0.010673038627083364,1.1591372916636838e-05
1.0,242.0,222.0,0.004132,0.004132,5.493061,0.235372,1.0,242.0,1.0,65.0,Adverse Event,Period 1,FG001,diabetes type 2,INDUSTRY,0.00534231,0.00534742736705359,5.117367053589575e-06
0.0,242.0,222.0,0.0,0.0,5.493061,0.235372,1.0,242.0,1.0,65.0,Lack of Efficacy,Period 1,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,242.0,222.0,0.008264,0.008264,5.493061,0.235372,1.0,242.0,1.0,65.0,Lack of Efficacy,Period 1,FG001,diabetes type 2,INDUSTRY,0.01068463,0.010682742963571462,1.8870364285380331e-06
5.0,242.0,222.0,0.020661,0.020661,5.493061,0.235372,1.0,242.0,1.0,65.0,Unclassified,Period 1,FG000,diabetes type 2,INDUSTRY,0.02671286,0.02762722778931548,0.0009143677893154768
1.0,242.0,222.0,0.004132,0.004132,5.493061,0.235372,1.0,242.0,1.0,65.0,Unclassified,Period 1,FG001,diabetes type 2,INDUSTRY,0.00534231,0.005347733089553589,5.423089553588563e-06
0.0,242.0,222.0,0.0,0.0,5.493061,0.235372,1.0,242.0,1.0,65.0,Adverse Event,Period 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,242.0,222.0,0.004132,0.004132,5.493061,0.235372,1.0,242.0,1.0,65.0,Adverse Event,Period 2,FG001,diabetes type 2,INDUSTRY,0.00534231,0.005347629167053591,5.319167053590736e-06
1.0,242.0,222.0,0.004132,0.004132,5.493061,0.235372,1.0,242.0,1.0,65.0,Lack of Efficacy,Period 2,FG000,diabetes type 2,INDUSTRY,0.00534231,0.005345419160625019,3.1091606250187656e-06
0.0,242.0,222.0,0.0,0.0,5.493061,0.235372,1.0,242.0,1.0,65.0,Lack of Efficacy,Period 2,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,242.0,222.0,0.0,0.0,5.493061,0.235372,1.0,242.0,1.0,65.0,Protocol Violation,Period 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,242.0,222.0,0.012397,0.012397,5.493061,0.235372,1.0,242.0,1.0,65.0,Protocol Violation,Period 2,FG001,diabetes type 2,INDUSTRY,0.01602823,0.016368438145466256,0.0003402081454662552
2.0,242.0,222.0,0.008264,0.008264,5.493061,0.235372,1.0,242.0,1.0,65.0,Unclassified,Period 2,FG000,diabetes type 2,INDUSTRY,0.01068463,0.010686436185000038,1.8061850000378882e-06
2.0,242.0,222.0,0.008264,0.008264,5.493061,0.235372,1.0,242.0,1.0,65.0,Unclassified,Period 2,FG001,diabetes type 2,INDUSTRY,0.01068463,0.0106811250919048,3.5049080952011258e-06
0.0,598.0,518.0,0.0,0.0,6.395262,0.238805,1.0,994.0,7.0,99.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,598.0,518.0,0.001672,0.001672,6.395262,0.238805,1.0,994.0,7.0,99.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00255351,0.0025867078919940517,3.319789199405154e-05
0.0,598.0,518.0,0.0,0.0,6.395262,0.238805,1.0,994.0,7.0,99.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,598.0,518.0,0.0,0.0,6.395262,0.238805,1.0,994.0,7.0,99.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,598.0,518.0,0.001672,0.001672,6.395262,0.238805,1.0,994.0,7.0,99.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00255351,0.002587642135208337,3.41321352083368e-05
0.0,598.0,518.0,0.0,0.0,6.395262,0.238805,1.0,994.0,7.0,99.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,598.0,518.0,0.003344,0.003344,6.395262,0.238805,1.0,994.0,7.0,99.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00510702,0.005461829634484128,0.00035480963448412776
6.0,598.0,518.0,0.010033,0.010033,6.395262,0.238805,1.0,994.0,7.0,99.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01532259,0.015342752028888901,2.0162028888900604e-05
6.0,598.0,518.0,0.010033,0.010033,6.395262,0.238805,1.0,994.0,7.0,99.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01532259,0.015354235394007957,3.1645394007956754e-05
4.0,598.0,518.0,0.006689,0.006689,6.395262,0.238805,1.0,994.0,7.0,99.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01021557,0.010228371353968256,1.2801353968255533e-05
6.0,598.0,518.0,0.010033,0.010033,6.395262,0.238805,1.0,994.0,7.0,99.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01532259,0.015345386331091284,2.2796331091283137e-05
9.0,598.0,518.0,0.01505,0.01505,6.395262,0.238805,1.0,994.0,7.0,99.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02298465,0.02301669384212933,3.204384212933051e-05
8.0,598.0,518.0,0.013378,0.013378,6.395262,0.238805,1.0,994.0,7.0,99.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02043114,0.02080712688879417,0.0003759868887941685
15.0,598.0,518.0,0.025084,0.025084,6.395262,0.238805,1.0,994.0,7.0,99.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03830878,0.038590521553097966,0.0002817415530979653
9.0,598.0,518.0,0.01505,0.01505,6.395262,0.238805,1.0,994.0,7.0,99.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02298465,0.023020356884629323,3.570688462932459e-05
3.0,598.0,518.0,0.005017,0.005017,6.395262,0.238805,1.0,994.0,7.0,99.0,"Non-compl., not met criteria, etc.",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00766206,0.007996214567847222,0.00033415456784722207
4.0,598.0,518.0,0.006689,0.006689,6.395262,0.238805,1.0,994.0,7.0,99.0,"Non-compl., not met criteria, etc.",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01021557,0.01021775844238096,2.188442380960179e-06
6.0,598.0,518.0,0.010033,0.010033,6.395262,0.238805,1.0,994.0,7.0,99.0,"Non-compl., not met criteria, etc.",Overall Study,FG002,diabetes type 2,INDUSTRY,0.01532259,0.015355665589722243,3.307558972224199e-05
7.0,883.0,770.0,0.007928,0.007928,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.02559797,0.025611714122678497,1.3744122678495396e-05
10.0,883.0,770.0,0.011325,0.011325,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.03656622,0.03653465890235112,3.156109764888143e-05
9.0,883.0,770.0,0.010193,0.010193,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.03291121,0.033047522609037705,0.00013631260903770176
10.0,883.0,770.0,0.011325,0.011325,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.03656622,0.036490200725267805,7.601927473219888e-05
4.0,883.0,770.0,0.00453,0.00453,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.01462649,0.014568220962192466,5.826903780753456e-05
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.003659363859206365,1.1238592063649196e-06
2.0,883.0,770.0,0.002265,0.002265,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.00731324,0.007376961526713568,6.372152671356782e-05
0.0,883.0,770.0,0.0,0.0,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.003659405103373033,1.1651033730328102e-06
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.00365824,0.0036588274268254096,5.874268254094615e-07
5.0,883.0,770.0,0.005663,0.005663,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.01828472,0.018422752303706682,0.00013803230370668107
14.0,883.0,770.0,0.015855,0.015855,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.05119271,0.05126860902494038,7.589902494038042e-05
11.0,883.0,770.0,0.012458,0.012458,6.784457,0.475912,1.0,905.0,6.0,110.0,Study-specific discontinuation criteria,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.04022446,0.039372493118373035,0.0008519668816269615
13.0,883.0,770.0,0.014723,0.014723,6.784457,0.475912,1.0,905.0,6.0,110.0,Study-specific discontinuation criteria,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.0475377,0.04786363612144846,0.0003259361214484613
20.0,883.0,770.0,0.02265,0.02265,6.784457,0.475912,1.0,905.0,6.0,110.0,Study-specific discontinuation criteria,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.07313244,0.07404805619692457,0.000915616196924568
6.0,883.0,770.0,0.006795,0.006795,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.02193973,0.021968020429404694,2.829042940469262e-05
6.0,883.0,770.0,0.006795,0.006795,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.02193973,0.02196244111011899,2.2711110118988492e-05
7.0,883.0,770.0,0.007928,0.007928,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.02559797,0.025613381877857076,1.5411877857075124e-05
0.0,883.0,770.0,0.0,0.0,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,1 -Modified Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,1 -Modified Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.00365824,0.0036485235735515984,9.716426448401656e-06
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,1 -Modified Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.0036593829633730333,1.14296337303324e-06
7.0,883.0,770.0,0.007928,0.007928,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.02559797,0.02561894140559516,2.0971405595159726e-05
10.0,883.0,770.0,0.011325,0.011325,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.03656622,0.03657944219008921,1.3222190089208496e-05
9.0,883.0,770.0,0.010193,0.010193,6.784457,0.475912,1.0,905.0,6.0,110.0,Participant decision,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.03291121,0.033076803322371034,0.00016559332237103125
10.0,883.0,770.0,0.011325,0.011325,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.03656622,0.036534984013005894,3.1235986994108955e-05
4.0,883.0,770.0,0.00453,0.00453,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.01462649,0.014568220962192466,5.826903780753456e-05
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Adverse Event,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.0036609253192658895,2.685319265889434e-06
2.0,883.0,770.0,0.002265,0.002265,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.00731324,0.007376961526713568,6.372152671356782e-05
0.0,883.0,770.0,0.0,0.0,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Severe non-compliance to protocol,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.0036609665634325574,2.7265634325573246e-06
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.00365824,0.0036584235493254103,1.835493254102004e-07
5.0,883.0,770.0,0.005663,0.005663,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.01828472,0.018422752303706682,0.00013803230370668107
14.0,883.0,770.0,0.015855,0.015855,6.784457,0.475912,1.0,905.0,6.0,110.0,Lack of therapeutic response,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.05119271,0.051282900888928465,9.01908889284625e-05
14.0,883.0,770.0,0.015855,0.015855,6.784457,0.475912,1.0,905.0,6.0,110.0,Study specific discontinuation criteria,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.05119271,0.051168876068452294,2.383393154770791e-05
15.0,883.0,770.0,0.016988,0.016988,6.784457,0.475912,1.0,905.0,6.0,110.0,Study specific discontinuation criteria,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.05485095,0.054721656346388904,0.00012929365361109835
21.0,883.0,770.0,0.023783,0.023783,6.784457,0.475912,1.0,905.0,6.0,110.0,Study specific discontinuation criteria,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.07679068,0.07644661444667664,0.00034406555332336386
6.0,883.0,770.0,0.006795,0.006795,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.02193973,0.021971596737321367,3.186673732136561e-05
6.0,883.0,770.0,0.006795,0.006795,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.02193973,0.021966017418035663,2.628741803566148e-05
7.0,883.0,770.0,0.007928,0.007928,6.784457,0.475912,1.0,905.0,6.0,110.0,Other,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.02559797,0.02562060916077374,2.2639160773739453e-05
0.0,883.0,770.0,0.0,0.0,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,2 - Enrolled Participants Set,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,2 - Enrolled Participants Set,FG001,diabetes type 2,INDUSTRY,0.00365824,0.0036487167448611235,9.523255138876602e-06
1.0,883.0,770.0,0.001133,0.001133,6.784457,0.475912,1.0,905.0,6.0,110.0,No treatment given,2 - Enrolled Participants Set,FG002,diabetes type 2,INDUSTRY,0.00365824,0.003660973198432558,2.7331984325577006e-06
8.0,922.0,807.0,0.008677,0.008677,6.827629,0.318867,1.0,922.0,9.0,140.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01889075,0.01891339757421625,2.2647574216248106e-05
3.0,922.0,807.0,0.003254,0.003254,6.827629,0.318867,1.0,922.0,9.0,140.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00708431,0.007101249828730161,1.693982873016142e-05
2.0,922.0,807.0,0.002169,0.002169,6.827629,0.318867,1.0,922.0,9.0,140.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00472214,0.004807078249007038,8.493824900703863e-05
10.0,922.0,807.0,0.010846,0.010846,6.827629,0.318867,1.0,922.0,9.0,140.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0236129,0.023653645734890847,4.0745734890847846e-05
12.0,922.0,807.0,0.013015,0.013015,6.827629,0.318867,1.0,922.0,9.0,140.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02833504,0.028539764769613115,0.00020472476961311617
16.0,922.0,807.0,0.017354,0.017354,6.827629,0.318867,1.0,922.0,9.0,140.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03778151,0.03825433034639879,0.0004728203463987904
2.0,922.0,807.0,0.002169,0.002169,6.827629,0.318867,1.0,922.0,9.0,140.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00472214,0.004809137630286801,8.699763028680117e-05
1.0,922.0,807.0,0.001085,0.001085,6.827629,0.318867,1.0,922.0,9.0,140.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00236216,0.0023595087610515895,2.6512389484103192e-06
26.0,922.0,807.0,0.0282,0.0282,6.827629,0.318867,1.0,922.0,9.0,140.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06139441,0.06151232960669646,0.00011791960669645801
17.0,922.0,807.0,0.018438,0.018438,6.827629,0.318867,1.0,922.0,9.0,140.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04014149,0.039794843980307505,0.0003466460196924967
5.0,922.0,807.0,0.005423,0.005423,6.827629,0.318867,1.0,922.0,9.0,140.0,Poor/Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01180645,0.011826391486875006,1.994148687500634e-05
6.0,922.0,807.0,0.006508,0.006508,6.827629,0.318867,1.0,922.0,9.0,140.0,Poor/Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01416861,0.01411319072571428,5.541927428572013e-05
1.0,922.0,807.0,0.001085,0.001085,6.827629,0.318867,1.0,922.0,9.0,140.0,Safety,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00236216,0.0023654356886309543,3.275688630954409e-06
0.0,922.0,807.0,0.0,0.0,6.827629,0.318867,1.0,922.0,9.0,140.0,Safety,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,922.0,807.0,0.001085,0.001085,6.827629,0.318867,1.0,922.0,9.0,140.0,Incorrect Enrolment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00236216,0.0023654356886309543,3.275688630954409e-06
2.0,922.0,807.0,0.002169,0.002169,6.827629,0.318867,1.0,922.0,9.0,140.0,Incorrect Enrolment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00472214,0.004798138531785715,7.599853178571515e-05
0.0,922.0,807.0,0.0,0.0,6.827629,0.318867,1.0,922.0,9.0,140.0,Administrative Reason by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,922.0,807.0,0.001085,0.001085,6.827629,0.318867,1.0,922.0,9.0,140.0,Administrative Reason by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00236216,0.0023615838585515896,5.761414484102383e-07
0.0,922.0,807.0,0.0,0.0,6.827629,0.318867,1.0,922.0,9.0,140.0,Various,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,922.0,807.0,0.002169,0.002169,6.827629,0.318867,1.0,922.0,9.0,140.0,Various,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00472214,0.004798138531785715,7.599853178571515e-05
2.0,443.0,417.0,0.004515,0.004515,6.095825,0.649807,1.0,443.0,1.0,34.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0178844,0.01781340289480158,7.099710519842262e-05
5.0,443.0,417.0,0.011287,0.011287,6.095825,0.649807,1.0,443.0,1.0,34.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04470901,0.04422997221866068,0.00047903778133932123
11.0,443.0,417.0,0.024831,0.024831,6.095825,0.649807,1.0,443.0,1.0,34.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.09835824,0.09634979775329901,0.002008442246700992
1.0,443.0,417.0,0.002257,0.002257,6.095825,0.649807,1.0,443.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00894022,0.009133658412499997,0.0001934384124999966
3.0,443.0,417.0,0.006772,0.006772,6.095825,0.649807,1.0,443.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02682461,0.02698684920053573,0.0001622392005357319
4.0,443.0,417.0,0.009029,0.009029,6.095825,0.649807,1.0,443.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03576483,0.03541957132919642,0.0003452586708035804
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,424.0,409.0,0.007075,0.007075,6.052089,0.457741,1.0,424.0,9.0,41.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01959979,0.019945759599774498,0.00034596959977449895
2.0,424.0,409.0,0.004717,0.004717,6.052089,0.457741,1.0,424.0,9.0,41.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01306745,0.013050832008005981,1.66179919940182e-05
2.0,424.0,409.0,0.004717,0.004717,6.052089,0.457741,1.0,424.0,9.0,41.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01306745,0.013062095840208366,5.354159791633867e-06
2.0,424.0,409.0,0.004717,0.004717,6.052089,0.457741,1.0,424.0,9.0,41.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01306745,0.013042981563779794,2.4468436220205503e-05
1.0,424.0,409.0,0.002358,0.002358,6.052089,0.457741,1.0,424.0,9.0,41.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00653234,0.006565894926991342,3.355492699134207e-05
2.0,424.0,409.0,0.004717,0.004717,6.052089,0.457741,1.0,424.0,9.0,41.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01306745,0.013056381009672643,1.1068990327356074e-05
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,424.0,409.0,0.004717,0.004717,6.052089,0.457741,1.0,424.0,9.0,41.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01306745,0.013051628600505977,1.582139949402213e-05
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,424.0,409.0,0.002358,0.002358,6.052089,0.457741,1.0,424.0,9.0,41.0,Noncompliant with Study Visits,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00653234,0.006561892690503249,2.9552690503248727e-05
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Noncompliant with Study Visits,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,424.0,409.0,0.0,0.0,6.052089,0.457741,1.0,424.0,9.0,41.0,Noncompliant with Study Visits,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
21.0,868.0,805.0,0.024194,0.024194,6.767343,0.553864,1.0,868.0,7.0,67.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0906836,0.09101189811417662,0.00032829811417661725
26.0,868.0,805.0,0.029954,0.029954,6.767343,0.553864,1.0,868.0,7.0,67.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11227314,0.11976695238755955,0.007493812387559556
9.0,868.0,805.0,0.010369,0.010369,6.767343,0.553864,1.0,868.0,7.0,67.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03886493,0.0393801879258036,0.0005152579258035986
3.0,868.0,805.0,0.003456,0.003456,6.767343,0.553864,1.0,868.0,7.0,67.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01295373,0.01307685790099208,0.0001231279009920802
1.0,868.0,805.0,0.001152,0.001152,6.767343,0.553864,1.0,868.0,7.0,67.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00431791,0.004331001112460307,1.309111246030649e-05
1.0,868.0,805.0,0.001152,0.001152,6.767343,0.553864,1.0,868.0,7.0,67.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00431791,0.004331591707103166,1.3681707103165713e-05
1.0,868.0,805.0,0.001152,0.001152,6.767343,0.553864,1.0,868.0,7.0,67.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00431791,0.0043476641860912615,2.9754186091261216e-05
1.0,868.0,805.0,0.001152,0.001152,6.767343,0.553864,1.0,868.0,7.0,67.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00431791,0.004340378503293642,2.2468503293641452e-05
0.0,868.0,805.0,0.0,0.0,6.767343,0.553864,1.0,868.0,7.0,67.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.01048135,0.010482578945019881,1.228945019880745e-06
4.0,414.0,365.0,0.009662,0.009662,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0209627,0.021118125527708326,0.00015542552770832566
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.01048135,0.010471504470019878,9.845529980121934e-06
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,414.0,365.0,0.002415,0.002415,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.00523959,0.0052346365892559366,4.953410744063143e-06
1.0,414.0,365.0,0.002415,0.002415,6.028279,0.359904,1.0,414.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.00523959,0.005239796796458319,2.0679645831942622e-07
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.01048135,0.010478318895436546,3.031104563453943e-06
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,414.0,365.0,0.002415,0.002415,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.00523959,0.005236509518005937,3.0804819940626407e-06
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,414.0,365.0,0.002415,0.002415,6.028279,0.359904,1.0,414.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.00523959,0.005237245777172603,2.344222827396769e-06
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase B - (Week 25 to 52),FG000,diabetes type 2,INDUSTRY,0.01048135,0.010476018610853217,5.331389146783286e-06
1.0,414.0,365.0,0.002415,0.002415,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase B - (Week 25 to 52),FG001,diabetes type 2,INDUSTRY,0.00523959,0.005236835590089271,2.7544099107284017e-06
0.0,414.0,365.0,0.0,0.0,6.028279,0.359904,1.0,414.0,0.0,0.0,Withdrawal by Subject,Phase B - (Week 25 to 52),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase B - (Week 25 to 52),FG000,diabetes type 2,INDUSTRY,0.01048135,0.010479695616686553,1.6543833134471941e-06
3.0,414.0,365.0,0.007246,0.007246,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase B - (Week 25 to 52),FG001,diabetes type 2,INDUSTRY,0.01572094,0.015292332432123018,0.0004286075678769808
2.0,414.0,365.0,0.004831,0.004831,6.028279,0.359904,1.0,414.0,0.0,0.0,Adverse Event,Phase B - (Week 25 to 52),FG002,diabetes type 2,INDUSTRY,0.01048135,0.01048150794746036,1.5794746035906193e-07
12.0,414.0,365.0,0.028986,0.028986,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase B - (Week 25 to 52),FG000,diabetes type 2,INDUSTRY,0.06288811,0.06275785555572783,0.00013025444427217092
10.0,414.0,365.0,0.024155,0.024155,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase B - (Week 25 to 52),FG001,diabetes type 2,INDUSTRY,0.05240676,0.05226733875636905,0.00013942124363094943
3.0,414.0,365.0,0.007246,0.007246,6.028279,0.359904,1.0,414.0,0.0,0.0,Lack of Efficacy,Phase B - (Week 25 to 52),FG002,diabetes type 2,INDUSTRY,0.01572094,0.015293380007420638,0.0004275599925793617
3.0,463.0,424.0,0.006479,0.006479,6.139885,0.538821,1.0,463.0,24.0,107.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02143445,0.021550875147708357,0.00011642514770835583
3.0,463.0,424.0,0.006479,0.006479,6.139885,0.538821,1.0,463.0,24.0,107.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02143445,0.021581478577053587,0.0001470285770535859
1.0,463.0,424.0,0.00216,0.00216,6.139885,0.538821,1.0,463.0,24.0,107.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00714592,0.007290690922351199,0.00014477092235119868
0.0,463.0,424.0,0.0,0.0,6.139885,0.538821,1.0,463.0,24.0,107.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,463.0,424.0,0.015119,0.015119,6.139885,0.538821,1.0,463.0,24.0,107.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05001812,0.04975900545904764,0.0002591145409523571
7.0,463.0,424.0,0.015119,0.015119,6.139885,0.538821,1.0,463.0,24.0,107.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05001812,0.049767417845714326,0.000250702154285673
0.0,463.0,424.0,0.0,0.0,6.139885,0.538821,1.0,463.0,24.0,107.0,Randomized and not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,463.0,424.0,0.00432,0.00432,6.139885,0.538821,1.0,463.0,24.0,107.0,Randomized and not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01429184,0.014373669225248025,8.182922524802537e-05
5.0,463.0,424.0,0.010799,0.010799,6.139885,0.538821,1.0,463.0,24.0,107.0,"Other, not specified above",Overall Study,FG000,diabetes type 2,INDUSTRY,0.03572629,0.03571697968714288,9.31031285712064e-06
11.0,463.0,424.0,0.023758,0.023758,6.139885,0.538821,1.0,463.0,24.0,107.0,"Other, not specified above",Overall Study,FG001,diabetes type 2,INDUSTRY,0.07859849,0.0733705414022817,0.005227948597718288
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
92.0,988.0,670.0,0.093117,0.093117,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.17093318,0.16939469457047607,0.0015384854295239225
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
24.0,988.0,670.0,0.024291,0.024291,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.04459055,0.044649977884474196,5.942788447419606e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,988.0,670.0,0.010121,0.010121,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.01857894,0.01877607155204817,0.00019713155204817076
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,988.0,670.0,0.011134,0.011134,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.02043848,0.02043285728984131,5.622710158689065e-06
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,988.0,670.0,0.006073,0.006073,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.0111481,0.011134772343147551,1.3327656852447911e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Run-in Period, Weeks -12-0",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Run-in Period, Weeks -12-0",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Run-in Period, Weeks -12-0",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
24.0,988.0,670.0,0.024291,0.024291,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Run-in Period, Weeks -12-0",FG003,diabetes type 2,INDUSTRY,0.04459055,0.04464312671983134,5.257671983133899e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Run-in Period, Weeks -12-0",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,988.0,670.0,0.006073,0.006073,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.0111481,0.011147725473445174,3.745265548249499e-07
4.0,988.0,670.0,0.004049,0.004049,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.00743268,0.007433699210487008,1.019210487008572e-06
9.0,988.0,670.0,0.009109,0.009109,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.01672123,0.017108815637271842,0.00038758563727184225
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,988.0,670.0,0.004049,0.004049,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.00743268,0.007440630843869039,7.950843869039374e-06
5.0,988.0,670.0,0.005061,0.005061,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.00929039,0.009301387439285684,1.099743928568292e-05
7.0,988.0,670.0,0.007085,0.007085,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.01300581,0.012982032353432567,2.3777646567432406e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,988.0,670.0,0.011134,0.011134,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.02043848,0.02043781246135916,6.675386408395989e-07
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,988.0,670.0,0.003036,0.003036,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.00557313,0.005587791020337289,1.4661020337289159e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,988.0,670.0,0.001012,0.001012,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.00185771,0.0019124044480654783,5.469444806547826e-05
1.0,988.0,670.0,0.001012,0.001012,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.00185771,0.0019120824290674633,5.4372429067463214e-05
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.00371542,0.0037149014628463377,5.185371536623948e-07
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,988.0,670.0,0.005061,0.005061,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.00929039,0.009307079327638862,1.6689327638860774e-05
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.00371542,0.0037215870438880045,6.167043888004407e-06
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,988.0,670.0,0.007085,0.007085,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Main Period, Weeks 0-26",FG000,diabetes type 2,INDUSTRY,0.01300581,0.01299251290164685,1.3297098353149198e-05
6.0,988.0,670.0,0.006073,0.006073,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Main Period, Weeks 0-26",FG001,diabetes type 2,INDUSTRY,0.0111481,0.011144489503564217,3.6104964357824842e-06
7.0,988.0,670.0,0.007085,0.007085,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Main Period, Weeks 0-26",FG002,diabetes type 2,INDUSTRY,0.01300581,0.012981645489920667,2.4164510079333068e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Main Period, Weeks 0-26",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Main Period, Weeks 0-26",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,988.0,670.0,0.003036,0.003036,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.00557313,0.005587004606587294,1.387460658729394e-05
3.0,988.0,670.0,0.003036,0.003036,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.00557313,0.005587676704503957,1.4546704503956738e-05
10.0,988.0,670.0,0.010121,0.010121,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.01857894,0.018713143817256504,0.00013420381725650493
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Adverse Event,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,988.0,670.0,0.006073,0.006073,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.0111481,0.011132533551897552,1.5566448102447353e-05
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.00371542,0.0037185664856439577,3.146485643957652e-06
5.0,988.0,670.0,0.005061,0.005061,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.00929039,0.009308625101369022,1.8235101369020942e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Protocol Violation,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.00371542,0.003715621425416684,2.014254166841055e-07
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,988.0,670.0,0.008097,0.008097,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.01486352,0.014999355268005976,0.00013583526800597587
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Withdrawal Criteria,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,988.0,670.0,0.005061,0.005061,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.00929039,0.00929200029249997,1.6102924999695373e-06
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.00371542,0.0037122984473106245,3.121552689375629e-06
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lost to Follow-up,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,988.0,670.0,0.004049,0.004049,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.00743268,0.007430274543225102,2.4054567748978822e-06
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.00371542,0.0037193521116856243,3.9321116856241844e-06
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.00371542,0.0037223006833522906,6.880683352290459e-06
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Lack of Efficacy,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,988.0,670.0,0.004049,0.004049,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Extension Period, Weeks 26-52",FG000,diabetes type 2,INDUSTRY,0.00743268,0.007427622902391768,5.057097608231545e-06
2.0,988.0,670.0,0.002024,0.002024,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Extension Period, Weeks 26-52",FG001,diabetes type 2,INDUSTRY,0.00371542,0.0037160106864772917,5.906864772916437e-07
11.0,988.0,670.0,0.011134,0.011134,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Extension Period, Weeks 26-52",FG002,diabetes type 2,INDUSTRY,0.02043848,0.0204102095968056,2.8270403194398386e-05
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Extension Period, Weeks 26-52",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,988.0,670.0,0.0,0.0,6.896694,0.266168,1.0,987.0,10.0,233.0,Unclassified,"Extension Period, Weeks 26-52",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,375.0,365.0,0.002667,0.002667,5.929589,0.740959,1.0,375.0,4.0,33.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01171769,0.011794397632331335,7.670763233133537e-05
1.0,375.0,365.0,0.002667,0.002667,5.929589,0.740959,1.0,375.0,4.0,33.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01171769,0.011785513998164672,6.782399816467229e-05
4.0,375.0,365.0,0.010667,0.010667,5.929589,0.740959,1.0,375.0,4.0,33.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04686635,0.04788866055751356,0.0010223105575135616
4.0,375.0,365.0,0.010667,0.010667,5.929589,0.740959,1.0,375.0,4.0,33.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04686635,0.04801120962554478,0.0011448596255447807
3.0,273.0,254.0,0.010989,0.010989,5.613128,0.193602,1.0,273.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01194188,0.012043851772261926,0.0001019717722619256
2.0,273.0,254.0,0.007326,0.007326,5.613128,0.193602,1.0,273.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00796125,0.00806379866875002,0.00010254866875001982
1.0,273.0,254.0,0.003663,0.003663,5.613128,0.193602,1.0,273.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00398063,0.004052189876567462,7.15598765674624e-05
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,273.0,254.0,0.010989,0.010989,5.613128,0.193602,1.0,273.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01194188,0.011976110252321434,3.423025232143426e-05
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,273.0,254.0,0.007326,0.007326,5.613128,0.193602,1.0,273.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00796125,0.008043675414583356,8.242541458335605e-05
1.0,273.0,254.0,0.003663,0.003663,5.613128,0.193602,1.0,273.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00398063,0.004051047869186511,7.041786918651153e-05
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,273.0,254.0,0.018315,0.018315,5.613128,0.193602,1.0,273.0,0.0,0.0,Withdrawal by Subject and Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01990313,0.020555126015525782,0.0006519960155257805
0.0,273.0,254.0,0.0,0.0,5.613128,0.193602,1.0,273.0,0.0,0.0,Withdrawal by Subject and Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,273.0,254.0,0.007326,0.007326,5.613128,0.193602,1.0,273.0,0.0,0.0,Withdrawal by Subject and Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00796125,0.008036492500000022,7.524250000002196e-05
30.0,547.0,355.0,0.054845,0.054845,6.306275,0.203691,1.0,547.0,4.0,79.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07045003,0.07481291478233289,0.00436288478233289
34.0,547.0,355.0,0.062157,0.062157,6.306275,0.203691,1.0,547.0,4.0,79.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07984251,0.08125123331119197,0.0014087233111919617
4.0,547.0,355.0,0.007313,0.007313,6.306275,0.203691,1.0,547.0,4.0,79.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00939377,0.009393392512053565,3.774879464343156e-07
1.0,547.0,355.0,0.001828,0.001828,6.306275,0.203691,1.0,547.0,4.0,79.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00234812,0.0024513351516567525,0.00010321515165675251
4.0,547.0,355.0,0.007313,0.007313,6.306275,0.203691,1.0,547.0,4.0,79.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00939377,0.009395148079374992,1.3780793749924858e-06
6.0,547.0,355.0,0.010969,0.010969,6.306275,0.203691,1.0,547.0,4.0,79.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01409001,0.01410721481984129,1.7204819841290173e-05
6.0,547.0,355.0,0.010969,0.010969,6.306275,0.203691,1.0,547.0,4.0,79.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01409001,0.014039235259990106,5.07747400098936e-05
8.0,547.0,355.0,0.014625,0.014625,6.306275,0.203691,1.0,547.0,4.0,79.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01878625,0.018772350685674614,1.3899314325386408e-05
6.0,547.0,355.0,0.010969,0.010969,6.306275,0.203691,1.0,547.0,4.0,79.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01409001,0.014058752513918677,3.1257486081322575e-05
3.0,547.0,355.0,0.005484,0.005484,6.306275,0.203691,1.0,547.0,4.0,79.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00704436,0.0070841968505754,3.9836850575399735e-05
40.0,547.0,355.0,0.073126,0.073126,6.306275,0.203691,1.0,547.0,4.0,79.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09393252,0.09732095549751003,0.0033884354975100284
34.0,547.0,355.0,0.062157,0.062157,6.306275,0.203691,1.0,547.0,4.0,79.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07984251,0.08102569780619197,0.0011831878061919626
7.0,547.0,355.0,0.012797,0.012797,6.306275,0.203691,1.0,547.0,4.0,79.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01643813,0.016342954438779762,9.517556122023638e-05
9.0,547.0,355.0,0.016453,0.016453,6.306275,0.203691,1.0,547.0,4.0,79.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02113437,0.020943447143640853,0.0001909228563591464
14.0,668.0,523.0,0.020958,0.020958,6.505784,0.218985,1.0,672.0,20.0,156.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02985822,0.02949471677501522,0.00036350322498478194
16.0,668.0,523.0,0.023952,0.023952,6.505784,0.218985,1.0,672.0,20.0,156.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03412368,0.0333629879778166,0.0007606920221834013
12.0,668.0,523.0,0.017964,0.017964,6.505784,0.218985,1.0,672.0,20.0,156.0,Baseline IVUS determined unevaluable,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02559276,0.02530163637833332,0.0002911236216666807
11.0,668.0,523.0,0.016467,0.016467,6.505784,0.218985,1.0,672.0,20.0,156.0,Baseline IVUS determined unevaluable,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02346003,0.023512012882311528,5.198288231152842e-05
8.0,668.0,523.0,0.011976,0.011976,6.505784,0.218985,1.0,672.0,20.0,156.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01706184,0.017154794807976187,9.295480797618522e-05
6.0,668.0,523.0,0.008982,0.008982,6.505784,0.218985,1.0,672.0,20.0,156.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01279638,0.012800913764394845,4.533764394845305e-06
3.0,668.0,523.0,0.004491,0.004491,6.505784,0.218985,1.0,672.0,20.0,156.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00639819,0.006444997224642851,4.680722464285147e-05
6.0,668.0,523.0,0.008982,0.008982,6.505784,0.218985,1.0,672.0,20.0,156.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01279638,0.012789819368323421,6.560631676578305e-06
1.0,668.0,523.0,0.001497,0.001497,6.505784,0.218985,1.0,672.0,20.0,156.0,Hypoglycaemic events,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213273,0.0021340082569841425,1.2782569841422557e-06
0.0,668.0,523.0,0.0,0.0,6.505784,0.218985,1.0,672.0,20.0,156.0,Hypoglycaemic events,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,668.0,523.0,0.001497,0.001497,6.505784,0.218985,1.0,672.0,20.0,156.0,Low haemoglobin on screening,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213273,0.0021340082569841425,1.2782569841422557e-06
0.0,668.0,523.0,0.0,0.0,6.505784,0.218985,1.0,672.0,20.0,156.0,Low haemoglobin on screening,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,668.0,523.0,0.001497,0.001497,6.505784,0.218985,1.0,672.0,20.0,156.0,Withdrawn investigational product,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213273,0.0021340082569841425,1.2782569841422557e-06
0.0,668.0,523.0,0.0,0.0,6.505784,0.218985,1.0,672.0,20.0,156.0,Withdrawn investigational product,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
32.0,668.0,523.0,0.047904,0.047904,6.505784,0.218985,1.0,672.0,20.0,156.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06824736,0.06786059053504957,0.0003867694649504344
32.0,668.0,523.0,0.047904,0.047904,6.505784,0.218985,1.0,672.0,20.0,156.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06824736,0.06796758486493056,0.0002797751350694516
0.0,668.0,523.0,0.0,0.0,6.505784,0.218985,1.0,672.0,20.0,156.0,Insufficient therapeutic effect,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,668.0,523.0,0.001497,0.001497,6.505784,0.218985,1.0,672.0,20.0,156.0,Insufficient therapeutic effect,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00213273,0.00213176337713024,9.666228697603578e-07
1.0,668.0,523.0,0.001497,0.001497,6.505784,0.218985,1.0,672.0,20.0,156.0,Missing data for participant,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213273,0.0021340082569841425,1.2782569841422557e-06
0.0,668.0,523.0,0.0,0.0,6.505784,0.218985,1.0,672.0,20.0,156.0,Missing data for participant,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,683.0,665.0,0.014641,0.014641,6.527958,0.836516,1.0,683.0,14.0,136.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07995075,0.07801174311307538,0.001939006886924624
5.0,683.0,665.0,0.007321,0.007321,6.527958,0.836516,1.0,683.0,14.0,136.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03997811,0.039911801629672596,6.630837032740172e-05
1.0,683.0,665.0,0.001464,0.001464,6.527958,0.836516,1.0,683.0,14.0,136.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00799453,0.008139693972658728,0.0001451639726587281
0.0,683.0,665.0,0.0,0.0,6.527958,0.836516,1.0,683.0,14.0,136.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,683.0,665.0,0.002928,0.002928,6.527958,0.836516,1.0,683.0,14.0,136.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01598906,0.016184726314246042,0.00019566631424604297
0.0,683.0,665.0,0.0,0.0,6.527958,0.836516,1.0,683.0,14.0,136.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,3183.0,3172.0,0.000628,0.000628,8.065894,0.527932,1.0,3183.0,21.0,228.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00267418,0.0027089031991269852,3.472319912698526e-05
5.0,3183.0,3172.0,0.001571,0.001571,8.065894,0.527932,1.0,3183.0,21.0,228.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0066897,0.006684238151994046,5.4618480059536595e-06
3.0,3183.0,3172.0,0.000943,0.000943,8.065894,0.527932,1.0,3183.0,21.0,228.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00401553,0.003971080311071422,4.4449688928577605e-05
1.0,3183.0,3172.0,0.000314,0.000314,8.065894,0.527932,1.0,3183.0,21.0,228.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00133709,0.0013634413714484134,2.6351371448413456e-05
4.0,614.0,595.0,0.006515,0.006515,6.421622,0.485843,1.0,614.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02032614,0.020173638582282653,0.00015250141771734615
3.0,614.0,595.0,0.004886,0.004886,6.421622,0.485843,1.0,614.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01524383,0.01551903307193226,0.0002752030719322604
4.0,614.0,595.0,0.006515,0.006515,6.421622,0.485843,1.0,614.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02032614,0.02021522587186599,0.0001109141281340105
8.0,614.0,595.0,0.013029,0.013029,6.421622,0.485843,1.0,614.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04064917,0.03979014105343254,0.0008590289465674611
4.0,213.0,201.0,0.018779,0.018779,5.365976,0.258509,1.0,213.0,1.0,9.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02604937,0.026358359273442482,0.00030898927344248303
4.0,213.0,201.0,0.018779,0.018779,5.365976,0.258509,1.0,213.0,1.0,9.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02604937,0.026291748498382957,0.00024237849838295786
1.0,213.0,201.0,0.004695,0.004695,5.365976,0.258509,1.0,213.0,1.0,9.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00651269,0.006529817408095272,1.7127408095272446e-05
1.0,213.0,201.0,0.004695,0.004695,5.365976,0.258509,1.0,213.0,1.0,9.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00651269,0.006523612908095274,1.0922908095274339e-05
1.0,213.0,201.0,0.004695,0.004695,5.365976,0.258509,1.0,213.0,1.0,9.0,Severe non-compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00651269,0.0065328501647619434,2.016016476194364e-05
1.0,213.0,201.0,0.004695,0.004695,5.365976,0.258509,1.0,213.0,1.0,9.0,Severe non-compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00651269,0.006525114360595279,1.2424360595278926e-05
1.0,814.0,636.0,0.001229,0.001229,6.703188,0.321222,1.0,1217.0,10.0,76.0,Incorrect Enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026463,0.002641093400505949,5.2065994940509765e-06
1.0,814.0,636.0,0.001229,0.001229,6.703188,0.321222,1.0,1217.0,10.0,76.0,Incorrect Enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0026463,0.002641601350505951,4.69864949404885e-06
33.0,814.0,636.0,0.040541,0.040541,6.703188,0.321222,1.0,1217.0,10.0,76.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08729342,0.0867463990042262,0.000547020995773792
19.0,814.0,636.0,0.023342,0.023342,6.703188,0.321222,1.0,1217.0,10.0,76.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05026031,0.05037185988688492,0.00011154988688491518
6.0,814.0,636.0,0.007371,0.007371,6.703188,0.321222,1.0,1217.0,10.0,76.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01587134,0.016065201883512795,0.0001938618835127942
27.0,814.0,636.0,0.03317,0.03317,6.703188,0.321222,1.0,1217.0,10.0,76.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07142209,0.07157198598618061,0.0001498959861806204
23.0,814.0,636.0,0.028256,0.028256,6.703188,0.321222,1.0,1217.0,10.0,76.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0608412,0.06074075094863092,0.00010044905136907811
32.0,814.0,636.0,0.039312,0.039312,6.703188,0.321222,1.0,1217.0,10.0,76.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08464712,0.08417956929473215,0.00046755070526785514
3.0,814.0,636.0,0.003686,0.003686,6.703188,0.321222,1.0,1217.0,10.0,76.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00793674,0.007955588448422613,1.8848448422613406e-05
3.0,814.0,636.0,0.003686,0.003686,6.703188,0.321222,1.0,1217.0,10.0,76.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00793674,0.007953069377291655,1.6329377291655206e-05
5.0,814.0,636.0,0.006143,0.006143,6.703188,0.321222,1.0,1217.0,10.0,76.0,Poor/Non-Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01322719,0.013379594246845226,0.00015240424684522663
1.0,814.0,636.0,0.001229,0.001229,6.703188,0.321222,1.0,1217.0,10.0,76.0,Poor/Non-Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0026463,0.002641601350505951,4.69864949404885e-06
1.0,814.0,636.0,0.001229,0.001229,6.703188,0.321222,1.0,1217.0,10.0,76.0,Safety,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026463,0.002641093400505949,5.2065994940509765e-06
0.0,814.0,636.0,0.0,0.0,6.703188,0.321222,1.0,1217.0,10.0,76.0,Safety,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,814.0,636.0,0.001229,0.001229,6.703188,0.321222,1.0,1217.0,10.0,76.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026463,0.0026418437255059496,4.456274494050224e-06
3.0,814.0,636.0,0.003686,0.003686,6.703188,0.321222,1.0,1217.0,10.0,76.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00793674,0.007951469413958323,1.4729413958324e-05
11.0,814.0,636.0,0.013514,0.013514,6.703188,0.321222,1.0,1217.0,10.0,76.0,Various,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02909852,0.02897972585604168,0.00011879414395831941
8.0,814.0,636.0,0.009828,0.009828,6.703188,0.321222,1.0,1217.0,10.0,76.0,Various,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02116178,0.021081311760843255,8.04682391567467e-05
29.0,1250.0,815.0,0.0232,0.0232,7.131699,0.233424,1.0,1246.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03862133,0.03865902075539679,3.7690755396786735e-05
33.0,1250.0,815.0,0.0264,0.0264,7.131699,0.233424,1.0,1246.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04394841,0.04353415871525791,0.00041425128474208844
0.0,1250.0,815.0,0.0,0.0,7.131699,0.233424,1.0,1246.0,0.0,0.0,Creatinine/Creatinine Clearance Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1250.0,815.0,0.0016,0.0016,7.131699,0.233424,1.0,1246.0,0.0,0.0,Creatinine/Creatinine Clearance Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00266354,0.002641881401517857,2.165859848214267e-05
7.0,1250.0,815.0,0.0056,0.0056,7.131699,0.233424,1.0,1246.0,0.0,0.0,Hyperglycemia Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00932239,0.00935943381809523,3.704381809523094e-05
5.0,1250.0,815.0,0.004,0.004,7.131699,0.233424,1.0,1246.0,0.0,0.0,Hyperglycemia Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00665885,0.006637707857440478,2.1142142559522382e-05
4.0,1250.0,815.0,0.0032,0.0032,7.131699,0.233424,1.0,1246.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00532708,0.005327512952648813,4.329526488129967e-07
16.0,1250.0,815.0,0.0128,0.0128,7.131699,0.233424,1.0,1246.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02130832,0.021294186481676584,1.4133518323414945e-05
86.0,1250.0,815.0,0.0688,0.0688,7.131699,0.233424,1.0,1246.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11453223,0.11730611511457342,0.002773885114573424
66.0,1250.0,815.0,0.0528,0.0528,7.131699,0.233424,1.0,1246.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08789682,0.08825397548436514,0.0003571554843651431
10.0,1250.0,815.0,0.008,0.008,7.131699,0.233424,1.0,1246.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0133177,0.013251866085119053,6.583391488094656e-05
7.0,1250.0,815.0,0.0056,0.0056,7.131699,0.233424,1.0,1246.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00932239,0.009348336779444437,2.5946779444436727e-05
4.0,1250.0,815.0,0.0032,0.0032,7.131699,0.233424,1.0,1246.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00532708,0.00532728655681548,2.065568154799996e-07
2.0,1250.0,815.0,0.0016,0.0016,7.131699,0.233424,1.0,1246.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00266354,0.002642398443184523,2.1141556815476668e-05
10.0,1250.0,815.0,0.008,0.008,7.131699,0.233424,1.0,1246.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0133177,0.013242068055714293,7.563194428570653e-05
18.0,1250.0,815.0,0.0144,0.0144,7.131699,0.233424,1.0,1246.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02397186,0.02352397131404763,0.00044788868595237175
67.0,1250.0,815.0,0.0536,0.0536,7.131699,0.233424,1.0,1246.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08922859,0.08885872360702388,0.00036986639297612034
69.0,1250.0,815.0,0.0552,0.0552,7.131699,0.233424,1.0,1246.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09189213,0.09093350001934528,0.0009586299806547266
11.0,706.0,651.0,0.015581,0.015581,6.561031,1.0,1.0,706.0,9.0,65.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10222742,0.10000727987609123,0.0022201401239087676
20.0,706.0,651.0,0.028329,0.028329,6.561031,1.0,1.0,706.0,9.0,65.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.18586744,0.17743764087930583,0.008429799120694165
3.0,706.0,651.0,0.004249,0.004249,6.561031,1.0,1.0,706.0,9.0,65.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02787782,0.027501013609027822,0.0003768063909721786
3.0,706.0,651.0,0.004249,0.004249,6.561031,1.0,1.0,706.0,9.0,65.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02787782,0.027452829770396873,0.00042499022960312827
0.0,706.0,651.0,0.0,0.0,6.561031,1.0,1.0,706.0,9.0,65.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,706.0,651.0,0.001416,0.001416,6.561031,1.0,1.0,706.0,9.0,65.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00929042,0.008796975969077385,0.000493444030922616
4.0,706.0,651.0,0.005666,0.005666,6.561031,1.0,1.0,706.0,9.0,65.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0371748,0.036496993361438454,0.0006778066385615469
4.0,706.0,651.0,0.005666,0.005666,6.561031,1.0,1.0,706.0,9.0,65.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0371748,0.03651829185659718,0.0006565081434028175
0.0,706.0,651.0,0.0,0.0,6.561031,1.0,1.0,706.0,9.0,65.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,706.0,651.0,0.001416,0.001416,6.561031,1.0,1.0,706.0,9.0,65.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00929042,0.008796430195327387,0.0004939898046726135
2.0,706.0,651.0,0.002833,0.002833,6.561031,1.0,1.0,706.0,9.0,65.0,Other reason (not specified),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0185874,0.018097474598829343,0.0004899254011706579
6.0,706.0,651.0,0.008499,0.008499,6.561031,1.0,1.0,706.0,9.0,65.0,Other reason (not specified),Overall Study,FG001,diabetes type 2,INDUSTRY,0.0557622,0.05446419745319452,0.0012980025468054754
9.0,1864.0,1758.0,0.004828,0.004828,7.531016,0.50573,1.0,1864.0,15.0,242.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0183882,0.018325302789255916,6.289721074408464e-05
7.0,1864.0,1758.0,0.003755,0.003755,7.531016,0.50573,1.0,1864.0,15.0,242.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01430151,0.014906489037916672,0.0006049790379166718
7.0,1864.0,1758.0,0.003755,0.003755,7.531016,0.50573,1.0,1864.0,15.0,242.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01430151,0.014910953367361113,0.0006094433673611132
5.0,1864.0,1758.0,0.002682,0.002682,7.531016,0.50573,1.0,1864.0,15.0,242.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01021482,0.010208500834922427,6.319165077572561e-06
18.0,1864.0,1758.0,0.009657,0.009657,7.531016,0.50573,1.0,1864.0,15.0,242.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03678021,0.036746082177509895,3.412782249010565e-05
18.0,1864.0,1758.0,0.009657,0.009657,7.531016,0.50573,1.0,1864.0,15.0,242.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03678021,0.03684664355432536,6.643355432536108e-05
17.0,1864.0,1758.0,0.00912,0.00912,7.531016,0.50573,1.0,1864.0,15.0,242.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03473497,0.03429571584992065,0.0004392541500793448
8.0,1864.0,1758.0,0.004292,0.004292,7.531016,0.50573,1.0,1864.0,15.0,242.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01634676,0.01655828794250994,0.00021152794250994117
5.0,1864.0,1758.0,0.002682,0.002682,7.531016,0.50573,1.0,1864.0,15.0,242.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01021482,0.010174285001321233,4.0534998678766476e-05
4.0,1864.0,1758.0,0.002146,0.002146,7.531016,0.50573,1.0,1864.0,15.0,242.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00817338,0.008153575006488094,1.9804993511904692e-05
1.0,1864.0,1758.0,0.000536,0.000536,7.531016,0.50573,1.0,1864.0,15.0,242.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00204144,0.00225561619290043,0.00021417619290042995
3.0,1864.0,1758.0,0.001609,0.001609,7.531016,0.50573,1.0,1864.0,15.0,242.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00612813,0.0059411511789781764,0.00018697882102182341
1.0,1864.0,1758.0,0.000536,0.000536,7.531016,0.50573,1.0,1864.0,15.0,242.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00204144,0.002249358892781383,0.0002079188927813832
1.0,1864.0,1758.0,0.000536,0.000536,7.531016,0.50573,1.0,1864.0,15.0,242.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00204144,0.002261227955281383,0.000219787955281383
2.0,1864.0,1758.0,0.001073,0.001073,7.531016,0.50573,1.0,1864.0,15.0,242.0,Unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00408669,0.004160678016587298,7.398801658729803e-05
0.0,1864.0,1758.0,0.0,0.0,7.531016,0.50573,1.0,1864.0,15.0,242.0,Unclassified,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,814.0,701.0,0.017199,0.017199,6.703188,0.47693,1.0,814.0,14.0,157.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05498436,0.05534037981842268,0.00035601981842267594
9.0,814.0,701.0,0.011057,0.011057,6.703188,0.47693,1.0,814.0,14.0,157.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03534869,0.035324123936289684,2.4566063710318442e-05
3.0,814.0,701.0,0.003686,0.003686,6.703188,0.47693,1.0,814.0,14.0,157.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01178396,0.011815909345386845,3.1949345386845726e-05
3.0,814.0,701.0,0.003686,0.003686,6.703188,0.47693,1.0,814.0,14.0,157.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01178396,0.01179011939139875,6.159391398750588e-06
6.0,814.0,701.0,0.007371,0.007371,6.703188,0.47693,1.0,814.0,14.0,157.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02356473,0.02339731413076115,0.00016741586923884819
8.0,814.0,701.0,0.009828,0.009828,6.703188,0.47693,1.0,814.0,14.0,157.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03141964,0.03193897551093885,0.0005193355109388495
1.0,814.0,701.0,0.001229,0.001229,6.703188,0.47693,1.0,814.0,14.0,157.0,Protocol defined stopping criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00392905,0.003943475022946424,1.4425022946424476e-05
3.0,814.0,701.0,0.003686,0.003686,6.703188,0.47693,1.0,814.0,14.0,157.0,Protocol defined stopping criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01178396,0.011790135372232087,6.175372232087792e-06
3.0,814.0,701.0,0.003686,0.003686,6.703188,0.47693,1.0,814.0,14.0,157.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01178396,0.011814045887668592,3.0085887668592284e-05
3.0,814.0,701.0,0.003686,0.003686,6.703188,0.47693,1.0,814.0,14.0,157.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01178396,0.01178662336576383,2.6633657638306524e-06
11.0,814.0,701.0,0.013514,0.013514,6.703188,0.47693,1.0,814.0,14.0,157.0,Study terminated by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0432036,0.04598573577810514,0.002782135778105141
11.0,814.0,701.0,0.013514,0.013514,6.703188,0.47693,1.0,814.0,14.0,157.0,Study terminated by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0432036,0.04596963554578374,0.0027660355457837377
8.0,814.0,701.0,0.009828,0.009828,6.703188,0.47693,1.0,814.0,14.0,157.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03141964,0.031857462606087655,0.00043782260608765666
12.0,814.0,701.0,0.014742,0.014742,6.703188,0.47693,1.0,814.0,14.0,157.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04712946,0.04729158160827389,0.00016212160827389077
0.0,814.0,701.0,0.0,0.0,6.703188,0.47693,1.0,814.0,14.0,157.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,814.0,701.0,0.001229,0.001229,6.703188,0.47693,1.0,814.0,14.0,157.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00392905,0.003949225435624998,2.017543562499776e-05
5.0,814.0,701.0,0.006143,0.006143,6.703188,0.47693,1.0,814.0,14.0,157.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01963887,0.0197116537624504,7.27837624504013e-05
12.0,814.0,701.0,0.014742,0.014742,6.703188,0.47693,1.0,814.0,14.0,157.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04712946,0.04732152186910723,0.00019206186910723094
5.0,301.0,233.0,0.016611,0.016611,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.03069488,0.031024224524057505,0.0003293445240575045
6.0,301.0,233.0,0.019934,0.019934,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03683533,0.03769273641877975,0.000857406418779752
15.0,301.0,233.0,0.049834,0.049834,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.09208648,0.0941263585771825,0.002039878577182505
3.0,301.0,233.0,0.009967,0.009967,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01841766,0.01846343313815471,4.577313815471232e-05
3.0,301.0,233.0,0.009967,0.009967,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01841766,0.018471623176071376,5.396317607137685e-05
4.0,301.0,233.0,0.013289,0.013289,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.02455627,0.024562110777519793,5.840777519791618e-06
10.0,301.0,233.0,0.033223,0.033223,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0613916,0.06324623980934524,0.0018546398093452418
7.0,301.0,233.0,0.023256,0.023256,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.04297393,0.043866881438402804,0.0008929514384028031
8.0,301.0,233.0,0.026578,0.026578,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.04911254,0.04923944239303571,0.00012690239303570633
18.0,301.0,233.0,0.059801,0.059801,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.11050414,0.10905975445416648,0.0014443855458335236
14.0,301.0,233.0,0.046512,0.046512,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.08594787,0.08714077845540666,0.0011929084554066632
11.0,301.0,233.0,0.036545,0.036545,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.06753021,0.06792575909139881,0.0003955490913988141
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,301.0,233.0,0.006645,0.006645,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01227906,0.012336687063214289,5.762706321428904e-05
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.00613916325666666,5.532566666596392e-07
3.0,301.0,233.0,0.009967,0.009967,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01841766,0.018456312503988045,3.865250398804587e-05
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00613861,0.006141267978749992,2.657978749992171e-06
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.006139238273333325,6.282733333246374e-07
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Increased Calcitonin,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138421868333326,1.881316666740157e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Increased Calcitonin,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Increased Calcitonin,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Discontinued-Thrombocytopenia,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138421868333326,1.881316666740157e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Discontinued-Thrombocytopenia,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Discontinued-Thrombocytopenia,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Moved to Africa,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138421868333326,1.881316666740157e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Moved to Africa,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Moved to Africa,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Pregnancy,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138346630833326,2.633691666741392e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Pregnancy,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Pregnancy,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.006139163035833325,5.530358333245139e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Decided to Move Out of State,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Decided to Move Out of State,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Decided to Move Out of State,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.006139238273333325,6.282733333246374e-07
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006137436237083326,1.1737629166744257e-06
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Adverse Event,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,301.0,233.0,0.006645,0.006645,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01227906,0.012309411209553572,3.0351209553572053e-05
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00613861,0.006140518452499991,1.9084524999907204e-06
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Noncompliance,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,301.0,233.0,0.043189,0.043189,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.07980742,0.08093050056831348,0.0011230805683134781
12.0,301.0,233.0,0.039867,0.039867,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.07366881,0.07711304302017857,0.003444233020178572
16.0,301.0,233.0,0.053156,0.053156,5.710427,0.323595,1.0,309.0,3.0,262.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.09822508,0.0994312697052677,0.0012061897052676879
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138010632916659,5.993670833407197e-07
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00613861,0.006140241335833325,1.6313358333248928e-06
4.0,301.0,233.0,0.013289,0.013289,5.710427,0.323595,1.0,309.0,3.0,262.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.02455627,0.024563397173353114,7.127173353112248e-06
4.0,301.0,233.0,0.013289,0.013289,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.02455627,0.024632479203988047,7.62092039880459e-05
2.0,301.0,233.0,0.006645,0.006645,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01227906,0.012333441324047621,5.438132404762125e-05
3.0,301.0,233.0,0.009967,0.009967,5.710427,0.323595,1.0,309.0,3.0,262.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.01841766,0.01847373863273805,5.607863273805053e-05
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00613861,0.006140443435833326,1.8334358333257222e-06
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Physician Decision,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.006138848355416659,2.3835541665927218e-07
3.0,301.0,233.0,0.009967,0.009967,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01841766,0.018458419225654717,4.0759225654718456e-05
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00613861,0.006140234033749992,1.6240337499919336e-06
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Termination of Study/ Site by GSK,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00613861,0.006139007765833326,3.977658333256459e-07
1.0,301.0,233.0,0.003322,0.003322,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Relocating to Africa,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00613861,0.006138287749583325,3.222504166748921e-07
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Relocating to Africa,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,301.0,233.0,0.0,0.0,5.710427,0.323595,1.0,309.0,3.0,262.0,Participant Relocating to Africa,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00250316,0.0025036350438888727,4.750438888727858e-07
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,825.0,787.0,0.006061,0.006061,6.716595,0.307494,1.0,825.0,12.0,120.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01251786,0.012482687981755955,3.5172018244045145e-05
5.0,825.0,787.0,0.006061,0.006061,6.716595,0.307494,1.0,825.0,12.0,120.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01251786,0.012483558268839285,3.4301731160715776e-05
6.0,825.0,787.0,0.007273,0.007273,6.716595,0.307494,1.0,825.0,12.0,120.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01502102,0.014734222643035708,0.00028679735696429155
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00250316,0.0025036350438888727,4.750438888727858e-07
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00250316,0.002500994535972205,2.165464027795074e-06
2.0,825.0,787.0,0.002424,0.002424,6.716595,0.307494,1.0,825.0,12.0,120.0,Non compliant with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00500632,0.005005459742540592,8.602574594080564e-07
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00250316,0.002501905271865063,1.2547281349369055e-06
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00250316,0.0024998193556150625,3.3406443849374502e-06
1.0,825.0,787.0,0.001212,0.001212,6.716595,0.307494,1.0,825.0,12.0,120.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00250316,0.002499006808531731,4.153191468268987e-06
5.0,825.0,787.0,0.006061,0.006061,6.716595,0.307494,1.0,825.0,12.0,120.0,"Patient refusal to continue,not due toAE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.01251786,0.012477993895714287,3.986610428571326e-05
4.0,825.0,787.0,0.004848,0.004848,6.716595,0.307494,1.0,825.0,12.0,120.0,"Patient refusal to continue,not due toAE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01001264,0.010037125952857145,2.4485952857145055e-05
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,"Patient refusal to continue,not due toAE",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,825.0,787.0,0.003636,0.003636,6.716595,0.307494,1.0,825.0,12.0,120.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00750948,0.00743928221311508,7.019778688492021e-05
0.0,825.0,787.0,0.0,0.0,6.716595,0.307494,1.0,825.0,12.0,120.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,825.0,787.0,0.002424,0.002424,6.716595,0.307494,1.0,825.0,12.0,120.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00500632,0.005005459742540592,8.602574594080564e-07
3.0,730.0,701.0,0.00411,0.00411,6.594413,0.844898,1.0,730.0,8.0,81.0,Adverse Event,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02289931,0.022931590090277697,3.2280090277697626e-05
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Adverse Event,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,730.0,701.0,0.005479,0.005479,6.594413,0.844898,1.0,730.0,8.0,81.0,Assigned Treatment by Mistake,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03052684,0.0304403540822421,8.648591775789818e-05
3.0,730.0,701.0,0.00411,0.00411,6.594413,0.844898,1.0,730.0,8.0,81.0,Assigned Treatment by Mistake,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02289931,0.02289994944777769,6.39447777690122e-07
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Death,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Death,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0076331,0.007648574384077401,1.5474384077400656e-05
2.0,730.0,701.0,0.00274,0.00274,6.594413,0.844898,1.0,730.0,8.0,81.0,Lost to Follow-up,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0152662,0.01529356476194448,2.736476194447994e-05
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Lost to Follow-up,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0076331,0.007651132954910735,1.8032954910734977e-05
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Non-Compliance with Study Drug,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0076331,0.007648112090744068,1.5012090744067653e-05
3.0,730.0,701.0,0.00411,0.00411,6.594413,0.844898,1.0,730.0,8.0,81.0,Non-Compliance with Study Drug,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02289931,0.022913692748611023,1.4382748611024149e-05
2.0,730.0,701.0,0.00274,0.00274,6.594413,0.844898,1.0,730.0,8.0,81.0,Physician Decision,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0152662,0.015301090715833365,3.489071583336403e-05
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Physician Decision,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Protocol Violation,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Protocol Violation,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0076331,0.007652244796577402,1.9144796577401715e-05
5.0,730.0,701.0,0.006849,0.006849,6.594413,0.844898,1.0,730.0,8.0,81.0,Withdrawal by Subject,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03815994,0.037662858391974155,0.0004970816080258483
12.0,730.0,701.0,0.016438,0.016438,6.594413,0.844898,1.0,730.0,8.0,81.0,Withdrawal by Subject,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.09158609,0.09132124804761908,0.000264841952380912
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Adverse Event,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.0076331,0.007654272312648826,2.1172312648825957e-05
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Adverse Event,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Death,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.0076331,0.007649960000148825,1.6860000148825015e-05
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Death,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,730.0,701.0,0.00411,0.00411,6.594413,0.844898,1.0,730.0,8.0,81.0,Lost to Follow-up,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.02289931,0.022950220794503894,5.091079450389446e-05
1.0,730.0,701.0,0.00137,0.00137,6.594413,0.844898,1.0,730.0,8.0,81.0,Lost to Follow-up,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0076331,0.007656983108065495,2.3883108065494638e-05
0.0,730.0,701.0,0.0,0.0,6.594413,0.844898,1.0,730.0,8.0,81.0,Withdrawal by Subject,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,730.0,701.0,0.005479,0.005479,6.594413,0.844898,1.0,730.0,8.0,81.0,Withdrawal by Subject,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.03052684,0.03048231431075401,4.452568924599026e-05
296.0,9306.0,8095.0,0.031807,0.031807,9.138522,0.242288,1.0,9306.0,38.0,38.0,lost to follow-up for all-cause death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07042559,0.07115631166243047,0.0007307216624304752
292.0,9306.0,8095.0,0.031378,0.031378,9.138522,0.242288,1.0,9306.0,38.0,38.0,lost to follow-up for all-cause death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06947572,0.0703582865673115,0.0008825665673114907
313.0,9306.0,8095.0,0.033634,0.033634,9.138522,0.242288,1.0,9306.0,38.0,38.0,lost to follow-up for all-cause death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07447085,0.07246952097751982,0.0020013290224801805
310.0,9306.0,8095.0,0.033312,0.033312,9.138522,0.242288,1.0,9306.0,38.0,38.0,lost to follow-up for all-cause death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.07375789,0.07234476029915675,0.0014131297008432575
57.0,4447.0,2233.0,0.012818,0.012818,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG000,diabetes type 2,INDUSTRY,0.02427181,0.024387484647688484,0.00011567464768848235
67.0,4447.0,2233.0,0.015066,0.015066,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG001,diabetes type 2,INDUSTRY,0.02852856,0.028272668273561483,0.0002558917264385181
54.0,4447.0,2233.0,0.012143,0.012143,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG002,diabetes type 2,INDUSTRY,0.02299365,0.02339062421195435,0.00039697421195434776
72.0,4447.0,2233.0,0.016191,0.016191,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG003,diabetes type 2,INDUSTRY,0.03065882,0.030751263149761857,9.244314976185677e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,4447.0,2233.0,0.001124,0.001124,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG000,diabetes type 2,INDUSTRY,0.00212837,0.0021666919978950215,3.8321997895021404e-05
8.0,4447.0,2233.0,0.001799,0.001799,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG001,diabetes type 2,INDUSTRY,0.00340654,0.0034201135586011916,1.3573558601191575e-05
10.0,4447.0,2233.0,0.002249,0.002249,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG002,diabetes type 2,INDUSTRY,0.00425864,0.004347948843571436,8.930884357143554e-05
11.0,4447.0,2233.0,0.002474,0.002474,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG003,diabetes type 2,INDUSTRY,0.0046847,0.0046746670368452495,1.0032963154750496e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
29.0,4447.0,2233.0,0.006521,0.006521,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG000,diabetes type 2,INDUSTRY,0.01234798,0.012219215138392863,0.0001287648616071363
29.0,4447.0,2233.0,0.006521,0.006521,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG001,diabetes type 2,INDUSTRY,0.01234798,0.012279158051845252,6.882194815474758e-05
25.0,4447.0,2233.0,0.005622,0.005622,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG002,diabetes type 2,INDUSTRY,0.01064566,0.010709065183303558,6.340518330355885e-05
26.0,4447.0,2233.0,0.005847,0.005847,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG003,diabetes type 2,INDUSTRY,0.01107172,0.011064880358333338,6.839641666662316e-06
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
46.0,4447.0,2233.0,0.010344,0.010344,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG000,diabetes type 2,INDUSTRY,0.01958711,0.020261381437589297,0.0006742714375892953
56.0,4447.0,2233.0,0.012593,0.012593,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG001,diabetes type 2,INDUSTRY,0.02384575,0.023799368051775783,4.638194822421601e-05
72.0,4447.0,2233.0,0.016191,0.016191,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG002,diabetes type 2,INDUSTRY,0.03065882,0.03084490639085312,0.0001860863908531192
70.0,4447.0,2233.0,0.015741,0.015741,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG003,diabetes type 2,INDUSTRY,0.02980672,0.029854561211924535,4.78412119245368e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
27.0,4447.0,2233.0,0.006072,0.006072,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG000,diabetes type 2,INDUSTRY,0.01149777,0.011471816358333352,2.5953641666647334e-05
25.0,4447.0,2233.0,0.005622,0.005622,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG001,diabetes type 2,INDUSTRY,0.01064566,0.010727276571398795,8.161657139879597e-05
32.0,4447.0,2233.0,0.007196,0.007196,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG002,diabetes type 2,INDUSTRY,0.01362614,0.013345348761269839,0.00028079123873016136
36.0,4447.0,2233.0,0.008095,0.008095,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG003,diabetes type 2,INDUSTRY,0.01532847,0.015290772513879874,3.769748612012652e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Moved to survival status follow-up only,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,4447.0,2233.0,0.000675,0.000675,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG000,diabetes type 2,INDUSTRY,0.00127816,0.0012797026862103077,1.5426862103077536e-06
2.0,4447.0,2233.0,0.00045,0.00045,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG001,diabetes type 2,INDUSTRY,0.00085211,0.0008552649270238101,3.15492702381015e-06
3.0,4447.0,2233.0,0.000675,0.000675,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG002,diabetes type 2,INDUSTRY,0.00127816,0.0012793698002579268,1.209800257926828e-06
3.0,4447.0,2233.0,0.000675,0.000675,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG003,diabetes type 2,INDUSTRY,0.00127816,0.0012791208602579269,9.60860257926896e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant moved,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,4447.0,2233.0,0.000675,0.000675,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG000,diabetes type 2,INDUSTRY,0.00127816,0.0012796968682936422,1.5368682936421803e-06
2.0,4447.0,2233.0,0.00045,0.00045,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG001,diabetes type 2,INDUSTRY,0.00085211,0.0008552794645238102,3.1694645238101744e-06
2.0,4447.0,2233.0,0.00045,0.00045,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG002,diabetes type 2,INDUSTRY,0.00085211,0.0008551689428571434,3.0589428571433904e-06
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG003,diabetes type 2,INDUSTRY,0.00042605,0.00042565367857143007,3.963214285699051e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Poor compliance,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,4447.0,2233.0,0.000675,0.000675,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG001,diabetes type 2,INDUSTRY,0.00127816,0.0012793731350595177,1.2131350595177316e-06
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG003,diabetes type 2,INDUSTRY,0.00042605,0.00042565367857143007,3.963214285699051e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Prohibited glucose lowering medication,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,4447.0,2233.0,0.000899,0.000899,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG000,diabetes type 2,INDUSTRY,0.00170232,0.0016557127340376995,4.660726596230052e-05
4.0,4447.0,2233.0,0.000899,0.000899,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG001,diabetes type 2,INDUSTRY,0.00170232,0.0016527907858531763,4.9529214146823734e-05
4.0,4447.0,2233.0,0.000899,0.000899,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG002,diabetes type 2,INDUSTRY,0.00170232,0.0016540545252281761,4.826547477182388e-05
8.0,4447.0,2233.0,0.001799,0.001799,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG003,diabetes type 2,INDUSTRY,0.00340654,0.003402380466815476,4.159533184523983e-06
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site closed,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG002,diabetes type 2,INDUSTRY,0.00042605,0.0004260572357142873,7.235714287337578e-09
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG003,diabetes type 2,INDUSTRY,0.00042605,0.00042565367857143007,3.963214285699051e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entry criteria violation,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG002,diabetes type 2,INDUSTRY,0.00042605,0.0004260572357142873,7.235714287337578e-09
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant did not take study drug,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,4447.0,2233.0,0.00045,0.00045,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG000,diabetes type 2,INDUSTRY,0.00085211,0.00085617121077381,4.061210773810054e-06
2.0,4447.0,2233.0,0.00045,0.00045,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG001,diabetes type 2,INDUSTRY,0.00085211,0.0008554322728571438,3.3222728571438275e-06
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG002,diabetes type 2,INDUSTRY,0.00042605,0.0004260572357142873,7.235714287337578e-09
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG003,diabetes type 2,INDUSTRY,0.00042605,0.00042565367857143007,3.963214285699051e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG000,diabetes type 2,INDUSTRY,0.00042605,0.00042579328071428715,2.567192857128248e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant completed study at visit 27,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG000,diabetes type 2,INDUSTRY,0.00042605,0.00042579328071428715,2.567192857128248e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Personal reasons,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG001,diabetes type 2,INDUSTRY,0.00042605,0.0004255890298809539,4.609701190460549e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Risk of heart failure,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG002,diabetes type 2,INDUSTRY,0.00042605,0.0004260572357142873,7.235714287337578e-09
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Investigator refused to log temperature,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG002,diabetes type 2,INDUSTRY,0.00042605,0.0004260572357142873,7.235714287337578e-09
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Reason unspecified,Main Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
78.0,4447.0,2233.0,0.01754,0.01754,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.03321325,0.03343741008794646,0.00022416008794646364
70.0,4447.0,2233.0,0.015741,0.015741,8.40021,0.22542,1.0,4447.0,25.0,446.0,Death,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.02980672,0.029788594196666622,1.8125803333376295e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00042605,0.00042581211833333464,2.3788166666533937e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Adverse Event,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
25.0,4447.0,2233.0,0.005622,0.005622,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.01064566,0.010677635183227799,3.197518322779931e-05
27.0,4447.0,2233.0,0.006072,0.006072,8.40021,0.22542,1.0,4447.0,25.0,446.0,Lost to Follow-up,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.01149777,0.0114098923423052,8.787765769479976e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,4447.0,2233.0,0.002698,0.002698,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00510886,0.005026161306011908,8.269869398809179e-05
12.0,4447.0,2233.0,0.002698,0.002698,8.40021,0.22542,1.0,4447.0,25.0,446.0,Withdrawal by Subject,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.00510886,0.005022842813095241,8.60171869047589e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,4447.0,2233.0,0.004048,0.004048,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00766518,0.007699414740892855,3.4234740892855053e-05
22.0,4447.0,2233.0,0.004947,0.004947,8.40021,0.22542,1.0,4447.0,25.0,446.0,Entered into Another Clinical Trial,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.0093675,0.009423651132529786,5.6151132529784833e-05
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,4447.0,2233.0,0.001799,0.001799,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00340654,0.003403784821934525,2.75517806547481e-06
8.0,4447.0,2233.0,0.001799,0.001799,8.40021,0.22542,1.0,4447.0,25.0,446.0,Physician Decision,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.00340654,0.0034037054883035724,2.834511696427587e-06
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,4447.0,2233.0,0.001349,0.001349,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00255443,0.002453313514732146,0.00010111648526785373
7.0,4447.0,2233.0,0.001574,0.001574,8.40021,0.22542,1.0,4447.0,25.0,446.0,Site Closed Early,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.00298048,0.0029767212308730168,3.7587691269834293e-06
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Participant Moved,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.00042605,0.0004257833183333347,2.666816666652941e-07
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,4447.0,2233.0,0.0,0.0,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG004,diabetes type 2,INDUSTRY,0.00042605,0.00042581211833333464,2.3788166666533937e-07
1.0,4447.0,2233.0,0.000225,0.000225,8.40021,0.22542,1.0,4447.0,25.0,446.0,Unknown; Reason Not Provided,Observational Follow-up,FG005,diabetes type 2,INDUSTRY,0.00042605,0.0004257833183333347,2.666816666652941e-07
8.0,502.0,432.0,0.015936,0.015936,6.22059,0.233646,1.0,502.0,4.0,31.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02316165,0.023142920847049983,1.8729152950015815e-05
6.0,502.0,432.0,0.011952,0.011952,6.22059,0.233646,1.0,502.0,4.0,31.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01737124,0.017353534965833344,1.770503416665542e-05
2.0,502.0,432.0,0.003984,0.003984,6.22059,0.233646,1.0,502.0,4.0,31.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00579041,0.005767680910357132,2.272908964286776e-05
2.0,502.0,432.0,0.003984,0.003984,6.22059,0.233646,1.0,502.0,4.0,31.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00579041,0.005776368312916658,1.4041687083341838e-05
4.0,502.0,432.0,0.007968,0.007968,6.22059,0.233646,1.0,502.0,4.0,31.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01158083,0.01158819913813493,7.369138134928968e-06
5.0,502.0,432.0,0.00996,0.00996,6.22059,0.233646,1.0,502.0,4.0,31.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01447603,0.014444208016299611,3.182198370038983e-05
4.0,502.0,432.0,0.007968,0.007968,6.22059,0.233646,1.0,502.0,4.0,31.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01158083,0.01157485998170636,5.9700182936401475e-06
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00289521,0.0028944632320238124,7.467679761876712e-07
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00289521,0.0028941859785119096,1.0240214880904638e-06
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00289521,0.0028924168736904786,2.793126309521502e-06
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,502.0,432.0,0.013944,0.013944,6.22059,0.233646,1.0,502.0,4.0,31.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02026645,0.02033201856486112,6.556856486112164e-05
7.0,502.0,432.0,0.013944,0.013944,6.22059,0.233646,1.0,502.0,4.0,31.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02026645,0.020338254536706356,7.180453670635814e-05
3.0,502.0,432.0,0.005976,0.005976,6.22059,0.233646,1.0,502.0,4.0,31.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00868562,0.00866862781801588,1.6992181984119142e-05
5.0,502.0,432.0,0.00996,0.00996,6.22059,0.233646,1.0,502.0,4.0,31.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01447603,0.014449522270049609,2.6507729950392064e-05
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Required restricted medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Required restricted medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Required restricted medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00289521,0.0028935694174404797,1.6405825595203899e-06
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Required restricted medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Met discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00289521,0.0028944854560119084,7.245439880916756e-07
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Met discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Met discontinuation criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00289521,0.0028938236620238123,1.386337976187757e-06
1.0,502.0,432.0,0.001992,0.001992,6.22059,0.233646,1.0,502.0,4.0,31.0,Met discontinuation criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00289521,0.0028950495141071447,1.6048589285538178e-07
0.0,502.0,432.0,0.0,0.0,6.22059,0.233646,1.0,502.0,4.0,31.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,502.0,432.0,0.003984,0.003984,6.22059,0.233646,1.0,502.0,4.0,31.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00579041,0.005771311003601181,1.9098996398818867e-05
5.0,502.0,432.0,0.00996,0.00996,6.22059,0.233646,1.0,502.0,4.0,31.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01447603,0.0144589975042758,1.703249572420143e-05
3.0,502.0,432.0,0.005976,0.005976,6.22059,0.233646,1.0,502.0,4.0,31.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00868562,0.008680368524682543,5.2514753174567885e-06
12.0,1208.0,517.0,0.009934,0.009934,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.01485751,0.014930234297043647,7.272429704364633e-05
9.0,1208.0,517.0,0.00745,0.00745,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.01114238,0.011203521690396807,6.114169039680636e-05
11.0,1208.0,517.0,0.009106,0.009106,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.01361913,0.013583559823788805,3.5570176211195334e-05
6.0,1208.0,517.0,0.004967,0.004967,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.00742875,0.007414561173313472,1.418882668652744e-05
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00619038,0.006195005954404788,4.625954404788128e-06
11.0,1208.0,517.0,0.009106,0.009106,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.01361913,0.01359228590795547,2.684409204452981e-05
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.00371363,0.0037150721245833513,1.442124583351384e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,1208.0,517.0,0.009106,0.009106,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.01361913,0.01358015618694356,3.897381305643932e-05
14.0,1208.0,517.0,0.011589,0.011589,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.01733276,0.01720472243771826,0.00012803756228173951
8.0,1208.0,517.0,0.006623,0.006623,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0099055,0.009904003176815442,1.496823184557114e-06
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.004952,0.0049487595070238305,3.240492976169275e-06
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00371363,0.0037138647925000173,2.3479250001743127e-07
14.0,1208.0,517.0,0.011589,0.011589,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.01733276,0.017216592352182546,0.00011616764781745281
19.0,1208.0,517.0,0.015728,0.015728,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.02352314,0.023230501700148808,0.0002926382998511938
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00619038,0.00619766210035717,7.282100357170439e-06
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.004952,0.004948769748690497,3.2302513095026214e-06
7.0,1208.0,517.0,0.005795,0.005795,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.00866713,0.008995504969791656,0.00032837496979165604
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.00619038,0.006191528660436535,1.148660436535616e-06
10.0,1208.0,517.0,0.008278,0.008278,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.01238076,0.012464176736349213,8.34167363492136e-05
9.0,1208.0,517.0,0.00745,0.00745,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.01114238,0.011192762803849192,5.038280384919193e-05
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.00371363,0.003717365772440493,3.7357724404930154e-06
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012383460158333253,2.3984166674624954e-08
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.00123837,0.0012378401111904694,5.29888809530513e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012383506095833255,1.9390416674440816e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.0012383745937499923,4.593749992377882e-09
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.00123837,0.0012383745937499923,4.593749992377882e-09
6.0,1208.0,517.0,0.004967,0.004967,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00742875,0.007405483430813471,2.3266569186528724e-05
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.004952,0.004944209045982162,7.790954017837526e-06
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.00247675,0.0024770556533730338,3.056533730339851e-07
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.004952,0.004946391987232163,5.608012767836963e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00371363,0.003712886577500017,7.434224999830139e-07
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.00371363,0.0037128798654166833,7.501345833165959e-07
17.0,1208.0,517.0,0.014073,0.014073,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.02104789,0.020899526054900787,0.00014836394509921275
16.0,1208.0,517.0,0.013245,0.013245,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.01980951,0.01981252371166667,3.013711666669666e-06
16.0,1208.0,517.0,0.013245,0.013245,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.01980951,0.01981966510863095,1.015510863095273e-05
15.0,1208.0,517.0,0.012417,0.012417,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.01857114,0.018571654319325358,5.143193253578926e-07
10.0,1208.0,517.0,0.008278,0.008278,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.01238076,0.012473358863908737,9.259886390873724e-05
15.0,1208.0,517.0,0.012417,0.012417,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.01857114,0.018570127895992026,1.0121040079739962e-06
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.004952,0.004947811662857163,4.188337142836673e-06
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00247675,0.0024768116284027944,6.162840279462858e-08
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.00619038,0.006192481534523839,2.1015345238392658e-06
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.00247675,0.0024768981346230345,1.4813462303467015e-07
6.0,1208.0,517.0,0.004967,0.004967,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.00742875,0.00740992541873014,1.8824581269859253e-05
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00619038,0.006190155802738122,2.2419726187789674e-07
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00371363,0.0037138996575000176,2.6965750001776284e-07
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.00619038,0.006190086919404789,2.930805952103613e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.00123837,0.001237673400773803,6.965992261969908e-07
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.001238600086249992,2.3008624999210948e-07
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.00247675,0.0024768508820932726,1.0088209327283049e-07
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00371363,0.0037139559775000177,3.259775000177996e-07
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012383460158333253,2.3984166674624954e-08
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.00247675,0.002476929308611127,1.7930861112742946e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00247675,0.002476887399652797,1.3739965279728136e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient incarcerated,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,laboratory reporting error,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,site error,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012383460158333253,2.3984166674624954e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient intolerance to rescue therapy,54-Week Base Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.00247675,0.0024767326200000176,1.737999998216097e-08
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.00371363,0.0037139053733333486,2.753733333487121e-07
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00247675,0.002476586328720258,1.6367127974193513e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Adverse Event,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.00123837,0.001237395880833326,9.741191666738647e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Death,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
26.0,1208.0,517.0,0.021523,0.021523,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.03219027,0.03110334827269845,0.00108692172730155
15.0,1208.0,517.0,0.012417,0.012417,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.01857114,0.018511255592142836,5.988440785716434e-05
13.0,1208.0,517.0,0.010762,0.010762,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.01609588,0.016035364114781746,6.0515885218253435e-05
16.0,1208.0,517.0,0.013245,0.013245,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.01980951,0.019799068722321428,1.0441277678571032e-05
8.0,1208.0,517.0,0.006623,0.006623,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0099055,0.009906781469077336,1.2814690773365472e-06
8.0,1208.0,517.0,0.006623,0.006623,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0099055,0.009908398519077335,2.898519077336112e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lack of Efficacy,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.004952,0.004949992724940492,2.0072750595082067e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.001237700565416659,6.694345833409016e-07
4.0,1208.0,517.0,0.003311,0.003311,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.004952,0.004948455263273829,3.5447367261708107e-06
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00371363,0.003716674013273826,3.0440132738262723e-06
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00371363,0.0037163856516071597,2.755651607159841e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Lost to Follow-up,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.00123837,0.0012380044308333263,3.65569166673645e-07
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.001238426436249992,5.643624999209125e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Physician Decision,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.0012384329987499922,6.299874999232333e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.0012383745937499923,4.593749992377882e-09
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Pregnancy,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012382789649999922,9.103500000768976e-08
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.00123837,0.0012374584004166598,9.115995833401495e-07
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.0012380471162499922,3.2288375000771863e-07
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.00247675,0.0024769143636904955,1.643636904956683e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00123837,0.001237990679999992,3.79320000007833e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Protocol Violation,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.00247675,0.002475461086408747,1.288913591252893e-06
5.0,1208.0,517.0,0.004139,0.004139,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.00619038,0.006186612170357165,3.7678296428344735e-06
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00247675,0.0024753462904861297,1.4037095138700467e-06
8.0,1208.0,517.0,0.006623,0.006623,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0099055,0.009898800964851158,6.6990351488410704e-06
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00371363,0.003709735415416685,3.894584583314861e-06
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00371363,0.0037094470537500186,4.1829462499812925e-06
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,Withdrawal by Subject,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.00247675,0.0024767887762500176,3.877625001777116e-08
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.00247675,0.0024768372889583503,8.728895835048017e-08
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00371363,0.0037183247638293824,4.694763829382522e-06
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.00247675,0.002476714344940496,3.565505950382797e-08
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00371363,0.0037142454154166856,6.154154166856766e-07
3.0,1208.0,517.0,0.002483,0.002483,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.00371363,0.0037139570537500187,3.270537500188117e-07
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,protocol discontinuation criteria,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.00123837,0.0012383615616666586,8.438333341321061e-09
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.00123837,0.001237395880833326,9.741191666738647e-07
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,non-compliance with study procedures,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.001238426436249992,5.643624999209125e-08
2.0,1208.0,517.0,0.001656,0.001656,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.00247675,0.002476714344940496,3.565505950382797e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient moved,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.00123837,0.001238426436249992,5.643624999209125e-08
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,patient scheduled for elective surgery,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1208.0,517.0,0.000828,0.000828,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG004,diabetes type 2,INDUSTRY,0.00123837,0.001238369999999992,8.023096076392733e-18
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1208.0,517.0,0.0,0.0,7.097549,0.210724,1.0,1208.0,0.0,0.0,reason unspecified,50-Week Extension Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,272.0,260.0,0.022059,0.022059,5.609472,0.419252,1.0,477.0,3.0,29.0,Adverse Event,Treatment,FG000,diabetes type 2,INDUSTRY,0.051878,0.053192194363065416,0.0013141943630654157
3.0,272.0,260.0,0.011029,0.011029,5.609472,0.419252,1.0,477.0,3.0,29.0,Adverse Event,Treatment,FG001,diabetes type 2,INDUSTRY,0.02593782,0.02670002902475197,0.0007622090247519711
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Subject request to discontinue treatment,Treatment,FG000,diabetes type 2,INDUSTRY,0.00864516,0.00864609228598211,9.322859821098844e-07
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Subject request to discontinue treatment,Treatment,FG001,diabetes type 2,INDUSTRY,0.00864516,0.008638255929642825,6.904070357175232e-06
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Withdrawal by Subject,Treatment,FG000,diabetes type 2,INDUSTRY,0.00864516,0.008642844171398779,2.31582860122162e-06
0.0,272.0,260.0,0.0,0.0,5.609472,0.419252,1.0,477.0,3.0,29.0,Withdrawal by Subject,Treatment,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Other,Treatment,FG000,diabetes type 2,INDUSTRY,0.00864516,0.008644849081815446,3.109181845543235e-07
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Other,Treatment,FG001,diabetes type 2,INDUSTRY,0.00864516,0.00863701272547616,8.147274523841175e-06
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Withdrawal by Subject,Follow-up,FG000,diabetes type 2,INDUSTRY,0.00864516,0.008634966494494026,1.019350550597424e-05
0.0,272.0,260.0,0.0,0.0,5.609472,0.419252,1.0,477.0,3.0,29.0,Withdrawal by Subject,Follow-up,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,272.0,260.0,0.007353,0.007353,5.609472,0.419252,1.0,477.0,3.0,29.0,Adverse Event,Follow-up,FG000,diabetes type 2,INDUSTRY,0.01729267,0.01737663750128782,8.396750128782104e-05
2.0,272.0,260.0,0.007353,0.007353,5.609472,0.419252,1.0,477.0,3.0,29.0,Adverse Event,Follow-up,FG001,diabetes type 2,INDUSTRY,0.01729267,0.017374775658690406,8.210565869040676e-05
1.0,272.0,260.0,0.003676,0.003676,5.609472,0.419252,1.0,477.0,3.0,29.0,Subjects not reporting status,Follow-up,FG000,diabetes type 2,INDUSTRY,0.00864516,0.008636700944494025,8.459055505975407e-06
2.0,272.0,260.0,0.007353,0.007353,5.609472,0.419252,1.0,477.0,3.0,29.0,Subjects not reporting status,Follow-up,FG001,diabetes type 2,INDUSTRY,0.01729267,0.017354972854583275,6.230285458327586e-05
10.0,560.0,490.0,0.017857,0.017857,6.329721,0.41352,1.0,560.0,6.0,120.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04674004,0.046794622226676574,5.458222667657775e-05
7.0,560.0,490.0,0.0125,0.0125,6.329721,0.41352,1.0,560.0,6.0,120.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03271829,0.03244778530209324,0.00027050469790675796
1.0,560.0,490.0,0.001786,0.001786,6.329721,0.41352,1.0,560.0,6.0,120.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00467479,0.004737923318165581,6.31333181655815e-05
3.0,560.0,490.0,0.005357,0.005357,6.329721,0.41352,1.0,560.0,6.0,120.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01402175,0.013942823415634941,7.892658436505808e-05
1.0,560.0,490.0,0.001786,0.001786,6.329721,0.41352,1.0,560.0,6.0,120.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00467479,0.00473851398691558,6.372398691558041e-05
0.0,560.0,490.0,0.0,0.0,6.329721,0.41352,1.0,560.0,6.0,120.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,560.0,490.0,0.005357,0.005357,6.329721,0.41352,1.0,560.0,6.0,120.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01402175,0.013946866661349224,7.488333865077537e-05
0.0,560.0,490.0,0.0,0.0,6.329721,0.41352,1.0,560.0,6.0,120.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,560.0,490.0,0.021429,0.021429,6.329721,0.41352,1.0,560.0,6.0,120.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05608962,0.05648224019538696,0.00039262019538695986
13.0,560.0,490.0,0.023214,0.023214,6.329721,0.41352,1.0,560.0,6.0,120.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06076179,0.05980449140272184,0.0009572985972781597
10.0,560.0,490.0,0.017857,0.017857,6.329721,0.41352,1.0,560.0,6.0,120.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04674004,0.04674908603560515,9.046035605156377e-06
10.0,560.0,490.0,0.017857,0.017857,6.329721,0.41352,1.0,560.0,6.0,120.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04674004,0.04684737693514883,0.00010733693514883291
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01880514,0.018849804809166856,4.466480916685486e-05
2.0,257.0,240.0,0.007782,0.007782,5.55296,0.870344,1.0,257.0,1.0,25.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03761029,0.038981723114970196,0.0013714331149701983
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01880514,0.0188433487525002,3.820875250019895e-05
2.0,257.0,240.0,0.007782,0.007782,5.55296,0.870344,1.0,257.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03761029,0.03896599850809519,0.001355708508095195
3.0,257.0,240.0,0.011673,0.011673,5.55296,0.870344,1.0,257.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05641543,0.057289881411934626,0.0008744514119346236
3.0,257.0,240.0,0.011673,0.011673,5.55296,0.870344,1.0,257.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05641543,0.05729954064729179,0.0008841106472917901
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01880514,0.018833426134583532,2.8286134583530714e-05
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01880514,0.01885614980184541,5.100980184540721e-05
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01880514,0.018839178425000186,3.4038425000184475e-05
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Assigned Treatment by Mistake,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01880514,0.01883887316875018,3.3733168750178094e-05
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Assigned Treatment by Mistake,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,257.0,240.0,0.0,0.0,5.55296,0.870344,1.0,257.0,1.0,25.0,Assigned Treatment by Mistake,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,240.0,0.003891,0.003891,5.55296,0.870344,1.0,257.0,1.0,25.0,Assigned Treatment by Mistake,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01880514,0.0188369921600002,3.185216000019947e-05
15.0,396.0,334.0,0.037879,0.037879,5.983936,0.527932,1.0,396.0,7.0,54.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11966404,0.12311472298632836,0.003450682986328363
6.0,396.0,334.0,0.015152,0.015152,5.983936,0.527932,1.0,396.0,7.0,54.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04786688,0.047959147094732285,9.226709473228456e-05
6.0,396.0,334.0,0.015152,0.015152,5.983936,0.527932,1.0,396.0,7.0,54.0,Protocol deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04786688,0.04799767767508944,0.00013079767508943768
6.0,396.0,334.0,0.015152,0.015152,5.983936,0.527932,1.0,396.0,7.0,54.0,Protocol deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04786688,0.047957392196518046,9.051219651804582e-05
1.0,396.0,334.0,0.002525,0.002525,5.983936,0.527932,1.0,396.0,7.0,54.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00797676,0.008006961801428588,3.0201801428588956e-05
1.0,396.0,334.0,0.002525,0.002525,5.983936,0.527932,1.0,396.0,7.0,54.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00797676,0.008006361418492081,2.9601418492081893e-05
2.0,396.0,334.0,0.005051,0.005051,5.983936,0.527932,1.0,396.0,7.0,54.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01595668,0.01635686276682091,0.0004001827668209078
3.0,396.0,334.0,0.007576,0.007576,5.983936,0.527932,1.0,396.0,7.0,54.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02393344,0.024174247371696444,0.0002408073716964436
8.0,396.0,334.0,0.020202,0.020202,5.983936,0.527932,1.0,396.0,7.0,54.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0638204,0.06438747697071438,0.0005670769707143836
14.0,396.0,334.0,0.035354,0.035354,5.983936,0.527932,1.0,396.0,7.0,54.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11168728,0.11335280317457241,0.0016655231745724142
1.0,471.0,429.0,0.002123,0.002123,6.156979,0.222179,1.0,471.0,4.0,17.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00290416,0.0029127911401289714,8.631140128971624e-06
0.0,471.0,429.0,0.0,0.0,6.156979,0.222179,1.0,471.0,4.0,17.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,471.0,429.0,0.006369,0.006369,6.156979,0.222179,1.0,471.0,4.0,17.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00871248,0.008763831196686505,5.135119668650545e-05
1.0,471.0,429.0,0.002123,0.002123,6.156979,0.222179,1.0,471.0,4.0,17.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00290416,0.0029114483019146865,7.288301914686653e-06
5.0,471.0,429.0,0.010616,0.010616,6.156979,0.222179,1.0,471.0,4.0,17.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01452217,0.014607402812440485,8.523281244048574e-05
3.0,471.0,429.0,0.006369,0.006369,6.156979,0.222179,1.0,471.0,4.0,17.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00871248,0.008761735666398806,4.9255666398805714e-05
1.0,471.0,429.0,0.002123,0.002123,6.156979,0.222179,1.0,471.0,4.0,17.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00290416,0.0029075479325099234,3.3879325099235406e-06
1.0,471.0,429.0,0.002123,0.002123,6.156979,0.222179,1.0,471.0,4.0,17.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00290416,0.0029064797217956393,2.3197217956395094e-06
7.0,471.0,429.0,0.014862,0.014862,6.156979,0.222179,1.0,471.0,4.0,17.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0203305,0.020357003681884932,2.6503681884931102e-05
4.0,471.0,429.0,0.008493,0.008493,6.156979,0.222179,1.0,471.0,4.0,17.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01161801,0.011761235541547612,0.0001432255415476126
1.0,471.0,429.0,0.002123,0.002123,6.156979,0.222179,1.0,471.0,4.0,17.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00290416,0.0029132154567956376,9.055456795637774e-06
0.0,471.0,429.0,0.0,0.0,6.156979,0.222179,1.0,471.0,4.0,17.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,471.0,429.0,0.012739,0.012739,6.156979,0.222179,1.0,471.0,4.0,17.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01742634,0.017339818964702366,8.6521035297632e-05
7.0,471.0,429.0,0.014862,0.014862,6.156979,0.222179,1.0,471.0,4.0,17.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0203305,0.020325707907619065,4.792092380936225e-06
2.0,471.0,429.0,0.004246,0.004246,6.156979,0.222179,1.0,471.0,4.0,17.0,Did Not Receive Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00580832,0.005723801834940481,8.451816505951858e-05
0.0,471.0,429.0,0.0,0.0,6.156979,0.222179,1.0,471.0,4.0,17.0,Did Not Receive Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,9901.0,9867.0,0.0,0.0,9.200492,0.523564,1.0,9901.0,25.0,300.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,9901.0,9867.0,0.000505,0.000505,9.200492,0.523564,1.0,9901.0,25.0,300.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00243261,0.002489193020982142,5.6583020982142046e-05
10.0,9901.0,9867.0,0.00101,0.00101,9.200492,0.523564,1.0,9901.0,25.0,300.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00486522,0.004927807687271828,6.258768727182822e-05
5.0,9901.0,9867.0,0.000505,0.000505,9.200492,0.523564,1.0,9901.0,25.0,300.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00243261,0.0025978766340178576,0.0001652666340178576
2.0,9901.0,9867.0,0.000202,0.000202,9.200492,0.523564,1.0,9901.0,25.0,300.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00097304,0.0009661445314583338,6.895468541666221e-06
0.0,9901.0,9867.0,0.0,0.0,9.200492,0.523564,1.0,9901.0,25.0,300.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,9901.0,9867.0,0.000505,0.000505,9.200492,0.523564,1.0,9901.0,25.0,300.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00243261,0.0024882032664583316,5.5593266458331576e-05
7.0,9901.0,9867.0,0.000707,0.000707,9.200492,0.523564,1.0,9901.0,25.0,300.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00340565,0.0034604788025992066,5.4828802599206534e-05
3.0,460.0,398.0,0.006522,0.006522,6.133398,0.266168,1.0,460.0,8.0,99.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01064727,0.010626485572023805,2.0784427976195535e-05
2.0,460.0,398.0,0.004348,0.004348,6.133398,0.266168,1.0,460.0,8.0,99.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00709818,0.007108590383124973,1.0410383124973346e-05
5.0,460.0,398.0,0.01087,0.01087,6.133398,0.266168,1.0,460.0,8.0,99.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01774545,0.017818445484434474,7.299548443447448e-05
1.0,460.0,398.0,0.002174,0.002174,6.133398,0.266168,1.0,460.0,8.0,99.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00354909,0.0035551577068650797,6.067706865079715e-06
12.0,460.0,398.0,0.026087,0.026087,6.133398,0.266168,1.0,460.0,8.0,99.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04258746,0.04266241980708327,7.495980708326772e-05
6.0,460.0,398.0,0.013043,0.013043,6.133398,0.266168,1.0,460.0,8.0,99.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02129291,0.02153531139434523,0.0002424013943452298
18.0,460.0,398.0,0.03913,0.03913,6.133398,0.266168,1.0,460.0,8.0,99.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06388037,0.06397345375542926,9.308375542925462e-05
15.0,460.0,398.0,0.032609,0.032609,6.133398,0.266168,1.0,460.0,8.0,99.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05323473,0.052878834221696425,0.00035589577830357627
97.0,17160.0,16906.0,0.005653,0.005653,9.750395,0.526181,1.0,17190.0,34.0,805.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02900254,0.029243274098561523,0.00024073409856152292
127.0,17160.0,16906.0,0.007401,0.007401,9.750395,0.526181,1.0,17190.0,34.0,805.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0379706,0.035679854395367035,0.0022907456046329655
12.0,17160.0,16906.0,0.000699,0.000699,9.750395,0.526181,1.0,17190.0,34.0,805.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0035862,0.003649281207619049,6.308120761904911e-05
18.0,17160.0,16906.0,0.001049,0.001049,9.750395,0.526181,1.0,17190.0,34.0,805.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00538186,0.005479294444345239,9.743444434523983e-05
3.0,521.0,500.0,0.005758,0.005758,6.257668,0.690028,1.0,521.0,6.0,66.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02486283,0.025353700451577383,0.000490870451577384
2.0,521.0,500.0,0.003839,0.003839,6.257668,0.690028,1.0,521.0,6.0,66.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01657666,0.016570938438402787,5.721561597213376e-06
6.0,521.0,500.0,0.011516,0.011516,6.257668,0.690028,1.0,521.0,6.0,66.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04972567,0.04934578888746041,0.00037988111253958734
6.0,521.0,500.0,0.011516,0.011516,6.257668,0.690028,1.0,521.0,6.0,66.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04972567,0.049270825293293734,0.0004548447067062658
0.0,521.0,500.0,0.0,0.0,6.257668,0.690028,1.0,521.0,6.0,66.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,521.0,500.0,0.0,0.0,6.257668,0.690028,1.0,521.0,6.0,66.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,521.0,500.0,0.0,0.0,6.257668,0.690028,1.0,521.0,6.0,66.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,521.0,500.0,0.001919,0.001919,6.257668,0.690028,1.0,521.0,6.0,66.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00828617,0.008324965635714268,3.879563571426714e-05
1.0,521.0,500.0,0.001919,0.001919,6.257668,0.690028,1.0,521.0,6.0,66.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00828617,0.008321487032946407,3.531703294640601e-05
2.0,521.0,500.0,0.003839,0.003839,6.257668,0.690028,1.0,521.0,6.0,66.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01657666,0.016564954793164686,1.1705206835313509e-05
0.0,521.0,500.0,0.0,0.0,6.257668,0.690028,1.0,521.0,6.0,66.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,521.0,500.0,0.0,0.0,6.257668,0.690028,1.0,521.0,6.0,66.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,361.0,350.0,0.00831,0.00831,5.891644,0.335325,1.0,361.0,1.0,15.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01641734,0.01654672212446428,0.00012938212446427996
1.0,361.0,350.0,0.00277,0.00277,5.891644,0.335325,1.0,361.0,1.0,15.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547245,0.005471884916388908,5.650836110921223e-07
2.0,361.0,350.0,0.00554,0.00554,5.891644,0.335325,1.0,361.0,1.0,15.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0109449,0.01105044271190478,0.00010554271190478005
1.0,361.0,350.0,0.00277,0.00277,5.891644,0.335325,1.0,361.0,1.0,15.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547245,0.005469685597013908,2.7644029860921307e-06
2.0,361.0,350.0,0.00554,0.00554,5.891644,0.335325,1.0,361.0,1.0,15.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0109449,0.011051562079761924,0.00010666207976192318
1.0,361.0,350.0,0.00277,0.00277,5.891644,0.335325,1.0,361.0,1.0,15.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547245,0.005469685597013908,2.7644029860921307e-06
1.0,361.0,350.0,0.00277,0.00277,5.891644,0.335325,1.0,361.0,1.0,15.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00547245,0.005470112395823426,2.337604176574047e-06
0.0,361.0,350.0,0.0,0.0,5.891644,0.335325,1.0,361.0,1.0,15.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,737.0,676.0,0.008141,0.008141,6.603944,0.368375,1.0,737.0,3.0,30.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01980483,0.01961101729959415,0.00019381270040584944
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00330121,0.0033115098985416875,1.0299898541687308e-05
2.0,737.0,676.0,0.002714,0.002714,6.603944,0.368375,1.0,737.0,3.0,30.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00660242,0.0063739590703075395,0.0002284609296924608
0.0,737.0,676.0,0.0,0.0,6.603944,0.368375,1.0,737.0,3.0,30.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00330121,0.003315658342648829,1.444834264882882e-05
0.0,737.0,676.0,0.0,0.0,6.603944,0.368375,1.0,737.0,3.0,30.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,737.0,676.0,0.004071,0.004071,6.603944,0.368375,1.0,737.0,3.0,30.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00990363,0.009633934760892861,0.00026969523910713895
8.0,737.0,676.0,0.010855,0.010855,6.603944,0.368375,1.0,737.0,3.0,30.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02640725,0.02658080924404763,0.00017355924404762954
0.0,737.0,676.0,0.0,0.0,6.603944,0.368375,1.0,737.0,3.0,30.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00330121,0.0033086358949107352,7.425894910735066e-06
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00330121,0.0033102291646131166,9.019164613116408e-06
0.0,737.0,676.0,0.0,0.0,6.603944,0.368375,1.0,737.0,3.0,30.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,737.0,676.0,0.014925,0.014925,6.603944,0.368375,1.0,737.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03630845,0.03580750531184522,0.0005009446881547794
12.0,737.0,676.0,0.016282,0.016282,6.603944,0.368375,1.0,737.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03960966,0.0395933880838988,1.62719161012001e-05
12.0,737.0,676.0,0.016282,0.016282,6.603944,0.368375,1.0,737.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03960966,0.039586131623244036,2.352837675596159e-05
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00330121,0.003309192788303592,7.982788303591802e-06
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00330121,0.003310919358005974,9.709358005973931e-06
1.0,737.0,676.0,0.001357,0.001357,6.603944,0.368375,1.0,737.0,3.0,30.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00330121,0.0033013485574107347,1.3855741073454456e-07
9.0,240.0,203.0,0.0375,0.0375,5.484797,0.453954,1.0,240.0,1.0,65.0,Pretreatment Event/Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0933691,0.09409830991988094,0.0007292099198809437
10.0,240.0,203.0,0.041667,0.041667,5.484797,0.453954,1.0,240.0,1.0,65.0,Pretreatment Event/Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10374428,0.10407339020011909,0.0003291102001190954
3.0,240.0,203.0,0.0125,0.0125,5.484797,0.453954,1.0,240.0,1.0,65.0,Voluntary Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03112303,0.03174848101827377,0.0006254510182737739
6.0,240.0,203.0,0.025,0.025,5.484797,0.453954,1.0,240.0,1.0,65.0,Voluntary Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06224607,0.06419252401725369,0.0019464540172536848
2.0,240.0,203.0,0.008333,0.008333,5.484797,0.453954,1.0,240.0,1.0,65.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02074786,0.02141289597767856,0.000665035977678561
3.0,240.0,203.0,0.0125,0.0125,5.484797,0.453954,1.0,240.0,1.0,65.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03112303,0.031669288121874965,0.0005462581218749658
0.0,240.0,203.0,0.0,0.0,5.484797,0.453954,1.0,240.0,1.0,65.0,Change Insulin Dosage Exceeding Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,240.0,203.0,0.008333,0.008333,5.484797,0.453954,1.0,240.0,1.0,65.0,Change Insulin Dosage Exceeding Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02074786,0.02168988428011904,0.0009420242801190387
2.0,240.0,203.0,0.008333,0.008333,5.484797,0.453954,1.0,240.0,1.0,65.0,Inconvenient Schedule,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02074786,0.02141144021517856,0.0006635802151785594
0.0,240.0,203.0,0.0,0.0,5.484797,0.453954,1.0,240.0,1.0,65.0,Inconvenient Schedule,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
28.0,1291.0,1222.0,0.021689,0.021689,7.163947,0.856205,1.0,1291.0,22.0,281.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13303607,0.13361156788131953,0.0005754978813195255
24.0,1291.0,1222.0,0.01859,0.01859,7.163947,0.856205,1.0,1291.0,22.0,281.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11402741,0.11913846635717258,0.005111056357172586
4.0,1291.0,1222.0,0.003098,0.003098,7.163947,0.856205,1.0,1291.0,22.0,281.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01900252,0.01921175478907737,0.000209234789077372
7.0,1291.0,1222.0,0.005422,0.005422,7.163947,0.856205,1.0,1291.0,22.0,281.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03325748,0.03614613685529761,0.002888656855297614
2.0,1291.0,1222.0,0.001549,0.001549,7.163947,0.856205,1.0,1291.0,22.0,281.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00950126,0.009559887268283723,5.8627268283723694e-05
3.0,1291.0,1222.0,0.002324,0.002324,7.163947,0.856205,1.0,1291.0,22.0,281.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01425496,0.01535114110517857,0.0010961811051785689
1.0,1291.0,1222.0,0.000775,0.000775,7.163947,0.856205,1.0,1291.0,22.0,281.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0047537,0.005143802364818718,0.00039010236481871845
0.0,1291.0,1222.0,0.0,0.0,7.163947,0.856205,1.0,1291.0,22.0,281.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,517.0,414.0,0.021277,0.021277,6.249975,0.243557,1.0,517.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03238833,0.03248183781297614,9.350781297613742e-05
12.0,517.0,414.0,0.023211,0.023211,6.249975,0.243557,1.0,517.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03533231,0.035187746204603194,0.0001445637953968043
0.0,517.0,414.0,0.0,0.0,6.249975,0.243557,1.0,517.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,517.0,414.0,0.005803,0.005803,6.249975,0.243557,1.0,517.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00883346,0.008834367760190288,9.077601902888338e-07
10.0,517.0,414.0,0.019342,0.019342,6.249975,0.243557,1.0,517.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02944283,0.029401587359761002,4.1242640238997597e-05
6.0,517.0,414.0,0.011605,0.011605,6.249975,0.243557,1.0,517.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01766539,0.017519873730456353,0.00014551626954364613
4.0,517.0,414.0,0.007737,0.007737,6.249975,0.243557,1.0,517.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01177744,0.011816195334295631,3.87553342956308e-05
5.0,517.0,414.0,0.009671,0.009671,6.249975,0.243557,1.0,517.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01472141,0.014549259103878958,0.00017215089612104308
1.0,517.0,414.0,0.001934,0.001934,6.249975,0.243557,1.0,517.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00294398,0.0029489612137265525,4.981213726552337e-06
0.0,517.0,414.0,0.0,0.0,6.249975,0.243557,1.0,517.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,517.0,414.0,0.007737,0.007737,6.249975,0.243557,1.0,517.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01177744,0.011816155850248011,3.8715850248010816e-05
2.0,517.0,414.0,0.003868,0.003868,6.249975,0.243557,1.0,517.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00588796,0.005862781137291666,2.517886270833429e-05
10.0,517.0,414.0,0.019342,0.019342,6.249975,0.243557,1.0,517.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02944283,0.02941369607886815,2.913392113184851e-05
9.0,517.0,414.0,0.017408,0.017408,6.249975,0.243557,1.0,517.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02649885,0.027352409486093097,0.0008535594860930966
11.0,517.0,414.0,0.021277,0.021277,6.249975,0.243557,1.0,517.0,0.0,0.0,Protocol Specific Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03238833,0.03246798125068447,7.965125068447321e-05
15.0,517.0,414.0,0.029014,0.029014,6.249975,0.243557,1.0,517.0,0.0,0.0,Protocol Specific Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04416576,0.045214321931451106,0.0010485619314511072
9.0,458.0,348.0,0.019651,0.019651,6.12905,0.266168,1.0,458.0,7.0,93.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03205784,0.03223011970261905,0.00017227970261905062
2.0,458.0,348.0,0.004367,0.004367,6.12905,0.266168,1.0,458.0,7.0,93.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00712415,0.007115657256071412,8.492743928587704e-06
0.0,458.0,348.0,0.0,0.0,6.12905,0.266168,1.0,458.0,7.0,93.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,458.0,348.0,0.002183,0.002183,6.12905,0.266168,1.0,458.0,7.0,93.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00356126,0.0035565827330853177,4.677266914682437e-06
7.0,458.0,348.0,0.015284,0.015284,6.12905,0.266168,1.0,458.0,7.0,93.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02493369,0.025070510072460327,0.00013682007246032524
12.0,458.0,348.0,0.026201,0.026201,6.12905,0.266168,1.0,458.0,7.0,93.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04274324,0.04262372328020828,0.00011951671979171935
3.0,458.0,348.0,0.00655,0.00655,6.12905,0.266168,1.0,458.0,7.0,93.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0106854,0.010650853869999992,3.454613000000717e-05
5.0,458.0,348.0,0.010917,0.010917,6.12905,0.266168,1.0,458.0,7.0,93.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01780955,0.017916745405386906,0.0001071954053869055
36.0,458.0,348.0,0.078603,0.078603,6.12905,0.266168,1.0,458.0,7.0,93.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12822973,0.13124175274530764,0.003012022745307652
35.0,458.0,348.0,0.076419,0.076419,6.12905,0.266168,1.0,458.0,7.0,93.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12466684,0.12715234254958335,0.0024855025495833516
7.0,462.0,425.0,0.015152,0.015152,6.137727,0.312053,1.0,462.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02902057,0.02917055592056545,0.00014998592056545204
5.0,462.0,425.0,0.010823,0.010823,6.137727,0.312053,1.0,462.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02072925,0.02074051641680551,1.1266416805509605e-05
5.0,462.0,425.0,0.010823,0.010823,6.137727,0.312053,1.0,462.0,1.0,1.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02072925,0.020736547829424565,7.297829424563612e-06
5.0,462.0,425.0,0.010823,0.010823,6.137727,0.312053,1.0,462.0,1.0,1.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02072925,0.020733157794007896,3.907794007895066e-06
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00414662,0.0041518453458630885,5.225345863088364e-06
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00414662,0.0041523987312797545,5.778731279754319e-06
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,462.0,425.0,0.006494,0.006494,6.137727,0.312053,1.0,462.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01243793,0.012512852538105149,7.492253810514882e-05
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00414662,0.004150296226339278,3.676226339278249e-06
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00414662,0.0041510643680059455,4.444368005945311e-06
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,462.0,425.0,0.006494,0.006494,6.137727,0.312053,1.0,462.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01243793,0.01250230223331348,6.437223331347969e-05
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00414662,0.004151132568839278,4.512568839277684e-06
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00414662,0.004151937823005946,5.317823005945854e-06
2.0,462.0,425.0,0.004329,0.004329,6.137727,0.312053,1.0,462.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00829132,0.00844429304479978,0.0001529730447997809
1.0,462.0,425.0,0.002165,0.002165,6.137727,0.312053,1.0,462.0,1.0,1.0,Personal matter,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00414662,0.004148981800089279,2.361800089278887e-06
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Personal matter,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Personal matter,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,462.0,425.0,0.0,0.0,6.137727,0.312053,1.0,462.0,1.0,1.0,Personal matter,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,300.0,271.0,0.033333,0.033333,5.70711,0.379199,1.0,300.0,8.0,31.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07213698,0.07365508427922617,0.0015181042792261623
0.0,300.0,271.0,0.0,0.0,5.70711,0.379199,1.0,300.0,8.0,31.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,300.0,271.0,0.003333,0.003333,5.70711,0.379199,1.0,300.0,8.0,31.0,Entry criteria not met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00721305,0.0071987484903869026,1.4301509613097799e-05
0.0,300.0,271.0,0.0,0.0,5.70711,0.379199,1.0,300.0,8.0,31.0,Entry criteria not met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,300.0,271.0,0.003333,0.003333,5.70711,0.379199,1.0,300.0,8.0,31.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00721305,0.007202359310624996,1.0690689375003962e-05
1.0,300.0,271.0,0.003333,0.003333,5.70711,0.379199,1.0,300.0,8.0,31.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00721305,0.00720932944645833,3.7205535416704252e-06
10.0,300.0,271.0,0.033333,0.033333,5.70711,0.379199,1.0,300.0,8.0,31.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07213698,0.07402093491264879,0.0018839549126487831
3.0,300.0,271.0,0.01,0.01,5.70711,0.379199,1.0,300.0,8.0,31.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02164131,0.022212905416547645,0.0005715954165476447
1.0,300.0,271.0,0.003333,0.003333,5.70711,0.379199,1.0,300.0,8.0,31.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00721305,0.0071987484903869026,1.4301509613097799e-05
0.0,300.0,271.0,0.0,0.0,5.70711,0.379199,1.0,300.0,8.0,31.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,300.0,271.0,0.006667,0.006667,5.70711,0.379199,1.0,300.0,8.0,31.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01442826,0.014347558159950386,8.070184004961393e-05
0.0,300.0,271.0,0.0,0.0,5.70711,0.379199,1.0,300.0,8.0,31.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
39.0,1538.0,1287.0,0.025358,0.025358,7.338888,0.350295,1.0,1538.0,23.0,167.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0651898,0.06458624159836307,0.0006035584016369361
21.0,1538.0,1287.0,0.013654,0.013654,7.338888,0.350295,1.0,1538.0,23.0,167.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03510141,0.03505217768391864,4.923231608135875e-05
7.0,1538.0,1287.0,0.004551,0.004551,7.338888,0.350295,1.0,1538.0,23.0,167.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01169961,0.011822962698030307,0.00012335269803030735
2.0,1538.0,1287.0,0.0013,0.0013,7.338888,0.350295,1.0,1538.0,23.0,167.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00334201,0.003314404896339286,2.7605103660713684e-05
22.0,1538.0,1287.0,0.014304,0.014304,7.338888,0.350295,1.0,1538.0,23.0,167.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03677242,0.03576379328302579,0.0010086267169742077
13.0,1538.0,1287.0,0.008453,0.008453,7.338888,0.350295,1.0,1538.0,23.0,167.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02173079,0.021705672448660743,2.5117551339257083e-05
16.0,1538.0,1287.0,0.010403,0.010403,7.338888,0.350295,1.0,1538.0,23.0,167.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02674381,0.026862837134771837,0.00011902713477183677
13.0,1538.0,1287.0,0.008453,0.008453,7.338888,0.350295,1.0,1538.0,23.0,167.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02173079,0.02171651100491074,1.4278995089260504e-05
66.0,1538.0,1287.0,0.042913,0.042913,7.338888,0.350295,1.0,1538.0,23.0,167.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11031982,0.1084071236957243,0.0019126963042756934
24.0,1538.0,1287.0,0.015605,0.015605,7.338888,0.350295,1.0,1538.0,23.0,167.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.040117,0.03927245648239087,0.0008445435176091323
20.0,1538.0,1287.0,0.013004,0.013004,7.338888,0.350295,1.0,1538.0,23.0,167.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0334304,0.0334812249223512,5.0824922351200286e-05
7.0,1538.0,1287.0,0.004551,0.004551,7.338888,0.350295,1.0,1538.0,23.0,167.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01169961,0.011815832810242611,0.00011622281024261175
1.0,1538.0,1287.0,0.00065,0.00065,7.338888,0.350295,1.0,1538.0,23.0,167.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00167101,0.001681187666785715,1.017766678571507e-05
0.0,1538.0,1287.0,0.0,0.0,7.338888,0.350295,1.0,1538.0,23.0,167.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,879.0,423.0,0.015927,0.015927,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.05103825,0.050467888109315434,0.0005703618906845662
7.0,879.0,423.0,0.007964,0.007964,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02552073,0.025443550856785714,7.717914321428432e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Open-label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,879.0,423.0,0.002275,0.002275,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00729026,0.0073057468008928565,1.5486800892856693e-05
2.0,879.0,423.0,0.002275,0.002275,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00729026,0.007306414463809521,1.6154463809521166e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Open-label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,879.0,423.0,0.003413,0.003413,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.010937,0.010879829391198114,5.7170608801886125e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Lost to Follow-up,Open-label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,879.0,423.0,0.004551,0.004551,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01458373,0.014340144793214278,0.00024358520678572151
7.0,879.0,423.0,0.007964,0.007964,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02552073,0.02546509038261905,5.5639617380948136e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Open-label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
204.0,879.0,423.0,0.232082,0.232082,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.74370935,0.7307469960212204,0.01296235397877965
189.0,879.0,423.0,0.215017,0.215017,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.68902437,0.6801133917663097,0.008910978233690359
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Open-label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,879.0,423.0,0.002275,0.002275,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00729026,0.007300411500059518,1.015150005951801e-05
6.0,879.0,423.0,0.006826,0.006826,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.02187399,0.021777804024583305,9.618597541669396e-05
4.0,879.0,423.0,0.004551,0.004551,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.01458373,0.014320679412321428,0.0002630505876785715
5.0,879.0,423.0,0.005688,0.005688,6.779922,0.472647,1.0,880.0,1.0,83.0,Adverse Event,Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.01822726,0.018209097806921,1.8162193078999356e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,879.0,423.0,0.001138,0.001138,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00364673,0.0036381888128373154,8.541187162684587e-06
1.0,879.0,423.0,0.001138,0.001138,6.779922,0.472647,1.0,880.0,1.0,83.0,Protocol Violation,Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00364673,0.0036380382545039822,8.69174549601769e-06
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,879.0,423.0,0.002275,0.002275,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00729026,0.007292979537559519,2.7195375595194526e-06
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,879.0,423.0,0.002275,0.002275,6.779922,0.472647,1.0,880.0,1.0,83.0,Withdrawal by Subject,Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00729026,0.007293890683392853,3.63068339285285e-06
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,879.0,423.0,0.001138,0.001138,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00364673,0.0036360637378373153,1.0666262162684678e-05
0.0,879.0,423.0,0.0,0.0,6.779922,0.472647,1.0,880.0,1.0,83.0,Other than specified above,Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02364787,0.0236655526650891,1.768266508909988e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03152374,0.03167152560346065,0.000147785603460647
6.0,857.0,743.0,0.007001,0.007001,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04728898,0.047320645656220225,3.166565622022416e-05
6.0,857.0,743.0,0.007001,0.007001,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04728898,0.04731621208300594,2.723208300593749e-05
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.03940636,0.03935057029562481,5.578970437519065e-05
2.0,857.0,743.0,0.002334,0.002334,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01576525,0.015749972304940504,1.527769505949711e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.03152374,0.031583758508044,6.001850804399772e-05
2.0,857.0,743.0,0.002334,0.002334,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01576525,0.0157449709972024,2.0279002797600476e-05
1.0,857.0,743.0,0.001167,0.001167,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00788262,0.007817344810674608,6.527518932539222e-05
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02364787,0.023643774547916493,4.095452083508616e-06
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02364787,0.023677461997112893,2.9591997112891205e-05
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02364787,0.023671530935862894,2.366093586289239e-05
2.0,857.0,743.0,0.002334,0.002334,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01576525,0.015762229958273838,3.0200417261636026e-06
0.0,857.0,743.0,0.0,0.0,6.754604,1.0,1.0,857.0,14.0,138.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,857.0,743.0,0.001167,0.001167,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00788262,0.007824582457202385,5.8037542797614514e-05
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02364787,0.023605698339136748,4.217166086325358e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03152374,0.03151892167792498,4.818322075023085e-06
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02364787,0.023623578362112898,2.429163788710345e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.03152374,0.03151368584042498,1.0054159575022259e-05
0.0,857.0,743.0,0.0,0.0,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,857.0,743.0,0.0,0.0,6.754604,1.0,1.0,857.0,14.0,138.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03940636,0.039215459410535544,0.0001909005894644572
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03152374,0.03157655820542495,5.281820542495097e-05
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03940636,0.03935274213907719,5.361786092281107e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03152374,0.03149451922167496,2.9220778325039776e-05
2.0,857.0,743.0,0.002334,0.002334,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01576525,0.01576240978410716,2.8402158928422794e-06
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02364787,0.023652318566874796,4.44856687479428e-06
1.0,857.0,743.0,0.001167,0.001167,6.754604,1.0,1.0,857.0,14.0,138.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00788262,0.007818075746091271,6.454425390872882e-05
7.0,857.0,743.0,0.008168,0.008168,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG000,diabetes type 2,INDUSTRY,0.05517161,0.05555242969354175,0.0003808196935417493
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG001,diabetes type 2,INDUSTRY,0.03940636,0.03928450082020814,0.00012185917979186389
3.0,857.0,743.0,0.003501,0.003501,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG002,diabetes type 2,INDUSTRY,0.02364787,0.023620333842142682,2.753615785731911e-05
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG003,diabetes type 2,INDUSTRY,0.03940636,0.039334548401041475,7.181159895852662e-05
2.0,857.0,743.0,0.002334,0.002334,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG004,diabetes type 2,INDUSTRY,0.01576525,0.015748694642440497,1.655535755950427e-05
4.0,857.0,743.0,0.004667,0.004667,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG005,diabetes type 2,INDUSTRY,0.03152374,0.03148960615875828,3.413384124172081e-05
5.0,857.0,743.0,0.005834,0.005834,6.754604,1.0,1.0,857.0,14.0,138.0,Other reason (incl. lack of efficacy),Overall Study,FG006,diabetes type 2,INDUSTRY,0.03940636,0.039305445614374795,0.00010091438562520594
3.0,480.0,404.0,0.00625,0.00625,6.175867,0.316529,1.0,480.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01221777,0.012875796425982135,0.0006580264259821358
4.0,480.0,404.0,0.008333,0.008333,6.175867,0.316529,1.0,480.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01628971,0.016615264828511885,0.0003255548285118863
7.0,480.0,404.0,0.014583,0.014583,6.175867,0.316529,1.0,480.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02850747,0.028438125194457015,6.934480554298544e-05
2.0,480.0,404.0,0.004167,0.004167,6.175867,0.316529,1.0,480.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00814583,0.008440389406201156,0.00029455940620115584
1.0,480.0,404.0,0.002083,0.002083,6.175867,0.316529,1.0,480.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00407194,0.004067051252470234,4.888747529765286e-06
7.0,480.0,404.0,0.014583,0.014583,6.175867,0.316529,1.0,480.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02850747,0.028390928603147497,0.0001165413968525035
1.0,480.0,404.0,0.002083,0.002083,6.175867,0.316529,1.0,480.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00407194,0.004067690516398806,4.249483601193385e-06
5.0,480.0,404.0,0.010417,0.010417,6.175867,0.316529,1.0,480.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0203636,0.020348990100743983,1.4609899256015635e-05
15.0,480.0,404.0,0.03125,0.03125,6.175867,0.316529,1.0,480.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06108884,0.06127968021271821,0.00019084021271820878
11.0,480.0,404.0,0.022917,0.022917,6.175867,0.316529,1.0,480.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04479914,0.045277275257182524,0.00047813525718252287
0.0,480.0,404.0,0.0,0.0,6.175867,0.316529,1.0,480.0,0.0,0.0,Non Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,480.0,404.0,0.002083,0.002083,6.175867,0.316529,1.0,480.0,0.0,0.0,Non Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407194,0.004063714868720233,8.225131279766297e-06
5.0,480.0,404.0,0.010417,0.010417,6.175867,0.316529,1.0,480.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0203636,0.020357737267023734,5.862732976265328e-06
4.0,480.0,404.0,0.008333,0.008333,6.175867,0.316529,1.0,480.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01628971,0.016571961807470222,0.00028225180747022335
5.0,480.0,404.0,0.010417,0.010417,6.175867,0.316529,1.0,480.0,0.0,0.0,Hyperglycemia Discontinuation Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0203636,0.020347289922023736,1.6310077976262882e-05
5.0,480.0,404.0,0.010417,0.010417,6.175867,0.316529,1.0,480.0,0.0,0.0,Hyperglycemia Discontinuation Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0203636,0.020365076520386848,1.476520386848451e-06
3.0,873.0,791.0,0.003436,0.003436,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00832822,0.00830672635141867,2.149364858133017e-05
4.0,873.0,791.0,0.004582,0.004582,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01110591,0.011025591866874993,8.031813312500691e-05
9.0,873.0,791.0,0.010309,0.010309,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02498708,0.024979192845505968,7.88715449403024e-06
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00555295,0.005546773324003417,6.176675996583461e-06
7.0,873.0,791.0,0.008018,0.008018,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01943413,0.019516028177364718,8.189817736471705e-05
3.0,873.0,791.0,0.003436,0.003436,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00832822,0.008308051012252005,2.016898774799547e-05
5.0,873.0,791.0,0.005727,0.005727,6.77308,0.35786,1.0,876.0,4.0,56.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01388117,0.013749897584613098,0.00013127241538690194
3.0,873.0,791.0,0.003436,0.003436,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00832822,0.008303560061478196,2.4659938521805203e-05
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00277526,0.0027768314266666426,1.5714266666426793e-06
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00277526,0.0027768420220833116,1.582022083311714e-06
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00555295,0.005550629814420083,2.320185579916985e-06
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00277526,0.002782433801924582,7.173801924581936e-06
3.0,873.0,791.0,0.003436,0.003436,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00832822,0.00830335669463296,2.486330536704065e-05
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Non compliance with protocol,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00555295,0.005533867102158184,1.9082897841815778e-05
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00277526,0.0027768271716666426,1.567171666642768e-06
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00555295,0.005539000177753418,1.3949822246581665e-05
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00555295,0.005539625847753419,1.3324152246581115e-05
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00277526,0.0027763603072618803,1.100307261880408e-06
8.0,873.0,791.0,0.009164,0.009164,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02221181,0.021594464843675137,0.0006173451563248611
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,873.0,791.0,0.004582,0.004582,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01110591,0.011023002597291656,8.290740270834422e-05
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00555295,0.00554774145858675,5.208541413249772e-06
8.0,873.0,791.0,0.009164,0.009164,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02221181,0.021564418570758467,0.0006473914292415318
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00277526,0.0027768420220833116,1.582022083311714e-06
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Refused to continue trial medication,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00277526,0.0027763645622618806,1.104562261880753e-06
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00277526,0.002777218001428552,1.958001428551976e-06
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00277526,0.002782136564007913,6.876564007913134e-06
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00277526,0.0027772636330952185,2.003633095218598e-06
1.0,873.0,791.0,0.001145,0.001145,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00277526,0.0027764633904166424,1.2033904166425594e-06
2.0,873.0,791.0,0.002291,0.002291,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00555295,0.00554774145858675,5.208541413249772e-06
0.0,873.0,791.0,0.0,0.0,6.77308,0.35786,1.0,876.0,4.0,56.0,Other Reason,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,441.0,159.0,0.022676,0.022676,6.09131,0.190909,1.0,441.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02636963,0.02728318748462031,0.000913557484620308
7.0,441.0,159.0,0.015873,0.015873,6.09131,0.190909,1.0,441.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01845851,0.01856267453476192,0.00010416453476191911
2.0,441.0,159.0,0.004535,0.004535,6.09131,0.190909,1.0,441.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00527369,0.005370698915615075,9.700891561507507e-05
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00263743,0.002642755453747316,5.325453747315797e-06
67.0,441.0,159.0,0.151927,0.151927,6.09131,0.190909,1.0,441.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.17667399,0.19227936941604176,0.01560537941604176
69.0,441.0,159.0,0.156463,0.156463,6.09131,0.190909,1.0,441.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.18194885,0.20906319366441475,0.02711434366441476
7.0,441.0,159.0,0.015873,0.015873,6.09131,0.190909,1.0,441.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01845851,0.01865837210708334,0.00019986210708334076
3.0,441.0,159.0,0.006803,0.006803,6.09131,0.190909,1.0,441.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00791112,0.008075855486393403,0.00016473548639340217
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00263743,0.002639213662497318,1.7836624973178485e-06
0.0,441.0,159.0,0.0,0.0,6.09131,0.190909,1.0,441.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,441.0,159.0,0.00907,0.00907,6.09131,0.190909,1.0,441.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01054739,0.010705592260267863,0.00015820226026786247
7.0,441.0,159.0,0.015873,0.015873,6.09131,0.190909,1.0,441.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01845851,0.01862644824541668,0.00016793824541667945
14.0,441.0,159.0,0.031746,0.031746,6.09131,0.190909,1.0,441.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03691702,0.036739320718293625,0.0001776992817063769
21.0,441.0,159.0,0.047619,0.047619,6.09131,0.190909,1.0,441.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05537553,0.055855359796081354,0.0004798297960813547
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Patient moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00263743,0.002639213662497318,1.7836624973178485e-06
0.0,441.0,159.0,0.0,0.0,6.09131,0.190909,1.0,441.0,0.0,0.0,Patient moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,441.0,159.0,0.0,0.0,6.09131,0.190909,1.0,441.0,0.0,0.0,Site terminated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Site terminated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00263743,0.002642755453747316,5.325453747315797e-06
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Planned major surgery,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00263743,0.002639213662497318,1.7836624973178485e-06
0.0,441.0,159.0,0.0,0.0,6.09131,0.190909,1.0,441.0,0.0,0.0,Planned major surgery,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
22.0,441.0,159.0,0.049887,0.049887,6.09131,0.190909,1.0,441.0,0.0,0.0,Patient Received Glycemic Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05801296,0.057687057931507926,0.00032590206849207604
41.0,441.0,159.0,0.092971,0.092971,6.09131,0.190909,1.0,441.0,0.0,0.0,Patient Received Glycemic Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.1081148,0.11913913666541215,0.011024336665412152
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Unable to re-enter US,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00263743,0.002639213662497318,1.7836624973178485e-06
0.0,441.0,159.0,0.0,0.0,6.09131,0.190909,1.0,441.0,0.0,0.0,Unable to re-enter US,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Laboratory test,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00263743,0.002638830952497318,1.4009524973179234e-06
1.0,441.0,159.0,0.002268,0.002268,6.09131,0.190909,1.0,441.0,0.0,0.0,Laboratory test,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00263743,0.002642187793747316,4.757793747315903e-06
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00798498,0.007995085796666631,1.0105796666631806e-05
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00798498,0.007993953531765838,8.973531765838622e-06
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00598873,0.006020875383032118,3.214538303211809e-05
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00399249,0.0039937907243452146,1.3007243452149708e-06
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00399249,0.003992892086845215,4.020868452150883e-07
5.0,1160.0,1064.0,0.00431,0.00431,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00998122,0.010145533324434498,0.00016431332443449763
6.0,1160.0,1064.0,0.005172,0.005172,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01197746,0.012017887141111138,4.042714111113753e-05
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00399249,0.003996758857261882,4.268857261882121e-06
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00598873,0.00601019585446069,2.146585446068973e-05
5.0,1160.0,1064.0,0.00431,0.00431,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00998122,0.010144873041101166,0.0001636530411011656
6.0,1160.0,1064.0,0.005172,0.005172,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG010,diabetes type 2,INDUSTRY,0.01197746,0.012017887141111138,4.042714111113753e-05
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00199624,0.001996352703731953,1.1270373195338204e-07
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Adverse Event,Overall Study,FG012,diabetes type 2,INDUSTRY,0.00598873,0.00601019585446069,2.146585446068973e-05
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00199624,0.0019977677665295747,1.527766529574922e-06
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00199624,0.0019945372387716355,1.7027612283643245e-06
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00399249,0.003996002323511883,3.5123235118837345e-06
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lack of Efficacy,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00199624,0.001996262540190286,2.2540190286295114e-08
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00199624,0.001996460104952191,2.2010495219102963e-07
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Protocol Violation,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Lost to Follow-up,Overall Study,FG012,diabetes type 2,INDUSTRY,0.00199624,0.0019965252537319533,2.8525373195345885e-07
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00798498,0.007993531282380908,8.551282380909325e-06
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00798498,0.007990837226230117,5.85722623011771e-06
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00199624,0.0019958606316486205,3.793683513793507e-07
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00199624,0.0019952361404383017,1.003859561698149e-06
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00598873,0.006000930490694455,1.2200490694455092e-05
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00798498,0.007987061139523764,2.0811395237650687e-06
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00399249,0.0039990516971725966,6.561697172596977e-06
5.0,1160.0,1064.0,0.00431,0.00431,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00998122,0.010145578470446408,0.0001643584704464074
4.0,1160.0,1064.0,0.003448,0.003448,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00798498,0.007987716739523764,2.736739523764853e-06
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00598873,0.006000980365694455,1.225036569445486e-05
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00399249,0.00399584713300593,3.357133005930761e-06
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Withdrawal by Subject,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00399249,0.003991611688511884,8.78311488115846e-07
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00199624,0.001995984374188302,2.5562581169782245e-07
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00199624,0.001997040408970049,8.004089700492517e-07
2.0,1160.0,1064.0,0.001724,0.001724,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00399249,0.0039929637280952165,4.737280952168965e-07
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1160.0,1064.0,0.000862,0.000862,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00199624,0.0019972379737319534,9.979737319535525e-07
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1160.0,1064.0,0.0,0.0,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1160.0,1064.0,0.002586,0.002586,7.057037,0.328159,1.0,1162.0,1.0,87.0,Other reason not defined above,Overall Study,FG012,diabetes type 2,INDUSTRY,0.00598873,0.006004532350294024,1.580235029402348e-05
2.0,321.0,310.0,0.006231,0.006231,5.774552,0.489083,1.0,321.0,8.0,87.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0175978,0.017687764763650783,8.99647636507829e-05
4.0,321.0,310.0,0.012461,0.012461,5.774552,0.489083,1.0,321.0,8.0,87.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03519278,0.035331743625059586,0.00013896362505958632
1.0,321.0,310.0,0.003115,0.003115,5.774552,0.489083,1.0,321.0,8.0,87.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00879749,0.008824415283134946,2.6925283134946604e-05
1.0,321.0,310.0,0.003115,0.003115,5.774552,0.489083,1.0,321.0,8.0,87.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00879749,0.008823773766706374,2.6283766706373946e-05
1.0,321.0,310.0,0.003115,0.003115,5.774552,0.489083,1.0,321.0,8.0,87.0,Other Eligibility criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00879749,0.008845235353015894,4.7745353015894373e-05
2.0,321.0,310.0,0.006231,0.006231,5.774552,0.489083,1.0,321.0,8.0,87.0,Other Eligibility criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0175978,0.017695986428650782,9.818642865078164e-05
10.0,170.0,92.0,0.058824,0.058824,5.141664,0.25113,1.0,572.0,14.0,74.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07595511,0.08080550011347225,0.004850390113472242
17.0,170.0,92.0,0.1,0.1,5.141664,0.25113,1.0,572.0,14.0,74.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12912265,0.1281673860748811,0.0009552639251189099
13.0,170.0,92.0,0.076471,0.076471,5.141664,0.25113,1.0,572.0,14.0,74.0,Study specific discontinuation criteris,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09874138,0.10424246451258941,0.005501084512589405
16.0,170.0,92.0,0.094118,0.094118,5.141664,0.25113,1.0,572.0,14.0,74.0,Study specific discontinuation criteris,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12152765,0.12402455437044661,0.002496904370446612
2.0,170.0,92.0,0.011765,0.011765,5.141664,0.25113,1.0,572.0,14.0,74.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01519128,0.015898377320049607,0.0007070973200496069
5.0,170.0,92.0,0.029412,0.029412,5.141664,0.25113,1.0,572.0,14.0,74.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03797755,0.04110656020228174,0.0031290102022817415
1.0,170.0,92.0,0.005882,0.005882,5.141664,0.25113,1.0,572.0,14.0,74.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00759499,0.008024896492738081,0.0004299064927380811
2.0,170.0,92.0,0.011765,0.011765,5.141664,0.25113,1.0,572.0,14.0,74.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01519128,0.015855919961240087,0.0006646399612400874
4.0,170.0,92.0,0.023529,0.023529,5.141664,0.25113,1.0,572.0,14.0,74.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03038127,0.031514665353988114,0.0011333953539881154
3.0,170.0,92.0,0.017647,0.017647,5.141664,0.25113,1.0,572.0,14.0,74.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02278627,0.027003314986448434,0.004217044986448433
4.0,170.0,92.0,0.023529,0.023529,5.141664,0.25113,1.0,572.0,14.0,74.0,Poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03038127,0.031514665353988114,0.0011333953539881154
0.0,170.0,92.0,0.0,0.0,5.141664,0.25113,1.0,572.0,14.0,74.0,Poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,170.0,92.0,0.005882,0.005882,5.141664,0.25113,1.0,572.0,14.0,74.0,Hospitalized due to kidney transplant,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00759499,0.008024896492738081,0.0004299064927380811
0.0,170.0,92.0,0.0,0.0,5.141664,0.25113,1.0,572.0,14.0,74.0,Hospitalized due to kidney transplant,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,7637.0,7489.0,0.0,0.0,8.940891,0.446155,1.0,7637.0,20.0,446.0,Adverse event (not hypoglycaemia),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Adverse event (not hypoglycaemia),Overall Study,FG001,diabetes type 2,INDUSTRY,0.00052256,0.0005253224095589851,2.7624095589850453e-06
4.0,7637.0,7489.0,0.000524,0.000524,8.940891,0.446155,1.0,7637.0,20.0,446.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00209025,0.001976100045644843,0.00011414995435515699
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00052256,0.0005256633812256517,3.103381225651701e-06
70.0,7637.0,7489.0,0.009166,0.009166,8.940891,0.446155,1.0,7637.0,20.0,446.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03656338,0.036150139317351185,0.0004132406826488147
68.0,7637.0,7489.0,0.008904,0.008904,8.940891,0.446155,1.0,7637.0,20.0,446.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03551825,0.03559420372800593,7.595372800592998e-05
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Hypoglycaemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00052256,0.0005245960994796199,2.036099479619819e-06
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Hypoglycaemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00052256,0.0005242955403129535,1.735540312953446e-06
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Lack of glycaemic control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00052256,0.0005247987587950962,2.238758795096202e-06
1.0,7637.0,7489.0,0.000131,0.000131,8.940891,0.446155,1.0,7637.0,20.0,446.0,Lack of glycaemic control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00052256,0.0005244981996284298,1.9381996284297204e-06
12.0,566.0,455.0,0.021201,0.021201,6.340359,1.0,1.0,567.0,14.0,112.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13442196,0.13263623567731148,0.001785724322688531
13.0,566.0,455.0,0.022968,0.022968,6.340359,1.0,1.0,567.0,14.0,112.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.14562537,0.13982426874031736,0.0058011012596826395
11.0,566.0,455.0,0.019435,0.019435,6.340359,1.0,1.0,567.0,14.0,112.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.12322488,0.12385075895432639,0.0006258789543263921
4.0,566.0,455.0,0.007067,0.007067,6.340359,1.0,1.0,567.0,14.0,112.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04480732,0.0441797322928572,0.0006275877071427946
1.0,566.0,455.0,0.001767,0.001767,6.340359,1.0,1.0,567.0,14.0,112.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01120341,0.011303763822123019,0.00010035382212301817
2.0,566.0,455.0,0.003534,0.003534,6.340359,1.0,1.0,567.0,14.0,112.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02240683,0.022677194268809587,0.0002703642688095878
1.0,566.0,455.0,0.001767,0.001767,6.340359,1.0,1.0,567.0,14.0,112.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01120341,0.011301535538134923,9.812553813492303e-05
2.0,566.0,455.0,0.003534,0.003534,6.340359,1.0,1.0,567.0,14.0,112.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02240683,0.02265096018556555,0.00024413018556555116
2.0,566.0,455.0,0.003534,0.003534,6.340359,1.0,1.0,567.0,14.0,112.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02240683,0.022589916648095308,0.00018308664809530903
9.0,566.0,455.0,0.015901,0.015901,6.340359,1.0,1.0,567.0,14.0,112.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10081805,0.0967991834086111,0.004018866591388906
15.0,566.0,455.0,0.026502,0.026502,6.340359,1.0,1.0,567.0,14.0,112.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.1680322,0.16117678656963288,0.006855413430367108
3.0,566.0,455.0,0.0053,0.0053,6.340359,1.0,1.0,567.0,14.0,112.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0336039,0.03346148260808537,0.00014241739191463154
6.0,566.0,455.0,0.010601,0.010601,6.340359,1.0,1.0,567.0,14.0,112.0,Refused to continue trial medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06721415,0.06607718896449404,0.001136961035505965
8.0,566.0,455.0,0.014134,0.014134,6.340359,1.0,1.0,567.0,14.0,112.0,Refused to continue trial medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08961464,0.08515822738946427,0.004456412610535726
4.0,566.0,455.0,0.007067,0.007067,6.340359,1.0,1.0,567.0,14.0,112.0,Refused to continue trial medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04480732,0.0441839852260715,0.0006233347739285008
4.0,566.0,455.0,0.007067,0.007067,6.340359,1.0,1.0,567.0,14.0,112.0,Any other reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04480732,0.044190026459523864,0.000617293540476134
7.0,566.0,455.0,0.012367,0.012367,6.340359,1.0,1.0,567.0,14.0,112.0,Any other reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07841122,0.07907191734491072,0.0006606973449107129
7.0,566.0,455.0,0.012367,0.012367,6.340359,1.0,1.0,567.0,14.0,112.0,Any other reason,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07841122,0.07883384611002976,0.00042262611002975847
0.0,1606.0,1502.0,0.0,0.0,7.382124,0.776432,1.0,1606.0,15.0,228.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1606.0,1502.0,0.001245,0.001245,7.382124,0.776432,1.0,1606.0,15.0,228.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00713599,0.0071372584260913,1.2684260912998457e-06
0.0,1606.0,1502.0,0.0,0.0,7.382124,0.776432,1.0,1606.0,15.0,228.0,Site closure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1606.0,1502.0,0.001245,0.001245,7.382124,0.776432,1.0,1606.0,15.0,228.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00713599,0.0071739229721924916,3.793297219249151e-05
2.0,1606.0,1502.0,0.001245,0.001245,7.382124,0.776432,1.0,1606.0,15.0,228.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00713599,0.007147226991091302,1.1236991091302315e-05
2.0,1606.0,1502.0,0.001245,0.001245,7.382124,0.776432,1.0,1606.0,15.0,228.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00713599,0.007168303956299635,3.2313956299634926e-05
1.0,1606.0,1502.0,0.000623,0.000623,7.382124,0.776432,1.0,1606.0,15.0,228.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00357086,0.0037399063190972207,0.00016904631909722082
6.0,1606.0,1502.0,0.003736,0.003736,7.382124,0.776432,1.0,1606.0,15.0,228.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0214137,0.020757651785436485,0.0006560482145635156
2.0,1606.0,1502.0,0.001245,0.001245,7.382124,0.776432,1.0,1606.0,15.0,228.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00713599,0.007158328345466298,2.233834546629815e-05
9.0,1606.0,1502.0,0.005604,0.005604,7.382124,0.776432,1.0,1606.0,15.0,228.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03212055,0.03384032912492062,0.0017197791249206201
19.0,1606.0,1502.0,0.011831,0.011831,7.382124,0.776432,1.0,1606.0,15.0,228.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06781195,0.0675982871943353,0.0002136628056646911
14.0,1606.0,1502.0,0.008717,0.008717,7.382124,0.776432,1.0,1606.0,15.0,228.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04996338,0.0488573451993056,0.0011060348006943985
17.0,1606.0,1502.0,0.010585,0.010585,7.382124,0.776432,1.0,1606.0,15.0,228.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06067023,0.0610161941818155,0.0003459641818155043
16.0,1606.0,1502.0,0.009963,0.009963,7.382124,0.776432,1.0,1606.0,15.0,228.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0571051,0.05644122147932539,0.0006638785206746073
12.0,1606.0,1502.0,0.007472,0.007472,7.382124,0.776432,1.0,1606.0,15.0,228.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04282739,0.0430904971544643,0.000263107154464301
2.0,227.0,177.0,0.008811,0.008811,5.429346,1.0,1.0,227.0,7.0,53.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04783796,0.04847148825583335,0.0006335282558333488
5.0,227.0,177.0,0.022026,0.022026,5.429346,1.0,1.0,227.0,7.0,53.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11958677,0.12095856468999998,0.0013717946899999833
1.0,227.0,177.0,0.004405,0.004405,5.429346,1.0,1.0,227.0,7.0,53.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02391627,0.023945508833151687,2.9238833151687404e-05
4.0,227.0,177.0,0.017621,0.017621,5.429346,1.0,1.0,227.0,7.0,53.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0956705,0.09607671699657734,0.00040621699657733545
2.0,227.0,177.0,0.008811,0.008811,5.429346,1.0,1.0,227.0,7.0,53.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04783796,0.04835173893874998,0.00051377893874998
6.0,227.0,177.0,0.026432,0.026432,5.429346,1.0,1.0,227.0,7.0,53.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.14350846,0.14398937511359114,0.0004809151135911349
3.0,227.0,177.0,0.013216,0.013216,5.429346,1.0,1.0,227.0,7.0,53.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07175423,0.06954005550101186,0.0022141744989881418
8.0,227.0,177.0,0.035242,0.035242,5.429346,1.0,1.0,227.0,7.0,53.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.191341,0.18948771934833336,0.00185328065166665
6.0,227.0,177.0,0.026432,0.026432,5.429346,1.0,1.0,227.0,7.0,53.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.14350846,0.14436282855594235,0.000854368555942342
8.0,227.0,177.0,0.035242,0.035242,5.429346,1.0,1.0,227.0,7.0,53.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.191341,0.19030344109047626,0.0010375589095237558
4.0,227.0,177.0,0.017621,0.017621,5.429346,1.0,1.0,227.0,7.0,53.0,Other reason (not specified),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0956705,0.09581310788363094,0.00014260788363093524
1.0,227.0,177.0,0.004405,0.004405,5.429346,1.0,1.0,227.0,7.0,53.0,Other reason (not specified),Overall Study,FG001,diabetes type 2,INDUSTRY,0.02391627,0.0239288382636874,1.25682636873993e-05
10.0,571.0,508.0,0.017513,0.017513,6.349139,0.575988,1.0,571.0,8.0,106.0,At the Participant's Own Request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06404548,0.06547879536675595,0.0014333153667559495
5.0,571.0,508.0,0.008757,0.008757,6.349139,0.575988,1.0,571.0,8.0,106.0,At the Participant's Own Request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03202457,0.03126849505626987,0.0007560749437301312
21.0,571.0,508.0,0.036778,0.036778,6.349139,0.575988,1.0,571.0,8.0,106.0,At the Participant's Own Request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.13449807,0.13417388567686975,0.0003241843231302499
2.0,571.0,508.0,0.003503,0.003503,6.349139,0.575988,1.0,571.0,8.0,106.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01281056,0.012960578127718283,0.00015001812771828216
2.0,571.0,508.0,0.003503,0.003503,6.349139,0.575988,1.0,571.0,8.0,106.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01281056,0.012960890362628999,0.0001503303626289986
6.0,571.0,508.0,0.010508,0.010508,6.349139,0.575988,1.0,571.0,8.0,106.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03842802,0.03900173280890494,0.0005737128089049401
0.0,571.0,508.0,0.0,0.0,6.349139,0.575988,1.0,571.0,8.0,106.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,571.0,508.0,0.0,0.0,6.349139,0.575988,1.0,571.0,8.0,106.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,571.0,508.0,0.001751,0.001751,6.349139,0.575988,1.0,571.0,8.0,106.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00640345,0.006493741238511921,9.029123851192131e-05
0.0,571.0,508.0,0.0,0.0,6.349139,0.575988,1.0,571.0,8.0,106.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,571.0,508.0,0.0,0.0,6.349139,0.575988,1.0,571.0,8.0,106.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,571.0,508.0,0.001751,0.001751,6.349139,0.575988,1.0,571.0,8.0,106.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00640345,0.006481191791428584,7.774179142858422e-05
3.0,571.0,508.0,0.005254,0.005254,6.349139,0.575988,1.0,571.0,8.0,106.0,Reason Not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01921401,0.019102665214748182,0.00011134478525181776
4.0,571.0,508.0,0.007005,0.007005,6.349139,0.575988,1.0,571.0,8.0,106.0,Reason Not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02561746,0.025392321696299618,0.000225138303700384
8.0,571.0,508.0,0.014011,0.014011,6.349139,0.575988,1.0,571.0,8.0,106.0,Reason Not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05123858,0.05001468769274802,0.001223892307251978
12.0,467.0,413.0,0.025696,0.025696,6.148468,0.244077,1.0,467.0,16.0,75.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03856205,0.03865681854996302,9.476854996302159e-05
2.0,467.0,413.0,0.004283,0.004283,6.148468,0.244077,1.0,467.0,16.0,75.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00642751,0.006415909853268382,1.1600146731617807e-05
2.0,467.0,413.0,0.004283,0.004283,6.148468,0.244077,1.0,467.0,16.0,75.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00642751,0.006414595750490605,1.291424950939507e-05
1.0,467.0,413.0,0.002141,0.002141,6.148468,0.244077,1.0,467.0,16.0,75.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.003213,0.0032117171219642783,1.2828780357218399e-06
3.0,467.0,413.0,0.006424,0.006424,6.148468,0.244077,1.0,467.0,16.0,75.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00964051,0.009627940362956371,1.2569637043628387e-05
1.0,467.0,413.0,0.002141,0.002141,6.148468,0.244077,1.0,467.0,16.0,75.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.003213,0.0032112665595833262,1.7334404166739065e-06
2.0,467.0,413.0,0.004283,0.004283,6.148468,0.244077,1.0,467.0,16.0,75.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00642751,0.0064102912768596535,1.7218723140346483e-05
0.0,467.0,413.0,0.0,0.0,6.148468,0.244077,1.0,467.0,16.0,75.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,467.0,413.0,0.006424,0.006424,6.148468,0.244077,1.0,467.0,16.0,75.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00964051,0.009628416896289705,1.2093103710295039e-05
0.0,467.0,413.0,0.0,0.0,6.148468,0.244077,1.0,467.0,16.0,75.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,467.0,413.0,0.012848,0.012848,6.148468,0.244077,1.0,467.0,16.0,75.0,Subject Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01928103,0.01968083594699676,0.0003998059469967584
19.0,467.0,413.0,0.040685,0.040685,6.148468,0.244077,1.0,467.0,16.0,75.0,Subject Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06105608,0.06239425323690472,0.001338173236904723
1.0,467.0,413.0,0.002141,0.002141,6.148468,0.244077,1.0,467.0,16.0,75.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.003213,0.0032108184810416586,2.181518958341549e-06
2.0,467.0,413.0,0.004283,0.004283,6.148468,0.244077,1.0,467.0,16.0,75.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00642751,0.006417145185768382,1.036481423161758e-05
3.0,2002.0,1801.0,0.001499,0.001499,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00752034,0.007472499246785719,4.784075321428126e-05
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00501189,0.005012582448750014,6.92448750014632e-07
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2002.0,1801.0,0.001499,0.001499,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.00752034,0.007488111926924611,3.222807307538909e-05
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Screen Failure,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Screen Failure,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00250845,0.0025079226204563466,5.273795436536166e-07
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Screen Failure,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Screen Failure,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,2002.0,1801.0,0.002997,0.002997,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.01503566,0.014882195689533728,0.00015346431046627147
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00501189,0.004983340807083347,2.854919291665238e-05
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.00501189,0.004981796015833347,3.009398416665282e-05
9.0,2002.0,1801.0,0.004496,0.004496,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.02255601,0.022757203546755925,0.00020119354675592407
4.0,2002.0,1801.0,0.001998,0.001998,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.01002378,0.009852723027619048,0.0001710569723809511
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00501189,0.005012529847916681,6.398479166815074e-07
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.00501189,0.005010482323333347,1.4076766666525423e-06
11.0,2002.0,1801.0,0.005495,0.005495,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.02756789,0.02782092999674603,0.0002530399967460295
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00250845,0.0025117614584722185,3.3114584722182885e-06
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00250845,0.0025081360154563465,3.1398454365368436e-07
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2002.0,1801.0,0.001499,0.001499,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.00752034,0.007491186650317469,2.9153349682531707e-05
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00250845,0.0025078240104563464,6.259895436538064e-07
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.00250845,0.0025083213242063462,1.2867579365395676e-07
5.0,2002.0,1801.0,0.002498,0.002498,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.01253223,0.012551615559781744,1.9385559781743764e-05
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,2002.0,1801.0,0.002498,0.002498,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.01253223,0.012568949919900785,3.671991990078505e-05
23.0,2002.0,1801.0,0.011489,0.011489,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.05763922,0.056123981058511914,0.001515238941488084
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00501189,0.005000809375000014,1.108062499998591e-05
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00501189,0.005013391437916682,1.5014379166821898e-06
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Treatment Period (52 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Treatment Period (52 Weeks),FG003,diabetes type 2,INDUSTRY,0.00501189,0.005011721973333348,1.6802666665156896e-07
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00250845,0.002515493004821425,7.043004821424923e-06
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00501189,0.005005822165178585,6.067834821414479e-06
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,2002.0,1801.0,0.003497,0.003497,7.602401,0.659911,1.0,2002.0,15.0,216.0,Adverse Event,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01754412,0.017923352102966254,0.00037923210296625376
9.0,2002.0,1801.0,0.004496,0.004496,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02255601,0.022746933041041646,0.00019092304104164487
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,2002.0,1801.0,0.002997,0.002997,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01503566,0.01493692126364087,9.873873635912918e-05
26.0,2002.0,1801.0,0.012987,0.012987,7.602401,0.659911,1.0,2002.0,15.0,216.0,Death,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.06515455,0.06500822994103161,0.00014632005896839106
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00501189,0.004990273527083345,2.1616472916654965e-05
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00250845,0.0025099119528571405,1.461952857140323e-06
4.0,2002.0,1801.0,0.001998,0.001998,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01002378,0.00984406938470238,0.00017971061529761974
11.0,2002.0,1801.0,0.005495,0.005495,7.602401,0.659911,1.0,2002.0,15.0,216.0,Lost to Follow-up,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.02756789,0.02782092999674603,0.0002530399967460295
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00501189,0.005004178885595251,7.711114404748351e-06
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00250845,0.002504185251666663,4.264748333337055e-06
6.0,2002.0,1801.0,0.002997,0.002997,7.602401,0.659911,1.0,2002.0,15.0,216.0,Personal Reason,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01503566,0.014949459733492057,8.620026650794227e-05
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2002.0,1801.0,0.001499,0.001499,7.602401,0.659911,1.0,2002.0,15.0,216.0,Physician Decision,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00752034,0.007484130371567468,3.6209628432532295e-05
0.0,2002.0,1801.0,0.0,0.0,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00250845,0.0025091926154166637,7.426154166635668e-07
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00250845,0.0025043166249999966,4.13337500000362e-06
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Protocol Violation,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00250845,0.0025095034083333296,1.0534083333293802e-06
2.0,2002.0,1801.0,0.000999,0.000999,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Variable Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00501189,0.00499119676184525,2.069323815474984e-05
1.0,2002.0,1801.0,0.0005,0.0005,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Variable Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00250845,0.0026527990175000014,0.00014434901750000123
4.0,2002.0,1801.0,0.001998,0.001998,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Variable Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01002378,0.009840424415952377,0.0001833555840476224
17.0,2002.0,1801.0,0.008492,0.008492,7.602401,0.659911,1.0,2002.0,15.0,216.0,Withdrawal by Subject,Variable Treatment Period,FG003,diabetes type 2,INDUSTRY,0.04260356,0.04315004128590276,0.0005464812859027612
3.0,351.0,311.0,0.008547,0.008547,5.863631,0.543187,1.0,351.0,2.0,43.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0272226,0.027064298178204407,0.00015830182179559296
2.0,351.0,311.0,0.005698,0.005698,5.863631,0.543187,1.0,351.0,2.0,43.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0181484,0.019389451219677133,0.001241051219677134
1.0,351.0,311.0,0.002849,0.002849,5.863631,0.543187,1.0,351.0,2.0,43.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0090742,0.009221818908125005,0.00014761890812500615
9.0,351.0,311.0,0.025641,0.025641,5.863631,0.543187,1.0,351.0,2.0,43.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0816678,0.08087982715741075,0.0007879728425892463
5.0,351.0,311.0,0.014245,0.014245,5.863631,0.543187,1.0,351.0,2.0,43.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.045371,0.04514785353917652,0.000223146460823484
1.0,351.0,311.0,0.002849,0.002849,5.863631,0.543187,1.0,351.0,2.0,43.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0090742,0.009225506476279767,0.00015130647627976772
5.0,351.0,311.0,0.014245,0.014245,5.863631,0.543187,1.0,351.0,2.0,43.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.045371,0.04524330778997014,0.00012769221002986025
9.0,351.0,311.0,0.025641,0.025641,5.863631,0.543187,1.0,351.0,2.0,43.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0816678,0.08087490596602186,0.0007928940339781421
4.0,351.0,311.0,0.011396,0.011396,5.863631,0.543187,1.0,351.0,2.0,43.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0362968,0.036516247753779735,0.00021944775377973763
0.0,351.0,311.0,0.0,0.0,5.863631,0.543187,1.0,351.0,2.0,43.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,351.0,311.0,0.002849,0.002849,5.863631,0.543187,1.0,351.0,2.0,43.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0090742,0.009234040635059533,0.0001598406350595341
0.0,351.0,311.0,0.0,0.0,5.863631,0.543187,1.0,351.0,2.0,43.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,518.0,421.0,0.007722,0.007722,6.251904,0.550717,1.0,518.0,4.0,93.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02658709,0.02680219810799605,0.00021510810799604818
6.0,518.0,421.0,0.011583,0.011583,6.251904,0.550717,1.0,518.0,4.0,93.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03988063,0.03973695197155553,0.00014367802844447025
21.0,518.0,421.0,0.040541,0.040541,6.251904,0.550717,1.0,518.0,4.0,93.0,At the participant's own request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13958392,0.1422545093654166,0.002670589365416587
25.0,518.0,421.0,0.048263,0.048263,6.251904,0.550717,1.0,518.0,4.0,93.0,At the participant's own request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.166171,0.16821951333024798,0.0020485133302479697
17.0,518.0,421.0,0.032819,0.032819,6.251904,0.550717,1.0,518.0,4.0,93.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11299683,0.11421722940311511,0.0012203994031151078
9.0,518.0,421.0,0.017375,0.017375,6.251904,0.550717,1.0,518.0,4.0,93.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05982266,0.059724512700089286,9.814729991071414e-05
7.0,518.0,421.0,0.013514,0.013514,6.251904,0.550717,1.0,518.0,4.0,93.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04652912,0.04690045505374005,0.00037133505374004755
8.0,518.0,421.0,0.015444,0.015444,6.251904,0.550717,1.0,518.0,4.0,93.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05317417,0.05194829975877975,0.001225870241220249
1.0,636.0,615.0,0.001572,0.001572,6.45677,0.656473,1.0,636.0,1.0,46.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00666323,0.006670010518154768,6.7805181547678575e-06
1.0,636.0,615.0,0.001572,0.001572,6.45677,0.656473,1.0,636.0,1.0,46.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00666323,0.006667504671369055,4.274671369055259e-06
2.0,636.0,615.0,0.003145,0.003145,6.45677,0.656473,1.0,636.0,1.0,46.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0133307,0.013320581213541667,1.0118786458332418e-05
4.0,636.0,615.0,0.006289,0.006289,6.45677,0.656473,1.0,636.0,1.0,46.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02665716,0.026630990580436487,2.6169419563511903e-05
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,636.0,615.0,0.001572,0.001572,6.45677,0.656473,1.0,636.0,1.0,46.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00666323,0.006639180821369051,2.4049178630949387e-05
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,636.0,615.0,0.001572,0.001572,6.45677,0.656473,1.0,636.0,1.0,46.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00666323,0.006665567943452387,2.33794345238722e-06
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,636.0,615.0,0.003145,0.003145,6.45677,0.656473,1.0,636.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0133307,0.013319356377708336,1.1343622291663108e-05
5.0,636.0,615.0,0.007862,0.007862,6.45677,0.656473,1.0,636.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03332463,0.0343358405518597,0.0010112105518597023
3.0,636.0,615.0,0.004717,0.004717,6.45677,0.656473,1.0,636.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01999393,0.02011046800305735,0.00011653800305734888
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,636.0,615.0,0.001572,0.001572,6.45677,0.656473,1.0,636.0,1.0,46.0,Relocation to other city,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00666323,0.0066681633264881,4.933326488099944e-06
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Relocation to other city,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Relocation to other city,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,636.0,615.0,0.0,0.0,6.45677,0.656473,1.0,636.0,1.0,46.0,Relocation to other city,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
50.0,745.0,598.0,0.067114,0.067114,6.614726,0.330504,1.0,779.0,4.0,337.0,Adverse Event,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.14672418,0.1463313219041072,0.0003928580958928174
11.0,745.0,598.0,0.014765,0.014765,6.614726,0.330504,1.0,779.0,4.0,337.0,Adverse Event,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03227915,0.032211099017539685,6.805098246031455e-05
12.0,745.0,598.0,0.016107,0.016107,6.614726,0.330504,1.0,779.0,4.0,337.0,Protocol Violation,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.03521302,0.03524926312416672,3.624312416672382e-05
3.0,745.0,598.0,0.004027,0.004027,6.614726,0.330504,1.0,779.0,4.0,337.0,Protocol Violation,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0088038,0.008820155530178548,1.635553017854778e-05
21.0,745.0,598.0,0.028188,0.028188,6.614726,0.330504,1.0,779.0,4.0,337.0,Noncompliance,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.06162442,0.06144118675416669,0.00018323324583330997
14.0,745.0,598.0,0.018792,0.018792,6.614726,0.330504,1.0,779.0,4.0,337.0,Noncompliance,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.04108295,0.04096290193735122,0.0001200480626487796
1.0,745.0,598.0,0.001342,0.001342,6.614726,0.330504,1.0,779.0,4.0,337.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00293387,0.002989628975109128,5.575897510912793e-05
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
19.0,745.0,598.0,0.025503,0.025503,6.614726,0.330504,1.0,779.0,4.0,337.0,Lost to Follow-up,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.05575449,0.05539645174091807,0.00035803825908192755
18.0,745.0,598.0,0.024161,0.024161,6.614726,0.330504,1.0,779.0,4.0,337.0,Lost to Follow-up,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.05282062,0.052989485711056945,0.00016886571105694664
81.0,745.0,598.0,0.108725,0.108725,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.23769388,0.23096163101900763,0.006732248980992367
29.0,745.0,598.0,0.038926,0.038926,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.08509976,0.08575936567686503,0.0006596056768650299
6.0,745.0,598.0,0.008054,0.008054,6.614726,0.330504,1.0,779.0,4.0,337.0,Physician Decision,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0176076,0.017565302525059525,4.2297474940476004e-05
1.0,745.0,598.0,0.001342,0.001342,6.614726,0.330504,1.0,779.0,4.0,337.0,Physician Decision,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00293387,0.002984472218799603,5.060221879960329e-05
1.0,745.0,598.0,0.001342,0.001342,6.614726,0.330504,1.0,779.0,4.0,337.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00293387,0.002989628975109128,5.575897510912793e-05
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,745.0,598.0,0.004027,0.004027,6.614726,0.330504,1.0,779.0,4.0,337.0,Missing,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0088038,0.008807764498928543,3.9644989285429755e-06
1.0,745.0,598.0,0.001342,0.001342,6.614726,0.330504,1.0,779.0,4.0,337.0,Missing,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00293387,0.002987584801299604,5.3714801299604206e-05
2.0,745.0,598.0,0.002685,0.002685,6.614726,0.330504,1.0,779.0,4.0,337.0,Pregnancy,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00586993,0.005874027306418645,4.097306418645447e-06
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Pregnancy,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,745.0,598.0,0.013423,0.013423,6.614726,0.330504,1.0,779.0,4.0,337.0,Adverse Event,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.02934527,0.029434333900396834,8.906390039683382e-05
5.0,745.0,598.0,0.006711,0.006711,6.614726,0.330504,1.0,779.0,4.0,337.0,Adverse Event,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01467154,0.014702648393184511,3.110839318451117e-05
6.0,745.0,598.0,0.008054,0.008054,6.614726,0.330504,1.0,779.0,4.0,337.0,Noncompliance,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0176076,0.01758668950541667,2.0910494583331607e-05
5.0,745.0,598.0,0.006711,0.006711,6.614726,0.330504,1.0,779.0,4.0,337.0,Noncompliance,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01467154,0.014731535455238082,5.9995455238081793e-05
38.0,745.0,598.0,0.051007,0.051007,6.614726,0.330504,1.0,779.0,4.0,337.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.11151117,0.11158102477801575,6.985477801574325e-05
22.0,745.0,598.0,0.02953,0.02953,6.614726,0.330504,1.0,779.0,4.0,337.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.06455829,0.06504318660092259,0.000484896600922588
7.0,745.0,598.0,0.009396,0.009396,6.614726,0.330504,1.0,779.0,4.0,337.0,Did not Enter Follow-up Period,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.02054147,0.020491092118988124,5.037788101187532e-05
7.0,745.0,598.0,0.009396,0.009396,6.614726,0.330504,1.0,779.0,4.0,337.0,Did not Enter Follow-up Period,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.02054147,0.02050038291253972,4.108708746028075e-05
26.0,745.0,598.0,0.034899,0.034899,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawn from Follow-up Participation,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.07629596,0.07617007319369051,0.00012588680630948312
12.0,745.0,598.0,0.016107,0.016107,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawn from Follow-up Participation,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.03521302,0.03527790394500006,6.488394500005906e-05
2.0,745.0,598.0,0.002685,0.002685,6.614726,0.330504,1.0,779.0,4.0,337.0,Physician Decision,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00586993,0.00587407154249007,4.141542490070267e-06
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Physician Decision,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,745.0,598.0,0.002685,0.002685,6.614726,0.330504,1.0,779.0,4.0,337.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00586993,0.005873096504990069,3.1665049900694853e-06
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,745.0,598.0,0.002685,0.002685,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00586993,0.005876249585823403,6.319585823403098e-06
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,745.0,598.0,0.004027,0.004027,6.614726,0.330504,1.0,779.0,4.0,337.0,Missing,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0088038,0.008810650164761884,6.850164761883909e-06
0.0,745.0,598.0,0.0,0.0,6.614726,0.330504,1.0,779.0,4.0,337.0,Missing,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,257.0,246.0,0.003891,0.003891,5.55296,0.327769,1.0,257.0,1.0,23.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00708197,0.007232241642559546,0.00015027164255954593
1.0,257.0,246.0,0.003891,0.003891,5.55296,0.327769,1.0,257.0,1.0,23.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00708197,0.007249587573035735,0.0001676175730357353
1.0,257.0,246.0,0.003891,0.003891,5.55296,0.327769,1.0,257.0,1.0,23.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00708197,0.007227735744226213,0.00014576574422621273
1.0,257.0,246.0,0.003891,0.003891,5.55296,0.327769,1.0,257.0,1.0,23.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00708197,0.007244766869702402,0.00016279686970240188
4.0,257.0,246.0,0.015564,0.015564,5.55296,0.327769,1.0,257.0,1.0,23.0,unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02832789,0.02872918182217259,0.0004012918221725885
3.0,257.0,246.0,0.011673,0.011673,5.55296,0.327769,1.0,257.0,1.0,23.0,unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02124592,0.021390895978392867,0.0001449759783928653
0.0,566.0,488.0,0.0,0.0,6.340359,0.328159,1.0,566.0,14.0,103.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,566.0,488.0,0.0,0.0,6.340359,0.328159,1.0,566.0,14.0,103.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,566.0,488.0,0.001767,0.001767,6.340359,0.328159,1.0,566.0,14.0,103.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0036765,0.003700155744414691,2.3655744414690944e-05
3.0,566.0,488.0,0.0053,0.0053,6.340359,0.328159,1.0,566.0,14.0,103.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01102741,0.011164278674143213,0.00013686867414321353
5.0,566.0,488.0,0.008834,0.008834,6.340359,0.328159,1.0,566.0,14.0,103.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01838041,0.018489635963343257,0.00010922596334325685
4.0,566.0,488.0,0.007067,0.007067,6.340359,0.328159,1.0,566.0,14.0,103.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01470391,0.014616836973898819,8.707302610118199e-05
24.0,566.0,488.0,0.042403,0.042403,6.340359,0.328159,1.0,566.0,14.0,103.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08822556,0.0875102414320536,0.0007153185679463908
22.0,566.0,488.0,0.038869,0.038869,6.340359,0.328159,1.0,566.0,14.0,103.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08087256,0.08190529605166663,0.0010327360516666356
16.0,566.0,488.0,0.028269,0.028269,6.340359,0.328159,1.0,566.0,14.0,103.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05881773,0.05913549647852179,0.00031776647852178874
1.0,566.0,488.0,0.001767,0.001767,6.340359,0.328159,1.0,566.0,14.0,103.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0036765,0.00369984401608136,2.3344016081359997e-05
1.0,566.0,488.0,0.001767,0.001767,6.340359,0.328159,1.0,566.0,14.0,103.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0036765,0.00369831542483136,2.1815424831359877e-05
1.0,566.0,488.0,0.001767,0.001767,6.340359,0.328159,1.0,566.0,14.0,103.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0036765,0.003699783965248026,2.328396524802585e-05
0.0,413.0,375.0,0.0,0.0,6.025866,0.307494,1.0,413.0,12.0,124.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,413.0,375.0,0.012107,0.012107,6.025866,0.307494,1.0,413.0,12.0,124.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02243327,0.022626159799585138,0.00019288979958513586
1.0,413.0,375.0,0.002421,0.002421,6.025866,0.307494,1.0,413.0,12.0,124.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00448591,0.004517709081785724,3.1799081785723916e-05
0.0,413.0,375.0,0.0,0.0,6.025866,0.307494,1.0,413.0,12.0,124.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,413.0,375.0,0.0,0.0,6.025866,0.307494,1.0,413.0,12.0,124.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,413.0,375.0,0.004843,0.004843,6.025866,0.307494,1.0,413.0,12.0,124.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00897368,0.009136072719434528,0.00016239271943452836
12.0,413.0,375.0,0.029056,0.029056,6.025866,0.307494,1.0,413.0,12.0,124.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05383837,0.05501109896359124,0.0011727289635912394
7.0,413.0,375.0,0.016949,0.016949,6.025866,0.307494,1.0,413.0,12.0,124.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0314051,0.03168535552131944,0.0002802555213194391
10.0,413.0,375.0,0.024213,0.024213,6.025866,0.307494,1.0,413.0,12.0,124.0,Withdrawal criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04486469,0.045423146655436494,0.0005584566554364956
0.0,413.0,375.0,0.0,0.0,6.025866,0.307494,1.0,413.0,12.0,124.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,413.0,375.0,0.0,0.0,6.025866,0.307494,1.0,413.0,12.0,124.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,413.0,375.0,0.002421,0.002421,6.025866,0.307494,1.0,413.0,12.0,124.0,Unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00448591,0.00451788226345239,3.1972263452390015e-05
0.0,399.0,354.0,0.0,0.0,5.991465,0.558087,1.0,399.0,3.0,70.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,399.0,354.0,0.002506,0.002506,5.991465,0.558087,1.0,399.0,3.0,70.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00837946,0.008376718567678578,2.7414323214222658e-06
1.0,399.0,354.0,0.002506,0.002506,5.991465,0.558087,1.0,399.0,3.0,70.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00837946,0.008374212853392862,5.247146607137779e-06
1.0,399.0,354.0,0.002506,0.002506,5.991465,0.558087,1.0,399.0,3.0,70.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00837946,0.00838300174994048,3.5417499404805097e-06
0.0,399.0,354.0,0.0,0.0,5.991465,0.558087,1.0,399.0,3.0,70.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,399.0,354.0,0.0,0.0,5.991465,0.558087,1.0,399.0,3.0,70.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,399.0,354.0,0.010025,0.010025,5.991465,0.558087,1.0,399.0,3.0,70.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03352117,0.03396959242482142,0.00044842242482141803
5.0,399.0,354.0,0.012531,0.012531,5.991465,0.558087,1.0,399.0,3.0,70.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04190063,0.041864642518968334,3.59874810316671e-05
0.0,399.0,354.0,0.0,0.0,5.991465,0.558087,1.0,399.0,3.0,70.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,399.0,354.0,0.027569,0.027569,5.991465,0.558087,1.0,399.0,3.0,70.0,At the Participant's own Request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09218406,0.09779741958182547,0.005613359581825475
5.0,399.0,354.0,0.012531,0.012531,5.991465,0.558087,1.0,399.0,3.0,70.0,At the Participant's own Request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04190063,0.04186972698230166,3.0903017698341584e-05
8.0,399.0,354.0,0.02005,0.02005,5.991465,0.558087,1.0,399.0,3.0,70.0,At the Participant's own Request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06704234,0.06750781123491074,0.0004654712349107387
3.0,399.0,354.0,0.007519,0.007519,5.991465,0.558087,1.0,399.0,3.0,70.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02514171,0.025218213772142867,7.65037721428656e-05
4.0,399.0,354.0,0.010025,0.010025,5.991465,0.558087,1.0,399.0,3.0,70.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03352117,0.03402774583529761,0.0005065758352976041
2.0,399.0,354.0,0.005013,0.005013,5.991465,0.558087,1.0,399.0,3.0,70.0,Reason not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01676226,0.01689556316696433,0.00013330316696432906
0.0,642.0,604.0,0.0,0.0,6.466145,0.377941,1.0,642.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,642.0,604.0,0.001558,0.001558,6.466145,0.377941,1.0,642.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00380747,0.0038270067803571396,1.9536780357139703e-05
4.0,642.0,604.0,0.006231,0.006231,6.466145,0.377941,1.0,642.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01522745,0.014922888163035703,0.00030456183696429655
1.0,642.0,604.0,0.001558,0.001558,6.466145,0.377941,1.0,642.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00380747,0.003831014317440473,2.3544317440473122e-05
16.0,642.0,604.0,0.024922,0.024922,6.466145,0.377941,1.0,642.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06090491,0.06047995865801597,0.00042495134198403117
16.0,642.0,604.0,0.024922,0.024922,6.466145,0.377941,1.0,642.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06090491,0.06044893086470243,0.000455979135297567
8.0,528.0,330.0,0.015152,0.015152,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.09501802,0.09393024454846235,0.0010877754515376398
2.0,528.0,330.0,0.003788,0.003788,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.0237545,0.02365333977940478,0.00010116022059522209
6.0,528.0,330.0,0.011364,0.011364,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.07126351,0.06748301173125183,0.0037804982687481697
13.0,528.0,330.0,0.024621,0.024621,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.15439801,0.1495326662361904,0.004865343763809593
2.0,528.0,330.0,0.003788,0.003788,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.0237545,0.02365232877732145,0.0001021712226785508
10.0,528.0,330.0,0.018939,0.018939,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.11876625,0.11837037236947508,0.00039587763052492675
21.0,528.0,330.0,0.039773,0.039773,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.24941602,0.23114245631878977,0.01827356368121022
10.0,528.0,330.0,0.018939,0.018939,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.11876625,0.11830142147855251,0.00046482852144749676
20.0,528.0,330.0,0.037879,0.037879,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.23753877,0.23156602418063513,0.005972745819364883
4.0,528.0,330.0,0.007576,0.007576,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.04750901,0.04421959508160717,0.0032894149183928245
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
20.0,528.0,330.0,0.037879,0.037879,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.23753877,0.23209223763605188,0.0054465323639481256
1.0,528.0,330.0,0.001894,0.001894,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.01187725,0.01183033347774802,4.691652225198052e-05
3.0,528.0,330.0,0.005682,0.005682,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.03563176,0.03569415531291657,6.239531291657441e-05
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,528.0,330.0,0.005682,0.005682,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Initial Treatment Phase (Weeks 0 - 12),FG000,diabetes type 2,INDUSTRY,0.03563176,0.03572781726249992,9.605726249992119e-05
1.0,528.0,330.0,0.001894,0.001894,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Initial Treatment Phase (Weeks 0 - 12),FG001,diabetes type 2,INDUSTRY,0.01187725,0.011830490662093261,4.675933790673943e-05
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Initial Treatment Phase (Weeks 0 - 12),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,528.0,330.0,0.005682,0.005682,6.270988,1.0,1.0,547.0,11.0,120.0,Adverse Event,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.03563176,0.0356166670232142,1.509297678579935e-05
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,528.0,330.0,0.001894,0.001894,6.270988,1.0,1.0,547.0,11.0,120.0,Lost to Follow-up,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.01187725,0.011853242399295643,2.4007600704357285e-05
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,528.0,330.0,0.005682,0.005682,6.270988,1.0,1.0,547.0,11.0,120.0,Physician Decision,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.03563176,0.035689184002499895,5.742400249989649e-05
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,528.0,330.0,0.001894,0.001894,6.270988,1.0,1.0,547.0,11.0,120.0,Protocol Violation,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.01187725,0.011842210138343263,3.503986165673788e-05
2.0,528.0,330.0,0.003788,0.003788,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0237545,0.023665455748630982,8.904425136901928e-05
2.0,528.0,330.0,0.003788,0.003788,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0237545,0.02367432725690479,8.017274309521025e-05
8.0,528.0,330.0,0.015152,0.015152,6.270988,1.0,1.0,547.0,11.0,120.0,Withdrawal by Subject,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.09501802,0.09326630681277781,0.0017517131872221842
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Transfer Treatment Phase (Weeks 12 - 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,528.0,330.0,0.0,0.0,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Transfer Treatment Phase (Weeks 12 - 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,528.0,330.0,0.00947,0.00947,6.270988,1.0,1.0,547.0,11.0,120.0,Various,Transfer Treatment Phase (Weeks 12 - 24),FG002,diabetes type 2,INDUSTRY,0.05938626,0.05775581914739095,0.0016304408526090566
14.0,807.0,712.0,0.017348,0.017348,6.694562,0.270051,1.0,1240.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03136293,0.032158910903640876,0.0007959809036408791
10.0,807.0,712.0,0.012392,0.012392,6.694562,0.270051,1.0,1240.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02240313,0.022591118956547623,0.0001879889565476224
8.0,807.0,712.0,0.009913,0.009913,6.694562,0.270051,1.0,1240.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01792142,0.01802753500053574,0.0001061150005357385
6.0,807.0,712.0,0.007435,0.007435,6.694562,0.270051,1.0,1240.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01344151,0.013457175828888833,1.5665828888832348e-05
6.0,807.0,712.0,0.007435,0.007435,6.694562,0.270051,1.0,1240.0,13.0,92.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01344151,0.013458629053769789,1.7119053769788437e-05
5.0,807.0,712.0,0.006196,0.006196,6.694562,0.270051,1.0,1240.0,13.0,92.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01120156,0.011202756524484127,1.1965244841281863e-06
9.0,807.0,712.0,0.011152,0.011152,6.694562,0.270051,1.0,1240.0,13.0,92.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02016137,0.020296368403472233,0.00013499840347223208
6.0,807.0,712.0,0.007435,0.007435,6.694562,0.270051,1.0,1240.0,13.0,92.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01344151,0.013457913066805499,1.6403066805498537e-05
1.0,807.0,712.0,0.001239,0.001239,6.694562,0.270051,1.0,1240.0,13.0,92.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00223995,0.002241921546706346,1.97154670634591e-06
2.0,807.0,712.0,0.002478,0.002478,6.694562,0.270051,1.0,1240.0,13.0,92.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0044799,0.004544579089077386,6.467908907738587e-05
1.0,807.0,712.0,0.001239,0.001239,6.694562,0.270051,1.0,1240.0,13.0,92.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00223995,0.0022417060306646804,1.7560306646803234e-06
2.0,807.0,712.0,0.002478,0.002478,6.694562,0.270051,1.0,1240.0,13.0,92.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0044799,0.004547371942589292,6.747194258929171e-05
0.0,807.0,712.0,0.0,0.0,6.694562,0.270051,1.0,1240.0,13.0,92.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,807.0,712.0,0.0,0.0,6.694562,0.270051,1.0,1240.0,13.0,92.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,807.0,712.0,0.001239,0.001239,6.694562,0.270051,1.0,1240.0,13.0,92.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00223995,0.0022423341484623,2.3841484622999856e-06
0.0,807.0,712.0,0.0,0.0,6.694562,0.270051,1.0,1240.0,13.0,92.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,807.0,712.0,0.009913,0.009913,6.694562,0.270051,1.0,1240.0,13.0,92.0,"Study criteria,compliance,safety, other",Overall Study,FG000,diabetes type 2,INDUSTRY,0.01792142,0.01804988180303574,0.00012846180303573845
5.0,807.0,712.0,0.006196,0.006196,6.694562,0.270051,1.0,1240.0,13.0,92.0,"Study criteria,compliance,safety, other",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01120156,0.011188603352936503,1.2956647063496265e-05
7.0,807.0,712.0,0.008674,0.008674,6.694562,0.270051,1.0,1240.0,13.0,92.0,"Study criteria,compliance,safety, other",Overall Study,FG002,diabetes type 2,INDUSTRY,0.01568147,0.015965492646696448,0.0002840226466964482
4.0,807.0,712.0,0.004957,0.004957,6.694562,0.270051,1.0,1240.0,13.0,92.0,"Study criteria,compliance,safety, other",Overall Study,FG003,diabetes type 2,INDUSTRY,0.00896161,0.009002837153521818,4.1227153521818105e-05
17.0,714.0,520.0,0.02381,0.02381,6.572283,0.330504,1.0,716.0,17.0,86.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05171927,0.05183716656742062,0.00011789656742062365
9.0,714.0,520.0,0.012605,0.012605,6.572283,0.330504,1.0,716.0,17.0,86.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02738015,0.027371037344136876,9.112655863122848e-06
23.0,714.0,520.0,0.032213,0.032213,6.572283,0.330504,1.0,716.0,17.0,86.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06997198,0.07068486307396832,0.0007128830739683151
8.0,714.0,520.0,0.011204,0.011204,6.572283,0.330504,1.0,716.0,17.0,86.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02433695,0.024191097347445848,0.00014585265255415147
2.0,714.0,520.0,0.002801,0.002801,6.572283,0.330504,1.0,716.0,17.0,86.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00608424,0.006062100049007938,2.213995099206202e-05
6.0,714.0,520.0,0.008403,0.008403,6.572283,0.330504,1.0,716.0,17.0,86.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01825271,0.01836917450250002,0.00011646450250002091
4.0,714.0,520.0,0.005602,0.005602,6.572283,0.330504,1.0,716.0,17.0,86.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01216847,0.012300100684702393,0.00013163068470239264
3.0,714.0,520.0,0.004202,0.004202,6.572283,0.330504,1.0,716.0,17.0,86.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00912744,0.00920206019751067,7.462019751067021e-05
1.0,714.0,520.0,0.001401,0.001401,6.572283,0.330504,1.0,716.0,17.0,86.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0030432,0.0030735518941765964,3.0351894176596558e-05
1.0,714.0,520.0,0.001401,0.001401,6.572283,0.330504,1.0,716.0,17.0,86.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0030432,0.0030814032586805634,3.820325868056362e-05
2.0,714.0,520.0,0.002801,0.002801,6.572283,0.330504,1.0,716.0,17.0,86.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00608424,0.006064189155257939,2.0050844742061646e-05
1.0,714.0,520.0,0.001401,0.001401,6.572283,0.330504,1.0,716.0,17.0,86.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0030432,0.003076306827182549,3.3106827182549214e-05
14.0,714.0,520.0,0.019608,0.019608,6.572283,0.330504,1.0,716.0,17.0,86.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04259183,0.04249376208459868,9.806791540131754e-05
7.0,714.0,520.0,0.009804,0.009804,6.572283,0.330504,1.0,716.0,17.0,86.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02129591,0.021734046540714317,0.00043813654071431576
4.0,714.0,520.0,0.005602,0.005602,6.572283,0.330504,1.0,716.0,17.0,86.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01216847,0.012317654045000015,0.00014918404500001425
1.0,714.0,520.0,0.001401,0.001401,6.572283,0.330504,1.0,716.0,17.0,86.0,Noncompliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0030432,0.0030843924830853253,4.119248308532544e-05
0.0,714.0,520.0,0.0,0.0,6.572283,0.330504,1.0,716.0,17.0,86.0,Noncompliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,714.0,520.0,0.002801,0.002801,6.572283,0.330504,1.0,716.0,17.0,86.0,Noncompliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00608424,0.00606204261484127,2.2197385158730272e-05
34.0,714.0,520.0,0.047619,0.047619,6.572283,0.330504,1.0,716.0,17.0,86.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10343636,0.10305384348403773,0.0003825165159622723
31.0,714.0,520.0,0.043417,0.043417,6.572283,0.330504,1.0,716.0,17.0,86.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09430892,0.09297971446837316,0.0013292055316268397
21.0,714.0,520.0,0.029412,0.029412,6.572283,0.330504,1.0,716.0,17.0,86.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06388774,0.06433431491080353,0.00044657491080353495
0.0,714.0,520.0,0.0,0.0,6.572283,0.330504,1.0,716.0,17.0,86.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,714.0,520.0,0.004202,0.004202,6.572283,0.330504,1.0,716.0,17.0,86.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00912744,0.009202156214177339,7.471621417733804e-05
0.0,714.0,520.0,0.0,0.0,6.572283,0.330504,1.0,716.0,17.0,86.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,357.0,254.0,0.036415,0.036415,5.880533,0.292333,1.0,357.0,1.0,107.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06260009,0.06285301544628603,0.00025292544628603697
22.0,357.0,254.0,0.061625,0.061625,5.880533,0.292333,1.0,357.0,1.0,107.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10593795,0.1094001477449161,0.003462197744916101
10.0,357.0,254.0,0.028011,0.028011,5.880533,0.292333,1.0,357.0,1.0,107.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04815299,0.048577815095704364,0.0004248250957043648
14.0,357.0,254.0,0.039216,0.039216,5.880533,0.292333,1.0,357.0,1.0,107.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06741522,0.06815430439839915,0.000739084398399148
8.0,357.0,254.0,0.022409,0.022409,5.880533,0.292333,1.0,357.0,1.0,107.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03852273,0.038489588995734125,3.31410042658728e-05
8.0,357.0,254.0,0.022409,0.022409,5.880533,0.292333,1.0,357.0,1.0,107.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03852273,0.03858563737249009,6.290737249009526e-05
3.0,357.0,254.0,0.008403,0.008403,5.880533,0.292333,1.0,357.0,1.0,107.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01444538,0.014494788034722223,4.940803472222241e-05
0.0,357.0,254.0,0.0,0.0,5.880533,0.292333,1.0,357.0,1.0,107.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,357.0,254.0,0.008403,0.008403,5.880533,0.292333,1.0,357.0,1.0,107.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01444538,0.014512102338769841,6.672233876984027e-05
0.0,357.0,254.0,0.0,0.0,5.880533,0.292333,1.0,357.0,1.0,107.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,357.0,254.0,0.0,0.0,5.880533,0.292333,1.0,357.0,1.0,107.0,hyperglycemia that met protocol-specifie,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,357.0,254.0,0.011204,0.011204,5.880533,0.292333,1.0,357.0,1.0,107.0,hyperglycemia that met protocol-specifie,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01926051,0.019288821582271815,2.8311582271813712e-05
11.0,357.0,254.0,0.030812,0.030812,5.880533,0.292333,1.0,357.0,1.0,107.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05296812,0.0527832059285263,0.00018491407147370326
7.0,357.0,254.0,0.019608,0.019608,5.880533,0.292333,1.0,357.0,1.0,107.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03370761,0.033476758895019845,0.0002308511049801537
0.0,331.0,288.0,0.0,0.0,5.805135,0.7378,1.0,331.0,2.0,40.0,Run-in failure,Run-in period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
23.0,331.0,288.0,0.069486,0.069486,5.805135,0.7378,1.0,331.0,2.0,40.0,Run-in failure,Run-in period,FG001,diabetes type 2,INDUSTRY,0.29761046,0.29225006669220255,0.005360393307797473
0.0,331.0,288.0,0.0,0.0,5.805135,0.7378,1.0,331.0,2.0,40.0,Withdrawn before randomisation,Run-in period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,331.0,288.0,0.024169,0.024169,5.805135,0.7378,1.0,331.0,2.0,40.0,Withdrawn before randomisation,Run-in period,FG001,diabetes type 2,INDUSTRY,0.10351649,0.10375013970045624,0.00023364970045623712
6.0,331.0,288.0,0.018127,0.018127,5.805135,0.7378,1.0,331.0,2.0,40.0,Withdrawal by Subject,Treatment period,FG000,diabetes type 2,INDUSTRY,0.07763844,0.08074067423085132,0.0031022342308513196
6.0,331.0,288.0,0.018127,0.018127,5.805135,0.7378,1.0,331.0,2.0,40.0,Withdrawal by Subject,Treatment period,FG001,diabetes type 2,INDUSTRY,0.07763844,0.08119561651114897,0.0035571765111489656
2.0,751.0,612.0,0.002663,0.002663,6.622736,0.384274,1.0,751.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00677718,0.006693571273789686,8.360872621031388e-05
1.0,751.0,612.0,0.001332,0.001332,6.622736,0.384274,1.0,751.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00338986,0.003379301083422616,1.0558916577384225e-05
10.0,751.0,612.0,0.013316,0.013316,6.622736,0.384274,1.0,751.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03388845,0.03400373250052579,0.00011528250052578876
13.0,751.0,612.0,0.01731,0.01731,6.622736,0.384274,1.0,751.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04405295,0.04431407363380953,0.0002611236338095277
1.0,751.0,612.0,0.001332,0.001332,6.622736,0.384274,1.0,751.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00338986,0.0033721601808630935,1.769981913690667e-05
1.0,751.0,612.0,0.001332,0.001332,6.622736,0.384274,1.0,751.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00338986,0.003375621931279761,1.4238068720239319e-05
56.0,751.0,612.0,0.074567,0.074567,6.622736,0.384274,1.0,751.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.18976871,0.19001976496846215,0.00025105496846214437
55.0,751.0,612.0,0.073236,0.073236,6.622736,0.384274,1.0,751.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.18638139,0.1849409466488194,0.001440443351180598
3.0,302.0,294.0,0.009934,0.009934,5.713733,0.521703,1.0,302.0,7.0,72.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02961199,0.029698808402003965,8.681840200396376e-05
2.0,302.0,294.0,0.006623,0.006623,5.713733,0.521703,1.0,302.0,7.0,72.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01974232,0.020055582855426576,0.000313262855426575
1.0,302.0,294.0,0.003311,0.003311,5.713733,0.521703,1.0,302.0,7.0,72.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00986967,0.009941341613988105,7.1671613988104e-05
2.0,302.0,294.0,0.006623,0.006623,5.713733,0.521703,1.0,302.0,7.0,72.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01974232,0.020039944745069437,0.0002976247450694365
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,Reason 'Other' in the protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Reason 'Other' in the protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412182,0.0041248699646726115,3.0499646726115173e-06
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Reason 'Other' in the protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412182,0.004123063874940469,1.2438749404687643e-06
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412182,0.004124291103005945,2.4711030059453368e-06
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412182,0.0041224850132738034,6.650132738034512e-07
8.0,534.0,490.0,0.014981,0.014981,6.282267,0.350295,1.0,1282.0,8.0,139.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03296792,0.033035137564880974,6.721756488097669e-05
6.0,534.0,490.0,0.011236,0.011236,6.282267,0.350295,1.0,1282.0,8.0,139.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02472649,0.024636595022083325,8.98949779166748e-05
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412182,0.0041230557074404695,1.2357074404695245e-06
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412182,0.004124801463839279,2.9814638392786086e-06
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412182,0.004122995374107136,1.1753741071358556e-06
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,discontinue study treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,534.0,490.0,0.003745,0.003745,6.282267,0.350295,1.0,1282.0,8.0,139.0,discontinue study treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00824143,0.008165121576408732,7.630842359126686e-05
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,discontinue study treatment,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412182,0.004122995374107136,1.1753741071358556e-06
6.0,534.0,490.0,0.011236,0.011236,6.282267,0.350295,1.0,1282.0,8.0,139.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02472649,0.024670485726845222,5.600427315477843e-05
8.0,534.0,490.0,0.014981,0.014981,6.282267,0.350295,1.0,1282.0,8.0,139.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03296792,0.03305311037663691,8.519037663691498e-05
5.0,534.0,490.0,0.009363,0.009363,6.282267,0.350295,1.0,1282.0,8.0,139.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02060468,0.020695526836220224,9.08468362202236e-05
1.0,534.0,490.0,0.001873,0.001873,6.282267,0.350295,1.0,1282.0,8.0,139.0,Poor/Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00412182,0.004121424542380948,3.954576190522835e-07
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,Poor/Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,534.0,490.0,0.0,0.0,6.282267,0.350295,1.0,1282.0,8.0,139.0,Poor/Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
25.0,743.0,229.0,0.033647,0.033647,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.05550014,0.0550198359026389,0.00048030409736110613
22.0,743.0,229.0,0.02961,0.02961,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.04884118,0.04928708416334321,0.0004459041633432109
27.0,743.0,229.0,0.036339,0.036339,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.05994055,0.059883305425555464,5.724457444453851e-05
44.0,743.0,229.0,0.059219,0.059219,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.09768071,0.09717052556718254,0.0005101844328174593
8.0,743.0,229.0,0.010767,0.010767,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.01775998,0.017601710216914698,0.000158269783085304
13.0,743.0,229.0,0.017497,0.017497,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.028861,0.028979977948422588,0.00011897794842258627
4.0,743.0,229.0,0.005384,0.005384,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.00888081,0.008883006862847202,2.1968628472028573e-06
11.0,743.0,229.0,0.014805,0.014805,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.02442059,0.024406838194662717,1.3751805337282319e-05
5.0,743.0,229.0,0.006729,0.006729,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.01109937,0.011097247284047675,2.122715952325438e-06
6.0,743.0,229.0,0.008075,0.008075,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.01331957,0.013291791225446459,2.7778774553540234e-05
5.0,743.0,229.0,0.006729,0.006729,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.01109937,0.011100182110297679,8.121102976783173e-07
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.00666061,0.00666255600848212,1.9460084821204537e-06
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.00666061,0.0066629602963392594,2.3502963392594764e-06
4.0,743.0,229.0,0.005384,0.005384,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.00888081,0.008887044339097205,6.234339097205971e-06
4.0,743.0,229.0,0.005384,0.005384,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.00888081,0.00887565640201387,5.1535979861301595e-06
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.00666061,0.0066604345813987866,1.7541860121341596e-07
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.0022202,0.0022209270238095287,7.27023809528847e-07
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.0022202,0.0022214255846428614,1.2255846428615644e-06
2.0,743.0,229.0,0.002692,0.002692,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.00444041,0.004429676177678553,1.0733822321446797e-05
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,743.0,229.0,0.002692,0.002692,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.00444041,0.004426383793095219,1.4026206904780951e-05
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,743.0,229.0,0.002692,0.002692,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.00444041,0.004429469060595218,1.0940939404781476e-05
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.00666061,0.006662225800505926,1.6158005059262529e-06
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.0022202,0.002222095796369051,1.8957963690510206e-06
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) Period,FG003,diabetes type 2,INDUSTRY,0.0022202,0.002221998423869051,1.798423869051307e-06
54.0,743.0,229.0,0.072678,0.072678,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.11988109,0.1181126693574107,0.001768420642589294
51.0,743.0,229.0,0.068641,0.068641,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.11322213,0.11409185844463286,0.0008697284446328585
42.0,743.0,229.0,0.056528,0.056528,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.09324195,0.09400747705676586,0.0007655270567658579
65.0,743.0,229.0,0.087483,0.087483,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lack of Efficacy,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.14430168,0.14506934624154752,0.0007676662415475322
38.0,743.0,229.0,0.051144,0.051144,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.08436113,0.08549319359089283,0.0011320635908928234
34.0,743.0,229.0,0.04576,0.04576,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.07548032,0.07540035033920635,7.996966079365508e-05
26.0,743.0,229.0,0.034993,0.034993,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.05772034,0.05714687131446424,0.0005734686855357607
30.0,743.0,229.0,0.040377,0.040377,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject Withdrew Consent,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.06660116,0.06642925408151774,0.00017190591848226244
12.0,743.0,229.0,0.016151,0.016151,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.02664079,0.026019844756398805,0.000620945243601196
18.0,743.0,229.0,0.024226,0.024226,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.03996036,0.03937205102403771,0.0005883089759622928
13.0,743.0,229.0,0.017497,0.017497,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.028861,0.029019468451666634,0.00015846845166663306
10.0,743.0,229.0,0.013459,0.013459,6.612041,0.249466,1.0,1462.0,9.0,152.0,Adverse Event,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.02220039,0.02219283697668652,7.5530233134800395e-06
11.0,743.0,229.0,0.014805,0.014805,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.02442059,0.024393548606269858,2.7041393730140723e-05
11.0,743.0,229.0,0.014805,0.014805,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.02442059,0.02439395450835321,2.66354916467898e-05
13.0,743.0,229.0,0.017497,0.017497,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.028861,0.02900665169437497,0.00014565169437496736
16.0,743.0,229.0,0.021534,0.021534,6.612041,0.249466,1.0,1462.0,9.0,152.0,Lost to Follow-up,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.03551996,0.03598748283506942,0.0004675228350694144
5.0,743.0,229.0,0.006729,0.006729,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.01109937,0.011104618975654823,5.248975654821922e-06
7.0,743.0,229.0,0.009421,0.009421,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.01553977,0.01544460085698947,9.516914301052962e-05
6.0,743.0,229.0,0.008075,0.008075,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.01331957,0.013299872115357176,1.969788464282335e-05
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Other Reason,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.00666061,0.006660165354315454,4.4464568454624653e-07
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.00666061,0.006663236780089259,2.6267800892591786e-06
6.0,743.0,229.0,0.008075,0.008075,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.01331957,0.013295310895327418,2.42591046725818e-05
5.0,743.0,229.0,0.006729,0.006729,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.01109937,0.011107651304404826,8.281304404824871e-06
9.0,743.0,229.0,0.012113,0.012113,6.612041,0.249466,1.0,1462.0,9.0,152.0,Subject No Longer Meets Study Criteria,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.01998018,0.019941355163426242,3.882483657375799e-05
3.0,743.0,229.0,0.004038,0.004038,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.00666061,0.006663236780089259,2.6267800892591786e-06
5.0,743.0,229.0,0.006729,0.006729,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.01109937,0.011102004119285773,2.634119285771855e-06
8.0,743.0,229.0,0.010767,0.010767,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.01775998,0.017627152510476207,0.00013282748952379506
4.0,743.0,229.0,0.005384,0.005384,6.612041,0.249466,1.0,1462.0,9.0,152.0,Poor / Non-compliance,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.00888081,0.008885582783978161,4.772783978162012e-06
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.0022202,0.002221108108809528,9.08108809528213e-07
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.0022202,0.002221088405476195,8.884054761952587e-07
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Pregnancy,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.0022202,0.002221878505119051,1.678505119050936e-06
1.0,743.0,229.0,0.001346,0.001346,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) + Long Term (LT) Period,FG000,diabetes type 2,INDUSTRY,0.0022202,0.0022212054813095282,1.0054813095283603e-06
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) + Long Term (LT) Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,743.0,229.0,0.0,0.0,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) + Long Term (LT) Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,743.0,229.0,0.002692,0.002692,6.612041,0.249466,1.0,1462.0,9.0,152.0,Death,Short Term (ST) + Long Term (LT) Period,FG003,diabetes type 2,INDUSTRY,0.00444041,0.00442939833497022,1.1011665029779516e-05
10.0,451.0,391.0,0.022173,0.022173,6.113682,0.330504,1.0,451.0,10.0,82.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04480269,0.044792725666007345,9.964333992654173e-06
11.0,451.0,391.0,0.02439,0.02439,6.113682,0.330504,1.0,451.0,10.0,82.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04928235,0.04933330123392851,5.0951233928508977e-05
10.0,451.0,391.0,0.022173,0.022173,6.113682,0.330504,1.0,451.0,10.0,82.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04480269,0.04474098315582878,6.170684417122069e-05
5.0,451.0,391.0,0.011086,0.011086,6.113682,0.330504,1.0,451.0,10.0,82.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02240033,0.02236659954592263,3.373045407736863e-05
8.0,451.0,391.0,0.017738,0.017738,6.113682,0.330504,1.0,451.0,10.0,82.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03584134,0.03589087049644656,4.953049644656343e-05
3.0,451.0,391.0,0.006652,0.006652,6.113682,0.330504,1.0,451.0,10.0,82.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01344101,0.013586648571984127,0.00014563857198412675
8.0,451.0,391.0,0.017738,0.017738,6.113682,0.330504,1.0,451.0,10.0,82.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03584134,0.03589087049644656,4.953049644656343e-05
5.0,451.0,391.0,0.011086,0.011086,6.113682,0.330504,1.0,451.0,10.0,82.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02240033,0.02238900517711311,1.1324822886890629e-05
13.0,435.0,362.0,0.029885,0.029885,6.077642,0.344523,1.0,435.0,8.0,87.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06257579,0.0627097814986905,0.00013399149869049165
10.0,435.0,362.0,0.022989,0.022989,6.077642,0.344523,1.0,435.0,8.0,87.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04813635,0.04813296574992064,3.3842500793621055e-06
9.0,435.0,362.0,0.02069,0.02069,6.077642,0.344523,1.0,435.0,8.0,87.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0433225,0.04343256543304561,0.00011006543304561273
2.0,435.0,362.0,0.004598,0.004598,6.077642,0.344523,1.0,435.0,8.0,87.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00962769,0.009649876519702375,2.2186519702375312e-05
2.0,435.0,362.0,0.004598,0.004598,6.077642,0.344523,1.0,435.0,8.0,87.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00962769,0.009657407960892848,2.9717960892848214e-05
10.0,435.0,362.0,0.022989,0.022989,6.077642,0.344523,1.0,435.0,8.0,87.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04813635,0.04812680301992064,9.546980079364054e-06
14.0,435.0,362.0,0.032184,0.032184,6.077642,0.344523,1.0,435.0,8.0,87.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06738963,0.06741432617948417,2.4696179484168246e-05
13.0,435.0,362.0,0.029885,0.029885,6.077642,0.344523,1.0,435.0,8.0,87.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06257579,0.06282022837541669,0.00024443837541668345
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00257919,0.0025794759432142766,2.8594321427669045e-07
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00257919,0.0025798226927380833,6.326927380834527e-07
4.0,638.0,552.0,0.00627,0.00627,6.459904,0.254793,1.0,1093.0,6.0,123.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01032003,0.010250411881889425,6.961811811057386e-05
9.0,638.0,552.0,0.014107,0.014107,6.459904,0.254793,1.0,1093.0,6.0,123.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02321925,0.023035491028204357,0.0001837589717956431
8.0,638.0,552.0,0.012539,0.012539,6.459904,0.254793,1.0,1093.0,6.0,123.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02063842,0.02067097857390692,3.255857390692049e-05
11.0,638.0,552.0,0.017241,0.017241,6.459904,0.254793,1.0,1093.0,6.0,123.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02837762,0.02843210976324405,5.448976324404914e-05
8.0,638.0,552.0,0.012539,0.012539,6.459904,0.254793,1.0,1093.0,6.0,123.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02063842,0.020686243891617058,4.7823891617056885e-05
11.0,638.0,552.0,0.017241,0.017241,6.459904,0.254793,1.0,1093.0,6.0,123.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02837762,0.028434317370744047,5.669737074404796e-05
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00257919,0.0025801641527380846,9.74152738084707e-07
10.0,638.0,552.0,0.015674,0.015674,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02579843,0.024994667082777745,0.000803762917222256
11.0,638.0,552.0,0.017241,0.017241,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02837762,0.028467704326964292,9.008432696429314e-05
5.0,638.0,552.0,0.007837,0.007837,6.459904,0.254793,1.0,1093.0,6.0,123.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01289922,0.013134260439226194,0.0002350404392261942
2.0,638.0,552.0,0.003135,0.003135,6.459904,0.254793,1.0,1093.0,6.0,123.0,poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00516002,0.005220164765337304,6.014476533730377e-05
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,poor/non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,No longer meets criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,No longer meets criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00257919,0.002579953723214276,7.637232142762053e-07
0.0,638.0,552.0,0.0,0.0,6.459904,0.254793,1.0,1093.0,6.0,123.0,No longer meets criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,non-specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00257919,0.002581489703392845,2.299703392845149e-06
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,non-specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00257919,0.0025788365444047506,3.5345559524927253e-07
1.0,638.0,552.0,0.001567,0.001567,6.459904,0.254793,1.0,1093.0,6.0,123.0,non-specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00257919,0.002579556358214272,3.66358214271955e-07
3.0,308.0,278.0,0.00974,0.00974,5.733341,0.469071,1.0,308.0,1.0,70.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02619418,0.02676340959385641,0.0005692295938564094
2.0,308.0,278.0,0.006494,0.006494,5.733341,0.469071,1.0,308.0,1.0,70.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01746458,0.017665227682838215,0.00020064768283821477
5.0,308.0,278.0,0.016234,0.016234,5.733341,0.469071,1.0,308.0,1.0,70.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04365877,0.04554428186148806,0.0018855118614880609
6.0,308.0,278.0,0.019481,0.019481,5.733341,0.469071,1.0,308.0,1.0,70.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05239106,0.053267131936160714,0.0008760719361607106
6.0,308.0,278.0,0.019481,0.019481,5.733341,0.469071,1.0,308.0,1.0,70.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05239106,0.05311032215395833,0.0007192621539583235
5.0,308.0,278.0,0.016234,0.016234,5.733341,0.469071,1.0,308.0,1.0,70.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04365877,0.0456004430932341,0.001941673093234099
2.0,308.0,278.0,0.006494,0.006494,5.733341,0.469071,1.0,308.0,1.0,70.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01746458,0.017660927790129885,0.00019634779012988463
1.0,308.0,278.0,0.003247,0.003247,5.733341,0.469071,1.0,308.0,1.0,70.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00873229,0.008933830878194443,0.00020154087819444257
3.0,546.0,339.0,0.005495,0.005495,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.00882678,0.008816225778174624,1.0554221825375201e-05
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.00294279,0.0029483574191666627,5.56741916666291e-06
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.01176797,0.011773790338869128,5.820338869127334e-06
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.01176797,0.011763731040416748,4.238959583253293e-06
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.00588398,0.00588821799047617,4.237990476170517e-06
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.01176797,0.011766898886190565,1.0711138094358919e-06
7.0,546.0,339.0,0.012821,0.012821,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.02059475,0.020615649724732118,2.0899724732119374e-05
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.01471076,0.014717289133452304,6.529133452304672e-06
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.01471076,0.014721820223035635,1.1060223035635336e-05
3.0,546.0,339.0,0.005495,0.005495,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.00882678,0.008821963664603201,4.816335396798377e-06
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.01471076,0.014708279007589212,2.480992410788113e-06
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.01176797,0.011767638207916742,3.317920832593413e-07
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.01176797,0.01177938505827389,1.1415058273889916e-05
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.01471076,0.014713766187589213,3.0061875892131024e-06
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.00588398,0.00588824764797617,4.267647976170623e-06
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.00588398,0.005887416181726175,3.4361817261756647e-06
3.0,546.0,339.0,0.005495,0.005495,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.00882678,0.008826003583888914,7.764161110857676e-07
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.00588398,0.005889530598809506,5.55059880950632e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Administrative reason by author,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.00294279,0.0029444423899999965,1.6523899999966972e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Administrative reason by author,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.00294279,0.0029444878008333284,1.6978008333286276e-06
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Administrative reason by author,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Administrative reason by author,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.00294279,0.002943195480416662,4.0548041666237794e-07
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Other,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Other,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Other,Short-term Period (Day 1 to Week 24),FG002,diabetes type 2,INDUSTRY,0.00294279,0.0029436357074999965,8.457074999967083e-07
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Other,Short-term Period (Day 1 to Week 24),FG003,diabetes type 2,INDUSTRY,0.00294279,0.0029431960408333293,4.060408333294435e-07
27.0,546.0,339.0,0.049451,0.049451,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.07943458,0.07885081948192466,0.0005837605180753491
16.0,546.0,339.0,0.029304,0.029304,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.04707187,0.04749708877591271,0.0004252187759127071
17.0,546.0,339.0,0.031136,0.031136,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.05001466,0.05001781705427579,3.157054275788884e-06
9.0,546.0,339.0,0.016484,0.016484,6.304449,0.254793,1.0,915.0,5.0,75.0,Lack of Efficacy,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.02647873,0.026252476052837283,0.0002262539471627155
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.01471076,0.014723961291517795,1.3201291517795158e-05
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.01176797,0.011764957802023888,3.0121979761130874e-06
3.0,546.0,339.0,0.005495,0.005495,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.00882678,0.008830233712123046,3.4537121230467788e-06
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,Adverse Event,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.00588398,0.005892481233333318,8.501233333318113e-06
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.01176797,0.011774972415833404,7.002415833403178e-06
6.0,546.0,339.0,0.010989,0.010989,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.01765195,0.017644610584574175,7.339415425824253e-06
8.0,546.0,339.0,0.014652,0.014652,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.02353593,0.023211487330357158,0.00032444266964284235
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.01176797,0.011768018608988174,4.860898817314607e-08
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Death,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Death,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.00294279,0.002942921265178566,1.312651785661742e-07
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Death,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Death,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,546.0,339.0,0.007326,0.007326,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.01176797,0.01177917225011912,1.1202250119119947e-05
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.01471076,0.014709041989553506,1.7180104464938756e-06
3.0,546.0,339.0,0.005495,0.005495,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.00882678,0.008827581153789711,8.011537897117949e-07
7.0,546.0,339.0,0.012821,0.012821,6.304449,0.254793,1.0,915.0,5.0,75.0,Lost to Follow-up,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.02059475,0.020606050047738068,1.1300047738069252e-05
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,546.0,339.0,0.009158,0.009158,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.01471076,0.01470582152151779,4.938478482209921e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.00294279,0.002943774521845234,9.845218452340064e-07
2.0,546.0,339.0,0.003663,0.003663,6.304449,0.254793,1.0,915.0,5.0,75.0,Poor compliance/noncompliance,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.00588398,0.005892510890833318,8.53089083331822e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,Pregnancy,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.00294279,0.002944604873095235,1.8148730952351547e-06
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Pregnancy,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Pregnancy,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,Pregnancy,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Long-term Period (Weeks 24 to 102),FG000,diabetes type 2,INDUSTRY,0.00294279,0.0029445654897619013,1.775489761901474e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Long-term Period (Weeks 24 to 102),FG001,diabetes type 2,INDUSTRY,0.00294279,0.0029446560130952327,1.8660130952329046e-06
1.0,546.0,339.0,0.001832,0.001832,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Long-term Period (Weeks 24 to 102),FG002,diabetes type 2,INDUSTRY,0.00294279,0.002943774521845234,9.845218452340064e-07
0.0,546.0,339.0,0.0,0.0,6.304449,0.254793,1.0,915.0,5.0,75.0,No longer meets study criteria,Long-term Period (Weeks 24 to 102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,498.0,440.0,0.01004,0.01004,6.212606,0.365067,1.0,498.0,0.0,0.0,Other Protocol Specified Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02277089,0.02326055415851191,0.0004896641585119127
14.0,498.0,440.0,0.028112,0.028112,6.212606,0.365067,1.0,498.0,0.0,0.0,Other Protocol Specified Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06375849,0.06337503226232145,0.00038345773767854696
8.0,498.0,440.0,0.016064,0.016064,6.212606,0.365067,1.0,498.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03643343,0.036350496215109177,8.293378489082626e-05
15.0,498.0,440.0,0.03012,0.03012,6.212606,0.365067,1.0,498.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06831267,0.06833646301412707,2.379301412706869e-05
1.0,498.0,440.0,0.002008,0.002008,6.212606,0.365067,1.0,498.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00455418,0.004557180930920318,3.0009309203186604e-06
2.0,498.0,440.0,0.004016,0.004016,6.212606,0.365067,1.0,498.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00910836,0.009008943818452395,9.941618154760481e-05
1.0,498.0,440.0,0.002008,0.002008,6.212606,0.365067,1.0,498.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00455418,0.00455540449532508,1.2244953250806212e-06
1.0,498.0,440.0,0.002008,0.002008,6.212606,0.365067,1.0,498.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00455418,0.004552166361178254,2.013638821745864e-06
1.0,498.0,440.0,0.002008,0.002008,6.212606,0.365067,1.0,498.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00455418,0.004556490799551271,2.310799551271704e-06
0.0,498.0,440.0,0.0,0.0,6.212606,0.365067,1.0,498.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,498.0,440.0,0.006024,0.006024,6.212606,0.365067,1.0,498.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01366253,0.013586588708065476,7.594129193452467e-05
7.0,498.0,440.0,0.014056,0.014056,6.212606,0.365067,1.0,498.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03187925,0.032223575869420096,0.0003443258694200979
18.0,792.0,745.0,0.022727,0.022727,6.675823,0.87262,1.0,792.0,21.0,194.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13239509,0.1339467981217794,0.0015517081217794049
12.0,792.0,745.0,0.015152,0.015152,6.675823,0.87262,1.0,792.0,21.0,194.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08826727,0.09000500527575397,0.0017377352757539793
8.0,792.0,745.0,0.010101,0.010101,6.675823,0.87262,1.0,792.0,21.0,194.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05884291,0.060668078298759906,0.0018251682987599077
5.0,792.0,745.0,0.006313,0.006313,6.675823,0.87262,1.0,792.0,21.0,194.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03677609,0.03663437914761899,0.00014171085238100928
4.0,792.0,745.0,0.005051,0.005051,6.675823,0.87262,1.0,792.0,21.0,194.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02942437,0.02998343067515693,0.0005590606751569305
0.0,792.0,745.0,0.0,0.0,6.675823,0.87262,1.0,792.0,21.0,194.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
23.0,859.0,600.0,0.026775,0.026775,6.756932,0.270051,1.0,859.0,16.0,16.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0488567,0.04873065709837305,0.00012604290162695347
71.0,859.0,600.0,0.082654,0.082654,6.756932,0.270051,1.0,859.0,16.0,16.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.15081985,0.15237754161681555,0.001557691616815543
24.0,859.0,600.0,0.027939,0.027939,6.756932,0.270051,1.0,859.0,16.0,16.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05098066,0.05084848052800595,0.00013217947199404417
16.0,859.0,600.0,0.018626,0.018626,6.756932,0.270051,1.0,859.0,16.0,16.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03398711,0.033981052469523806,6.057530476194506e-06
2.0,859.0,600.0,0.002328,0.002328,6.756932,0.270051,1.0,859.0,16.0,16.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00424793,0.004304171171309523,5.624117130952327e-05
9.0,859.0,600.0,0.010477,0.010477,6.756932,0.270051,1.0,859.0,16.0,16.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01911752,0.019231163144742068,0.0001136431447420691
13.0,859.0,600.0,0.015134,0.015134,6.756932,0.270051,1.0,859.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02761521,0.027842925987599198,0.00022771598759919673
23.0,859.0,600.0,0.026775,0.026775,6.756932,0.270051,1.0,859.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0488567,0.04871226739399805,0.0001444326060019499
7.0,859.0,600.0,0.008149,0.008149,6.756932,0.270051,1.0,859.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01486959,0.014912231426974214,4.264142697421418e-05
14.0,859.0,600.0,0.016298,0.016298,6.756932,0.270051,1.0,859.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02973918,0.03033204638185518,0.0005928663818551803
9.0,859.0,600.0,0.010477,0.010477,6.756932,0.270051,1.0,859.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01911752,0.01924596904465278,0.0001284490446527807
34.0,859.0,600.0,0.039581,0.039581,6.756932,0.270051,1.0,859.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07222398,0.07249861176498283,0.00027463176498283837
4.0,859.0,600.0,0.004657,0.004657,6.756932,0.270051,1.0,859.0,16.0,16.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00849769,0.008437136282926597,6.0553717073403776e-05
10.0,859.0,600.0,0.011641,0.011641,6.756932,0.270051,1.0,859.0,16.0,16.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02124149,0.021136972339345247,0.00010451766065475154
3.0,655.0,514.0,0.00458,0.00458,6.486161,0.209726,1.0,655.0,23.0,161.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00623024,0.0062072284654464275,2.301153455357228e-05
8.0,655.0,514.0,0.012214,0.012214,6.486161,0.209726,1.0,655.0,23.0,161.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01661488,0.01668778580111111,7.290580111111306e-05
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01246048,0.012482032517916672,2.1552517916672426e-05
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01246048,0.012492304451726196,3.182445172619612e-05
2.0,655.0,514.0,0.003053,0.003053,6.486161,0.209726,1.0,655.0,23.0,161.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00415304,0.004148325648154788,4.7143518452121e-06
3.0,655.0,514.0,0.00458,0.00458,6.486161,0.209726,1.0,655.0,23.0,161.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00623024,0.006210644203214287,1.9595796785712785e-05
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01246048,0.01245882038015873,1.6596198412696661e-06
7.0,655.0,514.0,0.010687,0.010687,6.486161,0.209726,1.0,655.0,23.0,161.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01453768,0.014815635962509914,0.00027795596250991365
2.0,655.0,514.0,0.003053,0.003053,6.486161,0.209726,1.0,655.0,23.0,161.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00415304,0.0041484565669643115,4.5834330356887484e-06
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01246048,0.012467445151468248,6.965151468248804e-06
5.0,655.0,514.0,0.007634,0.007634,6.486161,0.209726,1.0,655.0,23.0,161.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01038464,0.010362396663769842,2.2243336230158214e-05
5.0,655.0,514.0,0.007634,0.007634,6.486161,0.209726,1.0,655.0,23.0,161.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01038464,0.01036431391168651,2.0326088313491267e-05
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01246048,0.01246574509369048,5.265093690479811e-06
5.0,655.0,514.0,0.007634,0.007634,6.486161,0.209726,1.0,655.0,23.0,161.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01038464,0.010366595343829367,1.80446561706335e-05
5.0,655.0,514.0,0.007634,0.007634,6.486161,0.209726,1.0,655.0,23.0,161.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01038464,0.010363604692936507,2.1035307063493533e-05
12.0,655.0,514.0,0.018321,0.018321,6.486161,0.209726,1.0,655.0,23.0,161.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02492232,0.024669539186141776,0.00025278081385822493
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01246048,0.012470729999583334,1.0249999583334876e-05
4.0,655.0,514.0,0.006107,0.006107,6.486161,0.209726,1.0,655.0,23.0,161.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00830744,0.008335972605753954,2.8532605753955192e-05
2.0,655.0,514.0,0.003053,0.003053,6.486161,0.209726,1.0,655.0,23.0,161.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00415304,0.004153638837797647,5.988377976464537e-07
2.0,655.0,514.0,0.003053,0.003053,6.486161,0.209726,1.0,655.0,23.0,161.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00415304,0.004153727953125028,6.87953125027771e-07
1.0,655.0,514.0,0.001527,0.001527,6.486161,0.209726,1.0,655.0,23.0,161.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0020772,0.0020561992719480534,2.1000728051946606e-05
1.0,655.0,514.0,0.001527,0.001527,6.486161,0.209726,1.0,655.0,23.0,161.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0020772,0.0020489408796284243,2.825912037157565e-05
0.0,655.0,514.0,0.0,0.0,6.486161,0.209726,1.0,655.0,23.0,161.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,655.0,514.0,0.0,0.0,6.486161,0.209726,1.0,655.0,23.0,161.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,655.0,514.0,0.027481,0.027481,6.486161,0.209726,1.0,655.0,23.0,161.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0373828,0.037238480156498006,0.00014431984350199434
10.0,655.0,514.0,0.015267,0.015267,6.486161,0.209726,1.0,655.0,23.0,161.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02076792,0.02073058650050685,3.7333499493148736e-05
4.0,655.0,514.0,0.006107,0.006107,6.486161,0.209726,1.0,655.0,23.0,161.0,Hyperglycemic Rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00830744,0.008338595632103162,3.115563210316294e-05
6.0,655.0,514.0,0.00916,0.00916,6.486161,0.209726,1.0,655.0,23.0,161.0,Hyperglycemic Rescue,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01246048,0.01246615414825397,5.674148253970515e-06
1.0,261.0,239.0,0.003831,0.003831,5.568345,0.298717,1.0,261.0,1.0,26.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00637232,0.0063399065582440805,3.2413441755919405e-05
2.0,261.0,239.0,0.007663,0.007663,5.568345,0.298717,1.0,261.0,1.0,26.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0127463,0.012753731287916646,7.431287916645837e-06
3.0,261.0,239.0,0.011494,0.011494,5.568345,0.298717,1.0,261.0,1.0,26.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01911862,0.0190340046515972,8.461534840279936e-05
1.0,261.0,239.0,0.003831,0.003831,5.568345,0.298717,1.0,261.0,1.0,26.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00637232,0.006343000871755978,2.9319128244022045e-05
2.0,261.0,239.0,0.007663,0.007663,5.568345,0.298717,1.0,261.0,1.0,26.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0127463,0.012754762504583302,8.462504583301236e-06
2.0,261.0,239.0,0.007663,0.007663,5.568345,0.298717,1.0,261.0,1.0,26.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0127463,0.012753354037708307,7.054037708306357e-06
2.0,261.0,239.0,0.007663,0.007663,5.568345,0.298717,1.0,261.0,1.0,26.0,subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0127463,0.012738115824791651,8.184175208349187e-06
5.0,261.0,239.0,0.019157,0.019157,5.568345,0.298717,1.0,261.0,1.0,26.0,subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03186493,0.03136374382214287,0.0005011861778571325
2.0,261.0,239.0,0.007663,0.007663,5.568345,0.298717,1.0,261.0,1.0,26.0,subject no longer meets study criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0127463,0.012754227527708313,7.927527708312399e-06
1.0,261.0,239.0,0.003831,0.003831,5.568345,0.298717,1.0,261.0,1.0,26.0,poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00637232,0.0063372574330059816,3.506256699401834e-05
0.0,261.0,239.0,0.0,0.0,5.568345,0.298717,1.0,261.0,1.0,26.0,poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,261.0,239.0,0.003831,0.003831,5.568345,0.298717,1.0,261.0,1.0,26.0,poor/non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00637232,0.006339990569315505,3.2329430684495224e-05
20.0,1299.0,1173.0,0.015396,0.015396,7.17012,0.318867,1.0,1299.0,1.0,7.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03520012,0.034237795451378956,0.0009623245486210449
30.0,1299.0,1173.0,0.023095,0.023095,7.17012,0.318867,1.0,1299.0,1.0,7.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05280246,0.05205173560532016,0.0007507243946798456
1.0,1299.0,1173.0,0.00077,0.00077,7.17012,0.318867,1.0,1299.0,1.0,7.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00176046,0.0017680793543452364,7.619354345236471e-06
0.0,1299.0,1173.0,0.0,0.0,7.17012,0.318867,1.0,1299.0,1.0,7.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1299.0,1173.0,0.002309,0.002309,7.17012,0.318867,1.0,1299.0,1.0,7.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0052791,0.005225711913005956,5.338808699404448e-05
10.0,1299.0,1173.0,0.007698,0.007698,7.17012,0.318867,1.0,1299.0,1.0,7.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01760006,0.018473448645932526,0.0008733886459325255
27.0,1299.0,1173.0,0.020785,0.020785,7.17012,0.318867,1.0,1299.0,1.0,7.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04752107,0.04827227124220235,0.0007512012422023484
31.0,1299.0,1173.0,0.023865,0.023865,7.17012,0.318867,1.0,1299.0,1.0,7.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05456292,0.0539985551772916,0.0005643648227083992
1.0,1299.0,1173.0,0.00077,0.00077,7.17012,0.318867,1.0,1299.0,1.0,7.0,Clearly not eligible for the study,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00176046,0.0017672108010119028,6.750801011902886e-06
3.0,1299.0,1173.0,0.002309,0.002309,7.17012,0.318867,1.0,1299.0,1.0,7.0,Clearly not eligible for the study,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0052791,0.005211737238303573,6.736276169642692e-05
9.0,1700.0,1469.0,0.005294,0.005294,7.438972,0.579553,1.0,1700.0,10.0,157.0,Adverse Event,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.02282393,0.022744006355188476,7.992364481152273e-05
3.0,1700.0,1469.0,0.001765,0.001765,7.438972,0.579553,1.0,1700.0,10.0,157.0,Adverse Event,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.00760941,0.007674794085565479,6.538408556547911e-05
7.0,1700.0,1469.0,0.004118,0.004118,7.438972,0.579553,1.0,1700.0,10.0,157.0,Death,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.01775386,0.01798495151931547,0.0002310915193154718
7.0,1700.0,1469.0,0.004118,0.004118,7.438972,0.579553,1.0,1700.0,10.0,157.0,Death,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.01775386,0.017927491893898816,0.00017363189389881656
8.0,1700.0,1469.0,0.004706,0.004706,7.438972,0.579553,1.0,1700.0,10.0,157.0,Lost to Follow-up,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.02028889,0.020181663034880927,0.0001072269651190734
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,Lost to Follow-up,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.00253503,0.0025378090770238047,2.779077023804498e-06
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,Physician Decision,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.00253503,0.0025389899131547573,3.9599131547570984e-06
0.0,1700.0,1469.0,0.0,0.0,7.438972,0.579553,1.0,1700.0,10.0,157.0,Physician Decision,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,Protocol Violation,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.00253503,0.0025366533536904713,1.623353690471084e-06
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,Protocol Violation,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.00253503,0.0025368877620238046,1.857762023804374e-06
17.0,1700.0,1469.0,0.01,0.01,7.438972,0.579553,1.0,1700.0,10.0,157.0,Withdrawal by Subject,Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.04311282,0.042877420344890844,0.0002353996551091586
13.0,1700.0,1469.0,0.007647,0.007647,7.438972,0.579553,1.0,1700.0,10.0,157.0,Withdrawal by Subject,Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.03296837,0.03299196170712302,2.359170712302322e-05
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,"The subject was randomized, but did not take any investigational product",Completed the Study Through Week 24,FG000,diabetes type 2,INDUSTRY,0.00253503,0.0025382737048214236,3.243704821423443e-06
0.0,1700.0,1469.0,0.0,0.0,7.438972,0.579553,1.0,1700.0,10.0,157.0,"The subject was randomized, but did not take any investigational product",Completed the Study Through Week 24,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,1700.0,1469.0,0.008235,0.008235,7.438972,0.579553,1.0,1700.0,10.0,157.0,Adverse Event,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.03550341,0.03584622758071431,0.0003428175807143122
5.0,1700.0,1469.0,0.002941,0.002941,7.438972,0.579553,1.0,1700.0,10.0,157.0,Adverse Event,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.01267948,0.013184349993541667,0.0005048699935416671
39.0,1700.0,1469.0,0.022941,0.022941,7.438972,0.579553,1.0,1700.0,10.0,157.0,Death,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.09890512,0.0978869750298314,0.0010181449701685968
25.0,1700.0,1469.0,0.014706,0.014706,7.438972,0.579553,1.0,1700.0,10.0,157.0,Death,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.06340171,0.06295140651788686,0.0004503034821131402
31.0,1700.0,1469.0,0.018235,0.018235,7.438972,0.579553,1.0,1700.0,10.0,157.0,Lost to Follow-up,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.07861622,0.08079633811782745,0.002180118117827451
23.0,1700.0,1469.0,0.013529,0.013529,7.438972,0.579553,1.0,1700.0,10.0,157.0,Lost to Follow-up,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.05832733,0.06027827694780748,0.0019509469478074803
6.0,1700.0,1469.0,0.003529,0.003529,7.438972,0.579553,1.0,1700.0,10.0,157.0,Physician Decision,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.01521451,0.015342598755803582,0.00012808875580358134
0.0,1700.0,1469.0,0.0,0.0,7.438972,0.579553,1.0,1700.0,10.0,157.0,Physician Decision,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1700.0,1469.0,0.001176,0.001176,7.438972,0.579553,1.0,1700.0,10.0,157.0,Protocol Violation,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.00507007,0.004904404301458334,0.0001656656985416661
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,Protocol Violation,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.00253503,0.002540914319563488,5.884319563487922e-06
53.0,1700.0,1469.0,0.031176,0.031176,7.438972,0.579553,1.0,1700.0,10.0,157.0,Withdrawal by Subject,Completed the Study,FG000,diabetes type 2,INDUSTRY,0.13440852,0.13406585966410708,0.0003426603358929192
31.0,1700.0,1469.0,0.018235,0.018235,7.438972,0.579553,1.0,1700.0,10.0,157.0,Withdrawal by Subject,Completed the Study,FG001,diabetes type 2,INDUSTRY,0.07861622,0.08129276851034727,0.0026765485103472653
1.0,1700.0,1469.0,0.000588,0.000588,7.438972,0.579553,1.0,1700.0,10.0,157.0,"The subject was randomized, but did not take any investigational product",Completed the Study,FG000,diabetes type 2,INDUSTRY,0.00253503,0.002541918167361107,6.888167361106777e-06
0.0,1700.0,1469.0,0.0,0.0,7.438972,0.579553,1.0,1700.0,10.0,157.0,"The subject was randomized, but did not take any investigational product",Completed the Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,444.0,409.0,0.0,0.0,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,444.0,409.0,0.0,0.0,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,444.0,409.0,0.002252,0.002252,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00447352,0.004494948416815457,2.14284168154567e-05
2.0,444.0,409.0,0.004505,0.004505,6.098074,0.325753,1.0,1484.0,3.0,33.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00894902,0.009036691081319471,8.767108131947123e-05
1.0,444.0,409.0,0.002252,0.002252,6.098074,0.325753,1.0,1484.0,3.0,33.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00447352,0.0045030946872321245,2.95746872321246e-05
3.0,444.0,409.0,0.006757,0.006757,6.098074,0.325753,1.0,1484.0,3.0,33.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01342254,0.013721134635436507,0.0002985946354365065
2.0,444.0,409.0,0.004505,0.004505,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00894902,0.009036552600902806,8.753260090280622e-05
2.0,444.0,409.0,0.004505,0.004505,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00894902,0.009028091054831383,7.907105483138249e-05
0.0,444.0,409.0,0.0,0.0,6.098074,0.325753,1.0,1484.0,3.0,33.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,444.0,409.0,0.013514,0.013514,6.098074,0.325753,1.0,1484.0,3.0,33.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02684508,0.026936950710518586,9.187071051858578e-05
6.0,444.0,409.0,0.013514,0.013514,6.098074,0.325753,1.0,1484.0,3.0,33.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02684508,0.026924101491232862,7.902149123286198e-05
1.0,444.0,409.0,0.002252,0.002252,6.098074,0.325753,1.0,1484.0,3.0,33.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00447352,0.00449421016264879,2.0690162648789694e-05
7.0,444.0,409.0,0.015766,0.015766,6.098074,0.325753,1.0,1484.0,3.0,33.0,"Non-compliance, not met criteria etc.",Overall Study,FG000,diabetes type 2,INDUSTRY,0.0313186,0.0317105751106349,0.0003919751106348998
2.0,444.0,409.0,0.004505,0.004505,6.098074,0.325753,1.0,1484.0,3.0,33.0,"Non-compliance, not met criteria etc.",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00894902,0.009026301296498049,7.728129649804856e-05
2.0,444.0,409.0,0.004505,0.004505,6.098074,0.325753,1.0,1484.0,3.0,33.0,"Non-compliance, not met criteria etc.",Overall Study,FG002,diabetes type 2,INDUSTRY,0.00894902,0.0090435184123909,9.449841239089936e-05
96.0,4786.0,4474.0,0.020059,0.020059,8.473659,0.580517,1.0,4786.0,3.0,470.0,Death,Overall Study,FG000,diabetes type 2,OTHER,0.09867234,0.09609022301555925,0.0025821169844407466
83.0,4786.0,4474.0,0.017342,0.017342,8.473659,0.580517,1.0,4786.0,3.0,470.0,Death,Overall Study,FG001,diabetes type 2,OTHER,0.08530713,0.0843044985457341,0.0010026314542658926
5.0,4786.0,4474.0,0.001045,0.001045,8.473659,0.580517,1.0,4786.0,3.0,470.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,OTHER,0.00514047,0.005106071966904757,3.439803309524328e-05
5.0,4786.0,4474.0,0.001045,0.001045,8.473659,0.580517,1.0,4786.0,3.0,470.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,OTHER,0.00514047,0.005110455095922613,3.001490407738769e-05
60.0,4786.0,4474.0,0.012537,0.012537,8.473659,0.580517,1.0,4786.0,3.0,470.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,OTHER,0.06167083,0.059842774089365065,0.0018280559106349376
63.0,4786.0,4474.0,0.013163,0.013163,8.473659,0.580517,1.0,4786.0,3.0,470.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,OTHER,0.06475019,0.06362199780865076,0.001128192191349242
5.0,709.0,436.0,0.007052,0.007052,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01793536,0.017838949034174812,9.641096582518882e-05
15.0,709.0,436.0,0.021157,0.021157,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.05380863,0.05385548088983136,4.685088983135549e-05
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00358606,0.003584319506249973,1.74049375002705e-06
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00358606,0.003584348536130926,1.711463869073955e-06
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,709.0,436.0,0.007052,0.007052,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01793536,0.01783888727084148,9.647272915852198e-05
5.0,709.0,436.0,0.007052,0.007052,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01793536,0.017823657003511933,0.00011170299648806739
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,709.0,436.0,0.005642,0.005642,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01434931,0.01436382334246034,1.451334246034032e-05
3.0,709.0,436.0,0.004231,0.004231,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01076071,0.010660119309047636,0.00010059069095236413
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,709.0,436.0,0.005642,0.005642,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01434931,0.014354261823769863,4.951823769862654e-06
10.0,709.0,436.0,0.014104,0.014104,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03587073,0.03613150746945435,0.00026077746945434715
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00717465,0.0071744996408008785,1.50359199121812e-07
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00358606,0.00358390278696426,2.1572130357396836e-06
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
77.0,709.0,436.0,0.108604,0.108604,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG000,diabetes type 2,INDUSTRY,0.27621273,0.2735109228292143,0.0027018071707857194
94.0,709.0,436.0,0.132581,0.132581,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG001,diabetes type 2,INDUSTRY,0.33719347,0.3199712921603374,0.017222177839662622
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Open Label Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,709.0,436.0,0.005642,0.005642,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01434931,0.014329472491448439,1.9837508551561953e-05
5.0,709.0,436.0,0.007052,0.007052,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01793536,0.01783559966854981,9.976033145019103e-05
3.0,709.0,436.0,0.004231,0.004231,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.01076071,0.010638157389761918,0.00012255261023808202
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Adverse Event,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00717465,0.007169524039745692,5.125960254308282e-06
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Lack of Efficacy,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00358606,0.003586976350297587,9.163502975870555e-07
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00717465,0.007174829618912356,1.796189123557182e-07
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Protocol Violation,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,709.0,436.0,0.005642,0.005642,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01434931,0.014350223757847254,9.137578472536573e-07
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00358606,0.003588235957658703,2.1759576587032994e-06
5.0,709.0,436.0,0.007052,0.007052,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.01793536,0.01785627006831171,7.908993168828996e-05
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Lost to Follow-up,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00717465,0.0071705141659956905,4.135834004309787e-06
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00358606,0.003583476399464259,2.5836005357409396e-06
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00717465,0.007175116978479463,4.669784794625667e-07
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Withdrawal by Subject,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00358606,0.0035866041469642547,5.441469642548935e-07
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00717465,0.007175216241812799,5.662418127985389e-07
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00717465,0.0071738607370400685,7.892629599317788e-07
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Not treated,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,709.0,436.0,0.0,0.0,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,709.0,436.0,0.005642,0.005642,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01434931,0.01434486026499011,4.449735009889877e-06
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00717465,0.007174242319848513,4.076801514872261e-07
2.0,709.0,436.0,0.002821,0.002821,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00717465,0.007173005177575783,1.644822424217568e-06
1.0,709.0,436.0,0.00141,0.00141,6.565265,0.387388,1.0,708.0,11.0,114.0,Other reason not defined above,Double Blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.00358606,0.003586577467797588,5.174677975882183e-07
4.0,230.0,216.0,0.017391,0.017391,5.442418,0.212734,1.0,230.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02013509,0.020364351756378962,0.0002292617563789609
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,230.0,216.0,0.013043,0.013043,5.442418,0.212734,1.0,230.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01510103,0.015536769709771827,0.00043573970977182734
1.0,230.0,216.0,0.004348,0.004348,5.442418,0.212734,1.0,230.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00503406,0.00508735344455358,5.3293444553579976e-05
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,230.0,216.0,0.008696,0.008696,5.442418,0.212734,1.0,230.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01006812,0.010369256072400794,0.00030113607240079415
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,230.0,216.0,0.004348,0.004348,5.442418,0.212734,1.0,230.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00503406,0.0050819490128869126,4.7889012886912635e-05
1.0,230.0,216.0,0.004348,0.004348,5.442418,0.212734,1.0,230.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00503406,0.005092241255803579,5.818125580357887e-05
0.0,230.0,216.0,0.0,0.0,5.442418,0.212734,1.0,230.0,0.0,0.0,Participant Unavailability,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,230.0,216.0,0.004348,0.004348,5.442418,0.212734,1.0,230.0,0.0,0.0,Participant Unavailability,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00503406,0.005070296850089294,3.623685008929435e-05
1.0,230.0,216.0,0.004348,0.004348,5.442418,0.212734,1.0,230.0,0.0,0.0,Participant Unavailability,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00503406,0.005081285493005961,4.7225493005961273e-05
4.0,262.0,219.0,0.015267,0.015267,5.572154,0.21635,1.0,262.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0184049,0.018430522690476226,2.5622690476227727e-05
2.0,262.0,219.0,0.007634,0.007634,5.572154,0.21635,1.0,262.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00920305,0.00921805723573232,1.500723573231999e-05
0.0,262.0,219.0,0.0,0.0,5.572154,0.21635,1.0,262.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,262.0,219.0,0.015267,0.015267,5.572154,0.21635,1.0,262.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0184049,0.018434408456904798,2.9508456904799724e-05
2.0,262.0,219.0,0.007634,0.007634,5.572154,0.21635,1.0,262.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00920305,0.00922974657182359,2.669657182358988e-05
0.0,262.0,219.0,0.0,0.0,5.572154,0.21635,1.0,262.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,262.0,219.0,0.007634,0.007634,5.572154,0.21635,1.0,262.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00920305,0.009211291562537874,8.241562537873032e-06
4.0,262.0,219.0,0.015267,0.015267,5.572154,0.21635,1.0,262.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0184049,0.018456821072321467,5.192107232146817e-05
3.0,262.0,219.0,0.01145,0.01145,5.572154,0.21635,1.0,262.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01380338,0.013723935836428575,7.94441635714252e-05
1.0,262.0,219.0,0.003817,0.003817,5.572154,0.21635,1.0,262.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00460153,0.004604434317420633,2.9043174206329347e-06
9.0,262.0,219.0,0.034351,0.034351,5.572154,0.21635,1.0,262.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04141133,0.04200696656988095,0.0005956365698809446
8.0,262.0,219.0,0.030534,0.030534,5.572154,0.21635,1.0,262.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0368098,0.03676304761470235,4.675238529764508e-05
2.0,262.0,219.0,0.007634,0.007634,5.572154,0.21635,1.0,262.0,0.0,0.0,Patient Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00920305,0.009209743337537874,6.693337537872976e-06
1.0,262.0,219.0,0.003817,0.003817,5.572154,0.21635,1.0,262.0,0.0,0.0,Patient Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00460153,0.004603692017003967,2.1620170039668082e-06
0.0,262.0,219.0,0.0,0.0,5.572154,0.21635,1.0,262.0,0.0,0.0,Non-compliance with study procedures,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,262.0,219.0,0.003817,0.003817,5.572154,0.21635,1.0,262.0,0.0,0.0,Non-compliance with study procedures,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00460153,0.004603692017003967,2.1620170039668082e-06
21.0,4330.0,3996.0,0.00485,0.00485,8.373554,0.460028,1.0,4330.0,25.0,305.0,Closed Site,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01868255,0.018575034612589275,0.00010751538741072403
18.0,4330.0,3996.0,0.004157,0.004157,8.373554,0.460028,1.0,4330.0,25.0,305.0,Closed Site,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01601306,0.01600932162243057,3.73837756943024e-06
16.0,4330.0,3996.0,0.003695,0.003695,8.373554,0.460028,1.0,4330.0,25.0,305.0,Closed Site,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0142334,0.014230979630386916,2.420369613084436e-06
50.0,4330.0,3996.0,0.011547,0.011547,8.373554,0.460028,1.0,4330.0,25.0,305.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04447987,0.04405149274031748,0.00042837725968251916
36.0,4330.0,3996.0,0.008314,0.008314,8.373554,0.460028,1.0,4330.0,25.0,305.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03202612,0.03221964459329723,0.00019352459329723126
35.0,4330.0,3996.0,0.008083,0.008083,8.373554,0.460028,1.0,4330.0,25.0,305.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0311363,0.031495289023733754,0.0003589890237337551
74.0,4330.0,3996.0,0.01709,0.01709,8.373554,0.460028,1.0,4330.0,25.0,305.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06583191,0.06628213591327374,0.00045022591327374684
47.0,4330.0,3996.0,0.010855,0.010855,8.373554,0.460028,1.0,4330.0,25.0,305.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04181424,0.042322830226309574,0.0005085902263095715
37.0,4330.0,3996.0,0.008545,0.008545,8.373554,0.460028,1.0,4330.0,25.0,305.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03291595,0.032445198759388505,0.0004707512406114944
4.0,503.0,470.0,0.007952,0.007952,6.222576,1.0,1.0,503.0,11.0,69.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04948193,0.04902387031648811,0.0004580596835118897
5.0,503.0,470.0,0.00994,0.00994,6.222576,1.0,1.0,503.0,11.0,69.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06185241,0.05988866092096229,0.0019637490790377077
1.0,503.0,470.0,0.001988,0.001988,6.222576,1.0,1.0,503.0,11.0,69.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01237048,0.012270486695433801,9.999330456619826e-05
2.0,503.0,470.0,0.003976,0.003976,6.222576,1.0,1.0,503.0,11.0,69.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02474096,0.024766041240721168,2.5081240721168407e-05
4.0,503.0,470.0,0.007952,0.007952,6.222576,1.0,1.0,503.0,11.0,69.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04948193,0.04903637793428573,0.0004455520657142692
6.0,503.0,470.0,0.011928,0.011928,6.222576,1.0,1.0,503.0,11.0,69.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07422289,0.07345130991130953,0.0007715800886904656
6.0,503.0,470.0,0.011928,0.011928,6.222576,1.0,1.0,503.0,11.0,69.0,Other incl. lack of efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07422289,0.07351232861172619,0.0007105613882738143
5.0,503.0,470.0,0.00994,0.00994,6.222576,1.0,1.0,503.0,11.0,69.0,Other incl. lack of efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06185241,0.059878654506101185,0.0019737554938988114
2.0,337.0,310.0,0.005935,0.005935,5.823046,0.326604,1.0,337.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01128738,0.011391614293829358,0.00010423429382935834
4.0,337.0,310.0,0.011869,0.011869,5.823046,0.326604,1.0,337.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02257285,0.02264448860060696,7.163860060696234e-05
1.0,337.0,310.0,0.002967,0.002967,5.823046,0.326604,1.0,337.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00564274,0.005673464640410358,3.072464041035776e-05
3.0,337.0,310.0,0.008902,0.008902,5.823046,0.326604,1.0,337.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01693012,0.01686053029357142,6.958970642858067e-05
2.0,337.0,310.0,0.005935,0.005935,5.823046,0.326604,1.0,337.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01128738,0.011383019162579356,9.563916257935602e-05
5.0,337.0,310.0,0.014837,0.014837,5.823046,0.326604,1.0,337.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02821749,0.028060352084464283,0.00015713791553571832
1.0,337.0,310.0,0.002967,0.002967,5.823046,0.326604,1.0,337.0,0.0,0.0,Participant moved or relocated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564274,0.005669658388178218,2.6918388178217775e-05
0.0,337.0,310.0,0.0,0.0,5.823046,0.326604,1.0,337.0,0.0,0.0,Participant moved or relocated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,337.0,310.0,0.0,0.0,5.823046,0.326604,1.0,337.0,0.0,0.0,Participant moved or relocated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,337.0,310.0,0.002967,0.002967,5.823046,0.326604,1.0,337.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564274,0.005670903806511552,2.816380651155144e-05
4.0,337.0,310.0,0.011869,0.011869,5.823046,0.326604,1.0,337.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02257285,0.022679946597422437,0.00010709659742243888
2.0,337.0,310.0,0.005935,0.005935,5.823046,0.326604,1.0,337.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01128738,0.011382666199841263,9.528619984126331e-05
1.0,337.0,310.0,0.002967,0.002967,5.823046,0.326604,1.0,337.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564274,0.005669658388178218,2.6918388178217775e-05
1.0,337.0,310.0,0.002967,0.002967,5.823046,0.326604,1.0,337.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00564274,0.0056720905928508356,2.93505928508353e-05
0.0,337.0,310.0,0.0,0.0,5.823046,0.326604,1.0,337.0,0.0,0.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
28.0,500.0,363.0,0.056,0.056,6.216606,0.197876,1.0,500.0,15.0,68.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06888669,0.07191748038098215,0.003030790380982154
30.0,500.0,363.0,0.06,0.06,6.216606,0.197876,1.0,500.0,15.0,68.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07380717,0.0753091909726786,0.0015020209726785971
31.0,500.0,363.0,0.062,0.062,6.216606,0.197876,1.0,500.0,15.0,68.0,Hyperglycemic Rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07626741,0.07780489323056547,0.0015374832305654756
2.0,500.0,363.0,0.004,0.004,6.216606,0.197876,1.0,500.0,15.0,68.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00492048,0.004949747745793657,2.926774579365722e-05
6.0,500.0,363.0,0.012,0.012,6.216606,0.197876,1.0,500.0,15.0,68.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01476143,0.01479073735723216,2.930735723215977e-05
4.0,500.0,363.0,0.008,0.008,6.216606,0.197876,1.0,500.0,15.0,68.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00984096,0.009910454740505942,6.949474050594283e-05
0.0,500.0,363.0,0.0,0.0,6.216606,0.197876,1.0,500.0,15.0,68.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,500.0,363.0,0.006,0.006,6.216606,0.197876,1.0,500.0,15.0,68.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00738072,0.007380722215912705,2.2159127050641603e-09
1.0,500.0,363.0,0.002,0.002,6.216606,0.197876,1.0,500.0,15.0,68.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00246024,0.0024434175646031765,1.68224353968233e-05
1.0,500.0,363.0,0.002,0.002,6.216606,0.197876,1.0,500.0,15.0,68.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00246024,0.0024525902275198443,7.64977248015556e-06
1.0,500.0,363.0,0.002,0.002,6.216606,0.197876,1.0,500.0,15.0,68.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00246024,0.0024526040132936532,7.635986706346597e-06
2.0,500.0,363.0,0.004,0.004,6.216606,0.197876,1.0,500.0,15.0,68.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00492048,0.004953778597579373,3.329859757937332e-05
3.0,500.0,363.0,0.006,0.006,6.216606,0.197876,1.0,500.0,15.0,68.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00738072,0.007381429230734134,7.092307341338352e-07
8.0,500.0,363.0,0.016,0.016,6.216606,0.197876,1.0,500.0,15.0,68.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01968191,0.01985494530375001,0.00017303530375000972
11.0,500.0,363.0,0.022,0.022,6.216606,0.197876,1.0,500.0,15.0,68.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02706263,0.027246773866207618,0.00018414386620761725
3.0,500.0,363.0,0.006,0.006,6.216606,0.197876,1.0,500.0,15.0,68.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00738072,0.007384309241984133,3.5892419841324075e-06
2.0,500.0,363.0,0.004,0.004,6.216606,0.197876,1.0,500.0,15.0,68.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00492048,0.004949969527460325,2.9489527460325148e-05
1.0,500.0,363.0,0.002,0.002,6.216606,0.197876,1.0,500.0,15.0,68.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00246024,0.0024545369772222252,5.70302277777459e-06
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0075591,0.007566677238511882,7.577238511882051e-06
13.0,1615.0,1207.0,0.00805,0.00805,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01637976,0.016453745175863125,7.398517586312478e-05
9.0,1615.0,1207.0,0.005573,0.005573,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01133967,0.011559218239454369,0.0002195482394543695
10.0,1615.0,1207.0,0.006192,0.006192,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01259919,0.012470098197413425,0.0001290918025865749
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0075591,0.007555417476845212,3.682523154788231e-06
8.0,1615.0,1207.0,0.004954,0.004954,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01008016,0.010003192790605164,7.69672093948355e-05
4.0,1615.0,1207.0,0.002477,0.002477,7.387709,0.275424,1.0,1615.0,0.0,0.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00504008,0.00500462313272815,3.5456867271849504e-05
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00125951,0.0012594654220238167,4.4577976183231977e-08
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Contraindication,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00251902,0.0025196947859541974,6.747859541975446e-07
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00125951,0.0012622826994146893,2.77269941468942e-06
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00251902,0.002517702736728009,1.3172632719908248e-06
3.0,1615.0,1207.0,0.001858,0.001858,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00378057,0.0038008283668253895,2.0258366825389503e-05
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00251902,0.0025180885933946758,9.314066053240852e-07
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00125951,0.0012588609061904834,6.490938095164971e-07
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Creatinine / Creatinine clearance,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00125951,0.0012591532680952461,3.567319047537848e-07
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00125951,0.0012625228656646889,3.0128656646889566e-06
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00125951,0.0012595432907738166,3.329077381667746e-08
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Excluded medication,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00125951,0.0012594403793452459,6.962065475404726e-08
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00251902,0.002520085385954198,1.0653859541980351e-06
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0075591,0.007567429056488067,8.329056488067324e-06
4.0,1615.0,1207.0,0.002477,0.002477,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00504008,0.005008364015644817,3.17159843551823e-05
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00251902,0.0025187336669065807,2.863330934191159e-07
5.0,1615.0,1207.0,0.003096,0.003096,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00629959,0.006282813399791657,1.6776600208342693e-05
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00125951,0.001259073166011912,4.368339880879337e-07
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hyperglycemia,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00125951,0.001259507351250008,2.6487499919097823e-09
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00125951,0.0012580038028571488,1.5061971428511657e-06
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Hypoglycemia,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1615.0,1207.0,0.002477,0.002477,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00504008,0.005006023315644817,3.4056684355182956e-05
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0075591,0.007567861166904728,8.761166904728244e-06
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0075591,0.007560676502956316,1.576502956316013e-06
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0075591,0.007562284252956316,3.1842529563163094e-06
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00251902,0.0025181892317280093,8.307682719905715e-07
3.0,1615.0,1207.0,0.001858,0.001858,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00378057,0.0037989407968253876,1.8370796825387548e-05
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,1615.0,1207.0,0.006811,0.006811,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0138587,0.013856313546190484,2.386453809516062e-06
14.0,1615.0,1207.0,0.008669,0.008669,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01763927,0.01734382317817461,0.0002954468218253903
21.0,1615.0,1207.0,0.013003,0.013003,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02645788,0.026560656817129328,0.00010277681712932835
13.0,1615.0,1207.0,0.00805,0.00805,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01637976,0.016451635509434556,7.187550943455606e-05
8.0,1615.0,1207.0,0.004954,0.004954,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01008016,0.009980006334831353,0.00010015366516864625
16.0,1615.0,1207.0,0.009907,0.009907,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02015829,0.020625262330952375,0.00046697233095237614
13.0,1615.0,1207.0,0.00805,0.00805,7.387709,0.275424,1.0,1615.0,0.0,0.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01637976,0.016462540066160745,8.27800661607446e-05
5.0,1615.0,1207.0,0.003096,0.003096,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00629959,0.006283376925684514,1.621307431548622e-05
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00251902,0.0025148972869065804,4.122713093419449e-06
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00251902,0.002517302218394676,1.7177816053239037e-06
5.0,1615.0,1207.0,0.003096,0.003096,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00629959,0.006292787539851179,6.802460148821153e-06
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00251902,0.0025177047125613423,1.315287438657508e-06
3.0,1615.0,1207.0,0.001858,0.001858,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00378057,0.0038021810030753884,2.1611003075388407e-05
4.0,1615.0,1207.0,0.002477,0.002477,7.387709,0.275424,1.0,1615.0,0.0,0.0,Physician Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00504008,0.005006592968978149,3.3487031021850466e-05
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00125951,0.0012578660080952442,1.6439919047557712e-06
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00125951,0.0012622959771527846,2.7859771527846255e-06
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00125951,0.0012588027139285784,7.072860714215073e-07
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Pregnancy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,1615.0,1207.0,0.003715,0.003715,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0075591,0.007579059910039658,1.9959910039658163e-05
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00125951,0.001262788821914689,3.2788219146890913e-06
0.0,1615.0,1207.0,0.0,0.0,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00125951,0.001259295558690483,2.144413095168246e-07
4.0,1615.0,1207.0,0.002477,0.002477,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00504008,0.00500564918772815,3.443081227184983e-05
2.0,1615.0,1207.0,0.001238,0.001238,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00251902,0.0025173807752399114,1.639224760088473e-06
1.0,1615.0,1207.0,0.000619,0.000619,7.387709,0.275424,1.0,1615.0,0.0,0.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00125951,0.001259709760595246,1.9976059524606272e-07
18.0,1615.0,1207.0,0.011146,0.011146,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02267935,0.02288646988803573,0.00020711988803573042
27.0,1615.0,1207.0,0.016718,0.016718,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03401699,0.034384466756636874,0.0003674767566368767
19.0,1615.0,1207.0,0.011765,0.011765,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02393886,0.02413719200223216,0.00019833200223216135
23.0,1615.0,1207.0,0.014241,0.014241,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02897691,0.02867582486475826,0.00030108513524174096
19.0,1615.0,1207.0,0.011765,0.011765,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02393886,0.024127732790446454,0.00018887279044645447
18.0,1615.0,1207.0,0.011146,0.011146,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02267935,0.022876830296507958,0.00019748029650795695
26.0,1615.0,1207.0,0.016099,0.016099,7.387709,0.275424,1.0,1615.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.03275748,0.0328804435438591,0.00012296354385910035
0.0,219.0,213.0,0.0,0.0,5.393628,0.712329,1.0,219.0,1.0,24.0,Other than listed,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,219.0,213.0,0.0,0.0,5.393628,0.712329,1.0,219.0,1.0,24.0,Other than listed,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,219.0,213.0,0.004566,0.004566,5.393628,0.712329,1.0,219.0,1.0,24.0,Other than listed,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01754275,0.018534662712589307,0.000991912712589308
0.0,219.0,213.0,0.0,0.0,5.393628,0.712329,1.0,219.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,219.0,213.0,0.009132,0.009132,5.393628,0.712329,1.0,219.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0350855,0.03568661743300591,0.0006011174330059141
3.0,219.0,213.0,0.013699,0.013699,5.393628,0.712329,1.0,219.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0526321,0.05484775319741072,0.0022156531974107177
39.0,846.0,599.0,0.046099,0.046099,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Weeks 0-56,FG000,diabetes type 2,INDUSTRY,0.10040165,0.09904094119081355,0.0013607088091864422
18.0,846.0,599.0,0.021277,0.021277,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Weeks 0-56,FG001,diabetes type 2,INDUSTRY,0.04634039,0.04681396588791669,0.0004735758879166885
7.0,846.0,599.0,0.008274,0.008274,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Weeks 0-56,FG002,diabetes type 2,INDUSTRY,0.01802042,0.01807524496370944,5.4824963709440566e-05
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Weeks 0-56,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Weeks 0-56,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,846.0,599.0,0.003546,0.003546,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Weeks 0-56,FG002,diabetes type 2,INDUSTRY,0.00772304,0.007760039738690459,3.699973869045973e-05
12.0,846.0,599.0,0.014184,0.014184,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Weeks 0-56,FG000,diabetes type 2,INDUSTRY,0.03089214,0.03093251681077383,4.0376810773831706e-05
8.0,846.0,599.0,0.009456,0.009456,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Weeks 0-56,FG001,diabetes type 2,INDUSTRY,0.02059476,0.020503174327966285,9.158567203371507e-05
13.0,846.0,599.0,0.015366,0.015366,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Weeks 0-56,FG002,diabetes type 2,INDUSTRY,0.03346649,0.03355198573540673,8.54957354067265e-05
32.0,846.0,599.0,0.037825,0.037825,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Weeks 0-56,FG000,diabetes type 2,INDUSTRY,0.08238123,0.08316430312187498,0.0007830731218749776
14.0,846.0,599.0,0.016548,0.016548,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Weeks 0-56,FG001,diabetes type 2,INDUSTRY,0.03604084,0.036172906888511915,0.00013206688851191695
37.0,846.0,599.0,0.043735,0.043735,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Weeks 0-56,FG002,diabetes type 2,INDUSTRY,0.09525296,0.09516372373242067,8.923626757932623e-05
16.0,846.0,599.0,0.018913,0.018913,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Weeks 0-56,FG000,diabetes type 2,INDUSTRY,0.0411917,0.04108777570839288,0.00010392429160711869
7.0,846.0,599.0,0.008274,0.008274,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Weeks 0-56,FG001,diabetes type 2,INDUSTRY,0.01802042,0.018075279741467366,5.485974146736752e-05
12.0,846.0,599.0,0.014184,0.014184,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Weeks 0-56,FG002,diabetes type 2,INDUSTRY,0.03089214,0.030932065962440514,3.9925962440515855e-05
1.0,846.0,599.0,0.001182,0.001182,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Off Drug Follow-up Period (Weeks 56-68),FG000,diabetes type 2,INDUSTRY,0.00257435,0.002573517947638875,8.320523611250741e-07
1.0,846.0,599.0,0.001182,0.001182,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Off Drug Follow-up Period (Weeks 56-68),FG001,diabetes type 2,INDUSTRY,0.00257435,0.002573773817222208,5.761827777919955e-07
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Adverse Event,Off Drug Follow-up Period (Weeks 56-68),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,846.0,599.0,0.001182,0.001182,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Off Drug Follow-up Period (Weeks 56-68),FG000,diabetes type 2,INDUSTRY,0.00257435,0.002573363190972209,9.868090277910697e-07
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Off Drug Follow-up Period (Weeks 56-68),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Lack of Efficacy,Off Drug Follow-up Period (Weeks 56-68),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,846.0,599.0,0.001182,0.001182,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Off Drug Follow-up Period (Weeks 56-68),FG000,diabetes type 2,INDUSTRY,0.00257435,0.0025731253368055417,1.224663194458308e-06
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Off Drug Follow-up Period (Weeks 56-68),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,846.0,599.0,0.001182,0.001182,6.741701,0.323058,1.0,846.0,13.0,161.0,Protocol Violation,Off Drug Follow-up Period (Weeks 56-68),FG002,diabetes type 2,INDUSTRY,0.00257435,0.0025728759763888743,1.474023611125648e-06
9.0,846.0,599.0,0.010638,0.010638,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Off Drug Follow-up Period (Weeks 56-68),FG000,diabetes type 2,INDUSTRY,0.02316911,0.023080764350922614,8.834564907738568e-05
7.0,846.0,599.0,0.008274,0.008274,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Off Drug Follow-up Period (Weeks 56-68),FG001,diabetes type 2,INDUSTRY,0.01802042,0.018066547671884037,4.612767188403796e-05
4.0,846.0,599.0,0.004728,0.004728,6.741701,0.323058,1.0,846.0,13.0,161.0,Withdrawal criteria,Off Drug Follow-up Period (Weeks 56-68),FG002,diabetes type 2,INDUSTRY,0.01029738,0.010320860384494052,2.348038449405225e-05
2.0,846.0,599.0,0.002364,0.002364,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Off Drug Follow-up Period (Weeks 56-68),FG000,diabetes type 2,INDUSTRY,0.00514869,0.005103553275029755,4.5136724970244735e-05
2.0,846.0,599.0,0.002364,0.002364,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Off Drug Follow-up Period (Weeks 56-68),FG001,diabetes type 2,INDUSTRY,0.00514869,0.005097349398482134,5.134060151786631e-05
0.0,846.0,599.0,0.0,0.0,6.741701,0.323058,1.0,846.0,13.0,161.0,Unclassified,Off Drug Follow-up Period (Weeks 56-68),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,204.0,179.0,0.009804,0.009804,5.32301,0.279906,1.0,204.0,1.0,1.0,Adverse Event,Period 1Double Blind Period,FG000,diabetes type 2,INDUSTRY,0.01460739,0.014830310388809515,0.00022292038880951555
1.0,204.0,179.0,0.004902,0.004902,5.32301,0.279906,1.0,204.0,1.0,1.0,Adverse Event,Period 1Double Blind Period,FG001,diabetes type 2,INDUSTRY,0.00730369,0.007284892392519872,1.8797607480127917e-05
1.0,204.0,179.0,0.004902,0.004902,5.32301,0.279906,1.0,204.0,1.0,1.0,Lack of Efficacy,Period 1Double Blind Period,FG000,diabetes type 2,INDUSTRY,0.00730369,0.007275763010317488,2.7926989682511456e-05
0.0,204.0,179.0,0.0,0.0,5.32301,0.279906,1.0,204.0,1.0,1.0,Lack of Efficacy,Period 1Double Blind Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,204.0,179.0,0.0,0.0,5.32301,0.279906,1.0,204.0,1.0,1.0,Physician Decision,Period 1Double Blind Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,204.0,179.0,0.019608,0.019608,5.32301,0.279906,1.0,204.0,1.0,1.0,Physician Decision,Period 1Double Blind Period,FG001,diabetes type 2,INDUSTRY,0.02921478,0.029131792521315883,8.29874786841163e-05
4.0,204.0,179.0,0.019608,0.019608,5.32301,0.279906,1.0,204.0,1.0,1.0,Adverse Event,Period 2Open-label Period,FG000,diabetes type 2,INDUSTRY,0.02921478,0.02916861934411351,4.61606558864909e-05
5.0,204.0,179.0,0.02451,0.02451,5.32301,0.279906,1.0,204.0,1.0,1.0,Adverse Event,Period 2Open-label Period,FG001,diabetes type 2,INDUSTRY,0.03651847,0.035565793758343255,0.0009526762416567428
3.0,204.0,179.0,0.014706,0.014706,5.32301,0.279906,1.0,204.0,1.0,1.0,Physician Decision,Period 2Open-label Period,FG000,diabetes type 2,INDUSTRY,0.02191108,0.022336423907123044,0.000425343907123045
1.0,204.0,179.0,0.004902,0.004902,5.32301,0.279906,1.0,204.0,1.0,1.0,Physician Decision,Period 2Open-label Period,FG001,diabetes type 2,INDUSTRY,0.00730369,0.007285236571686536,1.845342831346356e-05
0.0,204.0,179.0,0.0,0.0,5.32301,0.279906,1.0,204.0,1.0,1.0,Withdrawal by Subject,Period 2Open-label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,204.0,179.0,0.019608,0.019608,5.32301,0.279906,1.0,204.0,1.0,1.0,Withdrawal by Subject,Period 2Open-label Period,FG001,diabetes type 2,INDUSTRY,0.02921478,0.029040234717982564,0.00017454528201743535
1.0,582.0,558.0,0.001718,0.001718,6.368187,0.819223,1.0,582.0,1.0,60.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00896275,0.008997776000089237,3.502600008923641e-05
1.0,582.0,558.0,0.001718,0.001718,6.368187,0.819223,1.0,582.0,1.0,60.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00896275,0.009012825510089242,5.00755100892418e-05
13.0,582.0,558.0,0.022337,0.022337,6.368187,0.819223,1.0,582.0,1.0,60.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11653141,0.11750527109074406,0.0009738610907440576
4.0,582.0,558.0,0.006873,0.006873,6.368187,0.819223,1.0,582.0,1.0,60.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03585622,0.03554632537488089,0.00030989462511911425
2.0,582.0,558.0,0.003436,0.003436,6.368187,0.819223,1.0,582.0,1.0,60.0,Non-compliance with study schedule,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0179255,0.018145038505499627,0.00021953850549962656
1.0,582.0,558.0,0.001718,0.001718,6.368187,0.819223,1.0,582.0,1.0,60.0,Non-compliance with study schedule,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00896275,0.009016122847589242,5.3372847589241296e-05
1.0,582.0,558.0,0.001718,0.001718,6.368187,0.819223,1.0,582.0,1.0,60.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00896275,0.009001073337589236,3.832333758923591e-05
1.0,582.0,558.0,0.001718,0.001718,6.368187,0.819223,1.0,582.0,1.0,60.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00896275,0.009016122847589242,5.3372847589241296e-05
6.0,342.0,263.0,0.017544,0.017544,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.03149266,0.03161258220640873,0.00011992220640873186
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00524878,0.005252059263720259,3.279263720259301e-06
4.0,342.0,263.0,0.011696,0.011696,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0209951,0.020982886411785747,1.2213588214252113e-05
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005251360843125021,2.5808431250214786e-06
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00524878,0.005250762351636925,1.9823516369255056e-06
2.0,342.0,263.0,0.005848,0.005848,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01049755,0.010604705978154813,0.0001071559781548135
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Protocol Violation,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005255204583125022,6.424583125021893e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Protocol Violation,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Protocol Violation,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,342.0,263.0,0.011696,0.011696,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0209951,0.02102628854157742,3.1188541577419765e-05
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00524878,0.0052443962220535875,4.383777946412315e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,342.0,263.0,0.008772,0.008772,5.83773,0.307494,1.0,344.0,11.0,83.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01574633,0.015902763811279766,0.00015643381127976655
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00524878,0.005257296041964307,8.516041964307108e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00524878,0.005251416968303593,2.6369683035929944e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005252015459791688,3.2354597916881e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005252015459791688,3.2354597916881e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,342.0,263.0,0.02924,0.02924,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.05248776,0.05323336277032738,0.0007456027703273763
2.0,342.0,263.0,0.005848,0.005848,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01049755,0.01058167388071434,8.412388071434018e-05
6.0,342.0,263.0,0.017544,0.017544,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.03149266,0.03158936273173611,9.670273173611327e-05
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00524878,0.0052496100772024025,8.30077202402732e-07
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00524878,0.0052479705187500215,8.094812499782889e-07
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Adverse Event,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005242009905535732,6.770094464267698e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Physician Decision,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,342.0,263.0,0.005848,0.005848,5.83773,0.307494,1.0,344.0,11.0,83.0,Physician Decision,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01049755,0.010567170955000055,6.962095500005587e-05
2.0,342.0,263.0,0.005848,0.005848,5.83773,0.307494,1.0,344.0,11.0,83.0,Physician Decision,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01049755,0.010573045080714341,7.549508071434154e-05
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00524878,0.005253349585416688,4.56958541668849e-06
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00524878,0.005248931731785736,1.5173178573649193e-07
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00524878,0.005247292173333355,1.487826666644529e-06
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,342.0,263.0,0.023392,0.023392,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.04199021,0.042469020809682574,0.0004788108096825741
3.0,342.0,263.0,0.008772,0.008772,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01574633,0.01591357788229167,0.00016724788229166912
4.0,342.0,263.0,0.011696,0.011696,5.83773,0.307494,1.0,344.0,11.0,83.0,Other,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0209951,0.020956586639791698,3.851336020830112e-05
1.0,342.0,263.0,0.002924,0.002924,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00524878,0.00524815378261907,6.262173809301955e-07
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,342.0,263.0,0.0,0.0,5.83773,0.307494,1.0,344.0,11.0,83.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,329.0,269.0,0.0,0.0,5.799093,0.397636,1.0,329.0,0.0,0.0,Death,Phase A (Weeks 0 to 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Death,Phase A (Weeks 0 to 24),FG001,diabetes type 2,INDUSTRY,0.00701002,0.007015224046904787,5.204046904787318e-06
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0 to 24),FG000,diabetes type 2,INDUSTRY,0.00701002,0.0070198910788095495,9.87107880954987e-06
3.0,329.0,269.0,0.009119,0.009119,5.799093,0.397636,1.0,329.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0 to 24),FG001,diabetes type 2,INDUSTRY,0.02102776,0.02076843848445437,0.00025932151554563035
12.0,329.0,269.0,0.036474,0.036474,5.799093,0.397636,1.0,329.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0 to 24),FG000,diabetes type 2,INDUSTRY,0.08410643,0.0832914890229167,0.0008149409770832894
6.0,329.0,269.0,0.018237,0.018237,5.799093,0.397636,1.0,329.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0 to 24),FG001,diabetes type 2,INDUSTRY,0.04205322,0.04217278269874005,0.0001195626987400486
4.0,329.0,269.0,0.012158,0.012158,5.799093,0.397636,1.0,329.0,0.0,0.0,Adverse Event,Phase A (Weeks 0 to 24),FG000,diabetes type 2,INDUSTRY,0.02803548,0.02791700080131939,0.00011847919868061135
2.0,329.0,269.0,0.006079,0.006079,5.799093,0.397636,1.0,329.0,0.0,0.0,Adverse Event,Phase A (Weeks 0 to 24),FG001,diabetes type 2,INDUSTRY,0.01401774,0.014488482499434524,0.00047074249943452294
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Non-Compliance with Study Drug,Phase A (Weeks 0 to 24),FG000,diabetes type 2,INDUSTRY,0.00701002,0.0070138993148809795,3.8793148809798325e-06
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Non-Compliance with Study Drug,Phase A (Weeks 0 to 24),FG001,diabetes type 2,INDUSTRY,0.00701002,0.007011642470238121,1.6224702381216136e-06
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Completed Phase A Did Not Enter Phase B,Interphase,FG000,diabetes type 2,INDUSTRY,0.00701002,0.007016848402440501,6.828402440501452e-06
0.0,329.0,269.0,0.0,0.0,5.799093,0.397636,1.0,329.0,0.0,0.0,Completed Phase A Did Not Enter Phase B,Interphase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,329.0,269.0,0.012158,0.012158,5.799093,0.397636,1.0,329.0,0.0,0.0,Study Terminated by Sponsor,Phase B (Weeks 24 to 54),FG000,diabetes type 2,INDUSTRY,0.02803548,0.027951031319444385,8.444868055561619e-05
4.0,329.0,269.0,0.012158,0.012158,5.799093,0.397636,1.0,329.0,0.0,0.0,Study Terminated by Sponsor,Phase B (Weeks 24 to 54),FG001,diabetes type 2,INDUSTRY,0.02803548,0.027967991370337272,6.748862966272917e-05
7.0,329.0,269.0,0.021277,0.021277,5.799093,0.397636,1.0,329.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24 to 54),FG000,diabetes type 2,INDUSTRY,0.04906324,0.049804391003224174,0.0007411510032241733
9.0,329.0,269.0,0.027356,0.027356,5.799093,0.397636,1.0,329.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24 to 54),FG001,diabetes type 2,INDUSTRY,0.06308098,0.06249290489954364,0.000588075100456352
1.0,329.0,269.0,0.00304,0.00304,5.799093,0.397636,1.0,329.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24 to 54),FG000,diabetes type 2,INDUSTRY,0.00701002,0.007022131998869071,1.2111998869071203e-05
3.0,329.0,269.0,0.009119,0.009119,5.799093,0.397636,1.0,329.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24 to 54),FG001,diabetes type 2,INDUSTRY,0.02102776,0.02076843848445437,0.00025932151554563035
20.0,303.0,122.0,0.066007,0.066007,5.717028,0.368375,1.0,303.0,2.0,25.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13901136,0.13744996785155747,0.0015613921484425308
14.0,303.0,122.0,0.046205,0.046205,5.717028,0.368375,1.0,303.0,2.0,25.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09730816,0.09762754896756942,0.00031938896756941726
13.0,303.0,122.0,0.042904,0.042904,5.717028,0.368375,1.0,303.0,2.0,25.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09035623,0.0909074274834001,0.000551197483400101
8.0,303.0,122.0,0.026403,0.026403,5.717028,0.368375,1.0,303.0,2.0,25.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05560497,0.05470537426647826,0.0008995957335217394
3.0,303.0,122.0,0.009901,0.009901,5.717028,0.368375,1.0,303.0,2.0,25.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0208516,0.021090353145853183,0.0002387531458531815
2.0,303.0,122.0,0.006601,0.006601,5.717028,0.368375,1.0,303.0,2.0,25.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01390177,0.013769413303313492,0.00013235669668650897
40.0,303.0,122.0,0.132013,0.132013,5.717028,0.368375,1.0,303.0,2.0,25.0,Withdrawal of Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.27802062,0.2708053987820043,0.007215221217995671
42.0,303.0,122.0,0.138614,0.138614,5.717028,0.368375,1.0,303.0,2.0,25.0,Withdrawal of Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.29192238,0.2753778738051588,0.016544506194841158
11.0,303.0,122.0,0.036304,0.036304,5.717028,0.368375,1.0,303.0,2.0,25.0,Investigator Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07645656,0.07641780809714287,3.875190285713981e-05
10.0,303.0,122.0,0.033003,0.033003,5.717028,0.368375,1.0,303.0,2.0,25.0,Investigator Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06950463,0.07068489068246028,0.0011802606824602851
5.0,303.0,122.0,0.016502,0.016502,5.717028,0.368375,1.0,303.0,2.0,25.0,Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03475337,0.034740988252499966,1.2381747500032902e-05
7.0,303.0,122.0,0.023102,0.023102,5.717028,0.368375,1.0,303.0,2.0,25.0,Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04865303,0.04878658573334323,0.0001335557333432269
1.0,303.0,122.0,0.0033,0.0033,5.717028,0.368375,1.0,303.0,2.0,25.0,Administrative,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00694983,0.0069884039005441035,3.857390054410378e-05
4.0,303.0,122.0,0.013201,0.013201,5.717028,0.368375,1.0,303.0,2.0,25.0,Administrative,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02780143,0.0279822186128869,0.00018078861288690212
1.0,303.0,122.0,0.0033,0.0033,5.717028,0.368375,1.0,303.0,2.0,25.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00694983,0.006987258015544103,3.742801554410327e-05
0.0,303.0,122.0,0.0,0.0,5.717028,0.368375,1.0,303.0,2.0,25.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,653.0,532.0,0.012251,0.012251,6.483107,0.298646,1.0,653.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0237198,0.023658900420674613,6.089957932538595e-05
29.0,653.0,532.0,0.04441,0.04441,6.483107,0.298646,1.0,653.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08598452,0.08479187257602573,0.0011926474239742635
1.0,653.0,532.0,0.001531,0.001531,6.483107,0.298646,1.0,653.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00296425,0.0029506663978814945,1.35836021185054e-05
0.0,653.0,532.0,0.0,0.0,6.483107,0.298646,1.0,653.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,653.0,532.0,0.015314,0.015314,6.483107,0.298646,1.0,653.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02965023,0.02933662954940476,0.0003136004505952389
7.0,653.0,532.0,0.01072,0.01072,6.483107,0.298646,1.0,653.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02075555,0.020666899681775784,8.865031822421696e-05
1.0,653.0,532.0,0.001531,0.001531,6.483107,0.298646,1.0,653.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00296425,0.0029506663978814945,1.35836021185054e-05
2.0,653.0,532.0,0.003063,0.003063,6.483107,0.298646,1.0,653.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00593043,0.005829694128561508,0.00010073587143849278
20.0,653.0,532.0,0.030628,0.030628,6.483107,0.298646,1.0,653.0,0.0,0.0,Other reason not specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05930047,0.058875027698670604,0.00042544230132939703
15.0,653.0,532.0,0.022971,0.022971,6.483107,0.298646,1.0,653.0,0.0,0.0,Other reason not specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04447535,0.043848053168822204,0.0006272968311777927
1.0,653.0,532.0,0.001531,0.001531,6.483107,0.298646,1.0,653.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00296425,0.0029493930353814944,1.4856964618505455e-05
3.0,653.0,532.0,0.004594,0.004594,6.483107,0.298646,1.0,653.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00889468,0.00876292399748015,0.00013175600251985088
0.0,653.0,532.0,0.0,0.0,6.483107,0.298646,1.0,653.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,653.0,532.0,0.001531,0.001531,6.483107,0.298646,1.0,653.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00296425,0.0029534760611553052,1.0773938844694641e-05
10.0,653.0,532.0,0.015314,0.015314,6.483107,0.298646,1.0,653.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02965023,0.029271440676726185,0.00037878932327381487
13.0,653.0,532.0,0.019908,0.019908,6.483107,0.298646,1.0,653.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03854492,0.03851254449715279,3.237550284721641e-05
4.0,965.0,869.0,0.004145,0.004145,6.873164,0.318867,1.0,964.0,10.0,135.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00908429,0.009156147094900795,7.185709490079538e-05
12.0,965.0,869.0,0.012435,0.012435,6.873164,0.318867,1.0,964.0,10.0,135.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02725287,0.02830022540303304,0.0010473554030330408
2.0,965.0,869.0,0.002073,0.002073,6.873164,0.318867,1.0,964.0,10.0,135.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00454324,0.004586322036615264,4.308203661526448e-05
1.0,965.0,869.0,0.001036,0.001036,6.873164,0.318867,1.0,964.0,10.0,135.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00227052,0.0022810288183901586,1.0508818390158811e-05
8.0,965.0,869.0,0.00829,0.00829,6.873164,0.318867,1.0,964.0,10.0,135.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01816858,0.018553979336378958,0.0003853993363789575
16.0,965.0,869.0,0.01658,0.01658,6.873164,0.318867,1.0,964.0,10.0,135.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03633716,0.03648642151437499,0.00014926151437499174
0.0,965.0,869.0,0.0,0.0,6.873164,0.318867,1.0,964.0,10.0,135.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,965.0,869.0,0.002073,0.002073,6.873164,0.318867,1.0,964.0,10.0,135.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00454324,0.004571915682935607,2.867568293560708e-05
3.0,965.0,869.0,0.003109,0.003109,6.873164,0.318867,1.0,964.0,10.0,135.0,Poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00681377,0.00696948082908729,0.00015571082908729002
4.0,965.0,869.0,0.004145,0.004145,6.873164,0.318867,1.0,964.0,10.0,135.0,Poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00908429,0.009161751309265876,7.746130926587595e-05
15.0,965.0,869.0,0.015544,0.015544,6.873164,0.318867,1.0,964.0,10.0,135.0,Subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03406664,0.03405824003806547,8.399961934531242e-06
13.0,965.0,869.0,0.013472,0.013472,6.873164,0.318867,1.0,964.0,10.0,135.0,Subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02952559,0.02946277169440478,6.281830559522195e-05
6.0,965.0,869.0,0.006218,0.006218,6.873164,0.318867,1.0,964.0,10.0,135.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01362753,0.013871865422351179,0.0002443354223511784
4.0,965.0,869.0,0.004145,0.004145,6.873164,0.318867,1.0,964.0,10.0,135.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00908429,0.009161751309265876,7.746130926587595e-05
0.0,965.0,869.0,0.0,0.0,6.873164,0.318867,1.0,964.0,10.0,135.0,Safety,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,965.0,869.0,0.002073,0.002073,6.873164,0.318867,1.0,964.0,10.0,135.0,Safety,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00454324,0.004575436956387988,3.219695638798873e-05
0.0,965.0,869.0,0.0,0.0,6.873164,0.318867,1.0,964.0,10.0,135.0,Administrative reason by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,965.0,869.0,0.001036,0.001036,6.873164,0.318867,1.0,964.0,10.0,135.0,Administrative reason by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00227052,0.0022822301113068254,1.1710111306825581e-05
3.0,965.0,869.0,0.003109,0.003109,6.873164,0.318867,1.0,964.0,10.0,135.0,Various,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00681377,0.00696948082908729,0.00015571082908729002
0.0,965.0,869.0,0.0,0.0,6.873164,0.318867,1.0,964.0,10.0,135.0,Various,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,1014.0,953.0,0.005917,0.005917,6.922644,0.428712,1.0,1014.0,18.0,162.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01756061,0.017763355867738105,0.0002027458677381043
6.0,1014.0,953.0,0.005917,0.005917,6.922644,0.428712,1.0,1014.0,18.0,162.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01756061,0.017839809552261915,0.0002791995522619141
2.0,1014.0,953.0,0.001972,0.001972,6.922644,0.428712,1.0,1014.0,18.0,162.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00585255,0.006025371514999994,0.00017282151499999412
0.0,1014.0,953.0,0.0,0.0,6.922644,0.428712,1.0,1014.0,18.0,162.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1014.0,953.0,0.002959,0.002959,6.922644,0.428712,1.0,1014.0,18.0,162.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00878179,0.008556934316547622,0.00022485568345237752
7.0,1014.0,953.0,0.006903,0.006903,6.922644,0.428712,1.0,1014.0,18.0,162.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02048689,0.02055358354624007,6.669354624007015e-05
0.0,1014.0,953.0,0.0,0.0,6.922644,0.428712,1.0,1014.0,18.0,162.0,Randomized but not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1014.0,953.0,0.000986,0.000986,6.922644,0.428712,1.0,1014.0,18.0,162.0,Randomized but not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00292627,0.002909117700714289,1.715229928571111e-05
1.0,1014.0,953.0,0.000986,0.000986,6.922644,0.428712,1.0,1014.0,18.0,162.0,Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00292627,0.0029071496629166694,1.9120337083330507e-05
0.0,1014.0,953.0,0.0,0.0,6.922644,0.428712,1.0,1014.0,18.0,162.0,Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
15.0,1014.0,953.0,0.014793,0.014793,6.922644,0.428712,1.0,1014.0,18.0,162.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04390301,0.04330096685439396,0.0006020431456060377
20.0,1014.0,953.0,0.019724,0.019724,6.922644,0.428712,1.0,1014.0,18.0,162.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05853735,0.058533513030297565,3.836969702436521e-06
12.0,222.0,191.0,0.054054,0.054054,5.407172,0.292333,1.0,222.0,2.0,34.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08544289,0.08417939347483133,0.0012634965251686614
5.0,222.0,191.0,0.022523,0.022523,5.407172,0.292333,1.0,222.0,2.0,34.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.035602,0.03607386200741072,0.0004718620074107213
1.0,222.0,191.0,0.004505,0.004505,5.407172,0.292333,1.0,222.0,2.0,34.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00712103,0.0071208583749404605,1.716250595399163e-07
0.0,222.0,191.0,0.0,0.0,5.407172,0.292333,1.0,222.0,2.0,34.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,191.0,0.004505,0.004505,5.407172,0.292333,1.0,222.0,2.0,34.0,Loss of glucose control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00712103,0.007122976249107126,1.946249107125618e-06
1.0,222.0,191.0,0.004505,0.004505,5.407172,0.292333,1.0,222.0,2.0,34.0,Loss of glucose control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00712103,0.00712593398648808,4.9039864880792705e-06
3.0,222.0,191.0,0.013514,0.013514,5.407172,0.292333,1.0,222.0,2.0,34.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02136151,0.02147810463367066,0.00011659463367065873
0.0,222.0,191.0,0.0,0.0,5.407172,0.292333,1.0,222.0,2.0,34.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,222.0,191.0,0.004505,0.004505,5.407172,0.292333,1.0,222.0,2.0,34.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00712103,0.00712390334994046,2.873349940459881e-06
6.0,222.0,191.0,0.027027,0.027027,5.407172,0.292333,1.0,222.0,2.0,34.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04272145,0.04304056324271825,0.0003191132427182511
1.0,222.0,191.0,0.004505,0.004505,5.407172,0.292333,1.0,222.0,2.0,34.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00712103,0.007125813969523793,4.78396952379237e-06
0.0,222.0,191.0,0.0,0.0,5.407172,0.292333,1.0,222.0,2.0,34.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,820.0,696.0,0.007317,0.007317,6.710523,0.270051,1.0,820.0,22.0,106.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01325972,0.013275552522499994,1.5832522499995005e-05
6.0,820.0,696.0,0.007317,0.007317,6.710523,0.270051,1.0,820.0,22.0,106.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01325972,0.013274774970416656,1.505497041665721e-05
5.0,820.0,696.0,0.006098,0.006098,6.710523,0.270051,1.0,820.0,22.0,106.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01105068,0.011043106639742072,7.573360257927958e-06
1.0,820.0,696.0,0.00122,0.00122,6.710523,0.270051,1.0,820.0,22.0,106.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00221086,0.002209912783174609,9.472168253908154e-07
4.0,820.0,696.0,0.004878,0.004878,6.710523,0.270051,1.0,820.0,22.0,106.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00883982,0.008903085853799586,6.326585379958644e-05
1.0,820.0,696.0,0.00122,0.00122,6.710523,0.270051,1.0,820.0,22.0,106.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00221086,0.002204497897638895,6.3621023611046094e-06
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00663077,0.00664487431094245,1.4104310942449766e-05
4.0,820.0,696.0,0.004878,0.004878,6.710523,0.270051,1.0,820.0,22.0,106.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00883982,0.008900012343898792,6.019234389879197e-05
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00663077,0.006643351497271819,1.2581497271818565e-05
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00663077,0.006642448683938488,1.1678683938487651e-05
2.0,820.0,696.0,0.002439,0.002439,6.710523,0.270051,1.0,820.0,22.0,106.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00441991,0.0044082151876091245,1.1694812390875518e-05
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00663077,0.0066439523793551504,1.3182379355150195e-05
5.0,820.0,696.0,0.006098,0.006098,6.710523,0.270051,1.0,820.0,22.0,106.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01105068,0.011041466770337302,9.213229662697817e-06
9.0,820.0,696.0,0.010976,0.010976,6.710523,0.270051,1.0,820.0,22.0,106.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01989049,0.019952247150793655,6.175715079365443e-05
2.0,820.0,696.0,0.002439,0.002439,6.710523,0.270051,1.0,820.0,22.0,106.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00441991,0.004413624463323411,6.285536676588557e-06
5.0,820.0,696.0,0.006098,0.006098,6.710523,0.270051,1.0,820.0,22.0,106.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01105068,0.011052622571587303,1.942571587303099e-06
17.0,820.0,696.0,0.020732,0.020732,6.710523,0.270051,1.0,820.0,22.0,106.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03757012,0.03762340653921626,5.328653921626153e-05
9.0,820.0,696.0,0.010976,0.010976,6.710523,0.270051,1.0,820.0,22.0,106.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01989049,0.019928113494067465,3.762349406746454e-05
12.0,820.0,696.0,0.014634,0.014634,6.710523,0.270051,1.0,820.0,22.0,106.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02651945,0.02666313781412698,0.0001436878141269811
6.0,820.0,696.0,0.007317,0.007317,6.710523,0.270051,1.0,820.0,22.0,106.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01325972,0.013281185304285707,2.1465304285707767e-05
0.0,820.0,696.0,0.0,0.0,6.710523,0.270051,1.0,820.0,22.0,106.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,820.0,696.0,0.002439,0.002439,6.710523,0.270051,1.0,820.0,22.0,106.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00441991,0.004414899323759919,5.01067624008103e-06
1.0,820.0,696.0,0.00122,0.00122,6.710523,0.270051,1.0,820.0,22.0,106.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00221086,0.0022122983701686576,1.4383701686577523e-06
1.0,820.0,696.0,0.00122,0.00122,6.710523,0.270051,1.0,820.0,22.0,106.0,Entry Criteria Not Met,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00221086,0.0022113450843055616,4.850843055618191e-07
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00663077,0.006639363090605149,8.5930906051487e-06
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00663077,0.006638460277271818,7.690277271817786e-06
5.0,820.0,696.0,0.006098,0.006098,6.710523,0.270051,1.0,820.0,22.0,106.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01105068,0.011031075341111116,1.960465888888388e-05
3.0,820.0,696.0,0.003659,0.003659,6.710523,0.270051,1.0,820.0,22.0,106.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00663077,0.006640069872688482,9.299872688482182e-06
50.0,783.0,600.0,0.063857,0.063857,6.664409,0.789629,1.0,783.0,5.0,70.0,Adverse Event,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.33604168,0.333510248556369,0.0025314314436309937
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Adverse Event,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Adverse Event,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.0067201,0.00673096809529756,1.0868095297560457e-05
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,783.0,600.0,0.01788,0.01788,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.09409188,0.093651213584891,0.00044066641510900895
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.0067201,0.006728959570714228,8.85957071422843e-06
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Physician Decision,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.0067201,0.006741685766964231,2.158576696423102e-05
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Physician Decision,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Physician Decision,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,783.0,600.0,0.012771,0.012771,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.06720623,0.06669448782715283,0.0005117421728471766
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
32.0,783.0,600.0,0.040868,0.040868,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.21506415,0.21552649115790584,0.0004623411579058323
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Covid-19,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.0067201,0.006731256962380895,1.1156962380895474e-05
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Covid-19,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Covid-19,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,783.0,600.0,0.002554,0.002554,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Open-label Lead-in Period (Week 0 - 36),FG000,diabetes type 2,INDUSTRY,0.01344019,0.01315541438593073,0.00028477561406926866
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Open-label Lead-in Period (Week 0 - 36),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Open-label Lead-in Period (Week 0 - 36),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.0067201,0.006722337318690427,2.2373186904268982e-06
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Death,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.0067201,0.006731259734940423,1.1159734940422925e-05
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,783.0,600.0,0.012771,0.012771,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.06720623,0.06687274732364093,0.0003334826763590759
8.0,783.0,600.0,0.010217,0.010217,6.664409,0.789629,1.0,783.0,5.0,70.0,Lost to Follow-up,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.05376604,0.05394491669721223,0.00017887669721222688
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,783.0,600.0,0.002554,0.002554,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.01344019,0.013170855212895016,0.00026933478710498317
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Pregnancy,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.0067201,0.006730821997857088,1.072199785708862e-05
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
22.0,783.0,600.0,0.028097,0.028097,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.14785792,0.14387626837908546,0.003981651620914545
13.0,783.0,600.0,0.016603,0.016603,6.664409,0.789629,1.0,783.0,5.0,70.0,Withdrawal by Subject,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.08737179,0.08620066242906754,0.001171127570932462
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.0067201,0.006725183687440427,5.083687440426976e-06
2.0,783.0,600.0,0.002554,0.002554,6.664409,0.789629,1.0,783.0,5.0,70.0,Protocol deviation,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.01344019,0.013155186276726183,0.0002850037232738165
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,783.0,600.0,0.010217,0.010217,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.05376604,0.05390088845617056,0.00013484845617055957
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Other - as reported by the investigator,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Perceived excessive weight loss,Double-blind Study Period (Week 36 - 92),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,783.0,600.0,0.001277,0.001277,6.664409,0.789629,1.0,783.0,5.0,70.0,Perceived excessive weight loss,Double-blind Study Period (Week 36 - 92),FG001,diabetes type 2,INDUSTRY,0.0067201,0.006725183687440427,5.083687440426976e-06
0.0,783.0,600.0,0.0,0.0,6.664409,0.789629,1.0,783.0,5.0,70.0,Perceived excessive weight loss,Double-blind Study Period (Week 36 - 92),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,577.0,566.0,0.010399,0.010399,6.359574,0.227085,1.0,577.0,2.0,2.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01501783,0.015027749318244054,9.919318244054967e-06
5.0,577.0,566.0,0.008666,0.008666,6.359574,0.227085,1.0,577.0,2.0,2.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0125151,0.012726115170595232,0.00021101517059523255
1.0,361.0,331.0,0.00277,0.00277,5.891644,0.245822,1.0,361.0,12.0,12.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00401178,0.004043544496934512,3.176449693451187e-05
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,361.0,331.0,0.01385,0.01385,5.891644,0.245822,1.0,361.0,12.0,12.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02005888,0.02025932692371033,0.0002004469237103304
3.0,361.0,331.0,0.00831,0.00831,5.891644,0.245822,1.0,361.0,12.0,12.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01203533,0.012020466201904709,1.486379809529162e-05
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,361.0,331.0,0.00277,0.00277,5.891644,0.245822,1.0,361.0,12.0,12.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00401178,0.004042879129702369,3.109912970236835e-05
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,361.0,331.0,0.00831,0.00831,5.891644,0.245822,1.0,361.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01203533,0.012031621372261849,3.7086277381512267e-06
3.0,361.0,331.0,0.00831,0.00831,5.891644,0.245822,1.0,361.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01203533,0.012018396739523752,1.6933260476248435e-05
4.0,361.0,331.0,0.01108,0.01108,5.891644,0.245822,1.0,361.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01604711,0.015903500794236098,0.00014360920576390185
8.0,361.0,331.0,0.022161,0.022161,5.891644,0.245822,1.0,361.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03209566,0.032400857657321425,0.00030519765732142656
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,361.0,331.0,0.00277,0.00277,5.891644,0.245822,1.0,361.0,12.0,12.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00401178,0.004041310545119035,2.9530545119034815e-05
1.0,361.0,331.0,0.00277,0.00277,5.891644,0.245822,1.0,361.0,12.0,12.0,Poor compliance to protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00401178,0.004042802679910701,3.1022679910701e-05
0.0,361.0,331.0,0.0,0.0,5.891644,0.245822,1.0,361.0,12.0,12.0,Poor compliance to protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,353.0,307.0,0.031161,0.031161,5.869297,0.172548,1.0,353.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03155782,0.03329521110052577,0.001737391100525773
2.0,353.0,307.0,0.005666,0.005666,5.869297,0.172548,1.0,353.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00573815,0.005721691373005953,1.6458626994047404e-05
0.0,353.0,307.0,0.0,0.0,5.869297,0.172548,1.0,353.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,353.0,307.0,0.005666,0.005666,5.869297,0.172548,1.0,353.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00573815,0.0057577745292559535,1.9624529255953503e-05
3.0,353.0,307.0,0.008499,0.008499,5.869297,0.172548,1.0,353.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00860723,0.008451579672738081,0.00015565032726191919
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00286908,0.0028815634670833236,1.2483467083323607e-05
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00286908,0.0028810151716864973,1.1935171686497294e-05
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00286908,0.0028810921837499896,1.2012183749989663e-05
0.0,353.0,307.0,0.0,0.0,5.869297,0.172548,1.0,353.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00286908,0.0028815821337499904,1.2502133749990423e-05
3.0,353.0,307.0,0.008499,0.008499,5.869297,0.172548,1.0,353.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00860723,0.008489502222529744,0.00011772777747025634
3.0,353.0,307.0,0.008499,0.008499,5.869297,0.172548,1.0,353.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00860723,0.008443152137648792,0.00016407786235120812
5.0,353.0,307.0,0.014164,0.014164,5.869297,0.172548,1.0,353.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01434437,0.015683149463374846,0.0013387794633748454
6.0,353.0,307.0,0.016997,0.016997,5.869297,0.172548,1.0,353.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01721345,0.017518933962202377,0.00030548396220237556
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Patient Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00286908,0.002881505121686498,1.2425121686498054e-05
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Patient Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00286908,0.0028815821337499904,1.2502133749990423e-05
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Protocol Discontinuation Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00286908,0.002881505121686498,1.2425121686498054e-05
3.0,353.0,307.0,0.008499,0.008499,5.869297,0.172548,1.0,353.0,0.0,0.0,Protocol Discontinuation Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00860723,0.008425855698065459,0.00018137430193454138
1.0,353.0,307.0,0.002833,0.002833,5.869297,0.172548,1.0,353.0,0.0,0.0,Patient Accidentally Unblinded,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00286908,0.002881505121686498,1.2425121686498054e-05
0.0,353.0,307.0,0.0,0.0,5.869297,0.172548,1.0,353.0,0.0,0.0,Patient Accidentally Unblinded,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,390.0,215.0,0.010256,0.010256,5.968708,0.196426,1.0,390.0,16.0,60.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01202421,0.01209620067550596,7.19906755059594e-05
1.0,390.0,215.0,0.002564,0.002564,5.968708,0.196426,1.0,390.0,16.0,60.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00300605,0.0030163032841666586,1.0253284166658518e-05
6.0,390.0,215.0,0.015385,0.015385,5.968708,0.196426,1.0,390.0,16.0,60.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01803748,0.018136876911553038,9.939691155303604e-05
52.0,390.0,215.0,0.133333,0.133333,5.968708,0.196426,1.0,390.0,16.0,60.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.15632053,0.16958653843078383,0.013266008430783821
27.0,390.0,215.0,0.069231,0.069231,5.968708,0.196426,1.0,390.0,16.0,60.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0811669,0.08437487482564485,0.0032079748256448465
25.0,390.0,215.0,0.064103,0.064103,5.968708,0.196426,1.0,390.0,16.0,60.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0751548,0.07865821843578373,0.0035034184357837367
2.0,390.0,215.0,0.005128,0.005128,5.968708,0.196426,1.0,390.0,16.0,60.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0060121,0.006027097627976187,1.4997627976186777e-05
4.0,390.0,215.0,0.010256,0.010256,5.968708,0.196426,1.0,390.0,16.0,60.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01202421,0.012131406595386904,0.00010719659538690335
3.0,390.0,215.0,0.007692,0.007692,5.968708,0.196426,1.0,390.0,16.0,60.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00901815,0.009019572567688518,1.4225676885169097e-06
10.0,390.0,215.0,0.025641,0.025641,5.968708,0.196426,1.0,390.0,16.0,60.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03006169,0.030460408314543636,0.00039871831454363696
7.0,390.0,215.0,0.017949,0.017949,5.968708,0.196426,1.0,390.0,16.0,60.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02104353,0.021066964767013894,2.3434767013892632e-05
7.0,390.0,215.0,0.017949,0.017949,5.968708,0.196426,1.0,390.0,16.0,60.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02104353,0.02112342366540675,7.989366540674808e-05
3.0,390.0,215.0,0.007692,0.007692,5.968708,0.196426,1.0,390.0,16.0,60.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00901815,0.00903615187719249,1.8001877192488913e-05
5.0,390.0,215.0,0.012821,0.012821,5.968708,0.196426,1.0,390.0,16.0,60.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01503143,0.015103633037394489,7.22030373944884e-05
4.0,390.0,215.0,0.010256,0.010256,5.968708,0.196426,1.0,390.0,16.0,60.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01202421,0.012088276198720238,6.406619872023796e-05
3.0,390.0,215.0,0.007692,0.007692,5.968708,0.196426,1.0,390.0,16.0,60.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00901815,0.00904454982784725,2.6399827847248952e-05
2.0,390.0,215.0,0.005128,0.005128,5.968708,0.196426,1.0,390.0,16.0,60.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0060121,0.0060268655142460305,1.4765514246030224e-05
6.0,390.0,215.0,0.015385,0.015385,5.968708,0.196426,1.0,390.0,16.0,60.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01803748,0.018161889720719707,0.00012440972071970507
1.0,390.0,215.0,0.002564,0.002564,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Error,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00300605,0.0030127861984523717,6.736198452371531e-06
1.0,390.0,215.0,0.002564,0.002564,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Error,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00300605,0.0030129100327976094,6.860032797609272e-06
1.0,390.0,215.0,0.002564,0.002564,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Error,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00300605,0.003002506399702371,3.5436002976292624e-06
0.0,390.0,215.0,0.0,0.0,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,390.0,215.0,0.002564,0.002564,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00300605,0.0030189270707142767,1.2877070714276562e-05
0.0,390.0,215.0,0.0,0.0,5.968708,0.196426,1.0,390.0,16.0,60.0,Administrative Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,711.0,685.0,0.0,0.0,6.568078,0.50597,1.0,711.0,13.0,108.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,711.0,685.0,0.001406,0.001406,6.568078,0.50597,1.0,711.0,13.0,108.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00467249,0.004706620066498002,3.413006649800269e-05
4.0,711.0,685.0,0.005626,0.005626,6.568078,0.50597,1.0,711.0,13.0,108.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0186966,0.018775759264157716,7.915926415771532e-05
5.0,711.0,685.0,0.007032,0.007032,6.568078,0.50597,1.0,711.0,13.0,108.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02336909,0.023310770142559535,5.83198574404635e-05
5.0,711.0,685.0,0.007032,0.007032,6.568078,0.50597,1.0,711.0,13.0,108.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02336909,0.023289826084675332,7.926391532466631e-05
3.0,711.0,685.0,0.004219,0.004219,6.568078,0.50597,1.0,711.0,13.0,108.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01402079,0.013995091957956347,2.5698042043652627e-05
3.0,711.0,685.0,0.004219,0.004219,6.568078,0.50597,1.0,711.0,13.0,108.0,Died,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01402079,0.01400980888271826,1.098111728174006e-05
4.0,711.0,685.0,0.005626,0.005626,6.568078,0.50597,1.0,711.0,13.0,108.0,Died,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0186966,0.018773254701147192,7.66547011471913e-05
1.0,711.0,685.0,0.001406,0.001406,6.568078,0.50597,1.0,711.0,13.0,108.0,Died,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00467249,0.004702269598819433,2.977959881943302e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Persistent Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Persistent Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,Persistent Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609164,0.006095417953706714,3.7779537067142432e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Persistent Hyperglycemia,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Persistent Hyperglycemia,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,New Antidiabetic Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,New Antidiabetic Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,New Antidiabetic Medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609164,0.006095417953706714,3.7779537067142432e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,New Antidiabetic Medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,New Antidiabetic Medication,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,374.0,344.0,0.010695,0.010695,5.926926,0.384365,1.0,374.0,1.0,49.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0243643,0.024382544894930556,1.8244894930557337e-05
4.0,374.0,344.0,0.010695,0.010695,5.926926,0.384365,1.0,374.0,1.0,49.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0243643,0.024333617393740084,3.0682606259914424e-05
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.384365,1.0,374.0,1.0,49.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01218329,0.012209158996815466,2.5868996815467046e-05
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00609164,0.006099732615135287,8.092615135287667e-06
3.0,374.0,344.0,0.008021,0.008021,5.926926,0.384365,1.0,374.0,1.0,49.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01827265,0.01829756837147818,2.4918371478180323e-05
4.0,374.0,344.0,0.010695,0.010695,5.926926,0.384365,1.0,374.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0243643,0.024382116902132937,1.7816902132938156e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00609164,0.00609767004846862,6.030048468620361e-06
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.384365,1.0,374.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01218329,0.012202012259851186,1.8722259851186238e-05
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.384365,1.0,374.0,1.0,49.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01218329,0.012218390159553559,3.5100159553559315e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609164,0.006096165501206715,4.525501206715035e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.384365,1.0,374.0,1.0,49.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01218329,0.012211279521636899,2.798952163689944e-05
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,"Moved, transfer abroad, did not enter FU",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00609164,0.0061085755097781465,1.693550977814682e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,"Moved, transfer abroad, did not enter FU",Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.384365,1.0,374.0,1.0,49.0,"Moved, transfer abroad, did not enter FU",Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609164,0.006094953872873382,3.3138728733825285e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,"Moved, transfer abroad, did not enter FU",Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,344.0,0.0,0.0,5.926926,0.384365,1.0,374.0,1.0,49.0,"Moved, transfer abroad, did not enter FU",Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,499.0,457.0,0.002004,0.002004,6.214608,1.0,1.0,499.0,7.0,68.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01245407,0.01240661777953103,4.745222046896938e-05
0.0,499.0,457.0,0.0,0.0,6.214608,1.0,1.0,499.0,7.0,68.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,499.0,457.0,0.0,0.0,6.214608,1.0,1.0,499.0,7.0,68.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,499.0,457.0,0.008016,0.008016,6.214608,1.0,1.0,499.0,7.0,68.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0498163,0.04761788697793652,0.0021984130220634793
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02490815,0.024845314332625868,6.283566737413232e-05
5.0,499.0,457.0,0.01002,0.01002,6.214608,1.0,1.0,499.0,7.0,68.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06227037,0.05920992163948416,0.0030604483605158397
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02490815,0.024864869144709197,4.3280855290803166e-05
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02490815,0.024853170824292534,5.497917570746608e-05
3.0,499.0,457.0,0.006012,0.006012,6.214608,1.0,1.0,499.0,7.0,68.0,Non compliant with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03736222,0.03724774670718253,0.00011447329281746854
4.0,499.0,457.0,0.008016,0.008016,6.214608,1.0,1.0,499.0,7.0,68.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0498163,0.04746114043589287,0.0023551595641071316
3.0,499.0,457.0,0.006012,0.006012,6.214608,1.0,1.0,499.0,7.0,68.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03736222,0.03721128348063491,0.00015093651936508995
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02490815,0.024820603463637823,8.754653636217774e-05
6.0,499.0,457.0,0.012024,0.012024,6.214608,1.0,1.0,499.0,7.0,68.0,"Patient refusal to continue,not due toAE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.07472445,0.07422995661845233,0.0004944933815476671
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,"Patient refusal to continue,not due toAE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.02490815,0.024853170824292534,5.497917570746608e-05
1.0,499.0,457.0,0.002004,0.002004,6.214608,1.0,1.0,499.0,7.0,68.0,"Patient refusal to continue,not due toAE",Overall Study,FG002,diabetes type 2,INDUSTRY,0.01245407,0.012418443509233419,3.562649076658056e-05
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02490815,0.024889166608756806,1.8983391243194286e-05
2.0,499.0,457.0,0.004008,0.004008,6.214608,1.0,1.0,499.0,7.0,68.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02490815,0.02487467475084014,3.347524915986097e-05
1.0,499.0,457.0,0.002004,0.002004,6.214608,1.0,1.0,499.0,7.0,68.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01245407,0.012422306104233418,3.1763895766581327e-05
2.0,2425.0,2171.0,0.000825,0.000825,7.793999,0.669377,1.0,2425.0,15.0,214.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00430413,0.0041176140954922134,0.00018651590450778632
3.0,2425.0,2171.0,0.001237,0.001237,7.793999,0.669377,1.0,2425.0,15.0,214.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00645358,0.0065090727906250015,5.54927906250011e-05
31.0,2425.0,2171.0,0.012784,0.012784,7.793999,0.669377,1.0,2425.0,15.0,214.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06669569,0.06629191806076382,0.00040377193923618604
24.0,2425.0,2171.0,0.009897,0.009897,7.793999,0.669377,1.0,2425.0,15.0,214.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05163386,0.051105942278660714,0.0005279177213392827
7.0,2425.0,2171.0,0.002887,0.002887,7.793999,0.669377,1.0,2425.0,15.0,214.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01506183,0.015006860278828464,5.496972117153588e-05
13.0,2425.0,2171.0,0.005361,0.005361,7.793999,0.669377,1.0,2425.0,15.0,214.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02796899,0.028138386688432528,0.00016939668843252847
61.0,2425.0,2171.0,0.025155,0.025155,7.793999,0.669377,1.0,2425.0,15.0,214.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.1312367,0.13517953019060522,0.0039428301906052066
72.0,2425.0,2171.0,0.029691,0.029691,7.793999,0.669377,1.0,2425.0,15.0,214.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.15490157,0.15620137414374724,0.0012998041437472518
26.0,2425.0,2171.0,0.010722,0.010722,7.793999,0.669377,1.0,2425.0,15.0,214.0,Other reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05593798,0.05616566481753973,0.0002276848175397292
15.0,2425.0,2171.0,0.006186,0.006186,7.793999,0.669377,1.0,2425.0,15.0,214.0,Other reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03227312,0.03088885911828372,0.0013842608817162816
12.0,307.0,279.0,0.039088,0.039088,5.7301,0.381185,1.0,307.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08537701,0.08630724281416677,0.0009302328141667648
15.0,307.0,279.0,0.04886,0.04886,5.7301,0.381185,1.0,307.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10672127,0.10929268047538691,0.0025714104753869205
1.0,307.0,279.0,0.003257,0.003257,5.7301,0.381185,1.0,307.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00711402,0.007055664481388898,5.8355518611102365e-05
0.0,307.0,279.0,0.0,0.0,5.7301,0.381185,1.0,307.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,894.0,834.0,0.0,0.0,6.796824,0.379199,1.0,894.0,18.0,199.0,Randomized but not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,894.0,834.0,0.0,0.0,6.796824,0.379199,1.0,894.0,18.0,199.0,Randomized but not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,894.0,834.0,0.001119,0.001119,6.796824,0.379199,1.0,894.0,18.0,199.0,Randomized but not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00288405,0.0030585770261210353,0.0001745270261210353
15.0,894.0,834.0,0.016779,0.016779,6.796824,0.379199,1.0,894.0,18.0,199.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04324534,0.0442367592632242,0.0009914192632241997
2.0,894.0,834.0,0.002237,0.002237,6.796824,0.379199,1.0,894.0,18.0,199.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00576553,0.005788045463898808,2.2515463898808118e-05
5.0,894.0,834.0,0.005593,0.005593,6.796824,0.379199,1.0,894.0,18.0,199.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01441511,0.014396591699285699,1.8518300714301036e-05
6.0,894.0,834.0,0.006711,0.006711,6.796824,0.379199,1.0,894.0,18.0,199.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01729659,0.016063978091339297,0.0012326119086607037
4.0,894.0,834.0,0.004474,0.004474,6.796824,0.379199,1.0,894.0,18.0,199.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01153106,0.011425227840873015,0.00010583215912698431
0.0,894.0,834.0,0.0,0.0,6.796824,0.379199,1.0,894.0,18.0,199.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,894.0,834.0,0.0,0.0,6.796824,0.379199,1.0,894.0,18.0,199.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,894.0,834.0,0.003356,0.003356,6.796824,0.379199,1.0,894.0,18.0,199.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00864958,0.00870306553806546,5.348553806545919e-05
2.0,894.0,834.0,0.002237,0.002237,6.796824,0.379199,1.0,894.0,18.0,199.0,Poor compliance to protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00576553,0.005784064143700395,1.853414370039507e-05
9.0,894.0,834.0,0.010067,0.010067,6.796824,0.379199,1.0,894.0,18.0,199.0,Other than specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02594618,0.025917598062777762,2.8581937222237064e-05
8.0,894.0,834.0,0.008949,0.008949,6.796824,0.379199,1.0,894.0,18.0,199.0,Other than specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0230647,0.022496117384736673,0.0005685826152633279
5.0,894.0,834.0,0.005593,0.005593,6.796824,0.379199,1.0,894.0,18.0,199.0,Other than specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01441511,0.014392738537232126,2.2371462767874564e-05
5.0,264.0,228.0,0.018939,0.018939,5.57973,0.214254,1.0,264.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02264124,0.02264636719193452,5.127191934520964e-06
2.0,264.0,228.0,0.007576,0.007576,5.57973,0.214254,1.0,264.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00905697,0.00906217137064487,5.201370644870515e-06
2.0,264.0,228.0,0.007576,0.007576,5.57973,0.214254,1.0,264.0,1.0,1.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00905697,0.009028764454236138,2.8205545763861084e-05
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452849,0.004529953299603176,1.463299603176628e-06
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,264.0,228.0,0.007576,0.007576,5.57973,0.214254,1.0,264.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00905697,0.00906179231953376,4.822319533760375e-06
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,264.0,228.0,0.064394,0.064394,5.57973,0.214254,1.0,264.0,1.0,1.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07698187,0.07789252335694445,0.0009106533569444575
2.0,264.0,228.0,0.007576,0.007576,5.57973,0.214254,1.0,264.0,1.0,1.0,Hypoglycaemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00905697,0.00906329307953376,6.323079533760573e-06
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Hypoglycaemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452849,0.004529210828769843,7.208287698436122e-07
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Hypoglycaemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Subject decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Subject decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Subject decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00452849,0.004526645883353175,1.8441166468249892e-06
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Withdrawal of consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Withdrawal of consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Withdrawal of consent,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00452849,0.004526645883353175,1.8441166468249892e-06
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Difficultulty in use of device,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Difficultulty in use of device,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Difficultulty in use of device,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00452849,0.004526645883353175,1.8441166468249892e-06
1.0,264.0,228.0,0.003788,0.003788,5.57973,0.214254,1.0,264.0,1.0,1.0,Unable to visit site on schedule,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00452849,0.004527092277519843,1.3977224801566338e-06
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Unable to visit site on schedule,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,264.0,228.0,0.0,0.0,5.57973,0.214254,1.0,264.0,1.0,1.0,Unable to visit site on schedule,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,19271.0,18999.0,0.000311,0.000311,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00166753,0.001590136661121034,7.739333887896594e-05
4.0,19271.0,18999.0,0.000208,0.000208,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00111526,0.0011060930356944457,9.166964305554366e-06
117.0,19271.0,18999.0,0.006071,0.006071,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03255178,0.03116621970243054,0.001385560297569463
94.0,19271.0,18999.0,0.004878,0.004878,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0261551,0.024035802678343265,0.002119297321656735
26.0,19271.0,18999.0,0.001349,0.001349,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Site prematurely closed by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00723313,0.0071417283062599176,9.140169374008238e-05
25.0,19271.0,18999.0,0.001297,0.001297,9.866409,0.543445,1.0,19271.0,43.0,1237.0,Site prematurely closed by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00695432,0.006521693541706354,0.0004326264582936463
16.0,507.0,452.0,0.031558,0.031558,6.230481,0.555839,1.0,507.0,10.0,76.0,At the Participant's own Request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10928997,0.11115693916103185,0.0018669691610318506
17.0,507.0,452.0,0.033531,0.033531,6.230481,0.555839,1.0,507.0,10.0,76.0,At the Participant's own Request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11612276,0.11729127256377975,0.0011685125637797417
3.0,507.0,452.0,0.005917,0.005917,6.230481,0.555839,1.0,507.0,10.0,76.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02049144,0.020550151809407446,5.87118094074468e-05
0.0,507.0,452.0,0.0,0.0,6.230481,0.555839,1.0,507.0,10.0,76.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,507.0,452.0,0.001972,0.001972,6.230481,0.555839,1.0,507.0,10.0,76.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00682932,0.006951767532658731,0.00012244753265873085
0.0,507.0,452.0,0.0,0.0,6.230481,0.555839,1.0,507.0,10.0,76.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,507.0,452.0,0.003945,0.003945,6.230481,0.555839,1.0,507.0,10.0,76.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01366211,0.013702531013442466,4.0421013442466444e-05
2.0,507.0,452.0,0.003945,0.003945,6.230481,0.555839,1.0,507.0,10.0,76.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01366211,0.013705189639424607,4.30796394246067e-05
11.0,507.0,452.0,0.021696,0.021696,6.230481,0.555839,1.0,507.0,10.0,76.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07513642,0.07537068538464287,0.0002342653846428705
3.0,507.0,452.0,0.005917,0.005917,6.230481,0.555839,1.0,507.0,10.0,76.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02049144,0.020546761396696395,5.532139669639502e-05
0.0,568.0,510.0,0.0,0.0,6.34388,0.242288,1.0,568.0,4.0,30.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,568.0,510.0,0.003521,0.003521,6.34388,0.242288,1.0,568.0,4.0,30.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00541194,0.005406935589695156,5.004410304843346e-06
0.0,568.0,510.0,0.0,0.0,6.34388,0.242288,1.0,568.0,4.0,30.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,568.0,510.0,0.003521,0.003521,6.34388,0.242288,1.0,568.0,4.0,30.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00541194,0.005400938113742786,1.1001886257213517e-05
3.0,568.0,510.0,0.005282,0.005282,6.34388,0.242288,1.0,568.0,4.0,30.0,Study specific discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00811868,0.008059669816607148,5.901018339285122e-05
4.0,568.0,510.0,0.007042,0.007042,6.34388,0.242288,1.0,568.0,4.0,30.0,Study specific discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01082388,0.010800873534682547,2.3006465317452e-05
11.0,568.0,510.0,0.019366,0.019366,6.34388,0.242288,1.0,568.0,4.0,30.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02976643,0.02946231883532646,0.00030411116467354143
23.0,568.0,510.0,0.040493,0.040493,6.34388,0.242288,1.0,568.0,4.0,30.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06223959,0.06219744914396826,4.214085603173462e-05
6.0,568.0,510.0,0.010563,0.010563,6.34388,0.242288,1.0,568.0,4.0,30.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01623581,0.016243176827470233,7.366827470232928e-06
1.0,568.0,510.0,0.001761,0.001761,6.34388,0.242288,1.0,568.0,4.0,30.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00270674,0.0027048286441964313,1.9113558035687393e-06
1.0,568.0,510.0,0.001761,0.001761,6.34388,0.242288,1.0,568.0,4.0,30.0,Severe non-compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00270674,0.002704328826577384,2.4111734226160177e-06
2.0,568.0,510.0,0.003521,0.003521,6.34388,0.242288,1.0,568.0,4.0,30.0,Severe non-compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00541194,0.005405910542076109,6.029457923890924e-06
0.0,568.0,510.0,0.0,0.0,6.34388,0.242288,1.0,568.0,4.0,30.0,Safety reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,568.0,510.0,0.003521,0.003521,6.34388,0.242288,1.0,568.0,4.0,30.0,Safety reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00541194,0.005405910542076109,6.029457923890924e-06
1.0,568.0,510.0,0.001761,0.001761,6.34388,0.242288,1.0,568.0,4.0,30.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00270674,0.002703771226577384,2.9687734226162103e-06
0.0,568.0,510.0,0.0,0.0,6.34388,0.242288,1.0,568.0,4.0,30.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Lack of Efficacy,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00495386,0.004947721814444476,6.138185555524221e-06
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Lack of Efficacy,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Lack of Efficacy,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Lack of Efficacy,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Adverse Event,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Adverse Event,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00495386,0.004951112368928606,2.747631071393919e-06
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Adverse Event,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00495386,0.004954871815277813,1.0118152778126888e-06
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Adverse Event,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,282.0,260.0,0.007092,0.007092,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00990773,0.010020920493601211,0.00011319049360121111
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00495386,0.004949747377261939,4.112622738061331e-06
3.0,282.0,260.0,0.010638,0.010638,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01486159,0.014998449101738807,0.00013685910173880794
3.0,282.0,260.0,0.010638,0.010638,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01486159,0.014993723093405473,0.00013213309340547388
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Lost to Follow-up,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Lost to Follow-up,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,282.0,260.0,0.007092,0.007092,5.645447,0.247461,1.0,497.0,7.0,62.0,Lost to Follow-up,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00990773,0.010013528413601211,0.00010579841360121127
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Lost to Follow-up,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00495386,0.004954428797301622,5.687973016216957e-07
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Poor non-compliance,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Poor non-compliance,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Poor non-compliance,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00495386,0.004953355565277812,5.044347221880643e-07
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Poor non-compliance,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00495386,0.004954436132301622,5.761323016223105e-07
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,No longer met criteria,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,No longer met criteria,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00495386,0.0049504157189286056,3.444281071394474e-06
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,No longer met criteria,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,No longer met criteria,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00495386,0.0049504157189286056,3.444281071394474e-06
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Double Blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Follow up Period - No Drug Treatment,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Follow up Period - No Drug Treatment,FG001,diabetes type 2,INDUSTRY,0.00495386,0.005015824513286456,6.196451328645616e-05
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Follow up Period - No Drug Treatment,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,Withdrawal by Subject,Follow up Period - No Drug Treatment,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,260.0,0.003546,0.003546,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Follow up Period - No Drug Treatment,FG000,diabetes type 2,INDUSTRY,0.00495386,0.005021758017007456,6.78980170074556e-05
2.0,282.0,260.0,0.007092,0.007092,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Follow up Period - No Drug Treatment,FG001,diabetes type 2,INDUSTRY,0.00990773,0.010044654514613116,0.00013692451461311608
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Follow up Period - No Drug Treatment,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,282.0,260.0,0.0,0.0,5.645447,0.247461,1.0,497.0,7.0,62.0,non-specified,Follow up Period - No Drug Treatment,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,833.0,777.0,0.003601,0.003601,6.726233,0.361617,1.0,833.0,7.0,81.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00875878,0.008707641943214278,5.113805678572288e-05
3.0,833.0,777.0,0.003601,0.003601,6.726233,0.361617,1.0,833.0,7.0,81.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00875878,0.008725320203333326,3.345979666667491e-05
3.0,833.0,777.0,0.003601,0.003601,6.726233,0.361617,1.0,833.0,7.0,81.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00875878,0.008702774323928563,5.600567607143801e-05
3.0,833.0,777.0,0.003601,0.003601,6.726233,0.361617,1.0,833.0,7.0,81.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00875878,0.008719392642321421,3.9387357678579565e-05
1.0,833.0,777.0,0.0012,0.0012,6.726233,0.361617,1.0,833.0,7.0,81.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00291878,0.0029263001956249916,7.520195624991476e-06
0.0,833.0,777.0,0.0,0.0,6.726233,0.361617,1.0,833.0,7.0,81.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
25.0,833.0,777.0,0.030012,0.030012,6.726233,0.361617,1.0,833.0,7.0,81.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07299879,0.07224855364258931,0.0007502363574106857
18.0,833.0,777.0,0.021609,0.021609,6.726233,0.361617,1.0,833.0,7.0,81.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05256,0.051331667266580075,0.0012283327334199276
4.0,291.0,276.0,0.013746,0.013746,5.676754,0.720663,1.0,291.0,1.0,27.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05623527,0.05689613080348217,0.0006608608034821759
0.0,291.0,276.0,0.0,0.0,5.676754,0.720663,1.0,291.0,1.0,27.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,291.0,276.0,0.017182,0.017182,5.676754,0.720663,1.0,291.0,1.0,27.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07029204,0.07180334182105973,0.0015113018210597268
3.0,291.0,276.0,0.010309,0.010309,5.676754,0.720663,1.0,291.0,1.0,27.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04217441,0.04291858939776785,0.000744179397767851
0.0,291.0,276.0,0.0,0.0,5.676754,0.720663,1.0,291.0,1.0,27.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,291.0,276.0,0.003436,0.003436,5.676754,0.720663,1.0,291.0,1.0,27.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01405677,0.014076592626121005,1.9822626121004938e-05
0.0,291.0,276.0,0.0,0.0,5.676754,0.720663,1.0,291.0,1.0,27.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,291.0,276.0,0.003436,0.003436,5.676754,0.720663,1.0,291.0,1.0,27.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01405677,0.014095456552867036,3.8686552867036456e-05
1.0,291.0,276.0,0.003436,0.003436,5.676754,0.720663,1.0,291.0,1.0,27.0,Non-Compliance with Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01405677,0.014099140575307513,4.237057530751334e-05
0.0,291.0,276.0,0.0,0.0,5.676754,0.720663,1.0,291.0,1.0,27.0,Non-Compliance with Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
45.0,639.0,436.0,0.070423,0.070423,6.461468,0.266168,1.0,639.0,18.0,18.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12111618,0.12276881724115102,0.0016526372411510143
45.0,639.0,436.0,0.070423,0.070423,6.461468,0.266168,1.0,639.0,18.0,18.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12111618,0.12296920233561526,0.0018530223356152536
19.0,639.0,436.0,0.029734,0.029734,6.461468,0.266168,1.0,639.0,18.0,18.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05113767,0.05084608842925869,0.0002915815707413144
6.0,639.0,436.0,0.00939,0.00939,6.461468,0.266168,1.0,639.0,18.0,18.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01614928,0.01612834865850199,2.0931341498008765e-05
2.0,639.0,436.0,0.00313,0.00313,6.461468,0.266168,1.0,639.0,18.0,18.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00538309,0.00536635550317461,1.6734496825389876e-05
1.0,639.0,436.0,0.001565,0.001565,6.461468,0.266168,1.0,639.0,18.0,18.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00269155,0.0027802866371789314,8.873663717893143e-05
1.0,639.0,436.0,0.001565,0.001565,6.461468,0.266168,1.0,639.0,18.0,18.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00269155,0.002782312836405121,9.076283640512082e-05
0.0,639.0,436.0,0.0,0.0,6.461468,0.266168,1.0,639.0,18.0,18.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,639.0,436.0,0.010955,0.010955,6.461468,0.266168,1.0,639.0,18.0,18.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01884083,0.01896453418323412,0.0001237041832341211
8.0,639.0,436.0,0.01252,0.01252,6.461468,0.266168,1.0,639.0,18.0,18.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02153238,0.021581113237212318,4.8733237212317954e-05
7.0,639.0,436.0,0.010955,0.010955,6.461468,0.266168,1.0,639.0,18.0,18.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01884083,0.01897456403588293,0.00013373403588293198
13.0,639.0,436.0,0.020344,0.020344,6.461468,0.266168,1.0,639.0,18.0,18.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03498839,0.03504413621604164,5.574621604163832e-05
12.0,639.0,436.0,0.018779,0.018779,6.461468,0.266168,1.0,639.0,18.0,18.0,Familial or Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03229684,0.032414168197361065,0.00011732819736106487
15.0,639.0,436.0,0.023474,0.023474,6.461468,0.266168,1.0,639.0,18.0,18.0,Familial or Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04037149,0.03991887159059525,0.000452618409404755
2.0,639.0,436.0,0.00313,0.00313,6.461468,0.266168,1.0,639.0,18.0,18.0,Serious Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00538309,0.00536447777442461,1.861222557539028e-05
3.0,639.0,436.0,0.004695,0.004695,6.461468,0.266168,1.0,639.0,18.0,18.0,Serious Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00807464,0.007959663245196895,0.00011497675480310471
9.0,639.0,436.0,0.014085,0.014085,6.461468,0.266168,1.0,639.0,18.0,18.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02422392,0.024484712237896816,0.0002607922378968161
8.0,639.0,436.0,0.01252,0.01252,6.461468,0.266168,1.0,639.0,18.0,18.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02153238,0.021546400427073432,1.4020427073432179e-05
5.0,1186.0,1069.0,0.004216,0.004216,7.079184,0.379289,1.0,1186.0,13.0,129.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0113202,0.011290702744275785,2.9497255724215965e-05
2.0,1186.0,1069.0,0.001686,0.001686,7.079184,0.379289,1.0,1186.0,13.0,129.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452701,0.0045004886784731305,2.65213215268692e-05
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0090567,0.009070567466111065,1.3867466111063681e-05
2.0,1186.0,1069.0,0.001686,0.001686,7.079184,0.379289,1.0,1186.0,13.0,129.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00452701,0.00449973983156837,2.727016843163e-05
3.0,1186.0,1069.0,0.00253,0.00253,7.079184,0.379289,1.0,1186.0,13.0,129.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0067932,0.0066756602631249965,0.00011753973687500356
6.0,1186.0,1069.0,0.005059,0.005059,7.079184,0.379289,1.0,1186.0,13.0,129.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01358371,0.013317657189930554,0.00026605281006944655
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0090567,0.009029426002916625,2.7273997083375467e-05
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0090567,0.009061363071527731,4.663071527730156e-06
2.0,1186.0,1069.0,0.001686,0.001686,7.079184,0.379289,1.0,1186.0,13.0,129.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00452701,0.004481664859176593,4.534514082340634e-05
5.0,1186.0,1069.0,0.004216,0.004216,7.079184,0.379289,1.0,1186.0,13.0,129.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0113202,0.011245599831081341,7.460016891865963e-05
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0090567,0.009046285353313454,1.0414646686546583e-05
3.0,1186.0,1069.0,0.00253,0.00253,7.079184,0.379289,1.0,1186.0,13.0,129.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0067932,0.0066763569618749985,0.00011684303812500157
7.0,1186.0,1069.0,0.005902,0.005902,7.079184,0.379289,1.0,1186.0,13.0,129.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01584721,0.01589342642261904,4.621642261903869e-05
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0090567,0.009053837467361067,2.862532638934004e-06
8.0,1186.0,1069.0,0.006745,0.006745,7.079184,0.379289,1.0,1186.0,13.0,129.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01811071,0.017800045144206342,0.00031066485579365685
1.0,1186.0,1069.0,0.000843,0.000843,7.079184,0.379289,1.0,1186.0,13.0,129.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0022635,0.0022654054950297484,1.905495029748492e-06
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Death,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1186.0,1069.0,0.000843,0.000843,7.079184,0.379289,1.0,1186.0,13.0,129.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0022635,0.0022679546806845096,4.454680684509715e-06
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1186.0,1069.0,0.000843,0.000843,7.079184,0.379289,1.0,1186.0,13.0,129.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0022635,0.002265180136696415,1.6801366964150355e-06
1.0,1186.0,1069.0,0.000843,0.000843,7.079184,0.379289,1.0,1186.0,13.0,129.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0022635,0.002267999757767843,4.499757767843088e-06
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1186.0,1069.0,0.000843,0.000843,7.079184,0.379289,1.0,1186.0,13.0,129.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0022635,0.002265180136696415,1.6801366964150355e-06
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1186.0,1069.0,0.0,0.0,7.079184,0.379289,1.0,1186.0,13.0,129.0,Pregnancy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,1186.0,1069.0,0.011804,0.011804,7.079184,0.379289,1.0,1186.0,13.0,129.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03169442,0.03153954475884922,0.00015487524115077866
15.0,1186.0,1069.0,0.012648,0.012648,7.079184,0.379289,1.0,1186.0,13.0,129.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03396061,0.03316301629785717,0.0007975937021428292
7.0,1186.0,1069.0,0.005902,0.005902,7.079184,0.379289,1.0,1186.0,13.0,129.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01584721,0.01589972688910712,5.251688910712024e-05
4.0,1186.0,1069.0,0.003373,0.003373,7.079184,0.379289,1.0,1186.0,13.0,129.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0090567,0.009045709250932494,1.0990749067506592e-05
9.0,1186.0,1069.0,0.007589,0.007589,7.079184,0.379289,1.0,1186.0,13.0,129.0,Other,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0203769,0.02008444916214285,0.00029245083785715137
3.0,621.0,542.0,0.004831,0.004831,6.43294,0.478063,1.0,621.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01485703,0.014855030815952354,1.9991840476459716e-06
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495132,0.0049486990850757424,2.620914924257936e-06
3.0,621.0,542.0,0.004831,0.004831,6.43294,0.478063,1.0,621.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01485703,0.014834804380029742,2.222561997025814e-05
3.0,621.0,542.0,0.004831,0.004831,6.43294,0.478063,1.0,621.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01485703,0.014873083734374981,1.6053734374981213e-05
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495132,0.00495078152614717,5.384738528306857e-07
2.0,621.0,542.0,0.003221,0.003221,6.43294,0.478063,1.0,621.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00990571,0.009634635564523814,0.000271074435476186
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Excluded Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00495132,0.004956835741682888,5.515741682888056e-06
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Excluded Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495132,0.0049488329219805035,2.4870780194969147e-06
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Excluded Medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,621.0,542.0,0.012882,0.012882,6.43294,0.478063,1.0,621.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0396167,0.03902838876039683,0.0005883112396031648
5.0,621.0,542.0,0.008052,0.008052,6.43294,0.478063,1.0,621.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02476275,0.024855727113958316,9.297711395831604e-05
6.0,621.0,542.0,0.009662,0.009662,6.43294,0.478063,1.0,621.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02971406,0.029764900957261902,5.0840957261901604e-05
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00495132,0.0049566025833495545,5.282583349554108e-06
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495132,0.004948580203379313,2.7397966206876845e-06
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00495132,0.004954704601176935,3.3846011769349954e-06
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Participant moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,621.0,542.0,0.00161,0.00161,6.43294,0.478063,1.0,621.0,0.0,0.0,Participant moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495132,0.00494859976364717,2.7202363528299953e-06
0.0,621.0,542.0,0.0,0.0,6.43294,0.478063,1.0,621.0,0.0,0.0,Participant moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,621.0,542.0,0.028986,0.028986,6.43294,0.478063,1.0,621.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08914219,0.0889350117159028,0.00020717828409719252
10.0,621.0,542.0,0.016103,0.016103,6.43294,0.478063,1.0,621.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04952242,0.04930837659749008,0.00021404340250991832
13.0,621.0,542.0,0.020934,0.020934,6.43294,0.478063,1.0,621.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06437945,0.06473564750306551,0.00035619750306550846
0.0,807.0,714.0,0.0,0.0,6.694562,0.340296,1.0,807.0,13.0,193.0,Randomized but not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,807.0,714.0,0.001239,0.001239,6.694562,0.340296,1.0,807.0,13.0,193.0,Randomized but not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00282261,0.0028359851841071315,1.3375184107131382e-05
12.0,807.0,714.0,0.01487,0.01487,6.694562,0.340296,1.0,807.0,13.0,193.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03387585,0.033446212285545604,0.000429637714454395
16.0,807.0,714.0,0.019827,0.019827,6.694562,0.340296,1.0,807.0,13.0,193.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04516857,0.04513877243997564,2.9797560024358294e-05
1.0,807.0,714.0,0.001239,0.001239,6.694562,0.340296,1.0,807.0,13.0,193.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00282261,0.0028290614551460865,6.451455146086384e-06
1.0,807.0,714.0,0.001239,0.001239,6.694562,0.340296,1.0,807.0,13.0,193.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00282261,0.0028320897847131867,9.479784713186529e-06
6.0,807.0,714.0,0.007435,0.007435,6.694562,0.340296,1.0,807.0,13.0,193.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01693793,0.01698562914195435,4.769914195434932e-05
8.0,807.0,714.0,0.009913,0.009913,6.694562,0.340296,1.0,807.0,13.0,193.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02258314,0.022809033984771833,0.00022589398477183137
18.0,807.0,714.0,0.022305,0.022305,6.694562,0.340296,1.0,807.0,13.0,193.0,Diverse Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05081378,0.04922348972591541,0.0015902902740845895
14.0,807.0,714.0,0.017348,0.017348,6.694562,0.340296,1.0,807.0,13.0,193.0,Diverse Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03952107,0.039452914376309496,6.815562369050232e-05
5.0,807.0,714.0,0.006196,0.006196,6.694562,0.340296,1.0,807.0,13.0,193.0,Site Closure for Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01411532,0.014095856235743144,1.946376425685653e-05
2.0,807.0,714.0,0.002478,0.002478,6.694562,0.340296,1.0,807.0,13.0,193.0,Site Closure for Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00564522,0.005641926510634912,3.2934893650880814e-06
2.0,807.0,714.0,0.002478,0.002478,6.694562,0.340296,1.0,807.0,13.0,193.0,Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00564522,0.005649609062678565,4.389062678565071e-06
3.0,807.0,714.0,0.003717,0.003717,6.694562,0.340296,1.0,807.0,13.0,193.0,Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00846782,0.008539042008809526,7.122200880952702e-05
1.0,807.0,714.0,0.001239,0.001239,6.694562,0.340296,1.0,807.0,13.0,193.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00282261,0.0028339123481114616,1.1302348111461458e-05
3.0,807.0,714.0,0.003717,0.003717,6.694562,0.340296,1.0,807.0,13.0,193.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00846782,0.008538478426726193,7.06584267261938e-05
3.0,393.0,343.0,0.007634,0.007634,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01362849,0.013599555447648817,2.8934552351183446e-05
0.0,393.0,343.0,0.0,0.0,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,393.0,343.0,0.0,0.0,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,393.0,343.0,0.002545,0.002545,5.976351,0.298717,1.0,1179.0,4.0,39.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00454342,0.0045524853956250035,9.065395625003185e-06
4.0,393.0,343.0,0.010178,0.010178,5.976351,0.298717,1.0,1179.0,4.0,39.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01817012,0.01825370530983131,8.358530983130705e-05
4.0,393.0,343.0,0.010178,0.010178,5.976351,0.298717,1.0,1179.0,4.0,39.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01817012,0.018239915172956315,6.979517295631343e-05
1.0,393.0,343.0,0.002545,0.002545,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00454342,0.004550803983125003,7.383983125002977e-06
0.0,393.0,343.0,0.0,0.0,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,393.0,343.0,0.010178,0.010178,5.976351,0.298717,1.0,1179.0,4.0,39.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01817012,0.018239091666825365,6.897166682536329e-05
4.0,393.0,343.0,0.010178,0.010178,5.976351,0.298717,1.0,1179.0,4.0,39.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01817012,0.018249462440367032,7.934244036703064e-05
5.0,393.0,343.0,0.012723,0.012723,5.976351,0.298717,1.0,1179.0,4.0,39.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02271355,0.02262401847315477,8.95315268452275e-05
3.0,393.0,343.0,0.007634,0.007634,5.976351,0.298717,1.0,1179.0,4.0,39.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01362849,0.013619934573690486,8.5554263095141e-06
10.0,393.0,343.0,0.025445,0.025445,5.976351,0.298717,1.0,1179.0,4.0,39.0,"non-compliance, not met criteria, etc.",Overall Study,FG000,diabetes type 2,INDUSTRY,0.04542531,0.04586972280290676,0.00044441280290675317
6.0,393.0,343.0,0.015267,0.015267,5.976351,0.298717,1.0,1179.0,4.0,39.0,"non-compliance, not met criteria, etc.",Overall Study,FG001,diabetes type 2,INDUSTRY,0.02725519,0.027086796194761925,0.00016839380523807346
5.0,393.0,343.0,0.012723,0.012723,5.976351,0.298717,1.0,1179.0,4.0,39.0,"non-compliance, not met criteria, etc.",Overall Study,FG002,diabetes type 2,INDUSTRY,0.02271355,0.022633471414047625,8.007858595237421e-05
3.0,299.0,269.0,0.010033,0.010033,5.703782,1.0,1.0,300.0,3.0,19.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05722605,0.05801387176299613,0.0007878217629961326
4.0,299.0,269.0,0.013378,0.013378,5.703782,1.0,1.0,300.0,3.0,19.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0763052,0.07509187375577386,0.00121332624422614
2.0,299.0,269.0,0.006689,0.006689,5.703782,1.0,1.0,300.0,3.0,19.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0381526,0.037863367158164754,0.0002892328418352477
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01907345,0.019214194871726094,0.00014074487172609576
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01907345,0.019183404586845147,0.00010995458684514778
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01907345,0.019188008298452283,0.00011455829845228443
4.0,299.0,269.0,0.013378,0.013378,5.703782,1.0,1.0,300.0,3.0,19.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0763052,0.07509934818523815,0.001205851814761849
9.0,299.0,269.0,0.0301,0.0301,5.703782,1.0,1.0,300.0,3.0,19.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.17168385,0.16823597768239085,0.003447872317609152
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01907345,0.01923216544803562,0.00015871544803562274
2.0,299.0,269.0,0.006689,0.006689,5.703782,1.0,1.0,300.0,3.0,19.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0381526,0.037887455408581405,0.00026514459141859653
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,patient's private reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01907345,0.019188598908452287,0.00011514890845228803
1.0,299.0,269.0,0.003344,0.003344,5.703782,1.0,1.0,300.0,3.0,19.0,patient's private reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01907345,0.01919251549047609,0.00011906549047609183
23.0,467.0,299.0,0.049251,0.049251,6.148468,0.231988,1.0,467.0,16.0,125.0,Adverse Event,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.07025025,0.06973179158268844,0.0005184584173115597
31.0,467.0,299.0,0.066381,0.066381,6.148468,0.231988,1.0,467.0,16.0,125.0,Adverse Event,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.094684,0.0948959399725595,0.00021193997255949948
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Lack of Efficacy,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003056544109285716,2.6841092857160867e-06
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Lack of Efficacy,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,467.0,299.0,0.008565,0.008565,6.148468,0.231988,1.0,467.0,16.0,125.0,Protocol Violation,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.01221688,0.012246875655727817,2.9995655727817205e-05
3.0,467.0,299.0,0.006424,0.006424,6.148468,0.231988,1.0,467.0,16.0,125.0,Protocol Violation,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00916301,0.009152289684583316,1.0720315416682877e-05
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawal criteria,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.00305386,0.0030540558274404785,1.9582744047869083e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawal criteria,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540279941666687,1.6799416666882921e-07
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Lost to follow up,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.00610915,0.006109880843571386,7.308435713863567e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Lost to follow up,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540634608333356,2.0346083333573628e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Subject decision,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054079527440479,2.195274404789664e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Subject decision,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540634608333356,2.0346083333573628e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawal of consent,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054079527440479,2.195274404789664e-07
3.0,467.0,299.0,0.006424,0.006424,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawal of consent,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00916301,0.00915292295291665,1.008704708335001e-05
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Loss of trust,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Loss of trust,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540634608333356,2.0346083333573628e-07
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Fear of hypoglycaemia,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Fear of hypoglycaemia,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540634608333356,2.0346083333573628e-07
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Hypoglycaemia,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Hypoglycaemia,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00610915,0.006118938086349167,9.788086349167557e-06
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Mutual consent,"Double-Blind, Week 0-26",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Mutual consent,"Double-Blind, Week 0-26",FG001,diabetes type 2,INDUSTRY,0.00305386,0.0030540634608333356,2.0346083333573628e-07
3.0,467.0,299.0,0.006424,0.006424,6.148468,0.231988,1.0,467.0,16.0,125.0,Adverse Event,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00916301,0.009165357332390852,2.347332390852455e-06
9.0,467.0,299.0,0.019272,0.019272,6.148468,0.231988,1.0,467.0,16.0,125.0,Adverse Event,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.02748904,0.02711789545666663,0.0003711445433333682
6.0,467.0,299.0,0.012848,0.012848,6.148468,0.231988,1.0,467.0,16.0,125.0,Lack of Efficacy,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.01832603,0.018197320098740078,0.00012870990125992202
5.0,467.0,299.0,0.010707,0.010707,6.148468,0.231988,1.0,467.0,16.0,125.0,Lack of Efficacy,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.01527217,0.015243577799883657,2.8592200116342795e-05
3.0,467.0,299.0,0.006424,0.006424,6.148468,0.231988,1.0,467.0,16.0,125.0,Protocol Violation,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00916301,0.00915804434905752,4.96565094247961e-06
4.0,467.0,299.0,0.008565,0.008565,6.148468,0.231988,1.0,467.0,16.0,125.0,Protocol Violation,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.01221688,0.012246904852037338,3.0024852037338276e-05
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawel criteria,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054233378690478,3.73378690477974e-07
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Withdrawel criteria,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.00610915,0.006115188999265833,6.03899926583315e-06
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Hypoglycaemia,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Hypoglycaemia,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.00305386,0.003054174602242064,3.146022420643345e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Lost to follow up,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054233378690478,3.73378690477974e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Lost to follow up,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.00305386,0.003054174602242064,3.146022420643345e-07
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Consent withdrawn,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00610915,0.006106239950238051,2.910049761948967e-06
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Consent withdrawn,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.00305386,0.003054174602242064,3.146022420643345e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Change in treatment,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00305386,0.0030542317224404782,3.717224404784121e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Change in treatment,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.00305386,0.003054189383492064,3.2938349206436054e-07
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Creatine increased,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054233378690478,3.73378690477974e-07
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Creatine increased,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,299.0,0.002141,0.002141,6.148468,0.231988,1.0,467.0,16.0,125.0,Decreased kidney function,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00305386,0.003054233378690478,3.73378690477974e-07
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Decreased kidney function,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Exclusion criteria,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00610915,0.006106239950238051,2.910049761948967e-06
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Exclusion criteria,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,299.0,0.004283,0.004283,6.148468,0.231988,1.0,467.0,16.0,125.0,Subject decision,"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.00610915,0.006106239950238051,2.910049761948967e-06
0.0,467.0,299.0,0.0,0.0,6.148468,0.231988,1.0,467.0,16.0,125.0,Subject decision,"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,467.0,299.0,0.038544,0.038544,6.148468,0.231988,1.0,467.0,16.0,125.0,Completed extension 1 (weeks 26-40),"Open-Label Extension, Week 26-78",FG000,diabetes type 2,INDUSTRY,0.05497808,0.05610160190880945,0.0011235219088094536
25.0,467.0,299.0,0.053533,0.053533,6.148468,0.231988,1.0,467.0,16.0,125.0,Completed extension 1 (weeks 26-40),"Open-Label Extension, Week 26-78",FG001,diabetes type 2,INDUSTRY,0.07635797,0.07745345837664669,0.0010954883766466916
1.0,464.0,433.0,0.002155,0.002155,6.142037,0.432392,1.0,464.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00572318,0.005778261036748468,5.508103674846821e-05
1.0,464.0,433.0,0.002155,0.002155,6.142037,0.432392,1.0,464.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00572318,0.005776353630042117,5.3173630042117545e-05
2.0,464.0,433.0,0.00431,0.00431,6.142037,0.432392,1.0,464.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01144635,0.011446198258829351,1.5174117064774284e-07
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,464.0,433.0,0.00431,0.00431,6.142037,0.432392,1.0,464.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01144635,0.011438826418472207,7.523581527791798e-06
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,464.0,433.0,0.00431,0.00431,6.142037,0.432392,1.0,464.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01144635,0.011451069669662684,4.7196696626849305e-06
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Screen failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,464.0,433.0,0.00431,0.00431,6.142037,0.432392,1.0,464.0,0.0,0.0,Screen failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01144635,0.011443765673055535,2.5843269444644767e-06
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Screen failure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,464.0,433.0,0.008621,0.008621,6.142037,0.432392,1.0,464.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02289536,0.02265857394502977,0.000236786054970229
7.0,464.0,433.0,0.015086,0.015086,6.142037,0.432392,1.0,464.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04006489,0.039976165373035694,8.872462696430522e-05
9.0,464.0,433.0,0.019397,0.019397,6.142037,0.432392,1.0,464.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0515139,0.049948140504543714,0.001565759495456287
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,464.0,433.0,0.0,0.0,6.142037,0.432392,1.0,464.0,0.0,0.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,464.0,433.0,0.002155,0.002155,6.142037,0.432392,1.0,464.0,0.0,0.0,Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00572318,0.00577517727536454,5.1997275364540005e-05
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00723846,0.007250255632341245,1.1795632341244679e-05
3.0,365.0,231.0,0.008219,0.008219,5.902633,0.22382,1.0,365.0,4.0,74.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01085835,0.010853401369999984,4.9486300000151084e-06
3.0,365.0,231.0,0.008219,0.008219,5.902633,0.22382,1.0,365.0,4.0,74.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01085835,0.010853296297916653,5.053702083345976e-06
4.0,365.0,231.0,0.010959,0.010959,5.902633,0.22382,1.0,365.0,4.0,74.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01447824,0.014472066093551556,6.173906448444025e-06
6.0,365.0,231.0,0.016438,0.016438,5.902633,0.22382,1.0,365.0,4.0,74.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02171669,0.021701842127083273,1.4847872916726873e-05
10.0,365.0,231.0,0.027397,0.027397,5.902633,0.22382,1.0,365.0,4.0,74.0,Withdrawal of Consent by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03619493,0.036654655487569465,0.0004597254875694651
8.0,365.0,231.0,0.021918,0.021918,5.902633,0.22382,1.0,365.0,4.0,74.0,Withdrawal of Consent by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02895647,0.028978102600741375,2.163260074137391e-05
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Withdrawal of Consent by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00723846,0.007248585029543619,1.0125029543619005e-05
9.0,365.0,231.0,0.024658,0.024658,5.902633,0.22382,1.0,365.0,4.0,74.0,Withdrawal of Consent by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03257636,0.0327920282000893,0.0002156682000893015
5.0,365.0,231.0,0.013699,0.013699,5.902633,0.22382,1.0,365.0,4.0,74.0,Withdrawal of Consent by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01809813,0.018244432194265886,0.00014630219426588556
7.0,365.0,231.0,0.019178,0.019178,5.902633,0.22382,1.0,365.0,4.0,74.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02533658,0.025159598336150776,0.00017698166384922526
6.0,365.0,231.0,0.016438,0.016438,5.902633,0.22382,1.0,365.0,4.0,74.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02171669,0.02172268746472217,5.997464722171109e-06
7.0,365.0,231.0,0.019178,0.019178,5.902633,0.22382,1.0,365.0,4.0,74.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02533658,0.025204147483650782,0.00013243251634921863
8.0,365.0,231.0,0.021918,0.021918,5.902633,0.22382,1.0,365.0,4.0,74.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02895647,0.02897598096716994,1.9510967169938248e-05
6.0,365.0,231.0,0.016438,0.016438,5.902633,0.22382,1.0,365.0,4.0,74.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02171669,0.021713957372916603,2.732627083397443e-06
6.0,365.0,231.0,0.016438,0.016438,5.902633,0.22382,1.0,365.0,4.0,74.0,Poor/noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02171669,0.021716282816666616,4.0718333338407575e-07
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Poor/noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00361989,0.0036210993065475977,1.2093065475974815e-06
4.0,365.0,231.0,0.010959,0.010959,5.902633,0.22382,1.0,365.0,4.0,74.0,Poor/noncompliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01447824,0.014464267979176548,1.3972020823451586e-05
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Poor/noncompliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00361989,0.003620128005357119,2.3800535711888948e-07
4.0,365.0,231.0,0.010959,0.010959,5.902633,0.22382,1.0,365.0,4.0,74.0,Poor/noncompliance,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01447824,0.014455594189593215,2.264581040678504e-05
4.0,365.0,231.0,0.010959,0.010959,5.902633,0.22382,1.0,365.0,4.0,74.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01447824,0.014470624715605123,7.615284394876451e-06
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00723846,0.007251980250317437,1.3520250317436422e-05
5.0,365.0,231.0,0.013699,0.013699,5.902633,0.22382,1.0,365.0,4.0,74.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01809813,0.018331588723670647,0.0002334587236706466
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00361989,0.0036191384911309294,7.515088690708029e-07
3.0,365.0,231.0,0.008219,0.008219,5.902633,0.22382,1.0,365.0,4.0,74.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01085835,0.010844699151666642,1.3650848333357155e-05
3.0,365.0,231.0,0.008219,0.008219,5.902633,0.22382,1.0,365.0,4.0,74.0,Subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01085835,0.010847910714583313,1.0439285416686053e-05
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00361989,0.003620816467321407,9.26467321406884e-07
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Subject no longer meets study criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00723846,0.007246009461626949,7.549461626948396e-06
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Subject no longer meets study criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00723846,0.007248313802400762,9.853802400761925e-06
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Subject no longer meets study criteria,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00361989,0.0036198795262499766,1.0473750023526351e-08
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00361989,0.003617624512976174,2.2654870238262084e-06
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00361989,0.0036207117344642637,8.21734464263521e-07
2.0,365.0,231.0,0.005479,0.005479,5.902633,0.22382,1.0,365.0,4.0,74.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00723846,0.007250500398293619,1.2040398293618193e-05
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00361989,0.003619753618273785,1.3638172621528027e-07
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00361989,0.0036197879783928326,1.0202160716753228e-07
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00361989,0.0036226721825595026,2.782182559502456e-06
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Death,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Administrative reason by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Administrative reason by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,365.0,231.0,0.00274,0.00274,5.902633,0.22382,1.0,365.0,4.0,74.0,Administrative reason by sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00361989,0.0036204819642261664,5.91964226166232e-07
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Administrative reason by sponsor,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,231.0,0.0,0.0,5.902633,0.22382,1.0,365.0,4.0,74.0,Administrative reason by sponsor,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,641.0,564.0,0.020281,0.020281,6.464588,0.222813,1.0,641.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02921261,0.02906926704396824,0.0001433429560317584
5.0,641.0,564.0,0.0078,0.0078,6.464588,0.222813,1.0,641.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01123507,0.011353989348234127,0.00011891934823412761
0.0,641.0,564.0,0.0,0.0,6.464588,0.222813,1.0,641.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,641.0,564.0,0.00156,0.00156,6.464588,0.222813,1.0,641.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00224701,0.0023187521257079756,7.174212570797579e-05
4.0,641.0,564.0,0.00624,0.00624,6.464588,0.222813,1.0,641.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00898805,0.008982090040208337,5.959959791662639e-06
4.0,641.0,564.0,0.00624,0.00624,6.464588,0.222813,1.0,641.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00898805,0.008980563453779766,7.486546220233231e-06
2.0,641.0,564.0,0.00312,0.00312,6.464588,0.222813,1.0,641.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00449403,0.00442186721720239,7.216278279761033e-05
4.0,641.0,564.0,0.00624,0.00624,6.464588,0.222813,1.0,641.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00898805,0.008977063906279765,1.0986093720233986e-05
6.0,641.0,564.0,0.00936,0.00936,6.464588,0.222813,1.0,641.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01348208,0.013384681843452373,9.739815654762757e-05
8.0,641.0,564.0,0.01248,0.01248,6.464588,0.222813,1.0,641.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01797611,0.018069529931984126,9.341993198412613e-05
11.0,641.0,564.0,0.017161,0.017161,6.464588,0.222813,1.0,641.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02471859,0.025363127235337322,0.0006445372353373231
12.0,641.0,564.0,0.018721,0.018721,6.464588,0.222813,1.0,641.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0269656,0.02675161544408731,0.0002139845559126878
5.0,641.0,564.0,0.0078,0.0078,6.464588,0.222813,1.0,641.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01123507,0.011394420024940477,0.00015935002494047758
2.0,641.0,564.0,0.00312,0.00312,6.464588,0.222813,1.0,641.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00449403,0.004429614334583342,6.441566541665836e-05
3.0,219.0,205.0,0.013699,0.013699,5.393628,0.541513,1.0,219.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04001095,0.040691618595426624,0.0006806685954266201
5.0,219.0,205.0,0.022831,0.022831,5.393628,0.541513,1.0,219.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06668297,0.06779853174704369,0.0011155617470436918
0.0,219.0,205.0,0.0,0.0,5.393628,0.541513,1.0,219.0,1.0,38.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01333601,0.013343521290595241,7.511290595240555e-06
0.0,219.0,205.0,0.0,0.0,5.393628,0.541513,1.0,219.0,1.0,38.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01333601,0.013345301181130954,9.291181130953799e-06
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01333601,0.013330059386369055,5.950613630945761e-06
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01333601,0.013335341026309528,6.689736904725435e-07
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Per sponsor due to noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01333601,0.0133359749352381,3.506476190136276e-08
0.0,219.0,205.0,0.0,0.0,5.393628,0.541513,1.0,219.0,1.0,38.0,Per sponsor due to noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,219.0,205.0,0.0,0.0,5.393628,0.541513,1.0,219.0,1.0,38.0,Subject off study medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,219.0,205.0,0.004566,0.004566,5.393628,0.541513,1.0,219.0,1.0,38.0,Subject off study medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01333601,0.01333934959809524,3.3395980952397736e-06
12.0,1369.0,1238.0,0.008766,0.008766,7.222566,0.337801,1.0,1369.0,25.0,156.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02138722,0.021256653130922634,0.00013056686907736426
9.0,1369.0,1238.0,0.006574,0.006574,7.222566,0.337801,1.0,1369.0,25.0,156.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01603919,0.01624540421829367,0.00020621421829367104
4.0,1369.0,1238.0,0.002922,0.002922,7.222566,0.337801,1.0,1369.0,25.0,156.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00712907,0.007125869976607148,3.2000233928519695e-06
1.0,1369.0,1238.0,0.00073,0.00073,7.222566,0.337801,1.0,1369.0,25.0,156.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00178105,0.001787557319880951,6.5073198809511516e-06
10.0,1369.0,1238.0,0.007305,0.007305,7.222566,0.337801,1.0,1369.0,25.0,156.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01782268,0.017762779206527766,5.990079347223398e-05
5.0,1369.0,1238.0,0.003652,0.003652,7.222566,0.337801,1.0,1369.0,25.0,156.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00891012,0.008920738073710306,1.0618073710305653e-05
8.0,1369.0,1238.0,0.005844,0.005844,7.222566,0.337801,1.0,1369.0,25.0,156.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01425814,0.0143605901289484,0.00010245012894839929
2.0,1369.0,1238.0,0.001461,0.001461,7.222566,0.337801,1.0,1369.0,25.0,156.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00356454,0.003643180787480156,7.864078748015578e-05
28.0,1369.0,1238.0,0.020453,0.020453,7.222566,0.337801,1.0,1369.0,25.0,156.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04990106,0.04976034299312498,0.00014071700687501992
28.0,1369.0,1238.0,0.020453,0.020453,7.222566,0.337801,1.0,1369.0,25.0,156.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04990106,0.04978899853542657,0.00011206146457342497
8.0,1369.0,1238.0,0.005844,0.005844,7.222566,0.337801,1.0,1369.0,25.0,156.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01425814,0.014361720097103159,0.0001035800971031578
15.0,1369.0,1238.0,0.010957,0.010957,7.222566,0.337801,1.0,1369.0,25.0,156.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0267328,0.026596556254365078,0.00013624374563492303
1.0,1369.0,1238.0,0.00073,0.00073,7.222566,0.337801,1.0,1369.0,25.0,156.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00178105,0.001790616785119046,9.56678511904608e-06
0.0,1369.0,1238.0,0.0,0.0,7.222566,0.337801,1.0,1369.0,25.0,156.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
45.0,1551.0,1191.0,0.029014,0.029014,7.3473,1.0,1.0,1560.0,16.0,221.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.21317455,0.20792619713220237,0.005248352867797623
15.0,1551.0,1191.0,0.009671,0.009671,7.3473,1.0,1.0,1560.0,16.0,221.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07105574,0.06941622597419633,0.0016395140258036733
61.0,1551.0,1191.0,0.039329,0.039329,7.3473,1.0,1.0,1560.0,16.0,221.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.28896195,0.2766299434792166,0.012332006520783423
90.0,1551.0,1191.0,0.058027,0.058027,7.3473,1.0,1.0,1560.0,16.0,221.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.42634176,0.3802475514887693,0.046094208511230694
12.0,1551.0,1191.0,0.007737,0.007737,7.3473,1.0,1.0,1560.0,16.0,221.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05684606,0.056865415153412695,1.935515341269789e-05
5.0,1551.0,1191.0,0.003224,0.003224,7.3473,1.0,1.0,1560.0,16.0,221.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02368769,0.022883087746011905,0.0008046022539880959
11.0,1551.0,1191.0,0.007092,0.007092,7.3473,1.0,1.0,1560.0,16.0,221.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05210705,0.052498420970228166,0.0003913709702281637
13.0,1551.0,1191.0,0.008382,0.008382,7.3473,1.0,1.0,1560.0,16.0,221.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06158507,0.0615790933597222,5.976640277800815e-06
27.0,1551.0,1191.0,0.017408,0.017408,7.3473,1.0,1.0,1560.0,16.0,221.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12790179,0.1256367774406052,0.002265012559394791
24.0,1551.0,1191.0,0.015474,0.015474,7.3473,1.0,1.0,1560.0,16.0,221.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11369212,0.11393444213827374,0.00024232213827374283
33.0,1551.0,1191.0,0.021277,0.021277,7.3473,1.0,1.0,1560.0,16.0,221.0,Other reason (not specified),Overall Study,FG000,diabetes type 2,INDUSTRY,0.1563285,0.15257915562188487,0.003749344378115138
24.0,1551.0,1191.0,0.015474,0.015474,7.3473,1.0,1.0,1560.0,16.0,221.0,Other reason (not specified),Overall Study,FG001,diabetes type 2,INDUSTRY,0.11369212,0.11381083657797607,0.0001187165779760746
6.0,695.0,445.0,0.008633,0.008633,6.54535,0.49504,1.0,695.0,6.0,133.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02797272,0.02751414971673614,0.0004585702832638587
12.0,695.0,445.0,0.017266,0.017266,6.54535,0.49504,1.0,695.0,6.0,133.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05594544,0.05542121476148812,0.0005242252385118801
12.0,695.0,445.0,0.017266,0.017266,6.54535,0.49504,1.0,695.0,6.0,133.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05594544,0.05531556649964289,0.000629873500357106
2.0,695.0,445.0,0.002878,0.002878,6.54535,0.49504,1.0,695.0,6.0,133.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00932532,0.009292376448898828,3.29435511011722e-05
3.0,695.0,445.0,0.004317,0.004317,6.54535,0.49504,1.0,695.0,6.0,133.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01398798,0.013994086977549587,6.106977549586931e-06
1.0,695.0,445.0,0.001439,0.001439,6.54535,0.49504,1.0,695.0,6.0,133.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00466266,0.004676786039087286,1.4126039087286081e-05
14.0,695.0,445.0,0.020144,0.020144,6.54535,0.49504,1.0,695.0,6.0,133.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06527076,0.06569194457665678,0.0004211845766567829
14.0,695.0,445.0,0.020144,0.020144,6.54535,0.49504,1.0,695.0,6.0,133.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06527076,0.06547599773588297,0.00020523773588297656
21.0,695.0,445.0,0.030216,0.030216,6.54535,0.49504,1.0,695.0,6.0,133.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.09790614,0.09903973351934382,0.0011335935193438201
2.0,695.0,445.0,0.002878,0.002878,6.54535,0.49504,1.0,695.0,6.0,133.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00932532,0.009304381948303587,2.0938051696412635e-05
1.0,695.0,445.0,0.001439,0.001439,6.54535,0.49504,1.0,695.0,6.0,133.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00466266,0.004686717930367049,2.4057930367049098e-05
0.0,695.0,445.0,0.0,0.0,6.54535,0.49504,1.0,695.0,6.0,133.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,695.0,445.0,0.0,0.0,6.54535,0.49504,1.0,695.0,6.0,133.0,Patient Incorrectly Randomized,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,695.0,445.0,0.0,0.0,6.54535,0.49504,1.0,695.0,6.0,133.0,Patient Incorrectly Randomized,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,695.0,445.0,0.001439,0.001439,6.54535,0.49504,1.0,695.0,6.0,133.0,Patient Incorrectly Randomized,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00466266,0.004677366547748,1.470654774800035e-05
10.0,695.0,445.0,0.014388,0.014388,6.54535,0.49504,1.0,695.0,6.0,133.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04662012,0.04660159476483134,1.8525235168660725e-05
18.0,695.0,445.0,0.025899,0.025899,6.54535,0.49504,1.0,695.0,6.0,133.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08391816,0.08189153832919648,0.00202662167080353
15.0,695.0,445.0,0.021583,0.021583,6.54535,0.49504,1.0,695.0,6.0,133.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06993342,0.06925829340893852,0.0006751265910614757
42.0,695.0,445.0,0.060432,0.060432,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.19581229,0.1991375753793948,0.0033252853793948045
28.0,695.0,445.0,0.040288,0.040288,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.13054152,0.14005697928444438,0.009515459284444389
41.0,695.0,445.0,0.058993,0.058993,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.19114963,0.19606836474353176,0.004918734743531772
0.0,695.0,445.0,0.0,0.0,6.54535,0.49504,1.0,695.0,6.0,133.0,Study-Specific Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,695.0,445.0,0.001439,0.001439,6.54535,0.49504,1.0,695.0,6.0,133.0,Study-Specific Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00466266,0.004688523042867049,2.586304286704942e-05
3.0,695.0,445.0,0.004317,0.004317,6.54535,0.49504,1.0,695.0,6.0,133.0,Study-Specific Withdrawal Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01398798,0.013979265245466253,8.714754533747926e-06
2.0,695.0,445.0,0.002878,0.002878,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrew; No Record on Termination Page,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00932532,0.009293751486398827,3.156851360117292e-05
0.0,695.0,445.0,0.0,0.0,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrew; No Record on Termination Page,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,695.0,445.0,0.001439,0.001439,6.54535,0.49504,1.0,695.0,6.0,133.0,Withdrew; No Record on Termination Page,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00466266,0.004677366547748,1.470654774800035e-05
2.0,1012.0,965.0,0.001976,0.001976,6.920672,0.528936,1.0,1012.0,16.0,143.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00723333,0.007191546211071431,4.1783788928568405e-05
6.0,1012.0,965.0,0.005929,0.005929,6.920672,0.528936,1.0,1012.0,16.0,143.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02170364,0.021981979687351213,0.0002783396873512131
7.0,1012.0,965.0,0.006917,0.006917,6.920672,0.528936,1.0,1012.0,16.0,143.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0253203,0.025524055939345248,0.00020375593934524733
4.0,1012.0,965.0,0.003953,0.003953,6.920672,0.528936,1.0,1012.0,16.0,143.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01447031,0.014298803244880937,0.00017150675511906285
10.0,1012.0,965.0,0.009881,0.009881,6.920672,0.528936,1.0,1012.0,16.0,143.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0361703,0.03632159151083333,0.00015129151083332487
15.0,1012.0,965.0,0.014822,0.014822,6.920672,0.528936,1.0,1012.0,16.0,143.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05425727,0.052411029304503975,0.0018462406954960278
3.0,1012.0,965.0,0.002964,0.002964,6.920672,0.528936,1.0,1012.0,16.0,143.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01084999,0.011040703700009931,0.00019071370000993057
0.0,1012.0,965.0,0.0,0.0,6.920672,0.528936,1.0,1012.0,16.0,143.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,795.0,723.0,0.003774,0.003774,6.679599,0.874071,1.0,795.0,4.0,71.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02203428,0.022196063537172586,0.00016178353717258634
3.0,795.0,723.0,0.003774,0.003774,6.679599,0.874071,1.0,795.0,4.0,71.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02203428,0.022216253943839255,0.00018197394383925522
3.0,795.0,723.0,0.003774,0.003774,6.679599,0.874071,1.0,795.0,4.0,71.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02203428,0.022215174234553544,0.00018089423455354414
8.0,795.0,723.0,0.010063,0.010063,6.679599,0.874071,1.0,795.0,4.0,71.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05875224,0.05844693742373019,0.00030530257626981
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00734476,0.007364735707023835,1.9975707023835512e-05
2.0,795.0,723.0,0.002516,0.002516,6.679599,0.874071,1.0,795.0,4.0,71.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01468952,0.0148872117998611,0.0001976917998611008
2.0,795.0,723.0,0.002516,0.002516,6.679599,0.874071,1.0,795.0,4.0,71.0,Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01468952,0.01487955101646824,0.0001900310164682402
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00734476,0.007378537956190499,3.3777956190499635e-05
14.0,795.0,723.0,0.01761,0.01761,6.679599,0.874071,1.0,795.0,4.0,71.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10281496,0.10335874667319446,0.0005437866731944629
14.0,795.0,723.0,0.01761,0.01761,6.679599,0.874071,1.0,795.0,4.0,71.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10281496,0.1031827913846528,0.0003678313846528086
5.0,795.0,723.0,0.006289,0.006289,6.679599,0.874071,1.0,795.0,4.0,71.0,Assigned Treatment by Mistake,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03671796,0.03649946802815471,0.00021849197184529295
7.0,795.0,723.0,0.008805,0.008805,6.679599,0.874071,1.0,795.0,4.0,71.0,Assigned Treatment by Mistake,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05140748,0.05594790132591276,0.004540421325912765
4.0,795.0,723.0,0.005031,0.005031,6.679599,0.874071,1.0,795.0,4.0,71.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0293732,0.029739397090831527,0.00036619709083152846
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00734476,0.007378537956190499,3.3777956190499635e-05
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Due to Bariatric surgery,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00734476,0.007364232257023835,1.947225702383492e-05
0.0,795.0,723.0,0.0,0.0,6.679599,0.874071,1.0,795.0,4.0,71.0,Due to Bariatric surgery,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,795.0,723.0,0.0,0.0,6.679599,0.874071,1.0,795.0,4.0,71.0,Subject Moving out of State,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Subject Moving out of State,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00734476,0.007378537956190499,3.3777956190499635e-05
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,Subject Missed the Schedule,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00734476,0.007364232257023835,1.947225702383492e-05
0.0,795.0,723.0,0.0,0.0,6.679599,0.874071,1.0,795.0,4.0,71.0,Subject Missed the Schedule,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,795.0,723.0,0.001258,0.001258,6.679599,0.874071,1.0,795.0,4.0,71.0,The Patient Moved to Another City,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00734476,0.007364232257023835,1.947225702383492e-05
0.0,795.0,723.0,0.0,0.0,6.679599,0.874071,1.0,795.0,4.0,71.0,The Patient Moved to Another City,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Adverse Event,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.00590091,0.005909742791250002,8.832791250002435e-06
9.0,461.0,378.0,0.019523,0.019523,6.135565,0.44341,1.0,461.0,6.0,79.0,Adverse Event,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.05311367,0.05199059755074403,0.0011230724492559685
2.0,461.0,378.0,0.004338,0.004338,6.135565,0.44341,1.0,461.0,6.0,79.0,Discontinuation by the subject,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.01180183,0.011793869106140857,7.960893859142518e-06
2.0,461.0,378.0,0.004338,0.004338,6.135565,0.44341,1.0,461.0,6.0,79.0,Discontinuation by the subject,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.01180183,0.01180141457680644,4.15423193558459e-07
7.0,461.0,378.0,0.015184,0.015184,6.135565,0.44341,1.0,461.0,6.0,79.0,Withrawal of the consent by the subject,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.04130912,0.04174405641781749,0.00043493641781749276
10.0,461.0,378.0,0.021692,0.021692,6.135565,0.44341,1.0,461.0,6.0,79.0,Withrawal of the consent by the subject,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.05901459,0.0593575506200199,0.0003429606200198998
3.0,461.0,378.0,0.006508,0.006508,6.135565,0.44341,1.0,461.0,6.0,79.0,Lost to Follow-up,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.01770546,0.01767980743726195,2.565256273804814e-05
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Lost to Follow-up,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.00590091,0.005906719931279761,5.809931279761489e-06
5.0,461.0,378.0,0.010846,0.010846,6.135565,0.44341,1.0,461.0,6.0,79.0,Subject no longer meets study criteria,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.02950729,0.029575282499940462,6.799249994046339e-05
8.0,461.0,378.0,0.017354,0.017354,6.135565,0.44341,1.0,461.0,6.0,79.0,Subject no longer meets study criteria,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.04721276,0.047681767595099185,0.00046900759509918566
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Other,26 Week (Short Term),FG000,diabetes type 2,INDUSTRY,0.00590091,0.005906259426875001,5.3494268750014715e-06
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Other,26 Week (Short Term),FG001,diabetes type 2,INDUSTRY,0.00590091,0.005902465008958333,1.5550089583335133e-06
3.0,461.0,378.0,0.006508,0.006508,6.135565,0.44341,1.0,461.0,6.0,79.0,Adverse Event,52 Week (Long Term),FG000,diabetes type 2,INDUSTRY,0.01770546,0.017686030952381006,1.9429047618993445e-05
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Adverse Event,52 Week (Long Term),FG001,diabetes type 2,INDUSTRY,0.00590091,0.005906696770625001,5.786770625001124e-06
0.0,461.0,378.0,0.0,0.0,6.135565,0.44341,1.0,461.0,6.0,79.0,Subject no longer meets study criteria,52 Week (Long Term),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,378.0,0.002169,0.002169,6.135565,0.44341,1.0,461.0,6.0,79.0,Subject no longer meets study criteria,52 Week (Long Term),FG001,diabetes type 2,INDUSTRY,0.00590091,0.005904080313125001,3.1703131250010105e-06
4.0,461.0,378.0,0.008677,0.008677,6.135565,0.44341,1.0,461.0,6.0,79.0,Withrawal of the consent by the subject,52 Week (Long Term),FG000,diabetes type 2,INDUSTRY,0.02360638,0.02327965377194443,0.00032672622805557036
6.0,461.0,378.0,0.013015,0.013015,6.135565,0.44341,1.0,461.0,6.0,79.0,Withrawal of the consent by the subject,52 Week (Long Term),FG001,diabetes type 2,INDUSTRY,0.03540821,0.035744975883501964,0.00033676588350196185
2.0,461.0,378.0,0.004338,0.004338,6.135565,0.44341,1.0,461.0,6.0,79.0,Lost to Follow-up,52 Week (Long Term),FG000,diabetes type 2,INDUSTRY,0.01180183,0.011801948844404745,1.1884440474611846e-07
2.0,461.0,378.0,0.004338,0.004338,6.135565,0.44341,1.0,461.0,6.0,79.0,Lost to Follow-up,52 Week (Long Term),FG001,diabetes type 2,INDUSTRY,0.01180183,0.011810110590070328,8.280590070328803e-06
2.0,461.0,378.0,0.004338,0.004338,6.135565,0.44341,1.0,461.0,6.0,79.0,Non-Compliance,52 Week (Long Term),FG000,diabetes type 2,INDUSTRY,0.01180183,0.01180157938926585,2.506107341492675e-07
3.0,461.0,378.0,0.006508,0.006508,6.135565,0.44341,1.0,461.0,6.0,79.0,Non-Compliance,52 Week (Long Term),FG001,diabetes type 2,INDUSTRY,0.01770546,0.0176604274940179,4.5032505982100374e-05
11.0,858.0,312.0,0.012821,0.012821,6.755769,0.260419,1.0,891.0,11.0,94.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02255634,0.02201830088842262,0.0005380391115773799
13.0,858.0,312.0,0.015152,0.015152,6.755769,0.260419,1.0,891.0,11.0,94.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02665733,0.025713771808968257,0.0009435581910317431
27.0,858.0,312.0,0.031469,0.031469,6.755769,0.260419,1.0,891.0,11.0,94.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05536428,0.05440791474146823,0.0009563652585317731
31.0,858.0,312.0,0.036131,0.036131,6.755769,0.260419,1.0,891.0,11.0,94.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06356626,0.062334116862066115,0.0012321431379338846
1.0,858.0,312.0,0.001166,0.001166,6.755769,0.260419,1.0,891.0,11.0,94.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00205138,0.002050556892083345,8.231079166548354e-07
3.0,858.0,312.0,0.003497,0.003497,6.755769,0.260419,1.0,891.0,11.0,94.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00615237,0.0061482841713888835,4.085828611116379e-06
4.0,858.0,312.0,0.004662,0.004662,6.755769,0.260419,1.0,891.0,11.0,94.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00820198,0.008204901169920628,2.9211699206291297e-06
2.0,858.0,312.0,0.002331,0.002331,6.755769,0.260419,1.0,891.0,11.0,94.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00410099,0.004101343256626978,3.5325662697816007e-07
8.0,858.0,312.0,0.009324,0.009324,6.755769,0.260419,1.0,891.0,11.0,94.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01640397,0.016155289543819458,0.0002486804561805424
4.0,858.0,312.0,0.004662,0.004662,6.755769,0.260419,1.0,891.0,11.0,94.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00820198,0.008205868666884915,3.888666884915848e-06
203.0,858.0,312.0,0.236597,0.236597,6.755769,0.260419,1.0,891.0,11.0,94.0,Study specific discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.41625162,0.4200267776354741,0.0037751576354740912
218.0,858.0,312.0,0.254079,0.254079,6.755769,0.260419,1.0,891.0,11.0,94.0,Study specific discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.44700818,0.42719989771734906,0.019808282282650913
5.0,858.0,312.0,0.005828,0.005828,6.755769,0.260419,1.0,891.0,11.0,94.0,Severe non-compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01025336,0.010285006611230158,3.164661123015826e-05
7.0,858.0,312.0,0.008159,0.008159,6.755769,0.260419,1.0,891.0,11.0,94.0,Severe non-compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01435435,0.014354337920654764,1.2079345235865846e-08
2.0,858.0,312.0,0.002331,0.002331,6.755769,0.260419,1.0,891.0,11.0,94.0,Safety reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00410099,0.004097969680297613,3.0203197023863718e-06
1.0,858.0,312.0,0.001166,0.001166,6.755769,0.260419,1.0,891.0,11.0,94.0,Safety reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00205138,0.0020485835958234245,2.796404176575243e-06
1.0,858.0,312.0,0.001166,0.001166,6.755769,0.260419,1.0,891.0,11.0,94.0,Elevated triglyceride,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00205138,0.0020548562606845363,3.476260684536544e-06
0.0,858.0,312.0,0.0,0.0,6.755769,0.260419,1.0,891.0,11.0,94.0,Elevated triglyceride,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,858.0,312.0,0.001166,0.001166,6.755769,0.260419,1.0,891.0,11.0,94.0,Patient moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00205138,0.0020548562606845363,3.476260684536544e-06
3.0,858.0,312.0,0.003497,0.003497,6.755769,0.260419,1.0,891.0,11.0,94.0,Patient moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00615237,0.006151830385833331,5.396141666688323e-07
0.0,858.0,312.0,0.0,0.0,6.755769,0.260419,1.0,891.0,11.0,94.0,Impossible to determine HbA1c,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,858.0,312.0,0.001166,0.001166,6.755769,0.260419,1.0,891.0,11.0,94.0,Impossible to determine HbA1c,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00205138,0.0020485835958234245,2.796404176575243e-06
11.0,1091.0,529.0,0.010082,0.010082,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.01578632,0.01582174661985122,3.542661985122056e-05
23.0,1091.0,529.0,0.021082,0.021082,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.03301004,0.03273087892080891,0.00027916107919108424
29.0,1091.0,529.0,0.026581,0.026581,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.04162033,0.041192408014335304,0.00042792198566469347
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0028701,0.0028673263056547505,2.7736943452494507e-06
8.0,1091.0,529.0,0.007333,0.007333,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.01148196,0.011475101977239348,6.858022760651214e-06
19.0,1091.0,529.0,0.017415,0.017415,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.02726828,0.027398151286577365,0.00012987128657736616
8.0,1091.0,529.0,0.007333,0.007333,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.01148196,0.011469256479739348,1.2703520260651593e-05
13.0,1091.0,529.0,0.011916,0.011916,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.01865798,0.01849658601055556,0.0001613939894444423
29.0,1091.0,529.0,0.026581,0.026581,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.04162033,0.04117929433061506,0.0004410356693849357
9.0,1091.0,529.0,0.008249,0.008249,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.01291622,0.012782477790588926,0.00013374220941107448
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0028701,0.00286314382607142,6.956173928580108e-06
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0057402,0.005748806226607129,8.606226607129307e-06
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0057402,0.005744107319523795,3.907319523794618e-06
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0057402,0.005744897463273792,4.6974632737922795e-06
5.0,1091.0,529.0,0.004583,0.004583,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.00717603,0.007176780854593268,7.508545932684296e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lost to follow up,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lost to follow up,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.00143583,0.001435144786488109,6.85213511890945e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lost to follow up,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lost to follow up,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lost to follow up,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Poor compliance/Non-compliance,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Poor compliance/Non-compliance,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.00143583,0.001435144786488109,6.85213511890945e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Poor compliance/Non-compliance,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Poor compliance/Non-compliance,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Poor compliance/Non-compliance,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Consent withdrawn,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1091.0,529.0,0.00275,0.00275,6.995766,0.22382,1.0,1091.0,20.0,190.0,Consent withdrawn,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.00430593,0.004253037649553564,5.289235044643632e-05
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Consent withdrawn,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0057402,0.0057433901453571275,3.1901453571275135e-06
10.0,1091.0,529.0,0.009166,0.009166,6.995766,0.22382,1.0,1091.0,20.0,190.0,Consent withdrawn,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.01435205,0.013624439166273454,0.0007276108337265462
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Consent withdrawn,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0057402,0.005741321949226175,1.1219492261748537e-06
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Subject decision/No wish to continue,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,Subject decision/No wish to continue,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0028701,0.0028647279298214183,5.3720701785817115e-06
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Subject decision/No wish to continue,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.00143583,0.0014360902667262053,2.602667262053323e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Subject decision/No wish to continue,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,Subject decision/No wish to continue,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0028701,0.0028683941914880843,1.7058085119156866e-06
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Move,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Move,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.00143583,0.001435144786488109,6.85213511890945e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Move,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Move,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Move,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Tendency to low blood glucose levels,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Tendency to low blood glucose levels,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Tendency to low blood glucose levels,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Tendency to low blood glucose levels,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Tendency to low blood glucose levels,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.00143583,0.0014349926971428716,8.373028571283248e-07
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,FPG exceeds limits/too high,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.00143583,0.0014362254161309662,3.954161309663133e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,FPG exceeds limits/too high,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,FPG exceeds limits/too high,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,FPG exceeds limits/too high,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0028701,0.002867644838988084,2.455161011916205e-06
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,FPG exceeds limits/too high,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Work commitment,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Work commitment,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Work commitment,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Work commitment,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Work commitment,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.00143583,0.0014349926971428716,8.373028571283248e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Investigator decision,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Investigator decision,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Investigator decision,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Investigator decision,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Investigator decision,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.00143583,0.0014349926971428716,8.373028571283248e-07
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of time,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.00143583,0.0014362254161309662,3.954161309663133e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of time,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of time,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of time,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of time,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hypoglycaemia/Hypoglycemia,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hypoglycaemia/Hypoglycemia,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hypoglycaemia/Hypoglycemia,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hypoglycaemia/Hypoglycemia,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1091.0,529.0,0.001833,0.001833,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hypoglycaemia/Hypoglycemia,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0028701,0.002867474691488084,2.625308511916124e-06
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hyperglicaemia,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hyperglicaemia,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hyperglicaemia,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hyperglicaemia,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.00143583,0.0014360902667262053,2.602667262053323e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Hyperglicaemia,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,metformin titrated <1500 mg or >2000 mg,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,metformin titrated <1500 mg or >2000 mg,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,metformin titrated <1500 mg or >2000 mg,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,metformin titrated <1500 mg or >2000 mg,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,metformin titrated <1500 mg or >2000 mg,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.00143583,0.0014349926971428716,8.373028571283248e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Fear of experiencing AE again,"Double-Blind, 6 Months",FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Fear of experiencing AE again,"Double-Blind, 6 Months",FG001,diabetes type 2,INDUSTRY,0.00143583,0.001435144786488109,6.85213511890945e-07
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Fear of experiencing AE again,"Double-Blind, 6 Months",FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Fear of experiencing AE again,"Double-Blind, 6 Months",FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1091.0,529.0,0.0,0.0,6.995766,0.22382,1.0,1091.0,20.0,190.0,Fear of experiencing AE again,"Double-Blind, 6 Months",FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
19.0,1091.0,529.0,0.017415,0.017415,6.995766,0.22382,1.0,1091.0,20.0,190.0,Withdrawals between 6 and 24 months,"Open-Label Extension, 18 Months",FG000,diabetes type 2,INDUSTRY,0.02726828,0.027375566805148795,0.00010728680514879643
14.0,1091.0,529.0,0.012832,0.012832,6.995766,0.22382,1.0,1091.0,20.0,190.0,Withdrawals between 6 and 24 months,"Open-Label Extension, 18 Months",FG001,diabetes type 2,INDUSTRY,0.02009225,0.01993953540216269,0.00015271459783730915
27.0,1091.0,529.0,0.024748,0.024748,6.995766,0.22382,1.0,1091.0,20.0,190.0,Withdrawals between 6 and 24 months,"Open-Label Extension, 18 Months",FG002,diabetes type 2,INDUSTRY,0.03875023,0.03881080796136813,6.0577961368130095e-05
11.0,1091.0,529.0,0.010082,0.010082,6.995766,0.22382,1.0,1091.0,20.0,190.0,Withdrawals between 6 and 24 months,"Open-Label Extension, 18 Months",FG003,diabetes type 2,INDUSTRY,0.01578632,0.015809314623333365,2.2994623333365966e-05
22.0,1091.0,529.0,0.020165,0.020165,6.995766,0.22382,1.0,1091.0,20.0,190.0,Withdrawals between 6 and 24 months,"Open-Label Extension, 18 Months",FG004,diabetes type 2,INDUSTRY,0.03157421,0.03144409473529762,0.00013011526470237816
11.0,1091.0,529.0,0.010082,0.010082,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Open-Label Extension, 18 Months",FG000,diabetes type 2,INDUSTRY,0.01578632,0.015816302119434564,2.9982119434564247e-05
8.0,1091.0,529.0,0.007333,0.007333,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Open-Label Extension, 18 Months",FG001,diabetes type 2,INDUSTRY,0.01148196,0.011467593568072676,1.43664319273238e-05
6.0,1091.0,529.0,0.0055,0.0055,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Open-Label Extension, 18 Months",FG002,diabetes type 2,INDUSTRY,0.00861186,0.008613469875952358,1.609875952357162e-06
1.0,1091.0,529.0,0.000917,0.000917,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Open-Label Extension, 18 Months",FG003,diabetes type 2,INDUSTRY,0.00143583,0.0014362736522023942,4.4365220239423256e-07
6.0,1091.0,529.0,0.0055,0.0055,6.995766,0.22382,1.0,1091.0,20.0,190.0,Adverse Event,"Open-Label Extension, 18 Months",FG004,diabetes type 2,INDUSTRY,0.00861186,0.008612603773035686,7.437730356850414e-07
41.0,1091.0,529.0,0.03758,0.03758,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Open-Label Extension, 18 Months",FG000,diabetes type 2,INDUSTRY,0.05884248,0.059347622065009896,0.0005051420650098934
33.0,1091.0,529.0,0.030247,0.030247,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Open-Label Extension, 18 Months",FG001,diabetes type 2,INDUSTRY,0.04736053,0.04633074333022814,0.0010297866697718608
37.0,1091.0,529.0,0.033914,0.033914,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Open-Label Extension, 18 Months",FG002,diabetes type 2,INDUSTRY,0.05310229,0.05327338040682625,0.00017109040682624505
27.0,1091.0,529.0,0.024748,0.024748,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Open-Label Extension, 18 Months",FG003,diabetes type 2,INDUSTRY,0.03875023,0.038807463540862175,5.7233540862178245e-05
63.0,1091.0,529.0,0.057745,0.057745,6.995766,0.22382,1.0,1091.0,20.0,190.0,Lack of Efficacy,"Open-Label Extension, 18 Months",FG004,diabetes type 2,INDUSTRY,0.09041669,0.09079307747078527,0.0003763874707852777
7.0,1091.0,529.0,0.006416,0.006416,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Open-Label Extension, 18 Months",FG000,diabetes type 2,INDUSTRY,0.01004612,0.01002639546607864,1.9724533921360726e-05
5.0,1091.0,529.0,0.004583,0.004583,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Open-Label Extension, 18 Months",FG001,diabetes type 2,INDUSTRY,0.00717603,0.0071802602641766015,4.2302641766016336e-06
3.0,1091.0,529.0,0.00275,0.00275,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Open-Label Extension, 18 Months",FG002,diabetes type 2,INDUSTRY,0.00430593,0.004258110511755946,4.781948824405472e-05
4.0,1091.0,529.0,0.003666,0.003666,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Open-Label Extension, 18 Months",FG003,diabetes type 2,INDUSTRY,0.0057402,0.005748172971607128,7.972971607128274e-06
6.0,1091.0,529.0,0.0055,0.0055,6.995766,0.22382,1.0,1091.0,20.0,190.0,Protocol Violation,"Open-Label Extension, 18 Months",FG004,diabetes type 2,INDUSTRY,0.00861186,0.008608074832678544,3.7851673214562426e-06
61.0,14671.0,13877.0,0.004158,0.004158,9.593696,0.390063,1.0,14671.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01555986,0.015332779763303573,0.00022708023669642738
71.0,14671.0,13877.0,0.004839,0.004839,9.593696,0.390063,1.0,14671.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01810827,0.01690082758375,0.0012074424162499993
299.0,14671.0,13877.0,0.02038,0.02038,9.593696,0.390063,1.0,14671.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07626503,0.07557447342654751,0.0006905565734524888
363.0,14671.0,13877.0,0.024743,0.024743,9.593696,0.390063,1.0,14671.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09259203,0.08750345081364085,0.00508857918635916
16.0,441.0,258.0,0.036281,0.036281,6.09131,0.260419,1.0,441.0,11.0,80.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05755219,0.057764397853035575,0.00021220785303557171
20.0,441.0,258.0,0.045351,0.045351,6.09131,0.260419,1.0,441.0,11.0,80.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07193984,0.07116239190613101,0.0007774480938689959
4.0,441.0,258.0,0.00907,0.00907,6.09131,0.260419,1.0,441.0,11.0,80.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01438765,0.014303428310565476,8.4221689434524e-05
7.0,441.0,258.0,0.015873,0.015873,6.09131,0.260419,1.0,441.0,11.0,80.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02517918,0.024619176750267844,0.000560003249732155
0.0,441.0,258.0,0.0,0.0,6.09131,0.260419,1.0,441.0,11.0,80.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,441.0,258.0,0.00907,0.00907,6.09131,0.260419,1.0,441.0,11.0,80.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01438765,0.014320268441458332,6.738155854166782e-05
12.0,441.0,258.0,0.027211,0.027211,6.09131,0.260419,1.0,441.0,11.0,80.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04316454,0.042974942256607154,0.00018959774339284696
16.0,441.0,258.0,0.036281,0.036281,6.09131,0.260419,1.0,441.0,11.0,80.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05755219,0.05766559345042647,0.00011340345042646499
55.0,441.0,258.0,0.124717,0.124717,6.09131,0.260419,1.0,441.0,11.0,80.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.19783734,0.1901798612084963,0.007657478791503691
47.0,441.0,258.0,0.106576,0.106576,6.09131,0.260419,1.0,441.0,11.0,80.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.16906045,0.16495710860898716,0.0041033413910128436
2.0,441.0,258.0,0.004535,0.004535,6.09131,0.260419,1.0,441.0,11.0,80.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00719383,0.0071595338428815,3.4296157118500134e-05
0.0,441.0,258.0,0.0,0.0,6.09131,0.260419,1.0,441.0,11.0,80.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,427.0,394.0,0.025761,0.025761,6.059123,0.281906,1.0,427.0,1.0,22.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04400249,0.04348719802937499,0.000515291970625005
6.0,427.0,394.0,0.014052,0.014052,6.059123,0.281906,1.0,427.0,1.0,22.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02400229,0.024062511168402773,6.0221168402773556e-05
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00400038,0.003995040461647716,5.3395383522846646e-06
0.0,427.0,394.0,0.0,0.0,6.059123,0.281906,1.0,427.0,1.0,22.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00400038,0.0039986620625405735,1.7179374594269645e-06
0.0,427.0,394.0,0.0,0.0,6.059123,0.281906,1.0,427.0,1.0,22.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00400038,0.003995937669564382,4.4423304356184384e-06
2.0,427.0,394.0,0.004684,0.004684,6.059123,0.281906,1.0,427.0,1.0,22.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00800076,0.00798103414107142,1.972585892858099e-05
2.0,427.0,394.0,0.004684,0.004684,6.059123,0.281906,1.0,427.0,1.0,22.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00800076,0.007983742317351184,1.7017682648817062e-05
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00400038,0.004009856714682531,9.47671468253062e-06
2.0,427.0,394.0,0.004684,0.004684,6.059123,0.281906,1.0,427.0,1.0,22.0,Subject Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00800076,0.00797716436985118,2.359563014882153e-05
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Subject Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00400038,0.004004857955318349,4.47795531834886e-06
0.0,427.0,394.0,0.0,0.0,6.059123,0.281906,1.0,427.0,1.0,22.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,427.0,394.0,0.002342,0.002342,6.059123,0.281906,1.0,427.0,1.0,22.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00400038,0.004004857955318349,4.47795531834886e-06
4.0,427.0,394.0,0.009368,0.009368,6.059123,0.281906,1.0,427.0,1.0,22.0,Loss Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01600153,0.015984341930952373,1.718806904762657e-05
0.0,427.0,394.0,0.0,0.0,6.059123,0.281906,1.0,427.0,1.0,22.0,Loss Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,458.0,448.0,0.0,0.0,6.12905,0.35786,1.0,458.0,1.0,40.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,458.0,448.0,0.0,0.0,6.12905,0.35786,1.0,458.0,1.0,40.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,458.0,448.0,0.0,0.0,6.12905,0.35786,1.0,458.0,1.0,40.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,458.0,448.0,0.002183,0.002183,6.12905,0.35786,1.0,458.0,1.0,40.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00478806,0.004814768011294414,2.670801129441361e-05
1.0,458.0,448.0,0.002183,0.002183,6.12905,0.35786,1.0,458.0,1.0,40.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00478806,0.004820067490306697,3.200749030669685e-05
2.0,458.0,448.0,0.004367,0.004367,6.12905,0.35786,1.0,458.0,1.0,40.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00957831,0.009696500445248007,0.00011819044524800752
1.0,458.0,448.0,0.002183,0.002183,6.12905,0.35786,1.0,458.0,1.0,40.0,Withdrawal Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00478806,0.004815426537782508,2.7366537782507784e-05
5.0,458.0,448.0,0.010917,0.010917,6.12905,0.35786,1.0,458.0,1.0,40.0,Withdrawal Criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02394469,0.023987560267589286,4.287026758928447e-05
1.0,543.0,518.0,0.001842,0.001842,6.298949,0.472984,1.0,543.0,1.0,42.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00548787,0.005527063506965508,3.91935069655085e-05
6.0,543.0,518.0,0.01105,0.01105,6.298949,0.472984,1.0,543.0,1.0,42.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03292128,0.03274878586173609,0.00017249413826390947
4.0,543.0,518.0,0.007366,0.007366,6.298949,0.472984,1.0,543.0,1.0,42.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02194554,0.021886475399553584,5.9064600446415844e-05
2.0,543.0,518.0,0.003683,0.003683,6.298949,0.472984,1.0,543.0,1.0,42.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01097277,0.01112202330825383,0.00014925330825383068
4.0,543.0,518.0,0.007366,0.007366,6.298949,0.472984,1.0,543.0,1.0,42.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02194554,0.021862502693184536,8.303730681546301e-05
2.0,543.0,518.0,0.003683,0.003683,6.298949,0.472984,1.0,543.0,1.0,42.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01097277,0.011144046025674465,0.00017127602567446575
6.0,543.0,518.0,0.01105,0.01105,6.298949,0.472984,1.0,543.0,1.0,42.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03292128,0.03283831356804561,8.296643195438574e-05
0.0,543.0,518.0,0.0,0.0,6.298949,0.472984,1.0,543.0,1.0,42.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,597.0,527.0,0.0134,0.0134,6.393591,0.54177,1.0,597.0,7.0,82.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0464157,0.04569662821537542,0.0007190717846245753
6.0,597.0,527.0,0.01005,0.01005,6.393591,0.54177,1.0,597.0,7.0,82.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03481177,0.03437772486129579,0.0004340451387042088
0.0,597.0,527.0,0.0,0.0,6.393591,0.54177,1.0,597.0,7.0,82.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,597.0,527.0,0.0067,0.0067,6.393591,0.54177,1.0,597.0,7.0,82.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02320785,0.023367518070902777,0.0001596680709027784
6.0,597.0,527.0,0.01005,0.01005,6.393591,0.54177,1.0,597.0,7.0,82.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03481177,0.03424709504962912,0.0005646749503708803
2.0,597.0,527.0,0.00335,0.00335,6.393591,0.54177,1.0,597.0,7.0,82.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01160392,0.011716202238333352,0.00011228223833335133
1.0,597.0,527.0,0.001675,0.001675,6.393591,0.54177,1.0,597.0,7.0,82.0,Non-serious Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00580196,0.0058989026932305235,9.694269323052337e-05
0.0,597.0,527.0,0.0,0.0,6.393591,0.54177,1.0,597.0,7.0,82.0,Non-serious Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
22.0,597.0,527.0,0.036851,0.036851,6.393591,0.54177,1.0,597.0,7.0,82.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12764663,0.12713908110403785,0.0005075488959621621
21.0,597.0,527.0,0.035176,0.035176,6.393591,0.54177,1.0,597.0,7.0,82.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12184467,0.12166322012943462,0.00018144987056538386
1.0,7437.0,7334.0,0.000134,0.000134,8.914357,0.647651,1.0,7352.0,48.0,975.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00077363,0.000782636025605159,9.00602560515904e-06
7.0,7437.0,7334.0,0.000941,0.000941,8.914357,0.647651,1.0,7352.0,48.0,975.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00543276,0.004809830464285718,0.0006229295357142823
4.0,7437.0,7334.0,0.000538,0.000538,8.914357,0.647651,1.0,7352.0,48.0,975.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00310608,0.0029671098293055542,0.00013897017069444597
6.0,7437.0,7334.0,0.000807,0.000807,8.914357,0.647651,1.0,7352.0,48.0,975.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00465912,0.004264947826130953,0.0003941721738690467
37.0,7437.0,7334.0,0.004975,0.004975,8.914357,0.647651,1.0,7352.0,48.0,975.0,GCP violations,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02872261,0.02819350076080353,0.000529109239196468
48.0,7437.0,7334.0,0.006454,0.006454,8.914357,0.647651,1.0,7352.0,48.0,975.0,GCP violations,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03726145,0.0352270387503373,0.0020344112496627
228.0,8246.0,7212.0,0.02765,0.02765,9.017605,0.588565,1.0,8246.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.14675093,0.143530428052051,0.0032205019479490116
233.0,8246.0,7212.0,0.028256,0.028256,9.017605,0.588565,1.0,8246.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.14996724,0.1453361342857414,0.004631105714258593
247.0,8246.0,7212.0,0.029954,0.029954,9.017605,0.588565,1.0,8246.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.15897929,0.15433256228404482,0.004646727715955173
51.0,8246.0,7212.0,0.006185,0.006185,9.017605,0.588565,1.0,8246.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03282656,0.03236450813468251,0.0004620518653174893
44.0,8246.0,7212.0,0.005336,0.005336,9.017605,0.588565,1.0,8246.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02832054,0.028840411887738105,0.0005198718877381034
55.0,8246.0,7212.0,0.00667,0.00667,9.017605,0.588565,1.0,8246.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03540068,0.034803497809375014,0.0005971821906249827
7.0,8246.0,7212.0,0.000849,0.000849,9.017605,0.588565,1.0,8246.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00450602,0.004161522712351192,0.00034449728764880845
4.0,8246.0,7212.0,0.000485,0.000485,9.017605,0.588565,1.0,8246.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00257411,0.00261243053451389,3.8320534513889854e-05
6.0,8246.0,7212.0,0.000728,0.000728,9.017605,0.588565,1.0,8246.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00386382,0.0036769032000496093,0.00018691679995039073
2.0,8246.0,7212.0,0.000243,0.000243,9.017605,0.588565,1.0,8246.0,0.0,0.0,Study Site Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00128971,0.001292287700257936,2.5777002579361902e-06
2.0,8246.0,7212.0,0.000243,0.000243,9.017605,0.588565,1.0,8246.0,0.0,0.0,Study Site Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00128971,0.0012868903952579357,2.819604742064193e-06
3.0,8246.0,7212.0,0.000364,0.000364,9.017605,0.588565,1.0,8246.0,0.0,0.0,Study Site Terminated by Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00193191,0.0019293453501984122,2.564649801587793e-06
41.0,8246.0,7212.0,0.004972,0.004972,9.017605,0.588565,1.0,8246.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02638863,0.024875803000505976,0.001512826999494024
60.0,8246.0,7212.0,0.007276,0.007276,9.017605,0.588565,1.0,8246.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03861699,0.03674413250953374,0.0018728574904662565
45.0,8246.0,7212.0,0.005457,0.005457,9.017605,0.588565,1.0,8246.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02896274,0.029445098832083353,0.0004823588320833523
0.0,8246.0,7212.0,0.0,0.0,9.017605,0.588565,1.0,8246.0,0.0,0.0,Subject Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,8246.0,7212.0,0.000121,0.000121,9.017605,0.588565,1.0,8246.0,0.0,0.0,Subject Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0006422,0.0006807282904861122,3.852829048611218e-05
0.0,8246.0,7212.0,0.0,0.0,9.017605,0.588565,1.0,8246.0,0.0,0.0,Subject Moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,8246.0,7212.0,0.000121,0.000121,9.017605,0.588565,1.0,8246.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0006422,0.0006837885500694455,4.158855006944546e-05
2.0,8246.0,7212.0,0.000243,0.000243,9.017605,0.588565,1.0,8246.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00128971,0.0012851893471031743,4.520652896825624e-06
2.0,8246.0,7212.0,0.000243,0.000243,9.017605,0.588565,1.0,8246.0,0.0,0.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00128971,0.0012904499908531744,7.399908531745009e-07
15.0,691.0,573.0,0.021708,0.021708,6.539586,0.275882,1.0,691.0,5.0,42.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03916458,0.038848928416597185,0.0003156515834028123
36.0,691.0,573.0,0.052098,0.052098,6.539586,0.275882,1.0,691.0,5.0,42.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09399282,0.09398552567160712,7.294328392887239e-06
2.0,691.0,573.0,0.002894,0.002894,6.539586,0.275882,1.0,691.0,5.0,42.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00522122,0.005212500602430547,8.719397569452968e-06
4.0,691.0,573.0,0.005789,0.005789,6.539586,0.275882,1.0,691.0,5.0,42.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01044425,0.010527166988611093,8.291698861109288e-05
9.0,691.0,573.0,0.013025,0.013025,6.539586,0.275882,1.0,691.0,5.0,42.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02349911,0.023313790445305734,0.00018531955469426598
18.0,691.0,573.0,0.026049,0.026049,6.539586,0.275882,1.0,691.0,5.0,42.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04699641,0.04485067852526785,0.0021457314747321543
5.0,691.0,573.0,0.007236,0.007236,6.539586,0.275882,1.0,691.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01305486,0.013077094403551585,2.2234403551585694e-05
12.0,691.0,573.0,0.017366,0.017366,6.539586,0.275882,1.0,691.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03133094,0.031610256874930555,0.0002793168749305533
0.0,691.0,573.0,0.0,0.0,6.539586,0.275882,1.0,691.0,5.0,42.0,Lost to follow up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,691.0,573.0,0.002894,0.002894,6.539586,0.275882,1.0,691.0,5.0,42.0,Lost to follow up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00522122,0.005211561135486103,9.658864513897164e-06
1.0,691.0,573.0,0.001447,0.001447,6.539586,0.275882,1.0,691.0,5.0,42.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00261061,0.0026977684226190484,8.71584226190482e-05
0.0,691.0,573.0,0.0,0.0,6.539586,0.275882,1.0,691.0,5.0,42.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,691.0,573.0,0.007236,0.007236,6.539586,0.275882,1.0,691.0,5.0,42.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01305486,0.013077548868134921,2.2688868134921464e-05
5.0,691.0,573.0,0.007236,0.007236,6.539586,0.275882,1.0,691.0,5.0,42.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01305486,0.013100377637063494,4.55176370634941e-05
2.0,691.0,573.0,0.002894,0.002894,6.539586,0.275882,1.0,691.0,5.0,42.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00522122,0.005214860962430545,6.359037569455411e-06
2.0,691.0,573.0,0.002894,0.002894,6.539586,0.275882,1.0,691.0,5.0,42.0,Lack of Efficacy-Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00522122,0.005213907075486102,7.312924513898367e-06
5.0,460.0,401.0,0.01087,0.01087,6.133398,0.266168,1.0,460.0,8.0,116.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01774545,0.01781814507889877,7.269507889877055e-05
4.0,460.0,401.0,0.008696,0.008696,6.133398,0.266168,1.0,460.0,8.0,116.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01419636,0.01432675258345239,0.00013039258345239058
0.0,460.0,401.0,0.0,0.0,6.133398,0.266168,1.0,460.0,8.0,116.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,460.0,401.0,0.004348,0.004348,6.133398,0.266168,1.0,460.0,8.0,116.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00709818,0.007112541676874974,1.4361676874973667e-05
5.0,460.0,401.0,0.01087,0.01087,6.133398,0.266168,1.0,460.0,8.0,116.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01774545,0.017810343762648746,6.489376264874613e-05
2.0,460.0,401.0,0.004348,0.004348,6.133398,0.266168,1.0,460.0,8.0,116.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00709818,0.00712674890913688,2.856890913688001e-05
3.0,460.0,401.0,0.006522,0.006522,6.133398,0.266168,1.0,460.0,8.0,116.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01064727,0.010655062764523804,7.792764523803161e-06
9.0,460.0,401.0,0.019565,0.019565,6.133398,0.266168,1.0,460.0,8.0,116.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03194018,0.03195792445431545,1.7744454315453406e-05
17.0,460.0,401.0,0.036957,0.036957,6.133398,0.266168,1.0,460.0,8.0,116.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06033291,0.06093934612166664,0.0006064361216666439
12.0,460.0,401.0,0.026087,0.026087,6.133398,0.266168,1.0,460.0,8.0,116.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04258746,0.04267595921949402,8.849921949401901e-05
3.0,961.0,933.0,0.003122,0.003122,6.869014,0.634714,1.0,961.0,11.0,129.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01361148,0.013708684955376093,9.720495537609251e-05
10.0,961.0,933.0,0.010406,0.010406,6.869014,0.634714,1.0,961.0,11.0,129.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04536868,0.04653209845987098,0.001163418459870981
6.0,961.0,933.0,0.006243,0.006243,6.869014,0.634714,1.0,961.0,11.0,129.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02721859,0.027281015877926598,6.242587792659737e-05
6.0,961.0,933.0,0.006243,0.006243,6.869014,0.634714,1.0,961.0,11.0,129.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02721859,0.027419530962569466,0.00020094096256946525
1.0,961.0,933.0,0.001041,0.001041,6.869014,0.634714,1.0,961.0,11.0,129.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00453861,0.004652206889821427,0.00011359688982142714
2.0,961.0,933.0,0.002081,0.002081,6.869014,0.634714,1.0,961.0,11.0,129.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00907286,0.009182314313690473,0.00010945431369047305
2.0,303.0,298.0,0.006601,0.006601,5.717028,0.510676,1.0,303.0,7.0,82.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01927193,0.019601186187699293,0.0003292561876992936
0.0,303.0,298.0,0.0,0.0,5.717028,0.510676,1.0,303.0,7.0,82.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,303.0,298.0,0.0033,0.0033,5.717028,0.510676,1.0,303.0,7.0,82.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00963451,0.009740491851726197,0.0001059818517261963
2.0,303.0,298.0,0.006601,0.006601,5.717028,0.510676,1.0,303.0,7.0,82.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01927193,0.01962603238804562,0.0003541023880456219
1.0,377.0,275.0,0.002653,0.002653,5.934894,0.368375,1.0,377.0,1.0,58.0,Loss of glucose control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00580016,0.005818384718511912,1.822471851191127e-05
0.0,377.0,275.0,0.0,0.0,5.934894,0.368375,1.0,377.0,1.0,58.0,Loss of glucose control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,377.0,275.0,0.0,0.0,5.934894,0.368375,1.0,377.0,1.0,58.0,Administrative,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,377.0,275.0,0.005305,0.005305,5.934894,0.368375,1.0,377.0,1.0,58.0,Administrative,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01159814,0.011631714741904744,3.357474190474399e-05
1.0,377.0,275.0,0.002653,0.002653,5.934894,0.368375,1.0,377.0,1.0,58.0,Investigator decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00580016,0.005818384718511912,1.822471851191127e-05
4.0,377.0,275.0,0.01061,0.01061,5.934894,0.368375,1.0,377.0,1.0,58.0,Investigator decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02319628,0.02345361238723215,0.0002573323872321516
12.0,377.0,275.0,0.03183,0.03183,5.934894,0.368375,1.0,377.0,1.0,58.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06958884,0.06872898820542664,0.0008598517945733603
11.0,377.0,275.0,0.029178,0.029178,5.934894,0.368375,1.0,377.0,1.0,58.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06379087,0.06419905762863094,0.00040818762863094327
2.0,377.0,275.0,0.005305,0.005305,5.934894,0.368375,1.0,377.0,1.0,58.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01159814,0.011634247713154746,3.610771315474583e-05
1.0,377.0,275.0,0.002653,0.002653,5.934894,0.368375,1.0,377.0,1.0,58.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00580016,0.005815085462738101,1.4925462738100276e-05
7.0,377.0,275.0,0.018568,0.018568,5.934894,0.368375,1.0,377.0,1.0,58.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04059459,0.040452591279131464,0.00014199872086853582
10.0,377.0,275.0,0.026525,0.026525,5.934894,0.368375,1.0,377.0,1.0,58.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0579907,0.05590143744049611,0.002089262559503889
33.0,377.0,275.0,0.087533,0.087533,5.934894,0.368375,1.0,377.0,1.0,58.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.19137041,0.1959790240309919,0.004608614030991914
18.0,377.0,275.0,0.047745,0.047745,5.934894,0.368375,1.0,377.0,1.0,58.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10438327,0.10531061812728179,0.0009273481272817907
2.0,435.0,394.0,0.004598,0.004598,6.077642,0.269027,1.0,435.0,6.0,53.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00751795,0.007490859342661447,2.709065733855296e-05
3.0,435.0,394.0,0.006897,0.006897,6.077642,0.269027,1.0,435.0,6.0,53.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01127693,0.011325224166507976,4.829416650797662e-05
1.0,435.0,394.0,0.002299,0.002299,6.077642,0.269027,1.0,435.0,6.0,53.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00375898,0.003707475773541659,5.1504226458340754e-05
0.0,435.0,394.0,0.0,0.0,6.077642,0.269027,1.0,435.0,6.0,53.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,435.0,394.0,0.006897,0.006897,6.077642,0.269027,1.0,435.0,6.0,53.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01127693,0.011344225074603203,6.729507460320402e-05
2.0,435.0,394.0,0.004598,0.004598,6.077642,0.269027,1.0,435.0,6.0,53.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00751795,0.007504741062215017,1.3208937784983145e-05
13.0,435.0,394.0,0.029885,0.029885,6.077642,0.269027,1.0,435.0,6.0,53.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04886343,0.04902428026369322,0.00016085026369322408
2.0,435.0,394.0,0.004598,0.004598,6.077642,0.269027,1.0,435.0,6.0,53.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00751795,0.007504621780131683,1.332821986831708e-05
12.0,435.0,394.0,0.027586,0.027586,6.077642,0.269027,1.0,435.0,6.0,53.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04510446,0.04482872524467267,0.00027573475532732816
3.0,435.0,394.0,0.006897,0.006897,6.077642,0.269027,1.0,435.0,6.0,53.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01127693,0.011325099127162744,4.816912716274456e-05
6.0,300.0,272.0,0.02,0.02,5.70711,0.407575,1.0,300.0,7.0,40.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04652149,0.04629548706167654,0.00022600293832345658
2.0,300.0,272.0,0.006667,0.006667,5.70711,0.407575,1.0,300.0,7.0,40.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01550794,0.015566595983749978,5.865598374997852e-05
3.0,300.0,272.0,0.01,0.01,5.70711,0.407575,1.0,300.0,7.0,40.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02326075,0.02321934221742069,4.140778257931063e-05
7.0,300.0,272.0,0.023333,0.023333,5.70711,0.407575,1.0,300.0,7.0,40.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0542743,0.05387453523312503,0.00039976476687497015
2.0,300.0,272.0,0.006667,0.006667,5.70711,0.407575,1.0,300.0,7.0,40.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01550794,0.015549340105771985,4.1400105771985385e-05
3.0,300.0,272.0,0.01,0.01,5.70711,0.407575,1.0,300.0,7.0,40.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02326075,0.023207878203908783,5.287179609121673e-05
1.0,300.0,272.0,0.003333,0.003333,5.70711,0.407575,1.0,300.0,7.0,40.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00775281,0.007748541004781737,4.268995218262815e-06
0.0,300.0,272.0,0.0,0.0,5.70711,0.407575,1.0,300.0,7.0,40.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,300.0,272.0,0.0,0.0,5.70711,0.407575,1.0,300.0,7.0,40.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,300.0,272.0,0.003333,0.003333,5.70711,0.407575,1.0,300.0,7.0,40.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00775281,0.007753856998809514,1.0469988095144697e-06
0.0,300.0,272.0,0.0,0.0,5.70711,0.407575,1.0,300.0,7.0,40.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,300.0,272.0,0.006667,0.006667,5.70711,0.407575,1.0,300.0,7.0,40.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01550794,0.015563697584107125,5.5757584107125543e-05
0.0,300.0,272.0,0.0,0.0,5.70711,0.407575,1.0,300.0,7.0,40.0,Reason Not Given,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,300.0,272.0,0.003333,0.003333,5.70711,0.407575,1.0,300.0,7.0,40.0,Reason Not Given,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00775281,0.007753083071726183,2.730717261834395e-07
4.0,467.0,434.0,0.008565,0.008565,6.148468,0.365154,1.0,467.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01922958,0.019236638929146885,7.05892914688519e-06
3.0,467.0,434.0,0.006424,0.006424,6.148468,0.365154,1.0,467.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01442275,0.014300166678511902,0.00012258332148809732
0.0,467.0,434.0,0.0,0.0,6.148468,0.365154,1.0,467.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,434.0,0.004283,0.004283,6.148468,0.365154,1.0,467.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00961591,0.009605314300277766,1.0595699722233676e-05
0.0,467.0,434.0,0.0,0.0,6.148468,0.365154,1.0,467.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,434.0,0.002141,0.002141,6.148468,0.365154,1.0,467.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00480683,0.0047104246069162034,9.640539308379634e-05
4.0,467.0,434.0,0.008565,0.008565,6.148468,0.365154,1.0,467.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01922958,0.019239360643432596,9.780643432596298e-06
1.0,467.0,434.0,0.002141,0.002141,6.148468,0.365154,1.0,467.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00480683,0.004711094192332873,9.573580766712719e-05
7.0,467.0,434.0,0.014989,0.014989,6.148468,0.365154,1.0,467.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03365233,0.03363530302902325,1.7026970976753708e-05
5.0,467.0,434.0,0.010707,0.010707,6.148468,0.365154,1.0,467.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02403866,0.024157924784861118,0.00011926478486111794
2.0,467.0,434.0,0.004283,0.004283,6.148468,0.365154,1.0,467.0,0.0,0.0,Other Protocol Specified Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00961591,0.009624074680039674,8.164680039673619e-06
4.0,467.0,434.0,0.008565,0.008565,6.148468,0.365154,1.0,467.0,0.0,0.0,Other Protocol Specified Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01922958,0.019245997073521873,1.6417073521873826e-05
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00284973,0.0028481155166823376,1.6144833176624102e-06
6.0,744.0,644.0,0.008065,0.008065,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01710051,0.017298513746488112,0.00019800374648811306
3.0,744.0,644.0,0.004032,0.004032,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00854919,0.00854709163992065,2.0983600793507418e-06
2.0,744.0,644.0,0.002688,0.002688,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00569946,0.005705343150228182,5.8831502281822545e-06
3.0,744.0,644.0,0.004032,0.004032,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00854919,0.008541187562837315,8.002437162684534e-06
3.0,744.0,644.0,0.004032,0.004032,6.613384,0.320613,1.0,744.0,0.0,0.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00854919,0.008541187562837315,8.002437162684534e-06
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00284973,0.002849287676622813,4.4232337718681097e-07
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00284973,0.002849761789956148,3.1789956147967174e-08
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00284973,0.0028490929594799587,6.37040520041262e-07
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00284973,0.0028499822584680534,2.522584680534484e-07
2.0,744.0,644.0,0.002688,0.002688,6.613384,0.320613,1.0,744.0,0.0,0.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00569946,0.005703778280853182,4.318280853182407e-06
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00284973,0.0028484082882299588,1.321711770041218e-06
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00284973,0.0028489212025156695,8.087974843304542e-07
3.0,744.0,644.0,0.004032,0.004032,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00854919,0.008538303735218269,1.0886264781731145e-05
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00284973,0.002849453147872815,2.76852127184795e-07
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00284973,0.002849923801027576,1.938010275761952e-07
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Physician Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,744.0,644.0,0.010753,0.010753,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02279997,0.02247887965011903,0.000321090349880971
8.0,744.0,644.0,0.010753,0.010753,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02279997,0.022442603616547596,0.0003573663834524031
14.0,744.0,644.0,0.018817,0.018817,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03989836,0.039983884299712315,8.552429971231401e-05
10.0,744.0,644.0,0.013441,0.013441,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02849943,0.02839713779064481,0.00010229220935518979
11.0,744.0,644.0,0.014785,0.014785,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.03134917,0.03102571237383927,0.0003234576261607336
17.0,744.0,644.0,0.022849,0.022849,6.613384,0.320613,1.0,744.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.04844755,0.04845263614330359,5.086143303592583e-06
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,744.0,644.0,0.0,0.0,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,744.0,644.0,0.001344,0.001344,6.613384,0.320613,1.0,744.0,0.0,0.0,Other protocol specified criteria,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00284973,0.0028481505934680527,1.5794065319472451e-06
19.0,527.0,413.0,0.036053,0.036053,6.269096,0.197876,1.0,527.0,17.0,56.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04472396,0.045065109333214295,0.00034114933321429536
17.0,527.0,413.0,0.032258,0.032258,6.269096,0.197876,1.0,527.0,17.0,56.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04001624,0.04117742351667661,0.0011611835166766074
25.0,527.0,413.0,0.047438,0.047438,6.269096,0.197876,1.0,527.0,17.0,56.0,Hyperglycemic Rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05884712,0.05901302839148812,0.00016590839148811903
7.0,527.0,413.0,0.013283,0.013283,6.269096,0.197876,1.0,527.0,17.0,56.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01647764,0.016663300806001993,0.00018566080600199153
6.0,527.0,413.0,0.011385,0.011385,6.269096,0.197876,1.0,527.0,17.0,56.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01412316,0.013841485393244065,0.00028167460675593455
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00235448,0.0023638347418452523,9.354741845252375e-06
2.0,527.0,413.0,0.003795,0.003795,6.269096,0.197876,1.0,527.0,17.0,56.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00470772,0.004703333360773828,4.386639226172315e-06
4.0,527.0,413.0,0.00759,0.00759,6.269096,0.197876,1.0,527.0,17.0,56.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00941544,0.00943727494714285,2.1834947142848615e-05
2.0,527.0,413.0,0.003795,0.003795,6.269096,0.197876,1.0,527.0,17.0,56.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00470772,0.004707560052023828,1.5994797617196327e-07
5.0,527.0,413.0,0.009488,0.009488,6.269096,0.197876,1.0,527.0,17.0,56.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01176992,0.011691096657976196,7.882334202380381e-05
2.0,527.0,413.0,0.003795,0.003795,6.269096,0.197876,1.0,527.0,17.0,56.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00470772,0.0047142252332936655,6.505233293665168e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00235448,0.002363431826845252,8.951826845252087e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00235448,0.0023632754134523966,8.795413452396695e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235448,0.0023624577585714436,7.977758571443665e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00235448,0.002363645876964301,9.165876964300872e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Administrative Error,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00235448,0.0023632359283333472,8.755928333347308e-06
1.0,527.0,413.0,0.001898,0.001898,6.269096,0.197876,1.0,527.0,17.0,56.0,Administrative Error,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235448,0.002362418273452395,7.938273452395145e-06
0.0,527.0,413.0,0.0,0.0,6.269096,0.197876,1.0,527.0,17.0,56.0,Administrative Error,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,527.0,413.0,0.003795,0.003795,6.269096,0.197876,1.0,527.0,17.0,56.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00470772,0.0047075251348214445,1.948651785557698e-07
14.0,527.0,413.0,0.026565,0.026565,6.269096,0.197876,1.0,527.0,17.0,56.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03295404,0.03283600230954367,0.00011803769045632545
2.0,527.0,413.0,0.003795,0.003795,6.269096,0.197876,1.0,527.0,17.0,56.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00470772,0.004712210413571445,4.490413571444675e-06
3.0,455.0,371.0,0.006593,0.006593,6.122493,0.252985,1.0,455.0,10.0,80.0,Lack of Efficacy,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01021189,0.010265707550416649,5.3817550416649165e-05
2.0,455.0,371.0,0.004396,0.004396,6.122493,0.252985,1.0,455.0,10.0,80.0,Lack of Efficacy,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00680896,0.0068601373976045375,5.117739760453731e-05
6.0,455.0,371.0,0.013187,0.013187,6.122493,0.252985,1.0,455.0,10.0,80.0,Adverse Event,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.02042532,0.02054446737325396,0.000119147373253959
3.0,455.0,371.0,0.006593,0.006593,6.122493,0.252985,1.0,455.0,10.0,80.0,Adverse Event,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.01021189,0.010249658249999986,3.7768249999986514e-05
13.0,455.0,371.0,0.028571,0.028571,6.122493,0.252985,1.0,455.0,10.0,80.0,Withdrawal by Subject,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.04425357,0.04455801656474206,0.00030444656474205856
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,Withdrawal by Subject,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.01702084,0.017002289768749915,1.8550231250084176e-05
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Death,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.00340448,0.0034041640609821376,3.159390178624627e-07
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Death,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,455.0,371.0,0.006593,0.006593,6.122493,0.252985,1.0,455.0,10.0,80.0,Lost to Follow-up,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01021189,0.010264868602083317,5.297860208331763e-05
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,Lost to Follow-up,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.01702084,0.017010644097708253,1.0195902291745829e-05
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,Poor compliance or noncompliance,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01702084,0.016993982799196332,2.685720080366702e-05
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Poor compliance or noncompliance,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00340448,0.0034061754752380898,1.6954752380896748e-06
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,No longer meets study criteria,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01702084,0.01700082718252966,2.0012817470337757e-05
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,No longer meets study criteria,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Other,Period 1: Short-term (24-week) Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Other,Period 1: Short-term (24-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00340448,0.0034061762002380895,1.69620023808938e-06
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Lack of Efficacy,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.00340448,0.003406170917648806,1.690917648805839e-06
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Lack of Efficacy,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,455.0,371.0,0.008791,0.008791,6.122493,0.252985,1.0,455.0,10.0,80.0,Adverse Event,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01361637,0.01364752622144841,3.115622144841089e-05
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Adverse Event,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,455.0,371.0,0.008791,0.008791,6.122493,0.252985,1.0,455.0,10.0,80.0,Withdrawal by Subject,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01361637,0.013633310277162696,1.6940277162697318e-05
2.0,455.0,371.0,0.004396,0.004396,6.122493,0.252985,1.0,455.0,10.0,80.0,Withdrawal by Subject,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00680896,0.00686080445760454,5.184445760453987e-05
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Lost to Follow-up,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.00340448,0.003404417491815472,6.250818452820453e-08
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Lost to Follow-up,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00340448,0.0034062801119047583,1.8001119047581816e-06
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,Poor or noncompliance,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01702084,0.01698385691008921,3.6983089910788e-05
2.0,455.0,371.0,0.004396,0.004396,6.122493,0.252985,1.0,455.0,10.0,80.0,Poor or noncompliance,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.00680896,0.006858783761771205,4.98237617712052e-05
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Pregnancy,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.00340448,0.0034040223926488054,4.576073511946589e-07
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Pregnancy,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,455.0,371.0,0.010989,0.010989,6.122493,0.252985,1.0,455.0,10.0,80.0,No longer meets study criteria,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.01702084,0.01699070129342254,3.0138706577458735e-05
4.0,455.0,371.0,0.008791,0.008791,6.122493,0.252985,1.0,455.0,10.0,80.0,No longer meets study criteria,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.01361637,0.013635455827579359,1.908582757935949e-05
1.0,455.0,371.0,0.002198,0.002198,6.122493,0.252985,1.0,455.0,10.0,80.0,Other,Period 2: Long-term (52-week) Phase,FG000,diabetes type 2,INDUSTRY,0.00340448,0.0034034941926488053,9.858073511948007e-07
0.0,455.0,371.0,0.0,0.0,6.122493,0.252985,1.0,455.0,10.0,80.0,Other,Period 2: Long-term (52-week) Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,305.0,244.0,0.042623,0.042623,5.723585,0.233646,1.0,305.0,1.0,64.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05699947,0.057696057440704385,0.0006965874407043812
5.0,305.0,244.0,0.016393,0.016393,5.723585,0.233646,1.0,305.0,1.0,64.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02192226,0.022221061488601177,0.0002988014886011782
8.0,305.0,244.0,0.02623,0.02623,5.723585,0.233646,1.0,305.0,1.0,64.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03507721,0.034941122781567496,0.00013608721843250127
6.0,305.0,244.0,0.019672,0.019672,5.723585,0.233646,1.0,305.0,1.0,64.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02630724,0.02636362295337304,5.638295337304089e-05
4.0,305.0,244.0,0.013115,0.013115,5.723585,0.233646,1.0,305.0,1.0,64.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01753861,0.017524865680396805,1.3744319603194166e-05
7.0,305.0,244.0,0.022951,0.022951,5.723585,0.233646,1.0,305.0,1.0,64.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03069223,0.030571784395238093,0.00012044560476190749
1.0,305.0,244.0,0.003279,0.003279,5.723585,0.233646,1.0,305.0,1.0,64.0,Lack of Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00438499,0.004406599928492052,2.160992849205203e-05
4.0,305.0,244.0,0.013115,0.013115,5.723585,0.233646,1.0,305.0,1.0,64.0,Lack of Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01753861,0.01748522793173609,5.338206826390954e-05
2.0,305.0,244.0,0.006557,0.006557,5.723585,0.233646,1.0,305.0,1.0,64.0,Worsening of Glycosolated Hemoglobin,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00876863,0.00877163781132578,3.0078113257801797e-06
2.0,305.0,244.0,0.006557,0.006557,5.723585,0.233646,1.0,305.0,1.0,64.0,Worsening of Glycosolated Hemoglobin,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00876863,0.008783375040938882,1.4745040938882528e-05
2.0,305.0,244.0,0.006557,0.006557,5.723585,0.233646,1.0,305.0,1.0,64.0,Fasting Glucose > 240 mg/dL,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00876863,0.008773531461742444,4.901461742444491e-06
1.0,305.0,244.0,0.003279,0.003279,5.723585,0.233646,1.0,305.0,1.0,64.0,Fasting Glucose > 240 mg/dL,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00438499,0.004406707816765863,2.17178167658625e-05
0.0,305.0,244.0,0.0,0.0,5.723585,0.233646,1.0,305.0,1.0,64.0,> Three Moderate Hypoglycemic Episodes,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,305.0,244.0,0.006557,0.006557,5.723585,0.233646,1.0,305.0,1.0,64.0,> Three Moderate Hypoglycemic Episodes,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00876863,0.008785287374688878,1.6657374688878665e-05
1.0,305.0,244.0,0.003279,0.003279,5.723585,0.233646,1.0,305.0,1.0,64.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00438499,0.004406039446825385,2.1049446825385267e-05
2.0,305.0,244.0,0.006557,0.006557,5.723585,0.233646,1.0,305.0,1.0,64.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00876863,0.00878750521427221,1.887521427221088e-05
1.0,305.0,244.0,0.003279,0.003279,5.723585,0.233646,1.0,305.0,1.0,64.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00438499,0.004406858685158718,2.1868685158718364e-05
0.0,305.0,244.0,0.0,0.0,5.723585,0.233646,1.0,305.0,1.0,64.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,241.0,220.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,5.0,34.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0227736,0.022650266758611107,0.00012333324138889476
8.0,241.0,220.0,0.033195,0.033195,5.488938,1.0,1.0,241.0,5.0,34.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.18220529,0.18297066931744044,0.0007653793174404455
3.0,241.0,220.0,0.012448,0.012448,5.488938,1.0,1.0,241.0,5.0,34.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0683263,0.06873371160282733,0.00040741160282732614
7.0,241.0,220.0,0.029046,0.029046,5.488938,1.0,1.0,241.0,5.0,34.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.15943169,0.16043484032799596,0.001003150327995972
1.0,241.0,220.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,5.0,34.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0227736,0.022612062103611108,0.00016153789638889346
1.0,241.0,220.0,0.004149,0.004149,5.488938,1.0,1.0,241.0,5.0,34.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0227736,0.0226519254473611,0.00012167455263890209
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1479.0,1342.0,0.000676,0.000676,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00493466,0.004920042407169906,1.4617592830093798e-05
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1479.0,1342.0,0.000676,0.000676,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00493466,0.004919232042169905,1.54279578300949e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00986933,0.00986703495753961,2.2950424603904868e-06
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Not treated,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00986933,0.009865363837499929,3.966162500071771e-06
7.0,1479.0,1342.0,0.004733,0.004733,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03454994,0.03453454554264873,1.5394457351269875e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00986933,0.009824580737212237,4.474926278776395e-05
5.0,1479.0,1342.0,0.003381,0.003381,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02468061,0.024783474247797633,0.00010286424779763423
1.0,1479.0,1342.0,0.000676,0.000676,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00493466,0.004915461523003237,1.9198476996762186e-05
8.0,1479.0,1342.0,0.005409,0.005409,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0394846,0.03931756782053571,0.0001670321794642951
6.0,1479.0,1342.0,0.004057,0.004057,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.02961528,0.029272749279174767,0.00034253072082523345
7.0,1479.0,1342.0,0.004733,0.004733,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.03454994,0.03453956993669636,1.0370063303642707e-05
5.0,1479.0,1342.0,0.003381,0.003381,7.299797,1.0,1.0,1504.0,12.0,148.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.02468061,0.024783731612380965,0.00010312161238096654
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00986933,0.009856686683789612,1.2643316210389152e-05
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1479.0,1342.0,0.000676,0.000676,7.299797,1.0,1.0,1504.0,12.0,148.0,Lack of Efficacy,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00493466,0.00491921607550324,1.544392449675993e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00986933,0.009844482544503909,2.484745549609195e-05
1.0,1479.0,1342.0,0.000676,0.000676,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00493466,0.004917935266336573,1.6724733663426965e-05
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00986933,0.009865718432539609,3.6115674603917625e-06
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00986933,0.009866487980456277,2.842019543723706e-06
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Non compliant with protocol,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00986933,0.009844749219503911,2.4580780496089374e-05
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01480399,0.01478441275543915,1.957724456084879e-05
4.0,1479.0,1342.0,0.002705,0.002705,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01974595,0.01979200254476185,4.605254476184803e-05
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01480399,0.014809238367939155,5.248367939155937e-06
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01480399,0.014816452536689156,1.24625366891562e-05
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01480399,0.01481863467002249,1.4644670022490036e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00986933,0.009866267260416596,3.0627395834047916e-06
7.0,1479.0,1342.0,0.004733,0.004733,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.03454994,0.03454473829089279,5.201709107213737e-06
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00986933,0.009826328562212237,4.300143778776348e-05
4.0,1479.0,1342.0,0.002705,0.002705,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG002,diabetes type 2,INDUSTRY,0.01974595,0.019768518725357075,2.2568725357073605e-05
5.0,1479.0,1342.0,0.003381,0.003381,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG003,diabetes type 2,INDUSTRY,0.02468061,0.024811551612797626,0.00013094161279762762
4.0,1479.0,1342.0,0.002705,0.002705,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG004,diabetes type 2,INDUSTRY,0.01974595,0.01977166016196423,2.5710161964228456e-05
4.0,1479.0,1342.0,0.002705,0.002705,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG005,diabetes type 2,INDUSTRY,0.01974595,0.019762169002857082,1.62190028570805e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG006,diabetes type 2,INDUSTRY,0.00986933,0.009866816292956276,2.5137070437247777e-06
5.0,1479.0,1342.0,0.003381,0.003381,7.299797,1.0,1.0,1504.0,12.0,148.0,"Patient refusal to continue,not due toAE",Overall Study,FG007,diabetes type 2,INDUSTRY,0.02468061,0.02479706706988096,0.0001164570698809625
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01480399,0.014803452585568127,5.374144318726071e-07
0.0,1479.0,1342.0,0.0,0.0,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1479.0,1342.0,0.002705,0.002705,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01974595,0.019774361883035656,2.8411883035654034e-05
2.0,1479.0,1342.0,0.001352,0.001352,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00986933,0.009862544155456279,6.785844543721886e-06
5.0,1479.0,1342.0,0.003381,0.003381,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02468061,0.024812104592797625,0.00013149459279762632
7.0,1479.0,1342.0,0.004733,0.004733,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG005,diabetes type 2,INDUSTRY,0.03454994,0.03455328667035708,3.3466703570766976e-06
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01480399,0.014786088924734788,1.7901075265211452e-05
3.0,1479.0,1342.0,0.002028,0.002028,7.299797,1.0,1.0,1504.0,12.0,148.0,Other reason not defined above,Overall Study,FG007,diabetes type 2,INDUSTRY,0.01480399,0.014782517608068122,2.1472391931877388e-05
2.0,506.0,480.0,0.003953,0.003953,6.228511,0.494922,1.0,506.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01218563,0.012063068462698405,0.00012256153730159404
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00609127,0.006062036176269857,2.923382373014316e-05
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609127,0.006064146265079381,2.7123734920619577e-05
0.0,506.0,480.0,0.0,0.0,6.228511,0.494922,1.0,506.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00609127,0.0060584727513740225,3.279724862597765e-05
2.0,506.0,480.0,0.003953,0.003953,6.228511,0.494922,1.0,506.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01218563,0.012065490627162698,0.00012013937283730097
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00609127,0.006067509268971006,2.3760731028994557e-05
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00609127,0.006058743178040688,3.252682195931198e-05
0.0,506.0,480.0,0.0,0.0,6.228511,0.494922,1.0,506.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,480.0,0.0,0.0,6.228511,0.494922,1.0,506.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,480.0,0.001976,0.001976,6.228511,0.494922,1.0,506.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00609127,0.006058743178040688,3.252682195931198e-05
0.0,506.0,480.0,0.0,0.0,6.228511,0.494922,1.0,506.0,0.0,0.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,506.0,480.0,0.007905,0.007905,6.228511,0.494922,1.0,506.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02436818,0.02309296616619587,0.0012752138338041306
5.0,506.0,480.0,0.009881,0.009881,6.228511,0.494922,1.0,506.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03045946,0.03057496723497024,0.00011550723497023851
7.0,506.0,480.0,0.013834,0.013834,6.228511,0.494922,1.0,506.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04264509,0.04268208118697418,3.699118697418624e-05
6.0,774.0,672.0,0.007752,0.007752,6.652863,0.379199,1.0,774.0,4.0,30.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01955643,0.019756005536588187,0.00019957553658818752
11.0,774.0,672.0,0.014212,0.014212,6.652863,0.379199,1.0,774.0,4.0,30.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03585346,0.03568032979459326,0.0001731302054067338
2.0,774.0,672.0,0.002584,0.002584,6.652863,0.379199,1.0,774.0,4.0,30.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00651881,0.006567281020307554,4.847102030755383e-05
9.0,774.0,672.0,0.011628,0.011628,6.652863,0.379199,1.0,774.0,4.0,30.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02933465,0.029096382805982132,0.00023826719401786808
6.0,774.0,672.0,0.007752,0.007752,6.652863,0.379199,1.0,774.0,4.0,30.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01955643,0.01974492035349295,0.00018849035349294968
8.0,774.0,672.0,0.010336,0.010336,6.652863,0.379199,1.0,774.0,4.0,30.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02607524,0.026190562297063492,0.0001153222970634929
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00325941,0.0032580872862996092,1.3227137003906687e-06
2.0,774.0,672.0,0.002584,0.002584,6.652863,0.379199,1.0,774.0,4.0,30.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00651881,0.006573031715515886,5.4221715515886254e-05
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00325941,0.0032515886680654815,7.82133193451837e-06
15.0,774.0,672.0,0.01938,0.01938,6.652863,0.379199,1.0,774.0,4.0,30.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04889108,0.04892496143913692,3.388143913691383e-05
17.0,774.0,672.0,0.021964,0.021964,6.652863,0.379199,1.0,774.0,4.0,30.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05540989,0.05562705854221234,0.00021716854221233428
17.0,774.0,672.0,0.021964,0.021964,6.652863,0.379199,1.0,774.0,4.0,30.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05540989,0.05563885066170638,0.00022896066170637747
0.0,774.0,672.0,0.0,0.0,6.652863,0.379199,1.0,774.0,4.0,30.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00325941,0.003257818447668658,1.591552331342127e-06
3.0,774.0,672.0,0.003876,0.003876,6.652863,0.379199,1.0,774.0,4.0,30.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00977822,0.009757140304494039,2.1079695505962087e-05
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00325941,0.003260753457013894,1.3434570138941802e-06
0.0,774.0,672.0,0.0,0.0,6.652863,0.379199,1.0,774.0,4.0,30.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,774.0,672.0,0.0,0.0,6.652863,0.379199,1.0,774.0,4.0,30.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,774.0,672.0,0.0,0.0,6.652863,0.379199,1.0,774.0,4.0,30.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00325941,0.003260968713740085,1.5587137400852914e-06
1.0,774.0,672.0,0.001292,0.001292,6.652863,0.379199,1.0,774.0,4.0,30.0,Sponsor Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00325941,0.0032508735350297666,8.536464970233283e-06
8.0,1663.0,1211.0,0.004811,0.004811,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 0 to Week 26,FG000,diabetes type 2,INDUSTRY,0.01135388,0.011546283304077379,0.00019240330407737857
10.0,1663.0,1211.0,0.006013,0.006013,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 0 to Week 26,FG001,diabetes type 2,INDUSTRY,0.01419058,0.014432739905515883,0.00024215990551588323
24.0,1663.0,1211.0,0.014432,0.014432,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 0 to Week 26,FG002,diabetes type 2,INDUSTRY,0.03405929,0.03270501532145834,0.001354274678541656
0.0,1663.0,1211.0,0.0,0.0,7.41698,0.318187,1.0,1663.0,20.0,302.0,Lack of Efficacy,Week 0 to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1663.0,1211.0,0.000601,0.000601,7.41698,0.318187,1.0,1663.0,20.0,302.0,Lack of Efficacy,Week 0 to Week 26,FG001,diabetes type 2,INDUSTRY,0.00141835,0.0014245782269047666,6.22822690476651e-06
0.0,1663.0,1211.0,0.0,0.0,7.41698,0.318187,1.0,1663.0,20.0,302.0,Lack of Efficacy,Week 0 to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1663.0,1211.0,0.000601,0.000601,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 0 to Week 26,FG000,diabetes type 2,INDUSTRY,0.00141835,0.0014251403037500046,6.79030375000454e-06
2.0,1663.0,1211.0,0.001203,0.001203,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 0 to Week 26,FG001,diabetes type 2,INDUSTRY,0.00283906,0.0028313764290277756,7.683570972224444e-06
0.0,1663.0,1211.0,0.0,0.0,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 0 to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
34.0,1663.0,1211.0,0.020445,0.020445,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 0 to Week 26,FG000,diabetes type 2,INDUSTRY,0.04824987,0.048574730356696405,0.0003248603566964048
69.0,1663.0,1211.0,0.041491,0.041491,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 0 to Week 26,FG001,diabetes type 2,INDUSTRY,0.09791809,0.09760465165571429,0.00031343834428571027
40.0,1663.0,1211.0,0.024053,0.024053,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 0 to Week 26,FG002,diabetes type 2,INDUSTRY,0.05676469,0.05621260779407738,0.0005520822059226216
5.0,1663.0,1211.0,0.003007,0.003007,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 0 to Week 26,FG000,diabetes type 2,INDUSTRY,0.00709647,0.007173579468452388,7.710946845238854e-05
16.0,1663.0,1211.0,0.009621,0.009621,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 0 to Week 26,FG001,diabetes type 2,INDUSTRY,0.0227054,0.022839480912886918,0.00013408091288691706
9.0,1663.0,1211.0,0.005412,0.005412,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 0 to Week 26,FG002,diabetes type 2,INDUSTRY,0.01277223,0.012908125195138903,0.00013589519513890203
1.0,1663.0,1211.0,0.000601,0.000601,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 27 to 52,FG000,diabetes type 2,INDUSTRY,0.00141835,0.0014269040768750039,8.554076875003785e-06
5.0,1663.0,1211.0,0.003007,0.003007,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 27 to 52,FG001,diabetes type 2,INDUSTRY,0.00709647,0.007171990118452385,7.552011845238498e-05
2.0,1663.0,1211.0,0.001203,0.001203,7.41698,0.318187,1.0,1663.0,20.0,302.0,Adverse Event,Week 27 to 52,FG002,diabetes type 2,INDUSTRY,0.00283906,0.0028375774901785683,1.4825098214317316e-06
0.0,1663.0,1211.0,0.0,0.0,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 27 to 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1663.0,1211.0,0.001203,0.001203,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 27 to 52,FG001,diabetes type 2,INDUSTRY,0.00283906,0.002830639748670632,8.42025132936821e-06
1.0,1663.0,1211.0,0.000601,0.000601,7.41698,0.318187,1.0,1663.0,20.0,302.0,Protocol Violation,Week 27 to 52,FG002,diabetes type 2,INDUSTRY,0.00141835,0.0014237995556547665,5.449555654766375e-06
14.0,1663.0,1211.0,0.008419,0.008419,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 27 to 52,FG000,diabetes type 2,INDUSTRY,0.0198687,0.020103747816269845,0.0002350478162698455
19.0,1663.0,1211.0,0.011425,0.011425,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 27 to 52,FG001,diabetes type 2,INDUSTRY,0.02696282,0.026684192875595238,0.00027862712440476084
16.0,1663.0,1211.0,0.009621,0.009621,7.41698,0.318187,1.0,1663.0,20.0,302.0,Withdrawal Criteria,Week 27 to 52,FG002,diabetes type 2,INDUSTRY,0.0227054,0.02282167912387897,0.00011627912387896996
13.0,1663.0,1211.0,0.007817,0.007817,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 27 to 52,FG000,diabetes type 2,INDUSTRY,0.01844799,0.018867633770585302,0.0004196437705853012
18.0,1663.0,1211.0,0.010824,0.010824,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 27 to 52,FG001,diabetes type 2,INDUSTRY,0.02554447,0.025596819416666673,5.234941666667353e-05
9.0,1663.0,1211.0,0.005412,0.005412,7.41698,0.318187,1.0,1663.0,20.0,302.0,Unclassified,Week 27 to 52,FG002,diabetes type 2,INDUSTRY,0.01277223,0.012908125195138903,0.00013589519513890203
4.0,447.0,385.0,0.008949,0.008949,6.104793,0.261782,1.0,447.0,10.0,53.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01430163,0.014345607843095264,4.397784309526434e-05
4.0,447.0,385.0,0.008949,0.008949,6.104793,0.261782,1.0,447.0,10.0,53.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01430163,0.014351122080595262,4.949208059526304e-05
0.0,447.0,385.0,0.0,0.0,6.104793,0.261782,1.0,447.0,10.0,53.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,447.0,385.0,0.002237,0.002237,6.104793,0.261782,1.0,447.0,10.0,53.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00357501,0.0035884623733234092,1.3452373323409247e-05
2.0,447.0,385.0,0.004474,0.004474,6.104793,0.261782,1.0,447.0,10.0,53.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00715001,0.007217107598983519,6.709759898351937e-05
3.0,447.0,385.0,0.006711,0.006711,6.104793,0.261782,1.0,447.0,10.0,53.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01072502,0.010793971022430553,6.895102243055333e-05
4.0,447.0,385.0,0.008949,0.008949,6.104793,0.261782,1.0,447.0,10.0,53.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01430163,0.014348642442380967,4.701244238096772e-05
6.0,447.0,385.0,0.013423,0.013423,6.104793,0.261782,1.0,447.0,10.0,53.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02145164,0.02151499585005953,6.335585005952729e-05
17.0,447.0,385.0,0.038031,0.038031,6.104793,0.261782,1.0,447.0,10.0,53.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06077831,0.06097539807814483,0.00019708807814482893
21.0,447.0,385.0,0.04698,0.04698,6.104793,0.261782,1.0,447.0,10.0,53.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07507994,0.07371162996562501,0.0013683100343749866
5.0,938.0,859.0,0.00533,0.00533,6.844815,0.782538,1.0,938.0,8.0,75.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02854923,0.02821122019677581,0.0003380098032241888
1.0,938.0,859.0,0.001066,0.001066,6.844815,0.782538,1.0,938.0,8.0,75.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00570985,0.005739512089345249,2.9662089345248825e-05
5.0,938.0,859.0,0.00533,0.00533,6.844815,0.782538,1.0,938.0,8.0,75.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02854923,0.028192346953442474,0.000356883046557524
0.0,938.0,859.0,0.0,0.0,6.844815,0.782538,1.0,938.0,8.0,75.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,938.0,859.0,0.002132,0.002132,6.844815,0.782538,1.0,938.0,8.0,75.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01141969,0.011455752096041667,3.6062096041667574e-05
0.0,938.0,859.0,0.0,0.0,6.844815,0.782538,1.0,938.0,8.0,75.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,938.0,859.0,0.008529,0.008529,6.844815,0.782538,1.0,938.0,8.0,75.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04568413,0.0459749507135913,0.00029082071359129436
4.0,938.0,859.0,0.004264,0.004264,6.844815,0.782538,1.0,938.0,8.0,75.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02283939,0.022351637637559527,0.0004877523624404745
10.0,938.0,859.0,0.010661,0.010661,6.844815,0.782538,1.0,938.0,8.0,75.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05710382,0.057200581293224084,9.676129322408467e-05
3.0,938.0,859.0,0.003198,0.003198,6.844815,0.782538,1.0,938.0,8.0,75.0,Other - As Reported by Investigator,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01712954,0.016917602047767866,0.00021193795223213227
2.0,938.0,859.0,0.002132,0.002132,6.844815,0.782538,1.0,938.0,8.0,75.0,Other - As Reported by Investigator,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01141969,0.01145128323479167,3.159323479167038e-05
2.0,938.0,859.0,0.002132,0.002132,6.844815,0.782538,1.0,938.0,8.0,75.0,Other - As Reported by Investigator,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01141969,0.011448625481696428,2.8935481696428303e-05
2.0,938.0,859.0,0.002132,0.002132,6.844815,0.782538,1.0,938.0,8.0,75.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01141969,0.011502440524017861,8.275052401786158e-05
0.0,938.0,859.0,0.0,0.0,6.844815,0.782538,1.0,938.0,8.0,75.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,938.0,859.0,0.002132,0.002132,6.844815,0.782538,1.0,938.0,8.0,75.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01141969,0.011452108339613092,3.241833961309219e-05
16.0,938.0,859.0,0.017058,0.017058,6.844815,0.782538,1.0,938.0,8.0,75.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09136826,0.09056368734501989,0.0008045726549801152
7.0,938.0,859.0,0.007463,0.007463,6.844815,0.782538,1.0,938.0,8.0,75.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03997428,0.0398764522906151,9.782770938489976e-05
10.0,938.0,859.0,0.010661,0.010661,6.844815,0.782538,1.0,938.0,8.0,75.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05710382,0.05732160522450387,0.00021778522450387194
31.0,1006.0,722.0,0.030815,0.030815,6.914731,0.265916,1.0,1006.0,12.0,136.0,Adverse Event,Main: Week 0 to 52 (NN1250-3582),FG000,diabetes type 2,INDUSTRY,0.05666064,0.056155022621160684,0.000505617378839314
9.0,1006.0,722.0,0.008946,0.008946,6.914731,0.265916,1.0,1006.0,12.0,136.0,Adverse Event,Main: Week 0 to 52 (NN1250-3582),FG001,diabetes type 2,INDUSTRY,0.01644933,0.016544686867867073,9.535686786707118e-05
3.0,1006.0,722.0,0.002982,0.002982,6.914731,0.265916,1.0,1006.0,12.0,136.0,Lack of Efficacy,Main: Week 0 to 52 (NN1250-3582),FG000,diabetes type 2,INDUSTRY,0.00548311,0.005540073119027773,5.6963119027773033e-05
0.0,1006.0,722.0,0.0,0.0,6.914731,0.265916,1.0,1006.0,12.0,136.0,Lack of Efficacy,Main: Week 0 to 52 (NN1250-3582),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
23.0,1006.0,722.0,0.022863,0.022863,6.914731,0.265916,1.0,1006.0,12.0,136.0,Protocol Violation,Main: Week 0 to 52 (NN1250-3582),FG000,diabetes type 2,INDUSTRY,0.04203902,0.042043497449732146,4.477449732143146e-06
12.0,1006.0,722.0,0.011928,0.011928,6.914731,0.265916,1.0,1006.0,12.0,136.0,Protocol Violation,Main: Week 0 to 52 (NN1250-3582),FG001,diabetes type 2,INDUSTRY,0.02193244,0.02260357954207339,0.0006711395420733873
8.0,1006.0,722.0,0.007952,0.007952,6.914731,0.265916,1.0,1006.0,12.0,136.0,Withdrawal criteria,Main: Week 0 to 52 (NN1250-3582),FG000,diabetes type 2,INDUSTRY,0.01462163,0.01475788567206351,0.0001362556720635108
2.0,1006.0,722.0,0.001988,0.001988,6.914731,0.265916,1.0,1006.0,12.0,136.0,Withdrawal criteria,Main: Week 0 to 52 (NN1250-3582),FG001,diabetes type 2,INDUSTRY,0.00365541,0.0036611552641071404,5.74526410714038e-06
72.0,1006.0,722.0,0.071571,0.071571,6.914731,0.265916,1.0,1006.0,12.0,136.0,Unclassified,Main: Week 0 to 52 (NN1250-3582),FG000,diabetes type 2,INDUSTRY,0.13160016,0.1331935528313692,0.0015933928313691947
17.0,1006.0,722.0,0.016899,0.016899,6.914731,0.265916,1.0,1006.0,12.0,136.0,Unclassified,Main: Week 0 to 52 (NN1250-3582),FG001,diabetes type 2,INDUSTRY,0.0310728,0.03141002152306551,0.0003372215230655097
4.0,1006.0,722.0,0.003976,0.003976,6.914731,0.265916,1.0,1006.0,12.0,136.0,Adverse Event,Extension: Week 53 to 78 (NN1250-3667),FG000,diabetes type 2,INDUSTRY,0.00731081,0.007333386773056456,2.257677305645637e-05
0.0,1006.0,722.0,0.0,0.0,6.914731,0.265916,1.0,1006.0,12.0,136.0,Adverse Event,Extension: Week 53 to 78 (NN1250-3667),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1006.0,722.0,0.000994,0.000994,6.914731,0.265916,1.0,1006.0,12.0,136.0,Lack of Efficacy,Extension: Week 53 to 78 (NN1250-3667),FG000,diabetes type 2,INDUSTRY,0.0018277,0.0018453888951488063,1.7688895148806286e-05
1.0,1006.0,722.0,0.000994,0.000994,6.914731,0.265916,1.0,1006.0,12.0,136.0,Lack of Efficacy,Extension: Week 53 to 78 (NN1250-3667),FG001,diabetes type 2,INDUSTRY,0.0018277,0.0018448351797916644,1.713517979166435e-05
5.0,1006.0,722.0,0.00497,0.00497,6.914731,0.265916,1.0,1006.0,12.0,136.0,Protocol Violation,Extension: Week 53 to 78 (NN1250-3667),FG000,diabetes type 2,INDUSTRY,0.00913852,0.009158827269454365,2.0307269454363994e-05
0.0,1006.0,722.0,0.0,0.0,6.914731,0.265916,1.0,1006.0,12.0,136.0,Protocol Violation,Extension: Week 53 to 78 (NN1250-3667),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,1006.0,722.0,0.005964,0.005964,6.914731,0.265916,1.0,1006.0,12.0,136.0,Withdrawal criteria,Extension: Week 53 to 78 (NN1250-3667),FG000,diabetes type 2,INDUSTRY,0.01096622,0.010975396056996744,9.176056996743759e-06
2.0,1006.0,722.0,0.001988,0.001988,6.914731,0.265916,1.0,1006.0,12.0,136.0,Withdrawal criteria,Extension: Week 53 to 78 (NN1250-3667),FG001,diabetes type 2,INDUSTRY,0.00365541,0.0036611552641071404,5.74526410714038e-06
11.0,1006.0,722.0,0.010934,0.010934,6.914731,0.265916,1.0,1006.0,12.0,136.0,Unclassified,Extension: Week 53 to 78 (NN1250-3667),FG000,diabetes type 2,INDUSTRY,0.02010474,0.019891436548268405,0.0002133034517315946
5.0,1006.0,722.0,0.00497,0.00497,6.914731,0.265916,1.0,1006.0,12.0,136.0,Unclassified,Extension: Week 53 to 78 (NN1250-3667),FG001,diabetes type 2,INDUSTRY,0.00913852,0.009161918864196426,2.3398864196425354e-05
4.0,640.0,565.0,0.00625,0.00625,6.463029,0.438178,1.0,1136.0,1.0,17.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01769973,0.01775297251088298,5.324251088298024e-05
3.0,640.0,565.0,0.004687,0.004687,6.463029,0.438178,1.0,1136.0,1.0,17.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01327338,0.013284367221458331,1.0987221458331337e-05
3.0,640.0,565.0,0.004687,0.004687,6.463029,0.438178,1.0,1136.0,1.0,17.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01327338,0.013290653711279757,1.7273711279757256e-05
0.0,640.0,565.0,0.0,0.0,6.463029,0.438178,1.0,1136.0,1.0,17.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,640.0,565.0,0.0,0.0,6.463029,0.438178,1.0,1136.0,1.0,17.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00442635,0.004437741239851168,1.1391239851167925e-05
0.0,640.0,565.0,0.0,0.0,6.463029,0.438178,1.0,1136.0,1.0,17.0,Dev. of study spec. withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Dev. of study spec. withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00442635,0.004433047846517834,6.6978465178340815e-06
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Dev. of study spec. withdrawal criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00442635,0.004435975427767834,9.62542776783426e-06
0.0,640.0,565.0,0.0,0.0,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00442635,0.004434299275267834,7.949275267833851e-06
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00442635,0.004437226856517834,1.087685651783403e-05
17.0,640.0,565.0,0.026562,0.026562,6.463029,0.438178,1.0,1136.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07522245,0.07396208513289046,0.0012603648671095369
14.0,640.0,565.0,0.021875,0.021875,6.463029,0.438178,1.0,1136.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06194907,0.061964690309871055,1.562030987105334e-05
16.0,640.0,565.0,0.025,0.025,6.463029,0.438178,1.0,1136.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07079894,0.07011836380690567,0.0006805761930943344
0.0,640.0,565.0,0.0,0.0,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,640.0,565.0,0.003125,0.003125,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00884987,0.008561718912529784,0.0002881510874702155
3.0,640.0,565.0,0.004687,0.004687,6.463029,0.438178,1.0,1136.0,1.0,17.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01327338,0.01331587845928571,4.2498459285710347e-05
3.0,640.0,565.0,0.004687,0.004687,6.463029,0.438178,1.0,1136.0,1.0,17.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01327338,0.013325779313660715,5.2399313660715305e-05
1.0,640.0,565.0,0.001563,0.001563,6.463029,0.438178,1.0,1136.0,1.0,17.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00442635,0.004427737561041647,1.387561041647431e-06
4.0,640.0,565.0,0.00625,0.00625,6.463029,0.438178,1.0,1136.0,1.0,17.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01769973,0.01776530876418655,6.557876418655101e-05
0.0,615.0,582.0,0.0,0.0,6.423247,0.393038,1.0,881.0,0.0,0.0,Adverse event prior to treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Adverse event prior to treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00410496,0.004107882692470264,2.9226924702632426e-06
0.0,615.0,582.0,0.0,0.0,6.423247,0.393038,1.0,881.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,615.0,582.0,0.004878,0.004878,6.423247,0.393038,1.0,881.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01231489,0.012319441336101175,4.551336101174877e-06
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00410496,0.004111605851339309,6.645851339308513e-06
4.0,615.0,582.0,0.006504,0.006504,6.423247,0.393038,1.0,881.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01641986,0.01647340751030754,5.354751030754029e-05
0.0,615.0,582.0,0.0,0.0,6.423247,0.393038,1.0,881.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,615.0,582.0,0.004878,0.004878,6.423247,0.393038,1.0,881.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01231489,0.012296919642559507,1.7970357440492968e-05
0.0,615.0,582.0,0.0,0.0,6.423247,0.393038,1.0,881.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00410496,0.004107882692470264,2.9226924702632426e-06
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00410496,0.004110309091339309,5.349091339308491e-06
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00410496,0.004107954604970263,2.9946049702623406e-06
1.0,615.0,582.0,0.001626,0.001626,6.423247,0.393038,1.0,881.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00410496,0.004111301672589308,6.341672589308019e-06
2.0,615.0,582.0,0.003252,0.003252,6.423247,0.393038,1.0,881.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00820993,0.008218867505148823,8.937505148822605e-06
9.0,615.0,582.0,0.014634,0.014634,6.423247,0.393038,1.0,881.0,0.0,0.0,Reason not specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03694468,0.03677929453194444,0.0001653854680555636
6.0,615.0,582.0,0.009756,0.009756,6.423247,0.393038,1.0,881.0,0.0,0.0,Reason not specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02462979,0.024565252006785703,6.453799321429546e-05
41.0,1554.0,1232.0,0.026384,0.026384,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04094716,0.0416405595284226,0.0006933995284225947
18.0,1554.0,1232.0,0.011583,0.011583,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01797646,0.017988048313382955,1.1588313382954879e-05
16.0,1554.0,1232.0,0.010296,0.010296,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01597908,0.016965681618194447,0.0009866016181944472
13.0,1554.0,1232.0,0.008366,0.008366,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01298378,0.013889132230614179,0.0009053522306141787
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00599215,0.006013982500824933,2.1832500824933015e-05
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00499424,0.00499464689458336,4.0689458336018447e-07
19.0,1554.0,1232.0,0.012227,0.012227,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01897593,0.019558718210962306,0.0005827882109623074
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00599215,0.006013982500824933,2.1832500824933015e-05
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00599215,0.006013982500824933,2.1832500824933015e-05
11.0,1554.0,1232.0,0.007079,0.007079,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG009,diabetes type 2,INDUSTRY,0.01098639,0.01113667452627976,0.00015028452627975988
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00299685,0.002999934424166676,3.0844241666757276e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Hyperglycemic Rescue,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00199738,0.001996889650902791,4.903490972091654e-07
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00299685,0.002997977224583342,1.1272245833420132e-06
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00099947,0.000999117722500002,3.522774999979283e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00199738,0.001997662266250014,2.822662500141099e-07
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00299685,0.0029988482524404836,1.9982524404834646e-06
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00099947,0.000999747187500002,2.771875000019859e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00199738,0.0019976827486111247,3.0274861112468063e-07
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00099947,0.0009997452375000019,2.752375000019715e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00199738,0.0019976903698611247,3.103698611246937e-07
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,1554.0,1232.0,0.004505,0.004505,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00699162,0.007030828918045628,3.920891804562801e-05
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00499424,0.004995146459702404,9.064597024047855e-07
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Adverse Event,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00399477,0.003995701374732161,9.313747321611221e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00199738,0.0019978489315277876,4.689315277876284e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00199738,0.0019911865569444565,6.1934430555434655e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00199738,0.0019973480766666807,3.1923333319253816e-08
8.0,1554.0,1232.0,0.005148,0.005148,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00798954,0.008032790632936514,4.325063293651385e-05
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00499424,0.005003205916398833,8.96591639883322e-06
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00499424,0.00500285342354169,8.613423541690632e-06
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00599215,0.0059887740789201695,3.3759210798303685e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00199738,0.0019973722719444586,7.72805554142067e-09
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00099947,0.0009995164167857164,4.64167857164733e-08
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00399477,0.003996212557648829,1.4425576488289599e-06
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00599215,0.0059887740789201695,3.3759210798303685e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Protocol Violation,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00199738,0.0019973722719444586,7.72805554142067e-09
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00399477,0.0039963711174107325,1.6011174107325582e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00199738,0.0019876307350992165,9.74926490078347e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00199738,0.001993800364613108,3.5796353868920543e-06
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00399477,0.0039987138326488285,3.943832648828534e-06
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00199738,0.001993816156974219,3.563843025780958e-06
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00299685,0.003000209755416676,3.359755416675915e-06
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00299685,0.0030002070470833424,3.3570470833422725e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00199738,0.0019938237782242186,3.5562217757813784e-06
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Lost to Follow-up,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00099947,0.0009989483417857164,5.216582142834967e-07
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00499424,0.005001640994583357,7.400994583357801e-06
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00399477,0.0039917022410416855,3.0677589583144246e-06
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00499424,0.004988510661160739,5.729338839260793e-06
6.0,1554.0,1232.0,0.003861,0.003861,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00599215,0.006017309011201919,2.5159011201919025e-05
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00199738,0.0019970723525694575,3.0764743054250906e-07
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00499424,0.004993702190178598,5.378098214018842e-07
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00399477,0.003994225043125021,5.449568749793174e-07
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00399477,0.003994225043125021,5.449568749793174e-07
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00399477,0.003994225043125021,5.449568749793174e-07
5.0,1554.0,1232.0,0.003218,0.003218,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00499424,0.004994394437202407,1.5443720240756326e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00199738,0.0019970723525694575,3.0764743054250906e-07
7.0,1554.0,1232.0,0.004505,0.004505,7.349231,0.211174,1.0,1554.0,19.0,90.0,Withdrawal by Subject,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00699162,0.007025476912123008,3.385691212300871e-05
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00099947,0.000998779728452383,6.902715476168799e-07
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Pregnancy,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1554.0,1232.0,0.002574,0.002574,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00399477,0.003996204698244066,1.4346982440656755e-06
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00299685,0.002994718936666676,2.1310633333240965e-06
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00099947,0.0009995978337500018,1.2783375000192075e-07
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00199738,0.0019960394459027906,1.3405540972093698e-06
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00099947,0.0009995978337500018,1.2783375000192075e-07
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00099947,0.0009995978337500018,1.2783375000192075e-07
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00099947,0.0009995978337500018,1.2783375000192075e-07
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1554.0,1232.0,0.001931,0.001931,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00299685,0.002997997975416675,1.147975416674902e-06
2.0,1554.0,1232.0,0.001287,0.001287,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00199738,0.001996889650902791,4.903490972091654e-07
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00099947,0.0009995978337500018,1.2783375000192075e-07
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Physician Decision,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00099947,0.0009997082850000019,2.3828500000195804e-07
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00099947,0.0009994719500000019,1.950000001966004e-09
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00099947,0.000999473900000002,3.900000001980444e-09
1.0,1554.0,1232.0,0.000644,0.000644,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00099947,0.000999473900000002,3.900000001980444e-09
0.0,1554.0,1232.0,0.0,0.0,7.349231,0.211174,1.0,1554.0,19.0,90.0,Other,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,577.0,569.0,0.0,0.0,6.359574,0.522571,1.0,577.0,12.0,92.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,577.0,569.0,0.005199,0.005199,6.359574,0.522571,1.0,577.0,12.0,92.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01727798,0.01731360646041896,3.562646041896031e-05
3.0,577.0,569.0,0.005199,0.005199,6.359574,0.522571,1.0,577.0,12.0,92.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01727798,0.017362784685123648,8.480468512364961e-05
2.0,577.0,569.0,0.003466,0.003466,6.359574,0.522571,1.0,577.0,12.0,92.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01151866,0.01161338999804563,9.472999804563051e-05
11.0,1035.0,936.0,0.010628,0.010628,6.943122,0.242288,1.0,1035.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01787879,0.017749996663750014,0.00012879333624998476
2.0,1035.0,936.0,0.001932,0.001932,6.943122,0.242288,1.0,1035.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00325008,0.003240146677440474,9.933322559525695e-06
0.0,1035.0,936.0,0.0,0.0,6.943122,0.242288,1.0,1035.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1035.0,936.0,0.000966,0.000966,6.943122,0.242288,1.0,1035.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00162504,0.0015972246408333314,2.7815359166668456e-05
5.0,1035.0,936.0,0.004831,0.004831,6.943122,0.242288,1.0,1035.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00812688,0.008158939450337301,3.2059450337301384e-05
4.0,1035.0,936.0,0.003865,0.003865,6.943122,0.242288,1.0,1035.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00650184,0.0065492856903373005,4.744569033730047e-05
9.0,1035.0,936.0,0.008696,0.008696,6.943122,0.242288,1.0,1035.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01462871,0.014602438460377004,2.627153962299518e-05
9.0,1035.0,936.0,0.008696,0.008696,6.943122,0.242288,1.0,1035.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01462871,0.01460462426647819,2.4085733521809344e-05
3.0,1035.0,936.0,0.002899,0.002899,6.943122,0.242288,1.0,1035.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0048768,0.0049555274985118945,7.872749851189475e-05
4.0,1035.0,936.0,0.003865,0.003865,6.943122,0.242288,1.0,1035.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00650184,0.006560200018373017,5.8360018373017006e-05
2.0,1035.0,936.0,0.001932,0.001932,6.943122,0.242288,1.0,1035.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00325008,0.003231434491924602,1.864550807539802e-05
3.0,1035.0,936.0,0.002899,0.002899,6.943122,0.242288,1.0,1035.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0048768,0.00495299719985118,7.619719985117995e-05
11.0,1035.0,936.0,0.010628,0.010628,6.943122,0.242288,1.0,1035.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01787879,0.017781350386964306,9.74396130356929e-05
16.0,1035.0,936.0,0.015459,0.015459,6.943122,0.242288,1.0,1035.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02600567,0.025736964131349193,0.00026870586865080856
7.0,1035.0,936.0,0.006763,0.006763,6.943122,0.242288,1.0,1035.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01137695,0.011498616846666669,0.00012166684666666851
12.0,1035.0,936.0,0.011594,0.011594,6.943122,0.242288,1.0,1035.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01950383,0.01873275855866073,0.0007710714413392689
98.0,505.0,275.0,0.194059,0.194059,6.226537,0.235372,1.0,505.0,1.0,53.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.28440345,0.2923375426911786,0.007934092691178618
26.0,505.0,275.0,0.051485,0.051485,6.226537,0.235372,1.0,505.0,1.0,53.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07545392,0.07475125746218249,0.0007026625378175055
22.0,505.0,275.0,0.043564,0.043564,6.226537,0.235372,1.0,505.0,1.0,53.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06384528,0.06343041354056543,0.00041486645943457356
15.0,505.0,275.0,0.029703,0.029703,6.226537,0.235372,1.0,505.0,1.0,53.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04353128,0.043657868477839964,0.0001265884778399659
21.0,505.0,275.0,0.041584,0.041584,6.226537,0.235372,1.0,505.0,1.0,53.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06094349,0.061240186198749956,0.00029669619874995307
15.0,505.0,275.0,0.029703,0.029703,6.226537,0.235372,1.0,505.0,1.0,53.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04353128,0.043607970210459,7.66902104590017e-05
3.0,505.0,275.0,0.005941,0.005941,6.226537,0.235372,1.0,505.0,1.0,53.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00870684,0.00871387330069445,7.033300694450281e-06
4.0,505.0,275.0,0.007921,0.007921,6.226537,0.235372,1.0,505.0,1.0,53.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01160863,0.011555834602420616,5.2795397579383924e-05
5.0,505.0,275.0,0.009901,0.009901,6.226537,0.235372,1.0,505.0,1.0,53.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01451043,0.014545728490178586,3.5298490178586536e-05
6.0,505.0,275.0,0.011881,0.011881,6.226537,0.235372,1.0,505.0,1.0,53.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01741222,0.017369837502033733,4.2382497966265975e-05
11.0,505.0,275.0,0.021782,0.021782,6.226537,0.235372,1.0,505.0,1.0,53.0,"Drug noncompliance, other",Overall Study,FG000,diabetes type 2,INDUSTRY,0.03192264,0.031532264127192455,0.0003903758728075468
4.0,505.0,275.0,0.007921,0.007921,6.226537,0.235372,1.0,505.0,1.0,53.0,"Drug noncompliance, other",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01160863,0.01154664585343252,6.198414656747968e-05
231.0,2639.0,1392.0,0.087533,0.087533,7.878534,0.314283,1.0,2639.0,32.0,261.0,Hyperglycemic rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.21673966,0.21523905930005946,0.0015006006999405408
201.0,2639.0,1392.0,0.076165,0.076165,7.878534,0.314283,1.0,2639.0,32.0,261.0,Hyperglycemic rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.18859146,0.18989263683261914,0.0013011768326191553
235.0,2639.0,1392.0,0.089049,0.089049,7.878534,0.314283,1.0,2639.0,32.0,261.0,Hyperglycemic rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.22049341,0.21688918944434515,0.0036042205556548468
60.0,2639.0,1392.0,0.022736,0.022736,7.878534,0.314283,1.0,2639.0,32.0,261.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0562964,0.05553486162113093,0.0007615383788690741
74.0,2639.0,1392.0,0.028041,0.028041,7.878534,0.314283,1.0,2639.0,32.0,261.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06943206,0.0680841215177976,0.0013479384822024099
82.0,2639.0,1392.0,0.031072,0.031072,7.878534,0.314283,1.0,2639.0,32.0,261.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07693709,0.0778962807454762,0.0009591907454762072
24.0,2639.0,1392.0,0.009094,0.009094,7.878534,0.314283,1.0,2639.0,32.0,261.0,Major protocol deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02251757,0.022522217197599215,4.647197599214753e-06
16.0,2639.0,1392.0,0.006063,0.006063,7.878534,0.314283,1.0,2639.0,32.0,261.0,Major protocol deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01501254,0.01495469326324405,5.784673675594994e-05
15.0,2639.0,1392.0,0.005684,0.005684,7.878534,0.314283,1.0,2639.0,32.0,261.0,Major protocol deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0140741,0.01425569883970238,0.00018159883970237864
20.0,2639.0,1392.0,0.007579,0.007579,7.878534,0.314283,1.0,2639.0,32.0,261.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01876629,0.018857576589126974,9.128658912697235e-05
22.0,2639.0,1392.0,0.008336,0.008336,7.878534,0.314283,1.0,2639.0,32.0,261.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02064069,0.021229605457539685,0.0005889154575396856
28.0,2639.0,1392.0,0.01061,0.01061,7.878534,0.314283,1.0,2639.0,32.0,261.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02627132,0.026097085985327374,0.0001742340146726265
48.0,2639.0,1392.0,0.018189,0.018189,7.878534,0.314283,1.0,2639.0,32.0,261.0,Voluntary withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04503762,0.04486189112688493,0.0001757288731150733
52.0,2639.0,1392.0,0.019704,0.019704,7.878534,0.314283,1.0,2639.0,32.0,261.0,Voluntary withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04878889,0.04902897512480156,0.00024008512480155897
62.0,2639.0,1392.0,0.023494,0.023494,7.878534,0.314283,1.0,2639.0,32.0,261.0,Voluntary withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05817328,0.056958363284017856,0.001214916715982145
1.0,2639.0,1392.0,0.000379,0.000379,7.878534,0.314283,1.0,2639.0,32.0,261.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00093844,0.0009303590309722214,8.080969027778637e-06
2.0,2639.0,1392.0,0.000758,0.000758,7.878534,0.314283,1.0,2639.0,32.0,261.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00187688,0.00183545661666667,4.142338333332999e-05
0.0,2639.0,1392.0,0.0,0.0,7.878534,0.314283,1.0,2639.0,32.0,261.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,2639.0,1392.0,0.00341,0.00341,7.878534,0.314283,1.0,2639.0,32.0,261.0,Investigator discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00844347,0.008417359758670638,2.611024132936207e-05
8.0,2639.0,1392.0,0.003031,0.003031,7.878534,0.314283,1.0,2639.0,32.0,261.0,Investigator discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00750503,0.007458344939761905,4.66850602380952e-05
10.0,2639.0,1392.0,0.003789,0.003789,7.878534,0.314283,1.0,2639.0,32.0,261.0,Investigator discretion,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00938191,0.009408311144126992,2.640114412699214e-05
15.0,2639.0,1392.0,0.005684,0.005684,7.878534,0.314283,1.0,2639.0,32.0,261.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0140741,0.014289803329315476,0.0002157033293154753
17.0,2639.0,1392.0,0.006442,0.006442,7.878534,0.314283,1.0,2639.0,32.0,261.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01595098,0.0158678346295734,8.314537042659886e-05
14.0,2639.0,1392.0,0.005305,0.005305,7.878534,0.314283,1.0,2639.0,32.0,261.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01313566,0.013016007745347216,0.00011965225465278458
0.0,2639.0,1392.0,0.0,0.0,7.878534,0.314283,1.0,2639.0,32.0,261.0,Randomized in error,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2639.0,1392.0,0.0,0.0,7.878534,0.314283,1.0,2639.0,32.0,261.0,Randomized in error,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2639.0,1392.0,0.000379,0.000379,7.878534,0.314283,1.0,2639.0,32.0,261.0,Randomized in error,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00093844,0.000927841229999999,1.0598770000001053e-05
3.0,641.0,595.0,0.00468,0.00468,6.464588,0.360417,1.0,641.0,11.0,63.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01090416,0.010897298472400787,6.861527599212949e-06
2.0,641.0,595.0,0.00312,0.00312,6.464588,0.360417,1.0,641.0,11.0,63.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00726944,0.007283374373998005,1.393437399800461e-05
4.0,641.0,595.0,0.00624,0.00624,6.464588,0.360417,1.0,641.0,11.0,63.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01453888,0.014512126392380954,2.6753607619046244e-05
0.0,641.0,595.0,0.0,0.0,6.464588,0.360417,1.0,641.0,11.0,63.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,641.0,595.0,0.0078,0.0078,6.464588,0.360417,1.0,641.0,11.0,63.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0181736,0.01827396197034723,0.00010036197034722985
2.0,641.0,595.0,0.00312,0.00312,6.464588,0.360417,1.0,641.0,11.0,63.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00726944,0.00728884803358134,1.940803358133937e-05
13.0,641.0,595.0,0.020281,0.020281,6.464588,0.360417,1.0,641.0,11.0,63.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04725369,0.04784516836980157,0.0005914783698015708
2.0,641.0,595.0,0.00312,0.00312,6.464588,0.360417,1.0,641.0,11.0,63.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00726944,0.007268378330664672,1.0616693353285994e-06
3.0,641.0,595.0,0.00468,0.00468,6.464588,0.360417,1.0,641.0,11.0,63.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01090416,0.01089793510573412,6.224894265879216e-06
1.0,641.0,595.0,0.00156,0.00156,6.464588,0.360417,1.0,641.0,11.0,63.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00363472,0.0036779411727380913,4.322117273809116e-05
0.0,641.0,595.0,0.0,0.0,6.464588,0.360417,1.0,641.0,11.0,63.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,641.0,595.0,0.00468,0.00468,6.464588,0.360417,1.0,641.0,11.0,63.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01090416,0.010890088771845233,1.407122815476683e-05
7.0,641.0,595.0,0.01092,0.01092,6.464588,0.360417,1.0,641.0,11.0,63.0,Protocol Required Discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02544304,0.02523346240265876,0.00020957759734124143
1.0,641.0,595.0,0.00156,0.00156,6.464588,0.360417,1.0,641.0,11.0,63.0,Protocol Required Discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00363472,0.0036778385669047602,4.311856690476009e-05
6.0,492.0,446.0,0.012195,0.012195,6.200509,0.360417,1.0,492.0,1.0,14.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02725302,0.02707208556925595,0.00018093443074404872
3.0,492.0,446.0,0.006098,0.006098,6.200509,0.360417,1.0,492.0,1.0,14.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01362763,0.01366704390985119,3.941390985118948e-05
4.0,492.0,446.0,0.00813,0.00813,6.200509,0.360417,1.0,492.0,1.0,14.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01816868,0.01840610268104168,0.00023742268104167893
1.0,492.0,446.0,0.002033,0.002033,6.200509,0.360417,1.0,492.0,1.0,14.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00454329,0.004549356576774885,6.066576774884681e-06
0.0,492.0,446.0,0.0,0.0,6.200509,0.360417,1.0,492.0,1.0,14.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,492.0,446.0,0.0,0.0,6.200509,0.360417,1.0,492.0,1.0,14.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,492.0,446.0,0.002033,0.002033,6.200509,0.360417,1.0,492.0,1.0,14.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00454329,0.004551355612548694,8.065612548693868e-06
0.0,492.0,446.0,0.0,0.0,6.200509,0.360417,1.0,492.0,1.0,14.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,492.0,446.0,0.0,0.0,6.200509,0.360417,1.0,492.0,1.0,14.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,492.0,446.0,0.020325,0.020325,6.200509,0.360417,1.0,492.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0454217,0.046354313348105185,0.0009326133481051824
6.0,492.0,446.0,0.012195,0.012195,6.200509,0.360417,1.0,492.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02725302,0.027105646447529785,0.00014737355247021466
12.0,492.0,446.0,0.02439,0.02439,6.200509,0.360417,1.0,492.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05450604,0.05494881610799607,0.0004427761079960693
0.0,492.0,446.0,0.0,0.0,6.200509,0.360417,1.0,492.0,1.0,14.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,492.0,446.0,0.004065,0.004065,6.200509,0.360417,1.0,492.0,1.0,14.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00908434,0.009071618654166676,1.2721345833324044e-05
1.0,492.0,446.0,0.002033,0.002033,6.200509,0.360417,1.0,492.0,1.0,14.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00454329,0.004549369813214279,6.079813214278883e-06
2.0,206.0,195.0,0.009709,0.009709,5.332719,0.542543,1.0,206.0,1.0,25.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02809034,0.02825616297616075,0.00016582297616075242
2.0,206.0,195.0,0.009709,0.009709,5.332719,0.542543,1.0,206.0,1.0,25.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02809034,0.028272305291696446,0.00018196529169644746
3.0,206.0,195.0,0.014563,0.014563,5.332719,0.542543,1.0,206.0,1.0,25.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04213406,0.04241175774071428,0.00027769774071428194
3.0,206.0,195.0,0.014563,0.014563,5.332719,0.542543,1.0,206.0,1.0,25.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04213406,0.04246903350613097,0.0003349735061309658
0.0,206.0,195.0,0.0,0.0,5.332719,0.542543,1.0,206.0,1.0,25.0,Other than listed above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,206.0,195.0,0.004854,0.004854,5.332719,0.542543,1.0,206.0,1.0,25.0,Other than listed above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01404372,0.014262056782559525,0.00021833678255952366
62.0,1132.0,917.0,0.05477,0.05477,7.032624,0.245123,1.0,1512.0,0.0,0.0,Only one reason for discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09441554,0.09351466173738095,0.0009008782626190592
61.0,1132.0,917.0,0.053887,0.053887,7.032624,0.245123,1.0,1512.0,0.0,0.0,Only one reason for discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09289338,0.09266077289785717,0.00023260710214283165
48.0,1132.0,917.0,0.042403,0.042403,7.032624,0.245123,1.0,1512.0,0.0,0.0,Only one reason for discontinuation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07309663,0.07305271587267854,4.391412732145106e-05
17.0,1132.0,917.0,0.015018,0.015018,7.032624,0.245123,1.0,1512.0,0.0,0.0,Two or more reasons for discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02588886,0.025529133608809516,0.00035972639119048397
19.0,1132.0,917.0,0.016784,0.016784,7.032624,0.245123,1.0,1512.0,0.0,0.0,Two or more reasons for discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02893318,0.029469648016011887,0.000536468016011888
8.0,1132.0,917.0,0.007067,0.007067,7.032624,0.245123,1.0,1512.0,0.0,0.0,Two or more reasons for discontinuation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01218248,0.012059458382351184,0.0001230216176488167
0.0,465.0,401.0,0.0,0.0,6.144186,0.264217,1.0,465.0,9.0,65.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,465.0,401.0,0.002151,0.002151,6.144186,0.264217,1.0,465.0,9.0,65.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00349193,0.003505473296309527,1.3543296309527237e-05
3.0,465.0,401.0,0.006452,0.006452,6.144186,0.264217,1.0,465.0,9.0,65.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01047416,0.010417153373804122,5.700662619587821e-05
1.0,465.0,401.0,0.002151,0.002151,6.144186,0.264217,1.0,465.0,9.0,65.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00349193,0.00350576850089286,1.3838500892860133e-05
6.0,465.0,401.0,0.012903,0.012903,6.144186,0.264217,1.0,465.0,9.0,65.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0209467,0.020912785478758113,3.391452124188593e-05
3.0,465.0,401.0,0.006452,0.006452,6.144186,0.264217,1.0,465.0,9.0,65.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01047416,0.010401605375589835,7.255462441016491e-05
10.0,465.0,401.0,0.021505,0.021505,6.144186,0.264217,1.0,465.0,9.0,65.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03491116,0.034101785030515856,0.0008093749694841404
10.0,465.0,401.0,0.021505,0.021505,6.144186,0.264217,1.0,465.0,9.0,65.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03491116,0.03411523611190475,0.0007959238880952471
17.0,465.0,401.0,0.036559,0.036559,6.144186,0.264217,1.0,465.0,9.0,65.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05934979,0.05976136489255951,0.0004115748925595103
13.0,465.0,401.0,0.027957,0.027957,6.144186,0.264217,1.0,465.0,9.0,65.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04538532,0.044680631662192466,0.0007046883378075339
0.0,650.0,583.0,0.0,0.0,6.47851,0.489431,1.0,650.0,10.0,40.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,650.0,583.0,0.003077,0.003077,6.47851,0.489431,1.0,650.0,10.0,40.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00975651,0.009426433795551963,0.00033007620444803695
0.0,650.0,583.0,0.0,0.0,6.47851,0.489431,1.0,650.0,10.0,40.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,650.0,583.0,0.001538,0.001538,6.47851,0.489431,1.0,650.0,10.0,40.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00487667,0.004868868275343603,7.80172465639651e-06
10.0,650.0,583.0,0.015385,0.015385,6.47851,0.489431,1.0,650.0,10.0,40.0,Reason not reported,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04878253,0.0485516930772024,0.00023083692279760037
4.0,650.0,583.0,0.006154,0.006154,6.47851,0.489431,1.0,650.0,10.0,40.0,Reason not reported,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01951301,0.019462017326378957,5.0992673621044066e-05
0.0,650.0,583.0,0.0,0.0,6.47851,0.489431,1.0,650.0,10.0,40.0,Did not receive randomized treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,650.0,583.0,0.010769,0.010769,6.47851,0.489431,1.0,650.0,10.0,40.0,Did not receive randomized treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03414618,0.034112600902718254,3.357909728174402e-05
18.0,650.0,583.0,0.027692,0.027692,6.47851,0.489431,1.0,650.0,10.0,40.0,Did not enter long-term study,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08780538,0.08715327009324404,0.0006521099067559599
25.0,650.0,583.0,0.038462,0.038462,6.47851,0.489431,1.0,650.0,10.0,40.0,Did not enter long-term study,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12195473,0.12280685062547617,0.0008521206254761687
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG000,diabetes type 2,INDUSTRY,0.00180294,0.0018051269483333344,2.1869483333343282e-06
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG001,diabetes type 2,INDUSTRY,0.00180294,0.0018045581368452393,1.618136845239239e-06
2.0,1363.0,1201.0,0.001467,0.001467,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG002,diabetes type 2,INDUSTRY,0.00360342,0.0036129427179166632,9.522717916663273e-06
4.0,1363.0,1201.0,0.002935,0.002935,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG003,diabetes type 2,INDUSTRY,0.00720929,0.007209058660873031,2.3133912696940429e-07
2.0,1363.0,1201.0,0.001467,0.001467,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG004,diabetes type 2,INDUSTRY,0.00360342,0.00361347909083333,1.0059090833330203e-05
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG006,diabetes type 2,INDUSTRY,0.00180294,0.0018043666016666676,1.426601666667561e-06
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG007,diabetes type 2,INDUSTRY,0.00540636,0.0053974836199756635,8.876380024336328e-06
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG008,diabetes type 2,INDUSTRY,0.00540636,0.005398069120808999,8.290879191000591e-06
4.0,1363.0,1201.0,0.002935,0.002935,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 24,FG009,diabetes type 2,INDUSTRY,0.00720929,0.007207903224206363,1.3867757936367187e-06
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG000,diabetes type 2,INDUSTRY,0.00900978,0.00899658969760911,1.3190302390889835e-05
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG001,diabetes type 2,INDUSTRY,0.00180294,0.0018047297801785725,1.789780178572441e-06
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG002,diabetes type 2,INDUSTRY,0.00540636,0.005402971344558995,3.3886554410044248e-06
4.0,1363.0,1201.0,0.002935,0.002935,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG003,diabetes type 2,INDUSTRY,0.00720929,0.007209260964652796,2.9035347203811013e-08
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG004,diabetes type 2,INDUSTRY,0.00900978,0.009004252833085301,5.527166914699039e-06
6.0,1363.0,1201.0,0.004402,0.004402,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG005,diabetes type 2,INDUSTRY,0.01081271,0.010975974289761922,0.00016326428976192256
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG006,diabetes type 2,INDUSTRY,0.00900978,0.009001335853918635,8.444146081365567e-06
4.0,1363.0,1201.0,0.002935,0.002935,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG007,diabetes type 2,INDUSTRY,0.00720929,0.007209956765486128,6.667654861274713e-07
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG008,diabetes type 2,INDUSTRY,0.00540636,0.005404418147475664,1.9418525243359436e-06
6.0,1363.0,1201.0,0.004402,0.004402,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 24,FG009,diabetes type 2,INDUSTRY,0.01081271,0.010975974289761922,0.00016326428976192256
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG001,diabetes type 2,INDUSTRY,0.00180294,0.0018038490839285728,9.090839285727514e-07
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 24,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG000,diabetes type 2,INDUSTRY,0.00540636,0.005380283381642326,2.607661835767397e-05
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG001,diabetes type 2,INDUSTRY,0.00900978,0.008996526204216253,1.3253795783747455e-05
7.0,1363.0,1201.0,0.005136,0.005136,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG002,diabetes type 2,INDUSTRY,0.01261565,0.01268980031364087,7.415031364086874e-05
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG003,diabetes type 2,INDUSTRY,0.00900978,0.009008936622132917,8.433778670834807e-07
8.0,1363.0,1201.0,0.005869,0.005869,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG004,diabetes type 2,INDUSTRY,0.01441613,0.014426997395119021,1.0867395119022044e-05
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG005,diabetes type 2,INDUSTRY,0.00900978,0.009008741122132917,1.0388778670829268e-06
5.0,1363.0,1201.0,0.003668,0.003668,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG006,diabetes type 2,INDUSTRY,0.00900978,0.009005751505466252,4.028494533748692e-06
8.0,1363.0,1201.0,0.005869,0.005869,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG007,diabetes type 2,INDUSTRY,0.01441613,0.014426997395119021,1.0867395119022044e-05
7.0,1363.0,1201.0,0.005136,0.005136,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG008,diabetes type 2,INDUSTRY,0.01261565,0.012699385165724195,8.37351657241945e-05
8.0,1363.0,1201.0,0.005869,0.005869,7.218177,0.340296,1.0,1405.0,22.0,211.0,Lost to Follow-up,Week 52,FG009,diabetes type 2,INDUSTRY,0.01441613,0.01443154545761902,1.541545761902033e-05
9.0,1363.0,1201.0,0.006603,0.006603,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG000,diabetes type 2,INDUSTRY,0.01621907,0.016236685095763898,1.7615095763898886e-05
4.0,1363.0,1201.0,0.002935,0.002935,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG001,diabetes type 2,INDUSTRY,0.00720929,0.007210385160039694,1.0951600396937392e-06
6.0,1363.0,1201.0,0.004402,0.004402,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG002,diabetes type 2,INDUSTRY,0.01081271,0.010936776833988117,0.00012406683398811721
12.0,1363.0,1201.0,0.008804,0.008804,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG003,diabetes type 2,INDUSTRY,0.02162543,0.021551281771011944,7.414822898805726e-05
7.0,1363.0,1201.0,0.005136,0.005136,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG004,diabetes type 2,INDUSTRY,0.01261565,0.01268845055733134,7.280055733133867e-05
12.0,1363.0,1201.0,0.008804,0.008804,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG005,diabetes type 2,INDUSTRY,0.02162543,0.021550751041845277,7.467895815472386e-05
10.0,1363.0,1201.0,0.007337,0.007337,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG006,diabetes type 2,INDUSTRY,0.01802201,0.01805271709656745,3.0707096567449826e-05
12.0,1363.0,1201.0,0.008804,0.008804,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG007,diabetes type 2,INDUSTRY,0.02162543,0.021551281771011944,7.414822898805726e-05
13.0,1363.0,1201.0,0.009538,0.009538,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG008,diabetes type 2,INDUSTRY,0.02342836,0.023168426573194442,0.00025993342680555656
9.0,1363.0,1201.0,0.006603,0.006603,7.218177,0.340296,1.0,1405.0,22.0,211.0,Consent withdrawn,Week 52,FG009,diabetes type 2,INDUSTRY,0.01621907,0.016247600963650806,2.853096365080729e-05
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG001,diabetes type 2,INDUSTRY,0.00180294,0.0018021163137500026,8.236862499974226e-07
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG003,diabetes type 2,INDUSTRY,0.00180294,0.0018032071427380976,2.6714273809757584e-07
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG006,diabetes type 2,INDUSTRY,0.00180294,0.001801957613571431,9.823864285691142e-07
3.0,1363.0,1201.0,0.002201,0.002201,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG007,diabetes type 2,INDUSTRY,0.00540636,0.005406431442892331,7.144289233124157e-08
1.0,1363.0,1201.0,0.000734,0.000734,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG008,diabetes type 2,INDUSTRY,0.00180294,0.001801957613571431,9.823864285691142e-07
0.0,1363.0,1201.0,0.0,0.0,7.218177,0.340296,1.0,1405.0,22.0,211.0,Death,Week 52,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,458.0,447.0,0.002183,0.002183,6.12905,0.49917,1.0,458.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00667875,0.00666995147387898,8.79852612101998e-06
2.0,458.0,447.0,0.004367,0.004367,6.12905,0.49917,1.0,458.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01336056,0.01331384320243055,4.6716797569450186e-05
2.0,458.0,447.0,0.004367,0.004367,6.12905,0.49917,1.0,458.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01336056,0.013339615309960315,2.0944690039685285e-05
6.0,458.0,447.0,0.0131,0.0131,6.12905,0.49917,1.0,458.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04007863,0.03973773587133924,0.00034089412866075697
22.0,308.0,251.0,0.071429,0.071429,5.733341,0.645808,1.0,308.0,1.0,26.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.26447586,0.2636145898883135,0.0008612701116865185
10.0,308.0,251.0,0.032468,0.032468,5.733341,0.645808,1.0,308.0,1.0,26.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12021731,0.1203858786393751,0.00016856863937510236
3.0,308.0,251.0,0.00974,0.00974,5.733341,0.645808,1.0,308.0,1.0,26.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03606371,0.035983917448125013,7.979255187498535e-05
3.0,308.0,251.0,0.00974,0.00974,5.733341,0.645808,1.0,308.0,1.0,26.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03606371,0.0359356367669147,0.00012807323308530044
4.0,308.0,251.0,0.012987,0.012987,5.733341,0.645808,1.0,308.0,1.0,26.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04808618,0.04898474209976196,0.0008985620997619612
13.0,308.0,251.0,0.042208,0.042208,5.733341,0.645808,1.0,308.0,1.0,26.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.15628102,0.155698108996288,0.0005829110037119944
1.0,308.0,251.0,0.003247,0.003247,5.733341,0.645808,1.0,308.0,1.0,26.0,Progressive Disease,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01202247,0.012111993255922595,8.952325592259495e-05
1.0,308.0,251.0,0.003247,0.003247,5.733341,0.645808,1.0,308.0,1.0,26.0,Progressive Disease,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01202247,0.012099344975922592,7.687497592259208e-05
1.0,200.0,163.0,0.005,0.005,5.303305,0.577631,1.0,200.0,0.0,0.0,Not Treated,Randomization,FG000,diabetes type 2,INDUSTRY,0.01531676,0.015369189446339337,5.242944633933669e-05
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Not Treated,Randomization,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Not Treated,Randomization,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Not Treated,Randomization,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,200.0,163.0,0.01,0.01,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.03063351,0.030845074518452358,0.00021156451845235832
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,200.0,163.0,0.025,0.025,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.07658379,0.07738462669181564,0.0008008366918156457
2.0,200.0,163.0,0.01,0.01,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.03063351,0.030790530610119007,0.00015702061011900817
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,200.0,163.0,0.015,0.015,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG000,diabetes type 2,INDUSTRY,0.04595027,0.04615702556503968,0.00020675556503967768
2.0,200.0,163.0,0.01,0.01,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG001,diabetes type 2,INDUSTRY,0.03063351,0.030799157016785688,0.00016564701678568883
1.0,200.0,163.0,0.005,0.005,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG002,diabetes type 2,INDUSTRY,0.01531676,0.01536926139366078,5.250139366077926e-05
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 0-20,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,200.0,163.0,0.02,0.02,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.06126703,0.06309438617067469,0.001827356170674685
3.0,200.0,163.0,0.015,0.015,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.04595027,0.04622667974450395,0.00027640974450394984
1.0,200.0,163.0,0.005,0.005,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.01531676,0.015343199273660789,2.6439273660788104e-05
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Lost to Follow-up,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,200.0,163.0,0.01,0.01,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.03063351,0.030917100799702363,0.0002835907997023636
2.0,200.0,163.0,0.01,0.01,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.03063351,0.03084595544845235,0.00021244544845235025
1.0,200.0,163.0,0.005,0.005,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.01531676,0.01534492068199412,2.8160681994120196e-05
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Parent/Guardian,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,200.0,163.0,0.025,0.025,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG000,diabetes type 2,INDUSTRY,0.07658379,0.07732724454038706,0.000743454540387059
3.0,200.0,163.0,0.015,0.015,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG001,diabetes type 2,INDUSTRY,0.04595027,0.04622485087295636,0.00027458087295635647
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,200.0,163.0,0.0,0.0,5.303305,0.577631,1.0,200.0,0.0,0.0,Withdrawal by Subject,Weeks 20-54,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,360.0,286.0,0.011111,0.011111,5.888878,0.410878,1.0,360.0,1.0,34.0,Subject non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02688427,0.026889236853434292,4.966853434294066e-06
3.0,360.0,286.0,0.008333,0.008333,5.888878,0.410878,1.0,360.0,1.0,34.0,Subject non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0201626,0.01976406886234128,0.00039853113765871834
5.0,360.0,286.0,0.013889,0.013889,5.888878,0.410878,1.0,360.0,1.0,34.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03360594,0.03255947246044644,0.0010464675395535639
1.0,360.0,286.0,0.002778,0.002778,5.888878,0.410878,1.0,360.0,1.0,34.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00672167,0.0067395580661084075,1.788806610840757e-05
14.0,360.0,286.0,0.038889,0.038889,5.888878,0.410878,1.0,360.0,1.0,34.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09409615,0.09382694078791673,0.000269209212083274
8.0,360.0,286.0,0.022222,0.022222,5.888878,0.410878,1.0,360.0,1.0,34.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05376854,0.05270333380577385,0.0010652061942261482
19.0,360.0,286.0,0.052778,0.052778,5.888878,0.410878,1.0,360.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.12770209,0.12481080566333336,0.002891284336666633
15.0,360.0,286.0,0.041667,0.041667,5.888878,0.410878,1.0,360.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10081782,0.1010220534382143,0.0002042334382142963
1.0,360.0,286.0,0.002778,0.002778,5.888878,0.410878,1.0,360.0,1.0,34.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00672167,0.006746357145929837,2.4687145929837458e-05
2.0,360.0,286.0,0.005556,0.005556,5.888878,0.410878,1.0,360.0,1.0,34.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01344334,0.013738281738885276,0.00029494173888527583
0.0,360.0,286.0,0.0,0.0,5.888878,0.410878,1.0,360.0,1.0,34.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,360.0,286.0,0.002778,0.002778,5.888878,0.410878,1.0,360.0,1.0,34.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00672167,0.00673824427694174,1.6574276941740476e-05
0.0,360.0,286.0,0.0,0.0,5.888878,0.410878,1.0,360.0,1.0,34.0,Non-completion of visit activity,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,360.0,286.0,0.002778,0.002778,5.888878,0.410878,1.0,360.0,1.0,34.0,Non-completion of visit activity,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00672167,0.00673824427694174,1.6574276941740476e-05
1.0,203.0,188.0,0.004926,0.004926,5.31812,0.405933,1.0,203.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01063426,0.010752169211130938,0.0001179092111309385
2.0,203.0,188.0,0.009852,0.009852,5.31812,0.405933,1.0,203.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02126852,0.021407046321031745,0.00013852632103174625
1.0,203.0,188.0,0.004926,0.004926,5.31812,0.405933,1.0,203.0,0.0,0.0,Study site terminated by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01063426,0.010732201363571406,9.794136357140631e-05
1.0,203.0,188.0,0.004926,0.004926,5.31812,0.405933,1.0,203.0,0.0,0.0,Study site terminated by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01063426,0.010731257656994024,9.699765699402486e-05
6.0,203.0,188.0,0.029557,0.029557,5.31812,0.405933,1.0,203.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06380773,0.06837281573353175,0.00456508573353176
4.0,203.0,188.0,0.019704,0.019704,5.31812,0.405933,1.0,203.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04253705,0.04252993242467263,7.117575327370007e-06
7.0,391.0,310.0,0.017903,0.017903,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.02225603,0.022108932540913586,0.00014709745908641353
3.0,391.0,310.0,0.007673,0.007673,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.00953865,0.009519740517738124,1.8909482261875513e-05
3.0,391.0,310.0,0.007673,0.007673,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.00953865,0.0095127937514286,2.5856248571399024e-05
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.00317997,0.0031821418527083287,2.1718527083288905e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Death,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.00635869,0.006367399149732099,8.709149732099089e-06
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.00635869,0.006369344982886877,1.0654982886876621e-05
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.00317997,0.0031756058768749947,4.364123125005174e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
4.0,391.0,310.0,0.01023,0.01023,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.01271737,0.01289384276431548,0.0001764727643154794
6.0,391.0,310.0,0.015345,0.015345,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.01907606,0.018402350458125005,0.0006737095418749943
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.00635869,0.006365934130922572,7.244130922571396e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
9.0,391.0,310.0,0.023018,0.023018,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.02861471,0.028516705035654774,9.800496434522743e-05
4.0,391.0,310.0,0.01023,0.01023,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.01271737,0.012938203430982146,0.00022083343098214595
5.0,391.0,310.0,0.012788,0.012788,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.01589734,0.015595427201408728,0.0003019127985912709
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.00317997,0.003190291753958326,1.0321753958326095e-05
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.00635869,0.0063679387520833046,9.248752083304383e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG000,diabetes type 2,OTHER,0.00635869,0.006364805130595191,6.115130595191025e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG001,diabetes type 2,OTHER,0.0,0.0,0.0
5.0,391.0,310.0,0.012788,0.012788,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG002,diabetes type 2,OTHER,0.01589734,0.015608691757420636,0.00028864824257936357
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,First Period (First 6 Months),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
3.0,391.0,310.0,0.007673,0.007673,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.00953865,0.009513137393700428,2.5512606299571416e-05
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.00635869,0.006365330487172568,6.640487172567509e-06
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.00317997,0.0031801111419345156,1.4114193451573304e-07
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Lost to Follow-up,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.00635869,0.006362338278005902,3.6482780059014785e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.00317997,0.0031825768260416607,2.6068260416609035e-06
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.00317997,0.0031763517365178493,3.6182634821505313e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Protocol Violation,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.00635869,0.006363766527678525,5.076527678524699e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Withdrawal by Subject,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.00317997,0.003181469375267851,1.49937526785094e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Adverse Event,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.00317997,0.003182983847351182,3.0138473511823367e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.00317997,0.003183970309434516,4.000309434516302e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Clinically significant lab abnormalities,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
4.0,391.0,310.0,0.01023,0.01023,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG000,diabetes type 2,OTHER,0.01271737,0.012906123651815482,0.00018875365181548164
2.0,391.0,310.0,0.005115,0.005115,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG001,diabetes type 2,OTHER,0.00635869,0.006366645220416634,7.955220416634191e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG003,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,391.0,310.0,0.002558,0.002558,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG004,diabetes type 2,OTHER,0.00317997,0.003183970309434516,4.000309434516302e-06
0.0,391.0,310.0,0.0,0.0,5.971262,0.208188,1.0,391.0,1.0,1.0,Administrative reasons,Second Period (Additional Drug Added),FG005,diabetes type 2,OTHER,0.0,0.0,0.0
2.0,291.0,282.0,0.006873,0.006873,5.676754,0.421848,1.0,291.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01645895,0.017345863830325586,0.0008869138303255857
1.0,291.0,282.0,0.003436,0.003436,5.676754,0.421848,1.0,291.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00822828,0.008340923759880946,0.00011264375988094717
3.0,291.0,282.0,0.010309,0.010309,5.676754,0.421848,1.0,291.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02468723,0.02483599688955358,0.0001487668895535782
0.0,291.0,282.0,0.0,0.0,5.676754,0.421848,1.0,291.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,291.0,282.0,0.0,0.0,5.676754,0.421848,1.0,291.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,291.0,282.0,0.010309,0.010309,5.676754,0.421848,1.0,291.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02468723,0.024801262551220248,0.00011403255122024655
9.0,446.0,405.0,0.020179,0.020179,6.102559,0.283988,1.0,446.0,26.0,140.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03497134,0.03517524903678569,0.00020390903678569466
19.0,446.0,405.0,0.042601,0.042601,6.102559,0.283988,1.0,446.0,26.0,140.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07382992,0.0747763551247124,0.0009464351247124025
1.0,446.0,405.0,0.002242,0.002242,6.102559,0.283988,1.0,446.0,26.0,140.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00388551,0.003914192572321411,2.868257232141111e-05
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00777102,0.007768445863232573,2.5741367674272236e-06
0.0,446.0,405.0,0.0,0.0,6.102559,0.283988,1.0,446.0,26.0,140.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00777102,0.007769644443232573,1.3755567674269414e-06
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00777102,0.0077623944972206715,8.62550277932854e-06
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00777102,0.007768068286089716,2.9517139102843565e-06
0.0,446.0,405.0,0.0,0.0,6.102559,0.283988,1.0,446.0,26.0,140.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00777102,0.00776852096989924,2.499030100759983e-06
0.0,446.0,405.0,0.0,0.0,6.102559,0.283988,1.0,446.0,26.0,140.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,446.0,405.0,0.004484,0.004484,6.102559,0.283988,1.0,446.0,26.0,140.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00777102,0.007767752130732573,3.267869267426643e-06
7.0,461.0,419.0,0.015184,0.015184,6.135565,0.4411,1.0,464.0,6.0,123.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04109395,0.04153037249017858,0.00043642249017858403
4.0,461.0,419.0,0.008677,0.008677,6.135565,0.4411,1.0,464.0,6.0,123.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02348342,0.023534475939622976,5.105593962297442e-05
0.0,461.0,419.0,0.0,0.0,6.135565,0.4411,1.0,464.0,6.0,123.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,419.0,0.002169,0.002169,6.135565,0.4411,1.0,464.0,6.0,123.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00587018,0.005870135322053582,4.4677946418013315e-08
5.0,461.0,419.0,0.010846,0.010846,6.135565,0.4411,1.0,464.0,6.0,123.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0293536,0.029648162174970218,0.0002945621749702171
3.0,461.0,419.0,0.006508,0.006508,6.135565,0.4411,1.0,464.0,6.0,123.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01761324,0.01752967494661705,8.356505338294809e-05
4.0,461.0,419.0,0.008677,0.008677,6.135565,0.4411,1.0,464.0,6.0,123.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02348342,0.023456712438194423,2.6707561805578567e-05
6.0,461.0,419.0,0.013015,0.013015,6.135565,0.4411,1.0,464.0,6.0,123.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03522378,0.03588784892506942,0.0006640689250694137
1.0,461.0,419.0,0.002169,0.002169,6.135565,0.4411,1.0,464.0,6.0,123.0,Did not receive treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00587018,0.005873587684761915,3.4076847619151154e-06
0.0,461.0,419.0,0.0,0.0,6.135565,0.4411,1.0,464.0,6.0,123.0,Did not receive treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,461.0,419.0,0.006508,0.006508,6.135565,0.4411,1.0,464.0,6.0,123.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01761324,0.01754126453265873,7.197546734126828e-05
8.0,461.0,419.0,0.017354,0.017354,6.135565,0.4411,1.0,464.0,6.0,123.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04696684,0.047342200197529764,0.0003753601975297616
4.0,484.0,379.0,0.008264,0.008264,6.184149,0.270051,1.0,484.0,15.0,15.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01380115,0.013845524671051586,4.437467105158563e-05
6.0,484.0,379.0,0.012397,0.012397,6.184149,0.270051,1.0,484.0,15.0,15.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0207034,0.02092455197545635,0.0002211519754563504
19.0,484.0,379.0,0.039256,0.039256,6.184149,0.270051,1.0,484.0,15.0,15.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06555881,0.06590451564832611,0.0003457056483261167
14.0,484.0,379.0,0.028926,0.028926,6.184149,0.270051,1.0,484.0,15.0,15.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04830737,0.04849645166403046,0.0001890816640304563
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00345029,0.0034532390602380787,2.9490602380787684e-06
4.0,484.0,379.0,0.008264,0.008264,6.184149,0.270051,1.0,484.0,15.0,15.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01380115,0.013832626624742057,3.1476624742057466e-05
3.0,484.0,379.0,0.006198,0.006198,6.184149,0.270051,1.0,484.0,15.0,15.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01035086,0.010370620362018386,1.9760362018386365e-05
2.0,484.0,379.0,0.004132,0.004132,6.184149,0.270051,1.0,484.0,15.0,15.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00690058,0.006914853702093236,1.427370209323639e-05
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00345029,0.0034515162039880786,1.2262039880786037e-06
6.0,484.0,379.0,0.012397,0.012397,6.184149,0.270051,1.0,484.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0207034,0.02102667734714285,0.0003232773471428495
9.0,484.0,379.0,0.018595,0.018595,6.184149,0.270051,1.0,484.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03105426,0.03156018825954365,0.0005059282595436532
7.0,484.0,379.0,0.014463,0.014463,6.184149,0.270051,1.0,484.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02415368,0.0241424185883135,1.1261411686499384e-05
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00345029,0.0034477409023809364,2.549097619063568e-06
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00345029,0.0034514468039880787,1.1568039880787903e-06
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00345029,0.0034514808239682403,1.1908239682402975e-06
2.0,484.0,379.0,0.004132,0.004132,6.184149,0.270051,1.0,484.0,15.0,15.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00690058,0.006916173014315459,1.5593014315458918e-05
2.0,484.0,379.0,0.004132,0.004132,6.184149,0.270051,1.0,484.0,15.0,15.0,Poor Compliance to Protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00690058,0.006916353250505933,1.5773250505933013e-05
5.0,484.0,379.0,0.010331,0.010331,6.184149,0.270051,1.0,484.0,15.0,15.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01725311,0.017521105943095246,0.00026799594309524777
3.0,484.0,379.0,0.006198,0.006198,6.184149,0.270051,1.0,484.0,15.0,15.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01035086,0.010356815600530287,5.955600530287153e-06
5.0,484.0,379.0,0.010331,0.010331,6.184149,0.270051,1.0,484.0,15.0,15.0,Familial and Personal Reasons,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01725311,0.01751831257267858,0.00026520257267858074
4.0,484.0,379.0,0.008264,0.008264,6.184149,0.270051,1.0,484.0,15.0,15.0,Familial and Personal Reasons,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01380115,0.013842554959384919,4.1404959384918824e-05
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Randomized but not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00345029,0.003451382912321412,1.0929123214118396e-06
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Randomized but not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00345029,0.0034514169323015737,1.1269323015737805e-06
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Randomized but not Treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Randomized but not Treated,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,484.0,379.0,0.0,0.0,6.184149,0.270051,1.0,484.0,15.0,15.0,Study Site Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Study Site Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00345029,0.00345113857396824,8.485739682400316e-07
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Study Site Reason,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00345029,0.003449444885714269,8.451142857308046e-07
1.0,484.0,379.0,0.002066,0.002066,6.184149,0.270051,1.0,484.0,15.0,15.0,Study Site Reason,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00345029,0.003450625277380936,3.3527738093610746e-07
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00301474,0.0030167666952976304,2.0266952976302592e-06
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00301474,0.0030108023584722336,3.9376415277665375e-06
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00301474,0.0030134382318055667,1.3017681944334052e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00602947,0.006025245994583378,4.2240054166226004e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00602947,0.006024980363869092,4.489636130908248e-06
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00301474,0.003013952529404773,7.874705952272062e-07
4.0,369.0,322.0,0.01084,0.01084,5.913503,0.18812,1.0,369.0,6.0,85.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.01205895,0.012056228937738096,2.721062261904633e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00602947,0.006032128504345277,2.65850434527648e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00602947,0.00601739459107147,1.2075408928530207e-05
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00602947,0.006028133336428613,1.3366635713872935e-06
3.0,369.0,322.0,0.00813,0.00813,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00904421,0.009098596667192456,5.4386667192455815e-05
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00602947,0.006027892562678616,1.577437321383969e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00301474,0.0030143546174404867,3.853825595134634e-07
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00602947,0.006027228997678615,2.24100232138532e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00301474,0.003015604073115089,8.640731150887961e-07
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00301474,0.0030160510629762007,1.311062976200577e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Protocol Violation,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00301474,0.0030162076238095348,1.4676238095346315e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00301474,0.0030066824625793755,8.057537420624612e-06
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00301474,0.0030093790275793754,5.360972420624752e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00602947,0.006027619691607188,1.8503083928124442e-06
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00602947,0.006027317873392901,2.1521266070989933e-06
3.0,369.0,322.0,0.00813,0.00813,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00904421,0.009117675271507938,7.346527150793765e-05
2.0,369.0,322.0,0.00542,0.00542,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00602947,0.006026248251607186,3.2217483928141666e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00301474,0.0030177970812500106,3.057081250010512e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Fasting plasma glucose >240 mg/dL,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Glycemia over 13.3 millimole per litre,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00301474,0.0030148754488690593,1.3544886905917514e-07
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00301474,0.0030148959047023916,1.5590470239150792e-07
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Investigator's Decision,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Non-compliance with study medication,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00301474,0.0030148754488690593,1.3544886905917514e-07
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00301474,0.0030177970812500106,3.057081250010512e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant travelled Overseas,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00301474,0.0030115598956746135,3.180104325386634e-06
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Participant out of assessment window,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,369.0,322.0,0.00271,0.00271,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00301474,0.0030147188880357252,2.1111964274879436e-08
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,369.0,322.0,0.0,0.0,5.913503,0.18812,1.0,369.0,6.0,85.0,Withdrawal by participant,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,701.0,310.0,0.024251,0.024251,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.03057438,0.03113061575011904,0.0005562357501190385
9.0,701.0,310.0,0.012839,0.012839,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.01618673,0.016207655403849205,2.0925403849205576e-05
7.0,701.0,310.0,0.009986,0.009986,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.01258982,0.012990599835416667,0.0004007798354166668
13.0,701.0,310.0,0.018545,0.018545,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.02338055,0.02322863610894932,0.0001519138910506812
4.0,701.0,310.0,0.005706,0.005706,6.553933,0.192365,1.0,701.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.00719382,0.007241460164166655,4.764016416665493e-05
5.0,701.0,310.0,0.007133,0.007133,6.553933,0.192365,1.0,701.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.00899291,0.008963381785297585,2.952821470241472e-05
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.005396,0.005396995619910702,9.956199107019267e-07
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.00179909,0.001798554213750002,5.357862499979094e-07
10.0,701.0,310.0,0.014265,0.014265,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.01798456,0.01799790402047624,1.3344020476240698e-05
10.0,701.0,310.0,0.014265,0.014265,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.01798456,0.017991173173392903,6.6131733929032654e-06
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Moved,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.00359691,0.0035752878855357002,2.1622114464299805e-05
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Moved,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.005396,0.005389940685267844,6.059314732155367e-06
4.0,701.0,310.0,0.005706,0.005706,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Spec lab discon criteria,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.00719382,0.007241301992797613,4.748199279761261e-05
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Spec lab discon criteria,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.005396,0.005386808435267845,9.191564732154676e-06
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Poor compliance,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.00179909,0.001799768750000003,6.787500000031248e-07
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Poor compliance,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.00179909,0.0017977802720833356,1.309727916664347e-06
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Personal Circumstance,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017992981416666699,2.0814166666995385e-07
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Personal Circumstance,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00359691,0.0035729151522023643,2.3994847797635752e-05
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.00179909,0.001797980914583336,1.109085416663982e-06
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00359691,0.0035753484255356977,2.156157446430232e-05
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.00359691,0.0035634557486607025,3.34542513392975e-05
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017990330500000033,5.694999999665204e-08
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.00179909,0.0017987402312500025,3.49768749997436e-07
16.0,701.0,310.0,0.022825,0.022825,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient received Phase A rescue therapy,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.02877655,0.028722185378422617,5.43646215773845e-05
23.0,701.0,310.0,0.03281,0.03281,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient received Phase A rescue therapy,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.04136511,0.04152203378239089,0.00015692378239089144
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Spec lab discon criteria,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017990330500000033,5.694999999665204e-08
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Spec lab discon criteria,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.00179909,0.001797980914583336,1.109085416663982e-06
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Poor compliance,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017990330500000033,5.694999999665204e-08
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Poor compliance,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase A to Phase B Transition Period,FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017990330500000033,5.694999999665204e-08
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase A to Phase B Transition Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
16.0,701.0,310.0,0.022825,0.022825,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.02877655,0.028790416414553564,1.3866414553562884e-05
10.0,701.0,310.0,0.014265,0.014265,6.553933,0.192365,1.0,701.0,0.0,0.0,Adverse Event,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.01798456,0.017942964360654824,4.159563934517593e-05
94.0,701.0,310.0,0.134094,0.134094,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.16905861,0.17698970693908733,0.007931096939087334
19.0,701.0,310.0,0.027104,0.027104,6.553933,0.192365,1.0,701.0,0.0,0.0,Lack of Efficacy,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.03417129,0.033655856666855145,0.0005154333331448546
13.0,701.0,310.0,0.018545,0.018545,6.553933,0.192365,1.0,701.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.02338055,0.023304428846786632,7.612115321336752e-05
4.0,701.0,310.0,0.005706,0.005706,6.553933,0.192365,1.0,701.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.00719382,0.007246891748452371,5.307174845237128e-05
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Physician Decision,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.005396,0.005385047318898797,1.0952681101203052e-05
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Physician Decision,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017995735041666692,4.835041666692574e-07
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol Violation,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
15.0,701.0,310.0,0.021398,0.021398,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.02697746,0.02739844965389882,0.0004209896538988171
5.0,701.0,310.0,0.007133,0.007133,6.553933,0.192365,1.0,701.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.00899291,0.008972883298611076,2.0026701388923748e-05
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Moved,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.00359691,0.0035805379022023644,1.6372097797635616e-05
2.0,701.0,310.0,0.002853,0.002853,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Moved,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.00359691,0.0035690025086607038,2.7907491339296264e-05
5.0,701.0,310.0,0.007133,0.007133,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Specific discontinuation,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.00899291,0.008967813629801556,2.5096370198443574e-05
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Specific discontinuation,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.005396,0.00538601529627975,9.984703720249816e-06
36.0,701.0,310.0,0.051355,0.051355,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Specific lab discon criteria,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.06474566,0.06943502752360119,0.00468936752360119
10.0,701.0,310.0,0.014265,0.014265,6.553933,0.192365,1.0,701.0,0.0,0.0,Protocol-Specific lab discon criteria,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.01798456,0.017987585259047683,3.02525904768286e-06
3.0,701.0,310.0,0.00428,0.00428,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Died,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.005396,0.005387967525148796,8.032474851203328e-06
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient Died,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.00179909,0.0017975013345833352,1.5886654166647612e-06
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Patient needed prohibited treatment,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.00179909,0.0017975013345833352,1.5886654166647612e-06
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Personal Circumstance,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017990230791666694,6.692083333054849e-08
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Personal Circumstance,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,701.0,310.0,0.001427,0.001427,6.553933,0.192365,1.0,701.0,0.0,0.0,Discontinued in error,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.00179909,0.0017994936875000028,4.036875000028393e-07
0.0,701.0,310.0,0.0,0.0,6.553933,0.192365,1.0,701.0,0.0,0.0,Discontinued in error,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,431.0,375.0,0.013921,0.013921,6.068426,0.337801,1.0,431.0,12.0,140.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02853696,0.028512779302820118,2.4180697179881916e-05
5.0,431.0,375.0,0.011601,0.011601,6.068426,0.337801,1.0,431.0,12.0,140.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02378114,0.023676747576934543,0.00010439242306545596
6.0,431.0,375.0,0.013921,0.013921,6.068426,0.337801,1.0,431.0,12.0,140.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02853696,0.02849613589407012,4.0824105929881255e-05
4.0,431.0,375.0,0.009281,0.009281,6.068426,0.337801,1.0,431.0,12.0,140.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01902532,0.01894665583554561,7.866416445438673e-05
1.0,431.0,375.0,0.00232,0.00232,6.068426,0.337801,1.0,431.0,12.0,140.0,Investigator's Discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00475582,0.004781448073872859,2.562807387285898e-05
2.0,431.0,375.0,0.00464,0.00464,6.068426,0.337801,1.0,431.0,12.0,140.0,Investigator's Discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00951164,0.00967483741869048,0.0001631974186904802
1.0,431.0,375.0,0.00232,0.00232,6.068426,0.337801,1.0,431.0,12.0,140.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00475582,0.004779967561372855,2.4147561372854856e-05
1.0,431.0,375.0,0.00232,0.00232,6.068426,0.337801,1.0,431.0,12.0,140.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00475582,0.004776980579468098,2.116057946809774e-05
3.0,431.0,375.0,0.006961,0.006961,6.068426,0.337801,1.0,431.0,12.0,140.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01426951,0.014279246009265887,9.736009265888176e-06
3.0,431.0,375.0,0.006961,0.006961,6.068426,0.337801,1.0,431.0,12.0,140.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01426951,0.014255168809553584,1.4341190446414895e-05
9.0,431.0,375.0,0.020882,0.020882,6.068426,0.337801,1.0,431.0,12.0,140.0,Subject Non-Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04280647,0.04267367722370036,0.00013279277629964226
10.0,431.0,375.0,0.023202,0.023202,6.068426,0.337801,1.0,431.0,12.0,140.0,Subject Non-Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04756228,0.047677744862400756,0.0001154648624007576
2.0,431.0,375.0,0.00464,0.00464,6.068426,0.337801,1.0,431.0,12.0,140.0,Subject Withdrew Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00951164,0.009699550558769844,0.0001879105587698441
3.0,431.0,375.0,0.006961,0.006961,6.068426,0.337801,1.0,431.0,12.0,140.0,Subject Withdrew Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01426951,0.014258016616636917,1.1493383363082171e-05
3.0,680.0,511.0,0.004412,0.004412,6.523562,0.273859,1.0,680.0,16.0,16.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00788221,0.007869483410803573,1.2726589196427121e-05
3.0,680.0,511.0,0.004412,0.004412,6.523562,0.273859,1.0,680.0,16.0,16.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00788221,0.007880232054583334,1.977945416667057e-06
21.0,680.0,511.0,0.030882,0.030882,6.523562,0.273859,1.0,680.0,16.0,16.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05517188,0.054086893919791636,0.0010849860802083638
26.0,680.0,511.0,0.038235,0.038235,6.523562,0.273859,1.0,680.0,16.0,16.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.06830829,0.06739912207571433,0.0009091679242856643
2.0,680.0,511.0,0.002941,0.002941,6.523562,0.273859,1.0,680.0,16.0,16.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00525421,0.0052558851014483975,1.6751014483978865e-06
8.0,680.0,511.0,0.011765,0.011765,6.523562,0.273859,1.0,680.0,16.0,16.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02101862,0.02095079356602543,6.782643397456808e-05
8.0,680.0,511.0,0.011765,0.011765,6.523562,0.273859,1.0,680.0,16.0,16.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02101862,0.020953171148247657,6.544885175234147e-05
6.0,680.0,511.0,0.008824,0.008824,6.523562,0.273859,1.0,680.0,16.0,16.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01576441,0.0157235225325,4.0887467500000385e-05
3.0,680.0,511.0,0.004412,0.004412,6.523562,0.273859,1.0,680.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00788221,0.00787154322163691,1.0666778363090448e-05
3.0,680.0,511.0,0.004412,0.004412,6.523562,0.273859,1.0,680.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00788221,0.00788229186541667,8.186541666961589e-08
4.0,680.0,511.0,0.005882,0.005882,6.523562,0.273859,1.0,680.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01050842,0.010500962487380945,7.457512619053752e-06
16.0,680.0,511.0,0.023529,0.023529,6.523562,0.273859,1.0,680.0,16.0,16.0,Poor Compliance to Protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04203546,0.0411822797488393,0.0008531802511606984
1.0,680.0,511.0,0.001471,0.001471,6.523562,0.273859,1.0,680.0,16.0,16.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.002628,0.002650223270297621,2.2223270297620692e-05
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,680.0,511.0,0.002941,0.002941,6.523562,0.273859,1.0,680.0,16.0,16.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00525421,0.005261853529265856,7.643529265856722e-06
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,680.0,511.0,0.008824,0.008824,6.523562,0.273859,1.0,680.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01576441,0.015663752754166663,0.00010065724583333685
7.0,680.0,511.0,0.010294,0.010294,6.523562,0.273859,1.0,680.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01839063,0.0186095393016369,0.00021890930163689926
15.0,680.0,511.0,0.022059,0.022059,6.523562,0.273859,1.0,680.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03940925,0.03923563420976186,0.00017361579023814078
20.0,680.0,511.0,0.029412,0.029412,6.523562,0.273859,1.0,680.0,16.0,16.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.05254566,0.05188435442023812,0.0006613055797618783
5.0,680.0,511.0,0.007353,0.007353,6.523562,0.273859,1.0,680.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01313642,0.0131197838274008,1.663617259919925e-05
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,680.0,511.0,0.007353,0.007353,6.523562,0.273859,1.0,680.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01313642,0.013117758769484128,1.8661230515871693e-05
2.0,680.0,511.0,0.002941,0.002941,6.523562,0.273859,1.0,680.0,16.0,16.0,Familial and Personal Reasons,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00525421,0.00525838429117062,4.1742911706206184e-06
1.0,680.0,511.0,0.001471,0.001471,6.523562,0.273859,1.0,680.0,16.0,16.0,Investigator's Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.002628,0.0026484901467261914,2.049014672619127e-05
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Investigator's Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Investigator's Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Investigator's Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,680.0,511.0,0.002941,0.002941,6.523562,0.273859,1.0,680.0,16.0,16.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00525421,0.005264599294682524,1.0389294682524447e-05
0.0,680.0,511.0,0.0,0.0,6.523562,0.273859,1.0,680.0,16.0,16.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,548.0,346.0,0.007299,0.007299,6.308098,0.254793,1.0,548.0,10.0,81.0,Adverse Event,Main: Week 0 to 26 (NN5401-3594),FG000,diabetes type 2,INDUSTRY,0.01173138,0.011672945742202392,5.8434257797607483e-05
3.0,548.0,346.0,0.005474,0.005474,6.308098,0.254793,1.0,548.0,10.0,81.0,Adverse Event,Main: Week 0 to 26 (NN5401-3594),FG001,diabetes type 2,INDUSTRY,0.00879814,0.00863835843149801,0.00015978156850198974
2.0,548.0,346.0,0.00365,0.00365,6.308098,0.254793,1.0,548.0,10.0,81.0,Lack of Efficacy,Main: Week 0 to 26 (NN5401-3594),FG000,diabetes type 2,INDUSTRY,0.0058665,0.005864640139940476,1.8598600595243556e-06
0.0,548.0,346.0,0.0,0.0,6.308098,0.254793,1.0,548.0,10.0,81.0,Lack of Efficacy,Main: Week 0 to 26 (NN5401-3594),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,548.0,346.0,0.014599,0.014599,6.308098,0.254793,1.0,548.0,10.0,81.0,Protocol Violation,Main: Week 0 to 26 (NN5401-3594),FG000,diabetes type 2,INDUSTRY,0.02346437,0.02295765905461311,0.0005067109453868873
6.0,548.0,346.0,0.010949,0.010949,6.308098,0.254793,1.0,548.0,10.0,81.0,Protocol Violation,Main: Week 0 to 26 (NN5401-3594),FG001,diabetes type 2,INDUSTRY,0.01759788,0.017496158123511886,0.00010172187648811379
7.0,548.0,346.0,0.012774,0.012774,6.308098,0.254793,1.0,548.0,10.0,81.0,Withdrawal criteria,Main: Week 0 to 26 (NN5401-3594),FG000,diabetes type 2,INDUSTRY,0.02053113,0.02045329301205358,7.783698794642038e-05
5.0,548.0,346.0,0.009124,0.009124,6.308098,0.254793,1.0,548.0,10.0,81.0,Withdrawal criteria,Main: Week 0 to 26 (NN5401-3594),FG001,diabetes type 2,INDUSTRY,0.01466463,0.014577575089067443,8.705491093255642e-05
25.0,548.0,346.0,0.04562,0.04562,6.308098,0.254793,1.0,548.0,10.0,81.0,Unclassified,Main: Week 0 to 26 (NN5401-3594),FG000,diabetes type 2,INDUSTRY,0.07332316,0.07319174101949406,0.0001314189805059346
12.0,548.0,346.0,0.021898,0.021898,6.308098,0.254793,1.0,548.0,10.0,81.0,Unclassified,Main: Week 0 to 26 (NN5401-3594),FG001,diabetes type 2,INDUSTRY,0.03519576,0.035289590846160686,9.383084616068627e-05
3.0,548.0,346.0,0.005474,0.005474,6.308098,0.254793,1.0,548.0,10.0,81.0,Adverse Event,Extension: Week 27 to 52 (NN5401-3645),FG000,diabetes type 2,INDUSTRY,0.00879814,0.008639411194295635,0.00015872880570436468
0.0,548.0,346.0,0.0,0.0,6.308098,0.254793,1.0,548.0,10.0,81.0,Adverse Event,Extension: Week 27 to 52 (NN5401-3645),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,548.0,346.0,0.007299,0.007299,6.308098,0.254793,1.0,548.0,10.0,81.0,Protocol Violation,Extension: Week 27 to 52 (NN5401-3645),FG000,diabetes type 2,INDUSTRY,0.01173138,0.011683128935952388,4.8251064047611855e-05
1.0,548.0,346.0,0.001825,0.001825,6.308098,0.254793,1.0,548.0,10.0,81.0,Protocol Violation,Extension: Week 27 to 52 (NN5401-3645),FG001,diabetes type 2,INDUSTRY,0.00293325,0.002851456292159087,8.17937078409132e-05
2.0,548.0,346.0,0.00365,0.00365,6.308098,0.254793,1.0,548.0,10.0,81.0,Withdrawal criteria,Extension: Week 27 to 52 (NN5401-3645),FG000,diabetes type 2,INDUSTRY,0.0058665,0.005865540044107142,9.599558928579527e-07
1.0,548.0,346.0,0.001825,0.001825,6.308098,0.254793,1.0,548.0,10.0,81.0,Withdrawal criteria,Extension: Week 27 to 52 (NN5401-3645),FG001,diabetes type 2,INDUSTRY,0.00293325,0.0028515972459090873,8.165275409091274e-05
12.0,548.0,346.0,0.021898,0.021898,6.308098,0.254793,1.0,548.0,10.0,81.0,Unclassified,Extension: Week 27 to 52 (NN5401-3645),FG000,diabetes type 2,INDUSTRY,0.03519576,0.03525875091050594,6.299091050594036e-05
7.0,548.0,346.0,0.012774,0.012774,6.308098,0.254793,1.0,548.0,10.0,81.0,Unclassified,Extension: Week 27 to 52 (NN5401-3645),FG001,diabetes type 2,INDUSTRY,0.02053113,0.020472079586339294,5.9050413660707846e-05
11.0,514.0,402.0,0.021401,0.021401,6.244167,0.237054,1.0,514.0,3.0,62.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03167786,0.031117167429484168,0.000560692570515834
5.0,514.0,402.0,0.009728,0.009728,6.244167,0.237054,1.0,514.0,3.0,62.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01439943,0.014378751299523816,2.067870047618367e-05
7.0,514.0,402.0,0.013619,0.013619,6.244167,0.237054,1.0,514.0,3.0,62.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02015891,0.02028141642815478,0.00012250642815478038
8.0,514.0,402.0,0.015564,0.015564,6.244167,0.237054,1.0,514.0,3.0,62.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02303791,0.022809368229037716,0.00022854177096228584
9.0,514.0,402.0,0.01751,0.01751,6.244167,0.237054,1.0,514.0,3.0,62.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02591839,0.025828243920158762,9.014607984123707e-05
13.0,514.0,402.0,0.025292,0.025292,6.244167,0.237054,1.0,514.0,3.0,62.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03743734,0.03771970118154762,0.000282361181547619
2.0,514.0,402.0,0.003891,0.003891,6.244167,0.237054,1.0,514.0,3.0,62.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00575948,0.0057148492709821405,4.4630729017859465e-05
4.0,514.0,402.0,0.007782,0.007782,6.244167,0.237054,1.0,514.0,3.0,62.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01151895,0.01159217641642856,7.322641642855919e-05
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00288048,0.0028760243680357052,4.455631964294694e-06
18.0,514.0,402.0,0.035019,0.035019,6.244167,0.237054,1.0,514.0,3.0,62.0,Withdrawal of Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05183529,0.05183905449377967,3.7644937796732503e-06
6.0,514.0,402.0,0.011673,0.011673,6.244167,0.237054,1.0,514.0,3.0,62.0,Withdrawal of Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01727843,0.01714207640372025,0.00013635359627975005
18.0,514.0,402.0,0.035019,0.035019,6.244167,0.237054,1.0,514.0,3.0,62.0,Withdrawal of Consent,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05183529,0.05184686537288681,1.1575372886811486e-05
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Investigator Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00288048,0.0028791334920238,1.346507976199892e-06
3.0,514.0,402.0,0.005837,0.005837,6.244167,0.237054,1.0,514.0,3.0,62.0,Investigator Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00863996,0.008685863801460147,4.590380146014643e-05
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Investigator Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00288048,0.002879424474285705,1.0555257142948193e-06
2.0,514.0,402.0,0.003891,0.003891,6.244167,0.237054,1.0,514.0,3.0,62.0,Administrative,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00575948,0.005709107465565474,5.0372534434526064e-05
0.0,514.0,402.0,0.0,0.0,6.244167,0.237054,1.0,514.0,3.0,62.0,Administrative,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,514.0,402.0,0.0,0.0,6.244167,0.237054,1.0,514.0,3.0,62.0,Administrative,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00288048,0.0028780997899404675,2.3802100595324456e-06
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00288048,0.0028770693547023707,3.4106452976292653e-06
1.0,514.0,402.0,0.001946,0.001946,6.244167,0.237054,1.0,514.0,3.0,62.0,Loss of Glucose Control,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00288048,0.002878360290952372,2.1197090476279823e-06
33.0,685.0,514.0,0.048175,0.048175,6.530878,0.166394,1.0,685.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05235157,0.055710997749216305,0.003359427749216305
31.0,685.0,514.0,0.045255,0.045255,6.530878,0.166394,1.0,685.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04917842,0.05135015281887898,0.002171732818878981
24.0,685.0,514.0,0.035036,0.035036,6.530878,0.166394,1.0,685.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03807347,0.0396801547560119,0.001606684756011903
19.0,685.0,514.0,0.027737,0.027737,6.530878,0.166394,1.0,685.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03014168,0.03185501306218255,0.0017133330621825517
14.0,685.0,514.0,0.020438,0.020438,6.530878,0.166394,1.0,685.0,1.0,1.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02220989,0.022493896777867953,0.0002840067778679539
22.0,685.0,514.0,0.032117,0.032117,6.530878,0.166394,1.0,685.0,1.0,1.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03490141,0.037352889750872975,0.0024514797508729744
16.0,685.0,514.0,0.023358,0.023358,6.530878,0.166394,1.0,685.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02538304,0.02557014542095236,0.00018710542095235969
9.0,685.0,514.0,0.013139,0.013139,6.530878,0.166394,1.0,685.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0142781,0.01611118511461309,0.0018330851146130898
0.0,685.0,514.0,0.0,0.0,6.530878,0.166394,1.0,685.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,685.0,514.0,0.00438,0.00438,6.530878,0.166394,1.0,685.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00475973,0.0051319498799305505,0.0003722198799305503
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02307005,0.02315675460415675,8.670460415674888e-05
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02307005,0.02312656916195437,5.6519161954367986e-05
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,206.0,193.0,0.014563,0.014563,5.332719,0.891251,1.0,206.0,1.0,28.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06921491,0.06968384138223226,0.0004689313822322516
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02307005,0.02316188245332342,9.183245332341702e-05
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02307005,0.023131697011121038,6.164701112103613e-05
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02307005,0.023152198691954375,8.214869195437291e-05
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,206.0,193.0,0.009709,0.009709,5.332719,0.891251,1.0,206.0,1.0,28.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04614486,0.051295551085853194,0.0051506910858531915
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02307005,0.02313227072195437,6.222072195436953e-05
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02307005,0.02313538523445437,6.533523445436881e-05
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Subject Required long-term Initiation of Rescue Antihyperglycemic Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Subject Required long-term Initiation of Rescue Antihyperglycemic Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,206.0,193.0,0.0,0.0,5.332719,0.891251,1.0,206.0,1.0,28.0,Subject Required long-term Initiation of Rescue Antihyperglycemic Medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,206.0,193.0,0.004854,0.004854,5.332719,0.891251,1.0,206.0,1.0,28.0,Subject Required long-term Initiation of Rescue Antihyperglycemic Medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02307005,0.02313426975945437,6.421975945436822e-05
1.0,240.0,234.0,0.004167,0.004167,5.484797,0.789441,1.0,240.0,1.0,6.0,Physician Decision,Overall Study,FG000,diabetes type 2,OTHER,0.0180428,0.01804124290758926,1.5570924107415063e-06
1.0,240.0,234.0,0.004167,0.004167,5.484797,0.789441,1.0,240.0,1.0,6.0,Physician Decision,Overall Study,FG001,diabetes type 2,OTHER,0.0180428,0.017992027713363064,5.077228663693742e-05
1.0,240.0,234.0,0.004167,0.004167,5.484797,0.789441,1.0,240.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,OTHER,0.0180428,0.018038552264255926,4.247735744075665e-06
1.0,240.0,234.0,0.004167,0.004167,5.484797,0.789441,1.0,240.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,OTHER,0.0180428,0.01798837617002973,5.4423829970270954e-05
2.0,240.0,234.0,0.008333,0.008333,5.484797,0.789441,1.0,240.0,1.0,6.0,Did not receive IV loop diuretics,Overall Study,FG000,diabetes type 2,OTHER,0.03608127,0.03661974537577462,0.0005384753757746233
0.0,240.0,234.0,0.0,0.0,5.484797,0.789441,1.0,240.0,1.0,6.0,Did not receive IV loop diuretics,Overall Study,FG001,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00194755,0.0019516994529166778,4.149452916677853e-06
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00194755,0.0019418613330357253,5.688666964274612e-06
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00194755,0.0019471449013690595,4.0509863094041754e-07
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00389235,0.0038944539110957977,2.103911095797592e-06
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00194755,0.0019470482875000123,5.017124999875857e-07
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00389235,0.003894516898595798,2.166898595797658e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0058399,0.005825139945535697,1.4760054464303674e-05
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Non compliant with protocol,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,1413.0,1284.0,0.004246,0.004246,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0116798,0.01162600128903769,5.379871096231059e-05
5.0,1413.0,1284.0,0.003539,0.003539,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.009735,0.009713665449017875,2.1334550982125833e-05
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00778745,0.007792017043767102,4.567043767102381e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0058399,0.005835590472291653,4.309527708347589e-06
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00778745,0.0077828143007909086,4.635699209091029e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0058399,0.005828863098124983,1.1036901875017234e-05
6.0,1413.0,1284.0,0.004246,0.004246,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0116798,0.011618526353561505,6.127364643849532e-05
5.0,1413.0,1284.0,0.003539,0.003539,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG007,diabetes type 2,INDUSTRY,0.009735,0.009697016043303586,3.798395669641491e-05
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Adverse Event,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,1413.0,1284.0,0.004246,0.004246,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0116798,0.011643443380109125,3.635661989087602e-05
7.0,1413.0,1284.0,0.004954,0.004954,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01362735,0.013533683033482147,9.366696651785279e-05
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00389235,0.0038993866611850858,7.03666118508561e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0058399,0.005822344977678556,1.7555022321444e-05
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00778745,0.007789804879392113,2.3548793921133668e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0058399,0.005817198502023794,2.270149797620625e-05
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00389235,0.003896180161185086,3.830161185085917e-06
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lost to Follow-up,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00389235,0.003896180161185086,3.830161185085917e-06
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00389235,0.003898875170381508,6.525170381507794e-06
5.0,1413.0,1284.0,0.003539,0.003539,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.009735,0.009713785294970252,2.1214705029748426e-05
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG002,diabetes type 2,INDUSTRY,0.00778745,0.007794104668697656,6.65466869765631e-06
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG003,diabetes type 2,INDUSTRY,0.00778745,0.007793937007864328,6.487007864328445e-06
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG004,diabetes type 2,INDUSTRY,0.00778745,0.007784406443221465,3.0435567785341844e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG005,diabetes type 2,INDUSTRY,0.0058399,0.0058267307992856945,1.3169200714305794e-05
8.0,1413.0,1284.0,0.005662,0.005662,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG006,diabetes type 2,INDUSTRY,0.0155749,0.01573165361710316,0.0001567536171031593
7.0,1413.0,1284.0,0.004954,0.004954,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG007,diabetes type 2,INDUSTRY,0.01362735,0.01351130433104167,0.00011604566895833009
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,"Refusal to continue, not due to AE",Overall Study,FG008,diabetes type 2,INDUSTRY,0.00194755,0.0019455823864484233,1.9676135515765865e-06
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1413.0,1284.0,0.001415,0.001415,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00389235,0.003894551219429131,2.2012194291309677e-06
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0058399,0.0058385558826190296,1.34411738097074e-06
4.0,1413.0,1284.0,0.002831,0.002831,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00778745,0.007788036671415912,5.866714159127873e-07
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00194755,0.0019456395743650903,1.9104256349096287e-06
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1413.0,1284.0,0.002123,0.002123,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0058399,0.005830064242202363,9.835757797637713e-06
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Reason other than those specified,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00194755,0.0019455823864484233,1.9676135515765865e-06
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1413.0,1284.0,0.000708,0.000708,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00194755,0.0019458220364484233,1.7279635515766133e-06
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1413.0,1284.0,0.0,0.0,7.254178,0.379199,1.0,1413.0,21.0,190.0,Lack of Efficacy,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,315.0,280.0,0.003175,0.003175,5.755742,0.382,1.0,315.0,9.0,83.0,Adverse Event,Short-Term (ST) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00698085,0.006983379394315496,2.5293943154954326e-06
0.0,315.0,280.0,0.0,0.0,5.755742,0.382,1.0,315.0,9.0,83.0,Adverse Event,Short-Term (ST) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Withdrawal by Subject,Short-Term (ST) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0139595,0.013964590273303585,5.090273303585621e-06
5.0,315.0,280.0,0.015873,0.015873,5.755742,0.382,1.0,315.0,9.0,83.0,Withdrawal by Subject,Short-Term (ST) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03489985,0.0351658175889583,0.0002659675889582977
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Lost to Follow-up,Short-Term (ST) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0139595,0.013991000018541684,3.150001854168409e-05
4.0,315.0,280.0,0.012698,0.012698,5.755742,0.382,1.0,315.0,9.0,83.0,Lost to Follow-up,Short-Term (ST) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.027919,0.027906506032460317,1.2493967539682627e-05
1.0,315.0,280.0,0.003175,0.003175,5.755742,0.382,1.0,315.0,9.0,83.0,"Non-compliance, not Met Study Criteria",Short-Term (ST) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00698085,0.006985804788065495,4.954788065494528e-06
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,"Non-compliance, not Met Study Criteria",Short-Term (ST) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0139595,0.013963511763184538,4.011763184538081e-06
0.0,315.0,280.0,0.0,0.0,5.755742,0.382,1.0,315.0,9.0,83.0,Lack of Efficacy,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,315.0,280.0,0.003175,0.003175,5.755742,0.382,1.0,315.0,9.0,83.0,Lack of Efficacy,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00698085,0.006986723823720256,5.8738237202560564e-06
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Adverse Event,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0139595,0.013979067112976206,1.9567112976206363e-05
3.0,315.0,280.0,0.009524,0.009524,5.755742,0.382,1.0,315.0,9.0,83.0,Adverse Event,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02094035,0.020974607307013886,3.425730701388588e-05
3.0,315.0,280.0,0.009524,0.009524,5.755742,0.382,1.0,315.0,9.0,83.0,Withdrawal by Subject,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02094035,0.020984985221636897,4.463522163689754e-05
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Withdrawal by Subject,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0139595,0.013944205787470253,1.5294212529746304e-05
1.0,315.0,280.0,0.003175,0.003175,5.755742,0.382,1.0,315.0,9.0,83.0,Death,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00698085,0.006986711661220256,5.861661220255866e-06
0.0,315.0,280.0,0.0,0.0,5.755742,0.382,1.0,315.0,9.0,83.0,Death,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Lost to Follow-up,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0139595,0.013985611746875022,2.6111746875022435e-05
2.0,315.0,280.0,0.006349,0.006349,5.755742,0.382,1.0,315.0,9.0,83.0,Lost to Follow-up,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0139595,0.013969139200208352,9.639200208352156e-06
0.0,315.0,280.0,0.0,0.0,5.755742,0.382,1.0,315.0,9.0,83.0,Not Met Study Criteria,Long-Term (LT) Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,315.0,280.0,0.003175,0.003175,5.755742,0.382,1.0,315.0,9.0,83.0,Not Met Study Criteria,Long-Term (LT) Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00698085,0.006986723823720256,5.8738237202560564e-06
3.0,427.0,339.0,0.007026,0.007026,6.059123,0.295753,1.0,427.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01259063,0.012636141583601187,4.551158360118629e-05
9.0,427.0,339.0,0.021077,0.021077,6.059123,0.295753,1.0,427.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03777009,0.03789793233106158,0.00012784233106158394
5.0,427.0,339.0,0.01171,0.01171,6.059123,0.295753,1.0,427.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02098438,0.020872407001289662,0.0001119729987103385
4.0,427.0,339.0,0.009368,0.009368,6.059123,0.295753,1.0,427.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0167875,0.01642458424669645,0.00036291575330354986
6.0,427.0,339.0,0.014052,0.014052,6.059123,0.295753,1.0,427.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02518126,0.024989288521646825,0.00019197147835317563
5.0,427.0,339.0,0.01171,0.01171,6.059123,0.295753,1.0,427.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02098438,0.02088068847156564,0.00010369152843436175
19.0,427.0,339.0,0.044496,0.044496,6.059123,0.295753,1.0,427.0,0.0,0.0,other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07973706,0.07969272964749993,4.4330352500066006e-05
9.0,427.0,339.0,0.021077,0.021077,6.059123,0.295753,1.0,427.0,0.0,0.0,other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03777009,0.0379376452891866,0.00016755528918659807
0.0,427.0,339.0,0.0,0.0,6.059123,0.295753,1.0,427.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,427.0,339.0,0.002342,0.002342,6.059123,0.295753,1.0,427.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00419688,0.004185561078035709,1.1318921964291115e-05
8.0,427.0,339.0,0.018735,0.018735,6.059123,0.295753,1.0,427.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03357322,0.03317652070099206,0.00039669929900794376
19.0,427.0,339.0,0.044496,0.044496,6.059123,0.295753,1.0,427.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07973706,0.07978574887041662,4.8688870416618846e-05
1.0,373.0,338.0,0.002681,0.002681,5.924256,0.294492,1.0,373.0,1.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0046774,0.004722358815183074,4.4958815183074145e-05
2.0,373.0,338.0,0.005362,0.005362,5.924256,0.294492,1.0,373.0,1.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0093548,0.009166667119196423,0.00018813288080357649
2.0,373.0,338.0,0.005362,0.005362,5.924256,0.294492,1.0,373.0,1.0,45.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0093548,0.009179136347827374,0.00017566365217262618
0.0,373.0,338.0,0.0,0.0,5.924256,0.294492,1.0,373.0,1.0,45.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,373.0,338.0,0.037534,0.037534,5.924256,0.294492,1.0,373.0,1.0,45.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06548359,0.06640528995704995,0.0009216999570499512
10.0,373.0,338.0,0.02681,0.02681,5.924256,0.294492,1.0,373.0,1.0,45.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04677399,0.046006494644950394,0.0007674953550496078
3.0,373.0,338.0,0.008043,0.008043,5.924256,0.294492,1.0,373.0,1.0,45.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0140322,0.014012248033472223,1.9951966527776907e-05
3.0,373.0,338.0,0.008043,0.008043,5.924256,0.294492,1.0,373.0,1.0,45.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0140322,0.014007852990347234,2.434700965276565e-05
4.0,784.0,609.0,0.005102,0.005102,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00951913,0.009581710959742078,6.258095974207706e-05
4.0,784.0,609.0,0.005102,0.005102,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00951913,0.00958861956613097,6.94895661309692e-05
7.0,784.0,609.0,0.008929,0.008929,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01665941,0.016661739163918676,2.329163918676075e-06
3.0,784.0,609.0,0.003827,0.003827,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00714028,0.0071629385050902125,2.2658505090212763e-05
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00475956,0.004760550119156784,9.901191567835907e-07
5.0,784.0,609.0,0.006378,0.006378,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01189984,0.011905404892817448,5.564892817448014e-06
11.0,784.0,609.0,0.014031,0.014031,6.665684,0.279906,1.0,784.0,13.0,201.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.02617854,0.02641684745496031,0.0002383074549603091
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00475956,0.004759614833382971,5.4833382970471967e-08
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,784.0,609.0,0.003827,0.003827,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00714028,0.007167153779554497,2.6873779554497518e-05
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Major protocol deviation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,784.0,609.0,0.005102,0.005102,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00951913,0.009559782855456354,4.065285545635372e-05
8.0,784.0,609.0,0.010204,0.010204,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01903826,0.019125568991611653,8.730899161165165e-05
7.0,784.0,609.0,0.008929,0.008929,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01665941,0.016685746324752008,2.633632475200834e-05
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00475956,0.004757886955386947,1.6730446130534815e-06
5.0,784.0,609.0,0.006378,0.006378,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01189984,0.011910957610734112,1.1117610734112313e-05
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00475956,0.004759266783125044,2.9321687495652976e-07
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00475956,0.0047589478124702815,6.121875297188453e-07
13.0,784.0,609.0,0.016582,0.016582,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0309381,0.03114727257991072,0.00020917257991072066
8.0,784.0,609.0,0.010204,0.010204,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01903826,0.019063273567534282,2.50135675342808e-05
16.0,784.0,609.0,0.020408,0.020408,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03807651,0.03803417946959323,4.23305304067742e-05
10.0,784.0,609.0,0.012755,0.012755,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02379782,0.0234998647822998,0.00029795521770020067
6.0,784.0,609.0,0.007653,0.007653,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01427869,0.014211961363482144,6.672863651785606e-05
8.0,784.0,609.0,0.010204,0.010204,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01903826,0.019060583461879516,2.2323461879514978e-05
5.0,784.0,609.0,0.006378,0.006378,6.665684,0.279906,1.0,784.0,13.0,201.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01189984,0.011912351591289666,1.2511591289666307e-05
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00475956,0.0047601381054067846,5.781054067842059e-07
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00238071,0.0023835227237166147,2.8127237166148886e-06
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Pregnancy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,784.0,609.0,0.01148,0.01148,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02141897,0.02122263518960318,0.0001963348103968185
3.0,784.0,609.0,0.003827,0.003827,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00714028,0.007160455597054492,2.0175597054492532e-05
6.0,784.0,609.0,0.007653,0.007653,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01427869,0.014208185154077384,7.050484592261569e-05
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00475956,0.004758073520942496,1.486479057503931e-06
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00238071,0.002382057065472565,1.3470654725649366e-06
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00475956,0.004759802923680593,2.42923680593074e-07
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00238071,0.0023826276295499465,1.917629549946613e-06
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00475956,0.004758352330882966,1.2076691170339465e-06
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,784.0,609.0,0.002551,0.002551,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00475956,0.004762206421240115,2.646421240114216e-06
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00238071,0.0023806913264150273,1.867358497258803e-08
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00238071,0.002380329052754312,3.809472456880493e-07
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00238071,0.0023806913264150273,1.867358497258803e-08
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Physician Decision,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00238071,0.0023806866730816936,2.332691830626496e-08
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00238071,0.0023841904746094715,3.480474609471665e-06
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00238071,0.002384399120383281,3.689120383281331e-06
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,784.0,609.0,0.001276,0.001276,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00238071,0.0023828924163058983,2.1824163058984866e-06
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,784.0,609.0,0.0,0.0,6.665684,0.279906,1.0,784.0,13.0,201.0,Other,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,466.0,431.0,0.0,0.0,6.146329,0.422148,1.0,953.0,1.0,11.0,Did not take study medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,466.0,431.0,0.002146,0.002146,6.146329,0.422148,1.0,953.0,1.0,11.0,Did not take study medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00556815,0.005640180297505935,7.203029750593466e-05
6.0,466.0,431.0,0.012876,0.012876,6.146329,0.422148,1.0,953.0,1.0,11.0,Study specific discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03340888,0.03360099028916664,0.00019211028916663736
1.0,466.0,431.0,0.002146,0.002146,6.146329,0.422148,1.0,953.0,1.0,11.0,Study specific discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00556815,0.005640180297505935,7.203029750593466e-05
2.0,466.0,431.0,0.004292,0.004292,6.146329,0.422148,1.0,953.0,1.0,11.0,Other listed,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01113629,0.01118982580961219,5.353580961219018e-05
1.0,466.0,431.0,0.002146,0.002146,6.146329,0.422148,1.0,953.0,1.0,11.0,Other listed,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00556815,0.005640180297505935,7.203029750593466e-05
0.0,466.0,431.0,0.0,0.0,6.146329,0.422148,1.0,953.0,1.0,11.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,466.0,431.0,0.002146,0.002146,6.146329,0.422148,1.0,953.0,1.0,11.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00556815,0.0056365852745892675,6.84352745892675e-05
4.0,466.0,431.0,0.008584,0.008584,6.146329,0.422148,1.0,953.0,1.0,11.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02227258,0.022107158872767853,0.00016542112723214736
3.0,466.0,431.0,0.006438,0.006438,6.146329,0.422148,1.0,953.0,1.0,11.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01670444,0.01687488202019841,0.00017044202019840873
4.0,466.0,431.0,0.008584,0.008584,6.146329,0.422148,1.0,953.0,1.0,11.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02227258,0.022101904977351188,0.00017067502264881199
12.0,466.0,431.0,0.025751,0.025751,6.146329,0.422148,1.0,953.0,1.0,11.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06681516,0.0652834544485814,0.0015317055514185995
6.0,381.0,341.0,0.015748,0.015748,5.945421,0.327614,1.0,380.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03067399,0.030612432542569446,6.155745743055552e-05
4.0,381.0,341.0,0.010499,0.010499,5.945421,0.327614,1.0,380.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02044998,0.020872682962073418,0.00042270296207341795
0.0,381.0,341.0,0.0,0.0,5.945421,0.327614,1.0,380.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,381.0,341.0,0.002625,0.002625,5.945421,0.327614,1.0,380.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00511298,0.005304819827609132,0.00019183982760913234
3.0,381.0,341.0,0.007874,0.007874,5.945421,0.327614,1.0,380.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.015337,0.015457420694077366,0.00012042069407736632
4.0,381.0,341.0,0.010499,0.010499,5.945421,0.327614,1.0,380.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02044998,0.020869818489335334,0.0004198384893353349
0.0,381.0,341.0,0.0,0.0,5.945421,0.327614,1.0,380.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,381.0,341.0,0.007874,0.007874,5.945421,0.327614,1.0,380.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.015337,0.015482062033244032,0.00014506203324403215
0.0,381.0,341.0,0.0,0.0,5.945421,0.327614,1.0,380.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,381.0,341.0,0.005249,0.005249,5.945421,0.327614,1.0,380.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01022402,0.010895846621504326,0.0006718266215043258
5.0,381.0,341.0,0.013123,0.013123,5.945421,0.327614,1.0,380.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02556101,0.02556861878982144,7.608789821440115e-06
12.0,381.0,341.0,0.031496,0.031496,5.945421,0.327614,1.0,380.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06134799,0.062031942965724216,0.0006839529657242174
4.0,420.0,406.0,0.009524,0.009524,6.042633,0.487344,1.0,420.0,11.0,88.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02804669,0.027790128727232168,0.00025656127276783153
1.0,420.0,406.0,0.002381,0.002381,6.042633,0.487344,1.0,420.0,11.0,88.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00701167,0.007006272004593226,5.397995406774235e-06
5.0,420.0,406.0,0.011905,0.011905,6.042633,0.487344,1.0,420.0,11.0,88.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03505836,0.03516860983398815,0.00011024983398815608
1.0,420.0,406.0,0.002381,0.002381,6.042633,0.487344,1.0,420.0,11.0,88.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00701167,0.007004285456974177,7.384543025823129e-06
1.0,420.0,406.0,0.002381,0.002381,6.042633,0.487344,1.0,420.0,11.0,88.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00701167,0.007020405173700368,8.735173700367624e-06
1.0,420.0,406.0,0.002381,0.002381,6.042633,0.487344,1.0,420.0,11.0,88.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00701167,0.007012643330307505,9.73330307504905e-07
0.0,420.0,406.0,0.0,0.0,6.042633,0.487344,1.0,420.0,11.0,88.0,Missing,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,420.0,406.0,0.002381,0.002381,6.042633,0.487344,1.0,420.0,11.0,88.0,Missing,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00701167,0.0070085374108432245,3.132589156775757e-06
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,606.0,314.0,0.014851,0.014851,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.0370619,0.036902102865178546,0.0001597971348214558
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,606.0,314.0,0.00165,0.00165,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.00411771,0.0041202070232440715,2.4970232440713405e-06
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
13.0,606.0,314.0,0.021452,0.021452,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.05353524,0.054901083473125015,0.0013658434731250169
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,606.0,314.0,0.023102,0.023102,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.05765295,0.05734345778511909,0.00030949221488091316
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,606.0,314.0,0.019802,0.019802,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.04941753,0.04860139036470234,0.0008161396352976621
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Other Reasons,Open-Label Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Other Reasons,Open-Label Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Other Reasons,Open-Label Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
224.0,606.0,314.0,0.369637,0.369637,6.408529,0.389416,1.0,607.0,11.0,90.0,Other Reasons,Open-Label Period,FG003,diabetes type 2,INDUSTRY,0.92245973,0.9368156277061306,0.01435589770613055
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,606.0,314.0,0.00495,0.00495,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.01235313,0.01217916420267857,0.00017396579732143098
2.0,606.0,314.0,0.0033,0.0033,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.00823542,0.008191316307665075,4.41036923349257e-05
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Adverse Event,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,606.0,314.0,0.00165,0.00165,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.00411771,0.004117499934613121,2.1006538687869114e-07
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lack of Efficacy,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,606.0,314.0,0.00165,0.00165,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.00411771,0.0041163371537797895,1.372846220210576e-06
1.0,606.0,314.0,0.00165,0.00165,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.00411771,0.004116405047172645,1.3049528273549257e-06
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Protocol Violation,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,606.0,314.0,0.0033,0.0033,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.00823542,0.008193825026130983,4.159497386901738e-05
4.0,606.0,314.0,0.006601,0.006601,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.01647334,0.01623062170786707,0.00024271829213292836
2.0,606.0,314.0,0.0033,0.0033,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.00823542,0.008189502739748406,4.5917260251594066e-05
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Lost to Follow-up,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,606.0,314.0,0.0033,0.0033,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.00823542,0.008189888090714314,4.553190928568637e-05
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Withdrawal by Subject,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,606.0,314.0,0.00165,0.00165,6.408529,0.389416,1.0,607.0,11.0,90.0,Not treated,Double-Blind Period,FG000,diabetes type 2,INDUSTRY,0.00411771,0.0041177905899702615,8.058997026140491e-08
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Not treated,Double-Blind Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Not treated,Double-Blind Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,606.0,314.0,0.0,0.0,6.408529,0.389416,1.0,607.0,11.0,90.0,Not treated,Double-Blind Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528929,0.005294753247335463,5.463247335462697e-06
7.0,282.0,249.0,0.024823,0.024823,5.645447,0.264217,1.0,282.0,5.0,35.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03702654,0.03780297369099205,0.0007764336909920552
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,No longer met study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528929,0.005294124849835463,4.834849835462854e-06
5.0,282.0,249.0,0.01773,0.01773,5.645447,0.264217,1.0,282.0,5.0,35.0,No longer met study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02644646,0.02672296802088295,0.00027650802088294985
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528929,0.005289948675727561,6.586757275604468e-07
2.0,282.0,249.0,0.007092,0.007092,5.645447,0.264217,1.0,282.0,5.0,35.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01057859,0.010674136972440493,9.554697244049289e-05
3.0,282.0,249.0,0.010638,0.010638,5.645447,0.264217,1.0,282.0,5.0,35.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01586788,0.01597238821550595,0.00010450821550594958
3.0,282.0,249.0,0.010638,0.010638,5.645447,0.264217,1.0,282.0,5.0,35.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01586788,0.01595660700461309,8.872700461308794e-05
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,Severe non-compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528929,0.005294124849835463,4.834849835462854e-06
2.0,282.0,249.0,0.007092,0.007092,5.645447,0.264217,1.0,282.0,5.0,35.0,Severe non-compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01057859,0.010689953440178588,0.00011136344017858776
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528929,0.005294124849835463,4.834849835462854e-06
5.0,282.0,249.0,0.01773,0.01773,5.645447,0.264217,1.0,282.0,5.0,35.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02644646,0.02672296802088295,0.00027650802088294985
0.0,282.0,249.0,0.0,0.0,5.645447,0.264217,1.0,282.0,5.0,35.0,Did not attend the termination visit,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,282.0,249.0,0.003546,0.003546,5.645447,0.264217,1.0,282.0,5.0,35.0,Did not attend the termination visit,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00528929,0.005296796224449467,7.506224449466831e-06
18.0,1326.0,1006.0,0.013575,0.013575,7.190676,0.466074,1.0,1326.0,0.0,0.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04549506,0.04534993004326384,0.00014512995673615636
17.0,1326.0,1006.0,0.012821,0.012821,7.190676,0.466074,1.0,1326.0,0.0,0.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04296811,0.04281199097681558,0.0001561190231844159
17.0,1326.0,1006.0,0.012821,0.012821,7.190676,0.466074,1.0,1326.0,0.0,0.0,Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04296811,0.042829737782410816,0.0001383722175891805
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00252694,0.0025348104805357034,7.870480535703342e-06
0.0,1326.0,1006.0,0.0,0.0,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00252694,0.002534987060595227,8.047060595226928e-06
22.0,1326.0,1006.0,0.016591,0.016591,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05560283,0.05687407810942369,0.001271248109423688
17.0,1326.0,1006.0,0.012821,0.012821,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04296811,0.04276097061372032,0.00020713938627967693
18.0,1326.0,1006.0,0.013575,0.013575,7.190676,0.466074,1.0,1326.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04549506,0.04534357137963291,0.00015148862036708927
6.0,1326.0,1006.0,0.004525,0.004525,7.190676,0.466074,1.0,1326.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01516502,0.014773124822410716,0.0003918951775892833
4.0,1326.0,1006.0,0.003017,0.003017,7.190676,0.466074,1.0,1326.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01011113,0.010077558809940452,3.357119005954756e-05
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Non-Compliance With Study Drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00252694,0.0025370898692261795,1.0149869226179411e-05
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00252694,0.0025369132891666563,9.973289166656258e-06
4.0,1326.0,1006.0,0.003017,0.003017,7.190676,0.466074,1.0,1326.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01011113,0.0100873921575595,2.3737842440498674e-05
6.0,1326.0,1006.0,0.004525,0.004525,7.190676,0.466074,1.0,1326.0,0.0,0.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01516502,0.014753258751279762,0.0004117612487202372
4.0,1326.0,1006.0,0.003017,0.003017,7.190676,0.466074,1.0,1326.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01011113,0.010052903863244027,5.822613675597263e-05
5.0,1326.0,1006.0,0.003771,0.003771,7.190676,0.466074,1.0,1326.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01263807,0.012657890155018964,1.9820155018964933e-05
4.0,1326.0,1006.0,0.003017,0.003017,7.190676,0.466074,1.0,1326.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01011113,0.010106707928363079,4.422071636920807e-06
0.0,1326.0,1006.0,0.0,0.0,7.190676,0.466074,1.0,1326.0,0.0,0.0,Screen failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Screen failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00252694,0.0025336369871230037,6.696987123003609e-06
0.0,1326.0,1006.0,0.0,0.0,7.190676,0.466074,1.0,1326.0,0.0,0.0,Screen failure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,1326.0,1006.0,0.005279,0.005279,7.190676,0.466074,1.0,1326.0,0.0,0.0,Study Terminated By Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01769196,0.017692203806944373,2.438069443728985e-07
5.0,1326.0,1006.0,0.003771,0.003771,7.190676,0.466074,1.0,1326.0,0.0,0.0,Study Terminated By Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01263807,0.012662463368768966,2.4393368768966042e-05
12.0,1326.0,1006.0,0.00905,0.00905,7.190676,0.466074,1.0,1326.0,0.0,0.0,Study Terminated By Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03033004,0.030328079775009918,1.960224990080889e-06
2.0,1326.0,1006.0,0.001508,0.001508,7.190676,0.466074,1.0,1326.0,0.0,0.0,Participant moves,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00505389,0.005014810903511878,3.90790964881222e-05
5.0,1326.0,1006.0,0.003771,0.003771,7.190676,0.466074,1.0,1326.0,0.0,0.0,Participant moves,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01263807,0.012662463368768966,2.4393368768966042e-05
3.0,1326.0,1006.0,0.002262,0.002262,7.190676,0.466074,1.0,1326.0,0.0,0.0,Participant moves,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00758083,0.007550531054332621,3.0298945667379257e-05
28.0,1326.0,1006.0,0.021116,0.021116,7.190676,0.466074,1.0,1326.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07076785,0.0710238149107639,0.00025596491076390615
29.0,1326.0,1006.0,0.02187,0.02187,7.190676,0.466074,1.0,1326.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0732948,0.07158919897868056,0.0017056010213194334
34.0,1326.0,1006.0,0.025641,0.025641,7.190676,0.466074,1.0,1326.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.08593287,0.07937032697785722,0.006562543022142778
0.0,1326.0,1006.0,0.0,0.0,7.190676,0.466074,1.0,1326.0,0.0,0.0,Creatinine/eGFR,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1326.0,1006.0,0.0,0.0,7.190676,0.466074,1.0,1326.0,0.0,0.0,Creatinine/eGFR,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Creatinine/eGFR,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00252694,0.0025370898692261795,1.0149869226179411e-05
7.0,1326.0,1006.0,0.005279,0.005279,7.190676,0.466074,1.0,1326.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01769196,0.017689217618611038,2.7423813889621007e-06
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00252694,0.002535247793373004,8.307793373003945e-06
2.0,1326.0,1006.0,0.001508,0.001508,7.190676,0.466074,1.0,1326.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00505389,0.0050283147822618775,2.5575217738122574e-05
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Excluded Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00252694,0.0025353777958333234,8.437795833323315e-06
1.0,1326.0,1006.0,0.000754,0.000754,7.190676,0.466074,1.0,1326.0,0.0,0.0,Excluded Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00252694,0.0025321014937896703,5.161493789670232e-06
2.0,1326.0,1006.0,0.001508,0.001508,7.190676,0.466074,1.0,1326.0,0.0,0.0,Excluded Medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00505389,0.005024305956428544,2.9584043571456373e-05
9.0,1326.0,1006.0,0.006787,0.006787,7.190676,0.466074,1.0,1326.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02274585,0.02291497949482143,0.0001691294948214274
7.0,1326.0,1006.0,0.005279,0.005279,7.190676,0.466074,1.0,1326.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01769196,0.01767747320895826,1.448679104174011e-05
7.0,1326.0,1006.0,0.005279,0.005279,7.190676,0.466074,1.0,1326.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01769196,0.017676446637589206,1.5513362410794068e-05
3.0,1326.0,1006.0,0.002262,0.002262,7.190676,0.466074,1.0,1326.0,0.0,0.0,Treated but excluded at 1 trial site,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00758083,0.007540923298499289,3.990670150071096e-05
5.0,1326.0,1006.0,0.003771,0.003771,7.190676,0.466074,1.0,1326.0,0.0,0.0,Treated but excluded at 1 trial site,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01263807,0.012662463368768966,2.4393368768966042e-05
2.0,1326.0,1006.0,0.001508,0.001508,7.190676,0.466074,1.0,1326.0,0.0,0.0,Treated but excluded at 1 trial site,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00505389,0.005024072798095211,2.9817201904789453e-05
18.0,1306.0,888.0,0.013783,0.013783,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02229395,0.0224080908518849,0.00011414085188490158
18.0,1306.0,888.0,0.013783,0.013783,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02229395,0.022409740459503946,0.00011579045950394634
35.0,1306.0,888.0,0.026799,0.026799,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04334728,0.04319029271038692,0.00015698728961308084
29.0,1306.0,888.0,0.022205,0.022205,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0359165,0.03626432266243052,0.00034782266243052473
20.0,1306.0,888.0,0.015314,0.015314,7.17549,0.22542,1.0,1306.0,13.0,211.0,Withdrawal of Consent by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02477034,0.024793123250694462,2.278325069446363e-05
24.0,1306.0,888.0,0.018377,0.018377,7.17549,0.22542,1.0,1306.0,13.0,211.0,Withdrawal of Consent by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02972473,0.02941984355296625,0.00030488644703375103
28.0,1306.0,888.0,0.02144,0.02144,7.17549,0.22542,1.0,1306.0,13.0,211.0,Withdrawal of Consent by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03467912,0.03491101610118055,0.00023189610118055232
25.0,1306.0,888.0,0.019142,0.019142,7.17549,0.22542,1.0,1306.0,13.0,211.0,Withdrawal of Consent by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03096211,0.03049849842665675,0.00046361157334325054
22.0,1306.0,888.0,0.016845,0.016845,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02724672,0.027466404345992092,0.00021968434599209385
23.0,1306.0,888.0,0.017611,0.017611,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02848572,0.028656351562946422,0.00017063156294642307
29.0,1306.0,888.0,0.022205,0.022205,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0359165,0.036250897893620994,0.0003343978936209968
22.0,1306.0,888.0,0.016845,0.016845,7.17549,0.22542,1.0,1306.0,13.0,211.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02724672,0.027494986359910736,0.0002482663599107371
14.0,1306.0,888.0,0.01072,0.01072,7.17549,0.22542,1.0,1306.0,13.0,211.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01733956,0.017336973027142842,2.5869728571582817e-06
10.0,1306.0,888.0,0.007657,0.007657,7.17549,0.22542,1.0,1306.0,13.0,211.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01238517,0.01222297849716991,0.0001621915028300891
14.0,1306.0,888.0,0.01072,0.01072,7.17549,0.22542,1.0,1306.0,13.0,211.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01733956,0.017301349983680537,3.821001631946347e-05
14.0,1306.0,888.0,0.01072,0.01072,7.17549,0.22542,1.0,1306.0,13.0,211.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01733956,0.01733276238160712,6.797618392881399e-06
4.0,1306.0,888.0,0.003063,0.003063,7.17549,0.22542,1.0,1306.0,13.0,211.0,Subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00495439,0.004937144088958328,1.724591104167259e-05
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00247639,0.00247724493536706,8.549353670596338e-07
8.0,1306.0,888.0,0.006126,0.006126,7.17549,0.22542,1.0,1306.0,13.0,211.0,Subject no longer meets study criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00990878,0.009980704270542934,7.19242705429328e-05
7.0,1306.0,888.0,0.00536,0.00536,7.17549,0.22542,1.0,1306.0,13.0,211.0,Subject no longer meets study criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00866978,0.008695491423660722,2.5711423660722266e-05
11.0,1306.0,888.0,0.008423,0.008423,7.17549,0.22542,1.0,1306.0,13.0,211.0,Poor/Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01362417,0.013806172100177684,0.0001820021001776844
8.0,1306.0,888.0,0.006126,0.006126,7.17549,0.22542,1.0,1306.0,13.0,211.0,Poor/Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00990878,0.009976778032804839,6.799803280483838e-05
4.0,1306.0,888.0,0.003063,0.003063,7.17549,0.22542,1.0,1306.0,13.0,211.0,Poor/Noncompliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00495439,0.0049327258012797585,2.1664198720241883e-05
5.0,1306.0,888.0,0.003828,0.003828,7.17549,0.22542,1.0,1306.0,13.0,211.0,Poor/Noncompliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00619178,0.0061421355318948415,4.964446810515853e-05
0.0,1306.0,888.0,0.0,0.0,7.17549,0.22542,1.0,1306.0,13.0,211.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.001239,0.0012362320074404728,2.7679925595272808e-06
3.0,1306.0,888.0,0.002297,0.002297,7.17549,0.22542,1.0,1306.0,13.0,211.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00371539,0.003728542582915762,1.3152582915762316e-05
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00247639,0.002475700334474204,6.896655257962632e-07
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.001239,0.001239019451607138,1.9451607137944277e-08
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00247639,0.00247733618536706,9.461853670597424e-07
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00247639,0.0024766507327182515,2.60732718251281e-07
3.0,1306.0,888.0,0.002297,0.002297,7.17549,0.22542,1.0,1306.0,13.0,211.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00371539,0.00372425529837211,8.865298372110267e-06
0.0,1306.0,888.0,0.0,0.0,7.17549,0.22542,1.0,1306.0,13.0,211.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00247639,0.0024777628770337266,1.3728770337263774e-06
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.001239,0.001239143457916662,1.4345791666181204e-07
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.001239,0.001238068668273805,9.313317261951462e-07
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Administrative Reason by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.001239,0.001239019451607138,1.9451607137944277e-08
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Administrative Reason by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00247639,0.0024774197316170597,1.029731617059517e-06
2.0,1306.0,888.0,0.001531,0.001531,7.17549,0.22542,1.0,1306.0,13.0,211.0,Administrative Reason by Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00247639,0.002476825528968251,4.355289682507306e-07
1.0,1306.0,888.0,0.000766,0.000766,7.17549,0.22542,1.0,1306.0,13.0,211.0,Administrative Reason by Sponsor,Overall Study,FG003,diabetes type 2,INDUSTRY,0.001239,0.0012375658495238052,1.4341504761948998e-06
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Pregnancy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00288276,0.0028847059891017345,1.9459891017347027e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Pregnancy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Pregnancy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Pregnancy,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Pregnancy,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00576746,0.0057603819071428254,7.078092857174846e-06
5.0,675.0,452.0,0.007407,0.007407,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01441769,0.014251742486547614,0.00016594751345238613
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00865022,0.00865332021783725,3.100217837250646e-06
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00288276,0.0028828733429112595,1.1334291125965346e-07
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.00288276,0.002882964424220783,2.0442422078324404e-07
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00288276,0.0028828529029112575,9.290291125762726e-08
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00576746,0.005756062197261872,1.139780273812837e-05
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00576746,0.005765626106369017,1.8338936309831438e-06
5.0,675.0,452.0,0.007407,0.007407,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01441769,0.014185204537738092,0.0002324854622619086
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01153493,0.011536107144166596,1.1771441665951038e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.00576746,0.005757995900476157,9.464099523842986e-06
15.0,675.0,452.0,0.022222,0.022222,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.04325501,0.04198519522116074,0.001269814778839265
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00865022,0.008659203230595203,8.983230595203257e-06
9.0,675.0,452.0,0.013333,0.013333,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.02595262,0.025758628680982137,0.00019399131901786174
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00865022,0.008650494364226144,2.743642261437973e-07
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.00288276,0.0028830491992207835,2.891992207836383e-07
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00865022,0.008646238182003923,3.981817996077247e-06
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01153493,0.011537607569166598,2.677569166597074e-06
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00576746,0.005764120772083301,3.339227916699175e-06
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00576746,0.005763009965059489,4.450034940511015e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00288276,0.002883021890411258,2.6189041125827817e-07
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.01153493,0.011528525102499939,6.404897500061901e-06
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01153493,0.011533346685833258,1.5833141667424139e-06
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00865022,0.00865089295950392,6.729595039191988e-07
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00288276,0.0028829581179112595,1.9811791125961403e-07
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,675.0,452.0,0.004444,0.004444,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00865022,0.008646238182003923,3.981817996077247e-06
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00288276,0.0028857635321374504,3.0035321374505437e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Core Period: Baseline to Week 26,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00288276,0.0028814729727678606,1.2870272321392762e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Adverse Event,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00288276,0.002881390490625003,1.3695093749968058e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Death,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01153493,0.011547157409523758,1.222740952375699e-05
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01153493,0.011554201599107078,1.9271599107077708e-05
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00288276,0.0028849059146428624,2.1459146428625883e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00288276,0.002881583703125003,1.176296874996676e-06
2.0,675.0,452.0,0.002963,0.002963,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00576746,0.005776242285833308,8.782285833308125e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00288276,0.002882382095684527,3.7790431547295514e-07
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00288276,0.0028777503658703146,5.009634129685223e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00288276,0.002881583703125003,1.176296874996676e-06
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01153493,0.011541576920833265,6.646920833264583e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01153493,0.011532746018749939,2.183981250061459e-06
5.0,675.0,452.0,0.007407,0.007407,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01441769,0.014266081916964279,0.00015160808303572165
4.0,675.0,452.0,0.005926,0.005926,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01153493,0.011531390714999933,3.5392850000672688e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Other,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,675.0,452.0,0.01037,0.01037,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.02018515,0.020026478701031726,0.00015867129896827287
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00288276,0.0028845704688095285,1.8104688095286169e-06
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Lack of efficacy on rescue therapy,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Physician Decision,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,675.0,452.0,0.001481,0.001481,6.516193,0.298717,1.0,678.0,18.0,78.0,Physician Decision,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00288276,0.002883315343809528,5.553438095283296e-07
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Physician Decision,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Physician Decision,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,675.0,452.0,0.0,0.0,6.516193,0.298717,1.0,678.0,18.0,78.0,Physician Decision,Extension Period: Week 26 to Week 52,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,9340.0,9042.0,0.000428,0.000428,9.142169,0.415093,1.0,9341.0,33.0,428.0,Withdrawn - does not allow contact,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0016242,0.0015531247368154753,7.107526318452461e-05
8.0,9340.0,9042.0,0.000857,0.000857,9.142169,0.415093,1.0,9341.0,33.0,428.0,Withdrawn - does not allow contact,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00325219,0.0032281103883333305,2.407961166666934e-05
8.0,9340.0,9042.0,0.000857,0.000857,9.142169,0.415093,1.0,9341.0,33.0,428.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00325219,0.0032319242672619024,2.0265732738097408e-05
9.0,9340.0,9042.0,0.000964,0.000964,9.142169,0.415093,1.0,9341.0,33.0,428.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00365824,0.003483383477103175,0.00017485652289682494
127.0,9340.0,9042.0,0.013597,0.013597,9.142169,0.415093,1.0,9341.0,33.0,428.0,Alive,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05159859,0.05017756881243056,0.0014210211875694406
142.0,9340.0,9042.0,0.015203,0.015203,9.142169,0.415093,1.0,9341.0,33.0,428.0,Alive,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05769312,0.05559067687389878,0.002102443126101222
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00096646,0.0009678766166964298,1.4166166964297774e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0019303,0.0019370784364881057,6.778436488105678e-06
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00096646,0.0009678766166964298,1.4166166964297774e-06
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00096646,0.0009678565847123029,1.3965847123028523e-06
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Death,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2705.0,1659.0,0.001109,0.001109,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00289676,0.002912074227615441,1.531422761544103e-05
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0019303,0.001932408332976204,2.1083329762039155e-06
5.0,2705.0,1659.0,0.001848,0.001848,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00482707,0.004891113119166664,6.404311916666412e-05
5.0,2705.0,1659.0,0.001848,0.001848,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00482707,0.004890451452916664,6.338145291666375e-05
3.0,2705.0,1659.0,0.001109,0.001109,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00289676,0.0029143002943253964,1.7540294325396437e-05
4.0,2705.0,1659.0,0.001479,0.001479,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00386322,0.0038682368496428467,5.016849642846578e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0019303,0.0019339388929762043,3.638892976204301e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0019303,0.0019339388929762043,3.638892976204301e-06
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00096646,0.0009708893530654778,4.4293530654778085e-06
4.0,2705.0,1659.0,0.001479,0.001479,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG009,diabetes type 2,INDUSTRY,0.00386322,0.0038690078796428467,5.787879642846563e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0019303,0.0019339388929762043,3.638892976204301e-06
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG011,diabetes type 2,INDUSTRY,0.00096646,0.0009716231294146838,5.163129414683808e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Lost to Follow-up,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0019303,0.0019339388929762043,3.638892976204301e-06
15.0,2705.0,1659.0,0.005545,0.005545,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01448381,0.014639098641200403,0.0001552886412004035
14.0,2705.0,1659.0,0.005176,0.005176,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01351996,0.013428184771845243,9.177522815475604e-05
12.0,2705.0,1659.0,0.004436,0.004436,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01158705,0.01160373468934528,1.668468934527996e-05
13.0,2705.0,1659.0,0.004806,0.004806,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0125535,0.0125263073240215,2.719267597850114e-05
8.0,2705.0,1659.0,0.002957,0.002957,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00772383,0.0076411260405654735,8.270395943452656e-05
7.0,2705.0,1659.0,0.002588,0.002588,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00675998,0.00689609759945437,0.00013611759945437053
13.0,2705.0,1659.0,0.004806,0.004806,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0125535,0.012522266557354835,3.1233442645165616e-05
9.0,2705.0,1659.0,0.003327,0.003327,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00869028,0.008542747345396826,0.00014753265460317432
12.0,2705.0,1659.0,0.004436,0.004436,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG008,diabetes type 2,INDUSTRY,0.01158705,0.011644020553859163,5.697055385916333e-05
13.0,2705.0,1659.0,0.004806,0.004806,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0125535,0.012520287053188169,3.321294681183154e-05
11.0,2705.0,1659.0,0.004067,0.004067,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG010,diabetes type 2,INDUSTRY,0.0106232,0.010738160234146832,0.00011496023414683289
13.0,2705.0,1659.0,0.004806,0.004806,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0125535,0.012520287053188169,3.321294681183154e-05
16.0,2705.0,1659.0,0.005915,0.005915,7.903227,0.330504,1.0,2705.0,19.0,243.0,Withdrawal by Subject,Overall Study,FG012,diabetes type 2,INDUSTRY,0.01545027,0.015566330905684522,0.0001160609056845216
18.0,2705.0,1659.0,0.006654,0.006654,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01738057,0.017289484415055026,9.108558494497557e-05
20.0,2705.0,1659.0,0.007394,0.007394,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01931348,0.01924889393381493,6.458606618506973e-05
41.0,2705.0,1659.0,0.015157,0.015157,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03959082,0.03904195405608136,0.0005488659439186402
17.0,2705.0,1659.0,0.006285,0.006285,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01641672,0.016474990906652196,5.827090665219692e-05
11.0,2705.0,1659.0,0.004067,0.004067,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0106232,0.01073703901882937,0.00011383901882937135
12.0,2705.0,1659.0,0.004436,0.004436,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01158705,0.011600537599310097,1.3487599310097603e-05
18.0,2705.0,1659.0,0.006654,0.006654,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG006,diabetes type 2,INDUSTRY,0.01738057,0.0173195415353328,6.1028464667201715e-05
8.0,2705.0,1659.0,0.002957,0.002957,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG007,diabetes type 2,INDUSTRY,0.00772383,0.007634966315624996,8.886368437500437e-05
17.0,2705.0,1659.0,0.006285,0.006285,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG008,diabetes type 2,INDUSTRY,0.01641672,0.016481372953080768,6.465295308076893e-05
21.0,2705.0,1659.0,0.007763,0.007763,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG009,diabetes type 2,INDUSTRY,0.02027733,0.020874752035858576,0.0005974220358585768
17.0,2705.0,1659.0,0.006285,0.006285,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG010,diabetes type 2,INDUSTRY,0.01641672,0.016481372953080768,6.465295308076893e-05
17.0,2705.0,1659.0,0.006285,0.006285,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG011,diabetes type 2,INDUSTRY,0.01641672,0.016481372953080768,6.465295308076893e-05
24.0,2705.0,1659.0,0.008872,0.008872,7.903227,0.330504,1.0,2705.0,19.0,243.0,discontinued in preceding trial,Overall Study,FG012,diabetes type 2,INDUSTRY,0.02317409,0.023063698696964296,0.00011039130303570552
41.0,2705.0,1659.0,0.015157,0.015157,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03959082,0.038998892755962314,0.0005919272440376849
45.0,2705.0,1659.0,0.016636,0.016636,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04345403,0.043514848955833275,6.081895583327779e-05
51.0,2705.0,1659.0,0.018854,0.018854,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04924756,0.0488513350541369,0.0003962249458631037
51.0,2705.0,1659.0,0.018854,0.018854,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04924756,0.04885563617163689,0.00039192382836310963
48.0,2705.0,1659.0,0.017745,0.017745,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0463508,0.04557114969133926,0.0007796503086607356
50.0,2705.0,1659.0,0.018484,0.018484,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0482811,0.04777364191747026,0.0005074580825297423
54.0,2705.0,1659.0,0.019963,0.019963,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG006,diabetes type 2,INDUSTRY,0.05214432,0.05155367946874012,0.0005906405312598798
36.0,2705.0,1659.0,0.013309,0.013309,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG007,diabetes type 2,INDUSTRY,0.03476375,0.0345873269309028,0.00017642306909720212
44.0,2705.0,1659.0,0.016266,0.016266,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG008,diabetes type 2,INDUSTRY,0.04248758,0.04239461490494047,9.29650950595301e-05
48.0,2705.0,1659.0,0.017745,0.017745,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0463508,0.0455627147996726,0.0007880852003273944
45.0,2705.0,1659.0,0.016636,0.016636,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG010,diabetes type 2,INDUSTRY,0.04345403,0.043567750936309484,0.00011372093630948599
34.0,2705.0,1659.0,0.012569,0.012569,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG011,diabetes type 2,INDUSTRY,0.03283083,0.0327328122421726,9.801775782739691e-05
56.0,2705.0,1659.0,0.020702,0.020702,7.903227,0.330504,1.0,2705.0,19.0,243.0,did not continue in extension,Overall Study,FG012,diabetes type 2,INDUSTRY,0.05407462,0.05401263531514881,6.198468485118375e-05
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00096646,0.0009691699837797621,2.709983779762017e-06
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG008,diabetes type 2,INDUSTRY,0.00096646,0.0009683927879464293,1.932787946429303e-06
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2705.0,1659.0,0.00037,0.00037,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG010,diabetes type 2,INDUSTRY,0.00096646,0.0009691699837797621,2.709983779762017e-06
2.0,2705.0,1659.0,0.000739,0.000739,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG011,diabetes type 2,INDUSTRY,0.0019303,0.0019375154698214392,7.215469821439217e-06
0.0,2705.0,1659.0,0.0,0.0,7.903227,0.330504,1.0,2705.0,19.0,243.0,Not treated,Overall Study,FG012,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,810.0,723.0,0.01358,0.01358,6.698268,0.316604,1.0,810.0,20.0,78.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02879913,0.028815190302410705,1.6060302410705884e-05
7.0,810.0,723.0,0.008642,0.008642,6.698268,0.316604,1.0,810.0,20.0,78.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0183271,0.018582395139236093,0.000255295139236094
11.0,810.0,723.0,0.01358,0.01358,6.698268,0.316604,1.0,810.0,20.0,78.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02879913,0.02881680826407738,1.7678264077381628e-05
9.0,810.0,723.0,0.011111,0.011111,6.698268,0.316604,1.0,810.0,20.0,78.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02356311,0.023306397217440496,0.000256712782559506
8.0,810.0,723.0,0.009877,0.009877,6.698268,0.316604,1.0,810.0,20.0,78.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02094617,0.02088558830170635,6.058169829364912e-05
5.0,810.0,723.0,0.006173,0.006173,6.698268,0.316604,1.0,810.0,20.0,78.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01309109,0.013101771197053571,1.0681197053571609e-05
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00785508,0.00784705591166668,8.024088333320398e-06
2.0,810.0,723.0,0.002469,0.002469,6.698268,0.316604,1.0,810.0,20.0,78.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00523601,0.005230111298095224,5.8987019047763295e-06
0.0,810.0,723.0,0.0,0.0,6.698268,0.316604,1.0,810.0,20.0,78.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00785508,0.00785726105416668,2.181054166680227e-06
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00785508,0.007858392183333342,3.31218333334167e-06
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00785508,0.007831894904107146,2.318509589285464e-05
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00785508,0.007851197348333349,3.882651666651388e-06
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00785508,0.007853367419166679,1.7125808333216114e-06
3.0,810.0,723.0,0.003704,0.003704,6.698268,0.316604,1.0,810.0,20.0,78.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00785508,0.007827652860773818,2.7427139226182673e-05
1.0,810.0,723.0,0.001235,0.001235,6.698268,0.316604,1.0,810.0,20.0,78.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00261907,0.0026206733017568335,1.6033017568336909e-06
1.0,810.0,723.0,0.001235,0.001235,6.698268,0.316604,1.0,810.0,20.0,78.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00261907,0.0026222779778282616,3.2079778282618e-06
0.0,810.0,723.0,0.0,0.0,6.698268,0.316604,1.0,810.0,20.0,78.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,810.0,723.0,0.001235,0.001235,6.698268,0.316604,1.0,810.0,20.0,78.0,Treatment Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00261907,0.0026219811740674404,2.9111740674405556e-06
2.0,810.0,723.0,0.002469,0.002469,6.698268,0.316604,1.0,810.0,20.0,78.0,Treatment Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00523601,0.005231257753928555,4.752246071445566e-06
2.0,810.0,723.0,0.002469,0.002469,6.698268,0.316604,1.0,810.0,20.0,78.0,Treatment Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00523601,0.005235867565535699,1.4243446430119155e-07
0.0,810.0,723.0,0.0,0.0,6.698268,0.316604,1.0,810.0,20.0,78.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,810.0,723.0,0.002469,0.002469,6.698268,0.316604,1.0,810.0,20.0,78.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00523601,0.005230373220595223,5.636779404777532e-06
1.0,810.0,723.0,0.001235,0.001235,6.698268,0.316604,1.0,810.0,20.0,78.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00261907,0.0026212083307341066,2.1383307341068213e-06
0.0,810.0,723.0,0.0,0.0,6.698268,0.316604,1.0,810.0,20.0,78.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,810.0,723.0,0.001235,0.001235,6.698268,0.316604,1.0,810.0,20.0,78.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00261907,0.0026239659863888693,4.895986388869442e-06
2.0,810.0,723.0,0.002469,0.002469,6.698268,0.316604,1.0,810.0,20.0,78.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00523601,0.005234507172202367,1.5028277976329718e-06
31.0,812.0,686.0,0.038177,0.038177,6.700731,0.286086,1.0,841.0,8.0,173.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07318474,0.07470772845279762,0.0015229884527976217
41.0,812.0,686.0,0.050493,0.050493,6.700731,0.286086,1.0,841.0,8.0,173.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09679432,0.10420568227935517,0.007411362279355169
2.0,812.0,686.0,0.002463,0.002463,6.700731,0.286086,1.0,841.0,8.0,173.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00472153,0.004670851183363103,5.0678816636897175e-05
1.0,812.0,686.0,0.001232,0.001232,6.700731,0.286086,1.0,841.0,8.0,173.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00236173,0.0023701663559920504,8.436355992050629e-06
4.0,812.0,686.0,0.004926,0.004926,6.700731,0.286086,1.0,841.0,8.0,173.0,Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00944307,0.00952269837312499,7.962837312499096e-05
5.0,812.0,686.0,0.006158,0.006158,6.700731,0.286086,1.0,841.0,8.0,173.0,Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01180479,0.011800223248224207,4.5667517757936454e-06
8.0,812.0,686.0,0.009852,0.009852,6.700731,0.286086,1.0,841.0,8.0,173.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01888614,0.019067006646051585,0.0001808666460515855
8.0,812.0,686.0,0.009852,0.009852,6.700731,0.286086,1.0,841.0,8.0,173.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01888614,0.01912120366345238,0.00023506366345238047
10.0,812.0,686.0,0.012315,0.012315,6.700731,0.286086,1.0,841.0,8.0,173.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02360767,0.02406061143129962,0.0004529414312996194
12.0,812.0,686.0,0.014778,0.014778,6.700731,0.286086,1.0,841.0,8.0,173.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0283292,0.02853638877193453,0.0002071887719345307
2.0,812.0,686.0,0.002463,0.002463,6.700731,0.286086,1.0,841.0,8.0,173.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00472153,0.004669030689196432,5.24993108035679e-05
1.0,812.0,686.0,0.001232,0.001232,6.700731,0.286086,1.0,841.0,8.0,173.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00236173,0.0023713897091071296,9.659709107129755e-06
1.0,812.0,686.0,0.001232,0.001232,6.700731,0.286086,1.0,841.0,8.0,173.0,Conflicting HbA1c Results at Screening,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00236173,0.002375491838551574,1.3761838551574253e-05
0.0,812.0,686.0,0.0,0.0,6.700731,0.286086,1.0,841.0,8.0,173.0,Conflicting HbA1c Results at Screening,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
32.0,813.0,743.0,0.03936,0.03936,6.70196,0.399908,1.0,813.0,13.0,146.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10549137,0.10118177801673613,0.004309591983263875
38.0,813.0,743.0,0.04674,0.04674,6.70196,0.399908,1.0,813.0,13.0,146.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.125271,0.1250677461946132,0.00020325380538679938
6.0,254.0,204.0,0.023622,0.023622,5.541264,0.247637,1.0,254.0,1.0,41.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03241468,0.03256417559642855,0.00014949559642855187
6.0,254.0,204.0,0.023622,0.023622,5.541264,0.247637,1.0,254.0,1.0,41.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03241468,0.03257866517113093,0.0001639851711309273
5.0,254.0,204.0,0.019685,0.019685,5.541264,0.247637,1.0,254.0,1.0,41.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02701224,0.027472104733200796,0.000459864733200796
5.0,254.0,204.0,0.019685,0.019685,5.541264,0.247637,1.0,254.0,1.0,41.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02701224,0.027436733271385298,0.00042449327138529766
0.0,254.0,204.0,0.0,0.0,5.541264,0.247637,1.0,254.0,1.0,41.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,254.0,204.0,0.003937,0.003937,5.541264,0.247637,1.0,254.0,1.0,41.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00540245,0.00544113012380863,3.868012380863015e-05
6.0,254.0,204.0,0.023622,0.023622,5.541264,0.247637,1.0,254.0,1.0,41.0,Withdrawal of Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03241468,0.03256094632976187,0.00014626632976186965
12.0,254.0,204.0,0.047244,0.047244,5.541264,0.247637,1.0,254.0,1.0,41.0,Withdrawal of Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06482937,0.06671216485191468,0.0018827948519146848
0.0,254.0,204.0,0.0,0.0,5.541264,0.247637,1.0,254.0,1.0,41.0,Investigator Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,254.0,204.0,0.007874,0.007874,5.541264,0.247637,1.0,254.0,1.0,41.0,Investigator Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01080489,0.010983601967040027,0.00017871196704002772
3.0,254.0,204.0,0.011811,0.011811,5.541264,0.247637,1.0,254.0,1.0,41.0,Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01620734,0.016340073629910704,0.00013273362991070292
4.0,254.0,204.0,0.015748,0.015748,5.541264,0.247637,1.0,254.0,1.0,41.0,Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02160979,0.022169058472748016,0.000559268472748016
2.0,394.0,371.0,0.005076,0.005076,5.978886,0.31796,1.0,394.0,10.0,49.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00964972,0.009645246489285704,4.473510714296872e-06
3.0,394.0,371.0,0.007614,0.007614,5.978886,0.31796,1.0,394.0,10.0,49.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01447457,0.01450050347755954,2.5933477559539342e-05
3.0,394.0,371.0,0.007614,0.007614,5.978886,0.31796,1.0,394.0,10.0,49.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01447457,0.014488719995297645,1.4149995297644408e-05
0.0,394.0,371.0,0.0,0.0,5.978886,0.31796,1.0,394.0,10.0,49.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,394.0,371.0,0.01269,0.01269,5.978886,0.31796,1.0,394.0,10.0,49.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02412429,0.024310188034801575,0.00018589803480157513
10.0,394.0,371.0,0.025381,0.025381,5.978886,0.31796,1.0,394.0,10.0,49.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04825048,0.04793377713503962,0.0003167028649603762
13.0,1441.0,1372.0,0.009022,0.009022,7.273786,0.690028,1.0,1441.0,9.0,93.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04528244,0.04426059937379961,0.0010218406262003932
12.0,1441.0,1372.0,0.008328,0.008328,7.273786,0.690028,1.0,1441.0,9.0,93.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04179918,0.04229850967288693,0.0004993296728869334
21.0,1441.0,1372.0,0.014573,0.014573,7.273786,0.690028,1.0,1441.0,9.0,93.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07314354,0.071559867082748,0.0015836729172520048
7.0,1441.0,1372.0,0.004858,0.004858,7.273786,0.690028,1.0,1441.0,9.0,93.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02438285,0.024138964063065437,0.0002438859369345639
0.0,1441.0,1372.0,0.0,0.0,7.273786,0.690028,1.0,1441.0,9.0,93.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1441.0,1372.0,0.002082,0.002082,7.273786,0.690028,1.0,1441.0,9.0,93.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01044979,0.010387534764890871,6.225523510912899e-05
3.0,1441.0,1372.0,0.002082,0.002082,7.273786,0.690028,1.0,1441.0,9.0,93.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01044979,0.010375859392807541,7.393060719245934e-05
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00348326,0.0035072940681051767,2.403406810517648e-05
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00348326,0.003510880989652796,2.7620989652795813e-05
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00348326,0.0035014825084027958,1.8222508402795587e-05
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00348326,0.003499159778402797,1.5899778402796855e-05
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00348326,0.003493181728402797,9.921728402796821e-06
2.0,1441.0,1372.0,0.001388,0.001388,7.273786,0.690028,1.0,1441.0,9.0,93.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00696653,0.007087825058025783,0.00012129505802578253
2.0,1441.0,1372.0,0.001388,0.001388,7.273786,0.690028,1.0,1441.0,9.0,93.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00696653,0.00710527240013889,0.00013874240013888976
1.0,1441.0,1372.0,0.000694,0.000694,7.273786,0.690028,1.0,1441.0,9.0,93.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00348326,0.003512050101021844,2.8790101021843994e-05
0.0,1441.0,1372.0,0.0,0.0,7.273786,0.690028,1.0,1441.0,9.0,93.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,5734.0,5656.0,0.000872,0.000872,8.654343,0.603993,1.0,5734.0,48.0,978.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00455808,0.004482586851220237,7.549314877976308e-05
3.0,5734.0,5656.0,0.000523,0.000523,8.654343,0.603993,1.0,5734.0,48.0,978.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0027338,0.0027917038529166665,5.790385291666632e-05
4.0,5734.0,5656.0,0.000698,0.000698,8.654343,0.603993,1.0,5734.0,48.0,978.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00364856,0.003735317131130951,8.675713113095096e-05
6.0,5734.0,5656.0,0.001046,0.001046,8.654343,0.603993,1.0,5734.0,48.0,978.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00546761,0.005426124006160711,4.148599383928947e-05
33.0,5734.0,5656.0,0.005755,0.005755,8.654343,0.603993,1.0,5734.0,48.0,978.0,GCP violations,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0300823,0.03012896606517858,4.6666065178582045e-05
27.0,5734.0,5656.0,0.004709,0.004709,8.654343,0.603993,1.0,5734.0,48.0,978.0,GCP violations,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02461469,0.023855093508749984,0.0007595964912500176
2.0,1091.0,1062.0,0.001833,0.001833,6.995766,0.543961,1.0,1264.0,18.0,167.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00697534,0.007074688993224218,9.934899322421812e-05
1.0,1091.0,1062.0,0.000917,0.000917,6.995766,0.543961,1.0,1264.0,18.0,167.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00348957,0.0036310309148313525,0.00014146091483135254
2.0,1091.0,1062.0,0.001833,0.001833,6.995766,0.543961,1.0,1264.0,18.0,167.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00697534,0.007063716878700408,8.837687870040783e-05
2.0,1091.0,1062.0,0.001833,0.001833,6.995766,0.543961,1.0,1264.0,18.0,167.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00697534,0.00705621135298612,8.087135298612009e-05
11.0,1091.0,1062.0,0.010082,0.010082,6.995766,0.543961,1.0,1264.0,18.0,167.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03836629,0.03836135335421632,4.936645783680527e-06
11.0,1091.0,1062.0,0.010082,0.010082,6.995766,0.543961,1.0,1264.0,18.0,167.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03836629,0.03841014935478179,4.385935478179448e-05
7.0,660.0,598.0,0.010606,0.010606,6.493754,0.33342,1.0,660.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02296353,0.022982016123779765,1.84861237797658e-05
6.0,660.0,598.0,0.009091,0.009091,6.493754,0.33342,1.0,660.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01968333,0.019483839954156767,0.00019949004584323207
2.0,660.0,598.0,0.00303,0.00303,6.493754,0.33342,1.0,660.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00656039,0.006538383661388902,2.2006338611098124e-05
1.0,660.0,598.0,0.001515,0.001515,6.493754,0.33342,1.0,660.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00328019,0.0032985787988392763,1.8388798839276237e-05
0.0,660.0,598.0,0.0,0.0,6.493754,0.33342,1.0,660.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,660.0,598.0,0.00303,0.00303,6.493754,0.33342,1.0,660.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00656039,0.006544356491388907,1.6033508611092845e-05
4.0,660.0,598.0,0.006061,0.006061,6.493754,0.33342,1.0,660.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01312294,0.013115888247985187,7.051752014812507e-06
3.0,660.0,598.0,0.004545,0.004545,6.493754,0.33342,1.0,660.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00984058,0.009839578365982172,1.0016340178282956e-06
3.0,660.0,598.0,0.004545,0.004545,6.493754,0.33342,1.0,660.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00984058,0.009836223002351216,4.356997648783528e-06
0.0,660.0,598.0,0.0,0.0,6.493754,0.33342,1.0,660.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,660.0,598.0,0.012121,0.012121,6.493754,0.33342,1.0,660.0,0.0,0.0,"Creatinine and eGFR, excluded medication",Overall Study,FG000,diabetes type 2,INDUSTRY,0.02624372,0.026319925312678554,7.620531267855252e-05
4.0,660.0,598.0,0.006061,0.006061,6.493754,0.33342,1.0,660.0,0.0,0.0,"Creatinine and eGFR, excluded medication",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01312294,0.013147186399592335,2.4246399592335252e-05
2.0,660.0,598.0,0.00303,0.00303,6.493754,0.33342,1.0,660.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00656039,0.006536412538472236,2.397746152776447e-05
5.0,660.0,598.0,0.007576,0.007576,6.493754,0.33342,1.0,660.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01640314,0.01631588015227184,8.725984772816123e-05
1.0,660.0,598.0,0.001515,0.001515,6.493754,0.33342,1.0,660.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00328019,0.0032913183819345154,1.112838193451527e-05
3.0,660.0,598.0,0.004545,0.004545,6.493754,0.33342,1.0,660.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00984058,0.009831754564732174,8.825435267825754e-06
7.0,660.0,598.0,0.010606,0.010606,6.493754,0.33342,1.0,660.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02296353,0.02297693847116612,1.3408471166119484e-05
2.0,660.0,598.0,0.00303,0.00303,6.493754,0.33342,1.0,660.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00656039,0.006545837495555573,1.4552504444427343e-05
1.0,660.0,598.0,0.001515,0.001515,6.493754,0.33342,1.0,660.0,0.0,0.0,Screen failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00328019,0.0032884073147321337,8.217314732133617e-06
1.0,660.0,598.0,0.001515,0.001515,6.493754,0.33342,1.0,660.0,0.0,0.0,Screen failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00328019,0.003290963171696419,1.0773171696418747e-05
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0081716,0.008156330703253934,1.5269296746065267e-05
3.0,478.0,428.0,0.006276,0.006276,6.171701,0.632908,1.0,478.0,5.0,53.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02451481,0.02443827092466269,7.653907533730978e-05
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0081716,0.00817576277331345,4.162773313449997e-06
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081716,0.008176916335932495,5.316335932495364e-06
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081716,0.008176551412599164,4.95141259916447e-06
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0081716,0.008175028319861073,3.4283198610731563e-06
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,478.0,428.0,0.004184,0.004184,6.171701,0.632908,1.0,478.0,5.0,53.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01634321,0.01646070471936505,0.0001174947193650494
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0081716,0.008153522132003935,1.8077867996063937e-05
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081716,0.00817360884176583,2.0088417658301744e-06
2.0,478.0,428.0,0.004184,0.004184,6.171701,0.632908,1.0,478.0,5.0,53.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01634321,0.016494357604738427,0.00015114760473842678
3.0,478.0,428.0,0.006276,0.006276,6.171701,0.632908,1.0,478.0,5.0,53.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02451481,0.024469553718829366,4.525628117063585e-05
13.0,478.0,428.0,0.027197,0.027197,6.171701,0.632908,1.0,478.0,5.0,53.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.10623477,0.10319175383931546,0.0030430161606845446
6.0,478.0,428.0,0.012552,0.012552,6.171701,0.632908,1.0,478.0,5.0,53.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04902963,0.04734481418154764,0.0016848158184523607
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Participant left the country,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Participant left the country,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,478.0,428.0,0.002092,0.002092,6.171701,0.632908,1.0,478.0,5.0,53.0,Participant left the country,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0081716,0.008171654274980117,5.42749801178688e-08
0.0,478.0,428.0,0.0,0.0,6.171701,0.632908,1.0,478.0,5.0,53.0,Participant left the country,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,478.0,428.0,0.006276,0.006276,6.171701,0.632908,1.0,478.0,5.0,53.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02451481,0.024430510367559513,8.429963244048835e-05
2.0,478.0,428.0,0.004184,0.004184,6.171701,0.632908,1.0,478.0,5.0,53.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01634321,0.016440072351329337,9.68623513293368e-05
3.0,478.0,428.0,0.006276,0.006276,6.171701,0.632908,1.0,478.0,5.0,53.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02451481,0.02448233015103175,3.247984896825179e-05
5.0,478.0,428.0,0.01046,0.01046,6.171701,0.632908,1.0,478.0,5.0,53.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04085802,0.04178434490806365,0.0009263249080636513
5.0,721.0,580.0,0.006935,0.006935,6.582025,0.413814,1.0,721.0,2.0,166.0,Adverse Event,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.0188891,0.01851395834359941,0.0003751416564005891
7.0,721.0,580.0,0.009709,0.009709,6.582025,0.413814,1.0,721.0,2.0,166.0,Adverse Event,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.02644474,0.026360634433134966,8.410556686503506e-05
0.0,721.0,580.0,0.0,0.0,6.582025,0.413814,1.0,721.0,2.0,166.0,Lack of Efficacy,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Lack of Efficacy,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.00377782,0.003803767427579382,2.594742757938218e-05
11.0,721.0,580.0,0.015257,0.015257,6.582025,0.413814,1.0,721.0,2.0,166.0,Lost to Follow-up,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.04155602,0.040997125201279794,0.0005588947987202053
3.0,721.0,580.0,0.004161,0.004161,6.582025,0.413814,1.0,721.0,2.0,166.0,Lost to Follow-up,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.01133346,0.011233279323501983,0.00010018067649801739
22.0,721.0,580.0,0.030513,0.030513,6.582025,0.413814,1.0,721.0,2.0,166.0,Protocol Violation,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.08310933,0.08286126236590274,0.0002480676340972515
17.0,721.0,580.0,0.023578,0.023578,6.582025,0.413814,1.0,721.0,2.0,166.0,Protocol Violation,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.06422022,0.06372653639863089,0.000493683601369102
13.0,721.0,580.0,0.018031,0.018031,6.582025,0.413814,1.0,721.0,2.0,166.0,Withdrawal by Subject,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.04911167,0.04894060797981146,0.00017106202018854488
17.0,721.0,580.0,0.023578,0.023578,6.582025,0.413814,1.0,721.0,2.0,166.0,Withdrawal by Subject,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.06422022,0.0636474622547916,0.0005727577452083882
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Casebook Unsigned,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.00377782,0.0037956627113293817,1.78427113293818e-05
0.0,721.0,580.0,0.0,0.0,6.582025,0.413814,1.0,721.0,2.0,166.0,Casebook Unsigned,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Unclassified,Treatment Period 1,FG000,diabetes type 2,INDUSTRY,0.00377782,0.0037903663929960496,1.2546392996049763e-05
0.0,721.0,580.0,0.0,0.0,6.582025,0.413814,1.0,721.0,2.0,166.0,Unclassified,Treatment Period 1,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,721.0,580.0,0.005548,0.005548,6.582025,0.413814,1.0,721.0,2.0,166.0,Adverse Event,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.01511128,0.015055674305238142,5.560569476185766e-05
4.0,721.0,580.0,0.005548,0.005548,6.582025,0.413814,1.0,721.0,2.0,166.0,Adverse Event,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.01511128,0.015064735319404809,4.6544680595190374e-05
2.0,721.0,580.0,0.002774,0.002774,6.582025,0.413814,1.0,721.0,2.0,166.0,Lack of Efficacy,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.00755564,0.00751278175494049,4.2858245059509796e-05
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Lack of Efficacy,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.00377782,0.003801811517817477,2.3991517817476948e-05
4.0,721.0,580.0,0.005548,0.005548,6.582025,0.413814,1.0,721.0,2.0,166.0,Lost to Follow-up,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.01511128,0.015089381254345282,2.1898745654717888e-05
2.0,721.0,580.0,0.002774,0.002774,6.582025,0.413814,1.0,721.0,2.0,166.0,Lost to Follow-up,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.00755564,0.007519387507976212,3.625249202378767e-05
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Protocol Violation,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.00377782,0.003796795232638904,1.8975232638904303e-05
2.0,721.0,580.0,0.002774,0.002774,6.582025,0.413814,1.0,721.0,2.0,166.0,Protocol Violation,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.00755564,0.007516209170892878,3.943082910712152e-05
13.0,721.0,580.0,0.018031,0.018031,6.582025,0.413814,1.0,721.0,2.0,166.0,Withdrawal by Subject,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.04911167,0.04894060797981146,0.00017106202018854488
9.0,721.0,580.0,0.012483,0.012483,6.582025,0.413814,1.0,721.0,2.0,166.0,Withdrawal by Subject,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.03400038,0.033847223189196425,0.00015315681080357163
1.0,721.0,580.0,0.001387,0.001387,6.582025,0.413814,1.0,721.0,2.0,166.0,Unclassified,Treatment Period 2,FG000,diabetes type 2,INDUSTRY,0.00377782,0.003788516037162715,1.0696037162715322e-05
0.0,721.0,580.0,0.0,0.0,6.582025,0.413814,1.0,721.0,2.0,166.0,Unclassified,Treatment Period 2,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00979957,0.009837421991865138,3.78519918651371e-05
3.0,313.0,285.0,0.009585,0.009585,5.749393,0.266738,1.0,313.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01469936,0.014949245546547594,0.0002498855465475937
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00979957,0.009826385054156804,2.681505415680352e-05
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00979957,0.009815842970625061,1.6272970625060695e-05
0.0,313.0,285.0,0.0,0.0,5.749393,0.266738,1.0,313.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,313.0,285.0,0.009585,0.009585,5.749393,0.266738,1.0,313.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01469936,0.01496275345696426,0.0002633934569642605
0.0,313.0,285.0,0.0,0.0,5.749393,0.266738,1.0,313.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00979957,0.009819046162916727,1.947616291672616e-05
1.0,313.0,285.0,0.003195,0.003195,5.749393,0.266738,1.0,313.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00489979,0.00499251481222223,9.27248122222302e-05
5.0,313.0,285.0,0.015974,0.015974,5.749393,0.266738,1.0,313.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0244974,0.024863712538045663,0.00036631253804566416
0.0,313.0,285.0,0.0,0.0,5.749393,0.266738,1.0,313.0,0.0,0.0,Contradiction to study medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Contradiction to study medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00979957,0.009820366035833394,2.0796035833393553e-05
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Excluded medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00979957,0.009830908119365137,3.133811936513638e-05
2.0,313.0,285.0,0.00639,0.00639,5.749393,0.266738,1.0,313.0,0.0,0.0,Excluded medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00979957,0.009820366035833394,2.0796035833393553e-05
1.0,313.0,285.0,0.003195,0.003195,5.749393,0.266738,1.0,313.0,0.0,0.0,Lab abnormalities,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00489979,0.004969881935198422,7.009193519842173e-05
1.0,313.0,285.0,0.003195,0.003195,5.749393,0.266738,1.0,313.0,0.0,0.0,Lab abnormalities,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00489979,0.004963481915376996,6.369191537699583e-05
33.0,1261.0,1063.0,0.02617,0.02617,7.140453,1.0,1.0,1263.0,19.0,169.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.18686566,0.18201615011712313,0.004849509882876857
25.0,1261.0,1063.0,0.019826,0.019826,7.140453,1.0,1.0,1263.0,19.0,169.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.14156662,0.1398926529858142,0.0016739670141858176
17.0,1261.0,1063.0,0.013481,0.013481,7.140453,1.0,1.0,1263.0,19.0,169.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09626045,0.09497434224885914,0.0012861077511408525
3.0,1261.0,1063.0,0.002379,0.002379,7.140453,1.0,1.0,1263.0,19.0,169.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01698714,0.016649766560218285,0.00033737343978171644
5.0,1261.0,1063.0,0.003965,0.003965,7.140453,1.0,1.0,1263.0,19.0,169.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0283119,0.028168357543043827,0.00014354245695617426
7.0,1261.0,1063.0,0.005551,0.005551,7.140453,1.0,1.0,1263.0,19.0,169.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03963665,0.03970336131749999,6.671131749998865e-05
8.0,1261.0,1063.0,0.006344,0.006344,7.140453,1.0,1.0,1263.0,19.0,169.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04529903,0.04496329536898806,0.0003357346310119344
14.0,1261.0,1063.0,0.011102,0.011102,7.140453,1.0,1.0,1263.0,19.0,169.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07927331,0.07559308084151779,0.0036802291584822067
26.0,1261.0,1063.0,0.020619,0.020619,7.140453,1.0,1.0,1263.0,19.0,169.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.147229,0.14358739008969232,0.0036416099103076804
21.0,1261.0,1063.0,0.016653,0.016653,7.140453,1.0,1.0,1263.0,19.0,169.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11890996,0.11527031877912698,0.0036396412208730133
21.0,1261.0,1063.0,0.016653,0.016653,7.140453,1.0,1.0,1263.0,19.0,169.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11890996,0.11571726415728172,0.0031926958427182794
18.0,1261.0,1063.0,0.014274,0.014274,7.140453,1.0,1.0,1263.0,19.0,169.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10192283,0.10068020908427573,0.001242620915724274
1.0,93.0,90.0,0.010753,0.010753,4.543295,0.254793,1.0,219.0,4.0,21.0,Subject withdrew consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01244767,0.01282319593460316,0.0003755259346031603
1.0,93.0,90.0,0.010753,0.010753,4.543295,0.254793,1.0,219.0,4.0,21.0,Subject withdrew consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01244767,0.012845708590019829,0.00039803859001982973
1.0,93.0,90.0,0.010753,0.010753,4.543295,0.254793,1.0,219.0,4.0,21.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01244767,0.01287385276335316,0.00042618276335316084
0.0,93.0,90.0,0.0,0.0,4.543295,0.254793,1.0,219.0,4.0,21.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,365.0,311.0,0.038356,0.038356,5.902633,0.35786,1.0,365.0,1.0,60.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08101993,0.081365420456627,0.00034549045662699007
7.0,365.0,311.0,0.019178,0.019178,5.902633,0.35786,1.0,365.0,1.0,60.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04050996,0.040540546367236585,3.0586367236587475e-05
7.0,365.0,311.0,0.019178,0.019178,5.902633,0.35786,1.0,365.0,1.0,60.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04050996,0.04054764143431991,3.768143431991111e-05
4.0,365.0,311.0,0.010959,0.010959,5.902633,0.35786,1.0,365.0,1.0,60.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02314885,0.023307225856904736,0.00015837585690473693
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,365.0,311.0,0.008219,0.008219,5.902633,0.35786,1.0,365.0,1.0,60.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01736111,0.017452438045254905,9.132804525490562e-05
1.0,365.0,311.0,0.00274,0.00274,5.902633,0.35786,1.0,365.0,1.0,60.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00578774,0.005775271531071432,1.2468468928568573e-05
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,365.0,311.0,0.00274,0.00274,5.902633,0.35786,1.0,365.0,1.0,60.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00578774,0.005790738342012991,2.998342012990561e-06
1.0,365.0,311.0,0.00274,0.00274,5.902633,0.35786,1.0,365.0,1.0,60.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00578774,0.005770863919166671,1.6876080833329483e-05
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,365.0,311.0,0.016438,0.016438,5.902633,0.35786,1.0,365.0,1.0,60.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03472222,0.03465786692548609,6.43530745139051e-05
6.0,365.0,311.0,0.016438,0.016438,5.902633,0.35786,1.0,365.0,1.0,60.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03472222,0.034698703411994006,2.3516588005992323e-05
3.0,365.0,311.0,0.008219,0.008219,5.902633,0.35786,1.0,365.0,1.0,60.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01736111,0.0174139587802549,5.284878025490006e-05
1.0,365.0,311.0,0.00274,0.00274,5.902633,0.35786,1.0,365.0,1.0,60.0,Administrative,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00578774,0.005773297020654765,1.4442979345235044e-05
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Administrative,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,365.0,311.0,0.0,0.0,5.902633,0.35786,1.0,365.0,1.0,60.0,Administrative,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,395.0,356.0,0.022785,0.022785,5.981414,0.260914,1.0,395.0,0.0,0.0,Clinical adverse event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.035559,0.03521221235537427,0.000346787644625729
3.0,395.0,356.0,0.007595,0.007595,5.981414,0.260914,1.0,395.0,0.0,0.0,Clinical adverse event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.011853,0.011816746351825391,3.625364817460945e-05
0.0,395.0,356.0,0.0,0.0,5.981414,0.260914,1.0,395.0,0.0,0.0,Laboratory adverse event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,395.0,356.0,0.005063,0.005063,5.981414,0.260914,1.0,395.0,0.0,0.0,Laboratory adverse event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00790148,0.007929210026960693,2.7730026960692475e-05
1.0,395.0,356.0,0.002532,0.002532,5.981414,0.260914,1.0,395.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00395152,0.003985546057212298,3.402605721229777e-05
0.0,395.0,356.0,0.0,0.0,5.981414,0.260914,1.0,395.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,395.0,356.0,0.010127,0.010127,5.981414,0.260914,1.0,395.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01580452,0.015781262160595225,2.3257839404773606e-05
2.0,395.0,356.0,0.005063,0.005063,5.981414,0.260914,1.0,395.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00790148,0.007927424121544029,2.594412154402828e-05
2.0,395.0,356.0,0.005063,0.005063,5.981414,0.260914,1.0,395.0,0.0,0.0,Other reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00790148,0.00793895154722855,3.747154722854966e-05
2.0,395.0,356.0,0.005063,0.005063,5.981414,0.260914,1.0,395.0,0.0,0.0,Other reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00790148,0.007929210026960693,2.7730026960692475e-05
3.0,395.0,356.0,0.007595,0.007595,5.981414,0.260914,1.0,395.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.011853,0.011821444286845234,3.155571315476696e-05
2.0,395.0,356.0,0.005063,0.005063,5.981414,0.260914,1.0,395.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00790148,0.00793115029362736,2.9670293627359276e-05
4.0,395.0,356.0,0.010127,0.010127,5.981414,0.260914,1.0,395.0,0.0,0.0,Subject moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01580452,0.015784907716676573,1.9612283323425933e-05
0.0,395.0,356.0,0.0,0.0,5.981414,0.260914,1.0,395.0,0.0,0.0,Subject moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,395.0,356.0,0.0,0.0,5.981414,0.260914,1.0,395.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,395.0,356.0,0.012658,0.012658,5.981414,0.260914,1.0,395.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01975448,0.01976237587461307,7.895874613070286e-06
5.0,520.0,446.0,0.009615,0.009615,6.25575,0.217225,1.0,520.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01306586,0.01311413622544947,4.827622544946973e-05
6.0,520.0,446.0,0.011538,0.011538,6.25575,0.217225,1.0,520.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01567903,0.015488666593809524,0.00019036340619047604
7.0,520.0,446.0,0.013462,0.013462,6.25575,0.217225,1.0,520.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01829356,0.01848921147973215,0.00019565147973214791
10.0,520.0,446.0,0.019231,0.019231,6.25575,0.217225,1.0,520.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02613308,0.02575509672497025,0.00037798327502975085
8.0,520.0,446.0,0.015385,0.015385,6.25575,0.217225,1.0,520.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02090673,0.02062874622342262,0.0002779837765773778
9.0,520.0,446.0,0.017308,0.017308,6.25575,0.217225,1.0,520.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0235199,0.023563292174672644,4.339217467264414e-05
2.0,520.0,446.0,0.003846,0.003846,6.25575,0.217225,1.0,520.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00522634,0.005203071025009915,2.3268974990085095e-05
0.0,520.0,446.0,0.0,0.0,6.25575,0.217225,1.0,520.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,520.0,446.0,0.0,0.0,6.25575,0.217225,1.0,520.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,520.0,446.0,0.001923,0.001923,6.25575,0.217225,1.0,520.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00261317,0.0026219919758730214,8.821975873021283e-06
7.0,520.0,446.0,0.013462,0.013462,6.25575,0.217225,1.0,520.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01829356,0.018482505324732147,0.0001889453247321468
14.0,520.0,446.0,0.026923,0.026923,6.25575,0.217225,1.0,520.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03658576,0.036004602328492105,0.0005811576715078967
1.0,520.0,446.0,0.001923,0.001923,6.25575,0.217225,1.0,520.0,0.0,0.0,protocol discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00261317,0.0026214160701587374,8.246070158737275e-06
4.0,520.0,446.0,0.007692,0.007692,6.25575,0.217225,1.0,520.0,0.0,0.0,protocol discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01045269,0.010134920066101187,0.0003177699338988132
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Adverse Event,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00789308,0.007881809099166715,1.1270900833285427e-05
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Adverse Event,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007884981601666723,8.098398333277607e-06
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Death,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,444.0,338.0,0.004505,0.004505,6.098074,0.574758,1.0,444.0,10.0,84.0,Death,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01578966,0.015761171971498046,2.8488028501954393e-05
6.0,444.0,338.0,0.013514,0.013514,6.098074,0.574758,1.0,444.0,10.0,84.0,Lost to Follow-up,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.04736548,0.047419723289047526,5.424328904752446e-05
6.0,444.0,338.0,0.013514,0.013514,6.098074,0.574758,1.0,444.0,10.0,84.0,Lost to Follow-up,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.04736548,0.047404939099702295,3.9459099702293665e-05
9.0,444.0,338.0,0.02027,0.02027,6.098074,0.574758,1.0,444.0,10.0,84.0,Withdrawal by Subject,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.07104471,0.07097153963247015,7.317036752985118e-05
9.0,444.0,338.0,0.02027,0.02027,6.098074,0.574758,1.0,444.0,10.0,84.0,Withdrawal by Subject,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.07104471,0.07095176769895825,9.294230104174572e-05
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject Request To Discontinue Treatment,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00789308,0.007879881924166714,1.3198075833286554e-05
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject Request To Discontinue Treatment,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007883054426666723,1.0025573333277e-05
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Non-compliance with Study Drug,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,444.0,338.0,0.004505,0.004505,6.098074,0.574758,1.0,444.0,10.0,84.0,Non-compliance with Study Drug,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01578966,0.01576795981078376,2.1700189216239396e-05
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Worsening of liver function,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Worsening of liver function,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007883054426666723,1.0025573333277e-05
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject moved out of state,Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject moved out of state,Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007883054426666723,1.0025573333277e-05
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Non-compliance with Study Drug,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00789308,0.007894549449583396,1.469449583395288e-06
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Non-compliance with Study Drug,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007897108392083404,4.028392083403609e-06
6.0,444.0,338.0,0.013514,0.013514,6.098074,0.574758,1.0,444.0,10.0,84.0,Lost to Follow-up,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.04736548,0.04745119638696421,8.571638696421024e-05
4.0,444.0,338.0,0.009009,0.009009,6.098074,0.574758,1.0,444.0,10.0,84.0,Lost to Follow-up,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03157582,0.03145360326751987,0.00012221673248012654
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Lack of Efficacy,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00789308,0.007885679477083393,7.400522916607005e-06
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Lack of Efficacy,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.0078882384195834,4.841580416600419e-06
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Death,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,444.0,338.0,0.002252,0.002252,6.098074,0.574758,1.0,444.0,10.0,84.0,Death,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00789308,0.007895475550416737,2.395550416737016e-06
0.0,444.0,338.0,0.0,0.0,6.098074,0.574758,1.0,444.0,10.0,84.0,Adverse Event,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,444.0,338.0,0.011261,0.011261,6.098074,0.574758,1.0,444.0,10.0,84.0,Adverse Event,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03946889,0.03934830454354163,0.00012058545645837054
4.0,444.0,338.0,0.009009,0.009009,6.098074,0.574758,1.0,444.0,10.0,84.0,Other,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03157582,0.031528076556269886,4.774344373011108e-05
4.0,444.0,338.0,0.009009,0.009009,6.098074,0.574758,1.0,444.0,10.0,84.0,Other,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03157582,0.03147563442644844,0.0001001855735515561
2.0,444.0,338.0,0.004505,0.004505,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject Decision,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01578966,0.015761448671458365,2.8211328541635078e-05
4.0,444.0,338.0,0.009009,0.009009,6.098074,0.574758,1.0,444.0,10.0,84.0,Subject Decision,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03157582,0.03146695590144844,0.00010886409855155599
8.0,444.0,338.0,0.018018,0.018018,6.098074,0.574758,1.0,444.0,10.0,84.0,Withdrawal by Subject,Long-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.06315163,0.06521635425229166,0.0020647242522916637
2.0,444.0,338.0,0.004505,0.004505,6.098074,0.574758,1.0,444.0,10.0,84.0,Withdrawal by Subject,Long-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01578966,0.015775237127867096,1.4422872132904135e-05
498.0,3070.0,1787.0,0.162215,0.162215,8.029759,0.190909,1.0,3095.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.24866832,0.289092651093839,0.04042433109383903
107.0,3070.0,1787.0,0.034853,0.034853,8.029759,0.190909,1.0,3095.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05342809,0.056194823713869094,0.002766733713869096
33.0,3070.0,1787.0,0.010749,0.010749,8.029759,0.190909,1.0,3095.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01647774,0.017881949430009925,0.0014042094300099235
27.0,3070.0,1787.0,0.008795,0.008795,8.029759,0.190909,1.0,3095.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01348234,0.014059403619672594,0.0005770636196725937
5.0,3070.0,1787.0,0.001629,0.001629,8.029759,0.190909,1.0,3095.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00249718,0.002641222835535714,0.000144042835535714
2.0,3070.0,1787.0,0.000651,0.000651,8.029759,0.190909,1.0,3095.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00099795,0.001073250425714287,7.530042571428689e-05
187.0,3070.0,1787.0,0.060912,0.060912,8.029759,0.190909,1.0,3095.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09337537,0.10154407979478176,0.008168709794781764
72.0,3070.0,1787.0,0.023453,0.023453,8.029759,0.190909,1.0,3095.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0359524,0.03770903093146825,0.001756630931468245
120.0,3070.0,1787.0,0.039088,0.039088,8.029759,0.190909,1.0,3095.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05992015,0.06062892824978176,0.0007087782497817649
56.0,3070.0,1787.0,0.018241,0.018241,8.029759,0.190909,1.0,3095.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02796264,0.028899264775446444,0.0009366247754464437
118.0,3070.0,1787.0,0.038436,0.038436,8.029759,0.190909,1.0,3095.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05892066,0.05972513116984132,0.0008044711698413226
58.0,3070.0,1787.0,0.018893,0.018893,8.029759,0.190909,1.0,3095.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02896212,0.02955507733483138,0.0005929573348313795
3.0,700.0,647.0,0.004286,0.004286,6.552508,1.0,1.0,701.0,10.0,82.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02808405,0.02772370057208341,0.00036034942791659044
9.0,700.0,647.0,0.012857,0.012857,6.552508,1.0,1.0,701.0,10.0,82.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08424559,0.0829424464744642,0.001303143525535802
3.0,700.0,647.0,0.004286,0.004286,6.552508,1.0,1.0,701.0,10.0,82.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02808405,0.027775936208333424,0.0003081137916665748
2.0,700.0,647.0,0.002857,0.002857,6.552508,1.0,1.0,701.0,10.0,82.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01872052,0.01846803692299599,0.00025248307700401207
2.0,700.0,647.0,0.002857,0.002857,6.552508,1.0,1.0,701.0,10.0,82.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01872052,0.018452141371984098,0.00026837862801590284
6.0,700.0,647.0,0.008571,0.008571,6.552508,1.0,1.0,701.0,10.0,82.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05616155,0.0549893901011211,0.0011721598988789009
4.0,700.0,647.0,0.005714,0.005714,6.552508,1.0,1.0,701.0,10.0,82.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03744103,0.03701849547915672,0.0004225345208432804
13.0,700.0,647.0,0.018571,0.018571,6.552508,1.0,1.0,701.0,10.0,82.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12168662,0.12097795401387985,0.0007086659861201411
2.0,700.0,647.0,0.002857,0.002857,6.552508,1.0,1.0,701.0,10.0,82.0,Other incl. lack of efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01872052,0.018448055503234095,0.00027246449676590623
9.0,700.0,647.0,0.012857,0.012857,6.552508,1.0,1.0,701.0,10.0,82.0,Other incl. lack of efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08424559,0.08278486143904754,0.0014607285609524595
9.0,424.0,371.0,0.021226,0.021226,6.052089,0.269474,1.0,424.0,5.0,46.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0346171,0.03456544838471235,5.1651615287647e-05
5.0,424.0,371.0,0.011792,0.011792,6.052089,0.269474,1.0,424.0,5.0,46.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01923136,0.019370040945307546,0.00013868094530754618
2.0,424.0,371.0,0.004717,0.004717,6.052089,0.269474,1.0,424.0,5.0,46.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00769287,0.007719847885191219,2.6977885191219013e-05
2.0,424.0,371.0,0.004717,0.004717,6.052089,0.269474,1.0,424.0,5.0,46.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00769287,0.007721698952572167,2.882895257216682e-05
3.0,424.0,371.0,0.007075,0.007075,6.052089,0.269474,1.0,424.0,5.0,46.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01153849,0.011488055856031748,5.043414396825249e-05
1.0,424.0,371.0,0.002358,0.002358,6.052089,0.269474,1.0,424.0,5.0,46.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00384562,0.00385150184836309,5.881848363089963e-06
9.0,424.0,371.0,0.021226,0.021226,6.052089,0.269474,1.0,424.0,5.0,46.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0346171,0.034601930050287756,1.5169949712241781e-05
4.0,424.0,371.0,0.009434,0.009434,6.052089,0.269474,1.0,424.0,5.0,46.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01538574,0.015351949042321445,3.379095767855507e-05
14.0,424.0,371.0,0.033019,0.033019,6.052089,0.269474,1.0,424.0,5.0,46.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05385009,0.05269137639053573,0.0011587136094642764
4.0,424.0,371.0,0.009434,0.009434,6.052089,0.269474,1.0,424.0,5.0,46.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01538574,0.01535828016315478,2.7459836845220367e-05
5.0,397.0,380.0,0.012594,0.012594,5.986452,0.412539,1.0,397.0,6.0,99.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03110272,0.031032930179781655,6.978982021834529e-05
5.0,397.0,380.0,0.012594,0.012594,5.986452,0.412539,1.0,397.0,6.0,99.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03110272,0.03104044501644833,6.227498355167171e-05
7.0,397.0,380.0,0.017632,0.017632,5.986452,0.412539,1.0,397.0,6.0,99.0,Unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04354479,0.04355839926867064,1.3609268670639052e-05
2.0,222.0,189.0,0.009009,0.009009,5.407172,0.238805,1.0,222.0,8.0,51.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01163295,0.011718481538253982,8.553153825398285e-05
4.0,222.0,189.0,0.018018,0.018018,5.407172,0.238805,1.0,222.0,8.0,51.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0232659,0.023925441593700407,0.0006595415937004079
0.0,222.0,189.0,0.0,0.0,5.407172,0.238805,1.0,222.0,8.0,51.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,222.0,189.0,0.022523,0.022523,5.407172,0.238805,1.0,222.0,8.0,51.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02908302,0.02933282540610119,0.00024980540610118965
5.0,222.0,189.0,0.022523,0.022523,5.407172,0.238805,1.0,222.0,8.0,51.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02908302,0.02933934107319444,0.0002563210731944404
3.0,222.0,189.0,0.013514,0.013514,5.407172,0.238805,1.0,222.0,8.0,51.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01745007,0.01915985422654761,0.0017097842265476094
2.0,222.0,189.0,0.009009,0.009009,5.407172,0.238805,1.0,222.0,8.0,51.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01163295,0.011718489474087317,8.553947408731707e-05
4.0,222.0,189.0,0.018018,0.018018,5.407172,0.238805,1.0,222.0,8.0,51.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0232659,0.023976572016200404,0.0007106720162004046
5.0,222.0,189.0,0.022523,0.022523,5.407172,0.238805,1.0,222.0,8.0,51.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02908302,0.02932413125652777,0.00024111125652776996
3.0,222.0,189.0,0.013514,0.013514,5.407172,0.238805,1.0,222.0,8.0,51.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01745007,0.019153808819464276,0.001703738819464274
4.0,269.0,207.0,0.01487,0.01487,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.02578749,0.025936664305507787,0.00014917430550778765
4.0,269.0,207.0,0.01487,0.01487,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.02578749,0.025905529183841116,0.00011803918384111628
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01289375,0.012895033983273756,1.2839832737553125e-06
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00644601,0.006446772763452318,7.627634523174956e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006445689184285651,3.208157143491999e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00644601,0.006445987075952317,2.2924047683552107e-08
4.0,269.0,207.0,0.01487,0.01487,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.02578749,0.025869510894495882,8.202089449588224e-05
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.01289375,0.012894484492321385,7.344923213838117e-07
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01289375,0.012891306867857093,2.44313214290727e-06
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00644601,0.006446844273868983,8.342738689829515e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,269.0,207.0,0.01487,0.01487,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.02578749,0.025889859180983976,0.0001023691809839758
7.0,269.0,207.0,0.026022,0.026022,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.04512724,0.04607430022265871,0.0009470602226587105
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01289375,0.012896853837023759,3.103837023758424e-06
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01289375,0.012895036895119,1.2868951189994038e-06
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00644601,0.006446021164999935,1.1164999935003861e-08
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Adverse Event,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01289375,0.012892246422857093,1.5035771429080386e-06
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00644601,0.006446746439583269,7.364395832685361e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Death,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006448249800416601,2.239800416600421e-06
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Physician Decision,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006445906523333268,1.0347666673255623e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Physician Decision,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Physician Decision,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006445449069166601,5.609308333992188e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00644601,0.006445596020833267,4.1397916673326096e-07
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006445906523333268,1.0347666673255623e-07
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,269.0,207.0,0.0,0.0,5.598422,0.309765,1.0,272.0,18.0,106.0,Noncompliance with study drug,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00644601,0.006445906523333268,1.0347666673255623e-07
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00644601,0.006446817949999934,8.07949999933992e-07
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00644601,0.0064460534749999346,4.347499993426901e-08
5.0,269.0,207.0,0.018587,0.018587,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0322335,0.03200368819824406,0.00022981180175593585
2.0,269.0,207.0,0.007435,0.007435,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01289375,0.012897329830238051,3.579830238050266e-06
1.0,269.0,207.0,0.003717,0.003717,5.598422,0.309765,1.0,272.0,18.0,106.0,Other,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00644601,0.0064460534749999346,4.347499993426901e-08
2.0,275.0,256.0,0.007273,0.007273,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01895254,0.01917885089769115,0.00022631089769115098
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,24-week Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00947497,0.009558353303452364,8.338330345236504e-05
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Lost to Follow-up,24-week Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,275.0,256.0,0.007273,0.007273,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01895254,0.019176766878197114,0.00022422687819711323
4.0,275.0,256.0,0.014545,0.014545,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03790248,0.03843908715031744,0.0005366071503174405
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,24-week Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,275.0,256.0,0.010909,0.010909,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02842751,0.02936229430983858,0.0009347843098385794
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Other than specified above,24-week Double-blind Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG002,diabetes type 2,INDUSTRY,0.00947497,0.009526595790892827,5.162579089282825e-05
2.0,275.0,256.0,0.007273,0.007273,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG003,diabetes type 2,INDUSTRY,0.01895254,0.019280059762393536,0.00032751976239353553
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG004,diabetes type 2,INDUSTRY,0.00947497,0.009527965388809494,5.299538880949514e-05
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Adverse Event,Extension Period,FG005,diabetes type 2,INDUSTRY,0.00947497,0.009527965388809494,5.299538880949514e-05
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG002,diabetes type 2,INDUSTRY,0.00947497,0.009543916550773779,6.89465507737793e-05
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Protocol Violation,Extension Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,275.0,256.0,0.003636,0.003636,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG002,diabetes type 2,INDUSTRY,0.00947497,0.009532386288273777,5.741628827377748e-05
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,275.0,256.0,0.0,0.0,5.620401,0.463646,1.0,275.0,1.0,40.0,Withdrawal by Subject,Extension Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,346.0,291.0,0.014451,0.014451,5.849325,0.350212,1.0,346.0,11.0,132.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02960295,0.0296549338179707,5.198381797070009e-05
3.0,346.0,291.0,0.008671,0.008671,5.849325,0.350212,1.0,346.0,11.0,132.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01776259,0.017848781855592185,8.619185559218326e-05
3.0,346.0,291.0,0.008671,0.008671,5.849325,0.350212,1.0,346.0,11.0,132.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01776259,0.017786192461842175,2.3602461842173184e-05
5.0,346.0,291.0,0.014451,0.014451,5.849325,0.350212,1.0,346.0,11.0,132.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02960295,0.029666923190143333,6.397319014333352e-05
1.0,346.0,291.0,0.00289,0.00289,5.849325,0.350212,1.0,346.0,11.0,132.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00592018,0.0059445278047321444,2.434780473214472e-05
4.0,346.0,291.0,0.011561,0.011561,5.849325,0.350212,1.0,346.0,11.0,132.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02368277,0.023668459459761912,1.4310540238086922e-05
5.0,346.0,291.0,0.014451,0.014451,5.849325,0.350212,1.0,346.0,11.0,132.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02960295,0.029637251769220697,3.4301769220698025e-05
29.0,346.0,291.0,0.083815,0.083815,5.849325,0.350212,1.0,346.0,11.0,132.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.17169545,0.16872255313911702,0.0029728968608829787
36.0,1609.0,1467.0,0.022374,0.022374,7.383989,0.548369,1.0,1609.0,12.0,229.0,Withdrawal by Subject,Maintenance Period 1 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.09059572,0.08799701790144848,0.0025987020985515225
36.0,1609.0,1467.0,0.022374,0.022374,7.383989,0.548369,1.0,1609.0,12.0,229.0,Withdrawal by Subject,Maintenance Period 1 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.09059572,0.0878563630131152,0.0027393569868848083
7.0,1609.0,1467.0,0.004351,0.004351,7.383989,0.548369,1.0,1609.0,12.0,229.0,Lost to Follow-up,Maintenance Period 1 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.01761786,0.017737615752321426,0.00011975575232142655
4.0,1609.0,1467.0,0.002486,0.002486,7.383989,0.548369,1.0,1609.0,12.0,229.0,Lost to Follow-up,Maintenance Period 1 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.01006619,0.009926951177529751,0.00013923882247024802
3.0,1609.0,1467.0,0.001865,0.001865,7.383989,0.548369,1.0,1609.0,12.0,229.0,Death,Maintenance Period 1 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.00755167,0.007592782255119943,4.11122551199428e-05
3.0,1609.0,1467.0,0.001865,0.001865,7.383989,0.548369,1.0,1609.0,12.0,229.0,Death,Maintenance Period 1 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.00755167,0.0075802999251794664,2.8629925179466525e-05
1.0,1609.0,1467.0,0.000622,0.000622,7.383989,0.548369,1.0,1609.0,12.0,229.0,Subject withdrawal reason not collected,Maintenance Period 1 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.00251857,0.002616198932718254,9.762893271825397e-05
0.0,1609.0,1467.0,0.0,0.0,7.383989,0.548369,1.0,1609.0,12.0,229.0,Subject withdrawal reason not collected,Maintenance Period 1 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,1609.0,1467.0,0.011187,0.011187,7.383989,0.548369,1.0,1609.0,12.0,229.0,Withdrawal by Subject,Maintencance Period 2 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.04529786,0.04473753972985123,0.0005603202701487744
13.0,1609.0,1467.0,0.00808,0.00808,7.383989,0.548369,1.0,1609.0,12.0,229.0,Withdrawal by Subject,Maintencance Period 2 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.03271715,0.03274693085088654,2.9780850886541865e-05
3.0,1609.0,1467.0,0.001865,0.001865,7.383989,0.548369,1.0,1609.0,12.0,229.0,Lost to Follow-up,Maintencance Period 2 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.00755167,0.00758198478196518,3.0314781965180143e-05
6.0,1609.0,1467.0,0.003729,0.003729,7.383989,0.548369,1.0,1609.0,12.0,229.0,Lost to Follow-up,Maintencance Period 2 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.01509929,0.01475759924357143,0.0003416907564285695
4.0,1609.0,1467.0,0.002486,0.002486,7.383989,0.548369,1.0,1609.0,12.0,229.0,Death,Maintencance Period 2 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.01006619,0.009922891876359108,0.00014329812364089096
6.0,1609.0,1467.0,0.003729,0.003729,7.383989,0.548369,1.0,1609.0,12.0,229.0,Death,Maintencance Period 2 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.01509929,0.014754754753154768,0.00034453524684523174
0.0,1609.0,1467.0,0.0,0.0,7.383989,0.548369,1.0,1609.0,12.0,229.0,Not reconsenting,Maintencance Period 2 (36 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1609.0,1467.0,0.001243,0.001243,7.383989,0.548369,1.0,1609.0,12.0,229.0,Not reconsenting,Maintencance Period 2 (36 Weeks),FG001,diabetes type 2,INDUSTRY,0.0050331,0.0050458524495734115,1.275244957341104e-05
11.0,1082.0,1018.0,0.010166,0.010166,6.98749,0.404875,1.0,1089.0,15.0,231.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02876021,0.029057329852454197,0.000297119852454196
7.0,1082.0,1018.0,0.00647,0.00647,6.98749,0.404875,1.0,1089.0,15.0,231.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01830401,0.018339023504573407,3.5013504573407767e-05
8.0,1082.0,1018.0,0.007394,0.007394,6.98749,0.404875,1.0,1089.0,15.0,231.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02091806,0.020565537961319446,0.00035252203868055276
2.0,1082.0,1018.0,0.001848,0.001848,6.98749,0.404875,1.0,1089.0,15.0,231.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0052281,0.005436381521934528,0.00020828152193452798
0.0,1082.0,1018.0,0.0,0.0,6.98749,0.404875,1.0,1089.0,15.0,231.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1082.0,1018.0,0.001848,0.001848,6.98749,0.404875,1.0,1089.0,15.0,231.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0052281,0.005431794269434529,0.00020369426943452843
2.0,1082.0,1018.0,0.001848,0.001848,6.98749,0.404875,1.0,1089.0,15.0,231.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0052281,0.005448505217767859,0.00022040521776785834
1.0,1082.0,1018.0,0.000924,0.000924,6.98749,0.404875,1.0,1089.0,15.0,231.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00261405,0.0027063031877380983,9.225318773809811e-05
1.0,1082.0,1018.0,0.000924,0.000924,6.98749,0.404875,1.0,1089.0,15.0,231.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00261405,0.002706103502519844,9.20535025198438e-05
12.0,1082.0,1018.0,0.011091,0.011091,6.98749,0.404875,1.0,1089.0,15.0,231.0,No reason for withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03137709,0.03131808711362014,5.900288637986084e-05
11.0,1082.0,1018.0,0.010166,0.010166,6.98749,0.404875,1.0,1089.0,15.0,231.0,No reason for withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02876021,0.029032462600817283,0.00027225260081728195
7.0,1082.0,1018.0,0.00647,0.00647,6.98749,0.404875,1.0,1089.0,15.0,231.0,No reason for withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01830401,0.01831260209687499,8.592096874992378e-06
19.0,565.0,360.0,0.033628,0.033628,6.338594,0.222179,1.0,565.0,8.0,133.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0473584,0.04642386308514882,0.0009345369148511806
7.0,565.0,360.0,0.012389,0.012389,6.338594,0.222179,1.0,565.0,8.0,133.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01744746,0.017566022680119055,0.00011856268011905396
16.0,565.0,360.0,0.028319,0.028319,6.338594,0.222179,1.0,565.0,8.0,133.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03988172,0.03987384942477191,7.870575228094423e-06
16.0,565.0,360.0,0.028319,0.028319,6.338594,0.222179,1.0,565.0,8.0,133.0,Withdrawal of consent by subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03988172,0.03981024515152789,7.147484847211394e-05
16.0,565.0,360.0,0.028319,0.028319,6.338594,0.222179,1.0,565.0,8.0,133.0,Withdrawal of consent by subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03988172,0.039905625372510044,2.3905372510041323e-05
26.0,565.0,360.0,0.046018,0.046018,6.338594,0.222179,1.0,565.0,8.0,133.0,Withdrawal of consent by subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06480727,0.06575678888361106,0.0009495188836110557
9.0,565.0,360.0,0.015929,0.015929,6.338594,0.222179,1.0,565.0,8.0,133.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02243285,0.02235040793724209,8.2442062757912e-05
17.0,565.0,360.0,0.030088,0.030088,6.338594,0.222179,1.0,565.0,8.0,133.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04237301,0.042205433802380954,0.00016757619761904874
9.0,565.0,360.0,0.015929,0.015929,6.338594,0.222179,1.0,565.0,8.0,133.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02243285,0.022340062816289703,9.27871837102974e-05
6.0,565.0,360.0,0.010619,0.010619,6.338594,0.222179,1.0,565.0,8.0,133.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01495477,0.014928814879394849,2.5955120605150248e-05
11.0,565.0,360.0,0.019469,0.019469,6.338594,0.222179,1.0,565.0,8.0,133.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02741824,0.027176039797946396,0.00024220020205360446
7.0,565.0,360.0,0.012389,0.012389,6.338594,0.222179,1.0,565.0,8.0,133.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01744746,0.017579633507291678,0.00013217350729167673
9.0,565.0,360.0,0.015929,0.015929,6.338594,0.222179,1.0,565.0,8.0,133.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02243285,0.022355264210595263,7.758578940473757e-05
10.0,565.0,360.0,0.017699,0.017699,6.338594,0.222179,1.0,565.0,8.0,133.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02492555,0.024874997026279756,5.055297372024564e-05
8.0,565.0,360.0,0.014159,0.014159,6.338594,0.222179,1.0,565.0,8.0,133.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01994016,0.019918996740049613,2.116325995038526e-05
2.0,565.0,360.0,0.00354,0.00354,6.338594,0.222179,1.0,565.0,8.0,133.0,Poor/Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00498539,0.004978405609099936,6.984390900063864e-06
2.0,565.0,360.0,0.00354,0.00354,6.338594,0.222179,1.0,565.0,8.0,133.0,Poor/Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00498539,0.0049832241004094625,2.1658995905376316e-06
6.0,565.0,360.0,0.010619,0.010619,6.338594,0.222179,1.0,565.0,8.0,133.0,Poor/Noncompliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01495477,0.01494485548772818,9.91451227181847e-06
0.0,565.0,360.0,0.0,0.0,6.338594,0.222179,1.0,565.0,8.0,133.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,565.0,360.0,0.00531,0.00531,6.338594,0.222179,1.0,565.0,8.0,133.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00747809,0.007440559332291687,3.753066770831315e-05
3.0,565.0,360.0,0.00531,0.00531,6.338594,0.222179,1.0,565.0,8.0,133.0,Subject No Longer Meets Study Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00747809,0.007446728686875018,3.136131312498139e-05
1.0,565.0,360.0,0.00177,0.00177,6.338594,0.222179,1.0,565.0,8.0,133.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0024927,0.0025052637855456404,1.2563785545640412e-05
1.0,565.0,360.0,0.00177,0.00177,6.338594,0.222179,1.0,565.0,8.0,133.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0024927,0.0025039839790773856,1.1283979077385525e-05
0.0,565.0,360.0,0.0,0.0,6.338594,0.222179,1.0,565.0,8.0,133.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,565.0,360.0,0.0,0.0,6.338594,0.222179,1.0,565.0,8.0,133.0,Administrative reason by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,565.0,360.0,0.0,0.0,6.338594,0.222179,1.0,565.0,8.0,133.0,Administrative reason by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,565.0,360.0,0.00177,0.00177,6.338594,0.222179,1.0,565.0,8.0,133.0,Administrative reason by sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0024927,0.0025063135647718287,1.361356477182869e-05
2.0,579.0,479.0,0.003454,0.003454,6.363028,0.788505,1.0,579.0,4.0,65.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01732968,0.017423444556944376,9.376455694437569e-05
4.0,579.0,479.0,0.006908,0.006908,6.363028,0.788505,1.0,579.0,4.0,65.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03465937,0.03463749899360113,2.1871006398874182e-05
1.0,579.0,479.0,0.001727,0.001727,6.363028,0.788505,1.0,579.0,4.0,65.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00866484,0.008647043472757899,1.779652724210115e-05
1.0,579.0,479.0,0.001727,0.001727,6.363028,0.788505,1.0,579.0,4.0,65.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00866484,0.008650068161716233,1.4771838283767283e-05
24.0,579.0,479.0,0.041451,0.041451,6.363028,0.788505,1.0,579.0,4.0,65.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.20797125,0.21502115038010836,0.007049900380108359
12.0,579.0,479.0,0.020725,0.020725,6.363028,0.788505,1.0,579.0,4.0,65.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10398312,0.10298031723416674,0.001002802765833255
1.0,579.0,479.0,0.001727,0.001727,6.363028,0.788505,1.0,579.0,4.0,65.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00866484,0.008639867126091234,2.4972873908766374e-05
2.0,579.0,479.0,0.003454,0.003454,6.363028,0.788505,1.0,579.0,4.0,65.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01732968,0.01731753287470229,1.2147125297710254e-05
2.0,579.0,479.0,0.003454,0.003454,6.363028,0.788505,1.0,579.0,4.0,65.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01732968,0.017419800689444362,9.01206894443618e-05
2.0,579.0,479.0,0.003454,0.003454,6.363028,0.788505,1.0,579.0,4.0,65.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01732968,0.017321650194702283,8.029805297717074e-06
1.0,579.0,479.0,0.001727,0.001727,6.363028,0.788505,1.0,579.0,4.0,65.0,Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00866484,0.008643951101091235,2.0888898908765288e-05
0.0,579.0,479.0,0.0,0.0,6.363028,0.788505,1.0,579.0,4.0,65.0,Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
28.0,579.0,479.0,0.048359,0.048359,6.363028,0.788505,1.0,579.0,4.0,65.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.24263061,0.23777133147731136,0.004859278522688637
14.0,579.0,479.0,0.02418,0.02418,6.363028,0.788505,1.0,579.0,4.0,65.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12131782,0.11942242743803572,0.0018953925619642903
6.0,579.0,479.0,0.010363,0.010363,6.363028,0.788505,1.0,579.0,4.0,65.0,Other - as reported by the investigator,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05199407,0.05076708197682878,0.0012269880231712202
0.0,579.0,479.0,0.0,0.0,6.363028,0.788505,1.0,579.0,4.0,65.0,Other - as reported by the investigator,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
105.0,12537.0,11325.0,0.008375,0.008375,9.436519,0.292333,1.0,12537.0,40.0,40.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02310333,0.022590909927470225,0.0005124200725297734
0.0,12537.0,11325.0,0.0,0.0,9.436519,0.292333,1.0,12537.0,40.0,40.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1090.0,12537.0,11325.0,0.086943,0.086943,9.436519,0.292333,1.0,12537.0,40.0,40.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.23984154,0.21764985490117056,0.022191685098829433
0.0,12537.0,11325.0,0.0,0.0,9.436519,0.292333,1.0,12537.0,40.0,40.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,12537.0,11325.0,0.001356,0.001356,9.436519,0.292333,1.0,12537.0,40.0,40.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00374067,0.003688422669599565,5.224733040043537e-05
0.0,12537.0,11325.0,0.0,0.0,9.436519,0.292333,1.0,12537.0,40.0,40.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,466.0,414.0,0.002146,0.002146,6.146329,0.347727,1.0,466.0,9.0,61.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458653,0.004602128458068311,1.559845806831106e-05
3.0,466.0,414.0,0.006438,0.006438,6.146329,0.347727,1.0,466.0,9.0,61.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01375958,0.013775562718373038,1.5982718373037594e-05
3.0,466.0,414.0,0.006438,0.006438,6.146329,0.347727,1.0,466.0,9.0,61.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01375958,0.013765617673482177,6.037673482176681e-06
3.0,466.0,414.0,0.006438,0.006438,6.146329,0.347727,1.0,466.0,9.0,61.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01375958,0.013781854562113123,2.227456211312262e-05
0.0,466.0,414.0,0.0,0.0,6.146329,0.347727,1.0,466.0,9.0,61.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,466.0,414.0,0.004292,0.004292,6.146329,0.347727,1.0,466.0,9.0,61.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00917306,0.009294840497420636,0.00012178049742063608
11.0,466.0,414.0,0.023605,0.023605,6.146329,0.347727,1.0,466.0,9.0,61.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05044967,0.0513716135433333,0.0009219435433332965
3.0,466.0,414.0,0.006438,0.006438,6.146329,0.347727,1.0,466.0,9.0,61.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01375958,0.013749413767827408,1.0166232172592604e-05
13.0,466.0,414.0,0.027897,0.027897,6.146329,0.347727,1.0,466.0,9.0,61.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05962273,0.06014769848142867,0.0005249684814286684
9.0,466.0,414.0,0.019313,0.019313,6.146329,0.347727,1.0,466.0,9.0,61.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04127662,0.0412616331533577,1.498684664229949e-05
3.0,466.0,414.0,0.006438,0.006438,6.146329,0.347727,1.0,466.0,9.0,61.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01375958,0.013743949156696461,1.5630843303538963e-05
0.0,466.0,414.0,0.0,0.0,6.146329,0.347727,1.0,466.0,9.0,61.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,466.0,414.0,0.002146,0.002146,6.146329,0.347727,1.0,466.0,9.0,61.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458653,0.004603674399734978,1.7144399734977944e-05
0.0,466.0,414.0,0.0,0.0,6.146329,0.347727,1.0,466.0,9.0,61.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00798626,0.00800169261521827,1.5432615218269677e-05
0.0,426.0,357.0,0.0,0.0,6.056784,0.561809,1.0,426.0,4.0,45.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,426.0,357.0,0.007042,0.007042,6.056784,0.561809,1.0,426.0,4.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02396219,0.024130236004702404,0.00016804600470240322
6.0,426.0,357.0,0.014085,0.014085,6.056784,0.561809,1.0,426.0,4.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04792778,0.04813482445199403,0.000207044451994029
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00798626,0.00800169261521827,1.5432615218269677e-05
2.0,426.0,357.0,0.004695,0.004695,6.056784,0.561809,1.0,426.0,4.0,45.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01597593,0.015123977948214273,0.0008519520517857263
14.0,426.0,357.0,0.032864,0.032864,6.056784,0.561809,1.0,426.0,4.0,45.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11182809,0.11336204499500997,0.0015339549950099673
16.0,426.0,357.0,0.037559,0.037559,6.056784,0.561809,1.0,426.0,4.0,45.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12780402,0.12730894396354167,0.0004950760364583195
9.0,426.0,357.0,0.021127,0.021127,6.056784,0.561809,1.0,426.0,4.0,45.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07188997,0.07195094680809533,6.0976808095331014e-05
9.0,426.0,357.0,0.021127,0.021127,6.056784,0.561809,1.0,426.0,4.0,45.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07188997,0.07198090106351202,9.093106351201752e-05
0.0,426.0,357.0,0.0,0.0,6.056784,0.561809,1.0,426.0,4.0,45.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00798626,0.008002068895218272,1.5808895218271876e-05
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00798626,0.00800169261521827,1.5432615218269677e-05
0.0,426.0,357.0,0.0,0.0,6.056784,0.561809,1.0,426.0,4.0,45.0,Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,426.0,357.0,0.0,0.0,6.056784,0.561809,1.0,426.0,4.0,45.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00798626,0.008000199795218273,1.3939795218272447e-05
4.0,426.0,357.0,0.00939,0.00939,6.056784,0.561809,1.0,426.0,4.0,45.0,Undefined,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03195186,0.03146642619485118,0.00048543380514881607
1.0,426.0,357.0,0.002347,0.002347,6.056784,0.561809,1.0,426.0,4.0,45.0,Undefined,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00798626,0.008000141557718271,1.3881557718271181e-05
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026056,0.002612026312807537,6.426312807537166e-06
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0104273,0.010436331849404724,9.031849404723263e-06
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0026056,0.0026072395018849163,1.6395018849163327e-06
3.0,1879.0,1783.0,0.001597,0.001597,7.539027,0.649652,1.0,1879.0,9.0,127.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0078217,0.007639851204642854,0.0001818487953571448
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0104273,0.010433996906626948,6.696906626947607e-06
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0104273,0.010426044589960276,1.2554100397247497e-06
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0104273,0.010404039708293606,2.3260291706394057e-05
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0026056,0.00260452410834325,1.0758916567498583e-06
5.0,1879.0,1783.0,0.002661,0.002661,7.539027,0.649652,1.0,1879.0,9.0,127.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0130329,0.013090636496220236,5.773649622023598e-05
6.0,1879.0,1783.0,0.003193,0.003193,7.539027,0.649652,1.0,1879.0,9.0,127.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0156385,0.015662118550882047,2.3618550882047867e-05
8.0,1879.0,1783.0,0.004258,0.004258,7.539027,0.649652,1.0,1879.0,9.0,127.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0208546,0.020955067572470204,0.0001004675724702031
12.0,1879.0,1783.0,0.006386,0.006386,7.539027,0.649652,1.0,1879.0,9.0,127.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03127701,0.03067095634396825,0.000606053656031752
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1879.0,1783.0,0.001064,0.001064,7.539027,0.649652,1.0,1879.0,9.0,127.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0052112,0.005073287545178563,0.00013791245482143704
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0104273,0.010430563645833293,3.263645833292972e-06
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026056,0.0026091923278670605,3.5923278670605026e-06
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0026056,0.00260449372944444,1.1062705555600107e-06
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0026056,0.0026059291138194407,3.291138194407191e-07
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0026056,0.00260740918834325,1.8091883432500358e-06
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Site terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Site terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Site terminated by Sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Site terminated by Sponsor,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0026056,0.002605524179176584,7.582082341616933e-08
7.0,1879.0,1783.0,0.003725,0.003725,7.539027,0.649652,1.0,1879.0,9.0,127.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01824411,0.018233847344091798,1.0262655908203216e-05
7.0,1879.0,1783.0,0.003725,0.003725,7.539027,0.649652,1.0,1879.0,9.0,127.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01824411,0.01825706344230608,1.2953442306080226e-05
8.0,1879.0,1783.0,0.004258,0.004258,7.539027,0.649652,1.0,1879.0,9.0,127.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0208546,0.020948274501220207,9.367450122020615e-05
4.0,1879.0,1783.0,0.002129,0.002129,7.539027,0.649652,1.0,1879.0,9.0,127.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0104273,0.010433272036458292,5.972036458291169e-06
1.0,1879.0,1783.0,0.000532,0.000532,7.539027,0.649652,1.0,1879.0,9.0,127.0,Other - as reported by the investigator,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0026056,0.002609309850307537,3.7098503075367988e-06
3.0,1879.0,1783.0,0.001597,0.001597,7.539027,0.649652,1.0,1879.0,9.0,127.0,Other - as reported by the investigator,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0078217,0.007639836184365078,0.00018186381563492157
2.0,1879.0,1783.0,0.001064,0.001064,7.539027,0.649652,1.0,1879.0,9.0,127.0,Other - as reported by the investigator,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0052112,0.005067010461249991,0.0001441895387500093
0.0,1879.0,1783.0,0.0,0.0,7.539027,0.649652,1.0,1879.0,9.0,127.0,Other - as reported by the investigator,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,466.0,194.0,0.006438,0.006438,6.146329,0.489315,1.0,635.0,1.0,47.0,Adverse Event,Main Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01936223,0.01935298084414672,9.249155853281038e-06
3.0,466.0,194.0,0.006438,0.006438,6.146329,0.489315,1.0,635.0,1.0,47.0,Adverse Event,Main Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01936223,0.019363471440813393,1.241440813391781e-06
7.0,466.0,194.0,0.015021,0.015021,6.146329,0.489315,1.0,635.0,1.0,47.0,Lack of Efficacy,Main Treatment Period,FG000,diabetes type 2,INDUSTRY,0.04517553,0.044930018933392865,0.00024551106660713334
17.0,466.0,194.0,0.036481,0.036481,6.146329,0.489315,1.0,635.0,1.0,47.0,Lack of Efficacy,Main Treatment Period,FG001,diabetes type 2,INDUSTRY,0.1097163,0.10756938787578281,0.002146912124217193
0.0,466.0,194.0,0.0,0.0,6.146329,0.489315,1.0,635.0,1.0,47.0,Protocol Violation,Main Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,466.0,194.0,0.002146,0.002146,6.146329,0.489315,1.0,635.0,1.0,47.0,Protocol Violation,Main Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00645408,0.006448369687708331,5.7103122916690036e-06
1.0,466.0,194.0,0.002146,0.002146,6.146329,0.489315,1.0,635.0,1.0,47.0,Withdrawal by Subject,Main Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00645408,0.006445267844533728,8.812155466272203e-06
8.0,466.0,194.0,0.017167,0.017167,6.146329,0.489315,1.0,635.0,1.0,47.0,Withdrawal by Subject,Main Treatment Period,FG001,diabetes type 2,INDUSTRY,0.05162961,0.05237021210097223,0.0007406021009722305
4.0,466.0,194.0,0.008584,0.008584,6.146329,0.489315,1.0,635.0,1.0,47.0,Unclassified,Main Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02581631,0.025284959320238082,0.0005313506797619168
10.0,466.0,194.0,0.021459,0.021459,6.146329,0.489315,1.0,635.0,1.0,47.0,Unclassified,Main Treatment Period,FG001,diabetes type 2,INDUSTRY,0.06453776,0.06417419861615087,0.0003635613838491314
5.0,466.0,194.0,0.01073,0.01073,6.146329,0.489315,1.0,635.0,1.0,47.0,Adverse Event,Extension Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03227038,0.03229948227916665,2.91022791666512e-05
0.0,466.0,194.0,0.0,0.0,6.146329,0.489315,1.0,635.0,1.0,47.0,Adverse Event,Extension Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,466.0,194.0,0.008584,0.008584,6.146329,0.489315,1.0,635.0,1.0,47.0,Lack of Efficacy,Extension Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02581631,0.025295984757738085,0.000520325242261914
0.0,466.0,194.0,0.0,0.0,6.146329,0.489315,1.0,635.0,1.0,47.0,Lack of Efficacy,Extension Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,466.0,194.0,0.012876,0.012876,6.146329,0.489315,1.0,635.0,1.0,47.0,Withdrawal by Subject,Extension Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03872446,0.03826382236593255,0.0004606376340674512
0.0,466.0,194.0,0.0,0.0,6.146329,0.489315,1.0,635.0,1.0,47.0,Withdrawal by Subject,Extension Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,466.0,194.0,0.006438,0.006438,6.146329,0.489315,1.0,635.0,1.0,47.0,Unclassified,Extension Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01936223,0.019360048794057453,2.1812059425481423e-06
0.0,466.0,194.0,0.0,0.0,6.146329,0.489315,1.0,635.0,1.0,47.0,Unclassified,Extension Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,1912.0,1482.0,0.006276,0.006276,7.556428,0.22936,1.0,1912.0,18.0,183.0,Participant Withdrew Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0108772,0.010994994871934526,0.00011779487193452551
21.0,1912.0,1482.0,0.010983,0.010983,7.556428,0.22936,1.0,1912.0,18.0,183.0,Participant Withdrew Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01903509,0.018883132877976203,0.0001519571220237985
47.0,1912.0,1482.0,0.024582,0.024582,7.556428,0.22936,1.0,1912.0,18.0,183.0,Participant Withdrew Consent,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04260408,0.042335573380873036,0.00026850661912696666
59.0,1912.0,1482.0,0.030858,0.030858,7.556428,0.22936,1.0,1912.0,18.0,183.0,Participant Withdrew Consent,Overall Study,FG003,diabetes type 2,INDUSTRY,0.05348128,0.053178681763492046,0.00030259823650795326
16.0,1912.0,1482.0,0.008368,0.008368,7.556428,0.22936,1.0,1912.0,18.0,183.0,Hyperglycemia Meeting Discontinuation Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01450293,0.014675096331359135,0.00017216633135913421
17.0,1912.0,1482.0,0.008891,0.008891,7.556428,0.22936,1.0,1912.0,18.0,183.0,Hyperglycemia Meeting Discontinuation Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01540936,0.015247551700009923,0.00016180829999007731
29.0,1912.0,1482.0,0.015167,0.015167,7.556428,0.22936,1.0,1912.0,18.0,183.0,Hyperglycemia Meeting Discontinuation Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02628656,0.02633987049664682,5.331049664681828e-05
38.0,1912.0,1482.0,0.019874,0.019874,7.556428,0.22936,1.0,1912.0,18.0,183.0,Hyperglycemia Meeting Discontinuation Criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03444445,0.03445045852836309,6.008528363091181e-06
3.0,1912.0,1482.0,0.001569,0.001569,7.556428,0.22936,1.0,1912.0,18.0,183.0,Therapeutic failure/ lack of efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0027193,0.002737993863303572,1.869386330357204e-05
2.0,1912.0,1482.0,0.001046,0.001046,7.556428,0.22936,1.0,1912.0,18.0,183.0,Therapeutic failure/ lack of efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00181287,0.0018739749850000007,6.11049850000006e-05
6.0,1912.0,1482.0,0.003138,0.003138,7.556428,0.22936,1.0,1912.0,18.0,183.0,Therapeutic failure/ lack of efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0054386,0.005426095097470243,1.2504902529756647e-05
8.0,1912.0,1482.0,0.004184,0.004184,7.556428,0.22936,1.0,1912.0,18.0,183.0,Therapeutic failure/ lack of efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00725146,0.00711679241202381,0.00013466758797619008
3.0,1912.0,1482.0,0.001569,0.001569,7.556428,0.22936,1.0,1912.0,18.0,183.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0027193,0.002736092868065478,1.6792868065477855e-05
11.0,1912.0,1482.0,0.005753,0.005753,7.556428,0.22936,1.0,1912.0,18.0,183.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00997076,0.010349186517222211,0.00037842651722221066
32.0,1912.0,1482.0,0.016736,0.016736,7.556428,0.22936,1.0,1912.0,18.0,183.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02900585,0.029430500485099206,0.00042465048509920597
31.0,1912.0,1482.0,0.016213,0.016213,7.556428,0.22936,1.0,1912.0,18.0,183.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02809942,0.02818330738764885,8.388738764885176e-05
0.0,1912.0,1482.0,0.0,0.0,7.556428,0.22936,1.0,1912.0,18.0,183.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1912.0,1482.0,0.002615,0.002615,7.556428,0.22936,1.0,1912.0,18.0,183.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00453216,0.004542497482231244,1.0337482231243672e-05
6.0,1912.0,1482.0,0.003138,0.003138,7.556428,0.22936,1.0,1912.0,18.0,183.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0054386,0.005428749941220244,9.850058779755852e-06
8.0,1912.0,1482.0,0.004184,0.004184,7.556428,0.22936,1.0,1912.0,18.0,183.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00725146,0.007105826673392858,0.00014563332660714242
7.0,1912.0,1482.0,0.003661,0.003661,7.556428,0.22936,1.0,1912.0,18.0,183.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00634503,0.006386147088045632,4.1117088045632653e-05
10.0,1912.0,1482.0,0.00523,0.00523,7.556428,0.22936,1.0,1912.0,18.0,183.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00906433,0.009011915414047627,5.2414585952374054e-05
31.0,1912.0,1482.0,0.016213,0.016213,7.556428,0.22936,1.0,1912.0,18.0,183.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02809942,0.028161858737896867,6.24387378968666e-05
28.0,1912.0,1482.0,0.014644,0.014644,7.556428,0.22936,1.0,1912.0,18.0,183.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02538012,0.025793879775505957,0.0004137597755059577
49.0,6042.0,3728.0,0.00811,0.00811,8.706656,0.523564,1.0,6103.0,43.0,613.0,Consent Withdrawn (Status Alive),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.03696938,0.03568819463456711,0.0012811853654328964
37.0,6042.0,3728.0,0.006124,0.006124,8.706656,0.523564,1.0,6103.0,43.0,613.0,Consent Withdrawn (Status Alive),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.02791621,0.028285601866646776,0.00036939186664677534
14.0,6042.0,3728.0,0.002317,0.002317,8.706656,0.523564,1.0,6103.0,43.0,613.0,Consent Withdrawn (Status Unknown),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.01056203,0.010458045224920633,0.00010398477507936668
12.0,6042.0,3728.0,0.001986,0.001986,8.706656,0.523564,1.0,6103.0,43.0,613.0,Consent Withdrawn (Status Unknown),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00905317,0.008716221223065469,0.0003369487769345307
15.0,6042.0,3728.0,0.002483,0.002483,8.706656,0.523564,1.0,6103.0,43.0,613.0,Site Closure (Status Alive),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.01131874,0.011236224977738104,8.25150222618972e-05
22.0,6042.0,3728.0,0.003641,0.003641,8.706656,0.523564,1.0,6103.0,43.0,613.0,Site Closure (Status Alive),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.01659747,0.016487632136815488,0.0001098378631845115
0.0,6042.0,3728.0,0.0,0.0,8.706656,0.523564,1.0,6103.0,43.0,613.0,Site Closure (Status Unknown),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,6042.0,3728.0,0.000166,0.000166,8.706656,0.523564,1.0,6103.0,43.0,613.0,Site Closure (Status Unknown),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00075671,0.0008151276506249991,5.841765062499914e-05
38.0,6042.0,3728.0,0.006289,0.006289,8.706656,0.523564,1.0,6103.0,43.0,613.0,LostToFollowUpfor3P-MACE(StatusAlive),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.02866836,0.02884509970058529,0.00017673970058528984
35.0,6042.0,3728.0,0.005793,0.005793,8.706656,0.523564,1.0,6103.0,43.0,613.0,LostToFollowUpfor3P-MACE(StatusAlive),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.02640735,0.027455323850922583,0.001047973850922583
8.0,6042.0,3728.0,0.001324,0.001324,8.706656,0.523564,1.0,6103.0,43.0,613.0,LostToFollowUpfor3P-MACE(StatusUnknown),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00603545,0.006077865065773814,4.241506577381399e-05
8.0,6042.0,3728.0,0.001324,0.001324,8.706656,0.523564,1.0,6103.0,43.0,613.0,LostToFollowUpfor3P-MACE(StatusUnknown),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00603545,0.006107343837886911,7.189383788691085e-05
5.0,6042.0,3728.0,0.000828,0.000828,8.706656,0.523564,1.0,6103.0,43.0,613.0,Not treated,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00377443,0.003817983601468253,4.35536014682528e-05
4.0,6042.0,3728.0,0.000662,0.000662,8.706656,0.523564,1.0,6103.0,43.0,613.0,Not treated,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00301772,0.003019138285416662,1.4182854166616514e-06
5.0,6042.0,3728.0,0.000828,0.000828,8.706656,0.523564,1.0,6103.0,43.0,613.0,Not treated,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00377443,0.00382606703063492,5.1637030634919725e-05
4.0,6042.0,3728.0,0.000662,0.000662,8.706656,0.523564,1.0,6103.0,43.0,613.0,Not treated,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00301772,0.003022320310416662,4.600310416661996e-06
457.0,6042.0,3728.0,0.075637,0.075637,8.706656,0.523564,1.0,6103.0,43.0,613.0,Adverse Event,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.34479076,0.335180902854365,0.009609857145634948
523.0,6042.0,3728.0,0.086561,0.086561,8.706656,0.523564,1.0,6103.0,43.0,613.0,Adverse Event,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.39458774,0.3820790249883816,0.012508715011618432
61.0,6042.0,3728.0,0.010096,0.010096,8.706656,0.523564,1.0,6103.0,43.0,613.0,Lack of Efficacy,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.04602255,0.04529186712557538,0.0007306828744246194
41.0,6042.0,3728.0,0.006786,0.006786,8.706656,0.523564,1.0,6103.0,43.0,613.0,Lack of Efficacy,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.03093394,0.030529329435684475,0.00040461056431552456
46.0,6042.0,3728.0,0.007613,0.007613,8.706656,0.523564,1.0,6103.0,43.0,613.0,Protocol Violation,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.03470381,0.03354588366516862,0.0011579263348313815
47.0,6042.0,3728.0,0.007779,0.007779,8.706656,0.523564,1.0,6103.0,43.0,613.0,Protocol Violation,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.03546052,0.03515583175801948,0.0003046882419805233
24.0,6042.0,3728.0,0.003972,0.003972,8.706656,0.523564,1.0,6103.0,43.0,613.0,Lost to Follow-up,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.01810634,0.017722702944831355,0.00038363705516864313
28.0,6042.0,3728.0,0.004634,0.004634,8.706656,0.523564,1.0,6103.0,43.0,613.0,Lost to Follow-up,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.02112406,0.020137790265843253,0.0009862697341567472
309.0,6042.0,3728.0,0.051142,0.051142,8.706656,0.523564,1.0,6103.0,43.0,613.0,Withdrawal by Subject,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.23313046,0.23133158307616072,0.0017988769238392877
328.0,6042.0,3728.0,0.054287,0.054287,8.706656,0.523564,1.0,6103.0,43.0,613.0,Withdrawal by Subject,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.24746693,0.2447234060944941,0.00274352390550589
230.0,6042.0,3728.0,0.038067,0.038067,8.706656,0.523564,1.0,6103.0,43.0,613.0,Other than listed above,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.17352816,0.17060333700963745,0.0029248229903625356
211.0,6042.0,3728.0,0.034922,0.034922,8.706656,0.523564,1.0,6103.0,43.0,613.0,Other than listed above,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.1591917,0.15798748214937508,0.0012042178506249113
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0044233,0.004423902589322359,6.025893223588624e-07
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0044233,0.004417923420096165,5.376579903834666e-06
0.0,746.0,708.0,0.0,0.0,6.616065,0.498933,1.0,746.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,746.0,708.0,0.002681,0.002681,6.616065,0.498933,1.0,746.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00884991,0.008832372763740066,1.7537236259934988e-05
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0044233,0.004426549087239023,3.249087239023604e-06
5.0,746.0,708.0,0.006702,0.006702,6.616065,0.498933,1.0,746.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02212312,0.022208029885952354,8.490988595235421e-05
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0044233,0.004423361953072358,6.195307235799807e-08
3.0,746.0,708.0,0.004021,0.004021,6.616065,0.498933,1.0,746.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01327321,0.013267128755317485,6.081244682515363e-06
3.0,746.0,708.0,0.004021,0.004021,6.616065,0.498933,1.0,746.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01327321,0.013331004399811539,5.7794399811537944e-05
4.0,746.0,708.0,0.005362,0.005362,6.616065,0.498933,1.0,746.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01769982,0.017983964614473914,0.0002841446144739128
0.0,746.0,708.0,0.0,0.0,6.616065,0.498933,1.0,746.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0044233,0.004419350084679497,3.949915320503039e-06
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Screen Failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0044233,0.00442502390390569,1.72390390569023e-06
2.0,746.0,708.0,0.002681,0.002681,6.616065,0.498933,1.0,746.0,0.0,0.0,Screen Failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00884991,0.008830121691240067,1.9788308759934037e-05
1.0,746.0,708.0,0.00134,0.00134,6.616065,0.498933,1.0,746.0,0.0,0.0,Site Discontinued Study Participation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0044233,0.00442502390390569,1.72390390569023e-06
0.0,746.0,708.0,0.0,0.0,6.616065,0.498933,1.0,746.0,0.0,0.0,Site Discontinued Study Participation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,746.0,708.0,0.006702,0.006702,6.616065,0.498933,1.0,746.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02212312,0.022208543464702347,8.542346470234718e-05
7.0,746.0,708.0,0.009383,0.009383,6.616065,0.498933,1.0,746.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03097303,0.03034930292398809,0.0006237270760119096
6.0,759.0,662.0,0.007905,0.007905,6.633318,0.312053,1.0,759.0,12.0,62.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01636293,0.01658583380422619,0.0002229038042261891
10.0,759.0,662.0,0.013175,0.013175,6.633318,0.312053,1.0,759.0,12.0,62.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02727155,0.02704742433190475,0.0002241256680952479
1.0,759.0,662.0,0.001318,0.001318,6.633318,0.312053,1.0,759.0,12.0,62.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00272819,0.0027458947501785764,1.7704750178576274e-05
1.0,759.0,662.0,0.001318,0.001318,6.633318,0.312053,1.0,759.0,12.0,62.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00272819,0.0027463425643452434,1.8152564345243292e-05
1.0,759.0,662.0,0.001318,0.001318,6.633318,0.312053,1.0,759.0,12.0,62.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00272819,0.0027462259112500044,1.8035911250004286e-05
2.0,759.0,662.0,0.002635,0.002635,6.633318,0.312053,1.0,759.0,12.0,62.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00545431,0.0055367772283631015,8.246722836310113e-05
8.0,759.0,662.0,0.01054,0.01054,6.633318,0.312053,1.0,759.0,12.0,62.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02181724,0.02179914655658728,1.809344341272001e-05
9.0,759.0,662.0,0.011858,0.011858,6.633318,0.312053,1.0,759.0,12.0,62.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02454543,0.024529499155248,1.5930844751998324e-05
9.0,759.0,662.0,0.011858,0.011858,6.633318,0.312053,1.0,759.0,12.0,62.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02454543,0.024502970347539663,4.2459652460337394e-05
9.0,759.0,662.0,0.011858,0.011858,6.633318,0.312053,1.0,759.0,12.0,62.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02454543,0.024516733952331324,2.8696047668676228e-05
8.0,759.0,662.0,0.01054,0.01054,6.633318,0.312053,1.0,759.0,12.0,62.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02181724,0.021769464948551566,4.777505144843569e-05
5.0,759.0,662.0,0.006588,0.006588,6.633318,0.312053,1.0,759.0,12.0,62.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01363681,0.013323146911914687,0.0003136630880853121
12.0,759.0,662.0,0.01581,0.01581,6.633318,0.312053,1.0,759.0,12.0,62.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03272586,0.03257960213521824,0.0001462578647817639
16.0,759.0,662.0,0.02108,0.02108,6.633318,0.312053,1.0,759.0,12.0,62.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04363448,0.044049037515476216,0.0004145575154762132
9.0,929.0,779.0,0.009688,0.009688,6.835185,0.228762,1.0,929.0,3.0,50.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01514844,0.015160821402093254,1.2381402093253335e-05
22.0,929.0,779.0,0.023681,0.023681,6.835185,0.228762,1.0,929.0,3.0,50.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03702829,0.037281316716275194,0.00025302671627519535
30.0,929.0,779.0,0.032293,0.032293,6.835185,0.228762,1.0,929.0,3.0,50.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05049427,0.05071532947605253,0.0002210594760525264
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00504896,0.005049428146130992,4.6814613099185193e-07
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00504896,0.005055026160803613,6.066160803613364e-06
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00504896,0.005051885055386946,2.925055386945874e-06
2.0,929.0,779.0,0.002153,0.002153,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00336649,0.0034427587376984147,7.62687376984145e-05
2.0,929.0,779.0,0.002153,0.002153,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00336649,0.0034377637768650804,7.127377686508025e-05
2.0,929.0,779.0,0.002153,0.002153,6.835185,0.228762,1.0,929.0,3.0,50.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00336649,0.0034316214520238096,6.51314520238094e-05
5.0,929.0,779.0,0.005382,0.005382,6.835185,0.228762,1.0,929.0,3.0,50.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00841545,0.008370715255267858,4.4734744732141674e-05
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00504896,0.005052154966220274,3.1949662202736956e-06
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00168246,0.0016801233280303136,2.3366719696864095e-06
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00168246,0.0016817197463275717,7.402536724282743e-07
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,929.0,779.0,0.009688,0.009688,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01514844,0.015173310498581349,2.4870498581347836e-05
10.0,929.0,779.0,0.010764,0.010764,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0168309,0.01671948074845238,0.00011141925154762103
16.0,929.0,779.0,0.017223,0.017223,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02693038,0.02729465990669643,0.00036427990669642835
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00504896,0.005050544968095281,1.5849680952808101e-06
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Did not meet trial criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Did not meet trial criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00168246,0.00168281829250001,3.582925000101059e-07
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Did not meet trial criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00168246,0.001682414783333344,4.5216666655920404e-08
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Did not meet trial criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00168246,0.001681727088446981,7.329115530190812e-07
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,hCG positive (not pregnant),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,hCG positive (not pregnant),Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,hCG positive (not pregnant),Overall Study,FG002,diabetes type 2,INDUSTRY,0.00168246,0.0016822397000000107,2.2029999998925479e-07
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,hCG positive (not pregnant),Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Hypoglycaemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Hypoglycaemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Hypoglycaemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Hypoglycaemia,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00168246,0.0016815520051136476,9.079948863524156e-07
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of trial product,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00504896,0.005056120339970279,7.160339970279338e-06
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of trial product,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00504896,0.005052746230386944,3.7862303869443115e-06
2.0,929.0,779.0,0.002153,0.002153,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of trial product,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00336649,0.003441575205555559,7.50852055555586e-05
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Lack of trial product,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,"Late syphilis, latent",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00168246,0.0016817197463275717,7.402536724282743e-07
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,"Late syphilis, latent",Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,"Late syphilis, latent",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,"Late syphilis, latent",Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Taken inhibition medication eg Prandin,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,929.0,779.0,0.0,0.0,6.835185,0.228762,1.0,929.0,3.0,50.0,Taken inhibition medication eg Prandin,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Taken inhibition medication eg Prandin,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00168246,0.0016822994000000111,1.6059999998884605e-07
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Taken inhibition medication eg Prandin,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00168246,0.0016815520051136476,9.079948863524156e-07
1.0,929.0,779.0,0.001076,0.001076,6.835185,0.228762,1.0,929.0,3.0,50.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00168246,0.0016825428138275717,8.281382757172918e-08
2.0,929.0,779.0,0.002153,0.002153,6.835185,0.228762,1.0,929.0,3.0,50.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00336649,0.003436531941626985,7.0041941626985e-05
3.0,929.0,779.0,0.003229,0.003229,6.835185,0.228762,1.0,929.0,3.0,50.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00504896,0.0050512119620536085,2.2519620536086415e-06
4.0,929.0,779.0,0.004306,0.004306,6.835185,0.228762,1.0,929.0,3.0,50.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00673299,0.006686195494970235,4.679450502976558e-05
4.0,312.0,299.0,0.012821,0.012821,5.746203,0.231988,1.0,312.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01709105,0.016944992276755957,0.00014605772324404256
1.0,312.0,299.0,0.003205,0.003205,5.746203,0.231988,1.0,312.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00427243,0.004285033988859146,1.2603988859146396e-05
2.0,312.0,299.0,0.00641,0.00641,5.746203,0.231988,1.0,312.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00854486,0.008547677098779788,2.8170987797886127e-06
1.0,312.0,299.0,0.003205,0.003205,5.746203,0.231988,1.0,312.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00427243,0.004287713982103194,1.5283982103194392e-05
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,312.0,299.0,0.00641,0.00641,5.746203,0.231988,1.0,312.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00854486,0.008549478428452403,4.6184284524034e-06
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,312.0,299.0,0.003205,0.003205,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00427243,0.004285523823650813,1.3093823650812964e-05
1.0,312.0,299.0,0.003205,0.003205,5.746203,0.231988,1.0,312.0,0.0,0.0,Treatment Complications,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00427243,0.004286930310436528,1.4500310436527802e-05
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Treatment Complications,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Treatment Complications,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Study Medication Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,312.0,299.0,0.003205,0.003205,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Study Medication Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00427243,0.004285050326359147,1.2620326359146818e-05
0.0,312.0,299.0,0.0,0.0,5.746203,0.231988,1.0,312.0,0.0,0.0,Lack of Study Medication Compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
19.0,884.0,719.0,0.021493,0.021493,6.785588,0.312053,1.0,884.0,16.0,101.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04551063,0.04609858652257933,0.0005879565225793276
25.0,884.0,719.0,0.028281,0.028281,6.785588,0.312053,1.0,884.0,16.0,101.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05988397,0.06016211665630948,0.00027814665630947893
21.0,884.0,719.0,0.023756,0.023756,6.785588,0.312053,1.0,884.0,16.0,101.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05030245,0.05041116416313494,0.00010871416313493892
21.0,884.0,719.0,0.023756,0.023756,6.785588,0.312053,1.0,884.0,16.0,101.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05030245,0.05050214869812501,0.00019969869812501428
13.0,884.0,719.0,0.014706,0.014706,6.785588,0.312053,1.0,884.0,16.0,101.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03113941,0.030843108233829377,0.0002963017661706223
8.0,884.0,719.0,0.00905,0.00905,6.785588,0.312053,1.0,884.0,16.0,101.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01916304,0.019142843106716205,2.019689328379426e-05
6.0,884.0,719.0,0.006787,0.006787,6.785588,0.312053,1.0,884.0,16.0,101.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01437122,0.014149773412093248,0.00022144658790675294
8.0,884.0,719.0,0.00905,0.00905,6.785588,0.312053,1.0,884.0,16.0,101.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01916304,0.019143398230585255,1.964176941474452e-05
9.0,884.0,719.0,0.010181,0.010181,6.785588,0.312053,1.0,884.0,16.0,101.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02155789,0.02159229785349209,3.440785349208969e-05
8.0,884.0,719.0,0.00905,0.00905,6.785588,0.312053,1.0,884.0,16.0,101.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01916304,0.019136649556001927,2.6390443998072083e-05
5.0,884.0,719.0,0.005656,0.005656,6.785588,0.312053,1.0,884.0,16.0,101.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01197637,0.012326867702529762,0.00035049770252976176
9.0,884.0,719.0,0.010181,0.010181,6.785588,0.312053,1.0,884.0,16.0,101.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02155789,0.021630582882539707,7.269288253970718e-05
3.0,884.0,719.0,0.003394,0.003394,6.785588,0.312053,1.0,884.0,16.0,101.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00718667,0.007223626653134911,3.6956653134911054e-05
1.0,884.0,719.0,0.001131,0.001131,6.785588,0.312053,1.0,884.0,16.0,101.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00239485,0.0023955292380852997,6.792380852996965e-07
1.0,884.0,719.0,0.001131,0.001131,6.785588,0.312053,1.0,884.0,16.0,101.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00239485,0.002396205160376966,1.3551603769658069e-06
0.0,884.0,719.0,0.0,0.0,6.785588,0.312053,1.0,884.0,16.0,101.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,884.0,719.0,0.001131,0.001131,6.785588,0.312053,1.0,884.0,16.0,101.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00239485,0.0023959480005852998,1.0980005852997618e-06
3.0,884.0,719.0,0.003394,0.003394,6.785588,0.312053,1.0,884.0,16.0,101.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00718667,0.007217851263432528,3.118126343252831e-05
1.0,884.0,719.0,0.001131,0.001131,6.785588,0.312053,1.0,884.0,16.0,101.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00239485,0.0023974194071924426,2.5694071924425334e-06
0.0,884.0,719.0,0.0,0.0,6.785588,0.312053,1.0,884.0,16.0,101.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,884.0,719.0,0.001131,0.001131,6.785588,0.312053,1.0,884.0,16.0,101.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00239485,0.002396658427043632,1.8084270436320715e-06
0.0,884.0,719.0,0.0,0.0,6.785588,0.312053,1.0,884.0,16.0,101.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,884.0,719.0,0.002262,0.002262,6.785588,0.312053,1.0,884.0,16.0,101.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0047897,0.0048322614875676365,4.2561487567636426e-05
0.0,884.0,719.0,0.0,0.0,6.785588,0.312053,1.0,884.0,16.0,101.0,Sponsor Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,468.0,430.0,0.002137,0.002137,6.150603,0.444253,1.0,468.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00583918,0.005840083825394478,9.038253944776073e-07
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,468.0,430.0,0.00641,0.00641,6.150603,0.444253,1.0,468.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01751482,0.017594207291170637,7.938729117063642e-05
4.0,468.0,430.0,0.008547,0.008547,6.150603,0.444253,1.0,468.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.023354,0.023111920673551594,0.0002420793264484057
4.0,468.0,430.0,0.008547,0.008547,6.150603,0.444253,1.0,468.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.023354,0.023104900104682552,0.0002490998953174478
2.0,468.0,430.0,0.004274,0.004274,6.150603,0.444253,1.0,468.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01167837,0.011670264500406752,8.105499593248286e-06
1.0,468.0,430.0,0.002137,0.002137,6.150603,0.444253,1.0,468.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00583918,0.005836514150513069,2.6658494869311045e-06
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Screen Failure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,468.0,430.0,0.002137,0.002137,6.150603,0.444253,1.0,468.0,0.0,0.0,Screen Failure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00583918,0.005832145379679738,7.034620320262551e-06
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Screen Failure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Participant Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,468.0,430.0,0.0,0.0,6.150603,0.444253,1.0,468.0,0.0,0.0,Participant Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,468.0,430.0,0.004274,0.004274,6.150603,0.444253,1.0,468.0,0.0,0.0,Participant Moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01167837,0.011678713611031753,3.43611031752844e-07
7.0,468.0,430.0,0.014957,0.014957,6.150603,0.444253,1.0,468.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04086882,0.040695269670882966,0.00017355032911703372
8.0,468.0,430.0,0.017094,0.017094,6.150603,0.444253,1.0,468.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04670801,0.047284579119990074,0.0005765691199900724
5.0,468.0,430.0,0.010684,0.010684,6.150603,0.444253,1.0,468.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02919319,0.029081621453303577,0.00011156854669642363
2.0,38.0,497.0,0.052632,0.052632,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Open-label Segment 1,FG000,diabetes type 2,INDUSTRY,0.05475881,0.0589607093904435,0.004201899390443499
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Open-label Segment 1,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Open-label Segment 1,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Open-label Segment 1,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Open-label Segment 1,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,38.0,497.0,0.026316,0.026316,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Open-label Segment 1,FG000,diabetes type 2,INDUSTRY,0.02737941,0.035102233741438504,0.0077228237414385045
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Open-label Segment 1,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Open-label Segment 1,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Open-label Segment 1,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Open-label Segment 1,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Adverse Event,Double-blind Segment 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,38.0,497.0,0.078947,0.078947,3.663562,0.283988,1.0,554.0,16.0,115.0,Adverse Event,Double-blind Segment 2,FG001,diabetes type 2,INDUSTRY,0.08213718,0.12724318093841275,0.045106000938412744
1.0,38.0,497.0,0.026316,0.026316,3.663562,0.283988,1.0,554.0,16.0,115.0,Adverse Event,Double-blind Segment 2,FG002,diabetes type 2,INDUSTRY,0.02737941,0.03561850361816468,0.008239093618164682
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Adverse Event,Double-blind Segment 2,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Adverse Event,Double-blind Segment 2,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Double-blind Segment 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,38.0,497.0,0.289474,0.289474,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Double-blind Segment 2,FG001,diabetes type 2,INDUSTRY,0.3011714,0.354769041653373,0.053597641653372996
5.0,38.0,497.0,0.131579,0.131579,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Double-blind Segment 2,FG002,diabetes type 2,INDUSTRY,0.136896,0.17865109146841274,0.04175509146841275
2.0,38.0,497.0,0.052632,0.052632,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Double-blind Segment 2,FG003,diabetes type 2,INDUSTRY,0.05475881,0.0584436148622887,0.0036848048622886986
5.0,38.0,497.0,0.131579,0.131579,3.663562,0.283988,1.0,554.0,16.0,115.0,Lost to Follow-up,Double-blind Segment 2,FG004,diabetes type 2,INDUSTRY,0.136896,0.17853405485912702,0.04163805485912703
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Double-blind Segment 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,38.0,497.0,0.263158,0.263158,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Double-blind Segment 2,FG001,diabetes type 2,INDUSTRY,0.27379199,0.3101104951188589,0.036318505118858924
6.0,38.0,497.0,0.157895,0.157895,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Double-blind Segment 2,FG002,diabetes type 2,INDUSTRY,0.1642754,0.20551753193368058,0.04124213193368059
7.0,38.0,497.0,0.184211,0.184211,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Double-blind Segment 2,FG003,diabetes type 2,INDUSTRY,0.19165481,0.2930776645862001,0.1014228545862001
2.0,38.0,497.0,0.052632,0.052632,3.663562,0.283988,1.0,554.0,16.0,115.0,Withdrawal by Subject,Double-blind Segment 2,FG004,diabetes type 2,INDUSTRY,0.05475881,0.05848468913169346,0.003725879131693463
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Other,Double-blind Segment 2,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,38.0,497.0,0.052632,0.052632,3.663562,0.283988,1.0,554.0,16.0,115.0,Other,Double-blind Segment 2,FG001,diabetes type 2,INDUSTRY,0.05475881,0.05847238958086013,0.0037135795808601324
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Other,Double-blind Segment 2,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Other,Double-blind Segment 2,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,38.0,497.0,0.0,0.0,3.663562,0.283988,1.0,554.0,16.0,115.0,Other,Double-blind Segment 2,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,30-week Core Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00925414,0.009246513608630913,7.626391369086605e-06
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,30-week Core Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00925414,0.009261523716785675,7.383716785675648e-06
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,30-week Core Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00925414,0.009254490349940437,3.503499404373944e-07
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,30-week Core Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,30-week Core Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01850829,0.018478970427083293,2.9319572916707004e-05
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,30-week Core Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01850829,0.01841770323779757,9.058676220242978e-05
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,30-week Core Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01850829,0.018442578405297574,6.571159470242574e-05
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,30-week Core Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,30-week Core Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,406.0,293.0,0.009852,0.009852,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,30-week Core Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03701657,0.03667879782351188,0.00033777217648811586
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,30-week Core Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01850829,0.018429570561130912,7.87194388690883e-05
3.0,406.0,293.0,0.007389,0.007389,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,30-week Core Treatment Period,FG003,diabetes type 2,INDUSTRY,0.02776243,0.027626738579623004,0.00013569142037699738
19.0,406.0,293.0,0.046798,0.046798,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,30-week Core Treatment Period,FG000,diabetes type 2,INDUSTRY,0.17583248,0.1748508399951306,0.0009816400048694163
12.0,406.0,293.0,0.029557,0.029557,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,30-week Core Treatment Period,FG001,diabetes type 2,INDUSTRY,0.11105348,0.1112538356079267,0.00020035560792670826
19.0,406.0,293.0,0.046798,0.046798,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,30-week Core Treatment Period,FG002,diabetes type 2,INDUSTRY,0.17583248,0.17500235622548777,0.0008301237745122481
19.0,406.0,293.0,0.046798,0.046798,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,30-week Core Treatment Period,FG003,diabetes type 2,INDUSTRY,0.17583248,0.17515010524194607,0.0006823747580539385
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,26-week Treatment Extension Period,FG000,diabetes type 2,INDUSTRY,0.01850829,0.01845503116541664,5.3258834583361225e-05
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,26-week Treatment Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,26-week Treatment Extension Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Protocol Violation,26-week Treatment Extension Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,26-week Treatment Extension Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,26-week Treatment Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,26-week Treatment Extension Period,FG002,diabetes type 2,INDUSTRY,0.00925414,0.009257336861785665,3.196861785665847e-06
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Other: Not related to COVID-19,26-week Treatment Extension Period,FG003,diabetes type 2,INDUSTRY,0.00925414,0.009267310091547572,1.317009154757319e-05
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,26-week Treatment Extension Period,FG000,diabetes type 2,INDUSTRY,0.00925414,0.00925210831839281,2.031681607188654e-06
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,26-week Treatment Extension Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,406.0,293.0,0.0,0.0,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,26-week Treatment Extension Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,406.0,293.0,0.002463,0.002463,6.008813,0.625292,1.0,406.0,5.0,54.0,Adverse Event,26-week Treatment Extension Period,FG003,diabetes type 2,INDUSTRY,0.00925414,0.00926915732696424,1.5017326964241254e-05
2.0,406.0,293.0,0.004926,0.004926,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,26-week Treatment Extension Period,FG000,diabetes type 2,INDUSTRY,0.01850829,0.01848844583904759,1.984416095240915e-05
3.0,406.0,293.0,0.007389,0.007389,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,26-week Treatment Extension Period,FG001,diabetes type 2,INDUSTRY,0.02776243,0.027612324171408697,0.00015010582859130428
3.0,406.0,293.0,0.007389,0.007389,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,26-week Treatment Extension Period,FG002,diabetes type 2,INDUSTRY,0.02776243,0.027639059112480113,0.00012337088751988856
12.0,406.0,293.0,0.029557,0.029557,6.008813,0.625292,1.0,406.0,5.0,54.0,Withdrawal by Subject,26-week Treatment Extension Period,FG003,diabetes type 2,INDUSTRY,0.11105348,0.11108016394078382,2.668394078382541e-05
14.0,807.0,651.0,0.017348,0.017348,6.694562,0.305312,1.0,807.0,19.0,91.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0354581,0.035384311287152734,7.378871284726557e-05
8.0,807.0,651.0,0.009913,0.009913,6.694562,0.305312,1.0,807.0,19.0,91.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02026148,0.02038709877027779,0.00012561877027779042
12.0,807.0,651.0,0.01487,0.01487,6.694562,0.305312,1.0,807.0,19.0,91.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03039324,0.029862795893521824,0.0005304441064781749
11.0,807.0,651.0,0.013631,0.013631,6.694562,0.305312,1.0,807.0,19.0,91.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02786081,0.027825265166398796,3.554483360120389e-05
19.0,807.0,651.0,0.023544,0.023544,6.694562,0.305312,1.0,807.0,19.0,91.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04812229,0.048143444738208904,2.115473820890612e-05
14.0,807.0,651.0,0.017348,0.017348,6.694562,0.305312,1.0,807.0,19.0,91.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0354581,0.03545251755577377,5.582444226229222e-06
5.0,807.0,651.0,0.006196,0.006196,6.694562,0.305312,1.0,807.0,19.0,91.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01266419,0.012462174950267852,0.0002020150497321488
4.0,807.0,651.0,0.004957,0.004957,6.694562,0.305312,1.0,807.0,19.0,91.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01013176,0.010075109965476208,5.6650034523791915e-05
7.0,807.0,651.0,0.008674,0.008674,6.694562,0.305312,1.0,807.0,19.0,91.0,Sponsor Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01772905,0.017635780339990074,9.326966000992518e-05
1.0,807.0,651.0,0.001239,0.001239,6.694562,0.305312,1.0,807.0,19.0,91.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00253243,0.002537331620297627,4.901620297626929e-06
1.0,807.0,651.0,0.001239,0.001239,6.694562,0.305312,1.0,807.0,19.0,91.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00253243,0.002533472785892864,1.0427858928639504e-06
2.0,807.0,651.0,0.002478,0.002478,6.694562,0.305312,1.0,807.0,19.0,91.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00506486,0.005065362688939404,5.026889394041043e-07
1.0,807.0,651.0,0.001239,0.001239,6.694562,0.305312,1.0,807.0,19.0,91.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00253243,0.0025378081381547696,5.378138154769636e-06
1.0,807.0,651.0,0.001239,0.001239,6.694562,0.305312,1.0,807.0,19.0,91.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00253243,0.00253390391208334,1.4739120833399434e-06
2.0,807.0,651.0,0.002478,0.002478,6.694562,0.305312,1.0,807.0,19.0,91.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00506486,0.005066016023106071,1.1560231060712967e-06
2.0,807.0,651.0,0.002478,0.002478,6.694562,0.305312,1.0,807.0,19.0,91.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00506486,0.005066151053225118,1.2910532251183757e-06
3.0,807.0,651.0,0.003717,0.003717,6.694562,0.305312,1.0,807.0,19.0,91.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00759729,0.00756112590469247,3.616409530752922e-05
4.0,807.0,651.0,0.004957,0.004957,6.694562,0.305312,1.0,807.0,19.0,91.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01013176,0.010117264398670642,1.4495601329357621e-05
0.0,807.0,651.0,0.0,0.0,6.694562,0.305312,1.0,807.0,19.0,91.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,807.0,651.0,0.001239,0.001239,6.694562,0.305312,1.0,807.0,19.0,91.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00253243,0.0025310134575595306,1.4165424404694558e-06
2.0,807.0,651.0,0.002478,0.002478,6.694562,0.305312,1.0,807.0,19.0,91.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00506486,0.0050704923814394055,5.632381439405441e-06
15.0,807.0,651.0,0.018587,0.018587,6.694562,0.305312,1.0,807.0,19.0,91.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03799053,0.03656484509495035,0.0014256849050496498
13.0,807.0,651.0,0.016109,0.016109,6.694562,0.305312,1.0,807.0,19.0,91.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03292567,0.032758025542896814,0.0001676444571031832
9.0,807.0,651.0,0.011152,0.011152,6.694562,0.305312,1.0,807.0,19.0,91.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02279391,0.022479411734791673,0.0003144982652083274
0.0,807.0,651.0,0.0,0.0,6.694562,0.305312,1.0,807.0,19.0,91.0,Treatment Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,807.0,651.0,0.002478,0.002478,6.694562,0.305312,1.0,807.0,19.0,91.0,Treatment Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00506486,0.0050637423415584555,1.1176584415444751e-06
3.0,807.0,651.0,0.003717,0.003717,6.694562,0.305312,1.0,807.0,19.0,91.0,Treatment Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00759729,0.007556919616180569,4.037038381943074e-05
1.0,506.0,499.0,0.001976,0.001976,6.228511,0.444991,1.0,506.0,12.0,117.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00547675,0.005515116718276375,3.836671827637476e-05
0.0,506.0,499.0,0.0,0.0,6.228511,0.444991,1.0,506.0,12.0,117.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,499.0,0.001976,0.001976,6.228511,0.444991,1.0,506.0,12.0,117.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00547675,0.005524888921887485,4.8138921887485274e-05
4.0,506.0,499.0,0.007905,0.007905,6.228511,0.444991,1.0,506.0,12.0,117.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02190976,0.022136741716597217,0.0002269817165972167
0.0,506.0,499.0,0.0,0.0,6.228511,0.444991,1.0,506.0,12.0,117.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,499.0,0.001976,0.001976,6.228511,0.444991,1.0,506.0,12.0,117.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547675,0.005517035084256228,4.028508425622801e-05
14.0,536.0,495.0,0.026119,0.026119,6.285998,0.600134,1.0,536.0,1.0,32.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09853236,0.09870811797857133,0.00017575797857133368
8.0,536.0,495.0,0.014925,0.014925,6.285998,0.600134,1.0,536.0,1.0,32.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05630367,0.0540167895219445,0.002286880478055503
4.0,536.0,495.0,0.007463,0.007463,6.285998,0.600134,1.0,536.0,1.0,32.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02815372,0.02766965392543651,0.0004840660745634891
2.0,536.0,495.0,0.003731,0.003731,6.285998,0.600134,1.0,536.0,1.0,32.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01407497,0.014023258694423713,5.171130557628592e-05
3.0,536.0,495.0,0.005597,0.005597,6.285998,0.600134,1.0,536.0,1.0,32.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02111435,0.021337435262688532,0.000223085262688532
2.0,536.0,495.0,0.003731,0.003731,6.285998,0.600134,1.0,536.0,1.0,32.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01407497,0.014003440135643948,7.1529864356051e-05
2.0,536.0,495.0,0.003731,0.003731,6.285998,0.600134,1.0,536.0,1.0,32.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01407497,0.013991268196834428,8.370180316557077e-05
2.0,536.0,495.0,0.003731,0.003731,6.285998,0.600134,1.0,536.0,1.0,32.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01407497,0.013994476331685617,8.049366831438219e-05
0.0,536.0,495.0,0.0,0.0,6.285998,0.600134,1.0,536.0,1.0,32.0,Non-Compliance with Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,536.0,495.0,0.005597,0.005597,6.285998,0.600134,1.0,536.0,1.0,32.0,Non-Compliance with Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02111435,0.021298571363392894,0.00018422136339289394
0.0,536.0,495.0,0.0,0.0,6.285998,0.600134,1.0,536.0,1.0,32.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,536.0,495.0,0.001866,0.001866,6.285998,0.600134,1.0,536.0,1.0,32.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00703937,0.007157627473323416,0.00011825747332341614
0.0,308.0,303.0,0.0,0.0,5.733341,0.411561,1.0,308.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,308.0,303.0,0.00974,0.00974,5.733341,0.411561,1.0,308.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02298269,0.023168879788452376,0.0001861897884523761
1.0,308.0,303.0,0.003247,0.003247,5.733341,0.411561,1.0,308.0,1.0,25.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00766168,0.00770332277416667,4.1642774166670594e-05
0.0,308.0,303.0,0.0,0.0,5.733341,0.411561,1.0,308.0,1.0,25.0,Missing follow-up information,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,308.0,303.0,0.0,0.0,5.733341,0.411561,1.0,308.0,1.0,25.0,Missing follow-up information,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,308.0,303.0,0.003247,0.003247,5.733341,0.411561,1.0,308.0,1.0,25.0,Missing follow-up information,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00766168,0.007712662091130956,5.098209113095671e-05
2.0,388.0,374.0,0.005155,0.005155,5.963579,0.813024,1.0,388.0,5.0,104.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02499419,0.025355871569613074,0.00036168156961307457
3.0,388.0,374.0,0.007732,0.007732,5.963579,0.813024,1.0,388.0,5.0,104.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03748886,0.03772619191794113,0.00023733191794113317
4.0,388.0,374.0,0.010309,0.010309,5.963579,0.813024,1.0,388.0,5.0,104.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04998353,0.05286275947374263,0.0028792294737426324
2.0,388.0,374.0,0.005155,0.005155,5.963579,0.813024,1.0,388.0,5.0,104.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02499419,0.025336300117946395,0.00034211011794639534
1.0,388.0,374.0,0.002577,0.002577,5.963579,0.813024,1.0,388.0,5.0,104.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01249467,0.01246265998284721,3.201001715278859e-05
1.0,388.0,374.0,0.002577,0.002577,5.963579,0.813024,1.0,388.0,5.0,104.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01249467,0.012461921909583317,3.274809041668193e-05
1.0,388.0,374.0,0.002577,0.002577,5.963579,0.813024,1.0,388.0,5.0,104.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01249467,0.012473456963263881,2.121303673611845e-05
0.0,388.0,374.0,0.0,0.0,5.963579,0.813024,1.0,388.0,5.0,104.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,458.0,448.0,0.00655,0.00655,6.12905,0.518616,1.0,458.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02082,0.02034399639057539,0.0004760036094246106
2.0,458.0,448.0,0.004367,0.004367,6.12905,0.518616,1.0,458.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01388106,0.01378155352981154,9.950647018846029e-05
2.0,458.0,448.0,0.004367,0.004367,6.12905,0.518616,1.0,458.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01388106,0.013794059198025826,8.700080197417484e-05
2.0,458.0,448.0,0.004367,0.004367,6.12905,0.518616,1.0,458.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01388106,0.013793969909871069,8.709009012893183e-05
0.0,458.0,448.0,0.0,0.0,6.12905,0.518616,1.0,458.0,1.0,34.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,458.0,448.0,0.0,0.0,6.12905,0.518616,1.0,458.0,1.0,34.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,458.0,448.0,0.002183,0.002183,6.12905,0.518616,1.0,458.0,1.0,34.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00693894,0.007011101487519849,7.216148751984855e-05
0.0,458.0,448.0,0.0,0.0,6.12905,0.518616,1.0,458.0,1.0,34.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,591.0,567.0,0.006768,0.006768,6.383507,0.785516,1.0,591.0,1.0,44.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03393709,0.03377426480208333,0.0001628251979166745
0.0,591.0,567.0,0.0,0.0,6.383507,0.785516,1.0,591.0,1.0,44.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,591.0,567.0,0.001692,0.001692,6.383507,0.785516,1.0,591.0,1.0,44.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00848427,0.008537723774454331,5.345377445433071e-05
0.0,591.0,567.0,0.0,0.0,6.383507,0.785516,1.0,591.0,1.0,44.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,591.0,567.0,0.005076,0.005076,6.383507,0.785516,1.0,591.0,1.0,44.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02545282,0.0253271892737996,0.0001256307262004
0.0,591.0,567.0,0.0,0.0,6.383507,0.785516,1.0,591.0,1.0,44.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,591.0,567.0,0.0,0.0,6.383507,0.785516,1.0,591.0,1.0,44.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,591.0,567.0,0.001692,0.001692,6.383507,0.785516,1.0,591.0,1.0,44.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00848427,0.008546158784662666,6.188878466266597e-05
9.0,591.0,567.0,0.015228,0.015228,6.383507,0.785516,1.0,591.0,1.0,44.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07635846,0.07607159245749014,0.00028686754250986657
5.0,591.0,567.0,0.00846,0.00846,6.383507,0.785516,1.0,591.0,1.0,44.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04242137,0.04266439246231791,0.00024302246231790864
1.0,591.0,567.0,0.001692,0.001692,6.383507,0.785516,1.0,591.0,1.0,44.0,Due to long-term overseas business trips,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00848427,0.008533336875704333,4.906687570433235e-05
0.0,591.0,567.0,0.0,0.0,6.383507,0.785516,1.0,591.0,1.0,44.0,Due to long-term overseas business trips,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,720.0,659.0,0.006944,0.006944,6.580639,0.565689,1.0,720.0,1.0,36.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02584972,0.025533157226488128,0.000316562773511872
1.0,720.0,659.0,0.001389,0.001389,6.580639,0.565689,1.0,720.0,1.0,36.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00517069,0.0053523178270436485,0.00018162782704364815
15.0,720.0,659.0,0.020833,0.020833,6.580639,0.565689,1.0,720.0,1.0,36.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07755289,0.07675364868657736,0.0007992413134226412
3.0,720.0,659.0,0.004167,0.004167,6.580639,0.565689,1.0,720.0,1.0,36.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01551207,0.015285285737986123,0.00022678426201387658
2.0,720.0,659.0,0.002778,0.002778,6.580639,0.565689,1.0,720.0,1.0,36.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01034138,0.010443216989547439,0.00010183698954743803
1.0,720.0,659.0,0.001389,0.001389,6.580639,0.565689,1.0,720.0,1.0,36.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00517069,0.0053553048981746,0.0001846148981745994
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,720.0,659.0,0.005556,0.005556,6.580639,0.565689,1.0,720.0,1.0,36.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02068276,0.02052940818854435,0.00015335181145565216
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,720.0,659.0,0.001389,0.001389,6.580639,0.565689,1.0,720.0,1.0,36.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00517069,0.005356591767460316,0.00018590176746031539
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,720.0,659.0,0.013889,0.013889,6.580639,0.565689,1.0,720.0,1.0,36.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05170317,0.0510737833358135,0.0006293866641865001
8.0,720.0,659.0,0.011111,0.011111,6.580639,0.565689,1.0,720.0,1.0,36.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04136179,0.04114945311782912,0.00021233688217088542
8.0,720.0,659.0,0.011111,0.011111,6.580639,0.565689,1.0,720.0,1.0,36.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04136179,0.04114656646759103,0.00021522353240897157
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Severe hypoglycaemic episode,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Severe hypoglycaemic episode,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,720.0,659.0,0.001389,0.001389,6.580639,0.565689,1.0,720.0,1.0,36.0,Severe hypoglycaemic episode,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00517069,0.005353151110674601,0.00018246111067460064
2.0,720.0,659.0,0.002778,0.002778,6.580639,0.565689,1.0,720.0,1.0,36.0,Non-compliance towards treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01034138,0.010477640486442287,0.00013626048644228665
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Non-compliance towards treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,720.0,659.0,0.0,0.0,6.580639,0.565689,1.0,720.0,1.0,36.0,Non-compliance towards treatment,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,296.0,274.0,0.003378,0.003378,5.693732,0.286086,1.0,296.0,1.0,50.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00550241,0.0055786016857738265,7.619168577382637e-05
1.0,296.0,274.0,0.003378,0.003378,5.693732,0.286086,1.0,296.0,1.0,50.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00550241,0.005575960763273829,7.355076327382904e-05
0.0,296.0,274.0,0.0,0.0,5.693732,0.286086,1.0,296.0,1.0,50.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,296.0,274.0,0.010135,0.010135,5.693732,0.286086,1.0,296.0,1.0,50.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01650887,0.01686513949696429,0.00035626949696429197
1.0,296.0,274.0,0.003378,0.003378,5.693732,0.286086,1.0,296.0,1.0,50.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00550241,0.005578183184107161,7.577318410716127e-05
1.0,296.0,274.0,0.003378,0.003378,5.693732,0.286086,1.0,296.0,1.0,50.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00550241,0.005575365436607163,7.295543660716317e-05
8.0,296.0,274.0,0.027027,0.027027,5.693732,0.286086,1.0,296.0,1.0,50.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04402419,0.04401759315364088,6.596846359119279e-06
7.0,296.0,274.0,0.023649,0.023649,5.693732,0.286086,1.0,296.0,1.0,50.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03852178,0.039418814562857216,0.0008970345628572171
26.0,495.0,376.0,0.052525,0.052525,6.206576,0.316604,1.0,507.0,15.0,218.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10321318,0.10096960492719234,0.0022435750728076603
26.0,495.0,376.0,0.052525,0.052525,6.206576,0.316604,1.0,507.0,15.0,218.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10321318,0.10085775242210301,0.0023554275778969874
1.0,495.0,376.0,0.00202,0.00202,6.206576,0.316604,1.0,507.0,15.0,218.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00396936,0.003935086056517852,3.4273943482147906e-05
4.0,495.0,376.0,0.008081,0.008081,6.206576,0.316604,1.0,507.0,15.0,218.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0158794,0.01594110361267862,6.170361267862287e-05
3.0,495.0,376.0,0.006061,0.006061,6.206576,0.316604,1.0,507.0,15.0,218.0,Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01191004,0.012131258795624994,0.00022121879562499343
5.0,495.0,376.0,0.010101,0.010101,6.206576,0.316604,1.0,507.0,15.0,218.0,Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01984876,0.01980324813892857,4.551186107143099e-05
4.0,495.0,376.0,0.008081,0.008081,6.206576,0.316604,1.0,507.0,15.0,218.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0158794,0.015946111666875065,6.671166687506613e-05
4.0,495.0,376.0,0.008081,0.008081,6.206576,0.316604,1.0,507.0,15.0,218.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0158794,0.015937075004256018,5.7675004256019236e-05
12.0,495.0,376.0,0.024242,0.024242,6.206576,0.316604,1.0,507.0,15.0,218.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04763625,0.048017854227460355,0.00038160422746035677
26.0,495.0,376.0,0.052525,0.052525,6.206576,0.316604,1.0,507.0,15.0,218.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10321318,0.10099462540436491,0.0022185545956350944
5.0,495.0,376.0,0.010101,0.010101,6.206576,0.316604,1.0,507.0,15.0,218.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01984876,0.019784349295119047,6.441070488095307e-05
3.0,495.0,376.0,0.006061,0.006061,6.206576,0.316604,1.0,507.0,15.0,218.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01191004,0.012169798086398802,0.00025975808639880187
2.0,676.0,646.0,0.002959,0.002959,6.517671,0.316604,1.0,678.0,3.0,25.0,Subject meets glycemic withdrawal crit.,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00610597,0.006169224678035719,6.325467803571915e-05
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Subject meets glycemic withdrawal crit.,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Subject meets glycemic withdrawal crit.,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,676.0,646.0,0.005917,0.005917,6.517671,0.316604,1.0,678.0,3.0,25.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01220987,0.01247501268244048,0.0002651426824404803
6.0,676.0,646.0,0.008876,0.008876,6.517671,0.316604,1.0,678.0,3.0,25.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01831584,0.018304344688621032,1.1495311378968004e-05
7.0,676.0,646.0,0.010355,0.010355,6.517671,0.316604,1.0,678.0,3.0,25.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02136779,0.02135583486990079,1.1955130099210176e-05
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Noncompliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Noncompliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Noncompliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00305195,0.003049807418833874,2.1425811661257566e-06
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00305195,0.0030567630111607135,4.813011160713625e-06
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00305195,0.003049803046542208,2.1469534577920647e-06
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00305195,0.003057417998273809,5.467998273808988e-06
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00305195,0.0030500263253219694,1.923674678030486e-06
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,676.0,646.0,0.0,0.0,6.517671,0.316604,1.0,678.0,3.0,25.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00305195,0.0030498436730005407,2.1063269994591773e-06
3.0,676.0,646.0,0.004438,0.004438,6.517671,0.316604,1.0,678.0,3.0,25.0,Early withdraw,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00915792,0.009247738250178572,8.981825017857249e-05
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Early withdraw,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00305195,0.0030567845984523796,4.8345984523796674e-06
1.0,676.0,646.0,0.001479,0.001479,6.517671,0.316604,1.0,678.0,3.0,25.0,Early withdraw,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00305195,0.0030495365671672076,2.4134328327923317e-06
17.0,494.0,341.0,0.034413,0.034413,6.204558,0.235372,1.0,494.0,1.0,39.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.050256,0.04978529561872023,0.000470704381279774
2.0,494.0,341.0,0.004049,0.004049,6.204558,0.235372,1.0,494.0,1.0,39.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00591307,0.005834462342941017,7.860765705898325e-05
14.0,494.0,341.0,0.02834,0.02834,6.204558,0.235372,1.0,494.0,1.0,39.0,Entry criteria not met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04138712,0.04161313460372019,0.0002260146037201885
16.0,494.0,341.0,0.032389,0.032389,6.204558,0.235372,1.0,494.0,1.0,39.0,Entry criteria not met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04730019,0.047514189775922616,0.00021399977592261726
0.0,494.0,341.0,0.0,0.0,6.204558,0.235372,1.0,494.0,1.0,39.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,494.0,341.0,0.002024,0.002024,6.204558,0.235372,1.0,494.0,1.0,39.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00295581,0.002957261942083333,1.451942083332755e-06
6.0,494.0,341.0,0.012146,0.012146,6.204558,0.235372,1.0,494.0,1.0,39.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01773775,0.017950468035843246,0.00021271803584324567
3.0,494.0,341.0,0.006073,0.006073,6.204558,0.235372,1.0,494.0,1.0,39.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00886888,0.00881448526872024,5.4394731279761716e-05
36.0,494.0,341.0,0.072874,0.072874,6.204558,0.235372,1.0,494.0,1.0,39.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.1064236,0.10546883084751993,0.0009547691524800644
27.0,494.0,341.0,0.054656,0.054656,6.204558,0.235372,1.0,494.0,1.0,39.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07981843,0.07993172271919641,0.0001132927191964117
1.0,494.0,341.0,0.002024,0.002024,6.204558,0.235372,1.0,494.0,1.0,39.0,Sponsor decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00295581,0.0029551422236309506,6.677763690495463e-07
0.0,494.0,341.0,0.0,0.0,6.204558,0.235372,1.0,494.0,1.0,39.0,Sponsor decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,494.0,341.0,0.016194,0.016194,6.204558,0.235372,1.0,494.0,1.0,39.0,Subject decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02364937,0.0234936391078869,0.00015573089211309843
22.0,494.0,341.0,0.044534,0.044534,6.204558,0.235372,1.0,494.0,1.0,39.0,Subject decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06503648,0.06462867888059522,0.00040780111940477703
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0161429,0.016189141595892922,4.624159589292076e-05
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01075966,0.010748167022629006,1.1492977370995e-05
8.0,2539.0,1961.0,0.003151,0.003151,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.02152615,0.021692113010386826,0.00016596301038682496
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0161429,0.016226423504226265,8.352350422626345e-05
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01075966,0.010708326956101228,5.13330438987724e-05
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01075966,0.010721793899017895,3.7866100982105605e-05
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00538325,0.005403028376607116,1.9778376607115962e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.002696362507916671,4.742507916670816e-06
41.0,2539.0,1961.0,0.016148,0.016148,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.11031554,0.11136505107089287,0.001049511070892864
17.0,2539.0,1961.0,0.006696,0.006696,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.04574392,0.04677285689541666,0.0010289368954166586
15.0,2539.0,1961.0,0.005908,0.005908,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.04036068,0.040652920851101115,0.00029224085110111236
13.0,2539.0,1961.0,0.00512,0.00512,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.03497743,0.03654929931836312,0.001571869318363124
21.0,2539.0,1961.0,0.008271,0.008271,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.05650358,0.056534570020796364,3.09900207963662e-05
7.0,2539.0,1961.0,0.002757,0.002757,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01883453,0.018697647258601246,0.00013688274139875278
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0161429,0.016258682408988163,0.00011578240898816108
12.0,2539.0,1961.0,0.004726,0.004726,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.03228581,0.03397747583437499,0.0016916658343749946
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00807487,0.008095117178690518,2.0247178690518258e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.0026950726772519886,3.4526772519885736e-06
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01075966,0.010737989579712342,2.1670420287658518e-05
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00807487,0.008117232710714318,4.236271071431791e-05
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01075966,0.010736932616379005,2.2727383620996244e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.002695999516250004,4.379516250003785e-06
58.0,2539.0,1961.0,0.022844,0.022844,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Primary Treatment Period,FG000,diabetes type 2,INDUSTRY,0.15605947,0.16402995256671637,0.00797048256671637
26.0,2539.0,1961.0,0.01024,0.01024,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Primary Treatment Period,FG001,diabetes type 2,INDUSTRY,0.06995487,0.07099828931435793,0.0010434193143579323
32.0,2539.0,1961.0,0.012603,0.012603,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Primary Treatment Period,FG002,diabetes type 2,INDUSTRY,0.08609777,0.08671453914928567,0.0006167691492856703
21.0,2539.0,1961.0,0.008271,0.008271,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Primary Treatment Period,FG003,diabetes type 2,INDUSTRY,0.05650358,0.056515428464692506,1.1848464692508498e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00269162,0.0026870385314880997,4.581468511900312e-06
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00538325,0.005424223360595211,4.097336059521138e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00269162,0.002694680252900437,3.060252900437179e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00269162,0.0026950432445671042,3.4232445671042097e-06
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Death,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.0026935873281547667,1.967328154766669e-06
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0161429,0.016180497527797686,3.7597527797684355e-05
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01075966,0.010758072032331385,1.5879676686161859e-06
8.0,2539.0,1961.0,0.003151,0.003151,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.02152615,0.02168258790559517,0.00015643790559517062
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0161429,0.016217657586131026,7.475758613102387e-05
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00538325,0.005390205106845214,6.9551068452135614e-06
5.0,2539.0,1961.0,0.001969,0.001969,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01345128,0.0135701681891964,0.00011888818919640089
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00538325,0.005397924975357112,1.4674975357112027e-05
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00269162,0.0026957821210452783,4.16212104527823e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.0026932243364880997,1.6043364880996384e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00269162,0.002694680252900437,3.060252900437179e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Site closed,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00269162,0.0026870385314880997,4.581468511900312e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Site closed,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Site closed,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00269162,0.002694680252900437,3.060252900437179e-06
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Site closed,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
21.0,2539.0,1961.0,0.008271,0.008271,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Additional Treatment Period,FG000,diabetes type 2,INDUSTRY,0.05650358,0.05646761795037972,3.59620496202806e-05
15.0,2539.0,1961.0,0.005908,0.005908,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Additional Treatment Period,FG001,diabetes type 2,INDUSTRY,0.04036068,0.040810600013868964,0.000449920013868961
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Additional Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00807487,0.008071492154940511,3.377845059488252e-06
7.0,2539.0,1961.0,0.002757,0.002757,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Additional Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01883453,0.018780269042023873,5.426095797612593e-05
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.0161429,0.01618518223839292,4.228223839291764e-05
8.0,2539.0,1961.0,0.003151,0.003151,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.02152615,0.0216598341388789,0.00013368413887889993
9.0,2539.0,1961.0,0.003545,0.003545,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.02421777,0.02477856747664681,0.0005607974766468106
16.0,2539.0,1961.0,0.006302,0.006302,7.839919,0.871378,1.0,2539.0,10.0,118.0,Adverse Event,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.0430523,0.04386846834573411,0.0008161683457341071
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.01075966,0.010751572510248053,8.087489751947702e-06
4.0,2539.0,1961.0,0.001575,0.001575,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.01075966,0.010761436557331385,1.7765573313843763e-06
10.0,2539.0,1961.0,0.003939,0.003939,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0269094,0.027267751018422562,0.0003583510184225619
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Lost to Follow-up,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.00807487,0.008092636938690516,1.7766938690516598e-05
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Missing Weight at Week 176,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.00807487,0.00811929351184527,4.442351184527106e-05
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Missing Weight at Week 176,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.00538325,0.00541278589684521,2.953589684520988e-05
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Missing Weight at Week 176,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.00538325,0.005388575936607111,5.3259366071109135e-06
2.0,2539.0,1961.0,0.000788,0.000788,7.839919,0.871378,1.0,2539.0,10.0,118.0,Missing Weight at Week 176,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.00538325,0.005397335606845209,1.4085606845209118e-05
10.0,2539.0,1961.0,0.003939,0.003939,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.0269094,0.02714914270205352,0.0002397427020535206
5.0,2539.0,1961.0,0.001969,0.001969,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.01345128,0.01356402044282735,0.00011274044282735124
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0161429,0.016254601201488156,0.0001117012014881548
5.0,2539.0,1961.0,0.001969,0.001969,7.839919,0.871378,1.0,2539.0,10.0,118.0,Other - as reported by the investigator,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.01345128,0.013579115491160691,0.00012783549116069173
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.00269162,0.002691633421924608,1.3421924607761454e-08
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Physician Decision,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.00269162,0.002693337352251989,1.7173522519889003e-06
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.00269162,0.002692300017916671,6.800179166710496e-07
3.0,2539.0,1961.0,0.001182,0.001182,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.00807487,0.008108663421964318,3.3793421964318365e-05
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,2539.0,1961.0,0.002363,0.002363,7.839919,0.871378,1.0,2539.0,10.0,118.0,Pregnancy,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.0161429,0.016229684938392924,8.678493839292187e-05
1.0,2539.0,1961.0,0.000394,0.000394,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.00269162,0.002692300017916671,6.800179166710496e-07
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,2539.0,1961.0,0.0,0.0,7.839919,0.871378,1.0,2539.0,10.0,118.0,Protocol deviation,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
31.0,2539.0,1961.0,0.01221,0.01221,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Safety Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.08341298,0.08518948363494053,0.0017765036349405294
13.0,2539.0,1961.0,0.00512,0.00512,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Safety Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.03497743,0.03679339980502975,0.0018159698050297518
7.0,2539.0,1961.0,0.002757,0.002757,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Safety Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.01883453,0.018825458536190533,9.071463809465913e-06
9.0,2539.0,1961.0,0.003545,0.003545,7.839919,0.871378,1.0,2539.0,10.0,118.0,Withdrawal by Subject,Safety Follow-up Period,FG003,diabetes type 2,INDUSTRY,0.02421777,0.02479506140643848,0.0005772914064384807
5.0,570.0,501.0,0.008772,0.008772,6.347389,0.240569,1.0,570.0,3.0,30.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01339469,0.013316819098839291,7.787090116070927e-05
4.0,570.0,501.0,0.007018,0.007018,6.347389,0.240569,1.0,570.0,3.0,30.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01071637,0.010720756348918649,4.386348918649502e-06
2.0,570.0,501.0,0.003509,0.003509,6.347389,0.240569,1.0,570.0,3.0,30.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00535818,0.005388302160328151,3.012216032815141e-05
0.0,570.0,501.0,0.0,0.0,6.347389,0.240569,1.0,570.0,3.0,30.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,570.0,501.0,0.007018,0.007018,6.347389,0.240569,1.0,570.0,3.0,30.0,Study specific discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01071637,0.010718614138204362,2.2441382043630886e-06
11.0,570.0,501.0,0.019298,0.019298,6.347389,0.240569,1.0,570.0,3.0,30.0,Study specific discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02946771,0.029139291906487154,0.00032841809351284723
13.0,570.0,501.0,0.022807,0.022807,6.347389,0.240569,1.0,570.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0348259,0.034407024568949306,0.00041887543105069425
23.0,570.0,501.0,0.040351,0.040351,6.347389,0.240569,1.0,570.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06161528,0.06190342067238097,0.0002881406723809696
3.0,570.0,501.0,0.005263,0.005263,6.347389,0.240569,1.0,570.0,3.0,30.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00803651,0.008031209515892864,5.300484107136072e-06
1.0,570.0,501.0,0.001754,0.001754,6.347389,0.240569,1.0,570.0,3.0,30.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00267833,0.0026795457081448273,1.2157081448272225e-06
0.0,570.0,501.0,0.0,0.0,6.347389,0.240569,1.0,570.0,3.0,30.0,Severe non-compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,570.0,501.0,0.001754,0.001754,6.347389,0.240569,1.0,570.0,3.0,30.0,Severe non-compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00267833,0.00267970172570435,1.3717257043499229e-06
1.0,570.0,501.0,0.001754,0.001754,6.347389,0.240569,1.0,570.0,3.0,30.0,Safety reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00267833,0.0026797813169543512,1.4513169543511895e-06
0.0,570.0,501.0,0.0,0.0,6.347389,0.240569,1.0,570.0,3.0,30.0,Safety reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,570.0,501.0,0.001754,0.001754,6.347389,0.240569,1.0,570.0,3.0,30.0,Metformin dose haven't decreasd to 2.5 g,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00267833,0.0026797813169543512,1.4513169543511895e-06
0.0,570.0,501.0,0.0,0.0,6.347389,0.240569,1.0,570.0,3.0,30.0,Metformin dose haven't decreasd to 2.5 g,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,2368.0,2312.0,0.007179,0.007179,7.770223,0.230287,1.0,2368.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,OTHER,0.01284599,0.012735168845783731,0.00011082115421626876
10.0,2368.0,2312.0,0.004223,0.004223,7.770223,0.230287,1.0,2368.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,OTHER,0.00755657,0.0075300257994543604,2.6544200545639864e-05
15.0,2368.0,2312.0,0.006334,0.006334,7.770223,0.230287,1.0,2368.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,OTHER,0.01133396,0.011364218802698424,3.0258802698423376e-05
14.0,2368.0,2312.0,0.005912,0.005912,7.770223,0.230287,1.0,2368.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,OTHER,0.01057884,0.010700084189153126,0.00012124418915312497
4.0,588.0,574.0,0.006803,0.006803,6.378426,0.730307,1.0,588.0,12.0,93.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03168981,0.03199563622932541,0.000305826229325408
4.0,588.0,574.0,0.006803,0.006803,6.378426,0.730307,1.0,588.0,12.0,93.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03168981,0.032011838331378974,0.00032202833137897485
0.0,588.0,574.0,0.0,0.0,6.378426,0.730307,1.0,588.0,12.0,93.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,588.0,574.0,0.001701,0.001701,6.378426,0.730307,1.0,588.0,12.0,93.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00792362,0.008032629072928123,0.0001090090729281238
0.0,588.0,574.0,0.0,0.0,6.378426,0.730307,1.0,588.0,12.0,93.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,588.0,574.0,0.003401,0.003401,6.378426,0.730307,1.0,588.0,12.0,93.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01584257,0.015953663323571444,0.00011109332357144355
2.0,588.0,574.0,0.003401,0.003401,6.378426,0.730307,1.0,588.0,12.0,93.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01584257,0.015902554339540062,5.998433954006177e-05
1.0,588.0,574.0,0.001701,0.001701,6.378426,0.730307,1.0,588.0,12.0,93.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00792362,0.007983413702957888,5.979370295788877e-05
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,326.0,292.0,0.006135,0.006135,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.00848268,0.008526321892410739,4.364189241073957e-05
1.0,326.0,292.0,0.003067,0.003067,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Enrolled - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.00424065,0.004255000599583336,1.4350599583335885e-05
1.0,326.0,292.0,0.003067,0.003067,5.78996,0.238805,1.0,336.0,0.0,0.0,Other,Enrolled - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00424065,0.004257593795833336,1.694379583333603e-05
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Other,Enrolled - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Other,Enrolled - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Other,Enrolled - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,326.0,292.0,0.018405,0.018405,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.02544805,0.025457672794236087,9.622794236087417e-06
6.0,326.0,292.0,0.018405,0.018405,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.02544805,0.025519772838839265,7.172283883926517e-05
2.0,326.0,292.0,0.006135,0.006135,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.00848268,0.008517414443244083,3.4734443244083604e-05
4.0,326.0,292.0,0.01227,0.01227,5.78996,0.238805,1.0,336.0,0.0,0.0,Adverse Event,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.01696537,0.017530219757008473,0.0005648497570084725
1.0,326.0,292.0,0.003067,0.003067,5.78996,0.238805,1.0,336.0,0.0,0.0,Lost to Follow-up,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00424065,0.004256842557083336,1.6192557083336e-05
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Lost to Follow-up,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Lost to Follow-up,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Lost to Follow-up,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,326.0,292.0,0.006135,0.006135,5.78996,0.238805,1.0,336.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.00848268,0.008512240370565506,2.9560370565506755e-05
3.0,326.0,292.0,0.009202,0.009202,5.78996,0.238805,1.0,336.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.01272334,0.012690273172886892,3.306682711310717e-05
1.0,326.0,292.0,0.003067,0.003067,5.78996,0.238805,1.0,336.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.00424065,0.004258459048125003,1.780904812500282e-05
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Withdrawal by Subject,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,326.0,292.0,0.006135,0.006135,5.78996,0.238805,1.0,336.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG001,diabetes type 2,INDUSTRY,0.00848268,0.008532134168898841,4.945416889884195e-05
3.0,326.0,292.0,0.009202,0.009202,5.78996,0.238805,1.0,336.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG002,diabetes type 2,INDUSTRY,0.01272334,0.012675979819017844,4.736018098215611e-05
0.0,326.0,292.0,0.0,0.0,5.78996,0.238805,1.0,336.0,0.0,0.0,Lack of Efficacy,Entered - Long-Term Extension Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,210.0,188.0,0.028571,0.028571,5.351858,0.464197,1.0,210.0,2.0,23.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07097936,0.07337018175134925,0.002390821751349248
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011847256985192997,1.694698519299695e-05
7.0,210.0,188.0,0.033333,0.033333,5.351858,0.464197,1.0,210.0,2.0,23.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08280967,0.08400990882632937,0.0012002388263293723
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011854555754240617,2.4245754240617007e-05
0.0,210.0,188.0,0.0,0.0,5.351858,0.464197,1.0,210.0,2.0,23.0,Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011847666245907282,1.7356245907282006e-05
0.0,210.0,188.0,0.0,0.0,5.351858,0.464197,1.0,210.0,2.0,23.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011829907138558802,4.0286144119792977e-07
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Subject non-compliant,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01183031,0.011852800125658359,2.249012565835873e-05
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,Subject non-compliant,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011847666245907282,1.7356245907282006e-05
2.0,210.0,188.0,0.009524,0.009524,5.351858,0.464197,1.0,210.0,2.0,23.0,GCP violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02366062,0.024427388640803592,0.0007667686408035918
1.0,210.0,188.0,0.004762,0.004762,5.351858,0.464197,1.0,210.0,2.0,23.0,GCP violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01183031,0.011847666245907282,1.7356245907282006e-05
5.0,490.0,440.0,0.010204,0.010204,6.196444,0.384821,1.0,494.0,1.0,74.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02433167,0.024371106997480144,3.9436997480143954e-05
7.0,490.0,440.0,0.014286,0.014286,6.196444,0.384821,1.0,494.0,1.0,74.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0340653,0.034509856783517326,0.00044455678351732614
8.0,490.0,440.0,0.016327,0.016327,6.196444,0.384821,1.0,494.0,1.0,74.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03893211,0.03880100549310517,0.0001311045068948316
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00486681,0.004867544550773808,7.345507738081361e-07
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00486681,0.004862193087380951,4.61691261904873e-06
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00486681,0.004865312992301586,1.497007698414432e-06
5.0,490.0,440.0,0.010204,0.010204,6.196444,0.384821,1.0,494.0,1.0,74.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02433167,0.024372825602718237,4.115560271823748e-05
3.0,490.0,440.0,0.006122,0.006122,6.196444,0.384821,1.0,494.0,1.0,74.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01459805,0.014516104286498015,8.194571350198486e-05
3.0,490.0,440.0,0.006122,0.006122,6.196444,0.384821,1.0,494.0,1.0,74.0,Persistent Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01459805,0.014550901649503964,4.71483504960353e-05
2.0,490.0,440.0,0.004082,0.004082,6.196444,0.384821,1.0,494.0,1.0,74.0,Persistent Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00973362,0.009740416977797619,6.7969777976188e-06
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Persistent Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Persistent Hyperglycemia,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00486681,0.0048654718239682536,1.3381760317465047e-06
2.0,490.0,440.0,0.004082,0.004082,6.196444,0.384821,1.0,494.0,1.0,74.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00973362,0.009755455445416665,2.183544541666492e-05
2.0,490.0,440.0,0.004082,0.004082,6.196444,0.384821,1.0,494.0,1.0,74.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00973362,0.009755045074166668,2.1425074166667862e-05
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00486681,0.0048618375044642845,4.972495535715549e-06
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Non-compliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,490.0,440.0,0.008163,0.008163,6.196444,0.384821,1.0,494.0,1.0,74.0,Intro of New Anti-Diabetic Medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01946486,0.019346740766371762,0.00011811923362823815
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Intro of New Anti-Diabetic Medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,Intro of New Anti-Diabetic Medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,Intro of New Anti-Diabetic Medication,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00486681,0.004867130194523808,3.2019452380835367e-07
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,"Inv Decision, HbA1c not controlled",Overall Study,FG000,diabetes type 2,INDUSTRY,0.00486681,0.004862134509880951,4.6754901190486364e-06
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,"Inv Decision, HbA1c not controlled",Overall Study,FG001,diabetes type 2,INDUSTRY,0.00486681,0.004865481218968254,1.328781031746315e-06
0.0,490.0,440.0,0.0,0.0,6.196444,0.384821,1.0,494.0,1.0,74.0,"Inv Decision, HbA1c not controlled",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,490.0,440.0,0.002041,0.002041,6.196444,0.384821,1.0,494.0,1.0,74.0,"Inv Decision, HbA1c not controlled",Overall Study,FG003,diabetes type 2,INDUSTRY,0.00486681,0.004867474124940476,6.641249404755467e-07
0.0,210.0,203.0,0.0,0.0,5.351858,0.490827,1.0,210.0,1.0,38.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,203.0,0.004762,0.004762,5.351858,0.490827,1.0,210.0,1.0,38.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01250901,0.012467181663244032,4.182833675596756e-05
0.0,210.0,203.0,0.0,0.0,5.351858,0.490827,1.0,210.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,210.0,203.0,0.009524,0.009524,5.351858,0.490827,1.0,210.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02501801,0.025864225398353213,0.0008462153983532124
0.0,210.0,203.0,0.0,0.0,5.351858,0.490827,1.0,210.0,1.0,38.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,203.0,0.004762,0.004762,5.351858,0.490827,1.0,210.0,1.0,38.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01250901,0.012481849658244034,2.7160341755965572e-05
0.0,210.0,203.0,0.0,0.0,5.351858,0.490827,1.0,210.0,1.0,38.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,210.0,203.0,0.014286,0.014286,5.351858,0.490827,1.0,210.0,1.0,38.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03752702,0.03848967156908728,0.0009626515690872792
3.0,475.0,451.0,0.006316,0.006316,6.165418,0.644583,1.0,475.0,8.0,48.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02510057,0.02537527910902775,0.0002747091090277501
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,475.0,451.0,0.004211,0.004211,6.165418,0.644583,1.0,475.0,8.0,48.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01673504,0.016793313291489958,5.827329148995822e-05
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,475.0,451.0,0.002105,0.002105,6.165418,0.644583,1.0,475.0,8.0,48.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00836553,0.008496315513452363,0.00013078551345236354
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,475.0,451.0,0.0,0.0,6.165418,0.644583,1.0,475.0,8.0,48.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,475.0,451.0,0.002105,0.002105,6.165418,0.644583,1.0,475.0,8.0,48.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00836553,0.008491493619166646,0.00012596361916664654
2.0,475.0,451.0,0.004211,0.004211,6.165418,0.644583,1.0,475.0,8.0,48.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01673504,0.016790776304406625,5.573630440662558e-05
1.0,475.0,451.0,0.002105,0.002105,6.165418,0.644583,1.0,475.0,8.0,48.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00836553,0.008487035796071409,0.00012150579607140936
4.0,475.0,451.0,0.008421,0.008421,6.165418,0.644583,1.0,475.0,8.0,48.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0334661,0.033890548367728174,0.0004244483677281752
3.0,475.0,451.0,0.006316,0.006316,6.165418,0.644583,1.0,475.0,8.0,48.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02510057,0.02564946773375,0.0005488977337500013
5.0,475.0,451.0,0.010526,0.010526,6.165418,0.644583,1.0,475.0,8.0,48.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04183163,0.042419872297341225,0.0005882422973412238
2.0,475.0,451.0,0.004211,0.004211,6.165418,0.644583,1.0,475.0,8.0,48.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01673504,0.01679227627631137,5.723627631137179e-05
11.0,663.0,507.0,0.016591,0.016591,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.03537978,0.03575048895953374,0.0003707089595337415
29.0,663.0,507.0,0.043741,0.043741,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.09327629,0.09279060533532119,0.0004856846646788121
22.0,663.0,507.0,0.033183,0.033183,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.07076169,0.07033124398206354,0.00043044601793645887
4.0,663.0,507.0,0.006033,0.006033,6.498282,0.328159,1.0,685.0,9.0,358.0,Protocol Violation,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01286518,0.012944260009732136,7.90800097321357e-05
7.0,663.0,507.0,0.010558,0.010558,6.498282,0.328159,1.0,685.0,9.0,358.0,Protocol Violation,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0225146,0.02249395229581348,2.0647704186520233e-05
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Protocol Violation,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.0032143963328571524,1.3636671428473614e-06
5.0,663.0,507.0,0.007541,0.007541,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01608094,0.016154649880962314,7.370988096231518e-05
6.0,663.0,507.0,0.00905,0.00905,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01929884,0.019267190483759942,3.1649516240059294e-05
16.0,663.0,507.0,0.024133,0.024133,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.05146285,0.052167351961220236,0.0007045019612202386
3.0,663.0,507.0,0.004525,0.004525,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00964942,0.009691642717291676,4.2222717291675455e-05
12.0,663.0,507.0,0.0181,0.0181,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03859767,0.03854941887229166,4.8251127708343056e-05
7.0,663.0,507.0,0.010558,0.010558,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0225146,0.022522193568849182,7.593568849183219e-06
32.0,663.0,507.0,0.048265,0.048265,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.10292357,0.10269184344822413,0.00023172655177587653
46.0,663.0,507.0,0.069382,0.069382,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.1479549,0.1480920687658334,0.00013716876583338977
64.0,663.0,507.0,0.096531,0.096531,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.20584928,0.21024326425990061,0.0043939842599006185
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032144665172619134,1.293482738086351e-06
6.0,663.0,507.0,0.00905,0.00905,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01929884,0.019267222022450417,3.161797754958409e-05
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.003213932504761915,1.8274952380847344e-06
3.0,663.0,507.0,0.004525,0.004525,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Site by Sponsor,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00964942,0.00968678259604168,3.736259604167867e-05
8.0,663.0,507.0,0.012066,0.012066,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Site by Sponsor,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.02573036,0.025793134393065485,6.277439306548449e-05
5.0,663.0,507.0,0.007541,0.007541,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Site by Sponsor,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.01608094,0.01614831889548612,6.737889548612264e-05
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00321576,0.003214968092916675,7.919070833246715e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Persistant Elevated HbA1c Results,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Persistant Elevated HbA1c Results,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Persistant Elevated HbA1c Results,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.0032151649364285813,5.950635714184645e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Pregnancy,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Pregnancy,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00321576,0.0032149385287500083,8.214712499915282e-07
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Pregnancy,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.003214850548928581,9.094510714188243e-07
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032156989489285797,6.105107142008112e-08
2.0,663.0,507.0,0.003017,0.003017,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00643366,0.00641627365660714,1.7386343392859598e-05
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Sponsor Decision on Blinding,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Sponsor Decision on Blinding,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Sponsor Decision on Blinding,Treatment Period (TP) (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.0032151649364285813,5.950635714184645e-07
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032157883312500103,2.833125001050138e-08
2.0,663.0,507.0,0.003017,0.003017,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00643366,0.006413062847440473,2.0597152559527314e-05
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Adverse Event,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.0032154533412500096,3.0665874999015116e-07
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.00321558381250001,1.7618749998966204e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,663.0,507.0,0.007541,0.007541,6.498282,0.328159,1.0,685.0,9.0,358.0,Noncompliance,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.01608094,0.01616680721215279,8.586721215279175e-05
8.0,663.0,507.0,0.012066,0.012066,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.02573036,0.025757843527380947,2.7483527380946227e-05
20.0,663.0,507.0,0.030166,0.030166,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.06432803,0.06487885120594244,0.0005508212059424505
29.0,663.0,507.0,0.043741,0.043741,6.498282,0.328159,1.0,685.0,9.0,358.0,Lost to Follow-up,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.09327629,0.09259566454370409,0.000680625456295908
12.0,663.0,507.0,0.0181,0.0181,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.03859767,0.03860150763324405,3.837633244047067e-06
21.0,663.0,507.0,0.031674,0.031674,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.06754379,0.06694848824065473,0.0005953017593452736
19.0,663.0,507.0,0.028658,0.028658,6.498282,0.328159,1.0,685.0,9.0,358.0,Withdrawal by Subject,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.06111227,0.06115547044672627,4.320044672626727e-05
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Physician Decision,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.003214180915833344,1.5790841666556664e-06
3.0,663.0,507.0,0.004525,0.004525,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Study by Sponsor,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00964942,0.00968678259604168,3.736259604167867e-05
10.0,663.0,507.0,0.015083,0.015083,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Study by Sponsor,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.03216402,0.03203812918692463,0.00012589081307537442
5.0,663.0,507.0,0.007541,0.007541,6.498282,0.328159,1.0,685.0,9.0,358.0,Termination of Study by Sponsor,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.01608094,0.01616680721215279,8.586721215279175e-05
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Informed Consent Recalled by Participant,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032157838125000103,2.3812500010451237e-08
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Informed Consent Recalled by Participant,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Informed Consent Recalled by Participant,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Investigator Closed Study at Site,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032157838125000103,2.3812500010451237e-08
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Investigator Closed Study at Site,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Investigator Closed Study at Site,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00321576,0.0032153990307142956,3.6096928570424763e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closed,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closing and Withdrew Consent,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00321576,0.0032157838125000103,2.3812500010451237e-08
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closing and Withdrew Consent,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Site Closing and Withdrew Consent,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.00321544882250001,3.111774999897676e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Unable to Complete Follow-up,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Unable to Complete Follow-up,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00321576,0.0032153990307142956,3.6096928570424763e-07
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Unable to Complete Follow-up,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,663.0,507.0,0.0,0.0,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing Follow-up Status,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing Follow-up Status,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00321576,0.0032153990307142956,3.6096928570424763e-07
1.0,663.0,507.0,0.001508,0.001508,6.498282,0.328159,1.0,685.0,9.0,358.0,Missing Follow-up Status,Follow-up Period (FUP) (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00321576,0.00321544882250001,3.111774999897676e-07
2.0,203.0,193.0,0.009852,0.009852,5.31812,0.256675,1.0,203.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01344825,0.013399892240853174,4.835775914682587e-05
2.0,203.0,193.0,0.009852,0.009852,5.31812,0.256675,1.0,203.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01344825,0.013410741867460316,3.750813253968442e-05
1.0,203.0,193.0,0.004926,0.004926,5.31812,0.256675,1.0,203.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00672413,0.00672637722394119,2.247223941189737e-06
0.0,203.0,193.0,0.0,0.0,5.31812,0.256675,1.0,203.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,203.0,193.0,0.014778,0.014778,5.31812,0.256675,1.0,203.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02017238,0.02080376198050596,0.0006313819805059614
0.0,203.0,193.0,0.0,0.0,5.31812,0.256675,1.0,203.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,203.0,193.0,0.004926,0.004926,5.31812,0.256675,1.0,203.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00672413,0.006726230328345951,2.1003283459507943e-06
0.0,203.0,193.0,0.0,0.0,5.31812,0.256675,1.0,203.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,203.0,193.0,0.004926,0.004926,5.31812,0.256675,1.0,203.0,1.0,1.0,Personal matter,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00672413,0.006724413778107856,2.83778107856153e-07
0.0,203.0,193.0,0.0,0.0,5.31812,0.256675,1.0,203.0,1.0,1.0,Personal matter,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
20.0,505.0,422.0,0.039604,0.039604,6.226537,0.217379,1.0,505.0,12.0,69.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05360486,0.0548502209822024,0.0012453609822024037
0.0,505.0,422.0,0.0,0.0,6.226537,0.217379,1.0,505.0,12.0,69.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,505.0,422.0,0.027723,0.027723,6.226537,0.217379,1.0,505.0,12.0,69.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03752367,0.03719785924709325,0.0003258107529067536
12.0,505.0,422.0,0.023762,0.023762,6.226537,0.217379,1.0,505.0,12.0,69.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03216237,0.03229686913874013,0.00013449913874012676
13.0,505.0,422.0,0.025743,0.025743,6.226537,0.217379,1.0,505.0,12.0,69.0,Patient Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0348437,0.03485986869318454,1.616869318454145e-05
6.0,505.0,422.0,0.011881,0.011881,6.226537,0.217379,1.0,505.0,12.0,69.0,Patient Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01608119,0.016072126750744046,9.06324925595281e-06
5.0,505.0,422.0,0.009901,0.009901,6.226537,0.217379,1.0,505.0,12.0,69.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01340121,0.013611985631676595,0.00021077563167659456
3.0,505.0,422.0,0.005941,0.005941,6.226537,0.217379,1.0,505.0,12.0,69.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00804127,0.008026947526845258,1.4322473154741722e-05
2.0,505.0,422.0,0.00396,0.00396,6.226537,0.217379,1.0,505.0,12.0,69.0,Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00535994,0.0053393138188789655,2.062618112103412e-05
2.0,505.0,422.0,0.00396,0.00396,6.226537,0.217379,1.0,505.0,12.0,69.0,Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00535994,0.005344598558878965,1.5341441121034978e-05
2.0,505.0,422.0,0.00396,0.00396,6.226537,0.217379,1.0,505.0,12.0,69.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00535994,0.005339182593878965,2.075740612103496e-05
1.0,505.0,422.0,0.00198,0.00198,6.226537,0.217379,1.0,505.0,12.0,69.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00267997,0.0027267379004166682,4.6767900416668385e-05
0.0,505.0,422.0,0.0,0.0,6.226537,0.217379,1.0,505.0,12.0,69.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,505.0,422.0,0.005941,0.005941,6.226537,0.217379,1.0,505.0,12.0,69.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00804127,0.008029987922380973,1.1282077619027137e-05
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00582576,0.005829641679583348,3.881679583347779e-06
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00582576,0.005825230576121046,5.294238789544867e-07
5.0,461.0,386.0,0.010846,0.010846,6.135565,0.437762,1.0,461.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02913147,0.02921296743844244,8.14974384424419e-05
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00582576,0.005825946806875013,1.868068750130944e-07
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Excluded medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Excluded medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Excluded medication,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00582576,0.005825076624761918,6.833752380823802e-07
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,461.0,386.0,0.004338,0.004338,6.135565,0.437762,1.0,461.0,0.0,0.0,Hyperglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01165151,0.011649682617460315,1.8273825396850768e-06
7.0,461.0,386.0,0.015184,0.015184,6.135565,0.437762,1.0,461.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04078298,0.04089078008840279,0.00010780008840278327
11.0,461.0,386.0,0.023861,0.023861,6.135565,0.437762,1.0,461.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06408869,0.0641651239385633,7.643393856329728e-05
7.0,461.0,386.0,0.015184,0.015184,6.135565,0.437762,1.0,461.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04078298,0.040816252390863096,3.327239086309275e-05
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00582576,0.00582736185604168,1.6018560416797625e-06
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00582576,0.0058220432119543775,3.716788045622643e-06
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00582576,0.005825076624761918,6.833752380823802e-07
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00582576,0.005825076624761918,6.833752380823802e-07
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00582576,0.00582223215403771,3.527845962290367e-06
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Study site terminated by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00582576,0.00582736185604168,1.6018560416797625e-06
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Study site terminated by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Study site terminated by sponsor,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00582576,0.005825076624761918,6.833752380823802e-07
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Participant moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,461.0,386.0,0.0,0.0,6.135565,0.437762,1.0,461.0,0.0,0.0,Participant moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,461.0,386.0,0.002169,0.002169,6.135565,0.437762,1.0,461.0,0.0,0.0,Participant moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00582576,0.005825076624761918,6.833752380823802e-07
8.0,461.0,386.0,0.017354,0.017354,6.135565,0.437762,1.0,461.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04661142,0.0466086967691766,2.723230823398204e-06
10.0,461.0,386.0,0.021692,0.021692,6.135565,0.437762,1.0,461.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05826294,0.05912463894485118,0.0008616989448511775
13.0,461.0,386.0,0.0282,0.0282,6.135565,0.437762,1.0,461.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07574289,0.0740045071462933,0.0017383828537066992
4.0,319.0,292.0,0.012539,0.012539,5.768321,0.273859,1.0,319.0,13.0,92.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01980796,0.020044526010039684,0.00023656601003968492
5.0,319.0,292.0,0.015674,0.015674,5.768321,0.273859,1.0,319.0,13.0,92.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02476035,0.02513756613444446,0.0003772161344444587
2.0,319.0,292.0,0.00627,0.00627,5.768321,0.273859,1.0,319.0,13.0,92.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00990477,0.009960323127906708,5.555312790670765e-05
1.0,319.0,292.0,0.003135,0.003135,5.768321,0.273859,1.0,319.0,13.0,92.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00495239,0.005073408587224033,0.00012101858722403293
5.0,319.0,292.0,0.015674,0.015674,5.768321,0.273859,1.0,319.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02476035,0.0250829533781151,0.0003226033781150994
3.0,319.0,292.0,0.009404,0.009404,5.768321,0.273859,1.0,319.0,13.0,92.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01485558,0.014969684192698389,0.00011410419269838878
3.0,319.0,292.0,0.009404,0.009404,5.768321,0.273859,1.0,319.0,13.0,92.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01485558,0.014982383625317442,0.0001268036253174419
0.0,319.0,292.0,0.0,0.0,5.768321,0.273859,1.0,319.0,13.0,92.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,319.0,292.0,0.00627,0.00627,5.768321,0.273859,1.0,319.0,13.0,92.0,Personal and Familial Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00990477,0.0099586480372817,5.3878037281700555e-05
2.0,319.0,292.0,0.00627,0.00627,5.768321,0.273859,1.0,319.0,13.0,92.0,Personal and Familial Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00990477,0.009957894933055517,5.312493305551641e-05
12.0,451.0,365.0,0.026608,0.026608,6.113682,0.342728,1.0,451.0,9.0,86.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05575258,0.05518068843281743,0.0005718915671825697
3.0,451.0,365.0,0.006652,0.006652,6.113682,0.342728,1.0,451.0,9.0,86.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01393815,0.01384270346215278,9.544653784722065e-05
8.0,451.0,365.0,0.017738,0.017738,6.113682,0.342728,1.0,451.0,9.0,86.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03716699,0.03635046495281562,0.0008165250471843799
7.0,451.0,365.0,0.015521,0.015521,6.113682,0.342728,1.0,451.0,9.0,86.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03252164,0.032309042375843255,0.00021259762415674205
12.0,451.0,365.0,0.026608,0.026608,6.113682,0.342728,1.0,451.0,9.0,86.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05575258,0.055233133695496,0.0005194463045040051
37.0,451.0,365.0,0.08204,0.08204,6.113682,0.342728,1.0,451.0,9.0,86.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.171901,0.17263970744816462,0.0007387074481646216
3.0,451.0,365.0,0.006652,0.006652,6.113682,0.342728,1.0,451.0,9.0,86.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01393815,0.013790500583452402,0.0001476494165475982
4.0,451.0,365.0,0.008869,0.008869,6.113682,0.342728,1.0,451.0,9.0,86.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0185835,0.018582324252638893,1.175747361106122e-06
24.0,1085.0,990.0,0.02212,0.02212,6.990257,0.742015,1.0,1085.0,8.0,180.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.1147337,0.11249059635056544,0.002243103649434558
20.0,1085.0,990.0,0.018433,0.018433,6.990257,0.742015,1.0,1085.0,8.0,180.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09560969,0.09717623042458333,0.001566540424583332
14.0,1085.0,990.0,0.012903,0.012903,6.990257,0.742015,1.0,1085.0,8.0,180.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06692626,0.0681231061722917,0.0011968461722916962
19.0,1085.0,990.0,0.017512,0.017512,6.990257,0.742015,1.0,1085.0,8.0,180.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09083258,0.0909092548380574,7.667483805740005e-05
3.0,1085.0,990.0,0.002765,0.002765,6.990257,0.742015,1.0,1085.0,8.0,180.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01434171,0.01433107332969247,1.0636670307531335e-05
5.0,1085.0,990.0,0.004608,0.004608,6.990257,0.742015,1.0,1085.0,8.0,180.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02390113,0.023773066693630943,0.0001280633063690563
3.0,1085.0,990.0,0.002765,0.002765,6.990257,0.742015,1.0,1085.0,8.0,180.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01434171,0.014321776600317472,1.993339968252815e-05
6.0,1085.0,990.0,0.00553,0.00553,6.990257,0.742015,1.0,1085.0,8.0,180.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02868343,0.02868148125530758,1.9487446924204566e-06
1.0,1085.0,990.0,0.000922,0.000922,6.990257,0.742015,1.0,1085.0,8.0,180.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0047823,0.004745246157718253,3.705384228174652e-05
0.0,1085.0,990.0,0.0,0.0,6.990257,0.742015,1.0,1085.0,8.0,180.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,3297.0,3232.0,0.00364,0.00364,8.101072,0.423956,1.0,3297.0,21.0,253.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01250157,0.012797906668571425,0.0002963366685714251
6.0,3297.0,3232.0,0.00182,0.00182,8.101072,0.423956,1.0,3297.0,21.0,253.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00625079,0.00639266630464286,0.0001418763046428604
16.0,3297.0,3232.0,0.004853,0.004853,8.101072,0.423956,1.0,3297.0,21.0,253.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01666762,0.016744402099255953,7.678209925595161e-05
16.0,3297.0,3232.0,0.004853,0.004853,8.101072,0.423956,1.0,3297.0,21.0,253.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01666762,0.016734711858005947,6.709185800594583e-05
2.0,3297.0,3232.0,0.000607,0.000607,8.101072,0.423956,1.0,3297.0,21.0,253.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00208474,0.0021243548241567482,3.961482415674837e-05
5.0,3297.0,3232.0,0.001517,0.001517,8.101072,0.423956,1.0,3297.0,21.0,253.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00521013,0.005361159788373014,0.00015102978837301401
4.0,3297.0,3232.0,0.001213,0.001213,8.101072,0.423956,1.0,3297.0,21.0,253.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00416605,0.004195504040982146,2.9454040982145567e-05
4.0,3297.0,3232.0,0.001213,0.001213,8.101072,0.423956,1.0,3297.0,21.0,253.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00416605,0.004191916278065479,2.5866278065478886e-05
83.0,1905.0,1607.0,0.04357,0.04357,7.552762,0.212734,1.0,4717.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07000523,0.07233822403914679,0.002332994039146788
91.0,1905.0,1607.0,0.047769,0.047769,7.552762,0.212734,1.0,4717.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07675189,0.08108654690445433,0.004334656904454323
36.0,1905.0,1607.0,0.018898,0.018898,7.552762,0.212734,1.0,4717.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03036399,0.029826856675494243,0.0005371333245057577
34.0,1905.0,1607.0,0.017848,0.017848,7.552762,0.212734,1.0,4717.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02867692,0.02899315477586309,0.0003162347758630876
8.0,1905.0,1607.0,0.004199,0.004199,7.552762,0.212734,1.0,4717.0,0.0,0.0,Mostly Lost to Follow Up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00674666,0.006748696548402775,2.036548402774979e-06
13.0,1905.0,1607.0,0.006824,0.006824,7.552762,0.212734,1.0,4717.0,0.0,0.0,Mostly Lost to Follow Up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01096433,0.010998709095734128,3.437909573412827e-05
17.0,1905.0,1607.0,0.008924,0.008924,7.552762,0.212734,1.0,4717.0,0.0,0.0,Patient Moving,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01433846,0.014415109480695333,7.664948069533231e-05
16.0,1905.0,1607.0,0.008399,0.008399,7.552762,0.212734,1.0,4717.0,0.0,0.0,Patient Moving,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01349493,0.013796068687242957,0.0003011386872429564
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.01707219,0.017025487881964375,4.670211803562557e-05
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.00853609,0.008629701236309583,9.36112363095834e-05
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Non-compliance with protocol by the subject,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.00853609,0.008519866049107204,1.6223950892796032e-05
9.0,660.0,210.0,0.013636,0.013636,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.07683048,0.07641733960761915,0.0004131403923808563
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.01707219,0.017032384695654844,3.980530434515711e-05
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.01707219,0.017025487881964375,4.670211803562557e-05
9.0,660.0,210.0,0.013636,0.013636,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.07683048,0.07634521935404773,0.000485260645952279
3.0,660.0,210.0,0.004545,0.004545,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.02560828,0.024849027228720257,0.0007592527712797434
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the investigator/sponsor,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,660.0,210.0,0.013636,0.013636,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.07683048,0.07638606938113102,0.00044441061886899
17.0,660.0,210.0,0.025758,0.025758,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.14513049,0.1459314760125893,0.0008009860125892942
8.0,660.0,210.0,0.012121,0.012121,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.06829438,0.0691521458543055,0.0008577658543054978
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,660.0,210.0,0.007576,0.007576,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.0426861,0.0425050003866665,0.0001810996133334991
19.0,660.0,210.0,0.028788,0.028788,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.16220268,0.16140234689001987,0.0008003331099801225
7.0,660.0,210.0,0.010606,0.010606,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.05975829,0.05947998212262186,0.00027830787737814083
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,660.0,210.0,0.013636,0.013636,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG000,diabetes type 2,INDUSTRY,0.07683048,0.07645501597738102,0.00037546402261898204
18.0,660.0,210.0,0.027273,0.027273,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG001,diabetes type 2,INDUSTRY,0.15366659,0.15357981388353176,8.677611646823458e-05
5.0,660.0,210.0,0.007576,0.007576,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG002,diabetes type 2,INDUSTRY,0.0426861,0.04252076693681531,0.00016533306318469027
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Main Study (Up to Wk 96),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.00853609,0.008545590416190548,9.50041619054813e-06
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Protocol Violation,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.00853609,0.00853698052452389,8.905245238895187e-07
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.00853609,0.008538002212023886,1.9122120238860424e-06
1.0,660.0,210.0,0.001515,0.001515,6.493754,0.867662,1.0,660.0,8.0,138.0,Adverse Event,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.00853609,0.008538002212023886,1.9122120238860424e-06
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,660.0,210.0,0.004545,0.004545,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.02560828,0.024970160546458352,0.0006381194535416482
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Decision by the Investigator/Sponsor,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.01707219,0.01699598297291674,7.620702708326099e-05
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,660.0,210.0,0.007576,0.007576,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.0426861,0.04256974073568432,0.00011635926431567689
10.0,660.0,210.0,0.015152,0.015152,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.0853722,0.085815943455744,0.0004437434557440084
5.0,660.0,210.0,0.007576,0.007576,6.493754,0.867662,1.0,660.0,8.0,138.0,Withdrawal by Subject,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.0426861,0.042577893481934324,0.00010820651806567327
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,660.0,210.0,0.004545,0.004545,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.02560828,0.02503938969532741,0.0005688903046725917
6.0,660.0,210.0,0.009091,0.009091,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.0512222,0.05035363499001361,0.0008685650099863954
6.0,660.0,210.0,0.009091,0.009091,6.493754,0.867662,1.0,660.0,8.0,138.0,Lost to Follow-up,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.0512222,0.05038638446709695,0.0008358155329030517
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,660.0,210.0,0.0,0.0,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG003,diabetes type 2,INDUSTRY,0.01707219,0.016973169438869107,9.90205611308935e-05
7.0,660.0,210.0,0.010606,0.010606,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG004,diabetes type 2,INDUSTRY,0.05975829,0.05956721405908019,0.00019107594091980623
2.0,660.0,210.0,0.00303,0.00303,6.493754,0.867662,1.0,660.0,8.0,138.0,Death,Extension Phase (Wk 96 to Wk 156),FG005,diabetes type 2,INDUSTRY,0.01707219,0.016981535233869118,9.065476613088347e-05
4.0,1225.0,1163.0,0.003265,0.003265,7.111512,0.408641,1.0,1231.0,18.0,141.0,unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00948826,0.009589689652321426,0.00010142965232142614
5.0,1225.0,1163.0,0.004082,0.004082,7.111512,0.408641,1.0,1231.0,18.0,141.0,unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0118625,0.011774425739781753,8.807426021824674e-05
3.0,1225.0,1163.0,0.002449,0.002449,7.111512,0.408641,1.0,1231.0,18.0,141.0,unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00711692,0.0071434408899702425,2.652088997024283e-05
2.0,1225.0,1163.0,0.001633,0.001633,7.111512,0.408641,1.0,1231.0,18.0,141.0,Missing follow-up information,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00474558,0.004745068420416681,5.115795833187525e-07
2.0,1225.0,1163.0,0.001633,0.001633,7.111512,0.408641,1.0,1231.0,18.0,141.0,Missing follow-up information,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00474558,0.004741431244642873,4.148755357127366e-06
3.0,1225.0,1163.0,0.002449,0.002449,7.111512,0.408641,1.0,1231.0,18.0,141.0,Missing follow-up information,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00711692,0.0071434408899702425,2.652088997024283e-05
5.0,1225.0,1163.0,0.004082,0.004082,7.111512,0.408641,1.0,1231.0,18.0,141.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0118625,0.011795808823144847,6.669117685515272e-05
2.0,1225.0,1163.0,0.001633,0.001633,7.111512,0.408641,1.0,1231.0,18.0,141.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00474558,0.004736446593273825,9.13340672617502e-06
2.0,1225.0,1163.0,0.001633,0.001633,7.111512,0.408641,1.0,1231.0,18.0,141.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00474558,0.004737044039523825,8.535960476174775e-06
2.0,1225.0,1163.0,0.001633,0.001633,7.111512,0.408641,1.0,1231.0,18.0,141.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00474558,0.0047495475212500134,3.967521250013324e-06
1.0,1225.0,1163.0,0.000816,0.000816,7.111512,0.408641,1.0,1231.0,18.0,141.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00237134,0.002519923396507937,0.00014858339650793704
3.0,1225.0,1163.0,0.002449,0.002449,7.111512,0.408641,1.0,1231.0,18.0,141.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00711692,0.0071434408899702425,2.652088997024283e-05
9.0,1225.0,1163.0,0.007347,0.007347,7.111512,0.408641,1.0,1231.0,18.0,141.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02135076,0.02062011676070436,0.0007306432392956384
11.0,1225.0,1163.0,0.00898,0.00898,7.111512,0.408641,1.0,1231.0,18.0,141.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02609635,0.02485171339358585,0.0012446366064141519
8.0,1225.0,1163.0,0.006531,0.006531,7.111512,0.408641,1.0,1231.0,18.0,141.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01897942,0.01870169398681548,0.0002777260131845219
13.0,301.0,246.0,0.043189,0.043189,5.710427,0.321222,1.0,310.0,6.0,331.0,Adverse Event,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.07922229,0.08042569925471231,0.0012034092547123093
11.0,301.0,246.0,0.036545,0.036545,5.710427,0.321222,1.0,310.0,6.0,331.0,Adverse Event,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.06703509,0.06724245941080356,0.00020736941080355675
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Protocol Violation,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01828263,0.0182926967041964,1.0066704196398657e-05
6.0,301.0,246.0,0.019934,0.019934,5.710427,0.321222,1.0,310.0,6.0,331.0,Protocol Violation,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03656526,0.03744780393145831,0.0008825439314583058
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Noncompliance,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01828263,0.01830446240586306,2.1832405863057847e-05
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Noncompliance,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01828263,0.018311766651279707,2.91366512797063e-05
7.0,301.0,246.0,0.023256,0.023256,5.710427,0.321222,1.0,310.0,6.0,331.0,Lost to Follow-up,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.04265886,0.04356891732579366,0.0009100573257936617
5.0,301.0,246.0,0.016611,0.016611,5.710427,0.321222,1.0,310.0,6.0,331.0,Lost to Follow-up,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03046983,0.030897782678998,0.000427952678997999
31.0,301.0,246.0,0.10299,0.10299,5.710427,0.321222,1.0,310.0,6.0,331.0,Withdrawal by Subject,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.18891624,0.1906677867569046,0.0017515467569045873
18.0,301.0,246.0,0.059801,0.059801,5.710427,0.321222,1.0,310.0,6.0,331.0,Withdrawal by Subject,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.10969395,0.10836848225946406,0.001325467740535935
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Physician Decision,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.01828263,0.0182943668979464,1.1736897946399566e-05
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Physician Decision,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01828263,0.01830167114336305,1.904114336304802e-05
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Termination of Study/Site by GSK,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006095853562202368,2.2535622023677968e-06
4.0,301.0,246.0,0.013289,0.013289,5.710427,0.321222,1.0,310.0,6.0,331.0,Termination of Study/Site by GSK,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.02437623,0.02442781038882931,5.1580388829311485e-05
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Calcitonin Out of Range,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006095853562202368,2.2535622023677968e-06
0.0,301.0,246.0,0.0,0.0,5.710427,0.321222,1.0,310.0,6.0,331.0,Calcitonin Out of Range,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Pregnancy,Treatment Period (TP) (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006095774794702368,2.1747947023679007e-06
0.0,301.0,246.0,0.0,0.0,5.710427,0.321222,1.0,310.0,6.0,331.0,Pregnancy,Treatment Period (TP) (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Adverse Event,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006092176735952366,1.4232640476339806e-06
3.0,301.0,246.0,0.009967,0.009967,5.710427,0.321222,1.0,310.0,6.0,331.0,Adverse Event,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01828263,0.018300974944196396,1.834494419639468e-05
0.0,301.0,246.0,0.0,0.0,5.710427,0.321222,1.0,310.0,6.0,331.0,Noncompliance,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Noncompliance,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0060936,0.006098479950952366,4.879950952365632e-06
14.0,301.0,246.0,0.046512,0.046512,5.710427,0.321222,1.0,310.0,6.0,331.0,Lost to Follow-up,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.08531772,0.08618280859440468,0.0008650885944046782
9.0,301.0,246.0,0.0299,0.0299,5.710427,0.321222,1.0,310.0,6.0,331.0,Lost to Follow-up,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.05484606,0.0552251629534523,0.0003791029534522955
9.0,301.0,246.0,0.0299,0.0299,5.710427,0.321222,1.0,310.0,6.0,331.0,Withdrawal by Subject,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.05484606,0.05527866689209317,0.0004326068920931653
7.0,301.0,246.0,0.023256,0.023256,5.710427,0.321222,1.0,310.0,6.0,331.0,Withdrawal by Subject,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.04265886,0.04363984949600199,0.000980989496001991
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Physician Decision,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006092840706785699,7.592932143012793e-07
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Physician Decision,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0060936,0.006098404934285699,4.804934285698899e-06
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Termination of Study/Site by GSK,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006092915723452366,6.842765476345464e-07
4.0,301.0,246.0,0.013289,0.013289,5.710427,0.321222,1.0,310.0,6.0,331.0,Termination of Study/Site by GSK,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.02437623,0.02442781038882931,5.1580388829311485e-05
1.0,301.0,246.0,0.003322,0.003322,5.710427,0.321222,1.0,310.0,6.0,331.0,Early Termination,Follow-up Period (FUP) (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0060936,0.006092915723452366,6.842765476345464e-07
0.0,301.0,246.0,0.0,0.0,5.710427,0.321222,1.0,310.0,6.0,331.0,Early Termination,Follow-up Period (FUP) (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,741.0,646.0,0.002699,0.002699,6.609349,0.307494,1.0,741.0,15.0,127.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00548527,0.005468395279811511,1.687472018848963e-05
0.0,741.0,646.0,0.0,0.0,6.609349,0.307494,1.0,741.0,15.0,127.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,741.0,646.0,0.00135,0.00135,6.609349,0.307494,1.0,741.0,15.0,127.0,Not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00274365,0.002744852287110387,1.202287110387175e-06
18.0,741.0,646.0,0.024291,0.024291,6.609349,0.307494,1.0,741.0,15.0,127.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04936745,0.049560674126984165,0.00019322412698416502
4.0,741.0,646.0,0.005398,0.005398,6.609349,0.307494,1.0,741.0,15.0,127.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01097055,0.011005539576507937,3.4989576507936035e-05
21.0,741.0,646.0,0.02834,0.02834,6.609349,0.307494,1.0,741.0,15.0,127.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05759638,0.0579140353267361,0.00031765532673609653
0.0,741.0,646.0,0.0,0.0,6.609349,0.307494,1.0,741.0,15.0,127.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,646.0,0.0,0.0,6.609349,0.307494,1.0,741.0,15.0,127.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,741.0,646.0,0.00135,0.00135,6.609349,0.307494,1.0,741.0,15.0,127.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00274365,0.002744852287110387,1.202287110387175e-06
1.0,741.0,646.0,0.00135,0.00135,6.609349,0.307494,1.0,741.0,15.0,127.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00274365,0.0027444019985119017,7.51998511901858e-07
1.0,741.0,646.0,0.00135,0.00135,6.609349,0.307494,1.0,741.0,15.0,127.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00274365,0.0027447021135119016,1.0521135119017852e-06
4.0,741.0,646.0,0.005398,0.005398,6.609349,0.307494,1.0,741.0,15.0,127.0,Non compliant with protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01097055,0.010994220634424614,2.367063442461348e-05
3.0,741.0,646.0,0.004049,0.004049,6.609349,0.307494,1.0,741.0,15.0,127.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00822893,0.00816662398396825,6.23060160317504e-05
0.0,741.0,646.0,0.0,0.0,6.609349,0.307494,1.0,741.0,15.0,127.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,741.0,646.0,0.004049,0.004049,6.609349,0.307494,1.0,741.0,15.0,127.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00822893,0.00819403896057539,3.4891039424609846e-05
10.0,741.0,646.0,0.013495,0.013495,6.609349,0.307494,1.0,741.0,15.0,127.0,"Patient refusal to continue,not due toAE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.02742636,0.027453647617251963,2.7287617251962187e-05
4.0,741.0,646.0,0.005398,0.005398,6.609349,0.307494,1.0,741.0,15.0,127.0,"Patient refusal to continue,not due toAE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01097055,0.01098670327775794,1.6153277757939566e-05
8.0,741.0,646.0,0.010796,0.010796,6.609349,0.307494,1.0,741.0,15.0,127.0,"Patient refusal to continue,not due toAE",Overall Study,FG002,diabetes type 2,INDUSTRY,0.02194109,0.021823586317480142,0.00011750368251985804
9.0,741.0,646.0,0.012146,0.012146,6.609349,0.307494,1.0,741.0,15.0,127.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02468474,0.024662163137450403,2.2576862549597565e-05
1.0,741.0,646.0,0.00135,0.00135,6.609349,0.307494,1.0,741.0,15.0,127.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00274365,0.0027447021135119016,1.0521135119017852e-06
4.0,741.0,646.0,0.005398,0.005398,6.609349,0.307494,1.0,741.0,15.0,127.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01097055,0.010994220634424614,2.367063442461348e-05
5.0,442.0,367.0,0.011312,0.011312,6.09357,0.342728,1.0,442.0,11.0,146.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02362442,0.02353181212101193,9.260787898807132e-05
7.0,442.0,367.0,0.015837,0.015837,6.09357,0.342728,1.0,442.0,11.0,146.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0330746,0.0327887332941964,0.00028586670580360574
0.0,442.0,367.0,0.0,0.0,6.09357,0.342728,1.0,442.0,11.0,146.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,442.0,367.0,0.002262,0.002262,6.09357,0.342728,1.0,442.0,11.0,146.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00472405,0.004847145781150794,0.00012309578115079437
2.0,442.0,367.0,0.004525,0.004525,6.09357,0.342728,1.0,442.0,11.0,146.0,Investigator's Discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00945018,0.009552158601755957,0.00010197860175595666
2.0,442.0,367.0,0.004525,0.004525,6.09357,0.342728,1.0,442.0,11.0,146.0,Investigator's Discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00945018,0.00953232272616072,8.214272616071869e-05
4.0,442.0,367.0,0.00905,0.00905,6.09357,0.342728,1.0,442.0,11.0,146.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01890037,0.018823681956468257,7.668804353174255e-05
3.0,442.0,367.0,0.006787,0.006787,6.09357,0.342728,1.0,442.0,11.0,146.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01417423,0.01412496740702381,4.926259297619029e-05
9.0,442.0,367.0,0.020362,0.020362,6.09357,0.342728,1.0,442.0,11.0,146.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04252478,0.04282498875562501,0.0003002087556250102
5.0,442.0,367.0,0.011312,0.011312,6.09357,0.342728,1.0,442.0,11.0,146.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02362442,0.023505176987619066,0.0001192430123809346
14.0,442.0,367.0,0.031674,0.031674,6.09357,0.342728,1.0,442.0,11.0,146.0,Subject Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0661492,0.066026478622638,0.00012272137736200894
6.0,442.0,367.0,0.013575,0.013575,6.09357,0.342728,1.0,442.0,11.0,146.0,Subject Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02835055,0.028276663148978174,7.388685102182463e-05
6.0,442.0,367.0,0.013575,0.013575,6.09357,0.342728,1.0,442.0,11.0,146.0,Subject Withdrew Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02835055,0.028257605807966272,9.294419203372678e-05
11.0,442.0,367.0,0.024887,0.024887,6.09357,0.342728,1.0,442.0,11.0,146.0,Subject Withdrew Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05197497,0.051380189600654734,0.0005947803993452683
1.0,493.0,455.0,0.002028,0.002028,6.202536,0.434965,1.0,493.0,7.0,44.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00547132,0.005495084812976187,2.376481297618714e-05
1.0,493.0,455.0,0.002028,0.002028,6.202536,0.434965,1.0,493.0,7.0,44.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547132,0.005493880571805551,2.2560571805551287e-05
0.0,493.0,455.0,0.0,0.0,6.202536,0.434965,1.0,493.0,7.0,44.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,493.0,455.0,0.002028,0.002028,6.202536,0.434965,1.0,493.0,7.0,44.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547132,0.005494900094305552,2.358009430555169e-05
0.0,493.0,455.0,0.0,0.0,6.202536,0.434965,1.0,493.0,7.0,44.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,493.0,455.0,0.002028,0.002028,6.202536,0.434965,1.0,493.0,7.0,44.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547132,0.005494900094305552,2.358009430555169e-05
2.0,493.0,455.0,0.004057,0.004057,6.202536,0.434965,1.0,493.0,7.0,44.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01094533,0.011082996976382575,0.00013766697638257532
4.0,493.0,455.0,0.008114,0.008114,6.202536,0.434965,1.0,493.0,7.0,44.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02189067,0.021917934818978187,2.7264818978186417e-05
3.0,493.0,455.0,0.006085,0.006085,6.202536,0.434965,1.0,493.0,7.0,44.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01641665,0.01664001150638507,0.0002233615063850676
4.0,493.0,455.0,0.008114,0.008114,6.202536,0.434965,1.0,493.0,7.0,44.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02189067,0.021954945589394863,6.427558939486183e-05
13.0,493.0,455.0,0.026369,0.026369,6.202536,0.434965,1.0,493.0,7.0,44.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07114062,0.06990328037078726,0.0012373396292127414
7.0,493.0,455.0,0.014199,0.014199,6.202536,0.434965,1.0,493.0,7.0,44.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03830732,0.03827617335988094,3.114664011905771e-05
0.0,493.0,455.0,0.0,0.0,6.202536,0.434965,1.0,493.0,7.0,44.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,493.0,455.0,0.002028,0.002028,6.202536,0.434965,1.0,493.0,7.0,44.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00547132,0.005493892819513886,2.257281951388579e-05
0.0,210.0,201.0,0.0,0.0,5.351858,0.763456,1.0,210.0,1.0,29.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,210.0,201.0,0.014286,0.014286,5.351858,0.763456,1.0,210.0,1.0,29.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05837127,0.05992588408500002,0.0015546140850000167
4.0,210.0,201.0,0.019048,0.019048,5.351858,0.763456,1.0,210.0,1.0,29.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.07782835,0.0823376749762401,0.004509324976240098
0.0,210.0,201.0,0.0,0.0,5.351858,0.763456,1.0,210.0,1.0,29.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,201.0,0.004762,0.004762,5.351858,0.763456,1.0,210.0,1.0,29.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01945709,0.019392243025922677,6.484697407732262e-05
0.0,210.0,201.0,0.0,0.0,5.351858,0.763456,1.0,210.0,1.0,29.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,210.0,201.0,0.004762,0.004762,5.351858,0.763456,1.0,210.0,1.0,29.0,Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01945709,0.019381774578839342,7.531542116065784e-05
0.0,210.0,201.0,0.0,0.0,5.351858,0.763456,1.0,210.0,1.0,29.0,Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,210.0,201.0,0.0,0.0,5.351858,0.763456,1.0,210.0,1.0,29.0,Protocol Deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,311.0,277.0,0.016077,0.016077,5.743003,0.256675,1.0,311.0,4.0,4.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02369885,0.023736845013125004,3.799501312500356e-05
14.0,311.0,277.0,0.045016,0.045016,5.743003,0.256675,1.0,311.0,4.0,4.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06635738,0.06646930896175589,0.0001119289617558944
2.0,311.0,277.0,0.006431,0.006431,5.743003,0.256675,1.0,311.0,4.0,4.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00947984,0.00971616599389883,0.00023632599389883033
1.0,311.0,277.0,0.003215,0.003215,5.743003,0.256675,1.0,311.0,4.0,4.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00473918,0.0047381908469345336,9.891530654664027e-07
1.0,311.0,277.0,0.003215,0.003215,5.743003,0.256675,1.0,311.0,4.0,4.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00473918,0.004733514188244054,5.665811755945632e-06
0.0,311.0,277.0,0.0,0.0,5.743003,0.256675,1.0,311.0,4.0,4.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,311.0,277.0,0.003215,0.003215,5.743003,0.256675,1.0,311.0,4.0,4.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00473918,0.004732579724077389,6.600275922610983e-06
1.0,311.0,277.0,0.003215,0.003215,5.743003,0.256675,1.0,311.0,4.0,4.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00473918,0.0047381908469345336,9.891530654664027e-07
4.0,311.0,277.0,0.012862,0.012862,5.743003,0.256675,1.0,311.0,4.0,4.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01895967,0.019566121979454357,0.0006064519794543553
5.0,311.0,277.0,0.016077,0.016077,5.743003,0.256675,1.0,311.0,4.0,4.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02369885,0.023743309568244057,4.445956824405614e-05
10.0,1210.0,1164.0,0.008264,0.008264,7.099202,0.606435,1.0,1210.0,13.0,147.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0355782,0.03618984853811508,0.0006116485381150796
5.0,1210.0,1164.0,0.004132,0.004132,7.099202,0.606435,1.0,1210.0,13.0,147.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0177891,0.018000560551934518,0.00021146055193451904
12.0,1210.0,1164.0,0.009917,0.009917,7.099202,0.606435,1.0,1210.0,13.0,147.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0426947,0.04332471132188491,0.0006300113218849074
2.0,1210.0,1164.0,0.001653,0.001653,7.099202,0.606435,1.0,1210.0,13.0,147.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0071165,0.006969854074692449,0.000146645925307551
7.0,1210.0,1164.0,0.005785,0.005785,7.099202,0.606435,1.0,1210.0,13.0,147.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0249056,0.02483853131946426,6.706868053573886e-05
7.0,1210.0,1164.0,0.005785,0.005785,7.099202,0.606435,1.0,1210.0,13.0,147.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0249056,0.024875003325476173,3.059667452382647e-05
1.0,1210.0,1164.0,0.000826,0.000826,7.099202,0.606435,1.0,1210.0,13.0,147.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0035561,0.003601762396712444,4.5662396712443844e-05
1.0,1210.0,1164.0,0.000826,0.000826,7.099202,0.606435,1.0,1210.0,13.0,147.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035561,0.0035896059601785634,3.3505960178563474e-05
1.0,1210.0,1164.0,0.000826,0.000826,7.099202,0.606435,1.0,1210.0,13.0,147.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0035561,0.0035881715446428476,3.2071544642847585e-05
0.0,531.0,484.0,0.0,0.0,6.276643,0.388308,1.0,531.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,531.0,484.0,0.00565,0.00565,6.276643,0.388308,1.0,531.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01377059,0.013996208478055558,0.00022561847805555903
1.0,531.0,484.0,0.001883,0.001883,6.276643,0.388308,1.0,531.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458938,0.004586891101656769,2.4888983432306763e-06
1.0,531.0,484.0,0.001883,0.001883,6.276643,0.388308,1.0,531.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00458938,0.0045911984162401,1.8184162401003318e-06
9.0,531.0,484.0,0.016949,0.016949,6.276643,0.388308,1.0,531.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04130932,0.04215137335084325,0.0008420533508432526
8.0,531.0,484.0,0.015066,0.015066,6.276643,0.388308,1.0,531.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03671994,0.03675394799908726,3.400799908725993e-05
1.0,531.0,484.0,0.001883,0.001883,6.276643,0.388308,1.0,531.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458938,0.0046017413182043885,1.236131820438885e-05
0.0,531.0,484.0,0.0,0.0,6.276643,0.388308,1.0,531.0,0.0,0.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,531.0,484.0,0.001883,0.001883,6.276643,0.388308,1.0,531.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458938,0.004603779928204388,1.439992820438836e-05
2.0,531.0,484.0,0.003766,0.003766,6.276643,0.388308,1.0,531.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00917877,0.009370464506488086,0.00019169450648808678
1.0,531.0,484.0,0.001883,0.001883,6.276643,0.388308,1.0,531.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458938,0.004599692125704387,1.0312125704387172e-05
0.0,531.0,484.0,0.0,0.0,6.276643,0.388308,1.0,531.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,531.0,484.0,0.022599,0.022599,6.276643,0.388308,1.0,531.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05507991,0.05497260049433537,0.00010730950566463504
8.0,531.0,484.0,0.015066,0.015066,6.276643,0.388308,1.0,531.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03671994,0.03673235606625988,1.2416066259880731e-05
2.0,213.0,170.0,0.00939,0.00939,5.365976,0.418358,1.0,213.0,0.0,0.0,Adverse Event,Phase A,FG000,diabetes type 2,INDUSTRY,0.02107958,0.021168589398442482,8.90093984424814e-05
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Adverse Event,Phase A,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010554462876220298,1.4672876220298003e-05
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Death,Phase A,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010552353858244108,1.2563858244107884e-05
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Death,Phase A,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010552303962886964,1.2513962886963326e-05
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Lack of Efficacy,Phase A,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010549946122827442,1.0156122827441674e-05
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Lack of Efficacy,Phase A,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Lost to Follow-up,Phase A,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010552522569136968,1.273256913696813e-05
2.0,213.0,170.0,0.00939,0.00939,5.365976,0.418358,1.0,213.0,0.0,0.0,Lost to Follow-up,Phase A,FG001,diabetes type 2,INDUSTRY,0.02107958,0.021200569991269867,0.0001209899912698667
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Protocol Violation,Phase A,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010549158316160776,9.368316160775561e-06
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Protocol Violation,Phase A,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,213.0,170.0,0.014085,0.014085,5.365976,0.418358,1.0,213.0,0.0,0.0,Withdrawal by Subject,Phase A,FG000,diabetes type 2,INDUSTRY,0.03161936,0.031679310680338274,5.9950680338274887e-05
4.0,213.0,170.0,0.018779,0.018779,5.365976,0.418358,1.0,213.0,0.0,0.0,Withdrawal by Subject,Phase A,FG001,diabetes type 2,INDUSTRY,0.04215691,0.04176022687941465,0.0003966831205853491
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Kidney [transplant],Phase A,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Kidney [transplant],Phase A,FG001,diabetes type 2,INDUSTRY,0.01053979,0.0105500379324703,1.0247932470300314e-05
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Hyperglycemia Discontinuation Criteria,Phase B,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Hyperglycemia Discontinuation Criteria,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010540565441250071,7.754412500709379e-07
6.0,213.0,170.0,0.028169,0.028169,5.365976,0.418358,1.0,213.0,0.0,0.0,Adverse Event,Phase B,FG000,diabetes type 2,INDUSTRY,0.06323648,0.06366565688567466,0.00042917688567466195
3.0,213.0,170.0,0.014085,0.014085,5.365976,0.418358,1.0,213.0,0.0,0.0,Adverse Event,Phase B,FG001,diabetes type 2,INDUSTRY,0.03161936,0.031709234201231125,8.987420123112572e-05
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Death,Phase B,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Death,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010542772427916737,2.9824279167370987e-06
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Lack of Efficacy,Phase B,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Lack of Efficacy,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010540565441250071,7.754412500709379e-07
0.0,213.0,170.0,0.0,0.0,5.365976,0.418358,1.0,213.0,0.0,0.0,Lost to Follow-up,Phase B,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Lost to Follow-up,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010544141280833405,4.3512808334048025e-06
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Physician Decision,Phase B,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010554166700416732,1.437670041673153e-05
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Physician Decision,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010545965507916734,6.1755079167336024e-06
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Protocol Violation,Phase B,FG000,diabetes type 2,INDUSTRY,0.01053979,0.010548010317083398,8.220317083397488e-06
1.0,213.0,170.0,0.004695,0.004695,5.365976,0.418358,1.0,213.0,0.0,0.0,Protocol Violation,Phase B,FG001,diabetes type 2,INDUSTRY,0.01053979,0.010540585728750072,7.957287500720556e-07
6.0,213.0,170.0,0.028169,0.028169,5.365976,0.418358,1.0,213.0,0.0,0.0,Withdrawal by Subject,Phase B,FG000,diabetes type 2,INDUSTRY,0.06323648,0.06383875395240085,0.000602273952400853
2.0,213.0,170.0,0.00939,0.00939,5.365976,0.418358,1.0,213.0,0.0,0.0,Withdrawal by Subject,Phase B,FG001,diabetes type 2,INDUSTRY,0.02107958,0.021179045415853203,9.946541585320254e-05
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Randomized But Not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00285201,0.002852534466171544,5.244661715440857e-07
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Randomized But Not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00285201,0.002855506824845786,3.4968248457862595e-06
12.0,811.0,629.0,0.014797,0.014797,6.6995,0.34526,1.0,811.0,13.0,213.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03422645,0.03321118172036706,0.0010152682796329415
7.0,811.0,629.0,0.008631,0.008631,6.6995,0.34526,1.0,811.0,13.0,213.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01996408,0.01984240837191472,0.00012167162808527851
2.0,811.0,629.0,0.002466,0.002466,6.6995,0.34526,1.0,811.0,13.0,213.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00570402,0.005685112736458342,1.8907263541657546e-05
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00285201,0.002852154320035175,1.4432003517510922e-07
6.0,811.0,629.0,0.007398,0.007398,6.6995,0.34526,1.0,811.0,13.0,213.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01711207,0.017020352527321408,9.171747267859229e-05
7.0,811.0,629.0,0.008631,0.008631,6.6995,0.34526,1.0,811.0,13.0,213.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01996408,0.019866056599831382,9.802340016861616e-05
32.0,811.0,629.0,0.039457,0.039457,6.6995,0.34526,1.0,811.0,13.0,213.0,Received Rescue Therapy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09126668,0.09059632091001982,0.0006703590899801853
40.0,811.0,629.0,0.049322,0.049322,6.6995,0.34526,1.0,811.0,13.0,213.0,Received Rescue Therapy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11408508,0.11070998715363091,0.003375092846369096
22.0,811.0,629.0,0.027127,0.027127,6.6995,0.34526,1.0,811.0,13.0,213.0,Diverse Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06274656,0.06177894171137896,0.0009676182886210472
25.0,811.0,629.0,0.030826,0.030826,6.6995,0.34526,1.0,811.0,13.0,213.0,Diverse Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0713026,0.07060770600158733,0.0006948939984126601
6.0,811.0,629.0,0.007398,0.007398,6.6995,0.34526,1.0,811.0,13.0,213.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01711207,0.01707852287660712,3.354712339288107e-05
4.0,811.0,629.0,0.004932,0.004932,6.6995,0.34526,1.0,811.0,13.0,213.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01140805,0.011289181597986116,0.00011886840201388339
0.0,811.0,629.0,0.0,0.0,6.6995,0.34526,1.0,811.0,13.0,213.0,Insulin Dropped Below Authorized Dose,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,811.0,629.0,0.006165,0.006165,6.6995,0.34526,1.0,811.0,13.0,213.0,Insulin Dropped Below Authorized Dose,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01426006,0.013956220063362198,0.00030383993663780223
3.0,811.0,629.0,0.003699,0.003699,6.6995,0.34526,1.0,811.0,13.0,213.0,Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00855603,0.008507566954285718,4.8463045714281644e-05
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00285201,0.00285611586942912,4.105869429120185e-06
2.0,811.0,629.0,0.002466,0.002466,6.6995,0.34526,1.0,811.0,13.0,213.0,Diagnosed With Type 1 Diabetes Mellitus,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00570402,0.005688280953402788,1.5739046597212057e-05
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Diagnosed With Type 1 Diabetes Mellitus,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00285201,0.0028560230444291197,4.013044429119865e-06
2.0,811.0,629.0,0.002466,0.002466,6.6995,0.34526,1.0,811.0,13.0,213.0,Change in Injection Schedule,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00570402,0.005688280953402788,1.5739046597212057e-05
0.0,811.0,629.0,0.0,0.0,6.6995,0.34526,1.0,811.0,13.0,213.0,Change in Injection Schedule,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Perceived Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00285201,0.0028529275357548774,9.175357548775465e-07
1.0,811.0,629.0,0.001233,0.001233,6.6995,0.34526,1.0,811.0,13.0,213.0,Perceived Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00285201,0.00285590270692912,3.892706929119975e-06
8.0,596.0,546.0,0.013423,0.013423,6.391917,0.254793,1.0,597.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0218609,0.02171816757232954,0.00014273242767045766
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00819845,0.008198293479434548,1.5652056545127635e-07
2.0,596.0,546.0,0.003356,0.003356,6.391917,0.254793,1.0,597.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00546563,0.00546685988585679,1.2298858567899931e-06
8.0,596.0,546.0,0.013423,0.013423,6.391917,0.254793,1.0,597.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0218609,0.0217347786840359,0.0001261213159640985
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,596.0,546.0,0.001678,0.001678,6.391917,0.254793,1.0,597.0,7.0,66.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00273282,0.0027273810535714273,5.438946428572636e-06
1.0,596.0,546.0,0.001678,0.001678,6.391917,0.254793,1.0,597.0,7.0,66.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00273282,0.002729021404285713,3.7985957142870966e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,596.0,546.0,0.001678,0.001678,6.391917,0.254793,1.0,597.0,7.0,66.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00273282,0.002727720635119048,5.099364880952004e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,596.0,546.0,0.001678,0.001678,6.391917,0.254793,1.0,597.0,7.0,66.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00273282,0.00273017264470238,2.647355297620037e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,596.0,546.0,0.008389,0.008389,6.391917,0.254793,1.0,597.0,7.0,66.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01366245,0.013673363981091275,1.0913981091275476e-05
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00819845,0.00819906414038694,6.14140386941131e-07
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00819845,0.008193569237886939,4.880762113060669e-06
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00819845,0.008204476219553605,6.0262195536054525e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Poor/Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,Poor/Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00819845,0.00818966169401788,8.788305982119007e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Poor/Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Poor/Non-compliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,596.0,546.0,0.003356,0.003356,6.391917,0.254793,1.0,597.0,7.0,66.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00546563,0.005466827888356789,1.1978883567888288e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,Subject No Longer Meets Study Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,596.0,546.0,0.003356,0.003356,6.391917,0.254793,1.0,597.0,7.0,66.0,Subject No Longer Meets Study Criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00546563,0.005470792937106792,5.162937106791866e-06
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,False Treatment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,596.0,546.0,0.001678,0.001678,6.391917,0.254793,1.0,597.0,7.0,66.0,False Treatment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00273282,0.002728196835654761,4.623164345238847e-06
3.0,596.0,546.0,0.005034,0.005034,6.391917,0.254793,1.0,597.0,7.0,66.0,False Treatment,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00819845,0.008184166791517879,1.4283208482120807e-05
0.0,596.0,546.0,0.0,0.0,6.391917,0.254793,1.0,597.0,7.0,66.0,False Treatment,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
29.0,677.0,462.0,0.042836,0.042836,6.519147,0.220602,1.0,677.0,10.0,151.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06160415,0.061202241512509865,0.00040190848749013797
12.0,677.0,462.0,0.017725,0.017725,6.519147,0.220602,1.0,677.0,10.0,151.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02549103,0.02545556741539682,3.546258460318183e-05
6.0,677.0,462.0,0.008863,0.008863,6.519147,0.220602,1.0,677.0,10.0,151.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01274623,0.012760031821378975,1.3801821378974302e-05
22.0,677.0,462.0,0.032496,0.032496,6.519147,0.220602,1.0,677.0,10.0,151.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04673379,0.04637127355814486,0.00036251644185513604
5.0,677.0,462.0,0.007386,0.007386,6.519147,0.220602,1.0,677.0,10.0,151.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0106221,0.01061907272339286,3.0272766071409024e-06
8.0,677.0,462.0,0.011817,0.011817,6.519147,0.220602,1.0,677.0,10.0,151.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0169945,0.017037954998888882,4.345499888888313e-05
6.0,677.0,462.0,0.008863,0.008863,6.519147,0.220602,1.0,677.0,10.0,151.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01274623,0.012744298496617068,1.9315033829327144e-06
3.0,677.0,462.0,0.004431,0.004431,6.519147,0.220602,1.0,677.0,10.0,151.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0063724,0.006401495194107133,2.909519410713296e-05
50.0,677.0,462.0,0.073855,0.073855,6.519147,0.220602,1.0,677.0,10.0,151.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10621381,0.10916463469336297,0.002950824693362969
32.0,677.0,462.0,0.047267,0.047267,6.519147,0.220602,1.0,677.0,10.0,151.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06797655,0.0680545349942956,7.798499429560735e-05
7.0,677.0,462.0,0.01034,0.01034,6.519147,0.220602,1.0,677.0,10.0,151.0,Various,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01487036,0.014996123701319444,0.00012576370131944445
7.0,677.0,462.0,0.01034,0.01034,6.519147,0.220602,1.0,677.0,10.0,151.0,Various,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01487036,0.015005435293015871,0.0001350752930158721
11.0,677.0,462.0,0.016248,0.016248,6.519147,0.220602,1.0,677.0,10.0,151.0,Randomized but not dosed,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02336689,0.023270555893095252,9.633410690474895e-05
12.0,677.0,462.0,0.017725,0.017725,6.519147,0.220602,1.0,677.0,10.0,151.0,Randomized but not dosed,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02549103,0.025472502205396822,1.8527794603179215e-05
4.0,677.0,462.0,0.005908,0.005908,6.519147,0.220602,1.0,677.0,10.0,151.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00849653,0.008488638841001995,7.891158998005188e-06
1.0,677.0,462.0,0.001477,0.001477,6.519147,0.220602,1.0,677.0,10.0,151.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00212413,0.002160556803445167,3.642680344516673e-05
14.0,484.0,348.0,0.028926,0.028926,6.184149,0.279906,1.0,484.0,13.0,150.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05007032,0.050020673492196924,4.964650780307778e-05
29.0,484.0,348.0,0.059917,0.059917,6.184149,0.279906,1.0,484.0,13.0,150.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10371511,0.10287835712735109,0.0008367528726489076
10.0,484.0,348.0,0.020661,0.020661,6.184149,0.279906,1.0,484.0,13.0,150.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03576377,0.03597149357970238,0.00020772357970237632
11.0,484.0,348.0,0.022727,0.022727,6.184149,0.279906,1.0,484.0,13.0,150.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03933997,0.03819824642868055,0.0011417235713194543
6.0,484.0,348.0,0.012397,0.012397,6.184149,0.279906,1.0,484.0,13.0,150.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02145895,0.02142331156980969,3.563843019031149e-05
6.0,484.0,348.0,0.012397,0.012397,6.184149,0.279906,1.0,484.0,13.0,150.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02145895,0.021499761312797596,4.081131279759509e-05
2.0,484.0,348.0,0.004132,0.004132,6.184149,0.279906,1.0,484.0,13.0,150.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00715241,0.007140243269921532,1.2166730078467386e-05
4.0,484.0,348.0,0.008264,0.008264,6.184149,0.279906,1.0,484.0,13.0,150.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01430482,0.014237118848045644,6.770115195435522e-05
1.0,484.0,348.0,0.002066,0.002066,6.184149,0.279906,1.0,484.0,13.0,150.0,Early Termination,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0035762,0.0035766020063095153,4.0200630951545135e-07
0.0,484.0,348.0,0.0,0.0,6.184149,0.279906,1.0,484.0,13.0,150.0,Early Termination,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,484.0,348.0,0.018595,0.018595,6.184149,0.279906,1.0,484.0,13.0,150.0,Familial and Personal Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03218757,0.032217201185624995,2.9631185624996725e-05
16.0,484.0,348.0,0.033058,0.033058,6.184149,0.279906,1.0,484.0,13.0,150.0,Familial and Personal Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05722272,0.05770481437635553,0.00048209437635553243
1.0,484.0,348.0,0.002066,0.002066,6.184149,0.279906,1.0,484.0,13.0,150.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0035762,0.003577177962142849,9.779621428489954e-07
0.0,484.0,348.0,0.0,0.0,6.184149,0.279906,1.0,484.0,13.0,150.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,484.0,348.0,0.014463,0.014463,6.184149,0.279906,1.0,484.0,13.0,150.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02503516,0.0247132286528869,0.0003219313471130997
12.0,484.0,348.0,0.024793,0.024793,6.184149,0.279906,1.0,484.0,13.0,150.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04291618,0.042309545929365075,0.0006066340706349233
2.0,484.0,348.0,0.004132,0.004132,6.184149,0.279906,1.0,484.0,13.0,150.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00715241,0.0071473144428381985,5.09555716180117e-06
5.0,484.0,348.0,0.010331,0.010331,6.184149,0.279906,1.0,484.0,13.0,150.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01788275,0.017937821267827374,5.507126782737515e-05
0.0,484.0,348.0,0.0,0.0,6.184149,0.279906,1.0,484.0,13.0,150.0,Sponsor's Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,484.0,348.0,0.002066,0.002066,6.184149,0.279906,1.0,484.0,13.0,150.0,Sponsor's Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035762,0.0035761553568452314,4.464315476841729e-08
20.0,400.0,335.0,0.05,0.05,5.993961,0.214254,1.0,400.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06421165,0.06405916708458329,0.0001524829154167101
8.0,400.0,335.0,0.02,0.02,5.993961,0.214254,1.0,400.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02568466,0.02579331414595241,0.00010865414595240958
1.0,400.0,335.0,0.0025,0.0025,5.993961,0.214254,1.0,400.0,1.0,1.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00321058,0.003255376979226183,4.479697922618294e-05
2.0,400.0,335.0,0.005,0.005,5.993961,0.214254,1.0,400.0,1.0,1.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00642117,0.0063774335758333455,4.373642416665487e-05
10.0,400.0,335.0,0.025,0.025,5.993961,0.214254,1.0,400.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03210583,0.031908322580377006,0.00019750741962299562
9.0,400.0,335.0,0.0225,0.0225,5.993961,0.214254,1.0,400.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02889524,0.028922044565711586,2.6804565711587014e-05
3.0,400.0,335.0,0.0075,0.0075,5.993961,0.214254,1.0,400.0,1.0,1.0,Hypoglycaemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00963175,0.00951526465852184,0.00011648534147815949
2.0,400.0,335.0,0.005,0.005,5.993961,0.214254,1.0,400.0,1.0,1.0,Hypoglycaemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00642117,0.006378750070654772,4.2419929345228514e-05
5.0,400.0,335.0,0.0125,0.0125,5.993961,0.214254,1.0,400.0,1.0,1.0,Subject decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01605291,0.015860500186894843,0.00019240981310515715
0.0,400.0,335.0,0.0,0.0,5.993961,0.214254,1.0,400.0,1.0,1.0,Subject decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,400.0,335.0,0.005,0.005,5.993961,0.214254,1.0,400.0,1.0,1.0,Withdrawal of consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00642117,0.006375385013869043,4.578498613095738e-05
1.0,400.0,335.0,0.0025,0.0025,5.993961,0.214254,1.0,400.0,1.0,1.0,Withdrawal of consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00321058,0.0032593974447023754,4.881744470237523e-05
1.0,400.0,335.0,0.0025,0.0025,5.993961,0.214254,1.0,400.0,1.0,1.0,Missed measurement,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00321058,0.0032561173530357072,4.553735303570701e-05
0.0,400.0,335.0,0.0,0.0,5.993961,0.214254,1.0,400.0,1.0,1.0,Missed measurement,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,335.0,0.0025,0.0025,5.993961,0.214254,1.0,400.0,1.0,1.0,Move,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00321058,0.0032561173530357072,4.553735303570701e-05
0.0,400.0,335.0,0.0,0.0,5.993961,0.214254,1.0,400.0,1.0,1.0,Move,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,530.0,439.0,0.011321,0.011321,6.274762,0.193602,1.0,530.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01375281,0.013529650287886915,0.00022315971211308606
4.0,530.0,439.0,0.007547,0.007547,6.274762,0.193602,1.0,530.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00916814,0.009172815545922615,4.675545922615265e-06
1.0,530.0,439.0,0.001887,0.001887,6.274762,0.193602,1.0,530.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00229234,0.002279566327440478,1.2773672559521741e-05
0.0,530.0,439.0,0.0,0.0,6.274762,0.193602,1.0,530.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
20.0,530.0,439.0,0.037736,0.037736,6.274762,0.193602,1.0,530.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04584189,0.04610737054157739,0.0002654805415773856
24.0,530.0,439.0,0.045283,0.045283,6.274762,0.193602,1.0,530.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05501003,0.05292489336619051,0.0020851366338094923
3.0,530.0,439.0,0.00566,0.00566,6.274762,0.193602,1.0,530.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0068758,0.007161204700972219,0.000285404700972219
1.0,530.0,439.0,0.001887,0.001887,6.274762,0.193602,1.0,530.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00229234,0.002282031669166669,1.0308330833330888e-05
5.0,530.0,439.0,0.009434,0.009434,6.274762,0.193602,1.0,530.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01146047,0.01144814795586309,1.232204413690978e-05
2.0,530.0,439.0,0.003774,0.003774,6.274762,0.193602,1.0,530.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00458468,0.004614035973035716,2.9355973035716243e-05
5.0,530.0,439.0,0.009434,0.009434,6.274762,0.193602,1.0,530.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01146047,0.011414515159404759,4.595484059524181e-05
11.0,530.0,439.0,0.020755,0.020755,6.274762,0.193602,1.0,530.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02521328,0.025456040492321422,0.00024276049232142133
6.0,530.0,439.0,0.011321,0.011321,6.274762,0.193602,1.0,530.0,0.0,0.0,Patient Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01375281,0.013541701002708344,0.00021110899729165702
2.0,530.0,439.0,0.003774,0.003774,6.274762,0.193602,1.0,530.0,0.0,0.0,Patient Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00458468,0.004614360700416667,2.9680700416667184e-05
0.0,530.0,439.0,0.0,0.0,6.274762,0.193602,1.0,530.0,0.0,0.0,Open-Label AHA Treatment Requested,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,530.0,439.0,0.001887,0.001887,6.274762,0.193602,1.0,530.0,0.0,0.0,Open-Label AHA Treatment Requested,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00229234,0.0022821813041666696,1.015869583333032e-05
5.0,1842.0,1665.0,0.002714,0.002714,7.51915,0.577768,1.0,1842.0,16.0,208.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01179049,0.012048103274196413,0.0002576132741964124
7.0,1842.0,1665.0,0.0038,0.0038,7.51915,0.577768,1.0,1842.0,16.0,208.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01650843,0.01684168127246032,0.0003332512724603179
10.0,1842.0,1665.0,0.005429,0.005429,7.51915,0.577768,1.0,1842.0,16.0,208.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02358533,0.023492145222936488,9.318477706351386e-05
3.0,1842.0,1665.0,0.001629,0.001629,7.51915,0.577768,1.0,1842.0,16.0,208.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0070769,0.007092037241825385,1.5137241825385374e-05
4.0,1842.0,1665.0,0.002172,0.002172,7.51915,0.577768,1.0,1842.0,16.0,208.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00943587,0.00943248254886904,3.3874511309612415e-06
4.0,1842.0,1665.0,0.002172,0.002172,7.51915,0.577768,1.0,1842.0,16.0,208.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00943587,0.00944146166488094,5.59166488093947e-06
15.0,1842.0,1665.0,0.008143,0.008143,7.51915,0.577768,1.0,1842.0,16.0,208.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03537582,0.03566510411882938,0.00028928411882937766
16.0,1842.0,1665.0,0.008686,0.008686,7.51915,0.577768,1.0,1842.0,16.0,208.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03773479,0.03800962403721229,0.0002748340372122904
17.0,1842.0,1665.0,0.009229,0.009229,7.51915,0.577768,1.0,1842.0,16.0,208.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04009375,0.03955602166552577,0.0005377283344742273
2.0,1842.0,1665.0,0.001086,0.001086,7.51915,0.577768,1.0,1842.0,16.0,208.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00471793,0.00479611355770833,7.818355770832994e-05
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1842.0,1665.0,0.001086,0.001086,7.51915,0.577768,1.0,1842.0,16.0,208.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00471793,0.004794571271815473,7.66412718154726e-05
25.0,1842.0,1665.0,0.013572,0.013572,7.51915,0.577768,1.0,1842.0,16.0,208.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05896115,0.059909276051230066,0.0009481260512300693
36.0,1842.0,1665.0,0.019544,0.019544,7.51915,0.577768,1.0,1842.0,16.0,208.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08490544,0.08486986032904767,3.557967095232928e-05
18.0,1842.0,1665.0,0.009772,0.009772,7.51915,0.577768,1.0,1842.0,16.0,208.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04245272,0.042218808118978164,0.0002339118810218352
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00235897,0.0023551535349900653,3.816465009934874e-06
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235897,0.002360308906051574,1.3389060515736455e-06
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1842.0,1665.0,0.001629,0.001629,7.51915,0.577768,1.0,1842.0,16.0,208.0,Site Closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0070769,0.007118411640277766,4.151164027776672e-05
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Site Closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235897,0.0023592761955753844,3.061955753842771e-07
2.0,1842.0,1665.0,0.001086,0.001086,7.51915,0.577768,1.0,1842.0,16.0,208.0,Site Closure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00471793,0.004794571271815473,7.66412718154726e-05
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00235897,0.002354655627013876,4.314372986124245e-06
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Non-compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant Duplicated at Another Site,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant Duplicated at Another Site,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant Duplicated at Another Site,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00235897,0.0023549842332241935,3.985766775806664e-06
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Primary Care Physician Recommendation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Primary Care Physician Recommendation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235897,0.0023592761955753844,3.061955753842771e-07
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Primary Care Physician Recommendation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Relocated to Another Country,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Relocated to Another Country,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00235897,0.0023592761955753844,3.061955753842771e-07
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Relocated to Another Country,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1842.0,1665.0,0.000543,0.000543,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant was in Rehabilitation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00235897,0.002354655627013876,4.314372986124245e-06
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant was in Rehabilitation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1842.0,1665.0,0.0,0.0,7.51915,0.577768,1.0,1842.0,16.0,208.0,Participant was in Rehabilitation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
104.0,2053.0,1264.0,0.050658,0.050658,7.627544,0.222179,1.0,2053.0,8.0,176.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08584912,0.08807855468724203,0.0022294346872420295
9.0,2053.0,1264.0,0.004384,0.004384,7.627544,0.222179,1.0,2053.0,8.0,176.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00742948,0.007402511575357137,2.6968424642863018e-05
0.0,2053.0,1264.0,0.0,0.0,7.627544,0.222179,1.0,2053.0,8.0,176.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,2053.0,1264.0,0.001948,0.001948,7.627544,0.222179,1.0,2053.0,8.0,176.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00330124,0.003306300745892855,5.060745892855167e-06
3.0,2053.0,1264.0,0.001461,0.001461,7.627544,0.222179,1.0,2053.0,8.0,176.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00247593,0.002465008827202378,1.0921172797621805e-05
0.0,2053.0,1264.0,0.0,0.0,7.627544,0.222179,1.0,2053.0,8.0,176.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
56.0,2053.0,1264.0,0.027277,0.027277,7.627544,0.222179,1.0,2053.0,8.0,176.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0462258,0.04664247842254965,0.0004166784225496517
80.0,2053.0,1264.0,0.038967,0.038967,7.627544,0.222179,1.0,2053.0,8.0,176.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06603661,0.06523715498441467,0.0007994550155853292
5.0,2053.0,1264.0,0.002435,0.002435,7.627544,0.222179,1.0,2053.0,8.0,176.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412655,0.004132517180218264,5.967180218264742e-06
15.0,2053.0,1264.0,0.007306,0.007306,7.627544,0.222179,1.0,2053.0,8.0,176.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01238133,0.012232991291934505,0.00014833870806549472
2.0,2053.0,1264.0,0.000974,0.000974,7.627544,0.222179,1.0,2053.0,8.0,176.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00165062,0.001616185406369046,3.4434593630953926e-05
1.0,2053.0,1264.0,0.000487,0.000487,7.627544,0.222179,1.0,2053.0,8.0,176.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00082531,0.0009371326262797615,0.00011182262627976148
34.0,2053.0,1264.0,0.016561,0.016561,7.627544,0.222179,1.0,2053.0,8.0,176.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0280656,0.02796413563752977,0.00010146436247022994
9.0,2053.0,1264.0,0.004384,0.004384,7.627544,0.222179,1.0,2053.0,8.0,176.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00742948,0.007404255617797612,2.52243822023877e-05
5.0,2053.0,1264.0,0.002435,0.002435,7.627544,0.222179,1.0,2053.0,8.0,176.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412655,0.004135248839801597,8.698839801597746e-06
218.0,2053.0,1264.0,0.106186,0.106186,7.627544,0.222179,1.0,2053.0,8.0,176.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.17995133,0.17283308206312487,0.007118247936875127
166.0,2053.0,1264.0,0.080857,0.080857,7.627544,0.222179,1.0,2053.0,8.0,176.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.13702677,0.14325969371782735,0.0062329237178273544
18.0,2053.0,1264.0,0.008768,0.008768,7.627544,0.222179,1.0,2053.0,8.0,176.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01485896,0.014835311196240987,2.364880375901185e-05
32.0,2053.0,1264.0,0.015587,0.015587,7.627544,0.222179,1.0,2053.0,8.0,176.0,Various,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02641498,0.026396539766190497,1.844023380950452e-05
20.0,2053.0,1264.0,0.009742,0.009742,7.627544,0.222179,1.0,2053.0,8.0,176.0,Various,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01650958,0.016744181682946415,0.00023460168294641565
8.0,2053.0,1264.0,0.003897,0.003897,7.627544,0.222179,1.0,2053.0,8.0,176.0,Various,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00660417,0.006587435210228167,1.673478977183302e-05
2.0,388.0,359.0,0.005155,0.005155,5.963579,0.393691,1.0,388.0,9.0,86.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01210296,0.012118706341369056,1.5746341369056796e-05
0.0,388.0,359.0,0.0,0.0,5.963579,0.393691,1.0,388.0,9.0,86.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,388.0,359.0,0.005155,0.005155,5.963579,0.393691,1.0,388.0,9.0,86.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01210296,0.012128778185416675,2.5818185416675438e-05
3.0,388.0,359.0,0.007732,0.007732,5.963579,0.393691,1.0,388.0,9.0,86.0,Missing follow-up information,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01815326,0.018257792564990084,0.00010453256499008343
5.0,388.0,359.0,0.012887,0.012887,5.963579,0.393691,1.0,388.0,9.0,86.0,Missing follow-up information,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03025622,0.03014277632940475,0.00011344367059525073
3.0,388.0,359.0,0.007732,0.007732,5.963579,0.393691,1.0,388.0,9.0,86.0,Missing follow-up information,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01815326,0.018239012291716275,8.57522917162741e-05
4.0,388.0,359.0,0.010309,0.010309,5.963579,0.393691,1.0,388.0,9.0,86.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02420357,0.02435873896503357,0.00015516896503357108
2.0,388.0,359.0,0.005155,0.005155,5.963579,0.393691,1.0,388.0,9.0,86.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01210296,0.0121203413829762,1.738138297620144e-05
7.0,388.0,359.0,0.018041,0.018041,5.963579,0.393691,1.0,388.0,9.0,86.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04235683,0.0426951803972321,0.00033835039723210253
1.0,388.0,359.0,0.002577,0.002577,5.963579,0.393691,1.0,388.0,9.0,86.0,Randomized but not exposed,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00605031,0.006113601856875005,6.329185687500502e-05
0.0,388.0,359.0,0.0,0.0,5.963579,0.393691,1.0,388.0,9.0,86.0,Randomized but not exposed,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,388.0,359.0,0.0,0.0,5.963579,0.393691,1.0,388.0,9.0,86.0,Randomized but not exposed,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,986.0,881.0,0.008114,0.008114,6.89467,1.0,1.0,986.0,9.0,124.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05594335,0.05562333007537694,0.0003200199246230634
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01398239,0.013890723640515799,9.166635948420175e-05
4.0,986.0,881.0,0.004057,0.004057,6.89467,1.0,1.0,986.0,9.0,124.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02797168,0.027790730502589303,0.00018094949741069566
6.0,986.0,881.0,0.006085,0.006085,6.89467,1.0,1.0,986.0,9.0,124.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04195407,0.04151993473422607,0.0004341352657739328
3.0,986.0,881.0,0.003043,0.003043,6.89467,1.0,1.0,986.0,9.0,124.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02098048,0.020934054989087448,4.6425010912551357e-05
1.0,986.0,881.0,0.001014,0.001014,6.89467,1.0,1.0,986.0,9.0,124.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0069912,0.006977162095535714,1.4037904464286183e-05
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,986.0,881.0,0.003043,0.003043,6.89467,1.0,1.0,986.0,9.0,124.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02098048,0.021001931495635038,2.1451495635038675e-05
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01398239,0.013890723640515799,9.166635948420175e-05
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01398239,0.01393242864200389,4.996135799611133e-05
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,986.0,881.0,0.001014,0.001014,6.89467,1.0,1.0,986.0,9.0,124.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0069912,0.006975391582619047,1.580841738095355e-05
12.0,986.0,881.0,0.01217,0.01217,6.89467,1.0,1.0,986.0,9.0,124.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08390813,0.08212047784149801,0.00178765215850199
5.0,986.0,881.0,0.005071,0.005071,6.89467,1.0,1.0,986.0,9.0,124.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03496287,0.03457859775788681,0.0003842722421131886
6.0,986.0,881.0,0.006085,0.006085,6.89467,1.0,1.0,986.0,9.0,124.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04195407,0.0415363778094344,0.00041769219056560225
3.0,986.0,881.0,0.003043,0.003043,6.89467,1.0,1.0,986.0,9.0,124.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02098048,0.020918436005396952,6.204399460304696e-05
0.0,986.0,881.0,0.0,0.0,6.89467,1.0,1.0,986.0,9.0,124.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,986.0,881.0,0.01217,0.01217,6.89467,1.0,1.0,986.0,9.0,124.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08390813,0.08214470569878969,0.0017634243012103062
7.0,986.0,881.0,0.007099,0.007099,6.89467,1.0,1.0,986.0,9.0,124.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04894526,0.050123014623045546,0.0011777546230455488
6.0,986.0,881.0,0.006085,0.006085,6.89467,1.0,1.0,986.0,9.0,124.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04195407,0.04157525971142844,0.00037881028857156274
5.0,986.0,881.0,0.005071,0.005071,6.89467,1.0,1.0,986.0,9.0,124.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03496287,0.034595050652261816,0.00036781934773818387
3.0,986.0,881.0,0.003043,0.003043,6.89467,1.0,1.0,986.0,9.0,124.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.02098048,0.02092700597158744,5.34740284125583e-05
5.0,986.0,881.0,0.005071,0.005071,6.89467,1.0,1.0,986.0,9.0,124.0,Other reason not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03496287,0.034590994589275705,0.00037187541072429553
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Other reason not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01398239,0.013925246411349117,5.7143588650884064e-05
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Other reason not defined above,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01398239,0.013967935296170537,1.445470382946401e-05
3.0,986.0,881.0,0.003043,0.003043,6.89467,1.0,1.0,986.0,9.0,124.0,Other reason not defined above,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02098048,0.020925153630396952,5.532636960304746e-05
2.0,986.0,881.0,0.002028,0.002028,6.89467,1.0,1.0,986.0,9.0,124.0,Other reason not defined above,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01398239,0.013947261001765776,3.512899823422504e-05
4.0,582.0,528.0,0.006873,0.006873,6.368187,0.323595,1.0,2245.0,16.0,298.0,Adverse Event,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01416327,0.014212889657202393,4.961965720239221e-05
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Adverse Event,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0035403,0.0035398946012500303,4.053987499698722e-07
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,Adverse Event,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00708061,0.00713841477599569,5.780477599568942e-05
6.0,582.0,528.0,0.010309,0.010309,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.02124388,0.0213876020235119,0.00014372202351189967
4.0,582.0,528.0,0.006873,0.006873,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01416327,0.014233810853928584,7.054085392858324e-05
4.0,582.0,528.0,0.006873,0.006873,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01416327,0.014246334763660723,8.306476366072221e-05
3.0,582.0,528.0,0.005155,0.005155,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lost to Follow-up,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01062297,0.010640058244421002,1.7088244421000973e-05
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lost to Follow-up,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00708061,0.00712649266411077,4.588266411076954e-05
3.0,582.0,528.0,0.005155,0.005155,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lost to Follow-up,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01062297,0.010646211733171002,2.3241733171001575e-05
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,Administrative reason,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00708061,0.007126497985579027,4.588798557902691e-05
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Administrative reason,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0035403,0.0035398497262500305,4.5027374996967073e-07
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Administrative reason,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0035403,0.003540529705416696,2.2970541669600428e-07
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Requested discontinue treatment,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0035403,0.00353177794208336,8.52205791664019e-06
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Requested discontinue treatment,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Requested discontinue treatment,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0035403,0.0035404971320833634,1.9713208336330154e-07
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,No Longer Meets Criteria,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0035403,0.003531810515416693,8.489484583307054e-06
5.0,582.0,528.0,0.008591,0.008591,6.368187,0.323595,1.0,2245.0,16.0,298.0,No Longer Meets Criteria,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01770358,0.018324045504920644,0.0006204655049206441
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,No Longer Meets Criteria,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00708061,0.007138480642662357,5.7870642662357155e-05
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lack of Efficacy,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00708061,0.007129690338912359,4.908033891235907e-05
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lack of Efficacy,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Lack of Efficacy,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,582.0,528.0,0.005155,0.005155,6.368187,0.323595,1.0,2245.0,16.0,298.0,Non-specified,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.01062297,0.010638124757337665,1.5154757337664665e-05
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Non-specified,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Non-specified,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Missing disposition information,Double Blind Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Missing disposition information,Double Blind Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0035403,0.0035396337845833644,6.662154166357792e-07
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Missing disposition information,Double Blind Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0035403,0.00354026888875003,3.111124997033643e-08
2.0,582.0,528.0,0.003436,0.003436,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Follow-Up(Week 13/1 Week Post Last Dose),FG000,diabetes type 2,INDUSTRY,0.00708061,0.00713713029557902,5.65202955790196e-05
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Follow-Up(Week 13/1 Week Post Last Dose),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,Withdrawal by Subject,Follow-Up(Week 13/1 Week Post Last Dose),FG002,diabetes type 2,INDUSTRY,0.0035403,0.0035375441725000235,2.7558274999766458e-06
1.0,582.0,528.0,0.001718,0.001718,6.368187,0.323595,1.0,2245.0,16.0,298.0,non-specified,Follow-Up(Week 13/1 Week Post Last Dose),FG000,diabetes type 2,INDUSTRY,0.0035403,0.0035281395045833543,1.216049541664585e-05
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,non-specified,Follow-Up(Week 13/1 Week Post Last Dose),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,582.0,528.0,0.0,0.0,6.368187,0.323595,1.0,2245.0,16.0,298.0,non-specified,Follow-Up(Week 13/1 Week Post Last Dose),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,413.0,346.0,0.002421,0.002421,6.025866,0.314507,1.0,413.0,7.0,86.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458822,0.004630796479236123,4.2576479236123774e-05
3.0,413.0,346.0,0.007264,0.007264,6.025866,0.314507,1.0,413.0,7.0,86.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01376657,0.01381102875170636,4.445875170635931e-05
1.0,413.0,346.0,0.002421,0.002421,6.025866,0.314507,1.0,413.0,7.0,86.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00458822,0.004629765599414694,4.1545599414694566e-05
2.0,413.0,346.0,0.004843,0.004843,6.025866,0.314507,1.0,413.0,7.0,86.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00917834,0.009208011308779771,2.967130877977106e-05
0.0,413.0,346.0,0.0,0.0,6.025866,0.314507,1.0,413.0,7.0,86.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,413.0,346.0,0.004843,0.004843,6.025866,0.314507,1.0,413.0,7.0,86.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00917834,0.009198029140863104,1.9689140863103985e-05
13.0,413.0,346.0,0.031477,0.031477,6.025866,0.314507,1.0,413.0,7.0,86.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0596545,0.059671677723819434,1.717772381943511e-05
15.0,413.0,346.0,0.03632,0.03632,6.025866,0.314507,1.0,413.0,7.0,86.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06883285,0.06787432038761898,0.0009585296123810205
8.0,413.0,346.0,0.01937,0.01937,6.025866,0.314507,1.0,413.0,7.0,86.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03670959,0.036236835797232164,0.0004727542027678361
7.0,413.0,346.0,0.016949,0.016949,6.025866,0.314507,1.0,413.0,7.0,86.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03212136,0.03229265978125001,0.0001712997812500089
9.0,413.0,346.0,0.021792,0.021792,6.025866,0.314507,1.0,413.0,7.0,86.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04129971,0.04121047427964289,8.923572035711425e-05
6.0,413.0,346.0,0.014528,0.014528,6.025866,0.314507,1.0,413.0,7.0,86.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02753314,0.0275335666036607,4.2660366069910416e-07
9.0,708.0,578.0,0.012712,0.012712,6.563856,0.238805,1.0,708.0,2.0,63.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01992581,0.020031485216641397,0.00010567521664139878
0.0,708.0,578.0,0.0,0.0,6.563856,0.238805,1.0,708.0,2.0,63.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,708.0,578.0,0.007062,0.007062,6.563856,0.238805,1.0,708.0,2.0,63.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01106955,0.011075418077113128,5.868077113129269e-06
3.0,708.0,578.0,0.004237,0.004237,6.563856,0.238805,1.0,708.0,2.0,63.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00664142,0.006633988906488061,7.431093511939095e-06
9.0,708.0,578.0,0.012712,0.012712,6.563856,0.238805,1.0,708.0,2.0,63.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01992581,0.019996301272365603,7.049127236560468e-05
7.0,708.0,578.0,0.009887,0.009887,6.563856,0.238805,1.0,708.0,2.0,63.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01549768,0.015552907599126998,5.522759912699772e-05
3.0,708.0,578.0,0.004237,0.004237,6.563856,0.238805,1.0,708.0,2.0,63.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00664142,0.006633588424196395,7.831575803605127e-06
1.0,708.0,578.0,0.001412,0.001412,6.563856,0.238805,1.0,708.0,2.0,63.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00221328,0.0022136574381349202,3.774381349200273e-07
3.0,708.0,578.0,0.004237,0.004237,6.563856,0.238805,1.0,708.0,2.0,63.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00664142,0.006631821801299567,9.598198700433262e-06
4.0,708.0,578.0,0.00565,0.00565,6.563856,0.238805,1.0,708.0,2.0,63.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00885627,0.008925682286309517,6.941228630951736e-05
6.0,708.0,578.0,0.008475,0.008475,6.563856,0.238805,1.0,708.0,2.0,63.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0132844,0.013188478226716269,9.5921773283731e-05
1.0,708.0,578.0,0.001412,0.001412,6.563856,0.238805,1.0,708.0,2.0,63.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00221328,0.0022181013348015867,4.821334801586533e-06
2.0,708.0,578.0,0.002825,0.002825,6.563856,0.238805,1.0,708.0,2.0,63.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00442813,0.0044203981679599505,7.731832040049243e-06
2.0,708.0,578.0,0.002825,0.002825,6.563856,0.238805,1.0,708.0,2.0,63.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00442813,0.004420503682840902,7.626317159097756e-06
3.0,708.0,578.0,0.004237,0.004237,6.563856,0.238805,1.0,708.0,2.0,63.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00664142,0.006632739547162663,8.680452837337566e-06
20.0,708.0,578.0,0.028249,0.028249,6.563856,0.238805,1.0,708.0,2.0,63.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04427976,0.04473021014915677,0.00045045014915676834
28.0,708.0,578.0,0.039548,0.039548,6.563856,0.238805,1.0,708.0,2.0,63.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06199072,0.062067510683571435,7.679068357143576e-05
12.0,708.0,578.0,0.016949,0.016949,6.563856,0.238805,1.0,708.0,2.0,63.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02656723,0.02649942861286709,6.780138713291181e-05
4.0,708.0,578.0,0.00565,0.00565,6.563856,0.238805,1.0,708.0,2.0,63.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00885627,0.008936645865059517,8.037586505951766e-05
5.0,708.0,578.0,0.007062,0.007062,6.563856,0.238805,1.0,708.0,2.0,63.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01106955,0.011056971004196458,1.2578995803541257e-05
3.0,708.0,578.0,0.004237,0.004237,6.563856,0.238805,1.0,708.0,2.0,63.0,Unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00664142,0.006631925083591233,9.494916408767096e-06
16.0,566.0,503.0,0.028269,0.028269,6.340359,0.303074,1.0,586.0,14.0,209.0,Adverse Event,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.05432157,0.05449627449015146,0.00017470449015145884
2.0,566.0,503.0,0.003534,0.003534,6.340359,0.303074,1.0,586.0,14.0,209.0,Adverse Event,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00679092,0.006812384103224194,2.14641032241945e-05
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Protocol Violation,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00339546,0.0034043981893749904,8.938189374990517e-06
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Protocol Violation,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00339546,0.003407172323958323,1.1712323958322935e-05
4.0,566.0,503.0,0.007067,0.007067,6.340359,0.303074,1.0,586.0,14.0,209.0,Noncompliance,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.01357991,0.013569158239285643,1.0751760714357642e-05
4.0,566.0,503.0,0.007067,0.007067,6.340359,0.303074,1.0,586.0,14.0,209.0,Noncompliance,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.01357991,0.013592374763958264,1.2464763958263195e-05
10.0,566.0,503.0,0.017668,0.017668,6.340359,0.303074,1.0,586.0,14.0,209.0,Lost to Follow-up,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.03395074,0.03379463974282735,0.00015610025717265053
8.0,566.0,503.0,0.014134,0.014134,6.340359,0.303074,1.0,586.0,14.0,209.0,Lost to Follow-up,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.02715982,0.027166583889672587,6.76388967258551e-06
9.0,566.0,503.0,0.015901,0.015901,6.340359,0.303074,1.0,586.0,14.0,209.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.03055528,0.03070405189450395,0.000148771894503949
19.0,566.0,503.0,0.033569,0.033569,6.340359,0.303074,1.0,586.0,14.0,209.0,Withdrawal by Subject,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.06450602,0.06415219211333961,0.000353827886660385
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Physician Decision,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00339546,0.0034050716830654653,9.611683065465382e-06
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Physician Decision,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.00339546,0.0034072525676487986,1.1792567648798678e-05
0.0,566.0,503.0,0.0,0.0,6.340359,0.303074,1.0,586.0,14.0,209.0,Termination of Study/Site by GSK,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,566.0,503.0,0.007067,0.007067,6.340359,0.303074,1.0,586.0,14.0,209.0,Termination of Study/Site by GSK,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.01357991,0.013592270123124927,1.2360123124926375e-05
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Pregnancy,Treatment Period (52 Weeks),FG000,diabetes type 2,INDUSTRY,0.00339546,0.003405192188482132,9.732188482131955e-06
0.0,566.0,503.0,0.0,0.0,6.340359,0.303074,1.0,586.0,14.0,209.0,Pregnancy,Treatment Period (52 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,566.0,503.0,0.0053,0.0053,6.340359,0.303074,1.0,586.0,14.0,209.0,Adverse Event,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01018445,0.009837375757359578,0.00034707424264042094
1.0,566.0,503.0,0.001767,0.001767,6.340359,0.303074,1.0,586.0,14.0,209.0,Adverse Event,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00339546,0.003416749350982134,2.1289350982134272e-05
2.0,566.0,503.0,0.003534,0.003534,6.340359,0.303074,1.0,586.0,14.0,209.0,Noncompliance,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00679092,0.006819710711815462,2.8790711815462368e-05
2.0,566.0,503.0,0.003534,0.003534,6.340359,0.303074,1.0,586.0,14.0,209.0,Noncompliance,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00679092,0.006808506849196413,1.7586849196412832e-05
14.0,566.0,503.0,0.024735,0.024735,6.340359,0.303074,1.0,586.0,14.0,209.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.04753065,0.04751198530652782,1.8664693472184024e-05
12.0,566.0,503.0,0.021201,0.021201,6.340359,0.303074,1.0,586.0,14.0,209.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.04073974,0.04146494484215282,0.0007252048421528198
6.0,566.0,503.0,0.010601,0.010601,6.340359,0.303074,1.0,586.0,14.0,209.0,Did not Entered Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.02037083,0.020460827684037706,8.999768403770633e-05
8.0,566.0,503.0,0.014134,0.014134,6.340359,0.303074,1.0,586.0,14.0,209.0,Did not Entered Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.02715982,0.027146430433422585,1.3389566577415996e-05
4.0,566.0,503.0,0.007067,0.007067,6.340359,0.303074,1.0,586.0,14.0,209.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01357991,0.013558021145952321,2.188885404767922e-05
7.0,566.0,503.0,0.012367,0.012367,6.340359,0.303074,1.0,586.0,14.0,209.0,Withdrawal by Subject,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.02376437,0.02382411707885913,5.9747078859129915e-05
0.0,566.0,503.0,0.0,0.0,6.340359,0.303074,1.0,586.0,14.0,209.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,566.0,503.0,0.007067,0.007067,6.340359,0.303074,1.0,586.0,14.0,209.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01357991,0.013589438938541603,9.528938541602042e-06
6.0,1036.0,539.0,0.005792,0.005792,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.0124588,0.01245525760574405,3.5423942559512783e-06
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1036.0,539.0,0.003861,0.003861,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.00830515,0.008249618433105151,5.5531566894849796e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
331.0,1036.0,539.0,0.319498,0.319498,6.944087,0.309765,1.0,1036.0,18.0,95.0,Entry criteria not met,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.68725169,0.5534114305410616,0.1338402594589384
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Entry criteria not met,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Entry criteria not met,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
47.0,1036.0,539.0,0.045367,0.045367,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.09758605,0.0967517571029563,0.0008342928970436897
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,1036.0,539.0,0.007722,0.007722,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.0166103,0.016543617323392858,6.668267660714378e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1036.0,539.0,0.002896,0.002896,6.944087,0.309765,1.0,1036.0,18.0,95.0,Sponsor decision,Basal Insulin Optimization Phase (BIO),FG000,diabetes type 2,INDUSTRY,0.0062294,0.006208340964315492,2.1059035684508655e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Sponsor decision,Basal Insulin Optimization Phase (BIO),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Sponsor decision,Basal Insulin Optimization Phase (BIO),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,1036.0,539.0,0.016409,0.016409,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.03529635,0.03457234002498106,0.0007240099750189383
8.0,1036.0,539.0,0.007722,0.007722,6.944087,0.309765,1.0,1036.0,18.0,95.0,Adverse Event,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0166103,0.016544434274692457,6.586572530754495e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Death,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1036.0,539.0,0.000965,0.000965,6.944087,0.309765,1.0,1036.0,18.0,95.0,Death,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.00207575,0.0020263869927678565,4.9363007232143454e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Death,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1036.0,539.0,0.001931,0.001931,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lost to Follow-up,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.00415365,0.004094056781537683,5.959321846231696e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,entry criteria not met,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1036.0,539.0,0.002896,0.002896,6.944087,0.309765,1.0,1036.0,18.0,95.0,entry criteria not met,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.0062294,0.0062094615733333525,1.993842666664792e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,entry criteria not met,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Protocol Violation,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,1036.0,539.0,0.006757,0.006757,6.944087,0.309765,1.0,1036.0,18.0,95.0,Protocol Violation,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.01453455,0.014316559109910703,0.0002179908900892969
2.0,1036.0,539.0,0.001931,0.001931,6.944087,0.309765,1.0,1036.0,18.0,95.0,Protocol Violation,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.00415365,0.004105157576597207,4.849242340279267e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
18.0,1036.0,539.0,0.017375,0.017375,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.03737425,0.03731338162500086,6.0868374999134556e-05
29.0,1036.0,539.0,0.027992,0.027992,6.944087,0.309765,1.0,1036.0,18.0,95.0,Withdrawal by Subject,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0602118,0.060772926490846826,0.0005611264908468236
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1036.0,539.0,0.002896,0.002896,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.0062294,0.0062097918300000185,1.9608169999981925e-05
5.0,1036.0,539.0,0.004826,0.004826,6.944087,0.309765,1.0,1036.0,18.0,95.0,Physician Decision,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0103809,0.010273811145863097,0.00010708885413690354
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,sponsor decision,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1036.0,539.0,0.000965,0.000965,6.944087,0.309765,1.0,1036.0,18.0,95.0,sponsor decision,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.00207575,0.00202611010110119,4.963989889880975e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,sponsor decision,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lack of Efficacy,Interventional Phase,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1036.0,539.0,0.001931,0.001931,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lack of Efficacy,Interventional Phase,FG001,diabetes type 2,INDUSTRY,0.00415365,0.004093227297371017,6.0422702628982854e-05
0.0,1036.0,539.0,0.0,0.0,6.944087,0.309765,1.0,1036.0,18.0,95.0,Lack of Efficacy,Interventional Phase,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,561.0,494.0,0.005348,0.005348,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG000,diabetes type 2,INDUSTRY,0.03386087,0.03387097465572411,1.010465572411079e-05
3.0,561.0,494.0,0.005348,0.005348,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG001,diabetes type 2,INDUSTRY,0.03386087,0.03380768047308523,5.318952691477086e-05
3.0,561.0,494.0,0.005348,0.005348,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG002,diabetes type 2,INDUSTRY,0.03386087,0.03379431931475196,6.655068524804436e-05
3.0,561.0,494.0,0.005348,0.005348,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG003,diabetes type 2,INDUSTRY,0.03386087,0.03383859279121021,2.2277208789792113e-05
2.0,561.0,494.0,0.003565,0.003565,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG004,diabetes type 2,INDUSTRY,0.0225718,0.02261039458030748,3.859458030748206e-05
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,1st Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.011291504412777827,2.4344127778266195e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG003,diabetes type 2,INDUSTRY,0.01128907,0.01130392731000005,1.485731000005e-05
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,1st Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.011296224268333382,7.154268333382091e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG003,diabetes type 2,INDUSTRY,0.01128907,0.011296094504444494,7.024504444494428e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,1st Stage,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,561.0,494.0,0.003565,0.003565,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG000,diabetes type 2,INDUSTRY,0.0225718,0.02259827714697415,2.6477146974152044e-05
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,561.0,494.0,0.003565,0.003565,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG002,diabetes type 2,INDUSTRY,0.0225718,0.022594972599236058,2.3172599236058466e-05
3.0,561.0,494.0,0.005348,0.005348,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG003,diabetes type 2,INDUSTRY,0.03386087,0.03381872761162693,4.214238837307177e-05
7.0,561.0,494.0,0.012478,0.012478,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG004,diabetes type 2,INDUSTRY,0.07900448,0.07897596191036688,2.851808963312552e-05
2.0,561.0,494.0,0.003565,0.003565,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,2nd Stage,FG005,diabetes type 2,INDUSTRY,0.0225718,0.02260370136780748,3.1901367807479764e-05
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG004,diabetes type 2,INDUSTRY,0.01128907,0.011299046635833386,9.976635833386024e-06
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,2nd Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.011292950748333381,3.880748333380882e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG002,diabetes type 2,INDUSTRY,0.01128907,0.01130574363611116,1.667363611116031e-05
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG003,diabetes type 2,INDUSTRY,0.01128907,0.011291518567777827,2.448567777826871e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Investigator's decision,2nd Stage,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG000,diabetes type 2,INDUSTRY,0.01128907,0.011293368939166716,4.29893916671642e-06
2.0,561.0,494.0,0.003565,0.003565,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG001,diabetes type 2,INDUSTRY,0.0225718,0.02265496799471226,8.316799471225905e-05
9.0,561.0,494.0,0.016043,0.016043,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG002,diabetes type 2,INDUSTRY,0.10157628,0.0978709771862401,0.0037053028137599003
7.0,561.0,494.0,0.012478,0.012478,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG003,diabetes type 2,INDUSTRY,0.07900448,0.07897596191036688,2.851808963312552e-05
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG004,diabetes type 2,INDUSTRY,0.01128907,0.011288195983333381,8.740166666191401e-07
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Adverse Event,Extension Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.01128934498333338,2.749833333797608e-07
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG003,diabetes type 2,INDUSTRY,0.01128907,0.011294019162023862,4.949162023861961e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Protocol Violation,Extension Stage,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG002,diabetes type 2,INDUSTRY,0.01128907,0.011303289789166716,1.4219789166715693e-05
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Lack of Efficacy,Extension Stage,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG002,diabetes type 2,INDUSTRY,0.01128907,0.01130537416000005,1.630416000004964e-05
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG003,diabetes type 2,INDUSTRY,0.01128907,0.011290613291666717,1.5432916667165036e-06
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG004,diabetes type 2,INDUSTRY,0.01128907,0.011291646341666715,2.5763416667146793e-06
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Withdrawal by Subject,Extension Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.011291064716666714,1.994716666713775e-06
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,561.0,494.0,0.0,0.0,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG004,diabetes type 2,INDUSTRY,0.01128907,0.011288470666666715,5.993333332850181e-07
1.0,561.0,494.0,0.001783,0.001783,6.331502,1.0,1.0,561.0,1.0,47.0,Closure of the trial site,Extension Stage,FG005,diabetes type 2,INDUSTRY,0.01128907,0.011289619666666716,5.496666667156175e-07
20.0,1030.0,659.0,0.019417,0.019417,6.938284,0.268071,1.0,1030.0,15.0,187.0,Adverse Event,Main: Week 0 to 52 (NN1250-3579),FG000,diabetes type 2,INDUSTRY,0.03611465,0.03600339265079365,0.00011125734920634789
5.0,1030.0,659.0,0.004854,0.004854,6.938284,0.268071,1.0,1030.0,15.0,187.0,Adverse Event,Main: Week 0 to 52 (NN1250-3579),FG001,diabetes type 2,INDUSTRY,0.0090282,0.009044141321964265,1.5941321964264496e-05
7.0,1030.0,659.0,0.006796,0.006796,6.938284,0.268071,1.0,1030.0,15.0,187.0,Lack of Efficacy,Main: Week 0 to 52 (NN1250-3579),FG000,diabetes type 2,INDUSTRY,0.01264022,0.012669739351774898,2.9519351774897826e-05
2.0,1030.0,659.0,0.001942,0.001942,6.938284,0.268071,1.0,1030.0,15.0,187.0,Lack of Efficacy,Main: Week 0 to 52 (NN1250-3579),FG001,diabetes type 2,INDUSTRY,0.00361202,0.003652012006170637,3.99920061706369e-05
46.0,1030.0,659.0,0.04466,0.04466,6.938284,0.268071,1.0,1030.0,15.0,187.0,Protocol Violation,Main: Week 0 to 52 (NN1250-3579),FG000,diabetes type 2,INDUSTRY,0.08306537,0.08092411752405759,0.0021412524759424068
18.0,1030.0,659.0,0.017476,0.017476,6.938284,0.268071,1.0,1030.0,15.0,187.0,Protocol Violation,Main: Week 0 to 52 (NN1250-3579),FG001,diabetes type 2,INDUSTRY,0.03250449,0.033820181829771874,0.001315691829771877
9.0,1030.0,659.0,0.008738,0.008738,6.938284,0.268071,1.0,1030.0,15.0,187.0,Withdrawal criteria,Main: Week 0 to 52 (NN1250-3579),FG000,diabetes type 2,INDUSTRY,0.01625224,0.016224592245238104,2.7647754761897514e-05
5.0,1030.0,659.0,0.004854,0.004854,6.938284,0.268071,1.0,1030.0,15.0,187.0,Withdrawal criteria,Main: Week 0 to 52 (NN1250-3579),FG001,diabetes type 2,INDUSTRY,0.0090282,0.00903948895249998,1.1288952499979854e-05
84.0,1030.0,659.0,0.081553,0.081553,6.938284,0.268071,1.0,1030.0,15.0,187.0,Unclassified,Main: Week 0 to 52 (NN1250-3579),FG000,diabetes type 2,INDUSTRY,0.15168451,0.15238374562520834,0.0006992356252083498
30.0,1030.0,659.0,0.029126,0.029126,6.938284,0.268071,1.0,1030.0,15.0,187.0,Unclassified,Main: Week 0 to 52 (NN1250-3579),FG001,diabetes type 2,INDUSTRY,0.05417291,0.053690588584722185,0.00048232141527781297
12.0,1030.0,659.0,0.01165,0.01165,6.938284,0.268071,1.0,1030.0,15.0,187.0,Adverse Event,Extension: Week 53 to 104 (NN1250-3643),FG000,diabetes type 2,INDUSTRY,0.02166842,0.021860763784702354,0.00019234378470235278
5.0,1030.0,659.0,0.004854,0.004854,6.938284,0.268071,1.0,1030.0,15.0,187.0,Adverse Event,Extension: Week 53 to 104 (NN1250-3643),FG001,diabetes type 2,INDUSTRY,0.0090282,0.009046659528214266,1.8459528214265913e-05
3.0,1030.0,659.0,0.002913,0.002913,6.938284,0.268071,1.0,1030.0,15.0,187.0,Lack of Efficacy,Extension: Week 53 to 104 (NN1250-3643),FG000,diabetes type 2,INDUSTRY,0.00541803,0.005452508207380944,3.447820738094413e-05
1.0,1030.0,659.0,0.000971,0.000971,6.938284,0.268071,1.0,1030.0,15.0,187.0,Lack of Efficacy,Extension: Week 53 to 104 (NN1250-3643),FG001,diabetes type 2,INDUSTRY,0.00180601,0.0018451763797023783,3.916637970237825e-05
2.0,1030.0,659.0,0.001942,0.001942,6.938284,0.268071,1.0,1030.0,15.0,187.0,Protocol Violation,Extension: Week 53 to 104 (NN1250-3643),FG000,diabetes type 2,INDUSTRY,0.00361202,0.00365264032859127,4.062032859126997e-05
4.0,1030.0,659.0,0.003883,0.003883,6.938284,0.268071,1.0,1030.0,15.0,187.0,Protocol Violation,Extension: Week 53 to 104 (NN1250-3643),FG001,diabetes type 2,INDUSTRY,0.00722219,0.0073087794720833365,8.65894720833366e-05
6.0,1030.0,659.0,0.005825,0.005825,6.938284,0.268071,1.0,1030.0,15.0,187.0,Withdrawal criteria,Extension: Week 53 to 104 (NN1250-3643),FG000,diabetes type 2,INDUSTRY,0.01083421,0.010884116582224936,4.9906582224935533e-05
3.0,1030.0,659.0,0.002913,0.002913,6.938284,0.268071,1.0,1030.0,15.0,187.0,Withdrawal criteria,Extension: Week 53 to 104 (NN1250-3643),FG001,diabetes type 2,INDUSTRY,0.00541803,0.005452051754464275,3.402175446427531e-05
23.0,1030.0,659.0,0.02233,0.02233,6.938284,0.268071,1.0,1030.0,15.0,187.0,Unclassified,Extension: Week 53 to 104 (NN1250-3643),FG000,diabetes type 2,INDUSTRY,0.04153269,0.04130419036765872,0.00022849963234127663
7.0,1030.0,659.0,0.006796,0.006796,6.938284,0.268071,1.0,1030.0,15.0,187.0,Unclassified,Extension: Week 53 to 104 (NN1250-3643),FG001,diabetes type 2,INDUSTRY,0.01264022,0.012671949492608237,3.1729492608236626e-05
6.0,954.0,789.0,0.006289,0.006289,6.861711,0.573123,1.0,954.0,4.0,142.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02473217,0.024603122695793646,0.00012904730420635474
4.0,954.0,789.0,0.004193,0.004193,6.861711,0.573123,1.0,954.0,4.0,142.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01648942,0.0160432898515377,0.0004461301484623009
1.0,954.0,789.0,0.001048,0.001048,6.861711,0.573123,1.0,954.0,4.0,142.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412137,0.004157521341011906,3.6151341011906105e-05
3.0,954.0,789.0,0.003145,0.003145,6.861711,0.573123,1.0,954.0,4.0,142.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01236805,0.0124257836674991,5.773366749910018e-05
0.0,954.0,789.0,0.0,0.0,6.861711,0.573123,1.0,954.0,4.0,142.0,Poor Compliance to Protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,954.0,789.0,0.001048,0.001048,6.861711,0.573123,1.0,954.0,4.0,142.0,Poor Compliance to Protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412137,0.00415307399339286,3.170399339286027e-05
0.0,954.0,789.0,0.0,0.0,6.861711,0.573123,1.0,954.0,4.0,142.0,Poor Compliance to Protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,954.0,789.0,0.001048,0.001048,6.861711,0.573123,1.0,954.0,4.0,142.0,Poor Compliance to Protocol,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00412137,0.004153464749761908,3.2094749761907813e-05
2.0,954.0,789.0,0.002096,0.002096,6.861711,0.573123,1.0,954.0,4.0,142.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00824275,0.00825301605834324,1.0266058343240056e-05
2.0,954.0,789.0,0.002096,0.002096,6.861711,0.573123,1.0,954.0,4.0,142.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00824275,0.008264334030009906,2.1584030009905858e-05
1.0,954.0,789.0,0.001048,0.001048,6.861711,0.573123,1.0,954.0,4.0,142.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00412137,0.004158639162678573,3.7269162678573234e-05
2.0,954.0,789.0,0.002096,0.002096,6.861711,0.573123,1.0,954.0,4.0,142.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00824275,0.008260054526081332,1.7304526081332247e-05
20.0,954.0,789.0,0.020964,0.020964,6.861711,0.573123,1.0,954.0,4.0,142.0,At the Participant's own request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08244319,0.08235365154526775,8.953845473225197e-05
26.0,954.0,789.0,0.027254,0.027254,6.861711,0.573123,1.0,954.0,4.0,142.0,At the Participant's own request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10717929,0.10732952548759922,0.00015023548759922345
14.0,954.0,789.0,0.014675,0.014675,6.861711,0.573123,1.0,954.0,4.0,142.0,At the Participant's own request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05771102,0.057566154669255944,0.0001448653307440581
23.0,954.0,789.0,0.024109,0.024109,6.861711,0.573123,1.0,954.0,4.0,142.0,At the Participant's own request,Overall Study,FG003,diabetes type 2,INDUSTRY,0.09481124,0.0934420285558982,0.001369211444101806
6.0,954.0,789.0,0.006289,0.006289,6.861711,0.573123,1.0,954.0,4.0,142.0,Reason Not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02473217,0.024600549758591262,0.00013162024140873918
18.0,954.0,789.0,0.018868,0.018868,6.861711,0.573123,1.0,954.0,4.0,142.0,Reason Not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07420044,0.07573963416645829,0.0015391941664582853
16.0,954.0,789.0,0.016771,0.016771,6.861711,0.573123,1.0,954.0,4.0,142.0,Reason Not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06595376,0.06696275674832342,0.0010089967483234152
19.0,954.0,789.0,0.019916,0.019916,6.861711,0.573123,1.0,954.0,4.0,142.0,Reason Not Specified,Overall Study,FG003,diabetes type 2,INDUSTRY,0.07832181,0.0794982837532142,0.0011764737532141967
102.0,796.0,575.0,0.128141,0.128141,6.680855,0.218985,1.0,796.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.18747119,0.18339356364199408,0.004077626358005931
31.0,796.0,575.0,0.038945,0.038945,6.680855,0.218985,1.0,796.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05697681,0.05694337520802579,3.343479197421423e-05
0.0,796.0,575.0,0.0,0.0,6.680855,0.218985,1.0,796.0,0.0,0.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,796.0,575.0,0.001256,0.001256,6.680855,0.218985,1.0,796.0,0.0,0.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00183754,0.0018569661877678655,1.9426187767865614e-05
5.0,796.0,575.0,0.006281,0.006281,6.680855,0.218985,1.0,796.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00918915,0.009345160010436516,0.00015601001043651606
1.0,796.0,575.0,0.001256,0.001256,6.680855,0.218985,1.0,796.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00183754,0.0018556756366666755,1.8135636666675612e-05
3.0,796.0,575.0,0.003769,0.003769,6.680855,0.218985,1.0,796.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00551407,0.005529370660396829,1.5300660396828578e-05
3.0,796.0,575.0,0.003769,0.003769,6.680855,0.218985,1.0,796.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00551407,0.005530336517896829,1.6266517896828744e-05
11.0,796.0,575.0,0.013819,0.013819,6.680855,0.218985,1.0,796.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0202173,0.02032044911887896,0.00010314911887895906
2.0,796.0,575.0,0.002513,0.002513,6.680855,0.218985,1.0,796.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00367654,0.0037004289306845233,2.3888930684523493e-05
32.0,796.0,575.0,0.040201,0.040201,6.680855,0.218985,1.0,796.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05881435,0.059089377508244036,0.00027502750824403427
27.0,796.0,575.0,0.03392,0.03392,6.680855,0.218985,1.0,796.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0496252,0.04928551283271914,0.000339687167280861
3.0,796.0,575.0,0.003769,0.003769,6.680855,0.218985,1.0,796.0,0.0,0.0,Study Terminated by Sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00551407,0.005531694201468258,1.7624201468257814e-05
0.0,796.0,575.0,0.0,0.0,6.680855,0.218985,1.0,796.0,0.0,0.0,Study Terminated by Sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,7028.0,6809.0,0.000711,0.000711,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Study drug stopped, reason missing",Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00245775,0.00244038898895834,1.73610110416598e-05
3.0,7028.0,6809.0,0.000427,0.000427,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Study drug stopped, reason missing",Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00147603,0.001490506505664683,1.4476505664683115e-05
4.0,7028.0,6809.0,0.000569,0.000569,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Study drug stopped, reason missing",Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.00196689,0.0019807451977877076,1.385519778770777e-05
4.0,7028.0,6809.0,0.000569,0.000569,8.8578,0.390249,1.0,7064.0,42.0,615.0,Not treated,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00196689,0.001979873957251994,1.2983957251994083e-05
2.0,7028.0,6809.0,0.000285,0.000285,8.8578,0.390249,1.0,7064.0,42.0,615.0,Not treated,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00098517,0.0010050356631646823,1.9865663164682227e-05
2.0,7028.0,6809.0,0.000285,0.000285,8.8578,0.390249,1.0,7064.0,42.0,615.0,Not treated,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.00098517,0.001000319926557539,1.5149926557538919e-05
11.0,7028.0,6809.0,0.001565,0.001565,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lack of Efficacy,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00540981,0.005409947676309521,1.3767630952128684e-07
1.0,7028.0,6809.0,0.000142,0.000142,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lack of Efficacy,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00049086,0.0004866608064655488,4.1991935344511924e-06
0.0,7028.0,6809.0,0.0,0.0,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lack of Efficacy,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
15.0,7028.0,6809.0,0.002134,0.002134,8.8578,0.390249,1.0,7064.0,42.0,615.0,Non compliant with protocol,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00737669,0.007324839258051946,5.1850741948054196e-05
15.0,7028.0,6809.0,0.002134,0.002134,8.8578,0.390249,1.0,7064.0,42.0,615.0,Non compliant with protocol,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00737669,0.007312260154718617,6.442984528138261e-05
12.0,7028.0,6809.0,0.001707,0.001707,8.8578,0.390249,1.0,7064.0,42.0,615.0,Non compliant with protocol,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.00590066,0.005603479693333335,0.00029718030666666534
15.0,7028.0,6809.0,0.002134,0.002134,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to Follow-up,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.00737669,0.0073162281866828984,6.0461813317101536e-05
9.0,7028.0,6809.0,0.001281,0.001281,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to Follow-up,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.00442809,0.0043217777580104606,0.00010631224198953942
6.0,7028.0,6809.0,0.000854,0.000854,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to Follow-up,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.00295206,0.0029201131213762617,3.1946878623738146e-05
172.0,7028.0,6809.0,0.024474,0.024474,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Refusal to continue, not due to AE",Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.08460037,0.08379445659016956,0.0008059134098304388
118.0,7028.0,6809.0,0.01679,0.01679,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Refusal to continue, not due to AE",Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.05803875,0.05897558815472222,0.0009368381547222165
122.0,7028.0,6809.0,0.017359,0.017359,8.8578,0.390249,1.0,7064.0,42.0,615.0,"Refusal to continue, not due to AE",Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.06000563,0.060700643645208316,0.0006950136452083186
162.0,7028.0,6809.0,0.023051,0.023051,8.8578,0.390249,1.0,7064.0,42.0,615.0,Other than those specified,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.07968143,0.07989201823751077,0.0002105882375107726
142.0,7028.0,6809.0,0.020205,0.020205,8.8578,0.390249,1.0,7064.0,42.0,615.0,Other than those specified,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.06984353,0.0697532689873312,9.026101266880471e-05
125.0,7028.0,6809.0,0.017786,0.017786,8.8578,0.390249,1.0,7064.0,42.0,615.0,Other than those specified,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.06148166,0.061390801370624984,9.08586293750166e-05
303.0,7028.0,6809.0,0.043113,0.043113,8.8578,0.390249,1.0,7064.0,42.0,615.0,Adverse Event,Discontinuation From Treatment,FG000,diabetes type 2,INDUSTRY,0.14903064,0.14830839283096237,0.0007222471690376264
267.0,7028.0,6809.0,0.037991,0.037991,8.8578,0.390249,1.0,7064.0,42.0,615.0,Adverse Event,Discontinuation From Treatment,FG001,diabetes type 2,INDUSTRY,0.13132519,0.13041723438061514,0.0009079556193848648
273.0,7028.0,6809.0,0.038845,0.038845,8.8578,0.390249,1.0,7064.0,42.0,615.0,Adverse Event,Discontinuation From Treatment,FG002,diabetes type 2,INDUSTRY,0.13427725,0.13111910830882942,0.0031581416911705684
23.0,7028.0,6809.0,0.003273,0.003273,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn: Final VS available,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.01131393,0.011247562878561513,6.63671214384872e-05
35.0,7028.0,6809.0,0.00498,0.00498,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn: Final VS available,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.01721459,0.016440010009662692,0.0007745799903373062
25.0,7028.0,6809.0,0.003557,0.003557,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn: Final VS available,Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.01229564,0.01289812477333333,0.00060248477333333
8.0,7028.0,6809.0,0.001138,0.001138,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn:Final VS not available,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00393378,0.003937826453323415,4.046453323415002e-06
6.0,7028.0,6809.0,0.000854,0.000854,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn:Final VS not available,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00295206,0.0029022128783703096,4.984712162969026e-05
5.0,7028.0,6809.0,0.000711,0.000711,8.8578,0.390249,1.0,7064.0,42.0,615.0,Consent withdrawn:Final VS not available,Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.00245775,0.002445445717500008,1.2304282499992023e-05
20.0,7028.0,6809.0,0.002846,0.002846,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure: Final VS available,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.0098379,0.010009525510496031,0.00017162551049603077
21.0,7028.0,6809.0,0.002988,0.002988,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure: Final VS available,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.01032875,0.010462129768690471,0.00013337976869047183
19.0,7028.0,6809.0,0.002703,0.002703,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure: Final VS available,Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.00934358,0.009700515525813495,0.00035693552581349437
5.0,7028.0,6809.0,0.000711,0.000711,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure:Final VS not available (NA),Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00245775,0.0024468245214583424,1.0925478541657426e-05
9.0,7028.0,6809.0,0.001281,0.001281,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure:Final VS not available (NA),Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00442809,0.004318282300093794,0.00010980769990620587
7.0,7028.0,6809.0,0.000996,0.000996,8.8578,0.390249,1.0,7064.0,42.0,615.0,Site closure:Final VS not available (NA),Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.00344292,0.0035682495128472203,0.0001253295128472204
7.0,7028.0,6809.0,0.000996,0.000996,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3PMACE:Final VS available,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00344292,0.003558635612162696,0.00011571561216269614
6.0,7028.0,6809.0,0.000854,0.000854,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3PMACE:Final VS available,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00295206,0.0029019039346203095,5.015606537969036e-05
5.0,7028.0,6809.0,0.000711,0.000711,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3PMACE:Final VS available,Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.00245775,0.0024451367737500077,1.2613226249992126e-05
4.0,7028.0,6809.0,0.000569,0.000569,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3P-MACE:Final VS NA,Discontinuation From Study (Treated Set),FG000,diabetes type 2,INDUSTRY,0.00196689,0.0019850510447519927,1.8161044751992955e-05
4.0,7028.0,6809.0,0.000569,0.000569,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3P-MACE:Final VS NA,Discontinuation From Study (Treated Set),FG001,diabetes type 2,INDUSTRY,0.00196689,0.0019811684002877064,1.4278400287706574e-05
2.0,7028.0,6809.0,0.000285,0.000285,8.8578,0.390249,1.0,7064.0,42.0,615.0,Lost to FU for 3P-MACE:Final VS NA,Discontinuation From Study (Treated Set),FG002,diabetes type 2,INDUSTRY,0.00098517,0.0009992806302480158,1.411063024801579e-05
6.0,469.0,310.0,0.012793,0.012793,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.02368622,0.02348012773194447,0.00020609226805553063
8.0,469.0,310.0,0.017058,0.017058,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.03158285,0.03158835183855157,5.501838551566496e-06
8.0,469.0,310.0,0.017058,0.017058,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.03158285,0.03156681573408727,1.603426591273438e-05
5.0,469.0,310.0,0.010661,0.010661,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.01973882,0.01980840342797435,6.958342797434847e-05
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01579143,0.015759938685573648,3.1491314426351086e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00394739,0.003948240292380948,8.502923809477342e-07
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00789479,0.007839109162549577,5.5680837450423903e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00394739,0.003949113004880949,1.7230048809484255e-06
3.0,469.0,310.0,0.006397,0.006397,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01184403,0.011660831192708306,0.0001831988072916943
6.0,469.0,310.0,0.012793,0.012793,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.02368622,0.023556066557638908,0.0001301534423610931
9.0,469.0,310.0,0.01919,0.01919,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.03553025,0.0346588789163492,0.0008713710836507974
7.0,469.0,310.0,0.014925,0.014925,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.02763361,0.02749027907825395,0.00014333092174604808
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.01579143,0.01577041236700221,2.1017632997787777e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00394739,0.003943216131547615,4.173868452385203e-06
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,"Creatinine, or eGFR withdrawal criteria",Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,"Creatinine, or eGFR withdrawal criteria",Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00394739,0.0039435504648809485,3.8395351190517735e-06
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,"Creatinine, or eGFR withdrawal criteria",Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00394739,0.003947185383630948,2.046163690523281e-07
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00394739,0.003947125244166663,2.6475583333757796e-07
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00394739,0.003943182604166663,4.207395833337457e-06
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,469.0,310.0,0.017058,0.017058,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.03158285,0.031589840607956304,6.990607956301742e-06
7.0,469.0,310.0,0.014925,0.014925,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.02763361,0.027471801493789666,0.00016180850621033346
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01579143,0.015768512902240312,2.2917097759686533e-05
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00789479,0.007879358000882906,1.543199911709439e-05
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00789479,0.007888190243799574,6.599756200426424e-06
3.0,469.0,310.0,0.006397,0.006397,6.152733,0.300923,1.0,469.0,12.0,76.0,Adverse Event,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01184403,0.011673495617767829,0.00017053438223217122
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00394739,0.003945772395297615,1.6176047023851517e-06
3.0,469.0,310.0,0.006397,0.006397,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01184403,0.01167485724562497,0.00016917275437502988
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00789479,0.007887537838978146,7.2521610218548305e-06
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00789479,0.007881120351299575,1.3669648700425849e-05
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Physician Decision,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00394739,0.003945572174047615,1.817825952384923e-06
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00394739,0.0039412227298809485,6.167270119051757e-06
0.0,469.0,310.0,0.0,0.0,6.152733,0.300923,1.0,469.0,12.0,76.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01579143,0.01576395344843078,2.7476551569219354e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00394739,0.00393514001238095,1.2249987619050544e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00394739,0.003944490653214282,2.899346785717981e-06
14.0,469.0,310.0,0.029851,0.029851,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.05526907,0.0554850282255456,0.00021595822554560523
5.0,469.0,310.0,0.010661,0.010661,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01973882,0.019766034055079332,2.7214055079331084e-05
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01579143,0.015775072553668886,1.6357446331112524e-05
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00394739,0.0039457347994642815,1.655200535718819e-06
1.0,469.0,310.0,0.002132,0.002132,6.152733,0.300923,1.0,469.0,12.0,76.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00394739,0.003935663187380949,1.172681261905114e-05
2.0,469.0,310.0,0.004264,0.004264,6.152733,0.300923,1.0,469.0,12.0,76.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00789479,0.007887726222728146,7.0637772718543795e-06
5.0,469.0,310.0,0.010661,0.010661,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01973882,0.019753988585525753,1.5168585525752315e-05
5.0,469.0,310.0,0.010661,0.010661,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.01973882,0.019766034055079332,2.7214055079331084e-05
4.0,469.0,310.0,0.008529,0.008529,6.152733,0.300923,1.0,469.0,12.0,76.0,Other,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.01579143,0.01577736303700222,1.406696299777882e-05
12.0,496.0,328.0,0.024194,0.024194,6.20859,0.272045,1.0,496.0,15.0,15.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04086407,0.04063366321064124,0.00023040678935876135
37.0,496.0,328.0,0.074597,0.074597,6.20859,0.272045,1.0,496.0,15.0,15.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12599557,0.1284473943669643,0.0024518243669643114
11.0,496.0,328.0,0.022177,0.022177,6.20859,0.272045,1.0,496.0,15.0,15.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03745732,0.037385438135056716,7.188186494328647e-05
11.0,496.0,328.0,0.022177,0.022177,6.20859,0.272045,1.0,496.0,15.0,15.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03745732,0.0374538348881249,3.485111875103919e-06
1.0,496.0,328.0,0.002016,0.002016,6.20859,0.272045,1.0,496.0,15.0,15.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00340506,0.003411544062261894,6.484062261893735e-06
2.0,496.0,328.0,0.004032,0.004032,6.20859,0.272045,1.0,496.0,15.0,15.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00681011,0.006821569498065467,1.1459498065466596e-05
1.0,496.0,328.0,0.002016,0.002016,6.20859,0.272045,1.0,496.0,15.0,15.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00340506,0.003406807923095227,1.7479230952268526e-06
0.0,496.0,328.0,0.0,0.0,6.20859,0.272045,1.0,496.0,15.0,15.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,496.0,328.0,0.022177,0.022177,6.20859,0.272045,1.0,496.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03745732,0.03741703687297338,4.028312702662046e-05
25.0,496.0,328.0,0.050403,0.050403,6.20859,0.272045,1.0,496.0,15.0,15.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0851315,0.08333968632659725,0.0017918136734027534
10.0,496.0,328.0,0.020161,0.020161,6.20859,0.272045,1.0,496.0,15.0,15.0,Familial and personal reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03405226,0.03491356802794641,0.0008613080279464072
22.0,496.0,328.0,0.044355,0.044355,6.20859,0.272045,1.0,496.0,15.0,15.0,Familial and personal reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07491633,0.07364973261726193,0.0012665973827380717
6.0,496.0,328.0,0.012097,0.012097,6.20859,0.272045,1.0,496.0,15.0,15.0,Poor compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02043203,0.020371895142222214,6.013485777778618e-05
13.0,496.0,328.0,0.02621,0.02621,6.20859,0.272045,1.0,496.0,15.0,15.0,Poor compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04426912,0.042895937862361094,0.0013731821376389078
0.0,496.0,328.0,0.0,0.0,6.20859,0.272045,1.0,496.0,15.0,15.0,Sponsor decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,496.0,328.0,0.008065,0.008065,6.20859,0.272045,1.0,496.0,15.0,15.0,Sponsor decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01362192,0.013597183627777771,2.4736372222227895e-05
0.0,496.0,328.0,0.0,0.0,6.20859,0.272045,1.0,496.0,15.0,15.0,Incorrect randomization (not treated),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,496.0,328.0,0.002016,0.002016,6.20859,0.272045,1.0,496.0,15.0,15.0,Incorrect randomization (not treated),Overall Study,FG001,diabetes type 2,INDUSTRY,0.00340506,0.003409676552003959,4.616552003958857e-06
0.0,496.0,328.0,0.0,0.0,6.20859,0.272045,1.0,496.0,15.0,15.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,496.0,328.0,0.002016,0.002016,6.20859,0.272045,1.0,496.0,15.0,15.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00340506,0.003409600452003959,4.540452003958927e-06
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,ST Period,FG000,diabetes type 2,INDUSTRY,0.03747723,0.037517154278650953,3.9924278650953215e-05
4.0,245.0,187.0,0.016327,0.016327,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,ST Period,FG001,diabetes type 2,INDUSTRY,0.07495906,0.07664338770621286,0.0016843277062128653
6.0,245.0,187.0,0.02449,0.02449,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,ST Period,FG002,diabetes type 2,INDUSTRY,0.1124363,0.11216050510856151,0.00027579489143848834
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,ST Period,FG000,diabetes type 2,INDUSTRY,0.01874091,0.01873100226065476,9.907739345237782e-06
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,ST Period,FG001,diabetes type 2,INDUSTRY,0.01874091,0.01873682954541667,4.080454583329368e-06
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,ST Period,FG002,diabetes type 2,INDUSTRY,0.01874091,0.018738895091250003,2.014908749996963e-06
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,ST Period,FG000,diabetes type 2,INDUSTRY,0.03747723,0.03758086437290693,0.00010363437290693278
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,ST Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,ST Period,FG002,diabetes type 2,INDUSTRY,0.01874091,0.01877062793333334,2.971793333333972e-05
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,LT Period,FG000,diabetes type 2,INDUSTRY,0.01874091,0.018730663998154762,1.0246001845237718e-05
3.0,245.0,187.0,0.012245,0.012245,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,LT Period,FG001,diabetes type 2,INDUSTRY,0.05621815,0.0568419942487796,0.0006238442487795995
3.0,245.0,187.0,0.012245,0.012245,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,LT Period,FG002,diabetes type 2,INDUSTRY,0.05621815,0.05668229648622014,0.00046414648622013915
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,LT Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,LT Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,LT Period,FG002,diabetes type 2,INDUSTRY,0.01874091,0.0187490722175,8.162217499999708e-06
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,LT Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,LT Period,FG001,diabetes type 2,INDUSTRY,0.01874091,0.018777941951250002,3.703195125000225e-05
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,LT Period,FG002,diabetes type 2,INDUSTRY,0.01874091,0.01878080505958334,3.989505958333986e-05
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,LT Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,LT Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,LT Period,FG002,diabetes type 2,INDUSTRY,0.03747723,0.03754827631144855,7.104631144855267e-05
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,Non-treatment Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.03747723,0.03751356232382954,3.63323238295396e-05
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,Non-treatment Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.01874091,0.018732163191250005,8.746808749994506e-06
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by Subject,Non-treatment Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,Non-treatment Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.03747723,0.03750551861746053,2.8288617460528465e-05
3.0,245.0,187.0,0.012245,0.012245,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,Non-treatment Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.05621815,0.056712305626279595,0.0004941556262795938
2.0,245.0,187.0,0.008163,0.008163,5.505332,0.833939,1.0,256.0,23.0,122.0,Withdrawal by parent/guardian,Non-treatment Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.03747723,0.03753102056579381,5.3790565793812584e-05
3.0,245.0,187.0,0.012245,0.012245,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,Non-treatment Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.05621815,0.05688183702184516,0.0006636870218451607
4.0,245.0,187.0,0.016327,0.016327,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,Non-treatment Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.07495906,0.07637074606373272,0.0014116860637327228
5.0,245.0,187.0,0.020408,0.020408,5.505332,0.833939,1.0,256.0,23.0,122.0,Lost to Follow-up,Non-treatment Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.09369538,0.09535947280169652,0.0016640928016965206
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,Non-treatment Follow-up Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,187.0,0.004082,0.004082,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,Non-treatment Follow-up Period,FG001,diabetes type 2,INDUSTRY,0.01874091,0.018732997017500006,7.912982499993365e-06
0.0,245.0,187.0,0.0,0.0,5.505332,0.833939,1.0,256.0,23.0,122.0,Miscellaneous,Non-treatment Follow-up Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,263.0,248.0,0.0,0.0,5.575949,0.441834,1.0,263.0,6.0,32.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,263.0,248.0,0.003802,0.003802,5.575949,0.441834,1.0,263.0,6.0,32.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00936677,0.009583276052063508,0.000216506052063508
1.0,263.0,248.0,0.003802,0.003802,5.575949,0.441834,1.0,263.0,6.0,32.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00936677,0.009606722386825414,0.0002399523868254136
1.0,263.0,248.0,0.003802,0.003802,5.575949,0.441834,1.0,263.0,6.0,32.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00936677,0.009610913580158746,0.0002441435801587462
4.0,263.0,248.0,0.015209,0.015209,5.575949,0.441834,1.0,263.0,6.0,32.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03746953,0.03850946456718251,0.0010399345671825086
3.0,263.0,248.0,0.011407,0.011407,5.575949,0.441834,1.0,263.0,6.0,32.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02810277,0.029283303694114395,0.0011805336941143954
5.0,263.0,248.0,0.019011,0.019011,5.575949,0.441834,1.0,263.0,6.0,32.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0468363,0.046462781992647875,0.00037351800735212215
0.0,263.0,248.0,0.0,0.0,5.575949,0.441834,1.0,263.0,6.0,32.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,687.0,610.0,0.002911,0.002911,6.533789,0.262342,1.0,687.0,14.0,72.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00498971,0.004999338625470791,9.62862547079172e-06
1.0,687.0,610.0,0.001456,0.001456,6.533789,0.262342,1.0,687.0,14.0,72.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00249571,0.0025300030293750075,3.4293029375007545e-05
2.0,687.0,610.0,0.002911,0.002911,6.533789,0.262342,1.0,687.0,14.0,72.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00498971,0.005000278492276347,1.0568492276347152e-05
2.0,687.0,610.0,0.002911,0.002911,6.533789,0.262342,1.0,687.0,14.0,72.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00498971,0.004996950990054126,7.240990054126727e-06
2.0,687.0,610.0,0.002911,0.002911,6.533789,0.262342,1.0,687.0,14.0,72.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00498971,0.004992705587276347,2.995587276347772e-06
1.0,687.0,610.0,0.001456,0.001456,6.533789,0.262342,1.0,687.0,14.0,72.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00249571,0.0025272664184821493,3.15564184821494e-05
3.0,687.0,610.0,0.004367,0.004367,6.533789,0.262342,1.0,687.0,14.0,72.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00748542,0.00744890525616071,3.6514743839289286e-05
3.0,687.0,610.0,0.004367,0.004367,6.533789,0.262342,1.0,687.0,14.0,72.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00748542,0.007455035105803568,3.0384894196431797e-05
3.0,687.0,610.0,0.004367,0.004367,6.533789,0.262342,1.0,687.0,14.0,72.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00748542,0.007446858077648808,3.856192235119141e-05
5.0,687.0,610.0,0.007278,0.007278,6.533789,0.262342,1.0,687.0,14.0,72.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01247513,0.012363032766081352,0.00011209723391864684
4.0,687.0,610.0,0.005822,0.005822,6.533789,0.262342,1.0,687.0,14.0,72.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00997941,0.010061117041160701,8.170704116070189e-05
4.0,687.0,610.0,0.005822,0.005822,6.533789,0.262342,1.0,687.0,14.0,72.0,Withdrawal criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00997941,0.0100631072786607,8.369727866070105e-05
14.0,687.0,610.0,0.020378,0.020378,6.533789,0.262342,1.0,687.0,14.0,72.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03492967,0.03502179710004055,9.212710004054964e-05
14.0,687.0,610.0,0.020378,0.020378,6.533789,0.262342,1.0,687.0,14.0,72.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03492967,0.035051301919028645,0.0001216319190286419
17.0,687.0,610.0,0.024745,0.024745,6.533789,0.262342,1.0,687.0,14.0,72.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04241508,0.042205411440357124,0.00020966855964287684
2.0,278.0,241.0,0.007194,0.007194,5.631212,1.0,1.0,278.0,4.0,52.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04051094,0.04123567201909735,0.0007247320190973475
5.0,278.0,241.0,0.017986,0.017986,5.631212,1.0,1.0,278.0,4.0,52.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10128298,0.10275552864851178,0.00147254864851179
0.0,278.0,241.0,0.0,0.0,5.631212,1.0,1.0,278.0,4.0,52.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,278.0,241.0,0.003597,0.003597,5.631212,1.0,1.0,278.0,4.0,52.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02025547,0.021968767447648797,0.0017132974476487955
2.0,278.0,241.0,0.007194,0.007194,5.631212,1.0,1.0,278.0,4.0,52.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04051094,0.04099130281504972,0.0004803628150497202
5.0,278.0,241.0,0.017986,0.017986,5.631212,1.0,1.0,278.0,4.0,52.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10128298,0.10259610893720224,0.001313128937202243
3.0,278.0,241.0,0.010791,0.010791,5.631212,1.0,1.0,278.0,4.0,52.0,Non-compliance issues,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06076641,0.06172430248656759,0.0009578924865675867
3.0,278.0,241.0,0.010791,0.010791,5.631212,1.0,1.0,278.0,4.0,52.0,Non-compliance issues,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06076641,0.06091490419963306,0.0001484941996330591
9.0,278.0,241.0,0.032374,0.032374,5.631212,1.0,1.0,278.0,4.0,52.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.18230485,0.1805294227112104,0.0017754272887895994
7.0,278.0,241.0,0.02518,0.02518,5.631212,1.0,1.0,278.0,4.0,52.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.14179391,0.14073033372115076,0.001063576278849232
27.0,551.0,470.0,0.049002,0.049002,6.313548,0.217379,1.0,551.0,13.0,91.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0672521,0.06674617188458333,0.000505928115416665
2.0,551.0,470.0,0.00363,0.00363,6.313548,0.217379,1.0,551.0,13.0,91.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00498194,0.0049881710718777,6.231071877700611e-06
5.0,551.0,470.0,0.009074,0.009074,6.313548,0.217379,1.0,551.0,13.0,91.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01245348,0.012535409955238086,8.192995523808623e-05
7.0,551.0,470.0,0.012704,0.012704,6.313548,0.217379,1.0,551.0,13.0,91.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01743542,0.01741183007530755,2.3589924692448555e-05
8.0,551.0,470.0,0.014519,0.014519,6.313548,0.217379,1.0,551.0,13.0,91.0,Patient Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0199264,0.019833084425734126,9.33155742658745e-05
4.0,551.0,470.0,0.00726,0.00726,6.313548,0.217379,1.0,551.0,13.0,91.0,Patient Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00996388,0.00994416611005952,1.971388994048001e-05
1.0,551.0,470.0,0.001815,0.001815,6.313548,0.217379,1.0,551.0,13.0,91.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00249097,0.002508990823432541,1.8020823432541005e-05
2.0,551.0,470.0,0.00363,0.00363,6.313548,0.217379,1.0,551.0,13.0,91.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00498194,0.004986132073961034,4.19207396103443e-06
10.0,551.0,470.0,0.018149,0.018149,6.313548,0.217379,1.0,551.0,13.0,91.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02490834,0.024825916917460306,8.242308253969544e-05
11.0,551.0,470.0,0.019964,0.019964,6.313548,0.217379,1.0,551.0,13.0,91.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02739931,0.02740104960234126,1.7396023412608042e-06
4.0,551.0,470.0,0.00726,0.00726,6.313548,0.217379,1.0,551.0,13.0,91.0,Loss of Glucose Control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00996388,0.009942320448720232,2.1559551279767483e-05
0.0,551.0,470.0,0.0,0.0,6.313548,0.217379,1.0,551.0,13.0,91.0,Loss of Glucose Control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,504.0,379.0,0.013889,0.013889,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Main Phase: 0 - 52 Weeks,FG000,diabetes type 2,INDUSTRY,0.04766764,0.04809060623619049,0.00042296623619049456
4.0,504.0,379.0,0.007937,0.007937,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Main Phase: 0 - 52 Weeks,FG001,diabetes type 2,INDUSTRY,0.02724012,0.027223662293273845,1.6457706726154264e-05
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Main Phase: 0 - 52 Weeks,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Main Phase: 0 - 52 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,504.0,379.0,0.009921,0.009921,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Main Phase: 0 - 52 Weeks,FG000,diabetes type 2,INDUSTRY,0.03404929,0.034120859702232144,7.156970223214099e-05
1.0,504.0,379.0,0.001984,0.001984,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Main Phase: 0 - 52 Weeks,FG001,diabetes type 2,INDUSTRY,0.00680917,0.0068413280476190275,3.215804761902766e-05
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Main Phase: 0 - 52 Weeks,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Main Phase: 0 - 52 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Death,Main Phase: 0 - 52 Weeks,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,504.0,379.0,0.003968,0.003968,6.224558,0.551371,1.0,504.0,10.0,83.0,Death,Main Phase: 0 - 52 Weeks,FG001,diabetes type 2,INDUSTRY,0.01361834,0.013543289536466467,7.505046353353285e-05
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Death,Main Phase: 0 - 52 Weeks,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Death,Main Phase: 0 - 52 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,504.0,379.0,0.003968,0.003968,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Extension Phase: 53 - 104 Weeks,FG000,diabetes type 2,INDUSTRY,0.01361834,0.013555464563252184,6.287543674781543e-05
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Extension Phase: 53 - 104 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Extension Phase: 53 - 104 Weeks,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Lost to Follow-up,Extension Phase: 53 - 104 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Other,Extension Phase: 53 - 104 Weeks,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Other,Extension Phase: 53 - 104 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,504.0,379.0,0.001984,0.001984,6.224558,0.551371,1.0,504.0,10.0,83.0,Other,Extension Phase: 53 - 104 Weeks,FG002,diabetes type 2,INDUSTRY,0.00680917,0.006812369192182524,3.1991921825239716e-06
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Other,Extension Phase: 53 - 104 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,504.0,379.0,0.001984,0.001984,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Extension Phase: 53 - 104 Weeks,FG000,diabetes type 2,INDUSTRY,0.00680917,0.0068329671593849025,2.3797159384902726e-05
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Extension Phase: 53 - 104 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Extension Phase: 53 - 104 Weeks,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,504.0,379.0,0.0,0.0,6.224558,0.551371,1.0,504.0,10.0,83.0,Withdrawal by Subject,Extension Phase: 53 - 104 Weeks,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,324.0,314.0,0.009259,0.009259,5.783825,0.511525,1.0,324.0,8.0,117.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02739341,0.026916823856537722,0.00047658614346227784
1.0,324.0,314.0,0.003086,0.003086,5.783825,0.511525,1.0,324.0,8.0,117.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00913015,0.009198829836378953,6.867983637895252e-05
1.0,324.0,314.0,0.003086,0.003086,5.783825,0.511525,1.0,324.0,8.0,117.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00913015,0.009189842351706333,5.969235170633254e-05
2.0,324.0,314.0,0.006173,0.006173,5.783825,0.511525,1.0,324.0,8.0,117.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01826326,0.018449671548471328,0.0001864115484713283
1.0,324.0,314.0,0.003086,0.003086,5.783825,0.511525,1.0,324.0,8.0,117.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00913015,0.009188497828224191,5.834782822419088e-05
2.0,324.0,314.0,0.006173,0.006173,5.783825,0.511525,1.0,324.0,8.0,117.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01826326,0.0183955046371618,0.00013224463716179913
14.0,768.0,557.0,0.018229,0.018229,6.645091,0.220602,1.0,768.0,13.0,115.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02672231,0.026879087811845222,0.0001567778118452233
9.0,768.0,557.0,0.011719,0.011719,6.645091,0.220602,1.0,768.0,13.0,115.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01717915,0.017162040577876944,1.7109422123056522e-05
20.0,768.0,557.0,0.026042,0.026042,6.645091,0.220602,1.0,768.0,13.0,115.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03817557,0.038264790304195585,8.922030419558635e-05
18.0,768.0,557.0,0.023438,0.023438,6.645091,0.220602,1.0,768.0,13.0,115.0,Withdrawal of consent by subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03435831,0.034309484215277804,4.8825784722199284e-05
17.0,768.0,557.0,0.022135,0.022135,6.645091,0.220602,1.0,768.0,13.0,115.0,Withdrawal of consent by subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03244821,0.03220419062244047,0.00024401937755953035
31.0,768.0,557.0,0.040365,0.040365,6.645091,0.220602,1.0,768.0,13.0,115.0,Withdrawal of consent by subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05917199,0.05977676747579363,0.0006047774757936275
10.0,768.0,557.0,0.013021,0.013021,6.645091,0.220602,1.0,768.0,13.0,115.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01908779,0.019087416582420625,3.7341757937528475e-07
7.0,768.0,557.0,0.009115,0.009115,6.645091,0.220602,1.0,768.0,13.0,115.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01336189,0.013281967882003955,7.992211799604486e-05
9.0,768.0,557.0,0.011719,0.011719,6.645091,0.220602,1.0,768.0,13.0,115.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01717915,0.017178727439186473,4.2256081352748387e-07
15.0,768.0,557.0,0.019531,0.019531,6.645091,0.220602,1.0,768.0,13.0,115.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02863095,0.02868358720598211,5.263720598211105e-05
16.0,768.0,557.0,0.020833,0.020833,6.645091,0.220602,1.0,768.0,13.0,115.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03053958,0.030560720121394182,2.1140121394182254e-05
12.0,768.0,557.0,0.015625,0.015625,6.645091,0.220602,1.0,768.0,13.0,115.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02290505,0.023010263813260302,0.00010521381326030269
2.0,768.0,557.0,0.002604,0.002604,6.645091,0.220602,1.0,768.0,13.0,115.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00381726,0.003796383656944442,2.0876343055557887e-05
6.0,768.0,557.0,0.007812,0.007812,6.645091,0.220602,1.0,768.0,13.0,115.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01145179,0.011478701395823415,2.6911395823414966e-05
4.0,768.0,557.0,0.005208,0.005208,6.645091,0.220602,1.0,768.0,13.0,115.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00763453,0.007724071889533729,8.954188953372907e-05
3.0,768.0,557.0,0.003906,0.003906,6.645091,0.220602,1.0,768.0,13.0,115.0,Poor/Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0057259,0.005724530590753968,1.3694092460322244e-06
6.0,768.0,557.0,0.007812,0.007812,6.645091,0.220602,1.0,768.0,13.0,115.0,Poor/Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01145179,0.011480264710823413,2.8474710823412838e-05
2.0,768.0,557.0,0.002604,0.002604,6.645091,0.220602,1.0,768.0,13.0,115.0,Poor/Noncompliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00381726,0.0038038964860119024,1.3363513988097486e-05
1.0,768.0,557.0,0.001302,0.001302,6.645091,0.220602,1.0,768.0,13.0,115.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00190863,0.00191739276321429,8.762763214289994e-06
2.0,768.0,557.0,0.002604,0.002604,6.645091,0.220602,1.0,768.0,13.0,115.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00381726,0.0038020062427182514,1.5253757281748388e-05
0.0,768.0,557.0,0.0,0.0,6.645091,0.220602,1.0,768.0,13.0,115.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,768.0,557.0,0.0,0.0,6.645091,0.220602,1.0,768.0,13.0,115.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,768.0,557.0,0.0,0.0,6.645091,0.220602,1.0,768.0,13.0,115.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,768.0,557.0,0.002604,0.002604,6.645091,0.220602,1.0,768.0,13.0,115.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00381726,0.0038038964860119024,1.3363513988097486e-05
0.0,768.0,557.0,0.0,0.0,6.645091,0.220602,1.0,768.0,13.0,115.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,768.0,557.0,0.003906,0.003906,6.645091,0.220602,1.0,768.0,13.0,115.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0057259,0.005728449342420633,2.5493424206327747e-06
2.0,768.0,557.0,0.002604,0.002604,6.645091,0.220602,1.0,768.0,13.0,115.0,Subject No Longer Meets Study Criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00381726,0.0038038964860119024,1.3363513988097486e-05
86.0,10251.0,9023.0,0.008389,0.008389,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG000,diabetes type 2,NIH,0.02470402,0.02456269958806546,0.0001413204119345389
67.0,10251.0,9023.0,0.006536,0.006536,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG001,diabetes type 2,NIH,0.01924728,0.018652781647807527,0.000594498352192472
112.0,10251.0,9023.0,0.010926,0.010926,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG002,diabetes type 2,NIH,0.032175,0.03095485453453374,0.0012201454654662616
126.0,10251.0,9023.0,0.012291,0.012291,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG003,diabetes type 2,NIH,0.03619467,0.0349323334575595,0.001262336542440498
64.0,10251.0,9023.0,0.006243,0.006243,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG004,diabetes type 2,NIH,0.01838445,0.017772790956855137,0.0006116590431448632
77.0,10251.0,9023.0,0.007511,0.007511,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG005,diabetes type 2,NIH,0.02211847,0.02086661671235117,0.0012518532876488325
91.0,10251.0,9023.0,0.008877,0.008877,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG006,diabetes type 2,NIH,0.02614109,0.025297698997232138,0.0008433910027678612
95.0,10251.0,9023.0,0.009267,0.009267,9.235228,0.318867,1.0,10251.0,2.0,7.0,Death,Overall Study,FG007,diabetes type 2,NIH,0.02728956,0.02620240400997024,0.0010871559900297624
14.0,10251.0,9023.0,0.001366,0.001366,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,NIH,0.00402261,0.004002551448699506,2.0058551300493853e-05
14.0,10251.0,9023.0,0.001366,0.001366,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,NIH,0.00402261,0.004026676373937604,4.06637393760359e-06
14.0,10251.0,9023.0,0.001366,0.001366,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,NIH,0.00402261,0.004021696784116175,9.132158838255286e-07
14.0,10251.0,9023.0,0.001366,0.001366,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,NIH,0.00402261,0.004015916937866175,6.6930621338253185e-06
15.0,10251.0,9023.0,0.001463,0.001463,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,NIH,0.00430826,0.004249969824761001,5.829017523899943e-05
15.0,10251.0,9023.0,0.001463,0.001463,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,NIH,0.00430826,0.004249650412261,5.8609587739000095e-05
13.0,10251.0,9023.0,0.001268,0.001268,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG006,diabetes type 2,NIH,0.00373402,0.003641020062767857,9.299993723214288e-05
14.0,10251.0,9023.0,0.001366,0.001366,9.235228,0.318867,1.0,10251.0,2.0,7.0,Lost to Follow-up,Overall Study,FG007,diabetes type 2,NIH,0.00402261,0.004015916937866175,6.6930621338253185e-06
40.0,10251.0,9023.0,0.003902,0.003902,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,NIH,0.01149065,0.011033691617113102,0.0004569583828868979
27.0,10251.0,9023.0,0.002634,0.002634,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,NIH,0.00775663,0.007809941887142855,5.331188714285517e-05
28.0,10251.0,9023.0,0.002731,0.002731,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,NIH,0.00804228,0.008005653200922619,3.662679907738206e-05
27.0,10251.0,9023.0,0.002634,0.002634,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,NIH,0.00775663,0.007812515983095238,5.588598309523834e-05
30.0,10251.0,9023.0,0.002927,0.002927,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,NIH,0.00861946,0.008506558573303574,0.00011290142669642678
32.0,10251.0,9023.0,0.003122,0.003122,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,NIH,0.0091937,0.00914040734637896,5.3292653621040895e-05
32.0,10251.0,9023.0,0.003122,0.003122,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,NIH,0.0091937,0.00914040734637896,5.3292653621040895e-05
21.0,10251.0,9023.0,0.002049,0.002049,9.235228,0.318867,1.0,10251.0,2.0,7.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,NIH,0.00603392,0.005667036322728171,0.00036688367727182904
22.0,10251.0,9023.0,0.002146,0.002146,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG000,diabetes type 2,NIH,0.00631956,0.006657505553859131,0.0003379455538591305
28.0,10251.0,9023.0,0.002731,0.002731,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG001,diabetes type 2,NIH,0.00804228,0.008000600251160709,4.1679748839291986e-05
16.0,10251.0,9023.0,0.001561,0.001561,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG002,diabetes type 2,NIH,0.00459685,0.004515211378353171,8.16386216468297e-05
11.0,10251.0,9023.0,0.001073,0.001073,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG003,diabetes type 2,NIH,0.00315978,0.003201835646904758,4.2055646904758104e-05
26.0,10251.0,9023.0,0.002536,0.002536,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG004,diabetes type 2,NIH,0.00746804,0.007430962456210316,3.7077543789683365e-05
28.0,10251.0,9023.0,0.002731,0.002731,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG005,diabetes type 2,NIH,0.00804228,0.00799655797627976,4.5722023720240826e-05
13.0,10251.0,9023.0,0.001268,0.001268,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG006,diabetes type 2,NIH,0.00373402,0.0036299180042559513,0.00010410199574404852
16.0,10251.0,9023.0,0.001561,0.001561,9.235228,0.318867,1.0,10251.0,2.0,7.0,missed closeout visit,Overall Study,FG007,diabetes type 2,NIH,0.00459685,0.004523430232936505,7.34197670634951e-05
13.0,261.0,213.0,0.049808,0.049808,5.568345,0.247637,1.0,261.0,6.0,59.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06868177,0.06897862049886905,0.0002968504988690446
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00528268,0.005288058887718291,5.378887718291564e-06
0.0,261.0,213.0,0.0,0.0,5.568345,0.247637,1.0,261.0,6.0,59.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00528268,0.005287406166884958,4.726166884958145e-06
2.0,261.0,213.0,0.007663,0.007663,5.568345,0.247637,1.0,261.0,6.0,59.0,Entry criteria not met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01056675,0.010574919630446454,8.169630446454301e-06
2.0,261.0,213.0,0.007663,0.007663,5.568345,0.247637,1.0,261.0,6.0,59.0,Entry criteria not met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01056675,0.0105706600755655,3.910075565501103e-06
0.0,261.0,213.0,0.0,0.0,5.568345,0.247637,1.0,261.0,6.0,59.0,Loss of glucose control,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,261.0,213.0,0.007663,0.007663,5.568345,0.247637,1.0,261.0,6.0,59.0,Loss of glucose control,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01056675,0.010575067096339305,8.31709633930533e-06
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528268,0.0052831195448016155,4.395448016157946e-07
3.0,261.0,213.0,0.011494,0.011494,5.568345,0.247637,1.0,261.0,6.0,59.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01584943,0.015401657024781745,0.0004477729752182559
2.0,261.0,213.0,0.007663,0.007663,5.568345,0.247637,1.0,261.0,6.0,59.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01056675,0.010578101680386922,1.1351680386921872e-05
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00528268,0.005289522364801624,6.842364801624631e-06
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00528268,0.005282868473194471,1.88473194471378e-07
1.0,261.0,213.0,0.003831,0.003831,5.568345,0.247637,1.0,261.0,6.0,59.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00528268,0.005287835599444478,5.155599444478173e-06
7.0,261.0,213.0,0.02682,0.02682,5.568345,0.247637,1.0,261.0,6.0,59.0,Subject decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03698292,0.03743111255592263,0.0004481925559226274
11.0,261.0,213.0,0.042146,0.042146,5.568345,0.247637,1.0,261.0,6.0,59.0,Subject decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05811641,0.06076628220127974,0.0026498722012797404
7.0,505.0,458.0,0.013861,0.013861,6.226537,0.419651,1.0,505.0,12.0,103.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03621837,0.036184121464880974,3.424853511902609e-05
7.0,505.0,458.0,0.013861,0.013861,6.226537,0.419651,1.0,505.0,12.0,103.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03621837,0.03615078656544645,6.758343455354893e-05
2.0,505.0,458.0,0.00396,0.00396,6.226537,0.419651,1.0,505.0,12.0,103.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01034736,0.010240186316279765,0.00010717368372023528
1.0,505.0,458.0,0.00198,0.00198,6.226537,0.419651,1.0,505.0,12.0,103.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00517368,0.005160604564960318,1.3075435039681775e-05
4.0,505.0,458.0,0.007921,0.007921,6.226537,0.419651,1.0,505.0,12.0,103.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02069733,0.020571350551820883,0.0001259794481791171
2.0,505.0,458.0,0.00396,0.00396,6.226537,0.419651,1.0,505.0,12.0,103.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01034736,0.01025110442508929,9.625557491070927e-05
12.0,505.0,458.0,0.023762,0.023762,6.226537,0.419651,1.0,505.0,12.0,103.0,Other than specified above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06208938,0.061816154350416604,0.00027322564958339596
12.0,505.0,458.0,0.023762,0.023762,6.226537,0.419651,1.0,505.0,12.0,103.0,Other than specified above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06208938,0.061834022199880885,0.0002553578001191145
15.0,467.0,107.0,0.03212,0.03212,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.04926683,0.049364300449603216,9.747044960321805e-05
21.0,467.0,107.0,0.044968,0.044968,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.06897357,0.0695268935984822,0.0005533235984822027
14.0,467.0,107.0,0.029979,0.029979,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.04598289,0.04659662956626984,0.0006137395662698386
25.0,467.0,107.0,0.053533,0.053533,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.08211088,0.08214552220645804,3.46422064580465e-05
30.0,467.0,107.0,0.06424,0.06424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.09853367,0.09381314598481152,0.004720524015188479
9.0,467.0,107.0,0.019272,0.019272,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0295601,0.029648366280119062,8.82662801190634e-05
11.0,467.0,107.0,0.023555,0.023555,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03612952,0.03601431277955351,0.00011520722044648657
5.0,467.0,107.0,0.010707,0.010707,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01642279,0.016477156257083337,5.4366257083337394e-05
10.0,467.0,107.0,0.021413,0.021413,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.03284404,0.03294048206896831,9.644206896831237e-05
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00985337,0.009855292911607196,1.922911607195668e-06
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00985337,0.009868168142916708,1.4798142916707877e-05
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00985337,0.009851120024940528,2.2499750594717066e-06
4.0,467.0,107.0,0.008565,0.008565,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01313731,0.013147568837410716,1.025883741071626e-05
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00656942,0.006567251586249976,2.168413750024134e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00656942,0.006551586512619025,1.7833487380975073e-05
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00985337,0.009856229846964331,2.859846964331156e-06
4.0,467.0,107.0,0.008565,0.008565,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.01313731,0.013134370881041675,2.9391189583245075e-06
4.0,467.0,107.0,0.008565,0.008565,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.01313731,0.013135793266458341,1.5167335416579886e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00985337,0.009855560324107194,2.190324107193345e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.00328394,0.003285024460833323,1.0844608333230449e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00328394,0.0032849864441666567,1.0464441666567861e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00328394,0.0032875969172618965,3.6569172618965314e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00328394,0.003286506991904755,2.5669919047552336e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.00328394,0.0032855952066666565,1.6552066666565904e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,24-week Short-term Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00328394,0.003287426150595229,3.4861505952290227e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,24-week Short-term Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,24-week Short-term Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,24-week Short-term Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,24-week Short-term Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
26.0,467.0,107.0,0.055675,0.055675,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.08539636,0.08573624079434512,0.0003398807943451182
27.0,467.0,107.0,0.057816,0.057816,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.0886803,0.08799436597925588,0.0006859340207441278
21.0,467.0,107.0,0.044968,0.044968,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.06897357,0.06941651815419647,0.0004429481541964736
26.0,467.0,107.0,0.055675,0.055675,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.08539636,0.08584142100333318,0.00044506100333317755
25.0,467.0,107.0,0.053533,0.053533,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lack of Efficacy,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.08211088,0.08230372452616042,0.00019284452616041836
25.0,467.0,107.0,0.053533,0.053533,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.08211088,0.08217133734483109,6.0457344831094106e-05
28.0,467.0,107.0,0.059957,0.059957,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.09196424,0.09115422835279764,0.0008100116472023605
17.0,467.0,107.0,0.036403,0.036403,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.05583626,0.05706145100008928,0.0012251910000892832
24.0,467.0,107.0,0.051392,0.051392,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.07882693,0.07900810948383934,0.00018117948383933324
10.0,467.0,107.0,0.021413,0.021413,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject Withdrew Consent,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.03284404,0.032878384427440545,3.434442744054689e-05
9.0,467.0,107.0,0.019272,0.019272,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0295601,0.029658601022886918,9.850102288691889e-05
10.0,467.0,107.0,0.021413,0.021413,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.03284404,0.03293312089431554,8.908089431554356e-05
10.0,467.0,107.0,0.021413,0.021413,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.03284404,0.032900886291815534,5.68462918155363e-05
5.0,467.0,107.0,0.010707,0.010707,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.01642279,0.016452873746051592,3.0083746051592225e-05
5.0,467.0,107.0,0.010707,0.010707,6.148468,0.249466,1.0,1035.0,6.0,134.0,Adverse Event,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.01642279,0.01645614277105159,3.335277105159101e-05
9.0,467.0,107.0,0.019272,0.019272,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0295601,0.02963275982178573,7.265982178573244e-05
7.0,467.0,107.0,0.014989,0.014989,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.02299068,0.023154490306994055,0.00016381030699405552
12.0,467.0,107.0,0.025696,0.025696,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.03941347,0.03947074934073316,5.7279340733164263e-05
11.0,467.0,107.0,0.023555,0.023555,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.03612952,0.03599174594038686,0.00013777405961314104
12.0,467.0,107.0,0.025696,0.025696,6.148468,0.249466,1.0,1035.0,6.0,134.0,Lost to Follow-up,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.03941347,0.0394707168865665,5.724688656649768e-05
4.0,467.0,107.0,0.008565,0.008565,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.01313731,0.013141768158601193,4.458158601193529e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.00328394,0.003283928461904754,1.153809524616009e-08
4.0,467.0,107.0,0.008565,0.008565,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.01313731,0.013139869519851187,2.559519851187339e-06
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.00656942,0.00657174989624997,2.329896249969772e-06
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Poor / Non-compliance,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.00656942,0.006569775660833304,3.556608333035033e-07
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.00328394,0.0032853968605952286,1.4568605952287005e-06
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.00985337,0.009851370897023861,1.999102976138825e-06
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.00656942,0.006571510472916637,2.0904729166370054e-06
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.00328394,0.003283978016666656,3.8016666655850406e-08
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Subject No Longer Meets Study Criteria,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.00656942,0.00656967854999997,2.5854999996955536e-07
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Pregnancy,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Pregnancy,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.00328394,0.0032843243744047537,3.843744047537026e-07
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Pregnancy,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Pregnancy,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.00328394,0.003284357516666657,4.175166666568926e-07
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Pregnancy,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Administrative Reason by Sponsor,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Administrative Reason by Sponsor,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.00656942,0.006557326030535688,1.2093969464312126e-05
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Administrative Reason by Sponsor,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.00328394,0.003285153581547609,1.2135815476090224e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Administrative Reason by Sponsor,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Administrative Reason by Sponsor,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.00328394,0.0032839869333333225,4.693333332259422e-08
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Death,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Death,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Death,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Death,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.00328394,0.003284005941666656,6.594166665615728e-08
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Death,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Missing,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Missing,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Missing,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.00328394,0.003285153581547609,1.2135815476090224e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Missing,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Missing,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,467.0,107.0,0.010707,0.010707,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,48-month Short Term + Long Term Period,FG000,diabetes type 2,INDUSTRY,0.01642279,0.016438064386597222,1.5274386597222134e-05
3.0,467.0,107.0,0.006424,0.006424,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,48-month Short Term + Long Term Period,FG001,diabetes type 2,INDUSTRY,0.00985337,0.009851370897023861,1.999102976138825e-06
2.0,467.0,107.0,0.004283,0.004283,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,48-month Short Term + Long Term Period,FG002,diabetes type 2,INDUSTRY,0.00656942,0.006571071810833304,1.6518108333033604e-06
0.0,467.0,107.0,0.0,0.0,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,48-month Short Term + Long Term Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,107.0,0.002141,0.002141,6.148468,0.249466,1.0,1035.0,6.0,134.0,Other Reason,48-month Short Term + Long Term Period,FG004,diabetes type 2,INDUSTRY,0.00328394,0.0032839869333333225,4.693333332259422e-08
4.0,878.0,651.0,0.004556,0.004556,6.778785,0.355236,1.0,878.0,16.0,217.0,Randomized But Not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01097116,0.010892333744474207,7.882625552579382e-05
1.0,878.0,651.0,0.001139,0.001139,6.778785,0.355236,1.0,878.0,16.0,217.0,Randomized But Not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00274279,0.0027526982561363687,9.908256136368504e-06
10.0,878.0,651.0,0.01139,0.01139,6.778785,0.355236,1.0,878.0,16.0,217.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02742789,0.026897250167678584,0.0005306398323214161
8.0,878.0,651.0,0.009112,0.009112,6.778785,0.355236,1.0,878.0,16.0,217.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02194231,0.021765601873050152,0.00017670812694984758
2.0,878.0,651.0,0.002278,0.002278,6.778785,0.355236,1.0,878.0,16.0,217.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00548558,0.005522185274494047,3.6605274494046734e-05
5.0,878.0,651.0,0.005695,0.005695,6.778785,0.355236,1.0,878.0,16.0,217.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01371395,0.013648691851736101,6.525814826389975e-05
11.0,878.0,651.0,0.012528,0.012528,6.778785,0.355236,1.0,878.0,16.0,217.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03016827,0.030201039879503164,3.276987950316321e-05
12.0,878.0,651.0,0.013667,0.013667,6.778785,0.355236,1.0,878.0,16.0,217.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03291106,0.032603265892539694,0.00030779410746030467
14.0,878.0,651.0,0.015945,0.015945,6.778785,0.355236,1.0,878.0,16.0,217.0,Received Rescue Therapy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03839664,0.03739951028725199,0.0009971297127480128
22.0,878.0,651.0,0.025057,0.025057,6.778785,0.355236,1.0,878.0,16.0,217.0,Received Rescue Therapy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06033895,0.06003878573496031,0.0003001642650396902
34.0,878.0,651.0,0.038724,0.038724,6.778785,0.355236,1.0,878.0,16.0,217.0,Personal Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09325002,0.09329376376788702,4.374376788701673e-05
45.0,878.0,651.0,0.051253,0.051253,6.778785,0.355236,1.0,878.0,16.0,217.0,Personal Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.1234207,0.12120212899578059,0.002218571004219405
11.0,878.0,651.0,0.012528,0.012528,6.778785,0.355236,1.0,878.0,16.0,217.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03016827,0.030194476316169828,2.620631616982727e-05
18.0,878.0,651.0,0.020501,0.020501,6.778785,0.355236,1.0,878.0,16.0,217.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0493678,0.049863629304583344,0.0004958293045833409
9.0,878.0,651.0,0.010251,0.010251,6.778785,0.355236,1.0,878.0,16.0,217.0,Selection Criterion/Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0246851,0.024725163426845248,4.006342684524655e-05
9.0,878.0,651.0,0.010251,0.010251,6.778785,0.355236,1.0,878.0,16.0,217.0,Selection Criterion/Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0246851,0.02476482351997026,7.972351997025812e-05
1.0,878.0,651.0,0.001139,0.001139,6.778785,0.355236,1.0,878.0,16.0,217.0,Site Closure/Site Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00274279,0.002751888742386367,9.09874238636671e-06
4.0,878.0,651.0,0.004556,0.004556,6.778785,0.355236,1.0,878.0,16.0,217.0,Site Closure/Site Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01097116,0.010881152934414686,9.000706558531454e-05
3.0,878.0,651.0,0.003417,0.003417,6.778785,0.355236,1.0,878.0,16.0,217.0,Perceived Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00822837,0.008266426243541675,3.805624354167453e-05
1.0,878.0,651.0,0.001139,0.001139,6.778785,0.355236,1.0,878.0,16.0,217.0,Perceived Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00274279,0.002752577918636369,9.787918636369047e-06
2.0,878.0,651.0,0.002278,0.002278,6.778785,0.355236,1.0,878.0,16.0,217.0,Non Serious Hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00548558,0.005525050687271826,3.947068727182604e-05
0.0,878.0,651.0,0.0,0.0,6.778785,0.355236,1.0,878.0,16.0,217.0,Non Serious Hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,878.0,651.0,0.001139,0.001139,6.778785,0.355236,1.0,878.0,16.0,217.0,No More Need of Insulin,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00274279,0.002751888742386367,9.09874238636671e-06
0.0,878.0,651.0,0.0,0.0,6.778785,0.355236,1.0,878.0,16.0,217.0,No More Need of Insulin,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,492.0,387.0,0.006098,0.006098,6.200509,0.248521,1.0,492.0,0.0,0.0,Adverse Event,Phase A,FG000,diabetes type 2,INDUSTRY,0.00939675,0.009393617275436509,3.1327245634919787e-06
0.0,492.0,387.0,0.0,0.0,6.200509,0.248521,1.0,492.0,0.0,0.0,Adverse Event,Phase A,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,492.0,387.0,0.0,0.0,6.200509,0.248521,1.0,492.0,0.0,0.0,Creatinine/CrCl -Increase in creatinine,Phase A,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,492.0,387.0,0.004065,0.004065,6.200509,0.248521,1.0,492.0,0.0,0.0,Creatinine/CrCl -Increase in creatinine,Phase A,FG001,diabetes type 2,INDUSTRY,0.00626398,0.006231319612772357,3.266038722764264e-05
0.0,492.0,387.0,0.0,0.0,6.200509,0.248521,1.0,492.0,0.0,0.0,Hyperglycemia,Phase A,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,492.0,387.0,0.002033,0.002033,6.200509,0.248521,1.0,492.0,0.0,0.0,Hyperglycemia,Phase A,FG001,diabetes type 2,INDUSTRY,0.00313276,0.003131762522708331,9.974772916692722e-07
6.0,492.0,387.0,0.012195,0.012195,6.200509,0.248521,1.0,492.0,0.0,0.0,Lost to Follow-up,Phase A,FG000,diabetes type 2,INDUSTRY,0.01879195,0.018885437382619007,9.348738261900566e-05
4.0,492.0,387.0,0.00813,0.00813,6.200509,0.248521,1.0,492.0,0.0,0.0,Lost to Follow-up,Phase A,FG001,diabetes type 2,INDUSTRY,0.01252797,0.01249371018922615,3.4259810773849125e-05
2.0,492.0,387.0,0.004065,0.004065,6.200509,0.248521,1.0,492.0,0.0,0.0,Physician Decision,Phase A,FG000,diabetes type 2,INDUSTRY,0.00626398,0.0062303172961056886,3.366270389431117e-05
0.0,492.0,387.0,0.0,0.0,6.200509,0.248521,1.0,492.0,0.0,0.0,Physician Decision,Phase A,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,492.0,387.0,0.004065,0.004065,6.200509,0.248521,1.0,492.0,0.0,0.0,Protocol Violation,Phase A,FG000,diabetes type 2,INDUSTRY,0.00626398,0.006225679178823944,3.8300821176055766e-05
3.0,492.0,387.0,0.006098,0.006098,6.200509,0.248521,1.0,492.0,0.0,0.0,Protocol Violation,Phase A,FG001,diabetes type 2,INDUSTRY,0.00939675,0.009397870372519844,1.120372519843385e-06
7.0,492.0,387.0,0.014228,0.014228,6.200509,0.248521,1.0,492.0,0.0,0.0,Withdrawal by Subject,Phase A,FG000,diabetes type 2,INDUSTRY,0.02192471,0.021819485092341318,0.00010522490765868184
7.0,492.0,387.0,0.014228,0.014228,6.200509,0.248521,1.0,492.0,0.0,0.0,Withdrawal by Subject,Phase A,FG001,diabetes type 2,INDUSTRY,0.02192471,0.02185558970633934,6.912029366066066e-05
6.0,492.0,387.0,0.012195,0.012195,6.200509,0.248521,1.0,492.0,0.0,0.0,Adverse Event,Phase B,FG000,diabetes type 2,INDUSTRY,0.01879195,0.01880598141877969,1.4031418779689164e-05
6.0,492.0,387.0,0.012195,0.012195,6.200509,0.248521,1.0,492.0,0.0,0.0,Adverse Event,Phase B,FG001,diabetes type 2,INDUSTRY,0.01879195,0.01879379211446422,1.8421144642177811e-06
10.0,492.0,387.0,0.020325,0.020325,6.200509,0.248521,1.0,492.0,0.0,0.0,Hyperglycemia,Phase B,FG000,diabetes type 2,INDUSTRY,0.03131992,0.03178273845867063,0.00046281845867062604
9.0,492.0,387.0,0.018293,0.018293,6.200509,0.248521,1.0,492.0,0.0,0.0,Hyperglycemia,Phase B,FG001,diabetes type 2,INDUSTRY,0.0281887,0.028175784943265697,1.2915056734303515e-05
6.0,492.0,387.0,0.012195,0.012195,6.200509,0.248521,1.0,492.0,0.0,0.0,Lost to Follow-up,Phase B,FG000,diabetes type 2,INDUSTRY,0.01879195,0.0188134493172023,2.149931720229689e-05
4.0,492.0,387.0,0.00813,0.00813,6.200509,0.248521,1.0,492.0,0.0,0.0,Lost to Follow-up,Phase B,FG001,diabetes type 2,INDUSTRY,0.01252797,0.012498143302142812,2.9826697857187126e-05
4.0,492.0,387.0,0.00813,0.00813,6.200509,0.248521,1.0,492.0,0.0,0.0,Physician Decision,Phase B,FG000,diabetes type 2,INDUSTRY,0.01252797,0.012491774786726147,3.619521327385272e-05
2.0,492.0,387.0,0.004065,0.004065,6.200509,0.248521,1.0,492.0,0.0,0.0,Physician Decision,Phase B,FG001,diabetes type 2,INDUSTRY,0.00626398,0.006231232094439023,3.274790556097654e-05
0.0,492.0,387.0,0.0,0.0,6.200509,0.248521,1.0,492.0,0.0,0.0,Pregnancy,Phase B,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,492.0,387.0,0.002033,0.002033,6.200509,0.248521,1.0,492.0,0.0,0.0,Pregnancy,Phase B,FG001,diabetes type 2,INDUSTRY,0.00313276,0.0031320550143749976,7.0498562500243e-07
3.0,492.0,387.0,0.006098,0.006098,6.200509,0.248521,1.0,492.0,0.0,0.0,Protocol Violation,Phase B,FG000,diabetes type 2,INDUSTRY,0.00939675,0.009391052340436506,5.697659563494786e-06
3.0,492.0,387.0,0.006098,0.006098,6.200509,0.248521,1.0,492.0,0.0,0.0,Protocol Violation,Phase B,FG001,diabetes type 2,INDUSTRY,0.00939675,0.009397870372519844,1.120372519843385e-06
8.0,492.0,387.0,0.01626,0.01626,6.200509,0.248521,1.0,492.0,0.0,0.0,Withdrawal by Subject,Phase B,FG000,diabetes type 2,INDUSTRY,0.02505593,0.024871998688313513,0.0001839313116864874
6.0,492.0,387.0,0.012195,0.012195,6.200509,0.248521,1.0,492.0,0.0,0.0,Withdrawal by Subject,Phase B,FG001,diabetes type 2,INDUSTRY,0.01879195,0.018805198935595176,1.3248935595174677e-05
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.00393219,0.00393609213666667,3.902136666669373e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Lost to Follow-up,Phase A (Up to 24 Weeks),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG005,diabetes type 2,INDUSTRY,0.00393219,0.003931424216666668,7.657833333320208e-07
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase A (Up to 24 Weeks),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.00393219,0.003931745940000003,4.4405999999764384e-07
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Protocol Violation,Phase A (Up to 24 Weeks),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.00393219,0.003932509349166669,3.193491666690293e-07
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.00393219,0.003926356231250002,5.833768749997914e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG006,diabetes type 2,INDUSTRY,0.00393219,0.003932635920833335,4.4592083333488963e-07
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase A (Up to 24 Weeks),FG009,diabetes type 2,INDUSTRY,0.00393219,0.003932635920833335,4.4592083333488963e-07
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG001,diabetes type 2,INDUSTRY,0.00786669,0.007879586019444454,1.289601944445308e-05
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG002,diabetes type 2,INDUSTRY,0.00393219,0.003931601463690478,5.885363095221169e-07
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG003,diabetes type 2,INDUSTRY,0.00786669,0.007864268031111123,2.421968888877829e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG006,diabetes type 2,INDUSTRY,0.00393219,0.003932167891666669,2.2108333331584407e-08
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase A (Up to 24 Weeks),FG009,diabetes type 2,INDUSTRY,0.00393219,0.003932167891666669,2.2108333331584407e-08
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG000,diabetes type 2,INDUSTRY,0.00393219,0.003930942402500004,1.2475974999967554e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG003,diabetes type 2,INDUSTRY,0.00393219,0.003935621666666669,3.431666666668838e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Physician Decision,Phase B (Week 25 to Week 52),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG000,diabetes type 2,INDUSTRY,0.00786669,0.007888532598015882,2.1842598015880954e-05
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG005,diabetes type 2,INDUSTRY,0.00393219,0.003933463104166668,1.2731041666678988e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG007,diabetes type 2,INDUSTRY,0.00393219,0.003933463104166668,1.2731041666678988e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Withdrawal by Subject,Phase B (Week 25 to Week 52),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG000,diabetes type 2,INDUSTRY,0.00786669,0.007888966590515885,2.2276590515884348e-05
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG001,diabetes type 2,INDUSTRY,0.00393219,0.003926032889583335,6.157110416665085e-06
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG002,diabetes type 2,INDUSTRY,0.00393219,0.0039315610636904775,6.289363095228831e-07
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG003,diabetes type 2,INDUSTRY,0.00786669,0.007870216049563507,3.5260495635063005e-06
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG005,diabetes type 2,INDUSTRY,0.00393219,0.003932127491666668,6.250833333235062e-08
1.0,585.0,555.0,0.001709,0.001709,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG006,diabetes type 2,INDUSTRY,0.00393219,0.003932127491666668,6.250833333235062e-08
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,585.0,555.0,0.003419,0.003419,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG008,diabetes type 2,INDUSTRY,0.00786669,0.00787995881873017,1.3268818730169038e-05
0.0,585.0,555.0,0.0,0.0,6.37332,0.361017,1.0,585.0,0.0,0.0,Adverse Event,Phase B (Week 25 to Week 52),FG009,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,243.0,237.0,0.012346,0.012346,5.497168,0.522819,1.0,243.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0354827,0.03558444252761906,0.00010174252761906144
0.0,243.0,237.0,0.0,0.0,5.497168,0.522819,1.0,243.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,243.0,237.0,0.004115,0.004115,5.497168,0.522819,1.0,243.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01182661,0.012218163146746041,0.00039155314674604175
2.0,243.0,237.0,0.00823,0.00823,5.497168,0.522819,1.0,243.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02365322,0.024685281442996025,0.001032061442996026
0.0,243.0,237.0,0.0,0.0,5.497168,0.522819,1.0,243.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,402.0,285.0,0.004975,0.004975,5.998937,0.424057,1.0,402.0,0.0,0.0,Adverse Event,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.01265585,0.01277699778865077,0.00012114778865076996
3.0,402.0,285.0,0.007463,0.007463,5.998937,0.424057,1.0,402.0,0.0,0.0,Adverse Event,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.01898504,0.01889493353946424,9.010646053576182e-05
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Lack of Efficacy,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0063292,0.006329188914250546,1.1085749453826343e-08
0.0,402.0,285.0,0.0,0.0,5.998937,0.424057,1.0,402.0,0.0,0.0,Lack of Efficacy,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,402.0,285.0,0.012438,0.012438,5.998937,0.424057,1.0,402.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.03164089,0.031151736454355154,0.0004891535456448444
3.0,402.0,285.0,0.007463,0.007463,5.998937,0.424057,1.0,402.0,0.0,0.0,Lost to Follow-up,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.01898504,0.018904695629107102,8.034437089289928e-05
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Non-compliance with study drug,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0063292,0.006329188914250546,1.1085749453826343e-08
0.0,402.0,285.0,0.0,0.0,5.998937,0.424057,1.0,402.0,0.0,0.0,Non-compliance with study drug,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,402.0,285.0,0.0,0.0,5.998937,0.424057,1.0,402.0,0.0,0.0,Physician Decision,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Physician Decision,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0063292,0.006314539291825402,1.4660708174598497e-05
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Protocol Violation,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0063292,0.006331394855917213,2.194855917212607e-06
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Protocol Violation,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0063292,0.0063165813259920675,1.261867400793263e-05
6.0,402.0,285.0,0.014925,0.014925,5.998937,0.424057,1.0,402.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.03796754,0.037860048545287704,0.00010749145471229682
13.0,402.0,285.0,0.032338,0.032338,5.998937,0.424057,1.0,402.0,0.0,0.0,Withdrawal by Subject,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.08226427,0.0839046996448313,0.0016404296448312983
0.0,402.0,285.0,0.0,0.0,5.998937,0.424057,1.0,402.0,0.0,0.0,Creatinine or eGFR Discon. Criteria,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,402.0,285.0,0.004975,0.004975,5.998937,0.424057,1.0,402.0,0.0,0.0,Creatinine or eGFR Discon. Criteria,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.01265585,0.012762756692103154,0.00010690669210315466
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Need for Excluded Med. Discon. Criteria,Phase A (Weeks 0-24),FG000,diabetes type 2,INDUSTRY,0.0063292,0.006330012951750547,8.12951750546638e-07
1.0,402.0,285.0,0.002488,0.002488,5.998937,0.424057,1.0,402.0,0.0,0.0,Need for Excluded Med. Discon. Criteria,Phase A (Weeks 0-24),FG001,diabetes type 2,INDUSTRY,0.0063292,0.006315581160575402,1.3618839424598371e-05
12.0,402.0,285.0,0.029851,0.029851,5.998937,0.424057,1.0,402.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.07593762,0.07596607192214283,2.8451922142833097e-05
5.0,402.0,285.0,0.012438,0.012438,5.998937,0.424057,1.0,402.0,0.0,0.0,Lost to Follow-up,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.03164089,0.031160395562351176,0.0004804944376488214
27.0,402.0,285.0,0.067164,0.067164,5.998937,0.424057,1.0,402.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24-104),FG000,diabetes type 2,INDUSTRY,0.17085774,0.17413483309348213,0.0032770930934821196
31.0,402.0,285.0,0.077114,0.077114,5.998937,0.424057,1.0,402.0,0.0,0.0,Withdrawal by Subject,Phase B (Weeks 24-104),FG001,diabetes type 2,INDUSTRY,0.19616943,0.20076774180407717,0.00459831180407716
30.0,1450.0,980.0,0.02069,0.02069,7.280008,0.321222,1.0,1452.0,20.0,138.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04838358,0.04842311140530755,3.953140530754684e-05
46.0,1450.0,980.0,0.031724,0.031724,7.280008,0.321222,1.0,1452.0,20.0,138.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0741866,0.07476913121604165,0.0005825312160416402
33.0,1450.0,980.0,0.022759,0.022759,7.280008,0.321222,1.0,1452.0,20.0,138.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05322194,0.0514241736812103,0.0017977663187897022
2.0,1450.0,980.0,0.001379,0.001379,7.280008,0.321222,1.0,1452.0,20.0,138.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00322479,0.0032065487359523776,1.8241264047622312e-05
2.0,1450.0,980.0,0.001379,0.001379,7.280008,0.321222,1.0,1452.0,20.0,138.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00322479,0.0032089010003571398,1.588899964286017e-05
1.0,1450.0,980.0,0.00069,0.00069,7.280008,0.321222,1.0,1452.0,20.0,138.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00161357,0.0016450989802182516,3.152898021825169e-05
9.0,1450.0,980.0,0.006207,0.006207,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01451507,0.014571694311259886,5.662431125988583e-05
7.0,1450.0,980.0,0.004828,0.004828,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01129028,0.011321173486785694,3.089348678569394e-05
16.0,1450.0,980.0,0.011034,0.011034,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02580302,0.025838382169097236,3.53621690972368e-05
17.0,1450.0,980.0,0.011724,0.011724,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02741658,0.02739208827117063,2.449172882936987e-05
12.0,1450.0,980.0,0.008276,0.008276,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01935343,0.01935338866651779,4.133348220983213e-08
11.0,1450.0,980.0,0.007586,0.007586,7.280008,0.321222,1.0,1452.0,20.0,138.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01773987,0.017729533439632933,1.0336560367068398e-05
8.0,1450.0,980.0,0.005517,0.005517,7.280008,0.321222,1.0,1452.0,20.0,138.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01290151,0.012937636838234137,3.612683823413752e-05
5.0,1450.0,980.0,0.003448,0.003448,7.280008,0.321222,1.0,1452.0,20.0,138.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00806315,0.008135291395952378,7.214139595237805e-05
9.0,1450.0,980.0,0.006207,0.006207,7.280008,0.321222,1.0,1452.0,20.0,138.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01451507,0.014588698714414658,7.362871441465857e-05
7.0,1450.0,980.0,0.004828,0.004828,7.280008,0.321222,1.0,1452.0,20.0,138.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01129028,0.011315333095982118,2.505309598211866e-05
4.0,1450.0,980.0,0.002759,0.002759,7.280008,0.321222,1.0,1452.0,20.0,138.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00645192,0.006596203606130959,0.00014428360613095905
3.0,1450.0,980.0,0.002069,0.002069,7.280008,0.321222,1.0,1452.0,20.0,138.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00483836,0.0047630436768127705,7.531632318722933e-05
17.0,1450.0,980.0,0.011724,0.011724,7.280008,0.321222,1.0,1452.0,20.0,138.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02741658,0.027347237030396834,6.934296960316513e-05
23.0,1450.0,980.0,0.015862,0.015862,7.280008,0.321222,1.0,1452.0,20.0,138.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0370933,0.03609738523230157,0.0009959147676984331
25.0,1450.0,980.0,0.017241,0.017241,7.280008,0.321222,1.0,1452.0,20.0,138.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04031809,0.040340641290765665,2.2551290765664145e-05
9.0,1450.0,980.0,0.006207,0.006207,7.280008,0.321222,1.0,1452.0,20.0,138.0,Creatinine or eGFR withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01451507,0.014571694311259886,5.662431125988583e-05
13.0,1450.0,980.0,0.008966,0.008966,7.280008,0.321222,1.0,1452.0,20.0,138.0,Creatinine or eGFR withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.020967,0.020306278119126962,0.0006607218808730372
7.0,1450.0,980.0,0.004828,0.004828,7.280008,0.321222,1.0,1452.0,20.0,138.0,Creatinine or eGFR withdrawal criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01129028,0.011288281318511879,1.9986814881207265e-06
4.0,1450.0,980.0,0.002759,0.002759,7.280008,0.321222,1.0,1452.0,20.0,138.0,Noncompliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00645192,0.00660061725991072,0.00014869725991072027
1.0,1450.0,980.0,0.00069,0.00069,7.280008,0.321222,1.0,1452.0,20.0,138.0,Noncompliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00161357,0.0016435968218849184,3.0026821884918467e-05
6.0,1450.0,980.0,0.004138,0.004138,7.280008,0.321222,1.0,1452.0,20.0,138.0,Noncompliance with study drug,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00967672,0.009690317011537705,1.3597011537705428e-05
12.0,1450.0,980.0,0.008276,0.008276,7.280008,0.321222,1.0,1452.0,20.0,138.0,Unable to take rescue therapy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01935343,0.01931404414336303,3.938585663697258e-05
12.0,1450.0,980.0,0.008276,0.008276,7.280008,0.321222,1.0,1452.0,20.0,138.0,Unable to take rescue therapy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01935343,0.019354446475684448,1.0164756844462108e-06
17.0,1450.0,980.0,0.011724,0.011724,7.280008,0.321222,1.0,1452.0,20.0,138.0,Unable to take rescue therapy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02741658,0.027256647931527787,0.00015993206847221206
25.0,1450.0,980.0,0.017241,0.017241,7.280008,0.321222,1.0,1452.0,20.0,138.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04031809,0.040352358707799386,3.426870779938557e-05
37.0,1450.0,980.0,0.025517,0.025517,7.280008,0.321222,1.0,1452.0,20.0,138.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05967152,0.059415388901904745,0.00025613109809525386
40.0,1450.0,980.0,0.027586,0.027586,7.280008,0.321222,1.0,1452.0,20.0,138.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06450988,0.06398621008123376,0.000523669918766248
47.0,1549.0,1199.0,0.030342,0.030342,7.34601,0.401716,1.0,1549.0,23.0,182.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08953946,0.08998553553955356,0.0004460755395535587
51.0,1549.0,1199.0,0.032924,0.032924,7.34601,0.401716,1.0,1549.0,23.0,182.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09715896,0.09871913903629972,0.001560179036299722
4.0,1549.0,1199.0,0.002582,0.002582,7.34601,0.401716,1.0,1549.0,23.0,182.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0076195,0.007792554665138892,0.00017305466513889162
7.0,1549.0,1199.0,0.004519,0.004519,7.34601,0.401716,1.0,1549.0,23.0,182.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0133356,0.01352948089404762,0.0001938808940476211
9.0,1549.0,1199.0,0.00581,0.00581,7.34601,0.401716,1.0,1549.0,23.0,182.0,Non compliant with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01714535,0.017390872693303562,0.0002455226933035619
18.0,1549.0,1199.0,0.01162,0.01162,7.34601,0.401716,1.0,1549.0,23.0,182.0,Non compliant with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0342907,0.03405821571136905,0.00023248428863095055
19.0,1549.0,1199.0,0.012266,0.012266,7.34601,0.401716,1.0,1549.0,23.0,182.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03619706,0.035797469683184556,0.00039959031681544716
20.0,1549.0,1199.0,0.012912,0.012912,7.34601,0.401716,1.0,1549.0,23.0,182.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03810341,0.03764356517107145,0.0004598448289285448
45.0,1549.0,1199.0,0.029051,0.029051,7.34601,0.401716,1.0,1549.0,23.0,182.0,"Patient refusal to cont., not due to AE",Overall Study,FG000,diabetes type 2,INDUSTRY,0.08572971,0.08692992219532741,0.001200212195327413
40.0,1549.0,1199.0,0.025823,0.025823,7.34601,0.401716,1.0,1549.0,23.0,182.0,"Patient refusal to cont., not due to AE",Overall Study,FG001,diabetes type 2,INDUSTRY,0.07620386,0.07597302918294642,0.00023083081705357889
4.0,1549.0,1199.0,0.002582,0.002582,7.34601,0.401716,1.0,1549.0,23.0,182.0,Not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0076195,0.007791893677638894,0.00017239367763889363
0.0,1549.0,1199.0,0.0,0.0,7.34601,0.401716,1.0,1549.0,23.0,182.0,Not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
31.0,1549.0,1199.0,0.020013,0.020013,7.34601,0.401716,1.0,1549.0,23.0,182.0,Other not defined above,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05905851,0.059846376934712266,0.0007878669347122641
55.0,1549.0,1199.0,0.035507,0.035507,7.34601,0.401716,1.0,1549.0,23.0,182.0,Other not defined above,Overall Study,FG001,diabetes type 2,INDUSTRY,0.10478142,0.10479983995615083,1.8419956150830807e-05
75.0,3472.0,2856.0,0.021601,0.021601,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG000,diabetes type 2,NIH,0.04329121,0.043407466709920614,0.00011625670992061743
80.0,3472.0,2856.0,0.023041,0.023041,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG001,diabetes type 2,NIH,0.04617716,0.045934486431944456,0.00024267356805554585
74.0,3472.0,2856.0,0.021313,0.021313,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG002,diabetes type 2,NIH,0.04271402,0.04288517646465277,0.0001711564646527733
62.0,3472.0,2856.0,0.017857,0.017857,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG003,diabetes type 2,NIH,0.03578775,0.036026955628313456,0.0002392056283134561
64.0,3472.0,2856.0,0.018433,0.018433,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG004,diabetes type 2,NIH,0.03694212,0.03658008094983136,0.0003620390501686416
89.0,3472.0,2856.0,0.025634,0.025634,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG005,diabetes type 2,NIH,0.05137386,0.05119874368274802,0.00017511631725197763
87.0,3472.0,2856.0,0.025058,0.025058,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG006,diabetes type 2,NIH,0.05021949,0.049883627404761946,0.00033586259523805256
85.0,3472.0,2856.0,0.024482,0.024482,8.152774,0.245822,1.0,3472.0,2.0,7.0,did not complete year 4 follow-up,Overall Study,FG007,diabetes type 2,NIH,0.04906511,0.048973848150952445,9.126184904755669e-05
2.0,438.0,393.0,0.004566,0.004566,6.084499,0.35608,1.0,438.0,5.0,109.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00989256,0.010237442967698405,0.00034488296769840526
14.0,438.0,393.0,0.031963,0.031963,6.084499,0.35608,1.0,438.0,5.0,109.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06925006,0.0687908194073115,0.00045924059268850903
1.0,438.0,393.0,0.002283,0.002283,6.084499,0.35608,1.0,438.0,5.0,109.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00494628,0.004992816116894841,4.653611689484083e-05
2.0,438.0,393.0,0.004566,0.004566,6.084499,0.35608,1.0,438.0,5.0,109.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00989256,0.010242220161031736,0.00034966016103173646
4.0,438.0,393.0,0.009132,0.009132,6.084499,0.35608,1.0,438.0,5.0,109.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01978511,0.01986537584865079,8.026584865078804e-05
10.0,438.0,393.0,0.022831,0.022831,6.084499,0.35608,1.0,438.0,5.0,109.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04946495,0.04926848320686512,0.00019646679313488347
9.0,438.0,393.0,0.020548,0.020548,6.084499,0.35608,1.0,438.0,5.0,109.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04451867,0.044408561486408725,0.00011010851359127827
3.0,438.0,393.0,0.006849,0.006849,6.084499,0.35608,1.0,438.0,5.0,109.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01483883,0.01432812535568454,0.0005107046443154611
3.0,218.0,202.0,0.013761,0.013761,5.389072,0.337801,1.0,311.0,6.0,42.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02505101,0.025290564772281816,0.00023955477228181782
1.0,218.0,202.0,0.004587,0.004587,5.389072,0.337801,1.0,311.0,6.0,42.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00835034,0.008879461909335322,0.0005291219093353228
0.0,218.0,202.0,0.0,0.0,5.389072,0.337801,1.0,311.0,6.0,42.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,218.0,202.0,0.009174,0.009174,5.389072,0.337801,1.0,311.0,6.0,42.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01670067,0.01678746725430551,8.679725430551025e-05
2.0,218.0,202.0,0.009174,0.009174,5.389072,0.337801,1.0,311.0,6.0,42.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01670067,0.016779297986626952,7.862798662695153e-05
3.0,218.0,202.0,0.013761,0.013761,5.389072,0.337801,1.0,311.0,6.0,42.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02505101,0.025266281249424677,0.00021527124942467835
3.0,218.0,202.0,0.013761,0.013761,5.389072,0.337801,1.0,311.0,6.0,42.0,Other reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02505101,0.02527451926317468,0.00022350926317468017
2.0,218.0,202.0,0.009174,0.009174,5.389072,0.337801,1.0,311.0,6.0,42.0,Other reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01670067,0.016782554458472182,8.188445847218118e-05
3.0,441.0,420.0,0.006803,0.006803,6.09131,0.227085,1.0,441.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0094102,0.009371063537261907,3.9136462738093014e-05
3.0,441.0,420.0,0.006803,0.006803,6.09131,0.227085,1.0,441.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0094102,0.009379997944107153,3.020205589284765e-05
0.0,441.0,420.0,0.0,0.0,6.09131,0.227085,1.0,441.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,441.0,420.0,0.002268,0.002268,6.09131,0.227085,1.0,441.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00313719,0.0031963321471527775,5.914214715277725e-05
6.0,441.0,420.0,0.013605,0.013605,6.09131,0.227085,1.0,441.0,1.0,1.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01881901,0.019082342483511903,0.0002633324835119022
8.0,441.0,420.0,0.018141,0.018141,6.09131,0.227085,1.0,441.0,1.0,1.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0250934,0.02516792243038692,7.452243038692102e-05
5.0,1055.0,976.0,0.004739,0.004739,6.962243,1.0,1.0,1058.0,11.0,100.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03299407,0.032987207425892846,6.862574107154018e-06
23.0,1055.0,976.0,0.021801,0.021801,6.962243,1.0,1.0,1058.0,11.0,100.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.15178387,0.14082131191187494,0.010962558088125046
4.0,1055.0,976.0,0.003791,0.003791,6.962243,1.0,1.0,1058.0,11.0,100.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02639386,0.026621691838750013,0.00022783183875001167
19.0,1055.0,976.0,0.018009,0.018009,6.962243,1.0,1.0,1058.0,11.0,100.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.12538304,0.12463506712473203,0.0007479728752679687
8.0,1055.0,976.0,0.007583,0.007583,6.962243,1.0,1.0,1058.0,11.0,100.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05279469,0.05310205128311505,0.0003073612831150513
14.0,1055.0,976.0,0.01327,0.01327,6.962243,1.0,1.0,1058.0,11.0,100.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09238897,0.09097226322550592,0.0014167067744940837
4.0,1055.0,976.0,0.003791,0.003791,6.962243,1.0,1.0,1058.0,11.0,100.0,Other incl. lack of efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02639386,0.0265840503359524,0.00019019033595239765
2.0,1055.0,976.0,0.001896,0.001896,6.962243,1.0,1.0,1058.0,11.0,100.0,Other incl. lack of efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01320041,0.01310390331801588,9.65066819841199e-05
6.0,389.0,355.0,0.015424,0.015424,5.966147,1.0,1.0,389.0,7.0,43.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.09202185,0.09213168025314479,0.00010983025314478811
4.0,389.0,355.0,0.010283,0.010283,5.966147,1.0,1.0,389.0,7.0,43.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06134989,0.06049629250358134,0.0008535974964186538
2.0,389.0,355.0,0.005141,0.005141,5.966147,1.0,1.0,389.0,7.0,43.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03067196,0.030682221077460246,1.0261077460244072e-05
3.0,389.0,355.0,0.007712,0.007712,5.966147,1.0,1.0,389.0,7.0,43.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04601092,0.04492285896460312,0.0010880610353968742
3.0,389.0,355.0,0.007712,0.007712,5.966147,1.0,1.0,389.0,7.0,43.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04601092,0.04473400992382933,0.0012769100761706662
2.0,389.0,355.0,0.005141,0.005141,5.966147,1.0,1.0,389.0,7.0,43.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03067196,0.030638295041368967,3.3664958631034886e-05
4.0,389.0,355.0,0.010283,0.010283,5.966147,1.0,1.0,389.0,7.0,43.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06134989,0.06125130329583331,9.858670416668797e-05
4.0,389.0,355.0,0.010283,0.010283,5.966147,1.0,1.0,389.0,7.0,43.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06134989,0.060603954223204345,0.0007459357767956518
4.0,389.0,355.0,0.010283,0.010283,5.966147,1.0,1.0,389.0,7.0,43.0,Other incl. lack of efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06134989,0.061179529416765854,0.00017036058323414288
2.0,389.0,355.0,0.005141,0.005141,5.966147,1.0,1.0,389.0,7.0,43.0,Other incl. lack of efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03067196,0.03065110676011897,2.0853239881032937e-05
4.0,467.0,417.0,0.008565,0.008565,6.148468,0.268071,1.0,467.0,7.0,105.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01411704,0.014277968598750017,0.000160928598750016
1.0,467.0,417.0,0.002141,0.002141,6.148468,0.268071,1.0,467.0,7.0,105.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00352885,0.0035655427090872938,3.669270908729372e-05
0.0,467.0,417.0,0.0,0.0,6.148468,0.268071,1.0,467.0,7.0,105.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,467.0,417.0,0.002141,0.002141,6.148468,0.268071,1.0,467.0,7.0,105.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00352885,0.0035662449070039608,3.739490700396071e-05
7.0,467.0,417.0,0.014989,0.014989,6.148468,0.268071,1.0,467.0,7.0,105.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02470522,0.025029534815684543,0.00032431481568454337
9.0,467.0,417.0,0.019272,0.019272,6.148468,0.268071,1.0,467.0,7.0,105.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03176457,0.031870117908373005,0.00010554790837300626
2.0,467.0,417.0,0.004283,0.004283,6.148468,0.268071,1.0,467.0,7.0,105.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00705934,0.007006461857410694,5.287814258930594e-05
2.0,467.0,417.0,0.004283,0.004283,6.148468,0.268071,1.0,467.0,7.0,105.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00705934,0.007002920364910694,5.641963508930606e-05
12.0,467.0,417.0,0.025696,0.025696,6.148468,0.268071,1.0,467.0,7.0,105.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04235275,0.04241361051514869,6.086051514869045e-05
12.0,467.0,417.0,0.025696,0.025696,6.148468,0.268071,1.0,467.0,7.0,105.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04235275,0.042303790460773726,4.895953922627594e-05
7.0,917.0,815.0,0.007634,0.007634,6.822197,0.694629,1.0,917.0,4.0,67.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03617675,0.036635851019930554,0.0004591010199305537
19.0,917.0,815.0,0.02072,0.02072,6.822197,0.694629,1.0,917.0,4.0,67.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09818996,0.09890388459653765,0.0007139245965376434
18.0,917.0,815.0,0.019629,0.019629,6.822197,0.694629,1.0,917.0,4.0,67.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.09301983,0.09438397858725195,0.001364148587251951
4.0,917.0,815.0,0.004362,0.004362,6.822197,0.694629,1.0,917.0,4.0,67.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02067107,0.021581409848918667,0.0009103398489186676
6.0,917.0,815.0,0.006543,0.006543,6.822197,0.694629,1.0,917.0,4.0,67.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03100661,0.030787290982470284,0.00021931901752971633
6.0,917.0,815.0,0.006543,0.006543,6.822197,0.694629,1.0,917.0,4.0,67.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03100661,0.030788344068660753,0.00021826593133924752
8.0,917.0,815.0,0.008724,0.008724,6.822197,0.694629,1.0,917.0,4.0,67.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04134214,0.04211547490793649,0.0007733349079364904
20.0,917.0,815.0,0.02181,0.02181,6.822197,0.694629,1.0,917.0,4.0,67.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.10335536,0.1042918063318155,0.0009364463318155131
2.0,917.0,815.0,0.002181,0.002181,6.822197,0.694629,1.0,917.0,4.0,67.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01033554,0.010355599389593222,2.005938959322162e-05
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00517014,0.005186384726428557,1.6244726428556525e-05
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00517014,0.005171631702142842,1.4917021428414307e-06
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00517014,0.005169944036726175,1.9596327382499779e-07
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00517014,0.005157667185059508,1.2472814940492176e-05
2.0,917.0,815.0,0.002181,0.002181,6.822197,0.694629,1.0,917.0,4.0,67.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01033554,0.010363272007648774,2.7732007648773038e-05
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Could Not Continue Due to Work Related Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Could Not Continue Due to Work Related Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00517014,0.005187836040595223,1.76960405952227e-05
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Could Not Continue Due to Work Related Reasons,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Could Not Continue Due to Work Related Reasons,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00517014,0.005170751391726175,6.113917261751228e-07
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Covid 19,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Covid 19,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Covid 19,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Covid 19,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00517014,0.005170751391726175,6.113917261751228e-07
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Thought there were Too Many Adverse Events,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Thought there were Too Many Adverse Events,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Thought there were Too Many Adverse Events,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00517014,0.005172387732142842,2.247732142841505e-06
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Thought there were Too Many Adverse Events,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant was Reluctant to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00517014,0.0051570345575595086,1.3105442440491596e-05
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant was Reluctant to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant was Reluctant to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant was Reluctant to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,917.0,815.0,0.001091,0.001091,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Did Not Come for the Visit,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00517014,0.0051570345575595086,1.3105442440491596e-05
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Did Not Come for the Visit,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Did Not Come for the Visit,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,917.0,815.0,0.0,0.0,6.822197,0.694629,1.0,917.0,4.0,67.0,Participant Did Not Come for the Visit,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
27.0,9651.0,9495.0,0.002798,0.002798,9.17492,0.881363,1.0,9651.0,34.0,492.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02262585,0.021404389364732147,0.0012214606352678528
34.0,9651.0,9495.0,0.003523,0.003523,9.17492,0.881363,1.0,9651.0,34.0,492.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02848851,0.02833914296563488,0.0001493670343651228
43.0,9651.0,9495.0,0.004455,0.004455,9.17492,0.881363,1.0,9651.0,34.0,492.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03602507,0.03497371334848215,0.00105135665151785
51.0,9651.0,9495.0,0.005284,0.005284,9.17492,0.881363,1.0,9651.0,34.0,492.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04272872,0.04195864577419641,0.0007700742258035867
0.0,9651.0,9495.0,0.0,0.0,9.17492,0.881363,1.0,9651.0,34.0,492.0,Randomised more than once,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,9651.0,9495.0,0.000104,0.000104,9.17492,0.881363,1.0,9651.0,34.0,492.0,Randomised more than once,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00084099,0.0006492941270833342,0.0001916958729166658
0.0,526.0,518.0,0.0,0.0,6.267201,0.710809,1.0,526.0,9.0,88.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,526.0,518.0,0.005703,0.005703,6.267201,0.710809,1.0,526.0,9.0,88.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02540563,0.026018612929265883,0.0006129829292658845
1.0,526.0,518.0,0.001901,0.001901,6.267201,0.710809,1.0,526.0,9.0,88.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00846854,0.008349709602946414,0.00011883039705358651
0.0,526.0,518.0,0.0,0.0,6.267201,0.710809,1.0,526.0,9.0,88.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,526.0,518.0,0.003802,0.003802,6.267201,0.710809,1.0,526.0,9.0,88.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01693709,0.016737609429153127,0.00019948057084687165
2.0,526.0,518.0,0.003802,0.003802,6.267201,0.710809,1.0,526.0,9.0,88.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01693709,0.016734294289791653,0.00020279571020834566
18.0,599.0,538.0,0.03005,0.03005,6.39693,0.34526,1.0,599.0,10.0,57.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06636847,0.06634119378401701,2.7276215982988128e-05
18.0,599.0,538.0,0.03005,0.03005,6.39693,0.34526,1.0,599.0,10.0,57.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06636847,0.06648323503419556,0.00011476503419556583
1.0,599.0,538.0,0.001669,0.001669,6.39693,0.34526,1.0,599.0,10.0,57.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00368616,0.003690236188214287,4.0761882142870305e-06
2.0,599.0,538.0,0.003339,0.003339,6.39693,0.34526,1.0,599.0,10.0,57.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00737452,0.007402832022698412,2.831202269841255e-05
5.0,599.0,538.0,0.008347,0.008347,6.39693,0.34526,1.0,599.0,10.0,57.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0184352,0.01849227444205356,5.707444205356113e-05
7.0,599.0,538.0,0.011686,0.011686,6.39693,0.34526,1.0,599.0,10.0,57.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02580972,0.02550783073383929,0.00030188926616071116
1.0,599.0,538.0,0.001669,0.001669,6.39693,0.34526,1.0,599.0,10.0,57.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00368616,0.003690306092440476,4.146092440475858e-06
1.0,599.0,538.0,0.001669,0.001669,6.39693,0.34526,1.0,599.0,10.0,57.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00368616,0.003691810424940476,5.650424940475875e-06
2.0,599.0,538.0,0.003339,0.003339,6.39693,0.34526,1.0,599.0,10.0,57.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00737452,0.007401120684007937,2.6600684007936984e-05
3.0,599.0,538.0,0.005008,0.005008,6.39693,0.34526,1.0,599.0,10.0,57.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01106068,0.011057082598749985,3.5974012500151337e-06
3.0,599.0,538.0,0.005008,0.005008,6.39693,0.34526,1.0,599.0,10.0,57.0,Abnormal laboratory measure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01106068,0.011036488390257919,2.4191609742081274e-05
0.0,599.0,538.0,0.0,0.0,6.39693,0.34526,1.0,599.0,10.0,57.0,Abnormal laboratory measure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,319.0,302.0,0.00627,0.00627,5.768321,0.200762,1.0,319.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00726105,0.007660029741145385,0.00039897974114538534
4.0,319.0,302.0,0.012539,0.012539,5.768321,0.200762,1.0,319.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01452095,0.014685569181984121,0.00016461918198412175
2.0,319.0,302.0,0.00627,0.00627,5.768321,0.200762,1.0,319.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00726105,0.00766835602447872,0.0004073060244787199
5.0,319.0,302.0,0.015674,0.015674,5.768321,0.200762,1.0,319.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01815147,0.018532785930416663,0.000381315930416664
3.0,319.0,302.0,0.009404,0.009404,5.768321,0.200762,1.0,319.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01089042,0.010921639012182556,3.1219012182556044e-05
0.0,319.0,302.0,0.0,0.0,5.768321,0.200762,1.0,319.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,319.0,302.0,0.003135,0.003135,5.768321,0.200762,1.0,319.0,0.0,0.0,Patient Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00363053,0.003645249459451663,1.471945945166319e-05
0.0,319.0,302.0,0.0,0.0,5.768321,0.200762,1.0,319.0,0.0,0.0,Patient Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,339.0,305.0,0.00885,0.00885,5.828946,0.245822,1.0,339.0,2.0,52.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01268101,0.012677357600089291,3.652399910708537e-06
2.0,339.0,305.0,0.0059,0.0059,5.828946,0.245822,1.0,339.0,2.0,52.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.008454,0.008454415743027582,4.1574302758230763e-07
1.0,339.0,305.0,0.00295,0.00295,5.828946,0.245822,1.0,339.0,2.0,52.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.004227,0.004300432224384916,7.343222438491604e-05
0.0,339.0,305.0,0.0,0.0,5.828946,0.245822,1.0,339.0,2.0,52.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,339.0,305.0,0.0,0.0,5.828946,0.245822,1.0,339.0,2.0,52.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,339.0,305.0,0.00295,0.00295,5.828946,0.245822,1.0,339.0,2.0,52.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.004227,0.0043000299315575355,7.30299315575356e-05
2.0,339.0,305.0,0.0059,0.0059,5.828946,0.245822,1.0,339.0,2.0,52.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.008454,0.008438165727849011,1.5834272150988538e-05
6.0,339.0,305.0,0.017699,0.017699,5.828946,0.245822,1.0,339.0,2.0,52.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02536058,0.02584653436638889,0.0004859543663888882
6.0,339.0,305.0,0.017699,0.017699,5.828946,0.245822,1.0,339.0,2.0,52.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02536058,0.025891271441785713,0.000530691441785712
5.0,339.0,305.0,0.014749,0.014749,5.828946,0.245822,1.0,339.0,2.0,52.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02113358,0.021279988314265887,0.00014640831426588827
2.0,339.0,305.0,0.0059,0.0059,5.828946,0.245822,1.0,339.0,2.0,52.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.008454,0.008440236602432344,1.376339756765585e-05
0.0,339.0,305.0,0.0,0.0,5.828946,0.245822,1.0,339.0,2.0,52.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,339.0,305.0,0.00885,0.00885,5.828946,0.245822,1.0,339.0,2.0,52.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01268101,0.012672286354077378,8.723645922621356e-06
3.0,339.0,305.0,0.00885,0.00885,5.828946,0.245822,1.0,339.0,2.0,52.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01268101,0.012675629135297607,5.380864702392296e-06
1.0,424.0,417.0,0.002358,0.002358,6.052089,0.478063,1.0,424.0,7.0,66.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00682236,0.0068271713619146865,4.811361914686119e-06
0.0,424.0,417.0,0.0,0.0,6.052089,0.478063,1.0,424.0,7.0,66.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,424.0,417.0,0.002358,0.002358,6.052089,0.478063,1.0,424.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00682236,0.006823115657331357,7.556573313567336e-07
1.0,424.0,417.0,0.002358,0.002358,6.052089,0.478063,1.0,424.0,7.0,66.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00682236,0.006822376178700404,1.6178700403685076e-08
0.0,424.0,417.0,0.0,0.0,6.052089,0.478063,1.0,424.0,7.0,66.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,424.0,417.0,0.002358,0.002358,6.052089,0.478063,1.0,424.0,7.0,66.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00682236,0.006822400785367062,4.0785367061944855e-08
3.0,424.0,417.0,0.007075,0.007075,6.052089,0.478063,1.0,424.0,7.0,66.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02046997,0.02053685129896914,6.688129896913891e-05
0.0,424.0,417.0,0.0,0.0,6.052089,0.478063,1.0,424.0,7.0,66.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,1201.0,1129.0,0.009992,0.009992,7.091742,0.469516,1.0,1201.0,17.0,209.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03327023,0.03411384511509921,0.0008436151150992138
8.0,1201.0,1129.0,0.006661,0.006661,7.091742,0.469516,1.0,1201.0,17.0,209.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02217905,0.021917029894821437,0.000262020105178562
2.0,1201.0,1129.0,0.001665,0.001665,7.091742,0.469516,1.0,1201.0,17.0,209.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00554393,0.005474556859990068,6.937314000993178e-05
6.0,1201.0,1129.0,0.004996,0.004996,7.091742,0.469516,1.0,1201.0,17.0,209.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01663512,0.016562441568731115,7.267843126888482e-05
5.0,1201.0,1129.0,0.004163,0.004163,7.091742,0.469516,1.0,1201.0,17.0,209.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01386149,0.013752567179344342,0.00010892282065565889
8.0,1201.0,1129.0,0.006661,0.006661,7.091742,0.469516,1.0,1201.0,17.0,209.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02217905,0.021937820697202383,0.0002412293027976159
4.0,1201.0,1129.0,0.003331,0.003331,7.091742,0.469516,1.0,1201.0,17.0,209.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01109119,0.01106193029491074,2.9259705089261512e-05
6.0,1201.0,1129.0,0.004996,0.004996,7.091742,0.469516,1.0,1201.0,17.0,209.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01663512,0.016531972028735697,0.00010314797126430297
4.0,1201.0,1129.0,0.003331,0.003331,7.091742,0.469516,1.0,1201.0,17.0,209.0,Missing follow-up information,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01109119,0.01101695880401788,7.423119598212041e-05
4.0,1201.0,1129.0,0.003331,0.003331,7.091742,0.469516,1.0,1201.0,17.0,209.0,Missing follow-up information,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01109119,0.011067060188898838,2.4129811101163134e-05
4.0,1201.0,1129.0,0.003331,0.003331,7.091742,0.469516,1.0,1201.0,17.0,209.0,Missing follow-up information,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01109119,0.011066698403660747,2.449159633925377e-05
2.0,1201.0,1129.0,0.001665,0.001665,7.091742,0.469516,1.0,1201.0,17.0,209.0,Missing follow-up information,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00554393,0.005491240346656739,5.26896533432613e-05
1.0,1201.0,1129.0,0.000833,0.000833,7.091742,0.469516,1.0,1201.0,17.0,209.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00277363,0.0027827239386011876,9.093938601187606e-06
1.0,1201.0,1129.0,0.000833,0.000833,7.091742,0.469516,1.0,1201.0,17.0,209.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00277363,0.002785134855982139,1.150485598213919e-05
2.0,1201.0,1129.0,0.001665,0.001665,7.091742,0.469516,1.0,1201.0,17.0,209.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00554393,0.005493314889454355,5.061511054564507e-05
2.0,1201.0,1129.0,0.001665,0.001665,7.091742,0.469516,1.0,1201.0,17.0,209.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00554393,0.005507309275704357,3.662072429564279e-05
0.0,1201.0,1129.0,0.0,0.0,7.091742,0.469516,1.0,1201.0,17.0,209.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1201.0,1129.0,0.0,0.0,7.091742,0.469516,1.0,1201.0,17.0,209.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1201.0,1129.0,0.000833,0.000833,7.091742,0.469516,1.0,1201.0,17.0,209.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00277363,0.0027760716231845207,2.4416231845206422e-06
0.0,1201.0,1129.0,0.0,0.0,7.091742,0.469516,1.0,1201.0,17.0,209.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,770.0,732.0,0.014286,0.014286,6.647688,0.557954,1.0,770.0,12.0,160.0,At the subject's own request,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0529883,0.05267460051777777,0.000313699482222235
12.0,770.0,732.0,0.015584,0.015584,6.647688,0.557954,1.0,770.0,12.0,160.0,At the subject's own request,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05780273,0.05845034511617062,0.0006476151161706259
5.0,770.0,732.0,0.006494,0.006494,6.647688,0.557954,1.0,770.0,12.0,160.0,At the subject's own request,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02408694,0.0239814277385615,0.00010551226143850137
1.0,770.0,732.0,0.001299,0.001299,6.647688,0.557954,1.0,770.0,12.0,160.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00481813,0.004827672027549629,9.542027549628782e-06
2.0,770.0,732.0,0.002597,0.002597,6.647688,0.557954,1.0,770.0,12.0,160.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00963255,0.009310732472678569,0.0003218175273214316
1.0,770.0,732.0,0.001299,0.001299,6.647688,0.557954,1.0,770.0,12.0,160.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00481813,0.00483113068004963,1.3000680049629447e-05
1.0,770.0,732.0,0.001299,0.001299,6.647688,0.557954,1.0,770.0,12.0,160.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00481813,0.004827806616180579,9.676616180578912e-06
0.0,770.0,732.0,0.0,0.0,6.647688,0.557954,1.0,770.0,12.0,160.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,770.0,732.0,0.0,0.0,6.647688,0.557954,1.0,770.0,12.0,160.0,Poor compliance to protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,770.0,732.0,0.001299,0.001299,6.647688,0.557954,1.0,770.0,12.0,160.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00481813,0.004828640099513912,1.0510099513911901e-05
3.0,770.0,732.0,0.003896,0.003896,6.647688,0.557954,1.0,770.0,12.0,160.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01445068,0.014404105649771834,4.657435022816653e-05
0.0,770.0,732.0,0.0,0.0,6.647688,0.557954,1.0,770.0,12.0,160.0,Reason not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,770.0,732.0,0.0,0.0,6.647688,0.557954,1.0,770.0,12.0,160.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,770.0,732.0,0.0,0.0,6.647688,0.557954,1.0,770.0,12.0,160.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,770.0,732.0,0.001299,0.001299,6.647688,0.557954,1.0,770.0,12.0,160.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00481813,0.004831239702847244,1.310970284724381e-05
0.0,1170.0,1085.0,0.0,0.0,7.065613,0.395941,1.0,1170.0,23.0,273.0,Randomized but not treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1170.0,1085.0,0.0,0.0,7.065613,0.395941,1.0,1170.0,23.0,273.0,Randomized but not treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1170.0,1085.0,0.000855,0.000855,7.065613,0.395941,1.0,1170.0,23.0,273.0,Randomized but not treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00239192,0.002474923339345237,8.300333934523714e-05
12.0,1170.0,1085.0,0.010256,0.010256,7.065613,0.395941,1.0,1170.0,23.0,273.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02869181,0.029140090242751836,0.0004482802427518348
9.0,1170.0,1085.0,0.007692,0.007692,7.065613,0.395941,1.0,1170.0,23.0,273.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02151886,0.02151886253904761,2.5390476075803914e-09
21.0,1170.0,1085.0,0.017949,0.017949,7.065613,0.395941,1.0,1170.0,23.0,273.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.05021347,0.052251281595009885,0.002037811595009882
1.0,1170.0,1085.0,0.000855,0.000855,7.065613,0.395941,1.0,1170.0,23.0,273.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00239192,0.002479121497678571,8.720149767857096e-05
0.0,1170.0,1085.0,0.0,0.0,7.065613,0.395941,1.0,1170.0,23.0,273.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1170.0,1085.0,0.002564,0.002564,7.065613,0.395941,1.0,1170.0,23.0,273.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00717295,0.007120878429970232,5.207157002976807e-05
8.0,1170.0,1085.0,0.006838,0.006838,7.065613,0.395941,1.0,1170.0,23.0,273.0,Poor compliance to protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01912974,0.019108926904692448,2.0813095307551516e-05
9.0,1170.0,1085.0,0.007692,0.007692,7.065613,0.395941,1.0,1170.0,23.0,273.0,Poor compliance to protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02151886,0.02152903285196428,1.0172851964279639e-05
4.0,1170.0,1085.0,0.003419,0.003419,7.065613,0.395941,1.0,1170.0,23.0,273.0,Poor compliance to protocol,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00956487,0.009731454951160696,0.00016658495116069622
8.0,1170.0,1085.0,0.006838,0.006838,7.065613,0.395941,1.0,1170.0,23.0,273.0,Other than specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01912974,0.019109096877470227,2.0643122529771796e-05
9.0,1170.0,1085.0,0.007692,0.007692,7.065613,0.395941,1.0,1170.0,23.0,273.0,Other than specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02151886,0.021531204287242058,1.2344287242057467e-05
0.0,1170.0,1085.0,0.0,0.0,7.065613,0.395941,1.0,1170.0,23.0,273.0,Other than specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,813.0,728.0,0.02091,0.02091,6.70196,0.508257,1.0,815.0,13.0,136.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07122612,0.07258403380083334,0.0013579138008333325
11.0,813.0,728.0,0.01353,0.01353,6.70196,0.508257,1.0,815.0,13.0,136.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04608749,0.04625111197779758,0.00016362197779757476
11.0,813.0,728.0,0.01353,0.01353,6.70196,0.508257,1.0,815.0,13.0,136.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04608749,0.04627124692214281,0.00018375692214280676
5.0,813.0,728.0,0.00615,0.00615,6.70196,0.508257,1.0,815.0,13.0,136.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02094886,0.020822313332232126,0.00012654666776787393
5.0,813.0,728.0,0.00615,0.00615,6.70196,0.508257,1.0,815.0,13.0,136.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02094886,0.02081871113098213,0.00013014886901786815
14.0,813.0,728.0,0.01722,0.01722,6.70196,0.508257,1.0,815.0,13.0,136.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0586568,0.0581999355889385,0.0004568644110614986
2.0,813.0,728.0,0.00246,0.00246,6.70196,0.508257,1.0,815.0,13.0,136.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00837954,0.008373661035622284,5.878964377715665e-06
3.0,813.0,728.0,0.00369,0.00369,6.70196,0.508257,1.0,815.0,13.0,136.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01256931,0.0123946922921825,0.00017461770781750097
1.0,813.0,728.0,0.00123,0.00123,6.70196,0.508257,1.0,815.0,13.0,136.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00418977,0.004194735103928561,4.965103928561074e-06
1.0,813.0,728.0,0.00123,0.00123,6.70196,0.508257,1.0,815.0,13.0,136.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00418977,0.004192099305009908,2.329305009908522e-06
1.0,813.0,728.0,0.00123,0.00123,6.70196,0.508257,1.0,815.0,13.0,136.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00418977,0.00418899872206348,7.712779365193906e-07
1.0,813.0,728.0,0.00123,0.00123,6.70196,0.508257,1.0,815.0,13.0,136.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00418977,0.004193202888452369,3.4328884523692274e-06
2.0,813.0,728.0,0.00246,0.00246,6.70196,0.508257,1.0,815.0,13.0,136.0,Discontinued due to DKA/hypoglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00837954,0.00836615878496752,1.338121503247948e-05
5.0,813.0,728.0,0.00615,0.00615,6.70196,0.508257,1.0,815.0,13.0,136.0,Discontinued due to DKA/hypoglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02094886,0.020779380126815464,0.00016947987318453525
4.0,813.0,728.0,0.00492,0.00492,6.70196,0.508257,1.0,815.0,13.0,136.0,Discontinued due to DKA/hypoglycemia,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01675909,0.016591147329642855,0.00016794267035714558
0.0,813.0,728.0,0.0,0.0,6.70196,0.508257,1.0,815.0,13.0,136.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,813.0,728.0,0.0,0.0,6.70196,0.508257,1.0,815.0,13.0,136.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,813.0,728.0,0.00246,0.00246,6.70196,0.508257,1.0,815.0,13.0,136.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00837954,0.008353740365661966,2.579963433803345e-05
3.0,320.0,281.0,0.009375,0.009375,5.771441,0.384821,1.0,320.0,8.0,66.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.02082162,0.020652942012638877,0.00016867798736112244
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Adverse Event,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,320.0,281.0,0.003125,0.003125,5.771441,0.384821,1.0,320.0,8.0,66.0,No longer meets study criteria,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.00694054,0.0069493160730555534,8.776073055553196e-06
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Not reported,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.01388108,0.013891172823075398,1.0092823075397508e-05
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Not reported,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.01388108,0.01385931796024802,2.1762039751981044e-05
1.0,320.0,281.0,0.003125,0.003125,5.771441,0.384821,1.0,320.0,8.0,66.0,Other,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.00694054,0.006948515276388884,7.975276388883477e-06
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Other,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,320.0,281.0,0.0125,0.0125,5.771441,0.384821,1.0,320.0,8.0,66.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.02776216,0.028234659692251977,0.0004724996922519757
4.0,320.0,281.0,0.0125,0.0125,5.771441,0.384821,1.0,320.0,8.0,66.0,Lost to Follow-up,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.02776216,0.028230742961835323,0.00046858296183532183
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG000,diabetes type 2,INDUSTRY,0.01388108,0.013876578552658725,4.501447341275638e-06
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Withdrawal by Subject,Short-term Period (Day 1 to Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Subject no longer meets study criteria,Long-term Period (Weeks 24 to 52),FG000,diabetes type 2,INDUSTRY,0.01388108,0.013900340155992062,1.9260155992061392e-05
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Subject no longer meets study criteria,Long-term Period (Weeks 24 to 52),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Withdrawal by Subject,Long-term Period (Weeks 24 to 52),FG001,diabetes type 2,INDUSTRY,0.01388108,0.013856149623164676,2.4930376835324494e-05
4.0,320.0,281.0,0.0125,0.0125,5.771441,0.384821,1.0,320.0,8.0,66.0,Adverse Event,Long-term Period (Weeks 24 to 52),FG000,diabetes type 2,INDUSTRY,0.02776216,0.02823881927165674,0.0004766592716567396
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Adverse Event,Long-term Period (Weeks 24 to 52),FG001,diabetes type 2,INDUSTRY,0.01388108,0.01386676576941468,1.4314230585321316e-05
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Lack of Efficacy,Long-term Period (Weeks 24 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,320.0,281.0,0.003125,0.003125,5.771441,0.384821,1.0,320.0,8.0,66.0,Lack of Efficacy,Long-term Period (Weeks 24 to 52),FG001,diabetes type 2,INDUSTRY,0.00694054,0.006948998936626983,8.45893662698282e-06
0.0,320.0,281.0,0.0,0.0,5.771441,0.384821,1.0,320.0,8.0,66.0,Lost to Follow-up,Long-term Period (Weeks 24 to 52),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,320.0,281.0,0.00625,0.00625,5.771441,0.384821,1.0,320.0,8.0,66.0,Lost to Follow-up,Long-term Period (Weeks 24 to 52),FG001,diabetes type 2,INDUSTRY,0.01388108,0.013880764324414681,3.1567558531932216e-07
7.0,1284.0,1020.0,0.005452,0.005452,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.01182842,0.011536046551349204,0.0002923734486507956
18.0,1284.0,1020.0,0.014019,0.014019,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.03041501,0.030092116365724186,0.0003228936342758136
6.0,1284.0,1020.0,0.004673,0.004673,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01013834,0.010135168521289704,3.171478710295092e-06
8.0,1284.0,1020.0,0.006231,0.006231,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0135185,0.013508131508462301,1.036849153769788e-05
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00169008,0.0016892788013095287,8.011986904713376e-07
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00169008,0.0016921432845833384,2.0632845833382964e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00506808,0.005071147503333345,3.067503333345316e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016901195907142912,3.9590714291139195e-08
6.0,1284.0,1020.0,0.004673,0.004673,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.01013834,0.010124176897599228,1.4163102400771219e-05
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00506808,0.005066295875416685,1.7841245833153524e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00338017,0.003384750009940486,4.5800099404860566e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016902686073809578,1.886073809577362e-07
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00506808,0.005071134926428589,3.0549264285889555e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00169008,0.0016904097379761957,3.2973797619564524e-07
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016920341052976246,1.954105297624544e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00506808,0.005072630387916685,4.550387916684752e-06
5.0,1284.0,1020.0,0.003894,0.003894,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00844825,0.00838022692090278,6.802307909721875e-05
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00506808,0.005075615107916685,7.535107916684623e-06
15.0,1284.0,1020.0,0.011682,0.011682,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.02534475,0.02541652695494049,7.177695494049036e-05
6.0,1284.0,1020.0,0.004673,0.004673,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.01013834,0.010138571147718281,2.311477182818933e-07
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00169008,0.0016907698154166716,6.898154166715825e-07
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00338017,0.0033853097490674695,5.139749067469435e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00338017,0.003384119191607152,3.949191607152073e-06
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.00506808,0.005070055508333351,1.9755083333506535e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.00169008,0.001688581637083338,1.4983629166619508e-06
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00506808,0.005069732006250018,1.6520062500182883e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Noncompliance with study drug,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Study terminated by sponsor,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Study terminated by sponsor,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016902048490476246,1.2484904762452564e-07
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Study terminated by sponsor,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00338017,0.003384192847857152,4.022847857151901e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Study terminated by sponsor,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Product quality complaint,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Product quality complaint,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016902048490476246,1.2484904762452564e-07
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Product quality complaint,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.00169008,0.001689566353392862,5.136466071380043e-07
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Product quality complaint,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,1284.0,1020.0,0.006231,0.006231,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0135185,0.013501402295486107,1.709770451389231e-05
14.0,1284.0,1020.0,0.010903,0.010903,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.02365467,0.023937889141845258,0.000283219141845259
8.0,1284.0,1020.0,0.006231,0.006231,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0135185,0.013496861930664673,2.1638069335326582e-05
23.0,1284.0,1020.0,0.017913,0.017913,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.03886326,0.038710164007290736,0.00015309599270926094
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Pregnancy,Core Period: Baseline to Week 26,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Pregnancy,Core Period: Baseline to Week 26,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016909134844642912,8.334844642911635e-07
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Pregnancy,Core Period: Baseline to Week 26,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Pregnancy,Core Period: Baseline to Week 26,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00169008,0.001691155238273814,1.075238273813995e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00169008,0.0016900179005952432,6.209940475688722e-08
5.0,1284.0,1020.0,0.003894,0.003894,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00844825,0.00843706037108135,1.1189628918649788e-05
9.0,1284.0,1020.0,0.007009,0.007009,7.158514,0.303074,1.0,1284.0,22.0,125.0,Adverse Event,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.01520642,0.015069383400773803,0.00013703659922619654
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Death,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00169008,0.0016899940936904812,8.590630951889854e-08
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00338017,0.0033792960633333446,8.739366666554553e-07
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1284.0,1020.0,0.003115,0.003115,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lack of Efficacy,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00675817,0.006763038561478156,4.86856147815639e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00338017,0.0033799843287103276,1.8567128967248922e-07
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00338017,0.0033787890962500107,1.3809037499893859e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Lost to Follow-up,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00338017,0.0033788746129166775,1.2953870833225418e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00338017,0.0033808500070833447,6.800070833446262e-07
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00506808,0.005068975638333353,8.956383333530785e-07
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00338017,0.003381567943750011,1.3979437500110693e-06
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Physician Decision,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00506808,0.00507090956125002,2.8295612500197492e-06
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00169008,0.0016931991498809573,3.1191498809572497e-06
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Protocol Violation,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00169008,0.001691000398630957,9.20398630956977e-07
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00506808,0.005075977528333352,7.89752833335166e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00338017,0.003380667030833344,4.970308333440351e-07
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Withdrawal by Subject,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00169008,0.0016897805882738145,2.9941172618552607e-07
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.00338017,0.0033792224070833448,9.475929166552835e-07
4.0,1284.0,1020.0,0.003115,0.003115,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00675817,0.006765095303144824,6.925303144823987e-06
3.0,1284.0,1020.0,0.002336,0.002336,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.00506808,0.005071935704345256,3.855704345256256e-06
2.0,1284.0,1020.0,0.001558,0.001558,7.158514,0.303074,1.0,1284.0,22.0,125.0,Creatinine or eGFR withdrawal criteria,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00338017,0.0033801847479166787,1.4747916678679862e-08
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1284.0,1020.0,0.0,0.0,7.158514,0.303074,1.0,1284.0,22.0,125.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1284.0,1020.0,0.000779,0.000779,7.158514,0.303074,1.0,1284.0,22.0,125.0,Unable to take rescue therapy,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00169008,0.0016901500832738146,7.008327381451129e-08
6.0,1284.0,1020.0,0.004673,0.004673,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Extension Period: Week 26 to Week 52,FG000,diabetes type 2,INDUSTRY,0.01013834,0.010133243736825415,5.096263174584129e-06
5.0,1284.0,1020.0,0.003894,0.003894,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Extension Period: Week 26 to Week 52,FG001,diabetes type 2,INDUSTRY,0.00844825,0.008417311461617066,3.093853838293317e-05
8.0,1284.0,1020.0,0.006231,0.006231,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Extension Period: Week 26 to Week 52,FG002,diabetes type 2,INDUSTRY,0.0135185,0.013500640161914672,1.785983808532711e-05
5.0,1284.0,1020.0,0.003894,0.003894,7.158514,0.303074,1.0,1284.0,22.0,125.0,Other,Extension Period: Week 26 to Week 52,FG003,diabetes type 2,INDUSTRY,0.00844825,0.008416591086617064,3.165891338293564e-05
3.0,234.0,171.0,0.012821,0.012821,5.459586,0.288131,1.0,234.0,1.0,93.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02016837,0.0205684525266369,0.0004000825266369003
2.0,234.0,171.0,0.008547,0.008547,5.459586,0.288131,1.0,234.0,1.0,93.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01344506,0.013952350490009924,0.0005072904900099238
5.0,234.0,171.0,0.021368,0.021368,5.459586,0.288131,1.0,234.0,1.0,93.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03361343,0.034507207349464296,0.0008937773494642962
4.0,234.0,171.0,0.017094,0.017094,5.459586,0.288131,1.0,234.0,1.0,93.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02689012,0.02700356638336304,0.00011344638336303892
9.0,234.0,171.0,0.038462,0.038462,5.459586,0.288131,1.0,234.0,1.0,93.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06050355,0.06052148192614089,1.7931926140885013e-05
7.0,234.0,171.0,0.029915,0.029915,5.459586,0.288131,1.0,234.0,1.0,93.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04705849,0.049925266168208866,0.002866776168208865
2.0,234.0,171.0,0.008547,0.008547,5.459586,0.288131,1.0,234.0,1.0,93.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01344506,0.013986401251974201,0.0005413412519742009
1.0,234.0,171.0,0.004274,0.004274,5.459586,0.288131,1.0,234.0,1.0,93.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00672332,0.006710768042142844,1.2551957857155974e-05
1.0,234.0,171.0,0.004274,0.004274,5.459586,0.288131,1.0,234.0,1.0,93.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00672332,0.006699397422519833,2.392257748016699e-05
1.0,234.0,171.0,0.004274,0.004274,5.459586,0.288131,1.0,234.0,1.0,93.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00672332,0.006712114288392843,1.1205711607156256e-05
4.0,234.0,171.0,0.017094,0.017094,5.459586,0.288131,1.0,234.0,1.0,93.0,Non-compliance issues,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02689012,0.027076904249374943,0.00018678424937494317
4.0,234.0,171.0,0.017094,0.017094,5.459586,0.288131,1.0,234.0,1.0,93.0,Non-compliance issues,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02689012,0.02700356638336304,0.00011344638336303892
12.0,234.0,171.0,0.051282,0.051282,5.459586,0.288131,1.0,234.0,1.0,93.0,Other Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08067035,0.08016141586002978,0.0005089341399702185
8.0,234.0,171.0,0.034188,0.034188,5.459586,0.288131,1.0,234.0,1.0,93.0,Other Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05378023,0.053690439801909226,8.979019809077227e-05
4.0,240.0,210.0,0.016667,0.016667,5.484797,0.281906,1.0,240.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0257705,0.026172231180902786,0.0004017311809027882
8.0,240.0,210.0,0.033333,0.033333,5.484797,0.281906,1.0,240.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05153945,0.05178597988315474,0.0002465298831547391
1.0,240.0,210.0,0.004167,0.004167,5.484797,0.281906,1.0,240.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00644301,0.006500866768174584,5.7856768174584065e-05
0.0,240.0,210.0,0.0,0.0,5.484797,0.281906,1.0,240.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,240.0,210.0,0.020833,0.020833,5.484797,0.281906,1.0,240.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03221196,0.0327117229636012,0.0004997629636011997
2.0,240.0,210.0,0.008333,0.008333,5.484797,0.281906,1.0,240.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01288448,0.013056955454186517,0.00017247545418651658
5.0,240.0,210.0,0.020833,0.020833,5.484797,0.281906,1.0,240.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03221196,0.03271168863693454,0.0004997286369345447
4.0,240.0,210.0,0.016667,0.016667,5.484797,0.281906,1.0,240.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0257705,0.02605900917795635,0.00028850917795635034
1.0,240.0,210.0,0.004167,0.004167,5.484797,0.281906,1.0,240.0,1.0,1.0,Other Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00644301,0.006497987932757916,5.497793275791637e-05
0.0,240.0,210.0,0.0,0.0,5.484797,0.281906,1.0,240.0,1.0,1.0,Other Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
61.0,2121.0,1880.0,0.02876,0.02876,7.660114,1.0,1.0,2122.0,32.0,232.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.22030489,0.21394314597409733,0.006361744025902671
18.0,2121.0,1880.0,0.008487,0.008487,7.660114,1.0,1.0,2122.0,32.0,232.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06501139,0.06488838866667741,0.00012300133332258933
10.0,2121.0,1880.0,0.004715,0.004715,7.660114,1.0,1.0,2122.0,32.0,232.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03611744,0.035966980047281744,0.00015045995271825707
4.0,2121.0,1880.0,0.001886,0.001886,7.660114,1.0,1.0,2122.0,32.0,232.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01444698,0.014292527182410683,0.0001544528175893168
12.0,2121.0,1880.0,0.005658,0.005658,7.660114,1.0,1.0,2122.0,32.0,232.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04334093,0.04269590429173611,0.0006450257082638924
5.0,2121.0,1880.0,0.002357,0.002357,7.660114,1.0,1.0,2122.0,32.0,232.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01805489,0.017356653223303608,0.0006982367766963926
42.0,2121.0,1880.0,0.019802,0.019802,7.660114,1.0,1.0,2122.0,32.0,232.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.15168558,0.15168168627623024,3.893723769743396e-06
13.0,2121.0,1880.0,0.006129,0.006129,7.660114,1.0,1.0,2122.0,32.0,232.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04694884,0.04617755199674603,0.0007712880032539685
15.0,2121.0,1880.0,0.007072,0.007072,7.660114,1.0,1.0,2122.0,32.0,232.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05417233,0.05471527526415673,0.0005429452641567342
8.0,2121.0,1880.0,0.003772,0.003772,7.660114,1.0,1.0,2122.0,32.0,232.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02889395,0.02831042043502977,0.0005835295649702331
43.0,2121.0,1880.0,0.020273,0.020273,7.660114,1.0,1.0,2122.0,32.0,232.0,Other reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.1552935,0.15462143959914681,0.0006720604008531861
10.0,2121.0,1880.0,0.004715,0.004715,7.660114,1.0,1.0,2122.0,32.0,232.0,Other reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03611744,0.0358053175551984,0.0003121224448016033
3.0,360.0,345.0,0.008333,0.008333,5.888878,0.41352,1.0,360.0,12.0,74.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02029224,0.020264379071914675,2.786092808532495e-05
4.0,360.0,345.0,0.011111,0.011111,5.888878,0.41352,1.0,360.0,12.0,74.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02705713,0.027098017417392636,4.088741739263768e-05
0.0,360.0,345.0,0.0,0.0,5.888878,0.41352,1.0,360.0,12.0,74.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,360.0,345.0,0.002778,0.002778,5.888878,0.41352,1.0,360.0,12.0,74.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00676489,0.006819040385493313,5.4150385493312823e-05
3.0,360.0,345.0,0.008333,0.008333,5.888878,0.41352,1.0,360.0,12.0,74.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02029224,0.02025615658858134,3.608341141865881e-05
1.0,360.0,345.0,0.002778,0.002778,5.888878,0.41352,1.0,360.0,12.0,74.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00676489,0.006818950033350452,5.406003335045161e-05
2.0,360.0,345.0,0.005556,0.005556,5.888878,0.41352,1.0,360.0,12.0,74.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01352978,0.0137837078698079,0.00025392786980790033
0.0,360.0,345.0,0.0,0.0,5.888878,0.41352,1.0,360.0,12.0,74.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,360.0,345.0,0.0,0.0,5.888878,0.41352,1.0,360.0,12.0,74.0,Other Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,360.0,345.0,0.002778,0.002778,5.888878,0.41352,1.0,360.0,12.0,74.0,Other Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00676489,0.006817727046326644,5.283704632664393e-05
2.0,252.0,204.0,0.007937,0.007937,5.533389,0.279906,1.0,631.0,13.0,96.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01229305,0.012394218232867049,0.000101168232867049
0.0,252.0,204.0,0.0,0.0,5.533389,0.279906,1.0,631.0,13.0,96.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,252.0,204.0,0.0,0.0,5.533389,0.279906,1.0,631.0,13.0,96.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
12.0,252.0,204.0,0.047619,0.047619,5.533389,0.279906,1.0,631.0,13.0,96.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07375365,0.07426571514577385,0.0005120651457738434
7.0,252.0,204.0,0.027778,0.027778,5.533389,0.279906,1.0,631.0,13.0,96.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04302335,0.04315178021919646,0.00012843021919645842
6.0,252.0,204.0,0.02381,0.02381,5.533389,0.279906,1.0,631.0,13.0,96.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0368776,0.03643491615693452,0.00044268384306548475
3.0,252.0,204.0,0.011905,0.011905,5.533389,0.279906,1.0,631.0,13.0,96.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0184388,0.01861774323902782,0.00017894323902781922
1.0,252.0,204.0,0.003968,0.003968,5.533389,0.279906,1.0,631.0,13.0,96.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00614575,0.006156070427678544,1.0320427678543916e-05
6.0,252.0,204.0,0.02381,0.02381,5.533389,0.279906,1.0,631.0,13.0,96.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0368776,0.0364183304181845,0.00045926958181550376
1.0,252.0,204.0,0.003968,0.003968,5.533389,0.279906,1.0,631.0,13.0,96.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00614575,0.006149286930178548,3.536930178548066e-06
0.0,252.0,204.0,0.0,0.0,5.533389,0.279906,1.0,631.0,13.0,96.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,252.0,204.0,0.003968,0.003968,5.533389,0.279906,1.0,631.0,13.0,96.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00614575,0.006154915373035688,9.165373035687624e-06
0.0,252.0,204.0,0.0,0.0,5.533389,0.279906,1.0,631.0,13.0,96.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,252.0,204.0,0.003968,0.003968,5.533389,0.279906,1.0,631.0,13.0,96.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00614575,0.006151976948928545,6.2269489285449175e-06
0.0,252.0,204.0,0.0,0.0,5.533389,0.279906,1.0,631.0,13.0,96.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,252.0,204.0,0.011905,0.011905,5.533389,0.279906,1.0,631.0,13.0,96.0,"non-compliance, not met criteria, etc.",Overall Study,FG000,diabetes type 2,INDUSTRY,0.0184388,0.018653160273789736,0.00021436027378973418
2.0,252.0,204.0,0.007937,0.007937,5.533389,0.279906,1.0,631.0,13.0,96.0,"non-compliance, not met criteria, etc.",Overall Study,FG001,diabetes type 2,INDUSTRY,0.01229305,0.012391365692113078,9.831569211307851e-05
3.0,252.0,204.0,0.011905,0.011905,5.533389,0.279906,1.0,631.0,13.0,96.0,"non-compliance, not met criteria, etc.",Overall Study,FG002,diabetes type 2,INDUSTRY,0.0184388,0.018670842627956402,0.00023204262795640043
9.0,363.0,332.0,0.024793,0.024793,5.897154,0.330112,1.0,363.0,1.0,36.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04826506,0.04816165729797613,0.00010340270202386509
4.0,363.0,332.0,0.011019,0.011019,5.897154,0.330112,1.0,363.0,1.0,36.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02145092,0.02187080938534724,0.0004198893853472434
1.0,363.0,332.0,0.002755,0.002755,5.897154,0.330112,1.0,363.0,1.0,36.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00536322,0.005385391349027785,2.2171349027784622e-05
2.0,363.0,332.0,0.00551,0.00551,5.897154,0.330112,1.0,363.0,1.0,36.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01072643,0.011015988243630965,0.0002895582436309649
1.0,363.0,332.0,0.002755,0.002755,5.897154,0.330112,1.0,363.0,1.0,36.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00536322,0.005385703311527785,2.2483311527784697e-05
0.0,363.0,332.0,0.0,0.0,5.897154,0.330112,1.0,363.0,1.0,36.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,363.0,332.0,0.030303,0.030303,5.897154,0.330112,1.0,363.0,1.0,36.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05899149,0.061670165677946455,0.0026786756779464543
3.0,363.0,332.0,0.008264,0.008264,5.897154,0.330112,1.0,363.0,1.0,36.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0160877,0.016126423911269852,3.872391126985217e-05
8.0,801.0,739.0,0.009988,0.009988,6.687109,0.230287,1.0,822.0,9.0,87.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01538108,0.015462731656765873,8.165165676587288e-05
7.0,801.0,739.0,0.008739,0.008739,6.687109,0.230287,1.0,822.0,9.0,87.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01345768,0.013563694575172265,0.00010601457517226548
5.0,801.0,739.0,0.006242,0.006242,6.687109,0.230287,1.0,822.0,9.0,87.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00961241,0.00974202235517857,0.00012961235517857002
4.0,801.0,739.0,0.004994,0.004994,6.687109,0.230287,1.0,822.0,9.0,87.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00769054,0.007754725450198413,6.418545019841286e-05
0.0,801.0,739.0,0.0,0.0,6.687109,0.230287,1.0,822.0,9.0,87.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,801.0,739.0,0.003745,0.003745,6.687109,0.230287,1.0,822.0,9.0,87.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00576714,0.005833105549295635,6.596554929563531e-05
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Administrative reason by sponsor,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00192187,0.001921409567678566,4.6043232143394737e-07
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Administrative reason by sponsor,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00192187,0.0019210814720238038,7.885279761962304e-07
7.0,801.0,739.0,0.008739,0.008739,6.687109,0.230287,1.0,822.0,9.0,87.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01345768,0.013535448407999645,7.776840799964511e-05
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00192187,0.0019208912499404708,9.787500595292466e-07
14.0,801.0,739.0,0.017478,0.017478,6.687109,0.230287,1.0,822.0,9.0,87.0,Study specific discontinuation criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02691536,0.027074150539533718,0.00015879053953371872
7.0,801.0,739.0,0.008739,0.008739,6.687109,0.230287,1.0,822.0,9.0,87.0,Study specific discontinuation criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01345768,0.013537529703207974,7.984970320797438e-05
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Severe non-compliance to the protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00192187,0.001921219345595233,6.506544047669635e-07
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Severe non-compliance to the protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00192187,0.0019208912499404708,9.787500595292466e-07
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Safety reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00192187,0.001921219345595233,6.506544047669635e-07
0.0,801.0,739.0,0.0,0.0,6.687109,0.230287,1.0,822.0,9.0,87.0,Safety reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,801.0,739.0,0.001248,0.001248,6.687109,0.230287,1.0,822.0,9.0,87.0,Medical history of anemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00192187,0.001921219345595233,6.506544047669635e-07
0.0,801.0,739.0,0.0,0.0,6.687109,0.230287,1.0,822.0,9.0,87.0,Medical history of anemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,247.0,180.0,0.008097,0.008097,5.513429,1.0,1.0,247.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04464223,0.04455718944353007,8.50405564699272e-05
2.0,247.0,180.0,0.008097,0.008097,5.513429,1.0,1.0,247.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04464223,0.04457132593983958,7.090406016041495e-05
0.0,247.0,180.0,0.0,0.0,5.513429,1.0,1.0,247.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,247.0,180.0,0.008097,0.008097,5.513429,1.0,1.0,247.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04464223,0.04451620413960149,0.00012602586039851121
0.0,247.0,180.0,0.0,0.0,5.513429,1.0,1.0,247.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,247.0,180.0,0.008097,0.008097,5.513429,1.0,1.0,247.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04464223,0.044649457692637194,7.227692637196137e-06
1.0,247.0,180.0,0.004049,0.004049,5.513429,1.0,1.0,247.0,1.0,1.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02232387,0.02208317393072419,0.00024069606927580936
3.0,247.0,180.0,0.012146,0.012146,5.513429,1.0,1.0,247.0,1.0,1.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06696611,0.06766415462014891,0.0006980446201489132
4.0,247.0,180.0,0.016194,0.016194,5.513429,1.0,1.0,247.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08928447,0.09027766661307522,0.0009931966130752173
5.0,247.0,180.0,0.020243,0.020243,5.513429,1.0,1.0,247.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11160834,0.11202514654723203,0.00041680654723202926
17.0,247.0,180.0,0.068826,0.068826,5.513429,1.0,1.0,247.0,1.0,1.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.37946725,0.3686464440264972,0.010820805973502767
29.0,247.0,180.0,0.117409,0.117409,5.513429,1.0,1.0,247.0,1.0,1.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.64732616,0.579298612094862,0.06802754790513799
0.0,254.0,208.0,0.0,0.0,5.541264,1.0,1.0,254.0,1.0,1.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,254.0,208.0,0.003937,0.003937,5.541264,1.0,1.0,254.0,1.0,1.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02181595,0.021893514176418622,7.756417641862148e-05
0.0,254.0,208.0,0.0,0.0,5.541264,1.0,1.0,254.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,254.0,208.0,0.003937,0.003937,5.541264,1.0,1.0,254.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02181595,0.02184185284600195,2.5902846001950308e-05
1.0,254.0,208.0,0.003937,0.003937,5.541264,1.0,1.0,254.0,1.0,1.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02181595,0.021847518260724185,3.156826072418448e-05
0.0,254.0,208.0,0.0,0.0,5.541264,1.0,1.0,254.0,1.0,1.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,254.0,208.0,0.011811,0.011811,5.541264,1.0,1.0,254.0,1.0,1.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06544786,0.06488974031499196,0.0005581196850080322
1.0,254.0,208.0,0.003937,0.003937,5.541264,1.0,1.0,254.0,1.0,1.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02181595,0.021871590843501952,5.5640843501951476e-05
6.0,254.0,208.0,0.023622,0.023622,5.541264,1.0,1.0,254.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.13089573,0.1297347860634822,0.0011609439365177776
9.0,254.0,208.0,0.035433,0.035433,5.541264,1.0,1.0,254.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.19634359,0.19198926971037703,0.004354320289622987
5.0,254.0,208.0,0.019685,0.019685,5.541264,1.0,1.0,254.0,1.0,1.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10907977,0.10935470006022807,0.0002749300602280652
19.0,254.0,208.0,0.074803,0.074803,5.541264,1.0,1.0,254.0,1.0,1.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.41450314,0.3874653225279853,0.02703781747201467
5.0,420.0,365.0,0.011905,0.011905,6.042633,0.468403,1.0,420.0,2.0,57.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03369575,0.03380276386104168,0.00010701386104168542
2.0,420.0,365.0,0.004762,0.004762,6.042633,0.468403,1.0,420.0,2.0,57.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0134783,0.013391954634851213,8.634536514878777e-05
2.0,420.0,365.0,0.004762,0.004762,6.042633,0.468403,1.0,420.0,2.0,57.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0134783,0.013428942856130978,4.935714386902247e-05
1.0,420.0,365.0,0.002381,0.002381,6.042633,0.468403,1.0,420.0,2.0,57.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00673915,0.0068378749873809486,9.872498738094839e-05
2.0,420.0,365.0,0.004762,0.004762,6.042633,0.468403,1.0,420.0,2.0,57.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0134783,0.01342819761553574,5.010238446426056e-05
6.0,420.0,365.0,0.014286,0.014286,6.042633,0.468403,1.0,420.0,2.0,57.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04043491,0.04047121793651786,3.630793651786257e-05
6.0,420.0,365.0,0.014286,0.014286,6.042633,0.468403,1.0,420.0,2.0,57.0,Non-Compliance with Study Drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04043491,0.04058596611087302,0.00015105611087302268
3.0,420.0,365.0,0.007143,0.007143,6.042633,0.468403,1.0,420.0,2.0,57.0,Non-Compliance with Study Drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02021745,0.020213625067688454,3.8249323115469025e-06
2.0,420.0,365.0,0.004762,0.004762,6.042633,0.468403,1.0,420.0,2.0,57.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0134783,0.013435028901547645,4.3271098452354884e-05
3.0,420.0,365.0,0.007143,0.007143,6.042633,0.468403,1.0,420.0,2.0,57.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02021745,0.020211044241021783,6.4057589782180735e-06
13.0,420.0,365.0,0.030952,0.030952,6.042633,0.468403,1.0,420.0,2.0,57.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.08760613,0.08754898340526786,5.714659473214645e-05
10.0,420.0,365.0,0.02381,0.02381,6.042633,0.468403,1.0,420.0,2.0,57.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06739151,0.06643926049382935,0.0009522495061706493
3.0,245.0,228.0,0.012245,0.012245,5.505332,1.0,1.0,245.0,7.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06741278,0.06792808801434529,0.000515308014345281
5.0,245.0,228.0,0.020408,0.020408,5.505332,1.0,1.0,245.0,7.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11235281,0.11298846013586303,0.0006356501358630307
0.0,245.0,228.0,0.0,0.0,5.505332,1.0,1.0,245.0,7.0,45.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,228.0,0.004082,0.004082,5.505332,1.0,1.0,245.0,7.0,45.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02247276,0.022617170094841273,0.00014441009484127132
2.0,245.0,228.0,0.008163,0.008163,5.505332,1.0,1.0,245.0,7.0,45.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04494002,0.04492317552289524,1.6844477104760447e-05
0.0,245.0,228.0,0.0,0.0,5.505332,1.0,1.0,245.0,7.0,45.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,245.0,228.0,0.004082,0.004082,5.505332,1.0,1.0,245.0,7.0,45.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02247276,0.02257041493079366,9.765493079366e-05
2.0,245.0,228.0,0.008163,0.008163,5.505332,1.0,1.0,245.0,7.0,45.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04494002,0.04498932384837142,4.9303848371422265e-05
1.0,245.0,228.0,0.004082,0.004082,5.505332,1.0,1.0,245.0,7.0,45.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02247276,0.02257305014501985,0.0001002901450198497
2.0,245.0,228.0,0.008163,0.008163,5.505332,1.0,1.0,245.0,7.0,45.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04494002,0.04501557495003808,7.555495003808144e-05
5.0,1444.0,1325.0,0.003463,0.003463,7.275865,0.643208,1.0,1444.0,13.0,122.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01620646,0.016274870195654767,6.841019565476808e-05
7.0,1444.0,1325.0,0.004848,0.004848,7.275865,0.643208,1.0,1444.0,13.0,122.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02268811,0.022624320725148778,6.378927485122324e-05
3.0,1444.0,1325.0,0.002078,0.002078,7.275865,0.643208,1.0,1444.0,13.0,122.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00972481,0.009642162875476168,8.264712452383215e-05
1.0,1444.0,1325.0,0.000693,0.000693,7.275865,0.643208,1.0,1444.0,13.0,122.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00324316,0.003257117755654773,1.3957755654772901e-05
1.0,1444.0,1325.0,0.000693,0.000693,7.275865,0.643208,1.0,1444.0,13.0,122.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00324316,0.003263331329107156,2.017132910715584e-05
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00648165,0.006487492432162698,5.842432162697815e-06
1.0,1444.0,1325.0,0.000693,0.000693,7.275865,0.643208,1.0,1444.0,13.0,122.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00324316,0.003262337454523822,1.9177454523821788e-05
1.0,1444.0,1325.0,0.000693,0.000693,7.275865,0.643208,1.0,1444.0,13.0,122.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00324316,0.003254426605238108,1.1266605238107689e-05
8.0,1444.0,1325.0,0.00554,0.00554,7.275865,0.643208,1.0,1444.0,13.0,122.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02592659,0.026110561290902723,0.00018397129090272357
9.0,1444.0,1325.0,0.006233,0.006233,7.275865,0.643208,1.0,1444.0,13.0,122.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02916976,0.02837883848908726,0.0007909215109127392
5.0,1444.0,1325.0,0.003463,0.003463,7.275865,0.643208,1.0,1444.0,13.0,122.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01620646,0.016205442130783742,1.0178692162569891e-06
5.0,1444.0,1325.0,0.003463,0.003463,7.275865,0.643208,1.0,1444.0,13.0,122.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01620646,0.016202127657569447,4.3323424305519165e-06
0.0,1444.0,1325.0,0.0,0.0,7.275865,0.643208,1.0,1444.0,13.0,122.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00648165,0.006493070769365078,1.1420769365077556e-05
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00648165,0.006476505970257939,5.144029742061573e-06
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00648165,0.006478872016091272,2.777983908728611e-06
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00648165,0.00646433145061508,1.7318549384920043e-05
0.0,1444.0,1325.0,0.0,0.0,7.275865,0.643208,1.0,1444.0,13.0,122.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1444.0,1325.0,0.0,0.0,7.275865,0.643208,1.0,1444.0,13.0,122.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1444.0,1325.0,0.0,0.0,7.275865,0.643208,1.0,1444.0,13.0,122.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,1444.0,1325.0,0.00554,0.00554,7.275865,0.643208,1.0,1444.0,13.0,122.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02592659,0.02610474701685511,0.0001781570168551093
17.0,1444.0,1325.0,0.011773,0.011773,7.275865,0.643208,1.0,1444.0,13.0,122.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05509635,0.05422497847248012,0.0008713715275198847
7.0,1444.0,1325.0,0.004848,0.004848,7.275865,0.643208,1.0,1444.0,13.0,122.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02268811,0.022578627259216232,0.00010948274078376868
22.0,1444.0,1325.0,0.015235,0.015235,7.275865,0.643208,1.0,1444.0,13.0,122.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.07129814,0.07087388378596232,0.00042425621403767433
2.0,1444.0,1325.0,0.001385,0.001385,7.275865,0.643208,1.0,1444.0,13.0,122.0,Personal Reason,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00648165,0.006459064291924606,2.2585708075394638e-05
3.0,1444.0,1325.0,0.002078,0.002078,7.275865,0.643208,1.0,1444.0,13.0,122.0,Personal Reason,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00972481,0.009636129041845217,8.868095815478365e-05
1.0,1444.0,1325.0,0.000693,0.000693,7.275865,0.643208,1.0,1444.0,13.0,122.0,Personal Reason,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00324316,0.0032633114049404883,2.0151404940488195e-05
3.0,1444.0,1325.0,0.002078,0.002078,7.275865,0.643208,1.0,1444.0,13.0,122.0,Personal Reason,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00972481,0.009652077531904741,7.273246809525943e-05
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00382045,0.0038274988100595415,7.0488100595415305e-06
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00382045,0.003822791245714304,2.3412457143038266e-06
5.0,339.0,328.0,0.014749,0.014749,5.828946,0.222179,1.0,339.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01910098,0.018973395896320376,0.00012758410367962394
0.0,339.0,328.0,0.0,0.0,5.828946,0.222179,1.0,339.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00382045,0.0038237007244643034,3.2507244643034325e-06
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00382045,0.003826810232083351,6.360232083351194e-06
0.0,339.0,328.0,0.0,0.0,5.828946,0.222179,1.0,339.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,339.0,328.0,0.0,0.0,5.828946,0.222179,1.0,339.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00382045,0.0038281857429166848,7.735742916684801e-06
1.0,339.0,328.0,0.00295,0.00295,5.828946,0.222179,1.0,339.0,0.0,0.0,Principal Investigator Discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00382045,0.003830476041309541,1.0026041309541076e-05
0.0,339.0,328.0,0.0,0.0,5.828946,0.222179,1.0,339.0,0.0,0.0,Principal Investigator Discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,339.0,328.0,0.0,0.0,5.828946,0.222179,1.0,339.0,0.0,0.0,Principal Investigator Discretion,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00407927,0.004082178553958356,2.908553958356e-06
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407927,0.004079841750505975,5.717505059746331e-07
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00407927,0.004085751607222244,6.4816072222438625e-06
2.0,647.0,511.0,0.003091,0.003091,6.473891,0.407575,1.0,647.0,4.0,45.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081559,0.008153114345238138,2.785654761862724e-06
3.0,647.0,511.0,0.004637,0.004637,6.473891,0.407575,1.0,647.0,4.0,45.0,Major Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01223517,0.011817588070168644,0.0004175819298313562
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Major Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407927,0.004079334246339308,6.424633930759982e-08
0.0,647.0,511.0,0.0,0.0,6.473891,0.407575,1.0,647.0,4.0,45.0,Major Protocol Deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Major Protocol Deviation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00407927,0.0040821978565972455,2.9278565972451834e-06
0.0,647.0,511.0,0.0,0.0,6.473891,0.407575,1.0,647.0,4.0,45.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407927,0.004089334077589306,1.0064077589305373e-05
2.0,647.0,511.0,0.003091,0.003091,6.473891,0.407575,1.0,647.0,4.0,45.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0081559,0.008161589570178622,5.689570178621026e-06
2.0,647.0,511.0,0.003091,0.003091,6.473891,0.407575,1.0,647.0,4.0,45.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081559,0.008156143965654809,2.4396565480831744e-07
8.0,647.0,511.0,0.012365,0.012365,6.473891,0.407575,1.0,647.0,4.0,45.0,Voluntary Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03262623,0.032519105275773834,0.00010712472422616526
8.0,647.0,511.0,0.012365,0.012365,6.473891,0.407575,1.0,647.0,4.0,45.0,Voluntary Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03262623,0.03257752199291669,4.8708007083307636e-05
2.0,647.0,511.0,0.003091,0.003091,6.473891,0.407575,1.0,647.0,4.0,45.0,Voluntary Withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0081559,0.00815866540601195,2.765406011949814e-06
11.0,647.0,511.0,0.017002,0.017002,6.473891,0.407575,1.0,647.0,4.0,45.0,Voluntary Withdrawal,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04486139,0.04467812488850195,0.0001832651114980488
14.0,647.0,511.0,0.021638,0.021638,6.473891,0.407575,1.0,647.0,4.0,45.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05709392,0.056476455328462336,0.0006174646715376639
24.0,647.0,511.0,0.037094,0.037094,6.473891,0.407575,1.0,647.0,4.0,45.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09787605,0.0970020900888691,0.0008739599111309004
7.0,647.0,511.0,0.010819,0.010819,6.473891,0.407575,1.0,647.0,4.0,45.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02854696,0.02828846466492446,0.0002584953350755412
41.0,647.0,511.0,0.063369,0.063369,6.473891,0.407575,1.0,647.0,4.0,45.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.16720513,0.17106730321772812,0.00386217321772811
0.0,647.0,511.0,0.0,0.0,6.473891,0.407575,1.0,647.0,4.0,45.0,Reason not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Reason not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407927,0.004079913913005976,6.439130059753342e-07
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Reason not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00407927,0.004085687869722245,6.417869722244625e-06
2.0,647.0,511.0,0.003091,0.003091,6.473891,0.407575,1.0,647.0,4.0,45.0,Reason not Specified,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0081559,0.008153219801488138,2.680198511862894e-06
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Randomized but not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00407927,0.0040816711372916896,2.4011372916892676e-06
1.0,647.0,511.0,0.001546,0.001546,6.473891,0.407575,1.0,647.0,4.0,45.0,Randomized but not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00407927,0.004079110708839309,1.592911606914868e-07
0.0,647.0,511.0,0.0,0.0,6.473891,0.407575,1.0,647.0,4.0,45.0,Randomized but not Treated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,647.0,511.0,0.0,0.0,6.473891,0.407575,1.0,647.0,4.0,45.0,Randomized but not Treated,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,933.0,783.0,0.003215,0.003215,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG000,diabetes type 2,INDUSTRY,0.01208383,0.012062333888105115,2.149611189488504e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0040292,0.0040302419305356905,1.0419305356904052e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,933.0,783.0,0.004287,0.004287,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG000,diabetes type 2,INDUSTRY,0.01611303,0.01574463050817462,0.0003683994918253809
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0040292,0.004030746159702358,1.546159702357948e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,933.0,783.0,0.003215,0.003215,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG000,diabetes type 2,INDUSTRY,0.01208383,0.012057130263105113,2.6699736894886944e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Eligibility Criteria,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,933.0,783.0,0.006431,0.006431,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG000,diabetes type 2,INDUSTRY,0.02417142,0.02408668547954364,8.473452045635807e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Physician Decision,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,933.0,783.0,0.007503,0.007503,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG000,diabetes type 2,INDUSTRY,0.02820062,0.027895651136716257,0.0003049688632837423
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,933.0,783.0,0.003215,0.003215,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG003,diabetes type 2,INDUSTRY,0.01208383,0.012079505700486064,4.324299513936217e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Protocol Deviation,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
41.0,933.0,783.0,0.043944,0.043944,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG000,diabetes type 2,INDUSTRY,0.16516699,0.16688366124440454,0.0017166712444045273
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,933.0,783.0,0.015005,0.015005,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG003,diabetes type 2,INDUSTRY,0.05639748,0.054418750903849206,0.001978729096150794
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG000,diabetes type 2,INDUSTRY,0.0040292,0.00401443911053569,1.4760889464310312e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Family Emergency,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,933.0,783.0,0.009646,0.009646,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG000,diabetes type 2,INDUSTRY,0.03625525,0.0357949970472024,0.000460252952797606
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Natural Disaster,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG000,diabetes type 2,INDUSTRY,0.0040292,0.00401443911053569,1.4760889464310312e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non Compliance,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,933.0,783.0,0.002144,0.002144,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG000,diabetes type 2,INDUSTRY,0.00805839,0.008034751061019125,2.363893898087513e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant Schedule,Lead-in,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0040292,0.004028730028749974,4.69971250026055e-07
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0040292,0.004031402022797593,2.2020227975925663e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0040292,0.004029082187202354,1.1781279764602748e-07
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Adverse Event,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0040292,0.004028688883869021,5.111161309788795e-07
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Non-Compliance with Study Drug,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,933.0,783.0,0.010718,0.010718,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.04028445,0.040052696427847236,0.00023175357215276388
8.0,933.0,783.0,0.008574,0.008574,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.03222605,0.031899084483283734,0.0003269655167162655
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,933.0,783.0,0.007503,0.007503,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.02820062,0.027990129777351186,0.00021049022264881326
11.0,933.0,783.0,0.01179,0.01179,6.839476,0.549542,1.0,933.0,16.0,141.0,Withdrawal by Subject,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.04431364,0.04332827489091273,0.000985365109087269
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0040292,0.004034966848333308,5.766848333308046e-06
2.0,933.0,783.0,0.002144,0.002144,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.00805839,0.00803600305292388,2.2386947076119892e-05
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Death,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,933.0,783.0,0.006431,0.006431,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02417142,0.02404618656595238,0.00012523343404761966
3.0,933.0,783.0,0.003215,0.003215,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.01208383,0.012087078551041632,3.2485510416315616e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Lost to Follow-up,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0040292,0.00403100871946426,1.8087194642597143e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Participant schedule,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,933.0,783.0,0.001072,0.001072,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG002,diabetes type 2,INDUSTRY,0.0040292,0.00403100871946426,1.8087194642597143e-06
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,933.0,783.0,0.0,0.0,6.839476,0.549542,1.0,933.0,16.0,141.0,Treatment Interruption,Treatment Period,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
25.0,1172.0,519.0,0.021331,0.021331,7.06732,0.196426,1.0,1172.0,0.0,0.0,Adverse Event,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.02961175,0.029881203430258005,0.00026945343025800567
26.0,1172.0,519.0,0.022184,0.022184,7.06732,0.196426,1.0,1172.0,0.0,0.0,Adverse Event,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.03079588,0.030974564283224214,0.00017868428322421331
86.0,1172.0,519.0,0.073379,0.073379,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lack of Efficacy,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.10186491,0.11090915213270831,0.00904424213270831
58.0,1172.0,519.0,0.049488,0.049488,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lack of Efficacy,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.06869936,0.07932809246737105,0.010628732467371046
19.0,1172.0,519.0,0.016212,0.016212,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lost to Follow-up,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.02250554,0.022858247020238077,0.0003527070202380758
10.0,1172.0,519.0,0.008532,0.008532,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lost to Follow-up,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.01184414,0.012021049721567471,0.00017690972156747184
10.0,1172.0,519.0,0.008532,0.008532,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Violation,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.01184414,0.012027222037638896,0.00018308203763889655
10.0,1172.0,519.0,0.008532,0.008532,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Violation,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.01184414,0.012007312155257948,0.00016317215525794848
19.0,1172.0,519.0,0.016212,0.016212,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Specified Discontinuation,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.02250554,0.02286558125315474,0.00036004125315473867
25.0,1172.0,519.0,0.021331,0.021331,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Specified Discontinuation,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.02961175,0.02987917957826398,0.0002674295782639814
6.0,1172.0,519.0,0.005119,0.005119,7.06732,0.196426,1.0,1172.0,0.0,0.0,Patient Moved,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.00710621,0.007121756501061493,1.5546501061493474e-05
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Patient Moved,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.00236827,0.002370732472648791,2.4624726487911495e-06
25.0,1172.0,519.0,0.021331,0.021331,7.06732,0.196426,1.0,1172.0,0.0,0.0,Withdrawal by Subject,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.02961175,0.02961851048698424,6.760486984239145e-06
28.0,1172.0,519.0,0.023891,0.023891,7.06732,0.196426,1.0,1172.0,0.0,0.0,Withdrawal by Subject,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.03316555,0.033853440592956356,0.0006878905929563542
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Site Terminated,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.00236827,0.0023756589765178402,7.388976517840214e-06
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Site Terminated,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.00236827,0.002370016965148791,1.7469651487911353e-06
10.0,1172.0,519.0,0.008532,0.008532,7.06732,0.196426,1.0,1172.0,0.0,0.0,Other,Year 1 ( Week 0 to Week 52),FG000,diabetes type 2,INDUSTRY,0.01184414,0.012037390001805561,0.00019325000180556162
11.0,1172.0,519.0,0.009386,0.009386,7.06732,0.196426,1.0,1172.0,0.0,0.0,Other,Year 1 ( Week 0 to Week 52),FG001,diabetes type 2,INDUSTRY,0.01302967,0.01318002645439484,0.00015035645439484026
35.0,1172.0,519.0,0.029863,0.029863,7.06732,0.196426,1.0,1172.0,0.0,0.0,Adverse Event,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.04145589,0.04236634033123014,0.0009104503312301407
36.0,1172.0,519.0,0.030717,0.030717,7.06732,0.196426,1.0,1172.0,0.0,0.0,Adverse Event,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.04264142,0.04305200310722221,0.00041058310722220936
180.0,1172.0,519.0,0.153584,0.153584,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lack of Efficacy,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.21320569,0.22086674303486103,0.007661053034861032
162.0,1172.0,519.0,0.138225,0.138225,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lack of Efficacy,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.19188429,0.1920806917607837,0.00019640176078369875
25.0,1172.0,519.0,0.021331,0.021331,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lost to Follow-up,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.02961175,0.02980912891674613,0.00019737891674613192
15.0,1172.0,519.0,0.012799,0.012799,7.06732,0.196426,1.0,1172.0,0.0,0.0,Lost to Follow-up,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.0177676,0.017997979386874988,0.00023037938687498621
13.0,1172.0,519.0,0.011092,0.011092,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Violation,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.01539794,0.015346872099732118,5.106790026788294e-05
12.0,1172.0,519.0,0.010239,0.010239,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Violation,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.01421381,0.014534787004107146,0.00032097700410714525
29.0,1172.0,519.0,0.024744,0.024744,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Specified Discontinuation,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.03434968,0.03473042478935517,0.00038074478935516687
30.0,1172.0,519.0,0.025597,0.025597,7.06732,0.196426,1.0,1172.0,0.0,0.0,Protocol Specified Discontinuation,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.03553382,0.03598651356722225,0.00045269356722225235
6.0,1172.0,519.0,0.005119,0.005119,7.06732,0.196426,1.0,1172.0,0.0,0.0,Patient Moved,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.00710621,0.007121756501061493,1.5546501061493474e-05
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Patient Moved,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.00236827,0.002370027066190457,1.7570661904569955e-06
28.0,1172.0,519.0,0.023891,0.023891,7.06732,0.196426,1.0,1172.0,0.0,0.0,Withdrawal by Subject,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.03316555,0.03375697967924421,0.000591429679244207
38.0,1172.0,519.0,0.032423,0.032423,7.06732,0.196426,1.0,1172.0,0.0,0.0,Withdrawal by Subject,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.04500969,0.046190742476855146,0.0011810524768551475
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Site Terminated,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.00236827,0.002374908980476172,6.638980476171823e-06
2.0,1172.0,519.0,0.001706,0.001706,7.06732,0.196426,1.0,1172.0,0.0,0.0,Site Terminated,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.00236827,0.00236949073577379,1.2207357737901124e-06
15.0,1172.0,519.0,0.012799,0.012799,7.06732,0.196426,1.0,1172.0,0.0,0.0,Other,Year 2 (Week 0 to Week 104),FG000,diabetes type 2,INDUSTRY,0.0177676,0.018064168606101175,0.00029656860610117325
23.0,1172.0,519.0,0.019625,0.019625,7.06732,0.196426,1.0,1172.0,0.0,0.0,Other,Year 2 (Week 0 to Week 104),FG001,diabetes type 2,INDUSTRY,0.02724347,0.02878117250518852,0.0015377025051885214
14.0,665.0,381.0,0.021053,0.021053,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 0-26 (Main Period),FG000,diabetes type 2,INDUSTRY,0.03513151,0.03497764437880945,0.00015386562119054648
15.0,665.0,381.0,0.022556,0.022556,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 0-26 (Main Period),FG001,diabetes type 2,INDUSTRY,0.03763959,0.03736625820356146,0.0002733317964385418
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 0-26 (Main Period),FG002,diabetes type 2,INDUSTRY,0.01003734,0.010047064969107058,9.72496910705764e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 0-26 (Main Period),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 0-26 (Main Period),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 0-26 (Main Period),FG000,diabetes type 2,INDUSTRY,0.01003734,0.01005185809511897,1.4518095118969815e-05
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 0-26 (Main Period),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 0-26 (Main Period),FG002,diabetes type 2,INDUSTRY,0.01003734,0.01003802660803562,6.866080356198595e-07
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 0-26 (Main Period),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 0-26 (Main Period),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,665.0,381.0,0.021053,0.021053,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 0-26 (Main Period),FG000,diabetes type 2,INDUSTRY,0.03513151,0.035010177268184464,0.00012133273181553356
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 0-26 (Main Period),FG001,diabetes type 2,INDUSTRY,0.01003734,0.01003657989208324,7.601079167612879e-07
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 0-26 (Main Period),FG002,diabetes type 2,INDUSTRY,0.01003734,0.010039988716666573,2.648716666572501e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 0-26 (Main Period),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 0-26 (Main Period),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,665.0,381.0,0.015038,0.015038,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 0-26 (Main Period),FG000,diabetes type 2,INDUSTRY,0.02509417,0.025014791248888838,7.937875111116086e-05
7.0,665.0,381.0,0.010526,0.010526,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 0-26 (Main Period),FG001,diabetes type 2,INDUSTRY,0.01756492,0.017483860324692457,8.10596753075439e-05
5.0,665.0,381.0,0.007519,0.007519,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 0-26 (Main Period),FG002,diabetes type 2,INDUSTRY,0.01254709,0.012449039293621001,9.805070637899926e-05
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 0-26 (Main Period),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 0-26 (Main Period),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
14.0,665.0,381.0,0.021053,0.021053,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 0-26 (Main Period),FG000,diabetes type 2,INDUSTRY,0.03513151,0.03502189338755946,0.00010961661244053567
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 0-26 (Main Period),FG001,diabetes type 2,INDUSTRY,0.01003734,0.010035082185833237,2.257814166763822e-06
8.0,665.0,381.0,0.01203,0.01203,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 0-26 (Main Period),FG002,diabetes type 2,INDUSTRY,0.02007467,0.01978239693322782,0.0002922730667721807
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 0-26 (Main Period),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 0-26 (Main Period),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,665.0,381.0,0.007519,0.007519,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 26-52 (Extension Period 1),FG000,diabetes type 2,INDUSTRY,0.01254709,0.012443346632767827,0.00010374336723217338
10.0,665.0,381.0,0.015038,0.015038,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 26-52 (Extension Period 1),FG001,diabetes type 2,INDUSTRY,0.02509417,0.025035430169067407,5.873983093259219e-05
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 26-52 (Extension Period 1),FG002,diabetes type 2,INDUSTRY,0.00752758,0.00753639362154225,8.813621542249836e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 26-52 (Extension Period 1),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 26-52 (Extension Period 1),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 26-52 (Extension Period 1),FG000,diabetes type 2,INDUSTRY,0.00752758,0.007523863269667236,3.7167303327638457e-06
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 26-52 (Extension Period 1),FG001,diabetes type 2,INDUSTRY,0.0050195,0.005022332325833308,2.8323258333086063e-06
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 26-52 (Extension Period 1),FG002,diabetes type 2,INDUSTRY,0.0050195,0.005019735322083309,2.353220833091474e-07
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 26-52 (Extension Period 1),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 26-52 (Extension Period 1),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 26-52 (Extension Period 1),FG000,diabetes type 2,INDUSTRY,0.0050195,0.005026405230714265,6.905230714265159e-06
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 26-52 (Extension Period 1),FG001,diabetes type 2,INDUSTRY,0.00752758,0.00753376570058987,6.185700589870537e-06
7.0,665.0,381.0,0.010526,0.010526,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 26-52 (Extension Period 1),FG002,diabetes type 2,INDUSTRY,0.01756492,0.017486618862609132,7.830113739086889e-05
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 26-52 (Extension Period 1),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 26-52 (Extension Period 1),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,665.0,381.0,0.009023,0.009023,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 26-52 (Extension Period 1),FG000,diabetes type 2,INDUSTRY,0.01505684,0.01491622533297619,0.00014061466702381016
8.0,665.0,381.0,0.01203,0.01203,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 26-52 (Extension Period 1),FG001,diabetes type 2,INDUSTRY,0.02007467,0.019757188684001628,0.00031748131599837123
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 26-52 (Extension Period 1),FG002,diabetes type 2,INDUSTRY,0.0050195,0.005020946645416643,1.4466454166433065e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 26-52 (Extension Period 1),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 26-52 (Extension Period 1),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 26-52 (Extension Period 1),FG000,diabetes type 2,INDUSTRY,0.01003734,0.010061584175595183,2.4244175595182146e-05
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 26-52 (Extension Period 1),FG001,diabetes type 2,INDUSTRY,0.00752758,0.007537052240173203,9.472240173203327e-06
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 26-52 (Extension Period 1),FG002,diabetes type 2,INDUSTRY,0.00250975,0.0025106607620833223,9.107620833224625e-07
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 26-52 (Extension Period 1),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 26-52 (Extension Period 1),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 52-78 (Extension Period 2),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 52-78 (Extension Period 2),FG001,diabetes type 2,INDUSTRY,0.00752758,0.007537985044637484,1.040504463748447e-05
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 52-78 (Extension Period 2),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,665.0,381.0,0.009023,0.009023,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 52-78 (Extension Period 2),FG003,diabetes type 2,INDUSTRY,0.01505684,0.014946942394940486,0.00010989760505951407
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Adverse Event,Week 52-78 (Extension Period 2),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 52-78 (Extension Period 2),FG000,diabetes type 2,INDUSTRY,0.00250975,0.0025096001154166535,1.4988458334631166e-07
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 52-78 (Extension Period 2),FG001,diabetes type 2,INDUSTRY,0.0050195,0.00502264200708331,3.1420070833107494e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 52-78 (Extension Period 2),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 52-78 (Extension Period 2),FG003,diabetes type 2,INDUSTRY,0.00250975,0.0025100451445833195,2.951445833196918e-07
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Protocol Violation,Week 52-78 (Extension Period 2),FG004,diabetes type 2,INDUSTRY,0.00250975,0.0025089577062499865,7.922937500133564e-07
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 52-78 (Extension Period 2),FG000,diabetes type 2,INDUSTRY,0.00752758,0.007527292025589857,2.8797441014270786e-07
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 52-78 (Extension Period 2),FG001,diabetes type 2,INDUSTRY,0.00752758,0.007532743311304152,5.163311304152464e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 52-78 (Extension Period 2),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 52-78 (Extension Period 2),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Lack of Efficacy,Week 52-78 (Extension Period 2),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 52-78 (Extension Period 2),FG000,diabetes type 2,INDUSTRY,0.01003734,0.010061140463095182,2.3800463095181162e-05
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 52-78 (Extension Period 2),FG001,diabetes type 2,INDUSTRY,0.00752758,0.007535710769637483,8.130769637483375e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 52-78 (Extension Period 2),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 52-78 (Extension Period 2),FG003,diabetes type 2,INDUSTRY,0.00250975,0.0025097148195833197,3.518041668008551e-08
3.0,665.0,381.0,0.004511,0.004511,6.50129,0.256675,1.0,665.0,15.0,166.0,Withdrawal criteria,Week 52-78 (Extension Period 2),FG004,diabetes type 2,INDUSTRY,0.00752758,0.007531334403089864,3.7544030898643485e-06
2.0,665.0,381.0,0.003008,0.003008,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 52-78 (Extension Period 2),FG000,diabetes type 2,INDUSTRY,0.0050195,0.005027492671964265,7.99267196426555e-06
4.0,665.0,381.0,0.006015,0.006015,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 52-78 (Extension Period 2),FG001,diabetes type 2,INDUSTRY,0.01003734,0.010043164903928502,5.824903928501254e-06
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 52-78 (Extension Period 2),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,665.0,381.0,0.0,0.0,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 52-78 (Extension Period 2),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,665.0,381.0,0.001504,0.001504,6.50129,0.256675,1.0,665.0,15.0,166.0,Unclassified,Week 52-78 (Extension Period 2),FG004,diabetes type 2,INDUSTRY,0.00250975,0.0025084840083333193,1.2659916666804896e-06
10.0,741.0,229.0,0.013495,0.013495,6.609349,0.192319,1.0,741.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01715357,0.01730224373529762,0.00014867373529761987
10.0,741.0,229.0,0.013495,0.013495,6.609349,0.192319,1.0,741.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01715357,0.017282582623005957,0.00012901262300595712
3.0,741.0,229.0,0.004049,0.004049,6.609349,0.192319,1.0,741.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00514671,0.005140165926061508,6.544073938491435e-06
6.0,741.0,229.0,0.008097,0.008097,6.609349,0.192319,1.0,741.0,0.0,0.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01029214,0.010309589472172564,1.744947217256418e-05
82.0,741.0,229.0,0.110661,0.110661,6.609349,0.192319,1.0,741.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.14066179,0.1490646971584424,0.008402907158442385
80.0,741.0,229.0,0.107962,0.107962,6.609349,0.192319,1.0,741.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.13723107,0.1424369297604959,0.005205859760495896
39.0,741.0,229.0,0.052632,0.052632,6.609349,0.192319,1.0,741.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06690082,0.07454258216515602,0.007641762165156024
29.0,741.0,229.0,0.039136,0.039136,6.609349,0.192319,1.0,741.0,0.0,0.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04974598,0.049584944874226225,0.00016103512577377715
8.0,741.0,229.0,0.010796,0.010796,6.609349,0.192319,1.0,741.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01372285,0.013724704434047618,1.8544340476180782e-06
6.0,741.0,229.0,0.008097,0.008097,6.609349,0.192319,1.0,741.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01029214,0.01028848414687495,3.655853125049749e-06
5.0,741.0,229.0,0.006748,0.006748,6.609349,0.192319,1.0,741.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00857742,0.008713885657797616,0.00013646565779761553
5.0,741.0,229.0,0.006748,0.006748,6.609349,0.192319,1.0,741.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00857742,0.008720239772142853,0.00014281977214285202
4.0,741.0,229.0,0.005398,0.005398,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00686143,0.007095729860178577,0.00023429986017857712
8.0,741.0,229.0,0.010796,0.010796,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01372285,0.013717383931785706,5.466068214294434e-06
3.0,741.0,229.0,0.004049,0.004049,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00514671,0.005141876444890875,4.83355510912456e-06
6.0,741.0,229.0,0.008097,0.008097,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01029214,0.01033750828008923,4.536828008923008e-05
16.0,741.0,229.0,0.021592,0.021592,6.609349,0.192319,1.0,741.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02744571,0.027842694788988105,0.00039698478898810355
27.0,741.0,229.0,0.036437,0.036437,6.609349,0.192319,1.0,741.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04631526,0.04723775806614089,0.0009224980661408921
11.0,741.0,229.0,0.014845,0.014845,6.609349,0.192319,1.0,741.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01886956,0.01891525516512897,4.56951651289679e-05
12.0,741.0,229.0,0.016194,0.016194,6.609349,0.192319,1.0,741.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02058428,0.0206380232650893,5.374326508929966e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Site terminated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,741.0,229.0,0.002699,0.002699,6.609349,0.192319,1.0,741.0,0.0,0.0,Site terminated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00343071,0.003423594583869045,7.1154161309550275e-06
1.0,741.0,229.0,0.00135,0.00135,6.609349,0.192319,1.0,741.0,0.0,0.0,Site terminated,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00171599,0.0017288288017261915,1.2838801726191553e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Site terminated,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
35.0,741.0,229.0,0.047233,0.047233,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06003812,0.06519099719311508,0.00515287719311508
33.0,741.0,229.0,0.044534,0.044534,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0566074,0.0536550801330754,0.0029523198669246034
33.0,741.0,229.0,0.044534,0.044534,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0566074,0.0537076385279266,0.002899761472073402
26.0,741.0,229.0,0.035088,0.035088,6.609349,0.192319,1.0,741.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.04460054,0.04497167441899805,0.0003711344189980467
3.0,741.0,229.0,0.004049,0.004049,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00514671,0.005153168697609127,6.458697609127567e-06
2.0,741.0,229.0,0.002699,0.002699,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00343071,0.003423594583869045,7.1154161309550275e-06
1.0,741.0,229.0,0.00135,0.00135,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00171599,0.0017288288017261915,1.2838801726191553e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient moved,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,741.0,229.0,0.004049,0.004049,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient was non-compliant,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00514671,0.005153168697609127,6.458697609127567e-06
1.0,741.0,229.0,0.00135,0.00135,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient was non-compliant,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00171599,0.0017298613722023814,1.3871372202381481e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient was non-compliant,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Patient was non-compliant,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Recommendation of Primary Care Physician,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Recommendation of Primary Care Physician,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Recommendation of Primary Care Physician,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,741.0,229.0,0.00135,0.00135,6.609349,0.192319,1.0,741.0,0.0,0.0,Recommendation of Primary Care Physician,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00171599,0.0017286587375595246,1.2668737559524707e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,741.0,229.0,0.00135,0.00135,6.609349,0.192319,1.0,741.0,0.0,0.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00171599,0.0017288288017261915,1.2838801726191553e-05
0.0,741.0,229.0,0.0,0.0,6.609349,0.192319,1.0,741.0,0.0,0.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,206.0,127.0,0.029126,0.029126,5.332719,0.211727,1.0,206.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03288553,0.03408555780270833,0.0012000278027083297
3.0,206.0,127.0,0.014563,0.014563,5.332719,0.211727,1.0,206.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01644276,0.017276334479166683,0.0008335744791666821
11.0,206.0,127.0,0.053398,0.053398,5.332719,0.211727,1.0,206.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06029051,0.06340723576189201,0.0031167257618920155
18.0,206.0,127.0,0.087379,0.087379,5.332719,0.211727,1.0,206.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.09865771,0.10201002006419639,0.0033523100641963954
0.0,206.0,127.0,0.0,0.0,5.332719,0.211727,1.0,206.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,206.0,127.0,0.019417,0.019417,5.332719,0.211727,1.0,206.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02192331,0.02405324047386906,0.002129930473869057
2.0,206.0,127.0,0.009709,0.009709,5.332719,0.211727,1.0,206.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01096222,0.011709896031081364,0.0007476760310813641
1.0,206.0,127.0,0.004854,0.004854,5.332719,0.211727,1.0,206.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00548054,0.0055519750687004,7.14350687004003e-05
12.0,206.0,127.0,0.058252,0.058252,5.332719,0.211727,1.0,206.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06577105,0.06940201451271817,0.003630964512718174
21.0,206.0,127.0,0.101942,0.101942,5.332719,0.211727,1.0,206.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.11510048,0.1201480613846727,0.005047581384672692
1.0,206.0,127.0,0.004854,0.004854,5.332719,0.211727,1.0,206.0,0.0,0.0,Patient moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00548054,0.005550513975783732,6.997397578373168e-05
0.0,206.0,127.0,0.0,0.0,5.332719,0.211727,1.0,206.0,0.0,0.0,Patient moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,386.0,369.0,0.012953,0.012953,5.958425,0.532463,1.0,386.0,6.0,56.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04109522,0.04087504298527778,0.00022017701472221846
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00822031,0.008230349449980164,1.0039449980164122e-05
4.0,386.0,369.0,0.010363,0.010363,5.958425,0.532463,1.0,386.0,6.0,56.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03287808,0.03358258871737101,0.0007045087173710163
2.0,386.0,369.0,0.005181,0.005181,5.958425,0.532463,1.0,386.0,6.0,56.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01643745,0.01687352985698779,0.00043607985698779217
0.0,386.0,369.0,0.0,0.0,5.958425,0.532463,1.0,386.0,6.0,56.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00822031,0.008224448072480161,4.138072480161514e-06
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00822031,0.008220366986666673,5.6986666673725095e-08
0.0,386.0,369.0,0.0,0.0,5.958425,0.532463,1.0,386.0,6.0,56.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00822031,0.008220366986666673,5.6986666673725095e-08
0.0,386.0,369.0,0.0,0.0,5.958425,0.532463,1.0,386.0,6.0,56.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00822031,0.008220366986666673,5.6986666673725095e-08
1.0,386.0,369.0,0.002591,0.002591,5.958425,0.532463,1.0,386.0,6.0,56.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00822031,0.008222572208313496,2.262208313496064e-06
5.0,530.0,388.0,0.009434,0.009434,6.274762,0.264217,1.0,530.0,9.0,92.0,Adverse Event,Main: Week 0 to 26 (NN5401-3590),FG000,diabetes type 2,INDUSTRY,0.01564061,0.015587576272822843,5.303372717715624e-05
3.0,530.0,388.0,0.00566,0.00566,6.274762,0.264217,1.0,530.0,9.0,92.0,Adverse Event,Main: Week 0 to 26 (NN5401-3590),FG001,diabetes type 2,INDUSTRY,0.0093837,0.009496491795992044,0.00011279179599204409
4.0,530.0,388.0,0.007547,0.007547,6.274762,0.264217,1.0,530.0,9.0,92.0,Lack of Efficacy,Main: Week 0 to 26 (NN5401-3590),FG000,diabetes type 2,INDUSTRY,0.01251216,0.012309183939424586,0.00020297606057541329
2.0,530.0,388.0,0.003774,0.003774,6.274762,0.264217,1.0,530.0,9.0,92.0,Lack of Efficacy,Main: Week 0 to 26 (NN5401-3590),FG001,diabetes type 2,INDUSTRY,0.00625691,0.006239622393809514,1.7287606190486207e-05
6.0,530.0,388.0,0.011321,0.011321,6.274762,0.264217,1.0,530.0,9.0,92.0,Protocol Violation,Main: Week 0 to 26 (NN5401-3590),FG000,diabetes type 2,INDUSTRY,0.01876906,0.018422173960922612,0.00034688603907738827
5.0,530.0,388.0,0.009434,0.009434,6.274762,0.264217,1.0,530.0,9.0,92.0,Protocol Violation,Main: Week 0 to 26 (NN5401-3590),FG001,diabetes type 2,INDUSTRY,0.01564061,0.015600093050739505,4.0516949260493984e-05
22.0,530.0,388.0,0.041509,0.041509,6.274762,0.264217,1.0,530.0,9.0,92.0,Withdrawal Criteria,Main: Week 0 to 26 (NN5401-3590),FG000,diabetes type 2,INDUSTRY,0.06881769,0.0679062278115277,0.0009114621884722951
11.0,530.0,388.0,0.020755,0.020755,6.274762,0.264217,1.0,530.0,9.0,92.0,Withdrawal Criteria,Main: Week 0 to 26 (NN5401-3590),FG001,diabetes type 2,INDUSTRY,0.03440967,0.03430038964928573,0.00010928035071427339
10.0,530.0,388.0,0.018868,0.018868,6.274762,0.264217,1.0,530.0,9.0,92.0,Unclassified,Main: Week 0 to 26 (NN5401-3590),FG000,diabetes type 2,INDUSTRY,0.03128122,0.030836263043571444,0.00044495695642855423
11.0,530.0,388.0,0.020755,0.020755,6.274762,0.264217,1.0,530.0,9.0,92.0,Unclassified,Main: Week 0 to 26 (NN5401-3590),FG001,diabetes type 2,INDUSTRY,0.03440967,0.034316104312410715,9.35656875892879e-05
3.0,530.0,388.0,0.00566,0.00566,6.274762,0.264217,1.0,530.0,9.0,92.0,Adverse Event,Extension: Week 27 to 52 (NN5401-3726),FG000,diabetes type 2,INDUSTRY,0.0093837,0.009511342151547603,0.00012764215154760332
3.0,530.0,388.0,0.00566,0.00566,6.274762,0.264217,1.0,530.0,9.0,92.0,Adverse Event,Extension: Week 27 to 52 (NN5401-3726),FG001,diabetes type 2,INDUSTRY,0.0093837,0.009496491795992044,0.00011279179599204409
2.0,530.0,388.0,0.003774,0.003774,6.274762,0.264217,1.0,530.0,9.0,92.0,Protocol Violation,Extension: Week 27 to 52 (NN5401-3726),FG000,diabetes type 2,INDUSTRY,0.00625691,0.006237022888253958,1.988711174604179e-05
3.0,530.0,388.0,0.00566,0.00566,6.274762,0.264217,1.0,530.0,9.0,92.0,Protocol Violation,Extension: Week 27 to 52 (NN5401-3726),FG001,diabetes type 2,INDUSTRY,0.0093837,0.009490112507242042,0.00010641250724204195
2.0,530.0,388.0,0.003774,0.003774,6.274762,0.264217,1.0,530.0,9.0,92.0,Withdrawal criteria,Extension: Week 27 to 52 (NN5401-3726),FG000,diabetes type 2,INDUSTRY,0.00625691,0.006238963292142848,1.794670785715182e-05
1.0,530.0,388.0,0.001887,0.001887,6.274762,0.264217,1.0,530.0,9.0,92.0,Withdrawal criteria,Extension: Week 27 to 52 (NN5401-3726),FG001,diabetes type 2,INDUSTRY,0.00312845,0.0033396366914285676,0.00021118669142856754
6.0,530.0,388.0,0.011321,0.011321,6.274762,0.264217,1.0,530.0,9.0,92.0,Unclassified,Extension: Week 27 to 52 (NN5401-3726),FG000,diabetes type 2,INDUSTRY,0.01876906,0.018423661748273805,0.0003453982517261957
5.0,530.0,388.0,0.009434,0.009434,6.274762,0.264217,1.0,530.0,9.0,92.0,Unclassified,Extension: Week 27 to 52 (NN5401-3726),FG001,diabetes type 2,INDUSTRY,0.01564061,0.015597050873656162,4.355912634383674e-05
2.0,506.0,464.0,0.003953,0.003953,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00719762,0.007200487327946389,2.8673279463889423e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035979,0.0035938529687301536,4.047031269846166e-06
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,506.0,464.0,0.003953,0.003953,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00719762,0.0072011615179463865,3.5415179463864355e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0035979,0.003598251617361102,3.51617361102341e-07
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,506.0,464.0,0.003953,0.003953,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00719762,0.007193224402113055,4.395597886944734e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035979,0.0035939755937301533,3.924406269846525e-06
3.0,506.0,464.0,0.005929,0.005929,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01079552,0.010688908938253961,0.00010661106174603835
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,506.0,464.0,0.003953,0.003953,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00719762,0.007189139597946383,8.480402053616908e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Major Protocol Deviation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0035979,0.003597552386111103,3.4761388889668204e-07
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,506.0,464.0,0.005929,0.005929,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01079552,0.010678484500634909,0.00011703549936509065
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lost to Follow-up,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0035979,0.003597608186111103,2.9181388889673587e-07
4.0,506.0,464.0,0.007905,0.007905,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01439342,0.014261549512182534,0.0001318704878174662
2.0,506.0,464.0,0.003953,0.003953,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00719762,0.007186810186696393,1.0809813303607266e-05
4.0,506.0,464.0,0.007905,0.007905,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01439342,0.014273275483134921,0.00012014451686507936
3.0,506.0,464.0,0.005929,0.005929,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01079552,0.010686676552123004,0.000108843447876995
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0035979,0.0035982779673611027,3.779673611028697e-07
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0035979,0.0035975678861111028,3.321138888970343e-07
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035979,0.0035938529687301536,4.047031269846166e-06
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Pregnancy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0035979,0.003594453478452374,3.4465215476256646e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0035979,0.0035989283458333237,1.0283458333239237e-06
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0035979,0.003597220229166658,6.797708333419923e-07
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0035979,0.0035982916416666573,3.9164166665750164e-07
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0035979,0.0035979435604166577,4.356041665787638e-08
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0035979,0.0035945497497420565,3.350250257943329e-06
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,506.0,464.0,0.001976,0.001976,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0035979,0.003595948744444437,1.9512555555628586e-06
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,506.0,464.0,0.0,0.0,6.228511,0.292333,1.0,506.0,3.0,21.0,Other,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,233.0,220.0,0.012876,0.012876,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG000,diabetes type 2,OTHER,0.02926127,0.029485396923571328,0.00022412692357132863
1.0,233.0,220.0,0.004292,0.004292,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG001,diabetes type 2,OTHER,0.00975376,0.009757164692500035,3.4046925000350003e-06
1.0,233.0,220.0,0.004292,0.004292,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG002,diabetes type 2,OTHER,0.00975376,0.00975535187375004,1.591873750039774e-06
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG003,diabetes type 2,OTHER,0.0,0.0,0.0
3.0,233.0,220.0,0.012876,0.012876,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG004,diabetes type 2,OTHER,0.02926127,0.02945233646232133,0.00019106646232133068
1.0,233.0,220.0,0.004292,0.004292,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG005,diabetes type 2,OTHER,0.00975376,0.009755412817916708,1.6528179167078771e-06
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG006,diabetes type 2,OTHER,0.0,0.0,0.0
3.0,233.0,220.0,0.012876,0.012876,5.455321,0.416574,1.0,256.0,1.0,1.0,Protocol Violation,Overall Study,FG007,diabetes type 2,OTHER,0.02926127,0.02945233646232133,0.00019106646232133068
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,OTHER,0.0,0.0,0.0
0.0,233.0,220.0,0.0,0.0,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,OTHER,0.0,0.0,0.0
1.0,233.0,220.0,0.004292,0.004292,5.455321,0.416574,1.0,256.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG007,diabetes type 2,OTHER,0.00975376,0.009753907940952418,1.4794095241736638e-07
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00651965,0.0065201733841666575,5.233841666573563e-07
6.0,574.0,538.0,0.010453,0.010453,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01956083,0.01998036274985117,0.0004195327498511675
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
7.0,574.0,538.0,0.012195,0.012195,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02282066,0.02291375498570436,9.309498570436031e-05
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00325983,0.0032636648825595106,3.834882559510585e-06
4.0,574.0,538.0,0.006969,0.006969,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG005,diabetes type 2,INDUSTRY,0.01304118,0.013012891772351185,2.8288227648814307e-05
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Adverse Event,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00325983,0.0032704774466071323,1.0647446607132266e-05
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00651965,0.006519520248333324,1.297516666757051e-07
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00325983,0.003261629977976176,1.7999779761759815e-06
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Protocol Violation,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00651965,0.006527913663154752,8.263663154752139e-06
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00651965,0.006519720515416658,7.051541665772237e-08
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00325983,0.003265975615059509,6.145615059508901e-06
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00325983,0.0032658347975595093,6.004797559509313e-06
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG005,diabetes type 2,INDUSTRY,0.00325983,0.0032658347975595093,6.004797559509313e-06
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Withdrawal by Subject,Overall Study,FG006,diabetes type 2,INDUSTRY,0.00651965,0.006521115123749991,1.4651237499911304e-06
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,574.0,538.0,0.003484,0.003484,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00651965,0.0065210012883333245,1.3512883333243603e-06
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Lack of Efficacy,Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,574.0,538.0,0.001742,0.001742,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG002,diabetes type 2,INDUSTRY,0.00325983,0.00326260450755951,2.7745075595101386e-06
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,574.0,538.0,0.0,0.0,6.35437,0.294492,1.0,574.0,1.0,43.0,Other (house moving),Overall Study,FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
11.0,521.0,376.0,0.021113,0.021113,6.257668,0.179995,1.0,521.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02378058,0.023093674094722235,0.000686905905277764
9.0,521.0,376.0,0.017274,0.017274,6.257668,0.179995,1.0,521.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01945653,0.01965771602395837,0.00020118602395836904
6.0,521.0,376.0,0.011516,0.011516,6.257668,0.179995,1.0,521.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01297102,0.01261127770205359,0.0003597422979464103
11.0,521.0,376.0,0.021113,0.021113,6.257668,0.179995,1.0,521.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02378058,0.022942754973888903,0.0008378250261110963
15.0,521.0,376.0,0.028791,0.028791,6.257668,0.179995,1.0,521.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03242868,0.03304674344805554,0.0006180634480555391
8.0,521.0,376.0,0.015355,0.015355,6.257668,0.179995,1.0,521.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01729507,0.01747431248273991,0.00017924248273991014
3.0,521.0,376.0,0.005758,0.005758,6.257668,0.179995,1.0,521.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00648551,0.006523738633293679,3.8228633293679176e-05
5.0,521.0,376.0,0.009597,0.009597,6.257668,0.179995,1.0,521.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01080956,0.010691527793184566,0.00011803220681543339
6.0,521.0,376.0,0.011516,0.011516,6.257668,0.179995,1.0,521.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01297102,0.012563596321577402,0.0004074236784225981
2.0,521.0,376.0,0.003839,0.003839,6.257668,0.179995,1.0,521.0,0.0,0.0,Patient Moved,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00432405,0.004448190035565479,0.00012414003556547853
1.0,521.0,376.0,0.001919,0.001919,6.257668,0.179995,1.0,521.0,0.0,0.0,Patient Moved,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00216146,0.002164960808571416,3.5008085714160163e-06
1.0,521.0,376.0,0.001919,0.001919,6.257668,0.179995,1.0,521.0,0.0,0.0,Patient Moved,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00216146,0.00215913248476189,2.3275152381098743e-06
8.0,521.0,376.0,0.015355,0.015355,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01729507,0.01744887770998197,0.00015380770998197138
5.0,521.0,376.0,0.009597,0.009597,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01080956,0.01069722026610123,0.00011233973389876938
3.0,521.0,376.0,0.005758,0.005758,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00648551,0.006478387415377015,7.122584622984603e-06
14.0,521.0,376.0,0.026871,0.026871,6.257668,0.179995,1.0,521.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03026609,0.030538961110882973,0.00027287111088297386
21.0,521.0,376.0,0.040307,0.040307,6.257668,0.179995,1.0,521.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0453997,0.04635118896208329,0.0009514889620832884
5.0,521.0,376.0,0.009597,0.009597,6.257668,0.179995,1.0,521.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01080956,0.010622288128809556,0.0001872718711904437
3.0,521.0,376.0,0.005758,0.005758,6.257668,0.179995,1.0,521.0,0.0,0.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00648551,0.006514910166627015,2.9400166627014876e-05
3.0,521.0,376.0,0.005758,0.005758,6.257668,0.179995,1.0,521.0,0.0,0.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00648551,0.006440570915079395,4.4939084920605187e-05
1.0,521.0,376.0,0.001919,0.001919,6.257668,0.179995,1.0,521.0,0.0,0.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00216146,0.0021555719847618907,5.888015238109286e-06
1.0,521.0,376.0,0.001919,0.001919,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00216146,0.0021602568080952246,1.2031919047754587e-06
3.0,521.0,376.0,0.005758,0.005758,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00648551,0.006440570915079395,4.4939084920605187e-05
0.0,521.0,376.0,0.0,0.0,6.257668,0.179995,1.0,521.0,0.0,0.0,Protocol specified discontinuation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,731.0,697.0,0.0,0.0,6.595781,0.523688,1.0,731.0,10.0,118.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,731.0,697.0,0.0,0.0,6.595781,0.523688,1.0,731.0,10.0,118.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,731.0,697.0,0.004104,0.004104,6.595781,0.523688,1.0,731.0,10.0,118.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01417577,0.014264994381795603,8.922438179560267e-05
0.0,731.0,697.0,0.0,0.0,6.595781,0.523688,1.0,731.0,10.0,118.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,731.0,697.0,0.0,0.0,6.595781,0.523688,1.0,731.0,10.0,118.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,731.0,697.0,0.008208,0.008208,6.595781,0.523688,1.0,731.0,10.0,118.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02835154,0.02849309073895837,0.00014155073895836742
2.0,731.0,697.0,0.002736,0.002736,6.595781,0.523688,1.0,731.0,10.0,118.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00945051,0.00949237083807539,4.18608380753898e-05
5.0,731.0,697.0,0.00684,0.00684,6.595781,0.523688,1.0,731.0,10.0,118.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.02362628,0.024132920999603166,0.0005066409996031668
10.0,731.0,697.0,0.01368,0.01368,6.595781,0.523688,1.0,731.0,10.0,118.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04725256,0.04727801425949402,2.5454259494017695e-05
3.0,731.0,697.0,0.004104,0.004104,6.595781,0.523688,1.0,731.0,10.0,118.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01417577,0.014257674714523778,8.190471452377765e-05
1.0,731.0,697.0,0.001368,0.001368,6.595781,0.523688,1.0,731.0,10.0,118.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00472526,0.005094256691309517,0.0003689966913095165
4.0,731.0,697.0,0.005472,0.005472,6.595781,0.523688,1.0,731.0,10.0,118.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01890102,0.019201171244673583,0.000300151244673582
8.0,819.0,765.0,0.009768,0.009768,6.709304,0.494335,1.0,819.0,1.0,76.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03239699,0.03217987770895833,0.0002171122910416684
6.0,819.0,765.0,0.007326,0.007326,6.709304,0.494335,1.0,819.0,1.0,76.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02429775,0.024066264488829345,0.00023148551117065444
6.0,819.0,765.0,0.007326,0.007326,6.709304,0.494335,1.0,819.0,1.0,76.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02429775,0.024077912947103153,0.00021983705289684713
1.0,819.0,765.0,0.001221,0.001221,6.709304,0.494335,1.0,819.0,1.0,76.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00404962,0.004042891078224195,6.7289217758051065e-06
4.0,819.0,765.0,0.004884,0.004884,6.709304,0.494335,1.0,819.0,1.0,76.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0161985,0.01603327452205355,0.00016522547794645126
0.0,819.0,765.0,0.0,0.0,6.709304,0.494335,1.0,819.0,1.0,76.0,Unclassified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,819.0,765.0,0.009768,0.009768,6.709304,0.494335,1.0,819.0,1.0,76.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03239699,0.0321167171782738,0.00028027282172619905
10.0,819.0,765.0,0.01221,0.01221,6.709304,0.494335,1.0,819.0,1.0,76.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04049624,0.03989052475994049,0.0006057152400595137
2.0,819.0,765.0,0.002442,0.002442,6.709304,0.494335,1.0,819.0,1.0,76.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00809925,0.008034305658390157,6.494434160984365e-05
0.0,819.0,765.0,0.0,0.0,6.709304,0.494335,1.0,819.0,1.0,76.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,819.0,765.0,0.001221,0.001221,6.709304,0.494335,1.0,819.0,1.0,76.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00404962,0.00404667690718253,2.9430928174698986e-06
1.0,819.0,765.0,0.001221,0.001221,6.709304,0.494335,1.0,819.0,1.0,76.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00404962,0.004043812056904749,5.807943095251233e-06
4.0,819.0,765.0,0.004884,0.004884,6.709304,0.494335,1.0,819.0,1.0,76.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0161985,0.016027080952351166,0.0001714190476488353
2.0,819.0,765.0,0.002442,0.002442,6.709304,0.494335,1.0,819.0,1.0,76.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00809925,0.008039762460235397,5.9487539764603234e-05
1.0,819.0,765.0,0.001221,0.001221,6.709304,0.494335,1.0,819.0,1.0,76.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00404962,0.004044327736071415,5.292263928585207e-06
21.0,755.0,464.0,0.027815,0.027815,6.628041,0.298717,1.0,756.0,17.0,184.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05507108,0.054852115503085275,0.0002189644969147267
14.0,755.0,464.0,0.018543,0.018543,6.628041,0.298717,1.0,756.0,17.0,184.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0367134,0.03601425479798606,0.0006991452020139385
6.0,755.0,464.0,0.007947,0.007947,6.628041,0.298717,1.0,756.0,17.0,184.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01573431,0.015274310474712305,0.00045999952528769615
8.0,755.0,464.0,0.010596,0.010596,6.628041,0.298717,1.0,756.0,17.0,184.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02097908,0.020692418731992245,0.00028666126800775543
25.0,755.0,464.0,0.033113,0.033113,6.628041,0.298717,1.0,756.0,17.0,184.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06556063,0.06512096506034365,0.0004396649396563451
17.0,755.0,464.0,0.022517,0.022517,6.628041,0.298717,1.0,756.0,17.0,184.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04458154,0.043327624019593246,0.001253915980406757
5.0,755.0,464.0,0.006623,0.006623,6.628041,0.298717,1.0,756.0,17.0,184.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01311292,0.012993618508382961,0.00011930149161703922
4.0,755.0,464.0,0.005298,0.005298,6.628041,0.298717,1.0,756.0,17.0,184.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01048954,0.010492794107609126,3.254107609125881e-06
5.0,755.0,464.0,0.006623,0.006623,6.628041,0.298717,1.0,756.0,17.0,184.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01311292,0.012990468257757966,0.0001224517422420343
13.0,755.0,464.0,0.017219,0.017219,6.628041,0.298717,1.0,756.0,17.0,184.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.034092,0.03411109269533727,1.9092695337272203e-05
2.0,755.0,464.0,0.002649,0.002649,6.628041,0.298717,1.0,756.0,17.0,184.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00524477,0.0051774519385515885,6.73180614484117e-05
0.0,755.0,464.0,0.0,0.0,6.628041,0.298717,1.0,756.0,17.0,184.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
40.0,755.0,464.0,0.05298,0.05298,6.628041,0.298717,1.0,756.0,17.0,184.0,Patient met glycemic withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.10489542,0.1093769683185018,0.004481548318501796
85.0,755.0,464.0,0.112583,0.112583,6.628041,0.298717,1.0,756.0,17.0,184.0,Patient met glycemic withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.22290376,0.20642563117983115,0.016478128820168858
19.0,755.0,464.0,0.025166,0.025166,6.628041,0.298717,1.0,756.0,17.0,184.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04982631,0.05022600540350199,0.00039969540350199423
27.0,755.0,464.0,0.035762,0.035762,6.628041,0.298717,1.0,756.0,17.0,184.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0708054,0.07035952929596227,0.0004458707040377319
0.0,274.0,230.0,0.0,0.0,5.616771,0.350961,1.0,274.0,5.0,51.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,274.0,230.0,0.018248,0.018248,5.616771,0.350961,1.0,274.0,5.0,51.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03597171,0.03641289573708153,0.0004411857370815314
21.0,274.0,230.0,0.076642,0.076642,5.616771,0.350961,1.0,274.0,5.0,51.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.15108199,0.15257687638901798,0.0014948863890179853
12.0,274.0,230.0,0.043796,0.043796,5.616771,0.350961,1.0,274.0,5.0,51.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.08633369,0.08692802393769568,0.0005943339376956736
4.0,274.0,230.0,0.014599,0.014599,5.616771,0.350961,1.0,274.0,5.0,51.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02877855,0.028918461431666605,0.00013991143166660475
2.0,274.0,230.0,0.007299,0.007299,5.616771,0.350961,1.0,274.0,5.0,51.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01438829,0.014307000591646819,8.128940835318114e-05
7.0,986.0,914.0,0.007099,0.007099,6.89467,0.860688,1.0,986.0,10.0,127.0,Adverse Event,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.04212658,0.04343916742711309,0.001312587427113092
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Adverse Event,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00601724,0.006027466976815468,1.0226976815468254e-05
6.0,986.0,914.0,0.006085,0.006085,6.89467,0.860688,1.0,986.0,10.0,127.0,Assigned Treatment by Mistake,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03610935,0.03611634633758927,6.9963375892712065e-06
3.0,986.0,914.0,0.003043,0.003043,6.89467,0.860688,1.0,986.0,10.0,127.0,Assigned Treatment by Mistake,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01805764,0.018538600026111143,0.0004809600261111435
5.0,986.0,914.0,0.005071,0.005071,6.89467,0.860688,1.0,986.0,10.0,127.0,Death,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03009211,0.030161684568025773,6.957456802577505e-05
2.0,986.0,914.0,0.002028,0.002028,6.89467,0.860688,1.0,986.0,10.0,127.0,Death,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.01203447,0.012462456493809511,0.00042798649380951063
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Protocol Violation,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00601724,0.0060223394820932445,5.099482093244394e-06
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Protocol Violation,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,986.0,914.0,0.005071,0.005071,6.89467,0.860688,1.0,986.0,10.0,127.0,Physician Decision,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03009211,0.03018208518635911,8.997518635911125e-05
4.0,986.0,914.0,0.004057,0.004057,6.89467,0.860688,1.0,986.0,10.0,127.0,Physician Decision,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.02407488,0.02498130893841267,0.0009064289384126713
5.0,986.0,914.0,0.005071,0.005071,6.89467,0.860688,1.0,986.0,10.0,127.0,Non-Compliance with Study Drug,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.03009211,0.030193170353442447,0.00010106035344244896
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Non-Compliance with Study Drug,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.00601724,0.006027160147648801,9.920147648801239e-06
30.0,986.0,914.0,0.030426,0.030426,6.89467,0.860688,1.0,986.0,10.0,127.0,Withdrawal by Subject,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.18055267,0.18394675099014252,0.0033940809901425173
12.0,986.0,914.0,0.01217,0.01217,6.89467,0.860688,1.0,986.0,10.0,127.0,Withdrawal by Subject,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.07221869,0.07499810328473215,0.002779413284732149
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Lost to Follow-up,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00601724,0.006030122852232136,1.2882852232136074e-05
5.0,986.0,914.0,0.005071,0.005071,6.89467,0.860688,1.0,986.0,10.0,127.0,Lost to Follow-up,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.03009211,0.030119240426061494,2.7130426061495322e-05
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Lack of Efficacy,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00601724,0.0060252712251488,8.031225148800135e-06
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Lack of Efficacy,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Sponsor Decision,Treatment Period,FG000,diabetes type 2,INDUSTRY,0.00601724,0.0060235939001488,6.353900148799857e-06
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Sponsor Decision,Treatment Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,986.0,914.0,0.002028,0.002028,6.89467,0.860688,1.0,986.0,10.0,127.0,Death,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.01203447,0.012386976802162695,0.0003525068021626946
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Death,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,986.0,914.0,0.001014,0.001014,6.89467,0.860688,1.0,986.0,10.0,127.0,Protocol Violation,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.00601724,0.006018048379910707,8.083799107067718e-07
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Protocol Violation,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,986.0,914.0,0.003043,0.003043,6.89467,0.860688,1.0,986.0,10.0,127.0,Withdrawal by Subject,Follow-Up Period,FG000,diabetes type 2,INDUSTRY,0.01805764,0.01847551200974209,0.00041787200974208877
0.0,986.0,914.0,0.0,0.0,6.89467,0.860688,1.0,986.0,10.0,127.0,Withdrawal by Subject,Follow-Up Period,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
20.0,3533.0,3432.0,0.005661,0.005661,8.170186,0.835128,1.0,3533.0,28.0,413.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03862584,0.03959548265312499,0.0009696426531249913
28.0,3533.0,3432.0,0.007925,0.007925,8.170186,0.835128,1.0,3533.0,28.0,413.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05407344,0.05409355258142858,2.0112581428581577e-05
23.0,3533.0,3432.0,0.00651,0.00651,8.170186,0.835128,1.0,3533.0,28.0,413.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04441869,0.044378101962490056,4.058803750994072e-05
30.0,3533.0,3432.0,0.008491,0.008491,8.170186,0.835128,1.0,3533.0,28.0,413.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05793534,0.056161426571629675,0.0017739134283703273
1.0,421.0,386.0,0.002375,0.002375,6.045005,0.335325,1.0,421.0,8.0,95.0,Pretreatment Event/Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00481422,0.00481861744098216,4.3974409821602445e-06
4.0,421.0,386.0,0.009501,0.009501,6.045005,0.335325,1.0,421.0,8.0,95.0,Pretreatment Event/Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0192589,0.01959292347395832,0.00033402347395831977
1.0,421.0,386.0,0.002375,0.002375,6.045005,0.335325,1.0,421.0,8.0,95.0,Pretreatment Event/Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00481422,0.0048107497911012145,3.4702088987856317e-06
3.0,421.0,386.0,0.007126,0.007126,6.045005,0.335325,1.0,421.0,8.0,95.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01444468,0.014458469497956402,1.378949795640197e-05
1.0,421.0,386.0,0.002375,0.002375,6.045005,0.335325,1.0,421.0,8.0,95.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00481422,0.0048135016793651,7.183206348999535e-07
3.0,421.0,386.0,0.007126,0.007126,6.045005,0.335325,1.0,421.0,8.0,95.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01444468,0.014474500803908791,2.9820803908791813e-05
5.0,421.0,386.0,0.011876,0.011876,6.045005,0.335325,1.0,421.0,8.0,95.0,Voluntary Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02407311,0.02400687237746212,6.62376225378826e-05
3.0,421.0,386.0,0.007126,0.007126,6.045005,0.335325,1.0,421.0,8.0,95.0,Voluntary Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01444468,0.014432136546795678,1.254345320432157e-05
7.0,421.0,386.0,0.016627,0.016627,6.045005,0.335325,1.0,421.0,8.0,95.0,Voluntary Withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03370358,0.0338552654417758,0.00015168544177580207
0.0,421.0,386.0,0.0,0.0,6.045005,0.335325,1.0,421.0,8.0,95.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,421.0,386.0,0.002375,0.002375,6.045005,0.335325,1.0,421.0,8.0,95.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00481422,0.004813421010793677,7.989892063233958e-07
0.0,421.0,386.0,0.0,0.0,6.045005,0.335325,1.0,421.0,8.0,95.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,421.0,386.0,0.004751,0.004751,6.045005,0.335325,1.0,421.0,8.0,95.0,Other Reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00963046,0.010108468197519848,0.00047800819751984795
1.0,421.0,386.0,0.002375,0.002375,6.045005,0.335325,1.0,421.0,8.0,95.0,Other Reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00481422,0.004815745973531772,1.5259735317721748e-06
3.0,421.0,386.0,0.007126,0.007126,6.045005,0.335325,1.0,421.0,8.0,95.0,Other Reasons,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01444468,0.014469241011170695,2.4561011170695646e-05
3.0,420.0,395.0,0.007143,0.007143,6.042633,0.415685,1.0,420.0,9.0,84.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.017942,0.01772341998867877,0.00021858001132122815
2.0,420.0,395.0,0.004762,0.004762,6.042633,0.415685,1.0,420.0,9.0,84.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01196134,0.011867781386150817,9.355861384918382e-05
2.0,420.0,395.0,0.004762,0.004762,6.042633,0.415685,1.0,420.0,9.0,84.0,Withdrawal criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01196134,0.01187367318534725,8.766681465275164e-05
0.0,420.0,395.0,0.0,0.0,6.042633,0.415685,1.0,420.0,9.0,84.0,Withdrawal criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,420.0,395.0,0.014286,0.014286,6.042633,0.415685,1.0,420.0,9.0,84.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03588401,0.03558405371095242,0.00029995628904758154
1.0,420.0,395.0,0.002381,0.002381,6.042633,0.415685,1.0,420.0,9.0,84.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00598067,0.00606439951253969,8.372951253968978e-05
2.0,420.0,395.0,0.004762,0.004762,6.042633,0.415685,1.0,420.0,9.0,84.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01196134,0.01186792644243058,9.341355756942171e-05
1.0,420.0,395.0,0.002381,0.002381,6.042633,0.415685,1.0,420.0,9.0,84.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00598067,0.006062051301111118,8.138130111111797e-05
6.0,420.0,395.0,0.014286,0.014286,6.042633,0.415685,1.0,420.0,9.0,84.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03588401,0.03560749877309527,0.00027651122690473123
2.0,420.0,395.0,0.004762,0.004762,6.042633,0.415685,1.0,420.0,9.0,84.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01196134,0.01187364317635915,8.769682364085166e-05
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.00586116,0.005858053076666659,3.106923333340457e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.00586116,0.005863929268333326,2.7692683333266008e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.00586116,0.005860910371249992,2.496287500076966e-07
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.01758511,0.017561700426339238,2.3409573660763267e-05
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.00879174,0.008791322571964254,4.1742803574482124e-07
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.00879174,0.008788281896964255,3.458103035744453e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.00293058,0.002930343857545991,2.3614245400890507e-07
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.00586116,0.005863718836249992,2.558836249992591e-06
7.0,558.0,343.0,0.012545,0.012545,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.02051569,0.02051588834343249,1.9834343249064412e-07
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.00293058,0.0029305105359090865,6.946409091337924e-08
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.01758511,0.017571891467669357,1.3218532330643712e-05
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.01172232,0.011707224351666656,1.50956483333433e-05
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.01758511,0.017571891467669357,1.3218532330643712e-05
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.00586116,0.005861247526666658,8.752666665837877e-08
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.01172232,0.011703576626666656,1.874337333334329e-05
5.0,558.0,343.0,0.008961,0.008961,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.01465453,0.014683383593720225,2.8853593720224585e-05
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.00293058,0.002932968668825754,2.3886688257541977e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.00586116,0.005862326415416658,1.1664154166580315e-06
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.00879174,0.008788141367976154,3.598632023845208e-06
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.00879174,0.008790560175238058,1.179824761941492e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.00586116,0.005861692827916658,5.328279166581101e-07
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.00586116,0.0058628695529166575,1.7095529166576834e-06
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.00879174,0.008790560175238058,1.179824761941492e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.00293058,0.00293135240424242,7.724042424199322e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.00586116,0.005862283575416659,1.1235754166592088e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.00293058,0.0029304664359090867,1.1356409091323877e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor or noncompliance,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.00293058,0.0029302997575459916,2.802424540083309e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.00293058,0.0029299787963257534,6.012036742465525e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.00293058,0.0029304664359090867,1.1356409091323877e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administration reason by sponsor,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG000,diabetes type 2,INDUSTRY,0.00879174,0.00878721830547616,4.521694523839867e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG003,diabetes type 2,INDUSTRY,0.00293058,0.0029305184946590863,6.150534091363055e-08
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG007,diabetes type 2,INDUSTRY,0.00293058,0.0029309552846590865,3.7528465908660824e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Short-term (ST) Period (Day 1-Week 24),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.01758511,0.017545222845347944,3.988715465205739e-05
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.01758511,0.017569903722580084,1.5206277419917147e-05
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00293058,0.0029347942887499945,4.214288749994615e-06
7.0,558.0,343.0,0.012545,0.012545,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.02051569,0.020508157025396764,7.532974603235987e-06
7.0,558.0,343.0,0.012545,0.012545,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.02051569,0.020508941898313423,6.748101686576691e-06
7.0,558.0,343.0,0.012545,0.012545,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.02051569,0.020509628031646757,6.061968353242991e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.00586116,0.005858907239999991,2.252760000008569e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lack of Efficacy,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.00879174,0.00878856678529759,3.1732147024090412e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.00293058,0.0029322164470833288,1.6364470833288638e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00293058,0.002930515635416662,6.436458333805226e-08
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.00586116,0.005861082048333326,7.79516666736535e-08
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.00879174,0.008793590894642824,1.8508946428245215e-06
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.01172232,0.011708989357023792,1.3330642976207632e-05
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Adverse Event,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.01758511,0.017553976014514607,3.113398548539384e-05
6.0,558.0,343.0,0.010753,0.010753,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.01758511,0.017576868985288416,8.241014711585226e-06
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00879174,0.008792674844999961,9.348449999616731e-07
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.00879174,0.008790842751071393,8.972489286065977e-07
7.0,558.0,343.0,0.012545,0.012545,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.02051569,0.020518976815515802,3.2868155158023715e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.01172232,0.011707027688690459,1.529231130954073e-05
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.00586116,0.005861130139999992,2.9860000008187504e-08
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Withdrawal by Subject,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.01172232,0.011706211782023794,1.6108217976205583e-05
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.00879174,0.008788599193988061,3.1408060119381825e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.00586116,0.0058662967320833245,5.13673208332472e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00293058,0.002931401603749995,8.216037499951187e-07
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.00293058,0.002931486150833329,9.061508333290703e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,558.0,343.0,0.007168,0.007168,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.01172232,0.01171885490797618,3.4650920238202265e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.00586116,0.005862456992499991,1.2969924999915033e-06
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.00879174,0.008790583936666627,1.1560633333719539e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Lost to Follow-up,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.00293058,0.002931486150833329,9.061508333290703e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.00293058,0.0029322164470833288,1.6364470833288638e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00293058,0.002930515635416662,6.436458333805226e-08
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.00293058,0.002930600182499995,2.018249999503202e-08
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.00293058,0.002930600182499995,2.018249999503202e-08
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Poor compliance or noncompliance,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.00586116,0.005861079084999991,8.091500000844548e-08
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.00293058,0.002930600182499995,2.018249999503202e-08
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,No longer met study criteria,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.00293058,0.00293165667708333,1.0766770833299695e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.00293058,0.002930040412499995,5.395875000047297e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Administrative reason by sponsor,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.00293058,0.002930040412499995,5.395875000047297e-07
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG000,diabetes type 2,INDUSTRY,0.00586116,0.005859987869821421,1.1721301785786592e-06
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG001,diabetes type 2,INDUSTRY,0.00586116,0.005865130985654754,3.970985654753838e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG002,diabetes type 2,INDUSTRY,0.00293058,0.002930548704166662,3.1295833338024215e-08
2.0,558.0,343.0,0.003584,0.003584,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG003,diabetes type 2,INDUSTRY,0.00586116,0.005862088726071421,9.287260714216025e-07
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG004,diabetes type 2,INDUSTRY,0.00879174,0.008792798749166627,1.0587491666280008e-06
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG005,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,558.0,343.0,0.005376,0.005376,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG006,diabetes type 2,INDUSTRY,0.00879174,0.008792798749166627,1.0587491666280008e-06
1.0,558.0,343.0,0.001792,0.001792,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG007,diabetes type 2,INDUSTRY,0.00293058,0.002931070041249995,4.900412499952989e-07
0.0,558.0,343.0,0.0,0.0,6.326149,0.258509,1.0,1067.0,4.0,78.0,Other,Long-term (LT) Period (Weeks 24-102),FG008,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0112214,0.01123847379789687,1.7073797896871232e-05
13.0,1012.0,799.0,0.012846,0.012846,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.02917428,0.02922310089163692,4.882089163691858e-05
17.0,1012.0,799.0,0.016798,0.016798,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.03814958,0.03831660715073411,0.0001670271507341059
25.0,1012.0,799.0,0.024704,0.024704,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.05610473,0.055554137195129,0.0005505928048709988
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Protocol Violation,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.002253342107916646,9.51210791664582e-06
6.0,1012.0,799.0,0.005929,0.005929,6.920672,0.328159,1.0,1049.0,11.0,386.0,Protocol Violation,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.01346523,0.013472891450099254,7.661450099253828e-06
6.0,1012.0,799.0,0.005929,0.005929,6.920672,0.328159,1.0,1049.0,11.0,386.0,Protocol Violation,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.01346523,0.01345762065123021,7.609348769789526e-06
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Protocol Violation,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0112214,0.011222646499007987,1.2464990079875948e-06
9.0,1012.0,799.0,0.008893,0.008893,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0201967,0.01959231118006944,0.0006043888199305618
13.0,1012.0,799.0,0.012846,0.012846,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.02917428,0.02921970479080358,4.542479080358111e-05
12.0,1012.0,799.0,0.011858,0.011858,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.02693045,0.027019310757576655,8.886075757665382e-05
6.0,1012.0,799.0,0.005929,0.005929,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.01346523,0.013469285853313542,4.055853313542426e-06
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.0022438299999999775,2.2551405187698492e-17
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Severe or Repeated Hypoglycaemia,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,1012.0,799.0,0.003953,0.003953,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00897757,0.008971798361259907,5.771638740093704e-06
16.0,1012.0,799.0,0.01581,0.01581,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.03590576,0.03562949632314482,0.00027626367685518183
15.0,1012.0,799.0,0.014822,0.014822,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.03366193,0.03331492964710315,0.0003470003528968507
13.0,1012.0,799.0,0.012846,0.012846,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.02917428,0.02922004448389882,4.576448389882054e-05
20.0,1012.0,799.0,0.019763,0.019763,6.920672,0.328159,1.0,1049.0,11.0,386.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.04488333,0.046097916812906765,0.0012145868129067663
55.0,1012.0,799.0,0.054348,0.054348,6.920672,0.328159,1.0,1049.0,11.0,386.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.12342859,0.12431756341134605,0.0008889734113460418
56.0,1012.0,799.0,0.055336,0.055336,6.920672,0.328159,1.0,1049.0,11.0,386.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.12567242,0.1258064038646428,0.00013398386464280598
53.0,1012.0,799.0,0.052372,0.052372,6.920672,0.328159,1.0,1049.0,11.0,386.0,Withdrawal by Subject,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.11894094,0.11841571747270828,0.000525222527291716
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.0022447176616666458,8.876616666457157e-07
2.0,1012.0,799.0,0.001976,0.001976,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00448765,0.004484886041418643,2.763958581356897e-06
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.002243925995833311,9.599583331108136e-08
2.0,1012.0,799.0,0.001976,0.001976,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.00448765,0.004485208820704357,2.4411792956431644e-06
3.0,1012.0,799.0,0.002964,0.002964,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00673148,0.006710321322470241,2.1158677529759147e-05
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0112214,0.011221842625079415,4.426250794151154e-07
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0112214,0.011204470759722269,1.69292402777306e-05
4.0,1012.0,799.0,0.003953,0.003953,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.00897757,0.008978271834890863,7.018348908618272e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Patient and PI Decision to Discontinue,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Patient and PI Decision to Discontinue,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00224383,0.002244656225292188,8.262252921878953e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Patient and PI Decision to Discontinue,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Patient and PI Decision to Discontinue,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Glycemic Control,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Glycemic Control,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Glycemic Control,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Glycemic Control,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.0022430310833333107,7.989166666893741e-07
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Therapeutic Response,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.002244435257499979,6.052574999791151e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Therapeutic Response,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Therapeutic Response,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Poor Therapeutic Response,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Pregnancy,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Pregnancy,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Pregnancy,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.0022438627833333107,3.2783333310613255e-08
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Pregnancy,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,PI Decided for Safety Purpose,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,PI Decided for Safety Purpose,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,PI Decided for Safety Purpose,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.0022438299999999775,2.2551405187698492e-17
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,PI Decided for Safety Purpose,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site closed,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site closed,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site closed,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.0022438299999999775,2.2551405187698492e-17
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site closed,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site Closed and Subject Withdrew Consent,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.002244435257499979,6.052574999791151e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site Closed and Subject Withdrew Consent,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site Closed and Subject Withdrew Consent,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Site Closed and Subject Withdrew Consent,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Migrated to Other Country,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Migrated to Other Country,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.00224383,0.002244656225292188,8.262252921878953e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Migrated to Other Country,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Migrated to Other Country,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.0022430310833333107,7.989166666893741e-07
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing Active Treatment Status,Treatment Period (156 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.002244435257499979,6.052574999791151e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing Active Treatment Status,Treatment Period (156 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing Active Treatment Status,Treatment Period (156 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing Active Treatment Status,Treatment Period (156 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,1012.0,799.0,0.002964,0.002964,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00673148,0.0067157412124702436,1.57387875297562e-05
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Adverse Event,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.0022433949870237875,4.350129762125711e-07
2.0,1012.0,799.0,0.001976,0.001976,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00448765,0.004484209274454352,3.4407255456482544e-06
8.0,1012.0,799.0,0.007905,0.007905,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01795288,0.01811569229948412,0.00016281229948411982
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0112214,0.011199477537222266,2.192246277773341e-05
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Noncompliance,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.0112214,0.011214900206507988,6.499793492011768e-06
6.0,1012.0,799.0,0.005929,0.005929,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01346523,0.013443895229146867,2.133477085313265e-05
28.0,1012.0,799.0,0.027668,0.027668,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.06283621,0.06310621539706711,0.00027000539706710514
22.0,1012.0,799.0,0.021739,0.021739,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.04937098,0.04924099512423883,0.00012998487576117157
24.0,1012.0,799.0,0.023715,0.023715,6.920672,0.328159,1.0,1049.0,11.0,386.0,Lost to Follow-up,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.05385863,0.0530794456674432,0.0007791843325567968
5.0,1012.0,799.0,0.004941,0.004941,6.920672,0.328159,1.0,1049.0,11.0,386.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0112214,0.011227364523313537,5.964523313537265e-06
7.0,1012.0,799.0,0.006917,0.006917,6.920672,0.328159,1.0,1049.0,11.0,386.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.01570905,0.015676238472202363,3.28115277976361e-05
12.0,1012.0,799.0,0.011858,0.011858,6.920672,0.328159,1.0,1049.0,11.0,386.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.02693045,0.02701545692007666,8.500692007665928e-05
7.0,1012.0,799.0,0.006917,0.006917,6.920672,0.328159,1.0,1049.0,11.0,386.0,Did Not Enter Follow-up Period,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.01570905,0.015709760762261892,7.107622618934828e-07
8.0,1012.0,799.0,0.007905,0.007905,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Withdrawn from Follow-up,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.01795288,0.018088965134841265,0.00013608513484126422
13.0,1012.0,799.0,0.012846,0.012846,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Withdrawn from Follow-up,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.02917428,0.029229059382053592,5.477938205359148e-05
14.0,1012.0,799.0,0.013834,0.013834,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Withdrawn from Follow-up,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0314181,0.03141879069021825,6.906902182551855e-07
14.0,1012.0,799.0,0.013834,0.013834,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Withdrawn from Follow-up,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.0314181,0.03142109020563491,2.990205634913201e-06
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.0022444112550595043,5.812550595042654e-07
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00224383,0.002245760001482665,1.930001482664933e-06
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.002243805534523788,2.4465476212206377e-08
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Physician Decision,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.0022433189328571208,5.110671428792783e-07
3.0,1012.0,799.0,0.002964,0.002964,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00673148,0.006708614294136907,2.2865705863093187e-05
4.0,1012.0,799.0,0.003953,0.003953,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00897757,0.008979382047628959,1.8120476289584103e-06
6.0,1012.0,799.0,0.005929,0.005929,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.01346523,0.013469709813432602,4.479813432602467e-06
4.0,1012.0,799.0,0.003953,0.003953,6.920672,0.328159,1.0,1049.0,11.0,386.0,Termination of Study/Site by GSK,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.00897757,0.008978423669474196,8.536694741951428e-07
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,ICF Withdrawn,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,ICF Withdrawn,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00224383,0.002245823761899332,1.993761899331866e-06
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,ICF Withdrawn,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,ICF Withdrawn,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Investigator Stopped Study at Site,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Investigator Stopped Study at Site,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00224383,0.002245823761899332,1.993761899331866e-06
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Investigator Stopped Study at Site,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Investigator Stopped Study at Site,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Moved out of Town,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Moved out of Town,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,1012.0,799.0,0.0,0.0,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Moved out of Town,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Subject Moved out of Town,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.0022433949870237875,4.350129762125711e-07
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing,Follow-up Period (8 Weeks),FG000,diabetes type 2,INDUSTRY,0.00224383,0.002244465346726171,6.3534672617091e-07
2.0,1012.0,799.0,0.001976,0.001976,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing,Follow-up Period (8 Weeks),FG001,diabetes type 2,INDUSTRY,0.00448765,0.00448206441475197,5.585585248030385e-06
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing,Follow-up Period (8 Weeks),FG002,diabetes type 2,INDUSTRY,0.00224383,0.0022440460345237874,2.1603452378740617e-07
1.0,1012.0,799.0,0.000988,0.000988,6.920672,0.328159,1.0,1049.0,11.0,386.0,Missing,Follow-up Period (8 Weeks),FG003,diabetes type 2,INDUSTRY,0.00224383,0.002243526649523787,3.0335047621283043e-07
3.0,391.0,363.0,0.007673,0.007673,5.971262,0.292333,1.0,391.0,4.0,35.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01339397,0.013389045664255972,4.924335744027966e-06
11.0,391.0,363.0,0.028133,0.028133,5.971262,0.292333,1.0,391.0,4.0,35.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04910889,0.049323186619930584,0.0002142966199305818
1.0,391.0,363.0,0.002558,0.002558,5.971262,0.292333,1.0,391.0,4.0,35.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00446524,0.004494337562440465,2.909756244046536e-05
0.0,391.0,363.0,0.0,0.0,5.971262,0.292333,1.0,391.0,4.0,35.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,391.0,363.0,0.002558,0.002558,5.971262,0.292333,1.0,391.0,4.0,35.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00446524,0.004493653179107132,2.8413179107132473e-05
1.0,391.0,363.0,0.002558,0.002558,5.971262,0.292333,1.0,391.0,4.0,35.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00446524,0.004490795412023795,2.5555412023795313e-05
3.0,391.0,363.0,0.007673,0.007673,5.971262,0.292333,1.0,391.0,4.0,35.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01339397,0.01339118783008931,2.7821699106894693e-06
2.0,391.0,363.0,0.005115,0.005115,5.971262,0.292333,1.0,391.0,4.0,35.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00892873,0.00887454368723214,5.418631276785969e-05
3.0,391.0,363.0,0.007673,0.007673,5.971262,0.292333,1.0,391.0,4.0,35.0,Familial and personal reasons,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01339397,0.013386906309255979,7.06369074402087e-06
3.0,391.0,363.0,0.007673,0.007673,5.971262,0.292333,1.0,391.0,4.0,35.0,Familial and personal reasons,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01339397,0.01343344772395836,3.947772395835984e-05
10.0,514.0,197.0,0.019455,0.019455,6.244167,0.534616,1.0,514.0,9.0,124.0,Adverse Event,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.06494531,0.06324589384794638,0.0016994161520536288
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Adverse Event,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,514.0,197.0,0.001946,0.001946,6.244167,0.534616,1.0,514.0,9.0,124.0,Lack of Efficacy,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.0064962,0.006500279203452363,4.079203452363178e-06
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Lack of Efficacy,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,514.0,197.0,0.003891,0.003891,6.244167,0.534616,1.0,514.0,9.0,124.0,Poor compliance to protocol,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.01298906,0.01300759545368057,1.853545368057062e-05
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Poor compliance to protocol,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,514.0,197.0,0.01751,0.01751,6.244167,0.534616,1.0,514.0,9.0,124.0,Withdrawal by Subject,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.05845245,0.059044847651875,0.0005923976518749999
9.0,514.0,197.0,0.01751,0.01751,6.244167,0.534616,1.0,514.0,9.0,124.0,Withdrawal by Subject,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.05845245,0.058734697420922626,0.0002822474209226225
2.0,514.0,197.0,0.003891,0.003891,6.244167,0.534616,1.0,514.0,9.0,124.0,Randomized but not treated,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.01298906,0.013006118516180571,1.705851618057086e-05
1.0,514.0,197.0,0.001946,0.001946,6.244167,0.534616,1.0,514.0,9.0,124.0,Randomized but not treated,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.0064962,0.006494321824285695,1.8781757143045141e-06
3.0,514.0,197.0,0.005837,0.005837,6.244167,0.534616,1.0,514.0,9.0,124.0,Other than specified,Core Period: 26 Weeks,FG000,diabetes type 2,INDUSTRY,0.01948526,0.019687045894345213,0.00020178589434521194
1.0,514.0,197.0,0.001946,0.001946,6.244167,0.534616,1.0,514.0,9.0,124.0,Other than specified,Core Period: 26 Weeks,FG001,diabetes type 2,INDUSTRY,0.0064962,0.006492474182619028,3.7258173809714967e-06
1.0,514.0,197.0,0.001946,0.001946,6.244167,0.534616,1.0,514.0,9.0,124.0,Adverse Event,Extension Period:26 Weeks(Upto 52 Weeks),FG000,diabetes type 2,INDUSTRY,0.0064962,0.006498635509702365,2.435509702365668e-06
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Adverse Event,Extension Period:26 Weeks(Upto 52 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,514.0,197.0,0.005837,0.005837,6.244167,0.534616,1.0,514.0,9.0,124.0,Poor compliance to protocol,Extension Period:26 Weeks(Upto 52 Weeks),FG000,diabetes type 2,INDUSTRY,0.01948526,0.019687045894345213,0.00020178589434521194
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Poor compliance to protocol,Extension Period:26 Weeks(Upto 52 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,514.0,197.0,0.009728,0.009728,6.244167,0.534616,1.0,514.0,9.0,124.0,Other than specified,Extension Period:26 Weeks(Upto 52 Weeks),FG000,diabetes type 2,INDUSTRY,0.03247433,0.032428535017470235,4.579498252976766e-05
0.0,514.0,197.0,0.0,0.0,6.244167,0.534616,1.0,514.0,9.0,124.0,Other than specified,Extension Period:26 Weeks(Upto 52 Weeks),FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
8.0,394.0,366.0,0.020305,0.020305,5.978886,0.347727,1.0,394.0,1.0,14.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04221451,0.042470149632351205,0.00025563963235120807
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00527655,0.005269697800218282,6.852199781717978e-06
6.0,394.0,366.0,0.015228,0.015228,5.978886,0.347727,1.0,394.0,1.0,14.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.03165933,0.03133665107202378,0.00032267892797621656
2.0,394.0,366.0,0.005076,0.005076,5.978886,0.347727,1.0,394.0,1.0,14.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01055311,0.010576616308660726,2.3506308660726713e-05
2.0,394.0,366.0,0.005076,0.005076,5.978886,0.347727,1.0,394.0,1.0,14.0,Adverse Event,Overall Study,FG004,diabetes type 2,INDUSTRY,0.01055311,0.010576616308660726,2.3506308660726713e-05
2.0,394.0,366.0,0.005076,0.005076,5.978886,0.347727,1.0,394.0,1.0,14.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01055311,0.010585686023244056,3.257602324405716e-05
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00527655,0.005283114813194473,6.5648131944732666e-06
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Protocol Violation,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00527655,0.005286414227361142,9.86422736114212e-06
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00527655,0.005280223539583364,3.673539583364145e-06
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Physician Decision,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00527655,0.005287555447500031,1.1005447500031518e-05
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00527655,0.005288554316944474,1.2004316944474493e-05
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Lost to Follow-up,Overall Study,FG004,diabetes type 2,INDUSTRY,0.00527655,0.005291541656111141,1.4991656111141768e-05
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,394.0,366.0,0.002538,0.002538,5.978886,0.347727,1.0,394.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00527655,0.005279302259801616,2.752259801615947e-06
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,394.0,366.0,0.0,0.0,5.978886,0.347727,1.0,394.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG004,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,728.0,630.0,0.013736,0.013736,6.591674,0.312053,1.0,728.0,1.0,38.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02825429,0.02843142545293651,0.00017713545293650962
17.0,728.0,630.0,0.023352,0.023352,6.591674,0.312053,1.0,728.0,1.0,38.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04803393,0.04834459071550868,0.0003106607155086774
11.0,728.0,630.0,0.01511,0.01511,6.591674,0.312053,1.0,728.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03108054,0.03079905568527779,0.0002814843147222086
28.0,728.0,630.0,0.038462,0.038462,6.591674,0.312053,1.0,728.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07911447,0.07820861861143844,0.000905851388561571
5.0,728.0,630.0,0.006868,0.006868,6.591674,0.312053,1.0,728.0,1.0,38.0,subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01412714,0.013857155164374997,0.0002699848356250024
20.0,728.0,630.0,0.027473,0.027473,6.591674,0.312053,1.0,728.0,1.0,38.0,subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05651063,0.05717141966581714,0.0006607896658171394
2.0,728.0,630.0,0.002747,0.002747,6.591674,0.312053,1.0,728.0,1.0,38.0,poor/non-compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00565045,0.005617245499464292,3.320450053570772e-05
5.0,728.0,630.0,0.006868,0.006868,6.591674,0.312053,1.0,728.0,1.0,38.0,poor/non-compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01412714,0.013932842948640872,0.00019429705135912828
2.0,453.0,429.0,0.004415,0.004415,6.118097,0.552419,1.0,453.0,2.0,37.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01492162,0.014909617284751963,1.2002715248036686e-05
2.0,453.0,429.0,0.004415,0.004415,6.118097,0.552419,1.0,453.0,2.0,37.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01492162,0.014915534701458311,6.085298541689058e-06
5.0,453.0,429.0,0.011038,0.011038,6.118097,0.552419,1.0,453.0,2.0,37.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03730574,0.03766322959595245,0.0003574895959524496
2.0,453.0,429.0,0.004415,0.004415,6.118097,0.552419,1.0,453.0,2.0,37.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01492162,0.014934880567351172,1.32605673511723e-05
1.0,453.0,429.0,0.002208,0.002208,6.118097,0.552419,1.0,453.0,2.0,37.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0074625,0.007624268147301598,0.00016176814730159764
0.0,453.0,429.0,0.0,0.0,6.118097,0.552419,1.0,453.0,2.0,37.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,453.0,429.0,0.004415,0.004415,6.118097,0.552419,1.0,453.0,2.0,37.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01492162,0.014908749316478155,1.2870683521844922e-05
5.0,453.0,429.0,0.011038,0.011038,6.118097,0.552419,1.0,453.0,2.0,37.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03730574,0.03789206912559529,0.0005863291255952946
2.0,453.0,429.0,0.004415,0.004415,6.118097,0.552419,1.0,453.0,2.0,37.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01492162,0.014899579274811487,2.204072518851262e-05
3.0,453.0,429.0,0.006623,0.006623,6.118097,0.552419,1.0,453.0,2.0,37.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02238412,0.022450400290059545,6.628029005954425e-05
7.0,235.0,203.0,0.029787,0.029787,5.463832,0.212734,1.0,235.0,1.0,31.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03462272,0.03487571992857143,0.0002529999285714249
4.0,235.0,203.0,0.017021,0.017021,5.463832,0.212734,1.0,235.0,1.0,31.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01978425,0.020180465707847227,0.0003962157078472271
1.0,235.0,203.0,0.004255,0.004255,5.463832,0.212734,1.0,235.0,1.0,31.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00494577,0.004972539724434515,2.6769724434514384e-05
1.0,235.0,203.0,0.004255,0.004255,5.463832,0.212734,1.0,235.0,1.0,31.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00494577,0.004974179010684513,2.8409010684512376e-05
2.0,235.0,203.0,0.008511,0.008511,5.463832,0.212734,1.0,235.0,1.0,31.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0098927,0.009917541145505946,2.484114550594524e-05
3.0,235.0,203.0,0.012766,0.012766,5.463832,0.212734,1.0,235.0,1.0,31.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01483848,0.015054310618095243,0.00021583061809524358
0.0,235.0,203.0,0.0,0.0,5.463832,0.212734,1.0,235.0,1.0,31.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,235.0,203.0,0.004255,0.004255,5.463832,0.212734,1.0,235.0,1.0,31.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00494577,0.004976170659017847,3.0400659017846242e-05
1.0,235.0,203.0,0.004255,0.004255,5.463832,0.212734,1.0,235.0,1.0,31.0,Entry criterion not met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00494577,0.004973472426517848,2.770242651784806e-05
2.0,235.0,203.0,0.008511,0.008511,5.463832,0.212734,1.0,235.0,1.0,31.0,Entry criterion not met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0098927,0.00991204036877975,1.934036877974943e-05
8.0,235.0,203.0,0.034043,0.034043,5.463832,0.212734,1.0,235.0,1.0,31.0,Subject decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03956966,0.04098053095883929,0.0014108709588392873
2.0,235.0,203.0,0.008511,0.008511,5.463832,0.212734,1.0,235.0,1.0,31.0,Subject decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0098927,0.00991204036877975,1.934036877974943e-05
8.0,276.0,258.0,0.028986,0.028986,5.624018,0.300923,1.0,276.0,7.0,42.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04905578,0.04992051337842263,0.000864733378422633
5.0,276.0,258.0,0.018116,0.018116,5.624018,0.300923,1.0,276.0,7.0,42.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03065944,0.030843061356130942,0.00018362135613094258
1.0,276.0,258.0,0.003623,0.003623,5.624018,0.300923,1.0,276.0,7.0,42.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00613155,0.0061932660281547635,6.17160281547631e-05
4.0,276.0,258.0,0.014493,0.014493,5.624018,0.300923,1.0,276.0,7.0,42.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02452789,0.02471421559571429,0.00018632559571429147
7.0,353.0,289.0,0.01983,0.01983,5.869297,0.335325,1.0,353.0,4.0,76.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03902781,0.03964885881962302,0.0006210488196230143
9.0,353.0,289.0,0.025496,0.025496,5.869297,0.335325,1.0,353.0,4.0,76.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.05017918,0.05002151989611106,0.0001576601038889361
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00557568,0.005576765153750004,1.0851537500036756e-06
2.0,353.0,289.0,0.005666,0.005666,5.869297,0.335325,1.0,353.0,4.0,76.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01115137,0.011274724577460316,0.0001233545774603148
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00557568,0.005577427935000003,1.747935000002629e-06
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00557568,0.005578178444393943,2.498444393942735e-06
10.0,353.0,289.0,0.028329,0.028329,5.869297,0.335325,1.0,353.0,4.0,76.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05575486,0.056743258486617106,0.0009883984866171022
14.0,353.0,289.0,0.03966,0.03966,5.869297,0.335325,1.0,353.0,4.0,76.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07805562,0.07963145868669641,0.0015758386866964041
6.0,353.0,289.0,0.016997,0.016997,5.869297,0.335325,1.0,353.0,4.0,76.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03345213,0.03363615991672622,0.00018402991672622493
4.0,353.0,289.0,0.011331,0.011331,5.869297,0.335325,1.0,353.0,4.0,76.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02230076,0.022422975270079363,0.00012221527007936356
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Non-compliance with study drug,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00557568,0.005577073303750004,1.3933037500040227e-06
3.0,353.0,289.0,0.008499,0.008499,5.869297,0.335325,1.0,353.0,4.0,76.0,Non-compliance with study drug,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01672705,0.016689204085466244,3.784591453375591e-05
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Non-compliance with protocol,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00557568,0.00557732826541667,1.6482654166694727e-06
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Non-compliance with protocol,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00557568,0.00557807877481061,2.398774810609579e-06
0.0,353.0,289.0,0.0,0.0,5.869297,0.335325,1.0,353.0,4.0,76.0,Moved out of country,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Moved out of country,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00557568,0.005577823813143944,2.1438131439432614e-06
0.0,353.0,289.0,0.0,0.0,5.869297,0.335325,1.0,353.0,4.0,76.0,Adverse Event + Elevated Fasting Glucose,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Adverse Event + Elevated Fasting Glucose,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00557568,0.005577823813143944,2.1438131439432614e-06
0.0,353.0,289.0,0.0,0.0,5.869297,0.335325,1.0,353.0,4.0,76.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,353.0,289.0,0.002833,0.002833,5.869297,0.335325,1.0,353.0,4.0,76.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00557568,0.005575436534810609,2.43465189391813e-07
103.0,3323.0,1996.0,0.030996,0.030996,8.108924,0.290259,1.0,3323.0,12.0,114.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07295483,0.07402599680267859,0.0010711668026785887
87.0,3323.0,1996.0,0.026181,0.026181,8.108924,0.290259,1.0,3323.0,12.0,114.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06162184,0.06193119273996033,0.0003093527399603349
40.0,3323.0,1996.0,0.012037,0.012037,8.108924,0.290259,1.0,3323.0,12.0,114.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02833131,0.028499985548749985,0.0001686755487499865
43.0,3323.0,1996.0,0.01294,0.01294,8.108924,0.290259,1.0,3323.0,12.0,114.0,Major protocol deviation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03045669,0.03060982469474206,0.00015313469474205824
51.0,3323.0,1996.0,0.015348,0.015348,8.108924,0.290259,1.0,3323.0,12.0,114.0,Major protocol deviation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03612436,0.03615907645130949,3.471645130948692e-05
18.0,3323.0,1996.0,0.005417,0.005417,8.108924,0.290259,1.0,3323.0,12.0,114.0,Major protocol deviation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01274991,0.01229545442229165,0.00045445557770834935
57.0,3323.0,1996.0,0.017153,0.017153,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04037277,0.04267254694790673,0.0022997769479067287
41.0,3323.0,1996.0,0.012338,0.012338,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02903977,0.029432288940178533,0.00039251894017853367
35.0,3323.0,1996.0,0.010533,0.010533,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02479137,0.02497121226574407,0.0001798422657440686
199.0,3323.0,1996.0,0.059886,0.059886,8.108924,0.290259,1.0,3323.0,12.0,114.0,Voluntary withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.1409528,0.1372621956027579,0.0036906043972420866
187.0,3323.0,1996.0,0.056274,0.056274,8.108924,0.290259,1.0,3323.0,12.0,114.0,Voluntary withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.13245129,0.1323851358182538,6.615418174618637e-05
91.0,3323.0,1996.0,0.027385,0.027385,8.108924,0.290259,1.0,3323.0,12.0,114.0,Voluntary withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06445567,0.06434578615060513,0.00010988384939487894
1.0,3323.0,1996.0,0.000301,0.000301,8.108924,0.290259,1.0,3323.0,12.0,114.0,Study termination,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00070846,0.0007070894105654757,1.370589434524297e-06
0.0,3323.0,1996.0,0.0,0.0,8.108924,0.290259,1.0,3323.0,12.0,114.0,Study termination,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,3323.0,1996.0,0.000301,0.000301,8.108924,0.290259,1.0,3323.0,12.0,114.0,Study termination,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00070846,0.0007174560568452381,8.9960568452382e-06
3.0,3323.0,1996.0,0.000903,0.000903,8.108924,0.290259,1.0,3323.0,12.0,114.0,Pregnancy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00212538,0.002050388598373015,7.499140162698509e-05
1.0,3323.0,1996.0,0.000301,0.000301,8.108924,0.290259,1.0,3323.0,12.0,114.0,Pregnancy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00070846,0.0007094932977786792,1.0332977786792121e-06
1.0,3323.0,1996.0,0.000301,0.000301,8.108924,0.290259,1.0,3323.0,12.0,114.0,Pregnancy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00070846,0.0007188738752976191,1.0413875297619131e-05
26.0,3323.0,1996.0,0.007824,0.007824,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01841523,0.018505258227847224,9.002822784722267e-05
40.0,3323.0,1996.0,0.012037,0.012037,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02833131,0.028569490969851164,0.00023818096985116569
38.0,3323.0,1996.0,0.011435,0.011435,8.108924,0.290259,1.0,3323.0,12.0,114.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02691439,0.02657614881759922,0.0003382411824007815
28.0,3323.0,1996.0,0.008426,0.008426,8.108924,0.290259,1.0,3323.0,12.0,114.0,Investigator discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01983215,0.01966714854686508,0.0001650014531349199
31.0,3323.0,1996.0,0.009329,0.009329,8.108924,0.290259,1.0,3323.0,12.0,114.0,Investigator discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02195753,0.02179076221982141,0.0001667677801785901
21.0,3323.0,1996.0,0.00632,0.00632,8.108924,0.290259,1.0,3323.0,12.0,114.0,Investigator discretion,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01487529,0.014747653141249983,0.00012763685875001596
80.0,3323.0,1996.0,0.024075,0.024075,8.108924,0.290259,1.0,3323.0,12.0,114.0,Other,Overall Study,FG000,diabetes type 2,INDUSTRY,0.05666498,0.05678389898560518,0.00011891898560518338
70.0,3323.0,1996.0,0.021065,0.021065,8.108924,0.290259,1.0,3323.0,12.0,114.0,Other,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04958038,0.052071430271899324,0.002491050271899324
32.0,3323.0,1996.0,0.00963,0.00963,8.108924,0.290259,1.0,3323.0,12.0,114.0,Other,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02266599,0.022710287043184518,4.429704318451716e-05
2.0,3323.0,1996.0,0.000602,0.000602,8.108924,0.290259,1.0,3323.0,12.0,114.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00141692,0.0013769085200892861,4.001147991071377e-05
0.0,3323.0,1996.0,0.0,0.0,8.108924,0.290259,1.0,3323.0,12.0,114.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,3323.0,1996.0,0.0,0.0,8.108924,0.290259,1.0,3323.0,12.0,114.0,Site closure,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,288.0,284.0,0.006944,0.006944,5.666427,0.231988,1.0,288.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00912819,0.009106332004878256,2.1857995121743815e-05
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,288.0,284.0,0.003472,0.003472,5.666427,0.231988,1.0,288.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0045641,0.0046882918466071575,0.0001241918466071577
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Schedule Conflict,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,288.0,284.0,0.003472,0.003472,5.666427,0.231988,1.0,288.0,0.0,0.0,Schedule Conflict,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0045641,0.004692346484047632,0.0001282464840476321
0.0,288.0,284.0,0.0,0.0,5.666427,0.231988,1.0,288.0,0.0,0.0,Schedule Conflict,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,978.0,860.0,0.009202,0.009202,6.886532,0.303074,1.0,978.0,4.0,89.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01920573,0.019240750882281776,3.5020882281775606e-05
4.0,978.0,860.0,0.00409,0.00409,6.886532,0.303074,1.0,978.0,4.0,89.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00853634,0.00850316720378968,3.317279621031961e-05
10.0,978.0,860.0,0.010225,0.010225,6.886532,0.303074,1.0,978.0,4.0,89.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02134086,0.021382301009871,4.144100987099955e-05
3.0,978.0,860.0,0.003067,0.003067,6.886532,0.303074,1.0,978.0,4.0,89.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00640121,0.006385561923787857,1.5648076212143418e-05
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213304,0.0021309622118452433,2.077788154756805e-06
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00213304,0.0021299044274504016,3.135572549598474e-06
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Death,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Death,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,978.0,860.0,0.003067,0.003067,6.886532,0.303074,1.0,978.0,4.0,89.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00640121,0.006380717346168813,2.0492653831186668e-05
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Entry Criteria Not Met,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Entry Criteria Not Met,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213304,0.0021303593002381005,2.680699761899597e-06
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,978.0,860.0,0.002045,0.002045,6.886532,0.303074,1.0,978.0,4.0,89.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00426817,0.004257952801200403,1.0217198799597309e-05
3.0,978.0,860.0,0.003067,0.003067,6.886532,0.303074,1.0,978.0,4.0,89.0,Lack of Efficacy,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00640121,0.0063869511154545245,1.425888454547556e-05
7.0,978.0,860.0,0.007157,0.007157,6.886532,0.303074,1.0,978.0,4.0,89.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01493756,0.014779934082351185,0.0001576259176488161
10.0,978.0,860.0,0.010225,0.010225,6.886532,0.303074,1.0,978.0,4.0,89.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02134086,0.021417219851061486,7.635985106148671e-05
13.0,978.0,860.0,0.013292,0.013292,6.886532,0.303074,1.0,978.0,4.0,89.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02774207,0.027694386935863114,4.768306413688653e-05
5.0,978.0,860.0,0.005112,0.005112,6.886532,0.303074,1.0,978.0,4.0,89.0,Lost to Follow-up,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01066939,0.01048410849609127,0.0001852815039087314
2.0,978.0,860.0,0.002045,0.002045,6.886532,0.303074,1.0,978.0,4.0,89.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00426817,0.004263227319176597,4.94268082340283e-06
2.0,978.0,860.0,0.002045,0.002045,6.886532,0.303074,1.0,978.0,4.0,89.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00426817,0.004257936946101198,1.0233053898802205e-05
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Physician Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213304,0.002131210945952386,1.8290540476141072e-06
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00213304,0.0021299127198908772,3.1272801091228666e-06
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Protocol Violation,Overall Study,FG003,diabetes type 2,INDUSTRY,0.00213304,0.0021315444591865134,1.4955408134866705e-06
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,978.0,860.0,0.003067,0.003067,6.886532,0.303074,1.0,978.0,4.0,89.0,Sponsor Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00640121,0.00637701239866881,2.419760133118981e-05
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Sponsor Decision,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
9.0,978.0,860.0,0.009202,0.009202,6.886532,0.303074,1.0,978.0,4.0,89.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01920573,0.019241789570615106,3.605957061510526e-05
7.0,978.0,860.0,0.007157,0.007157,6.886532,0.303074,1.0,978.0,4.0,89.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01493756,0.01480000477324404,0.0001375552267559605
12.0,978.0,860.0,0.01227,0.01227,6.886532,0.303074,1.0,978.0,4.0,89.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02560903,0.025917537251875036,0.00030850725187503425
5.0,978.0,860.0,0.005112,0.005112,6.886532,0.303074,1.0,978.0,4.0,89.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.01066939,0.010499684655376979,0.000169705344623022
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Treatment Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00213304,0.002131972031369053,1.0679686309471477e-06
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Treatment Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00213304,0.0021308206828075443,2.2193171924558136e-06
1.0,978.0,860.0,0.001022,0.001022,6.886532,0.303074,1.0,978.0,4.0,89.0,Treatment Noncompliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00213304,0.0021339335529365136,8.935529365134906e-07
0.0,978.0,860.0,0.0,0.0,6.886532,0.303074,1.0,978.0,4.0,89.0,Treatment Noncompliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00425554,0.004242935101249971,1.2604898750029521e-05
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00425554,0.004263777402976161,8.237402976160602e-06
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00425554,0.004255099936964252,4.40063035748485e-07
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Adverse Event,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,400.0,370.0,0.005,0.005,5.993961,0.283988,1.0,400.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00851108,0.008495280475634888,1.5799524365112463e-05
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00425554,0.004255053416130919,4.865838690816179e-07
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Lab value,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00425554,0.00424280651874997,1.2733481250030293e-05
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Lab value,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Lab value,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00425554,0.004254898029464251,6.419705357489994e-07
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Lab value,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,400.0,370.0,0.0125,0.0125,5.993961,0.283988,1.0,400.0,7.0,55.0,Subject no longer meets study criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0212777,0.02141756102378787,0.00013986102378786905
2.0,400.0,370.0,0.005,0.005,5.993961,0.283988,1.0,400.0,7.0,55.0,Subject no longer meets study criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00851108,0.00848526109438489,2.581890561511105e-05
4.0,400.0,370.0,0.01,0.01,5.993961,0.283988,1.0,400.0,7.0,55.0,Subject no longer meets study criteria,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01702216,0.01700580389450396,1.635610549604108e-05
8.0,400.0,370.0,0.02,0.02,5.993961,0.283988,1.0,400.0,7.0,55.0,Subject no longer meets study criteria,Overall Study,FG003,diabetes type 2,INDUSTRY,0.03404432,0.034443795029454397,0.0003994750294543936
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Incorrect enrollment,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Incorrect enrollment,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00425554,0.004263433611309495,7.89361130949448e-06
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Incorrect enrollment,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00425554,0.004254443861964252,1.0961380357485395e-06
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Incorrect enrollment,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Poor/Non-Compliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Poor/Non-Compliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,400.0,370.0,0.0025,0.0025,5.993961,0.283988,1.0,400.0,7.0,55.0,Poor/Non-Compliance,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00425554,0.0042545819494642515,9.580505357488847e-07
0.0,400.0,370.0,0.0,0.0,5.993961,0.283988,1.0,400.0,7.0,55.0,Poor/Non-Compliance,Overall Study,FG003,diabetes type 2,INDUSTRY,0.0,0.0,0.0
67.0,1791.0,1532.0,0.037409,0.037409,7.491088,0.215734,1.0,1791.0,2.0,21.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,FED,0.06045616,0.061024000466319415,0.0005678404663194137
43.0,1791.0,1532.0,0.024009,0.024009,7.491088,0.215734,1.0,1791.0,2.0,21.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,FED,0.03880061,0.03905521546044642,0.00025460546044642207
3.0,1791.0,1532.0,0.001675,0.001675,7.491088,0.215734,1.0,1791.0,2.0,21.0,Adverse Event,Overall Study,FG000,diabetes type 2,FED,0.00270694,0.002733024900416668,2.608490041666788e-05
7.0,1791.0,1532.0,0.003908,0.003908,7.491088,0.215734,1.0,1791.0,2.0,21.0,Adverse Event,Overall Study,FG001,diabetes type 2,FED,0.00631566,0.006401191783194439,8.553178319443879e-05
57.0,1791.0,1532.0,0.031826,0.031826,7.491088,0.215734,1.0,1791.0,2.0,21.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,FED,0.05143355,0.05256355117927672,0.001130001179276717
58.0,1791.0,1532.0,0.032384,0.032384,7.491088,0.215734,1.0,1791.0,2.0,21.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,FED,0.05233533,0.0532342530406656,0.0008989230406655987
12.0,1791.0,1532.0,0.0067,0.0067,7.491088,0.215734,1.0,1791.0,2.0,21.0,Had other reason,Overall Study,FG000,diabetes type 2,FED,0.01082778,0.010845233317619041,1.745331761904105e-05
12.0,1791.0,1532.0,0.0067,0.0067,7.491088,0.215734,1.0,1791.0,2.0,21.0,Had other reason,Overall Study,FG001,diabetes type 2,FED,0.01082778,0.01084167334904761,1.3893349047609457e-05
1.0,272.0,241.0,0.003676,0.003676,5.609472,0.309765,1.0,272.0,1.0,5.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00638749,0.006381386522437763,6.103477562236642e-06
2.0,272.0,241.0,0.007353,0.007353,5.609472,0.309765,1.0,272.0,1.0,5.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01277671,0.01277336176877973,3.3482312202706005e-06
2.0,272.0,241.0,0.007353,0.007353,5.609472,0.309765,1.0,272.0,1.0,5.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01277671,0.012775903609315443,8.063906845566515e-07
3.0,272.0,241.0,0.011029,0.011029,5.609472,0.309765,1.0,272.0,1.0,5.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0191642,0.01917033443011903,6.134430119032058e-06
0.0,272.0,241.0,0.0,0.0,5.609472,0.309765,1.0,272.0,1.0,5.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,272.0,241.0,0.007353,0.007353,5.609472,0.309765,1.0,272.0,1.0,5.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01277671,0.012776811694037665,1.016940376647596e-07
1.0,272.0,241.0,0.003676,0.003676,5.609472,0.309765,1.0,272.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00638749,0.006379629978032996,7.860021967003895e-06
4.0,272.0,241.0,0.014706,0.014706,5.609472,0.309765,1.0,272.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02555342,0.02560636192964285,5.2941929642849606e-05
4.0,272.0,241.0,0.014706,0.014706,5.609472,0.309765,1.0,272.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02555342,0.025602561899226182,4.914189922618217e-05
0.0,272.0,241.0,0.0,0.0,5.609472,0.309765,1.0,272.0,1.0,5.0,Clearly not eligible for the study,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,272.0,241.0,0.0,0.0,5.609472,0.309765,1.0,272.0,1.0,5.0,Clearly not eligible for the study,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,272.0,241.0,0.003676,0.003676,5.609472,0.309765,1.0,272.0,1.0,5.0,Clearly not eligible for the study,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00638749,0.00637979958856871,7.69041143129038e-06
1.0,272.0,241.0,0.003676,0.003676,5.609472,0.309765,1.0,272.0,1.0,5.0,Fasting plasma glucose level increased,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00638749,0.006380361044699664,7.128955300335707e-06
0.0,272.0,241.0,0.0,0.0,5.609472,0.309765,1.0,272.0,1.0,5.0,Fasting plasma glucose level increased,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
10.0,272.0,241.0,0.036765,0.036765,5.609472,0.309765,1.0,272.0,1.0,5.0,Fasting plasma glucose level increased,Overall Study,FG002,diabetes type 2,INDUSTRY,0.06388355,0.06333096166985112,0.0005525883301488732
12.0,387.0,330.0,0.031008,0.031008,5.961005,0.218985,1.0,387.0,9.0,28.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.04047694,0.0395749135705456,0.0009020264294544028
6.0,387.0,330.0,0.015504,0.015504,5.961005,0.218985,1.0,387.0,9.0,28.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02023847,0.02011834647654308,0.00012012352345691993
7.0,387.0,330.0,0.018088,0.018088,5.961005,0.218985,1.0,387.0,9.0,28.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02361155,0.023463769638392865,0.00014778036160713326
6.0,387.0,330.0,0.015504,0.015504,5.961005,0.218985,1.0,387.0,9.0,28.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02023847,0.020128848761424047,0.00010962123857595485
0.0,387.0,330.0,0.0,0.0,5.961005,0.218985,1.0,387.0,9.0,28.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
4.0,387.0,330.0,0.010336,0.010336,5.961005,0.218985,1.0,387.0,9.0,28.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01349231,0.01364904210648809,0.00015673210648808888
5.0,387.0,330.0,0.01292,0.01292,5.961005,0.218985,1.0,387.0,9.0,28.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01686539,0.01691088946144842,4.54994614484186e-05
5.0,387.0,330.0,0.01292,0.01292,5.961005,0.218985,1.0,387.0,9.0,28.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01686539,0.016873461551279764,8.071551279763278e-06
3.0,387.0,330.0,0.007752,0.007752,5.961005,0.218985,1.0,387.0,9.0,28.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01011924,0.01001756513894842,0.00010167486105158025
4.0,387.0,330.0,0.010336,0.010336,5.961005,0.218985,1.0,387.0,9.0,28.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01349231,0.013622155555833328,0.00012984555583332724
2.0,387.0,330.0,0.005168,0.005168,5.961005,0.218985,1.0,387.0,9.0,28.0,Sponsor Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00674616,0.0067269510873214375,1.920891267856266e-05
1.0,387.0,330.0,0.002584,0.002584,5.961005,0.218985,1.0,387.0,9.0,28.0,Sponsor Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00337308,0.0033519397640773764,2.1140235922623672e-05
2.0,387.0,330.0,0.005168,0.005168,5.961005,0.218985,1.0,387.0,9.0,28.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00674616,0.006724206891488103,2.1953108511897287e-05
0.0,387.0,330.0,0.0,0.0,5.961005,0.218985,1.0,387.0,9.0,28.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
6.0,984.0,949.0,0.006098,0.006098,6.892642,0.758758,1.0,984.0,13.0,198.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03189162,0.0315186171769643,0.00037300282303569937
8.0,984.0,949.0,0.00813,0.00813,6.892642,0.758758,1.0,984.0,13.0,198.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04251867,0.04219921930306549,0.000319450696934509
1.0,984.0,949.0,0.001016,0.001016,6.892642,0.758758,1.0,984.0,13.0,198.0,Site closure,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00531353,0.0054058762106845345,9.234621068453415e-05
0.0,984.0,949.0,0.0,0.0,6.892642,0.758758,1.0,984.0,13.0,198.0,Site closure,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,984.0,949.0,0.005081,0.005081,6.892642,0.758758,1.0,984.0,13.0,198.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02657286,0.026328048596765897,0.0002448114032341034
4.0,984.0,949.0,0.004065,0.004065,6.892642,0.758758,1.0,984.0,13.0,198.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02125934,0.0213692858731548,0.00010994587315479865
2.0,984.0,949.0,0.002033,0.002033,6.892642,0.758758,1.0,984.0,13.0,198.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01063228,0.010881811511130948,0.0002495315111309491
1.0,984.0,949.0,0.001016,0.001016,6.892642,0.758758,1.0,984.0,13.0,198.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00531353,0.005437786036934528,0.00012425603693452802
4.0,984.0,949.0,0.004065,0.004065,6.892642,0.758758,1.0,984.0,13.0,198.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02125934,0.021302733431934576,4.339343193457412e-05
4.0,984.0,949.0,0.004065,0.004065,6.892642,0.758758,1.0,984.0,13.0,198.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02125934,0.021368694082113143,0.00010935408211314168
4.0,317.0,292.0,0.012618,0.012618,5.762051,0.227085,1.0,317.0,0.0,0.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01651031,0.016668735105744046,0.0001584251057440457
0.0,317.0,292.0,0.0,0.0,5.762051,0.227085,1.0,317.0,0.0,0.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,317.0,292.0,0.0,0.0,5.762051,0.227085,1.0,317.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,317.0,292.0,0.006309,0.006309,5.762051,0.227085,1.0,317.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00825515,0.00857524829651788,0.000320098296517881
3.0,317.0,292.0,0.009464,0.009464,5.762051,0.227085,1.0,317.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01238339,0.012360276909722228,2.3113090277771323e-05
4.0,317.0,292.0,0.012618,0.012618,5.762051,0.227085,1.0,317.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01651031,0.016598492335595242,8.818233559524172e-05
0.0,317.0,292.0,0.0,0.0,5.762051,0.227085,1.0,317.0,0.0,0.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,317.0,292.0,0.003155,0.003155,5.762051,0.227085,1.0,317.0,0.0,0.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412823,0.004167373764160361,3.914376416036102e-05
6.0,317.0,292.0,0.018927,0.018927,5.762051,0.227085,1.0,317.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02476546,0.024938801186289692,0.00017334118628969247
3.0,317.0,292.0,0.009464,0.009464,5.762051,0.227085,1.0,317.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01238339,0.012394166394523818,1.0776394523818664e-05
1.0,317.0,292.0,0.003155,0.003155,5.762051,0.227085,1.0,317.0,0.0,0.0,Needed excluded medication,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00412823,0.004151381104190123,2.3151104190122576e-05
1.0,317.0,292.0,0.003155,0.003155,5.762051,0.227085,1.0,317.0,0.0,0.0,Needed excluded medication,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00412823,0.004153597664338933,2.536766433893292e-05
0.0,374.0,358.0,0.0,0.0,5.926926,0.384821,1.0,374.0,1.0,27.0,Pretreatment Event/Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
5.0,374.0,358.0,0.013369,0.013369,5.926926,0.384821,1.0,374.0,1.0,27.0,Pretreatment Event/Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.03049211,0.03094999726420638,0.00045788726420637957
2.0,374.0,358.0,0.005348,0.005348,5.926926,0.384821,1.0,374.0,1.0,27.0,Pretreatment Event/Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01219776,0.01223387681574404,3.611681574403926e-05
4.0,374.0,358.0,0.010695,0.010695,5.926926,0.384821,1.0,374.0,1.0,27.0,Voluntary Withdrawal,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02439323,0.024631551158561506,0.00023832115856150735
0.0,374.0,358.0,0.0,0.0,5.926926,0.384821,1.0,374.0,1.0,27.0,Voluntary Withdrawal,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,358.0,0.002674,0.002674,5.926926,0.384821,1.0,374.0,1.0,27.0,Voluntary Withdrawal,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00609888,0.006110217182456714,1.1337182456713953e-05
2.0,374.0,358.0,0.005348,0.005348,5.926926,0.384821,1.0,374.0,1.0,27.0,Lack of Efficacy,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01219776,0.012256637627648802,5.887762764880157e-05
1.0,374.0,358.0,0.002674,0.002674,5.926926,0.384821,1.0,374.0,1.0,27.0,Lack of Efficacy,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00609888,0.006106122229301951,7.242229301950877e-06
0.0,374.0,358.0,0.0,0.0,5.926926,0.384821,1.0,374.0,1.0,27.0,Lack of Efficacy,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,358.0,0.002674,0.002674,5.926926,0.384821,1.0,374.0,1.0,27.0,Other Reason Not Specified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00609888,0.006121832746861475,2.2952746861475137e-05
0.0,374.0,358.0,0.0,0.0,5.926926,0.384821,1.0,374.0,1.0,27.0,Other Reason Not Specified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
0.0,374.0,358.0,0.0,0.0,5.926926,0.384821,1.0,374.0,1.0,27.0,Other Reason Not Specified,Overall Study,FG002,diabetes type 2,INDUSTRY,0.0,0.0,0.0
17.0,279.0,210.0,0.060932,0.060932,5.63479,0.339328,1.0,279.0,6.0,97.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11650462,0.11670722275510911,0.0002026027551091103
4.0,279.0,210.0,0.014337,0.014337,5.63479,0.339328,1.0,279.0,6.0,97.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02741296,0.027282325704880952,0.00013063429511904825
0.0,279.0,210.0,0.0,0.0,5.63479,0.339328,1.0,279.0,6.0,97.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
3.0,279.0,210.0,0.010753,0.010753,5.63479,0.339328,1.0,279.0,6.0,97.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0205602,0.02144012905677124,0.0008799290567712385
17.0,279.0,210.0,0.060932,0.060932,5.63479,0.339328,1.0,279.0,6.0,97.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.11650462,0.11684089848138884,0.00033627848138884087
25.0,279.0,210.0,0.089606,0.089606,5.63479,0.339328,1.0,279.0,6.0,97.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.17133055,0.16682740548068456,0.0045031445193154385
1.0,279.0,210.0,0.003584,0.003584,5.63479,0.339328,1.0,279.0,6.0,97.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00685276,0.007019308076222329,0.00016654807622232867
2.0,279.0,210.0,0.007168,0.007168,5.63479,0.339328,1.0,279.0,6.0,97.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01370553,0.013680779222529743,2.4750777470257043e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.249466,1.0,374.0,10.0,50.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.249466,1.0,374.0,10.0,50.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00395369,0.003959995237499978,6.30523749997787e-06
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.249466,1.0,374.0,10.0,50.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00395369,0.003956089379067434,2.3993790674338433e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.249466,1.0,374.0,10.0,50.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.249466,1.0,374.0,10.0,50.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00395369,0.0039563545728174354,2.66457281743529e-06
0.0,374.0,344.0,0.0,0.0,5.926926,0.249466,1.0,374.0,10.0,50.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.249466,1.0,374.0,10.0,50.0,Entry Criteria Not Met,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00790739,0.007989188967946427,8.179896794642712e-05
0.0,374.0,344.0,0.0,0.0,5.926926,0.249466,1.0,374.0,10.0,50.0,Entry Criteria Not Met,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,374.0,344.0,0.002674,0.002674,5.926926,0.249466,1.0,374.0,10.0,50.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00395369,0.0039522283744245785,1.4616255754216698e-06
3.0,374.0,344.0,0.008021,0.008021,5.926926,0.249466,1.0,374.0,10.0,50.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0118596,0.011959190509097212,9.95905090972124e-05
7.0,374.0,344.0,0.018717,0.018717,5.926926,0.249466,1.0,374.0,10.0,50.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02767438,0.027593132743263894,8.124725673610417e-05
12.0,374.0,344.0,0.032086,0.032086,5.926926,0.249466,1.0,374.0,10.0,50.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04744137,0.04880865728066472,0.0013672872806647224
0.0,374.0,344.0,0.0,0.0,5.926926,0.249466,1.0,374.0,10.0,50.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
2.0,374.0,344.0,0.005348,0.005348,5.926926,0.249466,1.0,374.0,10.0,50.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00790739,0.007979501123869045,7.211112386904493e-05
0.0,465.0,397.0,0.0,0.0,6.144186,0.342728,1.0,465.0,10.0,159.0,Randomized but Not Treated,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,465.0,397.0,0.002151,0.002151,6.144186,0.342728,1.0,465.0,10.0,159.0,Randomized but Not Treated,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452955,0.004541704267013894,1.2154267013893966e-05
3.0,465.0,397.0,0.006452,0.006452,6.144186,0.342728,1.0,465.0,10.0,159.0,Adverse Event Other than Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01358653,0.013602198260150668,1.56682601506683e-05
10.0,465.0,397.0,0.021505,0.021505,6.144186,0.342728,1.0,465.0,10.0,159.0,Adverse Event Other than Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04528493,0.0451075981006701,0.00017733189932989807
5.0,465.0,397.0,0.010753,0.010753,6.144186,0.342728,1.0,465.0,10.0,159.0,Hyperglycemia,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02264352,0.02279793548652328,0.00015441548652327802
2.0,465.0,397.0,0.004301,0.004301,6.144186,0.342728,1.0,465.0,10.0,159.0,Hyperglycemia,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00905699,0.009205055647113092,0.00014806564711309332
3.0,465.0,397.0,0.006452,0.006452,6.144186,0.342728,1.0,465.0,10.0,159.0,Investigator's Discretion,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01358653,0.013602198260150668,1.56682601506683e-05
1.0,465.0,397.0,0.002151,0.002151,6.144186,0.342728,1.0,465.0,10.0,159.0,Investigator's Discretion,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452955,0.004541704267013894,1.2154267013893966e-05
4.0,465.0,397.0,0.008602,0.008602,6.144186,0.342728,1.0,465.0,10.0,159.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01811397,0.018465207443134936,0.00035123744313493577
1.0,465.0,397.0,0.002151,0.002151,6.144186,0.342728,1.0,465.0,10.0,159.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452955,0.004541911305347228,1.2361305347227333e-05
5.0,465.0,397.0,0.010753,0.010753,6.144186,0.342728,1.0,465.0,10.0,159.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02264352,0.022797412569439946,0.0001538925694399458
1.0,465.0,397.0,0.002151,0.002151,6.144186,0.342728,1.0,465.0,10.0,159.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00452955,0.004541300542013894,1.1750542013893445e-05
8.0,465.0,397.0,0.017204,0.017204,6.144186,0.342728,1.0,465.0,10.0,159.0,Subject Noncompliance,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03622794,0.03606861862250991,0.00015932137749009173
15.0,465.0,397.0,0.032258,0.032258,6.144186,0.342728,1.0,465.0,10.0,159.0,Subject Noncompliance,Overall Study,FG001,diabetes type 2,INDUSTRY,0.06792844,0.06818915085233043,0.0002607108523304258
6.0,465.0,397.0,0.012903,0.012903,6.144186,0.342728,1.0,465.0,10.0,159.0,Subject Withdrew Consent,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02717096,0.027198893776646797,2.7933776646796304e-05
3.0,465.0,397.0,0.006452,0.006452,6.144186,0.342728,1.0,465.0,10.0,159.0,Subject Withdrew Consent,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01358653,0.01363182833931733,4.529833931733035e-05
2.0,582.0,548.0,0.003436,0.003436,6.368187,0.729095,1.0,582.0,9.0,116.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01595339,0.01595673092641504,3.3409264150394136e-06
1.0,582.0,548.0,0.001718,0.001718,6.368187,0.729095,1.0,582.0,9.0,116.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00797669,0.007970648389761921,6.041610238078851e-06
3.0,582.0,548.0,0.005155,0.005155,6.368187,0.729095,1.0,582.0,9.0,116.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.02393472,0.02428431909400794,0.00034959909400793937
6.0,582.0,548.0,0.010309,0.010309,6.368187,0.729095,1.0,582.0,9.0,116.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0478648,0.04733307455506042,0.000531725444939582
2.0,582.0,548.0,0.003436,0.003436,6.368187,0.729095,1.0,582.0,9.0,116.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01595339,0.015953954047903132,5.640479031308876e-07
1.0,582.0,548.0,0.001718,0.001718,6.368187,0.729095,1.0,582.0,9.0,116.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00797669,0.007992059672440486,1.5369672440486426e-05
9.0,582.0,548.0,0.015464,0.015464,6.368187,0.729095,1.0,582.0,9.0,116.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.07179953,0.07460572716619052,0.002806197166190516
10.0,582.0,548.0,0.017182,0.017182,6.368187,0.729095,1.0,582.0,9.0,116.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.07977622,0.07995996292772817,0.0001837429277281727
12.0,493.0,384.0,0.024341,0.024341,6.202536,0.200762,1.0,493.0,14.0,77.0,Hyperglycemic rescue,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0303103,0.03079401954601192,0.0004837195460119202
19.0,493.0,384.0,0.03854,0.03854,6.202536,0.200762,1.0,493.0,14.0,77.0,Hyperglycemic rescue,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04799141,0.047347249955634926,0.0006441600443650719
18.0,493.0,384.0,0.036511,0.036511,6.202536,0.200762,1.0,493.0,14.0,77.0,Hyperglycemic rescue,Overall Study,FG002,diabetes type 2,INDUSTRY,0.04546483,0.04604705272161706,0.000582222721617065
2.0,493.0,384.0,0.004057,0.004057,6.202536,0.200762,1.0,493.0,14.0,77.0,Withdrawal by Subject,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00505192,0.004996419823730162,5.550017626983726e-05
10.0,493.0,384.0,0.020284,0.020284,6.202536,0.200762,1.0,493.0,14.0,77.0,Withdrawal by Subject,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02525838,0.025248890079256854,9.489920743146335e-06
9.0,493.0,384.0,0.018256,0.018256,6.202536,0.200762,1.0,493.0,14.0,77.0,Withdrawal by Subject,Overall Study,FG002,diabetes type 2,INDUSTRY,0.02273304,0.022627298292352074,0.00010574170764792584
3.0,493.0,384.0,0.006085,0.006085,6.202536,0.200762,1.0,493.0,14.0,77.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00757726,0.007501615364246037,7.564463575396307e-05
8.0,493.0,384.0,0.016227,0.016227,6.202536,0.200762,1.0,493.0,14.0,77.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.02020645,0.020273176979503958,6.67269795039567e-05
6.0,493.0,384.0,0.01217,0.01217,6.202536,0.200762,1.0,493.0,14.0,77.0,Adverse Event,Overall Study,FG002,diabetes type 2,INDUSTRY,0.01515453,0.01531122904717263,0.0001566990471726301
5.0,493.0,384.0,0.010142,0.010142,6.202536,0.200762,1.0,493.0,14.0,77.0,Physician Decision,Overall Study,FG000,diabetes type 2,INDUSTRY,0.01262919,0.01265613506310519,2.6945063105189918e-05
5.0,493.0,384.0,0.010142,0.010142,6.202536,0.200762,1.0,493.0,14.0,77.0,Physician Decision,Overall Study,FG001,diabetes type 2,INDUSTRY,0.01262919,0.012689417656362764,6.022765636276399e-05
1.0,493.0,384.0,0.002028,0.002028,6.202536,0.200762,1.0,493.0,14.0,77.0,Physician Decision,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00252534,0.0025308535011309614,5.5135011309613395e-06
3.0,493.0,384.0,0.006085,0.006085,6.202536,0.200762,1.0,493.0,14.0,77.0,Lost to Follow-up,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00757726,0.007512938899900798,6.43211000992015e-05
1.0,493.0,384.0,0.002028,0.002028,6.202536,0.200762,1.0,493.0,14.0,77.0,Lost to Follow-up,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00252534,0.002532579293214295,7.239293214294888e-06
3.0,493.0,384.0,0.006085,0.006085,6.202536,0.200762,1.0,493.0,14.0,77.0,Lost to Follow-up,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00757726,0.007492881956269848,8.437804373015185e-05
1.0,493.0,384.0,0.002028,0.002028,6.202536,0.200762,1.0,493.0,14.0,77.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00252534,0.002523117981488104,2.2220185118960838e-06
1.0,493.0,384.0,0.002028,0.002028,6.202536,0.200762,1.0,493.0,14.0,77.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00252534,0.002523839948571437,1.5000514285629964e-06
2.0,493.0,384.0,0.004057,0.004057,6.202536,0.200762,1.0,493.0,14.0,77.0,Protocol Violation,Overall Study,FG002,diabetes type 2,INDUSTRY,0.00505192,0.004997638290238102,5.4281709761897466e-05
2.0,557.0,515.0,0.003591,0.003591,6.324359,0.376776,1.0,557.0,10.0,91.0,Protocol Violation,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00855689,0.0086663064349603,0.00010941643496030148
1.0,557.0,515.0,0.001795,0.001795,6.324359,0.376776,1.0,557.0,10.0,91.0,Protocol Violation,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00427725,0.004317421388124979,4.017138812497951e-05
0.0,557.0,515.0,0.0,0.0,6.324359,0.376776,1.0,557.0,10.0,91.0,Death,Overall Study,FG000,diabetes type 2,INDUSTRY,0.0,0.0,0.0
1.0,557.0,515.0,0.001795,0.001795,6.324359,0.376776,1.0,557.0,10.0,91.0,Death,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00427725,0.00430628690044641,2.903690044640979e-05
9.0,557.0,515.0,0.016158,0.016158,6.324359,0.376776,1.0,557.0,10.0,91.0,Adverse Event,Overall Study,FG000,diabetes type 2,INDUSTRY,0.03850241,0.038492790026170676,9.619973829325112e-06
0.0,557.0,515.0,0.0,0.0,6.324359,0.376776,1.0,557.0,10.0,91.0,Adverse Event,Overall Study,FG001,diabetes type 2,INDUSTRY,0.0,0.0,0.0
16.0,557.0,515.0,0.028725,0.028725,6.324359,0.376776,1.0,557.0,10.0,91.0,Withdrawal Criteria,Overall Study,FG000,diabetes type 2,INDUSTRY,0.06844793,0.0677966339144047,0.0006512960855953043
11.0,557.0,515.0,0.019749,0.019749,6.324359,0.376776,1.0,557.0,10.0,91.0,Withdrawal Criteria,Overall Study,FG001,diabetes type 2,INDUSTRY,0.04705929,0.047296940102579385,0.0002376501025793884
1.0,557.0,515.0,0.001795,0.001795,6.324359,0.376776,1.0,557.0,10.0,91.0,Unclassified,Overall Study,FG000,diabetes type 2,INDUSTRY,0.00427725,0.004333056293214271,5.580629321427083e-05
1.0,557.0,515.0,0.001795,0.001795,6.324359,0.376776,1.0,557.0,10.0,91.0,Unclassified,Overall Study,FG001,diabetes type 2,INDUSTRY,0.00427725,0.004321032652113075,4.378265211307537e-05
11.0,919.0,615.0,0.01197,0.01197,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.06075761,0.06168904159890878,0.0009314315989087801
12.0,919.0,615.0,0.013058,0.013058,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0662801,0.06619190674168658,8.819325831341263e-05
15.0,919.0,615.0,0.016322,0.016322,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.08284759,0.0831798882206665,0.0003322982206665076
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523697510982187,1.1975109821876426e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non Adverse Event (AE) Related Issues,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523895285982188,1.395285982187973e-06
2.0,919.0,615.0,0.002176,0.002176,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.01104499,0.011011130401607117,3.3859598392882786e-05
2.0,919.0,615.0,0.002176,0.002176,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.01104499,0.010995783320833303,4.9206679166696396e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Death,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0055225,0.005533162288333372,1.0662288333372627e-05
5.0,919.0,615.0,0.005441,0.005441,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.02761755,0.02768432731288698,6.677731288697725e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523697510982187,1.1975109821876426e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Non-Compliance With Study Drug,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523697510982187,1.1975109821876426e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Participant moved to Kansas,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523697510982187,1.1975109821876426e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site cover and participant was not willing to be transferred,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0055225,0.00552831820500004,5.8182050000406965e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Stopped Investigational product (IP) due to an AE in Australia,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0055225,0.005523940012500047,1.4400125000471262e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Drug Holiday,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0055225,0.005523940012500047,1.4400125000471262e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Spouse underwent surgery and participant was unable to take IP regularly,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0055225,0.0055187793883929035,3.7206116070961567e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Site closure,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0055225,0.005522610366666712,1.1036666671196405e-07
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0055225,0.005523697510982187,1.1975109821876426e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
12.0,919.0,615.0,0.013058,0.013058,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG000,NASH,INDUSTRY,0.0662801,0.06625647777260918,2.362222739081543e-05
6.0,919.0,615.0,0.006529,0.006529,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG001,NASH,INDUSTRY,0.03314005,0.03281524170391864,0.0003248082960813567
9.0,919.0,615.0,0.009793,0.009793,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG002,NASH,INDUSTRY,0.04970754,0.04973402379037699,2.6483790376986838e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Double-blind Phase (18 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
8.0,919.0,615.0,0.008705,0.008705,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.04418504,0.04386796860625991,0.00031707139374009125
5.0,919.0,615.0,0.005441,0.005441,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.02761755,0.02770236168026798,8.481168026797797e-05
7.0,919.0,615.0,0.007617,0.007617,6.824374,0.743779,1.0,919.0,12.0,192.0,Adverse Event,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.03866255,0.03871832960437498,5.5779604374986413e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0055225,0.005522707462083379,2.0746208337970445e-07
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Bariatric Surgery,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0055225,0.0055233658687500456,8.65868750045927e-07
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Covid-19 Non-AE Related Issues,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0055225,0.005523678118750045,1.1781187500455037e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
2.0,919.0,615.0,0.002176,0.002176,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.01104499,0.011007944880833308,3.704511916669158e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Lost to Follow-up,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.0055225,0.005523851393750045,1.3513937500457193e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Increase CR from Baseline,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Medical reasons by Sponsor,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0055225,0.005523678118750045,1.1781187500455037e-06
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0055225,0.005521690066250044,8.099337499558809e-07
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Physician Decision,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
1.0,919.0,615.0,0.001088,0.001088,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.0055225,0.005523019712083379,5.197120833792812e-07
2.0,919.0,615.0,0.002176,0.002176,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.01104499,0.011000930010833306,4.4059989166693805e-05
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Progressive Disease,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG000,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG001,NASH,INDUSTRY,0.0,0.0,0.0
0.0,919.0,615.0,0.0,0.0,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG002,NASH,INDUSTRY,0.0,0.0,0.0
5.0,919.0,615.0,0.005441,0.005441,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG003,NASH,INDUSTRY,0.02761755,0.027685868681369165,6.831868136916372e-05
3.0,919.0,615.0,0.003264,0.003264,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG004,NASH,INDUSTRY,0.01656749,0.015249288948392862,0.0013182010516071384
5.0,919.0,615.0,0.005441,0.005441,6.824374,0.743779,1.0,919.0,12.0,192.0,Withdrawal by Subject,Open Label Extension Phase (12 Months),FG005,NASH,INDUSTRY,0.02761755,0.02768795969422631,7.040969422630883e-05
3.0,779.0,740.0,0.003851,0.003851,6.659294,0.523688,1.0,779.0,1.0,2.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01342996,0.013397439671686497,3.2520328313502544e-05
8.0,779.0,740.0,0.01027,0.01027,6.659294,0.523688,1.0,779.0,1.0,2.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03581555,0.03556956804296628,0.0002459819570337224
0.0,779.0,740.0,0.0,0.0,6.659294,0.523688,1.0,779.0,1.0,2.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,779.0,740.0,0.003851,0.003851,6.659294,0.523688,1.0,779.0,1.0,2.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01342996,0.013386760558710306,4.3199441289693e-05
0.0,779.0,740.0,0.0,0.0,6.659294,0.523688,1.0,779.0,1.0,2.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,779.0,740.0,0.001284,0.001284,6.659294,0.523688,1.0,779.0,1.0,2.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00447782,0.004481684522556453,3.864522556452227e-06
0.0,779.0,740.0,0.0,0.0,6.659294,0.523688,1.0,779.0,1.0,2.0,Moved out of the country,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,779.0,740.0,0.001284,0.001284,6.659294,0.523688,1.0,779.0,1.0,2.0,Moved out of the country,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00447782,0.004479851072556452,2.031072556451727e-06
2.0,779.0,740.0,0.002567,0.002567,6.659294,0.523688,1.0,779.0,1.0,2.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00895214,0.008651764715148821,0.0003003752848511794
2.0,779.0,740.0,0.002567,0.002567,6.659294,0.523688,1.0,779.0,1.0,2.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00895214,0.008660020291726203,0.00029211970827379766
1.0,779.0,740.0,0.001284,0.001284,6.659294,0.523688,1.0,779.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00447782,0.004476095093330262,1.7249066697382423e-06
7.0,779.0,740.0,0.008986,0.008986,6.659294,0.523688,1.0,779.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03133774,0.031165758806527773,0.00017198119347222943
0.0,779.0,740.0,0.0,0.0,6.659294,0.523688,1.0,779.0,1.0,2.0,Could not attend study visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,779.0,740.0,0.001284,0.001284,6.659294,0.523688,1.0,779.0,1.0,2.0,Could not attend study visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00447782,0.004479851072556452,2.031072556451727e-06
1.0,779.0,740.0,0.001284,0.001284,6.659294,0.523688,1.0,779.0,1.0,2.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00447782,0.004475259522913596,2.560477086404646e-06
9.0,779.0,740.0,0.011553,0.011553,6.659294,0.523688,1.0,779.0,1.0,2.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04028988,0.03909464886531775,0.0011952311346822495
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00210926,0.0021103033588329738,1.0433588329738022e-06
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00421852,0.004224394472619051,5.874472619050997e-06
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,654.0,551.0,0.006116,0.006116,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00843704,0.008461134924057546,2.4094924057546305e-05
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00210926,0.0021092665028409107,6.502840910714569e-09
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00421852,0.004218743070297622,2.230702976224741e-07
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00421852,0.004218859596369051,3.395963690507389e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00421852,0.004218859596369051,3.395963690507389e-07
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00632778,0.006348120817205066,2.0340817205066405e-05
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00632778,0.006348120817205066,2.0340817205066405e-05
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00210926,0.0021092358347853547,2.4165214645294197e-08
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00632778,0.006348120817205066,2.0340817205066405e-05
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00421852,0.004218859596369051,3.395963690507389e-07
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Adverse Event,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00421852,0.004218859596369051,3.395963690507389e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00421852,0.0042208747593452415,2.354759345241618e-06
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00210926,0.002109709261174244,4.492611742441463e-07
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00210926,0.002109709980618689,4.4998061868913725e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00210926,0.002109709980618689,4.4998061868913725e-07
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00210926,0.002109698011174244,4.3801117424399627e-07
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00421852,0.0042190631872619086,5.43187261908655e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00210926,0.0021097045306186888,4.4453061868879665e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lost to Follow-up,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00421852,0.0042231448869345265,4.624886934526638e-06
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00632778,0.0063496217378598285,2.1841737859828667e-05
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00210926,0.002109219385694446,4.061430555410417e-08
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00421852,0.00422076680339286,2.2468033928600695e-06
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00210926,0.0021092620437500017,2.043750001699818e-09
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00421852,0.004218955896071432,4.358960714323512e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00210926,0.0021092394762500014,2.0523749998547364e-08
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00421852,0.004218960677142861,4.406771428608694e-07
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00210926,0.002109255269444446,4.73055555404861e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Protocol Violation,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00210926,0.0021062831051803727,2.9768948196272696e-06
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00421852,0.004218460836369051,5.9163630949238266e-08
4.0,654.0,551.0,0.006116,0.006116,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00843704,0.008455380613402782,1.8340613402782063e-05
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00210926,0.0021092600000000013,1.3010426069826053e-18
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00421852,0.004218489493630956,3.05063690437396e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00210926,0.0021092600000000013,1.3010426069826053e-18
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00210926,0.0021092366600000013,2.3339999998678307e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00210926,0.002109263270000001,3.2700000012451935e-09
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00210926,0.0021092687200000015,8.720000001585793e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00632778,0.006352710338455068,2.4930338455068056e-05
4.0,654.0,551.0,0.006116,0.006116,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00843704,0.008456484154652784,1.944415465278404e-05
2.0,654.0,551.0,0.003058,0.003058,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00421852,0.0042186060197023844,8.601970238452522e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00210926,0.0021092366600000013,2.3339999998678307e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00210926,0.002110338502582974,1.0785025829742126e-06
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00210926,0.0021060321320490595,3.227867950940464e-06
3.0,654.0,551.0,0.004587,0.004587,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00632778,0.0063510599013717325,2.3279901371732643e-05
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00210926,0.002115757766868688,6.4977668686881825e-06
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00210926,0.002109270978535355,1.097853535511617e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00210926,0.002109270978535355,1.097853535511617e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00210926,0.0021092644590909103,4.459090910315794e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Lack of Efficacy,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00210926,0.0021103033588329738,1.0433588329738022e-06
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00210926,0.0021092562437500014,3.756249998543293e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00210926,0.002109261809444446,1.8094444458396919e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Reason not listed/blank,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00210926,0.002105996988299059,3.2630117009408745e-06
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Per sponsors instruction,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00210926,0.0021092665028409107,6.502840910714569e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,P.I. recommended due to blood pressure,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00210926,0.0021092487500000015,1.1249999998415305e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00210926,0.0021092374325000014,2.2567499998512458e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00210926,0.0021092364415909105,2.3558409089404625e-08
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00210926,0.0021092487500000015,1.1249999998415305e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject did not meet end of study ABPM,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00210926,0.0021092562437500014,3.756249998543293e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Abnormal lab values,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00210926,0.002109267894785355,7.894785354969902e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,PI recommended early withdrawal,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00210926,0.0021092313756944456,2.862430555430895e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Did not meet criteria before ABPM,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00210926,0.0021092358347853547,2.4165214645294197e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Randomized in error,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00210926,0.0021092358347853547,2.4165214645294197e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Failed inclusion criteria #4,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00210926,0.0021092303847853548,2.9615214645201116e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Prolonged duration between visits,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00210926,0.002109261809444446,1.8094444458396919e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,"Subject left town, ran out of study drug",Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Subject refuse to sign updated consent,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00210926,0.0021092358347853547,2.4165214645294197e-08
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,654.0,551.0,0.001529,0.001529,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00210926,0.0021092562437500014,3.756249998543293e-09
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,654.0,551.0,0.0,0.0,6.484635,0.212734,1.0,654.0,1.0,151.0,Visits conflicted with new job,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
448.0,17651.0,16738.0,0.025381,0.025381,9.778604,0.763818,1.0,20723.0,2.0,70.0,Death,Overall Study,FG000,cardiovascular disease,FED,0.18957264,0.15335007849446433,0.036222561505535655
446.0,17651.0,16738.0,0.025268,0.025268,9.778604,0.763818,1.0,20723.0,2.0,70.0,Death,Overall Study,FG001,cardiovascular disease,FED,0.18872863,0.15104429021154767,0.03768433978845234
0.0,17651.0,16738.0,0.0,0.0,9.778604,0.763818,1.0,20723.0,2.0,70.0,Death,Overall Study,FG002,cardiovascular disease,FED,0.0,4.323769583333333e-06,4.323769583333333e-06
7.0,17651.0,16738.0,0.000397,0.000397,9.778604,0.763818,1.0,20723.0,2.0,70.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,FED,0.00296522,0.002906745058323415,5.8474941676585e-05
12.0,17651.0,16738.0,0.00068,0.00068,9.778604,0.763818,1.0,20723.0,2.0,70.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,FED,0.00507897,0.00461763251257936,0.00046133748742064034
0.0,17651.0,16738.0,0.0,0.0,9.778604,0.763818,1.0,20723.0,2.0,70.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,FED,0.0,4.323769583333333e-06,4.323769583333333e-06
0.0,4744.0,4733.0,0.0,0.0,8.464847,0.566227,1.0,4744.0,20.0,419.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,4744.0,4733.0,0.000422,0.000422,8.464847,0.566227,1.0,4744.0,20.0,419.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00202266,0.002023892705595241,1.2327055952409717e-06
5.0,4744.0,4733.0,0.001054,0.001054,8.464847,0.566227,1.0,4744.0,20.0,419.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00505185,0.005053596464702378,1.7464647023776592e-06
4.0,4744.0,4733.0,0.000843,0.000843,8.464847,0.566227,1.0,4744.0,20.0,419.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00404052,0.004015081065973388,2.5438934026611286e-05
2.0,841.0,525.0,0.002378,0.002378,6.73578,0.523937,1.0,841.0,10.0,151.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00839226,0.00839883452907737,6.574529077369232e-06
3.0,841.0,525.0,0.003567,0.003567,6.73578,0.523937,1.0,841.0,10.0,151.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01258839,0.012562678856753233,2.571114324676632e-05
48.0,841.0,525.0,0.057075,0.057075,6.73578,0.523937,1.0,841.0,10.0,151.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.20142484,0.20177296049799615,0.00034812049799615163
48.0,841.0,525.0,0.057075,0.057075,6.73578,0.523937,1.0,841.0,10.0,151.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.20142484,0.2028825033450001,0.0014576633450001097
12.0,841.0,525.0,0.014269,0.014269,6.73578,0.523937,1.0,841.0,10.0,151.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05035709,0.050169909590218206,0.0001871804097817939
8.0,841.0,525.0,0.009512,0.009512,6.73578,0.523937,1.0,841.0,10.0,151.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03356904,0.033298835704851204,0.00027020429514879735
74.0,841.0,525.0,0.08799,0.08799,6.73578,0.523937,1.0,841.0,10.0,151.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.31052776,0.31530408673502985,0.004776326735029868
59.0,841.0,525.0,0.070155,0.070155,6.73578,0.523937,1.0,841.0,10.0,151.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.24758581,0.2513359051196231,0.003750095119623126
1.0,841.0,525.0,0.001189,0.001189,6.73578,0.523937,1.0,841.0,10.0,151.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00419613,0.004292482681279758,9.63526812797575e-05
2.0,841.0,525.0,0.002378,0.002378,6.73578,0.523937,1.0,841.0,10.0,151.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00839226,0.008396079285029752,3.819285029751929e-06
12.0,841.0,525.0,0.014269,0.014269,6.73578,0.523937,1.0,841.0,10.0,151.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05035709,0.050274652668551544,8.243733144845666e-05
13.0,841.0,525.0,0.015458,0.015458,6.73578,0.523937,1.0,841.0,10.0,151.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05455322,0.053397563671676605,0.0011556563283233942
17.0,841.0,525.0,0.020214,0.020214,6.73578,0.523937,1.0,841.0,10.0,151.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07133774,0.07132484741468254,1.2892585317461625e-05
17.0,841.0,525.0,0.020214,0.020214,6.73578,0.523937,1.0,841.0,10.0,151.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07133774,0.07121649193766862,0.00012124806233138052
124.0,3730.0,3688.0,0.033244,0.033244,8.224432,0.610334,1.0,3730.0,20.0,520.0,Withdrawal by Subject,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.16687329,0.16455554916582354,0.0023177408341764627
92.0,3730.0,3688.0,0.024665,0.024665,8.224432,0.610334,1.0,3730.0,20.0,520.0,Withdrawal by Subject,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.1238097,0.12699017274458327,0.0031804727445832737
11.0,3730.0,3688.0,0.002949,0.002949,8.224432,0.610334,1.0,3730.0,20.0,520.0,Lost to Follow-up,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.01480295,0.014583605938968262,0.00021934406103173848
17.0,3730.0,3688.0,0.004558,0.004558,8.224432,0.610334,1.0,3730.0,20.0,520.0,Lost to Follow-up,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.02287957,0.022161858685982114,0.000717711314017884
6.0,3730.0,3688.0,0.001609,0.001609,8.224432,0.610334,1.0,3730.0,20.0,520.0,Protocol Violation,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00807662,0.008032811635714295,4.3808364285705115e-05
5.0,3730.0,3688.0,0.00134,0.00134,8.224432,0.610334,1.0,3730.0,20.0,520.0,Protocol Violation,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00672633,0.0068322116445734115,0.00010588164457341152
4.0,3730.0,3688.0,0.001072,0.001072,8.224432,0.610334,1.0,3730.0,20.0,520.0,Not treated,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00538107,0.005392480168452405,1.1410168452404695e-05
0.0,3730.0,3688.0,0.0,0.0,8.224432,0.610334,1.0,3730.0,20.0,520.0,Not treated,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
343.0,3730.0,3688.0,0.091957,0.091957,8.224432,0.610334,1.0,3730.0,20.0,520.0,Adverse Event,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.46159209,0.459860031865544,0.0017320581344560382
337.0,3730.0,3688.0,0.090349,0.090349,8.224432,0.610334,1.0,3730.0,20.0,520.0,Adverse Event,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.45352049,0.4493710861835718,0.004149403816428199
0.0,3730.0,3688.0,0.0,0.0,8.224432,0.610334,1.0,3730.0,20.0,520.0,Reason Unknown,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Reason Unknown,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00134527,0.00134438176255682,8.882374431800222e-07
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Personal Reasons,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00134527,0.001349367235311149,4.0972353111490365e-06
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Personal Reasons,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00134527,0.0013440696873088043,1.2003126911956652e-06
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Unblinded medication,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00134527,0.0013496635641305934,4.393564130593473e-06
0.0,3730.0,3688.0,0.0,0.0,8.224432,0.610334,1.0,3730.0,20.0,520.0,Unblinded medication,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient received Empagliflozin for Diabetes,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00134527,0.0013496635641305934,4.393564130593473e-06
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient received Empagliflozin for Diabetes,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00134527,0.00134438176255682,8.882374431800222e-07
2.0,3730.0,3688.0,0.000536,0.000536,8.224432,0.610334,1.0,3730.0,20.0,520.0,Principle Investigator Decision,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00269053,0.0026812071792460244,9.32282075397561e-06
0.0,3730.0,3688.0,0.0,0.0,8.224432,0.610334,1.0,3730.0,20.0,520.0,Principle Investigator Decision,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3730.0,3688.0,0.000536,0.000536,8.224432,0.610334,1.0,3730.0,20.0,520.0,Other medical condition (no Adverse Event),Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00269053,0.0026812071792460244,9.32282075397561e-06
4.0,3730.0,3688.0,0.001072,0.001072,8.224432,0.610334,1.0,3730.0,20.0,520.0,Other medical condition (no Adverse Event),Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00538107,0.0053782054185119235,2.8645814880764314e-06
4.0,3730.0,3688.0,0.001072,0.001072,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient moved away/being abroad,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00538107,0.005392480168452405,1.1410168452404695e-05
3.0,3730.0,3688.0,0.000804,0.000804,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient moved away/being abroad,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.0040358,0.003983301701478175,5.2498298521825096e-05
4.0,3730.0,3688.0,0.001072,0.001072,8.224432,0.610334,1.0,3730.0,20.0,520.0,Unable to continue treatment,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00538107,0.005392480168452405,1.1410168452404695e-05
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Unable to continue treatment,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00134527,0.00134438176255682,8.882374431800222e-07
3.0,3730.0,3688.0,0.000804,0.000804,8.224432,0.610334,1.0,3730.0,20.0,520.0,Not attending study visit,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.0040358,0.003994384419132939,4.1415580867060556e-05
10.0,3730.0,3688.0,0.002681,0.002681,8.224432,0.610334,1.0,3730.0,20.0,520.0,Not attending study visit,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.01345769,0.013202154691974211,0.00025553530802578835
1.0,3730.0,3688.0,0.000268,0.000268,8.224432,0.610334,1.0,3730.0,20.0,520.0,Due to Covid-19 Pandemic,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.00134527,0.0013496635641305934,4.393564130593473e-06
4.0,3730.0,3688.0,0.001072,0.001072,8.224432,0.610334,1.0,3730.0,20.0,520.0,Due to Covid-19 Pandemic,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00538107,0.0053782054185119235,2.8645814880764314e-06
8.0,3730.0,3688.0,0.002145,0.002145,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient decision to stop/interrupt medication,Discontinuation From Treatment,FG000,cardiovascular disease,INDUSTRY,0.01076715,0.01074495951830357,2.219048169642933e-05
6.0,3730.0,3688.0,0.001609,0.001609,8.224432,0.610334,1.0,3730.0,20.0,520.0,Patient decision to stop/interrupt medication,Discontinuation From Treatment,FG001,cardiovascular disease,INDUSTRY,0.00807662,0.008016447441210325,6.017255878967495e-05
9.0,3730.0,3688.0,0.002413,0.002413,8.224432,0.610334,1.0,3730.0,20.0,520.0,Lost to follow-up to primary endpoint,Discontinuation From Trial,FG000,cardiovascular disease,INDUSTRY,0.01211242,0.012095997959751964,1.6422040248036118e-05
9.0,3730.0,3688.0,0.002413,0.002413,8.224432,0.610334,1.0,3730.0,20.0,520.0,Lost to follow-up to primary endpoint,Discontinuation From Trial,FG001,cardiovascular disease,INDUSTRY,0.01211242,0.012151506250228157,3.908625022815658e-05
2.0,3730.0,3688.0,0.000536,0.000536,8.224432,0.610334,1.0,3730.0,20.0,520.0,Limited follow-up agreed,Discontinuation From Trial,FG000,cardiovascular disease,INDUSTRY,0.00269053,0.002678049687996027,1.2480312003973048e-05
2.0,3730.0,3688.0,0.000536,0.000536,8.224432,0.610334,1.0,3730.0,20.0,520.0,Limited follow-up agreed,Discontinuation From Trial,FG001,cardiovascular disease,INDUSTRY,0.00269053,0.0026783134353769787,1.2216564623021304e-05
9.0,3730.0,3688.0,0.002413,0.002413,8.224432,0.610334,1.0,3730.0,20.0,520.0,Withdrawal by Subject,Discontinuation From Trial,FG000,cardiovascular disease,INDUSTRY,0.01211242,0.012097654905466253,1.4765094533747067e-05
11.0,3730.0,3688.0,0.002949,0.002949,8.224432,0.610334,1.0,3730.0,20.0,520.0,Withdrawal by Subject,Discontinuation From Trial,FG001,cardiovascular disease,INDUSTRY,0.01480295,0.014649646808581369,0.0001533031914186314
1.0,226.0,223.0,0.004425,0.004425,5.42495,0.451053,1.0,226.0,21.0,55.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01082772,0.01097717074387264,0.00014945074387263946
0.0,226.0,223.0,0.0,0.0,5.42495,0.451053,1.0,226.0,21.0,55.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,226.0,223.0,0.004425,0.004425,5.42495,0.451053,1.0,226.0,21.0,55.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01082772,0.01097717074387264,0.00014945074387263946
0.0,226.0,223.0,0.0,0.0,5.42495,0.451053,1.0,226.0,21.0,55.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,226.0,223.0,0.004425,0.004425,5.42495,0.451053,1.0,226.0,21.0,55.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01082772,0.010953297679440826,0.00012557767944082476
0.0,226.0,223.0,0.0,0.0,5.42495,0.451053,1.0,226.0,21.0,55.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,731.0,583.0,0.00684,0.00684,6.595781,0.252985,1.0,731.0,17.0,84.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01141345,0.011445805107103177,3.235510710317656e-05
4.0,731.0,583.0,0.005472,0.005472,6.595781,0.252985,1.0,731.0,17.0,84.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00913076,0.009026540941081348,0.00010421905891865209
9.0,731.0,583.0,0.012312,0.012312,6.595781,0.252985,1.0,731.0,17.0,84.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02054421,0.02058457267654761,4.036267654760825e-05
9.0,731.0,583.0,0.012312,0.012312,6.595781,0.252985,1.0,731.0,17.0,84.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02054421,0.020589986120386886,4.577612038688533e-05
26.0,731.0,583.0,0.035568,0.035568,6.595781,0.252985,1.0,731.0,17.0,84.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05934994,0.0597995814279987,0.00044964142799870654
29.0,731.0,583.0,0.039672,0.039672,6.595781,0.252985,1.0,731.0,17.0,84.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06619801,0.06549576980353439,0.0007022401964656144
28.0,731.0,583.0,0.038304,0.038304,6.595781,0.252985,1.0,731.0,17.0,84.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06391532,0.06369417349262174,0.00022114650737825592
29.0,731.0,583.0,0.039672,0.039672,6.595781,0.252985,1.0,731.0,17.0,84.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06619801,0.06547896131121295,0.0007190486887870551
2.0,731.0,583.0,0.002736,0.002736,6.595781,0.252985,1.0,731.0,17.0,84.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00456538,0.004506854978472224,5.852502152777633e-05
3.0,731.0,583.0,0.004104,0.004104,6.595781,0.252985,1.0,731.0,17.0,84.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00684807,0.006910564810625003,6.249481062500263e-05
3.0,731.0,583.0,0.004104,0.004104,6.595781,0.252985,1.0,731.0,17.0,84.0,Sponsor Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00684807,0.006914822852529767,6.675285252976705e-05
1.0,731.0,583.0,0.001368,0.001368,6.595781,0.252985,1.0,731.0,17.0,84.0,Sponsor Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00228269,0.002281868178273807,8.218217261929742e-07
109.0,12019.0,11745.0,0.009069,0.009069,9.394327,0.51007,1.0,12024.0,37.0,595.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04345651,0.03884773189226189,0.004608778107738104
120.0,12019.0,11745.0,0.009984,0.009984,9.394327,0.51007,1.0,12024.0,37.0,595.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04784098,0.044397199115198405,0.0034437808848015936
2.0,12019.0,11745.0,0.000166,0.000166,9.394327,0.51007,1.0,12024.0,37.0,595.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00079543,0.0008329574433531748,3.752744335317479e-05
3.0,12019.0,11745.0,0.00025,0.00025,9.394327,0.51007,1.0,12024.0,37.0,595.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00119794,0.0011777305734821438,2.0209426517856172e-05
20.0,12019.0,11745.0,0.001664,0.001664,9.394327,0.51007,1.0,12024.0,37.0,595.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0079735,0.007822433428045625,0.00015106657195437453
20.0,12019.0,11745.0,0.001664,0.001664,9.394327,0.51007,1.0,12024.0,37.0,595.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0079735,0.007783369934265864,0.0001901300657341353
0.0,748.0,0.0,0.0,0.0,6.618739,0.681239,1.0,748.0,20.0,235.0,No longer meeting study criteria,Pre-treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,No longer meeting study criteria,Pre-treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00602846,0.006073644122857149,4.518412285714913e-05
0.0,748.0,0.0,0.0,0.0,6.618739,0.681239,1.0,748.0,20.0,235.0,Participant request to discontinue,Pre-treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,Participant request to discontinue,Pre-treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00602846,0.006073644122857149,4.518412285714913e-05
0.0,748.0,0.0,0.0,0.0,6.618739,0.681239,1.0,748.0,20.0,235.0,Adverse event unrelated to study drug,Pre-treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,Adverse event unrelated to study drug,Pre-treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00602846,0.006073644122857149,4.518412285714913e-05
3.0,748.0,0.0,0.004011,0.004011,6.618739,0.681239,1.0,748.0,20.0,235.0,Consent withdrawal,Pre-treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01808537,0.018305639619756467,0.000220269619756467
0.0,748.0,0.0,0.0,0.0,6.618739,0.681239,1.0,748.0,20.0,235.0,Consent withdrawal,Pre-treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
117.0,748.0,0.0,0.156417,0.156417,6.618739,0.681239,1.0,748.0,20.0,235.0,Disease progression,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.70527533,0.7122890016645843,0.007013671664584331
145.0,748.0,0.0,0.19385,0.19385,6.618739,0.681239,1.0,748.0,20.0,235.0,Disease progression,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.87405859,0.8722219534389087,0.0018366365610912316
110.0,748.0,0.0,0.147059,0.147059,6.618739,0.681239,1.0,748.0,20.0,235.0,Adverse event unrelated to study drug,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.66308064,0.6740086345340872,0.010927994534087215
73.0,748.0,0.0,0.097594,0.097594,6.618739,0.681239,1.0,748.0,20.0,235.0,Adverse event unrelated to study drug,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.44004578,0.4297900409997619,0.010255739000238073
52.0,748.0,0.0,0.069519,0.069519,6.618739,0.681239,1.0,748.0,20.0,235.0,Study drug toxicity,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.3134572,0.3128668419634825,0.0005903580365174688
64.0,748.0,0.0,0.085561,0.085561,6.618739,0.681239,1.0,748.0,20.0,235.0,Study drug toxicity,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.38578967,0.38672628243669666,0.0009366124366966821
30.0,748.0,0.0,0.040107,0.040107,6.618739,0.681239,1.0,748.0,20.0,235.0,Participant request to discontinue,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.18084017,0.18042967472385918,0.0004104952761408154
22.0,748.0,0.0,0.029412,0.029412,6.618739,0.681239,1.0,748.0,20.0,235.0,Participant request to discontinue,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.13261703,0.13625546043404568,0.0036384304340456863
30.0,748.0,0.0,0.040107,0.040107,6.618739,0.681239,1.0,748.0,20.0,235.0,Other reasons,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.18084017,0.1804572099676092,0.0003829600323908
30.0,748.0,0.0,0.040107,0.040107,6.618739,0.681239,1.0,748.0,20.0,235.0,Other reasons,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.18084017,0.18059838024802588,0.00024178975197411412
10.0,748.0,0.0,0.013369,0.013369,6.618739,0.681239,1.0,748.0,20.0,235.0,Consent withdrawal,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.06028006,0.06036967097444439,8.961097444438321e-05
7.0,748.0,0.0,0.009358,0.009358,6.618739,0.681239,1.0,748.0,20.0,235.0,Consent withdrawal,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04219469,0.04209630675032741,9.838324967258866e-05
7.0,748.0,0.0,0.009358,0.009358,6.618739,0.681239,1.0,748.0,20.0,235.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.04219469,0.04211378492873017,8.090507126982949e-05
6.0,748.0,0.0,0.008021,0.008021,6.618739,0.681239,1.0,748.0,20.0,235.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03616623,0.037045725170575354,0.0008794951705753534
3.0,748.0,0.0,0.004011,0.004011,6.618739,0.681239,1.0,748.0,20.0,235.0,Poor/Non-compliance,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01808537,0.018305639619756467,0.000220269619756467
4.0,748.0,0.0,0.005348,0.005348,6.618739,0.681239,1.0,748.0,20.0,235.0,Poor/Non-compliance,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02411383,0.024578993208015872,0.00046516320801587296
2.0,748.0,0.0,0.002674,0.002674,6.618739,0.681239,1.0,748.0,20.0,235.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01205691,0.012114360011835332,5.745001183533188e-05
2.0,748.0,0.0,0.002674,0.002674,6.618739,0.681239,1.0,748.0,20.0,235.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01205691,0.012123750415168664,6.684041516866364e-05
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,Maximum clinical benefit,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00602846,0.006057140287440481,2.8680287440480817e-05
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,Maximum clinical benefit,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00602846,0.006057984446130959,2.9524446130958955e-05
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,No longer meet study criteria,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00602846,0.006052934239523815,2.4474239523814868e-05
1.0,748.0,0.0,0.001337,0.001337,6.618739,0.681239,1.0,748.0,20.0,235.0,No longer meet study criteria,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00602846,0.006053778398214294,2.5318398214293873e-05
8.0,748.0,0.0,0.010695,0.010695,6.618739,0.681239,1.0,748.0,20.0,235.0,Administrative reasons by Sponsor,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.04822314,0.0498218899029365,0.0015987499029364999
16.0,748.0,0.0,0.02139,0.02139,6.618739,0.681239,1.0,748.0,20.0,235.0,Administrative reasons by Sponsor,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.09644629,0.0974666005146626,0.0010203105146626007
172.0,569.0,0.0,0.302285,0.302285,6.345636,0.900395,1.0,569.0,18.0,145.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.72712953,1.7056101837937891,0.021519346206210876
153.0,569.0,0.0,0.268893,0.268893,6.345636,0.900395,1.0,569.0,18.0,145.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.53634166,1.4455799818259112,0.09076167817408876
16.0,569.0,0.0,0.02812,0.02812,6.345636,0.900395,1.0,569.0,18.0,145.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16066587,0.15909565722508306,0.0015702127749169237
12.0,569.0,0.0,0.02109,0.02109,6.345636,0.900395,1.0,569.0,18.0,145.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1204994,0.12248479600085328,0.001985396000853276
4.0,569.0,0.0,0.00703,0.00703,6.345636,0.900395,1.0,569.0,18.0,145.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04016647,0.04175569740146827,0.001589227401468267
2.0,569.0,0.0,0.003515,0.003515,6.345636,0.900395,1.0,569.0,18.0,145.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02008323,0.02264344004255952,0.0025602100425595187
1.0,569.0,0.0,0.001757,0.001757,6.345636,0.900395,1.0,569.0,18.0,145.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01003876,0.010341170374404749,0.000302410374404748
0.0,569.0,0.0,0.0,0.0,6.345636,0.900395,1.0,569.0,18.0,145.0,Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,569.0,0.0,0.0,0.0,6.345636,0.900395,1.0,569.0,18.0,145.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,569.0,0.0,0.001757,0.001757,6.345636,0.900395,1.0,569.0,18.0,145.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01003876,0.010334536732559524,0.0002957767325595228
90.0,569.0,0.0,0.158172,0.158172,6.345636,0.900395,1.0,569.0,18.0,145.0,End of data collection,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.90372837,0.8450791904028585,0.05864917959714144
118.0,569.0,0.0,0.207381,0.207381,6.345636,0.900395,1.0,569.0,18.0,145.0,End of data collection,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.18488793,1.1227481517423714,0.06213977825762851
395.0,16568.0,12123.0,0.023841,0.023841,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09267154,0.08906867250643946,0.0036028674935605354
365.0,16568.0,12123.0,0.02203,0.02203,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08563206,0.08297178894880956,0.0026602710511904326
372.0,16568.0,12123.0,0.022453,0.022453,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.08727629,0.08501539936530848,0.002260890634691523
333.0,16568.0,12123.0,0.020099,0.020099,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.07812614,0.07763322690684515,0.0004929130931548426
98.0,16568.0,12123.0,0.005915,0.005915,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02299199,0.0215091364545734,0.001482853545426599
90.0,16568.0,12123.0,0.005432,0.005432,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02111454,0.0202718503255267,0.0008426896744733008
65.0,16568.0,12123.0,0.003923,0.003923,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01524896,0.015029160030358042,0.00021979996964195843
46.0,16568.0,12123.0,0.002776,0.002776,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01079049,0.010640730741755956,0.00014975925824404351
37.0,16568.0,12123.0,0.002233,0.002233,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00867982,0.008470597542354802,0.000209222457645198
44.0,16568.0,12123.0,0.002656,0.002656,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01032405,0.010184083163591264,0.00013996683640873572
46.0,16568.0,12123.0,0.002776,0.002776,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01079049,0.010590054663511905,0.00020043533648809488
44.0,16568.0,12123.0,0.002656,0.002656,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01032405,0.01025217054570436,7.187945429563969e-05
3.0,16568.0,12123.0,0.000181,0.000181,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Met Protocol-Defined Stopping Critera,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00070356,0.0006520290769146832,5.153092308531678e-05
4.0,16568.0,12123.0,0.000241,0.000241,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Met Protocol-Defined Stopping Critera,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00093678,0.0008144442812202386,0.0001223357187797614
2.0,16568.0,12123.0,0.000121,0.000121,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Met Protocol-Defined Stopping Critera,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00047033,0.000450317530952381,2.0012469047618966e-05
11.0,16568.0,12123.0,0.000664,0.000664,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Met Protocol-Defined Stopping Critera,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00258101,0.0025626704826785733,1.833951732142661e-05
7.0,16568.0,12123.0,0.000423,0.000423,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Study Closed/terminated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00164423,0.0016342927180158727,9.937281984127248e-06
6.0,16568.0,12123.0,0.000362,0.000362,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Study Closed/terminated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00140712,0.0012418872131845244,0.00016523278681547559
9.0,16568.0,12123.0,0.000543,0.000543,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Study Closed/terminated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00211068,0.0021039561323214304,6.723867678569764e-06
9.0,16568.0,12123.0,0.000543,0.000543,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Study Closed/terminated,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00211068,0.002114851324285718,4.1713242857179325e-06
0.0,16568.0,12123.0,0.0,0.0,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,16568.0,12123.0,0.0,0.0,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00023322,0.0002385727141666679,5.352714166667914e-06
0.0,16568.0,12123.0,0.0,0.0,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
53.0,16568.0,12123.0,0.003199,0.003199,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01243472,0.012001084383025799,0.0004336356169742008
64.0,16568.0,12123.0,0.003863,0.003863,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01501574,0.01500685799488185,8.882005118148947e-06
62.0,16568.0,12123.0,0.003742,0.003742,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0145454,0.014328814077421535,0.00021658592257846505
48.0,16568.0,12123.0,0.002897,0.002897,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Physician Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01126083,0.011244230377440474,1.6599622559525587e-05
643.0,16568.0,12123.0,0.03881,0.03881,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Decision by Participant or Proxy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15085702,0.13475813398764896,0.016098886012351044
527.0,16568.0,12123.0,0.031808,0.031808,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Decision by Participant or Proxy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12363979,0.11981466547217268,0.0038251245278273227
515.0,16568.0,12123.0,0.031084,0.031084,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Decision by Participant or Proxy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.12082555,0.11774048184859132,0.0030850681514086875
492.0,16568.0,12123.0,0.029696,0.029696,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Decision by Participant or Proxy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.11543031,0.11086171639322419,0.004568593606775806
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Sponsor Terminated Study Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00023322,0.00023465354363095363,1.4335436309536329e-06
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Sponsor Terminated Study Treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00023322,0.0002378325891666681,4.612589166668119e-06
0.0,16568.0,12123.0,0.0,0.0,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Sponsor Terminated Study Treatment,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Sponsor Terminated Study Treatment,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00023322,0.00023518662500000137,1.96662500000138e-06
12.0,16568.0,12123.0,0.000724,0.000724,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Investigator Site Closed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00281424,0.0027071962319047595,0.00010704376809524043
11.0,16568.0,12123.0,0.000664,0.000664,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Investigator Site Closed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00258101,0.002572486268690477,8.523731309522786e-06
15.0,16568.0,12123.0,0.000905,0.000905,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Investigator Site Closed,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00351779,0.003369776481180557,0.00014801351881944293
10.0,16568.0,12123.0,0.000604,0.000604,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Investigator Site Closed,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00234779,0.002275291090823417,7.249890917658324e-05
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00023322,0.00023505583184523952,1.8358318452395262e-06
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00023322,0.00023814429613095396,4.924296130953969e-06
1.0,16568.0,12123.0,6e-05,6e-05,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Missing,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00023322,0.00023575886529762053,2.538865297620538e-06
0.0,16568.0,12123.0,0.0,0.0,9.715289,0.400098,1.0,16568.0,44.0,1611.0,Missing,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
181.0,330.0,0.0,0.548485,0.548485,5.802118,0.347232,1.0,330.0,2.0,7.0,Progression of Disease,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,1.105023,1.0282232074871218,0.07679979251287827
46.0,330.0,0.0,0.139394,0.139394,5.802118,0.347232,1.0,330.0,2.0,7.0,Adverse Event,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.28083462,0.25955566206092257,0.021278957939077414
40.0,330.0,0.0,0.121212,0.121212,5.802118,0.347232,1.0,330.0,2.0,7.0,Other,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.24420367,0.24127012632843262,0.0029335436715673957
14.0,330.0,0.0,0.042424,0.042424,5.802118,0.347232,1.0,330.0,2.0,7.0,Death,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.08547088,0.08542607156156475,4.480843843525373e-05
13.0,330.0,0.0,0.039394,0.039394,5.802118,0.347232,1.0,330.0,2.0,7.0,Lack of therapeutic effect,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.07936639,0.08031300132445432,0.0009466113244543245
13.0,330.0,0.0,0.039394,0.039394,5.802118,0.347232,1.0,330.0,2.0,7.0,Withdrawal by Subject,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.07936639,0.08022535230091268,0.0008589623009126884
2.0,330.0,0.0,0.006061,0.006061,5.802118,0.347232,1.0,330.0,2.0,7.0,Lost to Follow-up,Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01221099,0.012199736247400762,1.1253752599237402e-05
2.0,330.0,0.0,0.006061,0.006061,5.802118,0.347232,1.0,330.0,2.0,7.0,Adverse Event,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.01221099,0.012200893771984085,1.0096228015914546e-05
6.0,330.0,0.0,0.018182,0.018182,5.802118,0.347232,1.0,330.0,2.0,7.0,Progressive Disease,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.03663095,0.03673991279410531,0.00010896279410530646
2.0,330.0,0.0,0.006061,0.006061,5.802118,0.347232,1.0,330.0,2.0,7.0,Lack of therapeutic effect,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.01221099,0.012203017115734082,7.97288426591762e-06
1.0,330.0,0.0,0.00303,0.00303,5.802118,0.347232,1.0,330.0,2.0,7.0,Withdrawal by Subject,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00610449,0.006096357274484127,8.13272551587231e-06
1.0,330.0,0.0,0.00303,0.00303,5.802118,0.347232,1.0,330.0,2.0,7.0,Lost to Follow-up,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00610449,0.00609410099400794,1.0389005992059684e-05
9.0,330.0,0.0,0.027273,0.027273,5.802118,0.347232,1.0,330.0,2.0,7.0,Other,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.05494643,0.05538820960952382,0.00044177960952382356
11.0,9406.0,9329.0,0.001169,0.001169,9.149209,0.22382,1.0,9406.0,0.0,0.0,Consent Withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00239385,0.0023843060729563503,9.543927043649623e-06
14.0,9406.0,9329.0,0.001488,0.001488,9.149209,0.22382,1.0,9406.0,0.0,0.0,Consent Withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00304709,0.0029861270491865037,6.096295081349642e-05
7.0,9406.0,9329.0,0.000744,0.000744,9.149209,0.22382,1.0,9406.0,0.0,0.0,Technical reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00152355,0.0014918847354067483,3.166526459325177e-05
2.0,9406.0,9329.0,0.000213,0.000213,9.149209,0.22382,1.0,9406.0,0.0,0.0,Technical reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00043618,0.0004401751933982691,3.9951933982690976e-06
0.0,9406.0,9329.0,0.0,0.0,9.149209,0.22382,1.0,9406.0,0.0,0.0,Surgery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,9406.0,9329.0,0.000106,0.000106,9.149209,0.22382,1.0,9406.0,0.0,0.0,Surgery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00021706,0.00022924673353896165,1.2186733538961637e-05
0.0,9406.0,9329.0,0.0,0.0,9.149209,0.22382,1.0,9406.0,0.0,0.0,Bleeding,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,9406.0,9329.0,0.000213,0.000213,9.149209,0.22382,1.0,9406.0,0.0,0.0,Bleeding,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00043618,0.0004401751933982691,3.9951933982690976e-06
3.0,9406.0,9329.0,0.000319,0.000319,9.149209,0.22382,1.0,9406.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00065324,0.000646773095307541,6.466904692459079e-06
7.0,9406.0,9329.0,0.000744,0.000744,9.149209,0.22382,1.0,9406.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00152355,0.0014890943354067476,3.445566459325247e-05
6.0,9406.0,9329.0,0.000638,0.000638,9.149209,0.22382,1.0,9406.0,0.0,0.0,Exclusion criteria met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00130648,0.0012678483618154773,3.8631638184522714e-05
6.0,9406.0,9329.0,0.000638,0.000638,9.149209,0.22382,1.0,9406.0,0.0,0.0,Exclusion criteria met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00130648,0.0012668802697420652,3.959973025793482e-05
4.0,9406.0,9329.0,0.000425,0.000425,9.149209,0.22382,1.0,9406.0,0.0,0.0,Not otherwise specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0008703,0.000880833591071427,1.0533591071427008e-05
8.0,9406.0,9329.0,0.000851,0.000851,9.149209,0.22382,1.0,9406.0,0.0,0.0,Not otherwise specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00174266,0.0015370515074305572,0.00020560849256944284
4.0,9406.0,9329.0,0.000425,0.000425,9.149209,0.22382,1.0,9406.0,0.0,0.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0008703,0.000880833591071427,1.0533591071427008e-05
2.0,9406.0,9329.0,0.000213,0.000213,9.149209,0.22382,1.0,9406.0,0.0,0.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00043618,0.0004401963100649358,4.0163100649358275e-06
75.0,837.0,617.0,0.089606,0.089606,6.731018,0.290259,1.0,837.0,5.0,26.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17506649,0.1881128406602381,0.013046350660238099
37.0,837.0,617.0,0.044205,0.044205,6.731018,0.290259,1.0,837.0,5.0,26.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08636491,0.08751042198743432,0.0011455119874343167
6.0,837.0,617.0,0.007168,0.007168,6.731018,0.290259,1.0,837.0,5.0,26.0,Major Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01400438,0.013906382024930547,9.799797506945297e-05
7.0,837.0,617.0,0.008363,0.008363,6.731018,0.290259,1.0,837.0,5.0,26.0,Major Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0163391,0.016281733640466273,5.7366359533725375e-05
14.0,837.0,617.0,0.016726,0.016726,6.731018,0.290259,1.0,837.0,5.0,26.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03267819,0.032825625765744035,0.000147435765744032
16.0,837.0,617.0,0.019116,0.019116,6.731018,0.290259,1.0,837.0,5.0,26.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03734762,0.03661099098104164,0.0007366290189583583
31.0,837.0,617.0,0.037037,0.037037,6.731018,0.290259,1.0,837.0,5.0,26.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07236053,0.07290562696630952,0.0005450969663095134
20.0,837.0,617.0,0.023895,0.023895,6.731018,0.290259,1.0,837.0,5.0,26.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04668453,0.04863969176167937,0.0019551617616793693
0.0,837.0,617.0,0.0,0.0,6.731018,0.290259,1.0,837.0,5.0,26.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,837.0,617.0,0.002389,0.002389,6.731018,0.290259,1.0,837.0,5.0,26.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00466748,0.00465322519982143,1.4254800178570108e-05
5.0,837.0,617.0,0.005974,0.005974,6.731018,0.290259,1.0,837.0,5.0,26.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01167162,0.011394808527827373,0.00027681147217262746
7.0,837.0,617.0,0.008363,0.008363,6.731018,0.290259,1.0,837.0,5.0,26.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0163391,0.01628982986963294,4.927013036705799e-05
0.0,387.0,1.0,0.0,0.0,5.961005,0.720492,1.0,387.0,20.0,87.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,387.0,1.0,0.007752,0.007752,5.961005,0.720492,1.0,387.0,20.0,87.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03329374,0.03374666527179832,0.0004529252717983198
10.0,387.0,1.0,0.02584,0.02584,5.961005,0.720492,1.0,387.0,20.0,87.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11097913,0.11093398598267859,4.514401732140516e-05
23.0,387.0,1.0,0.059432,0.059432,5.961005,0.720492,1.0,387.0,20.0,87.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.25525201,0.2610354347074606,0.005783424707460627
29.0,387.0,1.0,0.074935,0.074935,5.961005,0.720492,1.0,387.0,20.0,87.0,Perceived Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.32183519,0.31588236536261916,0.005952824637380838
30.0,387.0,1.0,0.077519,0.077519,5.961005,0.720492,1.0,387.0,20.0,87.0,Perceived Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.3329331,0.3262884107856946,0.006644689214305388
7.0,387.0,1.0,0.018088,0.018088,5.961005,0.720492,1.0,387.0,20.0,87.0,Lab Abnormality or Adverse Event (AE),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07768539,0.07914482061325401,0.0014594306132540008
25.0,387.0,1.0,0.064599,0.064599,5.961005,0.720492,1.0,387.0,20.0,87.0,Lab Abnormality or Adverse Event (AE),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.27744354,0.2851547490429367,0.007711209042936706
2.0,387.0,1.0,0.005168,0.005168,5.961005,0.720492,1.0,387.0,20.0,87.0,Intercurrent Illness/Medical Condition,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02219583,0.022280460170386915,8.463017038691512e-05
3.0,387.0,1.0,0.007752,0.007752,5.961005,0.720492,1.0,387.0,20.0,87.0,Intercurrent Illness/Medical Condition,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03329374,0.03372084887150071,0.00042710887150070737
4.0,387.0,1.0,0.010336,0.010336,5.961005,0.720492,1.0,387.0,20.0,87.0,Other - Not Otherwise Specified (NOS),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04439165,0.0441186625547917,0.00027298744520829615
19.0,387.0,1.0,0.049096,0.049096,5.961005,0.720492,1.0,387.0,20.0,87.0,Other - Not Otherwise Specified (NOS),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.21086035,0.20933149906779797,0.001528850932202036
2.0,387.0,1.0,0.005168,0.005168,5.961005,0.720492,1.0,387.0,20.0,87.0,Subject Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02219583,0.022280460170386915,8.463017038691512e-05
5.0,387.0,1.0,0.01292,0.01292,5.961005,0.720492,1.0,387.0,20.0,87.0,Subject Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05548957,0.057089282244623014,0.0015997122446230125
0.0,387.0,1.0,0.0,0.0,5.961005,0.720492,1.0,387.0,20.0,87.0,Discontinuation due to Rash,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,387.0,1.0,0.002584,0.002584,5.961005,0.720492,1.0,387.0,20.0,87.0,Discontinuation due to Rash,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01109791,0.011495985372688486,0.00039807537268848545
0.0,387.0,1.0,0.0,0.0,5.961005,0.720492,1.0,387.0,20.0,87.0,Subsequent Ineligibility,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,387.0,1.0,0.005168,0.005168,5.961005,0.720492,1.0,387.0,20.0,87.0,Subsequent Ineligibility,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02219583,0.022261380180248022,6.55501802480224e-05
46.0,387.0,1.0,0.118863,0.118863,5.961005,0.720492,1.0,387.0,20.0,87.0,"Berotralstat Provided by alternative Means (i.e., Early Access Program or Commercially Available)",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.51049972,0.5295447347272123,0.019045014727212317
175.0,387.0,1.0,0.452196,0.452196,5.961005,0.720492,1.0,387.0,20.0,87.0,"Berotralstat Provided by alternative Means (i.e., Early Access Program or Commercially Available)",Overall Study,FG001,cardiovascular disease,INDUSTRY,1.94211765,1.8472142667017066,0.09490338329829329
3.0,208.0,182.0,0.014423,0.014423,5.342334,0.401716,1.0,208.0,7.0,36.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03095319,0.031282204976974204,0.0003290149769742054
5.0,208.0,182.0,0.024038,0.024038,5.342334,0.401716,1.0,208.0,7.0,36.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05158793,0.05282680624773811,0.0012388762477381146
3.0,208.0,182.0,0.014423,0.014423,5.342334,0.401716,1.0,208.0,7.0,36.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03095319,0.031272713095248005,0.00031952309524800604
4.0,208.0,182.0,0.019231,0.019231,5.342334,0.401716,1.0,208.0,7.0,36.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04127164,0.04105393734964284,0.0002177026503571572
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01031845,0.01033275835627983,1.4308356279829626e-05
2.0,208.0,182.0,0.009615,0.009615,5.342334,0.401716,1.0,208.0,7.0,36.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02063474,0.020780385777222257,0.00014564577722225858
2.0,208.0,182.0,0.009615,0.009615,5.342334,0.401716,1.0,208.0,7.0,36.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02063474,0.020754639605843294,0.00011989960584329537
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01031845,0.010322691696538669,4.241696538669071e-06
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01031845,0.010328601854375072,1.0151854375072336e-05
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01031845,0.01032307044463391,4.62044463390987e-06
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01031845,0.010328792071934599,1.0342071934598893e-05
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01031845,0.010322777974693435,4.327974693435488e-06
0.0,208.0,182.0,0.0,0.0,5.342334,0.401716,1.0,208.0,7.0,36.0,Abnormal laboratory value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,208.0,182.0,0.004808,0.004808,5.342334,0.401716,1.0,208.0,7.0,36.0,Abnormal laboratory value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01031845,0.010322691696538669,4.241696538669071e-06
10.0,447.0,410.0,0.022371,0.022371,6.104793,0.379199,1.0,447.0,2.0,50.0,Adverse Event,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.05178734,0.05172389755720239,6.344244279760797e-05
4.0,447.0,410.0,0.008949,0.008949,6.104793,0.379199,1.0,447.0,2.0,50.0,Adverse Event,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.02071633,0.020114343115198406,0.0006019868848015954
0.0,447.0,410.0,0.0,0.0,6.104793,0.379199,1.0,447.0,2.0,50.0,Death,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Death,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.0051785,0.005177494992886885,1.0050071131148877e-06
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Lost to Follow-up,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.0051785,0.00517219773122022,6.302268779780247e-06
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Lost to Follow-up,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.0051785,0.005178340724910694,1.5927508930594497e-07
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Withdrawal by Subject,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.0051785,0.00516836736357141,1.0132636428589886e-05
2.0,447.0,410.0,0.004474,0.004474,6.104793,0.379199,1.0,447.0,2.0,50.0,Withdrawal by Subject,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.01035701,0.010357793844781684,7.838447816845701e-07
0.0,447.0,410.0,0.0,0.0,6.104793,0.379199,1.0,447.0,2.0,50.0,Protocol Violation,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Protocol Violation,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.0051785,0.005176756992886885,1.7430071131150152e-06
0.0,447.0,410.0,0.0,0.0,6.104793,0.379199,1.0,447.0,2.0,50.0,Moved out of the area,"Treatment Period, 12 Weeks",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,447.0,410.0,0.004474,0.004474,6.104793,0.379199,1.0,447.0,2.0,50.0,Moved out of the area,"Treatment Period, 12 Weeks",FG001,cardiovascular disease,INDUSTRY,0.01035701,0.010359028930198353,2.018930198353572e-06
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Death,"Post Treatment Follow-Up, 3 Months",FG000,cardiovascular disease,INDUSTRY,0.0051785,0.005170112396101173,8.387603898827103e-06
5.0,447.0,410.0,0.011186,0.011186,6.104793,0.379199,1.0,447.0,2.0,50.0,Death,"Post Treatment Follow-Up, 3 Months",FG001,cardiovascular disease,INDUSTRY,0.02589483,0.02580902725696429,8.580274303571223e-05
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Lost to Follow-up,"Post Treatment Follow-Up, 3 Months",FG000,cardiovascular disease,INDUSTRY,0.0051785,0.005172253208541648,6.246791458351664e-06
2.0,447.0,410.0,0.004474,0.004474,6.104793,0.379199,1.0,447.0,2.0,50.0,Lost to Follow-up,"Post Treatment Follow-Up, 3 Months",FG001,cardiovascular disease,INDUSTRY,0.01035701,0.01035881144103169,1.8014410316895269e-06
2.0,447.0,410.0,0.004474,0.004474,6.104793,0.379199,1.0,447.0,2.0,50.0,Withdrawal by Subject,"Post Treatment Follow-Up, 3 Months",FG000,cardiovascular disease,INDUSTRY,0.01035701,0.010361421860257881,4.411860257881595e-06
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Withdrawal by Subject,"Post Treatment Follow-Up, 3 Months",FG001,cardiovascular disease,INDUSTRY,0.0051785,0.005177710981666648,7.89018333352369e-07
0.0,447.0,410.0,0.0,0.0,6.104793,0.379199,1.0,447.0,2.0,50.0,Site Closure,"Post Treatment Follow-Up, 3 Months",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,447.0,410.0,0.002237,0.002237,6.104793,0.379199,1.0,447.0,2.0,50.0,Site Closure,"Post Treatment Follow-Up, 3 Months",FG001,cardiovascular disease,INDUSTRY,0.0051785,0.00517616859937498,2.3314006250196515e-06
31.0,225.0,19.0,0.137778,0.137778,5.420535,0.242288,1.0,225.0,1.0,58.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.18094802,0.17955653179433548,0.0013914882056645095
44.0,225.0,19.0,0.195556,0.195556,5.420535,0.242288,1.0,225.0,1.0,58.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.25682962,0.28456832557262735,0.027738705572627365
10.0,225.0,19.0,0.044444,0.044444,5.420535,0.242288,1.0,225.0,1.0,58.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05836965,0.059298466363263885,0.0009288163632638832
8.0,225.0,19.0,0.035556,0.035556,5.420535,0.242288,1.0,225.0,1.0,58.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04669677,0.050151136177261905,0.003454366177261907
1.0,225.0,19.0,0.004444,0.004444,5.420535,0.242288,1.0,225.0,1.0,58.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00583644,0.0059398356588392775,0.00010339565883927745
1.0,225.0,19.0,0.004444,0.004444,5.420535,0.242288,1.0,225.0,1.0,58.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00583644,0.005945869009394834,0.00010942900939483417
2.0,225.0,19.0,0.008889,0.008889,5.420535,0.242288,1.0,225.0,1.0,58.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01167419,0.011805052960039683,0.00013086296003968385
4.0,225.0,19.0,0.017778,0.017778,5.420535,0.242288,1.0,225.0,1.0,58.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02334839,0.02438331901875994,0.0010349290187599385
7.0,225.0,19.0,0.031111,0.031111,5.420535,0.242288,1.0,225.0,1.0,58.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04085902,0.04452727954870039,0.003668259548700384
1.0,225.0,19.0,0.004444,0.004444,5.420535,0.242288,1.0,225.0,1.0,58.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00583644,0.005947741572936502,0.00011130157293650234
8.0,225.0,19.0,0.035556,0.035556,5.420535,0.242288,1.0,225.0,1.0,58.0,Disease Progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04669677,0.050715160401220184,0.004018390401220186
2.0,225.0,19.0,0.008889,0.008889,5.420535,0.242288,1.0,225.0,1.0,58.0,Disease Progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01167419,0.01180101505358135,0.00012682505358134998
28.0,225.0,19.0,0.124444,0.124444,5.420535,0.242288,1.0,225.0,1.0,58.0,Transplant planned,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16343607,0.16802924487928583,0.004593174879285844
27.0,225.0,19.0,0.12,0.12,5.420535,0.242288,1.0,225.0,1.0,58.0,Transplant planned,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15759963,0.16325225090065476,0.00565262090065477
19.0,225.0,19.0,0.084444,0.084444,5.420535,0.242288,1.0,225.0,1.0,58.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11090286,0.11267934469998561,0.001776484699985606
13.0,225.0,19.0,0.057778,0.057778,5.420535,0.242288,1.0,225.0,1.0,58.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0758816,0.0767969319188293,0.0009153319188293096
8.0,429.0,387.0,0.018648,0.018648,6.063785,0.206662,1.0,429.0,2.0,24.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02336877,0.02314293517883026,0.000225834821169741
1.0,429.0,387.0,0.002331,0.002331,6.063785,0.206662,1.0,429.0,2.0,24.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0029211,0.002933896628419912,1.2796628419912276e-05
7.0,429.0,387.0,0.016317,0.016317,6.063785,0.206662,1.0,429.0,2.0,24.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02044768,0.020568976824722217,0.0001212968247222175
6.0,429.0,387.0,0.013986,0.013986,6.063785,0.206662,1.0,429.0,2.0,24.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01752658,0.017731512740114534,0.00020493274011453358
0.0,429.0,387.0,0.0,0.0,6.063785,0.206662,1.0,429.0,2.0,24.0,Consent Withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,387.0,0.002331,0.002331,6.063785,0.206662,1.0,429.0,2.0,24.0,Consent Withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0029211,0.0029346568440746725,1.3556844074672642e-05
7.0,429.0,387.0,0.016317,0.016317,6.063785,0.206662,1.0,429.0,2.0,24.0,Other Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02044768,0.020534411166805544,8.673116680554468e-05
12.0,429.0,387.0,0.027972,0.027972,6.063785,0.206662,1.0,429.0,2.0,24.0,Other Reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03505316,0.03503732877452379,1.5831225476208022e-05
15.0,1183.0,1033.0,0.01268,0.01268,7.076654,0.205195,1.0,1183.0,12.0,12.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01841256,0.018585323724821457,0.00017276372482145572
84.0,1183.0,1033.0,0.071006,0.071006,7.076654,0.205195,1.0,1183.0,12.0,12.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10310746,0.10907760812510911,0.005970148125109112
10.0,1183.0,1033.0,0.008453,0.008453,7.076654,0.205195,1.0,1183.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01227456,0.012337441519910723,6.288151991072286e-05
22.0,1183.0,1033.0,0.018597,0.018597,7.076654,0.205195,1.0,1183.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02700461,0.027768789601964283,0.0007641796019642842
3.0,1183.0,1033.0,0.002536,0.002536,7.076654,0.205195,1.0,1183.0,12.0,12.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00368251,0.0036856221149702286,3.112114970228643e-06
3.0,1183.0,1033.0,0.002536,0.002536,7.076654,0.205195,1.0,1183.0,12.0,12.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00368251,0.0036828318749702275,3.218749702275231e-07
2.0,1183.0,1033.0,0.001691,0.001691,7.076654,0.205195,1.0,1183.0,12.0,12.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00245549,0.002461152304273989,5.662304273989279e-06
3.0,1183.0,1033.0,0.002536,0.002536,7.076654,0.205195,1.0,1183.0,12.0,12.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00368251,0.0036850029028868934,2.4929028868934944e-06
2.0,1183.0,1033.0,0.001691,0.001691,7.076654,0.205195,1.0,1183.0,12.0,12.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00245549,0.0024591829151073227,3.692915107322836e-06
1.0,1183.0,1033.0,0.000845,0.000845,7.076654,0.205195,1.0,1183.0,12.0,12.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00122702,0.0012376075800396868,1.058758003968669e-05
2.0,1183.0,1033.0,0.001691,0.001691,7.076654,0.205195,1.0,1183.0,12.0,12.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00245549,0.002461374095523989,5.8840955239891635e-06
1.0,1183.0,1033.0,0.000845,0.000845,7.076654,0.205195,1.0,1183.0,12.0,12.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00122702,0.0012375359383730198,1.05159383730197e-05
1.0,1183.0,1033.0,0.000845,0.000845,7.076654,0.205195,1.0,1183.0,12.0,12.0,Condition no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00122702,0.0012365433487896871,9.523348789687016e-06
1.0,1183.0,1033.0,0.000845,0.000845,7.076654,0.205195,1.0,1183.0,12.0,12.0,Condition no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00122702,0.0012368485175396873,9.828517539687241e-06
8.0,1151.0,1118.0,0.00695,0.00695,7.049255,0.53487,1.0,1151.0,1.0,70.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02620452,0.026155419713134957,4.9100286865041975e-05
9.0,1151.0,1118.0,0.007819,0.007819,7.049255,0.53487,1.0,1151.0,1.0,70.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.02948103,0.02979649425361113,0.00031546425361113004
9.0,1151.0,1118.0,0.007819,0.007819,7.049255,0.53487,1.0,1151.0,1.0,70.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02948103,0.029690891938501992,0.00020986193850199356
7.0,1151.0,1118.0,0.006082,0.006082,7.049255,0.53487,1.0,1151.0,1.0,70.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.02293179,0.022834670618472216,9.711938152778474e-05
3.0,305.0,295.0,0.009836,0.009836,5.723585,0.203691,1.0,305.0,1.0,14.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01146721,0.01187431424541667,0.00040710424541666977
4.0,305.0,295.0,0.013115,0.013115,5.723585,0.203691,1.0,305.0,1.0,14.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01529001,0.015563418682033713,0.0002734086820337135
1.0,305.0,295.0,0.003279,0.003279,5.723585,0.203691,1.0,305.0,1.0,14.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00382279,0.0038220304048980974,7.59595101902568e-07
0.0,305.0,295.0,0.0,0.0,5.723585,0.203691,1.0,305.0,1.0,14.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,305.0,295.0,0.003279,0.003279,5.723585,0.203691,1.0,305.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00382279,0.0038207768461480983,2.0131538519016327e-06
1.0,305.0,295.0,0.003279,0.003279,5.723585,0.203691,1.0,305.0,1.0,14.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00382279,0.003822710661921908,7.933807809204843e-08
3.0,258.0,241.0,0.011628,0.011628,5.556828,0.281906,1.0,245.0,2.0,26.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01821532,0.018368971107678572,0.0001536511076785721
7.0,258.0,241.0,0.027132,0.027132,5.556828,0.281906,1.0,245.0,2.0,26.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04250241,0.04226087357425592,0.0002415364257440794
5.0,258.0,241.0,0.01938,0.01938,5.556828,0.281906,1.0,245.0,2.0,26.0,Screen Failures,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03035886,0.029978672698194465,0.000380187301805536
1.0,258.0,241.0,0.003876,0.003876,5.556828,0.281906,1.0,245.0,2.0,26.0,Screen Failures,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00607177,0.006086347175664684,1.457717566468418e-05
1.0,258.0,241.0,0.003876,0.003876,5.556828,0.281906,1.0,245.0,2.0,26.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00607177,0.006084464052539682,1.26940525396824e-05
0.0,258.0,241.0,0.0,0.0,5.556828,0.281906,1.0,245.0,2.0,26.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
444.0,7141.0,6076.0,0.062176,0.062176,8.873748,0.273859,1.0,7141.0,28.0,328.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15109754,0.14747562122102184,0.0036219187789781615
456.0,7141.0,6076.0,0.063857,0.063857,8.873748,0.273859,1.0,7141.0,28.0,328.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15518264,0.14893041715236113,0.0062522228476388775
19.0,7141.0,6076.0,0.002661,0.002661,8.873748,0.273859,1.0,7141.0,28.0,328.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00646665,0.006350493578660712,0.00011615642133928818
24.0,7141.0,6076.0,0.003361,0.003361,8.873748,0.273859,1.0,7141.0,28.0,328.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00816776,0.008380837246438495,0.00021307724643849536
54.0,7141.0,6076.0,0.007562,0.007562,8.873748,0.273859,1.0,7141.0,28.0,328.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01837686,0.017781945352767867,0.0005949146472321309
68.0,7141.0,6076.0,0.009522,0.009522,8.873748,0.273859,1.0,7141.0,28.0,328.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02313997,0.02323742148053571,9.745148053571032e-05
19.0,2013.0,1809.0,0.009439,0.009439,7.607878,1.0,1.0,2055.0,19.0,108.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07181076,0.07070338128856866,0.0011073787114313366
10.0,2013.0,1809.0,0.004968,0.004968,7.607878,1.0,1.0,2055.0,19.0,108.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03779594,0.036601454684494,0.0011944853155059984
5.0,2013.0,1809.0,0.002484,0.002484,7.607878,1.0,1.0,2055.0,19.0,108.0,Non-compliant with protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01889797,0.01853396438082344,0.0003640056191765613
9.0,2013.0,1809.0,0.004471,0.004471,7.607878,1.0,1.0,2055.0,19.0,108.0,Non-compliant with protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03401482,0.03485402630529756,0.0008392063052975601
2.0,2013.0,1809.0,0.000994,0.000994,7.607878,1.0,1.0,2055.0,19.0,108.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00756223,0.0073560785947618945,0.00020615140523810513
0.0,2013.0,1809.0,0.0,0.0,7.607878,1.0,1.0,2055.0,19.0,108.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
51.0,2013.0,1809.0,0.025335,0.025335,7.607878,1.0,1.0,2055.0,19.0,108.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19274559,0.18846459701174598,0.004280992988254018
36.0,2013.0,1809.0,0.017884,0.017884,7.607878,1.0,1.0,2055.0,19.0,108.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13605929,0.134388019409395,0.0016712705906050118
38.0,2013.0,1809.0,0.018877,0.018877,7.607878,1.0,1.0,2055.0,19.0,108.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14361391,0.14486321957962034,0.001249309579620328
38.0,2013.0,1809.0,0.018877,0.018877,7.607878,1.0,1.0,2055.0,19.0,108.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14361391,0.14325135611970966,0.00036255388029035607
60.0,2013.0,1809.0,0.029806,0.029806,7.607878,1.0,1.0,2055.0,19.0,108.0,Adverse Event,Treatment,FG000,cardiovascular disease,INDUSTRY,0.22676041,0.22133583077326402,0.005424579226735976
53.0,2013.0,1809.0,0.026329,0.026329,7.607878,1.0,1.0,2055.0,19.0,108.0,Adverse Event,Treatment,FG001,cardiovascular disease,INDUSTRY,0.20030782,0.19843408254225184,0.0018737374577481591
10.0,2013.0,1809.0,0.004968,0.004968,7.607878,1.0,1.0,2055.0,19.0,108.0,Non-compliant with protocol,Treatment,FG000,cardiovascular disease,INDUSTRY,0.03779594,0.03658712653395829,0.0012088134660417083
9.0,2013.0,1809.0,0.004471,0.004471,7.607878,1.0,1.0,2055.0,19.0,108.0,Non-compliant with protocol,Treatment,FG001,cardiovascular disease,INDUSTRY,0.03401482,0.034848248580297565,0.0008334285802975641
1.0,2013.0,1809.0,0.000497,0.000497,7.607878,1.0,1.0,2055.0,19.0,108.0,Lost to Follow-up,Treatment,FG000,cardiovascular disease,INDUSTRY,0.00378112,0.0037519404147799452,2.9179585220054545e-05
0.0,2013.0,1809.0,0.0,0.0,7.607878,1.0,1.0,2055.0,19.0,108.0,Lost to Follow-up,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
23.0,2013.0,1809.0,0.011426,0.011426,7.607878,1.0,1.0,2055.0,19.0,108.0,Withdrawal by Subject,Treatment,FG000,cardiovascular disease,INDUSTRY,0.08692761,0.08317793756485119,0.0037496724351488153
20.0,2013.0,1809.0,0.009935,0.009935,7.607878,1.0,1.0,2055.0,19.0,108.0,Withdrawal by Subject,Treatment,FG001,cardiovascular disease,INDUSTRY,0.07558427,0.0745974020360813,0.0009868679639186972
13.0,2013.0,1809.0,0.006458,0.006458,7.607878,1.0,1.0,2055.0,19.0,108.0,Other,Treatment,FG000,cardiovascular disease,INDUSTRY,0.04913168,0.04850940506910716,0.0006222749308928341
15.0,2013.0,1809.0,0.007452,0.007452,7.607878,1.0,1.0,2055.0,19.0,108.0,Other,Treatment,FG001,cardiovascular disease,INDUSTRY,0.05669391,0.05629586388735117,0.0003980461126488269
7.0,1191.0,1106.0,0.005877,0.005877,7.083388,0.238805,1.0,1191.0,12.0,12.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00994122,0.010021692158492065,8.04721584920648e-05
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00284011,0.002840984388630932,8.743886309322234e-07
8.0,1191.0,1106.0,0.006717,0.006717,7.083388,0.238805,1.0,1191.0,12.0,12.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01136212,0.011353967751170629,8.152248829371156e-06
11.0,1191.0,1106.0,0.009236,0.009236,7.083388,0.238805,1.0,1191.0,12.0,12.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01562313,0.015547423718333333,7.570628166666746e-05
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Laboratory Value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Laboratory Value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Laboratory Value(s),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0014209,0.0014231778830952342,2.2778830952342732e-06
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Laboratory Value(s),Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Test Procedure Result(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0014209,0.0014218762670833295,9.762670833295996e-07
3.0,1191.0,1106.0,0.002519,0.002519,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Test Procedure Result(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00426101,0.004264953788065479,3.943788065479369e-06
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Test Procedure Result(s),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0014209,0.0014231778830952342,2.2778830952342732e-06
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Abnormal Test Procedure Result(s),Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00284011,0.002840391202499979,2.8120249997900387e-07
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00284011,0.0028419985479761706,1.8885479761707527e-06
3.0,1191.0,1106.0,0.002519,0.002519,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00426101,0.004264627040148813,3.6170401488131235e-06
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0014209,0.0014235894580952341,2.6894580952342186e-06
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00284011,0.0028393103448809314,7.996551190684806e-07
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00284011,0.002843379599345218,3.269599345218175e-06
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0014209,0.0014232919664285673,2.391966428567406e-06
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1191.0,1106.0,0.004198,0.004198,7.083388,0.238805,1.0,1191.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00710112,0.0070597385305853156,4.138146941468426e-05
7.0,1191.0,1106.0,0.005877,0.005877,7.083388,0.238805,1.0,1191.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00994122,0.009990945705158731,4.972570515873048e-05
3.0,1191.0,1106.0,0.002519,0.002519,7.083388,0.238805,1.0,1191.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00426101,0.004266695177529765,5.685177529765259e-06
8.0,1191.0,1106.0,0.006717,0.006717,7.083388,0.238805,1.0,1191.0,12.0,12.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01136212,0.011347007272182533,1.511272781746717e-05
4.0,1191.0,1106.0,0.003359,0.003359,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00568191,0.0057761675921951675,9.42575921951674e-05
6.0,1191.0,1106.0,0.005038,0.005038,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00852202,0.00850554858161706,1.6471418382939945e-05
2.0,1191.0,1106.0,0.001679,0.001679,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00284011,0.0028464750782142673,6.365078214267458e-06
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0014209,0.0014217199174999958,8.199174999958935e-07
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Randomized in Error - No Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Randomized in Error - No Study Drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0014209,0.0014211225441666626,2.2254416666271128e-07
0.0,1191.0,1106.0,0.0,0.0,7.083388,0.238805,1.0,1191.0,12.0,12.0,Randomized in Error - No Study Drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1191.0,1106.0,0.00084,0.00084,7.083388,0.238805,1.0,1191.0,12.0,12.0,Randomized in Error - No Study Drug,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0014209,0.0014211248841666624,2.248841666624684e-07
15.0,486.0,426.0,0.030864,0.030864,6.188264,0.363079,1.0,486.0,1.0,7.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NIH,0.06934616,0.06958534506365083,0.0002391850636508236
16.0,486.0,426.0,0.032922,0.032922,6.188264,0.363079,1.0,486.0,1.0,7.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NIH,0.07397014,0.0730403326957639,0.0009298073042360994
9.0,486.0,426.0,0.018519,0.018519,6.188264,0.363079,1.0,486.0,1.0,7.0,Less than full participation,Overall Study,FG000,cardiovascular disease,NIH,0.04160904,0.041730630595099225,0.00012159059509922465
19.0,486.0,426.0,0.039095,0.039095,6.188264,0.363079,1.0,486.0,1.0,7.0,Less than full participation,Overall Study,FG001,cardiovascular disease,NIH,0.08783982,0.08690122528204361,0.0009385947179563897
0.0,486.0,426.0,0.0,0.0,6.188264,0.363079,1.0,486.0,1.0,7.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,NIH,0.0,0.0,0.0
1.0,486.0,426.0,0.002058,0.002058,6.188264,0.363079,1.0,486.0,1.0,7.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,NIH,0.00462398,0.004644372782374635,2.039278237463485e-05
3.0,207.0,201.0,0.014493,0.014493,5.337538,0.89443,1.0,207.0,1.0,28.0,Participant decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0691904,0.06959560746976204,0.0004052074697620395
3.0,207.0,201.0,0.014493,0.014493,5.337538,0.89443,1.0,207.0,1.0,28.0,Participant decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0691904,0.06951596532654773,0.0003255653265477332
94.0,10154.0,9969.0,0.009257,0.009257,9.225721,0.227085,1.0,10154.0,1.0,16.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01939359,0.018617904209315483,0.000775685790684516
89.0,10154.0,9969.0,0.008765,0.008765,9.225721,0.227085,1.0,10154.0,1.0,16.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01836284,0.01789067670842263,0.00047216329157736756
0.0,10154.0,9969.0,0.0,0.0,9.225721,0.227085,1.0,10154.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,10154.0,9969.0,9.8e-05,9.8e-05,9.225721,0.227085,1.0,10154.0,1.0,16.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00020531,0.00021168174649531055,6.37174649531055e-06
1.0,10154.0,9969.0,9.8e-05,9.8e-05,9.225721,0.227085,1.0,10154.0,1.0,16.0,Institutional review board request,Overall Study,FG000,cardiovascular disease,OTHER,0.00020531,0.0002095590908134923,4.249090813492312e-06
0.0,10154.0,9969.0,0.0,0.0,9.225721,0.227085,1.0,10154.0,1.0,16.0,Institutional review board request,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
553.0,5988.0,4097.0,0.092351,0.092351,8.69768,0.660537,1.0,5988.0,23.0,619.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.53056974,0.5001393653655339,0.030430374634466073
575.0,5988.0,4097.0,0.096025,0.096025,8.69768,0.660537,1.0,5988.0,23.0,619.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.5516774,0.506973733944643,0.04470366605535703
30.0,5988.0,4097.0,0.00501,0.00501,8.69768,0.660537,1.0,5988.0,23.0,619.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02878317,0.028164108379702332,0.000619061620297668
24.0,5988.0,4097.0,0.004008,0.004008,8.69768,0.660537,1.0,5988.0,23.0,619.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02302653,0.022996200854146824,3.0329145853175837e-05
6.0,5988.0,4097.0,0.001002,0.001002,8.69768,0.660537,1.0,5988.0,23.0,619.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00575663,0.00574420773654764,1.2422263452360402e-05
16.0,5988.0,4097.0,0.002672,0.002672,8.69768,0.660537,1.0,5988.0,23.0,619.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01535102,0.01485718740118055,0.0004938325988194502
304.0,5988.0,4097.0,0.050768,0.050768,8.69768,0.660537,1.0,5988.0,23.0,619.0,"Patient refusal to continue, not due to AE",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.29166944,0.27043115436648807,0.021238285633511933
284.0,5988.0,4097.0,0.047428,0.047428,8.69768,0.660537,1.0,5988.0,23.0,619.0,"Patient refusal to continue, not due to AE",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.27248066,0.26659989140836315,0.005880768591636831
6.0,5988.0,4097.0,0.001002,0.001002,8.69768,0.660537,1.0,5988.0,23.0,619.0,"Study drug stopped, reason missing",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00575663,0.005735965165297639,2.066483470236115e-05
1.0,5988.0,4097.0,0.000167,0.000167,8.69768,0.660537,1.0,5988.0,23.0,619.0,"Study drug stopped, reason missing",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00095944,0.000981926123224207,2.2486123224207044e-05
6.0,5988.0,4097.0,0.001002,0.001002,8.69768,0.660537,1.0,5988.0,23.0,619.0,Medical advice,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00575663,0.005735965165297639,2.066483470236115e-05
2.0,5988.0,4097.0,0.000334,0.000334,8.69768,0.660537,1.0,5988.0,23.0,619.0,Medical advice,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191888,0.0019329932805654698,1.4113280565469788e-05
2.0,5988.0,4097.0,0.000334,0.000334,8.69768,0.660537,1.0,5988.0,23.0,619.0,Due to Covid-19 Pandemic,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191888,0.0019326826056547553,1.380260565475534e-05
8.0,5988.0,4097.0,0.001336,0.001336,8.69768,0.660537,1.0,5988.0,23.0,619.0,Due to Covid-19 Pandemic,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00767551,0.007556023394702382,0.00011948660529761783
2.0,5988.0,4097.0,0.000334,0.000334,8.69768,0.660537,1.0,5988.0,23.0,619.0,Investigator decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191888,0.0019326826056547553,1.380260565475534e-05
0.0,5988.0,4097.0,0.0,0.0,8.69768,0.660537,1.0,5988.0,23.0,619.0,Investigator decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,5988.0,4097.0,0.000835,0.000835,8.69768,0.660537,1.0,5988.0,23.0,619.0,Patient decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00479719,0.004525157182069093,0.0002720328179309072
2.0,5988.0,4097.0,0.000334,0.000334,8.69768,0.660537,1.0,5988.0,23.0,619.0,Patient decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191888,0.0019329932805654698,1.4113280565469788e-05
3.0,5988.0,4097.0,0.000501,0.000501,8.69768,0.660537,1.0,5988.0,23.0,619.0,Not attending study visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00287832,0.0028717684894146787,6.551510585321458e-06
0.0,5988.0,4097.0,0.0,0.0,8.69768,0.660537,1.0,5988.0,23.0,619.0,Not attending study visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,5988.0,4097.0,0.000501,0.000501,8.69768,0.660537,1.0,5988.0,23.0,619.0,Patient moved away,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00287832,0.0028717684894146787,6.551510585321458e-06
4.0,5988.0,4097.0,0.000668,0.000668,8.69768,0.660537,1.0,5988.0,23.0,619.0,Patient moved away,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00383776,0.0037605932011408765,7.716679885912342e-05
23.0,5988.0,4097.0,0.003841,0.003841,8.69768,0.660537,1.0,5988.0,23.0,619.0,Other reason than stated above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0220671,0.02192545286939483,0.00014164713060517073
29.0,5988.0,4097.0,0.004843,0.004843,8.69768,0.660537,1.0,5988.0,23.0,619.0,Other reason than stated above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02782373,0.027559638963611088,0.00026409103638891374
2.0,5988.0,4097.0,0.000334,0.000334,8.69768,0.660537,1.0,5988.0,23.0,619.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191888,0.0019326826056547553,1.380260565475534e-05
1.0,5988.0,4097.0,0.000167,0.000167,8.69768,0.660537,1.0,5988.0,23.0,619.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00095944,0.000981926123224207,2.2486123224207044e-05
11.0,565.0,436.0,0.019469,0.019469,6.338594,0.349133,1.0,565.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04308516,0.042676750537232175,0.00040840946276782253
16.0,565.0,436.0,0.028319,0.028319,6.338594,0.349133,1.0,565.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06267033,0.0620584370403607,0.0006118929596392944
1.0,565.0,436.0,0.00177,0.00177,6.338594,0.349133,1.0,565.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00391703,0.003930987133273803,1.395713327380279e-05
0.0,565.0,436.0,0.0,0.0,6.338594,0.349133,1.0,565.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,565.0,436.0,0.010619,0.010619,6.338594,0.349133,1.0,565.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02349999,0.023468352945982134,3.1637054017864125e-05
2.0,565.0,436.0,0.00354,0.00354,6.338594,0.349133,1.0,565.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00783407,0.007787097313670635,4.697268632936503e-05
0.0,565.0,436.0,0.0,0.0,6.338594,0.349133,1.0,565.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,565.0,436.0,0.00531,0.00531,6.338594,0.349133,1.0,565.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0117511,0.01169630450672619,5.479549327381053e-05
6.0,565.0,436.0,0.010619,0.010619,6.338594,0.349133,1.0,565.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02349999,0.023472387980982133,2.7602019017865242e-05
6.0,565.0,436.0,0.010619,0.010619,6.338594,0.349133,1.0,565.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02349999,0.023420452686577362,7.953731342263612e-05
0.0,565.0,436.0,0.0,0.0,6.338594,0.349133,1.0,565.0,0.0,0.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,565.0,436.0,0.00177,0.00177,6.338594,0.349133,1.0,565.0,0.0,0.0,Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00391703,0.003932905903065469,1.5875903065469023e-05
1.0,565.0,436.0,0.00177,0.00177,6.338594,0.349133,1.0,565.0,0.0,0.0,Recovery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00391703,0.003933340597857136,1.631059785713561e-05
0.0,565.0,436.0,0.0,0.0,6.338594,0.349133,1.0,565.0,0.0,0.0,Recovery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,565.0,436.0,0.00531,0.00531,6.338594,0.349133,1.0,565.0,0.0,0.0,Technical Problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0117511,0.011700362634017856,5.073736598214425e-05
5.0,565.0,436.0,0.00885,0.00885,6.338594,0.349133,1.0,565.0,0.0,0.0,Technical Problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01958517,0.019412171348422623,0.00017299865157737598
34.0,565.0,436.0,0.060177,0.060177,6.338594,0.349133,1.0,565.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13317251,0.13179991268568006,0.0013725973143199344
34.0,565.0,436.0,0.060177,0.060177,6.338594,0.349133,1.0,565.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13317251,0.1319925537145193,0.0011799562854807044
1.0,205.0,202.0,0.004878,0.004878,5.327876,0.549151,1.0,205.0,1.0,1.0,Toxicity,Overall Study,FG000,cardiovascular disease,OTHER,0.01427209,0.014548353382827386,0.00027626338282738666
0.0,205.0,202.0,0.0,0.0,5.327876,0.549151,1.0,205.0,1.0,1.0,Toxicity,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,205.0,202.0,0.0,0.0,5.327876,0.549151,1.0,205.0,1.0,1.0,Ineligible,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,205.0,202.0,0.009756,0.009756,5.327876,0.549151,1.0,205.0,1.0,1.0,Ineligible,Overall Study,FG001,cardiovascular disease,OTHER,0.02854417,0.028983763034067453,0.00043959303406745226
2.0,257.0,91.0,0.007782,0.007782,5.55296,0.206662,1.0,257.0,2.0,2.0,Adverse Event,Phase 1 - Amlodipine+Olmesartan,FG000,cardiovascular disease,INDUSTRY,0.0089305,0.008966495183670624,3.599518367062432e-05
1.0,257.0,91.0,0.003891,0.003891,5.55296,0.206662,1.0,257.0,2.0,2.0,Withdrawal by Subject,Phase 1 - Amlodipine+Olmesartan,FG000,cardiovascular disease,INDUSTRY,0.00446525,0.004481319088343248,1.6069088343248147e-05
2.0,257.0,91.0,0.007782,0.007782,5.55296,0.206662,1.0,257.0,2.0,2.0,Lost to Follow-up,Phase 1 - Amlodipine+Olmesartan,FG000,cardiovascular disease,INDUSTRY,0.0089305,0.008973231854742051,4.2731854742052156e-05
1.0,257.0,91.0,0.003891,0.003891,5.55296,0.206662,1.0,257.0,2.0,2.0,Administrative problems,Phase 1 - Amlodipine+Olmesartan,FG000,cardiovascular disease,INDUSTRY,0.00446525,0.004481186509176581,1.5936509176581355e-05
2.0,257.0,91.0,0.007782,0.007782,5.55296,0.206662,1.0,257.0,2.0,2.0,Adverse Event,Phase 2 - Amlodipine+Valsartan,FG000,cardiovascular disease,INDUSTRY,0.0089305,0.008966495183670624,3.599518367062432e-05
1.0,257.0,91.0,0.003891,0.003891,5.55296,0.206662,1.0,257.0,2.0,2.0,Lost to Follow-up,Phase 2 - Amlodipine+Valsartan,FG000,cardiovascular disease,INDUSTRY,0.00446525,0.004481731915426582,1.648191542658224e-05
1.0,515.0,471.0,0.001942,0.001942,6.246107,0.220602,1.0,515.0,1.0,1.0,Withdrawal due to adverse event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00267589,0.0027219047853571437,4.6014785357143505e-05
0.0,515.0,471.0,0.0,0.0,6.246107,0.220602,1.0,515.0,1.0,1.0,Withdrawal due to adverse event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
22.0,515.0,471.0,0.042718,0.042718,6.246107,0.220602,1.0,515.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0588614,0.05899643092174604,0.00013503092174604187
0.0,515.0,471.0,0.0,0.0,6.246107,0.220602,1.0,515.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,515.0,471.0,0.015534,0.015534,6.246107,0.220602,1.0,515.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0214044,0.02149777516839283,9.337516839283064e-05
8.0,515.0,471.0,0.015534,0.015534,6.246107,0.220602,1.0,515.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0214044,0.021474769666865054,7.036966686505344e-05
3.0,515.0,471.0,0.005825,0.005825,6.246107,0.220602,1.0,515.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0080263,0.008214105357212308,0.00018780535721230757
2.0,515.0,471.0,0.003883,0.003883,6.246107,0.220602,1.0,515.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00535041,0.005355671577926585,5.261577926585388e-06
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.01557108,0.015515632093115066,5.5447906884933604e-05
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.01557108,0.015530817790833326,4.026220916667281e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,673.0,533.0,0.007429,0.007429,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.02594831,0.025967522947946485,1.9212947946486286e-05
2.0,673.0,533.0,0.002972,0.002972,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.01038072,0.01028462244643851,9.60975535614899e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,673.0,533.0,0.010401,0.010401,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.03632903,0.036121209248404604,0.00020782075159539448
5.0,673.0,533.0,0.007429,0.007429,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.02594831,0.02594106863110125,7.241368898749934e-06
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,673.0,533.0,0.014859,0.014859,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.05190011,0.05041494115220239,0.0014851688477976119
9.0,673.0,533.0,0.013373,0.013373,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.04670975,0.04610489460625837,0.0006048553937416309
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,673.0,533.0,0.001486,0.001486,6.51323,0.536268,1.0,673.0,1.0,87.0,Physician Decision,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.00519036,0.005237441480793656,4.7081480793656656e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Physician Decision,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Physician Decision,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Physician Decision,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,673.0,533.0,0.001486,0.001486,6.51323,0.536268,1.0,673.0,1.0,87.0,Lack of Efficacy,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.00519036,0.005234259347460322,4.389934746032182e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lack of Efficacy,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lack of Efficacy,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lack of Efficacy,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603A: 0-12 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,673.0,533.0,0.001486,0.001486,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603A: 0-12 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.00519036,0.005218870877757945,2.851087775794514e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603A: 0-12 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603A: 0-12 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603B: 24-36 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603B: 24-36 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603B: 24-36 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,673.0,533.0,0.002972,0.002972,6.51323,0.536268,1.0,673.0,1.0,87.0,Protocol Violation,603B: 24-36 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.01038072,0.010304752899017873,7.596710098212688e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603B: 24-36 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603B: 24-36 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603B: 24-36 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.01557108,0.015537536898065456,3.3543101934542865e-05
1.0,673.0,533.0,0.001486,0.001486,6.51323,0.536268,1.0,673.0,1.0,87.0,Adverse Event,603B: 24-36 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.00519036,0.005222861411507942,3.250141150794219e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603B: 24-36 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603B: 24-36 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,673.0,533.0,0.002972,0.002972,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603B: 24-36 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.01038072,0.010272560327589305,0.00010815967241069487
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,Withdrawal by Subject,603B: 24-36 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.01557108,0.015573729652499984,2.649652499985e-06
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603B: 24-36 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603B: 24-36 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,673.0,533.0,0.008915,0.008915,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603B: 24-36 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.03113867,0.031003444403650833,0.0001352255963491672
6.0,673.0,533.0,0.008915,0.008915,6.51323,0.536268,1.0,673.0,1.0,87.0,Lost to Follow-up,603B: 24-36 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.03113867,0.0310440021365675,9.466786343249878e-05
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603B: 24-36 Week Study Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,673.0,533.0,0.0,0.0,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603B: 24-36 Week Study Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603B: 24-36 Week Study Period,FG002,cardiovascular disease,INDUSTRY,0.01557108,0.01554591044723212,2.5169552767878578e-05
3.0,673.0,533.0,0.004458,0.004458,6.51323,0.536268,1.0,673.0,1.0,87.0,24 hr ABPM not enough readings,603B: 24-36 Week Study Period,FG003,cardiovascular disease,INDUSTRY,0.01557108,0.015566580885654746,4.499114345253574e-06
43.0,7513.0,6941.0,0.005723,0.005723,8.924523,0.416574,1.0,7513.0,34.0,462.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02127652,0.02126753528898809,8.984711011909147e-06
29.0,7513.0,6941.0,0.00386,0.00386,8.924523,0.416574,1.0,7513.0,34.0,462.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01435041,0.014300812967817456,4.959703218254327e-05
206.0,7513.0,6941.0,0.027419,0.027419,8.924523,0.416574,1.0,7513.0,34.0,462.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10193622,0.10006794621842259,0.0018682737815774036
211.0,7513.0,6941.0,0.028085,0.028085,8.924523,0.416574,1.0,7513.0,34.0,462.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10441223,0.10291421367812495,0.0014980163218750453
11.0,7513.0,6941.0,0.001464,0.001464,8.924523,0.416574,1.0,7513.0,34.0,462.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00544275,0.0054400095185813515,2.7404814186482093e-06
17.0,7513.0,6941.0,0.002263,0.002263,8.924523,0.416574,1.0,7513.0,34.0,462.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00841321,0.008429535219728534,1.6325219728533305e-05
3.0,7513.0,6941.0,0.000399,0.000399,8.924523,0.416574,1.0,7513.0,34.0,462.0,Adverse event or serious adverse event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00148337,0.0015029372302876964,1.956723028769653e-05
3.0,7513.0,6941.0,0.000399,0.000399,8.924523,0.416574,1.0,7513.0,34.0,462.0,Adverse event or serious adverse event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00148337,0.001497306410079363,1.3936410079363028e-05
3.0,7513.0,6941.0,0.000399,0.000399,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient /Family decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00148337,0.0015029372302876964,1.956723028769653e-05
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient /Family decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Cannot contact patient directly,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00049446,0.0004939178135876637,5.421864123362737e-07
2.0,7513.0,6941.0,0.000266,0.000266,8.924523,0.416574,1.0,7513.0,34.0,462.0,Cannot contact patient directly,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00098891,0.0009962048001686534,7.294800168653479e-06
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,SOURCE DOCUMENT/COORDINATOR MISSING,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,7513.0,6941.0,0.000266,0.000266,8.924523,0.416574,1.0,7513.0,34.0,462.0,SOURCE DOCUMENT/COORDINATOR MISSING,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00098891,0.0009962048001686534,7.294800168653479e-06
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient did not wish to attend visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient did not wish to attend visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00049446,0.0004946669573484855,2.0695734848552496e-07
17.0,7513.0,6941.0,0.002263,0.002263,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient randomized but not dosed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00841321,0.00843582157028409,2.2611570284089555e-05
16.0,7513.0,6941.0,0.00213,0.00213,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient randomized but not dosed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00791875,0.007795895694926951,0.00012285430507304965
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was assessed via phone in person,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00049446,0.0004939178135876637,5.421864123362737e-07
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was assessed via phone in person,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,7513.0,6941.0,0.000266,0.000266,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient deemed ineligible after random,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00098891,0.0009967141946329381,7.804194632938166e-06
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient deemed ineligible after random,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was early terminated from study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was early terminated from study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00049446,0.0004946669573484855,2.0695734848552496e-07
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was randomized due to mistake,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00049446,0.0004939178135876637,5.421864123362737e-07
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Patient was randomized due to mistake,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,THE SUBJECT MOVED TO ANOTHER PROVINCE,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,THE SUBJECT MOVED TO ANOTHER PROVINCE,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00049446,0.0004946669573484855,2.0695734848552496e-07
1.0,7513.0,6941.0,0.000133,0.000133,8.924523,0.416574,1.0,7513.0,34.0,462.0,Withdraw of consent on day of random,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00049446,0.0004939178135876637,5.421864123362737e-07
0.0,7513.0,6941.0,0.0,0.0,8.924523,0.416574,1.0,7513.0,34.0,462.0,Withdraw of consent on day of random,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
47.0,1738.0,1511.0,0.027043,0.027043,7.461066,0.208188,1.0,1738.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04200601,0.04357536238743053,0.0015693523874305282
144.0,1738.0,1511.0,0.082854,0.082854,7.461066,0.208188,1.0,1738.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12869748,0.1380932091366965,0.009395729136696507
9.0,1738.0,1511.0,0.005178,0.005178,7.461066,0.208188,1.0,1738.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00804301,0.008072117467668654,2.910746766865424e-05
20.0,1738.0,1511.0,0.011507,0.011507,7.461066,0.208188,1.0,1738.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01787387,0.01802823044863098,0.0001543604486309788
7.0,1738.0,1511.0,0.004028,0.004028,7.461066,0.208188,1.0,1738.0,0.0,0.0,Non Compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00625671,0.006358838471035351,0.00010212847103535042
2.0,234.0,52.0,0.008547,0.008547,5.459586,0.234201,1.0,234.0,0.0,0.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01092856,0.010992132635906376,6.357263590637575e-05
3.0,234.0,52.0,0.012821,0.012821,5.459586,0.234201,1.0,234.0,0.0,0.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01639348,0.016441637761553912,4.815776155391374e-05
2.0,234.0,52.0,0.008547,0.008547,5.459586,0.234201,1.0,234.0,0.0,0.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01092856,0.01099589756173971,6.733756173970921e-05
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.005463447620297662,1.472379702337906e-06
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005465085769404806,1.657694048062472e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.005464348016130997,5.71983869003187e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.0054610362310714665,3.883768928533357e-06
0.0,234.0,52.0,0.0,0.0,5.459586,0.234201,1.0,234.0,0.0,0.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,234.0,52.0,0.025641,0.025641,5.459586,0.234201,1.0,234.0,0.0,0.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03278568,0.032927553141160706,0.00014187314116070882
6.0,234.0,52.0,0.025641,0.025641,5.459586,0.234201,1.0,234.0,0.0,0.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03278568,0.033055905869196406,0.00027022586919640823
2.0,234.0,52.0,0.008547,0.008547,5.459586,0.234201,1.0,234.0,0.0,0.0,Other,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01092856,0.01099589756173971,6.733756173970921e-05
2.0,234.0,52.0,0.008547,0.008547,5.459586,0.234201,1.0,234.0,0.0,0.0,Other,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01092856,0.010993485402632569,6.492540263256831e-05
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Ineligibility determined,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005465033711071473,1.1371107147290643e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Ineligibility determined,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.0054642959577976625,6.240422023373951e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Noncompliance,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005464896755654806,2.3244345193421112e-08
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Noncompliance,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.005464577909880997,3.4209011900293573e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Requirement for alternative therapy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005465033711071473,1.1371107147290643e-07
0.0,234.0,52.0,0.0,0.0,5.459586,0.234201,1.0,234.0,0.0,0.0,Requirement for alternative therapy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Adverse Event,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005464845465009964,7.453499003585995e-08
3.0,234.0,52.0,0.012821,0.012821,5.459586,0.234201,1.0,234.0,0.0,0.0,Adverse Event,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.01639348,0.016441637761553912,4.815776155391374e-05
3.0,234.0,52.0,0.012821,0.012821,5.459586,0.234201,1.0,234.0,0.0,0.0,Death,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.01639348,0.016469599269321775,7.611926932177618e-05
0.0,234.0,52.0,0.0,0.0,5.459586,0.234201,1.0,234.0,0.0,0.0,Death,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,234.0,52.0,0.008547,0.008547,5.459586,0.234201,1.0,234.0,0.0,0.0,Withdrawal by Subject,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.01092856,0.011010275402275425,8.171540227542434e-05
3.0,234.0,52.0,0.012821,0.012821,5.459586,0.234201,1.0,234.0,0.0,0.0,Withdrawal by Subject,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.01639348,0.01643775300447058,4.427300447058108e-05
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Other,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.0054646368670932975,2.831329067023644e-07
4.0,234.0,52.0,0.017094,0.017094,5.459586,0.234201,1.0,234.0,0.0,0.0,Other,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.02185712,0.02294619899818453,0.0010890789981845284
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Ineligibility determined,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.005464073310843298,8.466891567018506e-07
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Ineligibility determined,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.005461623560783772,3.2964392162274786e-06
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Noncompliance,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.00546492,0.0054636076658432986,1.3123341567012822e-06
0.0,234.0,52.0,0.0,0.0,5.459586,0.234201,1.0,234.0,0.0,0.0,Noncompliance,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,234.0,52.0,0.0,0.0,5.459586,0.234201,1.0,234.0,0.0,0.0,Requirement for alternative therapy,Safety Follow Up Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,234.0,52.0,0.004274,0.004274,5.459586,0.234201,1.0,234.0,0.0,0.0,Requirement for alternative therapy,Safety Follow Up Period,FG001,cardiovascular disease,INDUSTRY,0.00546492,0.005461576823283773,3.3431767162269907e-06
39.0,564.0,493.0,0.069149,0.069149,6.336826,0.242518,1.0,564.0,8.0,8.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10626784,0.10645471243346233,0.00018687243346232618
1.0,564.0,493.0,0.001773,0.001773,6.336826,0.242518,1.0,564.0,8.0,8.0,Abnormal Test Procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00272474,0.002679451660327383,4.5288339672616956e-05
3.0,564.0,493.0,0.005319,0.005319,6.336826,0.242518,1.0,564.0,8.0,8.0,Unsatisfactory Therapeutic Effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00817421,0.00811626643367064,5.794356632935968e-05
3.0,564.0,493.0,0.005319,0.005319,6.336826,0.242518,1.0,564.0,8.0,8.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00817421,0.008114186954503973,6.002304549602641e-05
17.0,564.0,493.0,0.030142,0.030142,6.336826,0.242518,1.0,564.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04632207,0.04710578367515875,0.0007837136751587467
8.0,564.0,493.0,0.014184,0.014184,6.336826,0.242518,1.0,564.0,8.0,8.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0217979,0.02182335877840277,2.545877840277183e-05
2.0,3506.0,3504.0,0.00057,0.00057,8.162516,0.819223,1.0,3506.0,6.0,133.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.00381155,0.0036763820383414482,0.00013516796165855167
0.0,3506.0,3504.0,0.0,0.0,8.162516,0.819223,1.0,3506.0,6.0,133.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,372.0,241.0,0.005376,0.005376,5.921578,0.631708,1.0,372.0,14.0,114.0,Withdrawal by parent/guardian,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02011004,0.0204778495278472,0.00036780952784720017
7.0,372.0,241.0,0.018817,0.018817,5.921578,0.631708,1.0,372.0,14.0,114.0,Withdrawal by parent/guardian,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07038886,0.07025226420033737,0.00013659579966263102
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01005502,0.01003939692014264,1.562307985735964e-05
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Transferred to another hospital to continue,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01005502,0.01002675640853551,2.826359146448909e-05
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Transferred to another hospital to continue,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
30.0,372.0,241.0,0.080645,0.080645,5.921578,0.631708,1.0,372.0,14.0,114.0,Other Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.30166923,0.3128768414800098,0.011207611480009816
20.0,372.0,241.0,0.053763,0.053763,5.921578,0.631708,1.0,372.0,14.0,114.0,Other Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.20111157,0.19723456450118243,0.0038770054988175595
6.0,372.0,241.0,0.016129,0.016129,5.921578,0.631708,1.0,372.0,14.0,114.0,"Adverse event, serious fatal",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06033385,0.06013092695090268,0.00020292304909732412
8.0,372.0,241.0,0.021505,0.021505,5.921578,0.631708,1.0,372.0,14.0,114.0,"Adverse event, serious fatal",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08044388,0.078837990181627,0.0016058898183729936
5.0,372.0,241.0,0.013441,0.013441,5.921578,0.631708,1.0,372.0,14.0,114.0,Consent withdrawn by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05027883,0.05036776371464288,8.893371464288591e-05
3.0,372.0,241.0,0.008065,0.008065,5.921578,0.631708,1.0,372.0,14.0,114.0,Consent withdrawn by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03016879,0.030433270826666657,0.00026448082666665623
2.0,372.0,241.0,0.005376,0.005376,5.921578,0.631708,1.0,372.0,14.0,114.0,Screen failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02011004,0.0204778495278472,0.00036780952784720017
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Screen failure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01005502,0.01003939692014264,1.562307985735964e-05
9.0,372.0,241.0,0.024194,0.024194,5.921578,0.631708,1.0,372.0,14.0,114.0,Disease relapse,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09050264,0.08934638107128968,0.0011562589287103103
6.0,372.0,241.0,0.016129,0.016129,5.921578,0.631708,1.0,372.0,14.0,114.0,Disease relapse,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06033385,0.06010339749131934,0.00023045250868065914
7.0,372.0,241.0,0.018817,0.018817,5.921578,0.631708,1.0,372.0,14.0,114.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07038886,0.07032331027259926,6.554972740073495e-05
6.0,372.0,241.0,0.016129,0.016129,5.921578,0.631708,1.0,372.0,14.0,114.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06033385,0.06011516738798602,0.00021868261201397898
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Transferred to hospital closer to home,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Transferred to hospital closer to home,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01005502,0.01003939692014264,1.562307985735964e-05
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Enrolled in an investigational study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Enrolled in an investigational study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01005502,0.01003939692014264,1.562307985735964e-05
1.0,372.0,241.0,0.002688,0.002688,5.921578,0.631708,1.0,372.0,14.0,114.0,Early recovery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01005502,0.01002675640853551,2.826359146448909e-05
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Early recovery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,372.0,241.0,0.018817,0.018817,5.921578,0.631708,1.0,372.0,14.0,114.0,"Adverse event, non-fatal",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07038886,0.07033647372759926,5.238627240074234e-05
5.0,372.0,241.0,0.013441,0.013441,5.921578,0.631708,1.0,372.0,14.0,114.0,"Adverse event, non-fatal",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05027883,0.05038141210755952,0.00010258210755952069
0.0,372.0,241.0,0.0,0.0,5.921578,0.631708,1.0,372.0,14.0,114.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,372.0,241.0,0.005376,0.005376,5.921578,0.631708,1.0,372.0,14.0,114.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02011004,0.02044690834278767,0.00033686834278767036
798.0,25673.0,23940.0,0.031083,0.031083,10.153234,0.314283,1.0,25673.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.09918557,0.09470198459705348,0.004483585402946522
732.0,25673.0,23940.0,0.028512,0.028512,10.153234,0.314283,1.0,25673.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.09098153,0.08806607357470224,0.002915456425297766
108.0,25673.0,23940.0,0.004207,0.004207,10.153234,0.314283,1.0,25673.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.0134245,0.012488411130525803,0.0009360888694741974
95.0,25673.0,23940.0,0.0037,0.0037,10.153234,0.314283,1.0,25673.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01180667,0.010887927762053572,0.0009187422379464284
24.0,8232.0,6036.0,0.002915,0.002915,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01646087,0.01609958255255956,0.00036128744744044067
21.0,8232.0,6036.0,0.002551,0.002551,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01440538,0.013800565722232145,0.000604814277767856
26.0,8232.0,6036.0,0.003158,0.003158,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01783308,0.017106534660744067,0.0007265453392559344
20.0,8232.0,6036.0,0.00243,0.00243,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01372209,0.013773587777113095,5.14977771130954e-05
1054.0,8232.0,6036.0,0.128037,0.128037,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.72301883,0.6970413383256145,0.025977491674385456
1051.0,8232.0,6036.0,0.127672,0.127672,9.015906,0.626332,1.0,8256.0,36.0,1033.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.72095769,0.697756964121716,0.023200725878284034
13.0,429.0,136.0,0.030303,0.030303,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.16922182,0.1665844228087499,0.002637397191250085
11.0,429.0,136.0,0.025641,0.025641,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.14318769,0.1433783203094343,0.00019063030943428094
17.0,429.0,136.0,0.039627,0.039627,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.22129007,0.2140656421308828,0.0072244278691172
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,429.0,136.0,0.011655,0.011655,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.06508531,0.06485193035328567,0.00023337964671432676
6.0,429.0,136.0,0.013986,0.013986,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.07810238,0.07608102879657734,0.0020213512034226583
10.0,429.0,136.0,0.02331,0.02331,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.13017063,0.1294985783293154,0.000672051670684598
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.01301706,0.012993552605535778,2.350739446422244e-05
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,COVID-19 logistical restrictions,Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.02603413,0.0260958422795734,6.171227957340111e-05
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,429.0,136.0,0.011655,0.011655,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.06508531,0.06485193035328567,0.00023337964671432676
5.0,429.0,136.0,0.011655,0.011655,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.06508531,0.06429944564481344,0.000785864355186558
5.0,429.0,136.0,0.011655,0.011655,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.06508531,0.064394491051619,0.0006908189483809946
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG002,cardiovascular disease,INDUSTRY,0.01301706,0.013001907090119114,1.5152909880886828e-05
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Did not receive randomized study drug,Period 1 (Baseline - Week 52),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
19.0,429.0,136.0,0.044289,0.044289,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.24732419,0.24549879276374986,0.001825397236250137
11.0,429.0,136.0,0.025641,0.025641,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.14318769,0.1429880432569343,0.00019964674306571784
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.02603413,0.026041834621775773,7.704621775773968e-06
27.0,429.0,136.0,0.062937,0.062937,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.35146069,0.34739893028778757,0.004061759712212454
8.0,429.0,136.0,0.018648,0.018648,6.063785,0.920931,1.0,438.0,24.0,172.0,Ongoing in Period 2,Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.1041365,0.10777609028186504,0.0036395902818650294
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.01301706,0.013017403826785784,3.4382678578380454e-07
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.01301706,0.013015671726785784,1.388273214216612e-06
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.02603413,0.02603293531302577,1.1946869742304744e-06
4.0,429.0,136.0,0.009324,0.009324,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.05206825,0.05353345101825409,0.001465201018254085
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,Adverse Event,Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.02603413,0.026037924185942446,3.794185942446876e-06
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.01301706,0.013014873476785784,2.1865232142162516e-06
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.01301706,0.013015521864285784,1.5381357142164875e-06
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,Withdrew consent,Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.02603413,0.02604682349469245,1.2693494692451318e-05
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.01301706,0.013014217869285782,2.842130714218391e-06
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Lost to Follow-up,Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.01301706,0.013020011851785784,2.9518517857835685e-06
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,Failure to meet continuation criteria,Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,429.0,136.0,0.004662,0.004662,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG003,cardiovascular disease,INDUSTRY,0.02603413,0.026050393415823412,1.6263415823412897e-05
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,429.0,136.0,0.0,0.0,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG006,cardiovascular disease,INDUSTRY,0.01301706,0.013016468426785784,5.915732142168506e-07
1.0,429.0,136.0,0.002331,0.002331,6.063785,0.920931,1.0,438.0,24.0,172.0,"Other, not specified",Period 2 (Week 52 - Week 104),FG007,cardiovascular disease,INDUSTRY,0.01301706,0.013014087939285783,2.9720607142170313e-06
53.0,1061.0,852.0,0.049953,0.049953,6.967909,0.230287,1.0,1061.0,39.0,211.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08015564,0.08344994806425599,0.003294308064255985
28.0,1061.0,852.0,0.02639,0.02639,6.967909,0.230287,1.0,1061.0,39.0,211.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04234595,0.0425396660548115,0.00019371605481149912
0.0,1061.0,852.0,0.0,0.0,6.967909,0.230287,1.0,1061.0,39.0,211.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1061.0,852.0,0.000943,0.000943,6.967909,0.230287,1.0,1061.0,39.0,211.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00151316,0.0015357013472123047,2.254134721230475e-05
5.0,1061.0,852.0,0.004713,0.004713,6.967909,0.230287,1.0,1061.0,39.0,211.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00756258,0.007705341442053573,0.0001427614420535725
2.0,1061.0,852.0,0.001885,0.001885,6.967909,0.230287,1.0,1061.0,39.0,211.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00302471,0.0030365206489484154,1.1810648948415523e-05
2.0,1061.0,852.0,0.001885,0.001885,6.967909,0.230287,1.0,1061.0,39.0,211.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00302471,0.0030427509012400816,1.804090124008168e-05
0.0,1061.0,852.0,0.0,0.0,6.967909,0.230287,1.0,1061.0,39.0,211.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1061.0,852.0,0.000943,0.000943,6.967909,0.230287,1.0,1061.0,39.0,211.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00151316,0.0015386484320337325,2.5488432033732517e-05
2.0,1061.0,852.0,0.001885,0.001885,6.967909,0.230287,1.0,1061.0,39.0,211.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00302471,0.003036120630198416,1.1410630198415914e-05
18.0,1061.0,852.0,0.016965,0.016965,6.967909,0.230287,1.0,1061.0,39.0,211.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0272224,0.027623071873740072,0.0004006718737400716
4.0,1061.0,852.0,0.00377,0.00377,6.967909,0.230287,1.0,1061.0,39.0,211.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00604942,0.006072012731488092,2.259273148809242e-05
21.0,1061.0,852.0,0.019793,0.019793,6.967909,0.230287,1.0,1061.0,39.0,211.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03176027,0.03211726328768847,0.00035699328768847016
21.0,1061.0,852.0,0.019793,0.019793,6.967909,0.230287,1.0,1061.0,39.0,211.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03176027,0.03205172034310514,0.0002914503431051402
31.0,1061.0,852.0,0.029218,0.029218,6.967909,0.230287,1.0,1061.0,39.0,211.0,Most due to osteomylitis status,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04688382,0.04758926163117064,0.0007054416311706377
20.0,1061.0,852.0,0.01885,0.01885,6.967909,0.230287,1.0,1061.0,39.0,211.0,Most due to osteomylitis status,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03024711,0.02978098577963294,0.0004661242203670597
12.0,721.0,603.0,0.016644,0.016644,6.582025,0.281906,1.0,721.0,15.0,64.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03088318,0.031737892796696435,0.000854712796696435
3.0,721.0,603.0,0.004161,0.004161,6.582025,0.281906,1.0,721.0,15.0,64.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0077208,0.0076392478798114945,8.155212018850534e-05
14.0,721.0,603.0,0.019417,0.019417,6.582025,0.281906,1.0,721.0,15.0,64.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03602852,0.035246648084474204,0.0007818719155257975
3.0,721.0,603.0,0.004161,0.004161,6.582025,0.281906,1.0,721.0,15.0,64.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0077208,0.0076327037970734014,8.809620292659845e-05
4.0,721.0,603.0,0.005548,0.005548,6.582025,0.281906,1.0,721.0,15.0,64.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01029439,0.010338956471359123,4.4566471359122964e-05
5.0,721.0,603.0,0.006935,0.006935,6.582025,0.281906,1.0,721.0,15.0,64.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01286799,0.012886691557052677,1.870155705267773e-05
31.0,721.0,603.0,0.042996,0.042996,6.582025,0.281906,1.0,721.0,15.0,64.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0797797,0.07998210649605161,0.00020240649605161865
20.0,721.0,603.0,0.027739,0.027739,6.582025,0.281906,1.0,721.0,15.0,64.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05147011,0.05089895010690478,0.0005711598930952175
25.0,721.0,603.0,0.034674,0.034674,6.582025,0.281906,1.0,721.0,15.0,64.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.06433811,0.06331823642470868,0.001019873575291319
0.0,721.0,603.0,0.0,0.0,6.582025,0.281906,1.0,721.0,15.0,64.0,Re-transplant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,721.0,603.0,0.0,0.0,6.582025,0.281906,1.0,721.0,15.0,64.0,Re-transplant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,721.0,603.0,0.001387,0.001387,6.582025,0.281906,1.0,721.0,15.0,64.0,Re-transplant,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0025736,0.0026034028382305196,2.9802838230519497e-05
12.0,1000.0,720.0,0.012,0.012,6.908755,0.79773,1.0,1000.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.06613586,0.06660229391387897,0.0004664339138789608
10.0,1000.0,720.0,0.01,0.01,6.908755,0.79773,1.0,1000.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.05511322,0.05494319287675595,0.00017002712324405006
17.0,1000.0,720.0,0.017,0.017,6.908755,0.79773,1.0,1000.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.09369247,0.09297413494212303,0.0007183350578769676
21.0,1000.0,720.0,0.021,0.021,6.908755,0.79773,1.0,1000.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,OTHER,0.11573775,0.1116379527821924,0.004099797217807594
46.0,1000.0,720.0,0.046,0.046,6.908755,0.79773,1.0,1000.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.25352079,0.25018248839184537,0.0033383016081546257
34.0,1000.0,720.0,0.034,0.034,6.908755,0.79773,1.0,1000.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.18738493,0.18811707988244064,0.0007321498824406358
35.0,1000.0,720.0,0.035,0.035,6.908755,0.79773,1.0,1000.0,1.0,1.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.19289626,0.19361169391305558,0.0007154339130555631
43.0,1000.0,720.0,0.043,0.043,6.908755,0.79773,1.0,1000.0,1.0,1.0,Death,Overall Study,FG003,cardiovascular disease,OTHER,0.23698683,0.2362434401339384,0.0007433898660616223
17.0,1000.0,720.0,0.017,0.017,6.908755,0.79773,1.0,1000.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.09369247,0.09288577628591277,0.000806693714087231
18.0,1000.0,720.0,0.018,0.018,6.908755,0.79773,1.0,1000.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.09920379,0.09884877552865066,0.0003550144713493353
16.0,1000.0,720.0,0.016,0.016,6.908755,0.79773,1.0,1000.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.08818115,0.08884368218679564,0.0006625321867956419
11.0,1000.0,720.0,0.011,0.011,6.908755,0.79773,1.0,1000.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,OTHER,0.06062454,0.05982222565556545,0.0008023143444345487
53.0,504.0,339.0,0.105159,0.105159,6.224558,0.222179,1.0,504.0,23.0,23.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14543135,0.14952858390502427,0.004097233905024283
14.0,504.0,339.0,0.027778,0.027778,6.224558,0.222179,1.0,504.0,23.0,23.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03841604,0.03841811076782744,2.0707678274403674e-06
32.0,504.0,339.0,0.063492,0.063492,6.224558,0.222179,1.0,504.0,23.0,23.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0878073,0.08648134553581349,0.0013259544641865129
45.0,504.0,339.0,0.089286,0.089286,6.224558,0.222179,1.0,504.0,23.0,23.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12347953,0.1339821346713393,0.010502604671339288
6.0,504.0,339.0,0.011905,0.011905,6.224558,0.222179,1.0,504.0,23.0,23.0,Poor compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01646421,0.016417957326904768,4.625267309523243e-05
2.0,504.0,339.0,0.003968,0.003968,6.224558,0.222179,1.0,504.0,23.0,23.0,Poor compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00548761,0.005439746583571429,4.786341642857173e-05
5.0,504.0,339.0,0.009921,0.009921,6.224558,0.222179,1.0,504.0,23.0,23.0,Not coded/ Not pre-specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01372041,0.013885560247777786,0.00016515024777778546
8.0,504.0,339.0,0.015873,0.015873,6.224558,0.222179,1.0,504.0,23.0,23.0,Not coded/ Not pre-specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02195182,0.021798094820297615,0.0001537251797023853
72.0,336.0,136.0,0.214286,0.214286,5.820083,0.211174,1.0,336.0,1.0,1.0,"Sponsor Termination of Study, etc.",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.26336875,0.2918318849121809,0.028463134912180943
16.0,336.0,136.0,0.047619,0.047619,5.820083,0.211174,1.0,336.0,1.0,1.0,"Sponsor Termination of Study, etc.",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05852625,0.058713674687003975,0.00018742468700397308
30.0,336.0,136.0,0.089286,0.089286,5.820083,0.211174,1.0,336.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10973718,0.11033544696631047,0.0005982669663104623
16.0,336.0,136.0,0.047619,0.047619,5.820083,0.211174,1.0,336.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05852625,0.05866507386617064,0.0001388238661706384
22.0,336.0,136.0,0.065476,0.065476,5.820083,0.211174,1.0,336.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08047344,0.08057736303212307,0.00010392303212307386
12.0,336.0,136.0,0.035714,0.035714,5.820083,0.211174,1.0,336.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04389438,0.04665400106559523,0.0027596210655952344
14.0,336.0,136.0,0.041667,0.041667,5.820083,0.211174,1.0,336.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05121093,0.052014090538829355,0.0008031605388293533
5.0,336.0,136.0,0.014881,0.014881,5.820083,0.211174,1.0,336.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01828953,0.018018752737559526,0.00027077726244047196
4.0,336.0,136.0,0.011905,0.011905,5.820083,0.211174,1.0,336.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01463187,0.01461419223089288,1.767776910712067e-05
7.0,336.0,136.0,0.020833,0.020833,5.820083,0.211174,1.0,336.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02560485,0.025679817394355178,7.496739435517916e-05
2.0,336.0,136.0,0.005952,0.005952,5.820083,0.211174,1.0,336.0,1.0,1.0,Treatment Failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00731532,0.007508709625426585,0.00019338962542658506
0.0,336.0,136.0,0.0,0.0,5.820083,0.211174,1.0,336.0,1.0,1.0,Treatment Failure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,10010.0,9963.0,0.000999,0.000999,9.21144,0.382,1.0,10010.0,23.0,23.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00351525,0.003507573142331345,7.676857668655144e-06
10.0,10010.0,9963.0,0.000999,0.000999,9.21144,0.382,1.0,10010.0,23.0,23.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00351525,0.003519505807926583,4.255807926582724e-06
6.0,10010.0,9963.0,0.000599,0.000599,9.21144,0.382,1.0,10010.0,23.0,23.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.00210774,0.001952872505863097,0.00015486749413690278
10.0,10010.0,9963.0,0.000999,0.000999,9.21144,0.382,1.0,10010.0,23.0,23.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,OTHER,0.00351525,0.0035103499606646774,4.900039335322716e-06
1.0,10010.0,9963.0,0.0001,0.0001,9.21144,0.382,1.0,10010.0,23.0,23.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.00035188,0.0002938841257440479,5.7995874255952113e-05
2.0,10010.0,9963.0,0.0002,0.0002,9.21144,0.382,1.0,10010.0,23.0,23.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00070375,0.000596787947708334,0.00010696205229166595
5.0,10010.0,9963.0,0.0005,0.0005,9.21144,0.382,1.0,10010.0,23.0,23.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.00175938,0.001728948711011904,3.0431288988096074e-05
3.0,10010.0,9963.0,0.0003,0.0003,9.21144,0.382,1.0,10010.0,23.0,23.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,OTHER,0.00105563,0.0010167064214087304,3.8923578591269466e-05
22.0,2492.0,2116.0,0.008828,0.008828,7.821242,0.245822,1.0,2500.0,2.0,232.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.016973,0.016845492004831337,0.00012750799516866168
46.0,2492.0,2116.0,0.018459,0.018459,7.821242,0.245822,1.0,2500.0,2.0,232.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03548986,0.03583713453041667,0.0003472745304166705
38.0,2492.0,2116.0,0.015249,0.015249,7.821242,0.245822,1.0,2500.0,2.0,232.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02931822,0.028702074698601185,0.0006161453013988141
48.0,2492.0,2116.0,0.019262,0.019262,7.821242,0.245822,1.0,2500.0,2.0,232.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.03703374,0.036747972123908734,0.00028576787609126825
15.0,2492.0,2116.0,0.006019,0.006019,7.821242,0.245822,1.0,2500.0,2.0,232.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01157232,0.011580445460575411,8.125460575410595e-06
17.0,2492.0,2116.0,0.006822,0.006822,7.821242,0.245822,1.0,2500.0,2.0,232.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0131162,0.012867765864255944,0.0002484341357440554
21.0,2492.0,2116.0,0.008427,0.008427,7.821242,0.245822,1.0,2500.0,2.0,232.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01620202,0.016151527735367058,5.0492264632943235e-05
26.0,2492.0,2116.0,0.010433,0.010433,7.821242,0.245822,1.0,2500.0,2.0,232.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02005882,0.019804173127182547,0.00025464687281745446
11.0,2492.0,2116.0,0.004414,0.004414,7.821242,0.245822,1.0,2500.0,2.0,232.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0084865,0.008505120693809516,1.8620693809517225e-05
13.0,2492.0,2116.0,0.005217,0.005217,7.821242,0.245822,1.0,2500.0,2.0,232.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01003037,0.009798052738353175,0.00023231726164682498
9.0,2492.0,2116.0,0.003612,0.003612,7.821242,0.245822,1.0,2500.0,2.0,232.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00694455,0.006872736073313487,7.181392668651268e-05
8.0,2492.0,2116.0,0.00321,0.00321,7.821242,0.245822,1.0,2500.0,2.0,232.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00617165,0.006139250752621752,3.239924737824789e-05
20.0,2492.0,2116.0,0.008026,0.008026,7.821242,0.245822,1.0,2500.0,2.0,232.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01543104,0.015645214384255948,0.0002141743842559475
21.0,2492.0,2116.0,0.008427,0.008427,7.821242,0.245822,1.0,2500.0,2.0,232.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01620202,0.016120846048234126,8.11739517658748e-05
19.0,2492.0,2116.0,0.007624,0.007624,7.821242,0.245822,1.0,2500.0,2.0,232.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01465815,0.01451595433030754,0.00014219566969246068
23.0,2492.0,2116.0,0.00923,0.00923,7.821242,0.245822,1.0,2500.0,2.0,232.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01774589,0.017464212897966257,0.0002816771020337436
3.0,2492.0,2116.0,0.001204,0.001204,7.821242,0.245822,1.0,2500.0,2.0,232.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00231485,0.0023076447402543294,7.20525974567043e-06
9.0,2492.0,2116.0,0.003612,0.003612,7.821242,0.245822,1.0,2500.0,2.0,232.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00694455,0.006890702032837298,5.3847967162701585e-05
1.0,2492.0,2116.0,0.000401,0.000401,7.821242,0.245822,1.0,2500.0,2.0,232.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00077098,0.0007731964189087304,2.216418908730384e-06
6.0,2492.0,2116.0,0.002408,0.002408,7.821242,0.245822,1.0,2500.0,2.0,232.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0046297,0.004621411958511906,8.288041488093735e-06
1.0,315.0,312.0,0.003175,0.003175,5.755742,0.307494,1.0,317.0,13.0,70.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00561929,0.005674262818363093,5.4972818363092923e-05
2.0,315.0,312.0,0.006349,0.006349,5.755742,0.307494,1.0,317.0,13.0,70.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01123682,0.011431008740138892,0.00019418874013889253
47.0,2568.0,2327.0,0.018302,0.018302,7.851272,1.0,1.0,2589.0,31.0,220.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14369398,0.1426937057916442,0.0010002742083558003
44.0,2568.0,2327.0,0.017134,0.017134,7.851272,1.0,1.0,2589.0,31.0,220.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13452369,0.13043214509152798,0.004091544908472022
31.0,2568.0,2327.0,0.012072,0.012072,7.851272,1.0,1.0,2589.0,31.0,220.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09478056,0.09441164828555552,0.00036891171444447535
26.0,2568.0,2327.0,0.010125,0.010125,7.851272,1.0,1.0,2589.0,31.0,220.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07949413,0.07860100050503696,0.0008931294949630353
11.0,2568.0,2327.0,0.004283,0.004283,7.851272,1.0,1.0,2589.0,31.0,220.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.033627,0.03340847418592258,0.00021852581407741378
6.0,2568.0,2327.0,0.002336,0.002336,7.851272,1.0,1.0,2589.0,31.0,220.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01834057,0.01819811718791668,0.00014245281208332197
32.0,2568.0,2327.0,0.012461,0.012461,7.851272,1.0,1.0,2589.0,31.0,220.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0978347,0.09728535178037685,0.0005493482196231442
39.0,2568.0,2327.0,0.015187,0.015187,7.851272,1.0,1.0,2589.0,31.0,220.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11923727,0.11757546772189573,0.0016618022781042796
4.0,2568.0,2327.0,0.001558,0.001558,7.851272,1.0,1.0,2589.0,31.0,220.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01223228,0.012154656503045636,7.76234969543637e-05
1.0,2568.0,2327.0,0.000389,0.000389,7.851272,1.0,1.0,2589.0,31.0,220.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00305414,0.0030230973560416655,3.104264395833436e-05
5.0,705.0,361.0,0.007092,0.007092,6.559615,0.730481,1.0,705.0,7.0,147.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03398253,0.033630432640039655,0.0003520973599603419
10.0,705.0,361.0,0.014184,0.014184,6.559615,0.730481,1.0,705.0,7.0,147.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06796507,0.06740223458969254,0.0005628354103074662
24.0,705.0,361.0,0.034043,0.034043,6.559615,0.730481,1.0,705.0,7.0,147.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16312287,0.16707672805705354,0.003953858057053533
22.0,705.0,361.0,0.031206,0.031206,6.559615,0.730481,1.0,705.0,7.0,147.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1495289,0.14961971614476186,9.081614476186273e-05
142.0,705.0,361.0,0.201418,0.201418,6.559615,0.730481,1.0,705.0,7.0,147.0,Reason not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.96512889,0.9734647937183931,0.0083359037183931
141.0,705.0,361.0,0.2,0.2,6.559615,0.730481,1.0,705.0,7.0,147.0,Reason not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.9583343,0.965057854910863,0.006723554910863072
35.0,2694.0,1539.0,0.012992,0.012992,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.02397813,0.024409500565753976,0.0004313705657539753
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
38.0,2694.0,1539.0,0.014105,0.014105,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.02603229,0.026030687993690457,1.6020063095430193e-06
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory value(s),Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
810.0,2694.0,1539.0,0.300668,0.300668,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.55491494,0.5892966741586613,0.0343817341586613
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure result(s),Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
86.0,2694.0,1539.0,0.031923,0.031923,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.05891731,0.05901783679473213,0.00010052679473213089
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,2694.0,1539.0,0.00631,0.00631,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.01164578,0.011659858781339287,1.4078781339287375e-05
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,2694.0,1539.0,0.004454,0.004454,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00822033,0.008126106969464291,9.422303053570856e-05
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,2694.0,1539.0,0.004083,0.004083,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00753561,0.007560817823501983,2.520782350198293e-05
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Single-blind Period (2 to 4 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00205601,0.0020505217054464266,5.48829455357348e-06
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00205601,0.002051380700565474,4.629299434526137e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00068472,0.0006875439708730183,2.8239708730182613e-06
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.00136944,0.0013689182702976233,5.217297023767196e-07
7.0,2694.0,1539.0,0.002598,0.002598,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00479489,0.004779205305357149,1.568469464285037e-05
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.00205601,0.0020547277034821407,1.2822965178593305e-06
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00274073,0.0027454149379166582,4.684937916658426e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00068472,0.0006845517783730182,1.6822162698178385e-07
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Adverse Event,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.00274073,0.0027454149379166582,4.684937916658426e-06
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00068472,0.0006845219390873038,1.9806091269619283e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00068472,0.0006845998724206372,1.2012757936281059e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal laboratory values,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00068472,0.0006835726754563514,1.1473245436486364e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00068472,0.0006847497753968274,2.977539682738964e-08
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Abnormal test procedure results,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,2694.0,1539.0,0.00631,0.00631,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.01164578,0.011653131940297618,7.351940297618473e-06
8.0,2694.0,1539.0,0.00297,0.00297,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00548145,0.005504100011498012,2.265001149801254e-05
8.0,2694.0,1539.0,0.00297,0.00297,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00548145,0.005501998757271822,2.054875727182208e-05
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.00274073,0.0027526761473214197,1.1946147321419912e-05
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00136944,0.0013690848298214332,3.5517017856682813e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.00136944,0.0013689305289880996,5.094710119003722e-07
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00068472,0.0006845456660714308,1.7433392856917862e-07
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00068472,0.0006845931565476213,1.268434523787193e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Unsatisfactory therapeutic effect,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.00136944,0.0013689157339880995,5.242660119004518e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00068472,0.0006875439708730183,2.8239708730182613e-06
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient no longer needs study drug,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00274073,0.0027399400399999918,7.899600000080449e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00136944,0.0013686478028571464,7.921971428535846e-07
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00274073,0.002743044530119036,2.3145301190361303e-06
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.00205601,0.0020536024447916647,2.407555208335313e-06
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00274073,0.002742038927261894,1.308927261894216e-06
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.00274073,0.002742553273095227,1.823273095227177e-06
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00205601,0.0020536127547916643,2.3972452083357437e-06
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00136944,0.0013685262462500036,9.137537499964016e-07
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Patient withdrew consent,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.00274073,0.00274205379392856,1.32379392856017e-06
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00136944,0.0013697208681547654,2.808681547653794e-07
4.0,2694.0,1539.0,0.001485,0.001485,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00274073,0.0027479619085118956,7.2319085118958265e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.00068472,0.0006845777962301608,1.4220376983917725e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00136944,0.0013697998227380995,3.5982273809955986e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.00136944,0.001369655609404766,2.1560940476604042e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00205601,0.002048946830863093,7.063169136907032e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Lost to Follow-up,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.00068472,0.0006845777962301608,1.4220376983917725e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00068472,0.0006845042878968277,2.1571210317224317e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,Administrative problems,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2694.0,1539.0,0.001856,0.001856,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00342545,0.0034501289985714254,2.46789985714254e-05
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00205601,0.0020519955840773785,4.014415922621532e-06
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.00068472,0.0006875439708730183,2.8239708730182613e-06
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.00136944,0.001368984044821433,4.5595517856700067e-07
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.00205601,0.0020552521369940455,7.578630059545607e-07
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.00068472,0.0006844738450396848,2.461549603151661e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00136944,0.0013685584770238134,8.815229761865474e-07
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.00136944,0.0013683938807738133,1.0461192261866387e-06
3.0,2694.0,1539.0,0.001114,0.001114,7.899153,0.233646,1.0,2694.0,18.0,18.0,Protocol deviation,Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.00205601,0.0020552521369940455,7.578630059545607e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2694.0,1539.0,0.000371,0.000371,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00068472,0.0006847497753968274,2.977539682738964e-08
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2694.0,1539.0,0.000742,0.000742,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG006,cardiovascular disease,INDUSTRY,0.00136944,0.0013684927025000037,9.472974999962663e-07
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2694.0,1539.0,0.0,0.0,7.899153,0.233646,1.0,2694.0,18.0,18.0,"Discont. single-blind, Mis- randomized",Double-blind:Randomized Period (8 Weeks),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,530.0,410.0,0.022642,0.022642,6.274762,0.666365,1.0,530.0,15.0,118.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09467252,0.09544515454881942,0.0007726345488194286
17.0,530.0,410.0,0.032075,0.032075,6.274762,0.666365,1.0,530.0,15.0,118.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13411452,0.1299899865692342,0.004124533430765798
6.0,530.0,410.0,0.011321,0.011321,6.274762,0.666365,1.0,530.0,15.0,118.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04733626,0.04684337574455359,0.0004928842554464061
2.0,530.0,410.0,0.003774,0.003774,6.274762,0.666365,1.0,530.0,15.0,118.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01578015,0.01607033554589283,0.0002901855458928293
34.0,530.0,410.0,0.064151,0.064151,6.274762,0.666365,1.0,530.0,15.0,118.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.26823323,0.28185383976159756,0.013620609761597569
23.0,530.0,410.0,0.043396,0.043396,6.274762,0.666365,1.0,530.0,15.0,118.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18145078,0.18186753521564383,0.000416755215643827
1.0,530.0,410.0,0.001887,0.001887,6.274762,0.666365,1.0,530.0,15.0,118.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00789007,0.007970711538740089,8.064153874008835e-05
5.0,530.0,410.0,0.009434,0.009434,6.274762,0.666365,1.0,530.0,15.0,118.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03944619,0.03858321067395833,0.0008629793260416657
10.0,530.0,410.0,0.018868,0.018868,6.274762,0.666365,1.0,530.0,15.0,118.0,Other reason not stated above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07889237,0.07976317533141854,0.0008708053314185338
10.0,530.0,410.0,0.018868,0.018868,6.274762,0.666365,1.0,530.0,15.0,118.0,Other reason not stated above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07889237,0.07993102242836299,0.001038652428362985
993.0,14236.0,9248.0,0.069753,0.069753,9.563599,0.262342,1.0,14269.0,44.0,932.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17500564,0.16246694888615804,0.012538691113841954
919.0,14236.0,9248.0,0.064555,0.064555,9.563599,0.262342,1.0,14269.0,44.0,932.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16196421,0.14339782063170645,0.01856638936829355
134.0,14236.0,9248.0,0.009413,0.009413,9.563599,0.262342,1.0,14269.0,44.0,932.0,Non-compliant with study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02361659,0.02301686636356153,0.0005997236364384713
164.0,14236.0,9248.0,0.01152,0.01152,9.563599,0.262342,1.0,14269.0,44.0,932.0,Non-compliant with study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02890291,0.026681752527619028,0.0022211574723809725
671.0,14236.0,9248.0,0.047134,0.047134,9.563599,0.262342,1.0,14269.0,44.0,932.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11825607,0.11456387727009477,0.0036921927299052304
673.0,14236.0,9248.0,0.047275,0.047275,9.563599,0.262342,1.0,14269.0,44.0,932.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11860983,0.11478441074271382,0.003825419257286175
191.0,14236.0,9248.0,0.013417,0.013417,9.563599,0.262342,1.0,14269.0,44.0,932.0,Investigator dec./not protocol-related,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03366236,0.0325775709160913,0.001084789083908702
178.0,14236.0,9248.0,0.012504,0.012504,9.563599,0.262342,1.0,14269.0,44.0,932.0,Investigator dec./not protocol-related,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03137171,0.030234245893908725,0.0011374641060912724
6.0,14236.0,9248.0,0.000421,0.000421,9.563599,0.262342,1.0,14269.0,44.0,932.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00105626,0.0010354361658928576,2.0823834107142405e-05
8.0,14236.0,9248.0,0.000562,0.000562,9.563599,0.262342,1.0,14269.0,44.0,932.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00141002,0.0013978634071130961,1.215659288690378e-05
142.0,14236.0,9248.0,0.009975,0.009975,9.563599,0.262342,1.0,14269.0,44.0,932.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02502661,0.024368401552202375,0.0006582084477976258
124.0,14236.0,9248.0,0.00871,0.00871,9.563599,0.262342,1.0,14269.0,44.0,932.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02185281,0.021212256503144858,0.0006405534968551424
300.0,14236.0,9248.0,0.021073,0.021073,9.563599,0.262342,1.0,14269.0,44.0,932.0,Clinical efficacy endpoint reached,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05287076,0.047955095038422574,0.004915664961577429
332.0,14236.0,9248.0,0.023321,0.023321,9.563599,0.262342,1.0,14269.0,44.0,932.0,Clinical efficacy endpoint reached,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05851084,0.05380285798398807,0.004707982016011934
82.0,14236.0,9248.0,0.00576,0.00576,9.563599,0.262342,1.0,14269.0,44.0,932.0,Study terminated by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01445146,0.014195500789722235,0.000255959210277764
69.0,14236.0,9248.0,0.004847,0.004847,9.563599,0.262342,1.0,14269.0,44.0,932.0,Study terminated by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0121608,0.012010232937448597,0.00015056706255140231
1.0,14236.0,9248.0,7e-05,7e-05,9.563599,0.262342,1.0,14269.0,44.0,932.0,Missing/incomplete data,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00017563,0.00020049015489087324,2.4860154890873242e-05
1.0,14236.0,9248.0,7e-05,7e-05,9.563599,0.262342,1.0,14269.0,44.0,932.0,Missing/incomplete data,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00017563,0.0002044861349476915,2.8856134947691513e-05
4.0,998.0,878.0,0.004008,0.004008,6.906755,0.553469,1.0,998.0,16.0,153.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01532129,0.01534094782166672,1.9657821666720088e-05
2.0,998.0,878.0,0.002004,0.002004,6.906755,0.553469,1.0,998.0,16.0,153.0,Lack of treatment efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00766064,0.007809091835982146,0.00014845183598214632
1.0,998.0,878.0,0.001002,0.001002,6.906755,0.553469,1.0,998.0,16.0,153.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00383032,0.0038943767413690557,6.405674136905582e-05
39.0,998.0,878.0,0.039078,0.039078,6.906755,0.553469,1.0,998.0,16.0,153.0,Participant did not wish to continue,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14938258,0.1496246396657539,0.00024205966575391313
41.0,998.0,878.0,0.041082,0.041082,6.906755,0.553469,1.0,998.0,16.0,153.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15704322,0.1591571172876586,0.002113897287658595
3.0,998.0,878.0,0.003006,0.003006,6.906755,0.553469,1.0,998.0,16.0,153.0,Poor compliance to study protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01149097,0.011452618626428584,3.8351373571415825e-05
6.0,998.0,878.0,0.006012,0.006012,6.906755,0.553469,1.0,998.0,16.0,153.0,Sponsor decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02298193,0.02292923101352184,5.2698986478159904e-05
5.0,998.0,878.0,0.00501,0.00501,6.906755,0.553469,1.0,998.0,16.0,153.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01915161,0.01893155626265338,0.0002200537373466191
5.0,998.0,878.0,0.00501,0.00501,6.906755,0.553469,1.0,998.0,16.0,153.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01915161,0.018951846556934524,0.0001997634430654753
4.0,998.0,878.0,0.004008,0.004008,6.906755,0.553469,1.0,998.0,16.0,153.0,Study ended treatment not available,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01532129,0.015348065964722277,2.6775964722277473e-05
4.0,998.0,878.0,0.004008,0.004008,6.906755,0.553469,1.0,998.0,16.0,153.0,Switched to commercial drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01532129,0.015348065964722277,2.6775964722277473e-05
1.0,998.0,878.0,0.001002,0.001002,6.906755,0.553469,1.0,998.0,16.0,153.0,Excluded from study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00383032,0.0038943767413690557,6.405674136905582e-05
1.0,998.0,878.0,0.001002,0.001002,6.906755,0.553469,1.0,998.0,16.0,153.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00383032,0.0038943767413690557,6.405674136905582e-05
4.0,998.0,878.0,0.004008,0.004008,6.906755,0.553469,1.0,998.0,16.0,153.0,Enrolled but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01532129,0.015348065964722277,2.6775964722277473e-05
3.0,768.0,204.0,0.003906,0.003906,6.645091,0.401525,1.0,767.0,34.0,210.0,Abnormal test proceedure results,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01042187,0.010124783743918642,0.00029708625608135773
8.0,768.0,204.0,0.010417,0.010417,6.645091,0.401525,1.0,767.0,34.0,210.0,Abnormal test proceedure results,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02779433,0.027493781825329168,0.00030054817467083106
2.0,768.0,204.0,0.002604,0.002604,6.645091,0.401525,1.0,767.0,34.0,210.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00694791,0.006991031793067286,4.312179306728645e-05
1.0,768.0,204.0,0.001302,0.001302,6.645091,0.401525,1.0,767.0,34.0,210.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00347396,0.003500619187797617,2.6659187797616925e-05
130.0,768.0,204.0,0.169271,0.169271,6.645091,0.401525,1.0,767.0,34.0,210.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.45164381,0.4685335656244045,0.016889755624404534
66.0,768.0,204.0,0.085938,0.085938,6.645091,0.401525,1.0,767.0,34.0,210.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.22929719,0.2329384512411906,0.003641261241190602
21.0,768.0,204.0,0.027344,0.027344,6.645091,0.401525,1.0,767.0,34.0,210.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07295844,0.07388174708998467,0.0009233070899846707
17.0,768.0,204.0,0.022135,0.022135,6.645091,0.401525,1.0,767.0,34.0,210.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05905994,0.05923777165029759,0.0001778316502975899
82.0,768.0,204.0,0.106771,0.106771,6.645091,0.401525,1.0,767.0,34.0,210.0,Disease progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.28488318,0.2869340502579048,0.002050870257904791
153.0,768.0,204.0,0.199219,0.199219,6.645091,0.401525,1.0,767.0,34.0,210.0,Disease progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.53155016,0.5986629936897018,0.06711283368970178
4.0,768.0,204.0,0.005208,0.005208,6.645091,0.401525,1.0,767.0,34.0,210.0,New Cancer therapy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01389583,0.013736899922129321,0.0001589300778706785
7.0,768.0,204.0,0.009115,0.009115,6.645091,0.401525,1.0,767.0,34.0,210.0,New Cancer therapy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02432037,0.02340798672728174,0.0009123832727182604
3.0,768.0,204.0,0.003906,0.003906,6.645091,0.401525,1.0,767.0,34.0,210.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01042187,0.010126520276001978,0.00029534972399802156
4.0,768.0,204.0,0.005208,0.005208,6.645091,0.401525,1.0,767.0,34.0,210.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01389583,0.01371376881492694,0.00018206118507306003
5.0,768.0,204.0,0.00651,0.00651,6.645091,0.401525,1.0,767.0,34.0,210.0,Untreated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01736979,0.016895083387857137,0.00047470661214286253
5.0,768.0,204.0,0.00651,0.00651,6.645091,0.401525,1.0,767.0,34.0,210.0,Untreated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01736979,0.01689878669779761,0.0004710033022023892
1.0,768.0,204.0,0.001302,0.001302,6.645091,0.401525,1.0,767.0,34.0,210.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00347396,0.0034942409939384923,2.02809939384924e-05
0.0,768.0,204.0,0.0,0.0,6.645091,0.401525,1.0,767.0,34.0,210.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
34.0,768.0,204.0,0.044271,0.044271,6.645091,0.401525,1.0,767.0,34.0,210.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11812255,0.11774944700714288,0.00037310299285713
18.0,768.0,204.0,0.023438,0.023438,6.645091,0.401525,1.0,767.0,34.0,210.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06253657,0.06386628951068449,0.0013297195106844878
13.0,210.0,190.0,0.061905,0.061905,5.351858,0.266168,1.0,210.0,2.0,24.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08818338,0.08912080627394842,0.0009374262739484107
5.0,210.0,190.0,0.02381,0.02381,5.351858,0.266168,1.0,210.0,2.0,24.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03391723,0.033839886027599214,7.734397240078544e-05
1.0,210.0,190.0,0.004762,0.004762,5.351858,0.266168,1.0,210.0,2.0,24.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00678345,0.006811363750664672,2.7913750664671985e-05
0.0,210.0,190.0,0.0,0.0,5.351858,0.266168,1.0,210.0,2.0,24.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,210.0,190.0,0.0,0.0,5.351858,0.266168,1.0,210.0,2.0,24.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,210.0,190.0,0.004762,0.004762,5.351858,0.266168,1.0,210.0,2.0,24.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00678345,0.006803257296617054,1.9807296617053993e-05
4.0,1002.0,973.0,0.003992,0.003992,6.910751,0.290259,1.0,1002.0,1.0,65.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00800757,0.008046839120168648,3.9269120168647365e-05
2.0,1002.0,973.0,0.001996,0.001996,6.910751,0.290259,1.0,1002.0,1.0,65.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00400379,0.004014929647083335,1.1139647083335119e-05
9.0,1002.0,973.0,0.008982,0.008982,6.910751,0.290259,1.0,1002.0,1.0,65.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01801704,0.018088077658154785,7.103765815478363e-05
7.0,1002.0,973.0,0.006986,0.006986,6.910751,0.290259,1.0,1002.0,1.0,65.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01401325,0.014111536245108218,9.828624510821796e-05
3.0,1002.0,973.0,0.002994,0.002994,6.910751,0.290259,1.0,1002.0,1.0,65.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00600568,0.006098740358906926,9.306035890692572e-05
3.0,1002.0,973.0,0.002994,0.002994,6.910751,0.290259,1.0,1002.0,1.0,65.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00600568,0.006077992053906924,7.231205390692379e-05
0.0,1002.0,973.0,0.0,0.0,6.910751,0.290259,1.0,1002.0,1.0,65.0,Informed consent not signed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1002.0,973.0,0.000998,0.000998,6.910751,0.290259,1.0,1002.0,1.0,65.0,Informed consent not signed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00200189,0.0020407882133234136,3.8898213323413505e-05
117.0,3876.0,3550.0,0.030186,0.030186,8.262817,0.410585,1.0,3876.0,8.0,183.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.10240872,0.10186806264069428,0.0005406573593057101
110.0,3876.0,3550.0,0.02838,0.02838,8.262817,0.410585,1.0,3876.0,8.0,183.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.09628171,0.09690480062444441,0.0006230906244444057
58.0,3876.0,3550.0,0.014964,0.014964,8.262817,0.410585,1.0,3876.0,8.0,183.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.05076672,0.04927574855076387,0.0014909714492361281
41.0,3876.0,3550.0,0.010578,0.010578,8.262817,0.410585,1.0,3876.0,8.0,183.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.03588682,0.0352637601351136,0.0006230598648864008
1.0,203.0,174.0,0.004926,0.004926,5.31812,0.218985,1.0,203.0,1.0,29.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00573676,0.005801448694821429,6.46886948214298e-05
9.0,203.0,174.0,0.044335,0.044335,5.31812,0.218985,1.0,203.0,1.0,29.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05163204,0.052830707286627004,0.0011986672866270073
1.0,203.0,174.0,0.004926,0.004926,5.31812,0.218985,1.0,203.0,1.0,29.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00573676,0.005802373353154762,6.561335315476233e-05
3.0,203.0,174.0,0.014778,0.014778,5.31812,0.218985,1.0,203.0,1.0,29.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01721029,0.018357306769881,0.001147016769881
15.0,203.0,174.0,0.073892,0.073892,5.31812,0.218985,1.0,203.0,1.0,29.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08605378,0.08750881705375992,0.0014550370537599194
29.0,4833.0,4321.0,0.006,0.006,8.48343,0.292333,1.0,4833.0,39.0,305.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01487992,0.014771275339861107,0.00010864466013889296
21.0,4833.0,4321.0,0.004345,0.004345,8.48343,0.292333,1.0,4833.0,39.0,305.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01077554,0.010852163155168643,7.662315516864318e-05
125.0,4833.0,4321.0,0.025864,0.025864,8.48343,0.292333,1.0,4833.0,39.0,305.0,Study terminated by sponsor,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.06414238,0.06443391248773817,0.0002915324877381664
132.0,4833.0,4321.0,0.027312,0.027312,8.48343,0.292333,1.0,4833.0,39.0,305.0,Study terminated by sponsor,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0677334,0.06787312334684534,0.0001397233468453385
0.0,4833.0,4321.0,0.0,0.0,8.48343,0.292333,1.0,4833.0,39.0,305.0,Site closed by investigator,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Site closed by investigator,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00051336,0.0005136245948214262,2.6459482142620044e-07
7.0,4833.0,4321.0,0.001448,0.001448,8.48343,0.292333,1.0,4833.0,39.0,305.0,Did not take study treatment,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00359102,0.0035986915349007892,7.671534900789354e-06
8.0,4833.0,4321.0,0.001655,0.001655,8.48343,0.292333,1.0,4833.0,39.0,305.0,Did not take study treatment,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00410438,0.004080700875158727,2.3679124841273144e-05
111.0,4833.0,4321.0,0.022967,0.022967,8.48343,0.292333,1.0,4833.0,39.0,305.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.05695786,0.05667755459619049,0.0002803054038095082
92.0,4833.0,4321.0,0.019036,0.019036,8.48343,0.292333,1.0,4833.0,39.0,305.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04720903,0.04772176037347668,0.000512730373476683
23.0,4833.0,4321.0,0.004759,0.004759,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01180226,0.01165718499127436,0.00014507500872563972
30.0,4833.0,4321.0,0.006207,0.006207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01539328,0.015178111269632916,0.00021516873036708448
66.0,4833.0,4321.0,0.013656,0.013656,8.48343,0.292333,1.0,4833.0,39.0,305.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0338667,0.033964616884990084,9.791688499008466e-05
118.0,4833.0,4321.0,0.024415,0.024415,8.48343,0.292333,1.0,4833.0,39.0,305.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.06054888,0.060183300852996086,0.0003655791470039138
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lack of Efficacy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00051336,0.0005134829144642835,1.2291446428345457e-07
4.0,4833.0,4321.0,0.000828,0.000828,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lack of Efficacy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00205343,0.0020427067598015845,1.0723240198415654e-05
8.0,4833.0,4321.0,0.001655,0.001655,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00410438,0.004075101679583331,2.927832041666953e-05
10.0,4833.0,4321.0,0.002069,0.002069,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00513109,0.004984001894236112,0.0001470881057638873
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol driven decision point,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00051336,0.0005134888055357121,1.2880553571209107e-07
3.0,4833.0,4321.0,0.000621,0.000621,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol driven decision point,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00154007,0.0015407837265773844,7.137265773844714e-07
7.0,4833.0,4321.0,0.001448,0.001448,8.48343,0.292333,1.0,4833.0,39.0,305.0,Physician Decision,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00359102,0.0036012928661507894,1.0272866150789518e-05
18.0,4833.0,4321.0,0.003724,0.003724,8.48343,0.292333,1.0,4833.0,39.0,305.0,Physician Decision,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00923547,0.00916989451747024,6.557548252976095e-05
26.0,4833.0,4321.0,0.00538,0.00538,8.48343,0.292333,1.0,4833.0,39.0,305.0,Clinical endpoint reached,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01334233,0.012916162979712303,0.00042616702028769674
13.0,4833.0,4321.0,0.00269,0.00269,8.48343,0.292333,1.0,4833.0,39.0,305.0,Clinical endpoint reached,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00667116,0.006413820526964285,0.0002573394730357144
3.0,4833.0,4321.0,0.000621,0.000621,8.48343,0.292333,1.0,4833.0,39.0,305.0,Technical problems,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00154007,0.0015417803778571468,1.7103778571468664e-06
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Technical problems,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00051336,0.0005136156906547595,2.556906547595151e-07
12.0,4833.0,4321.0,0.002483,0.002483,8.48343,0.292333,1.0,4833.0,39.0,305.0,Participant convenience,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00615781,0.006046475634553576,0.00011133436544642338
8.0,4833.0,4321.0,0.001655,0.001655,8.48343,0.292333,1.0,4833.0,39.0,305.0,Participant convenience,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00410438,0.004080700875158727,2.3679124841273144e-05
0.0,4833.0,4321.0,0.0,0.0,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol Violation,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,4833.0,4321.0,0.000414,0.000414,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol Violation,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00102671,0.0010470187532251075,2.0308753225107634e-05
9.0,4833.0,4321.0,0.001862,0.001862,8.48343,0.292333,1.0,4833.0,39.0,305.0,Withdrawal by Subject,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00461774,0.004527391790535713,9.034820946428757e-05
5.0,4833.0,4321.0,0.001035,0.001035,8.48343,0.292333,1.0,4833.0,39.0,305.0,Withdrawal by Subject,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00256679,0.0026338644312797637,6.707443127976394e-05
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lost to Follow-up,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00051336,0.0005136378893452359,2.7788934523582595e-07
11.0,4833.0,4321.0,0.002276,0.002276,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lost to Follow-up,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00564445,0.00570529025796627,6.0840257966270246e-05
27.0,4833.0,4321.0,0.005587,0.005587,8.48343,0.292333,1.0,4833.0,39.0,305.0,Death,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.01385569,0.013834406197123008,2.1283802876992733e-05
20.0,4833.0,4321.0,0.004138,0.004138,8.48343,0.292333,1.0,4833.0,39.0,305.0,Death,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.01026219,0.010224167561279753,3.80224387202463e-05
3.0,4833.0,4321.0,0.000621,0.000621,8.48343,0.292333,1.0,4833.0,39.0,305.0,Study terminated by sponsor,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00154007,0.0015441022923611152,4.032292361115302e-06
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Study terminated by sponsor,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00051336,0.0005133900499404737,3.004994047367017e-08
0.0,4833.0,4321.0,0.0,0.0,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol driven decision point,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Protocol driven decision point,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00051336,0.0005133569699404738,3.0300595262044983e-09
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lack of Efficacy,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00051336,0.0005132980799404739,6.192005952616354e-08
0.0,4833.0,4321.0,0.0,0.0,8.48343,0.292333,1.0,4833.0,39.0,305.0,Lack of Efficacy,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,4833.0,4321.0,0.0,0.0,8.48343,0.292333,1.0,4833.0,39.0,305.0,Technical problems,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,4833.0,4321.0,0.000207,0.000207,8.48343,0.292333,1.0,4833.0,39.0,305.0,Technical problems,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00051336,0.000513381145773807,2.1145773806984826e-08
3.0,505.0,498.0,0.005941,0.005941,6.226537,0.352883,1.0,525.0,2.0,62.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01305378,0.013254536444156742,0.00020075644415674249
1.0,505.0,498.0,0.00198,0.00198,6.226537,0.352883,1.0,525.0,2.0,62.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435053,0.004344298296142394,6.231703857605651e-06
2.0,505.0,498.0,0.00396,0.00396,6.226537,0.352883,1.0,525.0,2.0,62.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00870106,0.008712963129017861,1.1903129017861239e-05
0.0,505.0,498.0,0.0,0.0,6.226537,0.352883,1.0,525.0,2.0,62.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,505.0,498.0,0.0,0.0,6.226537,0.352883,1.0,525.0,2.0,62.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,505.0,498.0,0.00198,0.00198,6.226537,0.352883,1.0,525.0,2.0,62.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435053,0.0043496859426900136,8.440573099864623e-07
3.0,266.0,255.0,0.011278,0.011278,5.587249,0.330504,1.0,266.0,6.0,28.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02082605,0.021381138795173987,0.0005550887951739879
2.0,266.0,255.0,0.007519,0.007519,5.587249,0.330504,1.0,266.0,6.0,28.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01388465,0.01450415350069444,0.0006195035006944394
1.0,266.0,255.0,0.003759,0.003759,5.587249,0.330504,1.0,266.0,6.0,28.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0069414,0.007061554022692119,0.00012015402269211894
4.0,266.0,255.0,0.015038,0.015038,5.587249,0.330504,1.0,266.0,6.0,28.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02776929,0.02774776384113095,2.1526158869047268e-05
0.0,266.0,255.0,0.0,0.0,5.587249,0.330504,1.0,266.0,6.0,28.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,266.0,255.0,0.003759,0.003759,5.587249,0.330504,1.0,266.0,6.0,28.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0069414,0.00706299394832704,0.00012159394832703986
5.0,575.0,528.0,0.008696,0.008696,6.356108,0.342728,1.0,575.0,7.0,69.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01894352,0.01888147391032736,6.2046089672637e-05
6.0,575.0,528.0,0.010435,0.010435,6.356108,0.342728,1.0,575.0,7.0,69.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02273179,0.02265897943570437,7.28105642956306e-05
3.0,575.0,528.0,0.005217,0.005217,6.356108,0.342728,1.0,575.0,7.0,69.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0113648,0.011357732257456697,7.067742543302377e-06
4.0,575.0,528.0,0.006957,0.006957,6.356108,0.342728,1.0,575.0,7.0,69.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01515525,0.014851855892857148,0.0003033941071428521
6.0,575.0,528.0,0.010435,0.010435,6.356108,0.342728,1.0,575.0,7.0,69.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.02273179,0.02269923981629961,3.255018370039095e-05
1.0,575.0,528.0,0.001739,0.001739,6.356108,0.342728,1.0,575.0,7.0,69.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00378827,0.0037938363643254124,5.566364325412538e-06
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,575.0,528.0,0.003478,0.003478,6.356108,0.342728,1.0,575.0,7.0,69.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00757654,0.007600057889457985,2.3517889457985372e-05
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,575.0,528.0,0.003478,0.003478,6.356108,0.342728,1.0,575.0,7.0,69.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00757654,0.007587979957077034,1.1439957077034185e-05
2.0,575.0,528.0,0.003478,0.003478,6.356108,0.342728,1.0,575.0,7.0,69.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00757654,0.007582841895410364,6.301895410364133e-06
5.0,575.0,528.0,0.008696,0.008696,6.356108,0.342728,1.0,575.0,7.0,69.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01894352,0.01886996754491069,7.355245508930755e-05
4.0,575.0,528.0,0.006957,0.006957,6.356108,0.342728,1.0,575.0,7.0,69.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01515525,0.014892997999226195,0.00026225200077380564
3.0,575.0,528.0,0.005217,0.005217,6.356108,0.342728,1.0,575.0,7.0,69.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0113648,0.011351010561504313,1.3789438495686104e-05
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Administrative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,575.0,528.0,0.001739,0.001739,6.356108,0.342728,1.0,575.0,7.0,69.0,Administrative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00378827,0.003789968311825415,1.6983118254153794e-06
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Administrative,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Administrative,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,575.0,528.0,0.001739,0.001739,6.356108,0.342728,1.0,575.0,7.0,69.0,Administrative,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00378827,0.003788920136825416,6.501368254160575e-07
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,575.0,528.0,0.001739,0.001739,6.356108,0.342728,1.0,575.0,7.0,69.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00378827,0.0037895882793254126,1.3182793254127786e-06
0.0,575.0,528.0,0.0,0.0,6.356108,0.342728,1.0,575.0,7.0,69.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,575.0,528.0,0.001739,0.001739,6.356108,0.342728,1.0,575.0,7.0,69.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00378827,0.003789445487658747,1.1754876587471118e-06
123.0,13885.0,13649.0,0.008858,0.008858,9.538636,0.444042,1.0,13885.0,28.0,776.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03751852,0.03707591456687501,0.0004426054331249929
113.0,13885.0,13649.0,0.008138,0.008138,9.538636,0.444042,1.0,13885.0,28.0,776.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03446893,0.03445809466778135,1.083533221864913e-05
2.0,231.0,198.0,0.008658,0.008658,5.446737,0.54863,1.0,231.0,7.0,25.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02587219,0.026280214983680574,0.0004080249836805744
3.0,231.0,198.0,0.012987,0.012987,5.446737,0.54863,1.0,231.0,7.0,25.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03880828,0.03972772505645832,0.000919445056458322
8.0,231.0,198.0,0.034632,0.034632,5.446737,0.54863,1.0,231.0,7.0,25.0,were not scanned,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10348876,0.1047570820969444,0.0012683220969443992
13.0,231.0,198.0,0.056277,0.056277,5.446737,0.54863,1.0,231.0,7.0,25.0,were not scanned,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16816923,0.16422206953410726,0.003947160465892746
5.0,231.0,198.0,0.021645,0.021645,5.446737,0.54863,1.0,231.0,7.0,25.0,scans could not be evaluated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06468047,0.066057706828383,0.001377236828382991
2.0,231.0,198.0,0.008658,0.008658,5.446737,0.54863,1.0,231.0,7.0,25.0,scans could not be evaluated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02587219,0.026349448882767884,0.00047725888276788433
5.0,800.0,499.0,0.00625,0.00625,6.685861,0.360417,1.0,800.0,3.0,62.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01506062,0.014805307500535707,0.00025531249946429344
60.0,800.0,499.0,0.075,0.075,6.685861,0.360417,1.0,800.0,3.0,62.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18072744,0.1818772826111012,0.0011498426111012094
44.0,800.0,499.0,0.055,0.055,6.685861,0.360417,1.0,800.0,3.0,62.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.13253346,0.13207994952404747,0.0004535104759525177
3.0,800.0,499.0,0.00375,0.00375,6.685861,0.360417,1.0,800.0,3.0,62.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00903637,0.008730660041230158,0.0003057099587698425
18.0,800.0,499.0,0.0225,0.0225,6.685861,0.360417,1.0,800.0,3.0,62.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05421823,0.05292308633354441,0.0012951436664555907
44.0,800.0,499.0,0.055,0.055,6.685861,0.360417,1.0,800.0,3.0,62.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.13253346,0.13193114311404744,0.000602316885952553
2.0,800.0,499.0,0.0025,0.0025,6.685861,0.360417,1.0,800.0,3.0,62.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00602425,0.005660258714384925,0.00036399128561507513
22.0,800.0,499.0,0.0275,0.0275,6.685861,0.360417,1.0,800.0,3.0,62.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06626673,0.06533367411115439,0.0009330558888456103
13.0,800.0,499.0,0.01625,0.01625,6.685861,0.360417,1.0,800.0,3.0,62.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03915761,0.03867129673017857,0.0004863132698214312
0.0,800.0,499.0,0.0,0.0,6.685861,0.360417,1.0,800.0,3.0,62.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,800.0,499.0,0.00375,0.00375,6.685861,0.360417,1.0,800.0,3.0,62.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00903637,0.008782855810039686,0.00025351418996031466
10.0,800.0,499.0,0.0125,0.0125,6.685861,0.360417,1.0,800.0,3.0,62.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03012124,0.029757268583223317,0.00036397141677668374
16.0,800.0,499.0,0.02,0.02,6.685861,0.360417,1.0,800.0,3.0,62.0,Device not implanted,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04819398,0.04805025224293649,0.00014372775706350538
61.0,800.0,499.0,0.07625,0.07625,6.685861,0.360417,1.0,800.0,3.0,62.0,Device not implanted,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18373957,0.18352769697063484,0.0002118730293651505
0.0,800.0,499.0,0.0,0.0,6.685861,0.360417,1.0,800.0,3.0,62.0,Device not implanted,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,395.0,368.0,0.002532,0.002532,5.981414,0.321222,1.0,507.0,14.0,108.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00486489,0.00491817233312498,5.328233312497984e-05
2.0,395.0,368.0,0.005063,0.005063,5.981414,0.321222,1.0,507.0,14.0,108.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00972786,0.009749971659464254,2.2111659464254044e-05
7.0,395.0,368.0,0.017722,0.017722,5.981414,0.321222,1.0,507.0,14.0,108.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0340504,0.034667556712251975,0.0006171567122519733
3.0,395.0,368.0,0.007595,0.007595,5.981414,0.321222,1.0,507.0,14.0,108.0,Major Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01459276,0.01467242147988102,7.96614798810203e-05
2.0,395.0,368.0,0.005063,0.005063,5.981414,0.321222,1.0,507.0,14.0,108.0,Major Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00972786,0.009747732596964254,1.987259696425471e-05
3.0,395.0,368.0,0.007595,0.007595,5.981414,0.321222,1.0,507.0,14.0,108.0,Major Protocol Deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01459276,0.014682173014881006,8.941301488100614e-05
3.0,395.0,368.0,0.007595,0.007595,5.981414,0.321222,1.0,507.0,14.0,108.0,Voluntary Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01459276,0.014679084801547681,8.632480154768113e-05
0.0,395.0,368.0,0.0,0.0,5.981414,0.321222,1.0,507.0,14.0,108.0,Voluntary Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,395.0,368.0,0.005063,0.005063,5.981414,0.321222,1.0,507.0,14.0,108.0,Voluntary Withdrawal,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00972786,0.009751529112083301,2.366911208330144e-05
2.0,395.0,368.0,0.005063,0.005063,5.981414,0.321222,1.0,507.0,14.0,108.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00972786,0.00974825671065473,2.0396710654730157e-05
0.0,395.0,368.0,0.0,0.0,5.981414,0.321222,1.0,507.0,14.0,108.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,395.0,368.0,0.0,0.0,5.981414,0.321222,1.0,507.0,14.0,108.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,395.0,368.0,0.002532,0.002532,5.981414,0.321222,1.0,507.0,14.0,108.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00486489,0.004912672026249978,4.778202624997757e-05
1.0,395.0,368.0,0.002532,0.002532,5.981414,0.321222,1.0,507.0,14.0,108.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00486489,0.004921763987857123,5.687398785712318e-05
0.0,395.0,368.0,0.0,0.0,5.981414,0.321222,1.0,507.0,14.0,108.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
20.0,1489.0,1346.0,0.013432,0.013432,7.306531,0.816893,1.0,1489.0,1.0,55.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08017097,0.08119933906753975,0.0010283690675397528
10.0,1489.0,1346.0,0.006716,0.006716,7.306531,0.816893,1.0,1489.0,1.0,55.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04008549,0.04040293480791667,0.0003174448079166711
12.0,1489.0,1346.0,0.008059,0.008059,7.306531,0.816893,1.0,1489.0,1.0,55.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04810139,0.0468202552005258,0.0012811347994741984
5.0,1489.0,1346.0,0.003358,0.003358,7.306531,0.816893,1.0,1489.0,1.0,55.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02004274,0.02042026264818542,0.0003775226481854202
34.0,1489.0,1346.0,0.022834,0.022834,7.306531,0.816893,1.0,1489.0,1.0,55.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13628827,0.13746113226549603,0.0011728622654960386
44.0,1489.0,1346.0,0.02955,0.02955,7.306531,0.816893,1.0,1489.0,1.0,55.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.17637375,0.18143206616906743,0.005058316169067434
3.0,1489.0,1346.0,0.002015,0.002015,7.306531,0.816893,1.0,1489.0,1.0,55.0,not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01202684,0.01294267478598214,0.0009158347859821395
6.0,1489.0,1346.0,0.00403,0.00403,7.306531,0.816893,1.0,1489.0,1.0,55.0,not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02405368,0.024131236392946464,7.755639294646302e-05
1.0,1489.0,1346.0,0.000672,0.000672,7.306531,0.816893,1.0,1489.0,1.0,55.0,Investigator removed subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00401094,0.004086087462508378,7.514746250837818e-05
2.0,1489.0,1346.0,0.001343,0.001343,7.306531,0.816893,1.0,1489.0,1.0,55.0,Investigator removed subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0080159,0.008105418557361101,8.951855736110195e-05
1.0,1489.0,1346.0,0.000672,0.000672,7.306531,0.816893,1.0,1489.0,1.0,55.0,questionnaire result not evaluated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00401094,0.004086087462508378,7.514746250837818e-05
0.0,1489.0,1346.0,0.0,0.0,7.306531,0.816893,1.0,1489.0,1.0,55.0,questionnaire result not evaluated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1489.0,1346.0,0.000672,0.000672,7.306531,0.816893,1.0,1489.0,1.0,55.0,refuse of hospital visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00401094,0.004086087462508378,7.514746250837818e-05
3.0,1489.0,1346.0,0.002015,0.002015,7.306531,0.816893,1.0,1489.0,1.0,55.0,refuse of hospital visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01202684,0.012957034432113084,0.0009301944321130837
1.0,1489.0,1346.0,0.000672,0.000672,7.306531,0.816893,1.0,1489.0,1.0,55.0,Subject withdrew,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00401094,0.004086087462508378,7.514746250837818e-05
0.0,1489.0,1346.0,0.0,0.0,7.306531,0.816893,1.0,1489.0,1.0,55.0,Subject withdrew,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,350.0,104.0,0.002857,0.002857,5.860786,0.215837,1.0,475.0,1.0,1.0,Screen Failure,Phase II,FG000,cardiovascular disease,OTHER,0.00361403,0.0036465220007738113,3.249200077381142e-05
1.0,350.0,104.0,0.002857,0.002857,5.860786,0.215837,1.0,475.0,1.0,1.0,Withdrawal by Subject,Phase II,FG000,cardiovascular disease,OTHER,0.00361403,0.0036462744595238124,3.2244459523812514e-05
17.0,350.0,104.0,0.048571,0.048571,5.860786,0.215837,1.0,475.0,1.0,1.0,unable to collect blood and/or breath,Phase II,FG000,cardiovascular disease,OTHER,0.06144106,0.061638466922529805,0.00019740692252980668
2.0,350.0,104.0,0.005714,0.005714,5.860786,0.215837,1.0,475.0,1.0,1.0,Protocol Violation,Phase II,FG000,cardiovascular disease,OTHER,0.00722806,0.007305579179652778,7.751917965277862e-05
8.0,947.0,931.0,0.008448,0.008448,6.854355,0.340296,1.0,947.0,1.0,1.0,scientific integrity issue,Overall Study,FG000,cardiovascular disease,OTHER,0.01970505,0.019773223078650766,6.817307865076422e-05
8.0,947.0,931.0,0.008448,0.008448,6.854355,0.340296,1.0,947.0,1.0,1.0,scientific integrity issue,Overall Study,FG001,cardiovascular disease,OTHER,0.01970505,0.01977803901805553,7.298901805552829e-05
4.0,314.0,302.0,0.012739,0.012739,5.752573,1.0,1.0,314.0,1.0,5.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07328202,0.07385209043830361,0.0005700704383036076
3.0,314.0,302.0,0.009554,0.009554,5.752573,1.0,1.0,314.0,1.0,5.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05496008,0.05423504914034734,0.0007250308596526631
2.0,314.0,302.0,0.006369,0.006369,5.752573,1.0,1.0,314.0,1.0,5.0,Not able to visit the site,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03663814,0.03640500622767863,0.00023313377232137
3.0,314.0,302.0,0.009554,0.009554,5.752573,1.0,1.0,314.0,1.0,5.0,Not able to visit the site,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05496008,0.05429938295554575,0.0006606970444542545
27.0,6147.0,5673.0,0.004392,0.004392,8.723882,0.685782,1.0,6147.0,32.0,557.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02627594,0.026508090713432533,0.0002321507134325322
24.0,6147.0,5673.0,0.003904,0.003904,8.723882,0.685782,1.0,6147.0,32.0,557.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02335639,0.02322938324402778,0.00012700675597222127
0.0,6147.0,5673.0,0.0,0.0,8.723882,0.685782,1.0,6147.0,32.0,557.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,6147.0,5673.0,0.000163,0.000163,8.723882,0.685782,1.0,6147.0,32.0,557.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00097518,0.0009762857699503968,1.105769950396785e-06
24.0,6147.0,5673.0,0.003904,0.003904,8.723882,0.685782,1.0,6147.0,32.0,557.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02335639,0.023187818644027764,0.0001685713559722371
39.0,6147.0,5673.0,0.006345,0.006345,8.723882,0.685782,1.0,6147.0,32.0,557.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03796011,0.033463535898015886,0.004496574101984112
180.0,6147.0,5673.0,0.029283,0.029283,8.723882,0.685782,1.0,6147.0,32.0,557.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17519085,0.17083050340306524,0.0043603465969347666
179.0,6147.0,5673.0,0.02912,0.02912,8.723882,0.685782,1.0,6147.0,32.0,557.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.17421568,0.17024719626904733,0.003968483730952682
0.0,274.0,267.0,0.0,0.0,5.616771,0.529815,1.0,274.0,1.0,1.0,Comfort care,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,274.0,267.0,0.00365,0.00365,5.616771,0.529815,1.0,274.0,1.0,1.0,Comfort care,Overall Study,FG001,cardiovascular disease,OTHER,0.01086186,0.01089675939616221,3.489939616221037e-05
0.0,274.0,267.0,0.0,0.0,5.616771,0.529815,1.0,274.0,1.0,1.0,Concurrent trial enrollment,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,274.0,267.0,0.00365,0.00365,5.616771,0.529815,1.0,274.0,1.0,1.0,Concurrent trial enrollment,Overall Study,FG001,cardiovascular disease,OTHER,0.01086186,0.01089675939616221,3.489939616221037e-05
0.0,274.0,267.0,0.0,0.0,5.616771,0.529815,1.0,274.0,1.0,1.0,Discharged within 48 hours,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,274.0,267.0,0.00365,0.00365,5.616771,0.529815,1.0,274.0,1.0,1.0,Discharged within 48 hours,Overall Study,FG001,cardiovascular disease,OTHER,0.01086186,0.01089675939616221,3.489939616221037e-05
2.0,274.0,267.0,0.007299,0.007299,5.616771,0.529815,1.0,274.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02172074,0.02255936737577378,0.0008386273757737817
1.0,274.0,267.0,0.00365,0.00365,5.616771,0.529815,1.0,274.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.01086186,0.010897937850328877,3.6077850328877434e-05
1.0,274.0,267.0,0.00365,0.00365,5.616771,0.529815,1.0,274.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.01086186,0.01088404430026936,2.2184300269361204e-05
0.0,274.0,267.0,0.0,0.0,5.616771,0.529815,1.0,274.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
18.0,237.0,177.0,0.075949,0.075949,5.472271,0.57068,1.0,237.0,26.0,73.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.23718222,0.24369786015787717,0.006515640157877173
12.0,237.0,177.0,0.050633,0.050633,5.472271,0.57068,1.0,237.0,26.0,73.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15812252,0.15392846967919657,0.004194050320803416
3.0,237.0,177.0,0.012658,0.012658,5.472271,0.57068,1.0,237.0,26.0,73.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03952985,0.03994034943029762,0.00041049943029761865
2.0,237.0,177.0,0.008439,0.008439,5.472271,0.57068,1.0,237.0,26.0,73.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02635427,0.026572353393244055,0.00021808339324405623
1.0,237.0,177.0,0.004219,0.004219,5.472271,0.57068,1.0,237.0,26.0,73.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01317558,0.01325615715859132,8.057715859132071e-05
0.0,237.0,177.0,0.0,0.0,5.472271,0.57068,1.0,237.0,26.0,73.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,237.0,177.0,0.008439,0.008439,5.472271,0.57068,1.0,237.0,26.0,73.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02635427,0.026489012881894855,0.00013474288189485595
1.0,237.0,177.0,0.004219,0.004219,5.472271,0.57068,1.0,237.0,26.0,73.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01317558,0.01325288896853179,7.730896853179112e-05
10.0,237.0,177.0,0.042194,0.042194,5.472271,0.57068,1.0,237.0,26.0,73.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13176825,0.1341125802045733,0.0023443302045733083
5.0,237.0,177.0,0.021097,0.021097,5.472271,0.57068,1.0,237.0,26.0,73.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06588412,0.06731789219907748,0.0014337721990774766
1.0,237.0,177.0,0.004219,0.004219,5.472271,0.57068,1.0,237.0,26.0,73.0,Drug non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01317558,0.013256691925257984,8.111192525798484e-05
0.0,237.0,177.0,0.0,0.0,5.472271,0.57068,1.0,237.0,26.0,73.0,Drug non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,237.0,177.0,0.016878,0.016878,5.472271,0.57068,1.0,237.0,26.0,73.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05270855,0.055024082776994054,0.0023155327769940545
1.0,237.0,177.0,0.004219,0.004219,5.472271,0.57068,1.0,237.0,26.0,73.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01317558,0.013248907277281794,7.332727728179451e-05
16.0,9016.0,6232.0,0.001775,0.001775,9.106867,0.238805,1.0,9016.0,30.0,30.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00386021,0.003822291819180263,3.791818081973729e-05
14.0,9016.0,6232.0,0.001553,0.001553,9.106867,0.238805,1.0,9016.0,30.0,30.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00337741,0.0032400030852182517,0.00013740691478174825
127.0,9016.0,6232.0,0.014086,0.014086,9.106867,0.238805,1.0,9016.0,30.0,30.0,Symptomatic hypotension,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03063373,0.030973153291160734,0.00033942329116073283
64.0,9016.0,6232.0,0.007098,0.007098,9.106867,0.238805,1.0,9016.0,30.0,30.0,Symptomatic hypotension,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01543648,0.015041255647688503,0.00039522435231149726
84.0,9016.0,6232.0,0.009317,0.009317,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other Serious Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02026228,0.019643600325555573,0.0006186796744444278
93.0,9016.0,6232.0,0.010315,0.010315,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other Serious Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02243269,0.021918764883769856,0.0005139251162301454
26.0,9016.0,6232.0,0.002884,0.002884,9.106867,0.238805,1.0,9016.0,30.0,30.0,Qualifying condition not present,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00627202,0.005940456576378963,0.0003315634236210367
29.0,9016.0,6232.0,0.003217,0.003217,9.106867,0.238805,1.0,9016.0,30.0,30.0,Qualifying condition not present,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00699622,0.006595146442757938,0.00040107355724206244
678.0,9016.0,6232.0,0.0752,0.0752,9.106867,0.238805,1.0,9016.0,30.0,30.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16354226,0.15362080631594255,0.009921453684057446
742.0,9016.0,6232.0,0.082298,0.082298,9.106867,0.238805,1.0,9016.0,30.0,30.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.17897874,0.1660800887010913,0.012898651298908687
39.0,9016.0,6232.0,0.004326,0.004326,9.106867,0.238805,1.0,9016.0,30.0,30.0,Thromboembolic / outcome event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00940803,0.009268589965763886,0.0001394400342361133
45.0,9016.0,6232.0,0.004991,0.004991,9.106867,0.238805,1.0,9016.0,30.0,30.0,Thromboembolic / outcome event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01085425,0.01064261070564484,0.00021163929435515962
2.0,9016.0,6232.0,0.000222,0.000222,9.106867,0.238805,1.0,9016.0,30.0,30.0,Oral anticoagulant required,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0004828,0.0004728073076127351,9.992692387264935e-06
0.0,9016.0,6232.0,0.0,0.0,9.106867,0.238805,1.0,9016.0,30.0,30.0,Oral anticoagulant required,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,9016.0,6232.0,0.000776,0.000776,9.106867,0.238805,1.0,9016.0,30.0,30.0,"Minor bleeding (e.g.,bruising,epistaxis)",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00168762,0.0015880891531349203,9.95308468650796e-05
3.0,9016.0,6232.0,0.000333,0.000333,9.106867,0.238805,1.0,9016.0,30.0,30.0,"Minor bleeding (e.g.,bruising,epistaxis)",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0007242,0.0007327877742261913,8.5877742261913e-06
71.0,9016.0,6232.0,0.007875,0.007875,9.106867,0.238805,1.0,9016.0,30.0,30.0,Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01712627,0.017179822109553603,5.355210955360415e-05
69.0,9016.0,6232.0,0.007653,0.007653,9.106867,0.238805,1.0,9016.0,30.0,30.0,Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01664347,0.01592731228012899,0.000716157719871012
3.0,9016.0,6232.0,0.000333,0.000333,9.106867,0.238805,1.0,9016.0,30.0,30.0,Study drug intolerance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0007242,0.0007311907836904774,6.990783690477326e-06
3.0,9016.0,6232.0,0.000333,0.000333,9.106867,0.238805,1.0,9016.0,30.0,30.0,Study drug intolerance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0007242,0.000730119988809525,5.9199888095249915e-06
188.0,9016.0,6232.0,0.020852,0.020852,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other adverse events (non-serious),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04534818,0.04426416931349201,0.0010840106865079926
159.0,9016.0,6232.0,0.017635,0.017635,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other adverse events (non-serious),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03835196,0.03795547646774801,0.00039648353225198857
71.0,9016.0,6232.0,0.007875,0.007875,9.106867,0.238805,1.0,9016.0,30.0,30.0,Physician withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01712627,0.017183198551636938,5.6928551636938746e-05
63.0,9016.0,6232.0,0.006988,0.006988,9.106867,0.238805,1.0,9016.0,30.0,30.0,Physician withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01519725,0.014815954673075416,0.00038129532692458487
4.0,9016.0,6232.0,0.000444,0.000444,9.106867,0.238805,1.0,9016.0,30.0,30.0,Surgery / procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0009656,0.0009471146436210325,1.848535637896751e-05
5.0,9016.0,6232.0,0.000555,0.000555,9.106867,0.238805,1.0,9016.0,30.0,30.0,Surgery / procedure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00120699,0.0011985097197321464,8.480280267853576e-06
35.0,9016.0,6232.0,0.003882,0.003882,9.106867,0.238805,1.0,9016.0,30.0,30.0,Angiotensin II receptor blocker required,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00844243,0.008252073584374998,0.00019035641562500233
58.0,9016.0,6232.0,0.006433,0.006433,9.106867,0.238805,1.0,9016.0,30.0,30.0,Angiotensin II receptor blocker required,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01399026,0.014160439496230168,0.00017017949623016927
15.0,9016.0,6232.0,0.001664,0.001664,9.106867,0.238805,1.0,9016.0,30.0,30.0,Lightheadedness / dizziness,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00361881,0.0032904566560010796,0.0003283533439989205
11.0,9016.0,6232.0,0.00122,0.00122,9.106867,0.238805,1.0,9016.0,30.0,30.0,Lightheadedness / dizziness,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00265321,0.002490962725357141,0.00016224727464285915
5.0,9016.0,6232.0,0.000555,0.000555,9.106867,0.238805,1.0,9016.0,30.0,30.0,Hypotension (non-symptomatic),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00120699,0.0011970461324107172,9.943867589282855e-06
5.0,9016.0,6232.0,0.000555,0.000555,9.106867,0.238805,1.0,9016.0,30.0,30.0,Hypotension (non-symptomatic),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00120699,0.0011985097197321464,8.480280267853576e-06
1.0,9016.0,6232.0,0.000111,0.000111,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other contraindicated medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0002414,0.0002412840855952393,1.159144047607264e-07
1.0,9016.0,6232.0,0.000111,0.000111,9.106867,0.238805,1.0,9016.0,30.0,30.0,Other contraindicated medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0002414,0.00024133727583333447,6.272416666554433e-08
17.0,9016.0,6232.0,0.001886,0.001886,9.106867,0.238805,1.0,9016.0,30.0,30.0,Event related to cardiac condition,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00410161,0.0038732200795779897,0.0002283899204220106
16.0,9016.0,6232.0,0.001775,0.001775,9.106867,0.238805,1.0,9016.0,30.0,30.0,Event related to cardiac condition,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00386021,0.003834847233346931,2.536276665306928e-05
4.0,9016.0,6232.0,0.000444,0.000444,9.106867,0.238805,1.0,9016.0,30.0,30.0,Patient not wish to continue after May08,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0009656,0.0009471146436210325,1.848535637896751e-05
6.0,9016.0,6232.0,0.000665,0.000665,9.106867,0.238805,1.0,9016.0,30.0,30.0,Patient not wish to continue after May08,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00144622,0.0014326531252976179,1.3566874702382152e-05
1.0,9016.0,6232.0,0.000111,0.000111,9.106867,0.238805,1.0,9016.0,30.0,30.0,Site not agree to continue after May08,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0002414,0.0002414449310714297,4.493107142968704e-08
1.0,9016.0,6232.0,0.000111,0.000111,9.106867,0.238805,1.0,9016.0,30.0,30.0,Site not agree to continue after May08,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0002414,0.0002414981213095249,9.812130952489622e-08
0.0,9016.0,6232.0,0.0,0.0,9.106867,0.238805,1.0,9016.0,30.0,30.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,9016.0,6232.0,0.000222,0.000222,9.106867,0.238805,1.0,9016.0,30.0,30.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0004828,0.00047318439564844925,9.615604351550773e-06
0.0,9016.0,6232.0,0.0,0.0,9.106867,0.238805,1.0,9016.0,30.0,30.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,9016.0,6232.0,0.000111,0.000111,9.106867,0.238805,1.0,9016.0,30.0,30.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0002414,0.00024147659630952494,7.659630952492865e-08
2.0,112.0,93.0,0.017857,0.017857,4.727388,0.410585,1.0,291.0,1.0,41.0,Death,Treatment,FG000,cardiovascular disease,INDUSTRY,0.03466035,0.03574930376716255,0.0010889537671625524
3.0,112.0,93.0,0.026786,0.026786,4.727388,0.410585,1.0,291.0,1.0,41.0,Death,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0519915,0.05488283200321428,0.0028913320032142795
2.0,112.0,93.0,0.017857,0.017857,4.727388,0.410585,1.0,291.0,1.0,41.0,Death,Treatment,FG002,cardiovascular disease,INDUSTRY,0.03466035,0.03558364382285699,0.0009232938228569895
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Death,Treatment,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Lost to Follow-up,Treatment,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Lost to Follow-up,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,112.0,93.0,0.017857,0.017857,4.727388,0.410585,1.0,291.0,1.0,41.0,Lost to Follow-up,Treatment,FG002,cardiovascular disease,INDUSTRY,0.03466035,0.03583408166869034,0.0011737316686903435
1.0,112.0,93.0,0.008929,0.008929,4.727388,0.410585,1.0,291.0,1.0,41.0,Lost to Follow-up,Treatment,FG003,cardiovascular disease,INDUSTRY,0.01733115,0.01768776229305021,0.0003566122930502083
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Withdrawal by Subject,Treatment,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,112.0,93.0,0.008929,0.008929,4.727388,0.410585,1.0,291.0,1.0,41.0,Withdrawal by Subject,Treatment,FG001,cardiovascular disease,INDUSTRY,0.01733115,0.017731340628228773,0.00040019062822877274
6.0,112.0,93.0,0.053571,0.053571,4.727388,0.410585,1.0,291.0,1.0,41.0,Withdrawal by Subject,Treatment,FG002,cardiovascular disease,INDUSTRY,0.10398106,0.11176337487877984,0.007782314878779839
1.0,112.0,93.0,0.008929,0.008929,4.727388,0.410585,1.0,291.0,1.0,41.0,Withdrawal by Subject,Treatment,FG003,cardiovascular disease,INDUSTRY,0.01733115,0.01767302668543116,0.0003418766854311611
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Sponsor Decision,Treatment,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Sponsor Decision,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,112.0,93.0,0.0,0.0,4.727388,0.410585,1.0,291.0,1.0,41.0,Sponsor Decision,Treatment,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,112.0,93.0,0.008929,0.008929,4.727388,0.410585,1.0,291.0,1.0,41.0,Sponsor Decision,Treatment,FG003,cardiovascular disease,INDUSTRY,0.01733115,0.017687871068050212,0.0003567210680502121
5.0,719.0,528.0,0.006954,0.006954,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01174342,0.01166834236038691,7.50776396130897e-05
4.0,719.0,528.0,0.005563,0.005563,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00939439,0.009413195568750003,1.8805568750002166e-05
3.0,719.0,528.0,0.004172,0.004172,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00704537,0.007025349305833344,2.0020694166655514e-05
2.0,719.0,528.0,0.002782,0.002782,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00469804,0.004676177356438498,2.186264356150193e-05
6.0,719.0,528.0,0.008345,0.008345,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01409244,0.013983496550892848,0.00010894344910715101
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Death,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00234902,0.0023451573375000093,3.862662499990507e-06
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00234902,0.0023484836222619145,5.363777380853682e-07
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00234902,0.0023423727574107232,6.647242589276608e-06
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00234902,0.0023462508377976293,2.7691622023705807e-06
0.0,719.0,528.0,0.0,0.0,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,719.0,528.0,0.0,0.0,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00234902,0.0023461166711309625,2.903328869037318e-06
19.0,719.0,528.0,0.026426,0.026426,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04462633,0.04455137429742062,7.495570257937817e-05
19.0,719.0,528.0,0.026426,0.026426,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04462633,0.04455169279390872,7.463720609127839e-05
18.0,719.0,528.0,0.025035,0.025035,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04227731,0.0423399357702381,6.262577023809918e-05
23.0,719.0,528.0,0.031989,0.031989,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.05402072,0.05308162460047619,0.0009390953995238108
16.0,719.0,528.0,0.022253,0.022253,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.03757927,0.037842303797073394,0.0002630337970733962
21.0,719.0,528.0,0.029207,0.029207,6.579251,0.256675,1.0,720.0,4.0,19.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.04932268,0.04994000699230158,0.0006173269923015826
1.0,719.0,528.0,0.001391,0.001391,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00234902,0.0023455613407142944,3.458659285705476e-06
2.0,719.0,528.0,0.002782,0.002782,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00469804,0.004682315231646837,1.572476835316229e-05
3.0,719.0,528.0,0.004172,0.004172,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00704537,0.0070237401850000115,2.1629814999988076e-05
4.0,719.0,528.0,0.005563,0.005563,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00939439,0.009425147437916668,3.075743791666752e-05
5.0,719.0,528.0,0.006954,0.006954,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01174342,0.011666839652142862,7.65803478571369e-05
7.0,719.0,528.0,0.009736,0.009736,6.579251,0.256675,1.0,720.0,4.0,19.0,Sponsor Decision,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.01644146,0.016424392340456364,1.7067659543637537e-05
7.0,719.0,528.0,0.009736,0.009736,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01644146,0.016439242616765902,2.217383234099507e-06
2.0,719.0,528.0,0.002782,0.002782,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00469804,0.004682315231646837,1.572476835316229e-05
4.0,719.0,528.0,0.005563,0.005563,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00939439,0.009438313056428572,4.3923056428571416e-05
3.0,719.0,528.0,0.004172,0.004172,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00704537,0.007026772652023818,1.859734797618126e-05
5.0,719.0,528.0,0.006954,0.006954,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01174342,0.011666839652142862,7.65803478571369e-05
7.0,719.0,528.0,0.009736,0.009736,6.579251,0.256675,1.0,720.0,4.0,19.0,No study drug received,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.01644146,0.016443239129027797,1.779129027795756e-06
27.0,2415.0,2343.0,0.01118,0.01118,7.789869,0.279906,1.0,2415.0,1.0,1.0,Missing data needed for endpt analyses,Overall Study,FG000,cardiovascular disease,OTHER,0.02437721,0.02429039222869048,8.681777130951918e-05
45.0,2415.0,2343.0,0.018634,0.018634,7.789869,0.279906,1.0,2415.0,1.0,1.0,Missing data needed for endpt analyses,Overall Study,FG001,cardiovascular disease,OTHER,0.04063013,0.04075362512471231,0.00012349512471231117
2.0,324.0,317.0,0.006173,0.006173,5.783825,1.0,1.0,324.0,3.0,16.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03570355,0.036089233214910726,0.0003856832149107259
1.0,324.0,317.0,0.003086,0.003086,5.783825,1.0,1.0,324.0,3.0,16.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01784888,0.018099392236329365,0.0002505122363293637
2.0,324.0,317.0,0.006173,0.006173,5.783825,1.0,1.0,324.0,3.0,16.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03570355,0.03618767234669643,0.000484122346696432
1.0,324.0,317.0,0.003086,0.003086,5.783825,1.0,1.0,324.0,3.0,16.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01784888,0.018111716832996033,0.0002628368329960322
1.0,324.0,317.0,0.003086,0.003086,5.783825,1.0,1.0,324.0,3.0,16.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01784888,0.018114837168829362,0.0002659571688293609
0.0,324.0,317.0,0.0,0.0,5.783825,1.0,1.0,324.0,3.0,16.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
52.0,21162.0,20998.0,0.002457,0.002457,9.96001,0.379199,1.0,21379.0,31.0,827.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00927966,0.00916199482895561,0.0001176651710443899
50.0,21162.0,20998.0,0.002363,0.002363,9.96001,0.379199,1.0,21379.0,31.0,827.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00892464,0.008906344737894112,1.829526210588711e-05
52.0,21162.0,20998.0,0.002457,0.002457,9.96001,0.379199,1.0,21379.0,31.0,827.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00927966,0.009185721878122275,9.393812187772493e-05
3.0,21162.0,20998.0,0.000142,0.000142,9.96001,0.379199,1.0,21379.0,31.0,827.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00053631,0.0005728638119940481,3.6553811994048105e-05
6.0,21162.0,20998.0,0.000284,0.000284,9.96001,0.379199,1.0,21379.0,31.0,827.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00107262,0.0010608171482440485,1.180285175595157e-05
1.0,21162.0,20998.0,4.7e-05,4.7e-05,9.96001,0.379199,1.0,21379.0,31.0,827.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00017751,0.0001699428116369049,7.567188363095104e-06
8.0,357.0,307.0,0.022409,0.022409,5.880533,0.387388,1.0,357.0,18.0,78.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05104871,0.051035517711527756,1.3192288472241298e-05
3.0,357.0,307.0,0.008403,0.008403,5.880533,0.387388,1.0,357.0,18.0,78.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01914241,0.01899276332937501,0.00014964667062498938
5.0,357.0,307.0,0.014006,0.014006,5.880533,0.387388,1.0,357.0,18.0,78.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0319063,0.03203868490478178,0.0001323849047817835
8.0,357.0,307.0,0.022409,0.022409,5.880533,0.387388,1.0,357.0,18.0,78.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05104871,0.0510748870073611,2.617700736110007e-05
14.0,357.0,307.0,0.039216,0.039216,5.880533,0.387388,1.0,357.0,18.0,78.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08933581,0.08992251565922628,0.0005867056592262776
12.0,357.0,307.0,0.033613,0.033613,5.880533,0.387388,1.0,357.0,18.0,78.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07657193,0.0782011042211607,0.001629174221160698
9.0,269.0,228.0,0.033457,0.033457,5.598422,0.666206,1.0,269.0,1.0,4.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12478472,0.12402085777185516,0.0007638622281448404
7.0,269.0,228.0,0.026022,0.026022,5.598422,0.666206,1.0,269.0,1.0,4.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09705437,0.0977755121802479,0.000721142180247894
2.0,269.0,228.0,0.007435,0.007435,5.598422,0.666206,1.0,269.0,1.0,4.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02773035,0.028136213524945032,0.00040586352494503125
2.0,269.0,228.0,0.007435,0.007435,5.598422,0.666206,1.0,269.0,1.0,4.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02773035,0.028113531310064083,0.00038318131006408185
4.0,269.0,228.0,0.01487,0.01487,5.598422,0.666206,1.0,269.0,1.0,4.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05546071,0.05587039193019836,0.00040968193019835786
0.0,269.0,228.0,0.0,0.0,5.598422,0.666206,1.0,269.0,1.0,4.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,269.0,228.0,0.0,0.0,5.598422,0.666206,1.0,269.0,1.0,4.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,269.0,228.0,0.003717,0.003717,5.598422,0.666206,1.0,269.0,1.0,4.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01386331,0.014043240109166648,0.00017993010916664796
0.0,269.0,228.0,0.0,0.0,5.598422,0.666206,1.0,269.0,1.0,4.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,269.0,228.0,0.003717,0.003717,5.598422,0.666206,1.0,269.0,1.0,4.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01386331,0.014040510062837292,0.00017720006283729155
1.0,269.0,228.0,0.003717,0.003717,5.598422,0.666206,1.0,269.0,1.0,4.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01386331,0.01403021125051586,0.00016690125051586034
0.0,269.0,228.0,0.0,0.0,5.598422,0.666206,1.0,269.0,1.0,4.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,269.0,228.0,0.02974,0.02974,5.598422,0.666206,1.0,269.0,1.0,4.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11092141,0.11231296052498023,0.0013915505249802312
4.0,269.0,228.0,0.01487,0.01487,5.598422,0.666206,1.0,269.0,1.0,4.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05546071,0.055712490998769806,0.00025178099876980303
2.0,269.0,228.0,0.007435,0.007435,5.598422,0.666206,1.0,269.0,1.0,4.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02773035,0.028157799219990124,0.0004274492199901232
2.0,971.0,944.0,0.00206,0.00206,6.879356,0.214254,1.0,972.0,7.0,55.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0030363,0.003037876844970234,1.5768449702340676e-06
3.0,971.0,944.0,0.00309,0.00309,6.879356,0.214254,1.0,972.0,7.0,55.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00455445,0.004569931696325779,1.5481696325779504e-05
5.0,971.0,944.0,0.005149,0.005149,6.879356,0.214254,1.0,972.0,7.0,55.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00758928,0.0077212585185615044,0.0001319785185615041
3.0,971.0,944.0,0.00309,0.00309,6.879356,0.214254,1.0,972.0,7.0,55.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00455445,0.004571667075492445,1.7217075492445555e-05
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00151815,0.0015242751102678548,6.125110267854797e-06
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00151815,0.0015222091498511877,4.0591498511877155e-06
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00151815,0.0015216469848511882,3.4969848511881996e-06
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,responder at visit 4,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,responder at visit 4,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,971.0,944.0,0.00206,0.00206,6.879356,0.214254,1.0,972.0,7.0,55.0,responder at visit 4,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0030363,0.0030401811028273784,3.881102827378406e-06
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,responder at visit 4,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,conmed-BP-pulse-ABPM withdrawal criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,conmed-BP-pulse-ABPM withdrawal criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00151815,0.0015230321827678544,4.882182767854343e-06
2.0,971.0,944.0,0.00206,0.00206,6.879356,0.214254,1.0,972.0,7.0,55.0,conmed-BP-pulse-ABPM withdrawal criteria,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0030363,0.0030401811028273784,3.881102827378406e-06
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,conmed-BP-pulse-ABPM withdrawal criteria,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00151815,0.001520540982351188,2.390982351187926e-06
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00151815,0.0015237315025297586,5.581502529758637e-06
1.0,971.0,944.0,0.00103,0.00103,6.879356,0.214254,1.0,972.0,7.0,55.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00151815,0.0015254447869345212,7.294786934521156e-06
3.0,971.0,944.0,0.00309,0.00309,6.879356,0.214254,1.0,972.0,7.0,55.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00455445,0.004566864732892336,1.2414732892335884e-05
0.0,971.0,944.0,0.0,0.0,6.879356,0.214254,1.0,972.0,7.0,55.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
118.0,1294.0,907.0,0.09119,0.09119,7.166266,1.0,1.0,1295.0,1.0,151.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.65349179,0.6000250922739676,0.05346669772603241
105.0,1294.0,907.0,0.081144,0.081144,7.166266,1.0,1.0,1295.0,1.0,151.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.58149949,0.5423365758573211,0.03916291414267892
0.0,1294.0,907.0,0.0,0.0,7.166266,1.0,1.0,1295.0,1.0,151.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1294.0,907.0,0.002318,0.002318,7.166266,1.0,1.0,1295.0,1.0,151.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0166114,0.016633355531597265,2.1955531597266792e-05
17.0,1294.0,907.0,0.013138,0.013138,7.166266,1.0,1.0,1295.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0941504,0.09328821303344259,0.0008621869665574045
18.0,1294.0,907.0,0.01391,0.01391,7.166266,1.0,1.0,1295.0,1.0,151.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09968276,0.09789570872969251,0.0017870512703074826
58.0,1294.0,907.0,0.044822,0.044822,7.166266,1.0,1.0,1295.0,1.0,151.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.32120637,0.29889788978854204,0.02230848021145798
42.0,1294.0,907.0,0.032457,0.032457,7.166266,1.0,1.0,1295.0,1.0,151.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.23259549,0.2218403831595537,0.010755106840446282
7.0,1294.0,907.0,0.00541,0.00541,7.166266,1.0,1.0,1295.0,1.0,151.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0387695,0.03864156257662693,0.00012793742337306735
6.0,1294.0,907.0,0.004637,0.004637,7.166266,1.0,1.0,1295.0,1.0,151.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03322998,0.03315555332898808,7.442667101192207e-05
10.0,1294.0,907.0,0.007728,0.007728,7.166266,1.0,1.0,1295.0,1.0,151.0,IRB's rejection etc.,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0553809,0.05467000380860118,0.000710896191398816
3.0,1294.0,907.0,0.002318,0.002318,7.166266,1.0,1.0,1295.0,1.0,151.0,IRB's rejection etc.,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0166114,0.016623785430763937,1.2385430763938582e-05
2.0,244.0,215.0,0.008197,0.008197,5.501258,0.332945,1.0,244.0,5.0,66.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01501376,0.015309623353253993,0.00029586335325399414
6.0,244.0,215.0,0.02459,0.02459,5.501258,0.332945,1.0,244.0,5.0,66.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04503946,0.04661283497275701,0.0015733749727570093
2.0,244.0,215.0,0.008197,0.008197,5.501258,0.332945,1.0,244.0,5.0,66.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01501376,0.01532227082367066,0.0003085108236706609
6.0,244.0,215.0,0.02459,0.02459,5.501258,0.332945,1.0,244.0,5.0,66.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04503946,0.04655786411489988,0.0015184041148998753
4.0,244.0,215.0,0.016393,0.016393,5.501258,0.332945,1.0,244.0,5.0,66.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0300257,0.0301373516752976,0.0001116516752975999
4.0,244.0,215.0,0.016393,0.016393,5.501258,0.332945,1.0,244.0,5.0,66.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0300257,0.030184353301190466,0.00015865330119046658
3.0,244.0,215.0,0.012295,0.012295,5.501258,0.332945,1.0,244.0,5.0,66.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02251973,0.02350086984696607,0.0009811398469660691
2.0,244.0,215.0,0.008197,0.008197,5.501258,0.332945,1.0,244.0,5.0,66.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01501376,0.01534917787420638,0.0003354178742063802
8.0,476.0,444.0,0.016807,0.016807,6.167516,0.723921,1.0,476.0,1.0,11.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0750398,0.07558401403770831,0.0005442140377083099
4.0,476.0,444.0,0.008403,0.008403,6.167516,0.723921,1.0,476.0,1.0,11.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.03751767,0.03691485911228862,0.0006028108877113858
12.0,476.0,444.0,0.02521,0.02521,6.167516,0.723921,1.0,476.0,1.0,11.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.11255747,0.11299951005341273,0.00044204005341272334
8.0,476.0,444.0,0.016807,0.016807,6.167516,0.723921,1.0,476.0,1.0,11.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.0750398,0.07561413373609127,0.0005743337360912676
1.0,315.0,307.0,0.003175,0.003175,5.755742,0.404683,1.0,315.0,19.0,68.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00739537,0.00751029476990077,0.00011492476990076963
0.0,315.0,307.0,0.0,0.0,5.755742,0.404683,1.0,315.0,19.0,68.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,315.0,307.0,0.019048,0.019048,5.755742,0.404683,1.0,315.0,19.0,68.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04436754,0.04315817512439482,0.0012093648756051761
1.0,315.0,307.0,0.003175,0.003175,5.755742,0.404683,1.0,315.0,19.0,68.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00739537,0.007512447639433603,0.00011707763943360257
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Adverse Event,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.00620382,0.0062052238214286085,1.4038214286088077e-06
2.0,286.0,242.0,0.006993,0.006993,5.659482,0.313464,1.0,286.0,0.0,0.0,Adverse Event,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.01240587,0.01242857778863094,2.2707788630940348e-05
0.0,286.0,242.0,0.0,0.0,5.659482,0.313464,1.0,286.0,0.0,0.0,Lack of Efficacy,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Lack of Efficacy,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.00620382,0.006208380501904798,4.560501904798779e-06
0.0,286.0,242.0,0.0,0.0,5.659482,0.313464,1.0,286.0,0.0,0.0,Lost to Follow-up,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Lost to Follow-up,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.00620382,0.006208160951904798,4.3409519047982875e-06
4.0,286.0,242.0,0.013986,0.013986,5.659482,0.313464,1.0,286.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.02481175,0.0252318548489484,0.0004201048489483987
7.0,286.0,242.0,0.024476,0.024476,5.659482,0.313464,1.0,286.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.04342144,0.04465286524341178,0.0012314252434117781
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Protocol Violation,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.00620382,0.006209410421428609,5.590421428609653e-06
0.0,286.0,242.0,0.0,0.0,5.659482,0.313464,1.0,286.0,0.0,0.0,Protocol Violation,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Withdrawal by Subject,Double-blind Treatment (Weeks 1 to 8),FG000,cardiovascular disease,INDUSTRY,0.00620382,0.006208859832678609,5.039832678609309e-06
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Withdrawal by Subject,Double-blind Treatment (Weeks 1 to 8),FG001,cardiovascular disease,INDUSTRY,0.00620382,0.006207829913154799,4.009913154799302e-06
2.0,286.0,242.0,0.006993,0.006993,5.659482,0.313464,1.0,286.0,0.0,0.0,Withdrawal by Subject,Extension (Weeks 9 to 52),FG000,cardiovascular disease,INDUSTRY,0.01240587,0.012406276577172606,4.065771726062539e-07
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Withdrawal by Subject,Extension (Weeks 9 to 52),FG001,cardiovascular disease,INDUSTRY,0.00620382,0.006211896233988129,8.07623398812931e-06
2.0,286.0,242.0,0.006993,0.006993,5.659482,0.313464,1.0,286.0,0.0,0.0,Adverse Event,Extension (Weeks 9 to 52),FG000,cardiovascular disease,INDUSTRY,0.01240587,0.012411339493422609,5.469493422609328e-06
3.0,286.0,242.0,0.01049,0.01049,5.659482,0.313464,1.0,286.0,0.0,0.0,Adverse Event,Extension (Weeks 9 to 52),FG001,cardiovascular disease,INDUSTRY,0.0186097,0.01885620439825395,0.00024650439825394874
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Lost to Follow-up,Extension (Weeks 9 to 52),FG000,cardiovascular disease,INDUSTRY,0.00620382,0.006214281458452415,1.0461458452415591e-05
2.0,286.0,242.0,0.006993,0.006993,5.659482,0.313464,1.0,286.0,0.0,0.0,Lost to Follow-up,Extension (Weeks 9 to 52),FG001,cardiovascular disease,INDUSTRY,0.01240587,0.012418080158869032,1.2210158869032858e-05
4.0,286.0,242.0,0.013986,0.013986,5.659482,0.313464,1.0,286.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Extension (Weeks 9 to 52),FG000,cardiovascular disease,INDUSTRY,0.02481175,0.0252318548489484,0.0004201048489483987
9.0,286.0,242.0,0.031469,0.031469,5.659482,0.313464,1.0,286.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Extension (Weeks 9 to 52),FG001,cardiovascular disease,INDUSTRY,0.05582732,0.05656566262075394,0.0007383426207539373
1.0,286.0,242.0,0.003497,0.003497,5.659482,0.313464,1.0,286.0,0.0,0.0,Physician Decision,Extension (Weeks 9 to 52),FG000,cardiovascular disease,INDUSTRY,0.00620382,0.006214485108452416,1.0665108452416298e-05
0.0,286.0,242.0,0.0,0.0,5.659482,0.313464,1.0,286.0,0.0,0.0,Physician Decision,Extension (Weeks 9 to 52),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,251.0,240.0,0.023904,0.023904,5.529429,0.217379,1.0,251.0,14.0,45.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02873224,0.02939738080282739,0.0006651408028273895
2.0,251.0,240.0,0.007968,0.007968,5.529429,0.217379,1.0,251.0,14.0,45.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00957741,0.009646943980347236,6.953398034723578e-05
3.0,251.0,240.0,0.011952,0.011952,5.529429,0.217379,1.0,251.0,14.0,45.0,Enrolled but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01436612,0.01468123711967264,0.00031511711967264003
8.0,4304.0,4289.0,0.001859,0.001859,8.367532,0.612511,1.0,4304.0,21.0,390.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00952776,0.00916168586974206,0.00036607413025793907
3.0,4304.0,4289.0,0.000697,0.000697,8.367532,0.612511,1.0,4304.0,21.0,390.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00357227,0.0036757948021627,0.00010352480216270022
2.0,4304.0,4289.0,0.000465,0.000465,8.367532,0.612511,1.0,4304.0,21.0,390.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00238322,0.00237829981986472,4.920180135280228e-06
2.0,4304.0,4289.0,0.000465,0.000465,8.367532,0.612511,1.0,4304.0,21.0,390.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00238322,0.0023756284007575776,7.591599242422545e-06
34.0,605.0,453.0,0.056198,0.056198,6.40688,0.368287,1.0,610.0,14.0,143.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13260331,0.13223493480528767,0.0003683751947123337
27.0,605.0,453.0,0.044628,0.044628,6.40688,0.368287,1.0,610.0,14.0,143.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10530304,0.10179607761018852,0.003506962389811477
24.0,605.0,453.0,0.039669,0.039669,6.40688,0.368287,1.0,610.0,14.0,143.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.09360192,0.09295982869074405,0.0006420913092559516
1.0,605.0,453.0,0.001653,0.001653,6.40688,0.368287,1.0,610.0,14.0,143.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00390037,0.003916821920476189,1.645192047618942e-05
1.0,605.0,453.0,0.001653,0.001653,6.40688,0.368287,1.0,610.0,14.0,143.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00390037,0.003913231291726189,1.2861291726189075e-05
1.0,605.0,453.0,0.001653,0.001653,6.40688,0.368287,1.0,610.0,14.0,143.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00390037,0.003916275277142852,1.590527714285259e-05
2.0,605.0,453.0,0.003306,0.003306,6.40688,0.368287,1.0,610.0,14.0,143.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00780075,0.00762666259619048,0.0001740874038095204
0.0,605.0,453.0,0.0,0.0,6.40688,0.368287,1.0,610.0,14.0,143.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,605.0,453.0,0.004959,0.004959,6.40688,0.368287,1.0,610.0,14.0,143.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01170112,0.011531791556279758,0.00016932844372024268
14.0,605.0,453.0,0.02314,0.02314,6.40688,0.368287,1.0,610.0,14.0,143.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05460053,0.0533153161574008,0.001285213842599199
10.0,605.0,453.0,0.016529,0.016529,6.40688,0.368287,1.0,610.0,14.0,143.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03900139,0.03891662738497012,8.476261502987636e-05
10.0,605.0,453.0,0.016529,0.016529,6.40688,0.368287,1.0,610.0,14.0,143.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03900139,0.038938872999493945,6.251700050605158e-05
10.0,605.0,453.0,0.016529,0.016529,6.40688,0.368287,1.0,610.0,14.0,143.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03900139,0.038917182510208245,8.420748979175163e-05
6.0,605.0,453.0,0.009917,0.009917,6.40688,0.368287,1.0,610.0,14.0,143.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02339989,0.02337467403761906,2.521596238094087e-05
8.0,605.0,453.0,0.013223,0.013223,6.40688,0.368287,1.0,610.0,14.0,143.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03120064,0.03134967801682089,0.00014903801682088907
1.0,605.0,453.0,0.001653,0.001653,6.40688,0.368287,1.0,610.0,14.0,143.0,Missing Completion Status,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00390037,0.0039182936205952364,1.7923620595236642e-05
0.0,605.0,453.0,0.0,0.0,6.40688,0.368287,1.0,610.0,14.0,143.0,Missing Completion Status,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,605.0,453.0,0.0,0.0,6.40688,0.368287,1.0,610.0,14.0,143.0,Missing Completion Status,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,294.0,270.0,0.027211,0.027211,5.686975,0.619383,1.0,294.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09584849,0.09678164889124995,0.0009331588912499522
3.0,294.0,270.0,0.010204,0.010204,5.686975,0.619383,1.0,294.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03594274,0.03658546786650794,0.0006427278665079375
0.0,294.0,270.0,0.0,0.0,5.686975,0.619383,1.0,294.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,294.0,270.0,0.006803,0.006803,5.686975,0.619383,1.0,294.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.023963,0.024253280476517897,0.000290280476517895
4.0,294.0,270.0,0.013605,0.013605,5.686975,0.619383,1.0,294.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04792248,0.048223687016130994,0.00030120701613099016
2.0,294.0,270.0,0.006803,0.006803,5.686975,0.619383,1.0,294.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.023963,0.0242497579087798,0.0002867579087798
2.0,294.0,270.0,0.006803,0.006803,5.686975,0.619383,1.0,294.0,1.0,1.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.023963,0.024162283389295682,0.0001992833892956805
3.0,294.0,270.0,0.010204,0.010204,5.686975,0.619383,1.0,294.0,1.0,1.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03594274,0.036579537726865084,0.0006367977268650835
113.0,365.0,232.0,0.309589,0.309589,5.902633,0.350295,1.0,365.0,1.0,1.0,Screen Failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.64012638,0.6727580783389685,0.03263169833896851
11.0,365.0,232.0,0.030137,0.030137,5.902633,0.350295,1.0,365.0,1.0,1.0,Patient Request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06231322,0.06329637368433529,0.0009831536843352834
1.0,365.0,232.0,0.00274,0.00274,5.902633,0.350295,1.0,365.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0056654,0.005680145308402777,1.474530840277731e-05
2.0,365.0,232.0,0.005479,0.005479,5.902633,0.350295,1.0,365.0,1.0,1.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01132874,0.01161947047247023,0.00029073047247022907
1.0,365.0,232.0,0.00274,0.00274,5.902633,0.350295,1.0,365.0,1.0,1.0,Technical Problem,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0056654,0.005682640336974205,1.724033697420458e-05
1.0,365.0,232.0,0.00274,0.00274,5.902633,0.350295,1.0,365.0,1.0,1.0,Terminated by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0056654,0.005682640336974205,1.724033697420458e-05
4.0,365.0,232.0,0.010959,0.010959,5.902633,0.350295,1.0,365.0,1.0,1.0,Various reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02265954,0.022967773038531748,0.00030823303853174874
2.0,3002.0,2948.0,0.000666,0.000666,8.007367,0.237054,1.0,3002.0,17.0,227.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00126419,0.0012797325306349203,1.5542530634920235e-05
1.0,3002.0,2948.0,0.000333,0.000333,8.007367,0.237054,1.0,3002.0,17.0,227.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00063209,0.0006338043877380953,1.714387738095311e-06
9.0,3002.0,2948.0,0.002998,0.002998,8.007367,0.237054,1.0,3002.0,17.0,227.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00569074,0.005719955967361109,2.921596736110959e-05
18.0,3002.0,2948.0,0.005996,0.005996,8.007367,0.237054,1.0,3002.0,17.0,227.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01138148,0.011533089683406389,0.00015160968340638924
4.0,3002.0,2948.0,0.001332,0.001332,8.007367,0.237054,1.0,3002.0,17.0,227.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00252837,0.0025308436346428527,2.4736346428528254e-06
5.0,3002.0,2948.0,0.001666,0.001666,8.007367,0.237054,1.0,3002.0,17.0,227.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00316237,0.003161153567092353,1.2164329076468604e-06
1.0,3002.0,2948.0,0.000333,0.000333,8.007367,0.237054,1.0,3002.0,17.0,227.0,Did Not Meet Eligibility Criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00063209,0.0006341582698214289,2.068269821428907e-06
0.0,3002.0,2948.0,0.0,0.0,8.007367,0.237054,1.0,3002.0,17.0,227.0,Did Not Meet Eligibility Criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3002.0,2948.0,0.000666,0.000666,8.007367,0.237054,1.0,3002.0,17.0,227.0,Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00126419,0.0012802814531349203,1.609145313492019e-05
1.0,3002.0,2948.0,0.000333,0.000333,8.007367,0.237054,1.0,3002.0,17.0,227.0,Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00063209,0.0006338043877380953,1.714387738095311e-06
3.0,3002.0,2948.0,0.000999,0.000999,8.007367,0.237054,1.0,3002.0,17.0,227.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00189628,0.0019530130082142862,5.673300821428624e-05
4.0,3002.0,2948.0,0.001332,0.001332,8.007367,0.237054,1.0,3002.0,17.0,227.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00252837,0.0025233176820238018,5.052317976198071e-06
0.0,3002.0,2948.0,0.0,0.0,8.007367,0.237054,1.0,3002.0,17.0,227.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,3002.0,2948.0,0.001332,0.001332,8.007367,0.237054,1.0,3002.0,17.0,227.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00252837,0.0025263739473809447,1.996052619055149e-06
15.0,5177.0,4772.0,0.002897,0.002897,8.552174,0.486651,1.0,5177.0,4.0,54.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,FED,0.01205709,0.011685469536339284,0.0003716204636607153
18.0,5177.0,4772.0,0.003477,0.003477,8.552174,0.486651,1.0,5177.0,4.0,54.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,FED,0.014471,0.014453536573660733,1.7463426339266522e-05
13.0,5177.0,4772.0,0.002511,0.002511,8.552174,0.486651,1.0,5177.0,4.0,54.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,FED,0.01045059,0.010067541749543652,0.00038304825045634705
11.0,5177.0,4772.0,0.002125,0.002125,8.552174,0.486651,1.0,5177.0,4.0,54.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,FED,0.00884409,0.008424297138273813,0.00041979286172618736
10.0,5177.0,4772.0,0.001932,0.001932,8.552174,0.486651,1.0,5177.0,4.0,54.0,Revoked Consent Prior To Procedure,Overall Study,FG000,cardiovascular disease,FED,0.00804083,0.007859453556262625,0.00018137644373737542
9.0,5177.0,4772.0,0.001738,0.001738,8.552174,0.486651,1.0,5177.0,4.0,54.0,Revoked Consent Prior To Procedure,Overall Study,FG001,cardiovascular disease,FED,0.00723342,0.00595071321239088,0.00128270678760912
15.0,5177.0,4772.0,0.002897,0.002897,8.552174,0.486651,1.0,5177.0,4.0,54.0,Revoked Consent Prior To Procedure,Overall Study,FG002,cardiovascular disease,FED,0.01205709,0.011715115031081351,0.00034197496891864854
5.0,5177.0,4772.0,0.000966,0.000966,8.552174,0.486651,1.0,5177.0,4.0,54.0,Revoked Consent Prior To Procedure,Overall Study,FG003,cardiovascular disease,FED,0.00402042,0.0036106956955438366,0.0004097243044561636
46.0,5177.0,4772.0,0.008885,0.008885,8.552174,0.486651,1.0,5177.0,4.0,54.0,Procedure Cancelled,Overall Study,FG000,cardiovascular disease,FED,0.03697868,0.03561850605467262,0.0013601739453273781
45.0,5177.0,4772.0,0.008692,0.008692,8.552174,0.486651,1.0,5177.0,4.0,54.0,Procedure Cancelled,Overall Study,FG001,cardiovascular disease,FED,0.03617543,0.035521901678214285,0.0006535283217857166
25.0,5177.0,4772.0,0.004829,0.004829,8.552174,0.486651,1.0,5177.0,4.0,54.0,Procedure Cancelled,Overall Study,FG002,cardiovascular disease,FED,0.02009792,0.01959993827699405,0.0004979817230059483
29.0,5177.0,4772.0,0.005602,0.005602,8.552174,0.486651,1.0,5177.0,4.0,54.0,Procedure Cancelled,Overall Study,FG003,cardiovascular disease,FED,0.02331509,0.02352457814828376,0.000209488148283761
38.0,5177.0,4772.0,0.00734,0.00734,8.552174,0.486651,1.0,5177.0,4.0,54.0,No Endpoint Blood Draw,Overall Study,FG000,cardiovascular disease,FED,0.03054851,0.030162394899335317,0.0003861151006646843
32.0,5177.0,4772.0,0.006181,0.006181,8.552174,0.486651,1.0,5177.0,4.0,54.0,No Endpoint Blood Draw,Overall Study,FG001,cardiovascular disease,FED,0.02572484,0.025510873878432542,0.00021396612156745695
51.0,5177.0,4772.0,0.009851,0.009851,8.552174,0.486651,1.0,5177.0,4.0,54.0,No Endpoint Blood Draw,Overall Study,FG002,cardiovascular disease,FED,0.0409991,0.04074379186400795,0.0002553081359920467
43.0,5177.0,4772.0,0.008306,0.008306,8.552174,0.486651,1.0,5177.0,4.0,54.0,No Endpoint Blood Draw,Overall Study,FG003,cardiovascular disease,FED,0.03456893,0.03455613495734493,1.2795042655069921e-05
10.0,530.0,422.0,0.018868,0.018868,6.274762,0.572308,1.0,530.0,3.0,30.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.06775678,0.06757567780404766,0.00018110219595234012
4.0,530.0,422.0,0.007547,0.007547,6.274762,0.572308,1.0,530.0,3.0,30.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.02710199,0.026626424247490087,0.00047556575250991273
23.0,530.0,422.0,0.043396,0.043396,6.274762,0.572308,1.0,530.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.15583915,0.15571333333910709,0.00012581666089292454
17.0,530.0,422.0,0.032075,0.032075,6.274762,0.572308,1.0,530.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.11518437,0.11478244476273808,0.00040192523726191587
21.0,530.0,422.0,0.039623,0.039623,6.274762,0.572308,1.0,530.0,3.0,30.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.14228995,0.1384383736323809,0.0038515763676190973
20.0,530.0,422.0,0.037736,0.037736,6.274762,0.572308,1.0,530.0,3.0,30.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.13551356,0.13415211128187504,0.0013614487181249635
6.0,530.0,422.0,0.011321,0.011321,6.274762,0.572308,1.0,530.0,3.0,30.0,ESKD,Overall Study,FG000,cardiovascular disease,OTHER,0.04065478,0.04015594706543265,0.0004988329345673517
2.0,530.0,422.0,0.003774,0.003774,6.274762,0.572308,1.0,530.0,3.0,30.0,ESKD,Overall Study,FG001,cardiovascular disease,OTHER,0.01355279,0.013525350410722415,2.743958927758569e-05
2.0,530.0,422.0,0.003774,0.003774,6.274762,0.572308,1.0,530.0,3.0,30.0,Miscellaneous,Overall Study,FG000,cardiovascular disease,OTHER,0.01355279,0.013531817947924801,2.0972052075199366e-05
3.0,530.0,422.0,0.00566,0.00566,6.274762,0.572308,1.0,530.0,3.0,30.0,Miscellaneous,Overall Study,FG001,cardiovascular disease,OTHER,0.0203256,0.020186533850212837,0.00013906614978716203
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1243.0,1221.0,0.002414,0.002414,7.126087,0.256675,1.0,1351.0,6.0,122.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00441542,0.004428705930079361,1.328593007936165e-05
4.0,1243.0,1221.0,0.003218,0.003218,7.126087,0.256675,1.0,1351.0,6.0,122.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.005886,0.005887177161341989,1.1771613419890234e-06
4.0,1243.0,1221.0,0.003218,0.003218,7.126087,0.256675,1.0,1351.0,6.0,122.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.005886,0.005881917839913415,4.082160086584484e-06
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1243.0,1221.0,0.003218,0.003218,7.126087,0.256675,1.0,1351.0,6.0,122.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.005886,0.005876395511877701,9.60448812229852e-06
1.0,1243.0,1221.0,0.000805,0.000805,7.126087,0.256675,1.0,1351.0,6.0,122.0,Immobilization Stopped,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00147242,0.0014774483302083285,5.028330208328583e-06
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Immobilization Stopped,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1243.0,1221.0,0.000805,0.000805,7.126087,0.256675,1.0,1351.0,6.0,122.0,Investigator/Orthopedic Surgeon Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00147242,0.0014772385510416616,4.818551041661703e-06
1.0,1243.0,1221.0,0.000805,0.000805,7.126087,0.256675,1.0,1351.0,6.0,122.0,Investigator/Orthopedic Surgeon Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00147242,0.0014765595961904712,4.139596190471349e-06
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Orthopedic Surgery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1243.0,1221.0,0.001609,0.001609,7.126087,0.256675,1.0,1351.0,6.0,122.0,Orthopedic Surgery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.002943,0.002904320308928568,3.867969107143208e-05
1.0,1243.0,1221.0,0.000805,0.000805,7.126087,0.256675,1.0,1351.0,6.0,122.0,Visit Not Performed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00147242,0.0014774483302083285,5.028330208328583e-06
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Visit Not Performed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1243.0,1221.0,0.000805,0.000805,7.126087,0.256675,1.0,1351.0,6.0,122.0,Deep-vein Thrombosis,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00147242,0.0014774483302083285,5.028330208328583e-06
0.0,1243.0,1221.0,0.0,0.0,7.126087,0.256675,1.0,1351.0,6.0,122.0,Deep-vein Thrombosis,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1578.0,1419.0,0.000634,0.000634,7.364547,1.0,1.0,1578.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.00466912,0.004505986319156744,0.0001631336808432561
0.0,1578.0,1419.0,0.0,0.0,7.364547,1.0,1.0,1578.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,1578.0,1419.0,0.000634,0.000634,7.364547,1.0,1.0,1578.0,1.0,1.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.00466912,0.004510396619811506,0.0001587233801884939
0.0,1578.0,1419.0,0.0,0.0,7.364547,1.0,1.0,1578.0,1.0,1.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,1578.0,1419.0,0.001267,0.001267,7.364547,1.0,1.0,1578.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.00933088,0.00915303617640873,0.00017784382359127028
0.0,1578.0,1419.0,0.0,0.0,7.364547,1.0,1.0,1578.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
42.0,1578.0,1419.0,0.026616,0.026616,7.364547,1.0,1.0,1578.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.19601478,0.18690464832050607,0.009110131679493927
29.0,1578.0,1419.0,0.018378,0.018378,7.364547,1.0,1.0,1578.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.13534565,0.13497410769049606,0.00037154230950395273
37.0,1578.0,1419.0,0.023447,0.023447,7.364547,1.0,1.0,1578.0,1.0,1.0,Others,Overall Study,FG000,cardiovascular disease,OTHER,0.17267653,0.16529768927942456,0.00737884072057543
47.0,1578.0,1419.0,0.029785,0.029785,7.364547,1.0,1.0,1578.0,1.0,1.0,Others,Overall Study,FG001,cardiovascular disease,OTHER,0.21935303,0.2130675283531249,0.006285501646875108
9.0,4128.0,2419.0,0.00218,0.00218,8.325791,0.217379,1.0,4128.0,25.0,229.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00394549,0.004004610346071428,5.912034607142777e-05
9.0,4128.0,2419.0,0.00218,0.00218,8.325791,0.217379,1.0,4128.0,25.0,229.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00394549,0.003997692135238093,5.220213523809275e-05
331.0,4128.0,2419.0,0.080184,0.080184,8.325791,0.217379,1.0,4128.0,25.0,229.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1451215,0.14886343780898806,0.0037419378089880717
287.0,4128.0,2419.0,0.069525,0.069525,8.325791,0.217379,1.0,4128.0,25.0,229.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12583024,0.1271294883022916,0.0012992483022915835
208.0,4128.0,2419.0,0.050388,0.050388,8.325791,0.217379,1.0,4128.0,25.0,229.0,Subject Withdrew Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09119503,0.0911393691805159,5.566081948409074e-05
223.0,4128.0,2419.0,0.054021,0.054021,8.325791,0.217379,1.0,4128.0,25.0,229.0,Subject Withdrew Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09777023,0.09800837152116079,0.00023814152116079235
154.0,4128.0,2419.0,0.037306,0.037306,8.325791,0.217379,1.0,4128.0,25.0,229.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06751849,0.06776965628476188,0.00025116628476187786
170.0,4128.0,2419.0,0.041182,0.041182,8.325791,0.217379,1.0,4128.0,25.0,229.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07453349,0.07564141585176593,0.0011079258517659313
19.0,4128.0,2419.0,0.004603,0.004603,8.325791,0.217379,1.0,4128.0,25.0,229.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00833077,0.008609359402470247,0.0002785894024702473
24.0,4128.0,2419.0,0.005814,0.005814,8.325791,0.217379,1.0,4128.0,25.0,229.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0105225,0.010425659606140865,9.684039385913536e-05
44.0,4128.0,2419.0,0.010659,0.010659,8.325791,0.217379,1.0,4128.0,25.0,229.0,Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01929126,0.01964514089242064,0.00035388089242063825
45.0,4128.0,2419.0,0.010901,0.010901,8.325791,0.217379,1.0,4128.0,25.0,229.0,Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01972924,0.019909191624712295,0.0001799516247122969
4.0,4128.0,2419.0,0.000969,0.000969,8.325791,0.217379,1.0,4128.0,25.0,229.0,No longer met study criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00175375,0.0017210622185119021,3.268778148809797e-05
5.0,4128.0,2419.0,0.001211,0.001211,8.325791,0.217379,1.0,4128.0,25.0,229.0,No longer met study criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00219174,0.002268225688488458,7.648568848845792e-05
0.0,4128.0,2419.0,0.0,0.0,8.325791,0.217379,1.0,4128.0,25.0,229.0,Study terminated by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,4128.0,2419.0,0.000242,0.000242,8.325791,0.217379,1.0,4128.0,25.0,229.0,Study terminated by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00043799,0.0004547967046626984,1.680670466269838e-05
1.0,4128.0,2419.0,0.000242,0.000242,8.325791,0.217379,1.0,4128.0,25.0,229.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00043799,0.00045554571567460336,1.7555715674603338e-05
0.0,4128.0,2419.0,0.0,0.0,8.325791,0.217379,1.0,4128.0,25.0,229.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
87.0,4128.0,2419.0,0.021076,0.021076,8.325791,0.217379,1.0,4128.0,25.0,229.0,Other Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03814453,0.03835250979305557,0.00020797979305556963
88.0,4128.0,2419.0,0.021318,0.021318,8.325791,0.217379,1.0,4128.0,25.0,229.0,Other Reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03858251,0.038367674728194474,0.00021483527180552603
11.0,508.0,410.0,0.021654,0.021654,6.232448,0.360417,1.0,508.0,6.0,82.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04864098,0.048585220923154766,5.575907684523401e-05
1.0,508.0,410.0,0.001969,0.001969,6.232448,0.360417,1.0,508.0,6.0,82.0,Logistical difficulties,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00442293,0.004455578598168289,3.264859816828891e-05
5.0,508.0,410.0,0.009843,0.009843,6.232448,0.360417,1.0,508.0,6.0,82.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02211015,0.02208774191368058,2.240808631941843e-05
3.0,508.0,410.0,0.005906,0.005906,6.232448,0.360417,1.0,508.0,6.0,82.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01326654,0.013336961361190463,7.042136119046229e-05
26.0,508.0,410.0,0.051181,0.051181,6.232448,0.360417,1.0,508.0,6.0,82.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11496693,0.11502386394052583,5.6933940525832893e-05
1.0,508.0,410.0,0.001969,0.001969,6.232448,0.360417,1.0,508.0,6.0,82.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00442293,0.0044554363156682885,3.250631566828824e-05
51.0,508.0,410.0,0.100394,0.100394,6.232448,0.360417,1.0,508.0,6.0,82.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22551317,0.22025349712989062,0.005259672870109394
10.0,698.0,656.0,0.014327,0.014327,6.549651,0.205195,1.0,698.0,1.0,12.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01925487,0.019196633126201307,5.823687379869283e-05
8.0,698.0,656.0,0.011461,0.011461,6.549651,0.205195,1.0,698.0,1.0,12.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01540309,0.015373777853005942,2.931214699405764e-05
7.0,698.0,656.0,0.010029,0.010029,6.549651,0.205195,1.0,698.0,1.0,12.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01347854,0.014343565415476198,0.000865025415476197
5.0,698.0,656.0,0.007163,0.007163,6.549651,0.205195,1.0,698.0,1.0,12.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00962676,0.009807690079880938,0.00018093007988093796
2.0,698.0,656.0,0.002865,0.002865,6.549651,0.205195,1.0,698.0,1.0,12.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00385044,0.004035737238143936,0.00018529723814393606
3.0,698.0,656.0,0.004298,0.004298,6.549651,0.205195,1.0,698.0,1.0,12.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00577633,0.005758338462410725,1.79915375892745e-05
3.0,698.0,656.0,0.004298,0.004298,6.549651,0.205195,1.0,698.0,1.0,12.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00577633,0.005747157649702391,2.917235029760868e-05
1.0,698.0,656.0,0.001433,0.001433,6.549651,0.205195,1.0,698.0,1.0,12.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00192589,0.001917075108928566,8.814891071434088e-06
0.0,698.0,656.0,0.0,0.0,6.549651,0.205195,1.0,698.0,1.0,12.0,Subject no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,698.0,656.0,0.001433,0.001433,6.549651,0.205195,1.0,698.0,1.0,12.0,Subject no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00192589,0.0019169023922618997,8.98760773810031e-06
1.0,698.0,656.0,0.001433,0.001433,6.549651,0.205195,1.0,698.0,1.0,12.0,Abnormal laboratory value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00192589,0.0019178982995238048,7.991700476195221e-06
0.0,698.0,656.0,0.0,0.0,6.549651,0.205195,1.0,698.0,1.0,12.0,Abnormal laboratory value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,698.0,656.0,0.001433,0.001433,6.549651,0.205195,1.0,698.0,1.0,12.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00192589,0.001918360432857138,7.529567142862013e-06
0.0,698.0,656.0,0.0,0.0,6.549651,0.205195,1.0,698.0,1.0,12.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,850.0,832.0,0.003529,0.003529,6.746412,0.809558,1.0,850.0,9.0,81.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01927402,0.01932717138668651,5.315138668651048e-05
9.0,850.0,832.0,0.010588,0.010588,6.746412,0.809558,1.0,850.0,9.0,81.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05782751,0.05821609783737102,0.0003885878373710225
2.0,850.0,832.0,0.002353,0.002353,6.746412,0.809558,1.0,850.0,9.0,81.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01285117,0.013625168346031748,0.0007739983460317481
4.0,850.0,832.0,0.004706,0.004706,6.746412,0.809558,1.0,850.0,9.0,81.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02570233,0.025893874878154772,0.00019154487815477295
11.0,1275.0,1179.0,0.008627,0.008627,7.151485,0.222179,1.0,1275.0,3.0,85.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01370753,0.013891857346685616,0.00018432734668561573
3.0,1275.0,1179.0,0.002353,0.002353,7.151485,0.222179,1.0,1275.0,3.0,85.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00373871,0.003767672541468247,2.8962541468246974e-05
6.0,1275.0,1179.0,0.004706,0.004706,7.151485,0.222179,1.0,1275.0,3.0,85.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00747741,0.007496110965327354,1.870096532735361e-05
4.0,1275.0,1179.0,0.003137,0.003137,7.151485,0.222179,1.0,1275.0,3.0,85.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00498441,0.004979977922619076,4.432077380924111e-06
5.0,1275.0,1179.0,0.003922,0.003922,7.151485,0.222179,1.0,1275.0,3.0,85.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00623171,0.0062401191557674715,8.409155767471858e-06
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00124571,0.0012455219235119116,1.8807648808835675e-07
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00124571,0.0012420449575000058,3.6650424999941107e-06
2.0,1275.0,1179.0,0.001569,0.001569,7.151485,0.222179,1.0,1275.0,3.0,85.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.002493,0.0025104791498015817,1.747914980158166e-05
0.0,1275.0,1179.0,0.0,0.0,7.151485,0.222179,1.0,1275.0,3.0,85.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1275.0,1179.0,0.002353,0.002353,7.151485,0.222179,1.0,1275.0,3.0,85.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00373871,0.0037641579525613204,2.5447952561320243e-05
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00124571,0.001246079596845245,3.6959684524516534e-07
4.0,1275.0,1179.0,0.003137,0.003137,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00498441,0.004982843820357173,1.5661796428272437e-06
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00124571,0.0012459023697619115,1.9236976191161492e-07
2.0,1275.0,1179.0,0.001569,0.001569,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.002493,0.0025085810141468197,1.5581014146819755e-05
0.0,1275.0,1179.0,0.0,0.0,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1275.0,1179.0,0.003137,0.003137,7.151485,0.222179,1.0,1275.0,3.0,85.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00498441,0.004983505148869078,9.048511309221741e-07
8.0,1275.0,1179.0,0.006275,0.006275,7.151485,0.222179,1.0,1275.0,3.0,85.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00997041,0.010057211184953098,8.680118495309717e-05
6.0,1275.0,1179.0,0.004706,0.004706,7.151485,0.222179,1.0,1275.0,3.0,85.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00747741,0.0074854244614880674,8.014461488067143e-06
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00124571,0.0012434649876785781,2.2450123214217722e-06
0.0,1275.0,1179.0,0.0,0.0,7.151485,0.222179,1.0,1275.0,3.0,85.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00124571,0.0012460459326785781,3.359326785782116e-07
5.0,1275.0,1179.0,0.003922,0.003922,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00623171,0.006236165137136517,4.455137136516983e-06
4.0,1275.0,1179.0,0.003137,0.003137,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00498441,0.0049728623324405054,1.1547667559494434e-05
5.0,1275.0,1179.0,0.003922,0.003922,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00623171,0.00623358729048969,1.877290489690417e-06
3.0,1275.0,1179.0,0.002353,0.002353,7.151485,0.222179,1.0,1275.0,3.0,85.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00373871,0.003767133859704177,2.8423859704176848e-05
6.0,1275.0,1179.0,0.004706,0.004706,7.151485,0.222179,1.0,1275.0,3.0,85.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00747741,0.00748863458208331,1.1224582083309287e-05
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00124571,0.001243305929583339,2.404070416660905e-06
5.0,1275.0,1179.0,0.003922,0.003922,7.151485,0.222179,1.0,1275.0,3.0,85.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00623171,0.00622877644572779,2.933554272209829e-06
2.0,1275.0,1179.0,0.001569,0.001569,7.151485,0.222179,1.0,1275.0,3.0,85.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.002493,0.002509054097896819,1.6054097896818845e-05
1.0,1275.0,1179.0,0.000784,0.000784,7.151485,0.222179,1.0,1275.0,3.0,85.0,Other,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00124571,0.0012464908743452447,7.808743452447815e-07
7.0,250.0,238.0,0.028,0.028,5.525453,0.258509,1.0,250.0,0.0,0.0,Discontinued,30 Days Post-Procedure,FG000,cardiovascular disease,INDUSTRY,0.03999466,0.040810163337539666,0.000815503337539665
4.0,250.0,238.0,0.016,0.016,5.525453,0.258509,1.0,250.0,0.0,0.0,Missed Visit - Phone Contact f/u,30 Days Post-Procedure,FG000,cardiovascular disease,INDUSTRY,0.02285409,0.022853195414930562,8.945850694386248e-07
1.0,250.0,238.0,0.004,0.004,5.525453,0.258509,1.0,250.0,0.0,0.0,Missed Visit - No Phone Contact,30 Days Post-Procedure,FG000,cardiovascular disease,INDUSTRY,0.00571352,0.005741102937242068,2.758293724206863e-05
30.0,5883.0,4884.0,0.005099,0.005099,8.679992,0.318867,1.0,5897.0,35.0,567.0,Major/minor bleed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01411283,0.013733979574303739,0.00037885042569626125
44.0,5883.0,4884.0,0.007479,0.007479,8.679992,0.318867,1.0,5897.0,35.0,567.0,Major/minor bleed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02070011,0.020282708227787678,0.00041740177221232314
33.0,5883.0,4884.0,0.005609,0.005609,8.679992,0.318867,1.0,5897.0,35.0,567.0,Outcome event - other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01552439,0.015490733146984124,3.365685301587665e-05
25.0,5883.0,4884.0,0.00425,0.00425,8.679992,0.318867,1.0,5897.0,35.0,567.0,Outcome event - other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.011763,0.011914420907142858,0.00015142090714285843
111.0,5883.0,4884.0,0.018868,0.018868,8.679992,0.318867,1.0,5897.0,35.0,567.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05222218,0.05120708963425595,0.0010150903657440494
121.0,5883.0,4884.0,0.020568,0.020568,8.679992,0.318867,1.0,5897.0,35.0,567.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05692738,0.056758109665972195,0.00016927033402780456
18.0,5883.0,4884.0,0.00306,0.00306,8.679992,0.318867,1.0,5897.0,35.0,567.0,Hospitalization (not including surgery),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00846936,0.0085907599868254,0.00012139998682540037
17.0,5883.0,4884.0,0.00289,0.00289,8.679992,0.318867,1.0,5897.0,35.0,567.0,Hospitalization (not including surgery),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00799884,0.008000186352884199,1.3463528841985845e-06
37.0,5883.0,4884.0,0.006289,0.006289,8.679992,0.318867,1.0,5897.0,35.0,567.0,Hospitalization due to surgery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01740647,0.017451704443194434,4.5234443194434176e-05
40.0,5883.0,4884.0,0.006799,0.006799,8.679992,0.318867,1.0,5897.0,35.0,567.0,Hospitalization due to surgery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01881803,0.018574971456121022,0.00024305854387897743
53.0,5883.0,4884.0,0.009009,0.009009,8.679992,0.318867,1.0,5897.0,35.0,567.0,Reduced creatinine clearance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02493479,0.024900605099523805,3.4184900476193214e-05
55.0,5883.0,4884.0,0.009349,0.009349,8.679992,0.318867,1.0,5897.0,35.0,567.0,Reduced creatinine clearance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02587583,0.02569921235936507,0.0001766176406349275
7.0,5883.0,4884.0,0.00119,0.00119,8.679992,0.318867,1.0,5897.0,35.0,567.0,Elevated LFT results,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00329364,0.0032946438514682612,1.0038514682612042e-06
3.0,5883.0,4884.0,0.00051,0.00051,8.679992,0.318867,1.0,5897.0,35.0,567.0,Elevated LFT results,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00141156,0.0014094934711507909,2.06652884920922e-06
65.0,5883.0,4884.0,0.011049,0.011049,8.679992,0.318867,1.0,5897.0,35.0,567.0,Patient refused to take study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03058103,0.0300340809423016,0.0005469490576983996
76.0,5883.0,4884.0,0.012919,0.012919,8.679992,0.318867,1.0,5897.0,35.0,567.0,Patient refused to take study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03575675,0.035006162544940496,0.000750587455059501
1.0,5883.0,4884.0,0.00017,0.00017,8.679992,0.318867,1.0,5897.0,35.0,567.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00047052,0.0004894900181277059,1.8970018127705923e-05
0.0,5883.0,4884.0,0.0,0.0,8.679992,0.318867,1.0,5897.0,35.0,567.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,5883.0,4884.0,0.00017,0.00017,8.679992,0.318867,1.0,5897.0,35.0,567.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00047052,0.00048241939747294447,1.189939747294448e-05
1.0,5883.0,4884.0,0.00017,0.00017,8.679992,0.318867,1.0,5897.0,35.0,567.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00047052,0.0004830192059577929,1.2499205957792938e-05
6.0,5883.0,4884.0,0.00102,0.00102,8.679992,0.318867,1.0,5897.0,35.0,567.0,Procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00282312,0.0028194552139285695,3.6647860714306146e-06
7.0,5883.0,4884.0,0.00119,0.00119,8.679992,0.318867,1.0,5897.0,35.0,567.0,Procedure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00329364,0.0032931589946230216,4.810053769784689e-07
21.0,5883.0,4884.0,0.00357,0.00357,8.679992,0.318867,1.0,5897.0,35.0,567.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00988092,0.009908884467232143,2.7964467232143714e-05
25.0,5883.0,4884.0,0.00425,0.00425,8.679992,0.318867,1.0,5897.0,35.0,567.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.011763,0.011894219511488092,0.00013121951148809333
4.0,5883.0,4884.0,0.00068,0.00068,8.679992,0.318867,1.0,5897.0,35.0,567.0,Site closed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00188208,0.001899509244484128,1.742924448412805e-05
3.0,5883.0,4884.0,0.00051,0.00051,8.679992,0.318867,1.0,5897.0,35.0,567.0,Site closed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00141156,0.0014094934711507909,2.06652884920922e-06
47.0,5883.0,4884.0,0.007989,0.007989,8.679992,0.318867,1.0,5897.0,35.0,567.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02211167,0.022846056186815497,0.0007343861868154972
38.0,5883.0,4884.0,0.006459,0.006459,8.679992,0.318867,1.0,5897.0,35.0,567.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01787699,0.017866301716656728,1.0688283343270738e-05
3.0,5883.0,4884.0,0.00051,0.00051,8.679992,0.318867,1.0,5897.0,35.0,567.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00141156,0.0014057061368055533,5.8538631944468015e-06
11.0,5883.0,4884.0,0.00187,0.00187,8.679992,0.318867,1.0,5897.0,35.0,567.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00517572,0.005097396435565474,7.832356443452596e-05
7.0,5883.0,4884.0,0.00119,0.00119,8.679992,0.318867,1.0,5897.0,35.0,567.0,Patient elected,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00329364,0.0032946438514682612,1.0038514682612042e-06
9.0,5883.0,4884.0,0.00153,0.00153,8.679992,0.318867,1.0,5897.0,35.0,567.0,Patient elected,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00423468,0.004217874214246029,1.6805785753971382e-05
19.0,5883.0,4884.0,0.00323,0.00323,8.679992,0.318867,1.0,5897.0,35.0,567.0,Site closed for cause,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00893988,0.009134289866755954,0.00019440986675595302
19.0,5883.0,4884.0,0.00323,0.00323,8.679992,0.318867,1.0,5897.0,35.0,567.0,Site closed for cause,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00893988,0.009148013795714283,0.0002081337957142819
5.0,5883.0,4884.0,0.00085,0.00085,8.679992,0.318867,1.0,5897.0,35.0,567.0,Other reason not defined above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0023526,0.0023307504762996073,2.1849523700392514e-05
5.0,5883.0,4884.0,0.00085,0.00085,8.679992,0.318867,1.0,5897.0,35.0,567.0,Other reason not defined above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0023526,0.0023338810877822904,1.871891221770939e-05
13.0,5883.0,4884.0,0.00221,0.00221,8.679992,0.318867,1.0,5897.0,35.0,567.0,Excluded from analysis,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00611676,0.006296726613968253,0.00017996661396825313
19.0,5883.0,4884.0,0.00323,0.00323,8.679992,0.318867,1.0,5897.0,35.0,567.0,Excluded from analysis,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00893988,0.009148013795714283,0.0002081337957142819
11.0,2689.0,2439.0,0.004091,0.004091,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG000,cardiovascular disease,INDUSTRY,0.0088478,0.008662335119315478,0.0001854648806845216
3.0,2689.0,2439.0,0.001116,0.001116,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG001,cardiovascular disease,INDUSTRY,0.00241363,0.002419912584454356,6.282584454356255e-06
7.0,2689.0,2439.0,0.002603,0.002603,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG002,cardiovascular disease,INDUSTRY,0.00562963,0.005610413236577394,1.9216763422606233e-05
13.0,2689.0,2439.0,0.004835,0.004835,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG003,cardiovascular disease,INDUSTRY,0.01045689,0.010316773253472218,0.00014011674652778146
10.0,2689.0,2439.0,0.003719,0.003719,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG004,cardiovascular disease,INDUSTRY,0.00804326,0.007927237899365084,0.00011602210063491568
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG005,cardiovascular disease,INDUSTRY,0.00402055,0.004013288078630932,7.26192136906844e-06
9.0,2689.0,2439.0,0.003347,0.003347,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG006,cardiovascular disease,INDUSTRY,0.00723872,0.007396539684861109,0.00015781968486110968
17.0,2689.0,2439.0,0.006322,0.006322,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG007,cardiovascular disease,INDUSTRY,0.01367289,0.01366332665091268,9.563349087320441e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,"PeriodI-II (Randomized, Double-Blind)",FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2689.0,2439.0,0.001488,0.001488,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG000,cardiovascular disease,INDUSTRY,0.00321817,0.0032518008963095314,3.3630896309531574e-05
6.0,2689.0,2439.0,0.002231,0.002231,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG001,cardiovascular disease,INDUSTRY,0.00482509,0.004837529784583331,1.243978458333097e-05
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG002,cardiovascular disease,INDUSTRY,0.00402055,0.004024647063779739,4.097063779739084e-06
8.0,2689.0,2439.0,0.002975,0.002975,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG003,cardiovascular disease,INDUSTRY,0.00643418,0.006368961825625003,6.521817437499765e-05
7.0,2689.0,2439.0,0.002603,0.002603,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG004,cardiovascular disease,INDUSTRY,0.00562963,0.005620112978214303,9.517021785697063e-06
6.0,2689.0,2439.0,0.002231,0.002231,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG005,cardiovascular disease,INDUSTRY,0.00482509,0.004836501444404759,1.1411444404758886e-05
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG006,cardiovascular disease,INDUSTRY,0.00402055,0.00402220463815474,1.6546381547393602e-06
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG007,cardiovascular disease,INDUSTRY,0.00402055,0.00402220463815474,1.6546381547393602e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,"PeriodI-II (Randomized, Double-Blind)",FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG000,cardiovascular disease,INDUSTRY,0.00080454,0.0008082568072023822,3.7168072023822636e-06
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG001,cardiovascular disease,INDUSTRY,0.00080454,0.000806616302332253,2.0763023322530353e-06
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG002,cardiovascular disease,INDUSTRY,0.00080454,0.0008082141047023822,3.674104702382241e-06
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG003,cardiovascular disease,INDUSTRY,0.00402055,0.0040170322919642655,3.517708035734833e-06
4.0,2689.0,2439.0,0.001488,0.001488,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG004,cardiovascular disease,INDUSTRY,0.00321817,0.003241936172023817,2.3766172023817218e-05
2.0,2689.0,2439.0,0.000744,0.000744,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG005,cardiovascular disease,INDUSTRY,0.00160908,0.0016044058741269851,4.674125873014787e-06
4.0,2689.0,2439.0,0.001488,0.001488,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG006,cardiovascular disease,INDUSTRY,0.00321817,0.0032444719841071504,2.6301984107150646e-05
3.0,2689.0,2439.0,0.001116,0.001116,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG007,cardiovascular disease,INDUSTRY,0.00241363,0.002418112143204353,4.482143204352987e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,"PeriodI-II (Randomized, Double-Blind)",FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG005,cardiovascular disease,INDUSTRY,0.00080454,0.0008047720679761924,2.3206797619245833e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,"PeriodI-II (Randomized, Double-Blind)",FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG001,cardiovascular disease,INDUSTRY,0.00080454,0.0008042386547727299,3.0134522727002545e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG003,cardiovascular disease,INDUSTRY,0.00080454,0.0008063919883333357,1.8519883333357242e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG005,cardiovascular disease,INDUSTRY,0.00080454,0.0008050861391666693,5.461391666693226e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,"PeriodI-II (Randomized, Double-Blind)",FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG000,cardiovascular disease,INDUSTRY,0.00402055,0.004023111942400776,2.561942400775355e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period III (Single-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,2689.0,2439.0,0.003719,0.003719,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG000,cardiovascular disease,INDUSTRY,0.00804326,0.007957169015059527,8.60909849404734e-05
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period III (Single-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2689.0,2439.0,0.001116,0.001116,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG000,cardiovascular disease,INDUSTRY,0.00241363,0.002420797052251975,7.16705225197508e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period III (Single-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2689.0,2439.0,0.000744,0.000744,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG000,cardiovascular disease,INDUSTRY,0.00160908,0.0016076747186210324,1.4052813789675479e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period III (Single-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2689.0,2439.0,0.000744,0.000744,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG000,cardiovascular disease,INDUSTRY,0.00160908,0.0016082606301488105,8.193698511893815e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period IV (Double-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG001,cardiovascular disease,INDUSTRY,0.00080454,0.000803816463403682,7.235365963179433e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period IV (Double-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG001,cardiovascular disease,INDUSTRY,0.00080454,0.0008061396817965389,1.599681796538954e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period IV (Double-Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG008,cardiovascular disease,INDUSTRY,0.00080454,0.000805342319880955,8.02319880955e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period V (Double -Blind),FG012,cardiovascular disease,INDUSTRY,0.00080454,0.000805342319880955,8.02319880955e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period V (Double -Blind),FG012,cardiovascular disease,INDUSTRY,0.00080454,0.0008072647074404782,2.724707440478224e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG010,cardiovascular disease,INDUSTRY,0.00080454,0.0008049117107142883,3.717107142882977e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period V (Double -Blind),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,2689.0,2439.0,0.006322,0.006322,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG000,cardiovascular disease,INDUSTRY,0.01367289,0.01366372190091268,9.168099087320317e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2689.0,2439.0,0.001488,0.001488,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG002,cardiovascular disease,INDUSTRY,0.00321817,0.0032433717947619113,2.5201794761911533e-05
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG003,cardiovascular disease,INDUSTRY,0.00080454,0.0008050428248809545,5.02824880954547e-07
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG004,cardiovascular disease,INDUSTRY,0.00080454,0.0008039221873809545,6.1781261904547e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Adverse Event,Period VI (Open-Label),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
15.0,2689.0,2439.0,0.005578,0.005578,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG000,cardiovascular disease,INDUSTRY,0.01206381,0.012116489412906738,5.2679412906738235e-05
7.0,2689.0,2439.0,0.002603,0.002603,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG001,cardiovascular disease,INDUSTRY,0.00562963,0.005614816039464299,1.481396053570113e-05
5.0,2689.0,2439.0,0.001859,0.001859,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG002,cardiovascular disease,INDUSTRY,0.00402055,0.004024595728541646,4.045728541645678e-06
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG004,cardiovascular disease,INDUSTRY,0.00080454,0.0008047982390476214,2.5823904762148353e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Withdrawal by Subject,Period VI (Open-Label),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,2689.0,2439.0,0.002231,0.002231,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG000,cardiovascular disease,INDUSTRY,0.00482509,0.004843655560714281,1.856556071428133e-05
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG001,cardiovascular disease,INDUSTRY,0.00080454,0.0008061871259036819,1.6471259036819228e-06
3.0,2689.0,2439.0,0.001116,0.001116,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG002,cardiovascular disease,INDUSTRY,0.00241363,0.002422459480644831,8.829480644830922e-06
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG003,cardiovascular disease,INDUSTRY,0.00080454,0.0008081724582738113,3.6324582738113094e-06
4.0,2689.0,2439.0,0.001488,0.001488,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG004,cardiovascular disease,INDUSTRY,0.00321817,0.00324116939910715,2.2999399107150216e-05
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Protocol Violation,Period VI (Open-Label),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG000,cardiovascular disease,INDUSTRY,0.00080454,0.0008053528848809546,8.128848809546346e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG002,cardiovascular disease,INDUSTRY,0.00080454,0.0008053101823809546,7.701823809546119e-07
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Lost to Follow-up,Period VI (Open-Label),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG003,cardiovascular disease,INDUSTRY,0.00080454,0.0008057294144047646,1.1894144047645914e-06
1.0,2689.0,2439.0,0.000372,0.000372,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG004,cardiovascular disease,INDUSTRY,0.00080454,0.0008046087769047645,6.877690476457445e-08
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2689.0,2439.0,0.0,0.0,7.897296,0.273859,1.0,2689.0,15.0,133.0,Other Reason,Period VI (Open-Label),FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
46.0,13199.0,13097.0,0.003485,0.003485,9.487972,0.42265,1.0,13307.0,33.0,521.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01397516,0.013953256929315472,2.1903070684527876e-05
56.0,13199.0,13097.0,0.004243,0.004243,9.487972,0.42265,1.0,13307.0,33.0,521.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0170148,0.0163184696903869,0.000696330309613101
136.0,8292.0,7892.0,0.016401,0.016401,9.023167,0.328159,1.0,8292.0,38.0,454.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04856387,0.04640203233926589,0.002161837660734113
127.0,8292.0,7892.0,0.015316,0.015316,9.023167,0.328159,1.0,8292.0,38.0,454.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04535115,0.043303109474940496,0.002048040525059504
7.0,8292.0,7892.0,0.000844,0.000844,9.023167,0.328159,1.0,8292.0,38.0,454.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00249911,0.0025253922394318177,2.6282239431817556e-05
4.0,8292.0,7892.0,0.000482,0.000482,9.023167,0.328159,1.0,8292.0,38.0,454.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00142722,0.0014518181802876998,2.4598180287699724e-05
32.0,8292.0,7892.0,0.003859,0.003859,9.023167,0.328159,1.0,8292.0,38.0,454.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01142662,0.011258015517321432,0.00016860448267856827
33.0,8292.0,7892.0,0.00398,0.00398,9.023167,0.328159,1.0,8292.0,38.0,454.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0117849,0.011571957646011901,0.0002129423539880982
6.0,8292.0,7892.0,0.000724,0.000724,9.023167,0.328159,1.0,8292.0,38.0,454.0,investigator/subject decide not continue,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00214379,0.002200503390892857,5.671339089285705e-05
3.0,8292.0,7892.0,0.000362,0.000362,9.023167,0.328159,1.0,8292.0,38.0,454.0,investigator/subject decide not continue,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00107189,0.0010272216342162698,4.466836578373022e-05
25.0,8292.0,7892.0,0.003015,0.003015,9.023167,0.328159,1.0,8292.0,38.0,454.0,never received study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00892751,0.008788804127361117,0.0001387058726388824
27.0,8292.0,7892.0,0.003256,0.003256,9.023167,0.328159,1.0,8292.0,38.0,454.0,never received study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00964112,0.00950973715589286,0.00013138284410713942
7.0,485.0,433.0,0.014433,0.014433,6.186209,0.240569,1.0,485.0,6.0,6.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0214793,0.021465404463531755,1.3895536468244707e-05
16.0,485.0,433.0,0.03299,0.03299,6.186209,0.240569,1.0,485.0,6.0,6.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04909598,0.04967210672053571,0.0005761267205357107
0.0,485.0,433.0,0.0,0.0,6.186209,0.240569,1.0,485.0,6.0,6.0,Abnormal test procedure result(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,485.0,433.0,0.002062,0.002062,6.186209,0.240569,1.0,485.0,6.0,6.0,Abnormal test procedure result(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00306868,0.0030659280990377015,2.751900962298312e-06
2.0,485.0,433.0,0.004124,0.004124,6.186209,0.240569,1.0,485.0,6.0,6.0,Subject withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00613737,0.006162654012365622,2.5284012365621965e-05
4.0,485.0,433.0,0.008247,0.008247,6.186209,0.240569,1.0,485.0,6.0,6.0,Subject withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01227325,0.012186682003749987,8.656799625001224e-05
1.0,485.0,433.0,0.002062,0.002062,6.186209,0.240569,1.0,485.0,6.0,6.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00306868,0.003065029728382938,3.650271617061749e-06
1.0,485.0,433.0,0.002062,0.002062,6.186209,0.240569,1.0,485.0,6.0,6.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00306868,0.0030657432162996055,2.9367837003943346e-06
9.0,485.0,433.0,0.018557,0.018557,6.186209,0.240569,1.0,485.0,6.0,6.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02761667,0.027598485729791664,1.8184270208335823e-05
9.0,485.0,433.0,0.018557,0.018557,6.186209,0.240569,1.0,485.0,6.0,6.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02761667,0.02754280676493235,7.386323506764977e-05
1.0,485.0,433.0,0.002062,0.002062,6.186209,0.240569,1.0,485.0,6.0,6.0,Misrandomized,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00306868,0.0030653009386210346,3.3790613789652472e-06
0.0,485.0,433.0,0.0,0.0,6.186209,0.240569,1.0,485.0,6.0,6.0,Misrandomized,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,485.0,433.0,0.0,0.0,6.186209,0.240569,1.0,485.0,6.0,6.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,485.0,433.0,0.002062,0.002062,6.186209,0.240569,1.0,485.0,6.0,6.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00306868,0.0030659280990377015,2.751900962298312e-06
137.0,1725.0,1415.0,0.07942,0.07942,7.453562,0.619677,1.0,1725.0,30.0,503.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.36682535,0.36757133542414033,0.0007459854241403385
137.0,1725.0,1415.0,0.07942,0.07942,7.453562,0.619677,1.0,1725.0,30.0,503.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.36682535,0.3705914698443784,0.0037661198443784127
17.0,1725.0,1415.0,0.009855,0.009855,7.453562,0.619677,1.0,1725.0,30.0,503.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0455183,0.04735522652231148,0.0018369265223114814
9.0,1725.0,1415.0,0.005217,0.005217,7.453562,0.619677,1.0,1725.0,30.0,503.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0240963,0.023883491652698385,0.00021280834730161638
4.0,1725.0,1415.0,0.002319,0.002319,7.453562,0.619677,1.0,1725.0,30.0,503.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.010711,0.011049161389851195,0.00033816138985119475
6.0,1725.0,1415.0,0.003478,0.003478,7.453562,0.619677,1.0,1725.0,30.0,503.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0160642,0.016006838160853167,5.736183914683418e-05
0.0,222.0,211.0,0.0,0.0,5.407172,0.82547,1.0,222.0,7.0,19.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,222.0,211.0,0.004505,0.004505,5.407172,0.82547,1.0,222.0,7.0,19.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02010788,0.020136277481180635,2.8397481180632983e-05
4.0,222.0,211.0,0.018018,0.018018,5.407172,0.82547,1.0,222.0,7.0,19.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08042259,0.08258974143948399,0.002167151439483983
2.0,222.0,211.0,0.009009,0.009009,5.407172,0.82547,1.0,222.0,7.0,19.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04021129,0.040676768114642846,0.0004654781146428491
0.0,222.0,211.0,0.0,0.0,5.407172,0.82547,1.0,222.0,7.0,19.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,222.0,211.0,0.004505,0.004505,5.407172,0.82547,1.0,222.0,7.0,19.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02010788,0.020143029788680638,3.514978868063637e-05
1.0,222.0,211.0,0.004505,0.004505,5.407172,0.82547,1.0,222.0,7.0,19.0,Lack of Trial Compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02010788,0.02016196809805563,5.4088098055626865e-05
1.0,222.0,211.0,0.004505,0.004505,5.407172,0.82547,1.0,222.0,7.0,19.0,Lack of Trial Compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02010788,0.020140894701180637,3.3014701180635736e-05
0.0,222.0,211.0,0.0,0.0,5.407172,0.82547,1.0,222.0,7.0,19.0,Physical disability to come to the site for the closing visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,222.0,211.0,0.004505,0.004505,5.407172,0.82547,1.0,222.0,7.0,19.0,Physical disability to come to the site for the closing visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02010788,0.020140894701180637,3.3014701180635736e-05
1.0,3195.0,2953.0,0.000313,0.000313,8.069655,0.214254,1.0,3608.0,13.0,107.0,Death,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00054116,0.0005408841587698456,2.7584123015432244e-07
1.0,3195.0,2953.0,0.000313,0.000313,8.069655,0.214254,1.0,3608.0,13.0,107.0,Death,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00054116,0.0005406306160615124,5.293839384875373e-07
60.0,3195.0,2953.0,0.018779,0.018779,8.069655,0.214254,1.0,3608.0,13.0,107.0,Adverse Event,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.03246814,0.032150083041277984,0.00031805695872201556
58.0,3195.0,2953.0,0.018153,0.018153,8.069655,0.214254,1.0,3608.0,13.0,107.0,Adverse Event,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.03138581,0.03150540470521826,0.00011959470521825943
18.0,3195.0,2953.0,0.005634,0.005634,8.069655,0.214254,1.0,3608.0,13.0,107.0,Withdrawal by Subject,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00974096,0.009933029601994037,0.00019206960199403753
37.0,3195.0,2953.0,0.011581,0.011581,8.069655,0.214254,1.0,3608.0,13.0,107.0,Withdrawal by Subject,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.02002308,0.02022448121772817,0.00020140121772817265
0.0,3195.0,2953.0,0.0,0.0,8.069655,0.214254,1.0,3608.0,13.0,107.0,Lost to Follow-up,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3195.0,2953.0,0.000313,0.000313,8.069655,0.214254,1.0,3608.0,13.0,107.0,Lost to Follow-up,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00054116,0.0005405774628472267,5.825371527732725e-07
1.0,3195.0,2953.0,0.000313,0.000313,8.069655,0.214254,1.0,3608.0,13.0,107.0,No longer meets study criteria,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00054116,0.0005406683347222266,4.916652777733335e-07
2.0,3195.0,2953.0,0.000626,0.000626,8.069655,0.214254,1.0,3608.0,13.0,107.0,No longer meets study criteria,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00108233,0.0010859412539384922,3.6112539384921313e-06
1.0,3195.0,2953.0,0.000313,0.000313,8.069655,0.214254,1.0,3608.0,13.0,107.0,Administrative reason by sponsor,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00054116,0.0005406683347222266,4.916652777733335e-07
0.0,3195.0,2953.0,0.0,0.0,8.069655,0.214254,1.0,3608.0,13.0,107.0,Administrative reason by sponsor,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,3195.0,2953.0,0.002817,0.002817,8.069655,0.214254,1.0,3608.0,13.0,107.0,non-specified,DB Treatment Period-Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00487048,0.004813507699513885,5.697230048611491e-05
8.0,3195.0,2953.0,0.002504,0.002504,8.069655,0.214254,1.0,3608.0,13.0,107.0,non-specified,DB Treatment Period-Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00432932,0.004311764463690476,1.7555536309524396e-05
17.0,3195.0,2953.0,0.005321,0.005321,8.069655,0.214254,1.0,3608.0,13.0,107.0,Withdrawal by Subject,Follow-Up Period - Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.0091998,0.009273439200188504,7.3639200188505e-05
19.0,3195.0,2953.0,0.005947,0.005947,8.069655,0.214254,1.0,3608.0,13.0,107.0,Withdrawal by Subject,Follow-Up Period - Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.01028212,0.010319606892152776,3.7486892152775037e-05
0.0,3195.0,2953.0,0.0,0.0,8.069655,0.214254,1.0,3608.0,13.0,107.0,Death,Follow-Up Period - Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3195.0,2953.0,0.000626,0.000626,8.069655,0.214254,1.0,3608.0,13.0,107.0,Death,Follow-Up Period - Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00108233,0.0010859412539384922,3.6112539384921313e-06
38.0,3195.0,2953.0,0.011894,0.011894,8.069655,0.214254,1.0,3608.0,13.0,107.0,Lost to Follow-up,Follow-Up Period - Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.02056425,0.021690741237509917,0.0011264912375099183
39.0,3195.0,2953.0,0.012207,0.012207,8.069655,0.214254,1.0,3608.0,13.0,107.0,Lost to Follow-up,Follow-Up Period - Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.02110541,0.02257553585298609,0.0014701258529860872
6.0,3195.0,2953.0,0.001878,0.001878,8.069655,0.214254,1.0,3608.0,13.0,107.0,non-specified,Follow-Up Period - Randomized Patients,FG000,cardiovascular disease,INDUSTRY,0.00324699,0.003289646875624999,4.2656875624999015e-05
12.0,3195.0,2953.0,0.003756,0.003756,8.069655,0.214254,1.0,3608.0,13.0,107.0,non-specified,Follow-Up Period - Randomized Patients,FG001,cardiovascular disease,INDUSTRY,0.00649397,0.006685910621825391,0.00019194062182539134
5.0,466.0,385.0,0.01073,0.01073,6.146329,0.376508,1.0,466.0,1.0,51.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02483076,0.024782163984196495,4.859601580350578e-05
4.0,466.0,385.0,0.008584,0.008584,6.146329,0.376508,1.0,466.0,1.0,51.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01986461,0.019852357492371013,1.2252507628988246e-05
4.0,466.0,385.0,0.008584,0.008584,6.146329,0.376508,1.0,466.0,1.0,51.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01986461,0.019880073697728158,1.5463697728156783e-05
3.0,466.0,385.0,0.006438,0.006438,6.146329,0.376508,1.0,466.0,1.0,51.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01489846,0.01455815686267857,0.0003403031373214304
7.0,466.0,385.0,0.015021,0.015021,6.146329,0.376508,1.0,466.0,1.0,51.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03476075,0.03490243088303117,0.00014168088303116722
5.0,466.0,385.0,0.01073,0.01073,6.146329,0.376508,1.0,466.0,1.0,51.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02483076,0.024865230197232226,3.447019723222533e-05
9.0,466.0,385.0,0.019313,0.019313,6.146329,0.376508,1.0,466.0,1.0,51.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04469306,0.04488904662558532,0.00019598662558532182
11.0,466.0,385.0,0.023605,0.023605,6.146329,0.376508,1.0,466.0,1.0,51.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05462536,0.054575629221815455,4.973077818454241e-05
11.0,466.0,385.0,0.023605,0.023605,6.146329,0.376508,1.0,466.0,1.0,51.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05462536,0.054530577856041644,9.478214395835377e-05
2.0,466.0,385.0,0.004292,0.004292,6.146329,0.376508,1.0,466.0,1.0,51.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0099323,0.00995449370244047,2.2193702440470586e-05
4.0,466.0,385.0,0.008584,0.008584,6.146329,0.376508,1.0,466.0,1.0,51.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01986461,0.019823438838442443,4.1171161557558567e-05
5.0,466.0,385.0,0.01073,0.01073,6.146329,0.376508,1.0,466.0,1.0,51.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02483076,0.024857860465744133,2.7100465744132884e-05
4.0,466.0,385.0,0.008584,0.008584,6.146329,0.376508,1.0,466.0,1.0,51.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01986461,0.01982673653022816,3.787346977184025e-05
5.0,466.0,385.0,0.01073,0.01073,6.146329,0.376508,1.0,466.0,1.0,51.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02483076,0.024779079673898884,5.1680326101116725e-05
2.0,466.0,385.0,0.004292,0.004292,6.146329,0.376508,1.0,466.0,1.0,51.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0099323,0.009941360192619042,9.060192619042215e-06
1.0,558.0,423.0,0.001792,0.001792,6.326149,0.363079,1.0,558.0,1.0,7.0,Death,Overall Study,FG000,cardiovascular disease,NIH,0.00411603,0.0041408893517162855,2.4859351716285776e-05
1.0,558.0,423.0,0.001792,0.001792,6.326149,0.363079,1.0,558.0,1.0,7.0,Death,Overall Study,FG001,cardiovascular disease,NIH,0.00411603,0.00413662486150795,2.0594861507950563e-05
1.0,558.0,423.0,0.001792,0.001792,6.326149,0.363079,1.0,558.0,1.0,7.0,Death,Overall Study,FG002,cardiovascular disease,NIH,0.00411603,0.004136055849930571,2.002584993057114e-05
0.0,558.0,423.0,0.0,0.0,6.326149,0.363079,1.0,558.0,1.0,7.0,Death,Overall Study,FG003,cardiovascular disease,NIH,0.0,0.0,0.0
21.0,558.0,423.0,0.037634,0.037634,6.326149,0.363079,1.0,558.0,1.0,7.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NIH,0.08644128,0.0848113710510913,0.001629908948908701
31.0,558.0,423.0,0.055556,0.055556,6.326149,0.363079,1.0,558.0,1.0,7.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NIH,0.1276062,0.12632262878535255,0.0012835712146474498
26.0,558.0,423.0,0.046595,0.046595,6.326149,0.363079,1.0,558.0,1.0,7.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,NIH,0.10702374,0.10161411158186509,0.005409628418134915
20.0,558.0,423.0,0.035842,0.035842,6.326149,0.363079,1.0,558.0,1.0,7.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,NIH,0.08232525,0.08073228781029766,0.0015929621897023405
7.0,558.0,423.0,0.012545,0.012545,6.326149,0.363079,1.0,558.0,1.0,7.0,Less than full participation,Overall Study,FG000,cardiovascular disease,NIH,0.02881453,0.02876771756239089,4.6812437609112384e-05
9.0,558.0,423.0,0.016129,0.016129,6.326149,0.363079,1.0,558.0,1.0,7.0,Less than full participation,Overall Study,FG001,cardiovascular disease,NIH,0.03704659,0.036751050545089335,0.00029553945491066214
6.0,558.0,423.0,0.010753,0.010753,6.326149,0.363079,1.0,558.0,1.0,7.0,Less than full participation,Overall Study,FG002,cardiovascular disease,NIH,0.02469849,0.0244437060791766,0.00025478392082340165
12.0,558.0,423.0,0.021505,0.021505,6.326149,0.363079,1.0,558.0,1.0,7.0,Less than full participation,Overall Study,FG003,cardiovascular disease,NIH,0.04939469,0.049414648887063484,1.9958887063485642e-05
147.0,1718.0,460.0,0.085565,0.085565,7.449498,0.551633,1.0,1718.0,29.0,309.0,Death,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.3516199,0.3443146122226077,0.007305287777392311
137.0,1718.0,460.0,0.079744,0.079744,7.449498,0.551633,1.0,1718.0,29.0,309.0,Death,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.32769915,0.32804259727000024,0.0003434472700002411
103.0,1718.0,460.0,0.059953,0.059953,7.449498,0.551633,1.0,1718.0,29.0,309.0,Withdrawal by Subject,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.24637022,0.24929011415205374,0.002919894152053737
112.0,1718.0,460.0,0.065192,0.065192,7.449498,0.551633,1.0,1718.0,29.0,309.0,Withdrawal by Subject,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.26789931,0.26989449612079375,0.001995186120793746
21.0,1718.0,460.0,0.012224,0.012224,7.449498,0.551633,1.0,1718.0,29.0,309.0,Completed Survival Follow-up,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.05023318,0.05037499987846226,0.0001418198784622557
9.0,1718.0,460.0,0.005239,0.005239,7.449498,0.551633,1.0,1718.0,29.0,309.0,Completed Survival Follow-up,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.02152909,0.021625487798337804,9.639779833780365e-05
12.0,1718.0,460.0,0.006985,0.006985,7.449498,0.551633,1.0,1718.0,29.0,309.0,Disease Progression,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.02870408,0.028435077504097205,0.00026900249590279535
10.0,1718.0,460.0,0.005821,0.005821,7.449498,0.551633,1.0,1718.0,29.0,309.0,Disease Progression,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.02392076,0.02371989277805555,0.00020086722194444934
6.0,1718.0,460.0,0.003492,0.003492,7.449498,0.551633,1.0,1718.0,29.0,309.0,Adverse Event,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01434999,0.014384877009513923,3.488700951392344e-05
13.0,1718.0,460.0,0.007567,0.007567,7.449498,0.551633,1.0,1718.0,29.0,309.0,Adverse Event,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.03109575,0.031096060859285686,3.108592856876369e-07
10.0,1718.0,460.0,0.005821,0.005821,7.449498,0.551633,1.0,1718.0,29.0,309.0,Administrative Decision,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.02392076,0.023748870492817445,0.00017188950718255436
8.0,1718.0,460.0,0.004657,0.004657,7.449498,0.551633,1.0,1718.0,29.0,309.0,Administrative Decision,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01913743,0.018614884090952393,0.0005225459090476073
5.0,1718.0,460.0,0.00291,0.00291,7.449498,0.551633,1.0,1718.0,29.0,309.0,Noncompliance,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01195832,0.011939104239613108,1.921576038689185e-05
3.0,1718.0,460.0,0.001746,0.001746,7.449498,0.551633,1.0,1718.0,29.0,309.0,Noncompliance,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00717499,0.007150955970099225,2.40340299007746e-05
1.0,1718.0,460.0,0.000582,0.000582,7.449498,0.551633,1.0,1718.0,29.0,309.0,Ineligibility Determined,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00239166,0.002393324891468259,1.6648914682592005e-06
6.0,1718.0,460.0,0.003492,0.003492,7.449498,0.551633,1.0,1718.0,29.0,309.0,Ineligibility Determined,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01434999,0.014422772230942495,7.27822309424947e-05
5.0,1718.0,460.0,0.00291,0.00291,7.449498,0.551633,1.0,1718.0,29.0,309.0,Protocol Deviation,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01195832,0.01193716634294644,2.1153657053560315e-05
0.0,1718.0,460.0,0.0,0.0,7.449498,0.551633,1.0,1718.0,29.0,309.0,Protocol Deviation,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1718.0,460.0,0.001164,0.001164,7.449498,0.551633,1.0,1718.0,29.0,309.0,"Other, Not Specified",Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00478333,0.004817227750396816,3.389775039681648e-05
3.0,1718.0,460.0,0.001746,0.001746,7.449498,0.551633,1.0,1718.0,29.0,309.0,"Other, Not Specified",Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00717499,0.007150955970099225,2.40340299007746e-05
6.0,1718.0,460.0,0.003492,0.003492,7.449498,0.551633,1.0,1718.0,29.0,309.0,Lost to Follow-up,Blinded Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01434999,0.014404851883382967,5.486188338296727e-05
3.0,1718.0,460.0,0.001746,0.001746,7.449498,0.551633,1.0,1718.0,29.0,309.0,Lost to Follow-up,Blinded Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00717499,0.007150206141230174,2.478385876982566e-05
49.0,1718.0,460.0,0.028522,0.028522,7.449498,0.551633,1.0,1718.0,29.0,309.0,Death,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.117208,0.1175719627489088,0.00036396274890879154
48.0,1718.0,460.0,0.027939,0.027939,7.449498,0.551633,1.0,1718.0,29.0,309.0,Death,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.11481223,0.11481639412173626,4.164121736260906e-06
49.0,1718.0,460.0,0.028522,0.028522,7.449498,0.551633,1.0,1718.0,29.0,309.0,Withdrawal by Subject,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.117208,0.11722928058301589,2.128058301588409e-05
47.0,1718.0,460.0,0.027357,0.027357,7.449498,0.551633,1.0,1718.0,29.0,309.0,Withdrawal by Subject,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.11242056,0.11220901978732144,0.00021154021267856538
30.0,1718.0,460.0,0.017462,0.017462,7.449498,0.551633,1.0,1718.0,29.0,309.0,Adverse Event,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.07175816,0.07219991631433546,0.0004417563143354619
51.0,1718.0,460.0,0.029686,0.029686,7.449498,0.551633,1.0,1718.0,29.0,309.0,Adverse Event,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.12199133,0.12237390354274806,0.0003825735427480659
30.0,1718.0,460.0,0.017462,0.017462,7.449498,0.551633,1.0,1718.0,29.0,309.0,Administrative Decision,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.07175816,0.07224454767197437,0.00048638767197436983
15.0,1718.0,460.0,0.008731,0.008731,7.449498,0.551633,1.0,1718.0,29.0,309.0,Administrative Decision,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.03587908,0.03630985423660716,0.0004307742366071593
17.0,1718.0,460.0,0.009895,0.009895,7.449498,0.551633,1.0,1718.0,29.0,309.0,Disease Progression,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.04066241,0.04093591157877973,0.0002735015787797279
18.0,1718.0,460.0,0.010477,0.010477,7.449498,0.551633,1.0,1718.0,29.0,309.0,Disease Progression,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.04305407,0.04330634376217257,0.00025227376217257236
5.0,1718.0,460.0,0.00291,0.00291,7.449498,0.551633,1.0,1718.0,29.0,309.0,Noncompliance,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.01195832,0.011923038637529774,3.5281362470225563e-05
4.0,1718.0,460.0,0.002328,0.002328,7.449498,0.551633,1.0,1718.0,29.0,309.0,Noncompliance,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00956666,0.00965008964583333,8.34296458333307e-05
1.0,1718.0,460.0,0.000582,0.000582,7.449498,0.551633,1.0,1718.0,29.0,309.0,Lost to Follow-up,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00239166,0.0023986228739682593,6.962873968259422e-06
2.0,1718.0,460.0,0.001164,0.001164,7.449498,0.551633,1.0,1718.0,29.0,309.0,Lost to Follow-up,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00478333,0.004829734661220227,4.64046612202269e-05
1.0,1718.0,460.0,0.000582,0.000582,7.449498,0.551633,1.0,1718.0,29.0,309.0,Pregnancy,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00239166,0.0023911030110515923,5.569889484076211e-07
0.0,1718.0,460.0,0.0,0.0,7.449498,0.551633,1.0,1718.0,29.0,309.0,Pregnancy,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,1718.0,460.0,0.005239,0.005239,7.449498,0.551633,1.0,1718.0,29.0,309.0,"Other, Not Specified",Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.02152909,0.02156946723208779,4.037723208778765e-05
7.0,1718.0,460.0,0.004075,0.004075,7.449498,0.551633,1.0,1718.0,29.0,309.0,"Other, Not Specified",Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01674576,0.017048041571894865,0.00030228157189486626
0.0,1718.0,460.0,0.0,0.0,7.449498,0.551633,1.0,1718.0,29.0,309.0,Protocol Violation,Open Label Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1718.0,460.0,0.000582,0.000582,7.449498,0.551633,1.0,1718.0,29.0,309.0,Protocol Violation,Open Label Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00239166,0.0023961784025297666,4.5184025297666935e-06
1.0,2482.0,2051.0,0.000403,0.000403,7.817223,0.309765,1.0,2711.0,29.0,428.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00097587,0.001043127553650793,6.7257553650793e-05
3.0,2482.0,2051.0,0.001209,0.001209,7.817223,0.309765,1.0,2711.0,29.0,428.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0029276,0.0028992948321626987,2.8305167837301085e-05
9.0,2482.0,2051.0,0.003626,0.003626,7.817223,0.309765,1.0,2711.0,29.0,428.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00878037,0.00837137395549603,0.00040899604450396997
65.0,2482.0,2051.0,0.026189,0.026189,7.817223,0.309765,1.0,2711.0,29.0,428.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06341674,0.06384352636402776,0.0004267863640277647
58.0,2482.0,2051.0,0.023368,0.023368,7.817223,0.309765,1.0,2711.0,29.0,428.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05658568,0.05707246537990529,0.00048678537990529125
126.0,2482.0,2051.0,0.050766,0.050766,7.817223,0.309765,1.0,2711.0,29.0,428.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.12293002,0.12317477529977192,0.0002447552997719149
7.0,2482.0,2051.0,0.00282,0.00282,7.817223,0.309765,1.0,2711.0,29.0,428.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00682864,0.006783357753492068,4.528224650793278e-05
12.0,2482.0,2051.0,0.004835,0.004835,7.817223,0.309765,1.0,2711.0,29.0,428.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01170797,0.011794552477192468,8.658247719246781e-05
6.0,2482.0,2051.0,0.002417,0.002417,7.817223,0.309765,1.0,2711.0,29.0,428.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00585277,0.0057918225849431845,6.094741505681574e-05
2.0,2482.0,2051.0,0.000806,0.000806,7.817223,0.309765,1.0,2711.0,29.0,428.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00195173,0.001972782088710319,2.105208871031874e-05
4.0,2482.0,2051.0,0.001612,0.001612,7.817223,0.309765,1.0,2711.0,29.0,428.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00390346,0.003922114630238101,1.8654630238101183e-05
8.0,2482.0,2051.0,0.003223,0.003223,7.817223,0.309765,1.0,2711.0,29.0,428.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0078045,0.007587337102896824,0.0002171628971031755
5.0,2482.0,2051.0,0.002015,0.002015,7.817223,0.309765,1.0,2711.0,29.0,428.0,Poor/non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00487933,0.004762986232589289,0.00011634376741071102
12.0,2482.0,2051.0,0.004835,0.004835,7.817223,0.309765,1.0,2711.0,29.0,428.0,Poor/non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01170797,0.011793461611274354,8.549161127435409e-05
3.0,2482.0,2051.0,0.001209,0.001209,7.817223,0.309765,1.0,2711.0,29.0,428.0,Poor/non-compliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0029276,0.002906160947787699,2.1439052212300722e-05
2.0,2482.0,2051.0,0.000806,0.000806,7.817223,0.309765,1.0,2711.0,29.0,428.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00195173,0.0019773749201984128,2.5644920198412708e-05
1.0,2482.0,2051.0,0.000403,0.000403,7.817223,0.309765,1.0,2711.0,29.0,428.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00097587,0.0010382820418253962,6.24120418253962e-05
1.0,2482.0,2051.0,0.000403,0.000403,7.817223,0.309765,1.0,2711.0,29.0,428.0,Pregnancy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00097587,0.0010317678067063483,5.589780670634827e-05
4.0,2482.0,2051.0,0.001612,0.001612,7.817223,0.309765,1.0,2711.0,29.0,428.0,Not meet/no longer meets criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00390346,0.003923007433988105,1.954743398810497e-05
6.0,2482.0,2051.0,0.002417,0.002417,7.817223,0.309765,1.0,2711.0,29.0,428.0,Not meet/no longer meets criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00585277,0.005800843763336041,5.1926236663959145e-05
4.0,2482.0,2051.0,0.001612,0.001612,7.817223,0.309765,1.0,2711.0,29.0,428.0,Not meet/no longer meets criteria,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00390346,0.00392450311529763,2.1043115297630054e-05
28.0,2482.0,2051.0,0.011281,0.011281,7.817223,0.309765,1.0,2711.0,29.0,428.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02731697,0.02727600050900793,4.096949099206826e-05
33.0,2482.0,2051.0,0.013296,0.013296,7.817223,0.309765,1.0,2711.0,29.0,428.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0321963,0.032363827829345285,0.00016752782934528754
31.0,2482.0,2051.0,0.01249,0.01249,7.817223,0.309765,1.0,2711.0,29.0,428.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03024457,0.030667870573214278,0.0004233005732142796
1.0,250.0,241.0,0.004,0.004,5.525453,0.262342,1.0,250.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579823,0.005786761544910708,1.1468455089291493e-05
2.0,250.0,241.0,0.008,0.008,5.525453,0.262342,1.0,250.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01159647,0.01165501845827111,5.8548458271110576e-05
0.0,250.0,241.0,0.0,0.0,5.525453,0.262342,1.0,250.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,241.0,0.004,0.004,5.525453,0.262342,1.0,250.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00579823,0.005794785624464279,3.4443755357205924e-06
3.0,250.0,241.0,0.012,0.012,5.525453,0.262342,1.0,250.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0173947,0.01754792855880953,0.00015322855880953168
2.0,250.0,241.0,0.008,0.008,5.525453,0.262342,1.0,250.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01159647,0.011667044697616346,7.057469761634697e-05
16.0,341.0,261.0,0.046921,0.046921,5.834811,0.337801,1.0,364.0,1.0,326.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.09248159,0.09408655115279753,0.0016049611527975266
13.0,341.0,261.0,0.038123,0.038123,5.834811,0.337801,1.0,364.0,1.0,326.0,Adverse Event,Overall Study,FG001,cardiovascular disease,OTHER,0.07514068,0.07681496310860123,0.0016742831086012239
3.0,341.0,261.0,0.008798,0.008798,5.834811,0.337801,1.0,364.0,1.0,326.0,Medical condition changed,Overall Study,FG000,cardiovascular disease,OTHER,0.01734091,0.017326788112450357,1.4121887549643775e-05
5.0,341.0,261.0,0.014663,0.014663,5.834811,0.337801,1.0,364.0,1.0,326.0,Medical condition changed,Overall Study,FG001,cardiovascular disease,OTHER,0.02890087,0.02873272558098212,0.00016814441901787797
3.0,341.0,261.0,0.008798,0.008798,5.834811,0.337801,1.0,364.0,1.0,326.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,OTHER,0.01734091,0.01732535820578369,1.555179421630984e-05
7.0,341.0,261.0,0.020528,0.020528,5.834811,0.337801,1.0,364.0,1.0,326.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,OTHER,0.04046082,0.040865570401488124,0.00040475040148812286
6.0,341.0,261.0,0.017595,0.017595,5.834811,0.337801,1.0,364.0,1.0,326.0,Personal reasons,Overall Study,FG000,cardiovascular disease,OTHER,0.03467986,0.03482414459344249,0.00014428459344249106
7.0,341.0,261.0,0.020528,0.020528,5.834811,0.337801,1.0,364.0,1.0,326.0,Personal reasons,Overall Study,FG001,cardiovascular disease,OTHER,0.04046082,0.040865570401488124,0.00040475040148812286
4.0,341.0,261.0,0.01173,0.01173,5.834811,0.337801,1.0,364.0,1.0,326.0,Unknown reasons,Overall Study,FG000,cardiovascular disease,OTHER,0.0231199,0.023289719077083344,0.0001698190770833448
6.0,341.0,261.0,0.017595,0.017595,5.834811,0.337801,1.0,364.0,1.0,326.0,Unknown reasons,Overall Study,FG001,cardiovascular disease,OTHER,0.03467986,0.034839222315644874,0.00015936231564487452
1.0,341.0,261.0,0.002933,0.002933,5.834811,0.337801,1.0,364.0,1.0,326.0,Noncompliant,Overall Study,FG000,cardiovascular disease,OTHER,0.00578096,0.005785913252132941,4.95325213294151e-06
1.0,341.0,261.0,0.002933,0.002933,5.834811,0.337801,1.0,364.0,1.0,326.0,Noncompliant,Overall Study,FG001,cardiovascular disease,OTHER,0.00578096,0.005791474627996036,1.0514627996035912e-05
5.0,341.0,261.0,0.014663,0.014663,5.834811,0.337801,1.0,364.0,1.0,326.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02890087,0.02879986517872021,0.00010100482127978899
3.0,341.0,261.0,0.008798,0.008798,5.834811,0.337801,1.0,364.0,1.0,326.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01734091,0.017344097910843223,3.1879108432220082e-06
170.0,13970.0,13317.0,0.012169,0.012169,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08762907,0.08521220534752973,0.002416864652470277
196.0,13970.0,13317.0,0.01403,0.01403,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10103014,0.09199018321818443,0.009039956781815572
3.0,13970.0,13317.0,0.000215,0.000215,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00154822,0.001430897750932539,0.0001173222490674611
5.0,13970.0,13317.0,0.000358,0.000358,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00257796,0.002435913346964284,0.00014204665303571562
12.0,13970.0,13317.0,0.000859,0.000859,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00618567,0.005963931692875461,0.0002217383071245393
13.0,13970.0,13317.0,0.000931,0.000931,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00670414,0.0065563469930357155,0.00014779300696428441
105.0,13970.0,13317.0,0.007516,0.007516,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Unclassifiable Response,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05412278,0.0490898174896726,0.0050329625103274
139.0,13970.0,13317.0,0.00995,0.00995,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Unclassifiable Response,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07165003,0.06143809175280755,0.01021193824719245
1.0,13970.0,13317.0,7.2e-05,7.2e-05,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Administrative decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00051847,0.0005129157039069266,5.554296093073408e-06
0.0,13970.0,13317.0,0.0,0.0,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Administrative decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,13970.0,13317.0,0.000286,0.000286,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Sponsor decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00205949,0.002022245282311508,3.724471768849205e-05
5.0,13970.0,13317.0,0.000358,0.000358,9.544739,0.754448,1.0,13970.0,32.0,1319.0,Sponsor decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00257796,0.002437003377916665,0.00014095662208333474
9.0,663.0,584.0,0.013575,0.013575,6.498282,0.247637,1.0,663.0,1.0,178.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02184513,0.02184713933455177,2.0093345517689654e-06
14.0,663.0,584.0,0.021116,0.021116,6.498282,0.247637,1.0,663.0,1.0,178.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03398025,0.0340282960599215,4.8046059921501294e-05
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00485501,0.004849783719910708,5.226280089291706e-06
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00485501,0.004852003263303565,3.0067366964346004e-06
10.0,663.0,584.0,0.015083,0.015083,6.498282,0.247637,1.0,663.0,1.0,178.0,Withdrew Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02427183,0.02441332583061504,0.00014149583061504045
5.0,663.0,584.0,0.007541,0.007541,6.498282,0.247637,1.0,663.0,1.0,178.0,Withdrew Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01213511,0.012111159207509919,2.3950792490080516e-05
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,Withdrew Consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00485501,0.004849736234910708,5.273765089291484e-06
1.0,663.0,584.0,0.001508,0.001508,6.498282,0.247637,1.0,663.0,1.0,178.0,Withdrew Consent,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0024267,0.0024615193452218616,3.481934522186168e-05
3.0,663.0,584.0,0.004525,0.004525,6.498282,0.247637,1.0,663.0,1.0,178.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00728171,0.00728315205258929,1.4420525892896302e-06
5.0,663.0,584.0,0.007541,0.007541,6.498282,0.247637,1.0,663.0,1.0,178.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01213511,0.01210612309500992,2.8986904990079346e-05
0.0,663.0,584.0,0.0,0.0,6.498282,0.247637,1.0,663.0,1.0,178.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,663.0,584.0,0.004525,0.004525,6.498282,0.247637,1.0,663.0,1.0,178.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00728171,0.007280589370089289,1.1206299107115528e-06
5.0,663.0,584.0,0.007541,0.007541,6.498282,0.247637,1.0,663.0,1.0,178.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01213511,0.01212964854243056,5.461457569438943e-06
4.0,663.0,584.0,0.006033,0.006033,6.498282,0.247637,1.0,663.0,1.0,178.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00970841,0.009683853384166661,2.4556615833339415e-05
0.0,663.0,584.0,0.0,0.0,6.498282,0.247637,1.0,663.0,1.0,178.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00485501,0.004853267752886899,1.7422471131007047e-06
6.0,663.0,584.0,0.00905,0.00905,6.498282,0.247637,1.0,663.0,1.0,178.0,"Captured as ""Other""",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01456342,0.014279962777619054,0.0002834572223809461
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,"Captured as ""Other""",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00485501,0.004850334756636899,4.675243363100497e-06
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,"Captured as ""Other""",Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00485501,0.004852820297232136,2.1897027678635314e-06
2.0,663.0,584.0,0.003017,0.003017,6.498282,0.247637,1.0,663.0,1.0,178.0,"Captured as ""Other""",Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00485501,0.004854714584374993,2.9541562500661617e-07
8.0,445.0,31.0,0.017978,0.017978,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03334127,0.03307722697158724,0.0002640430284127568
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004169589624523799,2.3996245237982786e-06
7.0,445.0,31.0,0.01573,0.01573,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.02917222,0.029456717381071425,0.000284497381071426
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004167713767857132,5.237678571317142e-07
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.00833439,0.00833207136874995,2.318631250049913e-06
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Lack of Efficacy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Lack of Efficacy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Lack of Efficacy,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.00416719,0.004168158587083323,9.685870833225571e-07
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00416719,0.004167876553333323,6.865533333224802e-07
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Non-compliance,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00416719,0.004166717232916656,4.727670833443859e-07
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Non-compliance,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Non-compliance,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00416719,0.004168718894315464,1.5288943154634707e-06
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00833439,0.008332713682499954,1.6763175000461539e-06
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.00833439,0.00833137109041662,3.0189095833813018e-06
6.0,445.0,31.0,0.013483,0.013483,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02500502,0.025325275220892847,0.0003202552208928476
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00833439,0.008332204269345193,2.1857306548075245e-06
3.0,445.0,31.0,0.006742,0.006742,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.01250344,0.012377078346041652,0.00012636165395834772
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Not treated,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Not treated,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004167537264523799,3.4726452379906653e-07
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Not treated,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.00416719,0.004167472892083322,2.828920833220297e-07
3.0,445.0,31.0,0.006742,0.006742,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.01250344,0.012369911275952373,0.0001335287240476265
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004170897954940466,3.7079549404656076e-06
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Adverse Event,Follow-up Period (FUP),FG002,cardiovascular disease,INDUSTRY,0.00416719,0.004170316513333323,3.1265133333228945e-06
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.00833439,0.008332717041071379,1.6729589286217095e-06
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Death,Follow-up Period (FUP),FG002,cardiovascular disease,INDUSTRY,0.00416719,0.004168249681666656,1.0596816666557166e-06
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.00416719,0.004168058891249989,8.688912499889637e-07
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Lost to Follow-up,Follow-up Period (FUP),FG002,cardiovascular disease,INDUSTRY,0.00833439,0.008329372243809476,5.01775619052465e-06
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004172101101339275,4.91110133927445e-06
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Protocol Violation,Follow-up Period (FUP),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,445.0,31.0,0.004494,0.004494,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.00833439,0.00833096723291662,3.422767083380643e-06
1.0,445.0,31.0,0.002247,0.002247,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.00416719,0.004169796785773799,2.606785773798942e-06
0.0,445.0,31.0,0.0,0.0,6.100319,0.30401,1.0,445.0,30.0,122.0,Withdrawal by Subject,Follow-up Period (FUP),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,392.0,305.0,0.015306,0.015306,5.97381,0.256675,1.0,392.0,7.0,38.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.0234691,0.023332856755218248,0.0001362432447817516
9.0,392.0,305.0,0.022959,0.022959,5.97381,0.256675,1.0,392.0,7.0,38.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.03520364,0.03487368765514879,0.0003299523448512115
8.0,392.0,305.0,0.020408,0.020408,5.97381,0.256675,1.0,392.0,7.0,38.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.03129213,0.03201557556403771,0.0007234455640377085
9.0,392.0,305.0,0.022959,0.022959,5.97381,0.256675,1.0,392.0,7.0,38.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.03520364,0.034847627803124975,0.000356012196875026
27.0,392.0,305.0,0.068878,0.068878,5.97381,0.256675,1.0,392.0,7.0,38.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.10561246,0.10510721465486104,0.0005052453451389605
28.0,392.0,305.0,0.071429,0.071429,5.97381,0.256675,1.0,392.0,7.0,38.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.10952398,0.10866060139406741,0.0008633786059325937
8.0,201.0,180.0,0.039801,0.039801,5.308268,0.323595,1.0,201.0,4.0,24.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06836728,0.06982441460550595,0.0014571346055059498
5.0,201.0,180.0,0.024876,0.024876,5.308268,0.323595,1.0,201.0,4.0,24.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0427302,0.044888581683333297,0.0021583816833332936
0.0,201.0,180.0,0.0,0.0,5.308268,0.323595,1.0,201.0,4.0,24.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,201.0,180.0,0.004975,0.004975,5.308268,0.323595,1.0,201.0,4.0,24.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0085457,0.008645384036398794,9.968403639879463e-05
3.0,201.0,180.0,0.014925,0.014925,5.308268,0.323595,1.0,201.0,4.0,24.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02563709,0.02588567777285713,0.000248587772857127
0.0,201.0,180.0,0.0,0.0,5.308268,0.323595,1.0,201.0,4.0,24.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,201.0,180.0,0.0,0.0,5.308268,0.323595,1.0,201.0,4.0,24.0,Surgery on the Target Limb,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,201.0,180.0,0.004975,0.004975,5.308268,0.323595,1.0,201.0,4.0,24.0,Surgery on the Target Limb,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0085457,0.008645384036398794,9.968403639879463e-05
1.0,201.0,180.0,0.004975,0.004975,5.308268,0.323595,1.0,201.0,4.0,24.0,Patient Non-compliant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0085457,0.00864840998806546,0.00010270998806546049
0.0,201.0,180.0,0.0,0.0,5.308268,0.323595,1.0,201.0,4.0,24.0,Patient Non-compliant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,201.0,180.0,0.004975,0.004975,5.308268,0.323595,1.0,201.0,4.0,24.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0085457,0.008641758818898795,9.605881889879556e-05
1.0,201.0,180.0,0.004975,0.004975,5.308268,0.323595,1.0,201.0,4.0,24.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0085457,0.008640048483898799,9.434848389879881e-05
11.0,490.0,324.0,0.022449,0.022449,6.196444,0.230287,1.0,502.0,1.0,2.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.03203388,0.031570367034523796,0.0004635129654762052
5.0,490.0,324.0,0.010204,0.010204,6.196444,0.230287,1.0,502.0,1.0,2.0,Adverse Event,Overall Study,FG001,cardiovascular disease,OTHER,0.01456073,0.014584049808075414,2.3319808075414686e-05
8.0,490.0,324.0,0.016327,0.016327,6.196444,0.230287,1.0,502.0,1.0,2.0,Adverse Event,Overall Study,FG002,cardiovascular disease,OTHER,0.02329802,0.023145871560773794,0.00015214843922620527
8.0,490.0,324.0,0.016327,0.016327,6.196444,0.230287,1.0,502.0,1.0,2.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.02329802,0.023174445279781738,0.00012357472021826132
6.0,490.0,324.0,0.012245,0.012245,6.196444,0.230287,1.0,502.0,1.0,2.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.01747316,0.017531787424464283,5.862742446428176e-05
3.0,490.0,324.0,0.006122,0.006122,6.196444,0.230287,1.0,502.0,1.0,2.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.00873586,0.008714977941765878,2.088205823412223e-05
5.0,490.0,324.0,0.010204,0.010204,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Reasons,Overall Study,FG000,cardiovascular disease,OTHER,0.01456073,0.014576608849682558,1.5878849682559107e-05
12.0,490.0,324.0,0.02449,0.02449,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Reasons,Overall Study,FG001,cardiovascular disease,OTHER,0.03494631,0.03471193568998015,0.00023437431001985254
23.0,490.0,324.0,0.046939,0.046939,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Reasons,Overall Study,FG002,cardiovascular disease,OTHER,0.06698019,0.06723054207039678,0.000250352070396781
30.0,490.0,324.0,0.061224,0.061224,6.196444,0.230287,1.0,502.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.08736435,0.08468865029421783,0.0026756997057821585
23.0,490.0,324.0,0.046939,0.046939,6.196444,0.230287,1.0,502.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.06698019,0.06725057295950393,0.0002703829595039342
14.0,490.0,324.0,0.028571,0.028571,6.196444,0.230287,1.0,502.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.04076975,0.04047984751890868,0.00028990248109132116
1.0,490.0,324.0,0.002041,0.002041,6.196444,0.230287,1.0,502.0,1.0,2.0,Alternative Treatment,Overall Study,FG000,cardiovascular disease,OTHER,0.00291243,0.002918330818343253,5.90081834325306e-06
0.0,490.0,324.0,0.0,0.0,6.196444,0.230287,1.0,502.0,1.0,2.0,Alternative Treatment,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,490.0,324.0,0.0,0.0,6.196444,0.230287,1.0,502.0,1.0,2.0,Alternative Treatment,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
4.0,490.0,324.0,0.008163,0.008163,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Medical Problems,Overall Study,FG000,cardiovascular disease,OTHER,0.01164829,0.011720999127063475,7.270912706347499e-05
4.0,490.0,324.0,0.008163,0.008163,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Medical Problems,Overall Study,FG001,cardiovascular disease,OTHER,0.01164829,0.011702926181944429,5.463618194442854e-05
9.0,490.0,324.0,0.018367,0.018367,6.196444,0.230287,1.0,502.0,1.0,2.0,Other Medical Problems,Overall Study,FG002,cardiovascular disease,OTHER,0.02620902,0.025991591014226222,0.00021742898577377726
6.0,711.0,628.0,0.008439,0.008439,6.568078,0.42567,1.0,711.0,9.0,103.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02359406,0.02358173355996032,1.232644003967831e-05
3.0,711.0,628.0,0.004219,0.004219,6.568078,0.42567,1.0,711.0,9.0,103.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01179563,0.011898881256190477,0.0001032512561904772
1.0,711.0,628.0,0.001406,0.001406,6.568078,0.42567,1.0,711.0,9.0,103.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00393094,0.0041317675860119115,0.00020082758601191152
2.0,711.0,628.0,0.002813,0.002813,6.568078,0.42567,1.0,711.0,9.0,103.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00786469,0.007842979218154748,2.1710781845252908e-05
6.0,711.0,628.0,0.008439,0.008439,6.568078,0.42567,1.0,711.0,9.0,103.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02359406,0.02358574170412699,8.318295873010334e-06
4.0,711.0,628.0,0.005626,0.005626,6.568078,0.42567,1.0,711.0,9.0,103.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01572937,0.015979723270327394,0.0002503532703273942
20.0,711.0,628.0,0.028129,0.028129,6.568078,0.42567,1.0,711.0,9.0,103.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07864406,0.07821385486186355,0.00043020513813644967
23.0,711.0,628.0,0.032349,0.032349,6.568078,0.42567,1.0,711.0,9.0,103.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09044248,0.09074925377847222,0.00030677377847221354
7.0,711.0,628.0,0.009845,0.009845,6.568078,0.42567,1.0,711.0,9.0,103.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.027525,0.02738028947556548,0.0001447105244345194
8.0,711.0,628.0,0.011252,0.011252,6.568078,0.42567,1.0,711.0,9.0,103.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03145874,0.031324139662966266,0.00013460033703373286
0.0,711.0,628.0,0.0,0.0,6.568078,0.42567,1.0,711.0,9.0,103.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,711.0,628.0,0.001406,0.001406,6.568078,0.42567,1.0,711.0,9.0,103.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00393094,0.004117875937083338,0.00018693593708333806
0.0,711.0,628.0,0.0,0.0,6.568078,0.42567,1.0,711.0,9.0,103.0,Did not met inclusion criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,711.0,628.0,0.002813,0.002813,6.568078,0.42567,1.0,711.0,9.0,103.0,Did not met inclusion criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00786469,0.007842183216071415,2.2506783928585503e-05
7.0,290.0,247.0,0.024138,0.024138,5.673323,0.725125,1.0,290.0,34.0,140.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09930054,0.1029930289539285,0.0036924889539284994
2.0,290.0,247.0,0.006897,0.006897,5.673323,0.725125,1.0,290.0,34.0,140.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02837335,0.028493689839369687,0.0001203398393696889
3.0,290.0,247.0,0.010345,0.010345,5.673323,0.725125,1.0,290.0,34.0,140.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04255796,0.04304998346067459,0.0004920234606745899
7.0,290.0,247.0,0.024138,0.024138,5.673323,0.725125,1.0,290.0,34.0,140.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09930054,0.10178692911738085,0.0024863891173808467
2.0,290.0,247.0,0.006897,0.006897,5.673323,0.725125,1.0,290.0,34.0,140.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02837335,0.028516326559454446,0.00014297655945444757
3.0,290.0,247.0,0.010345,0.010345,5.673323,0.725125,1.0,290.0,34.0,140.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04255796,0.04298021333911703,0.0004222533391170305
0.0,290.0,247.0,0.0,0.0,5.673323,0.725125,1.0,290.0,34.0,140.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,290.0,247.0,0.003448,0.003448,5.673323,0.725125,1.0,290.0,34.0,140.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01418462,0.014401884077797616,0.00021726407779761557
5.0,290.0,247.0,0.017241,0.017241,5.673323,0.725125,1.0,290.0,34.0,140.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0709272,0.07499791163516303,0.004070711635163038
3.0,290.0,247.0,0.010345,0.010345,5.673323,0.725125,1.0,290.0,34.0,140.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04255796,0.04297419295161703,0.0004162329516170307
0.0,290.0,247.0,0.0,0.0,5.673323,0.725125,1.0,290.0,34.0,140.0,Subject withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,290.0,247.0,0.02069,0.02069,5.673323,0.725125,1.0,290.0,34.0,140.0,Subject withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08511593,0.09224915426047621,0.007133224260476204
2.0,290.0,247.0,0.006897,0.006897,5.673323,0.725125,1.0,290.0,34.0,140.0,Data entry error (reported as study completion and study discontinuation),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02837335,0.028486192302544285,0.00011284230254428665
0.0,290.0,247.0,0.0,0.0,5.673323,0.725125,1.0,290.0,34.0,140.0,Data entry error (reported as study completion and study discontinuation),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,290.0,247.0,0.0,0.0,5.673323,0.725125,1.0,290.0,34.0,140.0,"Randomized, but not treated",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,290.0,247.0,0.006897,0.006897,5.673323,0.725125,1.0,290.0,34.0,140.0,"Randomized, but not treated",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02837335,0.028488641746869693,0.00011529174686969457
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,404.0,402.0,0.002475,0.002475,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00539522,0.005397971498600304,2.751498600303895e-06
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,404.0,402.0,0.002475,0.002475,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00539522,0.00540191581943364,6.6958194336400045e-06
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,404.0,402.0,0.0,0.0,6.003887,0.363079,1.0,409.0,1.0,54.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
354.0,3065.0,2244.0,0.115498,0.115498,8.028129,0.770191,1.0,3065.0,13.0,345.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.71414615,0.6401561144288774,0.0739900355711226
367.0,3065.0,2244.0,0.119739,0.119739,8.028129,0.770191,1.0,3065.0,13.0,345.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.74036906,0.7099452204230555,0.0304238395769445
7.0,3065.0,2244.0,0.002284,0.002284,8.028129,0.770191,1.0,3065.0,13.0,345.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01412241,0.01393314967178571,0.00018926032821429094
4.0,3065.0,2244.0,0.001305,0.001305,8.028129,0.770191,1.0,3065.0,13.0,345.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00806906,0.007694204832529761,0.0003748551674702385
48.0,3065.0,2244.0,0.015661,0.015661,8.028129,0.770191,1.0,3065.0,13.0,345.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09683495,0.09349060968775795,0.003344340312242053
41.0,3065.0,2244.0,0.013377,0.013377,8.028129,0.770191,1.0,3065.0,13.0,345.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08271254,0.08192084194958336,0.0007916980504166365
0.0,251.0,244.0,0.0,0.0,5.529429,0.607155,1.0,251.0,13.0,71.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,251.0,244.0,0.003984,0.003984,5.529429,0.607155,1.0,251.0,13.0,71.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01337517,0.013387723556893959,1.2553556893958248e-05
1.0,251.0,244.0,0.003984,0.003984,5.529429,0.607155,1.0,251.0,13.0,71.0,Did not complete Week 30 assessments due to scheduling conflict,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01337517,0.013375027645227291,1.423547727093244e-07
0.0,251.0,244.0,0.0,0.0,5.529429,0.607155,1.0,251.0,13.0,71.0,Did not complete Week 30 assessments due to scheduling conflict,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,251.0,244.0,0.007968,0.007968,5.529429,0.607155,1.0,251.0,13.0,71.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02675034,0.027419350294305533,0.0006690102943055325
0.0,251.0,244.0,0.0,0.0,5.529429,0.607155,1.0,251.0,13.0,71.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,251.0,244.0,0.003984,0.003984,5.529429,0.607155,1.0,251.0,13.0,71.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01337517,0.013379232915643954,4.062915643953877e-06
1.0,251.0,244.0,0.003984,0.003984,5.529429,0.607155,1.0,251.0,13.0,71.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01337517,0.013385401878143957,1.0231878143956291e-05
0.0,251.0,244.0,0.0,0.0,5.529429,0.607155,1.0,251.0,13.0,71.0,Week 30 not completed due to circumstances surrounding the COVID-19 pandemic,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,251.0,244.0,0.003984,0.003984,5.529429,0.607155,1.0,251.0,13.0,71.0,Week 30 not completed due to circumstances surrounding the COVID-19 pandemic,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01337517,0.013379383807727291,4.2138077272907415e-06
251.0,4110.0,2788.0,0.061071,0.061071,8.321422,0.288131,1.0,4110.0,3.0,30.0,Death,Overall Study,FG000,cardiovascular disease,NIH,0.14642723,0.14582882969661706,0.0005984003033829288
242.0,4110.0,2788.0,0.058881,0.058881,8.321422,0.288131,1.0,4110.0,3.0,30.0,Death,Overall Study,FG001,cardiovascular disease,NIH,0.14117637,0.14084112895313491,0.00033524104686508127
198.0,4110.0,2788.0,0.048175,0.048175,8.321422,0.288131,1.0,4110.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,NIH,0.11550707,0.1146800622793255,0.0008270077206744969
171.0,4110.0,2788.0,0.041606,0.041606,8.321422,0.288131,1.0,4110.0,3.0,30.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,NIH,0.09975686,0.09931047734050588,0.00044638265949412115
225.0,4110.0,2788.0,0.054745,0.054745,8.321422,0.288131,1.0,4110.0,3.0,30.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NIH,0.13125966,0.1328912305583135,0.0016315705583135054
235.0,4110.0,2788.0,0.057178,0.057178,8.321422,0.288131,1.0,4110.0,3.0,30.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NIH,0.13709316,0.1370010747476289,9.2085252371088e-05
1.0,1147.0,1090.0,0.000872,0.000872,7.045777,0.379199,1.0,1147.0,4.0,69.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00232977,0.0023299895853571466,2.19585357146522e-07
1.0,1147.0,1090.0,0.000872,0.000872,7.045777,0.379199,1.0,1147.0,4.0,69.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00232977,0.002333554982023813,3.784982023812694e-06
3.0,1147.0,1090.0,0.002616,0.002616,7.045777,0.379199,1.0,1147.0,4.0,69.0,Randomized but Never Received Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0069893,0.006902230180654767,8.706981934523354e-05
2.0,1147.0,1090.0,0.001744,0.001744,7.045777,0.379199,1.0,1147.0,4.0,69.0,Randomized but Never Received Study Drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00465954,0.0046297398815873005,2.980011841269975e-05
16.0,1147.0,1090.0,0.013949,0.013949,7.045777,0.379199,1.0,1147.0,4.0,69.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03726827,0.037207827502876996,6.0442497123003314e-05
7.0,1147.0,1090.0,0.006103,0.006103,7.045777,0.379199,1.0,1147.0,4.0,69.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0163057,0.01627392885871032,3.177114128967776e-05
5.0,1147.0,1090.0,0.004359,0.004359,7.045777,0.379199,1.0,1147.0,4.0,69.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01164617,0.011488543012351192,0.0001576269876488092
3.0,1147.0,1090.0,0.002616,0.002616,7.045777,0.379199,1.0,1147.0,4.0,69.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0069893,0.00689821404357143,9.108595642857032e-05
9.0,1147.0,1090.0,0.007847,0.007847,7.045777,0.379199,1.0,1147.0,4.0,69.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02096524,0.02090722140773807,5.801859226193043e-05
9.0,1147.0,1090.0,0.007847,0.007847,7.045777,0.379199,1.0,1147.0,4.0,69.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02096524,0.0209181813441964,4.7058655803598054e-05
0.0,1147.0,1090.0,0.0,0.0,7.045777,0.379199,1.0,1147.0,4.0,69.0,Miscellaneous Reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1147.0,1090.0,0.000872,0.000872,7.045777,0.379199,1.0,1147.0,4.0,69.0,Miscellaneous Reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00232977,0.0023354960341071453,5.726034107145228e-06
8.0,808.0,775.0,0.009901,0.009901,6.695799,0.273859,1.0,808.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01815553,0.01804715463755413,0.00010837536244586929
3.0,808.0,775.0,0.003713,0.003713,6.695799,0.273859,1.0,808.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00680855,0.006913452914910707,0.00010490291491070669
1.0,808.0,775.0,0.001238,0.001238,6.695799,0.273859,1.0,808.0,0.0,0.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00227013,0.002291139246448409,2.1009246448409208e-05
0.0,808.0,775.0,0.0,0.0,6.695799,0.273859,1.0,808.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,808.0,775.0,0.0,0.0,6.695799,0.273859,1.0,808.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,775.0,0.001238,0.001238,6.695799,0.273859,1.0,808.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00227013,0.0022885199115674566,1.8389911567456667e-05
2.0,808.0,775.0,0.002475,0.002475,6.695799,0.273859,1.0,808.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00453842,0.004559473265158736,2.1053265158736158e-05
0.0,808.0,775.0,0.0,0.0,6.695799,0.273859,1.0,808.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,775.0,0.001238,0.001238,6.695799,0.273859,1.0,808.0,0.0,0.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00227013,0.002287515705615075,1.738570561507502e-05
9.0,808.0,775.0,0.011139,0.011139,6.695799,0.273859,1.0,808.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02042566,0.020538934154037704,0.00011327415403770275
2.0,808.0,775.0,0.002475,0.002475,6.695799,0.273859,1.0,808.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00453842,0.004568956683313496,3.053668331349634e-05
6.0,808.0,775.0,0.007426,0.007426,6.695799,0.273859,1.0,808.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01361711,0.01348016326734125,0.00013694673265875028
1.0,499.0,489.0,0.002004,0.002004,6.214608,0.524933,1.0,499.0,9.0,84.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00653756,0.006600186904285721,6.262690428572061e-05
5.0,499.0,489.0,0.01002,0.01002,6.214608,0.524933,1.0,499.0,9.0,84.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.03268778,0.03302230976990081,0.00033452976990080985
0.0,499.0,489.0,0.0,0.0,6.214608,0.524933,1.0,499.0,9.0,84.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
4.0,499.0,489.0,0.008016,0.008016,6.214608,0.524933,1.0,499.0,9.0,84.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.02615022,0.026659734194523818,0.0005095141945238198
0.0,302.0,250.0,0.0,0.0,5.713733,0.208188,1.0,302.0,3.0,39.0,Entered Rescue Procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,302.0,250.0,0.023179,0.023179,5.713733,0.208188,1.0,302.0,3.0,39.0,Entered Rescue Procedure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02757213,0.027764874869513886,0.00019274486951388614
7.0,302.0,250.0,0.023179,0.023179,5.713733,0.208188,1.0,302.0,3.0,39.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02757213,0.027766631083740077,0.00019450108374007707
7.0,302.0,250.0,0.023179,0.023179,5.713733,0.208188,1.0,302.0,3.0,39.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02757213,0.02767770874475198,0.00010557874475198084
5.0,302.0,250.0,0.016556,0.016556,5.713733,0.208188,1.0,302.0,3.0,39.0,Elective Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01969387,0.019951841967460318,0.0002579719674603194
5.0,302.0,250.0,0.016556,0.016556,5.713733,0.208188,1.0,302.0,3.0,39.0,Elective Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01969387,0.0199579166574008,0.0002640466574008009
0.0,302.0,250.0,0.0,0.0,5.713733,0.208188,1.0,302.0,3.0,39.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,302.0,250.0,0.003311,0.003311,5.713733,0.208188,1.0,302.0,3.0,39.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00393854,0.004009777179970252,7.123717997025228e-05
6.0,302.0,250.0,0.019868,0.019868,5.713733,0.208188,1.0,302.0,3.0,39.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0236336,0.024817647552291655,0.001184047552291654
9.0,302.0,250.0,0.029801,0.029801,5.713733,0.208188,1.0,302.0,3.0,39.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0354492,0.035691321040783736,0.00024212104078373542
0.0,302.0,250.0,0.0,0.0,5.713733,0.208188,1.0,302.0,3.0,39.0,Failed mobilization,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,302.0,250.0,0.013245,0.013245,5.713733,0.208188,1.0,302.0,3.0,39.0,Failed mobilization,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01575533,0.01596829476125991,0.0002129647612599088
1.0,302.0,250.0,0.003311,0.003311,5.713733,0.208188,1.0,302.0,3.0,39.0,Intercurrent illness,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00393854,0.004007914579980174,6.937457998017378e-05
0.0,302.0,250.0,0.0,0.0,5.713733,0.208188,1.0,302.0,3.0,39.0,Intercurrent illness,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Withdrawal by Subject,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,729.0,656.0,0.005487,0.005487,6.593045,0.800006,1.0,729.0,22.0,194.0,Withdrawal by Subject,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.02894103,0.029133006431289715,0.0001919764312897157
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Death,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.00723658,0.0072397187024999705,3.1387024999702737e-06
2.0,729.0,656.0,0.002743,0.002743,6.593045,0.800006,1.0,729.0,22.0,194.0,Death,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.01446788,0.014492537682936495,2.465768293649466e-05
2.0,729.0,656.0,0.002743,0.002743,6.593045,0.800006,1.0,729.0,22.0,194.0,Non-compliance with study drug,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.01446788,0.01449564698022817,2.7766980228169716e-05
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Non-compliance with study drug,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,729.0,656.0,0.002743,0.002743,6.593045,0.800006,1.0,729.0,22.0,194.0,Reason Not Specified,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.01446788,0.01450683120522817,3.895120522817014e-05
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Reason Not Specified,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Adverse Event,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.00723658,0.007241397334166639,4.817334166638647e-06
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Adverse Event,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.007238061417083303,1.481417083303016e-06
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Protocol Violation,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Protocol Violation,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.007237080822916636,5.008229166355085e-07
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Physician Decision,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Physician Decision,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.007237245214583303,6.652145833029033e-07
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Lost to Follow-up,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Lost to Follow-up,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.007237569299999969,9.89299999969162e-07
11.0,729.0,656.0,0.015089,0.015089,6.593045,0.800006,1.0,729.0,22.0,194.0,Withdrawal by Subject,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.07958653,0.07803459223113095,0.001551937768869055
11.0,729.0,656.0,0.015089,0.015089,6.593045,0.800006,1.0,729.0,22.0,194.0,Withdrawal by Subject,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.07958653,0.0781489442617163,0.0014375857382837032
3.0,729.0,656.0,0.004115,0.004115,6.593045,0.800006,1.0,729.0,22.0,194.0,Lost to Follow-up,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.02170446,0.021766732914444403,6.227291444440425e-05
9.0,729.0,656.0,0.012346,0.012346,6.593045,0.800006,1.0,729.0,22.0,194.0,Lost to Follow-up,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.06511865,0.06554417297148805,0.0004255229714880543
5.0,729.0,656.0,0.006859,0.006859,6.593045,0.800006,1.0,729.0,22.0,194.0,Adverse Event,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.03617761,0.03627627203459315,9.866203459315409e-05
5.0,729.0,656.0,0.006859,0.006859,6.593045,0.800006,1.0,729.0,22.0,194.0,Adverse Event,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.03617761,0.03621431599024791,3.670599024790944e-05
4.0,729.0,656.0,0.005487,0.005487,6.593045,0.800006,1.0,729.0,22.0,194.0,Death,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.02894103,0.02901409445545637,7.306445545637169e-05
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Death,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.0072422121535714,5.632153571399727e-06
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Other,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00723658,0.007243690991488068,7.1109914880681385e-06
3.0,729.0,656.0,0.004115,0.004115,6.593045,0.800006,1.0,729.0,22.0,194.0,Other,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.02170446,0.02177360957721226,6.914957721226161e-05
2.0,729.0,656.0,0.002743,0.002743,6.593045,0.800006,1.0,729.0,22.0,194.0,Physician Decision,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.01446788,0.01451330773141865,4.542773141864853e-05
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Physician Decision,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.00723658,0.007243701370238067,7.121370238066457e-06
1.0,729.0,656.0,0.001372,0.001372,6.593045,0.800006,1.0,729.0,22.0,194.0,Non-compliance with study drug,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00723658,0.007243690991488068,7.1109914880681385e-06
0.0,729.0,656.0,0.0,0.0,6.593045,0.800006,1.0,729.0,22.0,194.0,Non-compliance with study drug,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
27.0,665.0,613.0,0.040602,0.040602,6.50129,0.328159,1.0,665.0,3.0,38.0,withdrawn consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08662254,0.08643228003769837,0.00019025996230162545
21.0,665.0,613.0,0.031579,0.031579,6.50129,0.328159,1.0,665.0,3.0,38.0,withdrawn consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06737238,0.06722785709003964,0.00014452290996035122
1.0,665.0,613.0,0.001504,0.001504,6.50129,0.328159,1.0,665.0,3.0,38.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00320872,0.003205877615535716,2.8423844642840555e-06
0.0,665.0,613.0,0.0,0.0,6.50129,0.328159,1.0,665.0,3.0,38.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,665.0,613.0,0.003008,0.003008,6.50129,0.328159,1.0,665.0,3.0,38.0,administrative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00641743,0.0064055450364781715,1.1884963521828495e-05
1.0,665.0,613.0,0.001504,0.001504,6.50129,0.328159,1.0,665.0,3.0,38.0,administrative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00320872,0.0032066784404166672,2.041559583332731e-06
23.0,3463.0,3046.0,0.006642,0.006642,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05413349,0.053327756881755964,0.0008057331182440355
29.0,3463.0,3046.0,0.008374,0.008374,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0682496,0.06767668081830086,0.000572919181699133
31.0,3463.0,3046.0,0.008952,0.008952,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0729604,0.07133476379338025,0.0016256362066197488
16.0,3463.0,3046.0,0.00462,0.00462,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03765383,0.03667526410677579,0.0009785658932242106
11.0,3463.0,3046.0,0.003176,0.003176,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02588497,0.02543989711994044,0.00044507288005956117
11.0,3463.0,3046.0,0.003176,0.003176,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02588497,0.02545471609154758,0.0004302539084524194
13.0,3463.0,3046.0,0.003754,0.003754,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03059577,0.030395875816557526,0.00019989418344247556
4.0,3463.0,3046.0,0.001155,0.001155,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00941346,0.008745622262192478,0.0006678377378075227
15.0,3463.0,3046.0,0.004332,0.004332,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03530658,0.0346113375071726,0.0006952424928273956
43.0,3463.0,3046.0,0.012417,0.012417,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10120078,0.09832003622110115,0.0028807437788988532
41.0,3463.0,3046.0,0.011839,0.011839,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09648997,0.09347715416398801,0.003012815836011984
37.0,3463.0,3046.0,0.010684,0.010684,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.08707652,0.08404755620525797,0.0030289637947420317
22.0,3463.0,3046.0,0.006353,0.006353,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05177809,0.05043970931857146,0.0013383806814285387
24.0,3463.0,3046.0,0.00693,0.00693,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05648074,0.05594260640803578,0.0005381335919642238
30.0,3463.0,3046.0,0.008663,0.008663,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.070605,0.06945690178443181,0.0011480982155681885
77.0,3463.0,3046.0,0.022235,0.022235,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Treatment,FG000,cardiovascular disease,INDUSTRY,0.18121924,0.17565955929583346,0.005559680704166542
89.0,3463.0,3046.0,0.0257,0.0257,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Treatment,FG001,cardiovascular disease,INDUSTRY,0.20945961,0.19765799984139878,0.011801610158601206
68.0,3463.0,3046.0,0.019636,0.019636,8.150179,1.0,1.0,3494.0,16.0,116.0,Adverse Event,Treatment,FG002,cardiovascular disease,INDUSTRY,0.16003692,0.15921134004895846,0.000825579951041544
8.0,3463.0,3046.0,0.00231,0.00231,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Treatment,FG000,cardiovascular disease,INDUSTRY,0.01882691,0.01873199417534722,9.491582465277759e-05
11.0,3463.0,3046.0,0.003176,0.003176,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Treatment,FG001,cardiovascular disease,INDUSTRY,0.02588497,0.025388300665535685,0.0004966693344643155
11.0,3463.0,3046.0,0.003176,0.003176,8.150179,1.0,1.0,3494.0,16.0,116.0,Protocol Violation,Treatment,FG002,cardiovascular disease,INDUSTRY,0.02588497,0.02541873195738091,0.0004662380426190896
0.0,3463.0,3046.0,0.0,0.0,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Treatment,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3463.0,3046.0,0.000578,0.000578,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0047108,0.004170228867498197,0.000540571132501803
1.0,3463.0,3046.0,0.000289,0.000289,8.150179,1.0,1.0,3494.0,16.0,116.0,Lost to Follow-up,Treatment,FG002,cardiovascular disease,INDUSTRY,0.0023554,0.0021191093528273833,0.00023629064717261682
25.0,3463.0,3046.0,0.007219,0.007219,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Treatment,FG000,cardiovascular disease,INDUSTRY,0.05883614,0.059373796779751985,0.0005376567797519827
20.0,3463.0,3046.0,0.005775,0.005775,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Treatment,FG001,cardiovascular disease,INDUSTRY,0.04706729,0.04594044404976191,0.001126845950238091
22.0,3463.0,3046.0,0.006353,0.006353,8.150179,1.0,1.0,3494.0,16.0,116.0,Withdrawal by Subject,Treatment,FG002,cardiovascular disease,INDUSTRY,0.05177809,0.05052162436720243,0.0012564656327975696
23.0,3463.0,3046.0,0.006642,0.006642,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Treatment,FG000,cardiovascular disease,INDUSTRY,0.05413349,0.05362110372437507,0.0005123862756249292
29.0,3463.0,3046.0,0.008374,0.008374,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Treatment,FG001,cardiovascular disease,INDUSTRY,0.0682496,0.06755450612609848,0.0006950938739015144
31.0,3463.0,3046.0,0.008952,0.008952,8.150179,1.0,1.0,3494.0,16.0,116.0,Other,Treatment,FG002,cardiovascular disease,INDUSTRY,0.0729604,0.07122826593183267,0.0017321340681673292
112.0,637.0,44.0,0.175824,0.175824,6.458338,0.398676,1.0,637.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.45270859,0.4581245452806248,0.0054159552806247735
144.0,637.0,44.0,0.22606,0.22606,6.458338,0.398676,1.0,637.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.58205538,0.6320971797691461,0.050041799769146134
26.0,637.0,44.0,0.040816,0.040816,6.458338,0.398676,1.0,637.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10509233,0.10246604081539677,0.0026262891846032255
18.0,637.0,44.0,0.028257,0.028257,6.458338,0.398676,1.0,637.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07275563,0.07157798990914499,0.0011776400908550116
0.0,637.0,44.0,0.0,0.0,6.458338,0.398676,1.0,637.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,637.0,44.0,0.00157,0.00157,6.458338,0.398676,1.0,637.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00404241,0.004064701422599224,2.2291422599224515e-05
2.0,637.0,44.0,0.00314,0.00314,6.458338,0.398676,1.0,637.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00808482,0.008077905874702408,6.914125297591972e-06
2.0,637.0,44.0,0.00314,0.00314,6.458338,0.398676,1.0,637.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808482,0.00807407169742968,1.0748302570319154e-05
89.0,637.0,44.0,0.139717,0.139717,6.458338,0.398676,1.0,637.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.35974091,0.31534724225193445,0.04439366774806558
61.0,637.0,44.0,0.095761,0.095761,6.458338,0.398676,1.0,637.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.24656377,0.24821243101599183,0.0016486610159918424
61.0,637.0,44.0,0.095761,0.095761,6.458338,0.398676,1.0,637.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24656377,0.24905636602262873,0.002492596022628746
62.0,637.0,44.0,0.097331,0.097331,6.458338,0.398676,1.0,637.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.25060618,0.25128039708709293,0.0006742170870929209
5.0,637.0,44.0,0.007849,0.007849,6.458338,0.398676,1.0,637.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02020947,0.019528320885079366,0.0006811491149206345
8.0,637.0,44.0,0.012559,0.012559,6.458338,0.398676,1.0,637.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0323367,0.03226916240190478,6.753759809522558e-05
2.0,637.0,44.0,0.00314,0.00314,6.458338,0.398676,1.0,637.0,0.0,0.0,Not Treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00808482,0.008076680072916693,8.139927083306714e-06
0.0,637.0,44.0,0.0,0.0,6.458338,0.398676,1.0,637.0,0.0,0.0,Not Treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
50.0,1343.0,1173.0,0.03723,0.03723,7.203406,1.0,1.0,1353.0,21.0,147.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.26818279,0.2532197170741372,0.014963072925862797
81.0,1343.0,1173.0,0.060313,0.060313,7.203406,1.0,1.0,1353.0,21.0,147.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.434459,0.37955710029394785,0.05490189970605214
9.0,1343.0,1173.0,0.006701,0.006701,7.203406,1.0,1.0,1353.0,21.0,147.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04827002,0.048118865273869015,0.0001511547261309823
5.0,1343.0,1173.0,0.003723,0.003723,7.203406,1.0,1.0,1353.0,21.0,147.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02681828,0.027106093787341235,0.0002878137873412352
12.0,1343.0,1173.0,0.008935,0.008935,7.203406,1.0,1.0,1353.0,21.0,147.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06436243,0.06343138221526791,0.0009310477847320892
13.0,1343.0,1173.0,0.00968,0.00968,7.203406,1.0,1.0,1353.0,21.0,147.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06972897,0.06883983460125986,0.0008891353987401374
10.0,813.0,737.0,0.0123,0.0123,6.70196,0.215837,1.0,813.0,20.0,123.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01779233,0.017880126147410715,8.779614741071667e-05
6.0,813.0,737.0,0.00738,0.00738,6.70196,0.215837,1.0,813.0,20.0,123.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0106754,0.01065450104160714,2.0898958392859962e-05
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00177923,0.0017790998636904882,1.301363095117334e-07
0.0,813.0,737.0,0.0,0.0,6.70196,0.215837,1.0,813.0,20.0,123.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00177923,0.0017795569553571548,3.269553571548598e-07
3.0,813.0,737.0,0.00369,0.00369,6.70196,0.215837,1.0,813.0,20.0,123.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0053377,0.005376751203293637,3.905120329363715e-05
24.0,813.0,737.0,0.02952,0.02952,6.70196,0.215837,1.0,813.0,20.0,123.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04270158,0.04355444784202379,0.0008528678420237842
11.0,813.0,737.0,0.01353,0.01353,6.70196,0.215837,1.0,813.0,20.0,123.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01957156,0.019817185033779768,0.0002456250337797665
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00177923,0.0017790510734127104,1.789265872895185e-07
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177923,0.0017782096683531862,1.0203316468137581e-06
0.0,813.0,737.0,0.0,0.0,6.70196,0.215837,1.0,813.0,20.0,123.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,813.0,737.0,0.00492,0.00492,6.70196,0.215837,1.0,813.0,20.0,123.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00711693,0.007133793203214293,1.6863203214293257e-05
3.0,813.0,737.0,0.00369,0.00369,6.70196,0.215837,1.0,813.0,20.0,123.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0053377,0.005371662236091254,3.3962236091254414e-05
7.0,813.0,737.0,0.00861,0.00861,6.70196,0.215837,1.0,813.0,20.0,123.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01245463,0.012764201967123016,0.0003095719671230169
2.0,813.0,737.0,0.00246,0.00246,6.70196,0.215837,1.0,813.0,20.0,123.0,supply problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00355847,0.003638598907232142,8.01289072321419e-05
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,supply problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177923,0.0017780254169642972,1.2045830357027085e-06
0.0,813.0,737.0,0.0,0.0,6.70196,0.215837,1.0,813.0,20.0,123.0,non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,813.0,737.0,0.00123,0.00123,6.70196,0.215837,1.0,813.0,20.0,123.0,non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177923,0.0017780254169642972,1.2045830357027085e-06
2.0,409.0,376.0,0.00489,0.00489,6.016157,0.75642,1.0,409.0,15.0,80.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02225314,0.02215060501194445,0.00010253498805555192
6.0,409.0,376.0,0.01467,0.01467,6.016157,0.75642,1.0,409.0,15.0,80.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06675942,0.06537708453116077,0.0013823354688392298
1.0,409.0,376.0,0.002445,0.002445,6.016157,0.75642,1.0,409.0,15.0,80.0,Withdrawal by proxy/legal representative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01112657,0.01110761207252978,1.8957927470220418e-05
0.0,409.0,376.0,0.0,0.0,6.016157,0.75642,1.0,409.0,15.0,80.0,Withdrawal by proxy/legal representative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,409.0,376.0,0.012225,0.012225,6.016157,0.75642,1.0,409.0,15.0,80.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05563285,0.05630972699584687,0.0006768769958468701
2.0,409.0,376.0,0.00489,0.00489,6.016157,0.75642,1.0,409.0,15.0,80.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02225314,0.022144179643859147,0.00010896035614085461
1.0,409.0,376.0,0.002445,0.002445,6.016157,0.75642,1.0,409.0,15.0,80.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01112657,0.01112028839919645,6.281600803551349e-06
4.0,409.0,376.0,0.00978,0.00978,6.016157,0.75642,1.0,409.0,15.0,80.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04450628,0.04400061074203289,0.0005056692579671132
5.0,409.0,376.0,0.012225,0.012225,6.016157,0.75642,1.0,409.0,15.0,80.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05563285,0.056464384229001637,0.0008315342290016389
3.0,409.0,376.0,0.007335,0.007335,6.016157,0.75642,1.0,409.0,15.0,80.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03337971,0.033243092641717785,0.000136617358282215
2.0,409.0,376.0,0.00489,0.00489,6.016157,0.75642,1.0,409.0,15.0,80.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02225314,0.022150296191111116,0.00010284380888888472
2.0,409.0,376.0,0.00489,0.00489,6.016157,0.75642,1.0,409.0,15.0,80.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02225314,0.02213584938370041,0.00011729061629959028
2.0,2136.0,1187.0,0.000936,0.000936,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,5 Year Follow up,FG000,cardiovascular disease,OTHER,0.00294655,0.002924181657428265,2.236834257173491e-05
2.0,2136.0,1187.0,0.000936,0.000936,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,5 Year Follow up,FG001,cardiovascular disease,OTHER,0.00294655,0.0029192225520711223,2.732744792887775e-05
1.0,2136.0,1187.0,0.000468,0.000468,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,5 Year Follow up,FG002,cardiovascular disease,OTHER,0.00147327,0.0015436437690133492,7.037376901334919e-05
7.0,2136.0,1187.0,0.003277,0.003277,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,5 Year Follow up,FG003,cardiovascular disease,OTHER,0.01031607,0.010395554437311503,7.948443731150244e-05
3.0,2136.0,1187.0,0.001404,0.001404,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,5 Year Follow up,FG004,cardiovascular disease,OTHER,0.00441982,0.004425129644831356,5.309644831356063e-06
12.0,2136.0,1187.0,0.005618,0.005618,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,10 Year Follow up,FG000,cardiovascular disease,OTHER,0.01768558,0.017596486129236102,8.909387076389691e-05
10.0,2136.0,1187.0,0.004682,0.004682,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,10 Year Follow up,FG001,cardiovascular disease,OTHER,0.01473904,0.014429032286646833,0.0003100077133531675
3.0,2136.0,1187.0,0.001404,0.001404,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,10 Year Follow up,FG002,cardiovascular disease,OTHER,0.00441982,0.004424064865039688,4.24486503968792e-06
0.0,2136.0,1187.0,0.0,0.0,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,10 Year Follow up,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,2136.0,1187.0,0.0,0.0,7.667158,0.410585,1.0,2136.0,1.0,1.0,Lost to Follow-up,10 Year Follow up,FG004,cardiovascular disease,OTHER,0.0,0.0,0.0
7.0,220.0,186.0,0.031818,0.031818,5.398163,0.525182,1.0,220.0,9.0,48.0,Did not Receive Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09020466,0.0932235821735897,0.0030189221735896915
9.0,220.0,186.0,0.040909,0.040909,5.398163,0.525182,1.0,220.0,9.0,48.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11597783,0.12615222698176592,0.01017439698176592
17.0,220.0,186.0,0.077273,0.077273,5.398163,0.525182,1.0,220.0,9.0,48.0,Personal Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.21907049,0.22551754660391893,0.0064470566039189214
1.0,220.0,186.0,0.004545,0.004545,5.398163,0.525182,1.0,220.0,9.0,48.0,Other Miscellaneous,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01288517,0.013145511424255945,0.00026034142425594535
105.0,27564.0,27353.0,0.003809,0.003809,10.224302,0.448917,1.0,27564.0,49.0,1284.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01748279,0.017311008664037692,0.00017178133596230938
88.0,27564.0,27353.0,0.003193,0.003193,10.224302,0.448917,1.0,27564.0,49.0,1284.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01465543,0.012472722381470052,0.0021827076185299485
13.0,27564.0,27353.0,0.000472,0.000472,10.224302,0.448917,1.0,27564.0,49.0,1284.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00216642,0.002010145119196428,0.0001562748808035721
5.0,27564.0,27353.0,0.000181,0.000181,10.224302,0.448917,1.0,27564.0,49.0,1284.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00083077,0.0008077943705059522,2.2975629494047765e-05
8.0,1530.0,1462.0,0.005229,0.005229,7.333676,0.379199,1.0,1530.0,17.0,133.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01454145,0.014305922644484126,0.00023552735551587295
10.0,1530.0,1462.0,0.006536,0.006536,7.333676,0.379199,1.0,1530.0,17.0,133.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01817612,0.017808259952976205,0.0003678600470237957
6.0,1530.0,1462.0,0.003922,0.003922,7.333676,0.379199,1.0,1530.0,17.0,133.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01090678,0.01077639597073413,0.00013038402926587
1.0,1530.0,1462.0,0.000654,0.000654,7.333676,0.379199,1.0,1530.0,17.0,133.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00181872,0.0018200632899404814,1.34328994048135e-06
0.0,1530.0,1462.0,0.0,0.0,7.333676,0.379199,1.0,1530.0,17.0,133.0,Incarcerated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1530.0,1462.0,0.000654,0.000654,7.333676,0.379199,1.0,1530.0,17.0,133.0,Incarcerated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00181872,0.0018192089449404817,4.889449404816421e-07
21.0,1530.0,1462.0,0.013725,0.013725,7.333676,0.379199,1.0,1530.0,17.0,133.0,Missed 12-month visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03816817,0.03801925532803573,0.00014891467196426894
21.0,1530.0,1462.0,0.013725,0.013725,7.333676,0.379199,1.0,1530.0,17.0,133.0,Missed 12-month visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03816817,0.038073330885535724,9.483911446427767e-05
4.0,262.0,11.0,0.015267,0.015267,5.572154,0.307202,1.0,262.0,26.0,89.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02613371,0.026327147629614897,0.0001934376296148961
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01306771,0.01308540222378513,1.769222378513076e-05
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01306771,0.01308679975086846,1.908975086846107e-05
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01306771,0.013085253988368463,1.7543988368463534e-05
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Lack of Efficacy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01306771,0.013085932459201794,1.8222459201794675e-05
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Lack of Efficacy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00653386,0.0065427954576190005,8.935457619000699e-06
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Non-compliance,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00653386,0.006537890490118999,4.030490118999558e-06
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Non-compliance,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01306771,0.013087481634201793,1.9771634201793536e-05
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,262.0,11.0,0.007634,0.007634,5.572154,0.307202,1.0,262.0,26.0,89.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01306771,0.01308484252378513,1.7132523785129417e-05
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Not treated,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00653386,0.006537890490118999,4.030490118999558e-06
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Not treated,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Adverse Event,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Adverse Event,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.00653386,0.006540412780476144,6.55278047614373e-06
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Death,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Death,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.00653386,0.006541901626309477,8.041626309476801e-06
3.0,262.0,11.0,0.01145,0.01145,5.572154,0.307202,1.0,262.0,26.0,89.0,Lost to Follow-up,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.01959986,0.01951516318022818,8.469681977181856e-05
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Lost to Follow-up,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,262.0,11.0,0.015267,0.015267,5.572154,0.307202,1.0,262.0,26.0,89.0,Withdrawal by Subject,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.02613371,0.02625215643982323,0.00011844643982322767
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Withdrawal by Subject,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,262.0,11.0,0.003817,0.003817,5.572154,0.307202,1.0,262.0,26.0,89.0,Missing,Follow-up Period (FUP),FG000,cardiovascular disease,INDUSTRY,0.00653386,0.006536668962976143,2.8089629761432477e-06
0.0,262.0,11.0,0.0,0.0,5.572154,0.307202,1.0,262.0,26.0,89.0,Missing,Follow-up Period (FUP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,460.0,413.0,0.008696,0.008696,6.133398,0.205195,1.0,460.0,9.0,9.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01094429,0.011089567325922624,0.00014527732592262317
10.0,460.0,413.0,0.021739,0.021739,6.133398,0.205195,1.0,460.0,9.0,9.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02735948,0.02746285710190478,0.00010337710190478147
5.0,460.0,413.0,0.01087,0.01087,6.133398,0.205195,1.0,460.0,9.0,9.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01368037,0.013640261677976216,4.010832202378488e-05
3.0,460.0,413.0,0.006522,0.006522,6.133398,0.205195,1.0,460.0,9.0,9.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820822,0.00823444800231605,2.6228002316049798e-05
2.0,460.0,413.0,0.004348,0.004348,6.133398,0.205195,1.0,460.0,9.0,9.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00547215,0.005537400665476184,6.525066547618391e-05
0.0,460.0,413.0,0.0,0.0,6.133398,0.205195,1.0,460.0,9.0,9.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,460.0,413.0,0.0,0.0,6.133398,0.205195,1.0,460.0,9.0,9.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00273607,0.002762550337467532,2.648033746753195e-05
0.0,460.0,413.0,0.0,0.0,6.133398,0.205195,1.0,460.0,9.0,9.0,Administrative problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,460.0,413.0,0.004348,0.004348,6.133398,0.205195,1.0,460.0,9.0,9.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00547215,0.0055369661855952275,6.481618559522721e-05
4.0,460.0,413.0,0.008696,0.008696,6.133398,0.205195,1.0,460.0,9.0,9.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01094429,0.011101466475744053,0.00015717647574405198
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00273607,0.002757955482884199,2.1885482884198906e-05
3.0,460.0,413.0,0.006522,0.006522,6.133398,0.205195,1.0,460.0,9.0,9.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820822,0.008230821143982716,2.2601143982715205e-05
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00273607,0.002758878982408007,2.280898240800697e-05
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00273607,0.002750925437467532,1.4855437467531634e-05
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00273607,0.002756683981217534,2.061398121753393e-05
3.0,460.0,413.0,0.006522,0.006522,6.133398,0.205195,1.0,460.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00820822,0.008230345323843825,2.2125323843824596e-05
5.0,460.0,413.0,0.01087,0.01087,6.133398,0.205195,1.0,460.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01368037,0.013616155932272748,6.421406772725256e-05
1.0,460.0,413.0,0.002174,0.002174,6.133398,0.205195,1.0,460.0,9.0,9.0,Condition no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00273607,0.002761360754550867,2.5290754550866962e-05
0.0,460.0,413.0,0.0,0.0,6.133398,0.205195,1.0,460.0,9.0,9.0,Condition no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,460.0,413.0,0.0,0.0,6.133398,0.205195,1.0,460.0,9.0,9.0,Condition no longer requires study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
15.0,369.0,325.0,0.04065,0.04065,5.913503,0.601846,1.0,369.0,11.0,118.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14467403,0.1488076035972998,0.0041335735972997945
19.0,369.0,325.0,0.051491,0.051491,5.913503,0.601846,1.0,369.0,11.0,118.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18325734,0.18479823343978363,0.0015408934397836416
3.0,369.0,325.0,0.00813,0.00813,5.913503,0.601846,1.0,369.0,11.0,118.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02893481,0.029084530573829436,0.00014972057382943785
2.0,369.0,325.0,0.00542,0.00542,5.913503,0.601846,1.0,369.0,11.0,118.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01928987,0.019778376673109666,0.0004885066731096649
3.0,369.0,325.0,0.00813,0.00813,5.913503,0.601846,1.0,369.0,11.0,118.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02893481,0.02903864999210325,0.00010383999210325165
2.0,369.0,325.0,0.00542,0.00542,5.913503,0.601846,1.0,369.0,11.0,118.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01928987,0.019760393332817466,0.00047052333281746503
5.0,3489.0,3476.0,0.001433,0.001433,8.157657,0.414798,1.0,3503.0,34.0,341.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00484895,0.004985421931617069,0.00013647193161706907
8.0,3489.0,3476.0,0.002293,0.002293,8.157657,0.414798,1.0,3503.0,34.0,341.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.007759,0.008329985370988453,0.000570985370988453
50.0,1708.0,1222.0,0.029274,0.029274,7.443664,0.309765,1.0,1708.0,2.0,86.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.06749962,0.06811566798675604,0.0006160479867560464
65.0,1708.0,1222.0,0.038056,0.038056,7.443664,0.309765,1.0,1708.0,2.0,86.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.08774904,0.0877900617075098,4.102170750980294e-05
91.0,1708.0,1222.0,0.053279,0.053279,7.443664,0.309765,1.0,1708.0,2.0,86.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.12285004,0.12248224770037705,0.00036779229962294324
83.0,1708.0,1222.0,0.048595,0.048595,7.443664,0.309765,1.0,1708.0,2.0,86.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,OTHER,0.11204973,0.11254222236116085,0.0004924923611608484
42.0,1708.0,1222.0,0.02459,0.02459,7.443664,0.309765,1.0,1708.0,2.0,86.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.05669931,0.05676604483503974,6.67348350397376e-05
42.0,1708.0,1222.0,0.02459,0.02459,7.443664,0.309765,1.0,1708.0,2.0,86.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.05669931,0.05695220620758935,0.000252896207589344
42.0,1708.0,1222.0,0.02459,0.02459,7.443664,0.309765,1.0,1708.0,2.0,86.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.05669931,0.056798567427420704,9.925742742070143e-05
49.0,1708.0,1222.0,0.028689,0.028689,7.443664,0.309765,1.0,1708.0,2.0,86.0,Death,Overall Study,FG003,cardiovascular disease,OTHER,0.06615073,0.06688237502232149,0.000731645022321481
8.0,1708.0,1222.0,0.004684,0.004684,7.443664,0.309765,1.0,1708.0,2.0,86.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01080031,0.011004664990347225,0.0002043549903472247
5.0,1708.0,1222.0,0.002927,0.002927,7.443664,0.309765,1.0,1708.0,2.0,86.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00674904,0.006661287566140862,8.775243385913869e-05
5.0,1708.0,1222.0,0.002927,0.002927,7.443664,0.309765,1.0,1708.0,2.0,86.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.00674904,0.006677712587777765,7.132741222223501e-05
4.0,1708.0,1222.0,0.002342,0.002342,7.443664,0.309765,1.0,1708.0,2.0,86.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,OTHER,0.00540015,0.005436373544010643,3.6223544010643115e-05
1902.0,15968.0,12791.0,0.119113,0.119113,9.678405,0.509223,1.0,15991.0,18.0,130.0,did not finish experimental regimen,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.58704455,0.5299286075748117,0.05711594242518825
770.0,15968.0,12791.0,0.048221,0.048221,9.678405,0.509223,1.0,15991.0,18.0,130.0,did not finish experimental regimen,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.23765563,0.22244681723114113,0.015208812768858881
268.0,15968.0,12791.0,0.016784,0.016784,9.678405,0.509223,1.0,15991.0,18.0,130.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0827194,0.07985958915864072,0.002859810841359278
237.0,15968.0,12791.0,0.014842,0.014842,9.678405,0.509223,1.0,15991.0,18.0,130.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07314831,0.06559878019595242,0.007549529804047578
2.0,795.0,764.0,0.002516,0.002516,6.679599,0.340296,1.0,795.0,4.0,81.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00571897,0.005690363004246037,2.8606995753963256e-05
4.0,795.0,764.0,0.005031,0.005031,6.679599,0.340296,1.0,795.0,4.0,81.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01143568,0.011392488645029765,4.319135497023521e-05
18.0,795.0,764.0,0.022642,0.022642,6.679599,0.340296,1.0,795.0,4.0,81.0,Angio or SPECT not completed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05146622,0.050652024281612584,0.0008141957183874157
1.0,795.0,764.0,0.001258,0.001258,6.679599,0.340296,1.0,795.0,4.0,81.0,issue with vitals prior to dosing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00285949,0.0028877252440440105,2.8235244044010413e-05
1.0,795.0,764.0,0.001258,0.001258,6.679599,0.340296,1.0,795.0,4.0,81.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00285949,0.002888432099024169,2.8942099024168756e-05
2.0,795.0,764.0,0.002516,0.002516,6.679599,0.340296,1.0,795.0,4.0,81.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00571897,0.005693954069662704,2.5015930337296544e-05
3.0,795.0,764.0,0.003774,0.003774,6.679599,0.340296,1.0,795.0,4.0,81.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00857846,0.008627191906160717,4.873190616071742e-05
1.0,455.0,380.0,0.002198,0.002198,6.122493,0.393038,1.0,455.0,17.0,82.0,Administrative issue,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0052892,0.00534001624943452,5.0816249434520316e-05
0.0,455.0,380.0,0.0,0.0,6.122493,0.393038,1.0,455.0,17.0,82.0,Administrative issue,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,455.0,380.0,0.002198,0.002198,6.122493,0.393038,1.0,455.0,17.0,82.0,Administrative issue,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0052892,0.005336419864910713,4.721986491071275e-05
2.0,455.0,380.0,0.004396,0.004396,6.122493,0.393038,1.0,455.0,17.0,82.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01057841,0.010578830973551567,4.209735515667279e-07
0.0,455.0,380.0,0.0,0.0,6.122493,0.393038,1.0,455.0,17.0,82.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,455.0,380.0,0.015385,0.015385,6.122493,0.393038,1.0,455.0,17.0,82.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03702201,0.03722278845327379,0.00020077845327379218
0.0,455.0,380.0,0.0,0.0,6.122493,0.393038,1.0,455.0,17.0,82.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,455.0,380.0,0.006593,0.006593,6.122493,0.393038,1.0,455.0,17.0,82.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0158652,0.015878008364305616,1.2808364305616493e-05
0.0,455.0,380.0,0.0,0.0,6.122493,0.393038,1.0,455.0,17.0,82.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,455.0,380.0,0.004396,0.004396,6.122493,0.393038,1.0,455.0,17.0,82.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01057841,0.010596196271051567,1.7786271051567146e-05
1.0,455.0,380.0,0.002198,0.002198,6.122493,0.393038,1.0,455.0,17.0,82.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0052892,0.005346706945803572,5.7506945803572317e-05
2.0,455.0,380.0,0.004396,0.004396,6.122493,0.393038,1.0,455.0,17.0,82.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01057841,0.010590776179742044,1.2366179742043931e-05
3.0,455.0,380.0,0.006593,0.006593,6.122493,0.393038,1.0,455.0,17.0,82.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0158652,0.015889489451150866,2.428945115086692e-05
3.0,455.0,380.0,0.006593,0.006593,6.122493,0.393038,1.0,455.0,17.0,82.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0158652,0.015881887731448482,1.6687731448482984e-05
3.0,455.0,380.0,0.006593,0.006593,6.122493,0.393038,1.0,455.0,17.0,82.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0158652,0.015879349779484197,1.4149779484197433e-05
11.0,455.0,380.0,0.024176,0.024176,6.122493,0.393038,1.0,455.0,17.0,82.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05817642,0.05790559552830349,0.0002708244716965111
11.0,455.0,380.0,0.024176,0.024176,6.122493,0.393038,1.0,455.0,17.0,82.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05817642,0.05785910515324399,0.0003173148467560116
10.0,455.0,380.0,0.021978,0.021978,6.122493,0.393038,1.0,455.0,17.0,82.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05288722,0.053175548755922605,0.00028832875592260665
3.0,455.0,380.0,0.006593,0.006593,6.122493,0.393038,1.0,455.0,17.0,82.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0158652,0.015883139700615147,1.7939700615147297e-05
8.0,455.0,380.0,0.017582,0.017582,6.122493,0.393038,1.0,455.0,17.0,82.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04230881,0.04261662675071427,0.00030781675071427095
4.0,455.0,380.0,0.008791,0.008791,6.122493,0.393038,1.0,455.0,17.0,82.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0211544,0.020636263788353176,0.000518136211646824
14.0,976.0,930.0,0.014344,0.014344,6.884487,1.0,1.0,976.0,12.0,122.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09875108,0.09648574374157746,0.00226533625842254
4.0,976.0,930.0,0.004098,0.004098,6.884487,1.0,1.0,976.0,12.0,122.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02821263,0.029287758386853328,0.0010751283868533287
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,976.0,930.0,0.006148,0.006148,6.884487,1.0,1.0,976.0,12.0,122.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04232582,0.0424701902110912,0.0001443702110911979
1.0,976.0,930.0,0.001025,0.001025,6.884487,1.0,1.0,976.0,12.0,122.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0070566,0.00702980434964286,2.6795650357139267e-05
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,976.0,930.0,0.012295,0.012295,6.884487,1.0,1.0,976.0,12.0,122.0,Non compliant with the protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08464476,0.0852310650111309,0.0005863050111308971
2.0,976.0,930.0,0.002049,0.002049,6.884487,1.0,1.0,976.0,12.0,122.0,Non compliant with the protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01410631,0.014069218176111066,3.709182388893402e-05
1.0,976.0,930.0,0.001025,0.001025,6.884487,1.0,1.0,976.0,12.0,122.0,Non compliant with the protocol,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0070566,0.00703736597714286,1.923402285713971e-05
2.0,976.0,930.0,0.002049,0.002049,6.884487,1.0,1.0,976.0,12.0,122.0,Non compliant with the protocol,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01410631,0.01408759643176583,1.871356823416985e-05
3.0,976.0,930.0,0.003074,0.003074,6.884487,1.0,1.0,976.0,12.0,122.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02116291,0.020936255196984197,0.0002266548030158029
1.0,976.0,930.0,0.001025,0.001025,6.884487,1.0,1.0,976.0,12.0,122.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0070566,0.007035756138809527,2.0843861190472657e-05
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Consent withdrawn,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,976.0,930.0,0.0,0.0,6.884487,1.0,1.0,976.0,12.0,122.0,Consent withdrawn,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
186.0,2743.0,1098.0,0.067809,0.067809,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.15809977,0.1574086115265153,0.0006911584734846932
222.0,2743.0,1098.0,0.080933,0.080933,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.18869897,0.18793196749762903,0.000767002502370967
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
34.0,2743.0,1098.0,0.012395,0.012395,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.02889951,0.028898540225016228,9.697749837715708e-07
28.0,2743.0,1098.0,0.010208,0.010208,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.02380042,0.023856960542500003,5.654054250000401e-05
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
131.0,2743.0,1098.0,0.047758,0.047758,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.11134995,0.11091596410198429,0.0004339858980157152
148.0,2743.0,1098.0,0.053956,0.053956,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.12580087,0.1270220425157212,0.0012211725157211806
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
28.0,2743.0,1098.0,0.010208,0.010208,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.02380042,0.023883928708541665,8.350870854166581e-05
21.0,2743.0,1098.0,0.007656,0.007656,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.01785031,0.017669036950863085,0.00018127304913691591
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
83.0,2743.0,1098.0,0.030259,0.030259,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.07055023,0.07142601553554573,0.0008757855355457228
100.0,2743.0,1098.0,0.036456,0.036456,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.08499882,0.0850936977969147,9.487779691469411e-05
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
70.0,2743.0,1098.0,0.02552,0.02552,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.05950104,0.0605145839715675,0.0010135439715674988
75.0,2743.0,1098.0,0.027342,0.027342,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.06374912,0.06414174112944443,0.0003926211294444232
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2743.0,1098.0,0.001094,0.001094,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.00255071,0.0025478720223133067,2.8379776866932147e-06
4.0,2743.0,1098.0,0.001458,0.001458,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.00339939,0.0034501087485317426,5.071874853174261e-05
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,2743.0,1098.0,0.002187,0.002187,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Double-blind (DB) Phase,FG000,cardiovascular disease,INDUSTRY,0.00509909,0.005093778713521823,5.311286478176282e-06
7.0,2743.0,1098.0,0.002552,0.002552,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Double-blind (DB) Phase,FG001,cardiovascular disease,INDUSTRY,0.0059501,0.005771766147182542,0.00017833385281745742
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Double-blind (DB) Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
48.0,2743.0,1098.0,0.017499,0.017499,7.917172,0.294492,1.0,2743.0,29.0,307.0,Death,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.04079971,0.0415182693184632,0.0007185593184631939
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2743.0,1098.0,0.001823,0.001823,7.917172,0.294492,1.0,2743.0,29.0,307.0,Lost to Follow-up,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.00425041,0.004230156287132935,2.0253712867064448e-05
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2743.0,1098.0,0.001094,0.001094,7.917172,0.294492,1.0,2743.0,29.0,307.0,Protocol Violation,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.00255071,0.002546475888682352,4.234111317647903e-06
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Study terminated by sponsor,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Study terminated by sponsor,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2743.0,1098.0,0.001094,0.001094,7.917172,0.294492,1.0,2743.0,29.0,307.0,Study terminated by sponsor,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.00255071,0.0025465237470156847,4.186252984315127e-06
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
37.0,2743.0,1098.0,0.013489,0.013489,7.917172,0.294492,1.0,2743.0,29.0,307.0,Withdrawal by Subject,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.03145022,0.030476428603171013,0.000973791396828988
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,2743.0,1098.0,0.005833,0.005833,7.917172,0.294492,1.0,2743.0,29.0,307.0,Other,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0135999,0.013450675147718248,0.000149224852281752
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
25.0,2743.0,1098.0,0.009114,0.009114,7.917172,0.294492,1.0,2743.0,29.0,307.0,Adverse Event,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.02124971,0.020788222185456333,0.00046148781454366863
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,2743.0,1098.0,0.003646,0.003646,7.917172,0.294492,1.0,2743.0,29.0,307.0,Laboratory abnormality,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.00850081,0.008396950298621038,0.0001038597013789614
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2743.0,1098.0,0.0,0.0,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2743.0,1098.0,0.000365,0.000365,7.917172,0.294492,1.0,2743.0,29.0,307.0,Randomized but not treated,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.00085101,0.0008093897182043656,4.162028179563438e-05
40.0,6528.0,4958.0,0.006127,0.006127,8.784009,0.277854,1.0,6758.0,35.0,296.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01495398,0.014866862993998014,8.71170060019865e-05
47.0,6528.0,4958.0,0.0072,0.0072,8.784009,0.277854,1.0,6758.0,35.0,296.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01757282,0.017099416943630937,0.0004734030563690629
284.0,6528.0,4958.0,0.043505,0.043505,8.784009,0.277854,1.0,6758.0,35.0,296.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10618132,0.10463209629981327,0.0015492237001867304
260.0,6528.0,4958.0,0.039828,0.039828,8.784009,0.277854,1.0,6758.0,35.0,296.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09720698,0.09675540789949409,0.00045157210050590646
299.0,6528.0,4958.0,0.045803,0.045803,8.784009,0.277854,1.0,6758.0,35.0,296.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11178997,0.10886460382833331,0.0029253661716666934
271.0,6528.0,4958.0,0.041513,0.041513,8.784009,0.277854,1.0,6758.0,35.0,296.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1013195,0.10131772912970244,1.7708702975682833e-06
72.0,6528.0,4958.0,0.011029,0.011029,8.784009,0.277854,1.0,6758.0,35.0,296.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02691814,0.02674712450337303,0.00017101549662696877
71.0,6528.0,4958.0,0.010876,0.010876,8.784009,0.277854,1.0,6758.0,35.0,296.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02654472,0.02644477320684527,9.994679315472946e-05
46.0,6528.0,4958.0,0.007047,0.007047,8.784009,0.277854,1.0,6758.0,35.0,296.0,Poor/Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0171994,0.016576582051746017,0.0006228179482539835
33.0,6528.0,4958.0,0.005055,0.005055,8.784009,0.277854,1.0,6758.0,35.0,296.0,Poor/Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01233758,0.012322181152408906,1.5398847591094333e-05
41.0,6528.0,4958.0,0.006281,0.006281,8.784009,0.277854,1.0,6758.0,35.0,296.0,No longer met criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01532984,0.015164656008412675,0.00016518399158732544
37.0,6528.0,4958.0,0.005668,0.005668,8.784009,0.277854,1.0,6758.0,35.0,296.0,No longer met criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01383371,0.013941839269841274,0.0001081292698412728
1.0,6528.0,4958.0,0.000153,0.000153,8.784009,0.277854,1.0,6758.0,35.0,296.0,Administrative reason by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00037342,0.0003829445102678579,9.524510267857873e-06
0.0,6528.0,4958.0,0.0,0.0,8.784009,0.277854,1.0,6758.0,35.0,296.0,Administrative reason by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
29.0,6528.0,4958.0,0.004442,0.004442,8.784009,0.277854,1.0,6758.0,35.0,296.0,non-specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01084145,0.01114473207946429,0.0003032820794642895
38.0,6528.0,4958.0,0.005821,0.005821,8.784009,0.277854,1.0,6758.0,35.0,296.0,non-specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01420714,0.014190337586626993,1.6802413373007488e-05
1.0,6528.0,4958.0,0.000153,0.000153,8.784009,0.277854,1.0,6758.0,35.0,296.0,treated for 1 day; missing status/reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00037342,0.0003829445102678579,9.524510267857873e-06
0.0,6528.0,4958.0,0.0,0.0,8.784009,0.277854,1.0,6758.0,35.0,296.0,treated for 1 day; missing status/reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG001,cardiovascular disease,INDUSTRY,0.00149118,0.001497182841547619,6.002841547619094e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase I,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1547.0,689.0,0.001939,0.001939,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG001,cardiovascular disease,INDUSTRY,0.00447584,0.0042845798484325345,0.00019126015156746556
6.0,1547.0,689.0,0.003878,0.003878,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG002,cardiovascular disease,INDUSTRY,0.00895167,0.008889213595882944,6.245640411705645e-05
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase I,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1547.0,689.0,0.001939,0.001939,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG001,cardiovascular disease,INDUSTRY,0.00447584,0.0042955454163492,0.00018029458365079968
9.0,1547.0,689.0,0.005818,0.005818,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG002,cardiovascular disease,INDUSTRY,0.01342982,0.013457060690595227,2.7240690595226394e-05
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase I,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1547.0,689.0,0.001293,0.001293,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG000,cardiovascular disease,INDUSTRY,0.00298466,0.0029925793872023817,7.919387202381598e-06
10.0,1547.0,689.0,0.006464,0.006464,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG001,cardiovascular disease,INDUSTRY,0.01492099,0.014851977948571436,6.901205142856477e-05
29.0,1547.0,689.0,0.018746,0.018746,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG002,cardiovascular disease,INDUSTRY,0.0432718,0.042470089748611155,0.0008017102513888444
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase I,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG000,cardiovascular disease,INDUSTRY,0.00149118,0.0014949160243749996,3.736024374999692e-06
11.0,1547.0,689.0,0.007111,0.007111,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG001,cardiovascular disease,INDUSTRY,0.01641448,0.015778888131011904,0.0006355918689880946
12.0,1547.0,689.0,0.007757,0.007757,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG002,cardiovascular disease,INDUSTRY,0.01790565,0.01791452208948412,8.872089484121548e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase I,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG004,cardiovascular disease,INDUSTRY,0.00149118,0.0014915024771726185,3.2247717261855817e-07
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG005,cardiovascular disease,INDUSTRY,0.00149118,0.0014915539275892854,3.7392758928545683e-07
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG006,cardiovascular disease,INDUSTRY,0.00149118,0.0014914218963392853,2.4189633928534647e-07
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Adverse Event,Phase II,FG007,cardiovascular disease,INDUSTRY,0.00149118,0.0014915539275892854,3.7392758928545683e-07
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG006,cardiovascular disease,INDUSTRY,0.00149118,0.0014922631223809521,1.0831223809521905e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Physician Decision,Phase II,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG003,cardiovascular disease,INDUSTRY,0.00149118,0.0014924700633630946,1.2900633630946474e-06
2.0,1547.0,689.0,0.001293,0.001293,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG004,cardiovascular disease,INDUSTRY,0.00298466,0.0029896288536309518,4.968853630951675e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1547.0,689.0,0.001293,0.001293,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG006,cardiovascular disease,INDUSTRY,0.00298466,0.0029889823140476185,4.322314047618386e-06
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Lost to Follow-up,Phase II,FG007,cardiovascular disease,INDUSTRY,0.00149118,0.0014921988133630945,1.0188133630945236e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1547.0,689.0,0.000646,0.000646,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG004,cardiovascular disease,INDUSTRY,0.00149118,0.0014907428319047619,4.37168095238083e-07
2.0,1547.0,689.0,0.001293,0.001293,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG005,cardiovascular disease,INDUSTRY,0.00298466,0.0029891422644642853,4.482264464285204e-06
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Protocol Violation,Phase II,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1547.0,689.0,0.0,0.0,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1547.0,689.0,0.002586,0.002586,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG004,cardiovascular disease,INDUSTRY,0.00596932,0.006038068631954362,6.874863195436166e-05
2.0,1547.0,689.0,0.001293,0.001293,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG005,cardiovascular disease,INDUSTRY,0.00298466,0.0029863997498809514,1.7397498809513384e-06
5.0,1547.0,689.0,0.003232,0.003232,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG006,cardiovascular disease,INDUSTRY,0.0074605,0.0074501613616765935,1.0338638323406646e-05
4.0,1547.0,689.0,0.002586,0.002586,7.344719,0.314283,1.0,1547.0,0.0,0.0,Withdrawal by Subject,Phase II,FG007,cardiovascular disease,INDUSTRY,0.00596932,0.006037386556954362,6.806655695436141e-05
17.0,18113.0,17360.0,0.000939,0.000939,9.80444,1.0,1.0,18113.0,44.0,984.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00920637,0.008283657179851167,0.0009227128201488334
31.0,18113.0,17360.0,0.001711,0.001711,9.80444,1.0,1.0,18113.0,44.0,984.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0167754,0.01355394464882935,0.0032214553511706497
41.0,18113.0,17360.0,0.002264,0.002264,9.80444,1.0,1.0,18113.0,44.0,984.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02219725,0.019910282231666653,0.002286967768333349
128.0,18113.0,17360.0,0.007067,0.007067,9.80444,1.0,1.0,18113.0,44.0,984.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06928798,0.0640316020523909,0.005256377947609095
145.0,18113.0,17360.0,0.008005,0.008005,9.80444,1.0,1.0,18113.0,44.0,984.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07848455,0.06804825051493055,0.010436299485069453
139.0,18113.0,17360.0,0.007674,0.007674,9.80444,1.0,1.0,18113.0,44.0,984.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07523928,0.06854256929520833,0.006696710704791678
32.0,18113.0,17360.0,0.001767,0.001767,9.80444,1.0,1.0,18113.0,44.0,984.0,Not Treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01732445,0.015277880981507903,0.0020465690184920983
17.0,18113.0,17360.0,0.000939,0.000939,9.80444,1.0,1.0,18113.0,44.0,984.0,Not Treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00920637,0.008269800244404737,0.0009365697555952634
24.0,18113.0,17360.0,0.001325,0.001325,9.80444,1.0,1.0,18113.0,44.0,984.0,Not Treated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01299088,0.009938534973611092,0.003052345026388908
58.0,18113.0,17360.0,0.003202,0.003202,9.80444,1.0,1.0,18113.0,44.0,984.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03139382,0.025508954945029715,0.005884865054970288
59.0,18113.0,17360.0,0.003257,0.003257,9.80444,1.0,1.0,18113.0,44.0,984.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03193306,0.025559417497529723,0.006373642502470276
62.0,18113.0,17360.0,0.003423,0.003423,9.80444,1.0,1.0,18113.0,44.0,984.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0335606,0.0298918700906944,0.003668729909305602
67.0,17604.0,17061.0,0.003806,0.003806,9.775938,0.797541,1.0,17604.0,42.0,833.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02967427,0.027457293377876946,0.0022169766221230534
96.0,17604.0,17061.0,0.005453,0.005453,9.775938,0.797541,1.0,17604.0,42.0,833.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04251545,0.03954367190092264,0.0029717780990773657
192.0,17604.0,17061.0,0.010907,0.010907,9.775938,0.797541,1.0,17604.0,42.0,833.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08503871,0.08130543239556542,0.003733277604434579
188.0,17604.0,17061.0,0.010679,0.010679,9.775938,0.797541,1.0,17604.0,42.0,833.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08326106,0.0803307083726488,0.0029303516273511965
485.0,19102.0,17724.0,0.02539,0.02539,9.857601,0.350295,1.0,19102.0,2.0,2.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.0876735,0.081152464225,0.006521035775000003
458.0,19102.0,17724.0,0.023977,0.023977,9.857601,0.350295,1.0,19102.0,2.0,2.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.0827943,0.07919372198252976,0.0036005780174702406
3.0,19102.0,17724.0,0.000157,0.000157,9.857601,0.350295,1.0,19102.0,2.0,2.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00054213,0.000593511986755953,5.1381986755952964e-05
1.0,19102.0,17724.0,5.2e-05,5.2e-05,9.857601,0.350295,1.0,19102.0,2.0,2.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00017956,0.00018410951044642865,4.549510446428656e-06
1.0,19102.0,17724.0,5.2e-05,5.2e-05,9.857601,0.350295,1.0,19102.0,2.0,2.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.00017956,0.00018112038970238112,1.5603897023811289e-06
0.0,19102.0,17724.0,0.0,0.0,9.857601,0.350295,1.0,19102.0,2.0,2.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.0,7.98779339285714e-06,7.98779339285714e-06
231.0,19102.0,17724.0,0.012093,0.012093,9.857601,0.350295,1.0,19102.0,2.0,2.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.041758,0.03839944086855605,0.00335855913144395
199.0,19102.0,17724.0,0.010418,0.010418,9.857601,0.350295,1.0,19102.0,2.0,2.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.0359741,0.03459781049992513,0.0013762895000748732
11.0,820.0,777.0,0.013415,0.013415,6.710523,0.233646,1.0,818.0,9.0,9.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02103322,0.021207978041388905,0.00017475804138890674
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191282,0.0019123965513591335,4.2344864086647435e-07
3.0,820.0,777.0,0.003659,0.003659,6.710523,0.233646,1.0,818.0,9.0,9.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0057369,0.005731550791140885,5.349208859114878e-06
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,820.0,777.0,0.010976,0.010976,6.710523,0.233646,1.0,818.0,9.0,9.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01720914,0.017258838504325417,4.969850432541556e-05
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Condition no longer required study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191282,0.0019121333050496098,6.866949503901622e-07
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Condition no longer required study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Condition no longer required study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,820.0,777.0,0.003659,0.003659,6.710523,0.233646,1.0,818.0,9.0,9.0,Patient withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0057369,0.005728546526696443,8.353473303556944e-06
2.0,820.0,777.0,0.002439,0.002439,6.710523,0.233646,1.0,818.0,9.0,9.0,Patient withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00382408,0.003817840647264617,6.2393527353829005e-06
3.0,820.0,777.0,0.003659,0.003659,6.710523,0.233646,1.0,818.0,9.0,9.0,Patient withdrew consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0057369,0.005730944826855171,5.955173144828532e-06
3.0,820.0,777.0,0.003659,0.003659,6.710523,0.233646,1.0,818.0,9.0,9.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0057369,0.005728940063779776,7.959936220223833e-06
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191282,0.0019114953813591335,1.324618640866429e-06
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,820.0,777.0,0.002439,0.002439,6.710523,0.233646,1.0,818.0,9.0,9.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00382408,0.0038233650188717622,7.149811282378647e-07
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191282,0.0019115289888591335,1.2910111408664937e-06
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Protocol deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00191282,0.0019119594209424668,8.605790575331399e-07
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Randomized in error,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191282,0.0019121333050496098,6.866949503901622e-07
1.0,820.0,777.0,0.00122,0.00122,6.710523,0.233646,1.0,818.0,9.0,9.0,Randomized in error,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191282,0.0019115289888591335,1.2910111408664937e-06
0.0,820.0,777.0,0.0,0.0,6.710523,0.233646,1.0,818.0,9.0,9.0,Randomized in error,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,18624.0,18062.0,0.000376,0.000376,9.83226,0.230287,1.0,18624.0,44.0,672.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00085136,0.0008019627606547619,4.939723934523814e-05
2.0,18624.0,18062.0,0.000107,0.000107,9.83226,0.230287,1.0,18624.0,44.0,672.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00024227,0.00024279833750000094,5.283375000009476e-07
296.0,18624.0,18062.0,0.015893,0.015893,9.83226,0.230287,1.0,18624.0,44.0,672.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03598564,0.033984503510466266,0.0020011364895337336
249.0,18624.0,18062.0,0.01337,0.01337,9.83226,0.230287,1.0,18624.0,44.0,672.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03027295,0.030688203393769844,0.00041525339376984396
2.0,18624.0,18062.0,0.000107,0.000107,9.83226,0.230287,1.0,18624.0,44.0,672.0,Reason unknown,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00024227,0.00024221418184523902,5.5818154760979436e-08
4.0,18624.0,18062.0,0.000215,0.000215,9.83226,0.230287,1.0,18624.0,44.0,672.0,Reason unknown,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00048681,0.0004991101764439036,1.2300176443903624e-05
2.0,18624.0,18062.0,0.000107,0.000107,9.83226,0.230287,1.0,18624.0,44.0,672.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00024227,0.0002456787373214292,3.408737321429218e-06
0.0,18624.0,18062.0,0.0,0.0,9.83226,0.230287,1.0,18624.0,44.0,672.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,4.69389125e-06,4.69389125e-06
45.0,656.0,528.0,0.068598,0.068598,6.487684,0.811096,1.0,656.0,33.0,227.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.36097206,0.35663841354034687,0.004333646459653118
61.0,656.0,528.0,0.092988,0.092988,6.487684,0.811096,1.0,656.0,33.0,227.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.48931558,0.500852181918958,0.011536601918957945
2.0,656.0,528.0,0.003049,0.003049,6.487684,0.811096,1.0,656.0,33.0,227.0,Reason Not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01604426,0.01606873190282738,2.4471902827380432e-05
5.0,656.0,528.0,0.007622,0.007622,6.487684,0.811096,1.0,656.0,33.0,227.0,Reason Not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04010801,0.03968750232778768,0.00042050767221232105
8.0,656.0,528.0,0.012195,0.012195,6.487684,0.811096,1.0,656.0,33.0,227.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06417176,0.06343942143381943,0.0007323385661805598
7.0,656.0,528.0,0.010671,0.010671,6.487684,0.811096,1.0,656.0,33.0,227.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05615226,0.05694493735696428,0.0007926773569642762
54.0,1516.0,1421.0,0.03562,0.03562,7.32449,0.305312,1.0,1516.0,1.0,1.0,Death/Withdrew/Criteria Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.07965539,0.08140000619654764,0.0017446161965476298
41.0,1516.0,1421.0,0.027045,0.027045,7.32449,0.305312,1.0,1516.0,1.0,1.0,Death/Withdrew/Criteria Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.06047951,0.06009267072518847,0.00038683927481152763
14.0,287.0,174.0,0.04878,0.04878,5.66296,0.218985,1.0,287.0,1.0,78.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06049225,0.061447758485446445,0.0009555084854464477
12.0,287.0,174.0,0.041812,0.041812,5.66296,0.218985,1.0,287.0,1.0,78.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05185121,0.05203870916561511,0.00018749916561510566
17.0,287.0,174.0,0.059233,0.059233,5.66296,0.218985,1.0,287.0,1.0,78.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07345505,0.07508008745440778,0.001625037454407785
6.0,287.0,174.0,0.020906,0.020906,5.66296,0.218985,1.0,287.0,1.0,78.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0259256,0.026050354808065473,0.0001247548080654734
3.0,287.0,174.0,0.010453,0.010453,5.66296,0.218985,1.0,287.0,1.0,78.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0129628,0.012994834393534842,3.2034393534842096e-05
7.0,287.0,174.0,0.02439,0.02439,5.66296,0.218985,1.0,287.0,1.0,78.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03024613,0.030352053882083344,0.00010592388208334469
3.0,287.0,174.0,0.010453,0.010453,5.66296,0.218985,1.0,287.0,1.0,78.0,Consent Withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0129628,0.012957430539278897,5.369460721103489e-06
3.0,287.0,174.0,0.010453,0.010453,5.66296,0.218985,1.0,287.0,1.0,78.0,Consent Withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0129628,0.012988452164368187,2.5652164368186736e-05
5.0,287.0,174.0,0.017422,0.017422,5.66296,0.218985,1.0,287.0,1.0,78.0,Consent Withdrawn,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02160508,0.021721794334355102,0.00011671433435510303
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00432052,0.004319401111954396,1.118888045603672e-06
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00864228,0.008667268618511918,2.4988618511917124e-05
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,287.0,174.0,0.010453,0.010453,5.66296,0.218985,1.0,287.0,1.0,78.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0129628,0.012961303085112221,1.4969148877785193e-06
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00432052,0.004307271948412721,1.3248051587278278e-05
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00864228,0.008638953619166678,3.3263808333228867e-06
5.0,287.0,174.0,0.017422,0.017422,5.66296,0.218985,1.0,287.0,1.0,78.0,Amendment 4: > Month 12,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02160508,0.021718654595367006,0.0001135745953670074
7.0,287.0,174.0,0.02439,0.02439,5.66296,0.218985,1.0,287.0,1.0,78.0,Amendment 4: > Month 12,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03024613,0.03035976609386905,0.00011363609386905171
5.0,287.0,174.0,0.017422,0.017422,5.66296,0.218985,1.0,287.0,1.0,78.0,Amendment 4: > Month 12,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02160508,0.02172247334268842,0.00011739334268841967
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Woman of Child-bearing Potential,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00864228,0.008681995056309533,3.971505630953262e-05
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Woman of Child-bearing Potential,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Woman of Child-bearing Potential,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00864228,0.008639839984047631,2.4400159523690207e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Incorrectly Randomized,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Incorrectly Randomized,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Incorrectly Randomized,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00864228,0.008638953619166678,3.3263808333228867e-06
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00432052,0.004319401111954396,1.118888045603672e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Non-compliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00864228,0.008638953619166678,3.3263808333228867e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Stopped Study Medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Stopped Study Medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Stopped Study Medication,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00432052,0.0043152885073909015,5.2314926090981165e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Site Closed Study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,287.0,174.0,0.006969,0.006969,5.66296,0.218985,1.0,287.0,1.0,78.0,Site Closed Study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00864228,0.008667268618511918,2.4988618511917124e-05
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Site Closed Study,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Amendment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Amendment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00432052,0.004304559299365104,1.5960700634895346e-05
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Protocol Amendment,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Study Medication Not Tapered,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Study Medication Not Tapered,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00432052,0.004304559299365104,1.5960700634895346e-05
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Study Medication Not Tapered,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Subject Left Site Location,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00432052,0.004319401111954396,1.118888045603672e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Subject Left Site Location,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Subject Left Site Location,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Investigator Not at Site,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00432052,0.004319401111954396,1.118888045603672e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Investigator Not at Site,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Investigator Not at Site,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,287.0,174.0,0.003484,0.003484,5.66296,0.218985,1.0,287.0,1.0,78.0,Blood Pressure Not Controlled,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00432052,0.004319401111954396,1.118888045603672e-06
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Blood Pressure Not Controlled,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,287.0,174.0,0.0,0.0,5.66296,0.218985,1.0,287.0,1.0,78.0,Blood Pressure Not Controlled,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,1010.0,984.0,0.006931,0.006931,6.918695,0.222179,1.0,1011.0,4.0,41.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01065426,0.010615300214791656,3.8959785208344394e-05
6.0,1010.0,984.0,0.005941,0.005941,6.918695,0.222179,1.0,1011.0,4.0,41.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00913244,0.009175999787738096,4.3559787738095546e-05
1.0,1010.0,984.0,0.00099,0.00099,6.918695,0.222179,1.0,1011.0,4.0,41.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00152182,0.0015457981347880576,2.397813478805769e-05
0.0,1010.0,984.0,0.0,0.0,6.918695,0.222179,1.0,1011.0,4.0,41.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1010.0,984.0,0.00495,0.00495,6.918695,0.222179,1.0,1011.0,4.0,41.0,"concomitant medication,etc.",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00760909,0.007593633820059516,1.5456179940484017e-05
7.0,1010.0,984.0,0.006931,0.006931,6.918695,0.222179,1.0,1011.0,4.0,41.0,"concomitant medication,etc.",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01065426,0.01058888023517856,6.537976482143965e-05
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00114782,0.0012744293676686586,0.00012660936766865872
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00114782,0.001282163592430563,0.00013434359243056303
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00114782,0.0012841397118353252,0.00013631971183532526
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00057391,0.0005795000500000036,5.590050000003682e-06
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00057391,0.0005767050250000038,2.7950250000037926e-06
4.0,576.0,526.0,0.006944,0.006944,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00229563,0.0028765093529761914,0.0005808793529761915
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00114782,0.0012848365135019917,0.0001370165135019918
3.0,576.0,526.0,0.005208,0.005208,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172173,0.0019431224086192246,0.00022139240861922455
5.0,576.0,526.0,0.008681,0.008681,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00286987,0.005161013770267854,0.0022911437702678537
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00114782,0.0012880459201686583,0.0001402259201686584
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,576.0,526.0,0.005208,0.005208,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00172173,0.001941071149095415,0.0002193411490954149
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Lack of Efficacy,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00114782,0.0012755924864186587,0.00012777248641865878
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00057391,0.0005781025375000037,4.1925375000037915e-06
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00057391,0.0005804317250000037,6.5217250000037174e-06
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00057391,0.0005795000500000037,5.5900500000037904e-06
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00057391,0.0005813634000000037,7.453400000003753e-06
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00057391,0.0005771708625000037,3.260862500003756e-06
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00057391,0.0005795000500000036,5.590050000003682e-06
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00057391,0.0005781025375000037,4.1925375000037915e-06
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00114782,0.0012743091551686587,0.00012648915516865877
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00057391,0.000624453368750004,5.054336875000406e-05
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00057391,0.0005799658875000037,6.055887500003754e-06
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,576.0,526.0,0.010417,0.010417,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00344378,0.006735689455208333,0.0032919094552083332
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00057391,0.0005832267500000037,9.316750000003715e-06
2.0,576.0,526.0,0.003472,0.003472,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00114782,0.0012745140968353252,0.00012669409683532524
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,576.0,526.0,0.001736,0.001736,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00057391,0.0005795000500000037,5.5900500000037904e-06
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,576.0,526.0,0.0,0.0,6.357842,0.051998,1.0,576.0,0.0,0.0,Patient Uncooperative,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,217.0,197.0,0.009217,0.009217,5.384495,0.25113,1.0,217.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01246331,0.012566201606091277,0.00010289160609127691
5.0,217.0,197.0,0.023041,0.023041,5.384495,0.25113,1.0,217.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03115624,0.031233700588928544,7.746058892854277e-05
8.0,217.0,197.0,0.036866,0.036866,5.384495,0.25113,1.0,217.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04985053,0.0552957115256845,0.005445181525684503
5.0,217.0,197.0,0.023041,0.023041,5.384495,0.25113,1.0,217.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03115624,0.03116228368892854,6.043688928539931e-06
0.0,2341.0,1708.0,0.0,0.0,7.758761,0.376508,1.0,2341.0,27.0,320.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2341.0,1708.0,0.001282,0.001282,7.758761,0.376508,1.0,2341.0,27.0,320.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00374503,0.0037599381252083255,1.4908125208325587e-05
48.0,2341.0,1708.0,0.020504,0.020504,7.758761,0.376508,1.0,2341.0,27.0,320.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05989705,0.06205661286167664,0.0021595628616766366
113.0,2341.0,1708.0,0.04827,0.04827,7.758761,0.376508,1.0,2341.0,27.0,320.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14100813,0.14207495777473222,0.0010668277747322152
6.0,2341.0,1708.0,0.002563,0.002563,7.758761,0.376508,1.0,2341.0,27.0,320.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00748713,0.007482990595357147,4.139404642852437e-06
2.0,2341.0,1708.0,0.000854,0.000854,7.758761,0.376508,1.0,2341.0,27.0,320.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00249474,0.0024483598332936483,4.6380166706351793e-05
38.0,2341.0,1708.0,0.016232,0.016232,7.758761,0.376508,1.0,2341.0,27.0,320.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04741753,0.047211685359007924,0.00020584464099207556
60.0,2341.0,1708.0,0.02563,0.02563,7.758761,0.376508,1.0,2341.0,27.0,320.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07487132,0.07422776017282741,0.0006435598271725962
0.0,2341.0,1708.0,0.0,0.0,7.758761,0.376508,1.0,2341.0,27.0,320.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2341.0,1708.0,0.001709,0.001709,7.758761,0.376508,1.0,2341.0,27.0,320.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00499239,0.004862801816240084,0.00012958818375991606
5.0,2341.0,1708.0,0.002136,0.002136,7.758761,0.376508,1.0,2341.0,27.0,320.0,Participant moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00623976,0.006215119353124993,2.4640646875006937e-05
19.0,2341.0,1708.0,0.008116,0.008116,7.758761,0.376508,1.0,2341.0,27.0,320.0,Participant moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02370876,0.023498509142559514,0.0002102508574404853
34.0,2341.0,1708.0,0.014524,0.014524,7.758761,0.376508,1.0,2341.0,27.0,320.0,Consent withdrawn by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04242805,0.04243054648964284,2.496489642837829e-06
72.0,2341.0,1708.0,0.030756,0.030756,7.758761,0.376508,1.0,2341.0,27.0,320.0,Consent withdrawn by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08984558,0.09507992691533731,0.005234346915337321
5.0,2341.0,1708.0,0.002136,0.002136,7.758761,0.376508,1.0,2341.0,27.0,320.0,Related to study drug administration,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00623976,0.006215119353124993,2.4640646875006937e-05
14.0,2341.0,1708.0,0.00598,0.00598,7.758761,0.376508,1.0,2341.0,27.0,320.0,Related to study drug administration,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.017469,0.017155330467589283,0.00031366953241071527
51.0,2341.0,1708.0,0.021786,0.021786,7.758761,0.376508,1.0,2341.0,27.0,320.0,Last visit outside protocol visit window,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06364208,0.06385778844529764,0.000215708445297641
143.0,2341.0,1708.0,0.061085,0.061085,7.758761,0.376508,1.0,2341.0,27.0,320.0,Last visit outside protocol visit window,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.17844379,0.17894455406186505,0.0005007640618650555
0.0,2341.0,1708.0,0.0,0.0,7.758761,0.376508,1.0,2341.0,27.0,320.0,Selection criteria finally not met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2341.0,1708.0,0.000427,0.000427,7.758761,0.376508,1.0,2341.0,27.0,320.0,Selection criteria finally not met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00124737,0.001279403119742063,3.203311974206294e-05
0.0,2341.0,1708.0,0.0,0.0,7.758761,0.376508,1.0,2341.0,27.0,320.0,Site closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2341.0,1708.0,0.001282,0.001282,7.758761,0.376508,1.0,2341.0,27.0,320.0,Site closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00374503,0.0037599381252083255,1.4908125208325587e-05
3.0,2341.0,1708.0,0.001282,0.001282,7.758761,0.376508,1.0,2341.0,27.0,320.0,Potential lost to follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00374503,0.0037488994653273743,3.8694653273743836e-06
0.0,2341.0,1708.0,0.0,0.0,7.758761,0.376508,1.0,2341.0,27.0,320.0,Potential lost to follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2341.0,1708.0,0.001282,0.001282,7.758761,0.376508,1.0,2341.0,27.0,320.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00374503,0.0037488994653273743,3.8694653273743836e-06
6.0,2341.0,1708.0,0.002563,0.002563,7.758761,0.376508,1.0,2341.0,27.0,320.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00748713,0.007477767142797619,9.362857202380864e-06
316.0,1776.0,358.0,0.177928,0.177928,7.482682,0.288131,1.0,1779.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.38361085,0.37197389160519895,0.011636958394801056
310.0,1776.0,358.0,0.17455,0.17455,7.482682,0.288131,1.0,1779.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.37632792,0.36876606805668694,0.007561851943313047
104.0,1776.0,358.0,0.058559,0.058559,7.482682,0.288131,1.0,1779.0,0.0,0.0,Disease progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12625257,0.12702088542002976,0.0007683154200297526
126.0,1776.0,358.0,0.070946,0.070946,7.482682,0.288131,1.0,1779.0,0.0,0.0,Disease progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15295881,0.15159089911002696,0.0013679108899730397
143.0,1776.0,358.0,0.080518,0.080518,7.482682,0.288131,1.0,1779.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17359594,0.16720130060408728,0.006394639395912727
124.0,1776.0,358.0,0.06982,0.06982,7.482682,0.288131,1.0,1779.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15053117,0.1500571880608008,0.00047398193919920284
48.0,1776.0,358.0,0.027027,0.027027,7.482682,0.288131,1.0,1779.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05826992,0.057358599152718265,0.000911320847281738
36.0,1776.0,358.0,0.02027,0.02027,7.482682,0.288131,1.0,1779.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0437019,0.04393994288360574,0.000238042883605738
31.0,1776.0,358.0,0.017455,0.017455,7.482682,0.288131,1.0,1779.0,0.0,0.0,Participant request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03763279,0.037988107832887814,0.0003553178328878151
22.0,1776.0,358.0,0.012387,0.012387,7.482682,0.288131,1.0,1779.0,0.0,0.0,Participant request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02670624,0.02657544968979169,0.0001307903102083091
16.0,1776.0,358.0,0.009009,0.009009,7.482682,0.288131,1.0,1779.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01942331,0.019102971805178563,0.00032033819482143663
22.0,1776.0,358.0,0.012387,0.012387,7.482682,0.288131,1.0,1779.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02670624,0.026650877471378995,5.536252862100438e-05
15.0,1776.0,358.0,0.008446,0.008446,7.482682,0.288131,1.0,1779.0,0.0,0.0,Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01820948,0.017914013957876992,0.00029546604212300764
17.0,1776.0,358.0,0.009572,0.009572,7.482682,0.288131,1.0,1779.0,0.0,0.0,Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02063713,0.020325920333541646,0.0003112096664583536
1.0,1776.0,358.0,0.000563,0.000563,7.482682,0.288131,1.0,1779.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00121382,0.0012764788592613643,6.265885926136426e-05
2.0,1776.0,358.0,0.001126,0.001126,7.482682,0.288131,1.0,1779.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00242764,0.002430103651011894,2.46365101189399e-06
0.0,1776.0,358.0,0.0,0.0,7.482682,0.288131,1.0,1779.0,0.0,0.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1776.0,358.0,0.001126,0.001126,7.482682,0.288131,1.0,1779.0,0.0,0.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00242764,0.0024300007260118937,2.360726011893695e-06
2.0,1776.0,358.0,0.001126,0.001126,7.482682,0.288131,1.0,1779.0,0.0,0.0,Ineligibility determined,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00242764,0.002431399931011893,3.759931011892894e-06
1.0,1776.0,358.0,0.000563,0.000563,7.482682,0.288131,1.0,1779.0,0.0,0.0,Ineligibility determined,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00121382,0.0012848940891720794,7.10740891720794e-05
36.0,1776.0,358.0,0.02027,0.02027,7.482682,0.288131,1.0,1779.0,0.0,0.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0437019,0.04391095611509384,0.00020905611509383637
44.0,1776.0,358.0,0.024775,0.024775,7.482682,0.288131,1.0,1779.0,0.0,0.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05341463,0.05368052150145839,0.0002658915014583929
363.0,13078.0,172.0,0.027757,0.027757,9.478763,0.610189,1.0,13078.0,22.0,684.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16054204,0.15018641086824405,0.010355629131755945
330.0,13078.0,172.0,0.025233,0.025233,9.478763,0.610189,1.0,13078.0,22.0,684.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14594363,0.1365840722825,0.009359557717499994
3.0,13078.0,172.0,0.000229,0.000229,9.478763,0.610189,1.0,13078.0,22.0,684.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0013245,0.001326108401035354,1.6084010353539617e-06
2.0,13078.0,172.0,0.000153,0.000153,9.478763,0.610189,1.0,13078.0,22.0,684.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00088493,0.0008348361117857146,5.00938882142854e-05
0.0,13078.0,172.0,0.0,0.0,9.478763,0.610189,1.0,13078.0,22.0,684.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,13078.0,172.0,7.6e-05,7.6e-05,9.478763,0.610189,1.0,13078.0,22.0,684.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00043957,0.0004672587852678573,2.76887852678573e-05
5854.0,13078.0,172.0,0.447622,0.447622,9.478763,0.610189,1.0,13078.0,22.0,684.0,Study terminated by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,2.58897393,2.296300620856827,0.292673309143173
5901.0,13078.0,172.0,0.451216,0.451216,9.478763,0.610189,1.0,13078.0,22.0,684.0,Study terminated by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,2.60976105,2.290777027706112,0.318984022293888
111.0,13078.0,172.0,0.008488,0.008488,9.478763,0.610189,1.0,13078.0,22.0,684.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04909323,0.046520071690991996,0.0025731583090080057
78.0,13078.0,172.0,0.005964,0.005964,9.478763,0.610189,1.0,13078.0,22.0,684.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03449482,0.032349525108670604,0.002145294891329398
128.0,13078.0,172.0,0.009787,0.009787,9.478763,0.610189,1.0,13078.0,22.0,684.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05660644,0.05319317602751979,0.003413263972480214
135.0,13078.0,172.0,0.010323,0.010323,9.478763,0.610189,1.0,13078.0,22.0,684.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05970658,0.05668091070785713,0.003025669292142874
8.0,618.0,596.0,0.012945,0.012945,6.428105,0.211174,1.0,618.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01757221,0.017689406001775806,0.00011719600177580516
6.0,618.0,596.0,0.009709,0.009709,6.428105,0.211174,1.0,618.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01317949,0.013338101446349213,0.00015861144634921227
1.0,618.0,596.0,0.001618,0.001618,6.428105,0.211174,1.0,618.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00219636,0.0021878951253571474,8.46487464285263e-06
0.0,618.0,596.0,0.0,0.0,6.428105,0.211174,1.0,618.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,618.0,596.0,0.0,0.0,6.428105,0.211174,1.0,618.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,618.0,596.0,0.001618,0.001618,6.428105,0.211174,1.0,618.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00219636,0.0021824844305357183,1.3875569464281718e-05
0.0,618.0,596.0,0.0,0.0,6.428105,0.211174,1.0,618.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,618.0,596.0,0.001618,0.001618,6.428105,0.211174,1.0,618.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00219636,0.002183941630575401,1.2418369424599136e-05
4.0,618.0,596.0,0.006472,0.006472,6.428105,0.211174,1.0,618.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00878542,0.008879952042570353,9.45320425703531e-05
1.0,618.0,596.0,0.001618,0.001618,6.428105,0.211174,1.0,618.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00219636,0.0021842269222420675,1.213307775793258e-05
16.0,2530.0,2395.0,0.006324,0.006324,7.83637,0.888505,1.0,2530.0,8.0,181.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04403183,0.045212930725843314,0.0011811007258433134
38.0,2530.0,2395.0,0.01502,0.01502,7.83637,0.888505,1.0,2530.0,8.0,181.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10457908,0.1049420337137203,0.0003629537137202904
20.0,2530.0,2395.0,0.007905,0.007905,7.83637,0.888505,1.0,2530.0,8.0,181.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05503979,0.05554203362139155,0.0005022436213915488
27.0,2530.0,2395.0,0.010672,0.010672,7.83637,0.888505,1.0,2530.0,8.0,181.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07430545,0.07536287826471236,0.0010574282647123623
11.0,2530.0,2395.0,0.004348,0.004348,7.83637,0.888505,1.0,2530.0,8.0,181.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03027362,0.03214357336546628,0.0018699533654662759
17.0,2530.0,2395.0,0.006719,0.006719,7.83637,0.888505,1.0,2530.0,8.0,181.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04678208,0.047661095234434556,0.0008790152344345589
0.0,2530.0,2395.0,0.0,0.0,7.83637,0.888505,1.0,2530.0,8.0,181.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2530.0,2395.0,0.000395,0.000395,7.83637,0.888505,1.0,2530.0,8.0,181.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00275025,0.0027450446042757938,5.2053957242063215e-06
0.0,2530.0,2395.0,0.0,0.0,7.83637,0.888505,1.0,2530.0,8.0,181.0,Participant Moved Away,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2530.0,2395.0,0.000791,0.000791,7.83637,0.888505,1.0,2530.0,8.0,181.0,Participant Moved Away,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00550746,0.005522952817678557,1.549281767855744e-05
2.0,2530.0,2395.0,0.000791,0.000791,7.83637,0.888505,1.0,2530.0,8.0,181.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00550746,0.0054830691546428455,2.439084535715407e-05
1.0,2530.0,2395.0,0.000395,0.000395,7.83637,0.888505,1.0,2530.0,8.0,181.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00275025,0.0027421548964285726,8.09510357142754e-06
57.0,1012.0,863.0,0.056324,0.056324,6.920672,0.460684,1.0,1012.0,2.0,90.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.17957457,0.1780182692313989,0.0015563007686010821
35.0,1012.0,863.0,0.034585,0.034585,6.920672,0.460684,1.0,1012.0,2.0,90.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.11026537,0.10716044511172626,0.0031049248882737412
9.0,1012.0,863.0,0.008893,0.008893,6.920672,0.460684,1.0,1012.0,2.0,90.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.02835304,0.028479317852212332,0.00012627785221233298
12.0,1012.0,863.0,0.011858,0.011858,6.920672,0.460684,1.0,1012.0,2.0,90.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.03780618,0.037925947345089334,0.0001197673450893319
6.0,1012.0,863.0,0.005929,0.005929,6.920672,0.460684,1.0,1012.0,2.0,90.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01890309,0.0189933595450397,9.026954503969786e-05
4.0,1012.0,863.0,0.003953,0.003953,6.920672,0.460684,1.0,1012.0,2.0,90.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01260312,0.012509877649216274,9.324235078372704e-05
14.0,1012.0,863.0,0.013834,0.013834,6.920672,0.460684,1.0,1012.0,2.0,90.0,Other,Overall Study,FG000,cardiovascular disease,OTHER,0.04410615,0.04460076137365978,0.0004946113736597826
12.0,1012.0,863.0,0.011858,0.011858,6.920672,0.460684,1.0,1012.0,2.0,90.0,Other,Overall Study,FG001,cardiovascular disease,OTHER,0.03780618,0.03791838806934529,0.00011220806934528899
16.0,1316.0,1160.0,0.012158,0.012158,7.183112,0.217379,1.0,1613.0,3.0,3.0,Subject withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01898424,0.019033021064563477,4.8781064563477305e-05
21.0,1316.0,1160.0,0.015957,0.015957,7.183112,0.217379,1.0,1613.0,3.0,3.0,Subject withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02491623,0.025394488457648804,0.00047825845764880304
13.0,1316.0,1160.0,0.009878,0.009878,7.183112,0.217379,1.0,1613.0,3.0,3.0,Subject withdrew consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01542411,0.015695289252202378,0.00027117925220237864
12.0,1316.0,1160.0,0.009119,0.009119,7.183112,0.217379,1.0,1613.0,3.0,3.0,Subject withdrew consent,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01423896,0.014265475424453467,2.651542445346669e-05
9.0,1316.0,1160.0,0.006839,0.006839,7.183112,0.217379,1.0,1613.0,3.0,3.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01067883,0.010720426803839278,4.1596803839277774e-05
16.0,1316.0,1160.0,0.012158,0.012158,7.183112,0.217379,1.0,1613.0,3.0,3.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01898424,0.019002570578075386,1.83305780753866e-05
14.0,1316.0,1160.0,0.010638,0.010638,7.183112,0.217379,1.0,1613.0,3.0,3.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01661082,0.0167455330225496,0.00013471302254960266
8.0,1316.0,1160.0,0.006079,0.006079,7.183112,0.217379,1.0,1613.0,3.0,3.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00949212,0.009648160241557539,0.00015604024155753925
6.0,1316.0,1160.0,0.004559,0.004559,7.183112,0.217379,1.0,1613.0,3.0,3.0,Unsatisfactory therapeutic response,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0071187,0.007151755920168648,3.305592016864759e-05
2.0,1316.0,1160.0,0.00152,0.00152,7.183112,0.217379,1.0,1613.0,3.0,3.0,Unsatisfactory therapeutic response,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00237342,0.0024066043724107087,3.3184372410708946e-05
5.0,1316.0,1160.0,0.003799,0.003799,7.183112,0.217379,1.0,1613.0,3.0,3.0,Unsatisfactory therapeutic response,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00593199,0.005978696110090806,4.670611009080592e-05
4.0,1316.0,1160.0,0.00304,0.00304,7.183112,0.217379,1.0,1613.0,3.0,3.0,Unsatisfactory therapeutic response,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00474684,0.004758093519315453,1.1253519315453618e-05
4.0,1316.0,1160.0,0.00304,0.00304,7.183112,0.217379,1.0,1613.0,3.0,3.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00474684,0.004766401628839265,1.9561628839265786e-05
7.0,1316.0,1160.0,0.005319,0.005319,7.183112,0.217379,1.0,1613.0,3.0,3.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00830541,0.008316808852946434,1.1398852946434973e-05
4.0,1316.0,1160.0,0.00304,0.00304,7.183112,0.217379,1.0,1613.0,3.0,3.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00474684,0.004753677129523789,6.837129523789252e-06
4.0,1316.0,1160.0,0.00304,0.00304,7.183112,0.217379,1.0,1613.0,3.0,3.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00474684,0.004758156351398786,1.1316351398786735e-05
1.0,1316.0,1160.0,0.00076,0.00076,7.183112,0.217379,1.0,1613.0,3.0,3.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00118671,0.0012128319123511889,2.6121912351189e-05
1.0,1316.0,1160.0,0.00076,0.00076,7.183112,0.217379,1.0,1613.0,3.0,3.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00118671,0.001208338528839284,2.1628528839284095e-05
4.0,1316.0,1160.0,0.00304,0.00304,7.183112,0.217379,1.0,1613.0,3.0,3.0,Protocol deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00474684,0.004753614297440456,6.774297440456135e-06
1.0,1316.0,1160.0,0.00076,0.00076,7.183112,0.217379,1.0,1613.0,3.0,3.0,Protocol deviation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00118671,0.0012102227308630937,2.3512730863093842e-05
1.0,1316.0,1160.0,0.00076,0.00076,7.183112,0.217379,1.0,1613.0,3.0,3.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00118671,0.0012184543206845233,3.1744320684523424e-05
1.0,1316.0,1160.0,0.00076,0.00076,7.183112,0.217379,1.0,1613.0,3.0,3.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00118671,0.001214201058839285,2.7491058839285154e-05
0.0,1316.0,1160.0,0.0,0.0,7.183112,0.217379,1.0,1613.0,3.0,3.0,Administrative problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1316.0,1160.0,0.00152,0.00152,7.183112,0.217379,1.0,1613.0,3.0,3.0,Administrative problems,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00237342,0.002409777639077376,3.6357639077376405e-05
18.0,351.0,0.0,0.051282,0.051282,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.10409057,0.1058975984893651,0.0018070284893651062
12.0,351.0,0.0,0.034188,0.034188,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.06939371,0.06944899393578381,5.528393578381474e-05
67.0,351.0,0.0,0.190883,0.190883,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of disease,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.38744822,0.507902937416181,0.12045471741618097
122.0,351.0,0.0,0.347578,0.347578,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of disease,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.70550274,0.7110966238039883,0.0055938838039882866
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Lack of therapeutic effect,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.00578281,0.0057848594853273545,2.049485327354321e-06
3.0,351.0,0.0,0.008547,0.008547,5.863631,0.346162,1.0,351.0,15.0,69.0,Lack of therapeutic effect,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.01734843,0.017371033409851796,2.2603409851794376e-05
23.0,351.0,0.0,0.065527,0.065527,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.13300461,0.13131903563965816,0.001685574360341835
8.0,351.0,0.0,0.022792,0.022792,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.04626247,0.04680744047619043,0.0005449704761904331
11.0,351.0,0.0,0.031339,0.031339,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.0636109,0.06395897484079366,0.0003480748407936607
10.0,351.0,0.0,0.02849,0.02849,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.05782809,0.05857687116040682,0.0007487811604068237
2.0,351.0,0.0,0.005698,0.005698,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,Blinded Treatment (Up to 03 Aug 2005),FG000,cardiovascular disease,INDUSTRY,0.01156562,0.011774788924781749,0.0002091689247817486
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,Blinded Treatment (Up to 03 Aug 2005),FG001,cardiovascular disease,INDUSTRY,0.00578281,0.005783422152351161,6.12152351160862e-07
22.0,351.0,0.0,0.062678,0.062678,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.1272218,0.12637580492468797,0.0008459950753120227
12.0,351.0,0.0,0.034188,0.034188,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.06939371,0.06945499430453381,6.128430453380962e-05
92.0,351.0,0.0,0.262108,0.262108,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of disease,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.53201846,0.5893249343268256,0.057306474326825674
128.0,351.0,0.0,0.364672,0.364672,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of disease,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.74019959,0.7797002803558333,0.03950069035583326
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Lack of Efficacy,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.00578281,0.005784991788244026,2.1817882440260117e-06
3.0,351.0,0.0,0.008547,0.008547,5.863631,0.346162,1.0,351.0,15.0,69.0,Lack of Efficacy,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.01734843,0.01736960350318513,2.1173503185128312e-05
24.0,351.0,0.0,0.068376,0.068376,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.13878742,0.1383611544359822,0.0004262655640177859
9.0,351.0,0.0,0.025641,0.025641,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.05204528,0.052372448876716236,0.000327168876716237
11.0,351.0,0.0,0.031339,0.031339,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.0636109,0.06397536486371033,0.00036446486371033426
11.0,351.0,0.0,0.031339,0.031339,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.0636109,0.0643226364515972,0.0007117364515972086
5.0,351.0,0.0,0.014245,0.014245,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,On Study at Time of Unblinding,FG000,cardiovascular disease,INDUSTRY,0.02891405,0.0289045304438988,9.519556101199311e-06
4.0,351.0,0.0,0.011396,0.011396,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,On Study at Time of Unblinding,FG001,cardiovascular disease,INDUSTRY,0.02313124,0.02309549123862104,3.574876137896199e-05
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,Long Term Extension (Up to 25 Jun 2013),FG000,cardiovascular disease,INDUSTRY,0.00578281,0.005793916195089264,1.110619508926363e-05
0.0,351.0,0.0,0.0,0.0,5.863631,0.346162,1.0,351.0,15.0,69.0,Adverse Event,Long Term Extension (Up to 25 Jun 2013),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,351.0,0.0,0.0,0.0,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,Long Term Extension (Up to 25 Jun 2013),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Death,Long Term Extension (Up to 25 Jun 2013),FG001,cardiovascular disease,INDUSTRY,0.00578281,0.005786129120446401,3.3191204464010082e-06
12.0,351.0,0.0,0.034188,0.034188,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,Long Term Extension (Up to 25 Jun 2013),FG000,cardiovascular disease,INDUSTRY,0.06939371,0.06900523382313507,0.0003884761768649242
4.0,351.0,0.0,0.011396,0.011396,5.863631,0.346162,1.0,351.0,15.0,69.0,Other,Long Term Extension (Up to 25 Jun 2013),FG001,cardiovascular disease,INDUSTRY,0.02313124,0.02309549123862104,3.574876137896199e-05
7.0,351.0,0.0,0.019943,0.019943,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of Disease,Long Term Extension (Up to 25 Jun 2013),FG000,cardiovascular disease,INDUSTRY,0.04047967,0.040738408632113116,0.00025873863211311326
3.0,351.0,0.0,0.008547,0.008547,5.863631,0.346162,1.0,351.0,15.0,69.0,Progression of Disease,Long Term Extension (Up to 25 Jun 2013),FG001,cardiovascular disease,INDUSTRY,0.01734843,0.017371033409851796,2.2603409851794376e-05
1.0,351.0,0.0,0.002849,0.002849,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,Long Term Extension (Up to 25 Jun 2013),FG000,cardiovascular disease,INDUSTRY,0.00578281,0.005788246297172596,5.436297172595715e-06
0.0,351.0,0.0,0.0,0.0,5.863631,0.346162,1.0,351.0,15.0,69.0,Withdrawal by Subject,Long Term Extension (Up to 25 Jun 2013),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,1097.0,1046.0,0.005469,0.005469,7.001246,1.0,1.0,1098.0,12.0,129.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03828981,0.038426791460892826,0.0001369814608928252
22.0,1097.0,1046.0,0.020055,0.020055,7.001246,1.0,1.0,1098.0,12.0,129.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14040998,0.13631747848556627,0.004092501514433716
3.0,1097.0,1046.0,0.002735,0.002735,7.001246,1.0,1.0,1098.0,12.0,129.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01914841,0.01907906398660707,6.93460133929305e-05
4.0,1097.0,1046.0,0.003646,0.003646,7.001246,1.0,1.0,1098.0,12.0,129.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02552654,0.025942727704037712,0.00041618770403771196
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00638514,0.006389234958660683,4.094958660682581e-06
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00638514,0.00637303858053567,1.2101419464330063e-05
2.0,1097.0,1046.0,0.001823,0.001823,7.001246,1.0,1.0,1098.0,12.0,129.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01276327,0.01286074160401786,9.747160401786005e-05
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Non compliant with protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00638514,0.006359247634940437,2.589236505956289e-05
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Non compliant with protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Non compliant with protocol,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1097.0,1046.0,0.002735,0.002735,7.001246,1.0,1.0,1098.0,12.0,129.0,Non compliant with protocol,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01914841,0.01910376596505946,4.464403494053998e-05
2.0,1097.0,1046.0,0.001823,0.001823,7.001246,1.0,1.0,1098.0,12.0,129.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01276327,0.012830967595446434,6.769759544643372e-05
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00638514,0.006397285937202346,1.2145937202345976e-05
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Consent withdrawn,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Consent withdrawn,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00638514,0.006373535992023765,1.1604007976235252e-05
3.0,1097.0,1046.0,0.002735,0.002735,7.001246,1.0,1.0,1098.0,12.0,129.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01914841,0.0190598879251785,8.852207482150029e-05
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1097.0,1046.0,0.0,0.0,7.001246,1.0,1.0,1098.0,12.0,129.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1097.0,1046.0,0.000912,0.000912,7.001246,1.0,1.0,1098.0,12.0,129.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00638514,0.006369856984107096,1.5283015892903797e-05
3.0,531.0,521.0,0.00565,0.00565,6.276643,1.0,1.0,531.0,1.0,41.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03546304,0.03552624117135913,6.320117135912712e-05
2.0,531.0,521.0,0.003766,0.003766,6.276643,1.0,1.0,531.0,1.0,41.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02363784,0.022954718096805563,0.0006831219031944377
0.0,531.0,521.0,0.0,0.0,6.276643,1.0,1.0,531.0,1.0,41.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,531.0,521.0,0.001883,0.001883,6.276643,1.0,1.0,531.0,1.0,41.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01181892,0.011827636962857135,8.716962857134927e-06
1.0,531.0,521.0,0.001883,0.001883,6.276643,1.0,1.0,531.0,1.0,41.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01181892,0.011833764135892853,1.4844135892852495e-05
0.0,531.0,521.0,0.0,0.0,6.276643,1.0,1.0,531.0,1.0,41.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,531.0,521.0,0.0,0.0,6.276643,1.0,1.0,531.0,1.0,41.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,531.0,521.0,0.001883,0.001883,6.276643,1.0,1.0,531.0,1.0,41.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01181892,0.011827614687559513,8.69468755951286e-06
0.0,531.0,521.0,0.0,0.0,6.276643,1.0,1.0,531.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,531.0,521.0,0.001883,0.001883,6.276643,1.0,1.0,531.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01181892,0.011827821987857135,8.90198785713503e-06
1.0,531.0,521.0,0.001883,0.001883,6.276643,1.0,1.0,531.0,1.0,41.0,No visit within allowance period,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01181892,0.011828346327976183,9.42632797618255e-06
0.0,531.0,521.0,0.0,0.0,6.276643,1.0,1.0,531.0,1.0,41.0,No visit within allowance period,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,612.0,561.0,0.004902,0.004902,6.418365,0.486189,1.0,612.0,1.0,30.0,Pretreatment Event/Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01529688,0.015325817676355578,2.893767635557716e-05
6.0,612.0,561.0,0.009804,0.009804,6.418365,0.486189,1.0,612.0,1.0,30.0,Pretreatment Event/Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03059376,0.03082158523779764,0.00022782523779764016
3.0,612.0,561.0,0.004902,0.004902,6.418365,0.486189,1.0,612.0,1.0,30.0,Pretreatment Event/Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01529688,0.015316275317307974,1.9395317307973475e-05
1.0,612.0,561.0,0.001634,0.001634,6.418365,0.486189,1.0,612.0,1.0,30.0,Major Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00509896,0.005092629884305552,6.3301156944476494e-06
4.0,612.0,561.0,0.006536,0.006536,6.418365,0.486189,1.0,612.0,1.0,30.0,Major Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02039584,0.02017907454372024,0.00021676545627975774
3.0,612.0,561.0,0.004902,0.004902,6.418365,0.486189,1.0,612.0,1.0,30.0,Major Protocol Deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01529688,0.01532546129980797,2.8581299807969862e-05
0.0,612.0,561.0,0.0,0.0,6.418365,0.486189,1.0,612.0,1.0,30.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,612.0,561.0,0.001634,0.001634,6.418365,0.486189,1.0,612.0,1.0,30.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00509896,0.005083729993373012,1.5230006626987778e-05
2.0,612.0,561.0,0.003268,0.003268,6.418365,0.486189,1.0,612.0,1.0,30.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01019792,0.010124587633873073,7.333236612692626e-05
6.0,612.0,561.0,0.009804,0.009804,6.418365,0.486189,1.0,612.0,1.0,30.0,Voluntary Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03059376,0.030808702981011907,0.00021494298101190634
5.0,612.0,561.0,0.00817,0.00817,6.418365,0.486189,1.0,612.0,1.0,30.0,Voluntary Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0254948,0.02535224753352182,0.00014255246647818312
10.0,612.0,561.0,0.01634,0.01634,6.418365,0.486189,1.0,612.0,1.0,30.0,Voluntary Withdrawal,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05098959,0.04961439258016868,0.001375197419831324
0.0,612.0,561.0,0.0,0.0,6.418365,0.486189,1.0,612.0,1.0,30.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,612.0,561.0,0.004902,0.004902,6.418365,0.486189,1.0,612.0,1.0,30.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01529688,0.015325140979672677,2.8260979672676753e-05
3.0,612.0,561.0,0.004902,0.004902,6.418365,0.486189,1.0,612.0,1.0,30.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01529688,0.015313147513065551,1.626751306555048e-05
0.0,612.0,561.0,0.0,0.0,6.418365,0.486189,1.0,612.0,1.0,30.0,Reason not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,612.0,561.0,0.001634,0.001634,6.418365,0.486189,1.0,612.0,1.0,30.0,Reason not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00509896,0.005086024292852179,1.2935707147820712e-05
0.0,612.0,561.0,0.0,0.0,6.418365,0.486189,1.0,612.0,1.0,30.0,Reason not Specified,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
294.0,1913.0,0.0,0.153685,0.153685,7.556951,0.231988,1.0,1913.0,2.0,69.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.26942876,0.25085359533670626,0.01857516466329373
478.0,1913.0,0.0,0.249869,0.249869,7.556951,0.231988,1.0,1913.0,2.0,69.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.43805117,0.4375782188401473,0.0004729511598526859
83.0,1913.0,0.0,0.043387,0.043387,7.556951,0.231988,1.0,1913.0,2.0,69.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07606276,0.07417964037515869,0.0018831196248413062
4.0,1913.0,0.0,0.002091,0.002091,7.556951,0.231988,1.0,1913.0,2.0,69.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00366578,0.0035185892661011857,0.00014719073389881428
94.0,1913.0,0.0,0.049137,0.049137,7.556951,0.231988,1.0,1913.0,2.0,69.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08614322,0.08510272708115077,0.0010404929188492368
960.0,1913.0,0.0,0.50183,0.50183,7.556951,0.231988,1.0,1913.0,2.0,69.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.87976987,0.8007580822963505,0.07901178770364947
0.0,2572.0,2471.0,0.0,0.0,7.852828,0.580242,1.0,2572.0,32.0,380.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2572.0,2471.0,0.001555,0.001555,7.852828,0.580242,1.0,2572.0,32.0,380.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00708542,0.007131981756686506,4.656175668650564e-05
23.0,2572.0,2471.0,0.008942,0.008942,7.852828,0.580242,1.0,2572.0,32.0,380.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04074457,0.040951503322916645,0.00020693332291664424
17.0,2572.0,2471.0,0.00661,0.00661,7.852828,0.580242,1.0,2572.0,32.0,380.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03011872,0.030845953063154758,0.0007272330631547565
19.0,2572.0,2471.0,0.007387,0.007387,7.852828,0.580242,1.0,2572.0,32.0,380.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03365915,0.033357491802777785,0.00030165819722221404
25.0,2572.0,2471.0,0.00972,0.00972,7.852828,0.580242,1.0,2572.0,32.0,380.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04428956,0.04461336977491066,0.0003238097749106647
2.0,2572.0,2471.0,0.000778,0.000778,7.852828,0.580242,1.0,2572.0,32.0,380.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00354499,0.003528678344821421,1.6311655178579115e-05
0.0,2572.0,2471.0,0.0,0.0,7.852828,0.580242,1.0,2572.0,32.0,380.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2572.0,2471.0,0.000778,0.000778,7.852828,0.580242,1.0,2572.0,32.0,380.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00354499,0.0035366814313690376,8.308568630962469e-06
3.0,2572.0,2471.0,0.001166,0.001166,7.852828,0.580242,1.0,2572.0,32.0,380.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00531292,0.005302851785148805,1.0068214851194357e-05
5.0,2572.0,2471.0,0.001944,0.001944,7.852828,0.580242,1.0,2572.0,32.0,380.0,Technical problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00885791,0.009004227879478703,0.00014631787947870338
1.0,2572.0,2471.0,0.000389,0.000389,7.852828,0.580242,1.0,2572.0,32.0,380.0,Technical problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177249,0.001961989749017858,0.00018949974901785803
19.0,295.0,249.0,0.064407,0.064407,5.690359,0.788131,1.0,295.0,1.0,51.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.28884911,0.3003498901475693,0.011500780147569278
12.0,295.0,249.0,0.040678,0.040678,5.690359,0.788131,1.0,295.0,1.0,51.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.18243054,0.19836727738261895,0.015936737382618943
11.0,295.0,249.0,0.037288,0.037288,5.690359,0.788131,1.0,295.0,1.0,51.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16722725,0.1686531366444641,0.0014258866444641083
2.0,295.0,249.0,0.00678,0.00678,5.690359,0.788131,1.0,295.0,1.0,51.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03040659,0.031015201865218313,0.0006086118652183121
2.0,295.0,249.0,0.00678,0.00678,5.690359,0.788131,1.0,295.0,1.0,51.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03040659,0.03099500024230164,0.0005884102423016381
17.0,587.0,535.0,0.028961,0.028961,6.376727,0.22542,1.0,587.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04162968,0.04161417582421623,1.5504175783769003e-05
1.0,587.0,535.0,0.001704,0.001704,6.376727,0.22542,1.0,587.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0024494,0.00246674885588294,1.734885588293997e-05
8.0,587.0,535.0,0.013629,0.013629,6.376727,0.22542,1.0,587.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01959086,0.020029300306319428,0.00043844030631942643
4.0,587.0,535.0,0.006814,0.006814,6.376727,0.22542,1.0,587.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00979471,0.009784366995942461,1.034300405753849e-05
9.0,587.0,535.0,0.015332,0.015332,6.376727,0.22542,1.0,587.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02203882,0.02212707431095241,8.825431095240907e-05
6.0,587.0,535.0,0.010221,0.010221,6.376727,0.22542,1.0,587.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01469207,0.014855830724970244,0.0001637607249702442
1.0,587.0,535.0,0.001704,0.001704,6.376727,0.22542,1.0,587.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0024494,0.0024760726721924655,2.6672672192465472e-05
0.0,587.0,535.0,0.0,0.0,6.376727,0.22542,1.0,587.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,587.0,535.0,0.001704,0.001704,6.376727,0.22542,1.0,587.0,1.0,1.0,Failed Inclusion Exclusion Criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0024494,0.002476042449692465,2.664244969246502e-05
0.0,587.0,535.0,0.0,0.0,6.376727,0.22542,1.0,587.0,1.0,1.0,Failed Inclusion Exclusion Criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,587.0,535.0,0.008518,0.008518,6.376727,0.22542,1.0,587.0,1.0,1.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01224411,0.01231760682747024,7.349682747023918e-05
0.0,587.0,535.0,0.0,0.0,6.376727,0.22542,1.0,587.0,1.0,1.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
964.0,18144.0,13728.0,0.053131,0.053131,9.80615,0.372596,1.0,18144.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19412657,0.18791835400119056,0.006208215998809441
968.0,18144.0,13728.0,0.053351,0.053351,9.80615,0.372596,1.0,18144.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.19493039,0.187605270347262,0.007325119652738021
357.0,18144.0,13728.0,0.019676,0.019676,9.80615,0.372596,1.0,18144.0,0.0,0.0,Only Vital Status Known,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07189088,0.07114902882229168,0.000741851177708322
356.0,18144.0,13728.0,0.019621,0.019621,9.80615,0.372596,1.0,18144.0,0.0,0.0,Only Vital Status Known,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07168992,0.07055211825467265,0.0011378017453273492
44.0,18144.0,13728.0,0.002425,0.002425,9.80615,0.372596,1.0,18144.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00886031,0.008592683270545626,0.0002676267294543736
49.0,18144.0,13728.0,0.002701,0.002701,9.80615,0.372596,1.0,18144.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00986874,0.009404796177609125,0.00046394382239087553
39.0,18144.0,13728.0,0.002149,0.002149,9.80615,0.372596,1.0,18144.0,0.0,0.0,Site Closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00785188,0.0076983748703273805,0.00015350512967261982
36.0,18144.0,13728.0,0.001984,0.001984,9.80615,0.372596,1.0,18144.0,0.0,0.0,Site Closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00724901,0.006865682983065474,0.000383327016934526
795.0,18144.0,13728.0,0.043816,0.043816,9.80615,0.372596,1.0,18144.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16009203,0.15298173208858132,0.007110297911418678
808.0,18144.0,13728.0,0.044533,0.044533,9.80615,0.372596,1.0,18144.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16271176,0.15521039197953368,0.007501368020466331
12.0,2596.0,2382.0,0.004622,0.004622,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03633868,0.03575971782475195,0.0005789621752480476
10.0,2596.0,2382.0,0.003852,0.003852,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03028486,0.03010191265216091,0.00018294734783909014
9.0,2596.0,2382.0,0.003467,0.003467,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02725794,0.027348769399553587,9.082939955358527e-05
10.0,2596.0,2382.0,0.003852,0.003852,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03028486,0.029989201866277976,0.00029565813372202376
11.0,2596.0,2382.0,0.004237,0.004237,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03331177,0.03315331478321422,0.00015845521678577862
8.0,2596.0,2382.0,0.003082,0.003082,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02423103,0.024167132572618998,6.389742738100238e-05
17.0,2596.0,2382.0,0.006549,0.006549,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05148897,0.05003572059467262,0.0014532494053273795
14.0,2596.0,2382.0,0.005393,0.005393,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04240037,0.041872345239285694,0.000528024760714306
13.0,2596.0,2382.0,0.005008,0.005008,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03937346,0.03651742132985119,0.0028560386701488097
9.0,2596.0,2382.0,0.003467,0.003467,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02725794,0.02734840313042659,9.046313042658863e-05
8.0,2596.0,2382.0,0.003082,0.003082,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02423103,0.023992155394464258,0.0002388746055357431
14.0,2596.0,2382.0,0.005393,0.005393,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04240037,0.04193037405583332,0.00046999594416668317
3.0,2596.0,2382.0,0.001156,0.001156,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0090886,0.00882727093707343,0.0002613290629265713
5.0,2596.0,2382.0,0.001926,0.001926,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01514243,0.015002697127202374,0.0001397328727976259
5.0,2596.0,2382.0,0.001926,0.001926,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01514243,0.01506456095970238,7.786904029762065e-05
49.0,2596.0,2382.0,0.018875,0.018875,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Treatment,FG000,cardiovascular disease,INDUSTRY,0.14839737,0.14866847583963028,0.0002711058396302757
40.0,2596.0,2382.0,0.015408,0.015408,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Treatment,FG001,cardiovascular disease,INDUSTRY,0.12113942,0.11771506565638973,0.0034243543436102697
54.0,2596.0,2382.0,0.020801,0.020801,7.862112,1.0,1.0,2615.0,4.0,94.0,Adverse Event,Treatment,FG002,cardiovascular disease,INDUSTRY,0.1635398,0.16167228602543665,0.0018675139745633618
8.0,2596.0,2382.0,0.003082,0.003082,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Treatment,FG000,cardiovascular disease,INDUSTRY,0.02423103,0.024126554205535666,0.0001044757944643343
6.0,2596.0,2382.0,0.002311,0.002311,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Treatment,FG001,cardiovascular disease,INDUSTRY,0.01816934,0.017773517588472242,0.00039582241152775685
10.0,2596.0,2382.0,0.003852,0.003852,7.862112,1.0,1.0,2615.0,4.0,94.0,Protocol Violation,Treatment,FG002,cardiovascular disease,INDUSTRY,0.03028486,0.030015269718621042,0.00026959028137895844
1.0,2596.0,2382.0,0.000385,0.000385,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Treatment,FG000,cardiovascular disease,INDUSTRY,0.00302691,0.003159729772728175,0.00013281977272817502
2.0,2596.0,2382.0,0.00077,0.00077,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Treatment,FG001,cardiovascular disease,INDUSTRY,0.00605383,0.005322128095595225,0.0007317019044047746
1.0,2596.0,2382.0,0.000385,0.000385,7.862112,1.0,1.0,2615.0,4.0,94.0,Lost to Follow-up,Treatment,FG002,cardiovascular disease,INDUSTRY,0.00302691,0.0031618337922519834,0.00013492379225198354
4.0,2596.0,2382.0,0.001541,0.001541,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Treatment,FG000,cardiovascular disease,INDUSTRY,0.01211551,0.011940957667837315,0.0001745523321626842
4.0,2596.0,2382.0,0.001541,0.001541,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Treatment,FG001,cardiovascular disease,INDUSTRY,0.01211551,0.011965624853253984,0.0001498851467460153
5.0,2596.0,2382.0,0.001926,0.001926,7.862112,1.0,1.0,2615.0,4.0,94.0,Withdrawal by Subject,Treatment,FG002,cardiovascular disease,INDUSTRY,0.01514243,0.014965136523244047,0.00017729347675595267
9.0,2596.0,2382.0,0.003467,0.003467,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Treatment,FG000,cardiovascular disease,INDUSTRY,0.02725794,0.027568752590724204,0.0003108125907242028
11.0,2596.0,2382.0,0.004237,0.004237,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Treatment,FG001,cardiovascular disease,INDUSTRY,0.03331177,0.03312127680639875,0.00019049319360124606
10.0,2596.0,2382.0,0.003852,0.003852,7.862112,1.0,1.0,2615.0,4.0,94.0,Other,Treatment,FG002,cardiovascular disease,INDUSTRY,0.03028486,0.030205506898501978,7.935310149802255e-05
8.0,11016.0,11000.0,0.000726,0.000726,9.307195,0.586612,1.0,11016.0,28.0,387.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00396375,0.0038820550545138914,8.169494548610889e-05
7.0,11016.0,11000.0,0.000635,0.000635,9.307195,0.586612,1.0,11016.0,28.0,387.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00346692,0.0033104685318650785,0.0001564514681349216
1.0,11016.0,11000.0,9.1e-05,9.1e-05,9.307195,0.586612,1.0,11016.0,28.0,387.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00049683,0.0005172450734821427,2.041507348214276e-05
0.0,11016.0,11000.0,0.0,0.0,9.307195,0.586612,1.0,11016.0,28.0,387.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
21.0,4033.0,3882.0,0.005207,0.005207,8.302514,0.323595,1.0,4033.0,19.0,153.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01398939,0.013920159532061674,6.923046793832696e-05
16.0,4033.0,3882.0,0.003967,0.003967,8.302514,0.323595,1.0,4033.0,19.0,153.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01065794,0.010652405406250008,5.534593749991629e-06
1.0,4033.0,3882.0,0.000248,0.000248,8.302514,0.323595,1.0,4033.0,19.0,153.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00066629,0.0006692395209226236,2.9495209226235337e-06
0.0,4033.0,3882.0,0.0,0.0,8.302514,0.323595,1.0,4033.0,19.0,153.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,4033.0,3882.0,0.000744,0.000744,8.302514,0.323595,1.0,4033.0,19.0,153.0,Sponsor Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00199887,0.0019356382560218259,6.323174397817395e-05
7.0,4033.0,3882.0,0.001736,0.001736,8.302514,0.323595,1.0,4033.0,19.0,153.0,Sponsor Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00466402,0.004536853947916665,0.00012716605208333478
19.0,4033.0,3882.0,0.004711,0.004711,8.302514,0.323595,1.0,4033.0,19.0,153.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01265681,0.01266545446856153,8.644468561530214e-06
21.0,4033.0,3882.0,0.005207,0.005207,8.302514,0.323595,1.0,4033.0,19.0,153.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01398939,0.013899830471020008,8.955952897999296e-05
14.0,4033.0,3882.0,0.003471,0.003471,8.302514,0.323595,1.0,4033.0,19.0,153.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00932536,0.009514398696934526,0.00018903869693452646
19.0,4033.0,3882.0,0.004711,0.004711,8.302514,0.323595,1.0,4033.0,19.0,153.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01265681,0.012615150992711965,4.1659007288034205e-05
11.0,4033.0,3882.0,0.002727,0.002727,8.302514,0.323595,1.0,4033.0,19.0,153.0,Entry Criteria not Met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00732649,0.007300104319332612,2.6385680667387335e-05
14.0,4033.0,3882.0,0.003471,0.003471,8.302514,0.323595,1.0,4033.0,19.0,153.0,Entry Criteria not Met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00932536,0.009522398861517858,0.00019703886151785886
2.0,4033.0,3882.0,0.000496,0.000496,8.302514,0.323595,1.0,4033.0,19.0,153.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00133258,0.001324197097351191,8.382902648809134e-06
1.0,4033.0,3882.0,0.000248,0.000248,8.302514,0.323595,1.0,4033.0,19.0,153.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00066629,0.0006694027361904809,3.1127361904808573e-06
1.0,4033.0,3882.0,0.000248,0.000248,8.302514,0.323595,1.0,4033.0,19.0,153.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00066629,0.0006679301605059574,1.640160505957393e-06
1.0,4033.0,3882.0,0.000248,0.000248,8.302514,0.323595,1.0,4033.0,19.0,153.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00066629,0.0006670036378571483,7.136378571482357e-07
7.0,2076.0,1909.0,0.003372,0.003372,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02575763,0.025711071045426567,4.6558954573432815e-05
11.0,2076.0,1909.0,0.005299,0.005299,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04047736,0.04058566830184523,0.00010830830184523077
16.0,2076.0,1909.0,0.007707,0.007707,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05887131,0.05903184295213294,0.0001605329521329399
12.0,2076.0,1909.0,0.00578,0.00578,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04415157,0.04364412051164686,0.0005074494883531427
11.0,2076.0,1909.0,0.005299,0.005299,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04047736,0.04063502790142855,0.00015766790142855008
8.0,2076.0,1909.0,0.003854,0.003854,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02943947,0.029182451485059525,0.0002570185149404734
12.0,2076.0,1909.0,0.00578,0.00578,7.63868,1.0,1.0,2101.0,15.0,105.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04415157,0.04361213294861115,0.0005394370513888483
17.0,2076.0,1909.0,0.008189,0.008189,7.63868,1.0,1.0,2101.0,15.0,105.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06255315,0.06169939327172615,0.0008537567282738551
11.0,2076.0,1909.0,0.005299,0.005299,7.63868,1.0,1.0,2101.0,15.0,105.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04047736,0.04066078044476188,0.00018342044476188368
16.0,2076.0,1909.0,0.007707,0.007707,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05887131,0.058767906296150814,0.00010340370384918918
18.0,2076.0,1909.0,0.008671,0.008671,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06623499,0.06598974718075228,0.00024524281924771796
21.0,2076.0,1909.0,0.010116,0.010116,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07727289,0.07680371103851191,0.00046917896148808425
24.0,2076.0,1909.0,0.011561,0.011561,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08831078,0.0845485503467857,0.003762229653214308
21.0,2076.0,1909.0,0.010116,0.010116,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07727289,0.07719307077173337,7.981922826662269e-05
22.0,2076.0,1909.0,0.010597,0.010597,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.08094709,0.08001491908673333,0.0009321709132666667
25.0,2076.0,1909.0,0.012042,0.012042,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Treatment,FG000,cardiovascular disease,INDUSTRY,0.09198498,0.09096342134631943,0.0010215586536805599
26.0,2076.0,1909.0,0.012524,0.012524,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Treatment,FG001,cardiovascular disease,INDUSTRY,0.09566683,0.09308009859142857,0.0025867314085714216
32.0,2076.0,1909.0,0.015414,0.015414,7.63868,1.0,1.0,2101.0,15.0,105.0,Adverse Event,Treatment,FG002,cardiovascular disease,INDUSTRY,0.11774261,0.11596065166936491,0.001781958330635089
3.0,2076.0,1909.0,0.001445,0.001445,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Treatment,FG000,cardiovascular disease,INDUSTRY,0.01103789,0.010755906411230151,0.0002819835887698484
5.0,2076.0,1909.0,0.002408,0.002408,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Treatment,FG001,cardiovascular disease,INDUSTRY,0.01839394,0.018166411458323428,0.0002275285416765728
5.0,2076.0,1909.0,0.002408,0.002408,7.63868,1.0,1.0,2101.0,15.0,105.0,Protocol Violation,Treatment,FG002,cardiovascular disease,INDUSTRY,0.01839394,0.018292184429930577,0.0001017555700694242
3.0,2076.0,1909.0,0.001445,0.001445,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Treatment,FG000,cardiovascular disease,INDUSTRY,0.01103789,0.010796943169742052,0.00024094683025794802
7.0,2076.0,1909.0,0.003372,0.003372,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Treatment,FG001,cardiovascular disease,INDUSTRY,0.02575763,0.02565902611524801,9.860388475198961e-05
8.0,2076.0,1909.0,0.003854,0.003854,7.63868,1.0,1.0,2101.0,15.0,105.0,Withdrawal by Subject,Treatment,FG002,cardiovascular disease,INDUSTRY,0.02943947,0.02915574230151786,0.0002837276984821377
18.0,2076.0,1909.0,0.008671,0.008671,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Treatment,FG000,cardiovascular disease,INDUSTRY,0.06623499,0.06584596306004709,0.0003890269399529078
18.0,2076.0,1909.0,0.008671,0.008671,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Treatment,FG001,cardiovascular disease,INDUSTRY,0.06623499,0.065927970878669,0.0003070191213309925
17.0,2076.0,1909.0,0.008189,0.008189,7.63868,1.0,1.0,2101.0,15.0,105.0,Other,Treatment,FG002,cardiovascular disease,INDUSTRY,0.06255315,0.06174866150001979,0.000804488499980209
4.0,454.0,388.0,0.008811,0.008811,6.120297,0.780683,1.0,454.0,17.0,108.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04209905,0.04220364687247022,0.00010459687247021954
7.0,454.0,388.0,0.015419,0.015419,6.120297,0.780683,1.0,454.0,17.0,108.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07367214,0.0736857564530583,1.3616453058307165e-05
0.0,454.0,388.0,0.0,0.0,6.120297,0.780683,1.0,454.0,17.0,108.0,Decision by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,454.0,388.0,0.006608,0.006608,6.120297,0.780683,1.0,454.0,17.0,108.0,Decision by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03157309,0.0317178157680556,0.00014472576805560355
3.0,454.0,388.0,0.006608,0.006608,6.120297,0.780683,1.0,454.0,17.0,108.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03157309,0.03167895044136909,0.00010586044136909334
2.0,454.0,388.0,0.004405,0.004405,6.120297,0.780683,1.0,454.0,17.0,108.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02104714,0.021035604872073406,1.1535127926592947e-05
22.0,454.0,388.0,0.048458,0.048458,6.120297,0.780683,1.0,454.0,17.0,108.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.23153283,0.23471289114478164,0.003180061144781643
25.0,454.0,388.0,0.055066,0.055066,6.120297,0.780683,1.0,454.0,17.0,108.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.26310592,0.25748911195868057,0.005616808041319421
2.0,349.0,305.0,0.005731,0.005731,5.857933,0.342728,1.0,224.0,1.0,28.0,Withdrawal by Subject,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01150601,0.011614191658948416,0.00010818165894841553
3.0,349.0,305.0,0.008596,0.008596,5.857933,0.342728,1.0,224.0,1.0,28.0,Withdrawal by Subject,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.01725801,0.017362364547976187,0.00010435454797618621
2.0,349.0,305.0,0.005731,0.005731,5.857933,0.342728,1.0,224.0,1.0,28.0,Lost to Follow-up,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01150601,0.011615963936686511,0.00010995393668651078
0.0,349.0,305.0,0.0,0.0,5.857933,0.342728,1.0,224.0,1.0,28.0,Lost to Follow-up,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,349.0,305.0,0.005731,0.005731,5.857933,0.342728,1.0,224.0,1.0,28.0,Missed 12-Month Visit,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01150601,0.011615963936686511,0.00010995393668651078
0.0,349.0,305.0,0.0,0.0,5.857933,0.342728,1.0,224.0,1.0,28.0,Missed 12-Month Visit,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,349.0,305.0,0.008596,0.008596,5.857933,0.342728,1.0,224.0,1.0,28.0,Death,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01725801,0.01734240212041666,8.439212041665839e-05
2.0,349.0,305.0,0.005731,0.005731,5.857933,0.342728,1.0,224.0,1.0,28.0,Death,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.01150601,0.011619016276269845,0.00011300627626984437
23.0,349.0,305.0,0.065903,0.065903,5.857933,0.342728,1.0,224.0,1.0,28.0,No 9-Month Angiography Performed,9-Month Angiographic Follow-up,FG000,cardiovascular disease,INDUSTRY,0.13231208,0.13028092520166212,0.0020311547983378753
12.0,349.0,305.0,0.034384,0.034384,5.857933,0.342728,1.0,224.0,1.0,28.0,No 9-Month Angiography Performed,9-Month Angiographic Follow-up,FG001,cardiovascular disease,INDUSTRY,0.06903204,0.06862913280786717,0.00040290719213283144
4.0,349.0,305.0,0.011461,0.011461,5.857933,0.342728,1.0,224.0,1.0,28.0,Not Evaluable for 9-Month Angiography,9-Month Angiographic Follow-up,FG000,cardiovascular disease,INDUSTRY,0.02301001,0.022810150923199855,0.00019985907680014625
5.0,349.0,305.0,0.014327,0.014327,5.857933,0.342728,1.0,224.0,1.0,28.0,Not Evaluable for 9-Month Angiography,9-Month Angiographic Follow-up,FG001,cardiovascular disease,INDUSTRY,0.02876402,0.02854443859247026,0.00021958140752974253
1.0,332.0,328.0,0.003012,0.003012,5.808142,0.341753,1.0,332.0,1.0,18.0,No receive treatment/lost to follow-up,Overall Study,FG000,cardiovascular disease,NETWORK,0.00597868,0.0060101286982738155,3.14486982738154e-05
3.0,332.0,328.0,0.009036,0.009036,5.808142,0.341753,1.0,332.0,1.0,18.0,No receive treatment/lost to follow-up,Overall Study,FG001,cardiovascular disease,NETWORK,0.01793603,0.017780043319702378,0.00015598668029762064
4.0,517.0,467.0,0.007737,0.007737,6.249975,0.655383,1.0,517.0,5.0,92.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03169176,0.032479766664146786,0.000788006664146787
0.0,517.0,467.0,0.0,0.0,6.249975,0.655383,1.0,517.0,5.0,92.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,517.0,467.0,0.005803,0.005803,6.249975,0.655383,1.0,517.0,5.0,92.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02376984,0.025210964220138892,0.0014411242201388917
1.0,517.0,467.0,0.001934,0.001934,6.249975,0.655383,1.0,517.0,5.0,92.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00792192,0.007860150809047612,6.176919095238903e-05
7.0,517.0,467.0,0.01354,0.01354,6.249975,0.655383,1.0,517.0,5.0,92.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0554616,0.0560661848628274,0.0006045848628273981
5.0,517.0,467.0,0.009671,0.009671,6.249975,0.655383,1.0,517.0,5.0,92.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03961367,0.03904741752619047,0.0005662524738095295
11.0,517.0,467.0,0.021277,0.021277,6.249975,0.655383,1.0,517.0,5.0,92.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08715335,0.08628731349448407,0.0008660365055159353
4.0,517.0,467.0,0.007737,0.007737,6.249975,0.655383,1.0,517.0,5.0,92.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03169176,0.032339499284900784,0.0006477392849007849
10.0,517.0,467.0,0.019342,0.019342,6.249975,0.655383,1.0,517.0,5.0,92.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07922734,0.07995577437958336,0.0007284343795833648
5.0,517.0,467.0,0.009671,0.009671,6.249975,0.655383,1.0,517.0,5.0,92.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03961367,0.03917218639035714,0.0004414836096428565
73.0,1280.0,1226.0,0.057031,0.057031,7.155396,0.247637,1.0,1280.0,1.0,165.0,Adverse Event,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.10105574,0.09919978726441467,0.0018559527355853367
70.0,1280.0,1226.0,0.054688,0.054688,7.155396,0.247637,1.0,1280.0,1.0,165.0,Adverse Event,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.09690408,0.09645847081759916,0.000445609182400844
26.0,1280.0,1226.0,0.020313,0.020313,7.155396,0.247637,1.0,1280.0,1.0,165.0,Withdrawal by Subject,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0359935,0.0365570463637996,0.0005635463637995997
35.0,1280.0,1226.0,0.027344,0.027344,7.155396,0.247637,1.0,1280.0,1.0,165.0,Withdrawal by Subject,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04845204,0.04904200030348212,0.0005899603034821149
8.0,1280.0,1226.0,0.00625,0.00625,7.155396,0.247637,1.0,1280.0,1.0,165.0,Death,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01107465,0.011055747885238075,1.8902114761925118e-05
3.0,1280.0,1226.0,0.002344,0.002344,7.155396,0.247637,1.0,1280.0,1.0,165.0,Death,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00415344,0.004144918622351198,8.521377648802037e-06
4.0,1280.0,1226.0,0.003125,0.003125,7.155396,0.247637,1.0,1280.0,1.0,165.0,Physician Decision,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00553733,0.005529029733124988,8.30026687501182e-06
13.0,1280.0,1226.0,0.010156,0.010156,7.155396,0.247637,1.0,1280.0,1.0,165.0,Physician Decision,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01799586,0.01801271284386905,1.6852843869052253e-05
4.0,1280.0,1226.0,0.003125,0.003125,7.155396,0.247637,1.0,1280.0,1.0,165.0,Lost to Follow-up,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00553733,0.005537099817351179,2.3018264882091605e-07
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Lost to Follow-up,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.0013848934000000044,1.003400000004328e-06
9.0,1280.0,1226.0,0.007031,0.007031,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Violation,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01245854,0.012441281402767861,1.725859723213964e-05
9.0,1280.0,1226.0,0.007031,0.007031,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Violation,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01245854,0.012408118024732144,5.04219752678562e-05
18.0,1280.0,1226.0,0.014063,0.014063,7.155396,0.247637,1.0,1280.0,1.0,165.0,Clinical Endpoint Reached,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02491885,0.02433990866420635,0.0005789413357936493
28.0,1280.0,1226.0,0.021875,0.021875,7.155396,0.247637,1.0,1280.0,1.0,165.0,Clinical Endpoint Reached,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03876128,0.03911954507263889,0.00035826507263888446
3.0,1280.0,1226.0,0.002344,0.002344,7.155396,0.247637,1.0,1280.0,1.0,165.0,Non-compliant with Study Medication,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00415344,0.004143607518482153,9.832481517847713e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Non-compliant with Study Medication,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.0013841859333333375,2.9593333333746523e-07
12.0,1280.0,1226.0,0.009375,0.009375,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Driven Decision Point,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01661198,0.016616361537033743,4.381537033745081e-06
8.0,1280.0,1226.0,0.00625,0.00625,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Driven Decision Point,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01107465,0.011034540148452357,4.010985154764314e-05
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Site Closed by Investigator,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00138389,0.0013851592756547657,1.2692756547656465e-06
2.0,1280.0,1226.0,0.001563,0.001563,7.155396,0.247637,1.0,1280.0,1.0,165.0,Site Closed by Investigator,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00276955,0.002761206432500002,8.343567499998015e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Site Closed by Sponsor,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00138389,0.0013852009631547656,1.310963154765605e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Site Closed by Sponsor,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.0013842276208333377,3.376208333376405e-07
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Drop out before Treatment Start,Double-blind (DB) Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00138389,0.0013850813631547656,1.1913631547655866e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Drop out before Treatment Start,Double-blind (DB) Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.0013841080208333377,2.180208333376222e-07
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Adverse Event,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.00138389,0.0013878371635714318,3.947163571431812e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Adverse Event,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.001386264117083337,2.374117083337032e-06
13.0,1280.0,1226.0,0.010156,0.010156,7.155396,0.247637,1.0,1280.0,1.0,165.0,Death,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.01799586,0.017999857812886908,3.997812886909202e-06
12.0,1280.0,1226.0,0.009375,0.009375,7.155396,0.247637,1.0,1280.0,1.0,165.0,Death,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.01661198,0.016606297834712312,5.682165287686225e-06
6.0,1280.0,1226.0,0.004687,0.004687,7.155396,0.247637,1.0,1280.0,1.0,165.0,Lost to Follow-up,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.0083051,0.008348929059236116,4.382905923611645e-05
2.0,1280.0,1226.0,0.001563,0.001563,7.155396,0.247637,1.0,1280.0,1.0,165.0,Lost to Follow-up,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.00276955,0.002762503315833335,7.0466841666648634e-06
0.0,1280.0,1226.0,0.0,0.0,7.155396,0.247637,1.0,1280.0,1.0,165.0,Physician Decision,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Physician Decision,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.00138389,0.0013864968837500038,2.606883750003782e-06
1.0,1280.0,1226.0,0.000781,0.000781,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Violation,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.00138389,0.0013878371635714318,3.947163571431812e-06
0.0,1280.0,1226.0,0.0,0.0,7.155396,0.247637,1.0,1280.0,1.0,165.0,Protocol Violation,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1280.0,1226.0,0.003906,0.003906,7.155396,0.247637,1.0,1280.0,1.0,165.0,Withdrawal by Subject,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.00692121,0.006902581681141758,1.8628318858241594e-05
5.0,1280.0,1226.0,0.003906,0.003906,7.155396,0.247637,1.0,1280.0,1.0,165.0,Withdrawal by Subject,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.00692121,0.006895447832153663,2.576216784633701e-05
3.0,1280.0,1226.0,0.002344,0.002344,7.155396,0.247637,1.0,1280.0,1.0,165.0,Clinical Endpoint Reached,Follow-up (FU) Period,FG000,cardiovascular disease,INDUSTRY,0.00415344,0.004144715423065486,8.724576934514804e-06
2.0,1280.0,1226.0,0.001563,0.001563,7.155396,0.247637,1.0,1280.0,1.0,165.0,Clinical Endpoint Reached,Follow-up (FU) Period,FG001,cardiovascular disease,INDUSTRY,0.00276955,0.002761206432500002,8.343567499998015e-06
0.0,1873.0,1857.0,0.0,0.0,7.53583,0.212734,1.0,1873.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1873.0,1857.0,0.001068,0.001068,7.53583,0.212734,1.0,1873.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00171214,0.0018421263024467906,0.0001299863024467906
5.0,1873.0,1857.0,0.00267,0.00267,7.53583,0.212734,1.0,1873.0,0.0,0.0,Adminstrative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00428035,0.004324671930406742,4.4321930406742045e-05
9.0,1873.0,1857.0,0.004805,0.004805,7.53583,0.212734,1.0,1873.0,0.0,0.0,Adminstrative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00770303,0.00778226353886904,7.923353886904027e-05
3.0,304.0,93.0,0.009868,0.009868,5.720312,0.902321,1.0,304.0,10.0,40.0,Adverse Event,Overall Study,FG000,cardiovascular disease,NETWORK,0.05093424,0.051802239030386985,0.0008679990303869858
4.0,304.0,93.0,0.013158,0.013158,5.720312,0.902321,1.0,304.0,10.0,40.0,Adverse Event,Overall Study,FG001,cardiovascular disease,NETWORK,0.06791576,0.06882070711097237,0.0009049471109723595
10.0,304.0,93.0,0.032895,0.032895,5.720312,0.902321,1.0,304.0,10.0,40.0,Death,Overall Study,FG000,cardiovascular disease,NETWORK,0.16978939,0.1714168049430753,0.0016274149430752782
7.0,304.0,93.0,0.023026,0.023026,5.720312,0.902321,1.0,304.0,10.0,40.0,Death,Overall Study,FG001,cardiovascular disease,NETWORK,0.11884999,0.12219927112574401,0.003349281125744008
5.0,304.0,93.0,0.016447,0.016447,5.720312,0.902321,1.0,304.0,10.0,40.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,NETWORK,0.08489212,0.08722800075683795,0.002335880756837952
12.0,304.0,93.0,0.039474,0.039474,5.720312,0.902321,1.0,304.0,10.0,40.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,NETWORK,0.20374727,0.19434148928026768,0.009405780719732332
1.0,304.0,93.0,0.003289,0.003289,5.720312,0.902321,1.0,304.0,10.0,40.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NETWORK,0.01697636,0.017550884296964248,0.0005745242969642482
0.0,304.0,93.0,0.0,0.0,5.720312,0.902321,1.0,304.0,10.0,40.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NETWORK,0.0,0.0,0.0
66.0,304.0,93.0,0.217105,0.217105,5.720312,0.902321,1.0,304.0,10.0,40.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,NETWORK,1.12059967,1.0853805905906548,0.03521907940934521
87.0,304.0,93.0,0.286184,0.286184,5.720312,0.902321,1.0,304.0,10.0,40.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,NETWORK,1.47715481,1.4085361503615073,0.06861865963849278
4.0,304.0,93.0,0.013158,0.013158,5.720312,0.902321,1.0,304.0,10.0,40.0,Physician Decision,Overall Study,FG000,cardiovascular disease,NETWORK,0.06791576,0.06886972480573424,0.0009539648057342309
7.0,304.0,93.0,0.023026,0.023026,5.720312,0.902321,1.0,304.0,10.0,40.0,Physician Decision,Overall Study,FG001,cardiovascular disease,NETWORK,0.11884999,0.12218666328407737,0.003336673284077371
2.0,304.0,93.0,0.006579,0.006579,5.720312,0.902321,1.0,304.0,10.0,40.0,randomized but not treated,Overall Study,FG000,cardiovascular disease,NETWORK,0.03395788,0.03468677525404765,0.0007288952540476443
3.0,304.0,93.0,0.009868,0.009868,5.720312,0.902321,1.0,304.0,10.0,40.0,randomized but not treated,Overall Study,FG001,cardiovascular disease,NETWORK,0.05093424,0.05160504945340285,0.0006708094534028514
0.0,3275.0,2446.0,0.0,0.0,8.094378,0.772204,1.0,3275.0,13.0,238.0,Sponsor's Administrative Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,3275.0,2446.0,0.0,0.0,8.094378,0.772204,1.0,3275.0,13.0,238.0,Sponsor's Administrative Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
272.0,3275.0,2446.0,0.083053,0.083053,8.094378,0.772204,1.0,3275.0,13.0,238.0,Sponsor's Administrative Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.51912403,0.490574422877807,0.028549607122192955
80.0,3275.0,2446.0,0.024427,0.024427,8.094378,0.772204,1.0,3275.0,13.0,238.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15268133,0.15026316771399814,0.0024181622860018626
81.0,3275.0,2446.0,0.024733,0.024733,8.094378,0.772204,1.0,3275.0,13.0,238.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15459399,0.15077319485626,0.00382079514373998
4.0,3275.0,2446.0,0.001221,0.001221,8.094378,0.772204,1.0,3275.0,13.0,238.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00763188,0.007524244803839286,0.00010763519616071356
77.0,3275.0,2446.0,0.023511,0.023511,8.094378,0.772204,1.0,3275.0,13.0,238.0,Withdrew Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14695586,0.14659126580410706,0.0003645941958929366
78.0,3275.0,2446.0,0.023817,0.023817,8.094378,0.772204,1.0,3275.0,13.0,238.0,Withdrew Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14886852,0.14716977732035708,0.0016987426796429284
2.0,3275.0,2446.0,0.000611,0.000611,8.094378,0.772204,1.0,3275.0,13.0,238.0,Withdrew Consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00381906,0.003805221406815486,1.3838593184514053e-05
47.0,3275.0,2446.0,0.014351,0.014351,8.094378,0.772204,1.0,3275.0,13.0,238.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08970114,0.08538229344980158,0.004318846550198416
52.0,3275.0,2446.0,0.015878,0.015878,8.094378,0.772204,1.0,3275.0,13.0,238.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09924568,0.09520579054464287,0.004039889455357132
1.0,3275.0,2446.0,0.000305,0.000305,8.094378,0.772204,1.0,3275.0,13.0,238.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00190641,0.0019271166467361137,2.0706646736113558e-05
22.0,3275.0,2446.0,0.006718,0.006718,8.094378,0.772204,1.0,3275.0,13.0,238.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04199096,0.04222021374874006,0.0002292537487400617
23.0,3275.0,2446.0,0.007023,0.007023,8.094378,0.772204,1.0,3275.0,13.0,238.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04389737,0.04404264972607144,0.00014527972607144418
0.0,3275.0,2446.0,0.0,0.0,8.094378,0.772204,1.0,3275.0,13.0,238.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,3275.0,2446.0,0.002137,0.002137,8.094378,0.772204,1.0,3275.0,13.0,238.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01335735,0.01294002621785714,0.00041732378214285985
4.0,3275.0,2446.0,0.001221,0.001221,8.094378,0.772204,1.0,3275.0,13.0,238.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00763188,0.007507340854186511,0.0001245391458134888
2.0,3275.0,2446.0,0.000611,0.000611,8.094378,0.772204,1.0,3275.0,13.0,238.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00381906,0.0038005195755654846,1.854042443451536e-05
0.0,3275.0,2446.0,0.0,0.0,8.094378,0.772204,1.0,3275.0,13.0,238.0,Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,3275.0,2446.0,0.0,0.0,8.094378,0.772204,1.0,3275.0,13.0,238.0,Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3275.0,2446.0,0.000305,0.000305,8.094378,0.772204,1.0,3275.0,13.0,238.0,Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00190641,0.0019227806938194464,1.6370693819446266e-05
34.0,3275.0,2446.0,0.010382,0.010382,8.094378,0.772204,1.0,3275.0,13.0,238.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06489285,0.06385262462180558,0.001040225378194426
40.0,3275.0,2446.0,0.012214,0.012214,8.094378,0.772204,1.0,3275.0,13.0,238.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07634379,0.07726594716095238,0.0009221571609523832
2.0,3275.0,2446.0,0.000611,0.000611,8.094378,0.772204,1.0,3275.0,13.0,238.0,Other reasons,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00381906,0.003805221406815486,1.3838593184514053e-05
2.0,382.0,363.0,0.005236,0.005236,5.948035,0.519356,1.0,382.0,1.0,5.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01617476,0.016131151490647797,4.360850935220331e-05
3.0,382.0,363.0,0.007853,0.007853,5.948035,0.519356,1.0,382.0,1.0,5.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02425906,0.024020115356428593,0.00023894464357140585
3.0,382.0,363.0,0.007853,0.007853,5.948035,0.519356,1.0,382.0,1.0,5.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02425906,0.024019778037261918,0.00023928196273808114
1.0,382.0,363.0,0.002618,0.002618,5.948035,0.519356,1.0,382.0,1.0,5.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00808738,0.008088716533630998,1.3365336309981157e-06
1.0,382.0,363.0,0.002618,0.002618,5.948035,0.519356,1.0,382.0,1.0,5.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00808738,0.008080265532916709,7.1144670832912205e-06
2.0,382.0,363.0,0.005236,0.005236,5.948035,0.519356,1.0,382.0,1.0,5.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01617476,0.016151209028295345,2.3550971704654894e-05
0.0,382.0,363.0,0.0,0.0,5.948035,0.519356,1.0,382.0,1.0,5.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,382.0,363.0,0.0,0.0,5.948035,0.519356,1.0,382.0,1.0,5.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,382.0,363.0,0.005236,0.005236,5.948035,0.519356,1.0,382.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01617476,0.016140403200038823,3.435679996117644e-05
1.0,382.0,363.0,0.002618,0.002618,5.948035,0.519356,1.0,382.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808738,0.00808554019678576,1.8398032142399184e-06
2.0,382.0,363.0,0.005236,0.005236,5.948035,0.519356,1.0,382.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01617476,0.016121070917203325,5.368908279667489e-05
1.0,382.0,363.0,0.002618,0.002618,5.948035,0.519356,1.0,382.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00808738,0.008086133541547667,1.246458452333274e-06
0.0,382.0,363.0,0.0,0.0,5.948035,0.519356,1.0,382.0,1.0,5.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,382.0,363.0,0.002618,0.002618,5.948035,0.519356,1.0,382.0,1.0,5.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808738,0.008083453000952425,3.926999047575153e-06
0.0,382.0,363.0,0.0,0.0,5.948035,0.519356,1.0,382.0,1.0,5.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,382.0,363.0,0.0,0.0,5.948035,0.519356,1.0,382.0,1.0,5.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
27.0,202.0,150.0,0.133663,0.133663,5.313206,0.277854,1.0,202.0,14.0,95.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19732586,0.19061892350482146,0.006706936495178534
7.0,202.0,150.0,0.034653,0.034653,5.313206,0.277854,1.0,202.0,14.0,95.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05115801,0.05176501874012357,0.0006070087401235727
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00730765,0.007302750333571428,4.899666428572098e-06
5.0,202.0,150.0,0.024752,0.024752,5.313206,0.277854,1.0,202.0,14.0,95.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03654123,0.03560596698587302,0.000935263014126983
2.0,202.0,150.0,0.009901,0.009901,5.313206,0.277854,1.0,202.0,14.0,95.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01461679,0.014639115251805503,2.2325251805503654e-05
2.0,202.0,150.0,0.009901,0.009901,5.313206,0.277854,1.0,202.0,14.0,95.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01461679,0.014623041348888841,6.251348888841948e-06
2.0,202.0,150.0,0.009901,0.009901,5.313206,0.277854,1.0,202.0,14.0,95.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01461679,0.01465735908484122,4.056908484122157e-05
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00730765,0.0073073211635714275,3.288364285721976e-07
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Abnormal labs,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00730765,0.0073035390157142836,4.110984285716178e-06
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Abnormal labs,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00730765,0.0073084744400000005,8.244400000008076e-07
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00730765,0.007315893591934522,8.243591934522024e-06
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00730765,0.007316852882053571,9.202882053571497e-06
0.0,202.0,150.0,0.0,0.0,5.313206,0.277854,1.0,202.0,14.0,95.0,Administration problem,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,202.0,150.0,0.00495,0.00495,5.313206,0.277854,1.0,202.0,14.0,95.0,Administration problem,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00730765,0.0073084744400000005,8.244400000008076e-07
64.0,955.0,570.0,0.067016,0.067016,6.862758,0.448172,1.0,955.0,30.0,213.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.20612068,0.21239058857140866,0.006269908571408661
74.0,955.0,570.0,0.077487,0.077487,6.862758,0.448172,1.0,955.0,30.0,213.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.23832626,0.23981229188346237,0.0014860318834623576
14.0,955.0,570.0,0.01466,0.01466,6.862758,0.448172,1.0,955.0,30.0,213.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04508967,0.04650672095182453,0.001417050951824532
18.0,955.0,570.0,0.018848,0.018848,6.862758,0.448172,1.0,955.0,30.0,213.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05797067,0.05892372225430734,0.000953052254307335
16.0,955.0,570.0,0.016754,0.016754,6.862758,0.448172,1.0,955.0,30.0,213.0,Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05153017,0.05349321134326389,0.0019630413432638882
20.0,955.0,570.0,0.020942,0.020942,6.862758,0.448172,1.0,955.0,30.0,213.0,Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06441117,0.06564340523051765,0.0012322352305176448
15.0,955.0,570.0,0.015707,0.015707,6.862758,0.448172,1.0,955.0,30.0,213.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04830992,0.049526537994285726,0.0012166179942857264
14.0,955.0,570.0,0.01466,0.01466,6.862758,0.448172,1.0,955.0,30.0,213.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04508967,0.046583213985823456,0.0014935439858234575
9.0,955.0,570.0,0.009424,0.009424,6.862758,0.448172,1.0,955.0,30.0,213.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02898534,0.02915136220872025,0.0001660222087202512
8.0,955.0,570.0,0.008377,0.008377,6.862758,0.448172,1.0,955.0,30.0,213.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02576508,0.026082716469077383,0.0003176364690773842
54.0,955.0,570.0,0.056545,0.056545,6.862758,0.448172,1.0,955.0,30.0,213.0,Disease Progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17391509,0.1783988622746032,0.004483772274603198
48.0,955.0,570.0,0.050262,0.050262,6.862758,0.448172,1.0,955.0,30.0,213.0,Disease Progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15459051,0.15437917917178576,0.000211330828214229
7.0,955.0,570.0,0.00733,0.00733,6.862758,0.448172,1.0,955.0,30.0,213.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02254483,0.02305663019798337,0.0005118001979833725
8.0,955.0,570.0,0.008377,0.008377,6.862758,0.448172,1.0,955.0,30.0,213.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02576508,0.026111400359136908,0.00034632035913690837
1.0,955.0,570.0,0.001047,0.001047,6.862758,0.448172,1.0,955.0,30.0,213.0,Continuing Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00322025,0.003298585230942459,7.833523094245886e-05
4.0,955.0,570.0,0.004188,0.004188,6.862758,0.448172,1.0,955.0,30.0,213.0,Continuing Treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.012881,0.012873885672261911,7.114327738089177e-06
7.0,955.0,570.0,0.00733,0.00733,6.862758,0.448172,1.0,955.0,30.0,213.0,Randomized but not Dosed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02254483,0.02309530835965004,0.0005504783596500425
4.0,955.0,570.0,0.004188,0.004188,6.862758,0.448172,1.0,955.0,30.0,213.0,Randomized but not Dosed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.012881,0.012873885672261911,7.114327738089177e-06
7.0,250.0,197.0,0.028,0.028,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.07951602,0.0813230215306433,0.0018070015306432957
3.0,250.0,197.0,0.012,0.012,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.0340783,0.03438584114514875,0.00030754114514874864
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.02271886,0.02278304459202385,6.418459202384846e-05
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.01135943,0.01136518438496936,5.754384969360385e-06
3.0,250.0,197.0,0.012,0.012,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.0340783,0.034466124690267795,0.0003878246902677962
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.02271886,0.02273584262833337,1.6982628333370164e-05
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.02271886,0.022749149009166688,3.0289009166687558e-05
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.01135943,0.01136518438496936,5.754384969360385e-06
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Non-Compliance,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.01135943,0.011360299905535737,8.699055357372365e-07
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.01135943,0.011361383030535736,1.9530305357361166e-06
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Protocol Violation,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,250.0,197.0,0.024,0.024,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG000,cardiovascular disease,INDUSTRY,0.06815659,0.06958132437085317,0.0014247343708531646
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG001,cardiovascular disease,INDUSTRY,0.02271886,0.02273265325041669,1.3793250416688912e-05
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG002,cardiovascular disease,INDUSTRY,0.02271886,0.022746841687500043,2.7981687500042846e-05
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG003,cardiovascular disease,INDUSTRY,0.01135943,0.011377041295327399,1.7611295327398663e-05
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 1: Blinded Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.01135943,0.011361354812500024,1.9248125000242283e-06
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.01135943,0.011361205800000026,1.7758000000252933e-06
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Adverse Event,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.02271886,0.022800117567857173,8.125756785717225e-05
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.01135943,0.011359430000000026,2.6020852139652106e-17
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.01135943,0.011359280987500027,1.4901249997291421e-07
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Death,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.01135943,0.011359430000000026,2.6020852139652106e-17
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.01135943,0.011361458709166692,2.028709166691789e-06
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lost to Follow-up,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Lack of Efficacy,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.01135943,0.011359430000000026,2.6020852139652106e-17
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.01135943,0.01137446108562502,1.5031085625019647e-05
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.01135943,0.01137461009812502,1.5180098125020317e-05
3.0,250.0,197.0,0.012,0.012,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.0340783,0.03451008056747019,0.00043178056747018856
2.0,250.0,197.0,0.008,0.008,5.525453,0.513959,1.0,251.0,14.0,78.0,Withdrawal by Subject,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.02271886,0.022758866697083362,4.0006697083361936e-05
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG004,cardiovascular disease,INDUSTRY,0.01135943,0.011359280987500027,1.4901249997291421e-07
1.0,250.0,197.0,0.004,0.004,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG005,cardiovascular disease,INDUSTRY,0.01135943,0.011359430000000026,2.6020852139652106e-17
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,197.0,0.0,0.0,5.525453,0.513959,1.0,251.0,14.0,78.0,Physician Decision,Part 2: Open-label Period,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
30.0,3834.0,3724.0,0.007825,0.007825,8.251925,0.234313,1.0,3834.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01512988,0.015294864700158728,0.00016498470015872783
26.0,3834.0,3724.0,0.006781,0.006781,8.251925,0.234313,1.0,3834.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01311127,0.012841144670813504,0.0002701253291864953
21.0,3834.0,3724.0,0.005477,0.005477,8.251925,0.234313,1.0,3834.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01058995,0.01050588577632304,8.406422367696065e-05
15.0,3834.0,3724.0,0.003912,0.003912,8.251925,0.234313,1.0,3834.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00756397,0.007641019217509919,7.704921750991897e-05
11.0,3834.0,3724.0,0.002869,0.002869,8.251925,0.234313,1.0,3834.0,0.0,0.0,Investigator site closed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0055473,0.005507229105128966,4.0070894871033734e-05
7.0,3834.0,3724.0,0.001826,0.001826,8.251925,0.234313,1.0,3834.0,0.0,0.0,Investigator site closed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00353063,0.003545593186284341,1.4963186284341033e-05
5.0,314.0,271.0,0.015924,0.015924,5.752573,0.448065,1.0,314.0,8.0,35.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04104456,0.043749237025386904,0.0027046770253869035
8.0,314.0,271.0,0.025478,0.025478,5.752573,0.448065,1.0,314.0,8.0,35.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06567026,0.06647264202674778,0.0008023820267477888
9.0,314.0,271.0,0.028662,0.028662,5.752573,0.448065,1.0,314.0,8.0,35.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07387711,0.07433367720205354,0.0004565672020535455
4.0,314.0,271.0,0.012739,0.012739,5.752573,0.448065,1.0,314.0,8.0,35.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03283513,0.03282229465882934,1.2835341170656933e-05
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820943,0.008211894916726163,2.4649167261626276e-06
2.0,314.0,271.0,0.006369,0.006369,5.752573,0.448065,1.0,314.0,8.0,35.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01641628,0.016870208065348117,0.00045392806534811855
3.0,314.0,271.0,0.009554,0.009554,5.752573,0.448065,1.0,314.0,8.0,35.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0246257,0.02499452826261907,0.00036882826261907045
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00820943,0.008216870492083304,7.440492083303843e-06
4.0,314.0,271.0,0.012739,0.012739,5.752573,0.448065,1.0,314.0,8.0,35.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03283513,0.032870640381746016,3.5510381746019226e-05
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00820943,0.00821582057374997,6.390573749969625e-06
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820943,0.008210583163809498,1.1531638094974817e-06
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00820943,0.008214525199761877,5.095199761877278e-06
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Participant moved back to home country,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820943,0.008211894916726163,2.4649167261626276e-06
0.0,314.0,271.0,0.0,0.0,5.752573,0.448065,1.0,314.0,8.0,35.0,Participant moved back to home country,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Withdrew due to being out of the country,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820943,0.008211894916726163,2.4649167261626276e-06
0.0,314.0,271.0,0.0,0.0,5.752573,0.448065,1.0,314.0,8.0,35.0,Withdrew due to being out of the country,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,314.0,271.0,0.003185,0.003185,5.752573,0.448065,1.0,314.0,8.0,35.0,Participant moved out of province,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00820943,0.008211894916726163,2.4649167261626276e-06
0.0,314.0,271.0,0.0,0.0,5.752573,0.448065,1.0,314.0,8.0,35.0,Participant moved out of province,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Protocol Violation,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,553.0,489.0,0.005425,0.005425,6.317165,0.794329,1.0,553.0,22.0,150.0,Protocol Violation,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.02722214,0.027578625870565462,0.0003564858705654636
2.0,553.0,489.0,0.003617,0.003617,6.317165,0.794329,1.0,553.0,22.0,150.0,Lost to Follow-up,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.01814977,0.018191718841448407,4.1948841448407465e-05
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Lost to Follow-up,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Adverse Event,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009084266254488688,1.189625448868789e-05
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Adverse Event,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Withdrawal by Subject,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.00911631996722677,4.394996722677062e-05
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Withdrawal by Subject,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Death,Part 1 (Baseline up to Week 24),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009084669146988685,1.229914698868545e-05
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Death,Part 1 (Baseline up to Week 24),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,553.0,489.0,0.023508,0.023508,6.317165,0.794329,1.0,553.0,22.0,150.0,Withdrawal by Subject,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.11796093,0.11753101205309535,0.0004299179469046538
12.0,553.0,489.0,0.0217,0.0217,6.317165,0.794329,1.0,553.0,22.0,150.0,Withdrawal by Subject,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.10888856,0.10853304023467272,0.00035551976532727236
7.0,553.0,489.0,0.012658,0.012658,6.317165,0.794329,1.0,553.0,22.0,150.0,Lost to Follow-up,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.06351665,0.06289450423482142,0.0006221457651785778
6.0,553.0,489.0,0.01085,0.01085,6.317165,0.794329,1.0,553.0,22.0,150.0,Lost to Follow-up,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.05444428,0.05236864523491609,0.0020756347650839058
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Adverse Event,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,553.0,489.0,0.007233,0.007233,6.317165,0.794329,1.0,553.0,22.0,150.0,Adverse Event,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.03629451,0.03622601849999305,6.849150000694942e-05
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Physician Decision,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,553.0,489.0,0.007233,0.007233,6.317165,0.794329,1.0,553.0,22.0,150.0,Physician Decision,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.03629451,0.036304596401332344,1.0086401332341788e-05
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Missed Week 72 Visit Due to SAE,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009076171807976253,3.8018079762530688e-06
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Missed Week 72 Visit Due to SAE,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.00907237,0.009102048331250051,2.967833125005169e-05
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Death,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009075722753809584,3.3527538095840664e-06
2.0,553.0,489.0,0.003617,0.003617,6.317165,0.794329,1.0,553.0,22.0,150.0,Death,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.01814977,0.01800040426631943,0.00014936573368056968
2.0,553.0,489.0,0.003617,0.003617,6.317165,0.794329,1.0,553.0,22.0,150.0,Non-Compliance With Study Drug,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.01814977,0.018141359895376977,8.410104623022413e-06
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Non-Compliance With Study Drug,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.00907237,0.009101969435416716,2.9599435416716516e-05
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Could Not Return to Hospital Due to COVID-19 Epidemic,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009076092912142918,3.7229121429178946e-06
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Could Not Return to Hospital Due to COVID-19 Epidemic,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,553.0,489.0,0.001808,0.001808,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Refused to Continue Study,Part 2 (Week 24 to Week 72),FG000,cardiovascular disease,INDUSTRY,0.00907237,0.009076092912142918,3.7229121429178946e-06
0.0,553.0,489.0,0.0,0.0,6.317165,0.794329,1.0,553.0,22.0,150.0,Patient Refused to Continue Study,Part 2 (Week 24 to Week 72),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,858.0,798.0,0.01049,0.01049,6.755769,1.0,1.0,858.0,11.0,137.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07086802,0.06612112371594962,0.004746896284050381
6.0,858.0,798.0,0.006993,0.006993,6.755769,1.0,1.0,858.0,11.0,137.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04724309,0.047060237538720184,0.00018285246127981714
7.0,858.0,798.0,0.008159,0.008159,6.755769,1.0,1.0,858.0,11.0,137.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05512032,0.05510949445886908,1.0825541130923821e-05
0.0,858.0,798.0,0.0,0.0,6.755769,1.0,1.0,858.0,11.0,137.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,858.0,798.0,0.001166,0.001166,6.755769,1.0,1.0,858.0,11.0,137.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00787723,0.007885748234126983,8.518234126982452e-06
0.0,858.0,798.0,0.0,0.0,6.755769,1.0,1.0,858.0,11.0,137.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,858.0,798.0,0.002331,0.002331,6.755769,1.0,1.0,858.0,11.0,137.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0157477,0.015693734751150816,5.396524884918388e-05
0.0,858.0,798.0,0.0,0.0,6.755769,1.0,1.0,858.0,11.0,137.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,858.0,798.0,0.001166,0.001166,6.755769,1.0,1.0,858.0,11.0,137.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00787723,0.007884388082460315,7.1580824603147825e-06
4.0,858.0,798.0,0.004662,0.004662,6.755769,1.0,1.0,858.0,11.0,137.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03149539,0.03136020589125815,0.0001351841087418454
8.0,858.0,798.0,0.009324,0.009324,6.755769,1.0,1.0,858.0,11.0,137.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06299079,0.06126408301466272,0.0017267069853372854
6.0,858.0,798.0,0.006993,0.006993,6.755769,1.0,1.0,858.0,11.0,137.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04724309,0.04702153990169641,0.0002215500983035884
0.0,858.0,798.0,0.0,0.0,6.755769,1.0,1.0,858.0,11.0,137.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,858.0,798.0,0.004662,0.004662,6.755769,1.0,1.0,858.0,11.0,137.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03149539,0.031483242296258165,1.2147703741832716e-05
3.0,858.0,798.0,0.003497,0.003497,6.755769,1.0,1.0,858.0,11.0,137.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02362492,0.023627426021934416,2.506021934415431e-06
5.0,858.0,798.0,0.005828,0.005828,6.755769,1.0,1.0,858.0,11.0,137.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03937262,0.0387857706194344,0.0005868493805656003
3.0,858.0,798.0,0.003497,0.003497,6.755769,1.0,1.0,858.0,11.0,137.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02362492,0.023648659506904663,2.3739506904662394e-05
1.0,858.0,798.0,0.001166,0.001166,6.755769,1.0,1.0,858.0,11.0,137.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00787723,0.007895830811031743,1.8600811031742326e-05
603.0,1116.0,103.0,0.540323,0.540323,7.018402,0.768912,1.0,1116.0,5.0,124.0,Overall trial ended,Overall Study,FG000,cardiovascular disease,OTHER,2.91587112,2.484914745930844,0.43095637406915577
97.0,1116.0,103.0,0.086918,0.086918,7.018402,0.768912,1.0,1116.0,5.0,124.0,Ablation,Overall Study,FG000,cardiovascular disease,OTHER,0.46905589,0.46894598161468,0.00010990838531999003
66.0,1116.0,103.0,0.05914,0.05914,7.018402,0.768912,1.0,1116.0,5.0,124.0,Withdrawal of consent,Overall Study,FG000,cardiovascular disease,OTHER,0.31915099,0.3113630784137599,0.007787911586240148
50.0,1116.0,103.0,0.044803,0.044803,7.018402,0.768912,1.0,1116.0,5.0,124.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.24178089,0.2465707214926686,0.004789831492668595
39.0,1116.0,103.0,0.034946,0.034946,7.018402,0.768912,1.0,1116.0,5.0,124.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.18858726,0.18346438306107152,0.005122876938928489
38.0,1116.0,103.0,0.03405,0.03405,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant no longer meets the inclusion/exclusion criteria,Overall Study,FG000,cardiovascular disease,OTHER,0.18375196,0.18116475430976206,0.0025872056902379315
34.0,1116.0,103.0,0.030466,0.030466,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant wanted to try other therapy or treatment,Overall Study,FG000,cardiovascular disease,OTHER,0.16441079,0.16368095057469237,0.0007298394253076324
25.0,1116.0,103.0,0.022401,0.022401,7.018402,0.768912,1.0,1116.0,5.0,124.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.12088774,0.11957227642731161,0.0013154635726883857
25.0,1116.0,103.0,0.022401,0.022401,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant non-compliance / Protocol violation(s),Overall Study,FG000,cardiovascular disease,OTHER,0.12088774,0.11951463582106159,0.0013731041789384058
11.0,1116.0,103.0,0.009857,0.009857,7.018402,0.768912,1.0,1116.0,5.0,124.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.05319363,0.05208304349973848,0.0011105865002615165
8.0,1116.0,103.0,0.007168,0.007168,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant felt the drug did not work,Overall Study,FG000,cardiovascular disease,OTHER,0.03868235,0.039024983450695966,0.00034263345069596857
5.0,1116.0,103.0,0.00448,0.00448,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant tolerability,Overall Study,FG000,cardiovascular disease,OTHER,0.02417647,0.023965185700416655,0.00021128429958334333
5.0,1116.0,103.0,0.00448,0.00448,7.018402,0.768912,1.0,1116.0,5.0,124.0,Missing,Overall Study,FG000,cardiovascular disease,OTHER,0.02417647,0.023965185700416655,0.00021128429958334333
4.0,1116.0,103.0,0.003584,0.003584,7.018402,0.768912,1.0,1116.0,5.0,124.0,Participant withdrawn due to COVID-19 situation,Overall Study,FG000,cardiovascular disease,OTHER,0.01934118,0.01899184235408731,0.00034933764591268957
3.0,1116.0,103.0,0.002688,0.002688,7.018402,0.768912,1.0,1116.0,5.0,124.0,Pregnancy,Overall Study,FG000,cardiovascular disease,OTHER,0.01450588,0.01361230726479167,0.0008935727352083304
17.0,603.0,476.0,0.028192,0.028192,6.403574,0.159358,1.0,605.0,22.0,93.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02876881,0.029041872308402807,0.00027306230840280776
10.0,603.0,476.0,0.016584,0.016584,6.403574,0.159358,1.0,605.0,22.0,93.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01692331,0.01712524028166668,0.00020193028166667903
21.0,603.0,476.0,0.034826,0.034826,6.403574,0.159358,1.0,605.0,22.0,93.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03553855,0.03905621829452381,0.0035176682945238097
17.0,603.0,476.0,0.028192,0.028192,6.403574,0.159358,1.0,605.0,22.0,93.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02876881,0.02917992722625995,0.0004111172262599508
1.0,603.0,476.0,0.001658,0.001658,6.403574,0.159358,1.0,605.0,22.0,93.0,Insufficient Therapeutic Response,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00169192,0.001771852543710315,7.993254371031506e-05
0.0,603.0,476.0,0.0,0.0,6.403574,0.159358,1.0,605.0,22.0,93.0,Insufficient Therapeutic Response,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,603.0,476.0,0.001658,0.001658,6.403574,0.159358,1.0,605.0,22.0,93.0,Violation of Selection Criteria at Entry,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00169192,0.001771852543710315,7.993254371031506e-05
1.0,603.0,476.0,0.001658,0.001658,6.403574,0.159358,1.0,605.0,22.0,93.0,Violation of Selection Criteria at Entry,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00169192,0.0018005126045436478,0.0001085926045436478
23.0,603.0,476.0,0.038143,0.038143,6.403574,0.159358,1.0,605.0,22.0,93.0,Refused Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03892341,0.04287151825916668,0.00394810825916668
14.0,603.0,476.0,0.023217,0.023217,6.403574,0.159358,1.0,605.0,22.0,93.0,Refused Treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02369202,0.022984522524910723,0.0007074974750892783
2.0,603.0,476.0,0.003317,0.003317,6.403574,0.159358,1.0,605.0,22.0,93.0,Other Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00338487,0.003299769781765872,8.51002182341281e-05
3.0,603.0,476.0,0.004975,0.004975,6.403574,0.159358,1.0,605.0,22.0,93.0,Other Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00507679,0.005223834017777773,0.000147044017777773
3.0,603.0,476.0,0.004975,0.004975,6.403574,0.159358,1.0,605.0,22.0,93.0,Failure to Return,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00507679,0.005238103681051583,0.00016131368105158292
1.0,603.0,476.0,0.001658,0.001658,6.403574,0.159358,1.0,605.0,22.0,93.0,Failure to Return,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00169192,0.0018005126045436478,0.0001085926045436478
7.0,603.0,476.0,0.011609,0.011609,6.403574,0.159358,1.0,605.0,22.0,93.0,Other withdrawal reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01184652,0.011930635291309529,8.411529130952951e-05
6.0,603.0,476.0,0.00995,0.00995,6.403574,0.159358,1.0,605.0,22.0,93.0,Other withdrawal reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01015358,0.010133929615505957,1.965038449404377e-05
7.0,248.0,213.0,0.028226,0.028226,5.517453,0.373748,1.0,253.0,5.0,44.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05820585,0.05950594049178576,0.0013000904917857548
7.0,248.0,213.0,0.028226,0.028226,5.517453,0.373748,1.0,253.0,5.0,44.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05820585,0.05953999319613101,0.0013341431961310032
0.0,248.0,213.0,0.0,0.0,5.517453,0.373748,1.0,253.0,5.0,44.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,248.0,213.0,0.004032,0.004032,5.517453,0.373748,1.0,253.0,5.0,44.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00831453,0.008314896970674576,3.6697067457534815e-07
0.0,248.0,213.0,0.0,0.0,5.517453,0.373748,1.0,253.0,5.0,44.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,248.0,213.0,0.004032,0.004032,5.517453,0.373748,1.0,253.0,5.0,44.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00831453,0.008314919787341241,3.897873412407604e-07
0.0,248.0,213.0,0.0,0.0,5.517453,0.373748,1.0,253.0,5.0,44.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,248.0,213.0,0.008065,0.008065,5.517453,0.373748,1.0,253.0,5.0,44.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01663113,0.016740236137063488,0.00010910613706348674
1.0,248.0,213.0,0.004032,0.004032,5.517453,0.373748,1.0,253.0,5.0,44.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00831453,0.008312742067936484,1.7879320635162677e-06
0.0,248.0,213.0,0.0,0.0,5.517453,0.373748,1.0,253.0,5.0,44.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,248.0,213.0,0.0,0.0,5.517453,0.373748,1.0,253.0,5.0,44.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,248.0,213.0,0.012097,0.012097,5.517453,0.373748,1.0,253.0,5.0,44.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02494566,0.02498560444136907,3.9944441369069855e-05
4.0,248.0,213.0,0.016129,0.016129,5.517453,0.373748,1.0,253.0,5.0,44.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03326019,0.034637941989176566,0.0013777519891765636
9.0,248.0,213.0,0.03629,0.03629,5.517453,0.373748,1.0,253.0,5.0,44.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07483491,0.07635222523961309,0.0015173152396130846
4.0,2278.0,947.0,0.001756,0.001756,7.731492,0.31503,1.0,2278.0,36.0,754.0,Ineligibility determined,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00427701,0.00424918897688492,2.7821023115080085e-05
3.0,2278.0,947.0,0.001317,0.001317,7.731492,0.31503,1.0,2278.0,36.0,754.0,Ineligibility determined,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00320775,0.0030654659201984143,0.0001422840798015858
83.0,2278.0,947.0,0.036435,0.036435,7.731492,0.31503,1.0,2278.0,36.0,754.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08874301,0.08949106609123009,0.0007480560912300899
65.0,2278.0,947.0,0.028534,0.028534,7.731492,0.31503,1.0,2278.0,36.0,754.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06949892,0.06965157199622028,0.0001526519962202766
111.0,2278.0,947.0,0.048727,0.048727,7.731492,0.31503,1.0,2278.0,36.0,754.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11868205,0.11687073308234139,0.0018113169176586091
102.0,2278.0,947.0,0.044776,0.044776,7.731492,0.31503,1.0,2278.0,36.0,754.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10905879,0.10452102298282742,0.004537767017172581
65.0,2278.0,947.0,0.028534,0.028534,7.731492,0.31503,1.0,2278.0,36.0,754.0,Participant request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06949892,0.06947373677461313,2.5183225386873898e-05
64.0,2278.0,947.0,0.028095,0.028095,7.731492,0.31503,1.0,2278.0,36.0,754.0,Participant request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06842967,0.06808458393020833,0.0003450860697916669
47.0,2278.0,947.0,0.020632,0.020632,7.731492,0.31503,1.0,2278.0,36.0,754.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05025239,0.05039215354454368,0.00013976354454368206
39.0,2278.0,947.0,0.01712,0.01712,7.731492,0.31503,1.0,2278.0,36.0,754.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04169838,0.04182184232815476,0.0001234623281547581
16.0,2278.0,947.0,0.007024,0.007024,7.731492,0.31503,1.0,2278.0,36.0,754.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01710803,0.016760848573283738,0.0003471814267162615
22.0,2278.0,947.0,0.009658,0.009658,7.731492,0.31503,1.0,2278.0,36.0,754.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02352353,0.023416216819980143,0.0001073131800198579
265.0,2278.0,947.0,0.11633,0.11633,7.731492,0.31503,1.0,2278.0,36.0,754.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.28333949,0.2616127076644047,0.02172678233559533
281.0,2278.0,947.0,0.123354,0.123354,7.731492,0.31503,1.0,2278.0,36.0,754.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.30044752,0.2661122986954365,0.03433522130456351
64.0,2278.0,947.0,0.028095,0.028095,7.731492,0.31503,1.0,2278.0,36.0,754.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06842967,0.06804926104312502,0.0003804089568749808
59.0,2278.0,947.0,0.0259,0.0259,7.731492,0.31503,1.0,2278.0,36.0,754.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06308341,0.0636032629463194,0.000519852946319399
1.0,2278.0,947.0,0.000439,0.000439,7.731492,0.31503,1.0,2278.0,36.0,754.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00106925,0.0011096528920833335,4.040289208333335e-05
0.0,2278.0,947.0,0.0,0.0,7.731492,0.31503,1.0,2278.0,36.0,754.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
21.0,2278.0,947.0,0.009219,0.009219,7.731492,0.31503,1.0,2278.0,36.0,754.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02245428,0.02223510733653769,0.00021917266346230951
14.0,2278.0,947.0,0.006146,0.006146,7.731492,0.31503,1.0,2278.0,36.0,754.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01496952,0.01480050953532739,0.0001690104646726101
2.0,2278.0,947.0,0.000878,0.000878,7.731492,0.31503,1.0,2278.0,36.0,754.0,Did not receive investigational product,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0021385,0.0021313266319146836,7.173368085316642e-06
3.0,2278.0,947.0,0.001317,0.001317,7.731492,0.31503,1.0,2278.0,36.0,754.0,Did not receive investigational product,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00320775,0.0030654659201984143,0.0001422840798015858
3.0,399.0,327.0,0.007519,0.007519,5.991465,0.722891,1.0,399.0,2.0,85.0,Completed out of Window,Overall Study,FG000,cardiovascular disease,OTHER,0.03256609,0.0322521699317803,0.00031392006821969604
2.0,399.0,327.0,0.005013,0.005013,5.991465,0.722891,1.0,399.0,2.0,85.0,Completed out of Window,Overall Study,FG001,cardiovascular disease,OTHER,0.02171217,0.021780836915763872,6.866691576387293e-05
5.0,399.0,327.0,0.012531,0.012531,5.991465,0.722891,1.0,399.0,2.0,85.0,Missed Visit,Overall Study,FG000,cardiovascular disease,OTHER,0.05427394,0.05447749646883928,0.00020355646883928047
2.0,399.0,327.0,0.005013,0.005013,5.991465,0.722891,1.0,399.0,2.0,85.0,Missed Visit,Overall Study,FG001,cardiovascular disease,OTHER,0.02171217,0.021780836915763872,6.866691576387293e-05
12.0,399.0,327.0,0.030075,0.030075,5.991465,0.722891,1.0,399.0,2.0,85.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.13026005,0.13129585396237098,0.0010358039623709903
7.0,399.0,327.0,0.017544,0.017544,5.991465,0.722891,1.0,399.0,2.0,85.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.07598611,0.0779164923688294,0.0019303823688294058
9.0,399.0,327.0,0.022556,0.022556,5.991465,0.722891,1.0,399.0,2.0,85.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.09769395,0.1004462672845931,0.002752317284593103
13.0,399.0,327.0,0.032581,0.032581,5.991465,0.722891,1.0,399.0,2.0,85.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.14111397,0.14384525670090093,0.00273128670090092
11.0,399.0,327.0,0.027569,0.027569,5.991465,0.722891,1.0,399.0,2.0,85.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.11940613,0.1205999771092352,0.001193847109235202
8.0,399.0,327.0,0.02005,0.02005,5.991465,0.722891,1.0,399.0,2.0,85.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.08684003,0.08901874040488096,0.0021787104048809625
174.0,1751.0,1345.0,0.099372,0.099372,7.468513,0.619677,1.0,1751.0,20.0,439.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.45990039,0.4553737293265755,0.0045266606734244985
167.0,1751.0,1345.0,0.095374,0.095374,7.468513,0.619677,1.0,1751.0,20.0,439.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.44139738,0.4429357634955556,0.001538383495555573
16.0,1751.0,1345.0,0.009138,0.009138,7.468513,0.619677,1.0,1751.0,20.0,439.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04229129,0.04271290792259918,0.00042161792259917674
9.0,1751.0,1345.0,0.00514,0.00514,7.468513,0.619677,1.0,1751.0,20.0,439.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02378827,0.023771631528115057,1.663847188494369e-05
18.0,1751.0,1345.0,0.01028,0.01028,7.468513,0.619677,1.0,1751.0,20.0,439.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04757654,0.04929952874250994,0.0017229887425099372
21.0,1751.0,1345.0,0.011993,0.011993,7.468513,0.619677,1.0,1751.0,20.0,439.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05550442,0.05674506622535715,0.0012406462253571546
1.0,1751.0,1345.0,0.000571,0.000571,7.468513,0.619677,1.0,1751.0,20.0,439.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00264263,0.0026447152918253965,2.0852918253965076e-06
0.0,1751.0,1345.0,0.0,0.0,7.468513,0.619677,1.0,1751.0,20.0,439.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,6016.0,5982.0,0.000166,0.000166,8.702344,0.866839,1.0,6016.0,37.0,661.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00125223,0.0010482955439285709,0.00020393445607142912
5.0,6016.0,5982.0,0.000831,0.000831,8.702344,0.866839,1.0,6016.0,37.0,661.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00626867,0.00619931641306547,6.935358693452992e-05
6.0,6016.0,5982.0,0.000997,0.000997,8.702344,0.866839,1.0,6016.0,37.0,661.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0075209,0.007800234122767855,0.0002793341227678558
7.0,6016.0,5982.0,0.001164,0.001164,8.702344,0.866839,1.0,6016.0,37.0,661.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00878067,0.008648312410664705,0.00013235758933529546
8.0,6016.0,5982.0,0.00133,0.00133,8.702344,0.866839,1.0,6016.0,37.0,661.0,major GCP violations,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01003289,0.009667454927619055,0.000365435072380944
7.0,6016.0,5982.0,0.001164,0.001164,8.702344,0.866839,1.0,6016.0,37.0,661.0,major GCP violations,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00878067,0.008723481051914705,5.718894808529572e-05
152.0,407.0,68.0,0.373464,0.373464,6.011267,0.488387,1.0,407.0,1.0,41.0,Patient Still in Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.09642423,0.9753638972915272,0.12106033270847283
72.0,407.0,68.0,0.176904,0.176904,6.011267,0.488387,1.0,407.0,1.0,41.0,Patient Still in Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.51935885,0.5227110353581848,0.0033521853581847116
37.0,407.0,68.0,0.090909,0.090909,6.011267,0.488387,1.0,407.0,1.0,41.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.26689274,0.2773120333669328,0.010419293366932758
25.0,407.0,68.0,0.061425,0.061425,6.011267,0.488387,1.0,407.0,1.0,41.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18033293,0.1891810871218849,0.008848157121884886
13.0,407.0,68.0,0.031941,0.031941,6.011267,0.488387,1.0,407.0,1.0,41.0,Implant Attempt Unsuccessful,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09377313,0.09423285656376983,0.00045972656376983
0.0,407.0,68.0,0.0,0.0,6.011267,0.488387,1.0,407.0,1.0,41.0,Implant Attempt Unsuccessful,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,407.0,68.0,0.012285,0.012285,6.011267,0.488387,1.0,407.0,1.0,41.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03606659,0.03555965998494054,0.0005069300150594633
8.0,407.0,68.0,0.019656,0.019656,6.011267,0.488387,1.0,407.0,1.0,41.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05770654,0.05657891111139881,0.0011276288886011912
6.0,407.0,68.0,0.014742,0.014742,6.011267,0.488387,1.0,407.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0432799,0.04316543466934525,0.00011446533065475467
13.0,407.0,68.0,0.031941,0.031941,6.011267,0.488387,1.0,407.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09377313,0.09371287173624006,6.0258263759938036e-05
4.0,407.0,68.0,0.009828,0.009828,6.011267,0.488387,1.0,407.0,1.0,41.0,Implant Not Attempted,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02885327,0.029384549919543656,0.0005312799195436556
0.0,407.0,68.0,0.0,0.0,6.011267,0.488387,1.0,407.0,1.0,41.0,Implant Not Attempted,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,407.0,68.0,0.004914,0.004914,6.011267,0.488387,1.0,407.0,1.0,41.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01442663,0.014364696771468278,6.193322853172145e-05
0.0,407.0,68.0,0.0,0.0,6.011267,0.488387,1.0,407.0,1.0,41.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,407.0,68.0,0.002457,0.002457,6.011267,0.488387,1.0,407.0,1.0,41.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00721332,0.007238165609652764,2.4845609652764805e-05
1.0,407.0,68.0,0.002457,0.002457,6.011267,0.488387,1.0,407.0,1.0,41.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00721332,0.007231598350069429,1.8278350069429218e-05
14.0,466.0,151.0,0.030043,0.030043,6.146329,0.718443,1.0,466.0,19.0,113.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13266346,0.13275900408963096,9.554408963094452e-05
28.0,466.0,151.0,0.060086,0.060086,6.146329,0.718443,1.0,466.0,19.0,113.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.26532692,0.2671843277924306,0.0018574077924305987
13.0,466.0,151.0,0.027897,0.027897,6.146329,0.718443,1.0,466.0,19.0,113.0,Decision by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12318718,0.12450499170293568,0.001317811702935684
37.0,466.0,151.0,0.079399,0.079399,6.146329,0.718443,1.0,466.0,19.0,113.0,Decision by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.35060899,0.34641187288813496,0.004197117111865045
4.0,466.0,151.0,0.008584,0.008584,6.146329,0.718443,1.0,466.0,19.0,113.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03790511,0.03808288894955356,0.00017777894955356421
3.0,466.0,151.0,0.006438,0.006438,6.146329,0.718443,1.0,466.0,19.0,113.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02842883,0.02832982739255411,9.900260744588954e-05
74.0,466.0,151.0,0.158798,0.158798,6.146329,0.718443,1.0,466.0,19.0,113.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.70121799,0.7364947681929769,0.03527677819297692
142.0,466.0,151.0,0.304721,0.304721,6.146329,0.718443,1.0,466.0,19.0,113.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.34558273,1.421345648554663,0.07576291855466288
28.0,609.0,512.0,0.045977,0.045977,6.413459,0.244077,1.0,609.0,2.0,53.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07197151,0.07187892853310511,9.25814668948921e-05
19.0,609.0,512.0,0.031199,0.031199,6.413459,0.244077,1.0,609.0,2.0,53.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04883831,0.04902973850272822,0.0001914285027282206
2.0,609.0,512.0,0.003284,0.003284,6.413459,0.244077,1.0,609.0,2.0,53.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00514071,0.005130111786190495,1.0598213809504507e-05
2.0,609.0,512.0,0.003284,0.003284,6.413459,0.244077,1.0,609.0,2.0,53.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00514071,0.005133796266785739,6.913733214260892e-06
3.0,609.0,512.0,0.004926,0.004926,6.413459,0.244077,1.0,609.0,2.0,53.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00771107,0.007755717977043648,4.4647977043647466e-05
2.0,609.0,512.0,0.003284,0.003284,6.413459,0.244077,1.0,609.0,2.0,53.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00514071,0.005134708605119073,6.001394880926839e-06
16.0,609.0,512.0,0.026273,0.026273,6.413459,0.244077,1.0,609.0,2.0,53.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04112725,0.04065311842495032,0.0004741315750496772
14.0,609.0,512.0,0.022989,0.022989,6.413459,0.244077,1.0,609.0,2.0,53.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03598654,0.03584595524487193,0.00014058475512807034
0.0,609.0,512.0,0.0,0.0,6.413459,0.244077,1.0,609.0,2.0,53.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,609.0,512.0,0.003284,0.003284,6.413459,0.244077,1.0,609.0,2.0,53.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00514071,0.005133647825119072,7.062174880927835e-06
2.0,609.0,512.0,0.003284,0.003284,6.413459,0.244077,1.0,609.0,2.0,53.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00514071,0.005131054815357162,9.655184642837385e-06
7.0,609.0,512.0,0.011494,0.011494,6.413459,0.244077,1.0,609.0,2.0,53.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01799249,0.017924923053214286,6.756694678571387e-05
2.0,200.0,186.0,0.01,0.01,5.303305,0.387388,1.0,200.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02054434,0.020625291799791615,8.095179979161413e-05
2.0,200.0,186.0,0.01,0.01,5.303305,0.387388,1.0,200.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02054434,0.02065938624774797,0.00011504624774796857
2.0,200.0,186.0,0.01,0.01,5.303305,0.387388,1.0,200.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02054434,0.02068920132461305,0.00014486132461304785
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01027217,0.010289863552104045,1.7693552104043955e-05
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01027217,0.010285675283303547,1.3505283303546015e-05
0.0,200.0,186.0,0.0,0.0,5.303305,0.387388,1.0,200.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01027217,0.010287620608303547,1.545060830354661e-05
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01027217,0.010288657460437379,1.6487460437378254e-05
2.0,200.0,186.0,0.01,0.01,5.303305,0.387388,1.0,200.0,1.0,1.0,Withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02054434,0.02068008282377971,0.00013574282377970884
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01027217,0.010287891860437376,1.5721860437375654e-05
0.0,200.0,186.0,0.0,0.0,5.303305,0.387388,1.0,200.0,1.0,1.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,200.0,186.0,0.005,0.005,5.303305,0.387388,1.0,200.0,1.0,1.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01027217,0.010284295047937377,1.2125047937376274e-05
4.0,207.0,1.0,0.019324,0.019324,5.337538,0.617621,1.0,207.0,10.0,63.0,Adverse Event,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.06370306,0.06517792951976191,0.0014748695197619038
3.0,207.0,1.0,0.014493,0.014493,5.337538,0.617621,1.0,207.0,10.0,63.0,Adverse Event,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.0477773,0.048504482490297596,0.000727182490297594
8.0,207.0,1.0,0.038647,0.038647,5.337538,0.617621,1.0,207.0,10.0,63.0,Lack of Efficacy,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.12740283,0.12732668167866074,7.614832133925886e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Lack of Efficacy,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Non-Compliance with Study Drug,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.01592577,0.015936392765833293,1.0622765833294412e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Non-Compliance with Study Drug,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,207.0,1.0,0.024155,0.024155,5.337538,0.617621,1.0,207.0,10.0,63.0,Withdrawal by Subject,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.07962883,0.08041178986044643,0.0007829598604464361
4.0,207.0,1.0,0.019324,0.019324,5.337538,0.617621,1.0,207.0,10.0,63.0,Withdrawal by Subject,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.06370306,0.06495355289470242,0.0012504928947024152
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Lost to Follow-up,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.01592577,0.015941970577916627,1.6200577916628683e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Lost to Follow-up,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Protocol Violation,Placebo Controlled Phase (Weeks 0-12),FG000,cardiovascular disease,INDUSTRY,0.01592577,0.015928850846071395,3.080846071396026e-06
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Protocol Violation,Placebo Controlled Phase (Weeks 0-12),FG001,cardiovascular disease,INDUSTRY,0.01592577,0.015965354317321385,3.9584317321386675e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Miscellaneous,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Miscellaneous,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.01592577,0.015957450064166618,3.168006416661914e-05
4.0,207.0,1.0,0.019324,0.019324,5.337538,0.617621,1.0,207.0,10.0,63.0,Adverse Event,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.06370306,0.06517792951976191,0.0014748695197619038
9.0,207.0,1.0,0.043478,0.043478,5.337538,0.617621,1.0,207.0,10.0,63.0,Adverse Event,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.14332859,0.1413395260890477,0.001989063910952299
2.0,207.0,1.0,0.009662,0.009662,5.337538,0.617621,1.0,207.0,10.0,63.0,Lack of Efficacy,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.03185153,0.032182412503521905,0.00033088250352190235
2.0,207.0,1.0,0.009662,0.009662,5.337538,0.617621,1.0,207.0,10.0,63.0,Lack of Efficacy,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.03185153,0.0321589352004862,0.0003074052004861938
7.0,207.0,1.0,0.033816,0.033816,5.337538,0.617621,1.0,207.0,10.0,63.0,Withdrawal by Subject,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.11147706,0.11147819221266855,1.1322126685503475e-06
7.0,207.0,1.0,0.033816,0.033816,5.337538,0.617621,1.0,207.0,10.0,63.0,Withdrawal by Subject,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.11147706,0.11240666363573404,0.0009296036357340359
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Lost to Follow-up,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.01592577,0.01594518798624996,1.941798624996091e-05
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Lost to Follow-up,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.01592577,0.01596555343041662,3.978343041662058e-05
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Pregnancy,Active Treatment Phase (Weeks 13-64),FG000,cardiovascular disease,INDUSTRY,0.01592577,0.01593695565749996,1.1185657499961088e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Pregnancy,Active Treatment Phase (Weeks 13-64),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,207.0,1.0,0.004831,0.004831,5.337538,0.617621,1.0,207.0,10.0,63.0,Physician Decision,Long-term Extension,FG000,cardiovascular disease,INDUSTRY,0.01592577,0.01594868169499996,2.291169499996082e-05
0.0,207.0,1.0,0.0,0.0,5.337538,0.617621,1.0,207.0,10.0,63.0,Physician Decision,Long-term Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Run in failure,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Run in failure,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,755.0,232.0,0.001325,0.001325,6.628041,0.818835,1.0,755.0,5.0,47.0,Run in failure,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.00719113,0.00718746495583331,3.6650441666893213e-06
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Adverse Event,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,755.0,232.0,0.002649,0.002649,6.628041,0.818835,1.0,755.0,5.0,47.0,Adverse Event,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.01437684,0.01437665877366068,1.812263393206892e-07
2.0,755.0,232.0,0.002649,0.002649,6.628041,0.818835,1.0,755.0,5.0,47.0,Adverse Event,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.01437684,0.014376931385138856,9.13851388555098e-08
1.0,755.0,232.0,0.001325,0.001325,6.628041,0.818835,1.0,755.0,5.0,47.0,Lost to Follow-up,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.00719113,0.007179540124285692,1.158987571430771e-05
2.0,755.0,232.0,0.002649,0.002649,6.628041,0.818835,1.0,755.0,5.0,47.0,Lost to Follow-up,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.01437684,0.014361295768303537,1.554423169646338e-05
2.0,755.0,232.0,0.002649,0.002649,6.628041,0.818835,1.0,755.0,5.0,47.0,Lost to Follow-up,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.01437684,0.014364081169186473,1.2758830813527217e-05
21.0,755.0,232.0,0.027815,0.027815,6.628041,0.818835,1.0,755.0,5.0,47.0,Participant moved to open-label extension (OLE) study,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.15095949,0.14777336144154754,0.0031861285584524612
21.0,755.0,232.0,0.027815,0.027815,6.628041,0.818835,1.0,755.0,5.0,47.0,Participant moved to open-label extension (OLE) study,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.15095949,0.14763384739085303,0.0033256426091469726
8.0,755.0,232.0,0.010596,0.010596,6.628041,0.818835,1.0,755.0,5.0,47.0,Participant moved to open-label extension (OLE) study,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.05750734,0.05768795672904038,0.00018061672904038512
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Other,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,755.0,232.0,0.002649,0.002649,6.628041,0.818835,1.0,755.0,5.0,47.0,Other,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.01437684,0.014386084456339255,9.244456339254845e-06
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Other,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Missing,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,755.0,232.0,0.001325,0.001325,6.628041,0.818835,1.0,755.0,5.0,47.0,Missing,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.00719113,0.007189514828749977,1.6151712500227927e-06
0.0,755.0,232.0,0.0,0.0,6.628041,0.818835,1.0,755.0,5.0,47.0,Missing,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,5669.0,5181.0,0.000353,0.000353,8.642944,0.651351,1.0,5669.0,41.0,486.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00198725,0.002049896563253966,6.264656325396601e-05
4.0,5669.0,5181.0,0.000706,0.000706,8.642944,0.651351,1.0,5669.0,41.0,486.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00397449,0.003959421535109131,1.5068464890868882e-05
2.0,5669.0,5181.0,0.000353,0.000353,8.642944,0.651351,1.0,5669.0,41.0,486.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00198725,0.0020389312891468236,5.168128914682371e-05
5.0,5669.0,5181.0,0.000882,0.000882,8.642944,0.651351,1.0,5669.0,41.0,486.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0049653,0.004657683889970241,0.0003076161100297589
221.0,5669.0,5181.0,0.038984,0.038984,8.642944,0.651351,1.0,5669.0,41.0,486.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.21946392,0.20493335398553567,0.014530566014464341
247.0,5669.0,5181.0,0.04357,0.04357,8.642944,0.651351,1.0,5669.0,41.0,486.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.24528121,0.23975432171223235,0.005526888287767651
4.0,5669.0,5181.0,0.000706,0.000706,8.642944,0.651351,1.0,5669.0,41.0,486.0,Mis-randomized (one mis-randomized patient in the Ramipril group also died),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00397449,0.003957250086067465,1.7239913932535177e-05
3.0,5669.0,5181.0,0.000529,0.000529,8.642944,0.651351,1.0,5669.0,41.0,486.0,Mis-randomized (one mis-randomized patient in the Ramipril group also died),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00297805,0.0028683541014682544,0.00010969589853174547
3.0,267.0,109.0,0.011236,0.011236,5.590987,0.175065,1.0,267.0,11.0,52.0,Death,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.01099761,0.01099269502160715,4.914978392849337e-06
0.0,267.0,109.0,0.0,0.0,5.590987,0.175065,1.0,267.0,11.0,52.0,Death,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,267.0,109.0,0.044944,0.044944,5.590987,0.175065,1.0,267.0,11.0,52.0,Adverse Event,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.04399045,0.04477910373476198,0.0007886537347619807
6.0,267.0,109.0,0.022472,0.022472,5.590987,0.175065,1.0,267.0,11.0,52.0,Adverse Event,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.02199523,0.022989068118343267,0.000993838118343266
2.0,267.0,109.0,0.007491,0.007491,5.590987,0.175065,1.0,267.0,11.0,52.0,Lack of Efficacy,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.00733207,0.007261460634107125,7.060936589287515e-05
3.0,267.0,109.0,0.011236,0.011236,5.590987,0.175065,1.0,267.0,11.0,52.0,Lack of Efficacy,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.01099761,0.010770578575654761,0.00022703142434523857
5.0,267.0,109.0,0.018727,0.018727,5.590987,0.175065,1.0,267.0,11.0,52.0,Reason Unspecified,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.01832968,0.018647052403025794,0.0003173724030257931
3.0,267.0,109.0,0.011236,0.011236,5.590987,0.175065,1.0,267.0,11.0,52.0,Reason Unspecified,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.01099761,0.01090896373107143,8.86462689285699e-05
1.0,267.0,109.0,0.003745,0.003745,5.590987,0.175065,1.0,267.0,11.0,52.0,Subject Defaulted,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.00366554,0.0037534946752083385,8.795467520833836e-05
0.0,267.0,109.0,0.0,0.0,5.590987,0.175065,1.0,267.0,11.0,52.0,Subject Defaulted,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,267.0,109.0,0.007491,0.007491,5.590987,0.175065,1.0,267.0,11.0,52.0,Randomized but not Treated,Core Study - 16 Weeks,FG000,cardiovascular disease,INDUSTRY,0.00733207,0.007277506374940459,5.456362505954111e-05
0.0,267.0,109.0,0.0,0.0,5.590987,0.175065,1.0,267.0,11.0,52.0,Randomized but not Treated,Core Study - 16 Weeks,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
24.0,267.0,109.0,0.089888,0.089888,5.590987,0.175065,1.0,267.0,11.0,52.0,Death,Extension Study - up to 3 Years,FG000,cardiovascular disease,INDUSTRY,0.0879809,0.09391200156095236,0.005931101560952362
28.0,267.0,109.0,0.104869,0.104869,5.590987,0.175065,1.0,267.0,11.0,52.0,Death,Extension Study - up to 3 Years,FG001,cardiovascular disease,INDUSTRY,0.10264406,0.12707462395269295,0.024430563952692955
14.0,267.0,109.0,0.052434,0.052434,5.590987,0.175065,1.0,267.0,11.0,52.0,Adverse Event,Extension Study - up to 3 Years,FG000,cardiovascular disease,INDUSTRY,0.05132154,0.05244074564868054,0.001119205648680538
14.0,267.0,109.0,0.052434,0.052434,5.590987,0.175065,1.0,267.0,11.0,52.0,Adverse Event,Extension Study - up to 3 Years,FG001,cardiovascular disease,INDUSTRY,0.05132154,0.05244462450772817,0.0011230845077281684
5.0,267.0,109.0,0.018727,0.018727,5.590987,0.175065,1.0,267.0,11.0,52.0,Lack of Efficacy,Extension Study - up to 3 Years,FG000,cardiovascular disease,INDUSTRY,0.01832968,0.01841460939677579,8.492939677579026e-05
1.0,267.0,109.0,0.003745,0.003745,5.590987,0.175065,1.0,267.0,11.0,52.0,Lack of Efficacy,Extension Study - up to 3 Years,FG001,cardiovascular disease,INDUSTRY,0.00366554,0.0037545887988690517,8.904879886905163e-05
12.0,267.0,109.0,0.044944,0.044944,5.590987,0.175065,1.0,267.0,11.0,52.0,Reason Unspecified,Extension Study - up to 3 Years,FG000,cardiovascular disease,INDUSTRY,0.04399045,0.04459926024547628,0.0006088102454762795
19.0,267.0,109.0,0.071161,0.071161,5.590987,0.175065,1.0,267.0,11.0,52.0,Reason Unspecified,Extension Study - up to 3 Years,FG001,cardiovascular disease,INDUSTRY,0.06965122,0.0769993598631479,0.007348139863147904
7.0,267.0,109.0,0.026217,0.026217,5.590987,0.175065,1.0,267.0,11.0,52.0,Withdrawal by Subject,Extension Study - up to 3 Years,FG000,cardiovascular disease,INDUSTRY,0.02566077,0.027364609013541687,0.0017038390135416873
9.0,267.0,109.0,0.033708,0.033708,5.590987,0.175065,1.0,267.0,11.0,52.0,Withdrawal by Subject,Extension Study - up to 3 Years,FG001,cardiovascular disease,INDUSTRY,0.03299284,0.0362966472238492,0.003303807223849195
1.0,212.0,56.0,0.004717,0.004717,5.361292,0.580655,1.0,212.0,7.0,43.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01468431,0.014673837817678509,1.047218232149219e-05
5.0,212.0,56.0,0.023585,0.023585,5.361292,0.580655,1.0,212.0,7.0,43.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07342156,0.07495191522336313,0.0015303552233631307
1.0,212.0,56.0,0.004717,0.004717,5.361292,0.580655,1.0,212.0,7.0,43.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01468431,0.014666882239285655,1.7427760714346097e-05
1.0,212.0,56.0,0.004717,0.004717,5.361292,0.580655,1.0,212.0,7.0,43.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01468431,0.014657946933630895,2.6363066369106125e-05
2.0,212.0,56.0,0.009434,0.009434,5.361292,0.580655,1.0,212.0,7.0,43.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02936862,0.029501840221547636,0.00013322022154763427
1.0,212.0,56.0,0.004717,0.004717,5.361292,0.580655,1.0,212.0,7.0,43.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01468431,0.014659740786964226,2.456921303577511e-05
3.0,212.0,56.0,0.014151,0.014151,5.361292,0.580655,1.0,212.0,7.0,43.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04405294,0.04638143715898806,0.0023284971589880646
1.0,212.0,56.0,0.004717,0.004717,5.361292,0.580655,1.0,212.0,7.0,43.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01468431,0.014659740786964226,2.456921303577511e-05
0.0,212.0,56.0,0.0,0.0,5.361292,0.580655,1.0,212.0,7.0,43.0,Other (Unspecified),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,212.0,56.0,0.014151,0.014151,5.361292,0.580655,1.0,212.0,7.0,43.0,Other (Unspecified),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04405294,0.04650326976121028,0.0024503297612102834
17.0,212.0,56.0,0.080189,0.080189,5.361292,0.580655,1.0,212.0,7.0,43.0,Subject withdrawn-Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24963331,0.27642996756710314,0.026796657567103144
4.0,212.0,56.0,0.018868,0.018868,5.361292,0.580655,1.0,212.0,7.0,43.0,Subject withdrawn-Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05873725,0.061173454699206375,0.0024362046992063777
54.0,212.0,56.0,0.254717,0.254717,5.361292,0.580655,1.0,212.0,7.0,43.0,Subject withdrawn-to commercial product,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.79294974,0.8007442800858827,0.007794540085882762
63.0,212.0,56.0,0.29717,0.29717,5.361292,0.580655,1.0,212.0,7.0,43.0,Subject withdrawn-to commercial product,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.92510855,0.870175888226538,0.05493266177346201
129.0,522.0,0.0,0.247126,0.247126,6.259581,0.835723,1.0,522.0,18.0,146.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.2927836,1.2828844144468994,0.009899185553100542
124.0,522.0,0.0,0.237548,0.237548,6.259581,0.835723,1.0,522.0,18.0,146.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.24267846,1.2500633043781741,0.007384844378174105
2.0,522.0,0.0,0.003831,0.003831,6.259581,0.835723,1.0,522.0,18.0,146.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02004101,0.019887323921382576,0.00015368607861742517
4.0,522.0,0.0,0.007663,0.007663,6.259581,0.835723,1.0,522.0,18.0,146.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04008725,0.03948257669243053,0.0006046733075694699
10.0,522.0,0.0,0.019157,0.019157,6.259581,0.835723,1.0,522.0,18.0,146.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1002155,0.09944426415462292,0.0007712358453770829
10.0,522.0,0.0,0.019157,0.019157,6.259581,0.835723,1.0,522.0,18.0,146.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1002155,0.09985016451025785,0.000365335489742144
118.0,522.0,0.0,0.226054,0.226054,6.259581,0.835723,1.0,522.0,18.0,146.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.18255021,1.1540171110248902,0.028533098975109805
125.0,522.0,0.0,0.239464,0.239464,6.259581,0.835723,1.0,522.0,18.0,146.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.25270158,1.2400856324938885,0.012615947506111613
208.0,929.0,75.0,0.223897,0.223897,6.835185,0.499644,1.0,929.0,27.0,241.0,Disease Progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.76464394,0.7492889953830358,0.015354944616964183
183.0,929.0,75.0,0.196986,0.196986,6.835185,0.499644,1.0,929.0,27.0,241.0,Disease Progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.67273858,0.689205084298809,0.016466504298809026
94.0,929.0,75.0,0.101184,0.101184,6.835185,0.499644,1.0,929.0,27.0,241.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.34555949,0.3466578289456546,0.0010983389456545867
96.0,929.0,75.0,0.103337,0.103337,6.835185,0.499644,1.0,929.0,27.0,241.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.35291232,0.3486758897672221,0.004236430232777921
55.0,929.0,75.0,0.059203,0.059203,6.835185,0.499644,1.0,929.0,27.0,241.0,Patient Request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.20218768,0.2084972224953871,0.006309542495387094
71.0,929.0,75.0,0.076426,0.076426,6.835185,0.499644,1.0,929.0,27.0,241.0,Patient Request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.26100697,0.26527354735105174,0.004266577351051737
40.0,929.0,75.0,0.043057,0.043057,6.835185,0.499644,1.0,929.0,27.0,241.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14704652,0.1592801156654365,0.012233595665436525
32.0,929.0,75.0,0.034446,0.034446,6.835185,0.499644,1.0,929.0,27.0,241.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11763858,0.1213894022012988,0.003750822201298798
19.0,929.0,75.0,0.020452,0.020452,6.835185,0.499644,1.0,929.0,27.0,241.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06984684,0.0718955939127381,0.0020487539127381077
11.0,929.0,75.0,0.011841,0.011841,6.835185,0.499644,1.0,929.0,27.0,241.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0404389,0.039906518320902806,0.0005323816790971936
10.0,929.0,75.0,0.010764,0.010764,6.835185,0.499644,1.0,929.0,27.0,241.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03676078,0.03667735057081348,8.342942918652257e-05
18.0,929.0,75.0,0.019376,0.019376,6.835185,0.499644,1.0,929.0,27.0,241.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06617213,0.0664139020216062,0.00024177202160620415
2.0,929.0,75.0,0.002153,0.002153,6.835185,0.499644,1.0,929.0,27.0,241.0,Protocol Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00735284,0.007309700135744045,4.3139864255955195e-05
4.0,929.0,75.0,0.004306,0.004306,6.835185,0.499644,1.0,929.0,27.0,241.0,Protocol Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01470568,0.014436747457757932,0.00026893254224206846
1.0,929.0,75.0,0.001076,0.001076,6.835185,0.499644,1.0,929.0,27.0,241.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00367471,0.003760683172380956,8.597317238095634e-05
0.0,929.0,75.0,0.0,0.0,6.835185,0.499644,1.0,929.0,27.0,241.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,929.0,75.0,0.009688,0.009688,6.835185,0.499644,1.0,929.0,27.0,241.0,Randomized but Not Dosed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03308606,0.033198129869761936,0.00011206986976193545
1.0,929.0,75.0,0.001076,0.001076,6.835185,0.499644,1.0,929.0,27.0,241.0,Randomized but Not Dosed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00367471,0.0037563026577678597,8.159265776785983e-05
5.0,476.0,416.0,0.010504,0.010504,6.167516,0.69216,1.0,476.0,1.0,18.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04484063,0.04534998082817458,0.0005093508281745832
3.0,476.0,416.0,0.006303,0.006303,6.167516,0.69216,1.0,476.0,1.0,18.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02690694,0.026693048911527774,0.00021389108847222685
4.0,476.0,416.0,0.008403,0.008403,6.167516,0.69216,1.0,476.0,1.0,18.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03587165,0.03588584416692917,1.4194166929173968e-05
6.0,476.0,416.0,0.012605,0.012605,6.167516,0.69216,1.0,476.0,1.0,18.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05380961,0.054145865955118985,0.0003362559551189845
19.0,476.0,416.0,0.039916,0.039916,6.167516,0.69216,1.0,476.0,1.0,18.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17039781,0.16695347450409892,0.0034443354959010908
16.0,476.0,416.0,0.033613,0.033613,6.167516,0.69216,1.0,476.0,1.0,18.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14349087,0.14353926533988906,4.839533988906797e-05
3.0,476.0,416.0,0.006303,0.006303,6.167516,0.69216,1.0,476.0,1.0,18.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02690694,0.026519784565813494,0.00038715543418650633
4.0,476.0,416.0,0.008403,0.008403,6.167516,0.69216,1.0,476.0,1.0,18.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03587165,0.03574986889619503,0.00012178110380496598
14.0,230.0,185.0,0.06087,0.06087,5.442418,0.217379,1.0,230.0,2.0,9.0,Death or Transplant,Overall Study,FG000,cardiovascular disease,NIH,0.07201347,0.07446962467441771,0.002456154674417718
16.0,230.0,185.0,0.069565,0.069565,5.442418,0.217379,1.0,230.0,2.0,9.0,Death or Transplant,Overall Study,FG001,cardiovascular disease,NIH,0.08230026,0.08424546777647668,0.001945207776476679
10.0,230.0,185.0,0.043478,0.043478,5.442418,0.217379,1.0,230.0,2.0,9.0,Family or MD withdrew subject,Overall Study,FG000,cardiovascular disease,NIH,0.05143751,0.05199841570103183,0.0005609057010318302
5.0,230.0,185.0,0.021739,0.021739,5.442418,0.217379,1.0,230.0,2.0,9.0,Family or MD withdrew subject,Overall Study,FG001,cardiovascular disease,NIH,0.02571876,0.027924872540354424,0.002206112540354424
1.0,882.0,849.0,0.001134,0.001134,6.783325,0.447853,1.0,882.0,2.0,60.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00344501,0.0035264910455357185,8.148104553571843e-05
0.0,882.0,849.0,0.0,0.0,6.783325,0.447853,1.0,882.0,2.0,60.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,882.0,849.0,0.0,0.0,6.783325,0.447853,1.0,882.0,2.0,60.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,882.0,849.0,0.001134,0.001134,6.783325,0.447853,1.0,882.0,2.0,60.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00344501,0.0035203177110416685,7.53077110416684e-05
10.0,882.0,849.0,0.011338,0.011338,6.783325,0.447853,1.0,882.0,2.0,60.0,No longer eligible,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03444405,0.03448840462639882,4.435462639882509e-05
15.0,882.0,849.0,0.017007,0.017007,6.783325,0.447853,1.0,882.0,2.0,60.0,No longer eligible,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05166607,0.052294726907807544,0.0006286569078075427
3.0,882.0,849.0,0.003401,0.003401,6.783325,0.447853,1.0,882.0,2.0,60.0,Surgery initiated before infusion,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.010332,0.010399999239047632,6.799923904763326e-05
3.0,882.0,849.0,0.003401,0.003401,6.783325,0.447853,1.0,882.0,2.0,60.0,Surgery initiated before infusion,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.010332,0.010391529169424617,5.952916942461757e-05
154.0,587.0,256.0,0.262351,0.262351,6.376727,0.244077,1.0,587.0,5.0,5.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.40832711,0.3718942038718436,0.03643290612815642
107.0,587.0,256.0,0.182283,0.182283,6.376727,0.244077,1.0,587.0,5.0,5.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.28370805,0.29276937673990056,0.009061326739900566
28.0,587.0,256.0,0.0477,0.0477,6.376727,0.244077,1.0,587.0,5.0,5.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07424101,0.07375143085759922,0.0004895791424007756
18.0,587.0,256.0,0.030664,0.030664,6.376727,0.244077,1.0,587.0,5.0,5.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04772592,0.04790659810902057,0.0001806781090205739
14.0,587.0,256.0,0.02385,0.02385,6.376727,0.244077,1.0,587.0,5.0,5.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0371205,0.0368345702993948,0.00028592970060520306
8.0,587.0,256.0,0.013629,0.013629,6.376727,0.244077,1.0,587.0,5.0,5.0,Transplant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02121238,0.021037486674343433,0.00017489332565656657
1.0,587.0,256.0,0.001704,0.001704,6.376727,0.244077,1.0,587.0,5.0,5.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00265213,0.002641869617619044,1.0260382380956109e-05
1.0,587.0,256.0,0.001704,0.001704,6.376727,0.244077,1.0,587.0,5.0,5.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00265213,0.0026416409299999965,1.0489070000003434e-05
4.0,307.0,0.0,0.013029,0.013029,5.7301,0.82156,1.0,307.0,24.0,111.0,Randomized and not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06133561,0.06233733706083336,0.00100172706083336
2.0,307.0,0.0,0.006515,0.006515,5.7301,0.82156,1.0,307.0,24.0,111.0,Randomized and not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03067016,0.031277500565744076,0.0006073405657440779
23.0,307.0,0.0,0.074919,0.074919,5.7301,0.82156,1.0,307.0,24.0,111.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.35269037,0.3513322406672719,0.001358129332728053
22.0,307.0,0.0,0.071661,0.071661,5.7301,0.82156,1.0,307.0,24.0,111.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.33735293,0.34503287424389883,0.00767994424389884
118.0,307.0,0.0,0.384365,0.384365,5.7301,0.82156,1.0,307.0,24.0,111.0,Progressive disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.8094453,1.7446596138380364,0.06478568616196356
107.0,307.0,0.0,0.348534,0.348534,5.7301,0.82156,1.0,307.0,24.0,111.0,Progressive disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.64076648,1.6327792422051581,0.007987237794841784
0.0,307.0,0.0,0.0,0.0,5.7301,0.82156,1.0,307.0,24.0,111.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,307.0,0.0,0.003257,0.003257,5.7301,0.82156,1.0,307.0,24.0,111.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01533273,0.01584815008502974,0.0005154200850297393
6.0,307.0,0.0,0.019544,0.019544,5.7301,0.82156,1.0,307.0,24.0,111.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09200577,0.09167209967479172,0.0003336703252082851
8.0,307.0,0.0,0.026059,0.026059,5.7301,0.82156,1.0,307.0,24.0,111.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12267593,0.12079340810440488,0.001882521895595124
2.0,307.0,0.0,0.006515,0.006515,5.7301,0.82156,1.0,307.0,24.0,111.0,Physician's decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03067016,0.03125764416401788,0.0005874841640178784
6.0,307.0,0.0,0.019544,0.019544,5.7301,0.82156,1.0,307.0,24.0,111.0,Physician's decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09200577,0.09160816968762903,0.00039760031237097426
0.0,307.0,0.0,0.0,0.0,5.7301,0.82156,1.0,307.0,24.0,111.0,Treatment extension study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,307.0,0.0,0.019544,0.019544,5.7301,0.82156,1.0,307.0,24.0,111.0,Treatment extension study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09200577,0.09160816968762903,0.00039760031237097426
0.0,307.0,0.0,0.0,0.0,5.7301,0.82156,1.0,307.0,24.0,111.0,Unconfirmed disease progression per investigator,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,307.0,0.0,0.003257,0.003257,5.7301,0.82156,1.0,307.0,24.0,111.0,Unconfirmed disease progression per investigator,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01533273,0.01584815008502974,0.0005154200850297393
0.0,307.0,0.0,0.0,0.0,5.7301,0.82156,1.0,307.0,24.0,111.0,Continue with therapy available commercially,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,307.0,0.0,0.003257,0.003257,5.7301,0.82156,1.0,307.0,24.0,111.0,Continue with therapy available commercially,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01533273,0.01584815008502974,0.0005154200850297393
7.0,838.0,802.0,0.008353,0.008353,6.732211,1.0,1.0,838.0,12.0,92.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05623416,0.056462204192698456,0.00022804419269845805
6.0,838.0,802.0,0.00716,0.00716,6.732211,1.0,1.0,838.0,12.0,92.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04820263,0.047756255184940505,0.00044637481505949844
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,838.0,802.0,0.00358,0.00358,6.732211,1.0,1.0,838.0,12.0,92.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02410131,0.023995523887113093,0.00010578611288690823
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00803153,0.008058421333958274,2.6891333958273603e-05
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00803153,0.008030523660922557,1.0063390774427833e-06
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,838.0,802.0,0.002387,0.002387,6.732211,1.0,1.0,838.0,12.0,92.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01606979,0.01602069280582348,4.909719417652003e-05
3.0,838.0,802.0,0.00358,0.00358,6.732211,1.0,1.0,838.0,12.0,92.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02410131,0.02396063584663691,0.00014067415336308994
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00803153,0.008021912798422553,9.617201577447401e-06
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,838.0,802.0,0.002387,0.002387,6.732211,1.0,1.0,838.0,12.0,92.0,Non compliant with the protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01606979,0.01601738876624015,5.2401233759848814e-05
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Non compliant with the protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00803153,0.00802548223654755,6.047763452450908e-06
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Non compliant with the protocol,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00803153,0.008026575461547546,4.954538452454221e-06
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Non compliant with the protocol,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00803153,0.008027014203214214,4.51579678578673e-06
3.0,838.0,802.0,0.00358,0.00358,6.732211,1.0,1.0,838.0,12.0,92.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02410131,0.02399248160758928,0.00010882839241072029
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00803153,0.008022271290089223,9.258709910777568e-06
1.0,838.0,802.0,0.001193,0.001193,6.732211,1.0,1.0,838.0,12.0,92.0,Consent withdrawn,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00803153,0.00802336451508922,8.165484910780882e-06
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Consent withdrawn,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Changed job/ran out if meds,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,838.0,802.0,0.002387,0.002387,6.732211,1.0,1.0,838.0,12.0,92.0,Changed job/ran out if meds,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01606979,0.01604627926415681,2.3510735843189356e-05
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Changed job/ran out if meds,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,838.0,802.0,0.0,0.0,6.732211,1.0,1.0,838.0,12.0,92.0,Changed job/ran out if meds,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,255.0,9.0,0.015686,0.015686,5.545177,0.488387,1.0,255.0,19.0,82.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04248068,0.04368184944184521,0.0012011694418452082
1.0,255.0,9.0,0.003922,0.003922,5.545177,0.488387,1.0,255.0,19.0,82.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01062153,0.0106856703913492,6.41403913492003e-05
15.0,255.0,9.0,0.058824,0.058824,5.545177,0.488387,1.0,255.0,19.0,82.0,Adverse Events (treatment-related),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15930663,0.15992736909706357,0.0006207390970635607
8.0,255.0,9.0,0.031373,0.031373,5.545177,0.488387,1.0,255.0,19.0,82.0,Adverse Events (treatment-related),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08496408,0.08600891396432532,0.001044833964325323
9.0,255.0,9.0,0.035294,0.035294,5.545177,0.488387,1.0,255.0,19.0,82.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09558289,0.09686612565702378,0.0012832356570237763
6.0,255.0,9.0,0.023529,0.023529,5.545177,0.488387,1.0,255.0,19.0,82.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06372103,0.06436974389847216,0.0006487138984721669
85.0,255.0,9.0,0.333333,0.333333,5.545177,0.488387,1.0,255.0,19.0,82.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.90272945,0.781475284782481,0.12125416521751908
44.0,255.0,9.0,0.172549,0.172549,5.545177,0.488387,1.0,255.0,19.0,82.0,Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.46729566,0.5005087491248414,0.033213089124841444
9.0,255.0,9.0,0.035294,0.035294,5.545177,0.488387,1.0,255.0,19.0,82.0,Adverse Events (unrelated to,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09558289,0.09686612565702378,0.0012832356570237763
1.0,255.0,9.0,0.003922,0.003922,5.545177,0.488387,1.0,255.0,19.0,82.0,Adverse Events (unrelated to,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01062153,0.0106890069438492,6.747694384919879e-05
24.0,255.0,9.0,0.094118,0.094118,5.545177,0.488387,1.0,255.0,19.0,82.0,Patient Refusal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.25488953,0.26596901948085294,0.011079489480852966
12.0,255.0,9.0,0.047059,0.047059,5.545177,0.488387,1.0,255.0,19.0,82.0,Patient Refusal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12744476,0.13156316707555576,0.0041184070755557745
0.0,255.0,9.0,0.0,0.0,5.545177,0.488387,1.0,255.0,19.0,82.0,Death (due to adverse events,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,255.0,9.0,0.003922,0.003922,5.545177,0.488387,1.0,255.0,19.0,82.0,Death (due to adverse events,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01062153,0.0106890069438492,6.747694384919879e-05
19.0,255.0,9.0,0.07451,0.07451,5.545177,0.488387,1.0,255.0,19.0,82.0,Death (non-related to the study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.20178732,0.20983206412399788,0.008044744123997888
8.0,255.0,9.0,0.031373,0.031373,5.545177,0.488387,1.0,255.0,19.0,82.0,Death (non-related to the study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08496408,0.08600891396432532,0.001044833964325323
1.0,10061.0,736.0,9.9e-05,9.9e-05,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital status: missing),Core Phase,FG000,cardiovascular disease,INDUSTRY,0.00050524,0.0005209897250378777,1.5749725037877732e-05
2.0,10061.0,736.0,0.000199,0.000199,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital status: missing),Core Phase,FG001,cardiovascular disease,INDUSTRY,0.00101559,0.0010326738022619069,1.708380226190685e-05
2.0,10061.0,736.0,0.000199,0.000199,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital status: missing),Core Phase,FG002,cardiovascular disease,INDUSTRY,0.00101559,0.0010295315471428599,1.3941547142859835e-05
1.0,10061.0,736.0,9.9e-05,9.9e-05,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital status: missing),Core Phase,FG003,cardiovascular disease,INDUSTRY,0.00050524,0.0005196559321212108,1.4415932121210773e-05
0.0,10061.0,736.0,0.0,0.0,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: unkn),Core Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,10061.0,736.0,0.0,0.0,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: unkn),Core Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: unkn),Core Phase,FG002,cardiovascular disease,INDUSTRY,0.00152084,0.0015366425514980184,1.580255149801835e-05
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: unkn),Core Phase,FG003,cardiovascular disease,INDUSTRY,0.00152084,0.0015300352949503995,9.195294950399427e-06
1.0,10061.0,736.0,9.9e-05,9.9e-05,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: dead),Core Phase,FG000,cardiovascular disease,INDUSTRY,0.00050524,0.0005210984650378783,1.585846503787832e-05
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: dead),Core Phase,FG001,cardiovascular disease,INDUSTRY,0.00152084,0.0015201032901884944,7.367098115056755e-07
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: dead),Core Phase,FG002,cardiovascular disease,INDUSTRY,0.00203119,0.0020380635461309474,6.873546130947445e-06
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: dead),Core Phase,FG003,cardiovascular disease,INDUSTRY,0.00203119,0.0020302592172619,9.30782738100145e-07
23.0,10061.0,736.0,0.002286,0.002286,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: alive),Core Phase,FG000,cardiovascular disease,INDUSTRY,0.01166657,0.011503631931011902,0.00016293806898809785
24.0,10061.0,736.0,0.002385,0.002385,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: alive),Core Phase,FG001,cardiovascular disease,INDUSTRY,0.01217181,0.011922495991398814,0.0002493140086011862
13.0,10061.0,736.0,0.001292,0.001292,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: alive),Core Phase,FG002,cardiovascular disease,INDUSTRY,0.0065937,0.006315667605664683,0.0002780323943353171
20.0,10061.0,736.0,0.001988,0.001988,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Subject decision (vital stat: alive),Core Phase,FG003,cardiovascular disease,INDUSTRY,0.01014573,0.009599752838333324,0.0005459771616666761
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Core Phase,FG000,cardiovascular disease,INDUSTRY,0.00152084,0.0015434665721825425,2.2626572182542432e-05
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Core Phase,FG001,cardiovascular disease,INDUSTRY,0.00152084,0.001532041295128971,1.120129512897092e-05
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Core Phase,FG002,cardiovascular disease,INDUSTRY,0.00203119,0.0020496233193452343,1.8433319345234275e-05
5.0,10061.0,736.0,0.000497,0.000497,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Core Phase,FG003,cardiovascular disease,INDUSTRY,0.00253643,0.0025124562449206317,2.3973755079368438e-05
1073.0,10061.0,736.0,0.106649,0.106649,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Study terminated by sponsor,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.54428151,0.5027889568725887,0.04149255312741129
1124.0,10061.0,736.0,0.111719,0.111719,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Study terminated by sponsor,Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.57015617,0.5255000938659226,0.044656076134077405
1067.0,10061.0,736.0,0.106053,0.106053,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Study terminated by sponsor,Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.54123983,0.5010604058063387,0.04017942419366127
1660.0,10061.0,736.0,0.164994,0.164994,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Study terminated by sponsor,Extension Phase,FG003,cardiovascular disease,INDUSTRY,0.84204431,0.7584291716261603,0.08361513837383971
20.0,10061.0,736.0,0.001988,0.001988,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Withdrawal by Subject,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.01014573,0.009615879923660706,0.0005298500763392944
13.0,10061.0,736.0,0.001292,0.001292,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Withdrawal by Subject,Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.0065937,0.00631164808075397,0.00028205191924603017
19.0,10061.0,736.0,0.001888,0.001888,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Withdrawal by Subject,Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.00963538,0.00944017381369047,0.00019520618630953016
37.0,10061.0,736.0,0.003678,0.003678,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Withdrawal by Subject,Extension Phase,FG003,cardiovascular disease,INDUSTRY,0.01877062,0.0177173166770635,0.001053303322936499
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00203119,0.002029943521726185,1.2464782738149695e-06
3.0,10061.0,736.0,0.000298,0.000298,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.00152084,0.0015361485947123041,1.5308594712304044e-05
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.00203119,0.002037848174999994,6.6581749999941944e-06
7.0,10061.0,736.0,0.000696,0.000696,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Lost to Follow-up,Extension Phase,FG003,cardiovascular disease,INDUSTRY,0.00355203,0.0035367370564186517,1.5292943581348122e-05
2.0,10061.0,736.0,0.000199,0.000199,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Technical Problems,Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00101559,0.0010385511531547638,2.2961153154763773e-05
4.0,10061.0,736.0,0.000398,0.000398,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Technical Problems,Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.00203119,0.0020175089199999945,1.3681080000005515e-05
2.0,10061.0,736.0,0.000199,0.000199,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Technical Problems,Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.00101559,0.001031309341309526,1.5719341309525974e-05
2.0,10061.0,736.0,0.000199,0.000199,9.216521,0.553732,1.0,10066.0,40.0,1131.0,Technical Problems,Extension Phase,FG003,cardiovascular disease,INDUSTRY,0.00101559,0.001031849223154764,1.6259223154764003e-05
6.0,207.0,188.0,0.028986,0.028986,5.337538,0.325753,1.0,207.0,10.0,37.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05039847,0.052886743052043654,0.0024882730520436533
1.0,207.0,188.0,0.004831,0.004831,5.337538,0.325753,1.0,207.0,10.0,37.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00839975,0.008566851057966276,0.00016710105796627697
0.0,207.0,188.0,0.0,0.0,5.337538,0.325753,1.0,207.0,10.0,37.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,207.0,188.0,0.004831,0.004831,5.337538,0.325753,1.0,207.0,10.0,37.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00839975,0.008567880939216278,0.00016813093921627838
3.0,207.0,188.0,0.014493,0.014493,5.337538,0.325753,1.0,207.0,10.0,37.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02519924,0.025331846237648788,0.00013260623764878646
3.0,207.0,188.0,0.014493,0.014493,5.337538,0.325753,1.0,207.0,10.0,37.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02519924,0.025336910879523788,0.0001376708795237866
0.0,207.0,188.0,0.0,0.0,5.337538,0.325753,1.0,207.0,10.0,37.0,Surgery on the Target Limb,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,207.0,188.0,0.009662,0.009662,5.337538,0.325753,1.0,207.0,10.0,37.0,Surgery on the Target Limb,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01679949,0.017459772296577365,0.000660282296577365
1.0,207.0,188.0,0.004831,0.004831,5.337538,0.325753,1.0,207.0,10.0,37.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00839975,0.008562174644216276,0.0001624246442162771
0.0,207.0,188.0,0.0,0.0,5.337538,0.325753,1.0,207.0,10.0,37.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,207.0,188.0,0.009662,0.009662,5.337538,0.325753,1.0,207.0,10.0,37.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01679949,0.017447414653124993,0.0006479246531249927
0.0,207.0,188.0,0.0,0.0,5.337538,0.325753,1.0,207.0,10.0,37.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,309.0,303.0,0.006472,0.006472,5.736572,0.365674,1.0,309.0,1.0,30.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01357642,0.01365983448196609,8.341448196608897e-05
1.0,309.0,303.0,0.003236,0.003236,5.736572,0.365674,1.0,309.0,1.0,30.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00678821,0.006792543738710305,4.333738710304326e-06
1.0,309.0,303.0,0.003236,0.003236,5.736572,0.365674,1.0,309.0,1.0,30.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00678821,0.0067914178544543555,3.207854454355223e-06
0.0,309.0,303.0,0.0,0.0,5.736572,0.365674,1.0,309.0,1.0,30.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,309.0,303.0,0.003236,0.003236,5.736572,0.365674,1.0,309.0,1.0,30.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00678821,0.0067929706294543556,4.760629454355313e-06
0.0,309.0,303.0,0.0,0.0,5.736572,0.365674,1.0,309.0,1.0,30.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,309.0,303.0,0.0,0.0,5.736572,0.365674,1.0,309.0,1.0,30.0,Other than stated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,309.0,303.0,0.003236,0.003236,5.736572,0.365674,1.0,309.0,1.0,30.0,Other than stated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00678821,0.006792737663710305,4.527663710304428e-06
1.0,345.0,326.0,0.002899,0.002899,5.846439,0.258509,1.0,333.0,1.0,56.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.00438143,0.0044029537147321504,2.1523714732150055e-05
2.0,345.0,326.0,0.005797,0.005797,5.846439,0.258509,1.0,333.0,1.0,56.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.00876134,0.00885256693649801,9.122693649801089e-05
1.0,345.0,326.0,0.002899,0.002899,5.846439,0.258509,1.0,333.0,1.0,56.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.00438143,0.004401504427738107,2.0074427738106353e-05
3.0,345.0,326.0,0.008696,0.008696,5.846439,0.258509,1.0,333.0,1.0,56.0,Missed Visit,Overall Study,FG000,cardiovascular disease,OTHER,0.01314277,0.013329842996319447,0.00018707299631944702
5.0,345.0,326.0,0.014493,0.014493,5.846439,0.258509,1.0,333.0,1.0,56.0,Missed Visit,Overall Study,FG001,cardiovascular disease,OTHER,0.02190412,0.021624120123611115,0.0002799998763888846
1.0,345.0,326.0,0.002899,0.002899,5.846439,0.258509,1.0,333.0,1.0,56.0,Missed Visit,Overall Study,FG002,cardiovascular disease,OTHER,0.00438143,0.004402745065238107,2.1315065238106633e-05
1.0,345.0,326.0,0.002899,0.002899,5.846439,0.258509,1.0,333.0,1.0,56.0,Dropped,Overall Study,FG000,cardiovascular disease,OTHER,0.00438143,0.0044044041688988175,2.2974168898817066e-05
3.0,345.0,326.0,0.008696,0.008696,5.846439,0.258509,1.0,333.0,1.0,56.0,Dropped,Overall Study,FG001,cardiovascular disease,OTHER,0.01314277,0.013324259096319449,0.0001814890963194489
2.0,345.0,326.0,0.005797,0.005797,5.846439,0.258509,1.0,333.0,1.0,56.0,Dropped,Overall Study,FG002,cardiovascular disease,OTHER,0.00876134,0.008866022832708325,0.00010468283270832594
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00209742,0.002108089158184531,1.0669158184531055e-05
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00209742,0.0021044398000297686,7.019800029768597e-06
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00104871,0.001066688032380956,1.797803238095608e-05
4.0,1468.0,1401.0,0.002725,0.002725,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00419638,0.004230399826954365,3.4019826954364944e-05
6.0,1468.0,1401.0,0.004087,0.004087,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0062938,0.00629512517422979,1.3251742297902547e-06
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00209742,0.002108999461934531,1.1579461934530834e-05
3.0,1468.0,1401.0,0.002044,0.002044,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00314767,0.003145764927023813,1.9050729761871214e-06
8.0,1468.0,1401.0,0.00545,0.00545,7.292337,0.211174,1.0,1474.0,1.0,1.0,Adverse Event,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00839275,0.00842326427919643,3.0514279196430447e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00104871,0.001066566483392861,1.7856483392861017e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00104871,0.0010657780167261945,1.7068016726194506e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lost to Follow-up,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00104871,0.0010684294947023846,1.97194947023846e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00104871,0.0010646543126190515,1.5944312619051463e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1468.0,1401.0,0.003406,0.003406,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00524509,0.005383423216944446,0.00013833321694444595
3.0,1468.0,1401.0,0.002044,0.002044,7.292337,0.211174,1.0,1474.0,1.0,1.0,Protocol Violation,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00314767,0.0031512398721428615,3.5698721428615438e-06
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00209742,0.0021048720965773896,7.452096577389555e-06
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00209742,0.0021095379249107225,1.211792491072252e-05
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00104871,0.0010661360223809561,1.7426022380956103e-05
4.0,1468.0,1401.0,0.002725,0.002725,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00419638,0.004235255135525792,3.8875135525791825e-05
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00209742,0.002104927626994056,7.50762699405598e-06
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00209742,0.002104927626994056,7.50762699405598e-06
2.0,1468.0,1401.0,0.001362,0.001362,7.292337,0.211174,1.0,1474.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00209742,0.002104927626994056,7.50762699405598e-06
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1468.0,1401.0,0.000681,0.000681,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00104871,0.0010670251009523848,1.8315100952384774e-05
3.0,1468.0,1401.0,0.002044,0.002044,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00314767,0.0031481183612500035,4.483612500035504e-07
3.0,1468.0,1401.0,0.002044,0.002044,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00314767,0.0031481183612500035,4.483612500035504e-07
0.0,1468.0,1401.0,0.0,0.0,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1468.0,1401.0,0.003406,0.003406,7.292337,0.211174,1.0,1474.0,1.0,1.0,Lack of Efficacy,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00524509,0.005416736465505953,0.00017164646550595335
2.0,51.0,131.0,0.039216,0.039216,3.951244,0.316604,1.0,225.0,1.0,60.0,Lack of Efficacy,Study 306A,FG000,cardiovascular disease,INDUSTRY,0.04905848,0.05095582649043633,0.0018973464904363316
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Lack of Efficacy,Study 306A,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024731041417827216,0.00020180141782721525
0.0,51.0,131.0,0.0,0.0,3.951244,0.316604,1.0,225.0,1.0,60.0,Protocol Violation,Study 306A,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Protocol Violation,Study 306A,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024731041417827216,0.00020180141782721525
0.0,51.0,131.0,0.0,0.0,3.951244,0.316604,1.0,225.0,1.0,60.0,Withdrawal by Subject,Study 306A,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Withdrawal by Subject,Study 306A,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.02472794226366056,0.00019870226366056065
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Stop due to diverse problems,Study 306A,FG000,cardiovascular disease,INDUSTRY,0.02452924,0.024783121706755798,0.0002538817067557972
0.0,51.0,131.0,0.0,0.0,3.951244,0.316604,1.0,225.0,1.0,60.0,Stop due to diverse problems,Study 306A,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,51.0,131.0,0.098039,0.098039,3.951244,0.316604,1.0,225.0,1.0,60.0,Lack of Efficacy,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.12264496,0.1300436385025397,0.007398678502539696
3.0,51.0,131.0,0.058824,0.058824,3.951244,0.316604,1.0,225.0,1.0,60.0,Lack of Efficacy,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.07358773,0.07845475656229524,0.004867026562295235
10.0,51.0,131.0,0.196078,0.196078,3.951244,0.316604,1.0,225.0,1.0,60.0,Adverse Event,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.24528992,0.39426174251133905,0.14897182251133906
5.0,51.0,131.0,0.098039,0.098039,3.951244,0.316604,1.0,225.0,1.0,60.0,Adverse Event,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.12264496,0.12948418683593257,0.006839226835932577
2.0,51.0,131.0,0.039216,0.039216,3.951244,0.316604,1.0,225.0,1.0,60.0,Protocol Violation,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.04905848,0.050352770488114845,0.0012942904881148437
3.0,51.0,131.0,0.058824,0.058824,3.951244,0.316604,1.0,225.0,1.0,60.0,Protocol Violation,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.07358773,0.07854464686229524,0.004956916862295241
4.0,51.0,131.0,0.078431,0.078431,3.951244,0.316604,1.0,225.0,1.0,60.0,Withdrawal by Subject,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.09811572,0.11401345844249004,0.01589773844249004
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Withdrawal by Subject,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024638488838035547,0.0001092488380355465
2.0,51.0,131.0,0.039216,0.039216,3.951244,0.316604,1.0,225.0,1.0,60.0,Physician Decision,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.04905848,0.050352770488114845,0.0012942904881148437
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Physician Decision,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024655507160952207,0.00012626716095220578
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Supine Hypertension,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.02452924,0.024703814593630784,0.00017457459363078368
2.0,51.0,131.0,0.039216,0.039216,3.951244,0.316604,1.0,225.0,1.0,60.0,Supine Hypertension,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.04905848,0.05058673370261887,0.0015282537026188661
0.0,51.0,131.0,0.0,0.0,3.951244,0.316604,1.0,225.0,1.0,60.0,Lost to Follow-up,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,Lost to Follow-up,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024656882140118873,0.0001276421401188721
2.0,51.0,131.0,0.039216,0.039216,3.951244,0.316604,1.0,225.0,1.0,60.0,withdrew prior to dosing,Study 306B,FG000,cardiovascular disease,INDUSTRY,0.04905848,0.050352770488114845,0.0012942904881148437
1.0,51.0,131.0,0.019608,0.019608,3.951244,0.316604,1.0,225.0,1.0,60.0,withdrew prior to dosing,Study 306B,FG001,cardiovascular disease,INDUSTRY,0.02452924,0.024653948398452207,0.0001247083984522064
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Adverse Event,Double Blind Placebo Controlled (DBPC),FG000,cardiovascular disease,INDUSTRY,0.01359576,0.013609547195833363,1.3787195833362895e-05
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Adverse Event,Double Blind Placebo Controlled (DBPC),FG001,cardiovascular disease,INDUSTRY,0.01359576,0.013601754625000028,5.994625000027912e-06
2.0,323.0,291.0,0.006192,0.006192,5.780744,0.759659,1.0,324.0,21.0,120.0,Withdrawal by Subject,Double Blind Placebo Controlled (DBPC),FG000,cardiovascular disease,INDUSTRY,0.02719153,0.027485731881666572,0.00029420188166657396
3.0,323.0,291.0,0.009288,0.009288,5.780744,0.759659,1.0,324.0,21.0,120.0,Withdrawal by Subject,Double Blind Placebo Controlled (DBPC),FG001,cardiovascular disease,INDUSTRY,0.04078729,0.04086498029788696,7.769029788696341e-05
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Protocol Violation,Double Blind Placebo Controlled (DBPC),FG000,cardiovascular disease,INDUSTRY,0.01359576,0.01360746668541669,1.1706685416690635e-05
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Protocol Violation,Double Blind Placebo Controlled (DBPC),FG001,cardiovascular disease,INDUSTRY,0.01359576,0.013598925708333359,3.1657083333583996e-06
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Death,Double Blind Placebo Controlled (DBPC),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,323.0,291.0,0.01548,0.01548,5.780744,0.759659,1.0,324.0,21.0,120.0,Death,Double Blind Placebo Controlled (DBPC),FG001,cardiovascular disease,INDUSTRY,0.06797881,0.06956677618414499,0.0015879661841449871
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Clinical worsening event,Double Blind Placebo Controlled (DBPC),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,323.0,291.0,0.006192,0.006192,5.780744,0.759659,1.0,324.0,21.0,120.0,Clinical worsening event,Double Blind Placebo Controlled (DBPC),FG001,cardiovascular disease,INDUSTRY,0.02719153,0.027475731103382844,0.00028420110338284524
2.0,323.0,291.0,0.006192,0.006192,5.780744,0.759659,1.0,324.0,21.0,120.0,Adverse Event,Long Term Double Blind (LTDB),FG000,cardiovascular disease,INDUSTRY,0.02719153,0.02747939192520825,0.00028786192520825066
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Adverse Event,Long Term Double Blind (LTDB),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Withdrawal by Subject,Long Term Double Blind (LTDB),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,323.0,291.0,0.009288,0.009288,5.780744,0.759659,1.0,324.0,21.0,120.0,Withdrawal by Subject,Long Term Double Blind (LTDB),FG001,cardiovascular disease,INDUSTRY,0.04078729,0.04086498029788696,7.769029788696341e-05
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Protocol Violation,Long Term Double Blind (LTDB),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Protocol Violation,Long Term Double Blind (LTDB),FG001,cardiovascular disease,INDUSTRY,0.01359576,0.013571570246250022,2.4189753749978213e-05
2.0,323.0,291.0,0.006192,0.006192,5.780744,0.759659,1.0,324.0,21.0,120.0,Death,Long Term Double Blind (LTDB),FG000,cardiovascular disease,INDUSTRY,0.02719153,0.02751691414812492,0.00032538414812492006
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Death,Long Term Double Blind (LTDB),FG001,cardiovascular disease,INDUSTRY,0.01359576,0.013565064506666691,3.0695493333308954e-05
0.0,323.0,291.0,0.0,0.0,5.780744,0.759659,1.0,324.0,21.0,120.0,Sponsor decision,Long Term Double Blind (LTDB),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,323.0,291.0,0.003096,0.003096,5.780744,0.759659,1.0,324.0,21.0,120.0,Sponsor decision,Long Term Double Blind (LTDB),FG001,cardiovascular disease,INDUSTRY,0.01359576,0.013573783875416691,2.1976124583308887e-05
16.0,221.0,149.0,0.072398,0.072398,5.402677,0.404683,1.0,221.0,1.0,54.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15828881,0.1622548103061209,0.003966000306120904
18.0,221.0,149.0,0.081448,0.081448,5.402677,0.404683,1.0,221.0,1.0,54.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.17807546,0.19218529156760883,0.014109831567608838
6.0,221.0,149.0,0.027149,0.027149,5.402677,0.404683,1.0,221.0,1.0,54.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05935776,0.05877321894740081,0.0005845410525991898
5.0,221.0,149.0,0.022624,0.022624,5.402677,0.404683,1.0,221.0,1.0,54.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04946443,0.05033014014140879,0.0008657101414087931
1.0,221.0,149.0,0.004525,0.004525,5.402677,0.404683,1.0,221.0,1.0,54.0,Lab Abnormality,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00989332,0.009923811390456401,3.0491390456400397e-05
1.0,221.0,149.0,0.004525,0.004525,5.402677,0.404683,1.0,221.0,1.0,54.0,Lab Abnormality,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00989332,0.009929109433015927,3.578943301592655e-05
0.0,221.0,149.0,0.0,0.0,5.402677,0.404683,1.0,221.0,1.0,54.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,221.0,149.0,0.004525,0.004525,5.402677,0.404683,1.0,221.0,1.0,54.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00989332,0.00992407984688497,3.075984688497013e-05
5.0,221.0,149.0,0.022624,0.022624,5.402677,0.404683,1.0,221.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04946443,0.050207157345515924,0.000742727345515927
5.0,221.0,149.0,0.022624,0.022624,5.402677,0.404683,1.0,221.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04946443,0.050365378875694505,0.0009009488756945086
8.0,221.0,149.0,0.036199,0.036199,5.402677,0.404683,1.0,221.0,1.0,54.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07914441,0.07963583209006947,0.000491422090069471
6.0,221.0,149.0,0.027149,0.027149,5.402677,0.404683,1.0,221.0,1.0,54.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05935776,0.058801709977579365,0.0005560500224206372
1.0,488.0,470.0,0.002049,0.002049,6.192362,0.202245,1.0,488.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00256612,0.002561811869057544,4.308130942455839e-06
0.0,488.0,470.0,0.0,0.0,6.192362,0.202245,1.0,488.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,488.0,470.0,0.002049,0.002049,6.192362,0.202245,1.0,488.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00256612,0.0025608632598908766,5.256740109123217e-06
0.0,488.0,470.0,0.0,0.0,6.192362,0.202245,1.0,488.0,1.0,17.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,488.0,470.0,0.002049,0.002049,6.192362,0.202245,1.0,488.0,1.0,17.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00256612,0.002566056467390877,6.353260912283706e-08
0.0,488.0,470.0,0.0,0.0,6.192362,0.202245,1.0,488.0,1.0,17.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,488.0,470.0,0.006148,0.006148,6.192362,0.202245,1.0,488.0,1.0,17.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00769961,0.007939314464200951,0.00023970446420095142
7.0,488.0,470.0,0.014344,0.014344,6.192362,0.202245,1.0,488.0,1.0,17.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01796408,0.018461866283012263,0.000497786283012263
4.0,488.0,470.0,0.008197,0.008197,6.192362,0.202245,1.0,488.0,1.0,17.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01026573,0.01033660020651785,7.087020651784862e-05
0.0,488.0,470.0,0.0,0.0,6.192362,0.202245,1.0,488.0,1.0,17.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,488.0,470.0,0.0,0.0,6.192362,0.202245,1.0,488.0,1.0,17.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,488.0,470.0,0.002049,0.002049,6.192362,0.202245,1.0,488.0,1.0,17.0,Other reasons,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00256612,0.0025645876115575426,1.5323884424572887e-06
2.0,682.0,0.0,0.002933,0.002933,6.526495,0.586334,1.0,682.0,20.0,112.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01122373,0.01104549086794643,0.00017823913205356964
1.0,682.0,0.0,0.001466,0.001466,6.526495,0.586334,1.0,682.0,20.0,112.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00560995,0.005949623673263888,0.00033967367326388775
504.0,682.0,0.0,0.739003,0.739003,6.526495,0.586334,1.0,682.0,20.0,112.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,2.82794689,2.0575831503765496,0.7703637396234506
57.0,682.0,0.0,0.083578,0.083578,6.526495,0.586334,1.0,682.0,20.0,112.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.3198284,0.3268063335790575,0.00697793357905746
52.0,682.0,0.0,0.076246,0.076246,6.526495,0.586334,1.0,682.0,20.0,112.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.29177099,0.29590942839864093,0.00413843839864092
31.0,682.0,0.0,0.045455,0.045455,6.526495,0.586334,1.0,682.0,20.0,112.0,Miscellaneous,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1739429,0.1739997671314684,5.686713146837996e-05
21.0,682.0,0.0,0.030792,0.030792,6.526495,0.586334,1.0,682.0,20.0,112.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11783192,0.11901537250318443,0.0011834525031844262
8.0,682.0,0.0,0.01173,0.01173,6.526495,0.586334,1.0,682.0,20.0,112.0,Transition to Commercial Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04488726,0.04475508259334981,0.0001321774066501899
6.0,682.0,0.0,0.008798,0.008798,6.526495,0.586334,1.0,682.0,20.0,112.0,Participants Did Not Receive Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03366736,0.03402770258986111,0.00036034258986111095
33.0,6522.0,5063.0,0.00506,0.00506,8.78309,0.822341,1.0,6522.0,22.0,439.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03654682,0.035297485575357154,0.0012493344246428464
26.0,6522.0,5063.0,0.003987,0.003987,8.78309,0.822341,1.0,6522.0,22.0,439.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02879688,0.028085423741309484,0.0007114562586905161
9.0,6522.0,5063.0,0.00138,0.00138,8.78309,0.822341,1.0,6522.0,22.0,439.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00996732,0.010017701837916677,5.03818379166774e-05
10.0,6522.0,5063.0,0.001533,0.001533,8.78309,0.822341,1.0,6522.0,22.0,439.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01107239,0.011369037426894837,0.00029664742689483777
31.0,6522.0,5063.0,0.004753,0.004753,8.78309,0.822341,1.0,6522.0,22.0,439.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03432946,0.03185661630151784,0.0024728436984821564
39.0,6522.0,5063.0,0.00598,0.00598,8.78309,0.822341,1.0,6522.0,22.0,439.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0431917,0.04077575777502976,0.002415942224970241
452.0,6522.0,5063.0,0.069304,0.069304,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Patient refusal to continue, not due to adverse event",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.50056148,0.48511317202289694,0.01544830797710306
418.0,6522.0,5063.0,0.064091,0.064091,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Patient refusal to continue, not due to adverse event",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.46290959,0.46332730508153797,0.00041771508153798376
11.0,6522.0,5063.0,0.001687,0.001687,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Adverse event, serious fatal event",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01218468,0.011950178452609126,0.00023450154739087375
4.0,6522.0,5063.0,0.000613,0.000613,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Adverse event, serious fatal event",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00442751,0.004239545468978176,0.00018796453102182427
107.0,6522.0,5063.0,0.016406,0.016406,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Adverse event, non-fatal event",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11849549,0.11400253034724207,0.004492959652757922
118.0,6522.0,5063.0,0.018093,0.018093,8.78309,0.822341,1.0,6522.0,22.0,439.0,"Adverse event, non-fatal event",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13068018,0.12344679157126999,0.007233388428730017
106.0,6522.0,5063.0,0.016253,0.016253,8.78309,0.822341,1.0,6522.0,22.0,439.0,Other reason than listed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11739042,0.11303266100045631,0.004357758999543687
95.0,6522.0,5063.0,0.014566,0.014566,8.78309,0.822341,1.0,6522.0,22.0,439.0,Other reason than listed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10520574,0.10123592549522814,0.003969814504771865
36.0,258.0,160.0,0.139535,0.139535,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Meet Protocol Eligibility,Referral Screening Period,FG000,cardiovascular disease,INDUSTRY,0.20486637,0.19587809688988095,0.008988273110119044
24.0,258.0,160.0,0.093023,0.093023,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Meet Protocol Eligibility,Referral Screening Period,FG001,cardiovascular disease,INDUSTRY,0.13657709,0.13016754904943434,0.006409540950565673
3.0,258.0,160.0,0.011628,0.011628,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Wish To Continue,Referral Screening Period,FG000,cardiovascular disease,INDUSTRY,0.01707232,0.01700784838732142,6.447161267857798e-05
1.0,258.0,160.0,0.003876,0.003876,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Wish To Continue,Referral Screening Period,FG001,cardiovascular disease,INDUSTRY,0.00569077,0.005700993528313497,1.0223528313496426e-05
0.0,258.0,160.0,0.0,0.0,5.556828,0.264217,1.0,258.0,0.0,0.0,Adverse Event,Referral Screening Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,258.0,160.0,0.003876,0.003876,5.556828,0.264217,1.0,258.0,0.0,0.0,Adverse Event,Referral Screening Period,FG001,cardiovascular disease,INDUSTRY,0.00569077,0.005702157903015878,1.1387903015877207e-05
8.0,258.0,160.0,0.031008,0.031008,5.556828,0.264217,1.0,258.0,0.0,0.0,Withdrawal by Subject,Study Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.04552619,0.046380458138313534,0.0008542681383135325
12.0,258.0,160.0,0.046512,0.046512,5.556828,0.264217,1.0,258.0,0.0,0.0,Withdrawal by Subject,Study Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.06828928,0.06803798460312502,0.00025129539687497593
7.0,258.0,160.0,0.027132,0.027132,5.556828,0.264217,1.0,258.0,0.0,0.0,Adverse Event,Study Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03983541,0.040430619865545595,0.0005952098655455929
3.0,258.0,160.0,0.011628,0.011628,5.556828,0.264217,1.0,258.0,0.0,0.0,Adverse Event,Study Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01707232,0.01701733298110118,5.4987018898819406e-05
2.0,258.0,160.0,0.007752,0.007752,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Meet Protocol Eligibility,Study Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01138155,0.0115202546726957,0.0001387046726956994
0.0,258.0,160.0,0.0,0.0,5.556828,0.264217,1.0,258.0,0.0,0.0,Did Not Meet Protocol Eligibility,Study Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,258.0,160.0,0.0,0.0,5.556828,0.264217,1.0,258.0,0.0,0.0,Noncompliance with Protocol,Study Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,258.0,160.0,0.003876,0.003876,5.556828,0.264217,1.0,258.0,0.0,0.0,Noncompliance with Protocol,Study Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00569077,0.005703602323730166,1.2832323730165886e-05
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Ineligible,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,704.0,676.0,0.004261,0.004261,6.558198,0.477837,1.0,704.0,15.0,98.0,Ineligible,Overall Study,FG001,cardiovascular disease,OTHER,0.01335289,0.013338927782261952,1.3962217738047386e-05
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Ineligible,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Ineligible,Overall Study,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
4.0,704.0,676.0,0.005682,0.005682,6.558198,0.477837,1.0,704.0,15.0,98.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01780595,0.017931774718809485,0.00012582471880948423
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00444992,0.004452767237083367,2.8472370833670935e-06
3.0,704.0,676.0,0.004261,0.004261,6.558198,0.477837,1.0,704.0,15.0,98.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.01335289,0.01337265361163695,1.9763611636950187e-05
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,OTHER,0.00444992,0.00445330294361115,3.3829436111507127e-06
4.0,704.0,676.0,0.005682,0.005682,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.01780595,0.017967130444136864,0.00016118044413686305
3.0,704.0,676.0,0.004261,0.004261,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.01335289,0.013350813324523855,2.07667547614393e-06
2.0,704.0,676.0,0.002841,0.002841,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.00890297,0.008912753371746036,9.783371746036051e-06
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,OTHER,0.00444992,0.0044505173219444825,5.973219444829758e-07
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawn from Treatment,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawn from Treatment,Overall Study,FG001,cardiovascular disease,OTHER,0.00444992,0.0044494621904167,4.578095832994192e-07
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawn from Treatment,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Withdrawn from Treatment,Overall Study,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Multiple different reasons,Overall Study,FG000,cardiovascular disease,OTHER,0.00444992,0.004453538412916701,3.6184129167012025e-06
0.0,704.0,676.0,0.0,0.0,6.558198,0.477837,1.0,704.0,15.0,98.0,Multiple different reasons,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,704.0,676.0,0.004261,0.004261,6.558198,0.477837,1.0,704.0,15.0,98.0,Multiple different reasons,Overall Study,FG002,cardiovascular disease,OTHER,0.01335289,0.013376775026636954,2.3885026636954326e-05
1.0,704.0,676.0,0.00142,0.00142,6.558198,0.477837,1.0,704.0,15.0,98.0,Multiple different reasons,Overall Study,FG003,cardiovascular disease,OTHER,0.00444992,0.00444981070111115,1.0929888884930739e-07
1.0,514.0,478.0,0.001946,0.001946,6.244167,0.895918,1.0,514.0,1.0,61.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01088643,0.010985127475843211,9.869747584321034e-05
12.0,514.0,478.0,0.023346,0.023346,6.244167,0.895918,1.0,514.0,1.0,61.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.13060361,0.13260424608779758,0.002000636087797575
14.0,514.0,478.0,0.027237,0.027237,6.244167,0.895918,1.0,514.0,1.0,61.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.15237088,0.15378061692460326,0.0014097369246032776
1.0,514.0,478.0,0.001946,0.001946,6.244167,0.895918,1.0,514.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.01088643,0.01097284770697416,8.641770697415986e-05
5.0,514.0,478.0,0.009728,0.009728,6.244167,0.895918,1.0,514.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.05442097,0.05422789946077382,0.00019307053922618111
2.0,514.0,478.0,0.003891,0.003891,6.244167,0.895918,1.0,514.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.02176727,0.022400398417645767,0.0006331284176457688
1.0,514.0,478.0,0.001946,0.001946,6.244167,0.895918,1.0,514.0,1.0,61.0,Not due to the above reasons,Overall Study,FG000,cardiovascular disease,OTHER,0.01088643,0.010973351006974162,8.692100697416105e-05
0.0,514.0,478.0,0.0,0.0,6.244167,0.895918,1.0,514.0,1.0,61.0,Not due to the above reasons,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,514.0,478.0,0.0,0.0,6.244167,0.895918,1.0,514.0,1.0,61.0,Not due to the above reasons,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
7.0,7554.0,4970.0,0.000927,0.000927,8.929965,0.230287,1.0,7554.0,30.0,30.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00190634,0.0018488136828769858,5.752631712301428e-05
8.0,7554.0,4970.0,0.001059,0.001059,8.929965,0.230287,1.0,7554.0,30.0,30.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00217779,0.002185698508325211,7.908508325210964e-06
9.0,7554.0,4970.0,0.001191,0.001191,8.929965,0.230287,1.0,7554.0,30.0,30.0,Significant thrombocytopenia,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00244924,0.0024008524825396825,4.8387517460317647e-05
8.0,7554.0,4970.0,0.001059,0.001059,8.929965,0.230287,1.0,7554.0,30.0,30.0,Significant thrombocytopenia,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00217779,0.002185698508325211,7.908508325210964e-06
8.0,7554.0,4970.0,0.001059,0.001059,8.929965,0.230287,1.0,7554.0,30.0,30.0,Severe allergic reaction,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00217779,0.002185572034634735,7.782034634734765e-06
1.0,7554.0,4970.0,0.000132,0.000132,8.929965,0.230287,1.0,7554.0,30.0,30.0,Severe allergic reaction,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00027145,0.0002849778975595256,1.3527897559525613e-05
74.0,7554.0,4970.0,0.009796,0.009796,8.929965,0.230287,1.0,7554.0,30.0,30.0,Serious haemorrhagic Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02014506,0.02056546518357142,0.00042040518357142065
30.0,7554.0,4970.0,0.003971,0.003971,8.929965,0.230287,1.0,7554.0,30.0,30.0,Serious haemorrhagic Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00816619,0.008062970777063494,0.00010321922293650594
86.0,7554.0,4970.0,0.011385,0.011385,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other Serious Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02341277,0.022888314587390882,0.0005244554126091171
97.0,7554.0,4970.0,0.012841,0.012841,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other Serious Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02640697,0.026696681380654716,0.0002897113806547176
20.0,7554.0,4970.0,0.002648,0.002648,8.929965,0.230287,1.0,7554.0,30.0,30.0,Qualifying condition not present,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0054455,0.005189383043234128,0.00025611695676587207
23.0,7554.0,4970.0,0.003045,0.003045,8.929965,0.230287,1.0,7554.0,30.0,30.0,Qualifying condition not present,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00626191,0.005968101038105157,0.00029380896189484286
4.0,7554.0,4970.0,0.00053,0.00053,8.929965,0.230287,1.0,7554.0,30.0,30.0,Contraindication to oral anticoagulant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00108992,0.0010990954520734137,9.175452073413581e-06
8.0,7554.0,4970.0,0.001059,0.001059,8.929965,0.230287,1.0,7554.0,30.0,30.0,Contraindication to oral anticoagulant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00217779,0.002185698508325211,7.908508325210964e-06
504.0,7554.0,4970.0,0.06672,0.06672,8.929965,0.230287,1.0,7554.0,30.0,30.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13720685,0.13229575658124001,0.004911093418759976
466.0,7554.0,4970.0,0.061689,0.061689,8.929965,0.230287,1.0,7554.0,30.0,30.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12686081,0.1228161889474504,0.004044621052549588
4.0,7554.0,4970.0,0.00053,0.00053,8.929965,0.230287,1.0,7554.0,30.0,30.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00108992,0.0010968083850892867,6.8883850892866635e-06
7.0,7554.0,4970.0,0.000927,0.000927,8.929965,0.230287,1.0,7554.0,30.0,30.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00190634,0.001848408761210319,5.793123878968117e-05
99.0,7554.0,4970.0,0.013106,0.013106,8.929965,0.230287,1.0,7554.0,30.0,30.0,Minor bleeding,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02695193,0.027212984063749973,0.0002610540637499742
37.0,7554.0,4970.0,0.004898,0.004898,8.929965,0.230287,1.0,7554.0,30.0,30.0,Minor bleeding,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01007253,0.009934312579216278,0.0001382174207837216
41.0,7554.0,4970.0,0.005428,0.005428,8.929965,0.230287,1.0,7554.0,30.0,30.0,Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01116245,0.010940882557371029,0.0002215674426289723
46.0,7554.0,4970.0,0.006089,0.006089,8.929965,0.230287,1.0,7554.0,30.0,30.0,Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01252177,0.01266611893992064,0.00014434893992064032
112.0,7554.0,4970.0,0.014827,0.014827,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other non serious Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0304911,0.03040467457060519,8.642542939480899e-05
108.0,7554.0,4970.0,0.014297,0.014297,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other non serious Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02940117,0.02934779426639881,5.337573360119155e-05
1.0,7554.0,4970.0,0.000132,0.000132,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other contraindicated medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00027145,0.0002848226017261923,1.3372601726192304e-05
0.0,7554.0,4970.0,0.0,0.0,8.929965,0.230287,1.0,7554.0,30.0,30.0,Other contraindicated medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,7554.0,4970.0,0.000397,0.000397,8.929965,0.230287,1.0,7554.0,30.0,30.0,Patient not wish to continue after May08,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00081641,0.0007928432769345235,2.3566723065476564e-05
4.0,7554.0,4970.0,0.00053,0.00053,8.929965,0.230287,1.0,7554.0,30.0,30.0,Patient not wish to continue after May08,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00108992,0.0011015326036507955,1.1612603650795403e-05
59.0,7554.0,4970.0,0.00781,0.00781,8.929965,0.230287,1.0,7554.0,30.0,30.0,Physician withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01606093,0.01604310001416666,1.78299858333425e-05
60.0,7554.0,4970.0,0.007943,0.007943,8.929965,0.230287,1.0,7554.0,30.0,30.0,Physician withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01633444,0.016270293897073396,6.41461029266023e-05
31.0,7554.0,4970.0,0.004104,0.004104,8.929965,0.230287,1.0,7554.0,30.0,30.0,Open label clopidogrel required,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0084397,0.008298669148809525,0.00014103085119047433
42.0,7554.0,4970.0,0.00556,0.00556,8.929965,0.230287,1.0,7554.0,30.0,30.0,Open label clopidogrel required,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0114339,0.01188987808974207,0.0004559780897420689
1.0,7554.0,4970.0,0.000132,0.000132,8.929965,0.230287,1.0,7554.0,30.0,30.0,Angiotensin II receptor blocker required,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00027145,0.00028484764339285903,1.3397643392859017e-05
0.0,7554.0,4970.0,0.0,0.0,8.929965,0.230287,1.0,7554.0,30.0,30.0,Angiotensin II receptor blocker required,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
159.0,7554.0,4970.0,0.021048,0.021048,8.929965,0.230287,1.0,7554.0,30.0,30.0,Oral anticoagulant required,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04328432,0.04240230150733131,0.0008820184926686889
157.0,7554.0,4970.0,0.020784,0.020784,8.929965,0.230287,1.0,7554.0,30.0,30.0,Oral anticoagulant required,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04274142,0.0419138491415476,0.0008275708584523991
5.0,7554.0,4970.0,0.000662,0.000662,8.929965,0.230287,1.0,7554.0,30.0,30.0,Study drug intolerance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00136137,0.0013514554155059516,9.914584494048403e-06
0.0,7554.0,4970.0,0.0,0.0,8.929965,0.230287,1.0,7554.0,30.0,30.0,Study drug intolerance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,7554.0,4970.0,0.001191,0.001191,8.929965,0.230287,1.0,7554.0,30.0,30.0,Surgery/ procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00244924,0.0024008524825396825,4.8387517460317647e-05
9.0,7554.0,4970.0,0.001191,0.001191,8.929965,0.230287,1.0,7554.0,30.0,30.0,Surgery/ procedure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00244924,0.0023969440552777774,5.2295944722222706e-05
12.0,7554.0,4970.0,0.001589,0.001589,8.929965,0.230287,1.0,7554.0,30.0,30.0,Event related to cardiac condition,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00326771,0.003081023318571427,0.000186686681428573
21.0,7554.0,4970.0,0.00278,0.00278,8.929965,0.230287,1.0,7554.0,30.0,30.0,Event related to cardiac condition,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00571695,0.005648094506944438,6.885549305556214e-05
82.0,7554.0,4970.0,0.010855,0.010855,8.929965,0.230287,1.0,7554.0,30.0,30.0,Thromboembolic/outcome event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02232285,0.02200895895761906,0.0003138910423809427
122.0,7554.0,4970.0,0.01615,0.01615,8.929965,0.230287,1.0,7554.0,30.0,30.0,Thromboembolic/outcome event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03321179,0.03326612401425594,5.433401425593981e-05
65.0,244.0,26.0,0.266393,0.266393,5.501258,0.266168,1.0,244.0,0.0,0.0,Relapse or Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.39006884,0.35984864230643665,0.030220197693563322
101.0,244.0,26.0,0.413934,0.413934,5.501258,0.266168,1.0,244.0,0.0,0.0,Relapse or Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.60610735,0.6308692024723216,0.024761852472321544
12.0,244.0,26.0,0.04918,0.04918,5.501258,0.266168,1.0,244.0,0.0,0.0,Serious Adverse Events,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07201235,0.07031673383470237,0.0016956161652976337
3.0,244.0,26.0,0.012295,0.012295,5.501258,0.266168,1.0,244.0,0.0,0.0,Serious Adverse Events,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01800309,0.019866395106577384,0.001863305106577385
6.0,244.0,26.0,0.02459,0.02459,5.501258,0.266168,1.0,244.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03600617,0.03652187037360119,0.0005157003736011925
0.0,244.0,26.0,0.0,0.0,5.501258,0.266168,1.0,244.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,244.0,26.0,0.016393,0.016393,5.501258,0.266168,1.0,244.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02400363,0.024527587203253983,0.0005239572032539816
2.0,244.0,26.0,0.008197,0.008197,5.501258,0.266168,1.0,244.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01200255,0.012214647916547628,0.00021209791654762736
1.0,244.0,26.0,0.004098,0.004098,5.501258,0.266168,1.0,244.0,0.0,0.0,Unable to Complete,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00600054,0.006087705674325412,8.716567432541164e-05
1.0,244.0,26.0,0.004098,0.004098,5.501258,0.266168,1.0,244.0,0.0,0.0,Unable to Complete,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00600054,0.006087303395634934,8.676339563493379e-05
18.0,244.0,26.0,0.07377,0.07377,5.501258,0.266168,1.0,244.0,0.0,0.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10801852,0.10807636979184529,5.7849791845282494e-05
5.0,244.0,26.0,0.020492,0.020492,5.501258,0.266168,1.0,244.0,0.0,0.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03000563,0.031129084793412712,0.0011234547934127134
125.0,2773.0,2513.0,0.045078,0.045078,7.928046,0.222179,1.0,2776.0,25.0,239.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07940244,0.07950678791799602,0.00010434791799601717
132.0,2773.0,2513.0,0.047602,0.047602,7.928046,0.222179,1.0,2776.0,25.0,239.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08384833,0.08503556778053482,0.001187237780534825
1.0,2773.0,2513.0,0.000361,0.000361,7.928046,0.222179,1.0,2776.0,25.0,239.0,Option selected by investigator,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00063588,0.0006430849926488099,7.204992648809851e-06
2.0,2773.0,2513.0,0.000721,0.000721,7.928046,0.222179,1.0,2776.0,25.0,239.0,Option selected by investigator,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00127,0.0013076059843452376,3.76059843452375e-05
281.0,8179.0,7314.0,0.034356,0.034356,9.009447,0.509828,1.0,8179.0,11.0,410.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1578063,0.15643756202544634,0.0013687379745536687
297.0,8179.0,7314.0,0.036313,0.036313,9.009447,0.509828,1.0,8179.0,11.0,410.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16679532,0.16453209880758926,0.002263221192410736
12.0,8179.0,7314.0,0.001467,0.001467,9.009447,0.509828,1.0,8179.0,11.0,410.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00673832,0.0067478385865873,9.51858658730046e-06
12.0,8179.0,7314.0,0.001467,0.001467,9.009447,0.509828,1.0,8179.0,11.0,410.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00673832,0.006749227334861111,1.0907334861111166e-05
6.0,8179.0,7314.0,0.000734,0.000734,9.009447,0.509828,1.0,8179.0,11.0,410.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00337146,0.0034858307947420635,0.00011437079474206331
13.0,8179.0,7314.0,0.001589,0.001589,9.009447,0.509828,1.0,8179.0,11.0,410.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0072987,0.007134270861051584,0.00016442913894841593
106.0,8179.0,7314.0,0.01296,0.01296,9.009447,0.509828,1.0,8179.0,11.0,410.0,Other than specified above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05952875,0.05548941379887268,0.004039336201127321
138.0,8179.0,7314.0,0.016872,0.016872,9.009447,0.509828,1.0,8179.0,11.0,410.0,Other than specified above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07749761,0.07340622368199398,0.004091386318006013
6.0,623.0,565.0,0.009631,0.009631,6.43615,0.320385,1.0,623.0,6.0,54.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01985954,0.020067036958244057,0.00020749695824405848
12.0,623.0,565.0,0.019262,0.019262,6.43615,0.320385,1.0,623.0,6.0,54.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03971908,0.039929219110813506,0.00021013911081350922
0.0,623.0,565.0,0.0,0.0,6.43615,0.320385,1.0,623.0,6.0,54.0,Lack of Efficacy-No Sub-Reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,623.0,565.0,0.00321,0.00321,6.43615,0.320385,1.0,623.0,6.0,54.0,Lack of Efficacy-No Sub-Reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00661916,0.006767063353571437,0.00014790335357143733
4.0,623.0,565.0,0.006421,0.006421,6.43615,0.320385,1.0,623.0,6.0,54.0,Lack of Efficacy-Sub-Reason Exacerbation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01324038,0.013553832626805557,0.00031345262680555763
9.0,623.0,565.0,0.014446,0.014446,6.43615,0.320385,1.0,623.0,6.0,54.0,Lack of Efficacy-Sub-Reason Exacerbation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02978828,0.029452482685466252,0.00033579731453374853
4.0,623.0,565.0,0.006421,0.006421,6.43615,0.320385,1.0,623.0,6.0,54.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01324038,0.013538692792936511,0.0002983127929365118
10.0,623.0,565.0,0.016051,0.016051,6.43615,0.320385,1.0,623.0,6.0,54.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03309786,0.033333268914950434,0.0002354089149504343
1.0,623.0,565.0,0.001605,0.001605,6.43615,0.320385,1.0,623.0,6.0,54.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00330958,0.003353638718869053,4.405871886905329e-05
3.0,623.0,565.0,0.004815,0.004815,6.43615,0.320385,1.0,623.0,6.0,54.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00992874,0.009959287792172606,3.054779217260585e-05
1.0,623.0,565.0,0.001605,0.001605,6.43615,0.320385,1.0,623.0,6.0,54.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00330958,0.003353474672023814,4.389467202381425e-05
0.0,623.0,565.0,0.0,0.0,6.43615,0.320385,1.0,623.0,6.0,54.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,623.0,565.0,0.004815,0.004815,6.43615,0.320385,1.0,623.0,6.0,54.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00992874,0.00996059843267856,3.1858432678560575e-05
3.0,623.0,565.0,0.004815,0.004815,6.43615,0.320385,1.0,623.0,6.0,54.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00992874,0.009957610185595229,2.8870185595228706e-05
0.0,213.0,200.0,0.0,0.0,5.365976,0.58328,1.0,214.0,22.0,62.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,213.0,200.0,0.00939,0.00939,5.365976,0.58328,1.0,214.0,22.0,62.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02938944,0.02955473939392856,0.0001652993939285606
5.0,213.0,200.0,0.023474,0.023474,5.365976,0.58328,1.0,214.0,22.0,62.0,Other reasons,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07347047,0.07517210943836314,0.0017016394383631422
0.0,213.0,200.0,0.0,0.0,5.365976,0.58328,1.0,214.0,22.0,62.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,213.0,200.0,0.00939,0.00939,5.365976,0.58328,1.0,214.0,22.0,62.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02938944,0.029589202012023794,0.00019976201202379432
1.0,213.0,200.0,0.004695,0.004695,5.365976,0.58328,1.0,214.0,22.0,62.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01469472,0.014708622106666625,1.390210666662485e-05
1.0,213.0,200.0,0.004695,0.004695,5.365976,0.58328,1.0,214.0,22.0,62.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01469472,0.01471197395919638,1.725395919638037e-05
0.0,213.0,200.0,0.0,0.0,5.365976,0.58328,1.0,214.0,22.0,62.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,213.0,200.0,0.004695,0.004695,5.365976,0.58328,1.0,214.0,22.0,62.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01469472,0.014716267047499959,2.154704749995906e-05
0.0,213.0,200.0,0.0,0.0,5.365976,0.58328,1.0,214.0,22.0,62.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,213.0,200.0,0.0,0.0,5.365976,0.58328,1.0,214.0,22.0,62.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,213.0,200.0,0.004695,0.004695,5.365976,0.58328,1.0,214.0,22.0,62.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01469472,0.014717341530059477,2.262153005947766e-05
9.0,847.0,782.0,0.010626,0.010626,6.742881,0.235372,1.0,847.0,7.0,7.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01686436,0.01683645444645833,2.7905553541669043e-05
10.0,847.0,782.0,0.011806,0.011806,6.742881,0.235372,1.0,847.0,7.0,7.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01873712,0.01860293039492065,0.00013418960507935104
14.0,847.0,782.0,0.016529,0.016529,6.742881,0.235372,1.0,847.0,7.0,7.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02623292,0.026203306987896857,2.9613012103142655e-05
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Laboratory Value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00187435,0.0018777734547023937,3.423454702393587e-06
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Laboratory Value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Laboratory Value(s),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Test Procedure Result(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Test Procedure Result(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Abnormal Test Procedure Result(s),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00374711,0.0037486890686625144,1.5790686625142929e-06
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Unsatisfactory therapeutic response,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00187435,0.0018767806397023946,2.4306397023944517e-06
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Unsatisfactory therapeutic response,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00187435,0.0018747488801190615,3.988801190613761e-07
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Unsatisfactory therapeutic response,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00187435,0.0018753104601190612,9.604601190610611e-07
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient No Longer Requires Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient No Longer Requires Study Drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00187435,0.0018753255626190607,9.755626190605625e-07
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient No Longer Requires Study Drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,847.0,782.0,0.003542,0.003542,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient withdrew request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00562145,0.0056091248189583335,1.2325181041666564e-05
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient withdrew request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00187435,0.0018753255626190607,9.755626190605625e-07
6.0,847.0,782.0,0.007084,0.007084,6.742881,0.235372,1.0,847.0,7.0,7.0,Patient withdrew request,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01124291,0.011290022974226195,4.7112974226194704e-05
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00374711,0.003747210447063486,1.0044706348589713e-07
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00187435,0.0018767618467857264,2.411846785726297e-06
1.0,847.0,782.0,0.001181,0.001181,6.742881,0.235372,1.0,847.0,7.0,7.0,Administrative Problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00187435,0.0018777734547023937,3.423454702393587e-06
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Administrative Problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00374711,0.0037466262889682485,4.83711031751613e-07
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Administrative Problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,847.0,782.0,0.003542,0.003542,6.742881,0.235372,1.0,847.0,7.0,7.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00562145,0.005607046991041667,1.4403008958332846e-05
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00374711,0.003749689771440291,2.579771440290937e-06
0.0,847.0,782.0,0.0,0.0,6.742881,0.235372,1.0,847.0,7.0,7.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00374711,0.0037466262889682485,4.83711031751613e-07
2.0,847.0,782.0,0.002361,0.002361,6.742881,0.235372,1.0,847.0,7.0,7.0,Not treated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00374711,0.0037486890686625144,1.5790686625142929e-06
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.00672393,0.006746857947738106,2.292794773810572e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
31.0,706.0,488.0,0.043909,0.043909,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.20850366,0.21084165512602104,0.0023379951260210363
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,706.0,488.0,0.012748,0.012748,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.06053439,0.06117527209815479,0.0006408820981547922
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,706.0,488.0,0.005666,0.005666,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.02690523,0.02686801969929564,3.7210300704360044e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.00672393,0.006744145410357153,2.0215410357152415e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Valsartan Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.00672393,0.006744145410357153,2.0215410357152415e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Valsartan Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Valsartan Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
38.0,706.0,488.0,0.053824,0.053824,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.25558543,0.2478666062469347,0.00771882375306529
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,706.0,488.0,0.002833,0.002833,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.01345261,0.013472265936249972,1.9655936249972014e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,706.0,488.0,0.022663,0.022663,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.10761617,0.10894699865035719,0.0013308286503571909
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,706.0,488.0,0.008499,0.008499,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.04035784,0.04076852738086309,0.0004106873808630909
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Protocol deviation,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,706.0,488.0,0.004249,0.004249,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.02017655,0.020182172756894906,5.622756894904657e-06
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.00672393,0.006752990568273818,2.9060568273817783e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,LCZ696 Run-in Period,FG000,cardiovascular disease,INDUSTRY,0.00672393,0.006751221234940483,2.7291234940482467e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,LCZ696 Run-in Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,LCZ696 Run-in Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
28.0,706.0,488.0,0.03966,0.03966,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.18832711,0.18813871321346234,0.0001883967865376479
39.0,706.0,488.0,0.055241,0.055241,6.561031,0.723749,1.0,592.0,20.0,135.0,Death,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.26231412,0.25442485908962337,0.007889260910376616
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,706.0,488.0,0.014164,0.014164,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.06725833,0.06683896854290683,0.00041936145709317585
13.0,706.0,488.0,0.018414,0.018414,6.561031,0.723749,1.0,592.0,20.0,135.0,Patient/guardian decision,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.08743962,0.08859512403485117,0.0011555040348511791
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,706.0,488.0,0.005666,0.005666,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.02690523,0.026970924905962316,6.569490596231714e-05
4.0,706.0,488.0,0.005666,0.005666,6.561031,0.723749,1.0,592.0,20.0,135.0,Lost to Follow-up,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.02690523,0.026967062932212314,6.183293221231553e-05
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,706.0,488.0,0.002833,0.002833,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.01345261,0.013452151624226171,4.583757738287758e-07
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Physician Decision,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,706.0,488.0,0.004249,0.004249,6.561031,0.723749,1.0,592.0,20.0,135.0,Adverse Event,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.02017655,0.020182874494186574,6.324494186572133e-06
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Double-Blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,706.0,488.0,0.0,0.0,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Double-Blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,706.0,488.0,0.001416,0.001416,6.561031,0.723749,1.0,592.0,20.0,135.0,Non-compliance with study treatment,Double-Blind Period,FG002,cardiovascular disease,INDUSTRY,0.00672393,0.006771899319523814,4.7969319523813794e-05
8.0,478.0,458.0,0.016736,0.016736,6.171701,0.44881,1.0,478.0,4.0,24.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04635744,0.04780950276031741,0.0014520627603174102
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,PCI at external hospital,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Assessment discrepancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,CRC didn't contact participant for FU,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Could not get whole set of images,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Decline to return for GSPECT,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,GSPECT at rest was not done,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Participant didn't complete MRI,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Uncontactable by phone,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Moved out of position,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
1.0,478.0,458.0,0.002092,0.002092,6.171701,0.44881,1.0,478.0,4.0,24.0,Unable to contact,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00579468,0.005791926199482508,2.7538005174920083e-06
2.0,478.0,458.0,0.004184,0.004184,6.171701,0.44881,1.0,478.0,4.0,24.0,Withdrawal by PI for ICA not performed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01158936,0.01157491948873015,1.4440511269850353e-05
2.0,251.0,242.0,0.007968,0.007968,5.529429,0.464087,1.0,251.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.02044695,0.02071405142895837,0.00026710142895837105
0.0,251.0,242.0,0.0,0.0,5.529429,0.464087,1.0,251.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,251.0,242.0,0.007968,0.007968,5.529429,0.464087,1.0,251.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02044695,0.0207133247385417,0.00026637473854170327
0.0,251.0,242.0,0.0,0.0,5.529429,0.464087,1.0,251.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,251.0,242.0,0.0,0.0,5.529429,0.464087,1.0,251.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,251.0,242.0,0.011952,0.011952,5.529429,0.464087,1.0,251.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.03067043,0.03130103105193182,0.0006306010519318214
0.0,251.0,242.0,0.0,0.0,5.529429,0.464087,1.0,251.0,0.0,0.0,Moved out of area,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,251.0,242.0,0.003984,0.003984,5.529429,0.464087,1.0,251.0,0.0,0.0,Moved out of area,Overall Study,FG001,cardiovascular disease,OTHER,0.01022348,0.010325507354325405,0.00010202735432540515
0.0,251.0,242.0,0.0,0.0,5.529429,0.464087,1.0,251.0,0.0,0.0,Transferred to palliative care,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,251.0,242.0,0.003984,0.003984,5.529429,0.464087,1.0,251.0,0.0,0.0,Transferred to palliative care,Overall Study,FG001,cardiovascular disease,OTHER,0.01022348,0.010325507354325405,0.00010202735432540515
2.0,703.0,591.0,0.002845,0.002845,6.556778,0.218985,1.0,714.0,15.0,39.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00408495,0.004091503142529747,6.553142529746973e-06
5.0,703.0,591.0,0.007112,0.007112,6.556778,0.218985,1.0,714.0,15.0,39.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01021167,0.010195071026636892,1.6598973363108477e-05
8.0,703.0,591.0,0.01138,0.01138,6.556778,0.218985,1.0,714.0,15.0,39.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01633982,0.01616034743800594,0.00017947256199406236
5.0,703.0,591.0,0.007112,0.007112,6.556778,0.218985,1.0,714.0,15.0,39.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01021167,0.010196043217261893,1.562678273810819e-05
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,703.0,591.0,0.002845,0.002845,6.556778,0.218985,1.0,714.0,15.0,39.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00408495,0.0040937966642857,8.846664285699218e-06
14.0,703.0,591.0,0.019915,0.019915,6.556778,0.218985,1.0,714.0,15.0,39.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02859468,0.02870138114843251,0.00010670114843251005
10.0,703.0,591.0,0.014225,0.014225,6.556778,0.218985,1.0,714.0,15.0,39.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02042477,0.020356989991001995,6.778000899800365e-05
22.0,703.0,591.0,0.031294,0.031294,6.556778,0.218985,1.0,714.0,15.0,39.0,Withdrawal by Participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04493306,0.045105511225942446,0.00017245122594244933
34.0,703.0,591.0,0.048364,0.048364,6.556778,0.218985,1.0,714.0,15.0,39.0,Withdrawal by Participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06944278,0.07030488328376987,0.0008621032837698717
2.0,703.0,591.0,0.002845,0.002845,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant stopped study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00408495,0.004091503142529747,6.553142529746973e-06
2.0,703.0,591.0,0.002845,0.002845,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant stopped study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00408495,0.0040942033642857,9.253364285699561e-06
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant only allowed phone follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,703.0,591.0,0.001422,0.001422,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant only allowed phone follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00204176,0.0020433049517857168,1.5449517857166715e-06
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant used antipsychosis meds,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,703.0,591.0,0.001422,0.001422,6.556778,0.218985,1.0,714.0,15.0,39.0,Participant used antipsychosis meds,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00204176,0.0020433049517857168,1.5449517857166715e-06
1.0,703.0,591.0,0.001422,0.001422,6.556778,0.218985,1.0,714.0,15.0,39.0,lack of motivation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00204176,0.002047049869702383,5.289869702382929e-06
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,lack of motivation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,in prison,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,703.0,591.0,0.001422,0.001422,6.556778,0.218985,1.0,714.0,15.0,39.0,in prison,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00204176,0.0020433049517857168,1.5449517857166715e-06
2.0,703.0,591.0,0.002845,0.002845,6.556778,0.218985,1.0,714.0,15.0,39.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00408495,0.004093234290446414,8.284290446413344e-06
0.0,703.0,591.0,0.0,0.0,6.556778,0.218985,1.0,714.0,15.0,39.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
29.0,1342.0,867.0,0.02161,0.02161,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.04324779,0.04267814103422626,0.0005696489657737447
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Single Blind(Run-in Period, 4 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
25.0,1342.0,867.0,0.018629,0.018629,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.03728196,0.037264087453359476,1.787254664052662e-05
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal laboratory value(s),"Single Blind(Run-in Period, 4 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
308.0,1342.0,867.0,0.229508,0.229508,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.45931113,0.43796683466809355,0.02134429533190646
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Abnormal test procedure result(s),"Single Blind(Run-in Period, 4 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
28.0,1342.0,867.0,0.020864,0.020864,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.04175483,0.04181295970494321,5.812970494321196e-05
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Subject withdrew consent,"Single Blind(Run-in Period, 4 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,1342.0,867.0,0.005961,0.005961,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.01192967,0.012015431142519857,8.57611425198572e-05
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Single Blind(Run-in Period, 4 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,1342.0,867.0,0.008942,0.008942,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.0178955,0.01762529588014881,0.00027020411985119105
4.0,1342.0,867.0,0.002981,0.002981,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.00596583,0.006067032724712305,0.00010120272471230481
3.0,1342.0,867.0,0.002235,0.002235,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.00447287,0.004516077828670636,4.320782867063555e-05
2.0,1342.0,867.0,0.00149,0.00149,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.00298192,0.002991565959431822,9.64595943182215e-06
2.0,1342.0,867.0,0.00149,0.00149,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.00298192,0.0029917653107413462,9.845310741346362e-06
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Adverse Event,"Double Blind (Treatment Period, 8 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.00149096,0.0014915101833333367,5.501833333367793e-07
20.0,1342.0,867.0,0.014903,0.014903,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.02982516,0.02935268369508924,0.0004724763049107593
6.0,1342.0,867.0,0.004471,0.004471,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.00894775,0.008988389326329362,4.06393263293614e-05
7.0,1342.0,867.0,0.005216,0.005216,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.01043871,0.010383442999236108,5.526700076389189e-05
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.00149096,0.0014909926929166694,3.2692916669425226e-08
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Unsatisfactory therapeutic effect,"Double Blind (Treatment Period, 8 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.00149096,0.0014908802100000035,7.978999999646089e-08
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.00149096,0.0014935354960714312,2.575496071431215e-06
4.0,1342.0,867.0,0.002981,0.002981,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.00596583,0.0060690617705456374,0.00010323177054563735
4.0,1342.0,867.0,0.002981,0.002981,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.00596583,0.006088052707390876,0.00012222270739087587
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.00149096,0.0014909894891666695,2.9489166669541614e-08
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Withdrawal by Subject,"Double Blind (Treatment Period, 8 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.00149096,0.0014909188350000033,4.116499999662522e-08
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Administrative problems,"Double Blind (Treatment Period, 8 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.00149096,0.0014908802100000035,7.978999999646089e-08
0.0,1342.0,867.0,0.0,0.0,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG001,cardiovascular disease,INDUSTRY,0.00149096,0.0014914909236904792,5.309236904792441e-07
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG002,cardiovascular disease,INDUSTRY,0.00149096,0.0014918123887500032,8.523887500032964e-07
2.0,1342.0,867.0,0.00149,0.00149,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG003,cardiovascular disease,INDUSTRY,0.00298192,0.002991337663598489,9.417663598488939e-06
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG004,cardiovascular disease,INDUSTRY,0.00149096,0.0014910370604166695,7.706041666951692e-08
1.0,1342.0,867.0,0.000745,0.000745,7.202661,0.277854,1.0,1342.0,1.0,11.0,Protocol deviation(s),"Double Blind (Treatment Period, 8 Weeks)",FG005,cardiovascular disease,INDUSTRY,0.00149096,0.0014908982000000034,6.17999999965712e-08
4.0,421.0,378.0,0.009501,0.009501,6.045005,0.666048,1.0,421.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.03825355,0.0380827596469941,0.00017079035300589934
7.0,421.0,378.0,0.016627,0.016627,6.045005,0.666048,1.0,421.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.06694471,0.0671595752102085,0.00021486521020849803
4.0,421.0,378.0,0.009501,0.009501,6.045005,0.666048,1.0,421.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.03825355,0.038091494799355204,0.00016205520064479367
7.0,421.0,378.0,0.016627,0.016627,6.045005,0.666048,1.0,421.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,OTHER,0.06694471,0.06719829346729184,0.0002535834672918319
1.0,421.0,378.0,0.002375,0.002375,6.045005,0.666048,1.0,421.0,1.0,1.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,OTHER,0.00956238,0.009760015350476188,0.00019763535047618783
7.0,421.0,378.0,0.016627,0.016627,6.045005,0.666048,1.0,421.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.06694471,0.06722259900354179,0.00027788900354178137
3.0,421.0,378.0,0.007126,0.007126,6.045005,0.666048,1.0,421.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.02869117,0.028474129116617067,0.00021704088338293098
7.0,421.0,378.0,0.016627,0.016627,6.045005,0.666048,1.0,421.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.06694471,0.0670605286668751,0.00011581866687510045
3.0,421.0,378.0,0.007126,0.007126,6.045005,0.666048,1.0,421.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,OTHER,0.02869117,0.028522981242480164,0.00016818875751983473
0.0,421.0,378.0,0.0,0.0,6.045005,0.666048,1.0,421.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,OTHER,0.0,0.0,0.0
5.0,458.0,432.0,0.010917,0.010917,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Randomization Prior to Study Med,FG000,cardiovascular disease,OTHER,0.01742482,0.017232005742440434,0.0001928142575595669
2.0,458.0,432.0,0.004367,0.004367,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Randomization Prior to Study Med,FG001,cardiovascular disease,OTHER,0.00697025,0.006971464856959721,1.2148569597213166e-06
6.0,458.0,432.0,0.0131,0.0131,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Randomization Prior to Study Med,FG002,cardiovascular disease,OTHER,0.02090915,0.02083501648367063,7.413351632937215e-05
2.0,458.0,432.0,0.004367,0.004367,6.12905,0.260419,1.0,455.0,1.0,1.0,Met safety criteria for discontinuation,Started Study Medication,FG000,cardiovascular disease,OTHER,0.00697025,0.006983589645471628,1.3339645471627769e-05
4.0,458.0,432.0,0.008734,0.008734,6.12905,0.260419,1.0,455.0,1.0,1.0,Met safety criteria for discontinuation,Started Study Medication,FG001,cardiovascular disease,OTHER,0.0139405,0.0139412768611905,7.768611905000639e-07
3.0,458.0,432.0,0.00655,0.00655,6.12905,0.260419,1.0,455.0,1.0,1.0,Met safety criteria for discontinuation,Started Study Medication,FG002,cardiovascular disease,OTHER,0.01045458,0.010384695520029751,6.988447997024853e-05
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Started Study Medication,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,458.0,432.0,0.004367,0.004367,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Started Study Medication,FG001,cardiovascular disease,OTHER,0.00697025,0.006972864006959723,2.6140069597233376e-06
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Withdrawal by Subject,Started Study Medication,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Difficulty Swallowing,Started Study Medication,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,458.0,432.0,0.002183,0.002183,6.12905,0.260419,1.0,455.0,1.0,1.0,Difficulty Swallowing,Started Study Medication,FG001,cardiovascular disease,OTHER,0.00348433,0.0035085034828869067,2.417348288690684e-05
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Difficulty Swallowing,Started Study Medication,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Chest Discomfort,Started Study Medication,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,458.0,432.0,0.0,0.0,6.12905,0.260419,1.0,455.0,1.0,1.0,Chest Discomfort,Started Study Medication,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,458.0,432.0,0.002183,0.002183,6.12905,0.260419,1.0,455.0,1.0,1.0,Chest Discomfort,Started Study Medication,FG002,cardiovascular disease,OTHER,0.00348433,0.003511458455595239,2.7128455595239014e-05
331.0,18201.0,13398.0,0.018186,0.018186,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04984998,0.04683145096285712,0.003018529037142885
349.0,18201.0,13398.0,0.019175,0.019175,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05256095,0.04777935565168649,0.00478159434831351
679.0,18201.0,13398.0,0.037306,0.037306,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10226017,0.10104882543538687,0.0012113445646131232
738.0,18201.0,13398.0,0.040547,0.040547,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11114413,0.10489029505586309,0.006253834944136907
921.0,18201.0,13398.0,0.050602,0.050602,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13870608,0.1340999583598215,0.004606121640178512
989.0,18201.0,13398.0,0.054338,0.054338,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1489469,0.14284689927566466,0.006100000724335336
51.0,18201.0,13398.0,0.002802,0.002802,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00768061,0.006750194717410713,0.0009304152825892874
39.0,18201.0,13398.0,0.002143,0.002143,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00587422,0.005739548891805557,0.00013467110819444326
57.0,18201.0,13398.0,0.003132,0.003132,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Poor/Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00858518,0.007983906399831351,0.0006012736001686485
77.0,18201.0,13398.0,0.004231,0.004231,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Poor/Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01159767,0.011187178027113092,0.00041049197288690713
1.0,18201.0,13398.0,5.5e-05,5.5e-05,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00015076,0.00017787713807539674,2.7117138075396743e-05
0.0,18201.0,13398.0,0.0,0.0,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,4.670363333333334e-06,4.670363333333334e-06
87.0,18201.0,13398.0,0.00478,0.00478,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Subject No Longer Meets Study Criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01310255,0.01277898754622835,0.0003235624537716499
100.0,18201.0,13398.0,0.005494,0.005494,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Subject No Longer Meets Study Criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0150597,0.014138879244831346,0.0009208207551686543
11.0,18201.0,13398.0,0.000604,0.000604,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Administrative Reason by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00165564,0.0016339154513392844,2.1724548660715694e-05
8.0,18201.0,13398.0,0.00044,0.00044,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Administrative Reason by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00120609,0.0011082523963798713,9.783760362012863e-05
81.0,18201.0,13398.0,0.00445,0.00445,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Physician Refused to Continue Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01219798,0.012183735530188495,1.4244469811505733e-05
89.0,18201.0,13398.0,0.00489,0.00489,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Physician Refused to Continue Treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01340407,0.013113671794383107,0.00029039820561689404
80.0,18201.0,13398.0,0.004395,0.004395,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Other Reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01204722,0.012004844409593258,4.237559040674334e-05
92.0,18201.0,13398.0,0.005055,0.005055,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Other Reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01385635,0.013465651372460315,0.00039069862753968523
11.0,18201.0,13398.0,0.000604,0.000604,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Not Reported,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00165564,0.0016349100842559514,2.0729915744048663e-05
12.0,18201.0,13398.0,0.000659,0.000659,9.809287,0.279441,1.0,20976.0,41.0,1111.0,Not Reported,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0018064,0.0017594558244345248,4.694417556547529e-05
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,746.0,131.0,0.006702,0.006702,6.616065,0.475348,1.0,746.0,12.0,223.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02107733,0.021280704155892848,0.00020337415589284993
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Adverse Event,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Adverse Event,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Adverse Event,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,746.0,131.0,0.002681,0.002681,6.616065,0.475348,1.0,746.0,12.0,223.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00843156,0.008440340022172615,8.780022172616073e-06
2.0,746.0,131.0,0.002681,0.002681,6.616065,0.475348,1.0,746.0,12.0,223.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00843156,0.008453397090208328,2.18370902083289e-05
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Death,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Death,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Death,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,746.0,131.0,0.006702,0.006702,6.616065,0.475348,1.0,746.0,12.0,223.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02107733,0.021315505879761883,0.00023817587976188506
17.0,746.0,131.0,0.022788,0.022788,6.616065,0.475348,1.0,746.0,12.0,223.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.07166668,0.07091837007233849,0.0007483099276615057
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Lost to Follow-up,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Lost to Follow-up,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Lost to Follow-up,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Did Not Meet Entrance Criteria,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,746.0,131.0,0.00134,0.00134,6.616065,0.475348,1.0,746.0,12.0,223.0,Did Not Meet Entrance Criteria,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00421421,0.004267372053988098,5.3162053988097674e-05
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Did Not Meet Entrance Criteria,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Did Not Meet Entrance Criteria,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Did Not Meet Entrance Criteria,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,746.0,131.0,0.00134,0.00134,6.616065,0.475348,1.0,746.0,12.0,223.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00421421,0.004253398705000004,3.9188705000003585e-05
1.0,746.0,131.0,0.00134,0.00134,6.616065,0.475348,1.0,746.0,12.0,223.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00421421,0.004260629606250002,4.641960625000139e-05
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Protocol Violation,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Protocol Violation,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Protocol Violation,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,746.0,131.0,0.016086,0.016086,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.05058936,0.050046924167380935,0.0005424358326190648
37.0,746.0,131.0,0.049598,0.049598,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.15598227,0.1598233158283334,0.0038410458283333893
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrawal by Subject,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrawal by Subject,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrawal by Subject,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,746.0,131.0,0.012064,0.012064,6.616065,0.475348,1.0,746.0,12.0,223.0,Other,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03794044,0.037867600915248045,7.283908475195361e-05
11.0,746.0,131.0,0.014745,0.014745,6.616065,0.475348,1.0,746.0,12.0,223.0,Other,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.046372,0.046771039867519876,0.0003990398675198792
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Other,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Other,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Other,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrew consent,Extension Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrew consent,Extension Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,746.0,131.0,0.002681,0.002681,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrew consent,Extension Period,FG002,cardiovascular disease,INDUSTRY,0.00843156,0.008455852918422617,2.4292918422617882e-05
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrew consent,Extension Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,746.0,131.0,0.0,0.0,6.616065,0.475348,1.0,746.0,12.0,223.0,Withdrew consent,Extension Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
21.0,1974.0,1921.0,0.010638,0.010638,7.588324,0.448917,1.0,1974.0,30.0,416.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03623864,0.037336525863075426,0.0010978858630754235
31.0,1974.0,1921.0,0.015704,0.015704,7.588324,0.448917,1.0,1974.0,30.0,416.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0534961,0.05450448174839288,0.001008381748392885
1.0,1974.0,1921.0,0.000507,0.000507,7.588324,0.448917,1.0,1974.0,30.0,416.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172711,0.0018259359624206361,9.882596242063611e-05
0.0,1974.0,1921.0,0.0,0.0,7.588324,0.448917,1.0,1974.0,30.0,416.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
35.0,3687.0,3569.0,0.009493,0.009493,8.21284,0.303074,1.0,3687.0,1.0,65.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02362897,0.02336772853009919,0.0002612414699008081
24.0,3687.0,3569.0,0.006509,0.006509,8.21284,0.303074,1.0,3687.0,1.0,65.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01620151,0.01542439307473212,0.0007771169252678792
6.0,3687.0,3569.0,0.001627,0.001627,8.21284,0.303074,1.0,3687.0,1.0,65.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00404976,0.00405883818113095,9.078181130949686e-06
6.0,3687.0,3569.0,0.001627,0.001627,8.21284,0.303074,1.0,3687.0,1.0,65.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00404976,0.004055227876964284,5.467876964283629e-06
1.0,3687.0,3569.0,0.000271,0.000271,8.21284,0.303074,1.0,3687.0,1.0,65.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00067454,0.0007436810798511928,6.914107985119282e-05
2.0,3687.0,3569.0,0.000542,0.000542,8.21284,0.303074,1.0,3687.0,1.0,65.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00134909,0.0013430537442712836,6.036255728716477e-06
0.0,3687.0,3569.0,0.0,0.0,8.21284,0.303074,1.0,3687.0,1.0,65.0,Lost to follow-up for other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3687.0,3569.0,0.000271,0.000271,8.21284,0.303074,1.0,3687.0,1.0,65.0,Lost to follow-up for other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00067454,0.0007439857852786824,6.944578527868248e-05
27.0,3687.0,3569.0,0.007323,0.007323,8.21284,0.303074,1.0,3687.0,1.0,65.0,"All death, all MI, all Revascularization",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01822764,0.017609158460565474,0.0006184815394345254
16.0,3687.0,3569.0,0.00434,0.00434,8.21284,0.303074,1.0,3687.0,1.0,65.0,"All death, all MI, all Revascularization",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01080267,0.010530771137103177,0.000271898862896823
1.0,801.0,672.0,0.001248,0.001248,6.687109,0.307494,1.0,801.0,3.0,87.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00256619,0.0025379578682142895,2.823213178571038e-05
0.0,801.0,672.0,0.0,0.0,6.687109,0.307494,1.0,801.0,3.0,87.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
65.0,801.0,672.0,0.081149,0.081149,6.687109,0.307494,1.0,801.0,3.0,87.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16686229,0.17039242907333357,0.003530139073333577
63.0,801.0,672.0,0.078652,0.078652,6.687109,0.307494,1.0,801.0,3.0,87.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16172784,0.16782888353128,0.006101043531279993
16.0,1462.0,1372.0,0.010944,0.010944,7.288244,0.581345,1.0,1462.0,1.0,3.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04636953,0.046934413764722266,0.0005648837647222668
34.0,1462.0,1372.0,0.023256,0.023256,7.288244,0.581345,1.0,1462.0,1.0,3.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09853526,0.09850543471568995,2.982528431004494e-05
7.0,1462.0,1372.0,0.004788,0.004788,7.288244,0.581345,1.0,1462.0,1.0,3.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02028667,0.02022482557898807,6.184442101192858e-05
5.0,1462.0,1372.0,0.00342,0.00342,7.288244,0.581345,1.0,1462.0,1.0,3.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01449048,0.014540850962447704,5.03709624477041e-05
7.0,1462.0,1372.0,0.004788,0.004788,7.288244,0.581345,1.0,1462.0,1.0,3.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02028667,0.020199545115833314,8.712488416668523e-05
14.0,1462.0,1372.0,0.009576,0.009576,7.288244,0.581345,1.0,1462.0,1.0,3.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04057334,0.04033040483749997,0.000242935162500027
1.0,1462.0,1372.0,0.000684,0.000684,7.288244,0.581345,1.0,1462.0,1.0,3.0,Study Terminated by Sponsor or Investigator,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0028981,0.0029893305873412717,9.123058734127184e-05
0.0,1462.0,1372.0,0.0,0.0,7.288244,0.581345,1.0,1462.0,1.0,3.0,Study Terminated by Sponsor or Investigator,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1462.0,1372.0,0.000684,0.000684,7.288244,0.581345,1.0,1462.0,1.0,3.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0028981,0.0029893305873412717,9.123058734127184e-05
3.0,1462.0,1372.0,0.002052,0.002052,7.288244,0.581345,1.0,1462.0,1.0,3.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00869429,0.008770329426130954,7.603942613095341e-05
1.0,1462.0,1372.0,0.000684,0.000684,7.288244,0.581345,1.0,1462.0,1.0,3.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0028981,0.0029893305873412717,9.123058734127184e-05
1.0,1462.0,1372.0,0.000684,0.000684,7.288244,0.581345,1.0,1462.0,1.0,3.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0028981,0.0029994054566865103,0.00010130545668651054
4.0,276.0,111.0,0.014493,0.014493,5.624018,0.264217,1.0,276.0,17.0,63.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02153602,0.021413531858968257,0.0001224881410317423
1.0,276.0,111.0,0.003623,0.003623,5.624018,0.264217,1.0,276.0,17.0,63.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00538363,0.0053962348391086035,1.2604839108603175e-05
6.0,276.0,111.0,0.021739,0.021739,5.624018,0.264217,1.0,276.0,17.0,63.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03230329,0.032356900741537666,5.361074153766715e-05
6.0,276.0,111.0,0.021739,0.021739,5.624018,0.264217,1.0,276.0,17.0,63.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03230329,0.03233454713594244,3.1257135942444614e-05
1.0,276.0,111.0,0.003623,0.003623,5.624018,0.264217,1.0,276.0,17.0,63.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00538363,0.005399181719494603,1.555171949460272e-05
0.0,276.0,111.0,0.0,0.0,5.624018,0.264217,1.0,276.0,17.0,63.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,276.0,111.0,0.007246,0.007246,5.624018,0.264217,1.0,276.0,17.0,63.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01076727,0.01097635286181548,0.00020908286181547941
1.0,276.0,111.0,0.003623,0.003623,5.624018,0.264217,1.0,276.0,17.0,63.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00538363,0.005397443479464984,1.3813479464983881e-05
62.0,276.0,111.0,0.224638,0.224638,5.624018,0.264217,1.0,276.0,17.0,63.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.33380316,0.33111337109438316,0.00268978890561683
31.0,276.0,111.0,0.112319,0.112319,5.624018,0.264217,1.0,276.0,17.0,63.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16690158,0.16892699052615526,0.0020254105261552635
8.0,276.0,111.0,0.028986,0.028986,5.624018,0.264217,1.0,276.0,17.0,63.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04307205,0.04471199520024806,0.001639945200248058
4.0,276.0,111.0,0.014493,0.014493,5.624018,0.264217,1.0,276.0,17.0,63.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02153602,0.02168904637658731,0.0001530263765873105
23.0,276.0,111.0,0.083333,0.083333,5.624018,0.264217,1.0,276.0,17.0,63.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12382953,0.12173917352513886,0.002090356474861138
16.0,276.0,111.0,0.057971,0.057971,5.624018,0.264217,1.0,276.0,17.0,63.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08614261,0.0872587613606846,0.001116151360684603
7.0,613.0,524.0,0.011419,0.011419,6.419995,0.555971,1.0,696.0,2.0,41.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04075821,0.04063431878748194,0.00012389121251805968
5.0,613.0,524.0,0.008157,0.008157,6.419995,0.555971,1.0,696.0,2.0,41.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02911505,0.028996287072242107,0.00011876292775789277
13.0,613.0,524.0,0.021207,0.021207,6.419995,0.555971,1.0,696.0,2.0,41.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07569484,0.07590210929885914,0.0002072692988591418
6.0,613.0,524.0,0.009788,0.009788,6.419995,0.555971,1.0,696.0,2.0,41.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03493663,0.035355874307010066,0.0004192443070100624
17.0,613.0,524.0,0.027732,0.027732,6.419995,0.555971,1.0,696.0,2.0,41.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09898473,0.10053203550474214,0.0015473055047421358
14.0,613.0,524.0,0.022838,0.022838,6.419995,0.555971,1.0,696.0,2.0,41.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08151642,0.08125753251808533,0.00025888748191467414
13.0,613.0,524.0,0.021207,0.021207,6.419995,0.555971,1.0,696.0,2.0,41.0,Received a Kidney Transplant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07569484,0.07591468165597223,0.00021984165597223326
4.0,613.0,524.0,0.006525,0.006525,6.419995,0.555971,1.0,696.0,2.0,41.0,Received a Kidney Transplant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0232899,0.02325186143476462,3.803856523537999e-05
6.0,613.0,524.0,0.009788,0.009788,6.419995,0.555971,1.0,696.0,2.0,41.0,Randomized But Not Treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03493663,0.03534202569492673,0.0004053956949267301
4.0,613.0,524.0,0.006525,0.006525,6.419995,0.555971,1.0,696.0,2.0,41.0,Randomized But Not Treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0232899,0.02325186143476462,3.803856523537999e-05
10.0,568.0,265.0,0.017606,0.017606,6.34388,0.767635,1.0,568.0,12.0,141.0,Adverse Event,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.08573747,0.08475380276924602,0.000983667230753979
3.0,568.0,265.0,0.005282,0.005282,6.34388,0.767635,1.0,568.0,12.0,141.0,Adverse Event,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.02572222,0.0255297967018651,0.0001924232981348993
0.0,568.0,265.0,0.0,0.0,6.34388,0.767635,1.0,568.0,12.0,141.0,Non-compliance with Study Schedule,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Non-compliance with Study Schedule,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.0085757,0.008594722270476238,1.9022270476237377e-05
7.0,568.0,265.0,0.012324,0.012324,6.34388,0.767635,1.0,568.0,12.0,141.0,Withdrawal by Subject,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.06001526,0.05955117766491078,0.00046408233508921787
13.0,568.0,265.0,0.022887,0.022887,6.34388,0.767635,1.0,568.0,12.0,141.0,Withdrawal by Subject,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.11145482,0.11364114239127979,0.0021863223912797908
5.0,568.0,265.0,0.008803,0.008803,6.34388,0.767635,1.0,568.0,12.0,141.0,Lost to Follow-up,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.04286874,0.042996702420565344,0.0001279624205653418
5.0,568.0,265.0,0.008803,0.008803,6.34388,0.767635,1.0,568.0,12.0,141.0,Lost to Follow-up,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.04286874,0.04303693727348202,0.00016819727348201668
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Progressive Disease,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.0085757,0.008588806265684569,1.3106265684568671e-05
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Progressive Disease,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.0085757,0.008594078785059573,1.8378785059572356e-05
4.0,568.0,265.0,0.007042,0.007042,6.34388,0.767635,1.0,568.0,12.0,141.0,Sponsor Request,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.03429304,0.03490084746432617,0.0006078074643261766
5.0,568.0,265.0,0.008803,0.008803,6.34388,0.767635,1.0,568.0,12.0,141.0,Sponsor Request,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.04286874,0.04287023967901773,1.4996790177260189e-06
2.0,568.0,265.0,0.003521,0.003521,6.34388,0.767635,1.0,568.0,12.0,141.0,Participant left the country,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.01714652,0.017223578965684487,7.705896568448861e-05
0.0,568.0,265.0,0.0,0.0,6.34388,0.767635,1.0,568.0,12.0,141.0,Participant left the country,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,568.0,265.0,0.0,0.0,6.34388,0.767635,1.0,568.0,12.0,141.0,Participant moved to another city with no available site,Primary Study (Through Year 1),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Participant moved to another city with no available site,Primary Study (Through Year 1),FG001,cardiovascular disease,INDUSTRY,0.0085757,0.008594722270476238,1.9022270476237377e-05
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Adverse Event,Open-Label Extension Period,FG000,cardiovascular disease,INDUSTRY,0.0085757,0.008590283025684564,1.4583025684564155e-05
2.0,568.0,265.0,0.003521,0.003521,6.34388,0.767635,1.0,568.0,12.0,141.0,Adverse Event,Open-Label Extension Period,FG001,cardiovascular disease,INDUSTRY,0.01714652,0.017135263291339246,1.1256708660752762e-05
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Non-compliance with Study Schedule,Open-Label Extension Period,FG000,cardiovascular disease,INDUSTRY,0.0085757,0.008590283025684564,1.4583025684564155e-05
0.0,568.0,265.0,0.0,0.0,6.34388,0.767635,1.0,568.0,12.0,141.0,Non-compliance with Study Schedule,Open-Label Extension Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,568.0,265.0,0.008803,0.008803,6.34388,0.767635,1.0,568.0,12.0,141.0,Withdrawal by Subject,Open-Label Extension Period,FG000,cardiovascular disease,INDUSTRY,0.04286874,0.04271909324139871,0.00014964675860128923
7.0,568.0,265.0,0.012324,0.012324,6.34388,0.767635,1.0,568.0,12.0,141.0,Withdrawal by Subject,Open-Label Extension Period,FG001,cardiovascular disease,INDUSTRY,0.06001526,0.05969559084854174,0.0003196691514582642
1.0,568.0,265.0,0.001761,0.001761,6.34388,0.767635,1.0,568.0,12.0,141.0,Lost to Follow-up,Open-Label Extension Period,FG000,cardiovascular disease,INDUSTRY,0.0085757,0.00859588562735123,2.0185627351228946e-05
5.0,568.0,265.0,0.008803,0.008803,6.34388,0.767635,1.0,568.0,12.0,141.0,Lost to Follow-up,Open-Label Extension Period,FG001,cardiovascular disease,INDUSTRY,0.04286874,0.04300971071973206,0.00014097071973205588
73.0,568.0,265.0,0.128521,0.128521,6.34388,0.767635,1.0,568.0,12.0,141.0,Sponsor Request,Open-Label Extension Period,FG000,cardiovascular disease,INDUSTRY,0.62586992,0.6353837374259922,0.009513817425992221
84.0,568.0,265.0,0.147887,0.147887,6.34388,0.767635,1.0,568.0,12.0,141.0,Sponsor Request,Open-Label Extension Period,FG001,cardiovascular disease,INDUSTRY,0.72017822,0.6823044428943448,0.037873777105655204
0.0,12064.0,10046.0,0.0,0.0,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Mortality,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,12064.0,10046.0,0.000249,0.000249,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Mortality,Overall Study,FG001,cardiovascular disease,OTHER,0.00050138,0.0005219163293452387,2.0536329345238725e-05
2.0,12064.0,10046.0,0.000166,0.000166,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Mortality,Overall Study,FG002,cardiovascular disease,OTHER,0.00033425,0.00034936682624007884,1.5116826240078819e-05
2.0,12064.0,10046.0,0.000166,0.000166,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Mortality,Overall Study,FG003,cardiovascular disease,OTHER,0.00033425,0.00034896299409722167,1.4712994097221645e-05
15.0,12064.0,10046.0,0.001243,0.001243,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Morbidity,Overall Study,FG000,cardiovascular disease,OTHER,0.00250288,0.002433724102480162,6.915589751983796e-05
25.0,12064.0,10046.0,0.002072,0.002072,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Morbidity,Overall Study,FG001,cardiovascular disease,OTHER,0.00417213,0.0036682359715376977,0.0005038940284623019
19.0,12064.0,10046.0,0.001575,0.001575,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Morbidity,Overall Study,FG002,cardiovascular disease,OTHER,0.00317138,0.0029860973687103154,0.00018528263128968474
18.0,12064.0,10046.0,0.001492,0.001492,9.398064,0.214254,1.0,12064.0,1.0,1.0,Lost to Follow-up for Morbidity,Overall Study,FG003,cardiovascular disease,OTHER,0.00300426,0.002903135298273804,0.00010112470172619599
499.0,12064.0,10046.0,0.041363,0.041363,9.398064,0.214254,1.0,12064.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.0832876,0.08138735188765872,0.0019002481123412823
484.0,12064.0,10046.0,0.040119,0.040119,9.398064,0.214254,1.0,12064.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.08078271,0.0768253605082044,0.003957349491795589
471.0,12064.0,10046.0,0.039042,0.039042,9.398064,0.214254,1.0,12064.0,1.0,1.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.07861408,0.07506383072366073,0.0035502492763392762
480.0,12064.0,10046.0,0.039788,0.039788,9.398064,0.214254,1.0,12064.0,1.0,1.0,Death,Overall Study,FG003,cardiovascular disease,OTHER,0.08011621,0.0759331344244544,0.004183075575545592
2.0,278.0,235.0,0.007194,0.007194,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,8-week Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.01292681,0.012981921354880943,5.511135488094239e-05
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,8-week Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,8-week Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,8-week Double-blind Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,278.0,235.0,0.014388,0.014388,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,8-week Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.02585362,0.025765336371785713,8.828362821428765e-05
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,8-week Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.0064634,0.006470753055763842,7.353055763842202e-06
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,8-week Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,8-week Double-blind Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Lack of Efficacy,8-week Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0064634,0.006470198756597177,6.798756597176971e-06
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Lack of Efficacy,8-week Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Lack of Efficacy,8-week Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Lack of Efficacy,8-week Double-blind Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,8-week Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,278.0,235.0,0.010791,0.010791,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,8-week Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.01939021,0.019483308900233528,9.30989002335264e-05
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,8-week Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,8-week Double-blind Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,278.0,235.0,0.021583,0.021583,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,8-week Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.03878223,0.03906325503592268,0.00028102503592267875
3.0,278.0,235.0,0.010791,0.010791,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,8-week Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.01939021,0.019483308900233528,9.30989002335264e-05
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,8-week Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,8-week Double-blind Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,278.0,235.0,0.007194,0.007194,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.01292681,0.012972768353869044,4.59583538690439e-05
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Adverse Event,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.0064634,0.0064650747266963736,1.6747266963733354e-06
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,278.0,235.0,0.007194,0.007194,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.01292681,0.012968038808452376,4.122880845237528e-05
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Withdrawal by Subject,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.0064634,0.006465873436696373,2.4734366963728716e-06
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Physician Decision,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Physician Decision,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Physician Decision,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.0064634,0.006470127571220187,6.727571220186378e-06
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Physician Decision,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,278.0,235.0,0.007194,0.007194,5.631212,0.319094,1.0,278.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.01292681,0.012964613453630947,3.780345363094649e-05
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,278.0,235.0,0.021583,0.021583,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.03878223,0.039066094888244106,0.000283864888244105
7.0,278.0,235.0,0.02518,0.02518,5.631212,0.319094,1.0,278.0,0.0,0.0,Potassium Withdrawal Criteria Met,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.04524563,0.045811027027935596,0.0005653970279355935
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Death,44-week Open-label Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Death,44-week Open-label Extension,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,278.0,235.0,0.0,0.0,5.631212,0.319094,1.0,278.0,0.0,0.0,Death,44-week Open-label Extension,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,278.0,235.0,0.003597,0.003597,5.631212,0.319094,1.0,278.0,0.0,0.0,Death,44-week Open-label Extension,FG003,cardiovascular disease,INDUSTRY,0.0064634,0.006465812161696374,2.412161696373552e-06
2.0,269.0,257.0,0.007435,0.007435,5.598422,0.500475,1.0,269.0,1.0,1.0,Withdrawal by patient,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0208319,0.02113753187406746,0.00030563187406745795
0.0,269.0,257.0,0.0,0.0,5.598422,0.500475,1.0,269.0,1.0,1.0,Withdrawal by patient,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,269.0,257.0,0.003717,0.003717,5.598422,0.500475,1.0,269.0,1.0,1.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01041455,0.010422640546646836,8.090546646835964e-06
0.0,269.0,257.0,0.0,0.0,5.598422,0.500475,1.0,269.0,1.0,1.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,269.0,257.0,0.011152,0.011152,5.598422,0.500475,1.0,269.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03124646,0.03156819155386636,0.00032173155386635774
3.0,269.0,257.0,0.011152,0.011152,5.598422,0.500475,1.0,269.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03124646,0.031531349090205635,0.0002848890902056346
1.0,269.0,257.0,0.003717,0.003717,5.598422,0.500475,1.0,269.0,1.0,1.0,Sponsor decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01041455,0.0104243907895635,9.840789563500194e-06
0.0,269.0,257.0,0.0,0.0,5.598422,0.500475,1.0,269.0,1.0,1.0,Sponsor decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,269.0,257.0,0.0,0.0,5.598422,0.500475,1.0,269.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,269.0,257.0,0.007435,0.007435,5.598422,0.500475,1.0,269.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0208319,0.021237314240525804,0.0004054142405258039
20.0,984.0,154.0,0.020325,0.020325,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.03518155,0.03552403689132935,0.00034248689132935356
26.0,984.0,154.0,0.026423,0.026423,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.04573689,0.04404328751477182,0.0016936024852281795
19.0,984.0,154.0,0.019309,0.019309,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.03342291,0.03303105754303571,0.0003918524569642909
3.0,984.0,154.0,0.003049,0.003049,6.892642,0.25113,1.0,984.0,4.0,88.0,Protocol Violation,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00527767,0.0052631184434622945,1.4551556537705478e-05
2.0,984.0,154.0,0.002033,0.002033,6.892642,0.25113,1.0,984.0,4.0,88.0,Protocol Violation,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00351902,0.0033293489660119,0.00018967103398809986
3.0,984.0,154.0,0.003049,0.003049,6.892642,0.25113,1.0,984.0,4.0,88.0,Protocol Violation,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00527767,0.0052647306546825335,1.2939345317466468e-05
12.0,984.0,154.0,0.012195,0.012195,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.02110893,0.020995723360595207,0.00011320663940479411
12.0,984.0,154.0,0.012195,0.012195,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.02110893,0.02097687178041664,0.00013205821958336278
11.0,984.0,154.0,0.011179,0.011179,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.01935029,0.018966456168779774,0.0003838338312202247
22.0,984.0,154.0,0.022358,0.022358,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.03870057,0.038597791488482074,0.00010277851151792305
22.0,984.0,154.0,0.022358,0.022358,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.03870057,0.038598831637648705,0.00010173836235129186
22.0,984.0,154.0,0.022358,0.022358,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.03870057,0.03859426090577371,0.00010630909422628537
1.0,984.0,154.0,0.001016,0.001016,6.892642,0.25113,1.0,984.0,4.0,88.0,Pregnancy,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00175864,0.0017651996879464308,6.55968794643089e-06
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Pregnancy,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Pregnancy,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,984.0,154.0,0.01626,0.01626,6.892642,0.25113,1.0,984.0,4.0,88.0,Lack of Efficacy,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.02814524,0.027285039081666674,0.0008602009183333245
9.0,984.0,154.0,0.009146,0.009146,6.892642,0.25113,1.0,984.0,4.0,88.0,Lack of Efficacy,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01583127,0.015389343713630954,0.000441926286369047
25.0,984.0,154.0,0.025407,0.025407,6.892642,0.25113,1.0,984.0,4.0,88.0,Lack of Efficacy,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.04397824,0.04302462882758926,0.0009536111724107385
4.0,984.0,154.0,0.004065,0.004065,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.00703631,0.007029585573710334,6.7244262896655124e-06
9.0,984.0,154.0,0.009146,0.009146,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01583127,0.015385815430297621,0.0004454545697023804
4.0,984.0,154.0,0.004065,0.004065,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00703631,0.007024926321329383,1.138367867061646e-05
3.0,984.0,154.0,0.003049,0.003049,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Open-Label Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00527767,0.005262070409295628,1.5599590704371523e-05
5.0,984.0,154.0,0.005081,0.005081,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Open-Label Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.00879496,0.008732482845178552,6.247715482144735e-05
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Adverse Event,Open-Label Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,984.0,154.0,0.001016,0.001016,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Open-Label Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00175864,0.0017633025958630982,4.662595863098341e-06
4.0,984.0,154.0,0.004065,0.004065,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Open-Label Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.00703631,0.007031892730625917,4.417269374082551e-06
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Lost to Follow-up,Open-Label Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,984.0,154.0,0.001016,0.001016,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Open-Label Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00175864,0.0017617680016964318,3.128001696431869e-06
1.0,984.0,154.0,0.001016,0.001016,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Open-Label Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.00175864,0.0017642205808630987,5.580580863098761e-06
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Withdrawal by Subject,Open-Label Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,984.0,154.0,0.001016,0.001016,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Open-Label Extension Phase,FG000,cardiovascular disease,INDUSTRY,0.00175864,0.0017633294675297652,4.6894675297653315e-06
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Open-Label Extension Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,984.0,154.0,0.0,0.0,6.892642,0.25113,1.0,984.0,4.0,88.0,Other,Open-Label Extension Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
33.0,901.0,680.0,0.036626,0.036626,6.804615,0.209726,1.0,901.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05226905,0.052509263380505954,0.00024021338050595614
49.0,901.0,680.0,0.054384,0.054384,6.804615,0.209726,1.0,901.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07761153,0.08130259330701546,0.003691063307015463
2.0,901.0,680.0,0.00222,0.00222,6.804615,0.209726,1.0,901.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00316817,0.0032690493304861072,0.00010087933048610713
1.0,901.0,680.0,0.00111,0.00111,6.804615,0.209726,1.0,901.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00158408,0.0016575854558928602,7.35054558928601e-05
31.0,901.0,680.0,0.034406,0.034406,6.804615,0.209726,1.0,901.0,1.0,1.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04910088,0.04903430140804657,6.657859195342841e-05
24.0,901.0,680.0,0.026637,0.026637,6.804615,0.209726,1.0,901.0,1.0,1.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03801372,0.03944782971683534,0.001434109716835337
7.0,901.0,680.0,0.007769,0.007769,6.804615,0.209726,1.0,901.0,1.0,1.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01108716,0.011315080240238083,0.0002279202402380824
0.0,901.0,680.0,0.0,0.0,6.804615,0.209726,1.0,901.0,1.0,1.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
32.0,901.0,680.0,0.035516,0.035516,6.804615,0.209726,1.0,901.0,1.0,1.0,Patient withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05068497,0.05102353888934616,0.00033856888934615664
28.0,901.0,680.0,0.031077,0.031077,6.804615,0.209726,1.0,901.0,1.0,1.0,Patient withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04435006,0.04494480046816465,0.0005947404681646562
8.0,901.0,680.0,0.008879,0.008879,6.804615,0.209726,1.0,901.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01267124,0.01281322745571428,0.00014198745571428022
6.0,901.0,680.0,0.006659,0.006659,6.804615,0.209726,1.0,901.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00950307,0.009540440127798522,3.7370127798521877e-05
1.0,267.0,253.0,0.003745,0.003745,5.590987,0.582588,1.0,267.0,26.0,65.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01219837,0.012235414492509944,3.704449250994425e-05
2.0,267.0,253.0,0.007491,0.007491,5.590987,0.582588,1.0,267.0,26.0,65.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0244,0.024611124332470213,0.00021112433247021112
2.0,267.0,253.0,0.007491,0.007491,5.590987,0.582588,1.0,267.0,26.0,65.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0244,0.024527262833541664,0.0001272628335416623
0.0,267.0,253.0,0.0,0.0,5.590987,0.582588,1.0,267.0,26.0,65.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,267.0,253.0,0.003745,0.003745,5.590987,0.582588,1.0,267.0,26.0,65.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01219837,0.012228491471676612,3.012147167661197e-05
0.0,267.0,253.0,0.0,0.0,5.590987,0.582588,1.0,267.0,26.0,65.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,267.0,253.0,0.011236,0.011236,5.590987,0.582588,1.0,267.0,26.0,65.0,Other reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03659837,0.03839261059806543,0.001794240598065433
2.0,267.0,253.0,0.007491,0.007491,5.590987,0.582588,1.0,267.0,26.0,65.0,Other reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0244,0.02457555001913688,0.0001755500191368796
2.0,267.0,253.0,0.007491,0.007491,5.590987,0.582588,1.0,267.0,26.0,65.0,Non-compliance with the CTP,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0244,0.02456104444681546,0.0001610444468154587
1.0,267.0,253.0,0.003745,0.003745,5.590987,0.582588,1.0,267.0,26.0,65.0,Non-compliance with the CTP,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01219837,0.012233250605128983,3.488060512898267e-05
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.00359148,0.003588989374583349,2.490625416651151e-06
2.0,362.0,289.0,0.005525,0.005525,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.00718427,0.007219158366627009,3.4888366627008546e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.00359148,0.003589932433750016,1.5475662499841482e-06
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.00359148,0.003591097466666684,3.8253333331603884e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.00359148,0.0035910790708333514,4.009291666487967e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,362.0,289.0,0.01105,0.01105,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.01436853,0.01434663540520829,2.1894594791708674e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.00359148,0.003591067246666684,4.1275333331628264e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.00359148,0.003591048850833351,4.311491666490405e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,non-compliance,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.00359148,0.003591048850833351,4.311491666490405e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG006,cardiovascular disease,INDUSTRY,0.00359148,0.003591067246666684,4.1275333331628264e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,The blood pressure goal was met,Period 2 - Double-Blind Dose Response,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.00359148,0.0035918912593750174,4.112593750171985e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.00359148,0.003591471765625017,8.234374983089043e-09
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.00359148,0.003591436253125018,4.374687498235122e-08
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.00359148,0.003591436253125018,4.374687498235122e-08
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Met blood pressure goal,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.00359148,0.0035905589264583503,9.210735416498479e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.00359148,0.003590944320625017,5.356793749832119e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,"Period 3: Double-blind, Withdrawal",FG011,cardiovascular disease,INDUSTRY,0.00359148,0.003591436253125018,4.374687498235122e-08
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.00359148,0.0035910757789583514,4.042210416488161e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.00359148,0.0035910757789583514,4.042210416488161e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Increased blood pressure,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,362.0,289.0,0.013812,0.013812,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.01796001,0.018239723552341283,0.0002797135523412847
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,362.0,289.0,0.005525,0.005525,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.00718427,0.0072173826101686765,3.3112610168676074e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Withdrawal by Subject,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.00359148,0.003590162939791684,1.3170602083160086e-06
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,362.0,289.0,0.005525,0.005525,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.00718427,0.0072075599412103454,2.3289941210345028e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Adverse Event,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,362.0,289.0,0.046961,0.046961,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.06106431,0.062435565840158753,0.0013712558401587568
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,362.0,289.0,0.019337,0.019337,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.02514428,0.025228871776676584,8.45917766765826e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Lost to Follow-up,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,362.0,289.0,0.01105,0.01105,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.01436853,0.014349103267499946,1.942673250005314e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,362.0,289.0,0.01105,0.01105,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.01436853,0.014352425179999946,1.6104820000053394e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Non-compliance with protocol,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.00359148,0.0035910757789583514,4.042210416488161e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,362.0,289.0,0.008287,0.008287,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.01077575,0.010849416850119038,7.366685011903767e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Other,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,362.0,289.0,0.005525,0.005525,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.00718427,0.007216442070585344,3.2172070585343576e-05
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Physician Decision,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,362.0,289.0,0.002762,0.002762,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG004,cardiovascular disease,INDUSTRY,0.00359148,0.0035905483339583504,9.316660416498063e-07
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,362.0,289.0,0.0,0.0,5.894403,0.220602,1.0,362.0,11.0,65.0,Protocol Violation,Period 4: Open Label,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,837.0,751.0,0.011947,0.011947,6.731018,0.323595,1.0,837.0,1.0,48.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02602203,0.0259580260577354,6.400394226460313e-05
12.0,837.0,751.0,0.014337,0.014337,6.731018,0.323595,1.0,837.0,1.0,48.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03122774,0.03116119246107147,6.654753892853041e-05
12.0,837.0,751.0,0.014337,0.014337,6.731018,0.323595,1.0,837.0,1.0,48.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03122774,0.031178301297797667,4.9438702202333346e-05
6.0,837.0,751.0,0.007168,0.007168,6.731018,0.323595,1.0,837.0,1.0,48.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01561278,0.015440623299404774,0.00017215670059522563
6.0,837.0,751.0,0.007168,0.007168,6.731018,0.323595,1.0,837.0,1.0,48.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01561278,0.015416908015327387,0.00019587198467261278
4.0,837.0,751.0,0.004779,0.004779,6.731018,0.323595,1.0,837.0,1.0,48.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01040925,0.010366438058452386,4.281194154761442e-05
1.0,837.0,751.0,0.001195,0.001195,6.731018,0.323595,1.0,837.0,1.0,48.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00260286,0.00260092626160714,1.933738392859846e-06
1.0,837.0,751.0,0.001195,0.001195,6.731018,0.323595,1.0,837.0,1.0,48.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00260286,0.002601852280178568,1.0077198214319787e-06
1.0,837.0,751.0,0.001195,0.001195,6.731018,0.323595,1.0,837.0,1.0,48.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00260286,0.002600118442440473,2.741557559526875e-06
7.0,837.0,751.0,0.008363,0.008363,6.731018,0.323595,1.0,837.0,1.0,48.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01821564,0.018597683246656744,0.0003820432466567422
6.0,837.0,751.0,0.007168,0.007168,6.731018,0.323595,1.0,837.0,1.0,48.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01561278,0.015403859312589287,0.000208920687410713
8.0,837.0,751.0,0.009558,0.009558,6.731018,0.323595,1.0,837.0,1.0,48.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02081849,0.020891253442291653,7.276344229165468e-05
2.0,837.0,751.0,0.002389,0.002389,6.731018,0.323595,1.0,837.0,1.0,48.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00520353,0.005185108039166669,1.842196083333067e-05
3.0,837.0,751.0,0.003584,0.003584,6.731018,0.323595,1.0,837.0,1.0,48.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00780639,0.007883286485952377,7.68964859523772e-05
7.0,837.0,751.0,0.008363,0.008363,6.731018,0.323595,1.0,837.0,1.0,48.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01821564,0.01862367356647817,0.00040803356647816855
49.0,2204.0,749.0,0.022232,0.022232,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG000,cardiovascular disease,INDUSTRY,0.04522142,0.04394476501106149,0.0012766549889385095
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"1-Single-blind, Run-in, Single-Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
30.0,2204.0,749.0,0.013612,0.013612,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG000,cardiovascular disease,INDUSTRY,0.02768775,0.026917325120367052,0.0007704248796329485
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"1-Single-blind, Run-in, Single-Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
22.0,2204.0,749.0,0.009982,0.009982,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG000,cardiovascular disease,INDUSTRY,0.02030408,0.019924994647936508,0.0003790853520634907
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"1-Single-blind, Run-in, Single-Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,2204.0,749.0,0.005898,0.005898,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG000,cardiovascular disease,INDUSTRY,0.01199694,0.012001736054474212,4.796054474212955e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other Reason,"1-Single-blind, Run-in, Single-Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2204.0,749.0,0.001815,0.001815,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG000,cardiovascular disease,INDUSTRY,0.00369184,0.003676750469007917,1.5089530992083017e-05
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"1-Single-blind, Run-in, Single-Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2204.0,749.0,0.001815,0.001815,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG000,cardiovascular disease,INDUSTRY,0.00369184,0.003687321092341249,4.518907658750907e-06
2.0,2204.0,749.0,0.000907,0.000907,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0018449,0.0018436405708333369,1.2594291666631272e-06
3.0,2204.0,749.0,0.001361,0.001361,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG002,cardiovascular disease,INDUSTRY,0.00276837,0.002752050094632936,1.6319905367064187e-05
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,2-Randomized Double-blind 3 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG000,cardiovascular disease,INDUSTRY,0.00092347,0.0009245001487499967,1.0301487499966497e-06
2.0,2204.0,749.0,0.000907,0.000907,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0018449,0.0018437223208333372,1.1776791666627887e-06
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG002,cardiovascular disease,INDUSTRY,0.00092347,0.0009238705987499971,4.0059874999707513e-07
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,2-Randomized Double-blind 3 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG000,cardiovascular disease,INDUSTRY,0.00092347,0.0009264579037499966,2.9879037499965823e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2204.0,749.0,0.000907,0.000907,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0018449,0.0018420669143452428,2.833085654757204e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,2-Randomized Double-blind 3 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2204.0,749.0,0.000907,0.000907,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG000,cardiovascular disease,INDUSTRY,0.0018449,0.0018445539276785738,3.4607232142621833e-07
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG001,cardiovascular disease,INDUSTRY,0.00092347,0.0009246650337499983,1.1950337499982977e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Other,2-Randomized Double-blind 3 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG000,cardiovascular disease,INDUSTRY,0.00092347,0.0009243439733333304,8.7397333333036e-07
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG001,cardiovascular disease,INDUSTRY,0.00092347,0.0009248568624999987,1.386862499998644e-06
2.0,2204.0,749.0,0.000907,0.000907,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0018449,0.0018417517632738146,3.1482367261854386e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,2-Randomized Double-blind 3 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2204.0,749.0,0.002269,0.002269,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG001,cardiovascular disease,INDUSTRY,0.0046153,0.004540426283452383,7.487371654761685e-05
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,"3-Single-blind, Single Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2204.0,749.0,0.002269,0.002269,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG001,cardiovascular disease,INDUSTRY,0.0046153,0.004543114357678573,7.218564232142673e-05
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,"3-Single-blind, Single Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2204.0,749.0,0.001815,0.001815,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG001,cardiovascular disease,INDUSTRY,0.00369184,0.003689397692757916,2.4423072420838403e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,"3-Single-blind, Single Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG001,cardiovascular disease,INDUSTRY,0.00092347,0.0009274432929166648,3.973292916664771e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Lost to Follow-up,"3-Single-blind, Single Treatment",FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2204.0,749.0,0.001361,0.001361,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG003,cardiovascular disease,INDUSTRY,0.00276837,0.0027524572763591264,1.5912723640873656e-05
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG004,cardiovascular disease,INDUSTRY,0.00092347,0.0009240555499999971,5.855499999970386e-07
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Adverse Event,4-Randomized Double-blind 2 Treatments,FG005,cardiovascular disease,INDUSTRY,0.00092347,0.000923984189999997,5.141899999970339e-07
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2204.0,749.0,0.001361,0.001361,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG003,cardiovascular disease,INDUSTRY,0.00276837,0.0027544726096924597,1.3897390307540322e-05
1.0,2204.0,749.0,0.000454,0.000454,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG004,cardiovascular disease,INDUSTRY,0.00092347,0.000924664337499997,1.1943374999969598e-06
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Withdrawal by Subject,4-Randomized Double-blind 2 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2204.0,749.0,0.001361,0.001361,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG003,cardiovascular disease,INDUSTRY,0.00276837,0.0027524463705257936,1.592362947420642e-05
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2204.0,749.0,0.0,0.0,7.698483,0.264217,1.0,2204.0,14.0,117.0,Protocol Violation,4-Randomized Double-blind 2 Treatments,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,314.0,220.0,0.0,0.0,5.752573,0.470855,1.0,314.0,8.0,70.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,314.0,220.0,0.003185,0.003185,5.752573,0.470855,1.0,314.0,8.0,70.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00862699,0.008653534056884921,2.6544056884921993e-05
0.0,314.0,220.0,0.0,0.0,5.752573,0.470855,1.0,314.0,8.0,70.0,Randomized but not treated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,314.0,220.0,0.050955,0.050955,5.752573,0.470855,1.0,314.0,8.0,70.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13801825,0.13995670458785725,0.0019384545878572412
31.0,314.0,220.0,0.098726,0.098726,5.752573,0.470855,1.0,314.0,8.0,70.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.26741223,0.2708968135872703,0.003484583587270329
23.0,314.0,220.0,0.073248,0.073248,5.752573,0.470855,1.0,314.0,8.0,70.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.19840175,0.20082124294186493,0.0024194929418649425
2.0,314.0,220.0,0.006369,0.006369,5.752573,0.470855,1.0,314.0,8.0,70.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01725127,0.017190172430576293,6.109756942370564e-05
0.0,314.0,220.0,0.0,0.0,5.752573,0.470855,1.0,314.0,8.0,70.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,314.0,220.0,0.0,0.0,5.752573,0.470855,1.0,314.0,8.0,70.0,Poor compliance to protocol,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,314.0,220.0,0.009554,0.009554,5.752573,0.470855,1.0,314.0,8.0,70.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02587825,0.02582781418475198,5.043581524801985e-05
11.0,314.0,220.0,0.035032,0.035032,5.752573,0.470855,1.0,314.0,8.0,70.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09488873,0.094091164543888,0.0007975654561120094
7.0,314.0,220.0,0.022293,0.022293,5.752573,0.470855,1.0,314.0,8.0,70.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.06038349,0.061327869622708364,0.0009443796227083662
6.0,407.0,288.0,0.014742,0.014742,6.011267,0.273859,1.0,407.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02426889,0.02416676731767861,0.00010212268232138999
10.0,407.0,288.0,0.02457,0.02457,6.011267,0.273859,1.0,407.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04044815,0.04024455293763525,0.00020359706236475206
6.0,407.0,288.0,0.014742,0.014742,6.011267,0.273859,1.0,407.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02426889,0.024175481377678606,9.340862232139549e-05
8.0,407.0,288.0,0.019656,0.019656,6.011267,0.273859,1.0,407.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03235852,0.03243048934168657,7.196934168656605e-05
1.0,407.0,288.0,0.002457,0.002457,6.011267,0.273859,1.0,407.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00404482,0.004098402959285714,5.358295928571417e-05
1.0,407.0,288.0,0.002457,0.002457,6.011267,0.273859,1.0,407.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00404482,0.0041212381244642845,7.641812446428434e-05
8.0,407.0,288.0,0.019656,0.019656,6.011267,0.273859,1.0,407.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03235852,0.03247046456717268,0.00011194456717267959
2.0,407.0,288.0,0.004914,0.004914,6.011267,0.273859,1.0,407.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808963,0.008084344184712336,5.285815287664475e-06
0.0,407.0,288.0,0.0,0.0,6.011267,0.273859,1.0,407.0,0.0,0.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,407.0,288.0,0.004914,0.004914,6.011267,0.273859,1.0,407.0,0.0,0.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808963,0.008084236768879004,5.393231120996711e-06
2.0,407.0,288.0,0.004914,0.004914,6.011267,0.273859,1.0,407.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00808963,0.00808784317447424,1.7868255257607463e-06
0.0,407.0,288.0,0.0,0.0,6.011267,0.273859,1.0,407.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,407.0,288.0,0.02457,0.02457,6.011267,0.273859,1.0,407.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04044815,0.04047480321343881,2.6653213438809775e-05
12.0,407.0,288.0,0.029484,0.029484,6.011267,0.273859,1.0,407.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04853778,0.04827352892959601,0.0002642510704039952
11.0,407.0,288.0,0.027027,0.027027,6.011267,0.273859,1.0,407.0,0.0,0.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04449297,0.04390581623854171,0.0005871537614582922
2.0,407.0,288.0,0.004914,0.004914,6.011267,0.273859,1.0,407.0,0.0,0.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00808963,0.008079586883462334,1.004311653766618e-05
1.0,407.0,288.0,0.002457,0.002457,6.011267,0.273859,1.0,407.0,0.0,0.0,Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00404482,0.004098019292202381,5.319929220238065e-05
0.0,407.0,288.0,0.0,0.0,6.011267,0.273859,1.0,407.0,0.0,0.0,Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,407.0,288.0,0.017199,0.017199,6.011267,0.273859,1.0,407.0,0.0,0.0,Requirement for alternative therapy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02831371,0.03036336547415679,0.002049655474156791
15.0,407.0,288.0,0.036855,0.036855,6.011267,0.273859,1.0,407.0,0.0,0.0,Requirement for alternative therapy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06067223,0.06022113666370038,0.00045109333629961973
3.0,407.0,288.0,0.007371,0.007371,6.011267,0.273859,1.0,407.0,0.0,0.0,Protocol-specified Criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01213445,0.01211424383660715,2.020616339284964e-05
12.0,407.0,288.0,0.029484,0.029484,6.011267,0.273859,1.0,407.0,0.0,0.0,Protocol-specified Criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04853778,0.048499495061560295,3.828493843970743e-05
262.0,3554.0,2846.0,0.07372,0.07372,8.17611,0.601846,1.0,3554.0,18.0,278.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.36275824,0.34727661215568817,0.01548162784431184
278.0,3554.0,2846.0,0.078222,0.078222,8.17611,0.601846,1.0,3554.0,18.0,278.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.38491149,0.3726408281605094,0.012270661839490604
53.0,3554.0,2846.0,0.014913,0.014913,8.17611,0.601846,1.0,3554.0,18.0,278.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07338326,0.06762683595207336,0.005756424047926645
47.0,3554.0,2846.0,0.013225,0.013225,8.17611,0.601846,1.0,3554.0,18.0,278.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06507702,0.06445857971618052,0.0006184402838194797
37.0,3554.0,2846.0,0.010411,0.010411,8.17611,0.601846,1.0,3554.0,18.0,278.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05123001,0.05140540993785713,0.00017539993785713193
31.0,3554.0,2846.0,0.008723,0.008723,8.17611,0.601846,1.0,3554.0,18.0,278.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04292377,0.04350413032917654,0.0005803603291765422
4.0,216.0,198.0,0.018519,0.018519,5.379897,0.404683,1.0,216.0,1.0,32.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04031866,0.04037048741253964,5.1827412539638684e-05
7.0,216.0,198.0,0.032407,0.032407,5.379897,0.404683,1.0,216.0,1.0,32.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07055494,0.07386278432524794,0.003307844325247944
0.0,216.0,198.0,0.0,0.0,5.379897,0.404683,1.0,216.0,1.0,32.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,198.0,0.00463,0.00463,5.379897,0.404683,1.0,216.0,1.0,32.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01008021,0.01009073288854163,1.0522888541631553e-05
0.0,216.0,198.0,0.0,0.0,5.379897,0.404683,1.0,216.0,1.0,32.0,Participant moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,216.0,198.0,0.009259,0.009259,5.379897,0.404683,1.0,216.0,1.0,32.0,Participant moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02015824,0.020267032954702394,0.00010879295470239345
2.0,216.0,198.0,0.009259,0.009259,5.379897,0.404683,1.0,216.0,1.0,32.0,Consent withdrawn by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02015824,0.020229594526755962,7.135452675596093e-05
1.0,216.0,198.0,0.00463,0.00463,5.379897,0.404683,1.0,216.0,1.0,32.0,Consent withdrawn by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01008021,0.01009073288854163,1.0522888541631553e-05
0.0,216.0,198.0,0.0,0.0,5.379897,0.404683,1.0,216.0,1.0,32.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,198.0,0.00463,0.00463,5.379897,0.404683,1.0,216.0,1.0,32.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01008021,0.01009073288854163,1.0522888541631553e-05
16.0,568.0,411.0,0.028169,0.028169,6.34388,0.20799,1.0,514.0,3.0,120.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03716805,0.03683019214194444,0.00033785785805556107
19.0,568.0,411.0,0.033451,0.033451,6.34388,0.20799,1.0,514.0,3.0,120.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04413747,0.04386085833099209,0.0002766116690079076
21.0,568.0,411.0,0.036972,0.036972,6.34388,0.20799,1.0,514.0,3.0,120.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04878331,0.04882741340344246,4.4103403442456723e-05
19.0,568.0,411.0,0.033451,0.033451,6.34388,0.20799,1.0,514.0,3.0,120.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04413747,0.04381176320998021,0.0003257067900197877
14.0,568.0,411.0,0.024648,0.024648,6.34388,0.20799,1.0,514.0,3.0,120.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03252221,0.032881747256537704,0.00035953725653770086
18.0,568.0,411.0,0.03169,0.03169,6.34388,0.20799,1.0,514.0,3.0,120.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04181389,0.0414530560320139,0.0003608339679860989
7.0,568.0,411.0,0.012324,0.012324,6.34388,0.20799,1.0,514.0,3.0,120.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0162611,0.01637427441058532,0.00011317441058531982
25.0,568.0,411.0,0.044014,0.044014,6.34388,0.20799,1.0,514.0,3.0,120.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05807499,0.056609757585198414,0.0014652324148015858
6.0,568.0,411.0,0.010563,0.010563,6.34388,0.20799,1.0,514.0,3.0,120.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01393752,0.014021865659930577,8.434565993057676e-05
4.0,568.0,411.0,0.007042,0.007042,6.34388,0.20799,1.0,514.0,3.0,120.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00929168,0.009360705589682541,6.902558968254098e-05
3.0,568.0,411.0,0.005282,0.005282,6.34388,0.20799,1.0,514.0,3.0,120.0,Non-Compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00696942,0.006968915069414691,5.049305853085939e-07
1.0,568.0,411.0,0.001761,0.001761,6.34388,0.20799,1.0,514.0,3.0,120.0,Non-Compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00232358,0.002481607887559528,0.00015802788755952786
2.0,568.0,411.0,0.003521,0.003521,6.34388,0.20799,1.0,514.0,3.0,120.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00464584,0.004666802869136904,2.0962869136904178e-05
0.0,568.0,411.0,0.0,0.0,6.34388,0.20799,1.0,514.0,3.0,120.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,568.0,411.0,0.0,0.0,6.34388,0.20799,1.0,514.0,3.0,120.0,Worsening serum lipid levels,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,568.0,411.0,0.003521,0.003521,6.34388,0.20799,1.0,514.0,3.0,120.0,Worsening serum lipid levels,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00464584,0.004665358267073416,1.9518267073415953e-05
156.0,25086.0,24491.0,0.006219,0.006219,10.130105,0.240569,1.0,25086.0,38.0,38.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01515561,0.01486401405830357,0.00029159594169642956
144.0,25086.0,24491.0,0.00574,0.00574,10.130105,0.240569,1.0,25086.0,38.0,38.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0139883,0.013805820728025806,0.00018247927197419418
158.0,25086.0,24491.0,0.006298,0.006298,10.130105,0.240569,1.0,25086.0,38.0,38.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01534814,0.014939193373482137,0.0004089466265178622
129.0,25086.0,24491.0,0.005142,0.005142,10.130105,0.240569,1.0,25086.0,38.0,38.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01253098,0.012085805503303581,0.0004451744966964197
2.0,25086.0,24491.0,8e-05,8e-05,10.130105,0.240569,1.0,25086.0,38.0,38.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00019496,0.00021039407297619044,1.5434072976190454e-05
3.0,25086.0,24491.0,0.00012,0.00012,10.130105,0.240569,1.0,25086.0,38.0,38.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00029244,0.00029105796607142826,1.3820339285717251e-06
1.0,25086.0,24491.0,4e-05,4e-05,10.130105,0.240569,1.0,25086.0,38.0,38.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,9.748e-05,0.00011411223708333335,1.6632237083333352e-05
2.0,25086.0,24491.0,8e-05,8e-05,10.130105,0.240569,1.0,25086.0,38.0,38.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00019496,0.0002108440513095237,1.5884051309523713e-05
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant no longer meets study criteria,Randomized Participants,FG000,cardiovascular disease,INDUSTRY,0.0066102,0.006611416631666613,1.2166316666131771e-06
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant no longer meets study criteria,Randomized Participants,FG001,cardiovascular disease,INDUSTRY,0.0066102,0.006612050261309477,1.8502613094769499e-06
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant withdrew consent,Randomized Participants,FG000,cardiovascular disease,INDUSTRY,0.0066102,0.0066120219249999525,1.8219249999524428e-06
7.0,646.0,0.0,0.010836,0.010836,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant withdrew consent,Randomized Participants,FG001,cardiovascular disease,INDUSTRY,0.04627141,0.04729624881779757,0.0010248388177975729
0.0,646.0,0.0,0.0,0.0,6.472346,0.659754,1.0,646.0,23.0,216.0,Adverse event unrelated to study drug,Randomized Participants,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Adverse event unrelated to study drug,Randomized Participants,FG001,cardiovascular disease,INDUSTRY,0.0066102,0.006611992611726149,1.792611726148495e-06
185.0,646.0,0.0,0.286378,0.286378,6.472346,0.659754,1.0,646.0,23.0,216.0,Disease progression,Treated Participants,FG000,cardiovascular disease,INDUSTRY,1.22287875,1.206520047494302,0.01635870250569793
185.0,646.0,0.0,0.286378,0.286378,6.472346,0.659754,1.0,646.0,23.0,216.0,Disease progression,Treated Participants,FG001,cardiovascular disease,INDUSTRY,1.22287875,1.212708091167695,0.010170658832304946
39.0,646.0,0.0,0.060372,0.060372,6.472346,0.659754,1.0,646.0,23.0,216.0,Study drug toxicity,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.25779786,0.2560582015263198,0.0017396584736801834
45.0,646.0,0.0,0.069659,0.069659,6.472346,0.659754,1.0,646.0,23.0,216.0,Study drug toxicity,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.2974548,0.2979668975054268,0.0005120975054268007
31.0,646.0,0.0,0.047988,0.047988,6.472346,0.659754,1.0,646.0,23.0,216.0,Adverse event unrelated to study drug,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.20491625,0.2076374525902084,0.002721202590208416
37.0,646.0,0.0,0.057276,0.057276,6.472346,0.659754,1.0,646.0,23.0,216.0,Adverse event unrelated to study drug,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.24457746,0.2297932108997421,0.014784249100257885
28.0,646.0,0.0,0.043344,0.043344,6.472346,0.659754,1.0,646.0,23.0,216.0,Participants request to discontinue study treatment,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.18508564,0.18784307524201374,0.002757435242013745
18.0,646.0,0.0,0.027864,0.027864,6.472346,0.659754,1.0,646.0,23.0,216.0,Participants request to discontinue study treatment,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.11898363,0.11764696659867066,0.0013366634013293466
13.0,646.0,0.0,0.020124,0.020124,6.472346,0.659754,1.0,646.0,23.0,216.0,Administrative reason by sponsor,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.08593262,0.08755742049488083,0.0016248004948808265
4.0,646.0,0.0,0.006192,0.006192,6.472346,0.659754,1.0,646.0,23.0,216.0,Administrative reason by sponsor,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.02644081,0.02675197241971231,0.0003111624197123103
14.0,646.0,0.0,0.021672,0.021672,6.472346,0.659754,1.0,646.0,23.0,216.0,Other reasons,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.09254282,0.09155934019214275,0.0009834798078572488
14.0,646.0,0.0,0.021672,0.021672,6.472346,0.659754,1.0,646.0,23.0,216.0,Other reasons,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.09254282,0.09208238411616057,0.00046043588383942735
6.0,646.0,0.0,0.009288,0.009288,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant withdrew consent,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.03966121,0.039614754181696445,4.645581830355766e-05
11.0,646.0,0.0,0.017028,0.017028,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant withdrew consent,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.07271222,0.07364079103386904,0.0009285710338690495
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Death,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.0066102,0.006612037049464236,1.8370494642358515e-06
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Death,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.0066102,0.006612144311190431,1.9443111904313137e-06
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant no longer meets study criteria,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.0066102,0.006611724665416612,1.5246654166117118e-06
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Participant no longer meets study criteria,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.0066102,0.006612494870059474,2.2948700594740273e-06
0.0,646.0,0.0,0.0,0.0,6.472346,0.659754,1.0,646.0,23.0,216.0,Poor/non-compliance,Treated Participants,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,646.0,0.0,0.001548,0.001548,6.472346,0.659754,1.0,646.0,23.0,216.0,Poor/non-compliance,Treated Participants,FG001,cardiovascular disease,INDUSTRY,0.0066102,0.006612244901726147,2.0449017261465335e-06
1.0,1105.0,1096.0,0.000905,0.000905,7.008505,0.583418,1.0,1105.0,8.0,50.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00370045,0.003700865478154759,4.154781547589803e-07
1.0,1105.0,1096.0,0.000905,0.000905,7.008505,0.583418,1.0,1105.0,8.0,50.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00370045,0.003689208732261902,1.1241267738098127e-05
5.0,1105.0,1096.0,0.004525,0.004525,7.008505,0.583418,1.0,1105.0,8.0,50.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01850223,0.018280991053273795,0.00022123894672620645
2.0,1105.0,1096.0,0.00181,0.00181,7.008505,0.583418,1.0,1105.0,8.0,50.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00740089,0.007431231429732146,3.0341429732145403e-05
40.0,440.0,326.0,0.090909,0.090909,6.089045,0.820196,1.0,440.0,6.0,67.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.45401881,0.45613818550613033,0.0021193755061303388
16.0,440.0,326.0,0.036364,0.036364,6.089045,0.820196,1.0,440.0,6.0,67.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18160952,0.18715201421911692,0.005542494219116928
4.0,440.0,326.0,0.009091,0.009091,6.089045,0.820196,1.0,440.0,6.0,67.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04540238,0.043899290795238105,0.001503089204761894
2.0,440.0,326.0,0.004545,0.004545,6.089045,0.820196,1.0,440.0,6.0,67.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02269869,0.02274307542586317,4.43854258631686e-05
17.0,440.0,326.0,0.038636,0.038636,6.089045,0.820196,1.0,440.0,6.0,67.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19295637,0.19545139391986102,0.0024950239198610336
9.0,440.0,326.0,0.020455,0.020455,6.089045,0.820196,1.0,440.0,6.0,67.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1021566,0.10078354304486116,0.0013730569551388405
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,440.0,326.0,0.004545,0.004545,6.089045,0.820196,1.0,440.0,6.0,67.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02269869,0.02274002878461317,4.133878461316798e-05
7.0,440.0,326.0,0.015909,0.015909,6.089045,0.820196,1.0,440.0,6.0,67.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07945292,0.07902562165742333,0.000427298342576668
3.0,440.0,326.0,0.006818,0.006818,6.089045,0.820196,1.0,440.0,6.0,67.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03405054,0.03394304339972223,0.00010749660027777053
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,440.0,326.0,0.004545,0.004545,6.089045,0.820196,1.0,440.0,6.0,67.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02269869,0.022742593495803636,4.3903495803635645e-05
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,440.0,326.0,0.006818,0.006818,6.089045,0.820196,1.0,440.0,6.0,67.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03405054,0.033932652752877,0.0001178872471229997
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Physician Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,440.0,326.0,0.006818,0.006818,6.089045,0.820196,1.0,440.0,6.0,67.0,Other reason for early termination,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03405054,0.033932652752877,0.0001178872471229997
2.0,440.0,326.0,0.004545,0.004545,6.089045,0.820196,1.0,440.0,6.0,67.0,Other reason for early termination,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02269869,0.022726829781101254,2.8139781101253064e-05
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Other reason for early termination,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Other reason for early termination,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,440.0,326.0,0.006818,0.006818,6.089045,0.820196,1.0,440.0,6.0,67.0,Missed Visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03405054,0.033932652752877,0.0001178872471229997
1.0,440.0,326.0,0.002273,0.002273,6.089045,0.820196,1.0,440.0,6.0,67.0,Missed Visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01135184,0.011915783277946446,0.0005639432779464462
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Missed Visit,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,440.0,326.0,0.0,0.0,6.089045,0.820196,1.0,440.0,6.0,67.0,Missed Visit,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,792.0,781.0,0.008838,0.008838,6.675823,0.492344,1.0,792.0,20.0,127.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02904877,0.029047849643849183,9.203561508186464e-07
4.0,792.0,781.0,0.005051,0.005051,6.675823,0.492344,1.0,792.0,20.0,127.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01660165,0.01689924884552122,0.0002975988455212221
5.0,259.0,250.0,0.019305,0.019305,5.560682,1.0,1.0,259.0,1.0,7.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10734896,0.10819516230999003,0.0008462023099900379
3.0,259.0,250.0,0.011583,0.011583,5.560682,1.0,1.0,259.0,1.0,7.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06440938,0.061685575208017776,0.002723804791982226
1.0,259.0,250.0,0.003861,0.003861,5.560682,1.0,1.0,259.0,1.0,7.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02146979,0.021458940414206346,1.0849585793653443e-05
0.0,259.0,250.0,0.0,0.0,5.560682,1.0,1.0,259.0,1.0,7.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,27395.0,12745.0,0.000365,0.000365,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,Antithrombotic Part (Double Blind),FG000,cardiovascular disease,INDUSTRY,0.00249297,0.002438811538928574,5.415846107142616e-05
8.0,27395.0,12745.0,0.000292,0.000292,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,Antithrombotic Part (Double Blind),FG001,cardiovascular disease,INDUSTRY,0.00199438,0.002012602206091269,1.822220609126908e-05
9.0,27395.0,12745.0,0.000329,0.000329,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,Antithrombotic Part (Double Blind),FG002,cardiovascular disease,INDUSTRY,0.00224709,0.0022349058165873014,1.218418341269881e-05
10.0,27395.0,12745.0,0.000365,0.000365,10.218152,0.668424,1.0,27395.0,33.0,565.0,Withdrawal by Subject,Antithrombotic Part (Double Blind),FG000,cardiovascular disease,INDUSTRY,0.00249297,0.0024942196724404776,1.2496724404774742e-06
11.0,27395.0,12745.0,0.000402,0.000402,10.218152,0.668424,1.0,27395.0,33.0,565.0,Withdrawal by Subject,Antithrombotic Part (Double Blind),FG001,cardiovascular disease,INDUSTRY,0.00274568,0.002786421157003965,4.0741157003964905e-05
15.0,27395.0,12745.0,0.000548,0.000548,10.218152,0.668424,1.0,27395.0,33.0,565.0,Withdrawal by Subject,Antithrombotic Part (Double Blind),FG002,cardiovascular disease,INDUSTRY,0.00374287,0.0033923830263771627,0.0003504869736228374
6.0,27395.0,12745.0,0.000219,0.000219,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,LTOLE Part (Open Label),FG000,cardiovascular disease,INDUSTRY,0.00149578,0.0013995442886643224,9.62357113356775e-05
2.0,27395.0,12745.0,7.3e-05,7.3e-05,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,LTOLE Part (Open Label),FG001,cardiovascular disease,INDUSTRY,0.00049859,0.0005010379791747826,2.447979174782528e-06
5.0,27395.0,12745.0,0.000183,0.000183,10.218152,0.668424,1.0,27395.0,33.0,565.0,Lost to Follow-up,LTOLE Part (Open Label),FG002,cardiovascular disease,INDUSTRY,0.0012499,0.001179816248333334,7.008375166666606e-05
5.0,27395.0,12745.0,0.000183,0.000183,10.218152,0.668424,1.0,27395.0,33.0,565.0,Refused,LTOLE Part (Open Label),FG000,cardiovascular disease,INDUSTRY,0.0012499,0.0011834798226190487,6.642017738095127e-05
2.0,27395.0,12745.0,7.3e-05,7.3e-05,10.218152,0.668424,1.0,27395.0,33.0,565.0,Refused,LTOLE Part (Open Label),FG001,cardiovascular disease,INDUSTRY,0.00049859,0.0005030184500081159,4.428450008115846e-06
11.0,27395.0,12745.0,0.000402,0.000402,10.218152,0.668424,1.0,27395.0,33.0,565.0,Refused,LTOLE Part (Open Label),FG002,cardiovascular disease,INDUSTRY,0.00274568,0.0027150754834758266,3.060451652417331e-05
68.0,27395.0,12745.0,0.002482,0.002482,10.218152,0.668424,1.0,27395.0,33.0,565.0,Missing final visit,LTOLE Part (Open Label),FG000,cardiovascular disease,INDUSTRY,0.01695221,0.01563812598488097,0.0013140840151190276
58.0,27395.0,12745.0,0.002117,0.002117,10.218152,0.668424,1.0,27395.0,33.0,565.0,Missing final visit,LTOLE Part (Open Label),FG001,cardiovascular disease,INDUSTRY,0.01445924,0.013341818591309514,0.0011174214086904864
62.0,27395.0,12745.0,0.002263,0.002263,10.218152,0.668424,1.0,27395.0,33.0,565.0,Missing final visit,LTOLE Part (Open Label),FG002,cardiovascular disease,INDUSTRY,0.01545642,0.015021975548273827,0.00043444445172617294
3.0,302.0,219.0,0.009934,0.009934,5.713733,0.41352,1.0,302.0,1.0,4.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.02347146,0.023155893907638902,0.0003155660923610977
0.0,302.0,219.0,0.0,0.0,5.713733,0.41352,1.0,302.0,1.0,4.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
9.0,302.0,219.0,0.029801,0.029801,5.713733,0.41352,1.0,302.0,1.0,4.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.07041202,0.0711403725142162,0.000728352514216199
12.0,302.0,219.0,0.039735,0.039735,5.713733,0.41352,1.0,302.0,1.0,4.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.09388348,0.09342388443714274,0.0004595955628572679
26.0,302.0,219.0,0.086093,0.086093,5.713733,0.41352,1.0,302.0,1.0,4.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.20341539,0.21913877202773802,0.015723382027738014
33.0,302.0,219.0,0.109272,0.109272,5.713733,0.41352,1.0,302.0,1.0,4.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.25818134,0.265780314041248,0.007598974041248041
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Physician Decision,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,Physician Decision,Randomization,FG001,cardiovascular disease,INDUSTRY,0.0081875,0.008185623366607149,1.8766333928516704e-06
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,clinical progression,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,clinical progression,Randomization,FG001,cardiovascular disease,INDUSTRY,0.0081875,0.00818426316660715,3.2368333928497334e-06
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,progressive disease,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,559.0,0.0,0.003578,0.003578,6.327937,0.723234,1.0,559.0,22.0,321.0,progressive disease,Randomization,FG001,cardiovascular disease,INDUSTRY,0.016375,0.016144476579831337,0.0002305234201686636
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Withdrew informed consent,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,559.0,0.0,0.007156,0.007156,6.327937,0.723234,1.0,559.0,22.0,321.0,Withdrew informed consent,Randomization,FG001,cardiovascular disease,INDUSTRY,0.03275,0.03237110324810331,0.0003788967518966943
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,Death,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0081875,0.008187425364821439,7.463517856173829e-08
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Death,Randomization,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,Randomization error,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0081875,0.00819201652125001,4.516521250009717e-06
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Randomization error,Randomization,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,Lost to Follow-up,Randomization,FG000,cardiovascular disease,INDUSTRY,0.0081875,0.008209839585416677,2.2339585416676633e-05
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Lost to Follow-up,Randomization,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,559.0,0.0,0.003578,0.003578,6.327937,0.723234,1.0,559.0,22.0,321.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.016375,0.016161282294176574,0.00021371770582342617
167.0,559.0,0.0,0.298748,0.298748,6.327937,0.723234,1.0,559.0,22.0,321.0,Progressive Disease,Treatment Period,FG000,cardiovascular disease,INDUSTRY,1.36724368,1.5683723299354053,0.20112864993540525
165.0,559.0,0.0,0.29517,0.29517,6.327937,0.723234,1.0,559.0,22.0,321.0,Progressive Disease,Treatment Period,FG001,cardiovascular disease,INDUSTRY,1.35086868,1.378381541307486,0.02751286130748598
39.0,559.0,0.0,0.069767,0.069767,6.327937,0.723234,1.0,559.0,22.0,321.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.31929415,0.3177754350992067,0.0015187149007933054
52.0,559.0,0.0,0.093023,0.093023,6.327937,0.723234,1.0,559.0,22.0,321.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.42572706,0.42993208612969264,0.004205026129692646
25.0,559.0,0.0,0.044723,0.044723,6.327937,0.723234,1.0,559.0,22.0,321.0,Withdrawal of Consent,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.20467832,0.20777814077216278,0.0030998207721627813
22.0,559.0,0.0,0.039356,0.039356,6.327937,0.723234,1.0,559.0,22.0,321.0,Withdrawal of Consent,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.18011582,0.1804571864187003,0.0003413664187002785
20.0,559.0,0.0,0.035778,0.035778,6.327937,0.723234,1.0,559.0,22.0,321.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.16374083,0.16887168669152783,0.005130856691527824
9.0,559.0,0.0,0.0161,0.0161,6.327937,0.723234,1.0,559.0,22.0,321.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.07368291,0.07412590894526916,0.0004429989452691546
27.0,559.0,0.0,0.048301,0.048301,6.327937,0.723234,1.0,559.0,22.0,321.0,Other Reasons,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.22105332,0.21796777302513923,0.00308554697486077
19.0,559.0,0.0,0.033989,0.033989,6.327937,0.723234,1.0,559.0,22.0,321.0,Other Reasons,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.15555333,0.15811180759408733,0.0025584775940873383
0.0,559.0,0.0,0.0,0.0,6.327937,0.723234,1.0,559.0,22.0,321.0,Pregnancy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,559.0,0.0,0.001789,0.001789,6.327937,0.723234,1.0,559.0,22.0,321.0,Pregnancy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0081875,0.00818703346535715,4.665346428501388e-07
3.0,408.0,362.0,0.007353,0.007353,6.013715,0.305312,1.0,408.0,1.0,8.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.01350054,0.01350404177945435,3.5017794543495268e-06
4.0,408.0,362.0,0.009804,0.009804,6.013715,0.305312,1.0,408.0,1.0,8.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.01800073,0.01805345105267858,5.272105267857888e-05
6.0,408.0,362.0,0.014706,0.014706,6.013715,0.305312,1.0,408.0,1.0,8.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.02700109,0.027038022993065493,3.693299306549436e-05
6.0,408.0,362.0,0.014706,0.014706,6.013715,0.305312,1.0,408.0,1.0,8.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02700109,0.026933695295446473,6.739470455352503e-05
6.0,408.0,362.0,0.014706,0.014706,6.013715,0.305312,1.0,408.0,1.0,8.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.02700109,0.026963850447053614,3.7239552946384535e-05
2.0,408.0,362.0,0.004902,0.004902,6.013715,0.305312,1.0,408.0,1.0,8.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.00900036,0.008997715338571424,2.644661428576403e-06
6.0,408.0,362.0,0.014706,0.014706,6.013715,0.305312,1.0,408.0,1.0,8.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02700109,0.027000777474851217,3.1252514878093995e-07
7.0,408.0,362.0,0.017157,0.017157,6.013715,0.305312,1.0,408.0,1.0,8.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.03150127,0.031610032885704395,0.00010876288570439707
3.0,408.0,362.0,0.007353,0.007353,6.013715,0.305312,1.0,408.0,1.0,8.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.01350054,0.013515479630436492,1.4939630436491477e-05
1.0,408.0,362.0,0.002451,0.002451,6.013715,0.305312,1.0,408.0,1.0,8.0,Administrative Error,Overall Study,FG000,cardiovascular disease,OTHER,0.00450018,0.004505595545595228,5.4155455952277845e-06
0.0,408.0,362.0,0.0,0.0,6.013715,0.305312,1.0,408.0,1.0,8.0,Administrative Error,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,408.0,362.0,0.0,0.0,6.013715,0.305312,1.0,408.0,1.0,8.0,Administrative Error,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,408.0,362.0,0.002451,0.002451,6.013715,0.305312,1.0,408.0,1.0,8.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.00450018,0.00450412038392856,3.940383928559971e-06
1.0,408.0,362.0,0.002451,0.002451,6.013715,0.305312,1.0,408.0,1.0,8.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.00450018,0.004500413536785704,2.335367857040846e-07
0.0,408.0,362.0,0.0,0.0,6.013715,0.305312,1.0,408.0,1.0,8.0,Physician Decision,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
56.0,5390.0,5243.0,0.01039,0.01039,8.592486,0.522695,1.0,5390.0,42.0,569.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04666408,0.04659002540794013,7.405459205986342e-05
58.0,5390.0,5243.0,0.010761,0.010761,8.592486,0.522695,1.0,5390.0,42.0,569.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04833033,0.047569366293088965,0.0007609637069110331
19.0,5390.0,5243.0,0.003525,0.003525,8.592486,0.522695,1.0,5390.0,42.0,569.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01583165,0.015876338385019857,4.4688385019857335e-05
14.0,5390.0,5243.0,0.002597,0.002597,8.592486,0.522695,1.0,5390.0,42.0,569.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01166377,0.011564328631755962,9.944136824403815e-05
11.0,612.0,476.0,0.017974,0.017974,6.418365,0.444569,1.0,612.0,1.0,86.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05128713,0.05137407040876893,8.694040876892906e-05
3.0,612.0,476.0,0.004902,0.004902,6.418365,0.444569,1.0,612.0,1.0,86.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0139874,0.014098857655119076,0.00011145765511907588
7.0,612.0,476.0,0.011438,0.011438,6.418365,0.444569,1.0,612.0,1.0,86.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03263726,0.03287569946247024,0.00023843946247023573
0.0,612.0,476.0,0.0,0.0,6.418365,0.444569,1.0,612.0,1.0,86.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,612.0,476.0,0.006536,0.006536,6.418365,0.444569,1.0,612.0,1.0,86.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01864986,0.01866006109538963,1.0201095389628101e-05
1.0,612.0,476.0,0.001634,0.001634,6.418365,0.444569,1.0,612.0,1.0,86.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00466247,0.0047022257135515815,3.975571355158136e-05
13.0,612.0,476.0,0.021242,0.021242,6.418365,0.444569,1.0,612.0,1.0,86.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06061206,0.060640038540257964,2.7978540257961315e-05
8.0,612.0,476.0,0.013072,0.013072,6.418365,0.444569,1.0,612.0,1.0,86.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03729973,0.03715975869920632,0.00013997130079368425
8.0,612.0,476.0,0.013072,0.013072,6.418365,0.444569,1.0,612.0,1.0,86.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03729973,0.03719932103548608,0.00010040896451392334
4.0,612.0,476.0,0.006536,0.006536,6.418365,0.444569,1.0,612.0,1.0,86.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01864986,0.01867055540711582,2.0695407115817882e-05
2.0,612.0,476.0,0.003268,0.003268,6.418365,0.444569,1.0,612.0,1.0,86.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00932493,0.008993096611041673,0.0003318333889583275
4.0,612.0,476.0,0.006536,0.006536,6.418365,0.444569,1.0,612.0,1.0,86.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01864986,0.018677904039556298,2.8044039556297112e-05
10.0,612.0,476.0,0.01634,0.01634,6.418365,0.444569,1.0,612.0,1.0,86.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04662466,0.046846169609613096,0.0002215096096130978
5.0,612.0,476.0,0.00817,0.00817,6.418365,0.444569,1.0,612.0,1.0,86.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02331233,0.02385426851536706,0.0005419385153670603
11.0,612.0,476.0,0.017974,0.017974,6.418365,0.444569,1.0,612.0,1.0,86.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05128713,0.051410035533740094,0.00012290553374009333
3.0,612.0,476.0,0.004902,0.004902,6.418365,0.444569,1.0,612.0,1.0,86.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0139874,0.014166662969404793,0.00017926296940479203
1.0,612.0,476.0,0.001634,0.001634,6.418365,0.444569,1.0,612.0,1.0,86.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00466247,0.00469835033805555,3.5880338055549986e-05
1.0,612.0,476.0,0.001634,0.001634,6.418365,0.444569,1.0,612.0,1.0,86.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00466247,0.004697850534384917,3.538053438491718e-05
18.0,612.0,476.0,0.029412,0.029412,6.418365,0.444569,1.0,612.0,1.0,86.0,protocol specific treatment unrelated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08392439,0.08257406683599205,0.0013503231640079466
11.0,612.0,476.0,0.017974,0.017974,6.418365,0.444569,1.0,612.0,1.0,86.0,protocol specific treatment unrelated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05128713,0.051660686238134,0.0003735562381340027
11.0,612.0,476.0,0.017974,0.017974,6.418365,0.444569,1.0,612.0,1.0,86.0,protocol specific treatment unrelated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05128713,0.05144312540640782,0.0001559954064078231
20.0,5395.0,5107.0,0.003707,0.003707,8.593413,0.325753,1.0,5614.0,31.0,381.0,Death,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.01037711,0.010332762525049605,4.434747495039512e-05
26.0,5395.0,5107.0,0.004819,0.004819,8.593413,0.325753,1.0,5614.0,31.0,381.0,Death,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.01348996,0.013228461865757572,0.00026149813424242857
150.0,5395.0,5107.0,0.027804,0.027804,8.593413,0.325753,1.0,5614.0,31.0,381.0,Adverse Event,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.07783252,0.07820909437684523,0.0003765743768452262
182.0,5395.0,5107.0,0.033735,0.033735,8.593413,0.325753,1.0,5614.0,31.0,381.0,Adverse Event,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.09443533,0.09329183201967252,0.0011434979803274792
49.0,5395.0,5107.0,0.009082,0.009082,8.593413,0.325753,1.0,5614.0,31.0,381.0,Withdrawal by Subject,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.0254235,0.025242097622311506,0.0001814023776884957
49.0,5395.0,5107.0,0.009082,0.009082,8.593413,0.325753,1.0,5614.0,31.0,381.0,Withdrawal by Subject,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.0254235,0.025324650066984124,9.884993301587791e-05
14.0,5395.0,5107.0,0.002595,0.002595,8.593413,0.325753,1.0,5614.0,31.0,381.0,Lost to Follow-up,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.00726426,0.007236025656736098,2.8234343263901923e-05
14.0,5395.0,5107.0,0.002595,0.002595,8.593413,0.325753,1.0,5614.0,31.0,381.0,Lost to Follow-up,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.00726426,0.007248593771349192,1.5666228650807607e-05
20.0,5395.0,5107.0,0.003707,0.003707,8.593413,0.325753,1.0,5614.0,31.0,381.0,Poor or non-compliance,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.01037711,0.010325985229216272,5.1124770783728124e-05
23.0,5395.0,5107.0,0.004263,0.004263,8.593413,0.325753,1.0,5614.0,31.0,381.0,Poor or non-compliance,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.01193354,0.011985646539613079,5.2106539613079594e-05
3.0,5395.0,5107.0,0.000556,0.000556,8.593413,0.325753,1.0,5614.0,31.0,381.0,Pregnancy,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.00155643,0.001505088835734128,5.134116426587184e-05
2.0,5395.0,5107.0,0.000371,0.000371,8.593413,0.325753,1.0,5614.0,31.0,381.0,Pregnancy,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.00103855,0.0009687514691369042,6.979853086309582e-05
13.0,5395.0,5107.0,0.00241,0.00241,8.593413,0.325753,1.0,5614.0,31.0,381.0,Fails to meet inclusion/exclusion,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.00674638,0.006709441575049605,3.6938424950394566e-05
9.0,5395.0,5107.0,0.001668,0.001668,8.593413,0.325753,1.0,5614.0,31.0,381.0,Fails to meet inclusion/exclusion,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.00466928,0.004631430047589289,3.784995241071058e-05
1.0,5395.0,5107.0,0.000185,0.000185,8.593413,0.325753,1.0,5614.0,31.0,381.0,Administrative reason,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.00051788,0.0005171331660119036,7.468339880963926e-07
1.0,5395.0,5107.0,0.000185,0.000185,8.593413,0.325753,1.0,5614.0,31.0,381.0,Administrative reason,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.00051788,0.0005167579249404751,1.122075059524887e-06
107.0,5395.0,5107.0,0.019833,0.019833,8.593413,0.325753,1.0,5614.0,31.0,381.0,Other,"Randomized, Completed 6 Months of Study",FG000,cardiovascular disease,INDUSTRY,0.05551907,0.054939989846904756,0.0005790801530952405
107.0,5395.0,5107.0,0.019833,0.019833,8.593413,0.325753,1.0,5614.0,31.0,381.0,Other,"Randomized, Completed 6 Months of Study",FG001,cardiovascular disease,INDUSTRY,0.05551907,0.05491003195220236,0.0006090380477976401
28.0,5395.0,5107.0,0.00519,0.00519,8.593413,0.325753,1.0,5614.0,31.0,381.0,Death,Completed Study Follow Up,FG000,cardiovascular disease,INDUSTRY,0.01452851,0.014023262920009903,0.0005052470799900965
34.0,5395.0,5107.0,0.006302,0.006302,8.593413,0.325753,1.0,5614.0,31.0,381.0,Death,Completed Study Follow Up,FG001,cardiovascular disease,INDUSTRY,0.01764137,0.017700935921210307,5.956592121030696e-05
23.0,5395.0,5107.0,0.004263,0.004263,8.593413,0.325753,1.0,5614.0,31.0,381.0,Withdrawal by Subject,Completed Study Follow Up,FG000,cardiovascular disease,INDUSTRY,0.01193354,0.011989664813958321,5.612481395832203e-05
29.0,5395.0,5107.0,0.005375,0.005375,8.593413,0.325753,1.0,5614.0,31.0,381.0,Withdrawal by Subject,Completed Study Follow Up,FG001,cardiovascular disease,INDUSTRY,0.01504639,0.014514979970624991,0.0005314100293750089
18.0,5395.0,5107.0,0.003336,0.003336,8.593413,0.325753,1.0,5614.0,31.0,381.0,Lost to Follow-up,Completed Study Follow Up,FG000,cardiovascular disease,INDUSTRY,0.00933856,0.009362105564057548,2.354556405754875e-05
16.0,5395.0,5107.0,0.002966,0.002966,8.593413,0.325753,1.0,5614.0,31.0,381.0,Lost to Follow-up,Completed Study Follow Up,FG001,cardiovascular disease,INDUSTRY,0.00830281,0.00819541898197421,0.00010739101802579101
1.0,5395.0,5107.0,0.000185,0.000185,8.593413,0.325753,1.0,5614.0,31.0,381.0,non-specified,Completed Study Follow Up,FG000,cardiovascular disease,INDUSTRY,0.00051788,0.0005171331660119036,7.468339880963926e-07
0.0,5395.0,5107.0,0.0,0.0,8.593413,0.325753,1.0,5614.0,31.0,381.0,non-specified,Completed Study Follow Up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,2199.0,2055.0,0.004548,0.004548,7.696213,0.41985,1.0,2199.0,19.0,228.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01469574,0.014617956369801587,7.778363019841396e-05
9.0,2199.0,2055.0,0.004093,0.004093,7.696213,0.41985,1.0,2199.0,19.0,228.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01322552,0.013627894066289687,0.00040237406628968776
5.0,2199.0,2055.0,0.002274,0.002274,7.696213,0.41985,1.0,2199.0,19.0,228.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00734787,0.00802222989424242,0.0006743598942424199
10.0,2199.0,2055.0,0.004548,0.004548,7.696213,0.41985,1.0,2199.0,19.0,228.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01469574,0.014619590848958338,7.614915104166287e-05
1.0,2199.0,2055.0,0.000455,0.000455,7.696213,0.41985,1.0,2199.0,19.0,228.0,"Adverse event, serious fatal",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00147022,0.0014951820782792213,2.496207827922133e-05
6.0,2199.0,2055.0,0.002729,0.002729,7.696213,0.41985,1.0,2199.0,19.0,228.0,"Adverse event, serious fatal",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00881809,0.00894985534898811,0.00013176534898810995
7.0,2199.0,2055.0,0.003183,0.003183,7.696213,0.41985,1.0,2199.0,19.0,228.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01028508,0.01031824618478175,3.316618478175007e-05
6.0,2199.0,2055.0,0.002729,0.002729,7.696213,0.41985,1.0,2199.0,19.0,228.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00881809,0.008946382465654774,0.00012829246565477376
17.0,2199.0,2055.0,0.007731,0.007731,7.696213,0.41985,1.0,2199.0,19.0,228.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02498082,0.02488464922265872,9.617077734128121e-05
29.0,2199.0,2055.0,0.013188,0.013188,7.696213,0.41985,1.0,2199.0,19.0,228.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04261377,0.042153849728482136,0.0004599202715178663
14.0,2199.0,2055.0,0.006367,0.006367,7.696213,0.41985,1.0,2199.0,19.0,228.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02057339,0.020066525346904736,0.0005068646530952646
29.0,2199.0,2055.0,0.013188,0.013188,7.696213,0.41985,1.0,2199.0,19.0,228.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04261377,0.04215691828324404,0.0004568517167559613
0.0,2199.0,2055.0,0.0,0.0,7.696213,0.41985,1.0,2199.0,19.0,228.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2199.0,2055.0,0.000455,0.000455,7.696213,0.41985,1.0,2199.0,19.0,228.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00147022,0.0014908682812554122,2.0648281255412253e-05
6.0,381.0,359.0,0.015748,0.015748,5.945421,0.431879,1.0,506.0,1.0,49.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04043616,0.04054841121937498,0.00011225121937498417
7.0,381.0,359.0,0.018373,0.018373,5.945421,0.431879,1.0,506.0,1.0,49.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04717638,0.046764412972400755,0.00041196702759924153
3.0,381.0,359.0,0.007874,0.007874,5.945421,0.431879,1.0,506.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02021808,0.020986479436974195,0.0007683994369741959
2.0,381.0,359.0,0.005249,0.005249,5.945421,0.431879,1.0,506.0,1.0,49.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01347787,0.013912992664979034,0.00043512266497903497
0.0,381.0,359.0,0.0,0.0,5.945421,0.431879,1.0,506.0,1.0,49.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,381.0,359.0,0.002625,0.002625,5.945421,0.431879,1.0,506.0,1.0,49.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00674022,0.006762615611537702,2.239561153770213e-05
1.0,381.0,359.0,0.002625,0.002625,5.945421,0.431879,1.0,506.0,1.0,49.0,Subject Non-Compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00674022,0.0067690487039186575,2.8828703918657578e-05
0.0,381.0,359.0,0.0,0.0,5.945421,0.431879,1.0,506.0,1.0,49.0,Subject Non-Compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,381.0,359.0,0.002625,0.002625,5.945421,0.431879,1.0,506.0,1.0,49.0,System Explant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00674022,0.0067690487039186575,2.8828703918657578e-05
0.0,381.0,359.0,0.0,0.0,5.945421,0.431879,1.0,506.0,1.0,49.0,System Explant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,381.0,359.0,0.002625,0.002625,5.945421,0.431879,1.0,506.0,1.0,49.0,Hospice Admission,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00674022,0.0067690487039186575,2.8828703918657578e-05
0.0,381.0,359.0,0.0,0.0,5.945421,0.431879,1.0,506.0,1.0,49.0,Hospice Admission,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
34.0,646.0,0.0,0.052632,0.052632,6.472346,0.363079,1.0,646.0,17.0,108.0,Study closed by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12368385,0.12189915028952371,0.0017846997104762896
37.0,646.0,0.0,0.057276,0.057276,6.472346,0.363079,1.0,646.0,17.0,108.0,Study closed by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13459713,0.13207966774281746,0.002517462257182551
257.0,646.0,0.0,0.397833,0.397833,6.472346,0.363079,1.0,646.0,17.0,108.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.93489732,0.933446773185991,0.0014505468140090239
253.0,646.0,0.0,0.391641,0.391641,6.472346,0.363079,1.0,646.0,17.0,108.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.92034628,0.9287206051035507,0.00837432510355074
13.0,646.0,0.0,0.020124,0.020124,6.472346,0.363079,1.0,646.0,17.0,108.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04729088,0.04735165608433528,6.077608433528031e-05
13.0,646.0,0.0,0.020124,0.020124,6.472346,0.363079,1.0,646.0,17.0,108.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04729088,0.04734798845975194,5.710845975193807e-05
18.0,646.0,0.0,0.027864,0.027864,6.472346,0.363079,1.0,646.0,17.0,108.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06547968,0.06359582913854617,0.0018838508614538313
21.0,646.0,0.0,0.032508,0.032508,6.472346,0.363079,1.0,646.0,17.0,108.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07639296,0.07491578710821427,0.0014771728917857274
0.0,316.0,231.0,0.0,0.0,5.758902,0.35786,1.0,316.0,1.0,76.0,Randomized But Not Treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Randomized But Not Treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0130433,0.01305723639412697,1.3936394126969759e-05
8.0,316.0,231.0,0.025316,0.025316,5.758902,0.35786,1.0,316.0,1.0,76.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0521732,0.05357938503089285,0.001406185030892848
13.0,316.0,231.0,0.041139,0.041139,5.758902,0.35786,1.0,316.0,1.0,76.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08478248,0.08541773532662422,0.0006352553266242289
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00652268,0.006527019500126499,4.33950012649828e-06
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0130433,0.01306367293412697,2.0372934126969625e-05
9.0,316.0,231.0,0.028481,0.028481,5.758902,0.35786,1.0,316.0,1.0,76.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05869588,0.059278551933928586,0.0005826719339285871
10.0,316.0,231.0,0.031646,0.031646,5.758902,0.35786,1.0,316.0,1.0,76.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06521856,0.06524133906075398,2.2779060753985725e-05
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00652268,0.006527562950126499,4.882950126498635e-06
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0130433,0.01305723639412697,1.3936394126969759e-05
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Participant Moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00652268,0.006527019500126499,4.33950012649828e-06
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Participant Moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0130433,0.01305723639412697,1.3936394126969759e-05
3.0,316.0,231.0,0.009494,0.009494,5.758902,0.35786,1.0,316.0,1.0,76.0,Consent withdrawn by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01956598,0.01966594688996032,9.996688996032066e-05
4.0,316.0,231.0,0.012658,0.012658,5.758902,0.35786,1.0,316.0,1.0,76.0,Consent withdrawn by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0260866,0.026315789319771823,0.0002291893197718213
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Related to Autoinjector Administration,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0130433,0.013043519750525779,2.197505257778981e-07
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Related to Autoinjector Administration,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00652268,0.006525221752388404,2.5417523884033177e-06
4.0,316.0,231.0,0.012658,0.012658,5.758902,0.35786,1.0,316.0,1.0,76.0,Last visit outside protocol visit window,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0260866,0.026280548091408732,0.00019394809140873062
11.0,316.0,231.0,0.03481,0.03481,5.758902,0.35786,1.0,316.0,1.0,76.0,Last visit outside protocol visit window,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07173918,0.07175735515698417,1.8175156984170937e-05
0.0,316.0,231.0,0.0,0.0,5.758902,0.35786,1.0,316.0,1.0,76.0,Selection criteria finally not met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Selection criteria finally not met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00652268,0.006525221752388404,2.5417523884033177e-06
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Site closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0130433,0.013043519750525779,2.197505257778981e-07
2.0,316.0,231.0,0.006329,0.006329,5.758902,0.35786,1.0,316.0,1.0,76.0,Site closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0130433,0.01305723639412697,1.3936394126969759e-05
1.0,316.0,231.0,0.003165,0.003165,5.758902,0.35786,1.0,316.0,1.0,76.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00652268,0.006530487798459832,7.807798459831539e-06
0.0,316.0,231.0,0.0,0.0,5.758902,0.35786,1.0,316.0,1.0,76.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,316.0,231.0,0.0,0.0,5.758902,0.35786,1.0,316.0,1.0,76.0,Other than specified above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,316.0,231.0,0.009494,0.009494,5.758902,0.35786,1.0,316.0,1.0,76.0,Other than specified above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01956598,0.01969729315984128,0.00013131315984128006
28.0,716.0,619.0,0.039106,0.039106,6.575076,0.249466,1.0,716.0,2.0,3.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06414404,0.06400865408778776,0.00013538591221223806
26.0,716.0,619.0,0.036313,0.036313,6.575076,0.249466,1.0,716.0,2.0,3.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0595628,0.059941253912033664,0.0003784539120336647
3.0,716.0,619.0,0.00419,0.00419,6.575076,0.249466,1.0,716.0,2.0,3.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00687269,0.006866659758660697,6.03024133930246e-06
1.0,716.0,619.0,0.001397,0.001397,6.575076,0.249466,1.0,716.0,2.0,3.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00229144,0.002287019066190476,4.420933809524269e-06
2.0,716.0,619.0,0.002793,0.002793,6.575076,0.249466,1.0,716.0,2.0,3.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00458125,0.004575553635099209,5.696364900791354e-06
0.0,716.0,619.0,0.0,0.0,6.575076,0.249466,1.0,716.0,2.0,3.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,716.0,619.0,0.00419,0.00419,6.575076,0.249466,1.0,716.0,2.0,3.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00687269,0.006867615579077366,5.0744209226342984e-06
1.0,716.0,619.0,0.001397,0.001397,6.575076,0.249466,1.0,716.0,2.0,3.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00229144,0.002288386999523809,3.0530004761909584e-06
5.0,716.0,619.0,0.006983,0.006983,6.575076,0.249466,1.0,716.0,2.0,3.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01145394,0.011475591079077384,2.1651079077384533e-05
6.0,716.0,619.0,0.00838,0.00838,6.575076,0.249466,1.0,716.0,2.0,3.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01374539,0.013663002527767854,8.238747223214549e-05
10.0,716.0,619.0,0.013966,0.013966,6.575076,0.249466,1.0,716.0,2.0,3.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02290788,0.022550258014017856,0.0003576219859821421
12.0,716.0,619.0,0.01676,0.01676,6.575076,0.249466,1.0,716.0,2.0,3.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02749077,0.027703550403890668,0.00021278040389066666
170.0,498.0,0.0,0.341365,0.341365,6.212606,0.835326,1.0,498.0,15.0,105.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.77153086,1.7706486866264688,0.0008821733735311366
148.0,498.0,0.0,0.297189,0.297189,6.212606,0.835326,1.0,498.0,15.0,105.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.54227728,1.5597579821472376,0.017480702147237626
19.0,498.0,0.0,0.038153,0.038153,6.212606,0.835326,1.0,498.0,15.0,105.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19799691,0.1969262819207935,0.0010706280792064926
10.0,498.0,0.0,0.02008,0.02008,6.212606,0.835326,1.0,498.0,15.0,105.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10420617,0.10232921532941466,0.0018769546705853374
3.0,498.0,0.0,0.006024,0.006024,6.212606,0.835326,1.0,498.0,15.0,105.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03126185,0.03138876782654759,0.00012691782654759148
3.0,498.0,0.0,0.006024,0.006024,6.212606,0.835326,1.0,498.0,15.0,105.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03126185,0.031410406088630924,0.00014855608863092312
55.0,498.0,0.0,0.110442,0.110442,6.212606,0.835326,1.0,498.0,15.0,105.0,Uspecified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.57314432,0.5638603926657026,0.009283927334297393
90.0,498.0,0.0,0.180723,0.180723,6.212606,0.835326,1.0,498.0,15.0,105.0,Uspecified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.93787111,0.9177018117283751,0.020169298271624947
0.0,283.0,266.0,0.0,0.0,5.648974,0.425266,1.0,283.0,6.0,33.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,283.0,266.0,0.003534,0.003534,5.648974,0.425266,1.0,283.0,6.0,33.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00848979,0.008793207470357138,0.0003034174703571372
3.0,283.0,266.0,0.010601,0.010601,5.648974,0.425266,1.0,283.0,6.0,33.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02546698,0.025758102768700417,0.0002911227687004171
0.0,283.0,266.0,0.0,0.0,5.648974,0.425266,1.0,283.0,6.0,33.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,283.0,266.0,0.017668,0.017668,5.648974,0.425266,1.0,283.0,6.0,33.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04244416,0.04292227852826388,0.0004781185282638767
2.0,283.0,266.0,0.007067,0.007067,5.648974,0.425266,1.0,283.0,6.0,33.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01697718,0.01743371220098215,0.00045653220098215014
5.0,283.0,266.0,0.017668,0.017668,5.648974,0.425266,1.0,283.0,6.0,33.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04244416,0.04290286712900793,0.00045870712900792504
1.0,283.0,266.0,0.003534,0.003534,5.648974,0.425266,1.0,283.0,6.0,33.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00848979,0.00877893253803571,0.0002891425380357089
19.0,2124.0,1599.0,0.008945,0.008945,7.661527,0.437762,1.0,2124.0,25.0,348.0,Subject Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03000087,0.030326317301428582,0.000325447301428583
21.0,2124.0,1599.0,0.009887,0.009887,7.661527,0.437762,1.0,2124.0,25.0,348.0,Subject Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03316027,0.03286376167156747,0.00029650832843253205
57.0,2124.0,1599.0,0.026836,0.026836,7.661527,0.437762,1.0,2124.0,25.0,348.0,Subject Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.09000598,0.0871062363204756,0.0028997436795244053
91.0,2124.0,1599.0,0.042844,0.042844,7.661527,0.437762,1.0,2124.0,25.0,348.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14369564,0.14309794638388895,0.0005976936161110613
77.0,2124.0,1599.0,0.036252,0.036252,7.661527,0.437762,1.0,2124.0,25.0,348.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12158655,0.12214803374529765,0.0005614837452976446
76.0,2124.0,1599.0,0.035782,0.035782,7.661527,0.437762,1.0,2124.0,25.0,348.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.1200102,0.1211608238384325,0.0011506238384325074
20.0,2124.0,1599.0,0.009416,0.009416,7.661527,0.437762,1.0,2124.0,25.0,348.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03158057,0.031170845668105164,0.0004097243318948382
22.0,2124.0,1599.0,0.010358,0.010358,7.661527,0.437762,1.0,2124.0,25.0,348.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03473997,0.03483022763772819,9.025763772818607e-05
22.0,2124.0,1599.0,0.010358,0.010358,7.661527,0.437762,1.0,2124.0,25.0,348.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03473997,0.03483604155457342,9.60715545734181e-05
3.0,2124.0,1599.0,0.001412,0.001412,7.661527,0.437762,1.0,2124.0,25.0,348.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00473574,0.0047717175398611315,3.59775398611319e-05
7.0,2124.0,1599.0,0.003296,0.003296,7.661527,0.437762,1.0,2124.0,25.0,348.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01105454,0.01094174684842261,0.00011279315157738945
7.0,2124.0,1599.0,0.003296,0.003296,7.661527,0.437762,1.0,2124.0,25.0,348.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01105454,0.010949416647440471,0.00010512335255952882
11.0,2124.0,1599.0,0.005179,0.005179,7.661527,0.437762,1.0,2124.0,25.0,348.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01736999,0.01774794577372025,0.0003779557737202503
5.0,2124.0,1599.0,0.002354,0.002354,7.661527,0.437762,1.0,2124.0,25.0,348.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00789514,0.008208348340248011,0.0003132083402480109
12.0,2124.0,1599.0,0.00565,0.00565,7.661527,0.437762,1.0,2124.0,25.0,348.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01894969,0.019258999797886932,0.0003093097978869308
3.0,2124.0,1599.0,0.001412,0.001412,7.661527,0.437762,1.0,2124.0,25.0,348.0,Withdrawal by consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00473574,0.004763969558730181,2.822955873018132e-05
3.0,2124.0,1599.0,0.001412,0.001412,7.661527,0.437762,1.0,2124.0,25.0,348.0,Withdrawal by consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00473574,0.0047866854509920845,5.094545099208498e-05
3.0,2124.0,1599.0,0.001412,0.001412,7.661527,0.437762,1.0,2124.0,25.0,348.0,Withdrawal by consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00473574,0.004766370847480179,3.0630847480179156e-05
12.0,2124.0,1599.0,0.00565,0.00565,7.661527,0.437762,1.0,2124.0,25.0,348.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01894969,0.0191968873252282,0.0002471973252281996
17.0,2124.0,1599.0,0.008004,0.008004,7.661527,0.437762,1.0,2124.0,25.0,348.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02684483,0.027420464029464294,0.0005756340294642941
37.0,2124.0,1599.0,0.01742,0.01742,7.661527,0.437762,1.0,2124.0,25.0,348.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0584254,0.058020764148989885,0.00040463585101011695
3.0,6564.0,6538.0,0.000457,0.000457,8.789508,0.590384,1.0,6564.0,34.0,532.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00237146,0.0023876901970671,1.6230197067099942e-05
3.0,6564.0,6538.0,0.000457,0.000457,8.789508,0.590384,1.0,6564.0,34.0,532.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00237146,0.0023853842493885297,1.3924249388529587e-05
8.0,6564.0,6538.0,0.001219,0.001219,8.789508,0.590384,1.0,6564.0,34.0,532.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00632562,0.006147924743750001,0.00017769525624999893
12.0,6564.0,6538.0,0.001828,0.001828,8.789508,0.590384,1.0,6564.0,34.0,532.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00948583,0.009300429254637439,0.0001854007453625621
5.0,1438.0,1373.0,0.003477,0.003477,7.271704,0.368375,1.0,1438.0,7.0,50.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00931388,0.009154052771259918,0.00015982722874008197
4.0,1438.0,1373.0,0.002782,0.002782,7.271704,0.368375,1.0,1438.0,7.0,50.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00745218,0.007458936389474203,6.756389474203012e-06
6.0,1438.0,1373.0,0.004172,0.004172,7.271704,0.368375,1.0,1438.0,7.0,50.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01117559,0.011052245053224202,0.00012334494677579758
2.0,1438.0,1373.0,0.001391,0.001391,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00372609,0.003715582110803578,1.05078891964221e-05
0.0,1438.0,1373.0,0.0,0.0,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00186171,0.0018609214617559596,7.885382440403141e-07
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00186171,0.0018635973530654825,1.8873530654825617e-06
2.0,1438.0,1373.0,0.001391,0.001391,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00372609,0.00371966066848215,6.429331517850134e-06
0.0,1438.0,1373.0,0.0,0.0,7.271704,0.368375,1.0,1438.0,7.0,50.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00186171,0.001864314833125007,2.6048331250071513e-06
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00186171,0.0018602189188095314,1.4910811904685767e-06
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00186171,0.0018618405075892938,1.3050758929382573e-07
0.0,1438.0,1373.0,0.0,0.0,7.271704,0.368375,1.0,1438.0,7.0,50.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1438.0,1373.0,0.001391,0.001391,7.271704,0.368375,1.0,1438.0,7.0,50.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00372609,0.0037189217184821492,7.1682815178508025e-06
2.0,1438.0,1373.0,0.001391,0.001391,7.271704,0.368375,1.0,1438.0,7.0,50.0,Protocol deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00372609,0.003718766616577388,7.3233834226118545e-06
15.0,1438.0,1373.0,0.010431,0.010431,7.271704,0.368375,1.0,1438.0,7.0,50.0,Subject/guardian decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02794165,0.02831198436953374,0.00037033436953374035
10.0,1438.0,1373.0,0.006954,0.006954,7.271704,0.368375,1.0,1438.0,7.0,50.0,Subject/guardian decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01862777,0.01840450955656746,0.00022326044343253665
11.0,1438.0,1373.0,0.00765,0.00765,7.271704,0.368375,1.0,1438.0,7.0,50.0,Subject/guardian decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02049215,0.020184137949543643,0.0003080120504563577
0.0,1438.0,1373.0,0.0,0.0,7.271704,0.368375,1.0,1438.0,7.0,50.0,Technical problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1438.0,1373.0,0.0,0.0,7.271704,0.368375,1.0,1438.0,7.0,50.0,Technical problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1438.0,1373.0,0.000695,0.000695,7.271704,0.368375,1.0,1438.0,7.0,50.0,Technical problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00186171,0.0018608141617559599,8.958382440400411e-07
2.0,252.0,142.0,0.007937,0.007937,5.533389,0.393038,1.0,252.0,2.0,34.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01726163,0.017478155095952394,0.000216525095952394
3.0,252.0,142.0,0.011905,0.011905,5.533389,0.393038,1.0,252.0,2.0,34.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02589136,0.02600498872860122,0.00011362872860122206
5.0,252.0,142.0,0.019841,0.019841,5.533389,0.393038,1.0,252.0,2.0,34.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04315082,0.04367565854101188,0.0005248385410118808
6.0,252.0,142.0,0.02381,0.02381,5.533389,0.393038,1.0,252.0,2.0,34.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05178272,0.05215847168071429,0.00037575168071429105
44.0,252.0,142.0,0.174603,0.174603,5.533389,0.393038,1.0,252.0,2.0,34.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.37973199,0.4170700942623414,0.037338104262341354
25.0,252.0,142.0,0.099206,0.099206,5.533389,0.393038,1.0,252.0,2.0,34.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.21575627,0.23904193552502773,0.023285665525027727
18.0,252.0,142.0,0.071429,0.071429,5.533389,0.393038,1.0,252.0,2.0,34.0,Withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15534599,0.1597607724546626,0.004414782454662619
6.0,252.0,142.0,0.02381,0.02381,5.533389,0.393038,1.0,252.0,2.0,34.0,Withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05178272,0.052131209204047624,0.00034848920404762646
1.0,252.0,142.0,0.003968,0.003968,5.533389,0.393038,1.0,252.0,2.0,34.0,Didn't receive study treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00862973,0.008788799373323412,0.00015906937332341164
0.0,252.0,142.0,0.0,0.0,5.533389,0.393038,1.0,252.0,2.0,34.0,Didn't receive study treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2230.0,2110.0,0.0,0.0,7.710205,0.50573,1.0,2230.0,6.0,104.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2230.0,2110.0,0.000448,0.000448,7.710205,0.50573,1.0,2230.0,6.0,104.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00174688,0.0017799850044480537,3.310500444805376e-05
0.0,2230.0,2110.0,0.0,0.0,7.710205,0.50573,1.0,2230.0,6.0,104.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2230.0,2110.0,0.000897,0.000897,7.710205,0.50573,1.0,2230.0,6.0,104.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00349765,0.0035135423294047623,1.5892329404762137e-05
0.0,2230.0,2110.0,0.0,0.0,7.710205,0.50573,1.0,2230.0,6.0,104.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2230.0,2110.0,0.000448,0.000448,7.710205,0.50573,1.0,2230.0,6.0,104.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00174688,0.0017747432865313872,2.786328653138731e-05
12.0,2230.0,2110.0,0.005381,0.005381,7.710205,0.50573,1.0,2230.0,6.0,104.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02098202,0.020509678887113098,0.00047234111288690234
37.0,2230.0,2110.0,0.016592,0.016592,7.710205,0.50573,1.0,2230.0,6.0,104.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06469685,0.06456753102820341,0.0001293189717965909
23.0,2230.0,2110.0,0.010314,0.010314,7.710205,0.50573,1.0,2230.0,6.0,104.0,Withdrawal by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04021717,0.039767131509409276,0.00045003849059072065
40.0,2230.0,2110.0,0.017937,0.017937,7.710205,0.50573,1.0,2230.0,6.0,104.0,Withdrawal by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06994138,0.06851829376568448,0.0014230862343155154
0.0,2230.0,2110.0,0.0,0.0,7.710205,0.50573,1.0,2230.0,6.0,104.0,Sponsor decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2230.0,2110.0,0.000448,0.000448,7.710205,0.50573,1.0,2230.0,6.0,104.0,Sponsor decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00174688,0.00177991987111472,3.303987111472019e-05
1.0,2230.0,2110.0,0.000448,0.000448,7.710205,0.50573,1.0,2230.0,6.0,104.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00174688,0.001791903983823053,4.502398382305313e-05
2.0,2230.0,2110.0,0.000897,0.000897,7.710205,0.50573,1.0,2230.0,6.0,104.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00349765,0.003521747653809521,2.409765380952068e-05
20.0,201.0,0.0,0.099502,0.099502,5.308268,0.729961,1.0,201.0,12.0,58.0,Sponsor's Decision to End the Study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.38555294,0.3886857383297622,0.0031327983297622097
13.0,201.0,0.0,0.064677,0.064677,5.308268,0.729961,1.0,201.0,12.0,58.0,Sponsor's Decision to End the Study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.25061212,0.2719273779184327,0.021315257918432695
18.0,201.0,0.0,0.089552,0.089552,5.308268,0.729961,1.0,201.0,12.0,58.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.34699842,0.3693369911852977,0.02233857118529775
14.0,201.0,0.0,0.069652,0.069652,5.308268,0.729961,1.0,201.0,12.0,58.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.26988938,0.2798463080485218,0.009956928048521774
9.0,201.0,0.0,0.044776,0.044776,5.308268,0.729961,1.0,201.0,12.0,58.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17349921,0.18837741722389909,0.014878207223899098
8.0,201.0,0.0,0.039801,0.039801,5.308268,0.729961,1.0,201.0,12.0,58.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15422195,0.16302965421455343,0.00880770421455343
1.0,201.0,0.0,0.004975,0.004975,5.308268,0.729961,1.0,201.0,12.0,58.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01927726,0.019491359439325413,0.0002140994393254117
0.0,201.0,0.0,0.0,0.0,5.308268,0.729961,1.0,201.0,12.0,58.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
48.0,201.0,0.0,0.238806,0.238806,5.308268,0.729961,1.0,201.0,12.0,58.0,Enrolled in Long-term Extension Study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.92533171,0.9814847049075592,0.056152994907559206
66.0,201.0,0.0,0.328358,0.328358,5.308268,0.729961,1.0,201.0,12.0,58.0,Enrolled in Long-term Extension Study,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.27233013,1.5148997125239987,0.24256958252399863
2.0,201.0,0.0,0.00995,0.00995,5.308268,0.729961,1.0,201.0,12.0,58.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03855452,0.040035763242499994,0.0014812432424999925
1.0,201.0,0.0,0.004975,0.004975,5.308268,0.729961,1.0,201.0,12.0,58.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01927726,0.01946949923605161,0.00019223923605160911
1.0,201.0,0.0,0.004975,0.004975,5.308268,0.729961,1.0,201.0,12.0,58.0,Participant Randomized but died before dosing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01927726,0.01946559893724208,0.00018833893724207879
0.0,201.0,0.0,0.0,0.0,5.308268,0.729961,1.0,201.0,12.0,58.0,Participant Randomized but died before dosing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
19.0,478.0,444.0,0.039749,0.039749,6.171701,0.541128,1.0,478.0,20.0,140.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13274888,0.13616952546734118,0.0034206454673411657
10.0,478.0,444.0,0.020921,0.020921,6.171701,0.541128,1.0,478.0,20.0,140.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06986941,0.06926041792720233,0.0006089920727976733
2.0,478.0,444.0,0.004184,0.004184,6.171701,0.541128,1.0,478.0,20.0,140.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01397321,0.014130382080337294,0.00015717208033729467
3.0,478.0,444.0,0.006276,0.006276,6.171701,0.541128,1.0,478.0,20.0,140.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02095982,0.021553688070833337,0.0005938680708333366
1.0,225.0,222.0,0.004444,0.004444,5.420535,1.0,1.0,225.0,1.0,8.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02408886,0.024020338570079427,6.852142992057331e-05
1.0,225.0,222.0,0.004444,0.004444,5.420535,1.0,1.0,225.0,1.0,8.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02408886,0.024009991481746092,7.886851825390784e-05
0.0,225.0,222.0,0.0,0.0,5.420535,1.0,1.0,225.0,1.0,8.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,225.0,222.0,0.004444,0.004444,5.420535,1.0,1.0,225.0,1.0,8.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02408886,0.02399241070882942,9.644929117057915e-05
23.0,806.0,620.0,0.028536,0.028536,6.693324,0.296667,1.0,806.0,2.0,25.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.05666366,0.05722601013819448,0.0005623501381944798
21.0,806.0,620.0,0.026055,0.026055,6.693324,0.296667,1.0,806.0,2.0,25.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.05173716,0.05222208228757577,0.00048492228757577444
33.0,806.0,620.0,0.040943,0.040943,6.693324,0.296667,1.0,806.0,2.0,25.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.08130012,0.0821892673581349,0.0008891473581348897
37.0,806.0,620.0,0.045906,0.045906,6.693324,0.296667,1.0,806.0,2.0,25.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.0911551,0.091022715683605,0.0001323843163950067
36.0,806.0,620.0,0.044665,0.044665,6.693324,0.296667,1.0,806.0,2.0,25.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.08869085,0.0890662411525534,0.00037539115255340316
36.0,806.0,620.0,0.044665,0.044665,6.693324,0.296667,1.0,806.0,2.0,25.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.08869085,0.0888587158966308,0.00016786589663080054
10.0,5022.0,4900.0,0.001991,0.001991,8.521783,0.508378,1.0,5081.0,32.0,563.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00862558,0.008443481972797618,0.00018209802720238304
9.0,5022.0,4900.0,0.001792,0.001792,8.521783,0.508378,1.0,5081.0,32.0,563.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00776345,0.007862608603018583,9.915860301858322e-05
42.0,5022.0,4900.0,0.008363,0.008363,8.521783,0.508378,1.0,5081.0,32.0,563.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03623089,0.03520261546326752,0.0010282745367324805
55.0,5022.0,4900.0,0.010952,0.010952,8.521783,0.508378,1.0,5081.0,32.0,563.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04744718,0.04680746968207703,0.0006397103179229674
2.0,5022.0,4900.0,0.000398,0.000398,8.521783,0.508378,1.0,5081.0,32.0,563.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172425,0.0017991416837797633,7.489168377976317e-05
4.0,5022.0,4900.0,0.000796,0.000796,8.521783,0.508378,1.0,5081.0,32.0,563.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0034485,0.003538012946567462,8.951294656746192e-05
24.0,21105.0,18635.0,0.001137,0.001137,9.957313,0.330504,1.0,21105.0,46.0,1009.0,never received study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00374179,0.003679128348779763,6.26616512202369e-05
23.0,21105.0,18635.0,0.00109,0.00109,9.957313,0.330504,1.0,21105.0,46.0,1009.0,never received study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00358712,0.0035857388313392875,1.381168660712518e-06
32.0,21105.0,18635.0,0.001516,0.001516,9.957313,0.330504,1.0,21105.0,46.0,1009.0,never received study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00498905,0.004915598304910712,7.345169508928776e-05
19.0,21105.0,18635.0,0.0009,0.0009,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00296184,0.0029166855443921373,4.5154455607862576e-05
17.0,21105.0,18635.0,0.000805,0.000805,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0026492,0.0025551619724801583,9.403802751984172e-05
20.0,21105.0,18635.0,0.000948,0.000948,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0031198,0.002994410836121033,0.00012538916387896688
789.0,21105.0,18635.0,0.037385,0.037385,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12303149,0.11597102254662259,0.007060467453377406
730.0,21105.0,18635.0,0.034589,0.034589,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11383004,0.11013098186521374,0.0036990581347862567
706.0,21105.0,18635.0,0.033452,0.033452,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.11008825,0.1084550463943849,0.0016332036056150995
47.0,21105.0,18635.0,0.002227,0.002227,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00732891,0.00741051276859127,8.160276859126969e-05
37.0,21105.0,18635.0,0.001753,0.001753,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.005769,0.005490626704255951,0.0002783732957440492
25.0,21105.0,18635.0,0.001185,0.001185,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00389975,0.003714770680267857,0.00018497931973214315
0.0,21105.0,18635.0,0.0,0.0,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,2.7867762142857145e-05,2.7867762142857145e-05
0.0,21105.0,18635.0,0.0,0.0,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,2.7867762142857145e-05,2.7867762142857145e-05
1.0,21105.0,18635.0,4.7e-05,4.7e-05,9.957313,0.330504,1.0,21105.0,46.0,1009.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00015467,0.0001540887749404764,5.812250595236027e-07
4.0,652.0,400.0,0.006135,0.006135,6.481577,0.321222,1.0,613.0,11.0,129.0,Other,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.01277324,0.013167055587946423,0.00039381558794642293
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Other,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,652.0,400.0,0.013804,0.013804,6.481577,0.321222,1.0,613.0,11.0,129.0,Adverse Event,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.0287403,0.028652618196190503,8.76818038094973e-05
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Adverse Event,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,652.0,400.0,0.004601,0.004601,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal laboratory value,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.00957941,0.009601435599851195,2.2025599851194927e-05
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal laboratory value,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal test procedure result,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.00319383,0.0032012719443749982,7.441944374998299e-06
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal test procedure result,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,652.0,400.0,0.013804,0.013804,6.481577,0.321222,1.0,613.0,11.0,129.0,Withdrawal by Subject,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.0287403,0.02857175158571431,0.0001685484142856901
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Withdrawal by Subject,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Lost to Follow-up,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.00319383,0.003201996599434522,8.166599434521974e-06
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Lost to Follow-up,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,652.0,400.0,0.018405,0.018405,6.481577,0.321222,1.0,613.0,11.0,129.0,Protocol Violation,Single Blind Period (1 Week),FG000,cardiovascular disease,INDUSTRY,0.03831971,0.03833595888818457,1.6248888184570986e-05
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Protocol Violation,Single Blind Period (1 Week),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
25.0,652.0,400.0,0.038344,0.038344,6.481577,0.321222,1.0,613.0,11.0,129.0,Adverse Event,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.07983324,0.07963546355004963,0.00019777644995036536
14.0,652.0,400.0,0.021472,0.021472,6.481577,0.321222,1.0,613.0,11.0,129.0,Adverse Event,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.04470528,0.04486028670672169,0.00015500670672168732
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal laboratory values,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,652.0,400.0,0.004601,0.004601,6.481577,0.321222,1.0,613.0,11.0,129.0,Abnormal laboratory values,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00957941,0.009604611938184527,2.520193818452733e-05
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Lack of Efficacy,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00319383,0.003198606613124998,4.776613124997994e-06
0.0,652.0,400.0,0.0,0.0,6.481577,0.321222,1.0,613.0,11.0,129.0,Lack of Efficacy,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,652.0,400.0,0.004601,0.004601,6.481577,0.321222,1.0,613.0,11.0,129.0,Patient's no longer requires study drug,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00957941,0.009601435599851195,2.2025599851194927e-05
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Patient's no longer requires study drug,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00319383,0.0031985683260416634,4.7383260416635105e-06
2.0,652.0,400.0,0.003067,0.003067,6.481577,0.321222,1.0,613.0,11.0,129.0,Protocol Violation,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00638558,0.006307212496101194,7.836750389880569e-05
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Protocol Violation,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00319383,0.0031975093162202356,3.6793162202356823e-06
19.0,652.0,400.0,0.029141,0.029141,6.481577,0.321222,1.0,613.0,11.0,129.0,Withdrawal by Subject,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.06067235,0.06067452021384916,2.170213849163327e-06
18.0,652.0,400.0,0.027607,0.027607,6.481577,0.321222,1.0,613.0,11.0,129.0,Withdrawal by Subject,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.05747852,0.05769959535781385,0.00022107535781384913
8.0,652.0,400.0,0.01227,0.01227,6.481577,0.321222,1.0,613.0,11.0,129.0,Lost to Follow-up,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.02554647,0.02545572430093254,9.074569906746335e-05
10.0,652.0,400.0,0.015337,0.015337,6.481577,0.321222,1.0,613.0,11.0,129.0,Lost to Follow-up,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.03193205,0.031810570443075434,0.00012147955692456275
45.0,652.0,400.0,0.069018,0.069018,6.481577,0.321222,1.0,613.0,11.0,129.0,Administrative problems,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.14369734,0.1417804299943156,0.001916910005684419
56.0,652.0,400.0,0.08589,0.08589,6.481577,0.321222,1.0,613.0,11.0,129.0,Administrative problems,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.17882529,0.18000200961437493,0.0011767196143749326
1.0,652.0,400.0,0.001534,0.001534,6.481577,0.321222,1.0,613.0,11.0,129.0,Death,Double Blind Period (103 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00319383,0.003198567963124998,4.737963124998041e-06
6.0,652.0,400.0,0.009202,0.009202,6.481577,0.321222,1.0,613.0,11.0,129.0,Death,Double Blind Period (103 Weeks),FG001,cardiovascular disease,INDUSTRY,0.01915881,0.01919379698512896,3.4986985128961784e-05
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00676479,0.006763934370119088,8.556298809114446e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Death,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00676479,0.006763545982619088,1.2440173809118854e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00676479,0.00676450347791671,2.8652208328931034e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Protocol Violation,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,500.0,444.0,0.004,0.004,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01352958,0.01356468405946433,3.510405946433037e-05
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,500.0,444.0,0.004,0.004,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.01352958,0.013560637242797668,3.105724279766839e-05
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Efficacy outcome reached,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,500.0,444.0,0.004,0.004,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01352958,0.013570599715000041,4.101971500004159e-05
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00676479,0.0067646221312500435,1.678687499562237e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Patient convenience,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,500.0,444.0,0.01,0.01,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03382395,0.03389028099898812,6.633099898812472e-05
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00676479,0.006775198710000041,1.0408710000041344e-05
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00676479,0.006773735039166709,8.945039166709592e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,500.0,444.0,0.014,0.014,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.04735352,0.04749862978901793,0.00014510978901792482
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Withdrawal by Subject,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00676479,0.006763934370119088,8.556298809114446e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Recovery,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,500.0,444.0,0.004,0.004,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01352958,0.013564445692142895,3.4865692142895324e-05
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00676479,0.00676498734166671,1.9734166671007275e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00676479,0.00676498734166671,1.9734166671007275e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00676479,0.00676498734166671,1.9734166671007275e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Other,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,500.0,444.0,0.008,0.008,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02705916,0.027263001858799617,0.00020384185879961797
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00676479,0.00676488741125004,9.741125004021634e-08
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00676479,0.006763181743750043,1.608256249956315e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00676479,0.006763181743750043,1.608256249956315e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Physician Decision,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,500.0,444.0,0.01,0.01,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03382395,0.03390563337583336,8.168337583336349e-05
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00676479,0.00676847307375004,3.683073750039914e-06
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00676479,0.00676703714041671,2.247140416710737e-06
3.0,500.0,444.0,0.006,0.006,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02029437,0.02045628839499998,0.00016191839499998112
2.0,500.0,444.0,0.004,0.004,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01352958,0.013567623219166712,3.8043219166712314e-05
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00676479,0.006766767406250043,1.977406250043383e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00676479,0.006766767406250043,1.977406250043383e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Adverse Event,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00676479,0.006763934370119088,8.556298809114446e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00676479,0.0067646221312500435,1.678687499562237e-07
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00676479,0.0067646221312500435,1.678687499562237e-07
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Non-compliance with study drug,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00676479,0.006760045187619083,4.7448123809169795e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,500.0,444.0,0.002,0.002,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00676479,0.006758487315952418,6.302684047581296e-06
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,500.0,444.0,0.0,0.0,6.216606,0.54409,1.0,500.0,28.0,109.0,Lost to Follow-up,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,345.0,327.0,0.017391,0.017391,5.846439,0.504291,1.0,345.0,2.0,67.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05127401,0.053148943197489106,0.0018749331974891037
1.0,345.0,327.0,0.002899,0.002899,5.846439,0.504291,1.0,345.0,2.0,67.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00854714,0.008584374035158746,3.723403515874628e-05
5.0,345.0,327.0,0.014493,0.014493,5.846439,0.504291,1.0,345.0,2.0,67.0,Sponsor Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04272982,0.04295680974723218,0.0002269897472321758
2.0,345.0,327.0,0.005797,0.005797,5.846439,0.504291,1.0,345.0,2.0,67.0,Sponsor Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01709134,0.01744619712632576,0.00035485712632575897
1.0,345.0,327.0,0.002899,0.002899,5.846439,0.504291,1.0,345.0,2.0,67.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00854714,0.008564077663660736,1.6937663660735597e-05
1.0,345.0,327.0,0.002899,0.002899,5.846439,0.504291,1.0,345.0,2.0,67.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00854714,0.008575972175605177,2.8832175605177437e-05
1.0,345.0,327.0,0.002899,0.002899,5.846439,0.504291,1.0,345.0,2.0,67.0,Withdrawn by Mistake,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00854714,0.00856288204779764,1.574204779763999e-05
0.0,345.0,327.0,0.0,0.0,5.846439,0.504291,1.0,345.0,2.0,67.0,Withdrawn by Mistake,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,345.0,327.0,0.002899,0.002899,5.846439,0.504291,1.0,345.0,2.0,67.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00854714,0.008564062212797638,1.692221279763796e-05
0.0,345.0,327.0,0.0,0.0,5.846439,0.504291,1.0,345.0,2.0,67.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,892.0,734.0,0.002242,0.002242,6.794587,0.766543,1.0,892.0,1.0,17.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0116771,0.010746690813670629,0.0009304091863293704
3.0,892.0,734.0,0.003363,0.003363,6.794587,0.766543,1.0,892.0,1.0,17.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01751565,0.017620503973998024,0.0001048539739980231
3.0,892.0,734.0,0.003363,0.003363,6.794587,0.766543,1.0,892.0,1.0,17.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01751565,0.017646333818998022,0.00013068381899802167
2.0,892.0,734.0,0.002242,0.002242,6.794587,0.766543,1.0,892.0,1.0,17.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0116771,0.010744440503253965,0.0009326594967460338
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,892.0,734.0,0.008969,0.008969,6.794587,0.766543,1.0,892.0,1.0,17.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04671362,0.04503403887640874,0.0016795811235912547
6.0,892.0,734.0,0.006726,0.006726,6.794587,0.766543,1.0,892.0,1.0,17.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03503131,0.03488274239769846,0.0001485676023015442
6.0,892.0,734.0,0.006726,0.006726,6.794587,0.766543,1.0,892.0,1.0,17.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03503131,0.03493837854763893,9.29314523610697e-05
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Non-Compliance With Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,892.0,734.0,0.004484,0.004484,6.794587,0.766543,1.0,892.0,1.0,17.0,Non-Compliance With Study Drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0233542,0.023366257394434525,1.2057394434526053e-05
1.0,892.0,734.0,0.001121,0.001121,6.794587,0.766543,1.0,892.0,1.0,17.0,Non-Compliance With Study Drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00583855,0.005843655553898815,5.105553898815743e-06
20.0,892.0,734.0,0.022422,0.022422,6.794587,0.766543,1.0,892.0,1.0,17.0,Participant Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11678144,0.1158372558251984,0.0009441841748016044
19.0,892.0,734.0,0.0213,0.0213,6.794587,0.766543,1.0,892.0,1.0,17.0,Participant Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11093768,0.10909811864292662,0.0018395613570733743
26.0,892.0,734.0,0.029148,0.029148,6.794587,0.766543,1.0,892.0,1.0,17.0,Participant Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.15181275,0.15385503125251968,0.0020422812525196787
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,892.0,734.0,0.001121,0.001121,6.794587,0.766543,1.0,892.0,1.0,17.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00583855,0.005859940172886912,2.1390172886912723e-05
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,892.0,734.0,0.004484,0.004484,6.794587,0.766543,1.0,892.0,1.0,17.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0233542,0.023387623142410715,3.342314241071634e-05
3.0,892.0,734.0,0.003363,0.003363,6.794587,0.766543,1.0,892.0,1.0,17.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01751565,0.017694045115877525,0.00017839511587752419
7.0,892.0,734.0,0.007848,0.007848,6.794587,0.766543,1.0,892.0,1.0,17.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04087507,0.04079770920158731,7.736079841268867e-05
13.0,892.0,734.0,0.014574,0.014574,6.794587,0.766543,1.0,892.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07590637,0.07217510572400805,0.0037312642759919495
9.0,892.0,734.0,0.01009,0.01009,6.794587,0.766543,1.0,892.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05255217,0.052613454896994066,6.128489699406409e-05
20.0,892.0,734.0,0.022422,0.022422,6.794587,0.766543,1.0,892.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.11678144,0.11539274838249003,0.0013886916175099712
1.0,892.0,734.0,0.001121,0.001121,6.794587,0.766543,1.0,892.0,1.0,17.0,Mis-randomized,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00583855,0.005843738977232149,5.188977232149089e-06
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Mis-randomized,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,892.0,734.0,0.0,0.0,6.794587,0.766543,1.0,892.0,1.0,17.0,Mis-randomized,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,610.0,555.0,0.018033,0.018033,6.415097,0.25113,1.0,610.0,1.0,2.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02905159,0.029047390221190454,4.199778809544502e-06
21.0,610.0,555.0,0.034426,0.034426,6.415097,0.25113,1.0,610.0,1.0,2.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05546111,0.05380891297972219,0.0016521970202778083
1.0,610.0,555.0,0.001639,0.001639,6.415097,0.25113,1.0,610.0,1.0,2.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00264047,0.0026501304982142863,9.660498214286543e-06
0.0,610.0,555.0,0.0,0.0,6.415097,0.25113,1.0,610.0,1.0,2.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,610.0,555.0,0.003279,0.003279,6.415097,0.25113,1.0,610.0,1.0,2.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00528255,0.00513128601940478,0.00015126398059521918
3.0,610.0,555.0,0.004918,0.004918,6.415097,0.25113,1.0,610.0,1.0,2.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00792302,0.007904159793819428,1.886020618057163e-05
3.0,610.0,555.0,0.004918,0.004918,6.415097,0.25113,1.0,610.0,1.0,2.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00792302,0.00789609272676586,2.692727323413968e-05
0.0,610.0,555.0,0.0,0.0,6.415097,0.25113,1.0,610.0,1.0,2.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,610.0,555.0,0.009836,0.009836,6.415097,0.25113,1.0,610.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01584603,0.015712761860585334,0.0001332681394146662
8.0,610.0,555.0,0.013115,0.013115,6.415097,0.25113,1.0,610.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02112858,0.021172628639613097,4.404863961309652e-05
20.0,1085.0,948.0,0.018433,0.018433,6.990257,0.256675,1.0,1085.0,3.0,80.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03307291,0.032728443646924635,0.0003444663530753622
30.0,1085.0,948.0,0.02765,0.02765,6.990257,0.256675,1.0,1085.0,3.0,80.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04961026,0.05004849088422619,0.00043823088422619005
11.0,1085.0,948.0,0.010138,0.010138,6.990257,0.256675,1.0,1085.0,3.0,80.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01818983,0.01814175788985117,4.807211014883073e-05
5.0,1085.0,948.0,0.004608,0.004608,6.990257,0.256675,1.0,1085.0,3.0,80.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00826778,0.008244094575694446,2.3685424305554953e-05
4.0,1085.0,948.0,0.003687,0.003687,6.990257,0.256675,1.0,1085.0,3.0,80.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0066153,0.006561635610069441,5.366438993055934e-05
0.0,1085.0,948.0,0.0,0.0,6.990257,0.256675,1.0,1085.0,3.0,80.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,1085.0,948.0,0.007373,0.007373,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01322881,0.013093971163005945,0.00013483883699405563
2.0,1085.0,948.0,0.001843,0.001843,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00330675,0.0032162265388690466,9.05234611309532e-05
5.0,1085.0,948.0,0.004608,0.004608,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00826778,0.00825104904820437,1.6730951795631416e-05
11.0,1085.0,948.0,0.010138,0.010138,6.990257,0.256675,1.0,1085.0,3.0,80.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01818983,0.018118132357559505,7.169764244049567e-05
11.0,1085.0,948.0,0.010138,0.010138,6.990257,0.256675,1.0,1085.0,3.0,80.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01818983,0.0181298605375595,5.996946244049908e-05
9.0,1085.0,948.0,0.008295,0.008295,6.990257,0.256675,1.0,1085.0,3.0,80.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01488308,0.014734165576061513,0.00014891442393848674
1.0,1085.0,948.0,0.000922,0.000922,6.990257,0.256675,1.0,1085.0,3.0,80.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00165427,0.0016601177198412673,5.8477198412673365e-06
0.0,1085.0,948.0,0.0,0.0,6.990257,0.256675,1.0,1085.0,3.0,80.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1085.0,948.0,0.0,0.0,6.990257,0.256675,1.0,1085.0,3.0,80.0,Pregnancy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1085.0,948.0,0.000922,0.000922,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00165427,0.0016604499260912675,6.1799260912675114e-06
1.0,1085.0,948.0,0.000922,0.000922,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00165427,0.0016553251290972193,1.0551290972192658e-06
2.0,1085.0,948.0,0.001843,0.001843,6.990257,0.256675,1.0,1085.0,3.0,80.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00330675,0.0032201778966666657,8.657210333333411e-05
9.0,1085.0,948.0,0.008295,0.008295,6.990257,0.256675,1.0,1085.0,3.0,80.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01488308,0.014734219934960324,0.0001488600650396757
1.0,1085.0,948.0,0.000922,0.000922,6.990257,0.256675,1.0,1085.0,3.0,80.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00165427,0.0016537824165972193,4.875834027806992e-07
6.0,1085.0,948.0,0.00553,0.00553,6.990257,0.256675,1.0,1085.0,3.0,80.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00992205,0.009727621021527778,0.0001944289784722216
347.0,4822.0,4085.0,0.071962,0.071962,8.481151,0.560876,1.0,4822.0,43.0,715.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.34231411,0.33352811483984157,0.008785995160158433
356.0,4822.0,4085.0,0.073828,0.073828,8.481151,0.560876,1.0,4822.0,43.0,715.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.35119043,0.33597105407534733,0.015219375924652667
13.0,4822.0,4085.0,0.002696,0.002696,8.481151,0.560876,1.0,4822.0,43.0,715.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01282453,0.012891839437976182,6.730943797618114e-05
14.0,4822.0,4085.0,0.002903,0.002903,8.481151,0.560876,1.0,4822.0,43.0,715.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0138092,0.013777014442578466,3.2185557421534824e-05
4.0,4822.0,4085.0,0.00083,0.00083,8.481151,0.560876,1.0,4822.0,43.0,715.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0039482,0.0038704282060091025,7.777179399089725e-05
3.0,4822.0,4085.0,0.000622,0.000622,8.481151,0.560876,1.0,4822.0,43.0,715.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00295878,0.003007271299900794,4.84912999007942e-05
2.0,803.0,782.0,0.002491,0.002491,6.689599,0.395941,1.0,803.0,7.0,33.0,Physician decision: No 30-day visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00659787,0.006609446030853141,1.1576030853141343e-05
1.0,803.0,782.0,0.001245,0.001245,6.689599,0.395941,1.0,803.0,7.0,33.0,Physician decision: No 30-day visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00329761,0.0033017785691269712,4.168569126971385e-06
2.0,803.0,782.0,0.002491,0.002491,6.689599,0.395941,1.0,803.0,7.0,33.0,Reason Not Specified: No 30-day visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00659787,0.00660734659644838,9.476596448380718e-06
2.0,803.0,782.0,0.002491,0.002491,6.689599,0.395941,1.0,803.0,7.0,33.0,Reason Not Specified: No 30-day visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00659787,0.006599794414335288,1.924414335288671e-06
2.0,803.0,782.0,0.002491,0.002491,6.689599,0.395941,1.0,803.0,7.0,33.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00659787,0.006608477405495997,1.0607405495997174e-05
0.0,803.0,782.0,0.0,0.0,6.689599,0.395941,1.0,803.0,7.0,33.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,803.0,782.0,0.003736,0.003736,6.689599,0.395941,1.0,803.0,7.0,33.0,Inclusion/Exclusion Criteria Not Met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00989548,0.009730077701329345,0.00016540229867065444
0.0,803.0,782.0,0.0,0.0,6.689599,0.395941,1.0,803.0,7.0,33.0,Inclusion/Exclusion Criteria Not Met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,803.0,782.0,0.001245,0.001245,6.689599,0.395941,1.0,803.0,7.0,33.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00329761,0.0032931476368055408,4.4623631944590986e-06
2.0,803.0,782.0,0.002491,0.002491,6.689599,0.395941,1.0,803.0,7.0,33.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00659787,0.006603924115406716,6.05411540671643e-06
1.0,803.0,782.0,0.001245,0.001245,6.689599,0.395941,1.0,803.0,7.0,33.0,Physician decision: Day 30 visit <23 day,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00329761,0.003290888474305541,6.721525694458781e-06
5.0,803.0,782.0,0.006227,0.006227,6.689599,0.395941,1.0,803.0,7.0,33.0,Physician decision: Day 30 visit <23 day,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01649336,0.016540914840515872,4.7554840515873914e-05
3.0,713.0,698.0,0.004208,0.004208,6.570883,0.49917,1.0,713.0,3.0,35.0,Withdrawn by parent/guardian,Overall Study,FG000,cardiovascular disease,OTHER,0.01380218,0.013679586355694455,0.00012259364430554538
2.0,713.0,698.0,0.002805,0.002805,6.570883,0.49917,1.0,713.0,3.0,35.0,Withdrawn by parent/guardian,Overall Study,FG001,cardiovascular disease,OTHER,0.00920036,0.009105483486081353,9.487651391864617e-05
8.0,713.0,698.0,0.01122,0.01122,6.570883,0.49917,1.0,713.0,3.0,35.0,Randomized; did not receive intevention,Overall Study,FG000,cardiovascular disease,OTHER,0.03680145,0.03650663986974209,0.00029481013025790814
2.0,713.0,698.0,0.002805,0.002805,6.570883,0.49917,1.0,713.0,3.0,35.0,Randomized; did not receive intevention,Overall Study,FG001,cardiovascular disease,OTHER,0.00920036,0.009105483486081353,9.487651391864617e-05
11.0,524.0,460.0,0.020992,0.020992,6.263398,0.441414,1.0,524.0,16.0,91.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05803772,0.058214015516061514,0.0001762955160615129
8.0,524.0,460.0,0.015267,0.015267,6.263398,0.441414,1.0,524.0,16.0,91.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0422095,0.04193901876532736,0.00027048123467263846
7.0,524.0,460.0,0.013359,0.013359,6.263398,0.441414,1.0,524.0,16.0,91.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03693435,0.03704092967480149,0.00010657967480149494
3.0,524.0,460.0,0.005725,0.005725,6.263398,0.441414,1.0,524.0,16.0,91.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01582822,0.015935436055168693,0.00010721605516869279
1.0,524.0,460.0,0.001908,0.001908,6.263398,0.441414,1.0,524.0,16.0,91.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00527515,0.005308537341730538,3.338734173053814e-05
0.0,524.0,460.0,0.0,0.0,6.263398,0.441414,1.0,524.0,16.0,91.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,524.0,460.0,0.003817,0.003817,6.263398,0.441414,1.0,524.0,16.0,91.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01055307,0.010526820312727274,2.62496872727256e-05
1.0,524.0,460.0,0.001908,0.001908,6.263398,0.441414,1.0,524.0,16.0,91.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00527515,0.005305191357772204,3.0041357772203972e-05
2.0,524.0,460.0,0.003817,0.003817,6.263398,0.441414,1.0,524.0,16.0,91.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01055307,0.01052494720481061,2.8122795189390246e-05
7.0,524.0,460.0,0.013359,0.013359,6.263398,0.441414,1.0,524.0,16.0,91.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03693435,0.037044952556041566,0.00011060255604156827
4.0,524.0,460.0,0.007634,0.007634,6.263398,0.441414,1.0,524.0,16.0,91.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02110613,0.021107694011364517,1.5640113645160048e-06
4.0,524.0,460.0,0.007634,0.007634,6.263398,0.441414,1.0,524.0,16.0,91.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02110613,0.021101393223626412,4.736776373588658e-06
5.0,524.0,460.0,0.009542,0.009542,6.263398,0.441414,1.0,524.0,16.0,91.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02638128,0.026516754788095242,0.00013547478809524185
1.0,524.0,460.0,0.001908,0.001908,6.263398,0.441414,1.0,524.0,16.0,91.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00527515,0.005307855391340408,3.2705391340408056e-05
3.0,524.0,460.0,0.005725,0.005725,6.263398,0.441414,1.0,524.0,16.0,91.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01582822,0.01593187142897821,0.00010365142897821034
3.0,524.0,460.0,0.005725,0.005725,6.263398,0.441414,1.0,524.0,16.0,91.0,protocol specific treatment unrelated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01582822,0.015940011815585364,0.00011179181558536311
0.0,524.0,460.0,0.0,0.0,6.263398,0.441414,1.0,524.0,16.0,91.0,protocol specific treatment unrelated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,524.0,460.0,0.003817,0.003817,6.263398,0.441414,1.0,524.0,16.0,91.0,protocol specific treatment unrelated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01055307,0.010525474560465369,2.7595439534630964e-05
10.0,321.0,246.0,0.031153,0.031153,5.774552,1.0,1.0,321.0,1.0,38.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1798946,0.17611483673174605,0.0037797632682539384
34.0,321.0,246.0,0.105919,0.105919,5.774552,1.0,1.0,321.0,1.0,38.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.61163473,0.5680379979160416,0.04359673208395842
2.0,321.0,246.0,0.006231,0.006231,5.774552,1.0,1.0,321.0,1.0,38.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03598123,0.03602320075946446,4.1970759464458884e-05
1.0,321.0,246.0,0.003115,0.003115,5.774552,1.0,1.0,321.0,1.0,38.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01798773,0.018057692998234127,6.99629982341271e-05
5.0,321.0,246.0,0.015576,0.015576,5.774552,1.0,1.0,321.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08994441,0.09002259970197406,7.818970197405462e-05
7.0,321.0,246.0,0.021807,0.021807,5.774552,1.0,1.0,321.0,1.0,38.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12592565,0.12374232945043646,0.002183320549563536
4.0,321.0,246.0,0.012461,0.012461,5.774552,1.0,1.0,321.0,1.0,38.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07195669,0.07232367387916672,0.00036698387916671293
5.0,321.0,246.0,0.015576,0.015576,5.774552,1.0,1.0,321.0,1.0,38.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08994441,0.09005287815989071,0.00010846815989071223
2.0,321.0,246.0,0.006231,0.006231,5.774552,1.0,1.0,321.0,1.0,38.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03598123,0.03602992930863116,4.8699308631154625e-05
2.0,321.0,246.0,0.006231,0.006231,5.774552,1.0,1.0,321.0,1.0,38.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03598123,0.03603347535988115,5.224535988114509e-05
2.0,321.0,246.0,0.006231,0.006231,5.774552,1.0,1.0,321.0,1.0,38.0,"did not meet criteria, non-compliance",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03598123,0.036020486546964464,3.9256546964461236e-05
1.0,321.0,246.0,0.003115,0.003115,5.774552,1.0,1.0,321.0,1.0,38.0,"did not meet criteria, non-compliance",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01798773,0.018057692998234127,6.99629982341271e-05
13.0,537.0,487.0,0.024209,0.024209,6.287859,0.283988,1.0,537.0,8.0,70.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04322951,0.04161537510092355,0.0016141348990764484
7.0,537.0,487.0,0.013035,0.013035,6.287859,0.283988,1.0,537.0,8.0,70.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02327633,0.02303806576547619,0.000238264234523812
1.0,537.0,487.0,0.001862,0.001862,6.287859,0.283988,1.0,537.0,8.0,70.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00332493,0.0033834296426091246,5.849964260912482e-05
2.0,537.0,487.0,0.003724,0.003724,6.287859,0.283988,1.0,537.0,8.0,70.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00664987,0.006650714586755936,8.445867559353504e-07
5.0,537.0,487.0,0.009311,0.009311,6.287859,0.283988,1.0,537.0,8.0,70.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01662646,0.016486392270942455,0.00014006772905754417
8.0,537.0,487.0,0.014898,0.014898,6.287859,0.283988,1.0,537.0,8.0,70.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02660305,0.0263008647221032,0.0003021852778967993
3.0,537.0,487.0,0.005587,0.005587,6.287859,0.283988,1.0,537.0,8.0,70.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00997659,0.009931808819404751,4.4781180595249506e-05
3.0,537.0,487.0,0.005587,0.005587,6.287859,0.283988,1.0,537.0,8.0,70.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00997659,0.009936964477509908,3.962552249009259e-05
0.0,537.0,487.0,0.0,0.0,6.287859,0.283988,1.0,537.0,8.0,70.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,537.0,487.0,0.003724,0.003724,6.287859,0.283988,1.0,537.0,8.0,70.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00664987,0.006648716111755936,1.1538882440645035e-06
1.0,537.0,487.0,0.001862,0.001862,6.287859,0.283988,1.0,537.0,8.0,70.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00332493,0.003384209328859126,5.927932885912632e-05
5.0,537.0,487.0,0.009311,0.009311,6.287859,0.283988,1.0,537.0,8.0,70.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01662646,0.016490028588204354,0.00013643141179564555
32.0,932.0,625.0,0.034335,0.034335,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.05982453,0.058170062574871,0.0016544674251290012
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,932.0,625.0,0.011803,0.011803,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.02056528,0.019739037132708345,0.000826242867291653
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
96.0,932.0,625.0,0.103004,0.103004,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Test Procedure Result(s),Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.17947184,0.17385535166143842,0.0056164883385615705
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Test Procedure Result(s),Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Test Procedure Result(s),Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,932.0,625.0,0.007511,0.007511,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.013087,0.012981033306488102,0.00010596669351189796
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,932.0,625.0,0.001073,0.001073,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Laboratory Value,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.00186957,0.001869493681626978,7.631837302206866e-08
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Laboratory Value,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal Laboratory Value,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,932.0,625.0,0.004292,0.004292,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.00747828,0.007454207260565476,2.407273943452401e-05
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
82.0,932.0,625.0,0.087983,0.087983,6.838405,0.254793,1.0,932.0,1.0,2.0,Administrative problems,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.15329959,0.15575539421116066,0.0024558042111606504
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Administrative problems,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Administrative problems,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
45.0,932.0,625.0,0.048283,0.048283,6.838405,0.254793,1.0,932.0,1.0,2.0,Condition no longer requires study drug,Single-Blind Valsartan 160 mg,FG000,cardiovascular disease,INDUSTRY,0.08412721,0.08355379158301587,0.00057341841698412
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Condition no longer requires study drug,Single-Blind Valsartan 160 mg,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Condition no longer requires study drug,Single-Blind Valsartan 160 mg,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,932.0,625.0,0.002146,0.002146,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.00373914,0.0037231298632341247,1.601013676587543e-05
2.0,932.0,625.0,0.002146,0.002146,6.838405,0.254793,1.0,932.0,1.0,2.0,Adverse Event,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00373914,0.0037269048986805537,1.223510131944652e-05
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,932.0,625.0,0.008584,0.008584,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.01495657,0.014729853439712295,0.0002267165602877052
13.0,932.0,625.0,0.013948,0.013948,6.838405,0.254793,1.0,932.0,1.0,2.0,Withdrawal by Subject,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.02430268,0.022980577069394856,0.0013221029306051436
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal test procedure result(s),Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal test procedure result(s),Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,932.0,625.0,0.001073,0.001073,6.838405,0.254793,1.0,932.0,1.0,2.0,Abnormal test procedure result(s),Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00186957,0.001869135440317452,4.345596825480313e-07
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,932.0,625.0,0.001073,0.001073,6.838405,0.254793,1.0,932.0,1.0,2.0,Unsatisfactory therapeutic effect,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00186957,0.001869135440317452,4.345596825480313e-07
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Protocol deviation,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Protocol deviation,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,932.0,625.0,0.001073,0.001073,6.838405,0.254793,1.0,932.0,1.0,2.0,Protocol deviation,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00186957,0.001869135440317452,4.345596825480313e-07
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Double-Blind Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,932.0,625.0,0.0,0.0,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Double-Blind Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,932.0,625.0,0.001073,0.001073,6.838405,0.254793,1.0,932.0,1.0,2.0,Lost to Follow-up,Double-Blind Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00186957,0.001869310860317453,2.591396825470625e-07
4.0,1000.0,987.0,0.004,0.004,6.908755,0.298717,1.0,1000.0,1.0,1.0,Lost to Follow-up,28-Day Follow-up,FG000,cardiovascular disease,OTHER,0.00825504,0.008271143639295635,1.6103639295635477e-05
9.0,1000.0,987.0,0.009,0.009,6.908755,0.298717,1.0,1000.0,1.0,1.0,Lost to Follow-up,28-Day Follow-up,FG001,cardiovascular disease,OTHER,0.01857384,0.018513940850595264,5.9899149404737256e-05
3.0,507.0,490.0,0.005917,0.005917,6.230481,0.36498,1.0,507.0,1.0,4.0,Investigator Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01345527,0.013467320637886894,1.2050637886893908e-05
0.0,507.0,490.0,0.0,0.0,6.230481,0.36498,1.0,507.0,1.0,4.0,Investigator Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,507.0,490.0,0.009862,0.009862,6.230481,0.36498,1.0,507.0,1.0,4.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02242622,0.022544415609345267,0.00011819560934526671
2.0,507.0,490.0,0.003945,0.003945,6.230481,0.36498,1.0,507.0,1.0,4.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00897094,0.008953098980952385,1.784101904761526e-05
2.0,507.0,490.0,0.003945,0.003945,6.230481,0.36498,1.0,507.0,1.0,4.0,Administrative reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00897094,0.008940300776369049,3.063922363095127e-05
1.0,507.0,490.0,0.001972,0.001972,6.230481,0.36498,1.0,507.0,1.0,4.0,Administrative reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00448433,0.004480878556767394,3.451443232605801e-06
3.0,507.0,490.0,0.005917,0.005917,6.230481,0.36498,1.0,507.0,1.0,4.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01345527,0.013469497950386893,1.4227950386892785e-05
1.0,507.0,490.0,0.001972,0.001972,6.230481,0.36498,1.0,507.0,1.0,4.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00448433,0.004481733636648346,2.596363351653995e-06
1.0,18226.0,18022.0,5.5e-05,5.5e-05,9.810659,0.824687,1.0,18226.0,49.0,903.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00044499,0.0004353217972222235,9.668202777776507e-06
1.0,18226.0,18022.0,5.5e-05,5.5e-05,9.810659,0.824687,1.0,18226.0,49.0,903.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00044499,0.0004351804495138902,9.809550486109767e-06
47.0,18226.0,18022.0,0.002579,0.002579,9.810659,0.824687,1.0,18226.0,49.0,903.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02086596,0.020200212526190482,0.0006657474738095172
42.0,18226.0,18022.0,0.002304,0.002304,9.810659,0.824687,1.0,18226.0,49.0,903.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01864102,0.019002209093095242,0.0003611890930952412
32.0,18226.0,18022.0,0.001756,0.001756,9.810659,0.824687,1.0,18226.0,49.0,903.0,Indirect contact,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0142073,0.013822981988531722,0.00038431801146827926
29.0,18226.0,18022.0,0.001591,0.001591,9.810659,0.824687,1.0,18226.0,49.0,903.0,Indirect contact,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01287233,0.012580579515615071,0.00029175048438492834
32.0,18226.0,18022.0,0.001756,0.001756,9.810659,0.824687,1.0,18226.0,49.0,903.0,Other (Not specified),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0142073,0.013839335601031722,0.0003679643989682787
20.0,18226.0,18022.0,0.001097,0.001097,9.810659,0.824687,1.0,18226.0,49.0,903.0,Other (Not specified),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00887552,0.007404943821369049,0.0014705761786309507
1.0,4017.0,4008.0,0.000249,0.000249,8.29854,0.798677,1.0,4017.0,2.0,103.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00165034,0.0016128632623115071,3.74767376884928e-05
0.0,4017.0,4008.0,0.0,0.0,8.29854,0.798677,1.0,4017.0,2.0,103.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,4017.0,4008.0,0.000996,0.000996,8.29854,0.798677,1.0,4017.0,2.0,103.0,Consent Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00660135,0.006398847327380954,0.00020250267261904577
4.0,4017.0,4008.0,0.000996,0.000996,8.29854,0.798677,1.0,4017.0,2.0,103.0,Consent Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00660135,0.0064417559423809514,0.0001595940576190483
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Low Creatinine Clearance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00321064,0.003201668050333226,8.971949666774018e-06
2.0,1046.0,354.0,0.001912,0.001912,6.953684,0.482968,1.0,1046.0,6.0,9.0,Low Creatinine Clearance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00642128,0.006428699779414697,7.4197794146975415e-06
86.0,1046.0,354.0,0.082218,0.082218,6.953684,0.482968,1.0,1046.0,6.0,9.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.2761216,0.2771526893683335,0.0010310893683334599
100.0,1046.0,354.0,0.095602,0.095602,6.953684,0.482968,1.0,1046.0,6.0,9.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.32107053,0.315609623285048,0.00546090671495203
10.0,1046.0,354.0,0.00956,0.00956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Cancer Cured,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03210638,0.03207245664160357,3.392335839642879e-05
15.0,1046.0,354.0,0.01434,0.01434,6.953684,0.482968,1.0,1046.0,6.0,9.0,Cancer Cured,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04815957,0.0477762234903175,0.0003833465096824973
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Patient Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00321064,0.003201668050333226,8.971949666774018e-06
2.0,1046.0,354.0,0.001912,0.001912,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Patient Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00642128,0.006428699779414697,7.4197794146975415e-06
10.0,1046.0,354.0,0.00956,0.00956,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Palliative Treatment Only,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03210638,0.03207245664160357,3.392335839642879e-05
7.0,1046.0,354.0,0.006692,0.006692,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Palliative Treatment Only,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02247447,0.02220477454032738,0.00026969545967261976
0.0,1046.0,354.0,0.0,0.0,6.953684,0.482968,1.0,1046.0,6.0,9.0,Prohibited Concomitant Medication Use,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Prohibited Concomitant Medication Use,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00321064,0.0032047144805036802,5.925519496319601e-06
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,"Platelet Count <50,000/mL",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00321064,0.003201668050333226,8.971949666774018e-06
2.0,1046.0,354.0,0.001912,0.001912,6.953684,0.482968,1.0,1046.0,6.0,9.0,"Platelet Count <50,000/mL",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00642128,0.006428699779414697,7.4197794146975415e-06
3.0,1046.0,354.0,0.002868,0.002868,6.953684,0.482968,1.0,1046.0,6.0,9.0,Surgery/Medical Procedure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00963191,0.009514203062896824,0.00011770693710317671
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Surgery/Medical Procedure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00321064,0.0032047144805036802,5.925519496319601e-06
6.0,1046.0,354.0,0.005736,0.005736,6.953684,0.482968,1.0,1046.0,6.0,9.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01926383,0.01910494293959055,0.0001588870604094482
8.0,1046.0,354.0,0.007648,0.007648,6.953684,0.482968,1.0,1046.0,6.0,9.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02568511,0.02516650410986113,0.0005186058901388707
6.0,1046.0,354.0,0.005736,0.005736,6.953684,0.482968,1.0,1046.0,6.0,9.0,Start of New Chemotherapy Regimen,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01926383,0.01907509230459055,0.0001887376954094501
3.0,1046.0,354.0,0.002868,0.002868,6.953684,0.482968,1.0,1046.0,6.0,9.0,Start of New Chemotherapy Regimen,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00963191,0.00951528198489087,0.00011662801510912979
53.0,1046.0,354.0,0.050669,0.050669,6.953684,0.482968,1.0,1046.0,6.0,9.0,Cancer Progression,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17016718,0.16732568940870046,0.002841490591299539
33.0,1046.0,354.0,0.031549,0.031549,6.953684,0.482968,1.0,1046.0,6.0,9.0,Cancer Progression,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10595442,0.10511598886700402,0.0008384311329959759
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00321064,0.0032027823169998924,7.857683000107429e-06
0.0,1046.0,354.0,0.0,0.0,6.953684,0.482968,1.0,1046.0,6.0,9.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
79.0,1046.0,354.0,0.075526,0.075526,6.953684,0.482968,1.0,1046.0,6.0,9.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.25364713,0.25238025707941486,0.0012668729205851381
62.0,1046.0,354.0,0.059273,0.059273,6.953684,0.482968,1.0,1046.0,6.0,9.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.19906292,0.19319106161497043,0.005871858385029571
11.0,1046.0,354.0,0.010516,0.010516,6.953684,0.482968,1.0,1046.0,6.0,9.0,No reason provided,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03531702,0.035536705606398836,0.0002196856063988381
9.0,1046.0,354.0,0.008604,0.008604,6.953684,0.482968,1.0,1046.0,6.0,9.0,No reason provided,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02889574,0.028842194453002352,5.354554699764716e-05
21.0,1046.0,354.0,0.020076,0.020076,6.953684,0.482968,1.0,1046.0,6.0,9.0,PD: Inconvenience of Dosing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0674234,0.06832408251886816,0.0009006825188681705
78.0,1046.0,354.0,0.07457,0.07457,6.953684,0.482968,1.0,1046.0,6.0,9.0,PD: Inconvenience of Dosing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.25043649,0.24961494282139896,0.0008215471786010564
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00321064,0.003208047143011796,2.592856988203971e-06
1.0,1046.0,354.0,0.000956,0.000956,6.953684,0.482968,1.0,1046.0,6.0,9.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00321064,0.0032103020865155846,3.3791348441527397e-07
32.0,1046.0,354.0,0.030593,0.030593,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Benefit/Risk Judgment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10274378,0.10269769500238096,4.608499761904472e-05
46.0,1046.0,354.0,0.043977,0.043977,6.953684,0.482968,1.0,1046.0,6.0,9.0,ID: Benefit/Risk Judgment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14769271,0.1504230738821727,0.0027303638821726817
80.0,12546.0,8786.0,0.006377,0.006377,9.437237,0.449343,1.0,12546.0,8.0,466.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02704205,0.027249709493422616,0.0002076594934226142
69.0,12546.0,8786.0,0.0055,0.0055,9.437237,0.449343,1.0,12546.0,8.0,466.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02332308,0.023672919511706376,0.0003498395117063763
140.0,12546.0,8786.0,0.011159,0.011159,9.437237,0.449343,1.0,12546.0,8.0,466.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04732041,0.04634705889028229,0.0009733511097177114
137.0,12546.0,8786.0,0.01092,0.01092,9.437237,0.449343,1.0,12546.0,8.0,466.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04630692,0.04582783999733587,0.0004790800026641326
236.0,12546.0,8786.0,0.018811,0.018811,9.437237,0.449343,1.0,12546.0,8.0,466.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07976918,0.07646635501281736,0.003302824987182637
239.0,12546.0,8786.0,0.01905,0.01905,9.437237,0.449343,1.0,12546.0,8.0,466.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08078268,0.07755908672216263,0.003223593277837361
91.0,12546.0,8786.0,0.007253,0.007253,9.437237,0.449343,1.0,12546.0,8.0,466.0,Missing end-of-study page,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03075678,0.030160125294553572,0.000596654705446429
92.0,12546.0,8786.0,0.007333,0.007333,9.437237,0.449343,1.0,12546.0,8.0,466.0,Missing end-of-study page,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03109603,0.030754225095952378,0.0003418049040476226
110.0,12546.0,8786.0,0.008768,0.008768,9.437237,0.449343,1.0,12546.0,8.0,466.0,Clinical endpoint reached,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03718123,0.03642277394342259,0.000758456056577414
123.0,12546.0,8786.0,0.009804,0.009804,9.437237,0.449343,1.0,12546.0,8.0,466.0,Clinical endpoint reached,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04157445,0.04188490675383931,0.00031045675383931104
4.0,12546.0,8786.0,0.000319,0.000319,9.437237,0.449343,1.0,12546.0,8.0,466.0,Insufficient therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00135274,0.0013035046307837315,4.9235369216268574e-05
5.0,12546.0,8786.0,0.000399,0.000399,9.437237,0.449343,1.0,12546.0,8.0,466.0,Insufficient therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00169198,0.0017390598773250343,4.7079877325034237e-05
817.0,12546.0,8786.0,0.06512,0.06512,9.437237,0.449343,1.0,12546.0,8.0,466.0,Consent withdrawn by subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.27614529,0.26162754182699427,0.014517748173005718
873.0,12546.0,8786.0,0.069584,0.069584,9.437237,0.449343,1.0,12546.0,8.0,466.0,Consent withdrawn by subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.29507515,0.27626914881462317,0.01880600118537684
23.0,12546.0,8786.0,0.001833,0.001833,9.437237,0.449343,1.0,12546.0,8.0,466.0,Non-compliant with study treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00777295,0.007561716373097943,0.00021123362690205708
16.0,12546.0,8786.0,0.001275,0.001275,9.437237,0.449343,1.0,12546.0,8.0,466.0,Non-compliant with study treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00540671,0.005167920985634922,0.00023878901436507824
3.0,12546.0,8786.0,0.000239,0.000239,9.437237,0.449343,1.0,12546.0,8.0,466.0,Reason not given,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00101349,0.0010145105409027771,1.0205409027772266e-06
1.0,12546.0,8786.0,8e-05,8e-05,9.437237,0.449343,1.0,12546.0,8.0,466.0,Reason not given,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00033924,0.00034870465086309527,9.464650863095288e-06
129.0,12546.0,8786.0,0.010282,0.010282,9.437237,0.449343,1.0,12546.0,8.0,466.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04360144,0.043254908905942496,0.000346531094057502
122.0,12546.0,8786.0,0.009724,0.009724,9.437237,0.449343,1.0,12546.0,8.0,466.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04123521,0.041343162020595264,0.00010795202059526304
210.0,12546.0,8786.0,0.016738,0.016738,9.437237,0.449343,1.0,12546.0,8.0,466.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0709785,0.07161095026575387,0.00063245026575387
198.0,12546.0,8786.0,0.015782,0.015782,9.437237,0.449343,1.0,12546.0,8.0,466.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06692452,0.06609514744126985,0.0008293725587301543
25.0,12546.0,8786.0,0.001993,0.001993,9.437237,0.449343,1.0,12546.0,8.0,466.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00845144,0.008082671125585323,0.0003687688744146763
17.0,12546.0,8786.0,0.001355,0.001355,9.437237,0.449343,1.0,12546.0,8.0,466.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00574596,0.0054827465940377055,0.00026321340596229415
45.0,302.0,188.0,0.149007,0.149007,5.713733,0.909633,1.0,302.0,16.0,70.0,Ongoing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.77444879,0.7240305430912904,0.05041824690870955
69.0,302.0,188.0,0.228477,0.228477,5.713733,0.909633,1.0,302.0,16.0,70.0,Ongoing,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.18748606,1.1448518081975596,0.04263425180244029
0.0,252.0,226.0,0.0,0.0,5.533389,0.423855,1.0,252.0,7.0,34.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,252.0,226.0,0.003968,0.003968,5.533389,0.423855,1.0,252.0,7.0,34.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00930638,0.009478479034017849,0.0001720990340178495
2.0,252.0,226.0,0.007937,0.007937,5.533389,0.423855,1.0,252.0,7.0,34.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0186151,0.019055831968333308,0.00044073196833330913
0.0,252.0,226.0,0.0,0.0,5.533389,0.423855,1.0,252.0,7.0,34.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,252.0,226.0,0.027778,0.027778,5.533389,0.423855,1.0,252.0,7.0,34.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06514932,0.0658081946541171,0.0006588746541170976
2.0,252.0,226.0,0.007937,0.007937,5.533389,0.423855,1.0,252.0,7.0,34.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0186151,0.019033518931994023,0.0004184189319940239
6.0,252.0,226.0,0.02381,0.02381,5.533389,0.423855,1.0,252.0,7.0,34.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05584294,0.05686286081452388,0.0010199208145238794
6.0,252.0,226.0,0.02381,0.02381,5.533389,0.423855,1.0,252.0,7.0,34.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05584294,0.056907990256547684,0.0010650502565476838
2.0,252.0,226.0,0.007937,0.007937,5.533389,0.423855,1.0,252.0,7.0,34.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0186151,0.01903627315770831,0.00042117315770831207
0.0,252.0,226.0,0.0,0.0,5.533389,0.423855,1.0,252.0,7.0,34.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,608.0,543.0,0.018092,0.018092,6.411818,0.352883,1.0,608.0,3.0,26.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.04093531,0.041069746854414675,0.00013443685441467262
5.0,608.0,543.0,0.008224,0.008224,6.411818,0.352883,1.0,608.0,3.0,26.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.01860778,0.01865334905849117,4.556905849116902e-05
4.0,608.0,543.0,0.006579,0.006579,6.411818,0.352883,1.0,608.0,3.0,26.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.01488577,0.014707702645922633,0.0001780673540773669
2.0,608.0,543.0,0.003289,0.003289,6.411818,0.352883,1.0,608.0,3.0,26.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.00744175,0.00738933018290675,5.241981709324956e-05
7.0,608.0,543.0,0.011513,0.011513,6.411818,0.352883,1.0,608.0,3.0,26.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02604954,0.025762479908194448,0.00028706009180555145
6.0,608.0,543.0,0.009868,0.009868,6.411818,0.352883,1.0,608.0,3.0,26.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.02232753,0.022451956973214296,0.00012442697321429427
0.0,608.0,543.0,0.0,0.0,6.411818,0.352883,1.0,608.0,3.0,26.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,608.0,543.0,0.001645,0.001645,6.411818,0.352883,1.0,608.0,3.0,26.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.00372201,0.0037518012357738097,2.9791235773809696e-05
10.0,608.0,543.0,0.016447,0.016447,6.411818,0.352883,1.0,608.0,3.0,26.0,Underwent aortic root surgery,Overall Study,FG000,cardiovascular disease,OTHER,0.0372133,0.03717462462000995,3.8675379990048275e-05
18.0,608.0,543.0,0.029605,0.029605,6.411818,0.352883,1.0,608.0,3.0,26.0,Underwent aortic root surgery,Overall Study,FG001,cardiovascular disease,OTHER,0.06698484,0.06545067004616072,0.0015341699538392872
0.0,608.0,543.0,0.0,0.0,6.411818,0.352883,1.0,608.0,3.0,26.0,Pregnancy,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,608.0,543.0,0.001645,0.001645,6.411818,0.352883,1.0,608.0,3.0,26.0,Pregnancy,Overall Study,FG001,cardiovascular disease,OTHER,0.00372201,0.0037519463511904772,2.9936351190477245e-05
0.0,400.0,356.0,0.0,0.0,5.993961,0.878022,1.0,400.0,1.0,88.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01315707,0.013166529347002222,9.459347002221952e-06
0.0,400.0,356.0,0.0,0.0,5.993961,0.878022,1.0,400.0,1.0,88.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,400.0,356.0,0.005,0.005,5.993961,0.878022,1.0,400.0,1.0,88.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02631415,0.02632403660948417,9.886609484168613e-06
13.0,400.0,356.0,0.0325,0.0325,5.993961,0.878022,1.0,400.0,1.0,88.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17104195,0.1746279185575893,0.003585968557589303
9.0,400.0,356.0,0.0225,0.0225,5.993961,0.878022,1.0,400.0,1.0,88.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11841366,0.12086854179330356,0.002454881793303554
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01315707,0.013151003984583399,6.066015416601039e-06
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01315707,0.013152080237797681,4.989762202319004e-06
2.0,400.0,356.0,0.005,0.005,5.993961,0.878022,1.0,400.0,1.0,88.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02631415,0.026375195241686553,6.104524168655187e-05
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01315707,0.013162893047002222,5.8230470022218456e-06
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Subject decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01315707,0.013161745993787943,4.675993787943422e-06
8.0,400.0,356.0,0.02,0.02,5.993961,0.878022,1.0,400.0,1.0,88.0,Subject decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10525658,0.10842345815573419,0.0031668781557341874
0.0,400.0,356.0,0.0,0.0,5.993961,0.878022,1.0,400.0,1.0,88.0,Withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,400.0,356.0,0.01,0.01,5.993961,0.878022,1.0,400.0,1.0,88.0,Withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05262829,0.05410883703939486,0.001480547039394861
1.0,400.0,356.0,0.0025,0.0025,5.993961,0.878022,1.0,400.0,1.0,88.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01315707,0.013161745993787943,4.675993787943422e-06
0.0,400.0,356.0,0.0,0.0,5.993961,0.878022,1.0,400.0,1.0,88.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,5407.0,4931.0,0.00037,0.00037,8.595635,0.240569,1.0,5407.0,21.0,143.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0007651,0.000700646065208335,6.445393479166499e-05
0.0,5407.0,4931.0,0.0,0.0,8.595635,0.240569,1.0,5407.0,21.0,143.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
93.0,5407.0,4931.0,0.0172,0.0172,8.595635,0.240569,1.0,5407.0,21.0,143.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03556685,0.036233948868819456,0.0006670988688194587
112.0,5407.0,4931.0,0.020714,0.020714,8.595635,0.240569,1.0,5407.0,21.0,143.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04283324,0.04273173005623014,0.0001015099437698605
86.0,5407.0,4931.0,0.015905,0.015905,8.595635,0.240569,1.0,5407.0,21.0,143.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.032889,0.032453766800208304,0.0004352331997916972
99.0,5407.0,4931.0,0.01831,0.01831,8.595635,0.240569,1.0,5407.0,21.0,143.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03786215,0.03737296345880954,0.0004891865411904561
4.0,5407.0,4931.0,0.00074,0.00074,8.595635,0.240569,1.0,5407.0,21.0,143.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0015302,0.0015134276564682532,1.6772343531746853e-05
3.0,5407.0,4931.0,0.000555,0.000555,8.595635,0.240569,1.0,5407.0,21.0,143.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00114765,0.0011523833335416681,4.733333541668064e-06
1.0,5407.0,4931.0,0.000185,0.000185,8.595635,0.240569,1.0,5407.0,21.0,143.0,Poor compliance or noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00038255,0.00038379570999007935,1.2457099900793482e-06
1.0,5407.0,4931.0,0.000185,0.000185,8.595635,0.240569,1.0,5407.0,21.0,143.0,Poor compliance or noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00038255,0.00038298627856150794,4.362785615079335e-07
15.0,5407.0,4931.0,0.002774,0.002774,8.595635,0.240569,1.0,5407.0,21.0,143.0,No longer meets study criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00573619,0.00571547795974205,2.0712040257950606e-05
15.0,5407.0,4931.0,0.002774,0.002774,8.595635,0.240569,1.0,5407.0,21.0,143.0,No longer meets study criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00573619,0.005701210719206338,3.4979280793662713e-05
23.0,5407.0,4931.0,0.004254,0.004254,8.595635,0.240569,1.0,5407.0,21.0,143.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00879659,0.008751522201706349,4.5067798293651e-05
22.0,5407.0,4931.0,0.004069,0.004069,8.595635,0.240569,1.0,5407.0,21.0,143.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00841404,0.00829317689583333,0.00012086310416666891
18.0,310.0,270.0,0.058065,0.058065,5.739793,0.281906,1.0,310.0,12.0,62.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09395404,0.09541672242027775,0.00146268242027775
5.0,310.0,270.0,0.016129,0.016129,5.739793,0.281906,1.0,310.0,12.0,62.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02609807,0.026242682590426565,0.0001446125904265641
4.0,310.0,270.0,0.012903,0.012903,5.739793,0.281906,1.0,310.0,12.0,62.0,Clinical Worsening,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02087814,0.02071245392365079,0.0001656860763492099
4.0,310.0,270.0,0.012903,0.012903,5.739793,0.281906,1.0,310.0,12.0,62.0,Clinical Worsening,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02087814,0.02098265891050596,0.00010451891050596018
2.0,310.0,270.0,0.006452,0.006452,5.739793,0.281906,1.0,310.0,12.0,62.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01043988,0.01042867770874999,1.1202291250010307e-05
3.0,310.0,270.0,0.009677,0.009677,5.739793,0.281906,1.0,310.0,12.0,62.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0156582,0.01567630605544642,1.8106055446418662e-05
1.0,310.0,270.0,0.003226,0.003226,5.739793,0.281906,1.0,310.0,12.0,62.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00521994,0.005225651755505957,5.711755505956664e-06
2.0,310.0,270.0,0.006452,0.006452,5.739793,0.281906,1.0,310.0,12.0,62.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01043988,0.010430377564464275,9.502435535725315e-06
0.0,310.0,270.0,0.0,0.0,5.739793,0.281906,1.0,310.0,12.0,62.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,310.0,270.0,0.003226,0.003226,5.739793,0.281906,1.0,310.0,12.0,62.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00521994,0.005213117477648819,6.822522351181484e-06
57.0,5035.0,4174.0,0.011321,0.011321,8.524367,0.714192,1.0,5035.0,7.0,198.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06892263,0.06524186534603178,0.003680764653968216
56.0,5035.0,4174.0,0.011122,0.011122,8.524367,0.714192,1.0,5035.0,7.0,198.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06771111,0.06521338084269844,0.0024977291573015648
7.0,5035.0,4174.0,0.00139,0.00139,8.524367,0.714192,1.0,5035.0,7.0,198.0,Decision by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00846237,0.00832208979438493,0.00014028020561506968
7.0,5035.0,4174.0,0.00139,0.00139,8.524367,0.714192,1.0,5035.0,7.0,198.0,Decision by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00846237,0.008335181669107154,0.0001271883308928464
91.0,5035.0,4174.0,0.018073,0.018073,8.524367,0.714192,1.0,5035.0,7.0,198.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11002903,0.10846973408935513,0.0015592959106448673
78.0,5035.0,4174.0,0.015492,0.015492,8.524367,0.714192,1.0,5035.0,7.0,198.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09431582,0.09160142899339288,0.002714391006607114
2.0,5035.0,4174.0,0.000397,0.000397,8.524367,0.714192,1.0,5035.0,7.0,198.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00241695,0.0025655422510317467,0.0001485922510317465
1.0,5035.0,4174.0,0.000199,0.000199,8.524367,0.714192,1.0,5035.0,7.0,198.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00121152,0.0011749604155753973,3.6559584424602706e-05
294.0,5035.0,4174.0,0.058391,0.058391,8.524367,0.714192,1.0,5035.0,7.0,198.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.35548637,0.3327847648297913,0.022701605170208694
268.0,5035.0,4174.0,0.053227,0.053227,8.524367,0.714192,1.0,5035.0,7.0,198.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.32404777,0.31722844285380924,0.006819327146190768
5.0,1884.0,1804.0,0.002654,0.002654,7.541683,0.384821,1.0,1884.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.00770244,0.007859562043005953,0.00015712204300595382
4.0,1884.0,1804.0,0.002123,0.002123,7.541683,0.384821,1.0,1884.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.00616137,0.0061835005558631105,2.2130555863110295e-05
23.0,1884.0,1804.0,0.012208,0.012208,7.541683,0.384821,1.0,1884.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.03543005,0.03553379338497023,0.00010374338497023267
31.0,1884.0,1804.0,0.016454,0.016454,7.541683,0.384821,1.0,1884.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.04775279,0.04726072218230166,0.0004920678176983453
3.0,1884.0,1804.0,0.001592,0.001592,7.541683,0.384821,1.0,1884.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.0046203,0.004588777219822332,3.15227801776681e-05
3.0,1884.0,1804.0,0.001592,0.001592,7.541683,0.384821,1.0,1884.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.0046203,0.004592987738840191,2.731226115980888e-05
2.0,1884.0,1804.0,0.001062,0.001062,7.541683,0.384821,1.0,1884.0,1.0,1.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.00308214,0.003156542972428271,7.440297242827104e-05
1.0,1884.0,1804.0,0.000531,0.000531,7.541683,0.384821,1.0,1884.0,1.0,1.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.00154107,0.0016201588800892866,7.908888008928655e-05
4.0,1884.0,1804.0,0.002123,0.002123,7.541683,0.384821,1.0,1884.0,1.0,1.0,Other,Overall Study,FG000,cardiovascular disease,OTHER,0.00616137,0.006171211243065493,9.841243065493097e-06
4.0,1884.0,1804.0,0.002123,0.002123,7.541683,0.384821,1.0,1884.0,1.0,1.0,Other,Overall Study,FG001,cardiovascular disease,OTHER,0.00616137,0.006173416392410733,1.204639241073318e-05
20.0,256.0,215.0,0.078125,0.078125,5.549076,0.16882,1.0,256.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.07318731,0.08093932112126973,0.00775201112126972
21.0,256.0,215.0,0.082031,0.082031,5.549076,0.16882,1.0,256.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.07684644,0.08383188306341265,0.006985443063412644
5.0,432.0,389.0,0.011574,0.011574,6.070738,0.218985,1.0,348.0,1.0,76.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01538648,0.015122655687827377,0.00026382431217262213
6.0,432.0,389.0,0.013889,0.013889,6.070738,0.218985,1.0,348.0,1.0,76.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01846405,0.01854071628059525,7.666628059525143e-05
4.0,432.0,389.0,0.009259,0.009259,6.070738,0.218985,1.0,348.0,1.0,76.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01230892,0.012322934054047597,1.4014054047597688e-05
1.0,432.0,389.0,0.002315,0.002315,6.070738,0.218985,1.0,348.0,1.0,76.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00307756,0.0031369743164980134,5.941431649801338e-05
6.0,432.0,389.0,0.013889,0.013889,6.070738,0.218985,1.0,348.0,1.0,76.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01846405,0.01856392859839287,9.987859839287114e-05
5.0,432.0,389.0,0.011574,0.011574,6.070738,0.218985,1.0,348.0,1.0,76.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01538648,0.01512782414627977,0.0002586558537202299
0.0,432.0,389.0,0.0,0.0,6.070738,0.218985,1.0,348.0,1.0,76.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,432.0,389.0,0.006944,0.006944,6.070738,0.218985,1.0,348.0,1.0,76.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00923136,0.009116331060863105,0.00011502893913689465
4.0,432.0,389.0,0.009259,0.009259,6.070738,0.218985,1.0,348.0,1.0,76.0,Met protocol-defined stopping criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01230892,0.012321079121666642,1.2159121666643208e-05
9.0,432.0,389.0,0.020833,0.020833,6.070738,0.218985,1.0,348.0,1.0,76.0,Met protocol-defined stopping criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0276954,0.02649795630895836,0.00119744369104164
44.0,720.0,523.0,0.061111,0.061111,6.580639,0.39877,1.0,720.0,10.0,126.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16036528,0.1663790751771626,0.006013795177162606
20.0,720.0,523.0,0.027778,0.027778,6.580639,0.39877,1.0,720.0,10.0,126.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07289403,0.0733750533200144,0.00048102332001440096
26.0,720.0,523.0,0.036111,0.036111,6.580639,0.39877,1.0,720.0,10.0,126.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09476118,0.09455144887821433,0.00020973112178566955
14.0,720.0,523.0,0.019444,0.019444,6.580639,0.39877,1.0,720.0,10.0,126.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05102424,0.05068335541986115,0.0003408845801388463
1.0,720.0,523.0,0.001389,0.001389,6.580639,0.39877,1.0,720.0,10.0,126.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00364496,0.0036383402297023655,6.619770297634515e-06
3.0,720.0,523.0,0.004167,0.004167,6.580639,0.39877,1.0,720.0,10.0,126.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01093489,0.01092082525386905,1.4064746130949823e-05
7.0,720.0,523.0,0.009722,0.009722,6.580639,0.39877,1.0,720.0,10.0,126.0,Participant moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02551212,0.02560107225375003,8.895225375003118e-05
2.0,720.0,523.0,0.002778,0.002778,6.580639,0.39877,1.0,720.0,10.0,126.0,Participant moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00728993,0.007288047613084413,1.8823869155871684e-06
2.0,720.0,523.0,0.002778,0.002778,6.580639,0.39877,1.0,720.0,10.0,126.0,Related to auto-injector administration,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00728993,0.00728768308290583,2.2469170941697217e-06
2.0,720.0,523.0,0.002778,0.002778,6.580639,0.39877,1.0,720.0,10.0,126.0,Related to auto-injector administration,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00728993,0.007291239339334407,1.3093393344066132e-06
14.0,720.0,523.0,0.019444,0.019444,6.580639,0.39877,1.0,720.0,10.0,126.0,Consent withdrawn by participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05102424,0.05049071768799607,0.0005335223120039312
7.0,720.0,523.0,0.009722,0.009722,6.580639,0.39877,1.0,720.0,10.0,126.0,Consent withdrawn by participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02551212,0.025544234561041712,3.211456104171284e-05
2.0,720.0,523.0,0.002778,0.002778,6.580639,0.39877,1.0,720.0,10.0,126.0,Selection criteria finally not met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00728993,0.007284088656655835,5.841343344165084e-06
0.0,720.0,523.0,0.0,0.0,6.580639,0.39877,1.0,720.0,10.0,126.0,Selection criteria finally not met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,720.0,523.0,0.001389,0.001389,6.580639,0.39877,1.0,720.0,10.0,126.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00364496,0.003638731203035699,6.228796964301026e-06
0.0,720.0,523.0,0.0,0.0,6.580639,0.39877,1.0,720.0,10.0,126.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,720.0,523.0,0.005556,0.005556,6.580639,0.39877,1.0,720.0,10.0,126.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01457985,0.014477656098690476,0.00010219390130952397
3.0,720.0,523.0,0.004167,0.004167,6.580639,0.39877,1.0,720.0,10.0,126.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01093489,0.010924936524702382,9.953475297617281e-06
14.0,720.0,523.0,0.019444,0.019444,6.580639,0.39877,1.0,720.0,10.0,126.0,Last visit outside protocol visit window,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05102424,0.05049071768799607,0.0005335223120039312
16.0,720.0,523.0,0.022222,0.022222,6.580639,0.39877,1.0,720.0,10.0,126.0,Last visit outside protocol visit window,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05831417,0.05729146871477182,0.0010227012852281753
1.0,720.0,523.0,0.001389,0.001389,6.580639,0.39877,1.0,720.0,10.0,126.0,Site closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00364496,0.003640463616369032,4.496383630968239e-06
1.0,720.0,523.0,0.001389,0.001389,6.580639,0.39877,1.0,720.0,10.0,126.0,Site closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00364496,0.0036382331899404625,6.726810059537545e-06
6.0,720.0,523.0,0.008333,0.008333,6.580639,0.39877,1.0,720.0,10.0,126.0,Other than specified above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02186716,0.021665368631488092,0.00020179136851190826
7.0,720.0,523.0,0.009722,0.009722,6.580639,0.39877,1.0,720.0,10.0,126.0,Other than specified above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02551212,0.02551574963604171,3.6296360417104045e-06
50.0,1085.0,835.0,0.046083,0.046083,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG000,cardiovascular disease,NETWORK,0.26084628,0.2619964832578572,0.0011502032578571963
37.0,1085.0,835.0,0.034101,0.034101,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG001,cardiovascular disease,NETWORK,0.19302387,0.19593125134652786,0.0029073813465278764
48.0,1085.0,835.0,0.04424,0.04424,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG002,cardiovascular disease,NETWORK,0.25041424,0.25327756820420627,0.0028633282042062613
41.0,1085.0,835.0,0.037788,0.037788,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG003,cardiovascular disease,NETWORK,0.21389361,0.21138180832118042,0.002511801678819592
21.0,1085.0,835.0,0.019355,0.019355,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG004,cardiovascular disease,NETWORK,0.10955623,0.10771584324375977,0.0018403867562402365
25.0,1085.0,835.0,0.023041,0.023041,6.990257,0.80975,1.0,1085.0,3.0,107.0,Death,Overall Study,FG005,cardiovascular disease,NETWORK,0.13042031,0.1285179816011607,0.0019023283988393036
5.0,1085.0,835.0,0.004608,0.004608,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NETWORK,0.02608293,0.026315305998779764,0.0002323759987797637
3.0,1085.0,835.0,0.002765,0.002765,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NETWORK,0.01565089,0.016128122666845244,0.00047723266684524326
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,NETWORK,0.00521885,0.005241403505000036,2.255350500003639e-05
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,NETWORK,0.00521885,0.005242358667500038,2.350866750003809e-05
3.0,1085.0,835.0,0.002765,0.002765,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,NETWORK,0.01565089,0.01612553952892858,0.0004746495289285786
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,NETWORK,0.0,0.0,0.0
5.0,1085.0,835.0,0.004608,0.004608,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,NETWORK,0.02608293,0.02609627638050595,1.334638050595055e-05
6.0,1085.0,835.0,0.00553,0.00553,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,NETWORK,0.03130178,0.03189459231791665,0.0005928123179166495
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG002,cardiovascular disease,NETWORK,0.00521885,0.005232583630833368,1.373363083336833e-05
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG003,cardiovascular disease,NETWORK,0.00521885,0.005233538793333369,1.4688793333369164e-05
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG004,cardiovascular disease,NETWORK,0.0,0.0,0.0
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Consent withdrawn,Overall Study,FG005,cardiovascular disease,NETWORK,0.0,0.0,0.0
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG000,cardiovascular disease,NETWORK,0.00521885,0.005230968841666698,1.211884166669834e-05
1.0,1085.0,835.0,0.000922,0.000922,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG001,cardiovascular disease,NETWORK,0.00521885,0.005244017387083367,2.5167387083367514e-05
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG002,cardiovascular disease,NETWORK,0.0,0.0,0.0
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG003,cardiovascular disease,NETWORK,0.0,0.0,0.0
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG004,cardiovascular disease,NETWORK,0.0,0.0,0.0
0.0,1085.0,835.0,0.0,0.0,6.990257,0.80975,1.0,1085.0,3.0,107.0,Sponsor's decision,Overall Study,FG005,cardiovascular disease,NETWORK,0.0,0.0,0.0
5.0,588.0,545.0,0.008503,0.008503,6.378426,0.335325,1.0,588.0,7.0,79.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01818658,0.018226802231427707,4.022223142770634e-05
5.0,588.0,545.0,0.008503,0.008503,6.378426,0.335325,1.0,588.0,7.0,79.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01818658,0.018228246854066585,4.166685406658405e-05
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00363817,0.0036390805715575667,9.105715575667e-07
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00363817,0.0036396757179662943,1.5057179662942254e-06
5.0,588.0,545.0,0.008503,0.008503,6.378426,0.335325,1.0,588.0,7.0,79.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01818658,0.018200266686576518,1.3686686576516727e-05
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00363817,0.003641877429871053,3.707429871053179e-06
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00363817,0.003638583704474233,4.137044742331779e-07
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00363817,0.00363968458838296,1.5145883829601782e-06
1.0,588.0,545.0,0.001701,0.001701,6.378426,0.335325,1.0,588.0,7.0,79.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00363817,0.0036400670465575663,1.8970465575662322e-06
6.0,588.0,545.0,0.010204,0.010204,6.378426,0.335325,1.0,588.0,7.0,79.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02182475,0.0220086225061905,0.00018387250619050083
11.0,588.0,545.0,0.018707,0.018707,6.378426,0.335325,1.0,588.0,7.0,79.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04001134,0.040071605545456385,6.026554545638524e-05
5.0,588.0,545.0,0.008503,0.008503,6.378426,0.335325,1.0,588.0,7.0,79.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01818658,0.01822908555412611,4.250555412610782e-05
12.0,2333.0,1093.0,0.005144,0.005144,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.01116641,0.011023388289603173,0.00014302171039682655
15.0,2333.0,1093.0,0.006429,0.006429,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.01395585,0.01384607840774802,0.00010977159225197992
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
406.0,2333.0,1093.0,0.174025,0.174025,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.37776737,0.373812115520179,0.00395525447982098
409.0,2333.0,1093.0,0.175311,0.175311,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.38055897,0.3774647232501394,0.0030942467498605852
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
43.0,2333.0,1093.0,0.018431,0.018431,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.04000937,0.03985317899541487,0.00015619100458513085
40.0,2333.0,1093.0,0.017145,0.017145,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.03721776,0.03812443818188131,0.0009066781818813097
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,2333.0,1093.0,0.003,0.003,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00651229,0.006490482659672617,2.180734032738215e-05
6.0,2333.0,1093.0,0.002572,0.002572,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00558321,0.0052624843689087365,0.00032072563109126345
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2333.0,1093.0,0.000429,0.000429,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00093126,0.0009589467141332959,2.7686714133295866e-05
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2333.0,1093.0,0.000429,0.000429,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00093126,0.0009586584228832955,2.7398422883295422e-05
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,2333.0,1093.0,0.001715,0.001715,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part A (Run-in - 2 Weeks),FG000,cardiovascular disease,INDUSTRY,0.00372286,0.0036642256832341335,5.863431676586669e-05
4.0,2333.0,1093.0,0.001715,0.001715,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part A (Run-in - 2 Weeks),FG001,cardiovascular disease,INDUSTRY,0.00372286,0.003669761237876991,5.3098762123009353e-05
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part A (Run-in - 2 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part A (Run-in - 2 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
46.0,2333.0,1093.0,0.019717,0.019717,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.04280097,0.04272644591837305,7.452408162694768e-05
49.0,2333.0,1093.0,0.021003,0.021003,7.755339,0.279906,1.0,2333.0,14.0,195.0,Adverse Event,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.04559258,0.04524355099941468,0.0003490290005853172
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2333.0,1093.0,0.001286,0.001286,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.0027916,0.002792092633710313,4.92633710312898e-07
5.0,2333.0,1093.0,0.002143,0.002143,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.00465195,0.004634218629047623,1.773137095237732e-05
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
55.0,2333.0,1093.0,0.023575,0.023575,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.05117578,0.05028903015566739,0.00088674984433261
54.0,2333.0,1093.0,0.023146,0.023146,7.755339,0.279906,1.0,2333.0,14.0,195.0,Withdrawal by Subject,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.05024453,0.0493661865302904,0.0008783434697096013
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
20.0,2333.0,1093.0,0.008573,0.008573,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.01860997,0.018432329056329376,0.00017764094367062402
9.0,2333.0,1093.0,0.003858,0.003858,7.755339,0.279906,1.0,2333.0,14.0,195.0,Lost to Follow-up,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.00837481,0.008065561867450397,0.00030924813254960305
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,2333.0,1093.0,0.005572,0.005572,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.0120955,0.012207194342837301,0.00011169434283730094
16.0,2333.0,1093.0,0.006858,0.006858,7.755339,0.279906,1.0,2333.0,14.0,195.0,Protocol Violation,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.01488711,0.014739292336974215,0.00014781766302578506
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2333.0,1093.0,0.000857,0.000857,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.00186035,0.0018800547526984129,1.9704752698412875e-05
3.0,2333.0,1093.0,0.001286,0.001286,7.755339,0.279906,1.0,2333.0,14.0,195.0,Safety reasons,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.0027916,0.0027907458980753934,8.541019246065609e-07
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Study specific discontinuation criteris,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,Study specific discontinuation criteris,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,2333.0,1093.0,0.002572,0.002572,7.755339,0.279906,1.0,2333.0,14.0,195.0,Study specific discontinuation criteris,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.00558321,0.00526295390224207,0.0003202560977579299
6.0,2333.0,1093.0,0.002572,0.002572,7.755339,0.279906,1.0,2333.0,14.0,195.0,Study specific discontinuation criteris,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.00558321,0.005265299060575403,0.0003179109394245965
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part B (2 Year Core Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2333.0,1093.0,0.0,0.0,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part B (2 Year Core Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,2333.0,1093.0,0.001286,0.001286,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part B (2 Year Core Study),FG002,cardiovascular disease,INDUSTRY,0.0027916,0.002793993690515868,2.393690515867849e-06
2.0,2333.0,1093.0,0.000857,0.000857,7.755339,0.279906,1.0,2333.0,14.0,195.0,IVUS not available,Part B (2 Year Core Study),FG003,cardiovascular disease,INDUSTRY,0.00186035,0.0018820805641865087,2.173056418650868e-05
68.0,1623.0,845.0,0.041898,0.041898,7.392648,0.43631,1.0,1623.0,19.0,288.0,Adverse Event,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.13514134,0.13489096046092255,0.00025037953907744437
71.0,1623.0,845.0,0.043746,0.043746,7.392648,0.43631,1.0,1623.0,19.0,288.0,Adverse Event,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.14110204,0.1425072452397024,0.0014052052397023895
76.0,1623.0,845.0,0.046827,0.046827,7.392648,0.43631,1.0,1623.0,19.0,288.0,Adverse Event,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.15103975,0.15018531215393854,0.0008544378460614566
273.0,1623.0,845.0,0.168207,0.168207,7.392648,0.43631,1.0,1623.0,19.0,288.0,Disease Progression,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.54254903,0.5566799302480061,0.014130900248006117
362.0,1623.0,845.0,0.223044,0.223044,7.392648,0.43631,1.0,1623.0,19.0,288.0,Disease Progression,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.71942492,0.6954225596628579,0.024002360337142092
339.0,1623.0,845.0,0.208872,0.208872,7.392648,0.43631,1.0,1623.0,19.0,288.0,Disease Progression,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.67371335,0.6755959512791965,0.001882601279196483
16.0,1623.0,845.0,0.009858,0.009858,7.392648,0.43631,1.0,1623.0,19.0,288.0,Withdrawal by Subject,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.03179682,0.03199767391650792,0.000200853916507919
16.0,1623.0,845.0,0.009858,0.009858,7.392648,0.43631,1.0,1623.0,19.0,288.0,Withdrawal by Subject,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.03179682,0.03194964475990078,0.00015282475990077704
21.0,1623.0,845.0,0.012939,0.012939,7.392648,0.43631,1.0,1623.0,19.0,288.0,Withdrawal by Subject,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.04173454,0.04146842987508934,0.00026611012491065816
60.0,1623.0,845.0,0.036969,0.036969,7.392648,0.43631,1.0,1623.0,19.0,288.0,Death,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.11924293,0.11934827238530757,0.0001053423853075719
28.0,1623.0,845.0,0.017252,0.017252,7.392648,0.43631,1.0,1623.0,19.0,288.0,Death,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.05564605,0.055863052719158535,0.0002170027191585322
37.0,1623.0,845.0,0.022797,0.022797,7.392648,0.43631,1.0,1623.0,19.0,288.0,Death,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.07353137,0.07277556808600379,0.0007558019139962124
0.0,1623.0,845.0,0.0,0.0,7.392648,0.43631,1.0,1623.0,19.0,288.0,Lost to Follow-up,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1623.0,845.0,0.001232,0.001232,7.392648,0.43631,1.0,1623.0,19.0,288.0,Lost to Follow-up,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0039738,0.003972346998988107,1.4530010118930445e-06
2.0,1623.0,845.0,0.001232,0.001232,7.392648,0.43631,1.0,1623.0,19.0,288.0,Lost to Follow-up,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.0039738,0.00397354176339287,2.5823660713009816e-07
2.0,1623.0,845.0,0.001232,0.001232,7.392648,0.43631,1.0,1623.0,19.0,288.0,Protocol Violation,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.0039738,0.003962925361726201,1.0874638273799392e-05
2.0,1623.0,845.0,0.001232,0.001232,7.392648,0.43631,1.0,1623.0,19.0,288.0,Protocol Violation,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.0039738,0.00396900338357144,4.796616428560593e-06
4.0,1623.0,845.0,0.002465,0.002465,7.392648,0.43631,1.0,1623.0,19.0,288.0,Protocol Violation,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.00795082,0.00801122784517857,6.040784517856966e-05
64.0,1623.0,845.0,0.039433,0.039433,7.392648,0.43631,1.0,1623.0,19.0,288.0,Study Close Out,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.12719052,0.12577890662122027,0.0014116133787797358
26.0,1623.0,845.0,0.01602,0.01602,7.392648,0.43631,1.0,1623.0,19.0,288.0,Study Close Out,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.05167226,0.050928589092142894,0.0007436709078571038
21.0,1623.0,845.0,0.012939,0.012939,7.392648,0.43631,1.0,1623.0,19.0,288.0,Study Close Out,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.04173454,0.041481340881339354,0.00025319911866064637
52.0,1623.0,845.0,0.032039,0.032039,7.392648,0.43631,1.0,1623.0,19.0,288.0,Miscellaneous,Active Treatment Phase,FG000,cardiovascular disease,INDUSTRY,0.10334129,0.10551238220420636,0.0021710922042063596
34.0,1623.0,845.0,0.020949,0.020949,7.392648,0.43631,1.0,1623.0,19.0,288.0,Miscellaneous,Active Treatment Phase,FG001,cardiovascular disease,INDUSTRY,0.06757067,0.06708883376829551,0.0004818362317044883
47.0,1623.0,845.0,0.028959,0.028959,7.392648,0.43631,1.0,1623.0,19.0,288.0,Miscellaneous,Active Treatment Phase,FG002,cardiovascular disease,INDUSTRY,0.0934068,0.09415105834811355,0.0007442583481135495
127.0,1623.0,845.0,0.07825,0.07825,7.392648,0.43631,1.0,1623.0,19.0,288.0,Continue in Long Term Follow Up,Long-Term Follow Up Phase,FG000,cardiovascular disease,INDUSTRY,0.25239414,0.2653014650857539,0.012907325085753929
188.0,1623.0,845.0,0.115835,0.115835,7.392648,0.43631,1.0,1623.0,19.0,288.0,Continue in Long Term Follow Up,Long-Term Follow Up Phase,FG001,cardiovascular disease,INDUSTRY,0.37362397,0.37032844834292666,0.0032955216570733636
144.0,1623.0,845.0,0.088725,0.088725,7.392648,0.43631,1.0,1623.0,19.0,288.0,Continue in Long Term Follow Up,Long-Term Follow Up Phase,FG002,cardiovascular disease,INDUSTRY,0.28618109,0.29446669253558544,0.008285602535585412
7.0,300.0,281.0,0.023333,0.023333,5.70711,0.228762,1.0,300.0,11.0,11.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03046283,0.030608849171309526,0.0001460191713095263
0.0,300.0,281.0,0.0,0.0,5.70711,0.228762,1.0,300.0,11.0,11.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,300.0,281.0,0.01,0.01,5.70711,0.228762,1.0,300.0,11.0,11.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01305569,0.013242180080476182,0.00018649008047618224
0.0,300.0,281.0,0.0,0.0,5.70711,0.228762,1.0,300.0,11.0,11.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,300.0,281.0,0.006667,0.006667,5.70711,0.228762,1.0,300.0,11.0,11.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00870423,0.008761911222337685,5.768122233768512e-05
1.0,300.0,281.0,0.003333,0.003333,5.70711,0.228762,1.0,300.0,11.0,11.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435146,0.004354864673766254,3.404673766253981e-06
1.0,300.0,281.0,0.003333,0.003333,5.70711,0.228762,1.0,300.0,11.0,11.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00435146,0.004357638584421013,6.178584421013232e-06
1.0,300.0,281.0,0.003333,0.003333,5.70711,0.228762,1.0,300.0,11.0,11.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435146,0.00435528440073054,3.824400730540259e-06
0.0,300.0,281.0,0.0,0.0,5.70711,0.228762,1.0,300.0,11.0,11.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,300.0,281.0,0.006667,0.006667,5.70711,0.228762,1.0,300.0,11.0,11.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00870423,0.00876683487046269,6.260487046268887e-05
0.0,300.0,281.0,0.0,0.0,5.70711,0.228762,1.0,300.0,11.0,11.0,Condition no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,300.0,281.0,0.003333,0.003333,5.70711,0.228762,1.0,300.0,11.0,11.0,Condition no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435146,0.004355870840849587,4.410840849587705e-06
0.0,300.0,281.0,0.0,0.0,5.70711,0.228762,1.0,300.0,11.0,11.0,Abnormal laboratory values,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,300.0,281.0,0.003333,0.003333,5.70711,0.228762,1.0,300.0,11.0,11.0,Abnormal laboratory values,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00435146,0.004355870840849587,4.410840849587705e-06
572.0,10917.0,9578.0,0.052395,0.052395,9.298168,0.209726,1.0,10917.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.10217363,0.1040697755973909,0.0018961455973909025
547.0,10917.0,9578.0,0.050105,0.050105,9.298168,0.209726,1.0,10917.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.09770798,0.10055564668206361,0.0028476666820636126
114.0,10917.0,9578.0,0.010442,0.010442,9.298168,0.209726,1.0,10917.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02036257,0.020589218081388895,0.00022664808138889506
102.0,10917.0,9578.0,0.009343,0.009343,9.298168,0.209726,1.0,10917.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.01821945,0.018421925786755947,0.00020247578675594569
1.0,10917.0,9578.0,9.2e-05,9.2e-05,9.298168,0.209726,1.0,10917.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00017941,0.00021286804831349219,3.3458048313492195e-05
0.0,10917.0,9578.0,0.0,0.0,9.298168,0.209726,1.0,10917.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,10917.0,9578.0,0.0,0.0,9.298168,0.209726,1.0,10917.0,1.0,1.0,Withdrawn by sponsor's decision,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,10917.0,9578.0,0.000275,0.000275,9.298168,0.209726,1.0,10917.0,1.0,1.0,Withdrawn by sponsor's decision,Overall Study,FG001,cardiovascular disease,OTHER,0.00053627,0.0005437057251785723,7.43572517857222e-06
2.0,566.0,532.0,0.003534,0.003534,6.340359,0.231988,1.0,566.0,1.0,50.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00519812,0.005194133049613084,3.986950386915961e-06
2.0,566.0,532.0,0.003534,0.003534,6.340359,0.231988,1.0,566.0,1.0,50.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00519812,0.005192835239374987,5.284760625012992e-06
3.0,566.0,532.0,0.0053,0.0053,6.340359,0.231988,1.0,566.0,1.0,50.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00779571,0.0077719025924801585,2.3807407519841478e-05
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,532.0,0.001767,0.001767,6.340359,0.231988,1.0,566.0,1.0,50.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00259906,0.00260678323896825,7.72323896824998e-06
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,532.0,0.001767,0.001767,6.340359,0.231988,1.0,566.0,1.0,50.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00259906,0.0026060262595238052,6.966259523805401e-06
6.0,566.0,532.0,0.010601,0.010601,6.340359,0.231988,1.0,566.0,1.0,50.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01559289,0.015535101657698426,5.778834230157383e-05
2.0,566.0,532.0,0.003534,0.003534,6.340359,0.231988,1.0,566.0,1.0,50.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00519812,0.005193786477291656,4.333522708344084e-06
5.0,566.0,532.0,0.008834,0.008834,6.340359,0.231988,1.0,566.0,1.0,50.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01299383,0.013002291027483784,8.461027483783884e-06
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,566.0,532.0,0.003534,0.003534,6.340359,0.231988,1.0,566.0,1.0,50.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00519812,0.005197788738124989,3.3126187501050786e-07
0.0,566.0,532.0,0.0,0.0,6.340359,0.231988,1.0,566.0,1.0,50.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,532.0,0.001767,0.001767,6.340359,0.231988,1.0,566.0,1.0,50.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00259906,0.00260581779943452,6.757799434520349e-06
4.0,566.0,532.0,0.007067,0.007067,6.340359,0.231988,1.0,566.0,1.0,50.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01039477,0.010348975651547623,4.579434845237637e-05
5.0,566.0,532.0,0.008834,0.008834,6.340359,0.231988,1.0,566.0,1.0,50.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01299383,0.013002304775400448,8.474775400448345e-06
558.0,5598.0,2264.0,0.099678,0.099678,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Double Blind,FG000,cardiovascular disease,INDUSTRY,0.40447943,0.38919576052485155,0.01528366947514842
649.0,5598.0,2264.0,0.115934,0.115934,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Double Blind,FG001,cardiovascular disease,INDUSTRY,0.47044401,0.43696940386705385,0.03347460613294617
0.0,5598.0,2264.0,0.0,0.0,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Double Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,5598.0,2264.0,0.0,0.0,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Open Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,5598.0,2264.0,0.0,0.0,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Open Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1011.0,5598.0,2264.0,0.1806,0.1806,8.630343,0.470185,1.0,6421.0,36.0,503.0,>=1 reason assigned per patient,Open Label,FG002,cardiovascular disease,INDUSTRY,0.73284963,0.7107324104706261,0.022117219529373955
40.0,3602.0,2790.0,0.011105,0.011105,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Pharmacology Intervention/Randomization,FG000,cardiovascular disease,OTHER,0.02420659,0.024560589650843248,0.000353999650843248
43.0,3602.0,2790.0,0.011938,0.011938,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Pharmacology Intervention/Randomization,FG001,cardiovascular disease,OTHER,0.02602235,0.026331157863551568,0.0003088078635515683
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Pharmacology Intervention/Randomization,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Pharmacology Intervention/Randomization,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
97.0,3602.0,2790.0,0.026929,0.026929,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Pharmacology Intervention/Randomization,FG000,cardiovascular disease,OTHER,0.05869961,0.05702723899276783,0.001672371007232172
103.0,3602.0,2790.0,0.028595,0.028595,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Pharmacology Intervention/Randomization,FG001,cardiovascular disease,OTHER,0.06233114,0.06168346188114089,0.0006476781188591088
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Pharmacology Intervention/Randomization,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Pharmacology Intervention/Randomization,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
29.0,3602.0,2790.0,0.008051,0.008051,8.189522,0.266168,1.0,3602.0,1.0,1.0,Not true myocardial infarction,Pharmacology Intervention/Randomization,FG000,cardiovascular disease,OTHER,0.0175495,0.01772807741459325,0.0001785774145932513
28.0,3602.0,2790.0,0.007773,0.007773,8.189522,0.266168,1.0,3602.0,1.0,1.0,Not true myocardial infarction,Pharmacology Intervention/Randomization,FG001,cardiovascular disease,OTHER,0.01694352,0.01733821501875992,0.00039469501875992116
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Not true myocardial infarction,Pharmacology Intervention/Randomization,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Not true myocardial infarction,Pharmacology Intervention/Randomization,FG003,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Stent Intervention/Randomization,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Stent Intervention/Randomization,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
41.0,3602.0,2790.0,0.011383,0.011383,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Stent Intervention/Randomization,FG002,cardiovascular disease,OTHER,0.02481257,0.02505340892012895,0.00024083892012895236
15.0,3602.0,2790.0,0.004164,0.004164,8.189522,0.266168,1.0,3602.0,1.0,1.0,Withdrawal by Subject,Stent Intervention/Randomization,FG003,cardiovascular disease,OTHER,0.00907665,0.009028298423353169,4.8351576646831276e-05
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Stent Intervention/Randomization,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,3602.0,2790.0,0.0,0.0,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Stent Intervention/Randomization,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
113.0,3602.0,2790.0,0.031371,0.031371,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Stent Intervention/Randomization,FG002,cardiovascular disease,OTHER,0.06838224,0.06711563728014884,0.0012666027198511565
47.0,3602.0,2790.0,0.013048,0.013048,8.189522,0.266168,1.0,3602.0,1.0,1.0,Lost to Follow-up,Stent Intervention/Randomization,FG003,cardiovascular disease,OTHER,0.02844192,0.028770295864166656,0.0003283758641666572
19.0,18924.0,15325.0,0.001004,0.001004,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00492507,0.004740701601160716,0.00018436839883928437
11.0,18924.0,15325.0,0.000581,0.000581,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00285007,0.002689705679771825,0.00016036432022817522
347.0,18924.0,15325.0,0.018337,0.018337,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08995129,0.08248757706339269,0.007463712936607317
362.0,18924.0,15325.0,0.019129,0.019129,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09383641,0.08347483440800586,0.010361575591994132
0.0,18924.0,15325.0,0.0,0.0,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Two consecutive LDL-C <15 mg/dL,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,3.397334642857143e-06,3.397334642857143e-06
730.0,18924.0,15325.0,0.038575,0.038575,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Two consecutive LDL-C <15 mg/dL,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18922784,0.17671898178336296,0.012508858216637053
529.0,18924.0,15325.0,0.027954,0.027954,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Poor compliance to protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13712703,0.12691539831613105,0.01021163168386896
454.0,18924.0,15325.0,0.023991,0.023991,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Poor compliance to protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11768672,0.09815369269156847,0.019533027308431525
77.0,18924.0,15325.0,0.004069,0.004069,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01996029,0.019166236224702368,0.0007940537752976311
62.0,18924.0,15325.0,0.003276,0.003276,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01607026,0.014450100896855167,0.0016201591031448324
1.0,18924.0,15325.0,5.3e-05,5.3e-05,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Site terminated by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00025999,0.00027627245336309586,1.6282453363095876e-05
3.0,18924.0,15325.0,0.000159,0.000159,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Site terminated by sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00077997,0.0008049077673908733,2.4937767390873335e-05
139.0,18924.0,15325.0,0.007345,0.007345,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Participant moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03603055,0.03361839630622023,0.00241215369377977
104.0,18924.0,15325.0,0.005496,0.005496,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Participant moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02696037,0.025925315966865106,0.0010350540331348947
118.0,18924.0,15325.0,0.006235,0.006235,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0305855,0.02941214948886902,0.0011733505111309814
91.0,18924.0,15325.0,0.004809,0.004809,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02359032,0.022660301400654777,0.000930018599345224
96.0,18924.0,15325.0,0.005073,0.005073,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Related to study drug administration,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02488536,0.024080881865615092,0.0008044781343849068
105.0,18924.0,15325.0,0.005549,0.005549,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Related to study drug administration,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02722036,0.02661376483656747,0.0006065951634325294
17.0,18924.0,15325.0,0.000898,0.000898,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0044051,0.004212615039246035,0.00019248496075396568
15.0,18924.0,15325.0,0.000793,0.000793,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00389002,0.0037840595590376996,0.00010596044096230052
172.0,18924.0,15325.0,0.009089,0.009089,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Other than specified above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04458566,0.040591867354523824,0.0039937926454761755
147.0,18924.0,15325.0,0.007768,0.007768,9.848239,0.498105,1.0,18924.0,57.0,1388.0,Other than specified above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03810556,0.03728275188738097,0.0008228081126190265
315.0,7769.0,6402.0,0.040546,0.040546,8.958025,0.807638,1.0,7769.0,13.0,137.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,NIH,0.29334392,0.28643635653442523,0.006907563465574751
324.0,7769.0,6402.0,0.041704,0.041704,8.958025,0.807638,1.0,7769.0,13.0,137.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,NIH,0.30172187,0.2895951692164292,0.01212670078357081
258.0,7769.0,6402.0,0.033209,0.033209,8.958025,0.807638,1.0,7769.0,13.0,137.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,NIH,0.24026188,0.23769901537883956,0.0025628646211604544
249.0,7769.0,6402.0,0.03205,0.03205,8.958025,0.807638,1.0,7769.0,13.0,137.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,NIH,0.2318767,0.2228518962306648,0.009024803769335205
69.0,7769.0,6402.0,0.008881,0.008881,8.958025,0.807638,1.0,7769.0,13.0,137.0,Unable to get to clinic,Overall Study,FG000,cardiovascular disease,NIH,0.06425264,0.05464970399664955,0.009602936003350451
60.0,7769.0,6402.0,0.007723,0.007723,8.958025,0.807638,1.0,7769.0,13.0,137.0,Unable to get to clinic,Overall Study,FG001,cardiovascular disease,NIH,0.05587469,0.052387335759365064,0.0034873542406349337
25.0,7769.0,6402.0,0.003218,0.003218,8.958025,0.807638,1.0,7769.0,13.0,137.0,Physician Decision,Overall Study,FG000,cardiovascular disease,NIH,0.02328172,0.022749696465555535,0.0005320235344444639
25.0,7769.0,6402.0,0.003218,0.003218,8.958025,0.807638,1.0,7769.0,13.0,137.0,Physician Decision,Overall Study,FG001,cardiovascular disease,NIH,0.02328172,0.022697782642559505,0.0005839373574404935
15.0,7769.0,6402.0,0.001931,0.001931,8.958025,0.807638,1.0,7769.0,13.0,137.0,Site Closure,Overall Study,FG000,cardiovascular disease,NIH,0.01397048,0.013392771566190474,0.0005777084338095262
19.0,7769.0,6402.0,0.002446,0.002446,8.958025,0.807638,1.0,7769.0,13.0,137.0,Site Closure,Overall Study,FG001,cardiovascular disease,NIH,0.01769642,0.01764040197119046,5.6018028809539516e-05
5.0,7769.0,6402.0,0.000644,0.000644,8.958025,0.807638,1.0,7769.0,13.0,137.0,Other,Overall Study,FG000,cardiovascular disease,NIH,0.00465924,0.004309538398748471,0.00034970160125152947
3.0,7769.0,6402.0,0.000386,0.000386,8.958025,0.807638,1.0,7769.0,13.0,137.0,Other,Overall Study,FG001,cardiovascular disease,NIH,0.00279265,0.002824433721101192,3.1783721101192285e-05
51.0,3365.0,2902.0,0.015156,0.015156,8.12148,0.448172,1.0,3365.0,31.0,266.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05516507,0.055394465366537665,0.00022939536653766857
47.0,3365.0,2902.0,0.013967,0.013967,8.12148,0.448172,1.0,3365.0,31.0,266.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05083733,0.05144124715321428,0.000603917153214277
46.0,3365.0,2902.0,0.01367,0.01367,8.12148,0.448172,1.0,3365.0,31.0,266.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0497563,0.0506015788496726,0.0008452788496725941
0.0,3365.0,2902.0,0.0,0.0,8.12148,0.448172,1.0,3365.0,31.0,266.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3365.0,2902.0,0.000594,0.000594,8.12148,0.448172,1.0,3365.0,31.0,266.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00216205,0.0021614052766269955,6.44723373004457e-07
3.0,3365.0,2902.0,0.000892,0.000892,8.12148,0.448172,1.0,3365.0,31.0,266.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00324672,0.0032250953231547576,2.1624676845242215e-05
29.0,3365.0,2902.0,0.008618,0.008618,8.12148,0.448172,1.0,3365.0,31.0,266.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03136794,0.03131145069197777,5.6489308022225626e-05
18.0,3365.0,2902.0,0.005349,0.005349,8.12148,0.448172,1.0,3365.0,31.0,266.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01946938,0.019727756838035716,0.0002583768380357149
26.0,3365.0,2902.0,0.007727,0.007727,8.12148,0.448172,1.0,3365.0,31.0,266.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02812487,0.028538067415555556,0.0004131974155555558
3.0,3365.0,2902.0,0.000892,0.000892,8.12148,0.448172,1.0,3365.0,31.0,266.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00324672,0.003222129945595233,2.459005440476683e-05
5.0,3365.0,2902.0,0.001486,0.001486,8.12148,0.448172,1.0,3365.0,31.0,266.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00540877,0.005377381534954007,3.138846504599328e-05
3.0,3365.0,2902.0,0.000892,0.000892,8.12148,0.448172,1.0,3365.0,31.0,266.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00324672,0.003226151532678567,2.056846732143274e-05
1.0,3365.0,2902.0,0.000297,0.000297,8.12148,0.448172,1.0,3365.0,31.0,266.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00108103,0.0011247942455555548,4.3764245555554795e-05
3.0,3365.0,2902.0,0.000892,0.000892,8.12148,0.448172,1.0,3365.0,31.0,266.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00324672,0.0032301894584821377,1.653054151786208e-05
4.0,3365.0,2902.0,0.001189,0.001189,8.12148,0.448172,1.0,3365.0,31.0,266.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00432774,0.0042833241660119046,4.44158339880955e-05
21.0,3365.0,2902.0,0.006241,0.006241,8.12148,0.448172,1.0,3365.0,31.0,266.0,Non-compliance with study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0227161,0.022934124384751987,0.0002180243847519879
19.0,3365.0,2902.0,0.005646,0.005646,8.12148,0.448172,1.0,3365.0,31.0,266.0,Non-compliance with study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02055041,0.020603224041716262,5.281404171626064e-05
23.0,3365.0,2902.0,0.006835,0.006835,8.12148,0.448172,1.0,3365.0,31.0,266.0,Non-compliance with study medication,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02487815,0.024850053110833346,2.809688916665526e-05
0.0,3365.0,2902.0,0.0,0.0,8.12148,0.448172,1.0,3365.0,31.0,266.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3365.0,2902.0,0.000297,0.000297,8.12148,0.448172,1.0,3365.0,31.0,266.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00108103,0.0011197580569940468,3.872805699404688e-05
1.0,3365.0,2902.0,0.000297,0.000297,8.12148,0.448172,1.0,3365.0,31.0,266.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00108103,0.0011218889456547608,4.085894565476083e-05
6.0,3365.0,2902.0,0.001783,0.001783,8.12148,0.448172,1.0,3365.0,31.0,266.0,Logistical difficulties,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00648979,0.006628023957261906,0.00013823395726190665
5.0,3365.0,2902.0,0.001486,0.001486,8.12148,0.448172,1.0,3365.0,31.0,266.0,Logistical difficulties,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00540877,0.00538037592328734,2.8394076712659824e-05
2.0,3365.0,2902.0,0.000594,0.000594,8.12148,0.448172,1.0,3365.0,31.0,266.0,Logistical difficulties,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00216205,0.0021607223197222312,1.327680277768764e-06
18.0,3365.0,2902.0,0.005349,0.005349,8.12148,0.448172,1.0,3365.0,31.0,266.0,Efficacy outcome reached,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01946938,0.0196551821247619,0.00018580212476189753
16.0,3365.0,2902.0,0.004755,0.004755,8.12148,0.448172,1.0,3365.0,31.0,266.0,Efficacy outcome reached,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01730733,0.017137636456696453,0.00016969354330354652
57.0,3365.0,2902.0,0.016939,0.016939,8.12148,0.448172,1.0,3365.0,31.0,266.0,Efficacy outcome reached,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.06165486,0.06230051879819443,0.0006456587981944345
12.0,3365.0,2902.0,0.003566,0.003566,8.12148,0.448172,1.0,3365.0,31.0,266.0,Safety outcome reached,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01297959,0.013318892494464284,0.00033930249446428515
20.0,3365.0,2902.0,0.005944,0.005944,8.12148,0.448172,1.0,3365.0,31.0,266.0,Safety outcome reached,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02163507,0.021746834905218258,0.0001117649052182583
10.0,3365.0,2902.0,0.002972,0.002972,8.12148,0.448172,1.0,3365.0,31.0,266.0,Safety outcome reached,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01081754,0.01066383451639068,0.00015370548360931977
2.0,3365.0,2902.0,0.000594,0.000594,8.12148,0.448172,1.0,3365.0,31.0,266.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00216205,0.0021503484851388976,1.1701514861102349e-05
2.0,3365.0,2902.0,0.000594,0.000594,8.12148,0.448172,1.0,3365.0,31.0,266.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00216205,0.0021609604257341393,1.0895742658606836e-06
7.0,3365.0,2902.0,0.00208,0.00208,8.12148,0.448172,1.0,3365.0,31.0,266.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00757082,0.007264913025178568,0.0003059069748214318
40.0,601.0,145.0,0.066556,0.066556,6.400257,0.217379,1.0,601.0,4.0,4.0,Adverse Event,Core,FG000,cardiovascular disease,INDUSTRY,0.09259834,0.09527242261594251,0.0026740826159425135
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Adverse Event,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,601.0,145.0,0.004992,0.004992,6.400257,0.217379,1.0,601.0,4.0,4.0,Abnormal laboratory value(s),Core,FG000,cardiovascular disease,INDUSTRY,0.00694529,0.006859383177658733,8.590682234126644e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Abnormal laboratory value(s),Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
23.0,601.0,145.0,0.03827,0.03827,6.400257,0.217379,1.0,601.0,4.0,4.0,Unsatisfactory therapeutic effect,Core,FG000,cardiovascular disease,INDUSTRY,0.05324446,0.05328654283847216,4.20828384721586e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Unsatisfactory therapeutic effect,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,601.0,145.0,0.006656,0.006656,6.400257,0.217379,1.0,601.0,4.0,4.0,Condition no longer requires study drug,Core,FG000,cardiovascular disease,INDUSTRY,0.00926039,0.009082984924512092,0.00017740507548790786
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Condition no longer requires study drug,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
15.0,601.0,145.0,0.024958,0.024958,6.400257,0.217379,1.0,601.0,4.0,4.0,Patient withdrew consent,Core,FG000,cardiovascular disease,INDUSTRY,0.03472368,0.03409073092335322,0.0006329490766467799
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Patient withdrew consent,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
23.0,601.0,145.0,0.03827,0.03827,6.400257,0.217379,1.0,601.0,4.0,4.0,Lost to Follow-up,Core,FG000,cardiovascular disease,INDUSTRY,0.05324446,0.053300457808472174,5.599780847217323e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Lost to Follow-up,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,601.0,145.0,0.001664,0.001664,6.400257,0.217379,1.0,601.0,4.0,4.0,Administrative problems,Core,FG000,cardiovascular disease,INDUSTRY,0.0023151,0.0023444347525793698,2.93347525793697e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Administrative problems,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,601.0,145.0,0.009983,0.009983,6.400257,0.217379,1.0,601.0,4.0,4.0,Protocol Deviation,Core,FG000,cardiovascular disease,INDUSTRY,0.01388919,0.013892979335644871,3.7893356448718413e-06
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Protocol Deviation,Core,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Adverse Event,Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,601.0,145.0,0.009983,0.009983,6.400257,0.217379,1.0,601.0,4.0,4.0,Adverse Event,Extension,FG001,cardiovascular disease,INDUSTRY,0.01388919,0.013881112691478206,8.077308521793614e-06
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Abnormal laboratory value(s),Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,601.0,145.0,0.001664,0.001664,6.400257,0.217379,1.0,601.0,4.0,4.0,Abnormal laboratory value(s),Extension,FG001,cardiovascular disease,INDUSTRY,0.0023151,0.002327955017162702,1.28550171627018e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Administrative problems,Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,601.0,145.0,0.001664,0.001664,6.400257,0.217379,1.0,601.0,4.0,4.0,Administrative problems,Extension,FG001,cardiovascular disease,INDUSTRY,0.0023151,0.002327955017162702,1.28550171627018e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Lost to Follow-up,Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,601.0,145.0,0.004992,0.004992,6.400257,0.217379,1.0,601.0,4.0,4.0,Lost to Follow-up,Extension,FG001,cardiovascular disease,INDUSTRY,0.00694529,0.0068638407246825435,8.144927531745626e-05
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Patient withdrew consent,Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,601.0,145.0,0.008319,0.008319,6.400257,0.217379,1.0,601.0,4.0,4.0,Patient withdrew consent,Extension,FG001,cardiovascular disease,INDUSTRY,0.0115741,0.011372013936696417,0.0002020860633035835
0.0,601.0,145.0,0.0,0.0,6.400257,0.217379,1.0,601.0,4.0,4.0,Unsatisfactory therapeutic effect,Extension,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,601.0,145.0,0.001664,0.001664,6.400257,0.217379,1.0,601.0,4.0,4.0,Unsatisfactory therapeutic effect,Extension,FG001,cardiovascular disease,INDUSTRY,0.0023151,0.002327748479662702,1.2648479662702005e-05
194.0,9326.0,8753.0,0.020802,0.020802,9.140669,0.300923,1.0,9326.0,53.0,688.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05721874,0.05699228291784726,0.00022645708215273536
83.0,9326.0,8753.0,0.0089,0.0089,9.140669,0.300923,1.0,9326.0,53.0,688.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02448066,0.02302821861919644,0.001452441380803561
202.0,9326.0,8753.0,0.02166,0.02166,9.140669,0.300923,1.0,9326.0,53.0,688.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05957879,0.05748478588981157,0.0020940041101884313
80.0,9326.0,8753.0,0.008578,0.008578,9.140669,0.300923,1.0,9326.0,53.0,688.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02359496,0.02283935010711309,0.0007556098928869111
3.0,9326.0,8753.0,0.000322,0.000322,9.140669,0.300923,1.0,9326.0,53.0,688.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0008857,0.0008158590534523814,6.984094654761866e-05
2.0,9326.0,8753.0,0.000214,0.000214,9.140669,0.300923,1.0,9326.0,53.0,688.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00058864,0.0005915651627678577,2.925162767857762e-06
1.0,9326.0,8753.0,0.000107,0.000107,9.140669,0.300923,1.0,9326.0,53.0,688.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00029432,0.0003038578899007942,9.537889900794222e-06
1.0,9326.0,8753.0,0.000107,0.000107,9.140669,0.300923,1.0,9326.0,53.0,688.0,Physician Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00029432,0.0003039897149007942,9.669714900794235e-06
2.0,9326.0,8753.0,0.000214,0.000214,9.140669,0.300923,1.0,9326.0,53.0,688.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00058864,0.0005915874874702386,2.9474874702386513e-06
1.0,9326.0,8753.0,0.000107,0.000107,9.140669,0.300923,1.0,9326.0,53.0,688.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00029432,0.0003002348810714285,5.914881071428528e-06
3.0,9326.0,8753.0,0.000322,0.000322,9.140669,0.300923,1.0,9326.0,53.0,688.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0008857,0.0008264124843452381,5.9287515654761935e-05
1.0,9326.0,8753.0,0.000107,0.000107,9.140669,0.300923,1.0,9326.0,53.0,688.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00029432,0.0003009212248214287,6.601224821428686e-06
6.0,227.0,116.0,0.026432,0.026432,5.429346,0.298717,1.0,227.0,12.0,71.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.04286836,0.043396176354761916,0.0005278163547619147
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01428999,0.014347951203224203,5.7961203224201827e-05
5.0,227.0,116.0,0.022026,0.022026,5.429346,0.298717,1.0,227.0,12.0,71.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03572255,0.03587422328124993,0.00015167328124993107
9.0,227.0,116.0,0.039648,0.039648,5.429346,0.298717,1.0,227.0,12.0,71.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.06430254,0.06354928731342267,0.0007532526865773326
1.0,227.0,116.0,0.004405,0.004405,5.429346,0.298717,1.0,227.0,12.0,71.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00714419,0.007139590703869042,4.599296130957525e-06
3.0,227.0,116.0,0.013216,0.013216,5.429346,0.298717,1.0,227.0,12.0,71.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02143418,0.021785743289077408,0.000351563289077407
4.0,227.0,116.0,0.017621,0.017621,5.429346,0.298717,1.0,227.0,12.0,71.0,Required dialysis,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02857837,0.028304032021924587,0.0002743379780754118
1.0,227.0,116.0,0.004405,0.004405,5.429346,0.298717,1.0,227.0,12.0,71.0,Required dialysis,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00714419,0.007150557679345232,6.3676793452321565e-06
5.0,227.0,116.0,0.022026,0.022026,5.429346,0.298717,1.0,227.0,12.0,71.0,Change in RAAS inhibitor therapy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03572255,0.03585698825874993,0.00013443825874993182
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Change in RAAS inhibitor therapy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01428999,0.014352933813462301,6.294381346230032e-05
4.0,227.0,116.0,0.017621,0.017621,5.429346,0.298717,1.0,227.0,12.0,71.0,Unable to dose reduce per protocol,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02857837,0.028304032021924587,0.0002743379780754118
1.0,227.0,116.0,0.004405,0.004405,5.429346,0.298717,1.0,227.0,12.0,71.0,Unable to dose reduce per protocol,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00714419,0.007150557679345232,6.3676793452321565e-06
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Other Reason,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01428999,0.014378267467450394,8.827746745039382e-05
3.0,227.0,116.0,0.013216,0.013216,5.429346,0.298717,1.0,227.0,12.0,71.0,Other Reason,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02143418,0.02178071665782741,0.0003465366578274086
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Adverse Event,Long-term Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.01428999,0.01437624703245039,8.62570324503889e-05
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Adverse Event,Long-term Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.01428999,0.01435453536179563,6.45453617956291e-05
8.0,227.0,116.0,0.035242,0.035242,5.429346,0.298717,1.0,227.0,12.0,71.0,Withdrawal by Subject,Long-term Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.05715673,0.0563625455082837,0.000794184491716303
2.0,227.0,116.0,0.008811,0.008811,5.429346,0.298717,1.0,227.0,12.0,71.0,Withdrawal by Subject,Long-term Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.01428999,0.014358498215009917,6.850821500991623e-05
5.0,227.0,116.0,0.022026,0.022026,5.429346,0.298717,1.0,227.0,12.0,71.0,Lost to Follow-up,Long-term Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.03572255,0.03584864175214282,0.00012609175214282203
1.0,227.0,116.0,0.004405,0.004405,5.429346,0.298717,1.0,227.0,12.0,71.0,Lost to Follow-up,Long-term Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00714419,0.007144627105178568,4.371051785679453e-07
0.0,227.0,116.0,0.0,0.0,5.429346,0.298717,1.0,227.0,12.0,71.0,Other,Long-term Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,227.0,116.0,0.004405,0.004405,5.429346,0.298717,1.0,227.0,12.0,71.0,Other,Long-term Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00714419,0.007151190970178567,7.000970178566886e-06
102.0,2201.0,2008.0,0.046343,0.046343,7.697121,0.279906,1.0,2201.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.09984458,0.10006380642537875,0.00021922642537874903
91.0,2201.0,2008.0,0.041345,0.041345,7.697121,0.279906,1.0,2201.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.08907654,0.09099787483720238,0.0019213348372023875
41.0,13026.0,12675.0,0.003148,0.003148,9.474779,0.359819,1.0,13026.0,36.0,914.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01073217,0.010482045186150802,0.00025012481384919724
43.0,13026.0,12675.0,0.003301,0.003301,9.474779,0.359819,1.0,13026.0,36.0,914.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01125378,0.010783085114027782,0.00047069488597221813
111.0,13026.0,12675.0,0.008521,0.008521,9.474779,0.359819,1.0,13026.0,36.0,914.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02904983,0.027851842630029777,0.0011979873699702222
109.0,13026.0,12675.0,0.008368,0.008368,9.474779,0.359819,1.0,13026.0,36.0,914.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02852822,0.027657986597083347,0.0008702334029166529
23.0,13026.0,12675.0,0.001766,0.001766,9.474779,0.359819,1.0,13026.0,36.0,914.0,Study closed/terminated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00602065,0.005983363055029765,3.7286944970234964e-05
24.0,13026.0,12675.0,0.001842,0.001842,9.474779,0.359819,1.0,13026.0,36.0,914.0,Study closed/terminated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00627975,0.006345970376160713,6.622037616071334e-05
11.0,201.0,175.0,0.054726,0.054726,5.308268,0.831172,1.0,201.0,5.0,42.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24145572,0.2448635108620636,0.003407790862063581
7.0,201.0,175.0,0.034826,0.034826,5.308268,0.831172,1.0,201.0,5.0,42.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15365524,0.17269444720559524,0.019039207205595238
4.0,201.0,175.0,0.0199,0.0199,5.308268,0.831172,1.0,201.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08780047,0.08959281586923609,0.0017923458692360866
3.0,201.0,175.0,0.014925,0.014925,5.308268,0.831172,1.0,201.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06585036,0.06665670199178578,0.0008063419917857806
1.0,201.0,175.0,0.004975,0.004975,5.308268,0.831172,1.0,201.0,5.0,42.0,Other Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02195012,0.02142963246414683,0.0005204875358531709
0.0,201.0,175.0,0.0,0.0,5.308268,0.831172,1.0,201.0,5.0,42.0,Other Reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,357.0,217.0,0.005602,0.005602,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00977304,0.009785990366309467,1.2950366309466554e-05
9.0,357.0,217.0,0.02521,0.02521,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.0439804,0.044253161320405826,0.00027276132040582324
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,357.0,217.0,0.008403,0.008403,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.01465955,0.014581351781645064,7.819821835493637e-05
16.0,357.0,217.0,0.044818,0.044818,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.07818777,0.08054827711725196,0.002360507117251956
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,357.0,217.0,0.008403,0.008403,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.01465955,0.014586740097776017,7.280990222398309e-05
8.0,357.0,217.0,0.022409,0.022409,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.03909389,0.03895978773197332,0.00013410226802668124
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,357.0,217.0,0.002801,0.002801,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00488652,0.004870476242970756,1.6043757029244286e-05
5.0,357.0,217.0,0.014006,0.014006,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.02443433,0.024522819475873023,8.848947587302217e-05
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Sponsor Decision,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,357.0,217.0,0.002801,0.002801,5.880533,0.296667,1.0,357.0,10.0,10.0,Sponsor Decision,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.00488652,0.004873917043804091,1.2602956195909357e-05
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Sponsor Decision,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,357.0,217.0,0.002801,0.002801,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00488652,0.00487096916880409,1.5550831195910303e-05
2.0,357.0,217.0,0.005602,0.005602,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.00977304,0.009780821064196367,7.78106419636708e-06
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,357.0,217.0,0.002801,0.002801,5.880533,0.296667,1.0,357.0,10.0,10.0,New Drug Pulmonary Atrial Hypertension,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00488652,0.004870476242970756,1.6043757029244286e-05
10.0,357.0,217.0,0.028011,0.028011,5.880533,0.296667,1.0,357.0,10.0,10.0,New Drug Pulmonary Atrial Hypertension,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.04886692,0.04910986343340278,0.00024294343340278135
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,New Drug Pulmonary Atrial Hypertension,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,New condition or starts new therapy,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,357.0,217.0,0.005602,0.005602,5.880533,0.296667,1.0,357.0,10.0,10.0,New condition or starts new therapy,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.00977304,0.009773593633452322,5.536334523222053e-07
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,New condition or starts new therapy,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,357.0,217.0,0.030812,0.030812,5.880533,0.296667,1.0,357.0,10.0,10.0,Adverse Event,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.05375344,0.053764728070912655,1.1288070912655879e-05
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
40.0,357.0,217.0,0.112045,0.112045,5.880533,0.296667,1.0,357.0,10.0,10.0,Death,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.19546943,0.19953392749826362,0.004064497498263625
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,357.0,217.0,0.014006,0.014006,5.880533,0.296667,1.0,357.0,10.0,10.0,Investigator Decision,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.02443433,0.02455250595822421,0.00011817595822420993
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,357.0,217.0,0.005602,0.005602,5.880533,0.296667,1.0,357.0,10.0,10.0,Lost to Follow-up,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.00977304,0.009797105067410654,2.4065067410653646e-05
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Other,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Other,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,357.0,217.0,0.008403,0.008403,5.880533,0.296667,1.0,357.0,10.0,10.0,Other,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.01465955,0.014547478517240304,0.00011207148275969685
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,New drug pulmonary atrial hypertension,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,New drug pulmonary atrial hypertension,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,357.0,217.0,0.005602,0.005602,5.880533,0.296667,1.0,357.0,10.0,10.0,New drug pulmonary atrial hypertension,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.00977304,0.00978858944499994,1.5549444999939793e-05
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Open-Label,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,357.0,217.0,0.0,0.0,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Open-Label,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,357.0,217.0,0.016807,0.016807,5.880533,0.296667,1.0,357.0,10.0,10.0,Withdrawal by Subject,Open-Label,FG002,cardiovascular disease,INDUSTRY,0.02932085,0.030255655174732145,0.0009348051747321458
5.0,730.0,578.0,0.006849,0.006849,6.594413,0.721862,1.0,730.0,7.0,53.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03260299,0.03250462127563496,9.836872436504163e-05
21.0,730.0,578.0,0.028767,0.028767,6.594413,0.721862,1.0,730.0,7.0,53.0,Screen Failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13693826,0.13712451209646653,0.00018625209646652707
34.0,730.0,578.0,0.046575,0.046575,6.594413,0.721862,1.0,730.0,7.0,53.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22170888,0.2163755699185319,0.00533331008146809
30.0,730.0,578.0,0.041096,0.041096,6.594413,0.721862,1.0,730.0,7.0,53.0,Technical Problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.19562744,0.1950620304194136,0.0005654095805864012
4.0,730.0,578.0,0.005479,0.005479,6.594413,0.721862,1.0,730.0,7.0,53.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02608144,0.026209602587222238,0.00012816258722223722
3.0,730.0,578.0,0.00411,0.00411,6.594413,0.721862,1.0,730.0,7.0,53.0,Investigator Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01956465,0.019680572778521824,0.00011592277852182434
21.0,730.0,578.0,0.028767,0.028767,6.594413,0.721862,1.0,730.0,7.0,53.0,Investigational Medicinal Product (IMP) Supply Issues,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13693826,0.13712451209646653,0.00018625209646652707
20.0,730.0,578.0,0.027397,0.027397,6.594413,0.721862,1.0,730.0,7.0,53.0,Issues With Performing Invasive Coronary Angiography (ICA),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13041671,0.1290328710728949,0.0013838389271050855
9.0,730.0,578.0,0.012329,0.012329,6.594413,0.721862,1.0,730.0,7.0,53.0,COVID-19 Restrictions,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05868918,0.05984885548788696,0.001159675487886959
5.0,730.0,578.0,0.006849,0.006849,6.594413,0.721862,1.0,730.0,7.0,53.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03260299,0.03248828616563495,0.00011470383436505
7.0,1291.0,1175.0,0.005422,0.005422,7.163947,0.238805,1.0,1291.0,6.0,131.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00927588,0.009239423378452382,3.6456621547617876e-05
9.0,1291.0,1175.0,0.006971,0.006971,7.163947,0.238805,1.0,1291.0,6.0,131.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01192588,0.011997707863998008,7.182786399800856e-05
8.0,1291.0,1175.0,0.006197,0.006197,7.163947,0.238805,1.0,1291.0,6.0,131.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01060174,0.010602177617281732,4.376172817316393e-07
6.0,1291.0,1175.0,0.004648,0.004648,7.163947,0.238805,1.0,1291.0,6.0,131.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00795173,0.008040968309017862,8.923830901786181e-05
4.0,1291.0,1175.0,0.003098,0.003098,7.163947,0.238805,1.0,1291.0,6.0,131.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00530001,0.00531113845660535,1.112845660534989e-05
3.0,1291.0,1175.0,0.002324,0.002324,7.163947,0.238805,1.0,1291.0,6.0,131.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00397587,0.004008667925208347,3.2797925208346776e-05
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00265001,0.0026543063066666542,4.2963066666542975e-06
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00265001,0.002648940566666654,1.069433333346012e-06
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00132586,0.0013258297569345321,3.024306546796536e-08
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00132586,0.0013239822905555638,1.8777094444363124e-06
6.0,1291.0,1175.0,0.004648,0.004648,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00795173,0.008050994914166672,9.926491416667113e-05
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00265001,0.002650192963749987,1.8296374998698003e-07
4.0,1291.0,1175.0,0.003098,0.003098,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00530001,0.005322249951367251,2.223995136725089e-05
3.0,1291.0,1175.0,0.002324,0.002324,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00397587,0.004006976932410727,3.1106932410727116e-05
4.0,1291.0,1175.0,0.003098,0.003098,7.163947,0.238805,1.0,1291.0,6.0,131.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00530001,0.005326200679085503,2.619067908550283e-05
11.0,1291.0,1175.0,0.008521,0.008521,7.163947,0.238805,1.0,1291.0,6.0,131.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0145776,0.014788096829097208,0.00021049682909720854
5.0,1291.0,1175.0,0.003873,0.003873,7.163947,0.238805,1.0,1291.0,6.0,131.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00662587,0.0066576439545138885,3.177395451388863e-05
7.0,1291.0,1175.0,0.005422,0.005422,7.163947,0.238805,1.0,1291.0,6.0,131.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00927588,0.00924045634309524,3.542365690475946e-05
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00132586,0.0013258297569345321,3.024306546796536e-08
3.0,1291.0,1175.0,0.002324,0.002324,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00397587,0.004007884060833347,3.201406083334652e-05
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00132586,0.001325193204553578,6.667954464221332e-07
5.0,1291.0,1175.0,0.003873,0.003873,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00662587,0.006642276891964284,1.6406891964283743e-05
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00265001,0.002649514780416653,4.952195833468273e-07
4.0,1291.0,1175.0,0.003098,0.003098,7.163947,0.238805,1.0,1291.0,6.0,131.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00530001,0.0053123259603553505,1.231596035535052e-05
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Unavailability,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00265001,0.0026503882608333207,3.78260833320751e-07
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Unavailability,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Unavailability,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00265001,0.00264963748458332,3.725154166800415e-07
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Unavailability,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00132586,0.0013259553881250082,9.538812500813065e-08
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Unavailability,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Error,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00265001,0.0026503423274999876,3.3232749998765576e-07
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Error,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Error,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00265001,0.0026495915512499864,4.1844875001357043e-07
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Error,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Error,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Non-compliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00132586,0.001325864394017865,4.394017864839395e-09
2.0,1291.0,1175.0,0.001549,0.001549,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Non-compliance,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00265001,0.002649514780416653,4.952195833468273e-07
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Participant Non-compliance,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00132586,0.0013240192455555638,1.840754444436309e-06
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Administrative Decision,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00132586,0.001325193204553578,6.667954464221332e-07
1.0,1291.0,1175.0,0.000775,0.000775,7.163947,0.238805,1.0,1291.0,6.0,131.0,Missing,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00132586,0.001325864394017865,4.394017864839395e-09
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Missing,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1291.0,1175.0,0.0,0.0,7.163947,0.238805,1.0,1291.0,6.0,131.0,Missing,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,397.0,342.0,0.030227,0.030227,5.986452,0.708956,1.0,397.0,3.0,41.0,Enrolled but screen failures,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12828727,0.12932452702664687,0.001037257026646865
7.0,397.0,342.0,0.017632,0.017632,5.986452,0.708956,1.0,397.0,3.0,41.0,Enrolled but screen failures,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07483247,0.07618458989515872,0.0013521198951587238
11.0,397.0,342.0,0.027708,0.027708,5.986452,0.708956,1.0,397.0,3.0,41.0,Enrolled but no catheter inserted,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11759631,0.11930479691432443,0.0017084869143244308
13.0,397.0,342.0,0.032746,0.032746,5.986452,0.708956,1.0,397.0,3.0,41.0,Enrolled but no catheter inserted,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13897823,0.14022550696688313,0.0012472769668831207
0.0,397.0,342.0,0.0,0.0,5.986452,0.708956,1.0,397.0,3.0,41.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,397.0,342.0,0.005038,0.005038,5.986452,0.708956,1.0,397.0,3.0,41.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02138192,0.021148427955773815,0.00023349204422618355
1.0,397.0,342.0,0.002519,0.002519,5.986452,0.708956,1.0,397.0,3.0,41.0,Early termination by subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01069096,0.010810687472569415,0.00011972747256941592
0.0,397.0,342.0,0.0,0.0,5.986452,0.708956,1.0,397.0,3.0,41.0,Early termination by subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,397.0,342.0,0.0,0.0,5.986452,0.708956,1.0,397.0,3.0,41.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,397.0,342.0,0.015113,0.015113,5.986452,0.708956,1.0,397.0,3.0,41.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06414151,0.06450126466304569,0.0003597546630456916
0.0,397.0,342.0,0.0,0.0,5.986452,0.708956,1.0,397.0,3.0,41.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,397.0,342.0,0.005038,0.005038,5.986452,0.708956,1.0,397.0,3.0,41.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02138192,0.02114928989910715,0.0002326301008928472
0.0,397.0,342.0,0.0,0.0,5.986452,0.708956,1.0,397.0,3.0,41.0,Catheter inserted but did not undergo ablation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,397.0,342.0,0.002519,0.002519,5.986452,0.708956,1.0,397.0,3.0,41.0,Catheter inserted but did not undergo ablation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01069096,0.01080180102131942,0.0001108410213194206
7.0,250.0,225.0,0.028,0.028,5.525453,0.235372,1.0,250.0,9.0,9.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03641501,0.03754376997173611,0.0011287599717361152
2.0,250.0,225.0,0.008,0.008,5.525453,0.235372,1.0,250.0,9.0,9.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01040429,0.01049765726350921,9.33672635092097e-05
3.0,250.0,225.0,0.012,0.012,5.525453,0.235372,1.0,250.0,9.0,9.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01560643,0.015648607460585322,4.21774605853225e-05
1.0,250.0,225.0,0.004,0.004,5.525453,0.235372,1.0,250.0,9.0,9.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00520214,0.005242272114672616,4.0132114672616036e-05
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,250.0,225.0,0.004,0.004,5.525453,0.235372,1.0,250.0,9.0,9.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00520214,0.005236004087529754,3.386408752975405e-05
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,250.0,225.0,0.012,0.012,5.525453,0.235372,1.0,250.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01560643,0.015653494526656746,4.7064526656747166e-05
3.0,250.0,225.0,0.012,0.012,5.525453,0.235372,1.0,250.0,9.0,9.0,Administrative Problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01560643,0.015670335564573413,6.390556457341358e-05
0.0,250.0,225.0,0.0,0.0,5.525453,0.235372,1.0,250.0,9.0,9.0,Administrative Problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,250.0,225.0,0.016,0.016,5.525453,0.235372,1.0,250.0,9.0,9.0,Administrative Problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02080858,0.021386129529865613,0.0005775495298656133
1.0,250.0,225.0,0.004,0.004,5.525453,0.235372,1.0,250.0,9.0,9.0,Administrative Problems,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00520214,0.005240694364136902,3.855436413690173e-05
56.0,1506.0,1196.0,0.037185,0.037185,7.317876,0.560743,1.0,1506.0,18.0,200.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15258664,0.15251074786937951,7.589213062048072e-05
54.0,1506.0,1196.0,0.035857,0.035857,7.317876,0.560743,1.0,1506.0,18.0,200.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14713726,0.14626187879813493,0.0008753812018650609
31.0,1506.0,1196.0,0.020584,0.020584,7.317876,0.560743,1.0,1506.0,18.0,200.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08446533,0.08384589318889885,0.0006194368111011594
52.0,1506.0,1196.0,0.034529,0.034529,7.317876,0.560743,1.0,1506.0,18.0,200.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14168789,0.14142048781057548,0.00026740218942453153
30.0,1506.0,1196.0,0.01992,0.01992,7.317876,0.560743,1.0,1506.0,18.0,200.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08174064,0.08173475708377978,5.882916220223411e-06
23.0,1506.0,1196.0,0.015272,0.015272,7.317876,0.560743,1.0,1506.0,18.0,200.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06266783,0.06317009305304565,0.000502263053045654
7.0,1506.0,1196.0,0.004648,0.004648,7.317876,0.560743,1.0,1506.0,18.0,200.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01907282,0.018861617485059518,0.00021120251494048323
14.0,1506.0,1196.0,0.009296,0.009296,7.317876,0.560743,1.0,1506.0,18.0,200.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03814563,0.038079726098799616,6.590390120038425e-05
1.0,1506.0,1196.0,0.000664,0.000664,7.317876,0.560743,1.0,1506.0,18.0,200.0,Progressive disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00272469,0.002738518311200392,1.3828311200391862e-05
1.0,1506.0,1196.0,0.000664,0.000664,7.317876,0.560743,1.0,1506.0,18.0,200.0,Progressive disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00272469,0.0027466403308432467,2.1950330843246643e-05
2.0,1506.0,1196.0,0.001328,0.001328,7.317876,0.560743,1.0,1506.0,18.0,200.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00544938,0.005527127485297615,7.7747485297615e-05
0.0,1506.0,1196.0,0.0,0.0,7.317876,0.560743,1.0,1506.0,18.0,200.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1506.0,1196.0,0.0,0.0,7.317876,0.560743,1.0,1506.0,18.0,200.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1506.0,1196.0,0.000664,0.000664,7.317876,0.560743,1.0,1506.0,18.0,200.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00272469,0.0027466060225099158,2.191602250991567e-05
3.0,1506.0,1196.0,0.001992,0.001992,7.317876,0.560743,1.0,1506.0,18.0,200.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00817406,0.00809134352113185,8.271647886815003e-05
15.0,1506.0,1196.0,0.00996,0.00996,7.317876,0.560743,1.0,1506.0,18.0,200.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04087032,0.040679466708214235,0.00019085329178576693
5.0,1506.0,1196.0,0.00332,0.00332,7.317876,0.560743,1.0,1506.0,18.0,200.0,Did not receive treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01362344,0.013440981619494046,0.0001824583805059548
15.0,1506.0,1196.0,0.00996,0.00996,7.317876,0.560743,1.0,1506.0,18.0,200.0,Did not receive treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04087032,0.040679466708214235,0.00019085329178576693
10.0,216.0,174.0,0.046296,0.046296,5.379897,0.266168,1.0,216.0,6.0,69.0,Death / Serious Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06629395,0.06684544318404768,0.00055149318404768
5.0,216.0,174.0,0.023148,0.023148,5.379897,0.266168,1.0,216.0,6.0,69.0,Death / Serious Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03314697,0.03275598857531743,0.00039098142468256547
9.0,216.0,174.0,0.041667,0.041667,5.379897,0.266168,1.0,216.0,6.0,69.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05966541,0.06105664225205357,0.0013912322520535647
4.0,216.0,174.0,0.018519,0.018519,5.379897,0.266168,1.0,216.0,6.0,69.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02651844,0.027188891260029737,0.0006704512600297363
3.0,216.0,174.0,0.013889,0.013889,5.379897,0.266168,1.0,216.0,6.0,69.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01988847,0.02073134290076389,0.000842872900763892
7.0,216.0,174.0,0.032407,0.032407,5.379897,0.266168,1.0,216.0,6.0,69.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04640548,0.04746106947749011,0.0010555894774901126
1.0,216.0,174.0,0.00463,0.00463,5.379897,0.266168,1.0,216.0,6.0,69.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00662997,0.006704522211994049,7.455221199404935e-05
0.0,216.0,174.0,0.0,0.0,5.379897,0.266168,1.0,216.0,6.0,69.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,216.0,174.0,0.0,0.0,5.379897,0.266168,1.0,216.0,6.0,69.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,174.0,0.00463,0.00463,5.379897,0.266168,1.0,216.0,6.0,69.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00662997,0.0067091804566369075,7.921045663690767e-05
1.0,216.0,174.0,0.00463,0.00463,5.379897,0.266168,1.0,216.0,6.0,69.0,Intervention by primary care physician,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00662997,0.006703281442410717,7.331144241071695e-05
0.0,216.0,174.0,0.0,0.0,5.379897,0.266168,1.0,216.0,6.0,69.0,Intervention by primary care physician,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,174.0,0.00463,0.00463,5.379897,0.266168,1.0,216.0,6.0,69.0,Refused hospitalization,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00662997,0.006703281442410717,7.331144241071695e-05
0.0,216.0,174.0,0.0,0.0,5.379897,0.266168,1.0,216.0,6.0,69.0,Refused hospitalization,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,331.0,301.0,0.0,0.0,5.805135,0.580793,1.0,331.0,20.0,198.0,Withdrawal by parent/guardian,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,331.0,301.0,0.003021,0.003021,5.805135,0.580793,1.0,331.0,20.0,198.0,Withdrawal by parent/guardian,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01018555,0.01020402412946433,1.8474129464330843e-05
0.0,331.0,301.0,0.0,0.0,5.805135,0.580793,1.0,331.0,20.0,198.0,Did not meet eligibility criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,331.0,301.0,0.003021,0.003021,5.805135,0.580793,1.0,331.0,20.0,198.0,Did not meet eligibility criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01018555,0.01020402412946433,1.8474129464330843e-05
4.0,331.0,301.0,0.012085,0.012085,5.805135,0.580793,1.0,331.0,20.0,198.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04074556,0.04115192914360925,0.00040636914360925314
3.0,331.0,301.0,0.009063,0.009063,5.805135,0.580793,1.0,331.0,20.0,198.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03055664,0.030758757959553587,0.00020211795955358755
4.0,331.0,301.0,0.012085,0.012085,5.805135,0.580793,1.0,331.0,20.0,198.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04074556,0.04117870962527591,0.00043314962527590817
2.0,331.0,301.0,0.006042,0.006042,5.805135,0.580793,1.0,331.0,20.0,198.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0203711,0.020424429126805612,5.3329126805612415e-05
2.0,331.0,301.0,0.006042,0.006042,5.805135,0.580793,1.0,331.0,20.0,198.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0203711,0.020416689928809583,4.558992880958346e-05
1.0,331.0,301.0,0.003021,0.003021,5.805135,0.580793,1.0,331.0,20.0,198.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01018555,0.010210715542797663,2.5165542797663323e-05
3.0,331.0,301.0,0.009063,0.009063,5.805135,0.580793,1.0,331.0,20.0,198.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03055664,0.030735812959255964,0.0001791729592559646
6.0,331.0,301.0,0.018127,0.018127,5.805135,0.580793,1.0,331.0,20.0,198.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06111666,0.0628548545516171,0.0017381945516170977
2.0,331.0,301.0,0.006042,0.006042,5.805135,0.580793,1.0,331.0,20.0,198.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0203711,0.020407057674464348,3.595767446434861e-05
1.0,331.0,301.0,0.003021,0.003021,5.805135,0.580793,1.0,331.0,20.0,198.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01018555,0.01020294585946433,1.7395859464329477e-05
4.0,256.0,159.0,0.015625,0.015625,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.04304453,0.0437926524759623,0.0007481224759623012
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
14.0,256.0,159.0,0.054688,0.054688,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.15065722,0.15173786416902785,0.001080644169027839
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,256.0,159.0,0.023438,0.023438,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.06456817,0.06514969591639885,0.000581525916398859
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,256.0,159.0,0.007812,0.007812,5.549076,0.496452,1.0,256.0,3.0,23.0,Protocol Violation,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.02152089,0.02159107771107134,7.018771107134003e-05
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Protocol Violation,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Protocol Violation,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
14.0,256.0,159.0,0.054688,0.054688,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.15065722,0.152719675349266,0.002062455349265996
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,256.0,159.0,0.03125,0.03125,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.08608905,0.0877596147521428,0.0016705647521428058
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,256.0,159.0,0.019531,0.019531,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,Before Randomization (VCD Induction),FG000,cardiovascular disease,INDUSTRY,0.05380497,0.05463109457372029,0.000826124573720291
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,Before Randomization (VCD Induction),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,Before Randomization (VCD Induction),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,159.0,0.003906,0.003906,5.549076,0.496452,1.0,256.0,3.0,23.0,Physician Decision,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.01076044,0.010754673873452372,5.766126547627343e-06
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,159.0,0.003906,0.003906,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.01076044,0.010744666477777767,1.5773522222232647e-05
1.0,256.0,159.0,0.003906,0.003906,5.549076,0.496452,1.0,256.0,3.0,23.0,Other,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.01076044,0.01075706451511904,3.375484880959942e-06
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,159.0,0.003906,0.003906,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.01076044,0.010738487980932531,2.195201906746852e-05
1.0,256.0,159.0,0.003906,0.003906,5.549076,0.496452,1.0,256.0,3.0,23.0,Adverse Event,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.01076044,0.010751585276607136,8.85472339286382e-06
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Lost to Follow-up,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,256.0,159.0,0.007812,0.007812,5.549076,0.496452,1.0,256.0,3.0,23.0,Lost to Follow-up,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.02152089,0.02165582214244038,0.00013493214244037974
2.0,256.0,159.0,0.007812,0.007812,5.549076,0.496452,1.0,256.0,3.0,23.0,Lost to Follow-up,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.02152089,0.021660913842797527,0.00014002384279752575
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,256.0,159.0,0.019531,0.019531,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.05380497,0.054556994255863155,0.000752024255863154
4.0,256.0,159.0,0.015625,0.015625,5.549076,0.496452,1.0,256.0,3.0,23.0,Withdrawal by Subject,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.04304453,0.04381379944804564,0.0007692694480456452
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,256.0,159.0,0.023438,0.023438,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.06456817,0.06464618828838302,7.801828838302494e-05
3.0,256.0,159.0,0.011719,0.011719,5.549076,0.496452,1.0,256.0,3.0,23.0,Progressive Disease,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.03228408,0.03295088096234848,0.0006668009623484808
0.0,256.0,159.0,0.0,0.0,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,After Randomization (TP and VTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,256.0,159.0,0.023438,0.023438,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,After Randomization (TP and VTP),FG001,cardiovascular disease,INDUSTRY,0.06456817,0.06465886800796636,9.069800796636385e-05
11.0,256.0,159.0,0.042969,0.042969,5.549076,0.496452,1.0,256.0,3.0,23.0,Death,After Randomization (TP and VTP),FG002,cardiovascular disease,INDUSTRY,0.11837314,0.12279074628622025,0.004417606286220246
8.0,503.0,433.0,0.015905,0.015905,6.222576,0.376508,1.0,503.0,3.0,14.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03726305,0.037203862676319456,5.9187323680542914e-05
5.0,503.0,433.0,0.00994,0.00994,6.222576,0.376508,1.0,503.0,3.0,14.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02328794,0.023484712757619076,0.00019677275761907642
2.0,503.0,433.0,0.003976,0.003976,6.222576,0.376508,1.0,503.0,3.0,14.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00931518,0.009301211897509928,1.3968102490071604e-05
3.0,503.0,433.0,0.005964,0.005964,6.222576,0.376508,1.0,503.0,3.0,14.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01397277,0.013991885194027767,1.911519402776618e-05
8.0,503.0,433.0,0.015905,0.015905,6.222576,0.376508,1.0,503.0,3.0,14.0,Withdrawal by Participant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03726305,0.037203862676319456,5.9187323680542914e-05
11.0,503.0,433.0,0.021869,0.021869,6.222576,0.376508,1.0,503.0,3.0,14.0,Withdrawal by Participant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05123582,0.0516163841967857,0.00038056419678569875
1.0,503.0,433.0,0.001988,0.001988,6.222576,0.376508,1.0,503.0,3.0,14.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00465759,0.004656830516154422,7.594838455776687e-07
2.0,503.0,433.0,0.003976,0.003976,6.222576,0.376508,1.0,503.0,3.0,14.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00931518,0.009319413232986119,4.233232986119301e-06
0.0,503.0,433.0,0.0,0.0,6.222576,0.376508,1.0,503.0,3.0,14.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,503.0,433.0,0.001988,0.001988,6.222576,0.376508,1.0,503.0,3.0,14.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00465759,0.004654281645579027,3.308354420972215e-06
13.0,503.0,433.0,0.025845,0.025845,6.222576,0.376508,1.0,503.0,3.0,14.0,Recurrent Stroke,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06055099,0.060035121160386916,0.0005158688396130831
8.0,503.0,433.0,0.015905,0.015905,6.222576,0.376508,1.0,503.0,3.0,14.0,Recurrent Stroke,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03726305,0.03717310282179564,8.994717820436093e-05
3.0,503.0,433.0,0.005964,0.005964,6.222576,0.376508,1.0,503.0,3.0,14.0,Disallowed Concomitant Medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01397277,0.013987807180992053,1.5037180992051938e-05
2.0,503.0,433.0,0.003976,0.003976,6.222576,0.376508,1.0,503.0,3.0,14.0,Disallowed Concomitant Medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00931518,0.009306958621498024,8.221378501975518e-06
0.0,503.0,433.0,0.0,0.0,6.222576,0.376508,1.0,503.0,3.0,14.0,Carotid or Neurosurgery,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,503.0,433.0,0.001988,0.001988,6.222576,0.376508,1.0,503.0,3.0,14.0,Carotid or Neurosurgery,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00465759,0.00465365031998379,3.939680016209687e-06
0.0,503.0,433.0,0.0,0.0,6.222576,0.376508,1.0,503.0,3.0,14.0,General Anaesthesia,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,503.0,433.0,0.001988,0.001988,6.222576,0.376508,1.0,503.0,3.0,14.0,General Anaesthesia,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00465759,0.00465365031998379,3.939680016209687e-06
1.0,503.0,433.0,0.001988,0.001988,6.222576,0.376508,1.0,503.0,3.0,14.0,Other Miscellaneous Reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00465759,0.004656188708237755,1.4012917622444054e-06
0.0,503.0,433.0,0.0,0.0,6.222576,0.376508,1.0,503.0,3.0,14.0,Other Miscellaneous Reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,711.0,672.0,0.014065,0.014065,6.568078,0.850734,1.0,711.0,18.0,171.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07859086,0.07944864528878962,0.000857785288789617
3.0,711.0,672.0,0.004219,0.004219,6.568078,0.850734,1.0,711.0,18.0,171.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02357447,0.023371603624960286,0.00020286637503971403
10.0,711.0,672.0,0.014065,0.014065,6.568078,0.850734,1.0,711.0,18.0,171.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07859086,0.07962035070230156,0.0010294907023015581
3.0,711.0,672.0,0.004219,0.004219,6.568078,0.850734,1.0,711.0,18.0,171.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02357447,0.023413166996567432,0.00016130300343256826
1.0,711.0,672.0,0.001406,0.001406,6.568078,0.850734,1.0,711.0,18.0,171.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00785629,0.00797530532964285,0.00011901532964284957
2.0,711.0,672.0,0.002813,0.002813,6.568078,0.850734,1.0,711.0,18.0,171.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01571817,0.015576955837162718,0.00014121416283728247
4.0,711.0,672.0,0.005626,0.005626,6.568078,0.850734,1.0,711.0,18.0,171.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03143635,0.03137421589033726,6.213410966274258e-05
2.0,711.0,672.0,0.002813,0.002813,6.568078,0.850734,1.0,711.0,18.0,171.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01571817,0.015612013879752005,0.0001061561202479952
4.0,711.0,672.0,0.005626,0.005626,6.568078,0.850734,1.0,711.0,18.0,171.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03143635,0.031394817659087255,4.1532340912746324e-05
43.0,3445.0,2622.0,0.012482,0.012482,8.144969,0.332945,1.0,3445.0,6.0,270.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.03384903,0.033830138817648805,1.889118235119669e-05
41.0,3445.0,2622.0,0.011901,0.011901,8.144969,0.332945,1.0,3445.0,6.0,270.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.03227346,0.03200319807606151,0.000270261923938489
5.0,3445.0,2622.0,0.001451,0.001451,8.144969,0.332945,1.0,3445.0,6.0,270.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.00393486,0.003964212402271821,2.935240227182074e-05
8.0,3445.0,2622.0,0.002322,0.002322,8.144969,0.332945,1.0,3445.0,6.0,270.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.00629686,0.006446655541031747,0.0001497955410317475
103.0,3445.0,2622.0,0.029898,0.029898,8.144969,0.332945,1.0,3445.0,6.0,270.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.08107822,0.08070014648086304,0.0003780735191369622
111.0,3445.0,2622.0,0.032221,0.032221,8.144969,0.332945,1.0,3445.0,6.0,270.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.0873778,0.08856977781948411,0.0011919778194841024
266.0,3445.0,2622.0,0.077213,0.077213,8.144969,0.332945,1.0,3445.0,6.0,270.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.20938834,0.20491229876358152,0.004476041236418482
246.0,3445.0,2622.0,0.071408,0.071408,8.144969,0.332945,1.0,3445.0,6.0,270.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.19364618,0.18567893180748038,0.007967248192519621
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Protocol Violation,Dose Response Phase (Phase 1),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Protocol Violation,Dose Response Phase (Phase 1),FG001,cardiovascular disease,INDUSTRY,0.00771312,0.0077139345758333484,8.145758333480413e-07
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Protocol Violation,Dose Response Phase (Phase 1),FG002,cardiovascular disease,INDUSTRY,0.00771312,0.007718579391309539,5.4593913095387844e-06
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Unsatisfactory therapeutic effect,Dose Response Phase (Phase 1),FG000,cardiovascular disease,INDUSTRY,0.00771312,0.007719143227083351,6.0232270833503535e-06
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Unsatisfactory therapeutic effect,Dose Response Phase (Phase 1),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Unsatisfactory therapeutic effect,Dose Response Phase (Phase 1),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Dose Response Phase (Phase 1),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Dose Response Phase (Phase 1),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Dose Response Phase (Phase 1),FG002,cardiovascular disease,INDUSTRY,0.00771312,0.007717247657559541,4.127657559540275e-06
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Participants,Dose Response Phase (Phase 1),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,267.0,255.0,0.007491,0.007491,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Participants,Dose Response Phase (Phase 1),FG001,cardiovascular disease,INDUSTRY,0.01542831,0.015479358372837261,5.104837283726078e-05
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Participants,Dose Response Phase (Phase 1),FG002,cardiovascular disease,INDUSTRY,0.00771312,0.007718109178392873,4.989178392872905e-06
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Placebo-controlled Withdrawal (Phase 2),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Placebo-controlled Withdrawal (Phase 2),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,267.0,255.0,0.007491,0.007491,5.590987,0.368375,1.0,267.0,9.0,48.0,Adverse Event,Placebo-controlled Withdrawal (Phase 2),FG002,cardiovascular disease,INDUSTRY,0.01542831,0.015478154646765831,4.9844646765830405e-05
2.0,267.0,255.0,0.007491,0.007491,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Subject,Placebo-controlled Withdrawal (Phase 2),FG000,cardiovascular disease,INDUSTRY,0.01542831,0.015467219309087257,3.8909309087255955e-05
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Subject,Placebo-controlled Withdrawal (Phase 2),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Withdrawal by Subject,Placebo-controlled Withdrawal (Phase 2),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,267.0,255.0,0.003745,0.003745,5.590987,0.368375,1.0,267.0,9.0,48.0,Lost to Follow-up,Placebo-controlled Withdrawal (Phase 2),FG000,cardiovascular disease,INDUSTRY,0.00771312,0.007707400817916683,5.7191820833175575e-06
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Lost to Follow-up,Placebo-controlled Withdrawal (Phase 2),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,267.0,255.0,0.0,0.0,5.590987,0.368375,1.0,267.0,9.0,48.0,Lost to Follow-up,Placebo-controlled Withdrawal (Phase 2),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,854.0,799.0,0.008197,0.008197,6.751101,0.352883,1.0,691.0,1.0,50.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.01952809,0.019560189701312222,3.209970131222081e-05
5.0,854.0,799.0,0.005855,0.005855,6.751101,0.352883,1.0,691.0,1.0,50.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.01394864,0.013739743427083338,0.0002088965729166621
3.0,854.0,799.0,0.003513,0.003513,6.751101,0.352883,1.0,691.0,1.0,50.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.00836918,0.008328673932757937,4.050606724206353e-05
2.0,854.0,799.0,0.002342,0.002342,6.751101,0.352883,1.0,691.0,1.0,50.0,Death,Overall Study,FG003,cardiovascular disease,OTHER,0.00557946,0.0055329707041522295,4.6489295847770146e-05
11.0,854.0,799.0,0.012881,0.012881,6.751101,0.352883,1.0,691.0,1.0,50.0,Dropped,Overall Study,FG000,cardiovascular disease,OTHER,0.030687,0.030678639410744127,8.360589255872186e-06
11.0,854.0,799.0,0.012881,0.012881,6.751101,0.352883,1.0,691.0,1.0,50.0,Dropped,Overall Study,FG001,cardiovascular disease,OTHER,0.030687,0.030711338348720307,2.4338348720308323e-05
7.0,854.0,799.0,0.008197,0.008197,6.751101,0.352883,1.0,691.0,1.0,50.0,Dropped,Overall Study,FG002,cardiovascular disease,OTHER,0.01952809,0.019542662718038412,1.457271803841087e-05
7.0,854.0,799.0,0.008197,0.008197,6.751101,0.352883,1.0,691.0,1.0,50.0,Dropped,Overall Study,FG003,cardiovascular disease,OTHER,0.01952809,0.01954280983714556,1.471983714555758e-05
1.0,854.0,799.0,0.001171,0.001171,6.751101,0.352883,1.0,691.0,1.0,50.0,Missed visit,Overall Study,FG000,cardiovascular disease,OTHER,0.00278973,0.002799817888571432,1.0087888571432349e-05
0.0,854.0,799.0,0.0,0.0,6.751101,0.352883,1.0,691.0,1.0,50.0,Missed visit,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
0.0,854.0,799.0,0.0,0.0,6.751101,0.352883,1.0,691.0,1.0,50.0,Missed visit,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,854.0,799.0,0.001171,0.001171,6.751101,0.352883,1.0,691.0,1.0,50.0,Missed visit,Overall Study,FG003,cardiovascular disease,OTHER,0.00278973,0.002801871373154765,1.2141373154765135e-05
47.0,2539.0,2341.0,0.018511,0.018511,7.839919,1.0,1.0,2564.0,29.0,250.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14512475,0.1441531415825867,0.0009716084174132833
40.0,2539.0,2341.0,0.015754,0.015754,7.839919,1.0,1.0,2564.0,29.0,250.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12351009,0.12101734537151872,0.002492744628481286
13.0,2539.0,2341.0,0.00512,0.00512,7.839919,1.0,1.0,2564.0,29.0,250.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04014039,0.039155750118333325,0.0009846398816666727
20.0,2539.0,2341.0,0.007877,0.007877,7.839919,1.0,1.0,2564.0,29.0,250.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06175504,0.061722086153095226,3.295384690477077e-05
16.0,2539.0,2341.0,0.006302,0.006302,7.839919,1.0,1.0,2564.0,29.0,250.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04940717,0.047970426003412774,0.0014367439965872267
11.0,2539.0,2341.0,0.004332,0.004332,7.839919,1.0,1.0,2564.0,29.0,250.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03396253,0.03405629348261904,9.37634826190456e-05
22.0,2539.0,2341.0,0.008665,0.008665,7.839919,1.0,1.0,2564.0,29.0,250.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0679329,0.0678787982315476,5.410176845239978e-05
25.0,2539.0,2341.0,0.009846,0.009846,7.839919,1.0,1.0,2564.0,29.0,250.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07719185,0.07578672591910712,0.0014051240808928833
3.0,2539.0,2341.0,0.001182,0.001182,7.839919,1.0,1.0,2564.0,29.0,250.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00926678,0.008976270663125015,0.0002905093368749858
1.0,2539.0,2341.0,0.000394,0.000394,7.839919,1.0,1.0,2564.0,29.0,250.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00308893,0.0030430280411011894,4.5901958898810716e-05
10.0,1715.0,1470.0,0.005831,0.005831,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0112265,0.011294866855833323,6.836685583332287e-05
10.0,1715.0,1470.0,0.005831,0.005831,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0112265,0.011295202894107131,6.87028941071307e-05
6.0,1715.0,1470.0,0.003499,0.003499,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00673667,0.006735395225863092,1.2747741369081161e-06
19.0,1715.0,1470.0,0.011079,0.011079,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02133054,0.02057692490862103,0.0007536150913789695
11.0,1715.0,1470.0,0.006414,0.006414,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01234895,0.012222168140456345,0.00012678185954365442
22.0,1715.0,1470.0,0.012828,0.012828,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.02469791,0.024185288479007933,0.0005126215209920668
4.0,1715.0,1470.0,0.002332,0.002332,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00448983,0.004477741144583345,1.2088855416655421e-05
6.0,1715.0,1470.0,0.003499,0.003499,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00673667,0.006734275442113092,2.394557886907858e-06
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00336737,0.0033515192461607197,1.5850753839280474e-05
6.0,1715.0,1470.0,0.003499,0.003499,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00673667,0.006734275442113092,2.394557886907858e-06
6.0,1715.0,1470.0,0.003499,0.003499,7.447751,0.258509,1.0,1711.0,5.0,99.0,Adverse Event,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00673667,0.006734275442113092,2.394557886907858e-06
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00224491,0.0022510210750595347,6.111075059534593e-06
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00112246,0.0011212257480952348,1.2342519047651903e-06
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00224491,0.0022449228051785834,1.2805178583284726e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Protocol Violation,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00112246,0.001122542397222217,8.239722221691469e-08
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00112246,0.0011237315421230136,1.2715421230135356e-06
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00112246,0.0011242637304166622,1.8037304166621405e-06
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00112246,0.0011241456220833289,1.6856220833288277e-06
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00336737,0.0033529150250297657,1.4454974970234437e-05
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00112246,0.0011242637304166622,1.8037304166621405e-06
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00336737,0.0033536741778273853,1.3695822172614912e-05
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00112246,0.0011242637304166622,1.8037304166621405e-06
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lost to Follow-up,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00112246,0.0011242637304166622,1.8037304166621405e-06
5.0,1715.0,1470.0,0.002915,0.002915,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00561229,0.005617387032470238,5.097032470238218e-06
5.0,1715.0,1470.0,0.002915,0.002915,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00561229,0.005611557963720236,7.320362797637314e-07
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00336737,0.003355922996160719,1.1447003839281256e-05
8.0,1715.0,1470.0,0.004665,0.004665,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00898158,0.008924070529861104,5.7509470138895555e-05
12.0,1715.0,1470.0,0.006997,0.006997,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.01347141,0.013129174153789683,0.00034223584621031686
9.0,1715.0,1470.0,0.005248,0.005248,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.01010404,0.009790143349047615,0.000313896650952385
8.0,1715.0,1470.0,0.004665,0.004665,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00898158,0.008923785869265866,5.779413073413349e-05
4.0,1715.0,1470.0,0.002332,0.002332,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00448983,0.004479114169523821,1.0715830476178828e-05
4.0,1715.0,1470.0,0.002332,0.002332,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00448983,0.004479114169523821,1.0715830476178828e-05
5.0,1715.0,1470.0,0.002915,0.002915,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00561229,0.005611796854553572,4.931454464281865e-07
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Withdrawal by Subject,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00224491,0.002245370984404774,4.6098440477371216e-07
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00336737,0.003346483554910717,2.0886445089283046e-05
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00112246,0.0011214333960119017,1.0266039880983593e-06
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00112246,0.0011226458618055506,1.8586180555051936e-07
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00224491,0.002245035184226204,1.251842262038616e-07
0.0,1715.0,1470.0,0.0,0.0,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,1715.0,1470.0,0.003499,0.003499,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00673667,0.0067297209299404725,6.949070059527641e-06
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00224491,0.002244851381726204,5.8618273796138404e-08
5.0,1715.0,1470.0,0.002915,0.002915,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00561229,0.0056123643904563494,7.439045634962532e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00112246,0.0011227639701388839,3.0397013888383215e-07
7.0,1715.0,1470.0,0.004082,0.004082,7.447751,0.258509,1.0,1711.0,5.0,99.0,Lack of Efficacy,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00785913,0.007652796813521826,0.00020633318647817443
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00112246,0.0011232899376388838,8.299376388837872e-07
5.0,1715.0,1470.0,0.002915,0.002915,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00561229,0.005613686525456347,1.3965254563475665e-06
4.0,1715.0,1470.0,0.002332,0.002332,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00448983,0.0044779291099404876,1.1900890059512656e-05
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00112246,0.0011224402576388837,1.974236111634657e-08
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00224491,0.0022475804315476326,2.670431547632454e-06
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00224491,0.0022473966290476326,2.486629047632454e-06
2.0,1715.0,1470.0,0.001166,0.001166,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00224491,0.0022473966290476326,2.486629047632454e-06
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00336737,0.0033541460053273884,1.3223994672611778e-05
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00112246,0.001122558365972217,9.836597221696622e-08
1.0,1715.0,1470.0,0.000583,0.000583,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00112246,0.001122558365972217,9.836597221696622e-08
3.0,1715.0,1470.0,0.001749,0.001749,7.447751,0.258509,1.0,1711.0,5.0,99.0,Other,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00336737,0.003353382102827388,1.398789717261227e-05
191.0,6198.0,3410.0,0.030816,0.030816,8.732143,0.476251,1.0,6198.0,2.0,203.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1281543,0.12690243869369047,0.0012518613063095263
172.0,6198.0,3410.0,0.027751,0.027751,8.732143,0.476251,1.0,6198.0,2.0,203.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1154079,0.1154219330160715,1.403301607150187e-05
52.0,6198.0,3410.0,0.00839,0.00839,8.732143,0.476251,1.0,6198.0,2.0,203.0,Major Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03489144,0.03470188531897185,0.00018955468102815204
46.0,6198.0,3410.0,0.007422,0.007422,8.732143,0.476251,1.0,6198.0,2.0,203.0,Major Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03086582,0.030761111213422617,0.00010470878657738159
226.0,6198.0,3410.0,0.036463,0.036463,8.732143,0.476251,1.0,6198.0,2.0,203.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15163844,0.14722135436340733,0.0044170856365926825
223.0,6198.0,3410.0,0.035979,0.035979,8.732143,0.476251,1.0,6198.0,2.0,203.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14962563,0.14556101912215275,0.004064610877847263
595.0,6198.0,3410.0,0.095999,0.095999,8.732143,0.476251,1.0,6198.0,2.0,203.0,Voluntary Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.39923041,0.38674624888978065,0.012484161110219327
587.0,6198.0,3410.0,0.094708,0.094708,8.732143,0.476251,1.0,6198.0,2.0,203.0,Voluntary Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.39386153,0.3823841954682925,0.011477334531707517
333.0,6198.0,3410.0,0.053727,0.053727,8.732143,0.476251,1.0,6198.0,2.0,203.0,Reason not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22343412,0.21631973058402776,0.007114389415972255
363.0,6198.0,3410.0,0.058567,0.058567,8.732143,0.476251,1.0,6198.0,2.0,203.0,Reason not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.2435622,0.23003340507971234,0.013528794920287662
3.0,505.0,150.0,0.005941,0.005941,6.226537,0.240569,1.0,506.0,0.0,0.0,Protocol Violation,Main Study,FG000,cardiovascular disease,INDUSTRY,0.00889908,0.008873980587460301,2.509941253969923e-05
6.0,505.0,150.0,0.011881,0.011881,6.226537,0.240569,1.0,506.0,0.0,0.0,Protocol Violation,Main Study,FG001,cardiovascular disease,INDUSTRY,0.01779666,0.0177880118280754,8.648171924599546e-06
6.0,505.0,150.0,0.011881,0.011881,6.226537,0.240569,1.0,506.0,0.0,0.0,Adverse Event,Main Study,FG000,cardiovascular disease,INDUSTRY,0.01779666,0.01780950803801588,1.2848038015881441e-05
7.0,505.0,150.0,0.013861,0.013861,6.226537,0.240569,1.0,506.0,0.0,0.0,Adverse Event,Main Study,FG001,cardiovascular disease,INDUSTRY,0.02076252,0.020729165638115058,3.335436188494148e-05
3.0,505.0,150.0,0.005941,0.005941,6.226537,0.240569,1.0,506.0,0.0,0.0,Lack of Efficacy,Main Study,FG000,cardiovascular disease,INDUSTRY,0.00889908,0.008871194362460299,2.788563753970165e-05
0.0,505.0,150.0,0.0,0.0,6.226537,0.240569,1.0,506.0,0.0,0.0,Lack of Efficacy,Main Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
20.0,505.0,150.0,0.039604,0.039604,6.226537,0.240569,1.0,506.0,0.0,0.0,Withdrawal by Subject,Main Study,FG000,cardiovascular disease,INDUSTRY,0.05932321,0.05978949115303574,0.0004662811530357358
15.0,505.0,150.0,0.029703,0.029703,6.226537,0.240569,1.0,506.0,0.0,0.0,Withdrawal by Subject,Main Study,FG001,cardiovascular disease,INDUSTRY,0.04449241,0.044625256988849164,0.00013284698884916124
5.0,505.0,150.0,0.009901,0.009901,6.226537,0.240569,1.0,506.0,0.0,0.0,Lost to Follow-up,Main Study,FG000,cardiovascular disease,INDUSTRY,0.0148308,0.014782071397353894,4.872860264610625e-05
0.0,505.0,150.0,0.0,0.0,6.226537,0.240569,1.0,506.0,0.0,0.0,Lost to Follow-up,Main Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,505.0,150.0,0.0,0.0,6.226537,0.240569,1.0,506.0,0.0,0.0,Physician Decision,Main Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Physician Decision,Main Study,FG001,cardiovascular disease,INDUSTRY,0.00296586,0.0029656402327678496,2.197672321502947e-07
3.0,505.0,150.0,0.005941,0.005941,6.226537,0.240569,1.0,506.0,0.0,0.0,Protocol Violation,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.00889908,0.008873980587460301,2.509941253969923e-05
0.0,505.0,150.0,0.0,0.0,6.226537,0.240569,1.0,506.0,0.0,0.0,Protocol Violation,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Adverse Event,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.00296586,0.002966214737906738,3.5473790673803615e-07
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Adverse Event,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.00296586,0.0029675086277678475,1.648627767847615e-06
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Withdrawal by Subject,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.00296586,0.0029667581258234037,8.981258234038239e-07
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Withdrawal by Subject,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.00296586,0.0029680520156845137,2.1920156845138365e-06
0.0,505.0,150.0,0.0,0.0,6.226537,0.240569,1.0,506.0,0.0,0.0,Others,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,505.0,150.0,0.00198,0.00198,6.226537,0.240569,1.0,506.0,0.0,0.0,Others,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.00296586,0.0029672813652678477,1.4213652678478003e-06
86.0,1254.0,976.0,0.068581,0.068581,7.134891,0.266168,1.0,1254.0,10.0,10.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13024095,0.13083095610020848,0.0005900061002084844
44.0,1254.0,976.0,0.035088,0.035088,7.134891,0.266168,1.0,1254.0,10.0,10.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06663499,0.06666184099227988,2.6850992279878194e-05
58.0,1254.0,976.0,0.046252,0.046252,7.134891,0.266168,1.0,1254.0,10.0,10.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.08783635,0.08837980645144838,0.0005434564514483903
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,Abnormal Test Procedure Result,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1254.0,976.0,0.000797,0.000797,7.134891,0.266168,1.0,1254.0,10.0,10.0,Abnormal Test Procedure Result,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00151357,0.001524394199335318,1.082419933531799e-05
1.0,1254.0,976.0,0.000797,0.000797,7.134891,0.266168,1.0,1254.0,10.0,10.0,Abnormal Test Procedure Result,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00151357,0.0015252196174900799,1.1649617490079762e-05
1.0,1254.0,976.0,0.000797,0.000797,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00151357,0.0015301378483333337,1.6567848333333586e-05
7.0,1254.0,976.0,0.005582,0.005582,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01060068,0.0106012475436508,5.675436508013887e-07
6.0,1254.0,976.0,0.004785,0.004785,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00908711,0.00907329882313491,1.3811176865091007e-05
1.0,1254.0,976.0,0.000797,0.000797,7.134891,0.266168,1.0,1254.0,10.0,10.0,No longer required study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00151357,0.0015297412608333333,1.6171260833333168e-05
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,No longer required study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,No longer required study medication,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
14.0,1254.0,976.0,0.011164,0.011164,7.134891,0.266168,1.0,1254.0,10.0,10.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02120135,0.02162734351278772,0.00042599351278771805
7.0,1254.0,976.0,0.005582,0.005582,7.134891,0.266168,1.0,1254.0,10.0,10.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01060068,0.010617528198382943,1.6848198382943616e-05
7.0,1254.0,976.0,0.005582,0.005582,7.134891,0.266168,1.0,1254.0,10.0,10.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01060068,0.010636572631240094,3.589263124009409e-05
11.0,1254.0,976.0,0.008772,0.008772,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01665875,0.01670289177710317,4.414177710317102e-05
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1254.0,976.0,0.003987,0.003987,7.134891,0.266168,1.0,1254.0,10.0,10.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00757164,0.0075802874647826445,8.647464782644311e-06
4.0,1254.0,976.0,0.00319,0.00319,7.134891,0.266168,1.0,1254.0,10.0,10.0,Administrative Problem,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00605807,0.00608165767121032,2.3587671210320224e-05
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,Administrative Problem,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1254.0,976.0,0.0,0.0,7.134891,0.266168,1.0,1254.0,10.0,10.0,Administrative Problem,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1254.0,976.0,0.00319,0.00319,7.134891,0.266168,1.0,1254.0,10.0,10.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00605807,0.0060931448562103205,3.5074856210320915e-05
6.0,1254.0,976.0,0.004785,0.004785,7.134891,0.266168,1.0,1254.0,10.0,10.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00908711,0.009075362445873009,1.1747554126992008e-05
8.0,1254.0,976.0,0.00638,0.00638,7.134891,0.266168,1.0,1254.0,10.0,10.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01211614,0.01207485637729436,4.128362270563839e-05
3.0,1254.0,976.0,0.002392,0.002392,7.134891,0.266168,1.0,1254.0,10.0,10.0,Mis-randomized,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0045426,0.00449959079267856,4.300920732143963e-05
3.0,1254.0,976.0,0.002392,0.002392,7.134891,0.266168,1.0,1254.0,10.0,10.0,Mis-randomized,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0045426,0.004504989973234114,3.7610026765885936e-05
1.0,1254.0,976.0,0.000797,0.000797,7.134891,0.266168,1.0,1254.0,10.0,10.0,Mis-randomized,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00151357,0.0015277809910317465,1.4210991031746428e-05
5.0,281.0,257.0,0.017794,0.017794,5.641907,0.303074,1.0,281.0,1.0,1.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03042619,0.030434252875367065,8.06287536706668e-06
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00608558,0.006078910062827383,6.669937172617234e-06
4.0,281.0,257.0,0.014235,0.014235,5.641907,0.303074,1.0,281.0,1.0,1.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02434061,0.025122209375624992,0.0007815993756249938
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00608558,0.006080511171160715,5.068828839284965e-06
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00608558,0.006080558538273808,5.021461726192021e-06
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00608558,0.006088613172291665,3.033172291664818e-06
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Non-Compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00608558,0.006081505115357143,4.074884642856977e-06
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Non-Compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00608558,0.00608144620235119,4.133797648809764e-06
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Non-Compliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,281.0,257.0,0.007117,0.007117,5.641907,0.303074,1.0,281.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01216945,0.012348479082356603,0.00017902908235660313
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,281.0,257.0,0.010676,0.010676,5.641907,0.303074,1.0,281.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01825503,0.018678580297103165,0.0004235502971031667
1.0,281.0,257.0,0.003559,0.003559,5.641907,0.303074,1.0,281.0,1.0,1.0,Logistical error study assessments,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00608558,0.006080029259166666,5.550740833333914e-06
0.0,281.0,257.0,0.0,0.0,5.641907,0.303074,1.0,281.0,1.0,1.0,Logistical error study assessments,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,281.0,257.0,0.010676,0.010676,5.641907,0.303074,1.0,281.0,1.0,1.0,Logistical error study assessments,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01825503,0.01866497836138888,0.0004099483613888809
2.0,243.0,185.0,0.00823,0.00823,5.497168,0.350295,1.0,243.0,4.0,64.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01584796,0.016102398445545646,0.0002544384455456447
28.0,243.0,185.0,0.115226,0.115226,5.497168,0.350295,1.0,243.0,4.0,64.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.22188294,0.2157529548051192,0.00612998519488081
2.0,243.0,185.0,0.00823,0.00823,5.497168,0.350295,1.0,243.0,4.0,64.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01584796,0.01612688260617065,0.0002789226061706493
13.0,243.0,185.0,0.053498,0.053498,5.497168,0.350295,1.0,243.0,4.0,64.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10301749,0.1034116908649207,0.00039420086492070183
4.0,243.0,185.0,0.016461,0.016461,5.497168,0.350295,1.0,243.0,4.0,64.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03169784,0.03210063601589284,0.00040279601589283953
5.0,243.0,185.0,0.020576,0.020576,5.497168,0.350295,1.0,243.0,4.0,64.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03962182,0.04113969456660715,0.0015178745666071455
0.0,243.0,185.0,0.0,0.0,5.497168,0.350295,1.0,243.0,4.0,64.0,Protocol deviation(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,243.0,185.0,0.004115,0.004115,5.497168,0.350295,1.0,243.0,4.0,64.0,Protocol deviation(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00792398,0.007975715888936717,5.173588893671657e-05
1.0,243.0,185.0,0.004115,0.004115,5.497168,0.350295,1.0,243.0,4.0,64.0,Abnormal laboratory value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00792398,0.00795188307977006,2.790307977005961e-05
0.0,243.0,185.0,0.0,0.0,5.497168,0.350295,1.0,243.0,4.0,64.0,Abnormal laboratory value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,243.0,185.0,0.004115,0.004115,5.497168,0.350295,1.0,243.0,4.0,64.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00792398,0.00795188307977006,2.790307977005961e-05
0.0,243.0,185.0,0.0,0.0,5.497168,0.350295,1.0,243.0,4.0,64.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,243.0,185.0,0.004115,0.004115,5.497168,0.350295,1.0,243.0,4.0,64.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00792398,0.007947869929770061,2.388992977006045e-05
0.0,243.0,185.0,0.0,0.0,5.497168,0.350295,1.0,243.0,4.0,64.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,947.0,905.0,0.008448,0.008448,6.854355,1.0,1.0,947.0,14.0,97.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05790559,0.05941325363967269,0.0015076636396726892
10.0,947.0,905.0,0.01056,0.01056,6.854355,1.0,1.0,947.0,14.0,97.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07238198,0.06920150024471947,0.0031804797552805325
5.0,947.0,905.0,0.00528,0.00528,6.854355,1.0,1.0,947.0,14.0,97.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03619099,0.03545521540714281,0.0007357745928571885
3.0,947.0,905.0,0.003168,0.003168,6.854355,1.0,1.0,947.0,14.0,97.0,Non compliant with protocol,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0217146,0.021324575645476188,0.0003900243545238123
3.0,947.0,905.0,0.003168,0.003168,6.854355,1.0,1.0,947.0,14.0,97.0,Non compliant with protocol,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0217146,0.021295122181011913,0.0004194778189880871
2.0,947.0,905.0,0.002112,0.002112,6.854355,1.0,1.0,947.0,14.0,97.0,Non compliant with protocol,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0144764,0.014436155605982213,4.024439401778719e-05
0.0,947.0,905.0,0.0,0.0,6.854355,1.0,1.0,947.0,14.0,97.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,947.0,905.0,0.0,0.0,6.854355,1.0,1.0,947.0,14.0,97.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,947.0,905.0,0.001056,0.001056,6.854355,1.0,1.0,947.0,14.0,97.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0072382,0.007226480167976211,1.1719832023789588e-05
2.0,947.0,905.0,0.002112,0.002112,6.854355,1.0,1.0,947.0,14.0,97.0,Consent withdrawn,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0144764,0.014391971688690545,8.442831130945488e-05
3.0,947.0,905.0,0.003168,0.003168,6.854355,1.0,1.0,947.0,14.0,97.0,Consent withdrawn,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0217146,0.021206444457261914,0.0005081555427380868
1.0,947.0,905.0,0.001056,0.001056,6.854355,1.0,1.0,947.0,14.0,97.0,Consent withdrawn,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0072382,0.007226740557559543,1.145944244045679e-05
1.0,947.0,905.0,0.001056,0.001056,6.854355,1.0,1.0,947.0,14.0,97.0,Specified category,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0072382,0.007239005015059543,8.050150595425784e-07
2.0,947.0,905.0,0.002112,0.002112,6.854355,1.0,1.0,947.0,14.0,97.0,Specified category,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0144764,0.014384927204940539,9.14727950594614e-05
1.0,947.0,905.0,0.001056,0.001056,6.854355,1.0,1.0,947.0,14.0,97.0,Specified category,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0072382,0.00723049394089288,7.706059107119925e-06
0.0,380.0,379.0,0.0,0.0,5.942799,0.407575,1.0,380.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,380.0,379.0,0.002632,0.002632,5.942799,0.407575,1.0,380.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00637506,0.006420294819692462,4.523481969246224e-05
7.0,833.0,752.0,0.008403,0.008403,6.726233,0.220602,1.0,1743.0,9.0,9.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01246857,0.012907768691914694,0.00043919869191469396
11.0,833.0,752.0,0.013205,0.013205,6.726233,0.220602,1.0,1743.0,9.0,9.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01959389,0.019963659321309526,0.00036976932130952656
6.0,833.0,752.0,0.007203,0.007203,6.726233,0.220602,1.0,1743.0,9.0,9.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01068798,0.010764877860486115,7.689786048611577e-05
7.0,833.0,752.0,0.008403,0.008403,6.726233,0.220602,1.0,1743.0,9.0,9.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01246857,0.012919159583164691,0.0004505895831646914
5.0,833.0,752.0,0.006002,0.006002,6.726233,0.220602,1.0,1743.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00890591,0.009171121022549602,0.0002652110225496024
9.0,833.0,752.0,0.010804,0.010804,6.726233,0.220602,1.0,1743.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01603123,0.016236919668501975,0.00020568966850197448
3.0,833.0,752.0,0.003601,0.003601,6.726233,0.220602,1.0,1743.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00534325,0.005375932183452362,3.268218345236183e-05
4.0,833.0,752.0,0.004802,0.004802,6.726233,0.220602,1.0,1743.0,9.0,9.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00712532,0.007164567676031768,3.924767603176796e-05
4.0,833.0,752.0,0.004802,0.004802,6.726233,0.220602,1.0,1743.0,9.0,9.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00712532,0.007153460247847247,2.814024784724648e-05
2.0,833.0,752.0,0.002401,0.002401,6.726233,0.220602,1.0,1743.0,9.0,9.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00356266,0.003579430784821437,1.6770784821437158e-05
4.0,833.0,752.0,0.004802,0.004802,6.726233,0.220602,1.0,1743.0,9.0,9.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00712532,0.007155921888561534,3.060188856153414e-05
0.0,833.0,752.0,0.0,0.0,6.726233,0.220602,1.0,1743.0,9.0,9.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Incorrect enrolment/mis-randomisation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00178059,0.0017803164912500004,2.735087499996635e-07
2.0,833.0,752.0,0.002401,0.002401,6.726233,0.220602,1.0,1743.0,9.0,9.0,Incorrect enrolment/mis-randomisation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00356266,0.003579558583630963,1.6898583630963002e-05
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Incorrect enrolment/mis-randomisation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00178059,0.0017807815070833336,1.915070833335194e-07
2.0,833.0,752.0,0.002401,0.002401,6.726233,0.220602,1.0,1743.0,9.0,9.0,Incorrect enrolment/mis-randomisation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00356266,0.0035759720399404864,1.3312039940486381e-05
0.0,833.0,752.0,0.0,0.0,6.726233,0.220602,1.0,1743.0,9.0,9.0,Severe non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Severe non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00178059,0.0017804966607142861,9.333928571394513e-08
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Severe non-compliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00178059,0.0017809479720833335,3.579720833334077e-07
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Severe non-compliance,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00178059,0.0017799032112500003,6.867887499997349e-07
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Safety reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00178059,0.0017809626504166672,3.7265041666714217e-07
0.0,833.0,752.0,0.0,0.0,6.726233,0.220602,1.0,1743.0,9.0,9.0,Safety reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Safety reasons,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00178059,0.0017809139495833335,3.2394958333339594e-07
0.0,833.0,752.0,0.0,0.0,6.726233,0.220602,1.0,1743.0,9.0,9.0,Safety reasons,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00178059,0.001780471400416667,1.1859958333297616e-07
3.0,833.0,752.0,0.003601,0.003601,6.726233,0.220602,1.0,1743.0,9.0,9.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00534325,0.005381500797559507,3.825079755950724e-05
3.0,833.0,752.0,0.003601,0.003601,6.726233,0.220602,1.0,1743.0,9.0,9.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00534325,0.00537636795874998,3.311795874998049e-05
1.0,833.0,752.0,0.0012,0.0012,6.726233,0.220602,1.0,1743.0,9.0,9.0,Other,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00178059,0.001779891655416667,6.983445833331527e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00997667,0.00997531853928567,1.3514607143296636e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00997667,0.009975867319702318,8.026802976821706e-07
4.0,1461.0,1344.0,0.002738,0.002738,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01995334,0.01976047186396823,0.00019286813603177147
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00498469,0.00498340584380948,1.284156190519553e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00498469,0.00498340584380948,1.284156190519553e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00498469,0.00498340584380948,1.284156190519553e-06
6.0,1461.0,1344.0,0.004107,0.004107,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.02993001,0.030101289535811638,0.000171279535811638
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1461.0,1344.0,0.003422,0.003422,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.02493803,0.02549014719147817,0.0005521171914781714
8.0,1461.0,1344.0,0.005476,0.005476,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.03990668,0.03925337180202379,0.0006533081979762101
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00997667,0.009975803420892793,8.665791072070411e-07
3.0,1461.0,1344.0,0.002053,0.002053,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.01496136,0.015004384414754714,4.3024414754714094e-05
3.0,1461.0,1344.0,0.002053,0.002053,7.287561,1.0,1.0,1461.0,5.0,136.0,Adverse Event,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.01496136,0.014989590258326144,2.8230258326144078e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00498469,0.004985245569999959,5.555699999588645e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00498469,0.004984823254999957,1.33254999957165e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00498469,0.004984574504999957,1.154950000428756e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00997667,0.00997208681053566,4.583189464340762e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00498469,0.004984574504999957,1.154950000428756e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00997667,0.009972361089702324,4.308910297675522e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00498469,0.004984574504999957,1.154950000428756e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00498469,0.004984574504999957,1.154950000428756e-07
3.0,1461.0,1344.0,0.002053,0.002053,7.287561,1.0,1.0,1461.0,5.0,136.0,Protocol Violation,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.01496136,0.015007137764576142,4.57777645761423e-05
3.0,1461.0,1344.0,0.002053,0.002053,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01496136,0.01503734076892138,7.598076892137949e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00498469,0.004985024204583292,3.34204583292419e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00498469,0.004984601889583291,8.811041670928055e-08
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00498469,0.004984353139583291,3.3686041670932115e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00997667,0.010001341250714226,2.4671250714225837e-05
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00997667,0.010001341250714226,2.4671250714225837e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00498469,0.004984353139583291,3.3686041670932115e-07
4.0,1461.0,1344.0,0.002738,0.002738,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.01995334,0.019794274063968224,0.0001590659360317763
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00498469,0.004984545631249957,1.4436875004318617e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00498469,0.004984353139583291,3.3686041670932115e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00997667,0.010001341250714226,2.4671250714225837e-05
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00997667,0.01000128950904756,2.4619509047559343e-05
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00498469,0.004984353139583291,3.3686041670932115e-07
5.0,1461.0,1344.0,0.003422,0.003422,7.287561,1.0,1.0,1461.0,5.0,136.0,Withdrawal by Subject,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.02493803,0.025485399561537697,0.0005473695615376972
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00997667,0.00997195387303567,4.71612696432977e-06
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00498469,0.004982814849642817,1.8751503571825742e-06
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00498469,0.004984956506309484,2.665063094844239e-07
6.0,1461.0,1344.0,0.004107,0.004107,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02993001,0.030057472787299727,0.0001274627872997272
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.00997667,0.009972432378452318,4.237621547682063e-06
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00498469,0.0049842854413094835,4.045586905164489e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.00997667,0.009972368479642793,4.301520357206934e-06
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00498469,0.0049842854413094835,4.045586905164489e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lack of Efficacy,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1461.0,1344.0,0.002053,0.002053,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01496136,0.01502849017511185,6.713017511185068e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.00498469,0.005000917837936471,1.6227837936470813e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.00498469,0.005000917837936471,1.6227837936470813e-05
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00997667,0.009979290371785651,2.6203717856509295e-06
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00498469,0.005000917837936471,1.6227837936470813e-05
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00498469,0.005000917837936471,1.6227837936470813e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00498469,0.005000917837936471,1.6227837936470813e-05
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Lost to Follow-up,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00997667,0.009976881634285652,2.1163428565174058e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG005,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG006,cardiovascular disease,INDUSTRY,0.00498469,0.0049840708333332906,6.191666667093934e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG007,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG008,cardiovascular disease,INDUSTRY,0.00997667,0.00997683478428565,1.6478428565072645e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG009,cardiovascular disease,INDUSTRY,0.00498469,0.0049840708333332906,6.191666667093934e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG010,cardiovascular disease,INDUSTRY,0.00498469,0.004984263324999957,4.266750000432584e-07
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG011,cardiovascular disease,INDUSTRY,0.00498469,0.0049840708333332906,6.191666667093934e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG012,cardiovascular disease,INDUSTRY,0.00997667,0.009976881634285652,2.1163428565174058e-07
0.0,1461.0,1344.0,0.0,0.0,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG013,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1461.0,1344.0,0.000684,0.000684,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG014,cardiovascular disease,INDUSTRY,0.00498469,0.0049840708333332906,6.191666667093934e-07
2.0,1461.0,1344.0,0.001369,0.001369,7.287561,1.0,1.0,1461.0,5.0,136.0,Randomised in error; pregnancy; moving,Overall Study,FG015,cardiovascular disease,INDUSTRY,0.00997667,0.009976881634285652,2.1163428565174058e-07
9.0,551.0,495.0,0.016334,0.016334,6.313548,0.230287,1.0,551.0,1.0,46.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02374849,0.023766289026140863,1.7799026140862678e-05
9.0,551.0,495.0,0.016334,0.016334,6.313548,0.230287,1.0,551.0,1.0,46.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02374849,0.0237652941332242,1.680413322419777e-05
6.0,551.0,495.0,0.010889,0.010889,6.313548,0.230287,1.0,551.0,1.0,46.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01583184,0.01582496355770834,6.876442291661039e-06
2.0,551.0,495.0,0.00363,0.00363,6.313548,0.230287,1.0,551.0,1.0,46.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00527777,0.005286343117362001,8.573117362000761e-06
3.0,551.0,495.0,0.005445,0.005445,6.313548,0.230287,1.0,551.0,1.0,46.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00791665,0.007888895006438487,2.7754993561513938e-05
0.0,551.0,495.0,0.0,0.0,6.313548,0.230287,1.0,551.0,1.0,46.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,551.0,495.0,0.001815,0.001815,6.313548,0.230287,1.0,551.0,1.0,46.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00263888,0.0026467888275595254,7.908827559525294e-06
4.0,551.0,495.0,0.00726,0.00726,6.313548,0.230287,1.0,551.0,1.0,46.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01055553,0.010504267052172622,5.126294782737892e-05
1.0,551.0,495.0,0.001815,0.001815,6.313548,0.230287,1.0,551.0,1.0,46.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00263888,0.002645879657589286,6.999657589285696e-06
2.0,551.0,495.0,0.00363,0.00363,6.313548,0.230287,1.0,551.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00527777,0.005283273350278669,5.503350278668502e-06
5.0,551.0,495.0,0.009074,0.009074,6.313548,0.230287,1.0,551.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01319296,0.013168205993869045,2.4754006130955214e-05
3.0,551.0,495.0,0.005445,0.005445,6.313548,0.230287,1.0,551.0,1.0,46.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00791665,0.007889943227867059,2.6706772132942258e-05
1.0,551.0,495.0,0.001815,0.001815,6.313548,0.230287,1.0,551.0,1.0,46.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00263888,0.002647057538809525,8.177538809525046e-06
2.0,551.0,495.0,0.00363,0.00363,6.313548,0.230287,1.0,551.0,1.0,46.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00527777,0.005281673964862002,3.903964862001473e-06
2.0,551.0,495.0,0.00363,0.00363,6.313548,0.230287,1.0,551.0,1.0,46.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00527777,0.005283490779028668,5.72077902866782e-06
1.0,551.0,495.0,0.001815,0.001815,6.313548,0.230287,1.0,551.0,1.0,46.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00263888,0.0026460365138095254,7.156513809525224e-06
1.0,551.0,495.0,0.001815,0.001815,6.313548,0.230287,1.0,551.0,1.0,46.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00263888,0.002645032326200397,6.152326200396709e-06
4.0,551.0,495.0,0.00726,0.00726,6.313548,0.230287,1.0,551.0,1.0,46.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01055553,0.010526119321636909,2.941067836309194e-05
18.0,706.0,0.0,0.025496,0.025496,6.561031,0.878022,1.0,706.0,24.0,160.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14687553,0.14796091842876355,0.0010853884287635451
15.0,706.0,0.0,0.021246,0.021246,6.561031,0.878022,1.0,706.0,24.0,160.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12239243,0.12373094581160717,0.0013385158116071688
217.0,706.0,0.0,0.307365,0.307365,6.561031,0.878022,1.0,706.0,24.0,160.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.77064627,1.8110322600284314,0.04038599002843135
171.0,706.0,0.0,0.24221,0.24221,6.561031,0.878022,1.0,706.0,24.0,160.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.39530602,1.3626948659465956,0.03261115405340442
1.0,706.0,0.0,0.001416,0.001416,6.561031,0.878022,1.0,706.0,24.0,160.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00815719,0.00826336251255952,0.00010617251255952073
0.0,706.0,0.0,0.0,0.0,6.561031,0.878022,1.0,706.0,24.0,160.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
30.0,706.0,0.0,0.042493,0.042493,6.561031,0.878022,1.0,706.0,24.0,160.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24479063,0.24311261283045618,0.0016780171695438273
30.0,706.0,0.0,0.042493,0.042493,6.561031,0.878022,1.0,706.0,24.0,160.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.24479063,0.24311358163959304,0.0016770483604069686
3.0,706.0,0.0,0.004249,0.004249,6.561031,0.878022,1.0,706.0,24.0,160.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02447733,0.02617969219541668,0.0017023621954166818
4.0,706.0,0.0,0.005666,0.005666,6.561031,0.878022,1.0,706.0,24.0,160.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03264029,0.03277412065297614,0.00013383065297613989
87.0,706.0,0.0,0.123229,0.123229,6.561031,0.878022,1.0,706.0,24.0,160.0,Discontinued at clinical cutoff (due to end of data collection period),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.7098888,0.6984952268787501,0.01139357312124989
130.0,706.0,0.0,0.184136,0.184136,6.561031,0.878022,1.0,706.0,24.0,160.0,Discontinued at clinical cutoff (due to end of data collection period),Overall Study,FG001,cardiovascular disease,INDUSTRY,1.06075748,0.9987183355558336,0.06203914444416636
9.0,820.0,365.0,0.010976,0.010976,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Core Study,FG000,cardiovascular disease,INDUSTRY,0.02076373,0.020582822259732132,0.00018090774026786882
11.0,820.0,365.0,0.013415,0.013415,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Core Study,FG001,cardiovascular disease,INDUSTRY,0.02537768,0.025331107998948433,4.657200105156675e-05
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal laboratory values,Core Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,820.0,365.0,0.00122,0.00122,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal laboratory values,Core Study,FG001,cardiovascular disease,INDUSTRY,0.00230792,0.0023100999320238196,2.17993202381939e-06
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal laboratory values,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,820.0,365.0,0.00122,0.00122,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal test procedure results,Core Study,FG000,cardiovascular disease,INDUSTRY,0.00230792,0.0023111633007738197,3.243300773819475e-06
1.0,820.0,365.0,0.00122,0.00122,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal test procedure results,Core Study,FG001,cardiovascular disease,INDUSTRY,0.00230792,0.0023100999320238196,2.17993202381939e-06
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Abnormal test procedure results,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Protocol deviation,Core Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,820.0,365.0,0.00122,0.00122,6.710523,0.281906,1.0,820.0,23.0,23.0,Protocol deviation,Core Study,FG001,cardiovascular disease,INDUSTRY,0.00230792,0.002310424173690486,2.504173690486e-06
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Protocol deviation,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,820.0,365.0,0.012195,0.012195,6.710523,0.281906,1.0,820.0,23.0,23.0,Patient withdrew consent,Core Study,FG000,cardiovascular disease,INDUSTRY,0.02306975,0.023169827345486126,0.00010007734548612632
11.0,820.0,365.0,0.013415,0.013415,6.710523,0.281906,1.0,820.0,23.0,23.0,Patient withdrew consent,Core Study,FG001,cardiovascular disease,INDUSTRY,0.02537768,0.025353059889365103,2.462011063489658e-05
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Patient withdrew consent,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,820.0,365.0,0.008537,0.008537,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Core Study,FG000,cardiovascular disease,INDUSTRY,0.01614977,0.016117055236746062,3.271476325393888e-05
4.0,820.0,365.0,0.004878,0.004878,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Core Study,FG001,cardiovascular disease,INDUSTRY,0.0092279,0.009309464730912691,8.156473091269073e-05
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Core Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,820.0,365.0,0.002439,0.002439,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Core Study,FG001,cardiovascular disease,INDUSTRY,0.00461395,0.004471532198819436,0.00014241780118056432
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,820.0,365.0,0.008537,0.008537,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Core Study,FG000,cardiovascular disease,INDUSTRY,0.01614977,0.016100805405912733,4.896459408726753e-05
14.0,820.0,365.0,0.017073,0.017073,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Core Study,FG001,cardiovascular disease,INDUSTRY,0.03229766,0.03271786812395833,0.000420208123958328
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Core Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
14.0,820.0,365.0,0.017073,0.017073,6.710523,0.281906,1.0,820.0,23.0,23.0,Adverse Event,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.03229766,0.032712791247351186,0.0004151312473511873
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Unsatisfactory therapeutic effect,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Unsatisfactory therapeutic effect,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,820.0,365.0,0.002439,0.002439,6.710523,0.281906,1.0,820.0,23.0,23.0,Unsatisfactory therapeutic effect,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.00461395,0.004454780896805547,0.00015916910319445365
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Withdrawal by Subject,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Withdrawal by Subject,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,820.0,365.0,0.015854,0.015854,6.710523,0.281906,1.0,820.0,23.0,23.0,Withdrawal by Subject,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.02999163,0.02992211215585316,6.951784414683734e-05
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,820.0,365.0,0.012195,0.012195,6.710523,0.281906,1.0,820.0,23.0,23.0,Lost to Follow-up,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.02306975,0.023105137605019848,3.538760501984803e-05
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,820.0,365.0,0.00122,0.00122,6.710523,0.281906,1.0,820.0,23.0,23.0,Administrative problems,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.00230792,0.002310283766130961,2.3637661309607733e-06
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Extension Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,820.0,365.0,0.0,0.0,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Extension Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,820.0,365.0,0.020732,0.020732,6.710523,0.281906,1.0,820.0,23.0,23.0,Death,Extension Study,FG002,cardiovascular disease,INDUSTRY,0.03921953,0.03889071198681546,0.0003288180131845453
10.0,428.0,375.0,0.023364,0.023364,6.061457,0.057136,1.0,428.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00809162,0.01274985500739086,0.004658235007390859
0.0,428.0,375.0,0.0,0.0,6.061457,0.057136,1.0,428.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,428.0,375.0,0.007009,0.007009,6.061457,0.057136,1.0,428.0,0.0,0.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00242742,0.0024833565045833286,5.59365045833286e-05
3.0,428.0,375.0,0.007009,0.007009,6.061457,0.057136,1.0,428.0,0.0,0.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00242742,0.00246484010416666,3.742010416665992e-05
9.0,428.0,375.0,0.021028,0.021028,6.061457,0.057136,1.0,428.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00728259,0.010847334649751978,0.003564744649751978
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00161839,0.0016414038389285731,2.3013838928573208e-05
5.0,428.0,375.0,0.011682,0.011682,6.061457,0.057136,1.0,428.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00404581,0.0073697891263988,0.0033239791263987998
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Lack of Efficacy,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00161839,0.001640885133333335,2.249513333333502e-05
0.0,428.0,375.0,0.0,0.0,6.061457,0.057136,1.0,428.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00161839,0.0016386594493452403,2.026944934524033e-05
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00161839,0.001638140743750002,1.9750743750002143e-05
0.0,428.0,375.0,0.0,0.0,6.061457,0.057136,1.0,428.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,428.0,375.0,0.007009,0.007009,6.061457,0.057136,1.0,428.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00242742,0.002534551035297614,0.00010713103529761412
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00161839,0.0016367015305952398,1.831153059523986e-05
1.0,428.0,375.0,0.002336,0.002336,6.061457,0.057136,1.0,428.0,0.0,0.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00080902,0.0010082395596626968,0.00019921955966269677
2.0,428.0,375.0,0.004673,0.004673,6.061457,0.057136,1.0,428.0,0.0,0.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00161839,0.0016361828250000016,1.7792825000001672e-05
0.0,428.0,375.0,0.0,0.0,6.061457,0.057136,1.0,428.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,428.0,375.0,0.007009,0.007009,6.061457,0.057136,1.0,428.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00242742,0.0025934169532142812,0.00016599695321428123
1.0,428.0,375.0,0.002336,0.002336,6.061457,0.057136,1.0,428.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00080902,0.0010130316652579344,0.0002040116652579344
3.0,428.0,375.0,0.007009,0.007009,6.061457,0.057136,1.0,428.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00242742,0.0025123559477976108,8.493594779761075e-05
12.0,2499.0,2450.0,0.004802,0.004802,7.824046,0.715889,1.0,2499.0,7.0,113.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02689672,0.025577953277083332,0.0013187667229166665
21.0,2499.0,2450.0,0.008403,0.008403,7.824046,0.715889,1.0,2499.0,7.0,113.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.04706646,0.04658100765293656,0.0004854523470634378
7.0,2499.0,2450.0,0.002801,0.002801,7.824046,0.715889,1.0,2499.0,7.0,113.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.01568882,0.014875165008858241,0.0008136549911417577
9.0,2499.0,2450.0,0.003601,0.003601,7.824046,0.715889,1.0,2499.0,7.0,113.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.02016974,0.019340560627083326,0.0008291793729166726
14.0,621.0,619.0,0.022544,0.022544,6.43294,0.507413,1.0,621.0,19.0,119.0,Adverse Event,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.07358719,0.07158233534570431,0.0020048546542956874
11.0,621.0,619.0,0.017713,0.017713,6.43294,0.507413,1.0,621.0,19.0,119.0,Adverse Event,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.05781804,0.05806536830450398,0.00024732830450397564
1.0,621.0,619.0,0.00161,0.00161,6.43294,0.507413,1.0,621.0,19.0,119.0,Death,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.0052553,0.00527724790853173,2.1947908531730342e-05
4.0,621.0,619.0,0.006441,0.006441,6.43294,0.507413,1.0,621.0,19.0,119.0,Death,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.02102445,0.02058412626664681,0.0004403237333531901
1.0,621.0,619.0,0.00161,0.00161,6.43294,0.507413,1.0,621.0,19.0,119.0,Lost to Follow-up,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.0052553,0.005270433371865065,1.513337186506529e-05
0.0,621.0,619.0,0.0,0.0,6.43294,0.507413,1.0,621.0,19.0,119.0,Lost to Follow-up,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,621.0,619.0,0.00161,0.00161,6.43294,0.507413,1.0,621.0,19.0,119.0,Non-compliance with Study Drug,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.0052553,0.005266450946448397,1.1150946448396787e-05
1.0,621.0,619.0,0.00161,0.00161,6.43294,0.507413,1.0,621.0,19.0,119.0,Non-compliance with Study Drug,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.0052553,0.005259488049960304,4.188049960303711e-06
1.0,621.0,619.0,0.00161,0.00161,6.43294,0.507413,1.0,621.0,19.0,119.0,Protocol Deviation,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.0052553,0.005270433371865065,1.513337186506529e-05
7.0,621.0,619.0,0.011272,0.011272,6.43294,0.507413,1.0,621.0,19.0,119.0,Protocol Deviation,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.0367936,0.03670604777511912,8.755222488088243e-05
5.0,621.0,619.0,0.008052,0.008052,6.43294,0.507413,1.0,621.0,19.0,119.0,Withdrawal by Parent/Guardian,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.026283,0.02613374704664682,0.00014925295335318015
3.0,621.0,619.0,0.004831,0.004831,6.43294,0.507413,1.0,621.0,19.0,119.0,Withdrawal by Parent/Guardian,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.01576915,0.015944299572083345,0.00017514957208334542
0.0,621.0,619.0,0.0,0.0,6.43294,0.507413,1.0,621.0,19.0,119.0,Withdrawal of Informed Consent,Randomization (Visit 2),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,621.0,619.0,0.003221,0.003221,6.43294,0.507413,1.0,621.0,19.0,119.0,Withdrawal of Informed Consent,Randomization (Visit 2),FG001,cardiovascular disease,INDUSTRY,0.01051385,0.010209494585551947,0.0003043554144480532
74.0,3449.0,2749.0,0.021455,0.021455,8.14613,0.252985,1.0,3449.0,34.0,324.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.04421549,0.0442330216650297,1.753166502969916e-05
67.0,3449.0,2749.0,0.019426,0.019426,8.14613,0.252985,1.0,3449.0,34.0,324.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04003403,0.039631655353005966,0.00040237464699403175
19.0,3449.0,2749.0,0.005509,0.005509,8.14613,0.252985,1.0,3449.0,34.0,324.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01135321,0.011418876259672592,6.56662596725914e-05
22.0,3449.0,2749.0,0.006379,0.006379,8.14613,0.252985,1.0,3449.0,34.0,324.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01314615,0.013410102571696446,0.000263952571696445
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lack of Efficacy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lack of Efficacy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00059765,0.0006016686287500028,4.018628750002747e-06
12.0,3449.0,2749.0,0.003479,0.003479,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00716969,0.007200647438700399,3.0957438700398784e-05
18.0,3449.0,2749.0,0.005219,0.005219,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01075557,0.010697672555615075,5.789744438492589e-05
3.0,3449.0,2749.0,0.00087,0.00087,8.14613,0.252985,1.0,3449.0,34.0,324.0,Physician Decision,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00179294,0.0017698646728373005,2.3075327162699498e-05
6.0,3449.0,2749.0,0.00174,0.00174,8.14613,0.252985,1.0,3449.0,34.0,324.0,Physician Decision,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00358588,0.003483979322513599,0.000101900677486401
16.0,3449.0,2749.0,0.004639,0.004639,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00956027,0.009572624750515868,1.2354750515869081e-05
19.0,3449.0,2749.0,0.005509,0.005509,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01135321,0.011375193760109113,2.198376010911253e-05
36.0,3449.0,2749.0,0.010438,0.010438,8.14613,0.252985,1.0,3449.0,34.0,324.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02151113,0.021681599599166664,0.00017046959916666368
77.0,3449.0,2749.0,0.022325,0.022325,8.14613,0.252985,1.0,3449.0,34.0,324.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04600843,0.04551285562090275,0.0004955743790972522
28.0,3449.0,2749.0,0.008118,0.008118,8.14613,0.252985,1.0,3449.0,34.0,324.0,Clinical endpoint reached,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01672996,0.016671726614186505,5.823338581349355e-05
25.0,3449.0,2749.0,0.007248,0.007248,8.14613,0.252985,1.0,3449.0,34.0,324.0,Clinical endpoint reached,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01493703,0.014896650827470236,4.037917252976489e-05
102.0,3449.0,2749.0,0.029574,0.029574,8.14613,0.252985,1.0,3449.0,34.0,324.0,Study terminated by sponsor,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.06094752,0.06153947656485119,0.0005919565648511912
94.0,3449.0,2749.0,0.027254,0.027254,8.14613,0.252985,1.0,3449.0,34.0,324.0,Study terminated by sponsor,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.05616635,0.05620146117016857,3.511117016857107e-05
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol driven decision point,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00119529,0.001191878644345241,3.4113556547589376e-06
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol driven decision point,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00119529,0.001191860764464289,3.4292355357108326e-06
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Switch to commercial drug,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Switch to commercial drug,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00119529,0.001191860764464289,3.4292355357108326e-06
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Technical problems,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00059765,0.0006008814012500028,3.2314012500027573e-06
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Technical problems,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00059765,0.0006015236662500028,3.873666250002808e-06
5.0,3449.0,2749.0,0.00145,0.00145,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant convenience,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00298823,0.0029352907620238105,5.2939237976189647e-05
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant convenience,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00119529,0.001191860764464289,3.4292355357108326e-06
7.0,3449.0,2749.0,0.00203,0.00203,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant did not receive treatment,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00418352,0.0037017835096474394,0.0004817364903525602
13.0,3449.0,2749.0,0.003769,0.003769,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant did not receive treatment,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00776734,0.0076968027691071425,7.053723089285764e-05
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Site closed by investigator,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Site closed by investigator,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00119529,0.001191860764464289,3.4292355357108326e-06
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Adverse Event,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00119529,0.0011910396560119074,4.250343988092481e-06
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Adverse Event,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00119529,0.0011909832177976222,4.306782202377667e-06
15.0,3449.0,2749.0,0.004349,0.004349,8.14613,0.252985,1.0,3449.0,34.0,324.0,Death,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00896263,0.009027266347490076,6.46363474900765e-05
20.0,3449.0,2749.0,0.005799,0.005799,8.14613,0.252985,1.0,3449.0,34.0,324.0,Death,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.01195086,0.012106903543273815,0.00015604354327381463
12.0,3449.0,2749.0,0.003479,0.003479,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lost to Follow-up,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00716969,0.007189787919950402,2.0097919950401617e-05
8.0,3449.0,2749.0,0.00232,0.00232,8.14613,0.252985,1.0,3449.0,34.0,324.0,Lost to Follow-up,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00478117,0.004768599531875007,1.2570468124993572e-05
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol Violation,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00059765,0.0006008627437500027,3.212743750002716e-06
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Protocol Violation,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,3449.0,2749.0,0.003189,0.003189,8.14613,0.252985,1.0,3449.0,34.0,324.0,Withdrawal by Subject,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00657204,0.006514814247509921,5.7225752490079086e-05
8.0,3449.0,2749.0,0.00232,0.00232,8.14613,0.252985,1.0,3449.0,34.0,324.0,Withdrawal by Subject,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00478117,0.004767781803541673,1.3388196458327499e-05
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Physician Decision,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00059765,0.0006008627437500027,3.212743750002716e-06
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Physician Decision,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3449.0,2749.0,0.00029,0.00029,8.14613,0.252985,1.0,3449.0,34.0,324.0,Clinical endpoint reached,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00059765,0.0006008627437500027,3.212743750002716e-06
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Clinical endpoint reached,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,3449.0,2749.0,0.00058,0.00058,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant convenience,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00119529,0.0011910396560119074,4.250343988092481e-06
0.0,3449.0,2749.0,0.0,0.0,8.14613,0.252985,1.0,3449.0,34.0,324.0,Participant convenience,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
194.0,4038.0,2709.0,0.048044,0.048044,8.303752,0.237054,1.0,4038.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.09457162,0.09236016539582352,0.0022114546041764743
171.0,4038.0,2709.0,0.042348,0.042348,8.303752,0.237054,1.0,4038.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0833594,0.08091416697863008,0.0024452330213699247
96.0,4038.0,2709.0,0.023774,0.023774,8.303752,0.237054,1.0,4038.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04679764,0.047449544595625046,0.0006519045956250441
108.0,4038.0,2709.0,0.026746,0.026746,8.303752,0.237054,1.0,4038.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05264784,0.052559707401617084,8.813259838291732e-05
375.0,4038.0,2709.0,0.092868,0.092868,8.303752,0.237054,1.0,4038.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.18280488,0.1734858157511311,0.009319064248868913
385.0,4038.0,2709.0,0.095344,0.095344,8.303752,0.237054,1.0,4038.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.18767873,0.17610559011053575,0.011573139889464235
4.0,212.0,201.0,0.018868,0.018868,5.361292,0.294492,1.0,212.0,3.0,45.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.02978991,0.029066496649682513,0.000723413350317486
1.0,212.0,201.0,0.004717,0.004717,5.361292,0.294492,1.0,212.0,3.0,45.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.00744748,0.007427056008511932,2.042399148806818e-05
3.0,212.0,201.0,0.014151,0.014151,5.361292,0.294492,1.0,212.0,3.0,45.0,Death,Overall Study,FG002,cardiovascular disease,OTHER,0.02234243,0.022617351966250032,0.00027492196625003226
1.0,212.0,201.0,0.004717,0.004717,5.361292,0.294492,1.0,212.0,3.0,45.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.00744748,0.007437553511458359,9.926488541641548e-06
0.0,212.0,201.0,0.0,0.0,5.361292,0.294492,1.0,212.0,3.0,45.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,212.0,201.0,0.004717,0.004717,5.361292,0.294492,1.0,212.0,3.0,45.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,OTHER,0.00744748,0.007436060071875028,1.1419928124972202e-05
0.0,212.0,201.0,0.0,0.0,5.361292,0.294492,1.0,212.0,3.0,45.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,212.0,201.0,0.004717,0.004717,5.361292,0.294492,1.0,212.0,3.0,45.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00744748,0.0074320209710119324,1.5459028988067808e-05
0.0,212.0,201.0,0.0,0.0,5.361292,0.294492,1.0,212.0,3.0,45.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.0,0.0,0.0
2.0,327.0,311.0,0.006116,0.006116,5.793014,0.300923,1.0,327.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01066172,0.010800834546418647,0.00013911454641864739
0.0,327.0,311.0,0.0,0.0,5.793014,0.300923,1.0,327.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,327.0,311.0,0.0,0.0,5.793014,0.300923,1.0,327.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,327.0,311.0,0.003058,0.003058,5.793014,0.300923,1.0,327.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00533086,0.0053621396590340775,3.1279659034077686e-05
1.0,327.0,311.0,0.003058,0.003058,5.793014,0.300923,1.0,327.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00533086,0.0053567995446293145,2.5939544629314734e-05
0.0,327.0,311.0,0.0,0.0,5.793014,0.300923,1.0,327.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,327.0,311.0,0.018349,0.018349,5.793014,0.300923,1.0,327.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0319869,0.03200019161398811,1.3291613988108963e-05
4.0,327.0,311.0,0.012232,0.012232,5.793014,0.300923,1.0,327.0,0.0,0.0,Blood Pressure/Potassium Criteria Met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02132344,0.021462166058492077,0.00013872605849207797
0.0,327.0,311.0,0.0,0.0,5.793014,0.300923,1.0,327.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,327.0,311.0,0.003058,0.003058,5.793014,0.300923,1.0,327.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00533086,0.0053621396590340775,3.1279659034077686e-05
1.0,327.0,311.0,0.003058,0.003058,5.793014,0.300923,1.0,327.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00533086,0.005358053180760267,2.7193180760267006e-05
0.0,327.0,311.0,0.0,0.0,5.793014,0.300923,1.0,327.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
26.0,362.0,203.0,0.071823,0.071823,5.894403,0.254793,1.0,669.0,3.0,41.0,Adverse Event,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.10786754,0.10738005715103176,0.00048748284896824035
2.0,362.0,203.0,0.005525,0.005525,5.894403,0.254793,1.0,669.0,3.0,41.0,Protocol Violation,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.00829773,0.008349080292678574,5.135029267857444e-05
30.0,362.0,203.0,0.082873,0.082873,5.894403,0.254793,1.0,669.0,3.0,41.0,Lost to Follow-up,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.124463,0.12490427588344788,0.00044127588344787527
25.0,362.0,203.0,0.069061,0.069061,5.894403,0.254793,1.0,669.0,3.0,41.0,Withdrawal by Subject,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.10371942,0.10409969013876985,0.00038027013876984483
3.0,362.0,203.0,0.008287,0.008287,5.894403,0.254793,1.0,669.0,3.0,41.0,Lack of Efficacy,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.01244585,0.01252547026568452,7.962026568452026e-05
16.0,362.0,203.0,0.044199,0.044199,5.894403,0.254793,1.0,669.0,3.0,41.0,Other,Cohort 1,FG000,cardiovascular disease,INDUSTRY,0.06638037,0.065664742557867,0.0007156274421329933
24.0,362.0,203.0,0.066298,0.066298,5.894403,0.254793,1.0,669.0,3.0,41.0,Adverse Event,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.0995698,0.09960723126568456,3.743126568456212e-05
5.0,362.0,203.0,0.013812,0.013812,5.894403,0.254793,1.0,669.0,3.0,41.0,Protocol Violation,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.02074358,0.020835787801934545,9.220780193454348e-05
38.0,362.0,203.0,0.104972,0.104972,5.894403,0.254793,1.0,669.0,3.0,41.0,Lost to Follow-up,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.15765244,0.15599051857875984,0.0016619214212401645
28.0,362.0,203.0,0.077348,0.077348,5.894403,0.254793,1.0,669.0,3.0,41.0,Withdrawal by Subject,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.11616527,0.11677947576777332,0.0006142057677733237
4.0,362.0,203.0,0.01105,0.01105,5.894403,0.254793,1.0,669.0,3.0,41.0,Lack of Efficacy,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.01659547,0.01649600096904762,9.946903095238088e-05
5.0,362.0,203.0,0.013812,0.013812,5.894403,0.254793,1.0,669.0,3.0,41.0,Other,Cohort 2,FG000,cardiovascular disease,INDUSTRY,0.02074358,0.02080591698392858,6.233698392858061e-05
2.0,615.0,570.0,0.003252,0.003252,6.423247,0.521703,1.0,615.0,3.0,62.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01089755,0.010664337069454362,0.0002332129305456388
6.0,615.0,570.0,0.009756,0.009756,6.423247,0.521703,1.0,615.0,3.0,62.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03269264,0.03219767258660716,0.0004949674133928397
1.0,615.0,570.0,0.001626,0.001626,6.423247,0.521703,1.0,615.0,3.0,62.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00544877,0.0055117624838889,6.299248388889987e-05
0.0,615.0,570.0,0.0,0.0,6.423247,0.521703,1.0,615.0,3.0,62.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,615.0,570.0,0.003252,0.003252,6.423247,0.521703,1.0,615.0,3.0,62.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01089755,0.01065682995737103,0.00024072004262897136
1.0,615.0,570.0,0.001626,0.001626,6.423247,0.521703,1.0,615.0,3.0,62.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00544877,0.005501807780034734,5.3037780034733556e-05
1.0,615.0,570.0,0.001626,0.001626,6.423247,0.521703,1.0,615.0,3.0,62.0,Participant moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00544877,0.0055117624838889,6.299248388889987e-05
3.0,615.0,570.0,0.004878,0.004878,6.423247,0.521703,1.0,615.0,3.0,62.0,Participant moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01634632,0.016036055044523816,0.00031026495547618535
11.0,615.0,570.0,0.017886,0.017886,6.423247,0.521703,1.0,615.0,3.0,62.0,Other than specified above,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0599365,0.059954462458373076,1.7962458373078916e-05
15.0,615.0,570.0,0.02439,0.02439,6.423247,0.521703,1.0,615.0,3.0,62.0,Other than specified above,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0817316,0.07872463255964289,0.003006967440357111
1.0,615.0,570.0,0.001626,0.001626,6.423247,0.521703,1.0,615.0,3.0,62.0,Randomized but not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00544877,0.005513610125555567,6.484012555556685e-05
2.0,615.0,570.0,0.003252,0.003252,6.423247,0.521703,1.0,615.0,3.0,62.0,Randomized but not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01089755,0.01064596564231151,0.0002515843576884908
3.0,366.0,323.0,0.008197,0.008197,5.905362,0.055902,1.0,366.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.002706,0.0035513047482440487,0.0008453047482440486
0.0,366.0,323.0,0.0,0.0,5.905362,0.055902,1.0,366.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,366.0,323.0,0.019126,0.019126,5.905362,0.055902,1.0,366.0,0.0,0.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00631389,0.011616013381914685,0.005302123381914685
9.0,366.0,323.0,0.02459,0.02459,5.905362,0.055902,1.0,366.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00811767,0.01577513827965277,0.00765746827965277
6.0,366.0,323.0,0.016393,0.016393,5.905362,0.055902,1.0,366.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00541167,0.015159402276212128,0.009747732276212128
1.0,366.0,323.0,0.002732,0.002732,5.905362,0.055902,1.0,366.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00090189,0.0009547976064384935,5.290760643849343e-05
2.0,366.0,323.0,0.005464,0.005464,5.905362,0.055902,1.0,366.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00180378,0.0018200047137283592,1.6224713728359196e-05
3.0,366.0,323.0,0.008197,0.008197,5.905362,0.055902,1.0,366.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.002706,0.003511526128869047,0.0008055261288690469
1.0,366.0,323.0,0.002732,0.002732,5.905362,0.055902,1.0,366.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00090189,0.0009547976064384935,5.290760643849343e-05
2.0,366.0,323.0,0.005464,0.005464,5.905362,0.055902,1.0,366.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00180378,0.0018255094212283587,2.172942122835868e-05
2.0,366.0,323.0,0.005464,0.005464,5.905362,0.055902,1.0,366.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00180378,0.0018267939706033585,2.3013970603358433e-05
1.0,366.0,323.0,0.002732,0.002732,5.905362,0.055902,1.0,366.0,0.0,0.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00090189,0.0009492575295932552,4.736752959325519e-05
2.0,366.0,323.0,0.005464,0.005464,5.905362,0.055902,1.0,366.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00180378,0.0018241117155140736,2.0331715514073506e-05
1.0,366.0,323.0,0.002732,0.002732,5.905362,0.055902,1.0,366.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00090189,0.0009497208926884931,4.783089268849312e-05
2.0,366.0,323.0,0.005464,0.005464,5.905362,0.055902,1.0,366.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00180378,0.0018193985251569306,1.561852515693054e-05
0.0,366.0,323.0,0.0,0.0,5.905362,0.055902,1.0,366.0,0.0,0.0,Patient uncooperative,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,366.0,323.0,0.0,0.0,5.905362,0.055902,1.0,366.0,0.0,0.0,Patient uncooperative,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,366.0,323.0,0.002732,0.002732,5.905362,0.055902,1.0,366.0,0.0,0.0,Patient uncooperative,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00090189,0.0009547976064384935,5.290760643849343e-05
5.0,314.0,303.0,0.015924,0.015924,5.752573,0.633209,1.0,321.0,1.0,4.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.05800445,0.05797269439099202,3.175560900797736e-05
3.0,314.0,303.0,0.009554,0.009554,5.752573,0.633209,1.0,321.0,1.0,4.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.03480121,0.03514871934165175,0.00034750934165175135
2.0,314.0,303.0,0.006369,0.006369,5.752573,0.633209,1.0,321.0,1.0,4.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.02319959,0.02388473242375996,0.0006851424237599608
1.0,314.0,303.0,0.003185,0.003185,5.752573,0.633209,1.0,321.0,1.0,4.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01160162,0.011504163615178564,9.74563848214361e-05
11.0,360.0,220.0,0.030556,0.030556,5.888878,0.937251,1.0,370.0,1.0,32.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.1686494,0.1686249579667261,2.4442033273897046e-05
15.0,360.0,220.0,0.041667,0.041667,5.888878,0.937251,1.0,370.0,1.0,32.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.22997496,0.22950738768343246,0.0004675723165675494
22.0,360.0,220.0,0.061111,0.061111,5.888878,0.937251,1.0,370.0,1.0,32.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.33729329,0.3351559585410422,0.0021373314589578363
22.0,360.0,220.0,0.061111,0.061111,5.888878,0.937251,1.0,370.0,1.0,32.0,Adverse Event,Overall Study,FG001,cardiovascular disease,OTHER,0.33729329,0.33519765947116104,0.0020956305288389876
0.0,360.0,220.0,0.0,0.0,5.888878,0.937251,1.0,370.0,1.0,32.0,Alternative Therapy,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
3.0,360.0,220.0,0.008333,0.008333,5.888878,0.937251,1.0,370.0,1.0,32.0,Alternative Therapy,Overall Study,FG001,cardiovascular disease,OTHER,0.04599278,0.04619131754344093,0.00019853754344092978
9.0,360.0,220.0,0.025,0.025,5.888878,0.937251,1.0,370.0,1.0,32.0,Other Complicating Disease,Overall Study,FG000,cardiovascular disease,OTHER,0.13798387,0.13841468710287694,0.0004308171028769292
5.0,360.0,220.0,0.013889,0.013889,5.888878,0.937251,1.0,370.0,1.0,32.0,Other Complicating Disease,Overall Study,FG001,cardiovascular disease,OTHER,0.07665832,0.07516558777857142,0.0014927322214285804
21.0,360.0,220.0,0.058333,0.058333,5.888878,0.937251,1.0,370.0,1.0,32.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.32196052,0.28583454115638895,0.03612597884361102
16.0,360.0,220.0,0.044444,0.044444,5.888878,0.937251,1.0,370.0,1.0,32.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.2453022,0.24268627774234133,0.002615922257658665
2.0,360.0,220.0,0.005556,0.005556,5.888878,0.937251,1.0,370.0,1.0,32.0,Physician Decision,Overall Study,FG000,cardiovascular disease,OTHER,0.03066554,0.030816873124037643,0.0001513331240376413
2.0,360.0,220.0,0.005556,0.005556,5.888878,0.937251,1.0,370.0,1.0,32.0,Physician Decision,Overall Study,FG001,cardiovascular disease,OTHER,0.03066554,0.030820657077738046,0.00015511707773804492
2.0,360.0,220.0,0.005556,0.005556,5.888878,0.937251,1.0,370.0,1.0,32.0,Disease Progression,Overall Study,FG000,cardiovascular disease,OTHER,0.03066554,0.030820057193799558,0.0001545171937995561
8.0,360.0,220.0,0.022222,0.022222,5.888878,0.937251,1.0,370.0,1.0,32.0,Disease Progression,Overall Study,FG001,cardiovascular disease,OTHER,0.1226511,0.12309930547127969,0.000448205471279689
1.0,360.0,220.0,0.002778,0.002778,5.888878,0.937251,1.0,370.0,1.0,32.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.01533277,0.01525058396071425,8.218603928575145e-05
1.0,360.0,220.0,0.002778,0.002778,5.888878,0.937251,1.0,370.0,1.0,32.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.01533277,0.015267490239166627,6.527976083337342e-05
3.0,336.0,313.0,0.008929,0.008929,5.820083,0.29709,1.0,336.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01543904,0.015444903728452428,5.863728452428635e-06
3.0,336.0,313.0,0.008929,0.008929,5.820083,0.29709,1.0,336.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01543904,0.015453446901488145,1.4406901488146079e-05
0.0,336.0,313.0,0.0,0.0,5.820083,0.29709,1.0,336.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,336.0,313.0,0.005952,0.005952,5.820083,0.29709,1.0,336.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01029154,0.010306246653204343,1.4706653204342793e-05
2.0,336.0,313.0,0.005952,0.005952,5.820083,0.29709,1.0,336.0,0.0,0.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01029154,0.01029499609968252,3.4560996825198226e-06
0.0,336.0,313.0,0.0,0.0,5.820083,0.29709,1.0,336.0,0.0,0.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,336.0,313.0,0.002976,0.002976,5.820083,0.29709,1.0,336.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00514577,0.005207034833065477,6.126483306547695e-05
1.0,336.0,313.0,0.002976,0.002976,5.820083,0.29709,1.0,336.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00514577,0.005204381818125003,5.861181812500272e-05
4.0,336.0,313.0,0.011905,0.011905,5.820083,0.29709,1.0,336.0,0.0,0.0,Serum Potassium Withdrawal Criteria Met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02058481,0.02065694595019843,7.21359501984313e-05
2.0,336.0,313.0,0.005952,0.005952,5.820083,0.29709,1.0,336.0,0.0,0.0,Serum Potassium Withdrawal Criteria Met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01029154,0.010306246653204343,1.4706653204342793e-05
2.0,336.0,313.0,0.005952,0.005952,5.820083,0.29709,1.0,336.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01029154,0.010294897597599188,3.357597599187856e-06
3.0,336.0,313.0,0.008929,0.008929,5.820083,0.29709,1.0,336.0,0.0,0.0,Blood Pressure Withdrawal Criteria Met,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01543904,0.015462346343035758,2.33063430357585e-05
12.0,263.0,162.0,0.045627,0.045627,5.575949,0.262342,1.0,263.0,2.0,21.0,Adverse Event,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.06674343,0.06693832792112103,0.0001948979211210261
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Adverse Event,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Adverse Event,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
50.0,263.0,162.0,0.190114,0.190114,5.575949,0.262342,1.0,263.0,2.0,21.0,Treatment failure,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.2780998,0.2899239076057936,0.01182410760579361
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Treatment failure,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Treatment failure,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,263.0,162.0,0.019011,0.019011,5.575949,0.262342,1.0,263.0,2.0,21.0,Protocol Violation,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.0278094,0.027883625652093312,7.422565209331058e-05
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Protocol Violation,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Protocol Violation,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,263.0,162.0,0.019011,0.019011,5.575949,0.262342,1.0,263.0,2.0,21.0,Withdrawal by Subject,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.0278094,0.027823470634265924,1.4070634265922477e-05
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Withdrawal by Subject,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Withdrawal by Subject,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,263.0,162.0,0.060837,0.060837,5.575949,0.262342,1.0,263.0,2.0,21.0,Enrollment capped,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.0889927,0.08955212792006315,0.0005594279200631519
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Enrollment capped,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Enrollment capped,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,263.0,162.0,0.007605,0.007605,5.575949,0.262342,1.0,263.0,2.0,21.0,Did not meet responder criteria,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.01112464,0.011200343408660713,7.570340866071279e-05
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Did not meet responder criteria,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Did not meet responder criteria,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,263.0,162.0,0.019011,0.019011,5.575949,0.262342,1.0,263.0,2.0,21.0,Lost to Follow-up,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.0278094,0.027813271084950453,3.871084950451964e-06
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Lost to Follow-up,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Lost to Follow-up,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,263.0,162.0,0.022814,0.022814,5.575949,0.262342,1.0,263.0,2.0,21.0,Randomized in error,Open Label Titration,FG000,cardiovascular disease,INDUSTRY,0.03337244,0.03309682969693182,0.0002756103030681842
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Randomized in error,Open Label Titration,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,162.0,0.0,0.0,5.575949,0.262342,1.0,263.0,2.0,21.0,Randomized in error,Open Label Titration,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
15.0,632.0,485.0,0.023734,0.023734,6.45047,0.788318,1.0,632.0,18.0,104.0,Withdrawal of Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12068789,0.11925334726100217,0.0014345427389978321
6.0,632.0,485.0,0.009494,0.009494,6.45047,0.788318,1.0,632.0,18.0,104.0,Withdrawal of Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04827719,0.046481549576915644,0.0017956404230843534
75.0,632.0,485.0,0.118671,0.118671,6.45047,0.788318,1.0,632.0,18.0,104.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.60344451,0.5992395353756732,0.004204974624326785
51.0,632.0,485.0,0.080696,0.080696,6.45047,0.788318,1.0,632.0,18.0,104.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.41034084,0.4094701939450397,0.000870646054960289
1.0,310.0,283.0,0.003226,0.003226,5.739793,0.598143,1.0,310.0,2.0,4.0,Adverse Event,Overall Study,FG000,cardiovascular disease,OTHER,0.01107555,0.011132759147857158,5.7209147857157847e-05
2.0,310.0,283.0,0.006452,0.006452,5.739793,0.598143,1.0,310.0,2.0,4.0,Adverse Event,Overall Study,FG001,cardiovascular disease,OTHER,0.02215111,0.022277382927738117,0.0001262729277381157
11.0,310.0,283.0,0.035484,0.035484,5.739793,0.598143,1.0,310.0,2.0,4.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.12182421,0.12017962903651784,0.0016445809634821618
7.0,310.0,283.0,0.022581,0.022581,5.739793,0.598143,1.0,310.0,2.0,4.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.07752543,0.07866445848970235,0.0011390284897023484
1.0,310.0,283.0,0.003226,0.003226,5.739793,0.598143,1.0,310.0,2.0,4.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,OTHER,0.01107555,0.011125382164523823,4.983216452382304e-05
2.0,310.0,283.0,0.006452,0.006452,5.739793,0.598143,1.0,310.0,2.0,4.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,OTHER,0.02215111,0.022263054868571455,0.00011194486857145358
2.0,310.0,283.0,0.006452,0.006452,5.739793,0.598143,1.0,310.0,2.0,4.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.02215111,0.022352138807145594,0.00020102880714559235
1.0,310.0,283.0,0.003226,0.003226,5.739793,0.598143,1.0,310.0,2.0,4.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.01107555,0.011147188023154776,7.163802315477558e-05
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01239101,0.012381814954001615,9.195045998383958e-06
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01239101,0.012389719275919905,1.290724080093772e-06
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01239101,0.012318966603584945,7.204339641505436e-05
11.0,261.0,210.0,0.042146,0.042146,5.568345,0.193602,1.0,261.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04543514,0.046320756980297605,0.0008856169802976058
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01239101,0.012394166805668277,3.156805668277571e-06
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01239101,0.012394093277662326,3.0832776623263697e-06
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01239101,0.012393201547334944,2.1915473349450737e-06
1.0,261.0,210.0,0.003831,0.003831,5.568345,0.193602,1.0,261.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00412998,0.0041712160408928535,4.123604089285339e-05
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01239101,0.012356750661918279,3.425933808172063e-05
8.0,261.0,210.0,0.030651,0.030651,5.568345,0.193602,1.0,261.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03304305,0.03421509896455353,0.0011720489645535292
7.0,261.0,210.0,0.02682,0.02682,5.568345,0.193602,1.0,261.0,0.0,0.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02891308,0.02952142401148812,0.0006083440114881197
3.0,261.0,210.0,0.011494,0.011494,5.568345,0.193602,1.0,261.0,0.0,0.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01239101,0.01239861745758657,7.607457586570818e-06
24.0,1195.0,727.0,0.020084,0.020084,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #1,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.09693776,0.09823540817469244,0.0012976481746924395
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #1,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1195.0,727.0,0.004184,0.004184,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #2",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.02019456,0.020584065104186543,0.00038950510418654313
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #2",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #2 #4; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #2 #4; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #3",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #3",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #4",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #4",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Crit #1, #4; Withdraw By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Crit #1, #4; Withdraw By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #1, #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1195.0,727.0,0.003347,0.003347,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #1; AE,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.01615468,0.016785890328873565,0.0006312103288735639
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #1; AE,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #1; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #1; AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #1; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #1; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1195.0,727.0,0.004184,0.004184,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #2,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.02019456,0.020584065104186543,0.00038950510418654313
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #2,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #3",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #3",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #3, #4",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #3, #4",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1195.0,727.0,0.003347,0.003347,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #4",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.01615468,0.016785890328873565,0.0006312103288735639
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #2, #4",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,1195.0,727.0,0.009205,0.009205,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.044429,0.04350386217105158,0.0009251378289484233
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #3, #4",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #3, #4",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #3, #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criteria #3, #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #3; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #3; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1195.0,727.0,0.00251,0.00251,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #4,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.01211481,0.012091913902361098,2.2896097638901852e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #4,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3; Physician Decision,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3; Physician Decision,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1195.0,727.0,0.003347,0.003347,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #4; AE,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.01615468,0.016785890328873565,0.0006312103288735639
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #4; AE,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3; Exceeded 12 Weeks Of Run In,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Randomization Criterion #3; Exceeded 12 Weeks Of Run In,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"Randomization Criterion #4; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,1195.0,727.0,0.014226,0.014226,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE (Adverse Event),Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.06866344,0.06831413738309522,0.0003493026169047869
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE (Adverse Event),Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1195.0,727.0,0.00251,0.00251,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE; Withdrawal By Subject,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.01211481,0.012091913902361098,2.2896097638901852e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE; Withdrawal By Subject,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; Withdrawal By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; Withdrawal By Subject; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; 1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"AE; 2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
43.0,1195.0,727.0,0.035983,0.035983,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal by Subject,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.17367613,0.17104612632011096,0.0026300036798890536
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal by Subject,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE; Physician Decision,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,AE; Physician Decision,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,1195.0,727.0,0.008368,0.008368,7.086738,0.681077,1.0,1195.0,21.0,415.0,"1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.04038912,0.041698103543779744,0.0013089835437797431
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"1 Wk After 3 Patiromer Packets/Day, sK+ >5.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal By Subject; Withdrawal Of Consent,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal By Subject; Withdrawal Of Consent,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,1195.0,727.0,0.005021,0.005021,7.086738,0.681077,1.0,1195.0,21.0,415.0,"2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.02423444,0.02426545360178572,3.101360178572182e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,"2 Wks After Taking Min 0 Packet/Day, sK+ Is < 4.0 Meq/L",Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Death,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.0040395070541982435,3.729458017565773e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Death,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,Non-Compliance With Study Drug,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Non-Compliance With Study Drug,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Physician Decision,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00403548061211491,4.399387885089916e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Physician Decision,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,1195.0,727.0,0.010879,0.010879,7.086738,0.681077,1.0,1195.0,21.0,415.0,Protocol Violation,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.05250876,0.05287780143064483,0.00036904143064482586
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Protocol Violation,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
34.0,1195.0,727.0,0.028452,0.028452,7.086738,0.681077,1.0,1195.0,21.0,415.0,Sponsor Request,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.13732688,0.14040770612205355,0.0030808261220535427
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Sponsor Request,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
71.0,1195.0,727.0,0.059414,0.059414,7.086738,0.681077,1.0,1195.0,21.0,415.0,Study Terminated By Sponsor,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.28676857,0.28356061144003974,0.0032079585599602556
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Study Terminated By Sponsor,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal Of Consent,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00403988,0.00404010301211491,2.2301211491035366e-07
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Withdrawal Of Consent,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,Exceeded 12 Weeks Of Run In,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008069914906902747,9.84509309725351e-06
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Exceeded 12 Weeks Of Run In,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
27.0,1195.0,727.0,0.022594,0.022594,7.086738,0.681077,1.0,1195.0,21.0,415.0,Not treated with Patiromer during Run-in,Run-in Phase,FG000,cardiovascular disease,INDUSTRY,0.10905257,0.1086903034539584,0.0003622665460416008
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Not treated with Patiromer during Run-in,Run-in Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Protocol Violation,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Protocol Violation,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.00403988,0.004040196974187698,3.1697418769773e-07
20.0,1195.0,727.0,0.016736,0.016736,7.086738,0.681077,1.0,1195.0,21.0,415.0,Physician Decision,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.08077825,0.08227383528132108,0.0014955852813210851
13.0,1195.0,727.0,0.010879,0.010879,7.086738,0.681077,1.0,1195.0,21.0,415.0,Physician Decision,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.05250876,0.05294818989064478,0.0004394298906447783
27.0,1195.0,727.0,0.022594,0.022594,7.086738,0.681077,1.0,1195.0,21.0,415.0,Adverse Event,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.10905257,0.1087679795539584,0.00028459044604160766
21.0,1195.0,727.0,0.017573,0.017573,7.086738,0.681077,1.0,1195.0,21.0,415.0,Adverse Event,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.08481813,0.08580505509848385,0.0009869250984838457
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Lost to Follow-up,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.00403988,0.004058454304593893,1.857430459389301e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Lost to Follow-up,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
21.0,1195.0,727.0,0.017573,0.017573,7.086738,0.681077,1.0,1195.0,21.0,415.0,Consent withdrawn by subject,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.08481813,0.0853595644343767,0.0005414344343766947
25.0,1195.0,727.0,0.020921,0.020921,7.086738,0.681077,1.0,1195.0,21.0,415.0,Consent withdrawn by subject,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.10097764,0.10071438305548963,0.0002632569445103622
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,End of study visit not completed/delayed,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.00403988,0.004057328393662522,1.744839366252162e-05
3.0,1195.0,727.0,0.00251,0.00251,7.086738,0.681077,1.0,1195.0,21.0,415.0,End of study visit not completed/delayed,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.01211481,0.012126570812182522,1.1760812182522173e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Early study termination,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Early study termination,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.00403988,0.004040388949187698,5.089491876978172e-07
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,Treatment discontinuation,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.00807976,0.008060247818986063,1.951218101393752e-05
2.0,1195.0,727.0,0.001674,0.001674,7.086738,0.681077,1.0,1195.0,21.0,415.0,Treatment discontinuation,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.00807976,0.008050709187874948,2.9050812125052186e-05
6.0,1195.0,727.0,0.005021,0.005021,7.086738,0.681077,1.0,1195.0,21.0,415.0,Delayed visit and insufficient study,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.02423444,0.024292789181011916,5.834918101191647e-05
6.0,1195.0,727.0,0.005021,0.005021,7.086738,0.681077,1.0,1195.0,21.0,415.0,Delayed visit and insufficient study,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.02423444,0.024232008323809517,2.4316761904827344e-06
1.0,1195.0,727.0,0.000837,0.000837,7.086738,0.681077,1.0,1195.0,21.0,415.0,Sponsor's decision,Treatment Phase (Overall Study),FG000,cardiovascular disease,INDUSTRY,0.00403988,0.004057328393662522,1.744839366252162e-05
0.0,1195.0,727.0,0.0,0.0,7.086738,0.681077,1.0,1195.0,21.0,415.0,Sponsor's decision,Treatment Phase (Overall Study),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Serious Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019380862611958997,1.2962611958995673e-06
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Serious Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00193679,0.0019378625173340673,1.0725173340672602e-06
11.0,808.0,709.0,0.013614,0.013614,6.695799,0.233646,1.0,808.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02129839,0.021249196839117083,4.919316088291756e-05
16.0,808.0,709.0,0.019802,0.019802,6.695799,0.233646,1.0,808.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03097919,0.031002679037827365,2.3489037827364306e-05
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00193679,0.0019381199590007342,1.3299590007340763e-06
9.0,808.0,709.0,0.011139,0.011139,6.695799,0.233646,1.0,808.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01742638,0.017573945458125007,0.0001475654581250055
15.0,808.0,709.0,0.018564,0.018564,6.695799,0.233646,1.0,808.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02904241,0.028068191464831367,0.000974218535168634
3.0,808.0,709.0,0.003713,0.003713,6.695799,0.233646,1.0,808.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00580879,0.005801243339583334,7.546660416666434e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,808.0,709.0,0.007426,0.007426,6.695799,0.233646,1.0,808.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01161759,0.011549196571269842,6.839342873015894e-05
7.0,808.0,709.0,0.008663,0.008663,6.695799,0.233646,1.0,808.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01355281,0.013593736995446453,4.0926995446452855e-05
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Dyspnea,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Dyspnea,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,"Per Data Query, Less Than 4 Wks Coversyl",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,"Per Data Query, Less Than 4 Wks Coversyl",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Hip Replacement,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Hip Replacement,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Suicide,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Suicide,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Missing Cooperation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00193679,0.0019382086361958994,1.4186361958993393e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Missing Cooperation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Elevated Creatinine and Potassium levels,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Elevated Creatinine and Potassium levels,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00193679,0.0019379848923340673,1.194892334067249e-06
0.0,808.0,709.0,0.0,0.0,6.695799,0.233646,1.0,808.0,0.0,0.0,Patient's Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,808.0,709.0,0.001238,0.001238,6.695799,0.233646,1.0,808.0,0.0,0.0,Patient's Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00193679,0.0019379848923340673,1.194892334067249e-06
14.0,808.0,709.0,0.017327,0.017327,6.695799,0.233646,1.0,808.0,0.0,0.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02710719,0.026900379714474197,0.00020681028552580263
7.0,808.0,709.0,0.008663,0.008663,6.695799,0.233646,1.0,808.0,0.0,0.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01355281,0.01360247736788693,4.966736788692902e-05
2.0,906.0,892.0,0.002208,0.002208,6.810142,0.249466,1.0,906.0,31.0,31.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00375118,0.003753790035884738,2.6100358847380017e-06
1.0,906.0,892.0,0.001104,0.001104,6.810142,0.249466,1.0,906.0,31.0,31.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00187559,0.0018731346528869054,2.4553471130945095e-06
4.0,906.0,892.0,0.004415,0.004415,6.810142,0.249466,1.0,906.0,31.0,31.0,Parent(s)/guardian(s)'s request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00750065,0.0076745312774801665,0.0001738812774801663
7.0,906.0,892.0,0.007726,0.007726,6.810142,0.249466,1.0,906.0,31.0,31.0,Parent(s)/guardian(s)'s request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01312572,0.013485361405039682,0.00035964140503968144
1.0,3057.0,2785.0,0.000327,0.000327,8.025516,0.227085,1.0,3221.0,27.0,122.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00059595,0.0006037949484821459,7.844948482145812e-06
0.0,3057.0,2785.0,0.0,0.0,8.025516,0.227085,1.0,3221.0,27.0,122.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
40.0,3057.0,2785.0,0.013085,0.013085,8.025516,0.227085,1.0,3221.0,27.0,122.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02384703,0.0252315236853373,0.0013844936853372979
44.0,3057.0,2785.0,0.014393,0.014393,8.025516,0.227085,1.0,3221.0,27.0,122.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02623082,0.0265090179899008,0.0002781979899008011
68.0,3057.0,2785.0,0.022244,0.022244,8.025516,0.227085,1.0,3221.0,27.0,122.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04053904,0.04003703588247833,0.0005020041175216663
57.0,3057.0,2785.0,0.018646,0.018646,8.025516,0.227085,1.0,3221.0,27.0,122.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03398179,0.03330671436124998,0.0006750756387500154
1.0,3057.0,2785.0,0.000327,0.000327,8.025516,0.227085,1.0,3221.0,27.0,122.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00059595,0.0006047533974107173,8.803397410717226e-06
0.0,3057.0,2785.0,0.0,0.0,8.025516,0.227085,1.0,3221.0,27.0,122.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3057.0,2785.0,0.000327,0.000327,8.025516,0.227085,1.0,3221.0,27.0,122.0,Poor compliance/noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00059595,0.0006037290093154793,7.779009315479236e-06
2.0,3057.0,2785.0,0.000654,0.000654,8.025516,0.227085,1.0,3221.0,27.0,122.0,Poor compliance/noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0011919,0.0011900923657242064,1.8076342757937167e-06
18.0,3057.0,2785.0,0.005888,0.005888,8.025516,0.227085,1.0,3221.0,27.0,122.0,No longer met study criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01073071,0.010850391576084948,0.0001196815760849488
22.0,3057.0,2785.0,0.007197,0.007197,8.025516,0.227085,1.0,3221.0,27.0,122.0,No longer met study criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01311632,0.01311693152575396,6.115257539587859e-07
7.0,3057.0,2785.0,0.00229,0.00229,8.025516,0.227085,1.0,3221.0,27.0,122.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00417346,0.004346168691190483,0.00017270869119048304
11.0,3057.0,2785.0,0.003598,0.003598,8.025516,0.227085,1.0,3221.0,27.0,122.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00655725,0.006623861728194442,6.661172819444252e-05
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004678092302502595,2.1323025025951972e-06
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004674143166788314,1.8168332116862487e-06
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004677828910835929,1.8689108359287374e-06
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,The contrast was not seen,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004676737760835928,7.777608359285301e-07
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004677511327502595,1.551327502595165e-06
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,MRA unsuccessful,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004676737760835928,7.777608359285301e-07
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Bolus tracking failed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004676737760835928,7.777608359285301e-07
1.0,479.0,471.0,0.002088,0.002088,6.173786,0.362735,1.0,479.0,14.0,56.0,Error of power injector,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00467596,0.004676737760835928,7.777608359285301e-07
13.0,206.0,149.0,0.063107,0.063107,5.332719,0.262342,1.0,206.0,3.0,23.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08828644,0.08864768850043654,0.0003612485004365479
10.0,206.0,149.0,0.048544,0.048544,5.332719,0.262342,1.0,206.0,3.0,23.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06791286,0.06713939374348218,0.0007734662565178213
2.0,206.0,149.0,0.009709,0.009709,5.332719,0.262342,1.0,206.0,3.0,23.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01358285,0.01382607582783731,0.0002432258278373088
1.0,206.0,149.0,0.004854,0.004854,5.332719,0.262342,1.0,206.0,3.0,23.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00679073,0.006786429613167383,4.3003868326167705e-06
3.0,206.0,149.0,0.014563,0.014563,5.332719,0.262342,1.0,206.0,3.0,23.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02037358,0.0205924017196131,0.00021882171961310273
1.0,206.0,149.0,0.004854,0.004854,5.332719,0.262342,1.0,206.0,3.0,23.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00679073,0.006791686642869764,9.566428697642404e-07
3.0,206.0,149.0,0.014563,0.014563,5.332719,0.262342,1.0,206.0,3.0,23.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02037358,0.02061383305794644,0.00024025305794644208
5.0,206.0,149.0,0.024272,0.024272,5.332719,0.262342,1.0,206.0,3.0,23.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03395643,0.03431343731727185,0.00035700731727184715
7.0,206.0,149.0,0.033981,0.033981,5.332719,0.262342,1.0,206.0,3.0,23.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04753928,0.04830052385288695,0.0007612438528869434
8.0,206.0,149.0,0.038835,0.038835,5.332719,0.262342,1.0,206.0,3.0,23.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05433001,0.055937171454692514,0.0016071614546925156
1.0,206.0,149.0,0.004854,0.004854,5.332719,0.262342,1.0,206.0,3.0,23.0,PI tried alternative treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00679073,0.006785642317572146,5.087682427853783e-06
3.0,206.0,149.0,0.014563,0.014563,5.332719,0.262342,1.0,206.0,3.0,23.0,PI tried alternative treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02037358,0.020859667799295628,0.0004860877992956293
1.0,2016.0,1999.0,0.000496,0.000496,7.609367,0.233646,1.0,2016.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00088184,0.0009197129147916672,3.7872914791667214e-05
1.0,2016.0,1999.0,0.000496,0.000496,7.609367,0.233646,1.0,2016.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00088184,0.0009211176843750008,3.9277684375000894e-05
8.0,2016.0,1999.0,0.003968,0.003968,7.609367,0.233646,1.0,2016.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0070547,0.007089122715446432,3.442271544643223e-05
6.0,2016.0,1999.0,0.002976,0.002976,7.609367,0.233646,1.0,2016.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00529103,0.005400881202954546,0.00010985120295454575
0.0,2016.0,1999.0,0.0,0.0,7.609367,0.233646,1.0,2016.0,1.0,1.0,Missing Primary Outcome,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,2016.0,1999.0,0.000496,0.000496,7.609367,0.233646,1.0,2016.0,1.0,1.0,Missing Primary Outcome,Overall Study,FG001,cardiovascular disease,OTHER,0.00088184,0.0009218719266369058,4.003192663690582e-05
1.0,1899.0,1897.0,0.000527,0.000527,7.549609,0.312053,1.0,1899.0,16.0,201.0,Previous enrolment into this study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00124155,0.0012789400886165192,3.739008861651928e-05
1.0,1899.0,1897.0,0.000527,0.000527,7.549609,0.312053,1.0,1899.0,16.0,201.0,Previous enrolment into this study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00124155,0.0012857445478427101,4.419454784271022e-05
62.0,3148.0,2849.0,0.019695,0.019695,8.05484,0.208188,1.0,3148.0,13.0,124.0,Adverse Event,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.03302696,0.033180171658063674,0.00015321165806367332
56.0,3148.0,2849.0,0.017789,0.017789,8.05484,0.208188,1.0,3148.0,13.0,124.0,Adverse Event,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.02983075,0.03072364366090276,0.0008928936609027618
1.0,3148.0,2849.0,0.000318,0.000318,8.05484,0.208188,1.0,3148.0,13.0,124.0,Death,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00053326,0.0005333416008234137,8.160082341367343e-08
3.0,3148.0,2849.0,0.000953,0.000953,8.05484,0.208188,1.0,3148.0,13.0,124.0,Death,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.00159811,0.0016073515050396784,9.241505039678374e-06
3.0,3148.0,2849.0,0.000953,0.000953,8.05484,0.208188,1.0,3148.0,13.0,124.0,Lost to Follow-up,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00159811,0.0016092657612896788,1.1155761289678755e-05
1.0,3148.0,2849.0,0.000318,0.000318,8.05484,0.208188,1.0,3148.0,13.0,124.0,Lost to Follow-up,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.00053326,0.0005327396530257944,5.203469742056082e-07
2.0,3148.0,2849.0,0.000635,0.000635,8.05484,0.208188,1.0,3148.0,13.0,124.0,Physician Decision,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00106484,0.0010734424024107152,8.602402410715125e-06
5.0,3148.0,2849.0,0.001588,0.001588,8.05484,0.208188,1.0,3148.0,13.0,124.0,Physician Decision,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.00266295,0.002688892523847683,2.5942523847683266e-05
22.0,3148.0,2849.0,0.006989,0.006989,8.05484,0.208188,1.0,3148.0,13.0,124.0,Protocol Violation,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.01172,0.01150644890190475,0.00021355109809525
21.0,3148.0,2849.0,0.006671,0.006671,8.05484,0.208188,1.0,3148.0,13.0,124.0,Protocol Violation,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.01118674,0.011105544983640867,8.119501635913372e-05
49.0,3148.0,2849.0,0.015565,0.015565,8.05484,0.208188,1.0,3148.0,13.0,124.0,Withdrawal by Subject,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.02610128,0.027222963566130947,0.001121683566130946
47.0,3148.0,2849.0,0.01493,0.01493,8.05484,0.208188,1.0,3148.0,13.0,124.0,Withdrawal by Subject,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.02503643,0.025825244285337275,0.0007888142853372769
9.0,3148.0,2849.0,0.002859,0.002859,8.05484,0.208188,1.0,3148.0,13.0,124.0,Noncompliance to Study Drug,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00479432,0.004730026991071428,6.429300892857228e-05
0.0,3148.0,2849.0,0.0,0.0,8.05484,0.208188,1.0,3148.0,13.0,124.0,Noncompliance to Study Drug,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,3148.0,2849.0,0.000318,0.000318,8.05484,0.208188,1.0,3148.0,13.0,124.0,Technical Problems,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00053326,0.0005330793446924611,1.806553075389336e-07
0.0,3148.0,2849.0,0.0,0.0,8.05484,0.208188,1.0,3148.0,13.0,124.0,Technical Problems,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
10.0,3148.0,2849.0,0.003177,0.003177,8.05484,0.208188,1.0,3148.0,13.0,124.0,Clinical Endpoint Reached,Treatment (12 +/- 2 Days),FG000,cardiovascular disease,INDUSTRY,0.00532758,0.005349117673244053,2.1537673244052813e-05
18.0,3148.0,2849.0,0.005718,0.005718,8.05484,0.208188,1.0,3148.0,13.0,124.0,Clinical Endpoint Reached,Treatment (12 +/- 2 Days),FG001,cardiovascular disease,INDUSTRY,0.00958864,0.009791330286517847,0.00020269028651784607
2.0,3148.0,2849.0,0.000635,0.000635,8.05484,0.208188,1.0,3148.0,13.0,124.0,Adverse Event,Follow-up (30 (+ 5) Days),FG000,cardiovascular disease,INDUSTRY,0.00106484,0.0010734760669940484,8.636066994048347e-06
3.0,3148.0,2849.0,0.000953,0.000953,8.05484,0.208188,1.0,3148.0,13.0,124.0,Adverse Event,Follow-up (30 (+ 5) Days),FG001,cardiovascular disease,INDUSTRY,0.00159811,0.0016101873846230122,1.2077384623012137e-05
1.0,3148.0,2849.0,0.000318,0.000318,8.05484,0.208188,1.0,3148.0,13.0,124.0,Death,Follow-up (30 (+ 5) Days),FG000,cardiovascular disease,INDUSTRY,0.00053326,0.0005331715083234138,8.84916765862484e-08
1.0,3148.0,2849.0,0.000318,0.000318,8.05484,0.208188,1.0,3148.0,13.0,124.0,Death,Follow-up (30 (+ 5) Days),FG001,cardiovascular disease,INDUSTRY,0.00053326,0.0005326493958234139,6.106041765861032e-07
27.0,3148.0,2849.0,0.008577,0.008577,8.05484,0.208188,1.0,3148.0,13.0,124.0,Lost to Follow-up,Follow-up (30 (+ 5) Days),FG000,cardiovascular disease,INDUSTRY,0.01438295,0.014689829662678571,0.0003068796626785712
28.0,3148.0,2849.0,0.008895,0.008895,8.05484,0.208188,1.0,3148.0,13.0,124.0,Lost to Follow-up,Follow-up (30 (+ 5) Days),FG001,cardiovascular disease,INDUSTRY,0.01491621,0.015091359743740056,0.00017514974374005683
8.0,3148.0,2849.0,0.002541,0.002541,8.05484,0.208188,1.0,3148.0,13.0,124.0,Withdrawal by Subject,Follow-up (30 (+ 5) Days),FG000,cardiovascular disease,INDUSTRY,0.00426106,0.004207005709871031,5.405429012896902e-05
7.0,3148.0,2849.0,0.002224,0.002224,8.05484,0.208188,1.0,3148.0,13.0,124.0,Withdrawal by Subject,Follow-up (30 (+ 5) Days),FG001,cardiovascular disease,INDUSTRY,0.00372947,0.0037953655533630943,6.589555336309434e-05
1.0,366.0,351.0,0.002732,0.002732,5.905362,0.5719,1.0,366.0,3.0,20.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00922672,0.009403586797609128,0.00017686679760912753
3.0,366.0,351.0,0.008197,0.008197,5.905362,0.5719,1.0,366.0,3.0,20.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02768355,0.027559422607827372,0.00012412739217262936
0.0,366.0,351.0,0.0,0.0,5.905362,0.5719,1.0,366.0,3.0,20.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,366.0,351.0,0.002732,0.002732,5.905362,0.5719,1.0,366.0,3.0,20.0,Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00922672,0.009430739430555552,0.000204019430555551
2.0,366.0,351.0,0.005464,0.005464,5.905362,0.5719,1.0,366.0,3.0,20.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01845345,0.018721923164444435,0.0002684731644444355
2.0,366.0,351.0,0.005464,0.005464,5.905362,0.5719,1.0,366.0,3.0,20.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01845345,0.018717486395396818,0.0002640363953968182
2.0,366.0,351.0,0.005464,0.005464,5.905362,0.5719,1.0,366.0,3.0,20.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01845345,0.01869373501913419,0.00024028501913419056
4.0,366.0,351.0,0.010929,0.010929,5.905362,0.5719,1.0,366.0,3.0,20.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03691027,0.03713813112538693,0.00022786112538692588
1.0,407.0,398.0,0.002457,0.002457,6.011267,0.892733,1.0,407.0,1.0,45.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01318539,0.01317991033479981,5.4796652001892765e-06
2.0,407.0,398.0,0.004914,0.004914,6.011267,0.892733,1.0,407.0,1.0,45.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02637078,0.025686804236686525,0.0006839757633134748
1.0,407.0,398.0,0.002457,0.002457,6.011267,0.892733,1.0,407.0,1.0,45.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01318539,0.01318053635559525,4.853644404749155e-06
2.0,407.0,398.0,0.004914,0.004914,6.011267,0.892733,1.0,407.0,1.0,45.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.02637078,0.025706290577222245,0.0006644894227777545
1.0,407.0,398.0,0.002457,0.002457,6.011267,0.892733,1.0,407.0,1.0,45.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01318539,0.013183105819204571,2.2841807954289417e-06
1.0,407.0,398.0,0.002457,0.002457,6.011267,0.892733,1.0,407.0,1.0,45.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01318539,0.01317857222158552,6.817778414479683e-06
1.0,407.0,398.0,0.002457,0.002457,6.011267,0.892733,1.0,407.0,1.0,45.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01318539,0.013182137205000014,3.252794999986444e-06
0.0,407.0,398.0,0.0,0.0,6.011267,0.892733,1.0,407.0,1.0,45.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
19.0,992.0,689.0,0.019153,0.019153,6.900731,0.247637,1.0,992.0,0.0,0.0,Screening failures,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03273017,0.032354618364940475,0.00037555163505952754
17.0,992.0,689.0,0.017137,0.017137,6.900731,0.247637,1.0,992.0,0.0,0.0,Screening failures,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02928506,0.029470618159791663,0.0001855581597916614
19.0,992.0,689.0,0.019153,0.019153,6.900731,0.247637,1.0,992.0,0.0,0.0,Site 212 removal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03273017,0.032354618364940475,0.00037555163505952754
13.0,992.0,689.0,0.013105,0.013105,6.900731,0.247637,1.0,992.0,0.0,0.0,Site 212 removal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02239486,0.022260803900625032,0.00013405609937496704
33.0,992.0,689.0,0.033266,0.033266,6.900731,0.247637,1.0,992.0,0.0,0.0,No follow-up data,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05684758,0.05652407689785721,0.00032350310214279004
18.0,992.0,689.0,0.018145,0.018145,6.900731,0.247637,1.0,992.0,0.0,0.0,No follow-up data,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03100761,0.030749431213174604,0.00025817878682539777
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Dietician consultation >30 days,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172255,0.0017259820282719996,3.432028271999586e-06
9.0,992.0,689.0,0.009073,0.009073,6.900731,0.247637,1.0,992.0,0.0,0.0,Dietician consultation >30 days,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01550466,0.015407378508928572,9.728149107142772e-05
22.0,992.0,689.0,0.022177,0.022177,6.900731,0.247637,1.0,992.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03789782,0.03811042084575397,0.0002126008457539741
13.0,992.0,689.0,0.013105,0.013105,6.900731,0.247637,1.0,992.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02239486,0.022269886246458367,0.00012497375354163232
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172255,0.0017225145999386663,3.540006133367912e-08
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172255,0.0017261745657719996,3.624565771999594e-06
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
52.0,992.0,689.0,0.052419,0.052419,6.900731,0.247637,1.0,992.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08957774,0.08860661117079367,0.0009711288292063303
30.0,992.0,689.0,0.030242,0.030242,6.900731,0.247637,1.0,992.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05167993,0.05210603753333338,0.0004261075333333794
5.0,992.0,689.0,0.00504,0.00504,6.900731,0.247637,1.0,992.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00861275,0.00852740273547618,8.534726452382076e-05
5.0,992.0,689.0,0.00504,0.00504,6.900731,0.247637,1.0,992.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00861275,0.008560197977777767,5.255202222223358e-05
9.0,992.0,689.0,0.009073,0.009073,6.900731,0.247637,1.0,992.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01550466,0.015412443988095244,9.221601190475583e-05
9.0,992.0,689.0,0.009073,0.009073,6.900731,0.247637,1.0,992.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01550466,0.015409428616190475,9.523138380952527e-05
2.0,992.0,689.0,0.002016,0.002016,6.900731,0.247637,1.0,992.0,0.0,0.0,Reason missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0034451,0.003382227243452375,6.287275654762517e-05
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Reason missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,992.0,689.0,0.006048,0.006048,6.900731,0.247637,1.0,992.0,0.0,0.0,Clinic closed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0103353,0.01029606670657737,3.923329342262957e-05
4.0,992.0,689.0,0.004032,0.004032,6.900731,0.247637,1.0,992.0,0.0,0.0,Clinic closed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0068902,0.006863146524088203,2.7053475911796923e-05
3.0,992.0,689.0,0.003024,0.003024,6.900731,0.247637,1.0,992.0,0.0,0.0,Patient moved,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00516765,0.005185397014107141,1.774701410714105e-05
2.0,992.0,689.0,0.002016,0.002016,6.900731,0.247637,1.0,992.0,0.0,0.0,Patient moved,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0034451,0.0033874288705357095,5.767112946429044e-05
4.0,992.0,689.0,0.004032,0.004032,6.900731,0.247637,1.0,992.0,0.0,0.0,Non compliant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0068902,0.006874363677421535,1.5836322578464783e-05
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Non compliant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,992.0,689.0,0.003024,0.003024,6.900731,0.247637,1.0,992.0,0.0,0.0,Unable to attend visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00516765,0.005185397014107141,1.774701410714105e-05
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Unable to attend visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00172255,0.001725502866388883,2.9528663888830214e-06
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Home monitoring off meds,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00172255,0.0017259820282719996,3.432028271999586e-06
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Home monitoring off meds,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,992.0,689.0,0.0,0.0,6.900731,0.247637,1.0,992.0,0.0,0.0,Erectile dysfunction,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,992.0,689.0,0.001008,0.001008,6.900731,0.247637,1.0,992.0,0.0,0.0,Erectile dysfunction,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00172255,0.001725502866388883,2.9528663888830214e-06
10.0,312.0,283.0,0.032051,0.032051,5.746203,0.577356,1.0,312.0,11.0,109.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10633264,0.10990544344680554,0.0035728034468055364
9.0,312.0,283.0,0.028846,0.028846,5.746203,0.577356,1.0,312.0,11.0,109.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09569971,0.09633250649260917,0.0006327964926091806
0.0,312.0,283.0,0.0,0.0,5.746203,0.577356,1.0,312.0,11.0,109.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,312.0,283.0,0.00641,0.00641,5.746203,0.577356,1.0,312.0,11.0,109.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02126586,0.02136749231604167,0.00010163231604166933
3.0,312.0,283.0,0.009615,0.009615,5.746203,0.577356,1.0,312.0,11.0,109.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0318988,0.03172604090130952,0.0001727590986904809
1.0,312.0,283.0,0.003205,0.003205,5.746203,0.577356,1.0,312.0,11.0,109.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01063293,0.010650617511934503,1.768751193450234e-05
0.0,312.0,283.0,0.0,0.0,5.746203,0.577356,1.0,312.0,11.0,109.0,Not treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,312.0,283.0,0.003205,0.003205,5.746203,0.577356,1.0,312.0,11.0,109.0,Not treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01063293,0.010650638446994029,1.7708446994028557e-05
0.0,312.0,283.0,0.0,0.0,5.746203,0.577356,1.0,312.0,11.0,109.0,Patient did not attend all visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,312.0,283.0,0.00641,0.00641,5.746203,0.577356,1.0,312.0,11.0,109.0,Patient did not attend all visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02126586,0.02135719618901785,9.13361890178474e-05
0.0,312.0,283.0,0.0,0.0,5.746203,0.577356,1.0,312.0,11.0,109.0,Withdrawn by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,312.0,283.0,0.003205,0.003205,5.746203,0.577356,1.0,312.0,11.0,109.0,Withdrawn by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01063293,0.010650638446994029,1.7708446994028557e-05
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Subject's no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Subject's no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Subject's no longer requires study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Subject's no longer requires study drug,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00865838,0.008662150181051563,3.770181051562793e-06
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00865838,0.00866386203583331,5.48203583330964e-06
2.0,270.0,0.0,0.007407,0.007407,5.602119,0.417267,1.0,270.0,1.0,39.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01731443,0.017336371133365776,2.194113336577777e-05
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Protocol deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00865838,0.00866084936785712,2.4693678571195005e-06
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Protocol deviation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00865838,0.008661448541884895,3.0685418848947627e-06
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,270.0,0.0,0.014815,0.014815,5.602119,0.417267,1.0,270.0,1.0,39.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0346312,0.034676545087481025,4.5345087481024615e-05
2.0,270.0,0.0,0.007407,0.007407,5.602119,0.417267,1.0,270.0,1.0,39.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01731443,0.01730894613419911,5.483865800889887e-06
2.0,270.0,0.0,0.007407,0.007407,5.602119,0.417267,1.0,270.0,1.0,39.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01731443,0.017304082585865778,1.03474141342208e-05
3.0,270.0,0.0,0.011111,0.011111,5.602119,0.417267,1.0,270.0,1.0,39.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02597281,0.026198452100525786,0.0002256421005257872
5.0,270.0,0.0,0.018519,0.018519,5.602119,0.417267,1.0,270.0,1.0,39.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04328958,0.04323091340491066,5.86665950893378e-05
4.0,270.0,0.0,0.014815,0.014815,5.602119,0.417267,1.0,270.0,1.0,39.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0346312,0.034620042671528635,1.1157328471365913e-05
2.0,270.0,0.0,0.007407,0.007407,5.602119,0.417267,1.0,270.0,1.0,39.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01731443,0.01734254184844514,2.8111848445141335e-05
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00865838,0.008665771806249977,7.3918062499771925e-06
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,270.0,0.0,0.025926,0.025926,5.602119,0.417267,1.0,270.0,1.0,39.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.06060401,0.05706054884089288,0.003543461159107121
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Death,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00865838,0.008663382187301562,5.002187301561892e-06
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00865838,0.00866463543583331,6.255435833310563e-06
13.0,270.0,0.0,0.048148,0.048148,5.602119,0.417267,1.0,270.0,1.0,39.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11254964,0.11253041577276787,1.9224227232134128e-05
1.0,270.0,0.0,0.003704,0.003704,5.602119,0.417267,1.0,270.0,1.0,39.0,Unsatisfactory therapeutic effect,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00865838,0.008661646642857119,3.2666428571182654e-06
0.0,270.0,0.0,0.0,0.0,5.602119,0.417267,1.0,270.0,1.0,39.0,Unsatisfactory therapeutic effect,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
87.0,270.0,0.0,0.322222,0.322222,5.602119,0.417267,1.0,270.0,1.0,39.0,Early termination,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.75321863,0.7271462233097823,0.02607240669021771
60.0,270.0,0.0,0.222222,0.222222,5.602119,0.417267,1.0,270.0,1.0,39.0,Early termination,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.51946096,0.5841811974999209,0.06472023749992095
43.0,270.0,0.0,0.159259,0.159259,5.602119,0.417267,1.0,270.0,1.0,39.0,Early termination,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.37228012,0.42400582286720223,0.05172570286720224
28.0,270.0,0.0,0.103704,0.103704,5.602119,0.417267,1.0,270.0,1.0,39.0,Early termination,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.24241605,0.253494356658859,0.011078306658859005
58.0,502.0,145.0,0.115538,0.115538,6.22059,0.325753,1.0,502.0,2.0,235.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.23412325,0.23821524960416698,0.004091999604166979
67.0,502.0,145.0,0.133466,0.133466,6.22059,0.325753,1.0,502.0,2.0,235.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.27045209,0.2665218033279367,0.003930286672063299
65.0,502.0,145.0,0.129482,0.129482,6.22059,0.325753,1.0,502.0,2.0,235.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.26237901,0.2601658143467859,0.0022131956532141506
1.0,502.0,145.0,0.001992,0.001992,6.22059,0.325753,1.0,502.0,2.0,235.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00403654,0.004071333269517495,3.4793269517495104e-05
2.0,502.0,145.0,0.003984,0.003984,6.22059,0.325753,1.0,502.0,2.0,235.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00807308,0.008067914500634937,5.165499365062873e-06
0.0,502.0,145.0,0.0,0.0,6.22059,0.325753,1.0,502.0,2.0,235.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,502.0,145.0,0.013944,0.013944,6.22059,0.325753,1.0,502.0,2.0,235.0,Lack ofEfficacy / Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02825577,0.02821024921345237,4.5520786547629394e-05
7.0,502.0,145.0,0.013944,0.013944,6.22059,0.325753,1.0,502.0,2.0,235.0,Lack ofEfficacy / Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02825577,0.028162768253035687,9.300174696431213e-05
8.0,502.0,145.0,0.015936,0.015936,6.22059,0.325753,1.0,502.0,2.0,235.0,Lack ofEfficacy / Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0322923,0.032115537589156744,0.00017676241084325917
20.0,502.0,145.0,0.039841,0.039841,6.22059,0.325753,1.0,502.0,2.0,235.0,Progressive Disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08073278,0.08066102772728176,7.175227271824514e-05
10.0,502.0,145.0,0.01992,0.01992,6.22059,0.325753,1.0,502.0,2.0,235.0,Progressive Disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04036538,0.04201465786900794,0.0016492778690079396
13.0,502.0,145.0,0.025896,0.025896,6.22059,0.325753,1.0,502.0,2.0,235.0,Progressive Disease,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05247499,0.05264206187428843,0.00016707187428843112
18.0,502.0,145.0,0.035857,0.035857,6.22059,0.325753,1.0,502.0,2.0,235.0,Patient declined further treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07265971,0.07181840336547618,0.0008413066345238224
14.0,502.0,145.0,0.027888,0.027888,6.22059,0.325753,1.0,502.0,2.0,235.0,Patient declined further treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05651153,0.0567689336726822,0.0002574036726822049
11.0,502.0,145.0,0.021912,0.021912,6.22059,0.325753,1.0,502.0,2.0,235.0,Patient declined further treatment,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04440192,0.04460473488952381,0.00020281488952381133
11.0,502.0,145.0,0.021912,0.021912,6.22059,0.325753,1.0,502.0,2.0,235.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04440192,0.04456219777986111,0.00016027777986111352
16.0,502.0,145.0,0.031873,0.031873,6.22059,0.325753,1.0,502.0,2.0,235.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06458663,0.06536857667916667,0.000781946679166659
13.0,502.0,145.0,0.025896,0.025896,6.22059,0.325753,1.0,502.0,2.0,235.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05247499,0.0526398214697051,0.00016483146970509843
3.0,502.0,145.0,0.005976,0.005976,6.22059,0.325753,1.0,502.0,2.0,235.0,Did not Receive Study Treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01210961,0.012107620506904764,1.9894930952356338e-06
9.0,502.0,145.0,0.017928,0.017928,6.22059,0.325753,1.0,502.0,2.0,235.0,Did not Receive Study Treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03632884,0.036041877560238106,0.0002869624397618953
4.0,502.0,145.0,0.007968,0.007968,6.22059,0.325753,1.0,502.0,2.0,235.0,Did not Receive Study Treatment,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01614615,0.016010423619047646,0.00013572638095235567
27.0,418.0,282.0,0.064593,0.064593,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.09047637,0.08859251599217265,0.0018838540078273541
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
18.0,418.0,282.0,0.043062,0.043062,6.037871,0.231988,1.0,418.0,3.0,45.0,Protocol Violation,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.06031758,0.06023350026567458,8.407973432542071e-05
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Protocol Violation,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Protocol Violation,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
24.0,418.0,282.0,0.057416,0.057416,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.08042344,0.08046205505609126,3.861505609126237e-05
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
37.0,418.0,282.0,0.088517,0.088517,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.12398707,0.13113160463280304,0.00714453463280304
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,418.0,282.0,0.014354,0.014354,6.037871,0.231988,1.0,418.0,3.0,45.0,Other,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.02010586,0.01957584414880951,0.0005300158511904914
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Other,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Other,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,418.0,282.0,0.007177,0.007177,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.01005293,0.009852519633422634,0.0002004103665773655
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,418.0,282.0,0.009569,0.009569,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Open Label Phase,FG000,cardiovascular disease,INDUSTRY,0.01340344,0.01342462814435515,2.118814435514947e-05
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Open Label Phase,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Open Label Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Double Blind Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,418.0,282.0,0.004785,0.004785,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Double Blind Phase,FG001,cardiovascular disease,INDUSTRY,0.00670242,0.006697301340605156,5.118659394843551e-06
2.0,418.0,282.0,0.004785,0.004785,6.037871,0.231988,1.0,418.0,3.0,45.0,Adverse Event,Double Blind Phase,FG002,cardiovascular disease,INDUSTRY,0.00670242,0.006708709013224207,6.28901322420692e-06
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Double Blind Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,418.0,282.0,0.004785,0.004785,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Double Blind Phase,FG001,cardiovascular disease,INDUSTRY,0.00670242,0.006694591477390866,7.828522609133574e-06
1.0,418.0,282.0,0.002392,0.002392,6.037871,0.231988,1.0,418.0,3.0,45.0,Lost to Follow-up,Double Blind Phase,FG002,cardiovascular disease,INDUSTRY,0.00335051,0.0034271011119642787,7.659111196427855e-05
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Double Blind Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,418.0,282.0,0.009569,0.009569,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Double Blind Phase,FG001,cardiovascular disease,INDUSTRY,0.01340344,0.013430818962688485,2.7378962688484262e-05
3.0,418.0,282.0,0.007177,0.007177,6.037871,0.231988,1.0,418.0,3.0,45.0,Withdrawal by Subject,Double Blind Phase,FG002,cardiovascular disease,INDUSTRY,0.01005293,0.0098391690500893,0.00021376094991069905
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Double Blind Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,418.0,282.0,0.002392,0.002392,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Double Blind Phase,FG001,cardiovascular disease,INDUSTRY,0.00335051,0.0034266539484523752,7.61439484523751e-05
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Lack of Efficacy,Double Blind Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Double Blind Phase,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,418.0,282.0,0.004785,0.004785,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Double Blind Phase,FG001,cardiovascular disease,INDUSTRY,0.00670242,0.006698853902271821,3.566097728178834e-06
0.0,418.0,282.0,0.0,0.0,6.037871,0.231988,1.0,418.0,3.0,45.0,Physician Decision,Double Blind Phase,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,688.0,619.0,0.0,0.0,6.535241,0.231988,1.0,688.0,8.0,8.0,Abnormal laboratory value(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,688.0,619.0,0.00436,0.00436,6.535241,0.231988,1.0,688.0,8.0,8.0,Abnormal laboratory value(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00661019,0.006594321719454356,1.5868280545644486e-05
2.0,688.0,619.0,0.002907,0.002907,6.535241,0.231988,1.0,688.0,8.0,8.0,Abnormal test procedure result(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0044073,0.004450611605852278,4.331160585227794e-05
12.0,688.0,619.0,0.017442,0.017442,6.535241,0.231988,1.0,688.0,8.0,8.0,Abnormal test procedure result(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0264438,0.026457050250863107,1.3250250863107438e-05
11.0,688.0,619.0,0.015988,0.015988,6.535241,0.231988,1.0,688.0,8.0,8.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02423939,0.024370754007202403,0.00013136400720240374
15.0,688.0,619.0,0.021802,0.021802,6.535241,0.231988,1.0,688.0,8.0,8.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03305399,0.033659467853437854,0.0006054778534378552
3.0,688.0,619.0,0.00436,0.00436,6.535241,0.231988,1.0,688.0,8.0,8.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00661019,0.006607904971269828,2.285028730172195e-06
4.0,688.0,619.0,0.005814,0.005814,6.535241,0.231988,1.0,688.0,8.0,8.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0088146,0.00889720678980159,8.26067898015894e-05
2.0,688.0,619.0,0.002907,0.002907,6.535241,0.231988,1.0,688.0,8.0,8.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0044073,0.004450817167012991,4.351716701299097e-05
2.0,688.0,619.0,0.002907,0.002907,6.535241,0.231988,1.0,688.0,8.0,8.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0044073,0.004445006390346325,3.7706390346324906e-05
5.0,688.0,619.0,0.007267,0.007267,6.535241,0.231988,1.0,688.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01101749,0.01093820893305556,7.928106694444007e-05
10.0,688.0,619.0,0.014535,0.014535,6.535241,0.231988,1.0,688.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0220365,0.021838229064275794,0.00019827093572420684
44.0,1639.0,1289.0,0.026846,0.026846,7.402452,0.309765,1.0,1639.0,24.0,308.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06155845,0.0617915427849206,0.00023309278492059798
45.0,1639.0,1289.0,0.027456,0.027456,7.402452,0.309765,1.0,1639.0,24.0,308.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06295719,0.06455535333173615,0.001598163331736152
2.0,1639.0,1289.0,0.00122,0.00122,7.402452,0.309765,1.0,1639.0,24.0,308.0,Abnormal Laboratory values,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00279749,0.0028143334520833296,1.6843452083329432e-05
2.0,1639.0,1289.0,0.00122,0.00122,7.402452,0.309765,1.0,1639.0,24.0,308.0,Abnormal Laboratory values,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00279749,0.002809359257589281,1.1869257589280924e-05
0.0,1639.0,1289.0,0.0,0.0,7.402452,0.309765,1.0,1639.0,24.0,308.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1639.0,1289.0,0.00061,0.00061,7.402452,0.309765,1.0,1639.0,24.0,308.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00139874,0.0014007633835912698,2.0233835912697277e-06
3.0,1639.0,1289.0,0.00183,0.00183,7.402452,0.309765,1.0,1639.0,24.0,308.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00419623,0.004223625912559525,2.7395912559525712e-05
5.0,1639.0,1289.0,0.003051,0.003051,7.402452,0.309765,1.0,1639.0,24.0,308.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00699601,0.006982855606785705,1.315439321429579e-05
2.0,1639.0,1289.0,0.00122,0.00122,7.402452,0.309765,1.0,1639.0,24.0,308.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00279749,0.0028143334520833296,1.6843452083329432e-05
2.0,1639.0,1289.0,0.00122,0.00122,7.402452,0.309765,1.0,1639.0,24.0,308.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00279749,0.002809359257589281,1.1869257589280924e-05
77.0,1639.0,1289.0,0.04698,0.04698,7.402452,0.309765,1.0,1639.0,24.0,308.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10772614,0.10768208541560709,4.405458439291077e-05
76.0,1639.0,1289.0,0.04637,0.04637,7.402452,0.309765,1.0,1639.0,24.0,308.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10632739,0.10592234205183537,0.00040504794816462186
4.0,1639.0,1289.0,0.002441,0.002441,7.402452,0.309765,1.0,1639.0,24.0,308.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00559726,0.005650853431966997,5.359343196699711e-05
0.0,1639.0,1289.0,0.0,0.0,7.402452,0.309765,1.0,1639.0,24.0,308.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
25.0,1639.0,1289.0,0.015253,0.015253,7.402452,0.309765,1.0,1639.0,24.0,308.0,Patient's request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03497545,0.03483478070169642,0.00014066929830357927
30.0,1639.0,1289.0,0.018304,0.018304,7.402452,0.309765,1.0,1639.0,24.0,308.0,Patient's request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04197146,0.042068436907907666,9.697690790766433e-05
5.0,1639.0,1289.0,0.003051,0.003051,7.402452,0.309765,1.0,1639.0,24.0,308.0,Other (Missing),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00699601,0.006979986165297614,1.602383470238663e-05
3.0,1639.0,1289.0,0.00183,0.00183,7.402452,0.309765,1.0,1639.0,24.0,308.0,Other (Missing),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00419623,0.004225537889226191,2.9307889226191063e-05
13.0,1639.0,1289.0,0.007932,0.007932,7.402452,0.309765,1.0,1639.0,24.0,308.0,Mis-randomized,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01818824,0.018255669419593248,6.742941959324636e-05
9.0,1639.0,1289.0,0.005491,0.005491,7.402452,0.309765,1.0,1639.0,24.0,308.0,Mis-randomized,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01259098,0.012639107382886901,4.812738288690124e-05
0.0,1639.0,1289.0,0.0,0.0,7.402452,0.309765,1.0,1639.0,24.0,308.0,GCP non-compliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1639.0,1289.0,0.00122,0.00122,7.402452,0.309765,1.0,1639.0,24.0,308.0,GCP non-compliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00279749,0.002809359257589281,1.1869257589280924e-05
6.0,1262.0,289.0,0.004754,0.004754,7.141245,0.342728,1.0,1264.0,4.0,90.0,Death,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01163545,0.011241592575416667,0.00039385742458333296
2.0,1262.0,289.0,0.001585,0.001585,7.141245,0.342728,1.0,1264.0,4.0,90.0,Death,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0038793,0.0038773759652182367,1.924034781763343e-06
4.0,1262.0,289.0,0.00317,0.00317,7.141245,0.342728,1.0,1264.0,4.0,90.0,Withdrawal by Subject,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.0077586,0.007679751959642865,7.884804035713545e-05
0.0,1262.0,289.0,0.0,0.0,7.141245,0.342728,1.0,1264.0,4.0,90.0,Withdrawal by Subject,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1262.0,289.0,0.001585,0.001585,7.141245,0.342728,1.0,1264.0,4.0,90.0,Lost to Follow-up,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.0038793,0.0038858474700991918,6.547470099191755e-06
1.0,1262.0,289.0,0.000792,0.000792,7.141245,0.342728,1.0,1264.0,4.0,90.0,Lost to Follow-up,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.00193843,0.0019755954938988113,3.71654938988112e-05
13.0,1262.0,289.0,0.010301,0.010301,7.141245,0.342728,1.0,1264.0,4.0,90.0,Missed 12-Month Visit,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.02521176,0.024005999654930527,0.0012057603450694732
4.0,1262.0,289.0,0.00317,0.00317,7.141245,0.342728,1.0,1264.0,4.0,90.0,Missed 12-Month Visit,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0077586,0.007671829687976194,8.6770312023806e-05
3.0,1262.0,289.0,0.002377,0.002377,7.141245,0.342728,1.0,1264.0,4.0,90.0,Withdrawn at Investigator's discretion,12-Month Clinical Follow-up,FG000,cardiovascular disease,INDUSTRY,0.00581772,0.005585106260396824,0.00023261373960317602
2.0,1262.0,289.0,0.001585,0.001585,7.141245,0.342728,1.0,1264.0,4.0,90.0,Withdrawn at Investigator's discretion,12-Month Clinical Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0038793,0.003878914930634903,3.850693650968816e-07
25.0,1262.0,289.0,0.01981,0.01981,7.141245,0.342728,1.0,1264.0,4.0,90.0,No 9-Month Angiography Performed,9-Month Angiographic Follow-up,FG000,cardiovascular disease,INDUSTRY,0.0484851,0.04763446976153772,0.0008506302384622827
11.0,1262.0,289.0,0.008716,0.008716,7.141245,0.342728,1.0,1264.0,4.0,90.0,No 9-Month Angiography Performed,9-Month Angiographic Follow-up,FG001,cardiovascular disease,INDUSTRY,0.02133247,0.02019822276264881,0.0011342472373511887
3.0,1262.0,289.0,0.002377,0.002377,7.141245,0.342728,1.0,1264.0,4.0,90.0,Not Evaluable for Angiography Analysis,9-Month Angiographic Follow-up,FG000,cardiovascular disease,INDUSTRY,0.00581772,0.005585106260396824,0.00023261373960317602
2.0,1262.0,289.0,0.001585,0.001585,7.141245,0.342728,1.0,1264.0,4.0,90.0,Not Evaluable for Angiography Analysis,9-Month Angiographic Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0038793,0.003876730315218238,2.5696847817621195e-06
2.0,300.0,287.0,0.006667,0.006667,5.70711,0.588146,1.0,300.0,1.0,18.0,Withdrew prior to treatment,Overall Study,FG000,cardiovascular disease,OTHER,0.02237855,0.02286437916417662,0.00048582916417662034
7.0,300.0,287.0,0.023333,0.023333,5.70711,0.588146,1.0,300.0,1.0,18.0,Withdrew prior to treatment,Overall Study,FG001,cardiovascular disease,OTHER,0.07831989,0.07926685748505956,0.000946967485059555
3.0,300.0,287.0,0.01,0.01,5.70711,0.588146,1.0,300.0,1.0,18.0,Other,Overall Study,FG000,cardiovascular disease,OTHER,0.03356615,0.033608283524365075,4.213352436507195e-05
1.0,300.0,287.0,0.003333,0.003333,5.70711,0.588146,1.0,300.0,1.0,18.0,Other,Overall Study,FG001,cardiovascular disease,OTHER,0.0111876,0.011305882463224205,0.00011828246322420459
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01079196,0.010809270904702406,1.7310904702406288e-05
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01079196,0.010785870113154792,6.0898868452074345e-06
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
39.0,402.0,0.0,0.097015,0.097015,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.42081271,0.4184845771505357,0.0023281328494642595
41.0,402.0,0.0,0.10199,0.10199,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.4423923,0.4274262779879166,0.014966022012083413
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Adverse Event,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01079196,0.010809689167202405,1.772916720240575e-05
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Adverse Event,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Adverse Event,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Adverse Event,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
74.0,402.0,0.0,0.18408,0.18408,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.79846626,0.8432923542470043,0.044826094247004344
82.0,402.0,0.0,0.20398,0.20398,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.88478459,0.9131192346040977,0.028334644604097736
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
13.0,402.0,0.0,0.032338,0.032338,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.14026946,0.14193450591390694,0.0016650459139069262
8.0,402.0,0.0,0.0199,0.0199,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.08631833,0.08799792583515874,0.0016795958351587398
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Protocol Deviation,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01079196,0.010809689167202405,1.772916720240575e-05
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Protocol Deviation,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Protocol Deviation,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Protocol Deviation,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,402.0,0.0,0.004975,0.004975,5.998937,0.723062,1.0,402.0,21.0,157.0,Physician Decision,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02157958,0.021588563463015867,8.983463015865834e-06
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Physician Decision,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01079196,0.010781907927738121,1.005207226187875e-05
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Physician Decision,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Physician Decision,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
59.0,402.0,0.0,0.146766,0.146766,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.63661288,0.6668709181086112,0.030258038108611163
67.0,402.0,0.0,0.166667,0.166667,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.72293555,0.7674873954872322,0.04455184548723223
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,402.0,0.0,0.012438,0.012438,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.05395113,0.055432009062083364,0.0014808790620833637
4.0,402.0,0.0,0.00995,0.00995,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.04315917,0.041349902950766626,0.0018092670492333707
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Randomized but never treated,Initial Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,402.0,0.0,0.007463,0.007463,5.998937,0.723062,1.0,402.0,21.0,157.0,Randomized but never treated,Initial Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03237154,0.0316146395746203,0.0007569004253796946
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Randomized but never treated,Initial Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Randomized but never treated,Initial Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.01079196,0.010775406988630975,1.6553011369024526e-05
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Disease Progression,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,402.0,0.0,0.0199,0.0199,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.08631833,0.08843885848950396,0.0021205284895039617
6.0,402.0,0.0,0.014925,0.014925,5.998937,0.723062,1.0,402.0,21.0,157.0,Withdrawal by Subject,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.06473875,0.0636827890327977,0.001055960967202299
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
37.0,402.0,0.0,0.09204,0.09204,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.39923313,0.4015034586846928,0.0022703286846927906
3.0,402.0,0.0,0.007463,0.007463,5.998937,0.723062,1.0,402.0,21.0,157.0,Death,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.03237154,0.03164983680721498,0.0007217031927850143
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Lost to Follow-up,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.01079196,0.01079565467529764,3.6946752976409897e-06
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.01079196,0.010775825251130975,1.6134748869025065e-05
1.0,402.0,0.0,0.002488,0.002488,5.998937,0.723062,1.0,402.0,21.0,157.0,Other,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.01079196,0.010788995676547643,2.96432345235631e-06
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Crossover Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,402.0,0.0,0.0,0.0,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Crossover Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
19.0,402.0,0.0,0.047264,0.047264,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Crossover Period,FG002,cardiovascular disease,INDUSTRY,0.20501254,0.2063640249243454,0.0013514849243454197
3.0,402.0,0.0,0.007463,0.007463,5.998937,0.723062,1.0,402.0,21.0,157.0,Participants withdrawn due to company goals,Crossover Period,FG003,cardiovascular disease,INDUSTRY,0.03237154,0.03161349182965006,0.0007580481703499398
541.0,5050.0,3889.0,0.107129,0.107129,8.527342,0.57258,1.0,5050.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.52306602,0.5125258524078867,0.010540167592113292
552.0,5050.0,3889.0,0.109307,0.109307,8.527342,0.57258,1.0,5050.0,0.0,0.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.53370028,0.5174375147593259,0.01626276524067416
14.0,5050.0,3889.0,0.002772,0.002772,8.527342,0.57258,1.0,5050.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01353451,0.013484066866666684,5.0443133333315585e-05
14.0,5050.0,3889.0,0.002772,0.002772,8.527342,0.57258,1.0,5050.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01353451,0.01351026096351192,2.424903648808041e-05
4.0,5050.0,3889.0,0.000792,0.000792,8.527342,0.57258,1.0,5050.0,0.0,0.0,Site Terminated by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.003867,0.0035119296824603127,0.00035507031753968755
3.0,5050.0,3889.0,0.000594,0.000594,8.527342,0.57258,1.0,5050.0,0.0,0.0,Site Terminated by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00290025,0.002760806726755952,0.000139443273244048
15.0,5050.0,3889.0,0.00297,0.00297,8.527342,0.57258,1.0,5050.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01450127,0.01408270789433442,0.0004185621056655795
18.0,5050.0,3889.0,0.003564,0.003564,8.527342,0.57258,1.0,5050.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01740152,0.01690465516661437,0.000496864833385631
2.0,1524.0,1486.0,0.001312,0.001312,7.32975,0.208188,1.0,2207.0,6.0,27.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00200207,0.00201241708732143,1.0347087321429995e-05
4.0,1524.0,1486.0,0.002625,0.002625,7.32975,0.208188,1.0,2207.0,6.0,27.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00400566,0.004039754616765877,3.4094616765876357e-05
3.0,1524.0,1486.0,0.001969,0.001969,7.32975,0.208188,1.0,2207.0,6.0,27.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00300463,0.003006153309305545,1.5233093055449544e-06
3.0,1524.0,1486.0,0.001969,0.001969,7.32975,0.208188,1.0,2207.0,6.0,27.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00300463,0.0030037321354960188,8.978645039811259e-07
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00100103,0.0010009657510119119,6.424898808810031e-08
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1524.0,1486.0,0.001312,0.001312,7.32975,0.208188,1.0,2207.0,6.0,27.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00200207,0.002010306571815477,8.23657181547692e-06
2.0,1524.0,1486.0,0.001312,0.001312,7.32975,0.208188,1.0,2207.0,6.0,27.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00200207,0.0020033047757738102,1.2347757738103392e-06
4.0,1524.0,1486.0,0.002625,0.002625,7.32975,0.208188,1.0,2207.0,6.0,27.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00400566,0.00404238211367064,3.672211367064006e-05
6.0,1524.0,1486.0,0.003937,0.003937,7.32975,0.208188,1.0,2207.0,6.0,27.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00600773,0.006120028112999644,0.00011229811299964376
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Randomized in error,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Randomized in error,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Randomized in error,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Randomized in error,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00100103,0.001001579225178579,5.492251785789871e-07
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00100103,0.0010001039485119094,9.260514880905357e-07
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00100103,0.001001640775178579,6.107751785789425e-07
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00100103,0.0010063950441369113,5.3650441369113705e-06
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00100103,0.0010005743593452434,4.5564065475657556e-07
1.0,1524.0,1486.0,0.000656,0.000656,7.32975,0.208188,1.0,2207.0,6.0,27.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00100103,0.001001976380178579,9.463801785790892e-07
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Physician Decision,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1524.0,1486.0,0.001312,0.001312,7.32975,0.208188,1.0,2207.0,6.0,27.0,Patient Disposition Challenges,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00200207,0.002010746986815477,8.676986815476986e-06
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Patient Disposition Challenges,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1524.0,1486.0,0.0,0.0,7.32975,0.208188,1.0,2207.0,6.0,27.0,Patient Disposition Challenges,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1524.0,1486.0,0.001969,0.001969,7.32975,0.208188,1.0,2207.0,6.0,27.0,Patient Disposition Challenges,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00300463,0.003004206894781733,4.2310521826708844e-07
22.0,1197.0,1122.0,0.018379,0.018379,7.088409,0.240569,1.0,1197.0,33.0,322.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03134077,0.031788316053095275,0.00044754605309527823
19.0,1197.0,1122.0,0.015873,0.015873,7.088409,0.240569,1.0,1197.0,33.0,322.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02706742,0.026840870991736113,0.0002265490082638856
156.0,1197.0,1122.0,0.130326,0.130326,7.088409,0.240569,1.0,1197.0,33.0,322.0,Study terminated by sponsor,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.22223827,0.21643033027024253,0.005807939729757461
148.0,1197.0,1122.0,0.123642,0.123642,7.088409,0.240569,1.0,1197.0,33.0,322.0,Study terminated by sponsor,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.21084039,0.2103678377093795,0.0004725522906204871
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Site closed by investigator,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014238989699999981,1.896999999814221e-08
2.0,1197.0,1122.0,0.001671,0.001671,7.088409,0.240569,1.0,1197.0,33.0,322.0,Site closed by investigator,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00284947,0.002857588788392858,8.11878839285761e-06
39.0,1197.0,1122.0,0.032581,0.032581,7.088409,0.240569,1.0,1197.0,33.0,322.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.05555872,0.05685037146542653,0.0012916514654265285
18.0,1197.0,1122.0,0.015038,0.015038,7.088409,0.240569,1.0,1197.0,33.0,322.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02564353,0.025681739333382927,3.8209333382926286e-05
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Physician Decision,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014251995199999984,1.3195199999984156e-06
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Physician Decision,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014252422492857125,1.362249285712493e-06
2.0,1197.0,1122.0,0.001671,0.001671,7.088409,0.240569,1.0,1197.0,33.0,322.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00284947,0.0028597496166071447,1.027961660714444e-05
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014240483326190456,1.6833261904563093e-07
6.0,1197.0,1122.0,0.005013,0.005013,7.088409,0.240569,1.0,1197.0,33.0,322.0,Clinical endpoint reached,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00854841,0.008639617732192458,9.120773219245884e-05
50.0,1197.0,1122.0,0.041771,0.041771,7.088409,0.240569,1.0,1197.0,33.0,322.0,Clinical endpoint reached,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.07122995,0.07367684003169646,0.002446890031696458
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Technical problems,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014238989699999981,1.896999999814221e-08
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Technical problems,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014244748699999985,5.948699999985037e-07
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014245175992857126,6.375992857125812e-07
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant convenience,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014239026949999984,2.2694999998436674e-08
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant convenience,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Protocol driven decision point,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014238989699999981,1.896999999814221e-08
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Protocol driven decision point,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014239416992857124,6.169928571243648e-08
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.001424301009999998,4.210099999980236e-07
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014243437392857125,4.637392857125347e-07
4.0,1197.0,1122.0,0.003342,0.003342,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant did not receive treatment,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00569894,0.005818752180337302,0.0001198121803373019
4.0,1197.0,1122.0,0.003342,0.003342,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant did not receive treatment,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00569894,0.005817649196884924,0.00011870919688492399
2.0,1197.0,1122.0,0.001671,0.001671,7.088409,0.240569,1.0,1197.0,33.0,322.0,Withdrawal by Subject,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00284947,0.00285797368327381,8.50368327380991e-06
2.0,1197.0,1122.0,0.001671,0.001671,7.088409,0.240569,1.0,1197.0,33.0,322.0,Withdrawal by Subject,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00284947,0.0028554427329761916,5.972732976191383e-06
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Lost to Follow-up,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Lost to Follow-up,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.001424899230833332,1.0192308333319394e-06
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Death,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1197.0,1122.0,0.001671,0.001671,7.088409,0.240569,1.0,1197.0,33.0,322.0,Death,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00284947,0.002853573565476192,4.103565476191572e-06
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Study termination by sponsor,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014245657358333316,6.857358333316015e-07
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Study termination by sponsor,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014241491108333314,2.6911083333145194e-07
3.0,1197.0,1122.0,0.002506,0.002506,7.088409,0.240569,1.0,1197.0,33.0,322.0,Clinical endpoint reached,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00427335,0.0043696661933035775,9.631619330357707e-05
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Clinical endpoint reached,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.00142388,0.0014241461308333316,2.6613083333165005e-07
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Technical problems,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014245627558333318,6.827558333317996e-07
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Technical problems,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1197.0,1122.0,0.000835,0.000835,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant convenience,Observational Period,FG000,cardiovascular disease,INDUSTRY,0.00142388,0.0014245664808333316,6.864808333316604e-07
0.0,1197.0,1122.0,0.0,0.0,7.088409,0.240569,1.0,1197.0,33.0,322.0,Participant convenience,Observational Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,376.0,354.0,0.005319,0.005319,5.932245,0.368375,1.0,376.0,7.0,51.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01162356,0.01164705117244047,2.3491172440470373e-05
5.0,376.0,354.0,0.013298,0.013298,5.932245,0.368375,1.0,376.0,7.0,51.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02905999,0.029326594075267866,0.000266604075267865
1.0,376.0,354.0,0.00266,0.00266,5.932245,0.368375,1.0,376.0,7.0,51.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00581287,0.005821134815813495,8.264815813494898e-06
0.0,376.0,354.0,0.0,0.0,5.932245,0.368375,1.0,376.0,7.0,51.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,376.0,354.0,0.0,0.0,5.932245,0.368375,1.0,376.0,7.0,51.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,376.0,354.0,0.00266,0.00266,5.932245,0.368375,1.0,376.0,7.0,51.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00581287,0.005819687600456354,6.817600456354017e-06
0.0,376.0,354.0,0.0,0.0,5.932245,0.368375,1.0,376.0,7.0,51.0,Non-compliance with study treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,376.0,354.0,0.00266,0.00266,5.932245,0.368375,1.0,376.0,7.0,51.0,Non-compliance with study treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00581287,0.005819308581706354,6.438581706353329e-06
0.0,376.0,354.0,0.0,0.0,5.932245,0.368375,1.0,376.0,7.0,51.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,376.0,354.0,0.005319,0.005319,5.932245,0.368375,1.0,376.0,7.0,51.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01162356,0.011646426465654756,2.2866465654755933e-05
3.0,376.0,354.0,0.007979,0.007979,5.932245,0.368375,1.0,376.0,7.0,51.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01743643,0.017408727805092013,2.770219490798656e-05
3.0,376.0,354.0,0.007979,0.007979,5.932245,0.368375,1.0,376.0,7.0,51.0,Protocol deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01743643,0.017420854194794395,1.5575805205603893e-05
3.0,376.0,354.0,0.007979,0.007979,5.932245,0.368375,1.0,376.0,7.0,51.0,Subject/guardian decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01743643,0.01739870674229439,3.772325770561025e-05
1.0,376.0,354.0,0.00266,0.00266,5.932245,0.368375,1.0,376.0,7.0,51.0,Subject/guardian decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00581287,0.005819308581706354,6.438581706353329e-06
1.0,235.0,232.0,0.004255,0.004255,5.463832,0.474896,1.0,235.0,9.0,45.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01104068,0.011066799295992025,2.611929599202409e-05
0.0,235.0,232.0,0.0,0.0,5.463832,0.474896,1.0,235.0,9.0,45.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,232.0,0.0,0.0,5.463832,0.474896,1.0,235.0,9.0,45.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,235.0,232.0,0.004255,0.004255,5.463832,0.474896,1.0,235.0,9.0,45.0,Personal Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01104068,0.01106968060283726,2.900060283725879e-05
0.0,235.0,232.0,0.0,0.0,5.463832,0.474896,1.0,235.0,9.0,45.0,Personal Reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,235.0,232.0,0.004255,0.004255,5.463832,0.474896,1.0,235.0,9.0,45.0,Personal Reasons,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01104068,0.011069985649831313,2.9305649831312328e-05
2.0,235.0,230.0,0.008511,0.008511,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew consent prior to randomization,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01713042,0.017154152988184512,2.3732988184511916e-05
1.0,235.0,230.0,0.004255,0.004255,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew consent prior to randomization,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0085642,0.008586038631101165,2.1838631101165837e-05
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew consent prior to randomization,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew consent prior to randomization,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,235.0,230.0,0.004255,0.004255,5.463832,0.368375,1.0,235.0,1.0,12.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0085642,0.008579608934970211,1.5408934970212104e-05
1.0,235.0,230.0,0.004255,0.004255,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0085642,0.008584434772886883,2.0234772886883884e-05
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew Consent,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,235.0,230.0,0.0,0.0,5.463832,0.368375,1.0,235.0,1.0,12.0,Withdrew Consent,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
36.0,543.0,417.0,0.066298,0.066298,6.298949,0.543961,1.0,543.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22716236,0.22641793609297634,0.0007444239070236724
33.0,543.0,417.0,0.060773,0.060773,6.298949,0.543961,1.0,543.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.20823159,0.211967125559008,0.0037355355590080186
0.0,543.0,417.0,0.0,0.0,6.298949,0.543961,1.0,543.0,1.0,24.0,Eligibility Criteria not Fulfilled,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,543.0,417.0,0.001842,0.001842,6.298949,0.543961,1.0,543.0,1.0,24.0,Eligibility Criteria not Fulfilled,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0063114,0.006313176464999998,1.7764649999979162e-06
17.0,543.0,417.0,0.031308,0.031308,6.298949,0.543961,1.0,543.0,1.0,24.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10727321,0.10608425059407747,0.0011889594059225211
11.0,543.0,417.0,0.020258,0.020258,6.298949,0.543961,1.0,543.0,1.0,24.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06941167,0.06814224275719254,0.0012694272428074582
1.0,543.0,417.0,0.001842,0.001842,6.298949,0.543961,1.0,543.0,1.0,24.0,Patient Specific Reasons,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0063114,0.006313161098869043,1.7610988690425905e-06
2.0,543.0,417.0,0.003683,0.003683,6.298949,0.543961,1.0,543.0,1.0,24.0,Patient Specific Reasons,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01261937,0.012571573384124292,4.779661587570733e-05
2.0,543.0,417.0,0.003683,0.003683,6.298949,0.543961,1.0,543.0,1.0,24.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01261937,0.012609226304540968,1.0143695459031293e-05
3.0,543.0,417.0,0.005525,0.005525,6.298949,0.543961,1.0,543.0,1.0,24.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01893077,0.018944533316855174,1.3763316855174013e-05
2.0,543.0,417.0,0.003683,0.003683,6.298949,0.543961,1.0,543.0,1.0,24.0,Non-compliance with Study Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01261937,0.01260605797540406,1.3312024595939567e-05
2.0,543.0,417.0,0.003683,0.003683,6.298949,0.543961,1.0,543.0,1.0,24.0,Non-compliance with Study Drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01261937,0.012578620521654054,4.074947834594583e-05
2.0,543.0,417.0,0.003683,0.003683,6.298949,0.543961,1.0,543.0,1.0,24.0,Met Withdrawal Criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01261937,0.012599010837874302,2.035916212569759e-05
14.0,543.0,417.0,0.025783,0.025783,6.298949,0.543961,1.0,543.0,1.0,24.0,Met Withdrawal Criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08834244,0.08375853785413691,0.004583902145863086
5.0,204.0,176.0,0.02451,0.02451,5.32301,0.230287,1.0,204.0,4.0,10.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03004489,0.030933290885605178,0.000888400885605177
3.0,204.0,176.0,0.014706,0.014706,5.32301,0.230287,1.0,204.0,4.0,10.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01802693,0.018165458696954424,0.0001385286969544236
1.0,204.0,176.0,0.004902,0.004902,5.32301,0.230287,1.0,204.0,4.0,10.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00600898,0.006038155335714286,2.917533571428644e-05
1.0,204.0,176.0,0.004902,0.004902,5.32301,0.230287,1.0,204.0,4.0,10.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00600898,0.0060527550148412705,4.377501484127081e-05
3.0,204.0,176.0,0.014706,0.014706,5.32301,0.230287,1.0,204.0,4.0,10.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01802693,0.018146174547073478,0.00011924454707347779
6.0,204.0,176.0,0.029412,0.029412,5.32301,0.230287,1.0,204.0,4.0,10.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03605387,0.037191755896458296,0.0011378858964582947
5.0,204.0,176.0,0.02451,0.02451,5.32301,0.230287,1.0,204.0,4.0,10.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03004489,0.030869546804771844,0.0008246568047718429
3.0,204.0,176.0,0.014706,0.014706,5.32301,0.230287,1.0,204.0,4.0,10.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01802693,0.018160579175287763,0.00013364917528776304
0.0,204.0,176.0,0.0,0.0,5.32301,0.230287,1.0,204.0,4.0,10.0,Abnormal aPPT Levels,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,204.0,176.0,0.004902,0.004902,5.32301,0.230287,1.0,204.0,4.0,10.0,Abnormal aPPT Levels,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00600898,0.006056494963621036,4.75149636210365e-05
1.0,257.0,253.0,0.003891,0.003891,5.55296,0.663366,1.0,257.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.01433306,0.015277068787023805,0.0009440087870238052
3.0,257.0,253.0,0.011673,0.011673,5.55296,0.663366,1.0,257.0,1.0,6.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.04299918,0.04393780770252973,0.0009386277025297332
1.0,3024.0,3009.0,0.000331,0.000331,8.014666,0.416574,1.0,3024.0,2.0,9.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.00110511,0.0011079837935714274,2.873793571427346e-06
5.0,3024.0,3009.0,0.001653,0.001653,8.014666,0.416574,1.0,3024.0,2.0,9.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00551887,0.0052750764470057675,0.00024379355299423283
2.0,3024.0,3009.0,0.000661,0.000661,8.014666,0.416574,1.0,3024.0,2.0,9.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,OTHER,0.00220688,0.002274155135416668,6.727513541666778e-05
3.0,3024.0,3009.0,0.000992,0.000992,8.014666,0.416574,1.0,3024.0,2.0,9.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00331199,0.003301823224015571,1.0166775984428878e-05
3.0,3024.0,3009.0,0.000992,0.000992,8.014666,0.416574,1.0,3024.0,2.0,9.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00331199,0.003312529646991763,5.396469917630375e-07
1.0,3024.0,3009.0,0.000331,0.000331,8.014666,0.416574,1.0,3024.0,2.0,9.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,OTHER,0.00110511,0.0011087500684722215,3.6400684722214492e-06
22.0,2139.0,98.0,0.010285,0.010285,7.668561,0.475348,1.0,2139.0,12.0,249.0,Other,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03749121,0.03746760673125998,2.3603268740020333e-05
22.0,2139.0,98.0,0.010285,0.010285,7.668561,0.475348,1.0,2139.0,12.0,249.0,Other,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03749121,0.037557988618541704,6.677861854170741e-05
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Other,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Other,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Other,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
71.0,2139.0,98.0,0.033193,0.033193,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.12099619,0.11963612982581352,0.001360060174186481
61.0,2139.0,98.0,0.028518,0.028518,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.10395473,0.10361667443017857,0.0003380555698214299
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrawal by Subject,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrawal by Subject,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrawal by Subject,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2139.0,98.0,0.000935,0.000935,7.668561,0.475348,1.0,2139.0,12.0,249.0,Did Not Meet Entrance Criteria,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00340829,0.003382828023123201,2.546197687679913e-05
3.0,2139.0,98.0,0.001403,0.001403,7.668561,0.475348,1.0,2139.0,12.0,249.0,Did Not Meet Entrance Criteria,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00511426,0.004838085926378973,0.0002761740736210265
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Did Not Meet Entrance Criteria,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Did Not Meet Entrance Criteria,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Did Not Meet Entrance Criteria,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
26.0,2139.0,98.0,0.012155,0.012155,7.668561,0.475348,1.0,2139.0,12.0,249.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0443078,0.04176030552706354,0.002547494472936458
31.0,2139.0,98.0,0.014493,0.014493,7.668561,0.475348,1.0,2139.0,12.0,249.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.05283035,0.05208173992053567,0.0007486100794643277
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Lost to Follow-up,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Lost to Follow-up,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Lost to Follow-up,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2139.0,98.0,0.000468,0.000468,7.668561,0.475348,1.0,2139.0,12.0,249.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00170597,0.0018382950658468622,0.00013232506584686223
2.0,2139.0,98.0,0.000935,0.000935,7.668561,0.475348,1.0,2139.0,12.0,249.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00340829,0.0033881109776686584,2.017902233134158e-05
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Protocol Violation,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Protocol Violation,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Protocol Violation,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,2139.0,98.0,0.004208,0.004208,7.668561,0.475348,1.0,2139.0,12.0,249.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01533914,0.015074651061964291,0.00026448893803570836
8.0,2139.0,98.0,0.00374,0.00374,7.668561,0.475348,1.0,2139.0,12.0,249.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01363317,0.013157800052291679,0.00047536994770832133
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Adverse Event,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Adverse Event,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Adverse Event,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,2139.0,98.0,0.004208,0.004208,7.668561,0.475348,1.0,2139.0,12.0,249.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01533914,0.015097137139047628,0.00024200286095237174
2.0,2139.0,98.0,0.000935,0.000935,7.668561,0.475348,1.0,2139.0,12.0,249.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00340829,0.0033835287019543716,2.4761298045628422e-05
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Death,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Death,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Death,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,2139.0,98.0,0.002805,0.002805,7.668561,0.475348,1.0,2139.0,12.0,249.0,Randomized Not Treated,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01022488,0.00961172279020021,0.00061315720979979
5.0,2139.0,98.0,0.002338,0.002338,7.668561,0.475348,1.0,2139.0,12.0,249.0,Randomized Not Treated,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00852255,0.008414125954265867,0.00010842404573413282
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Randomized Not Treated,Treatment Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Randomized Not Treated,Treatment Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Randomized Not Treated,Treatment Period,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrew Consent,Extension Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrew Consent,Extension Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,2139.0,98.0,0.000935,0.000935,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrew Consent,Extension Period,FG002,cardiovascular disease,INDUSTRY,0.00340829,0.0033688295958017715,3.946040419822855e-05
0.0,2139.0,98.0,0.0,0.0,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrew Consent,Extension Period,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,2139.0,98.0,0.002338,0.002338,7.668561,0.475348,1.0,2139.0,12.0,249.0,Withdrew Consent,Extension Period,FG004,cardiovascular disease,INDUSTRY,0.00852255,0.008426050012956343,9.649998704365677e-05
9.0,737.0,0.0,0.012212,0.012212,6.603944,0.889772,1.0,737.0,13.0,206.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07175773,0.07275639083470237,0.0009986608347023612
6.0,737.0,0.0,0.008141,0.008141,6.603944,0.889772,1.0,737.0,13.0,206.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04783653,0.048412150219027804,0.0005756202190278017
218.0,737.0,0.0,0.295794,0.295794,6.603944,0.889772,1.0,737.0,13.0,206.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.73808591,1.7030034715564362,0.035082438443563735
175.0,737.0,0.0,0.237449,0.237449,6.603944,0.889772,1.0,737.0,13.0,206.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.39525062,1.3348685846136588,0.06038203538634135
20.0,737.0,0.0,0.027137,0.027137,6.603944,0.889772,1.0,737.0,13.0,206.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15945705,0.15914558853708705,0.0003114614629129431
15.0,737.0,0.0,0.020353,0.020353,6.603944,0.889772,1.0,737.0,13.0,206.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11959425,0.12110170397620132,0.00150745397620132
0.0,737.0,0.0,0.0,0.0,6.603944,0.889772,1.0,737.0,13.0,206.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,737.0,0.0,0.001357,0.001357,6.603944,0.889772,1.0,737.0,13.0,206.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00797373,0.00802067011107141,4.694011107140954e-05
122.0,737.0,0.0,0.165536,0.165536,6.603944,0.889772,1.0,737.0,13.0,206.0,End of data collection,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.97268974,0.9254076464158533,0.0472820935841467
170.0,737.0,0.0,0.230665,0.230665,6.603944,0.889772,1.0,737.0,13.0,206.0,End of data collection,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.35538782,1.2135512450793149,0.14183657492068513
0.0,737.0,0.0,0.0,0.0,6.603944,0.889772,1.0,737.0,13.0,206.0,Site closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,737.0,0.0,0.001357,0.001357,6.603944,0.889772,1.0,737.0,13.0,206.0,Site closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00797373,0.008016590295238076,4.2860295238075774e-05
70.0,392.0,79.0,0.178571,0.178571,5.97381,0.580517,1.0,392.0,13.0,83.0,Lack of Response in OL period,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.61926634,0.6446349947433522,0.025368654743352148
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Lack of Response in OL period,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Lack of Response in OL period,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
27.0,392.0,79.0,0.068878,0.068878,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.238862,0.24821045967830369,0.009348459678303694
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Death,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.00884661,0.008837868697222206,8.741302777793766e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Death,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Death,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Lost to Follow-up,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.00884661,0.008829036301388872,1.7573698611127175e-05
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Lost to Follow-up,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Lost to Follow-up,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,392.0,79.0,0.012755,0.012755,5.97381,0.580517,1.0,392.0,13.0,83.0,Non-compliance with study drug,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.04423306,0.044163743887061645,6.931611293835294e-05
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Non-compliance with study drug,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Non-compliance with study drug,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.00884661,0.00883808144055554,8.52855944446021e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,392.0,79.0,0.010204,0.010204,5.97381,0.580517,1.0,392.0,13.0,83.0,Protocol Violation,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.03538645,0.03527671220311515,0.00010973779688484842
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Protocol Violation,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Protocol Violation,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
17.0,392.0,79.0,0.043367,0.043367,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.15039241,0.15121598733597216,0.0008235773359721588
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,392.0,79.0,0.020408,0.020408,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.0707729,0.07049809766230154,0.0002748023376984571
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
41.0,392.0,79.0,0.104592,0.104592,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Open-label Period,FG000,cardiovascular disease,INDUSTRY,0.36271458,0.3651409798674007,0.002426399867400675
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Open-label Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Open-label Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Relapse,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
15.0,392.0,79.0,0.038265,0.038265,5.97381,0.580517,1.0,392.0,13.0,83.0,Relapse,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.13269919,0.1320527994268651,0.0006463905731348973
34.0,392.0,79.0,0.086735,0.086735,5.97381,0.580517,1.0,392.0,13.0,83.0,Relapse,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.30078829,0.30255227944147817,0.0017639894414781532
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,392.0,79.0,0.007653,0.007653,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.02653984,0.02669994938074407,0.00016010938074407025
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Adverse Event,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.00884661,0.008845351592837282,1.2584071627172455e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Noncompliance with study drug,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Noncompliance with study drug,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Noncompliance with study drug,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.00884661,0.008845131738670615,1.4782613293844171e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.00884661,0.008850438431656726,3.828431656726847e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Use of prohibited medication,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Physician Decision,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Physician Decision,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Physician Decision,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.00884661,0.008844750938670615,1.859061329384168e-06
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,392.0,79.0,0.015306,0.015306,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.05307967,0.05280805240905756,0.0002716175909424426
4.0,392.0,79.0,0.010204,0.010204,5.97381,0.580517,1.0,392.0,13.0,83.0,Withdrawal by Subject,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.03538645,0.03537093670394848,1.5513296051518355e-05
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,392.0,79.0,0.002551,0.002551,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.00884661,0.008850225688323393,3.61568832339329e-06
5.0,392.0,79.0,0.012755,0.012755,5.97381,0.580517,1.0,392.0,13.0,83.0,Not otherwise specified,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.04423306,0.04428155935622831,4.84993562283112e-05
0.0,392.0,79.0,0.0,0.0,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Double-blind Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
35.0,392.0,79.0,0.089286,0.089286,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Double-blind Period,FG001,cardiovascular disease,INDUSTRY,0.3096349,0.3110855540386806,0.00145065403868061
31.0,392.0,79.0,0.079082,0.079082,5.97381,0.580517,1.0,392.0,13.0,83.0,Administrative discont. at study termination,Double-blind Period,FG002,cardiovascular disease,INDUSTRY,0.27424845,0.2870422946595535,0.012793844659553522
60.0,1980.0,1660.0,0.030303,0.030303,7.591357,0.49504,1.0,1980.0,41.0,394.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1138794,0.12507595375373856,0.011196553753738556
172.0,1980.0,1660.0,0.086869,0.086869,7.591357,0.49504,1.0,1980.0,41.0,394.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.32645578,0.3348958499094231,0.008440069909423142
1.0,1980.0,1660.0,0.000505,0.000505,7.591357,0.49504,1.0,1980.0,41.0,394.0,Study terminated by sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0018978,0.0021395781585714303,0.0002417781585714303
4.0,1980.0,1660.0,0.00202,0.00202,7.591357,0.49504,1.0,1980.0,41.0,394.0,Technical problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00759121,0.0074357942013293645,0.0001554157986706356
13.0,1980.0,1660.0,0.006566,0.006566,7.591357,0.49504,1.0,1980.0,41.0,394.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02467519,0.024327875025178594,0.0003473149748214055
21.0,1980.0,1660.0,0.010606,0.010606,7.591357,0.49504,1.0,1980.0,41.0,394.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0398576,0.03927209125148811,0.0005855087485118898
36.0,1980.0,1660.0,0.018182,0.018182,7.591357,0.49504,1.0,1980.0,41.0,394.0,Withdrawal by parent/guardian,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06832839,0.0679538358249396,0.0003745541750603959
10.0,1980.0,1660.0,0.005051,0.005051,7.591357,0.49504,1.0,1980.0,41.0,394.0,Non-compliance with study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01898178,0.019262774707130205,0.0002809947071302048
1.0,1980.0,1660.0,0.000505,0.000505,7.591357,0.49504,1.0,1980.0,41.0,394.0,Protocol deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0018978,0.0021395781585714303,0.0002417781585714303
2.0,1980.0,1660.0,0.00101,0.00101,7.591357,0.49504,1.0,1980.0,41.0,394.0,missing treatment disposition pages,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0037956,0.0038099016381547652,1.4301638154765126e-05
1.0,315.0,291.0,0.003175,0.003175,5.755742,0.577631,1.0,315.0,11.0,108.0,Noncompliance of scheduled visits,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0105559,0.010586699712886883,3.079971288688296e-05
2.0,315.0,291.0,0.006349,0.006349,5.755742,0.577631,1.0,315.0,11.0,108.0,Noncompliance of scheduled visits,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02110848,0.0212971618993209,0.00018868189932090204
1.0,315.0,291.0,0.003175,0.003175,5.755742,0.577631,1.0,315.0,11.0,108.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0105559,0.01059252502782736,3.662502782736041e-05
2.0,315.0,291.0,0.006349,0.006349,5.755742,0.577631,1.0,315.0,11.0,108.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02110848,0.021302264339231613,0.00019378433923161395
1.0,315.0,291.0,0.003175,0.003175,5.755742,0.577631,1.0,315.0,11.0,108.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0105559,0.01058550198163688,2.9601981636880048e-05
0.0,315.0,291.0,0.0,0.0,5.755742,0.577631,1.0,315.0,11.0,108.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,315.0,291.0,0.025397,0.025397,5.755742,0.577631,1.0,315.0,11.0,108.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08443723,0.08507871133133917,0.0006414813313391637
9.0,315.0,291.0,0.028571,0.028571,5.755742,0.577631,1.0,315.0,11.0,108.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09498981,0.0960961634837401,0.0011063534837401079
194.0,15526.0,13124.0,0.012495,0.012495,9.650336,0.286086,1.0,15526.0,43.0,556.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03449651,0.033883050858988045,0.0006134591410119558
147.0,15526.0,13124.0,0.009468,0.009468,9.650336,0.286086,1.0,15526.0,43.0,556.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0261395,0.025551126779404777,0.0005883732205952223
196.0,15526.0,13124.0,0.012624,0.012624,9.650336,0.286086,1.0,15526.0,43.0,556.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03485266,0.034193693252480124,0.0006589667475198763
17.0,15526.0,13124.0,0.001095,0.001095,9.650336,0.286086,1.0,15526.0,43.0,556.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0030231,0.0030738523734722208,5.075237347222086e-05
10.0,15526.0,13124.0,0.000644,0.000644,9.650336,0.286086,1.0,15526.0,43.0,556.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177797,0.0016881305040773809,8.983949592261914e-05
18.0,15526.0,13124.0,0.001159,0.001159,9.650336,0.286086,1.0,15526.0,43.0,556.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0031998,0.0031583698810317457,4.143011896825437e-05
405.0,15526.0,13124.0,0.026085,0.026085,9.650336,0.286086,1.0,15526.0,43.0,556.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07201613,0.07074939682160714,0.001266733178392862
448.0,15526.0,13124.0,0.028855,0.028855,9.650336,0.286086,1.0,15526.0,43.0,556.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07966362,0.07890922569782743,0.0007543943021725702
441.0,15526.0,13124.0,0.028404,0.028404,9.650336,0.286086,1.0,15526.0,43.0,556.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07841849,0.07742628052110122,0.0009922094788987756
167.0,15526.0,13124.0,0.010756,0.010756,9.650336,0.286086,1.0,15526.0,43.0,556.0,Other Reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02969544,0.029708695895178577,1.325589517857731e-05
170.0,15526.0,13124.0,0.010949,0.010949,9.650336,0.286086,1.0,15526.0,43.0,556.0,Other Reason,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03022828,0.03021688974440477,1.139025559522902e-05
189.0,15526.0,13124.0,0.012173,0.012173,9.650336,0.286086,1.0,15526.0,43.0,556.0,Other Reason,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.03360753,0.03330638954898805,0.00030114045101194836
3.0,486.0,445.0,0.006173,0.006173,6.188264,0.25113,1.0,407.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00959321,0.00958691981530752,6.290184692479134e-06
18.0,486.0,445.0,0.037037,0.037037,6.188264,0.25113,1.0,407.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0575577,0.05834348274190474,0.0007857827419047378
17.0,486.0,445.0,0.034979,0.034979,6.188264,0.25113,1.0,407.0,0.0,0.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05435944,0.053740711468005964,0.000618728531994038
3.0,486.0,445.0,0.006173,0.006173,6.188264,0.25113,1.0,407.0,0.0,0.0,Study device could not be deployed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00959321,0.009581510827807518,1.1699172192481191e-05
8.0,706.0,0.0,0.011331,0.011331,6.561031,0.741487,1.0,706.0,35.0,275.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05512439,0.054857043786150736,0.0002673462138492663
8.0,706.0,0.0,0.011331,0.011331,6.561031,0.741487,1.0,706.0,35.0,275.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05512439,0.054776234211051544,0.00034815578894845794
49.0,706.0,0.0,0.069405,0.069405,6.561031,0.741487,1.0,706.0,35.0,275.0,Withdrawal by Patient,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.33764966,0.3313935099138197,0.006256150086180301
76.0,706.0,0.0,0.107649,0.107649,6.561031,0.741487,1.0,706.0,35.0,275.0,Withdrawal by Patient,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.5237036,0.5061709398880949,0.01753266011190513
107.0,706.0,0.0,0.151558,0.151558,6.561031,0.741487,1.0,706.0,35.0,275.0,Reason not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.73731731,0.7268839973308933,0.010433312669106742
159.0,706.0,0.0,0.225212,0.225212,6.561031,0.741487,1.0,706.0,35.0,275.0,Reason not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.09563801,1.1072679746404062,0.01162996464040611
2.0,706.0,0.0,0.002833,0.002833,6.561031,0.741487,1.0,706.0,35.0,275.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01378231,0.013592563839146811,0.00018974616085318946
1.0,706.0,0.0,0.001416,0.001416,6.561031,0.741487,1.0,706.0,35.0,275.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00688872,0.006841183742643397,4.7536257356602975e-05
115.0,706.0,0.0,0.16289,0.16289,6.561031,0.741487,1.0,706.0,35.0,275.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.79244656,0.8272103794817468,0.03476381948174678
181.0,706.0,0.0,0.256374,0.256374,6.561031,0.741487,1.0,706.0,35.0,275.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,1.2472386,1.2547998948771613,0.007561294877161284
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,Main Period (MP) (up to 16 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,222.0,0.003906,0.003906,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,Main Period (MP) (up to 16 Weeks),FG001,cardiovascular disease,INDUSTRY,0.01206768,0.012177802937113095,0.00011012293711309441
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,Main Period (MP) (up to 16 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,Main Period (MP) (up to 16 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,Main Period (MP) (up to 16 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,256.0,222.0,0.007812,0.007812,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,Main Period (MP) (up to 16 Weeks),FG000,cardiovascular disease,INDUSTRY,0.02413536,0.024486724542817476,0.00035136454281747484
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,Main Period (MP) (up to 16 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,222.0,0.003906,0.003906,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,Main Period (MP) (up to 16 Weeks),FG002,cardiovascular disease,INDUSTRY,0.01206768,0.012175269861636908,0.0001075898616369076
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,Main Period (MP) (up to 16 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,Main Period (MP) (up to 16 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,Main Period (MP) (up to 16 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,222.0,0.003906,0.003906,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,Main Period (MP) (up to 16 Weeks),FG001,cardiovascular disease,INDUSTRY,0.01206768,0.012180835062529762,0.00011315506252976108
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,Main Period (MP) (up to 16 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,Main Period (MP) (up to 16 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,Main Period (MP) (up to 16 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,"Randomized, not Treated",Main Period (MP) (up to 16 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,"Randomized, not Treated",Main Period (MP) (up to 16 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,222.0,0.003906,0.003906,5.549076,0.556764,1.0,256.0,6.0,31.0,"Randomized, not Treated",Main Period (MP) (up to 16 Weeks),FG002,cardiovascular disease,INDUSTRY,0.01206768,0.012170742274136908,0.00010306227413690687
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,"Randomized, not Treated",Main Period (MP) (up to 16 Weeks),FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,"Randomized, not Treated",Main Period (MP) (up to 16 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Physician Decision,OLEX Period (up to 48 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Physician Decision,OLEX Period (up to 48 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Physician Decision,OLEX Period (up to 48 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,256.0,222.0,0.003906,0.003906,5.549076,0.556764,1.0,256.0,6.0,31.0,Physician Decision,OLEX Period (up to 48 Weeks),FG003,cardiovascular disease,INDUSTRY,0.01206768,0.0122065619072105,0.00013888190721049985
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Physician Decision,OLEX Period (up to 48 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lack of Efficacy,OLEX Period (up to 48 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lack of Efficacy,OLEX Period (up to 48 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lack of Efficacy,OLEX Period (up to 48 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,256.0,222.0,0.007812,0.007812,5.549076,0.556764,1.0,256.0,6.0,31.0,Lack of Efficacy,OLEX Period (up to 48 Weeks),FG003,cardiovascular disease,INDUSTRY,0.02413536,0.024359760978829373,0.00022440097882937132
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lack of Efficacy,OLEX Period (up to 48 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,OLEX Period (up to 48 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,OLEX Period (up to 48 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,OLEX Period (up to 48 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,256.0,222.0,0.015625,0.015625,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,OLEX Period (up to 48 Weeks),FG003,cardiovascular disease,INDUSTRY,0.04827381,0.04971722431097222,0.0014434143109722172
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Adverse Event,OLEX Period (up to 48 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,OLEX Period (up to 48 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,OLEX Period (up to 48 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,OLEX Period (up to 48 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,256.0,222.0,0.0625,0.0625,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,OLEX Period (up to 48 Weeks),FG003,cardiovascular disease,INDUSTRY,0.19309525,0.20321690396007916,0.010121653960079163
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Withdrawal by Subject,OLEX Period (up to 48 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,OLEX Period (up to 48 Weeks),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,OLEX Period (up to 48 Weeks),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,OLEX Period (up to 48 Weeks),FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,256.0,222.0,0.007812,0.007812,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,OLEX Period (up to 48 Weeks),FG003,cardiovascular disease,INDUSTRY,0.02413536,0.024370577535138896,0.00023521753513889437
0.0,256.0,222.0,0.0,0.0,5.549076,0.556764,1.0,256.0,6.0,31.0,Lost to Follow-up,OLEX Period (up to 48 Weeks),FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,311.0,267.0,0.019293,0.019293,5.743003,0.536396,1.0,349.0,1.0,35.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05943253,0.05962331435181547,0.00019078435181547199
3.0,311.0,267.0,0.009646,0.009646,5.743003,0.536396,1.0,349.0,1.0,35.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02971472,0.029623635363888897,9.108463611110298e-05
12.0,311.0,267.0,0.038585,0.038585,5.743003,0.536396,1.0,349.0,1.0,35.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11886197,0.1212500228057628,0.0023880528057628053
8.0,311.0,267.0,0.025723,0.025723,5.743003,0.536396,1.0,349.0,1.0,35.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07924029,0.07864553091753974,0.0005947590824602611
7.0,311.0,267.0,0.022508,0.022508,5.743003,0.536396,1.0,349.0,1.0,35.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06933641,0.06865921950022819,0.0006771904997718153
3.0,311.0,267.0,0.009646,0.009646,5.743003,0.536396,1.0,349.0,1.0,35.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02971472,0.029607252366329374,0.00010746763367062637
5.0,311.0,267.0,0.016077,0.016077,5.743003,0.536396,1.0,349.0,1.0,35.0,received a kidney transplant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04952557,0.04969237850238099,0.00016680850238099537
0.0,311.0,267.0,0.0,0.0,5.743003,0.536396,1.0,349.0,1.0,35.0,received a kidney transplant,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,445.0,438.0,0.008989,0.008989,6.100319,0.268071,1.0,445.0,7.0,50.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01469986,0.015031683854613094,0.000331823854613094
2.0,445.0,438.0,0.004494,0.004494,6.100319,0.268071,1.0,445.0,7.0,50.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00734911,0.007392653306466735,4.3543306466734856e-05
1.0,445.0,438.0,0.002247,0.002247,6.100319,0.268071,1.0,445.0,7.0,50.0,Reason not specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00367456,0.00364476557675595,2.9794423244049704e-05
0.0,445.0,438.0,0.0,0.0,6.100319,0.268071,1.0,445.0,7.0,50.0,Reason not specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
7.0,2725.0,2438.0,0.002569,0.002569,7.910591,0.471415,1.0,2725.0,41.0,421.0,Trial disease worsening,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00958023,0.009424707575803565,0.00015552242419643487
5.0,2725.0,2438.0,0.001835,0.001835,7.910591,0.471415,1.0,2725.0,41.0,421.0,Trial disease worsening,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00684302,0.0069358643271753275,9.284432717532754e-05
1.0,2725.0,2438.0,0.000367,0.000367,7.910591,0.471415,1.0,2725.0,41.0,421.0,Trial disease worsening,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0013686,0.0014312171790530307,6.26171790530307e-05
6.0,2725.0,2438.0,0.002202,0.002202,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other pre-existing disease worsening,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00821163,0.008251604518392856,3.997451839285633e-05
4.0,2725.0,2438.0,0.001468,0.001468,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other pre-existing disease worsening,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00547442,0.00547331484963837,1.105150361629774e-06
9.0,2725.0,2438.0,0.003303,0.003303,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other pre-existing disease worsening,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01231744,0.011650751822291671,0.0006666881777083293
52.0,2725.0,2438.0,0.019083,0.019083,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other Adverse Event (AE),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07116372,0.07003227060701384,0.001131449392986164
32.0,2725.0,2438.0,0.011743,0.011743,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other Adverse Event (AE),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04379162,0.04322378157422624,0.0005678384257737645
49.0,2725.0,2438.0,0.017982,0.017982,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other Adverse Event (AE),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0670579,0.06800011421725198,0.0009422142172519771
2.0,2725.0,2438.0,0.000734,0.000734,7.910591,0.471415,1.0,2725.0,41.0,421.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00273721,0.00284401948815476,0.00010680948815475991
4.0,2725.0,2438.0,0.001468,0.001468,7.910591,0.471415,1.0,2725.0,41.0,421.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00547442,0.005469440677971701,4.979322028298566e-06
1.0,2725.0,2438.0,0.000367,0.000367,7.910591,0.471415,1.0,2725.0,41.0,421.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0013686,0.0014281890963446975,5.9589096344697494e-05
4.0,2725.0,2438.0,0.001468,0.001468,7.910591,0.471415,1.0,2725.0,41.0,421.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00547442,0.005467174284479636,7.245715520363787e-06
3.0,2725.0,2438.0,0.001101,0.001101,7.910591,0.471415,1.0,2725.0,41.0,421.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00410581,0.004111956272420633,6.146272420633203e-06
2.0,2725.0,2438.0,0.000734,0.000734,7.910591,0.471415,1.0,2725.0,41.0,421.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00273721,0.0028532740426785693,0.00011606404267856937
21.0,2725.0,2438.0,0.007706,0.007706,7.910591,0.471415,1.0,2725.0,41.0,421.0,"Consent withdrawn, not due to AE",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02873697,0.028983157289712295,0.00024618728971229423
8.0,2725.0,2438.0,0.002936,0.002936,7.910591,0.471415,1.0,2725.0,41.0,421.0,"Consent withdrawn, not due to AE",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01094884,0.010709491998900606,0.00023934800109939348
56.0,2725.0,2438.0,0.02055,0.02055,7.910591,0.471415,1.0,2725.0,41.0,421.0,"Consent withdrawn, not due to AE",Overall Study,FG002,cardiovascular disease,INDUSTRY,0.07663441,0.07527471070562493,0.0013596992943750719
3.0,2725.0,2438.0,0.001101,0.001101,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other than stated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00410581,0.0040983176411408685,7.492358859131215e-06
4.0,2725.0,2438.0,0.001468,0.001468,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other than stated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00547442,0.00547331484963837,1.105150361629774e-06
14.0,2725.0,2438.0,0.005138,0.005138,7.910591,0.471415,1.0,2725.0,41.0,421.0,Other than stated,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01916047,0.019193484326785696,3.3014326785697073e-05
5.0,236.0,199.0,0.021186,0.021186,5.46806,0.607876,1.0,236.0,3.0,21.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07042022,0.07115829315434526,0.0007380731543452507
6.0,236.0,199.0,0.025424,0.025424,5.46806,0.607876,1.0,236.0,3.0,21.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08450692,0.08369531287071423,0.0008116071292857685
3.0,236.0,199.0,0.012712,0.012712,5.46806,0.607876,1.0,236.0,3.0,21.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04225346,0.042765848009502144,0.0005123880095021446
1.0,236.0,199.0,0.004237,0.004237,5.46806,0.607876,1.0,236.0,3.0,21.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01408338,0.014270879351339272,0.0001874993513392726
0.0,236.0,199.0,0.0,0.0,5.46806,0.607876,1.0,236.0,3.0,21.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,236.0,199.0,0.004237,0.004237,5.46806,0.607876,1.0,236.0,3.0,21.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01408338,0.014259510065922605,0.00017613006592260595
4.0,236.0,199.0,0.016949,0.016949,5.46806,0.607876,1.0,236.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05633684,0.05749574651401788,0.001158906514017878
7.0,236.0,199.0,0.029661,0.029661,5.46806,0.607876,1.0,236.0,3.0,21.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0985903,0.10106641984182539,0.002476119841825386
3.0,236.0,199.0,0.012712,0.012712,5.46806,0.607876,1.0,236.0,3.0,21.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04225346,0.042725485171168816,0.00047202517116881615
4.0,236.0,199.0,0.016949,0.016949,5.46806,0.607876,1.0,236.0,3.0,21.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05633684,0.05738643038100198,0.001049590381001983
1.0,236.0,199.0,0.004237,0.004237,5.46806,0.607876,1.0,236.0,3.0,21.0,One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01408338,0.014265839063124992,0.00018245906312499248
2.0,236.0,199.0,0.008475,0.008475,5.46806,0.607876,1.0,236.0,3.0,21.0,One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02817008,0.02844273293205355,0.0002726529320535506
9.0,245.0,224.0,0.036735,0.036735,5.505332,0.220602,1.0,245.0,1.0,2.0,Technical Failure,Procedure,FG000,cardiovascular disease,INDUSTRY,0.04461427,0.04876304952318449,0.004148779523184494
2.0,245.0,224.0,0.008163,0.008163,5.505332,0.220602,1.0,245.0,1.0,2.0,Death / Reintervention / Medical Reasons,Follow-up Through 30 Days Post Procedure,FG000,cardiovascular disease,INDUSTRY,0.00991388,0.010131688966296909,0.0002178089662969087
6.0,245.0,224.0,0.02449,0.02449,5.505332,0.220602,1.0,245.0,1.0,2.0,Discontinued Prior to Visit,Follow-up Through 30 Days Post Procedure,FG000,cardiovascular disease,INDUSTRY,0.02974285,0.030427563489315523,0.0006847134893155221
4.0,245.0,224.0,0.016327,0.016327,5.505332,0.220602,1.0,245.0,1.0,2.0,Missed Visit - Phone Contact Follow-up,Follow-up Through 30 Days Post Procedure,FG000,cardiovascular disease,INDUSTRY,0.01982897,0.020125186261667576,0.00029621626166757495
91.0,3883.0,3575.0,0.023435,0.023435,8.264621,0.301566,1.0,3883.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05840781,0.05622886705698865,0.0021789429430113458
98.0,3883.0,3575.0,0.025238,0.025238,8.264621,0.301566,1.0,3883.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06290149,0.061708994844623,0.0011924951553770047
58.0,3883.0,3575.0,0.014937,0.014937,8.264621,0.301566,1.0,3883.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03722797,0.03482650235634918,0.0024014676436508176
61.0,3883.0,3575.0,0.01571,0.01571,8.264621,0.301566,1.0,3883.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03915454,0.038121877450833265,0.0010326625491667366
28.0,1071.0,892.0,0.026144,0.026144,6.977281,0.266168,1.0,1071.0,2.0,94.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04855285,0.048050854617718256,0.0005019953822817461
51.0,1071.0,892.0,0.047619,0.047619,6.977281,0.266168,1.0,1071.0,2.0,94.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08843474,0.08945469817869045,0.0010199581786904527
26.0,1071.0,892.0,0.024276,0.024276,6.977281,0.266168,1.0,1071.0,2.0,94.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.04508372,0.045266872073670646,0.0001831520736706449
0.0,1071.0,892.0,0.0,0.0,6.977281,0.266168,1.0,1071.0,2.0,94.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1071.0,892.0,0.001867,0.001867,6.977281,0.266168,1.0,1071.0,2.0,94.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00346726,0.0037236641246428527,0.0002564041246428529
1.0,1071.0,892.0,0.000934,0.000934,6.977281,0.266168,1.0,1071.0,2.0,94.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00173456,0.001737996825853178,3.4368258531780518e-06
4.0,1071.0,892.0,0.003735,0.003735,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00693639,0.00695947364560604,2.3083645606040114e-05
5.0,1071.0,892.0,0.004669,0.004669,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00867095,0.008702239880952376,3.12898809523756e-05
5.0,1071.0,892.0,0.004669,0.004669,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00867095,0.008695080137916663,2.4130137916663144e-05
17.0,1071.0,892.0,0.015873,0.015873,6.977281,0.266168,1.0,1071.0,2.0,94.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02947825,0.029705434241785705,0.00022718424178570437
14.0,1071.0,892.0,0.013072,0.013072,6.977281,0.266168,1.0,1071.0,2.0,94.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02427642,0.024602790142361126,0.0003263701423611258
11.0,1071.0,892.0,0.010271,0.010271,6.977281,0.266168,1.0,1071.0,2.0,94.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0190746,0.019458538993109686,0.0003839389931096851
0.0,1071.0,892.0,0.0,0.0,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1071.0,892.0,0.000934,0.000934,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00173456,0.0017371999053769876,2.6399053769876005e-06
1.0,1071.0,892.0,0.000934,0.000934,6.977281,0.266168,1.0,1071.0,2.0,94.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00173456,0.0017357376563293695,1.1776563293695343e-06
6.0,1071.0,892.0,0.005602,0.005602,6.977281,0.266168,1.0,1071.0,2.0,94.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01040365,0.010464012037450399,6.0362037450398254e-05
4.0,1071.0,892.0,0.003735,0.003735,6.977281,0.266168,1.0,1071.0,2.0,94.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00693639,0.006970686204384904,3.4296204384904466e-05
3.0,1071.0,892.0,0.002801,0.002801,6.977281,0.266168,1.0,1071.0,2.0,94.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00520183,0.005048556918035713,0.00015327308196428756
25.0,15828.0,15277.0,0.001579,0.001579,9.669599,0.344032,1.0,15828.0,39.0,650.0,Investigator Site Closed,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00525279,0.005154902481636906,9.788751836309426e-05
23.0,15828.0,15277.0,0.001453,0.001453,9.669599,0.344032,1.0,15828.0,39.0,650.0,Investigator Site Closed,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00483363,0.0046954534197086945,0.00013817658029130573
179.0,15828.0,15277.0,0.011309,0.011309,9.669599,0.344032,1.0,15828.0,39.0,650.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03762115,0.034345335197916646,0.003275814802083353
175.0,15828.0,15277.0,0.011056,0.011056,9.669599,0.344032,1.0,15828.0,39.0,650.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0367795,0.034499486683472205,0.0022800133165277944
69.0,15828.0,15277.0,0.004359,0.004359,9.669599,0.344032,1.0,15828.0,39.0,650.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01450089,0.013510483492649723,0.0009904065073502773
80.0,15828.0,15277.0,0.005054,0.005054,9.669599,0.344032,1.0,15828.0,39.0,650.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01681292,0.014456371669733032,0.0023565483302669665
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,1134.0,871.0,0.007937,0.007937,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.01145644,0.011516654011626966,6.021401162696616e-05
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lack of Efficacy,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1134.0,871.0,0.004409,0.004409,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lack of Efficacy,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.00636405,0.006466509606818171,0.00010245960681817129
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lack of Efficacy,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject no longer requires study drug,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
151.0,1134.0,871.0,0.133157,0.133157,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject no longer requires study drug,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.19220178,0.19422510599310525,0.002023325993105257
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject no longer requires study drug,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol Violation,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,1134.0,871.0,0.014109,0.014109,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol Violation,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.02036524,0.02043665123497024,7.141123497024157e-05
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol Violation,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Withdrawal by Subject,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
27.0,1134.0,871.0,0.02381,0.02381,7.034388,0.205195,1.0,1134.0,1.0,19.0,Withdrawal by Subject,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.03436788,0.03536102255658731,0.0009931425565873064
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Withdrawal by Subject,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Single-Blind,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,1134.0,871.0,0.007055,0.007055,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Single-Blind,FG001,cardiovascular disease,INDUSTRY,0.01018334,0.010265146077142852,8.180607714285137e-05
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Single-Blind,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,1134.0,871.0,0.005291,0.005291,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00763715,0.007672373611845235,3.522361184523509e-05
0.0,1134.0,871.0,0.0,0.0,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,1134.0,871.0,0.004409,0.004409,7.034388,0.205195,1.0,1134.0,1.0,19.0,Adverse Event,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.00636405,0.0064741948351515035,0.0001101448351515039
1.0,1134.0,871.0,0.000882,0.000882,7.034388,0.205195,1.0,1134.0,1.0,19.0,Unsatisfactory therapeutic effect,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.0012731,0.0012799272063988157,6.827206398815622e-06
2.0,1134.0,871.0,0.001764,0.001764,7.034388,0.205195,1.0,1134.0,1.0,19.0,Unsatisfactory therapeutic effect,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.0025462,0.002555408862776265,9.208862776264627e-06
1.0,1134.0,871.0,0.000882,0.000882,7.034388,0.205195,1.0,1134.0,1.0,19.0,Unsatisfactory therapeutic effect,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0012731,0.001279292531398817,6.192531398816793e-06
1.0,1134.0,871.0,0.000882,0.000882,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol deviation,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.0012731,0.0012796638938988162,6.5638938988160905e-06
2.0,1134.0,871.0,0.001764,0.001764,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol deviation,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.0025462,0.002555842175276265,9.642175276264667e-06
1.0,1134.0,871.0,0.000882,0.000882,7.034388,0.205195,1.0,1134.0,1.0,19.0,Protocol deviation,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0012731,0.001279029218898817,5.929218898816828e-06
4.0,1134.0,871.0,0.003527,0.003527,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject withdrew consent,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.00509095,0.005198633760267862,0.0001076837602678616
6.0,1134.0,871.0,0.005291,0.005291,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject withdrew consent,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.00763715,0.007681388649940476,4.42386499404767e-05
9.0,1134.0,871.0,0.007937,0.007937,7.034388,0.205195,1.0,1134.0,1.0,19.0,Subject withdrew consent,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.01145644,0.011506588829246012,5.0148829246011994e-05
3.0,1134.0,871.0,0.002646,0.002646,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Double-Blind,FG000,cardiovascular disease,INDUSTRY,0.0038193,0.00378797333299513,3.132666700486966e-05
4.0,1134.0,871.0,0.003527,0.003527,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Double-Blind,FG001,cardiovascular disease,INDUSTRY,0.00509095,0.005197107611041672,0.00010615761104167207
2.0,1134.0,871.0,0.001764,0.001764,7.034388,0.205195,1.0,1134.0,1.0,19.0,Lost to Follow-up,Double-Blind,FG002,cardiovascular disease,INDUSTRY,0.0025462,0.0025547716961095974,8.571696109597234e-06
22.0,572.0,397.0,0.038462,0.038462,6.350886,0.441414,1.0,572.0,2.0,34.0,Exited prior to EP study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1078233,0.1040103444705456,0.0038129555294544037
151.0,572.0,397.0,0.263986,0.263986,6.350886,0.441414,1.0,572.0,2.0,34.0,Inclusion/exclusion criteria not met,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.74005101,0.7267546153167558,0.013296394683244173
2.0,572.0,397.0,0.003497,0.003497,6.350886,0.441414,1.0,572.0,2.0,34.0,"Met inclusion/exclusion, not treated",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00980339,0.009842434392271691,3.9044392271691056e-05
27.0,291.0,0.0,0.092784,0.092784,5.676754,0.739553,1.0,291.0,16.0,97.0,Withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.38953154,0.38873507339058533,0.0007964666094146811
11.0,291.0,0.0,0.037801,0.037801,5.676754,0.739553,1.0,291.0,16.0,97.0,Withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1586985,0.16154857041367504,0.0028500704136750488
1.0,291.0,0.0,0.003436,0.003436,5.676754,0.739553,1.0,291.0,16.0,97.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01442523,0.014504448869484123,7.921886948412254e-05
0.0,291.0,0.0,0.0,0.0,5.676754,0.739553,1.0,291.0,16.0,97.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
78.0,291.0,0.0,0.268041,0.268041,5.676754,0.739553,1.0,291.0,16.0,97.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,1.12530634,1.1592538560460213,0.0339475160460212
36.0,291.0,0.0,0.123711,0.123711,5.676754,0.739553,1.0,291.0,16.0,97.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.51937119,0.5889031493096725,0.06953195930967249
67.0,291.0,0.0,0.230241,0.230241,5.676754,0.739553,1.0,291.0,16.0,97.0,Study terminated by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.96661204,1.0127149713540282,0.04610293135402821
47.0,291.0,0.0,0.161512,0.161512,5.676754,0.739553,1.0,291.0,16.0,97.0,Study terminated by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.67806969,0.7732903769513702,0.0952206869513702
20.0,291.0,0.0,0.068729,0.068729,5.676754,0.739553,1.0,291.0,16.0,97.0,"Other, not specified",Overall Study,FG000,cardiovascular disease,INDUSTRY,0.28854235,0.2923199484156646,0.003777598415664607
3.0,291.0,0.0,0.010309,0.010309,5.676754,0.739553,1.0,291.0,16.0,97.0,"Other, not specified",Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04327988,0.0437279332050893,0.0004480532050893035
1.0,291.0,0.0,0.003436,0.003436,5.676754,0.739553,1.0,291.0,16.0,97.0,Participant missing reason for study discontinuation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01442523,0.014499032397400793,7.380239740079238e-05
0.0,291.0,0.0,0.0,0.0,5.676754,0.739553,1.0,291.0,16.0,97.0,Participant missing reason for study discontinuation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,647.0,623.0,0.004637,0.004637,6.473891,0.305312,1.0,646.0,1.0,89.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00916529,0.009180350011051575,1.5060011051575353e-05
7.0,647.0,623.0,0.010819,0.010819,6.473891,0.305312,1.0,646.0,1.0,89.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02138436,0.021272132557450387,0.00011222744254961448
2.0,647.0,623.0,0.003091,0.003091,6.473891,0.305312,1.0,646.0,1.0,89.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00610954,0.0060739406039583355,3.5599396041664615e-05
0.0,647.0,623.0,0.0,0.0,6.473891,0.305312,1.0,646.0,1.0,89.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,647.0,623.0,0.001546,0.001546,6.473891,0.305312,1.0,646.0,1.0,89.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00305576,0.0030560362406845255,2.76240684525704e-07
2.0,647.0,623.0,0.003091,0.003091,6.473891,0.305312,1.0,646.0,1.0,89.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00610954,0.006073154953958335,3.638504604166516e-05
2.0,647.0,623.0,0.003091,0.003091,6.473891,0.305312,1.0,646.0,1.0,89.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00610954,0.0060719133719345265,3.7626628065473566e-05
3.0,647.0,623.0,0.004637,0.004637,6.473891,0.305312,1.0,646.0,1.0,89.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00916529,0.009178219760119042,1.2929760119042427e-05
1.0,647.0,623.0,0.001546,0.001546,6.473891,0.305312,1.0,646.0,1.0,89.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00305576,0.0030533422266666686,2.4177733333311836e-06
0.0,647.0,623.0,0.0,0.0,6.473891,0.305312,1.0,646.0,1.0,89.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,647.0,623.0,0.001546,0.001546,6.473891,0.305312,1.0,646.0,1.0,89.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00305576,0.0030541999984226203,1.5600015773795627e-06
0.0,647.0,623.0,0.0,0.0,6.473891,0.305312,1.0,646.0,1.0,89.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,647.0,623.0,0.001546,0.001546,6.473891,0.305312,1.0,646.0,1.0,89.0,Noncompliance,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00305576,0.0030500382335416684,5.721766458331463e-06
0.0,647.0,623.0,0.0,0.0,6.473891,0.305312,1.0,646.0,1.0,89.0,Noncompliance,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,647.0,623.0,0.001546,0.001546,6.473891,0.305312,1.0,646.0,1.0,89.0,Noncompliance,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00305576,0.0030527419250000014,3.0180749999984303e-06
0.0,2198.0,2164.0,0.0,0.0,7.695758,0.368375,1.0,2198.0,9.0,145.0,1 Year Visit Too Early (<335 days),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2198.0,2164.0,0.000455,0.000455,7.695758,0.368375,1.0,2198.0,9.0,145.0,1 Year Visit Too Early (<335 days),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00128989,0.0013037960086111117,1.3906008611111768e-05
10.0,2198.0,2164.0,0.00455,0.00455,7.695758,0.368375,1.0,2198.0,9.0,145.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0128989,0.012701659636597237,0.0001972403634027623
13.0,2198.0,2164.0,0.005914,0.005914,7.695758,0.368375,1.0,2198.0,9.0,145.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01676574,0.016749099143273834,1.6640856726167497e-05
2.0,2198.0,2164.0,0.00091,0.00091,7.695758,0.368375,1.0,2198.0,9.0,145.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00257978,0.002567942704722225,1.1837295277774672e-05
0.0,2198.0,2164.0,0.0,0.0,7.695758,0.368375,1.0,2198.0,9.0,145.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,2198.0,2164.0,0.000455,0.000455,7.695758,0.368375,1.0,2198.0,9.0,145.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00128989,0.0013036828442658736,1.3792844265873676e-05
4.0,2198.0,2164.0,0.00182,0.00182,7.695758,0.368375,1.0,2198.0,9.0,145.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00515956,0.005401430545982151,0.00024187054598215092
1.0,2198.0,2164.0,0.000455,0.000455,7.695758,0.368375,1.0,2198.0,9.0,145.0,Reason Not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00128989,0.0013021176386706355,1.2227638670635546e-05
2.0,2198.0,2164.0,0.00091,0.00091,7.695758,0.368375,1.0,2198.0,9.0,145.0,Reason Not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00257978,0.002565509309841273,1.4270690158726864e-05
2.0,263.0,240.0,0.007605,0.007605,5.575949,0.769825,1.0,266.0,1.0,24.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03264451,0.03413870049698573,0.0014941904969857298
0.0,263.0,240.0,0.0,0.0,5.575949,0.769825,1.0,266.0,1.0,24.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,263.0,240.0,0.0,0.0,5.575949,0.769825,1.0,266.0,1.0,24.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,263.0,240.0,0.003802,0.003802,5.575949,0.769825,1.0,266.0,1.0,24.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01632011,0.016654782096011896,0.0003346720960118975
3.0,263.0,240.0,0.011407,0.011407,5.575949,0.769825,1.0,266.0,1.0,24.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04896462,0.049197469991893936,0.0002328499918939353
1.0,263.0,240.0,0.003802,0.003802,5.575949,0.769825,1.0,266.0,1.0,24.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01632011,0.016631728351369036,0.00031161835136903765
0.0,263.0,240.0,0.0,0.0,5.575949,0.769825,1.0,266.0,1.0,24.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,263.0,240.0,0.003802,0.003802,5.575949,0.769825,1.0,266.0,1.0,24.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01632011,0.016614278482619038,0.0002941684826190394
7.0,263.0,240.0,0.026616,0.026616,5.575949,0.769825,1.0,266.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11424934,0.11519940799071426,0.0009500679907142595
8.0,263.0,240.0,0.030418,0.030418,5.575949,0.769825,1.0,266.0,1.0,24.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.13056945,0.13563176599567447,0.005062315995674471
3.0,415.0,365.0,0.007229,0.007229,6.030685,0.231988,1.0,413.0,2.0,64.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01011372,0.010015530924196457,9.818907580354252e-05
3.0,415.0,365.0,0.007229,0.007229,6.030685,0.231988,1.0,413.0,2.0,64.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01011372,0.01001936098538693,9.435901461306989e-05
1.0,415.0,365.0,0.00241,0.00241,6.030685,0.231988,1.0,413.0,2.0,64.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00337171,0.003389610561755944,1.7900561755944226e-05
2.0,415.0,365.0,0.004819,0.004819,6.030685,0.231988,1.0,413.0,2.0,64.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00674201,0.006757216272837283,1.5206272837283395e-05
2.0,415.0,365.0,0.004819,0.004819,6.030685,0.231988,1.0,413.0,2.0,64.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00674201,0.006748977882063472,6.967882063472694e-06
2.0,415.0,365.0,0.004819,0.004819,6.030685,0.231988,1.0,413.0,2.0,64.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00674201,0.006758945468015856,1.6935468015856145e-05
2.0,415.0,365.0,0.004819,0.004819,6.030685,0.231988,1.0,413.0,2.0,64.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00674201,0.006755145360158713,1.3135360158713673e-05
4.0,415.0,365.0,0.009639,0.009639,6.030685,0.231988,1.0,413.0,2.0,64.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01348542,0.013507379997926576,2.1959997926576658e-05
0.0,415.0,365.0,0.0,0.0,6.030685,0.231988,1.0,413.0,2.0,64.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,415.0,365.0,0.00241,0.00241,6.030685,0.231988,1.0,413.0,2.0,64.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00337171,0.003388764712053563,1.70547120535631e-05
7.0,415.0,365.0,0.016867,0.016867,6.030685,0.231988,1.0,413.0,2.0,64.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02359774,0.02396527810650793,0.00036753810650793153
6.0,415.0,365.0,0.014458,0.014458,6.030685,0.231988,1.0,413.0,2.0,64.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02022743,0.019931180355396812,0.0002962496446031887
1.0,415.0,365.0,0.00241,0.00241,6.030685,0.231988,1.0,413.0,2.0,64.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00337171,0.003390041359077373,1.8331359077373207e-05
0.0,415.0,365.0,0.0,0.0,6.030685,0.231988,1.0,413.0,2.0,64.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,415.0,365.0,0.007229,0.007229,6.030685,0.231988,1.0,413.0,2.0,64.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01011372,0.010016929662767881,9.679033723211834e-05
5.0,415.0,365.0,0.012048,0.012048,6.030685,0.231988,1.0,413.0,2.0,64.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01685573,0.016915081565148822,5.935156514882273e-05
5.0,415.0,365.0,0.012048,0.012048,6.030685,0.231988,1.0,413.0,2.0,64.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01685573,0.016865971146636925,1.0241146636925935e-05
3.0,415.0,365.0,0.007229,0.007229,6.030685,0.231988,1.0,413.0,2.0,64.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01011372,0.010021189165267883,9.253083473211715e-05
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191404,0.001913461734999987,5.782650000130292e-07
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00191404,0.0019128129153571309,1.2270846428692316e-06
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Missing,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00191404,0.0019132517011904633,7.882988095368401e-07
9.0,819.0,780.0,0.010989,0.010989,6.709304,0.233646,1.0,965.0,10.0,18.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01722639,0.017252495014027782,2.61050140277809e-05
4.0,819.0,780.0,0.004884,0.004884,6.709304,0.233646,1.0,965.0,10.0,18.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00765617,0.0077099938279762015,5.382382797620121e-05
3.0,819.0,780.0,0.003663,0.003663,6.709304,0.233646,1.0,965.0,10.0,18.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00574213,0.005745859865009908,3.7298650099083785e-06
0.0,819.0,780.0,0.0,0.0,6.709304,0.233646,1.0,965.0,10.0,18.0,Abnormal test procedure result(s),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,819.0,780.0,0.0,0.0,6.709304,0.233646,1.0,965.0,10.0,18.0,Abnormal test procedure result(s),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Abnormal test procedure result(s),Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00191404,0.0019132339970237978,8.060029762022979e-07
0.0,819.0,780.0,0.0,0.0,6.709304,0.233646,1.0,965.0,10.0,18.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,819.0,780.0,0.0,0.0,6.709304,0.233646,1.0,965.0,10.0,18.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00191404,0.0019132719136904645,7.680863095356396e-07
3.0,819.0,780.0,0.003663,0.003663,6.709304,0.233646,1.0,965.0,10.0,18.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00574213,0.00574605882306547,3.9288230654702105e-06
2.0,819.0,780.0,0.002442,0.002442,6.709304,0.233646,1.0,965.0,10.0,18.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00382809,0.003825728742264619,2.361257735380984e-06
4.0,819.0,780.0,0.004884,0.004884,6.709304,0.233646,1.0,965.0,10.0,18.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00765617,0.007697998805694452,4.182880569445196e-05
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00191404,0.0019134477224999882,5.922775000118986e-07
3.0,819.0,780.0,0.003663,0.003663,6.709304,0.233646,1.0,965.0,10.0,18.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00574213,0.005760153482093243,1.802348209324362e-05
1.0,819.0,780.0,0.001221,0.001221,6.709304,0.233646,1.0,965.0,10.0,18.0,Administrative problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00191404,0.0019132426386904641,7.973613095359731e-07
2.0,819.0,780.0,0.002442,0.002442,6.709304,0.233646,1.0,965.0,10.0,18.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00382809,0.003833494994228906,5.404994228905887e-06
2.0,819.0,780.0,0.002442,0.002442,6.709304,0.233646,1.0,965.0,10.0,18.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00382809,0.0038303755268479516,2.285526847951424e-06
0.0,819.0,780.0,0.0,0.0,6.709304,0.233646,1.0,965.0,10.0,18.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,201.0,200.0,0.0,0.0,5.308268,0.643819,1.0,213.0,1.0,1.0,surgery cancellation,Overall Study,FG000,cardiovascular disease,OTHER,0.0,0.0,0.0
1.0,201.0,200.0,0.004975,0.004975,5.308268,0.643819,1.0,213.0,1.0,1.0,surgery cancellation,Overall Study,FG001,cardiovascular disease,OTHER,0.01700237,0.01739559355702378,0.00039322355702377937
16.0,216.0,166.0,0.074074,0.074074,5.379897,0.83295,1.0,216.0,27.0,79.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.33193924,0.3527847008729858,0.020845460872985777
1.0,216.0,166.0,0.00463,0.00463,5.379897,0.83295,1.0,216.0,27.0,79.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02074788,0.020827532160754,7.965216075399989e-05
6.0,216.0,166.0,0.027778,0.027778,5.379897,0.83295,1.0,216.0,27.0,79.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12447833,0.12824098351165591,0.0037626535116559168
4.0,216.0,166.0,0.018519,0.018519,5.379897,0.83295,1.0,216.0,27.0,79.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08298705,0.08355224558854156,0.0005651955885415533
4.0,216.0,166.0,0.018519,0.018519,5.379897,0.83295,1.0,216.0,27.0,79.0,Guardian decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.08298705,0.08330318279622011,0.0003161327962201005
1.0,216.0,166.0,0.00463,0.00463,5.379897,0.83295,1.0,216.0,27.0,79.0,Guardian decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02074788,0.020827532160754,7.965216075399989e-05
1.0,216.0,166.0,0.00463,0.00463,5.379897,0.83295,1.0,216.0,27.0,79.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02074788,0.02093561273724208,0.00018773273724207937
0.0,216.0,166.0,0.0,0.0,5.379897,0.83295,1.0,216.0,27.0,79.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,216.0,166.0,0.037037,0.037037,5.379897,0.83295,1.0,216.0,27.0,79.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.16596962,0.17322685882128955,0.007257238821289536
5.0,216.0,166.0,0.023148,0.023148,5.379897,0.83295,1.0,216.0,27.0,79.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.10373045,0.10996296859458334,0.006232518594583333
2.0,216.0,166.0,0.009259,0.009259,5.379897,0.83295,1.0,216.0,27.0,79.0,Participant decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04149128,0.041419920968928554,7.135903107144403e-05
0.0,216.0,166.0,0.0,0.0,5.379897,0.83295,1.0,216.0,27.0,79.0,Participant decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,166.0,0.00463,0.00463,5.379897,0.83295,1.0,216.0,27.0,79.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02074788,0.020926124764503982,0.00017824476450398197
0.0,216.0,166.0,0.0,0.0,5.379897,0.83295,1.0,216.0,27.0,79.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,216.0,166.0,0.0,0.0,5.379897,0.83295,1.0,216.0,27.0,79.0,No treatment was received,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,216.0,166.0,0.00463,0.00463,5.379897,0.83295,1.0,216.0,27.0,79.0,No treatment was received,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02074788,0.020827532160754,7.965216075399989e-05
1.0,722.0,522.0,0.001385,0.001385,6.583409,0.707275,1.0,722.0,2.0,24.0,Site Terminated by Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00644895,0.0065986503210714136,0.00014970032107141339
0.0,722.0,522.0,0.0,0.0,6.583409,0.707275,1.0,722.0,2.0,24.0,Site Terminated by Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,722.0,522.0,0.01662,0.01662,6.583409,0.707275,1.0,722.0,2.0,24.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07738735,0.07878235215087477,0.0013950021508747773
14.0,722.0,522.0,0.019391,0.019391,6.583409,0.707275,1.0,722.0,2.0,24.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0902899,0.09347898370145825,0.003189083701458248
7.0,722.0,522.0,0.009695,0.009695,6.583409,0.707275,1.0,722.0,2.0,24.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04514262,0.04501312973055557,0.00012949026944442804
3.0,722.0,522.0,0.004155,0.004155,6.583409,0.707275,1.0,722.0,2.0,24.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01934684,0.01949016998175599,0.00014332998175599007
81.0,722.0,522.0,0.112188,0.112188,6.583409,0.707275,1.0,722.0,2.0,24.0,Reason not specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.52237857,0.5133655682562298,0.009013001743770177
82.0,722.0,522.0,0.113573,0.113573,6.583409,0.707275,1.0,722.0,2.0,24.0,Reason not specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.52882752,0.5176232342447418,0.011204285755258225
1.0,279.0,275.0,0.003584,0.003584,5.63479,0.316604,1.0,279.0,1.0,20.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00639385,0.006387488526009185,6.361473990815214e-06
1.0,279.0,275.0,0.003584,0.003584,5.63479,0.316604,1.0,279.0,1.0,20.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00639385,0.0063846690457512465,9.180954248753925e-06
0.0,279.0,275.0,0.0,0.0,5.63479,0.316604,1.0,279.0,1.0,20.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,279.0,275.0,0.007168,0.007168,5.63479,0.316604,1.0,279.0,1.0,20.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.01278771,0.013001122827023794,0.00021341282702379283
0.0,279.0,275.0,0.0,0.0,5.63479,0.316604,1.0,279.0,1.0,20.0,Lost to Follow-up,Overall Study,FG004,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
18.0,501.0,449.0,0.035928,0.035928,6.2186,1.0,1.0,502.0,5.0,47.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22342187,0.21415488939896846,0.009266980601031538
2.0,501.0,449.0,0.003992,0.003992,6.2186,1.0,1.0,502.0,5.0,47.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02482465,0.023085154555376984,0.0017394954446230161
12.0,501.0,449.0,0.023952,0.023952,6.2186,1.0,1.0,502.0,5.0,47.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14894791,0.14425228953398817,0.004695620466011824
3.0,501.0,449.0,0.005988,0.005988,6.2186,1.0,1.0,502.0,5.0,47.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03723698,0.03679392486287698,0.00044305513712302597
11.0,501.0,449.0,0.021956,0.021956,6.2186,1.0,1.0,502.0,5.0,47.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.13653558,0.13273483292052582,0.0038007470794741705
6.0,501.0,449.0,0.011976,0.011976,6.2186,1.0,1.0,502.0,5.0,47.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07447396,0.07363541456360116,0.0008385454363988437
7.0,451.0,417.0,0.015521,0.015521,6.113682,0.328159,1.0,451.0,1.0,50.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.03113913,0.031228876448422604,8.974644842260279e-05
11.0,451.0,417.0,0.02439,0.02439,6.113682,0.328159,1.0,451.0,1.0,50.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.04893264,0.04910422310978167,0.0001715831097816728
3.0,451.0,417.0,0.006652,0.006652,6.113682,0.328159,1.0,451.0,1.0,50.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.01334563,0.013501584182400796,0.00015595418240079567
13.0,451.0,417.0,0.028825,0.028825,6.113682,0.328159,1.0,451.0,1.0,50.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.05783039,0.0590761292565774,0.0012457392565774009
8.0,885.0,784.0,0.00904,0.00904,6.786717,0.231988,1.0,885.0,10.0,72.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01423292,0.014103653463852821,0.00012926653614717815
9.0,885.0,784.0,0.010169,0.010169,6.786717,0.231988,1.0,885.0,10.0,72.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01601046,0.016242572659087302,0.0002321126590873017
12.0,885.0,784.0,0.013559,0.013559,6.786717,0.231988,1.0,885.0,10.0,72.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02134781,0.02146943180833335,0.00012162180833335048
3.0,885.0,784.0,0.00339,0.00339,6.786717,0.231988,1.0,885.0,10.0,72.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00533735,0.005364808330317467,2.7458330317467125e-05
0.0,885.0,784.0,0.0,0.0,6.786717,0.231988,1.0,885.0,10.0,72.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,885.0,784.0,0.00339,0.00339,6.786717,0.231988,1.0,885.0,10.0,72.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00533735,0.005361790630942466,2.4440630942465513e-05
0.0,885.0,784.0,0.0,0.0,6.786717,0.231988,1.0,885.0,10.0,72.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,885.0,784.0,0.0,0.0,6.786717,0.231988,1.0,885.0,10.0,72.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,885.0,784.0,0.00113,0.00113,6.786717,0.231988,1.0,885.0,10.0,72.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00177912,0.0017826884903869161,3.5684903869162045e-06
12.0,885.0,784.0,0.013559,0.013559,6.786717,0.231988,1.0,885.0,10.0,72.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02134781,0.02143956478202383,9.175478202383056e-05
14.0,885.0,784.0,0.015819,0.015819,6.786717,0.231988,1.0,885.0,10.0,72.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02490604,0.02487187567891866,3.416432108134179e-05
13.0,885.0,784.0,0.014689,0.014689,6.786717,0.231988,1.0,885.0,10.0,72.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02312692,0.02285802598450396,0.00026889401549603717
3.0,885.0,784.0,0.00339,0.00339,6.786717,0.231988,1.0,885.0,10.0,72.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00533735,0.005369580695615085,3.223069561508491e-05
2.0,885.0,784.0,0.00226,0.00226,6.786717,0.231988,1.0,885.0,10.0,72.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00355823,0.0035708864737987,1.2656473798700139e-05
4.0,885.0,784.0,0.00452,0.00452,6.786717,0.231988,1.0,885.0,10.0,72.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00711646,0.007134986203055567,1.8526203055567632e-05
0.0,885.0,784.0,0.0,0.0,6.786717,0.231988,1.0,885.0,10.0,72.0,Pregnancy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,885.0,784.0,0.0,0.0,6.786717,0.231988,1.0,885.0,10.0,72.0,Pregnancy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,885.0,784.0,0.00113,0.00113,6.786717,0.231988,1.0,885.0,10.0,72.0,Pregnancy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00177912,0.0017820285220535833,2.9085220535833393e-06
1.0,885.0,784.0,0.00113,0.00113,6.786717,0.231988,1.0,885.0,10.0,72.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00177912,0.0017819732762400914,2.853276240091492e-06
1.0,885.0,784.0,0.00113,0.00113,6.786717,0.231988,1.0,885.0,10.0,72.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00177912,0.0017826838049900904,3.563804990090475e-06
1.0,885.0,784.0,0.00113,0.00113,6.786717,0.231988,1.0,885.0,10.0,72.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00177912,0.0017802810230258057,1.1610230258058286e-06
3.0,885.0,784.0,0.00339,0.00339,6.786717,0.231988,1.0,885.0,10.0,72.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00533735,0.005372473213948418,3.512321394841776e-05
4.0,885.0,784.0,0.00452,0.00452,6.786717,0.231988,1.0,885.0,10.0,72.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00711646,0.007144995373055566,2.8535373055566145e-05
6.0,885.0,784.0,0.00678,0.00678,6.786717,0.231988,1.0,885.0,10.0,72.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01067469,0.010668856824533746,5.8331754662546e-06
16.0,566.0,464.0,0.028269,0.028269,6.340359,0.688555,1.0,566.0,14.0,116.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.12341358,0.12342229611937502,8.716119375029585e-06
19.0,566.0,464.0,0.033569,0.033569,6.340359,0.688555,1.0,566.0,14.0,116.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.14655172,0.1484886244625497,0.00193690446254971
14.0,566.0,464.0,0.024735,0.024735,6.340359,0.688555,1.0,566.0,14.0,116.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.10798525,0.1099546758068154,0.001969425806815389
1.0,566.0,464.0,0.001767,0.001767,6.340359,0.688555,1.0,566.0,14.0,116.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00771417,0.007801527757549596,8.735775754959568e-05
0.0,566.0,464.0,0.0,0.0,6.340359,0.688555,1.0,566.0,14.0,116.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,464.0,0.001767,0.001767,6.340359,0.688555,1.0,566.0,14.0,116.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00771417,0.0077939753529662585,7.980535296625828e-05
0.0,566.0,464.0,0.0,0.0,6.340359,0.688555,1.0,566.0,14.0,116.0,Progressive disease,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,464.0,0.001767,0.001767,6.340359,0.688555,1.0,566.0,14.0,116.0,Progressive disease,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00771417,0.007793130541894831,7.896054189483054e-05
0.0,566.0,464.0,0.0,0.0,6.340359,0.688555,1.0,566.0,14.0,116.0,Progressive disease,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,566.0,464.0,0.0053,0.0053,6.340359,0.688555,1.0,566.0,14.0,116.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02313814,0.0232567612897223,0.00011862128972229755
0.0,566.0,464.0,0.0,0.0,6.340359,0.688555,1.0,566.0,14.0,116.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,566.0,464.0,0.001767,0.001767,6.340359,0.688555,1.0,566.0,14.0,116.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00771417,0.007799835647966258,8.566564796625743e-05
3.0,566.0,464.0,0.0053,0.0053,6.340359,0.688555,1.0,566.0,14.0,116.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02313814,0.023281131300019912,0.00014299130001991026
4.0,566.0,464.0,0.007067,0.007067,6.340359,0.688555,1.0,566.0,14.0,116.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0308523,0.030867740186091206,1.5440186091206926e-05
4.0,566.0,464.0,0.007067,0.007067,6.340359,0.688555,1.0,566.0,14.0,116.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0308523,0.030862811223204292,1.0511223204293096e-05
4.0,566.0,464.0,0.007067,0.007067,6.340359,0.688555,1.0,566.0,14.0,116.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0308523,0.03085497857449397,2.678574493972241e-06
8.0,566.0,464.0,0.014134,0.014134,6.340359,0.688555,1.0,566.0,14.0,116.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06170461,0.06108039604102182,0.00062421395897818
7.0,566.0,464.0,0.012367,0.012367,6.340359,0.688555,1.0,566.0,14.0,116.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05399044,0.05427324115741066,0.0002828011574106601
6.0,566.0,464.0,0.010601,0.010601,6.340359,0.688555,1.0,566.0,14.0,116.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04628064,0.04718406505413688,0.0009034250541368818
3.0,566.0,464.0,0.0053,0.0053,6.340359,0.688555,1.0,566.0,14.0,116.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02313814,0.0232855430312699,0.0001474030312698972
7.0,566.0,464.0,0.012367,0.012367,6.340359,0.688555,1.0,566.0,14.0,116.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05399044,0.054235359889493996,0.0002449198894939955
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Randomized but drug not received,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00437454,0.004376772726432157,2.2327264321570645e-06
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Randomized but drug not received,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Randomized but drug not received,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00437454,0.004376857988753588,2.317988753588497e-06
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00437454,0.004377617870142476,3.077870142476069e-06
3.0,347.0,207.0,0.008646,0.008646,5.852202,0.25937,1.0,347.0,1.0,25.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01312363,0.013075417963928573,4.82120360714277e-05
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00437454,0.004375874062582954,1.3340625829539807e-06
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Sponsor discontinued subject or study,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00437454,0.004377366850142475,2.826850142475558e-06
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Sponsor discontinued subject or study,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Sponsor discontinued subject or study,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
43.0,347.0,207.0,0.123919,0.123919,5.852202,0.25937,1.0,347.0,1.0,25.0,Reversible ischemic defect not present,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.18809471,0.18423367086538708,0.0038610391346129147
40.0,347.0,207.0,0.115274,0.115274,5.852202,0.25937,1.0,347.0,1.0,25.0,Reversible ischemic defect not present,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1749726,0.17541161423644852,0.000439014236448515
44.0,347.0,207.0,0.126801,0.126801,5.852202,0.25937,1.0,347.0,1.0,25.0,Reversible ischemic defect not present,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.19246925,0.18867402476074424,0.0037952252392557673
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Interpretation Failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00437454,0.004377366850142475,2.826850142475558e-06
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Interpretation Failure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Interpretation Failure,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Machine Failure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00437454,0.004377366850142475,2.826850142475558e-06
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,Machine Failure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00437454,0.00437730147924962,2.7614792496204535e-06
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,Machine Failure,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,347.0,207.0,0.0,0.0,5.852202,0.25937,1.0,347.0,1.0,25.0,One or more non-interpretable scan,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,One or more non-interpretable scan,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00437454,0.004377151025499619,2.6110254996193627e-06
1.0,347.0,207.0,0.002882,0.002882,5.852202,0.25937,1.0,347.0,1.0,25.0,One or more non-interpretable scan,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00437454,0.004377212342047239,2.672342047239061e-06
35.0,2651.0,2069.0,0.013203,0.013203,7.883069,0.384821,1.0,2651.0,15.0,218.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04005226,0.0406012478711607,0.0005489878711606999
29.0,2651.0,2069.0,0.010939,0.010939,7.883069,0.384821,1.0,2651.0,15.0,218.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03318425,0.03360200239080357,0.00041775239080357046
44.0,2651.0,2069.0,0.016598,0.016598,7.883069,0.384821,1.0,2651.0,15.0,218.0,Investigator-Initiated Early Closure,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05035123,0.05121667228175597,0.0008654422817559737
43.0,2651.0,2069.0,0.01622,0.01622,7.883069,0.384821,1.0,2651.0,15.0,218.0,Investigator-Initiated Early Closure,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04920454,0.049068749140585316,0.000135790859414682
137.0,2651.0,2069.0,0.051679,0.051679,7.883069,0.384821,1.0,2651.0,15.0,218.0,Participant Withdrew Consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15677199,0.15746937467492078,0.0006973846749207813
102.0,2651.0,2069.0,0.038476,0.038476,7.883069,0.384821,1.0,2651.0,15.0,218.0,Participant Withdrew Consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.11671973,0.11728459278014888,0.0005648627801488892
37.0,2651.0,2069.0,0.013957,0.013957,7.883069,0.384821,1.0,2651.0,15.0,218.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04233957,0.042956063760714265,0.0006164937607142651
51.0,2651.0,2069.0,0.019238,0.019238,7.883069,0.384821,1.0,2651.0,15.0,218.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.05835987,0.058377818393581374,1.7948393581372624e-05
26.0,2651.0,2069.0,0.009808,0.009808,7.883069,0.384821,1.0,2651.0,15.0,218.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02975328,0.02982531249612106,7.203249612106055e-05
15.0,2651.0,2069.0,0.005658,0.005658,7.883069,0.384821,1.0,2651.0,15.0,218.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01716395,0.017346432327847244,0.00018248232784724358
9.0,2651.0,2069.0,0.003395,0.003395,7.883069,0.384821,1.0,2651.0,15.0,218.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01029898,0.010419939576884935,0.000120959576884936
20.0,2651.0,2069.0,0.007544,0.007544,7.883069,0.384821,1.0,2651.0,15.0,218.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02288527,0.02199084149327381,0.000894428506726188
13.0,2651.0,2069.0,0.004904,0.004904,7.883069,0.384821,1.0,2651.0,15.0,218.0,Investigator's Discretion,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01487664,0.01489430618360118,1.766618360118065e-05
16.0,2651.0,2069.0,0.006035,0.006035,7.883069,0.384821,1.0,2651.0,15.0,218.0,Investigator's Discretion,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01830761,0.017967945952440476,0.00033966404755952223
2.0,2651.0,2069.0,0.000754,0.000754,7.883069,0.384821,1.0,2651.0,15.0,218.0,Study Terminated By Sponsor,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00228731,0.0023286500548611107,4.134005486111083e-05
3.0,2651.0,2069.0,0.001132,0.001132,7.883069,0.384821,1.0,2651.0,15.0,218.0,Study Terminated By Sponsor,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.003434,0.003424915876974205,9.084123025795195e-06
0.0,1198.0,1137.0,0.0,0.0,7.089243,0.31391,1.0,1198.0,0.0,0.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1198.0,1137.0,0.000835,0.000835,7.089243,0.31391,1.0,1198.0,0.0,0.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0018582,0.001858239314176588,3.9314176588029284e-08
14.0,1198.0,1137.0,0.011686,0.011686,7.089243,0.31391,1.0,1198.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02600587,0.025625466066746053,0.0003804039332539477
20.0,1198.0,1137.0,0.016694,0.016694,7.089243,0.31391,1.0,1198.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03715061,0.037417230880743994,0.00026662088074399376
2.0,1198.0,1137.0,0.001669,0.001669,7.089243,0.31391,1.0,1198.0,0.0,0.0,Never Entered Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00371417,0.0037276188506547682,1.3448850654768085e-05
1.0,1198.0,1137.0,0.000835,0.000835,7.089243,0.31391,1.0,1198.0,0.0,0.0,Never Entered Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0018582,0.0018578844766765884,3.1552332341159596e-07
1.0,1198.0,1137.0,0.000835,0.000835,7.089243,0.31391,1.0,1198.0,0.0,0.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0018582,0.0018613056839781753,3.1056839781753044e-06
0.0,1198.0,1137.0,0.0,0.0,7.089243,0.31391,1.0,1198.0,0.0,0.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1198.0,1137.0,0.003339,0.003339,7.089243,0.31391,1.0,1198.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00743057,0.007473481764682535,4.291176468253482e-05
2.0,1198.0,1137.0,0.001669,0.001669,7.089243,0.31391,1.0,1198.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00371417,0.0037390907634523895,2.4920763452389305e-05
0.0,1198.0,1137.0,0.0,0.0,7.089243,0.31391,1.0,1198.0,0.0,0.0,Did Not Meet Protocol Eligibility,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,1198.0,1137.0,0.001669,0.001669,7.089243,0.31391,1.0,1198.0,0.0,0.0,Did Not Meet Protocol Eligibility,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00371417,0.0037330565148809597,1.888651488095956e-05
3.0,1198.0,1137.0,0.002504,0.002504,7.089243,0.31391,1.0,1198.0,0.0,0.0,Not Treated,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00557237,0.0055317814509722295,4.058854902777055e-05
11.0,1198.0,1137.0,0.009182,0.009182,7.089243,0.31391,1.0,1198.0,0.0,0.0,Not Treated,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0204335,0.020462737903650795,2.9237903650794483e-05
293.0,4628.0,3216.0,0.06331,0.06331,8.440096,0.211174,1.0,4628.0,37.0,37.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11283945,0.11457606283109141,0.0017366128310914164
191.0,4628.0,3216.0,0.041271,0.041271,8.440096,0.211174,1.0,4628.0,37.0,37.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.07355863,0.07746915878899804,0.003910528788998044
14.0,4628.0,3216.0,0.003025,0.003025,8.440096,0.211174,1.0,4628.0,37.0,37.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00539155,0.005308022285783721,8.352771421627891e-05
14.0,4628.0,3216.0,0.003025,0.003025,8.440096,0.211174,1.0,4628.0,37.0,37.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00539155,0.005316776252450387,7.477374754961356e-05
173.0,4628.0,3216.0,0.037381,0.037381,8.440096,0.211174,1.0,4628.0,37.0,37.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06662536,0.0691741662005456,0.0025488062005456086
175.0,4628.0,3216.0,0.037813,0.037813,8.440096,0.211174,1.0,4628.0,37.0,37.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06739533,0.06927631002635733,0.0018809800263573234
110.0,4628.0,3216.0,0.023768,0.023768,8.440096,0.211174,1.0,4628.0,37.0,37.0,Atrial Fibrillation/Flutter recurrence,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04236247,0.0431333746581448,0.0007709046581447984
167.0,4628.0,3216.0,0.036085,0.036085,8.440096,0.211174,1.0,4628.0,37.0,37.0,Atrial Fibrillation/Flutter recurrence,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06431546,0.0657996007556133,0.001484140755613289
39.0,4628.0,3216.0,0.008427,0.008427,8.440096,0.211174,1.0,4628.0,37.0,37.0,Prohibited antiarrhythmic medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01501971,0.015264614295635817,0.0002449042956358168
88.0,4628.0,3216.0,0.019015,0.019015,8.440096,0.211174,1.0,4628.0,37.0,37.0,Prohibited antiarrhythmic medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03389105,0.03467097556939486,0.0007799255693948584
5.0,4628.0,3216.0,0.00108,0.00108,8.440096,0.211174,1.0,4628.0,37.0,37.0,Other prohibited medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00192492,0.002046354388821246,0.00012143438882124572
3.0,4628.0,3216.0,0.000648,0.000648,8.440096,0.211174,1.0,4628.0,37.0,37.0,Other prohibited medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00115495,0.0011294749326190485,2.5475067380951576e-05
6.0,4628.0,3216.0,0.001296,0.001296,8.440096,0.211174,1.0,4628.0,37.0,37.0,Family request,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0023099,0.002359602499444446,4.970249944444586e-05
8.0,4628.0,3216.0,0.001729,0.001729,8.440096,0.211174,1.0,4628.0,37.0,37.0,Family request,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00308165,0.0029394195637400798,0.00014223043625992025
56.0,4628.0,3216.0,0.0121,0.0121,8.440096,0.211174,1.0,4628.0,37.0,37.0,Not pre-specified/Not coded,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02156622,0.022721781579365077,0.0011555615793650761
70.0,4628.0,3216.0,0.015125,0.015125,8.440096,0.211174,1.0,4628.0,37.0,37.0,Not pre-specified/Not coded,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02695777,0.027582028784980162,0.0006242587849801633
342.0,13608.0,12804.0,0.025132,0.025132,9.518487,0.199291,1.0,13619.0,1.0,1.0,Withdrawal of consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.04767401,0.04662657534615082,0.001047434653849183
323.0,13608.0,12804.0,0.023736,0.023736,9.518487,0.199291,1.0,13619.0,1.0,1.0,Withdrawal of consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04502587,0.04353519499472223,0.001490675005277775
9.0,13608.0,12804.0,0.000661,0.000661,9.518487,0.199291,1.0,13619.0,1.0,1.0,Less than 6 months on study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00125388,0.0012205787863392868,3.330121366071316e-05
7.0,13608.0,12804.0,0.000514,0.000514,9.518487,0.199291,1.0,13619.0,1.0,1.0,Less than 6 months on study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00097503,0.0010454859928273818,7.04559928273818e-05
53.0,13608.0,12804.0,0.003895,0.003895,9.518487,0.199291,1.0,13619.0,1.0,1.0,Unable to attend termination visit,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0073886,0.007299549313313495,8.905068668650564e-05
51.0,13608.0,12804.0,0.003748,0.003748,9.518487,0.199291,1.0,13619.0,1.0,1.0,Unable to attend termination visit,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00710975,0.006904357964593261,0.00020539203540673873
6.0,13608.0,12804.0,0.000441,0.000441,9.518487,0.199291,1.0,13619.0,1.0,1.0,Lost to follow up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00083655,0.0008939701931249989,5.7420193124998824e-05
10.0,13608.0,12804.0,0.000735,0.000735,9.518487,0.199291,1.0,13619.0,1.0,1.0,Lost to follow up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00139425,0.0013856773646130941,8.572635386905943e-06
0.0,13608.0,12804.0,0.0,0.0,9.518487,0.199291,1.0,13619.0,1.0,1.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,13608.0,12804.0,0.00022,0.00022,9.518487,0.199291,1.0,13619.0,1.0,1.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00041733,0.00046687160077922145,4.954160077922146e-05
33.0,341.0,295.0,0.096774,0.096774,5.834811,0.428102,1.0,341.0,1.0,38.0,Pretreatment Event/Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24173136,0.2579978429342243,0.01626648293422428
7.0,341.0,295.0,0.020528,0.020528,5.834811,0.428102,1.0,341.0,1.0,38.0,Voluntary Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0512768,0.05123043769518846,4.63623048115383e-05
5.0,341.0,295.0,0.014663,0.014663,5.834811,0.428102,1.0,341.0,1.0,38.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03662665,0.03656389584839287,6.275415160712783e-05
1.0,341.0,295.0,0.002933,0.002933,5.834811,0.428102,1.0,341.0,1.0,38.0,Used Other Antihypertensive Drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00732633,0.007360196617946422,3.3866617946421915e-05
1.0,1161.0,1105.0,0.000861,0.000861,7.057898,0.328159,1.0,1161.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00199417,0.0019955874204978415,1.4174204978414928e-06
1.0,1161.0,1105.0,0.000861,0.000861,7.057898,0.328159,1.0,1161.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00199417,0.0019953038706764137,1.1338706764137292e-06
2.0,1161.0,1105.0,0.001723,0.001723,7.057898,0.328159,1.0,1161.0,1.0,61.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00399066,0.00400329427336308,1.2634273363079651e-05
1.0,1161.0,1105.0,0.000861,0.000861,7.057898,0.328159,1.0,1161.0,1.0,61.0,Technical Problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00199417,0.0019949611688311747,7.911688311747211e-07
0.0,1161.0,1105.0,0.0,0.0,7.057898,0.328159,1.0,1161.0,1.0,61.0,Technical Problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,1161.0,1105.0,0.0,0.0,7.057898,0.328159,1.0,1161.0,1.0,61.0,Technical Problems,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,1161.0,1105.0,0.002584,0.002584,7.057898,0.328159,1.0,1161.0,1.0,61.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00598483,0.005974186684014258,1.0643315985742197e-05
2.0,1161.0,1105.0,0.001723,0.001723,7.057898,0.328159,1.0,1161.0,1.0,61.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00399066,0.004008684873214274,1.8024873214273623e-05
2.0,1161.0,1105.0,0.001723,0.001723,7.057898,0.328159,1.0,1161.0,1.0,61.0,Physician Decision,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00399066,0.0040000585483333205,9.398548333320461e-06
0.0,1161.0,1105.0,0.0,0.0,7.057898,0.328159,1.0,1161.0,1.0,61.0,Non-compliance with study treatment,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1161.0,1105.0,0.000861,0.000861,7.057898,0.328159,1.0,1161.0,1.0,61.0,Non-compliance with study treatment,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00199417,0.001994679775259747,5.097752597471236e-07
0.0,1161.0,1105.0,0.0,0.0,7.057898,0.328159,1.0,1161.0,1.0,61.0,Non-compliance with study treatment,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
4.0,1161.0,1105.0,0.003445,0.003445,7.057898,0.328159,1.0,1161.0,1.0,61.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.007979,0.00802164467815477,4.2644678154769855e-05
4.0,1161.0,1105.0,0.003445,0.003445,7.057898,0.328159,1.0,1161.0,1.0,61.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.007979,0.008021755563253978,4.2755563253978404e-05
10.0,1161.0,1105.0,0.008613,0.008613,7.057898,0.328159,1.0,1161.0,1.0,61.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01994866,0.019890415881726187,5.824411827381332e-05
7.0,1161.0,1105.0,0.006029,0.006029,7.057898,0.328159,1.0,1161.0,1.0,61.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01396383,0.01425182564250992,0.0002879956425099195
6.0,1161.0,1105.0,0.005168,0.005168,7.057898,0.328159,1.0,1161.0,1.0,61.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01196966,0.012117969153323426,0.00014830915332342612
12.0,1161.0,1105.0,0.010336,0.010336,7.057898,0.328159,1.0,1161.0,1.0,61.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02393932,0.02423265363615078,0.00029333363615078115
8.0,756.0,700.0,0.010582,0.010582,6.629363,0.231988,1.0,756.0,8.0,8.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01627442,0.01619023613675595,8.418386324405072e-05
7.0,756.0,700.0,0.009259,0.009259,6.629363,0.231988,1.0,756.0,8.0,8.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01423973,0.014173986137321428,6.574386267857273e-05
2.0,756.0,700.0,0.002646,0.002646,6.629363,0.231988,1.0,756.0,8.0,8.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00406937,0.0040451737781935435,2.419622180645665e-05
3.0,756.0,700.0,0.003968,0.003968,6.629363,0.231988,1.0,756.0,8.0,8.0,Adverse Event,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00610252,0.006105827031984109,3.307031984109074e-06
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,756.0,700.0,0.001323,0.001323,6.629363,0.231988,1.0,756.0,8.0,8.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00203469,0.002011121951480885,2.3568048519115228e-05
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Lost to Follow-up,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
6.0,756.0,700.0,0.007937,0.007937,6.629363,0.231988,1.0,756.0,8.0,8.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01220658,0.012133637399345245,7.294260065475455e-05
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,756.0,700.0,0.003968,0.003968,6.629363,0.231988,1.0,756.0,8.0,8.0,Protocol Violation,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.00610252,0.0061016815836507764,8.384163492237279e-07
1.0,756.0,700.0,0.001323,0.001323,6.629363,0.231988,1.0,756.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00203469,0.002016743746011909,1.7946253988090997e-05
2.0,756.0,700.0,0.002646,0.002646,6.629363,0.231988,1.0,756.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00406937,0.004041265995098306,2.8104004901693784e-05
1.0,756.0,700.0,0.001323,0.001323,6.629363,0.231988,1.0,756.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00203469,0.0020157248485317505,1.896515146824953e-05
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Withdrawal by Subject,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,756.0,700.0,0.011905,0.011905,6.629363,0.231988,1.0,756.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0183091,0.0182780568567758,3.104314322419782e-05
3.0,756.0,700.0,0.003968,0.003968,6.629363,0.231988,1.0,756.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00610252,0.006105150976061494,2.6309760614937755e-06
3.0,756.0,700.0,0.003968,0.003968,6.629363,0.231988,1.0,756.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00610252,0.00609506636493054,7.453635069459841e-06
5.0,756.0,700.0,0.006614,0.006614,6.629363,0.231988,1.0,756.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0101719,0.010135955633740083,3.594436625991605e-05
2.0,756.0,700.0,0.002646,0.002646,6.629363,0.231988,1.0,756.0,8.0,8.0,Did not meet study criteria,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00406937,0.004048996797915765,2.0373202084235376e-05
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Did not meet study criteria,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Did not meet study criteria,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,756.0,700.0,0.0,0.0,6.629363,0.231988,1.0,756.0,8.0,8.0,Did not meet study criteria,Overall Study,FG003,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,426.0,415.0,0.002347,0.002347,6.056784,0.481252,1.0,426.0,7.0,23.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00684112,0.0068312999078373035,9.82009216269654e-06
10.0,426.0,415.0,0.023474,0.023474,6.056784,0.481252,1.0,426.0,7.0,23.0,Other reason,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06842287,0.067493944692877,0.0009289253071229908
28.0,602.0,533.0,0.046512,0.046512,6.401917,0.527807,1.0,632.0,11.0,75.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.15716294,0.1606168748211705,0.0034539348211705123
6.0,602.0,533.0,0.009967,0.009967,6.401917,0.527807,1.0,632.0,11.0,75.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.03367826,0.03381387396665294,0.00013561396665293796
7.0,602.0,533.0,0.011628,0.011628,6.401917,0.527807,1.0,632.0,11.0,75.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03929074,0.03917881592593252,0.00011192407406748067
5.0,602.0,533.0,0.008306,0.008306,6.401917,0.527807,1.0,632.0,11.0,75.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02806578,0.02813062888264886,6.484888264886302e-05
1.0,602.0,533.0,0.001661,0.001661,6.401917,0.527807,1.0,632.0,11.0,75.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00561248,0.005741487869880959,0.0001290078698809585
4.0,602.0,533.0,0.006645,0.006645,6.401917,0.527807,1.0,632.0,11.0,75.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0224533,0.022481391396676615,2.8091396676616087e-05
10.0,602.0,533.0,0.016611,0.016611,6.401917,0.527807,1.0,632.0,11.0,75.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05612817,0.05547115653373019,0.0006570134662698054
8.0,602.0,533.0,0.013289,0.013289,6.401917,0.527807,1.0,632.0,11.0,75.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04490322,0.043956090855593696,0.0009471291444063043
112.0,1426.0,781.0,0.078541,0.078541,7.26333,0.65166,1.0,1426.0,14.0,230.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.37175205,0.3682796560834163,0.003472393916583716
97.0,1426.0,781.0,0.068022,0.068022,7.26333,0.65166,1.0,1426.0,14.0,230.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.32196328,0.3255348812168194,0.0035716012168193756
63.0,1426.0,781.0,0.04418,0.04418,7.26333,0.65166,1.0,1426.0,14.0,230.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.20911378,0.21429817439201307,0.00518439439201307
126.0,1426.0,781.0,0.088359,0.088359,7.26333,0.65166,1.0,1426.0,14.0,230.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.41822283,0.4178564225098808,0.0003664074901191805
23.0,1426.0,781.0,0.016129,0.016129,7.26333,0.65166,1.0,1426.0,14.0,230.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.07634215,0.07675825367439658,0.00041610367439658125
47.0,1426.0,781.0,0.032959,0.032959,7.26333,0.65166,1.0,1426.0,14.0,230.0,Physician Decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15600229,0.1549029806416271,0.0010993093583728797
46.0,1426.0,781.0,0.032258,0.032258,7.26333,0.65166,1.0,1426.0,14.0,230.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.1526843,0.15190399944431543,0.0007803005556845655
46.0,1426.0,781.0,0.032258,0.032258,7.26333,0.65166,1.0,1426.0,14.0,230.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.1526843,0.1511148297469643,0.001569470253035693
1.0,1426.0,781.0,0.000701,0.000701,7.26333,0.65166,1.0,1426.0,14.0,230.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00331799,0.0036907280318315043,0.0003727380318315045
0.0,1426.0,781.0,0.0,0.0,7.26333,0.65166,1.0,1426.0,14.0,230.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
16.0,1426.0,781.0,0.01122,0.01122,7.26333,0.65166,1.0,1426.0,14.0,230.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05310676,0.05298986308268851,0.00011689691731149587
19.0,1426.0,781.0,0.013324,0.013324,7.26333,0.65166,1.0,1426.0,14.0,230.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.06306546,0.06404286274821419,0.0009774027482141873
21.0,1426.0,781.0,0.014727,0.014727,7.26333,0.65166,1.0,1426.0,14.0,230.0,Did not receive any study medication,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06970617,0.06886580252976182,0.0008403674702381764
28.0,1426.0,781.0,0.019635,0.019635,7.26333,0.65166,1.0,1426.0,14.0,230.0,Did not receive any study medication,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09293683,0.09372814320947782,0.0007913132094778258
438.0,8101.0,6145.0,0.054067,0.054067,8.999866,0.266168,1.0,8101.0,53.0,676.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.12951639,0.13048541854595247,0.0009690285459524606
385.0,8101.0,6145.0,0.047525,0.047525,8.999866,0.266168,1.0,8101.0,53.0,676.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.11384517,0.11347750531893402,0.00036766468106597117
50.0,8101.0,6145.0,0.006172,0.006172,8.999866,0.266168,1.0,8101.0,53.0,676.0,Clinical endpoint reached,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0147849,0.0148106773212004,2.577732120039901e-05
56.0,8101.0,6145.0,0.006913,0.006913,8.999866,0.266168,1.0,8101.0,53.0,676.0,Clinical endpoint reached,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01655995,0.016059178629255922,0.0005007713707440783
285.0,8101.0,6145.0,0.035181,0.035181,8.999866,0.266168,1.0,8101.0,53.0,676.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.08427537,0.0829626476846383,0.0013127223153616974
255.0,8101.0,6145.0,0.031478,0.031478,8.999866,0.266168,1.0,8101.0,53.0,676.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.07540491,0.07564308699521825,0.00023817699521824776
76.0,8101.0,6145.0,0.009382,0.009382,8.999866,0.266168,1.0,8101.0,53.0,676.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02247439,0.0225976152896627,0.0001232252896627012
59.0,8101.0,6145.0,0.007283,0.007283,8.999866,0.266168,1.0,8101.0,53.0,676.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01744628,0.016921975893958316,0.0005243041060416856
8.0,8101.0,6145.0,0.000988,0.000988,8.999866,0.266168,1.0,8101.0,53.0,676.0,Physician Decision,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00236673,0.0022088647512400797,0.0001578652487599203
9.0,8101.0,6145.0,0.001111,0.001111,8.999866,0.266168,1.0,8101.0,53.0,676.0,Physician Decision,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00266138,0.0028128693845238077,0.00015148938452380764
43.0,8101.0,6145.0,0.005308,0.005308,8.999866,0.266168,1.0,8101.0,53.0,676.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.01271521,0.012596640029236116,0.00011856997076388313
41.0,8101.0,6145.0,0.005061,0.005061,8.999866,0.266168,1.0,8101.0,53.0,676.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01212352,0.012245472673482156,0.00012195267348215529
88.0,8101.0,6145.0,0.010863,0.010863,8.999866,0.266168,1.0,8101.0,53.0,676.0,Non-compliant with study medication,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02602209,0.026176991978482163,0.0001549019784821623
89.0,8101.0,6145.0,0.010986,0.010986,8.999866,0.266168,1.0,8101.0,53.0,676.0,Non-compliant with study medication,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02631674,0.0264775786500397,0.0001608386500396991
11.0,8101.0,6145.0,0.001358,0.001358,8.999866,0.266168,1.0,8101.0,53.0,676.0,Patient convenience,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00325306,0.0032505399012500006,2.5200987499992764e-06
13.0,8101.0,6145.0,0.001605,0.001605,8.999866,0.266168,1.0,8101.0,53.0,676.0,Patient convenience,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00384474,0.0038452993616071413,5.593616071411685e-07
90.0,8101.0,6145.0,0.01111,0.01111,8.999866,0.266168,1.0,8101.0,53.0,676.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.02661378,0.02662608554170637,1.2305541706371381e-05
92.0,8101.0,6145.0,0.011357,0.011357,8.999866,0.266168,1.0,8101.0,53.0,676.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02720546,0.027037555772003966,0.00016790422799603522
3.0,8101.0,6145.0,0.00037,0.00037,8.999866,0.266168,1.0,8101.0,53.0,676.0,Technical problems,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00088633,0.0007997772635714295,8.655273642857041e-05
5.0,8101.0,6145.0,0.000617,0.000617,8.999866,0.266168,1.0,8101.0,53.0,676.0,Technical problems,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00147801,0.0014662190073214277,1.1790992678572393e-05
46.0,8101.0,6145.0,0.005678,0.005678,8.999866,0.266168,1.0,8101.0,53.0,676.0,Adverse Event,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.01360153,0.013771243578144849,0.00016971357814484812
40.0,8101.0,6145.0,0.004938,0.004938,8.999866,0.266168,1.0,8101.0,53.0,676.0,Adverse Event,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.01182888,0.01194931381997025,0.00012043381997024934
5.0,8101.0,6145.0,0.000617,0.000617,8.999866,0.266168,1.0,8101.0,53.0,676.0,Clinical endpoint reached,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.00147801,0.0014717031088392848,6.306891160715294e-06
2.0,8101.0,6145.0,0.000247,0.000247,8.999866,0.266168,1.0,8101.0,53.0,676.0,Clinical endpoint reached,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00059168,0.0006394850540575415,4.780505405754148e-05
119.0,8101.0,6145.0,0.01469,0.01469,8.999866,0.266168,1.0,8101.0,53.0,676.0,Withdrawal by Subject,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.0351896,0.03486472479468254,0.0003248752053174597
115.0,8101.0,6145.0,0.014196,0.014196,8.999866,0.266168,1.0,8101.0,53.0,676.0,Withdrawal by Subject,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.03400623,0.034066072895595226,5.9842895595227374e-05
132.0,8101.0,6145.0,0.016294,0.016294,8.999866,0.266168,1.0,8101.0,53.0,676.0,Death,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.03903194,0.039037839075635,5.899075635001916e-06
133.0,8101.0,6145.0,0.016418,0.016418,8.999866,0.266168,1.0,8101.0,53.0,676.0,Death,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.03932898,0.03926303101450403,6.594898549597272e-05
7.0,8101.0,6145.0,0.000864,0.000864,8.999866,0.266168,1.0,8101.0,53.0,676.0,Physician Decision,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.00206969,0.002070439559097221,7.495590972211863e-07
13.0,8101.0,6145.0,0.001605,0.001605,8.999866,0.266168,1.0,8101.0,53.0,676.0,Physician Decision,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00384474,0.0038532851591071425,8.545159107142385e-06
95.0,8101.0,6145.0,0.011727,0.011727,8.999866,0.266168,1.0,8101.0,53.0,676.0,Lost to Follow-up,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.02809179,0.028006336360545614,8.54536394543845e-05
92.0,8101.0,6145.0,0.011357,0.011357,8.999866,0.266168,1.0,8101.0,53.0,676.0,Lost to Follow-up,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.02720546,0.027273165743849206,6.770574384920569e-05
136.0,8101.0,6145.0,0.016788,0.016788,8.999866,0.266168,1.0,8101.0,53.0,676.0,Patient convenience,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.04021531,0.04075637216534723,0.0005410621653472308
121.0,8101.0,6145.0,0.014936,0.014936,8.999866,0.266168,1.0,8101.0,53.0,676.0,Patient convenience,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.03577888,0.035404444967599195,0.0003744350324008036
5.0,8101.0,6145.0,0.000617,0.000617,8.999866,0.266168,1.0,8101.0,53.0,676.0,Protocol Violation,Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.00147801,0.0014707630155059515,7.246984494048599e-06
12.0,8101.0,6145.0,0.001481,0.001481,8.999866,0.266168,1.0,8101.0,53.0,676.0,Protocol Violation,Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00354771,0.003532196378095241,1.5513621904759013e-05
2.0,450.0,407.0,0.004444,0.004444,6.111467,0.812445,1.0,450.0,1.0,43.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02206549,0.022030970246875,3.451975312500008e-05
1.0,450.0,407.0,0.002222,0.002222,6.111467,0.812445,1.0,450.0,1.0,43.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01103275,0.011096345234265885,6.359523426588583e-05
2.0,450.0,407.0,0.004444,0.004444,6.111467,0.812445,1.0,450.0,1.0,43.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02206549,0.02203239975663691,3.3090243363089605e-05
1.0,450.0,407.0,0.002222,0.002222,6.111467,0.812445,1.0,450.0,1.0,43.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01103275,0.01110538943593255,7.263943593255155e-05
3.0,450.0,407.0,0.006667,0.006667,6.111467,0.812445,1.0,450.0,1.0,43.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03310321,0.033006752598060095,9.645740193990615e-05
11.0,450.0,407.0,0.024444,0.024444,6.111467,0.812445,1.0,450.0,1.0,43.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.12137014,0.12105029237824405,0.0003198476217559504
0.0,450.0,407.0,0.0,0.0,6.111467,0.812445,1.0,450.0,1.0,43.0,Technical problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,450.0,407.0,0.002222,0.002222,6.111467,0.812445,1.0,450.0,1.0,43.0,Technical problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01103275,0.011098691088015884,6.594108801588443e-05
6.0,450.0,407.0,0.013333,0.013333,6.111467,0.812445,1.0,450.0,1.0,43.0,Subject decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06620144,0.06589925157000003,0.00030218842999997497
8.0,450.0,407.0,0.017778,0.017778,6.111467,0.812445,1.0,450.0,1.0,43.0,Subject decision,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0882719,0.08762047369058523,0.0006514263094147682
0.0,450.0,407.0,0.0,0.0,6.111467,0.812445,1.0,450.0,1.0,43.0,Withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,450.0,407.0,0.017778,0.017778,6.111467,0.812445,1.0,450.0,1.0,43.0,Withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0882719,0.08762047369058523,0.0006514263094147682
147.0,2856.0,2299.0,0.051471,0.051471,7.957527,1.0,1.0,2867.0,33.0,275.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.40958189,0.3732771533303271,0.03630473666967288
129.0,2856.0,2299.0,0.045168,0.045168,7.957527,1.0,1.0,2867.0,33.0,275.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.3594256,0.3497479932949801,0.009677606705019937
23.0,2856.0,2299.0,0.008053,0.008053,7.957527,1.0,1.0,2867.0,33.0,275.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.06408197,0.06323937281842262,0.0008425971815773786
34.0,2856.0,2299.0,0.011905,0.011905,7.957527,1.0,1.0,2867.0,33.0,275.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.09473436,0.0934757805763094,0.0012585794236906062
2.0,2856.0,2299.0,0.0007,0.0007,7.957527,1.0,1.0,2867.0,33.0,275.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00557027,0.005338135742380949,0.00023213425761905125
6.0,2856.0,2299.0,0.002101,0.002101,7.957527,1.0,1.0,2867.0,33.0,275.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01671877,0.016464732446193175,0.0002540375538068254
64.0,2856.0,2299.0,0.022409,0.022409,7.957527,1.0,1.0,2867.0,33.0,275.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.17832023,0.17362369141444453,0.004696538585555465
58.0,2856.0,2299.0,0.020308,0.020308,7.957527,1.0,1.0,2867.0,33.0,275.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.16160147,0.1599327698807541,0.0016687001192458861
40.0,2856.0,2299.0,0.014006,0.014006,7.957527,1.0,1.0,2867.0,33.0,275.0,Other reason (not specified),Overall Study,FG000,cardiovascular disease,INDUSTRY,0.11145313,0.10590992516014877,0.005543204839851226
54.0,2856.0,2299.0,0.018908,0.018908,7.957527,1.0,1.0,2867.0,33.0,275.0,Other reason (not specified),Overall Study,FG001,cardiovascular disease,INDUSTRY,0.15046093,0.15254359421687227,0.002082664216872282
4.0,1504.0,1370.0,0.00266,0.00266,7.316548,0.350295,1.0,1504.0,17.0,178.0,Death,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00681745,0.0070653990348881705,0.0002479490348881704
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Death,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00170436,0.0017079231627083278,3.563162708327761e-06
0.0,1504.0,1370.0,0.0,0.0,7.316548,0.350295,1.0,1504.0,17.0,178.0,Efficacy outcome reached,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Efficacy outcome reached,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00170436,0.001708249116874994,3.889116874994034e-06
3.0,1504.0,1370.0,0.001995,0.001995,7.316548,0.350295,1.0,1504.0,17.0,178.0,Physician Decision,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00511309,0.005100116005689952,1.2973994310047816e-05
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Physician Decision,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00170436,0.001708249116874994,3.889116874994034e-06
60.0,1504.0,1370.0,0.039894,0.039894,7.316548,0.350295,1.0,1504.0,17.0,178.0,Adverse Event,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.10224645,0.10113567610929568,0.0011107738907043252
22.0,1504.0,1370.0,0.014628,0.014628,7.316548,0.350295,1.0,1504.0,17.0,178.0,Adverse Event,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.03749088,0.03641559983017856,0.0010752801698214395
3.0,1504.0,1370.0,0.001995,0.001995,7.316548,0.350295,1.0,1504.0,17.0,178.0,Non-compliance with study drug,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00511309,0.0050971561244399525,1.59338755600473e-05
0.0,1504.0,1370.0,0.0,0.0,7.316548,0.350295,1.0,1504.0,17.0,178.0,Non-compliance with study drug,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Lost to Follow-up,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00170436,0.0017048134135714233,4.534135714232869e-07
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Lost to Follow-up,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00170436,0.0017081000360416607,3.740036041660665e-06
19.0,1504.0,1370.0,0.012633,0.012633,7.316548,0.350295,1.0,1504.0,17.0,178.0,Withdrawal by Subject,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.03237778,0.032637908595744065,0.00026012859574406355
16.0,1504.0,1370.0,0.010638,0.010638,7.316548,0.350295,1.0,1504.0,17.0,178.0,Withdrawal by Subject,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02726469,0.027455736852688525,0.00019104685268852423
5.0,1504.0,1370.0,0.003324,0.003324,7.316548,0.350295,1.0,1504.0,17.0,178.0,Switching to other therapy,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00851926,0.008429962409960318,8.929759003968238e-05
2.0,1504.0,1370.0,0.00133,0.00133,7.316548,0.350295,1.0,1504.0,17.0,178.0,Switching to other therapy,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.00340873,0.0033674105275595277,4.1319472440472325e-05
5.0,1504.0,1370.0,0.003324,0.003324,7.316548,0.350295,1.0,1504.0,17.0,178.0,Logistical difficulties,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.00851926,0.008429962409960318,8.929759003968238e-05
8.0,1504.0,1370.0,0.005319,0.005319,7.316548,0.350295,1.0,1504.0,17.0,178.0,Logistical difficulties,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.01363235,0.013565545833878954,6.680416612104591e-05
0.0,1504.0,1370.0,0.0,0.0,7.316548,0.350295,1.0,1504.0,17.0,178.0,Treatment failure,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
14.0,1504.0,1370.0,0.009309,0.009309,7.316548,0.350295,1.0,1504.0,17.0,178.0,Treatment failure,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.02385853,0.023553749368253985,0.00030478063174601416
56.0,1504.0,1370.0,0.037234,0.037234,7.316548,0.350295,1.0,1504.0,17.0,178.0,Protocol Violation,Treatment Period,FG000,cardiovascular disease,INDUSTRY,0.09542899,0.09607808817420642,0.0006490981742064139
36.0,1504.0,1370.0,0.023936,0.023936,7.316548,0.350295,1.0,1504.0,17.0,178.0,Protocol Violation,Treatment Period,FG001,cardiovascular disease,INDUSTRY,0.06134684,0.06042684362684523,0.0009199963731547703
3.0,1504.0,1370.0,0.001995,0.001995,7.316548,0.350295,1.0,1504.0,17.0,178.0,Death,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.00511309,0.005104322636106618,8.767363893382243e-06
2.0,1504.0,1370.0,0.00133,0.00133,7.316548,0.350295,1.0,1504.0,17.0,178.0,Death,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00340873,0.0033687964783928603,3.993352160713967e-05
0.0,1504.0,1370.0,0.0,0.0,7.316548,0.350295,1.0,1504.0,17.0,178.0,Non-compliance with study drug,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Non-compliance with study drug,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00170436,0.0017071633939583295,2.8033939583295073e-06
39.0,1504.0,1370.0,0.025931,0.025931,7.316548,0.350295,1.0,1504.0,17.0,178.0,Protocol Violation,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.06645993,0.06496525963327385,0.001494670366726153
22.0,1504.0,1370.0,0.014628,0.014628,7.316548,0.350295,1.0,1504.0,17.0,178.0,Protocol Violation,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.03749088,0.03638436359053571,0.0011065164094642907
1.0,1504.0,1370.0,0.000665,0.000665,7.316548,0.350295,1.0,1504.0,17.0,178.0,Logistical difficulties,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.00170436,0.0017039379339880917,4.2206601190831854e-07
3.0,1504.0,1370.0,0.001995,0.001995,7.316548,0.350295,1.0,1504.0,17.0,178.0,Logistical difficulties,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00511309,0.00510470451693995,8.385483060049936e-06
7.0,1504.0,1370.0,0.004654,0.004654,7.316548,0.350295,1.0,1504.0,17.0,178.0,Withdrawal by Subject,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.01192798,0.012143225707261916,0.00021524570726191676
8.0,1504.0,1370.0,0.005319,0.005319,7.316548,0.350295,1.0,1504.0,17.0,178.0,Withdrawal by Subject,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.01363235,0.013568265415783714,6.408458421628543e-05
8.0,1504.0,1370.0,0.005319,0.005319,7.316548,0.350295,1.0,1504.0,17.0,178.0,Lost to Follow-up,30-day Safety Follow-up Period,FG000,cardiovascular disease,INDUSTRY,0.01363235,0.013582093091587281,5.025690841271857e-05
5.0,1504.0,1370.0,0.003324,0.003324,7.316548,0.350295,1.0,1504.0,17.0,178.0,Lost to Follow-up,30-day Safety Follow-up Period,FG001,cardiovascular disease,INDUSTRY,0.00851926,0.008445736325376986,7.352367462301439e-05
2.0,1700.0,1695.0,0.001176,0.001176,7.438972,0.325753,1.0,1700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.00284976,0.0028551995298271736,5.4395298271737655e-06
1.0,1700.0,1695.0,0.000588,0.000588,7.438972,0.325753,1.0,1700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.00142488,0.0014251564367559536,2.764367559536778e-07
1.0,1700.0,1695.0,0.000588,0.000588,7.438972,0.325753,1.0,1700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.00142488,0.0014227249988095253,2.1550011904745807e-06
1.0,1700.0,1695.0,0.000588,0.000588,7.438972,0.325753,1.0,1700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.00142488,0.0014250916861309538,2.1168613095388054e-07
1.0,328.0,299.0,0.003049,0.003049,5.796058,0.419651,1.0,328.0,1.0,15.0,Pretreatment Event/Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00741614,0.00740923574602183,6.90425397816951e-06
3.0,328.0,299.0,0.009146,0.009146,5.796058,0.419651,1.0,328.0,1.0,15.0,Pretreatment Event/Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02224599,0.022002656225654792,0.00024333377434520784
2.0,328.0,299.0,0.006098,0.006098,5.796058,0.419651,1.0,328.0,1.0,15.0,Pretreatment Event/Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01483228,0.015505058443660706,0.000672778443660706
1.0,328.0,299.0,0.003049,0.003049,5.796058,0.419651,1.0,328.0,1.0,15.0,Major Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00741614,0.007409729045605163,6.4109543948366945e-06
1.0,328.0,299.0,0.003049,0.003049,5.796058,0.419651,1.0,328.0,1.0,15.0,Major Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00741614,0.00741001540374911,6.1245962508895205e-06
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Major Protocol Deviation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,328.0,299.0,0.003049,0.003049,5.796058,0.419651,1.0,328.0,1.0,15.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00741614,0.00741044554874911,5.694451250889618e-06
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,328.0,299.0,0.009146,0.009146,5.796058,0.419651,1.0,328.0,1.0,15.0,Voluntary Withdrawal,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02224599,0.022046893023869068,0.00019909697613093233
3.0,328.0,299.0,0.009146,0.009146,5.796058,0.419651,1.0,328.0,1.0,15.0,Voluntary Withdrawal,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02224599,0.022053432453571456,0.00019255754642854422
8.0,328.0,299.0,0.02439,0.02439,5.796058,0.419651,1.0,328.0,1.0,15.0,Voluntary Withdrawal,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05932425,0.05886247817547621,0.00046177182452378923
3.0,328.0,299.0,0.009146,0.009146,5.796058,0.419651,1.0,328.0,1.0,15.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02224599,0.0219949761084524,0.00025101389154760095
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,328.0,299.0,0.0,0.0,5.796058,0.419651,1.0,328.0,1.0,15.0,Reason Not Specified,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,328.0,299.0,0.006098,0.006098,5.796058,0.419651,1.0,328.0,1.0,15.0,Reason Not Specified,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01483228,0.015502660152172616,0.0006703801521726165
1.0,328.0,299.0,0.003049,0.003049,5.796058,0.419651,1.0,328.0,1.0,15.0,Reason Not Specified,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00741614,0.0074149409879157736,1.1990120842263197e-06
35.0,353.0,0.0,0.09915,0.09915,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.12929504,0.1308593520520933,0.0015643120520932863
18.0,353.0,0.0,0.050992,0.050992,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.06649534,0.06619256448109125,0.0003027755189087544
57.0,353.0,0.0,0.161473,0.161473,5.869297,0.222179,1.0,353.0,2.0,49.0,Progression of disease,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.21056639,0.2520060549808434,0.041439664980843394
124.0,353.0,0.0,0.351275,0.351275,5.869297,0.222179,1.0,353.0,2.0,49.0,Progression of disease,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.45807477,0.5155881918334524,0.05751342183345237
3.0,353.0,0.0,0.008499,0.008499,5.869297,0.222179,1.0,353.0,2.0,49.0,Lack of Efficacy,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.01108299,0.011081645860089265,1.3441399107343849e-06
5.0,353.0,0.0,0.014164,0.014164,5.869297,0.222179,1.0,353.0,2.0,49.0,Lack of Efficacy,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.01847035,0.018448637459583344,2.171254041665599e-05
8.0,353.0,0.0,0.022663,0.022663,5.869297,0.222179,1.0,353.0,2.0,49.0,Withdrawal by Subject,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.02955334,0.029523164511120928,3.017548887907298e-05
8.0,353.0,0.0,0.022663,0.022663,5.869297,0.222179,1.0,353.0,2.0,49.0,Withdrawal by Subject,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.02955334,0.02951440755433522,3.893244566478132e-05
2.0,353.0,0.0,0.005666,0.005666,5.869297,0.222179,1.0,353.0,2.0,49.0,Death,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.00738866,0.007430155321726206,4.149532172620634e-05
1.0,353.0,0.0,0.002833,0.002833,5.869297,0.222179,1.0,353.0,2.0,49.0,Death,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.00369433,0.0036912544814285807,3.0755185714192654e-06
8.0,353.0,0.0,0.022663,0.022663,5.869297,0.222179,1.0,353.0,2.0,49.0,Other,Up to Unblinding (07 Jun 2005),FG000,cardiovascular disease,INDUSTRY,0.02955334,0.029501603315882856,5.173668411714502e-05
7.0,353.0,0.0,0.01983,0.01983,5.869297,0.222179,1.0,353.0,2.0,49.0,Other,Up to Unblinding (07 Jun 2005),FG001,cardiovascular disease,INDUSTRY,0.02585901,0.02589881707765872,3.9807077658719076e-05
44.0,353.0,0.0,0.124646,0.124646,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.1625427,0.173473776657748,0.010931076657747979
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
87.0,353.0,0.0,0.246459,0.246459,5.869297,0.222179,1.0,353.0,2.0,49.0,Progression of disease,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.32139108,0.339997012235782,0.018605932235781997
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Progression of disease,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,353.0,0.0,0.008499,0.008499,5.869297,0.222179,1.0,353.0,2.0,49.0,Lack of Efficacy,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.01108299,0.011081645860089265,1.3441399107343849e-06
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Lack of Efficacy,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
11.0,353.0,0.0,0.031161,0.031161,5.869297,0.222179,1.0,353.0,2.0,49.0,Withdrawal by Subject,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.04063502,0.039642508046448366,0.000992511953551635
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Withdrawal by Subject,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
5.0,353.0,0.0,0.014164,0.014164,5.869297,0.222179,1.0,353.0,2.0,49.0,Death,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.01847035,0.018446720217380957,2.3629782619043194e-05
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Death,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
21.0,353.0,0.0,0.05949,0.05949,5.869297,0.222179,1.0,353.0,2.0,49.0,Other,Extended Follow-up Cutoff (23 Jul 2008),FG000,cardiovascular disease,INDUSTRY,0.07757702,0.07789278529834477,0.00031576529834477507
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Other,Extended Follow-up Cutoff (23 Jul 2008),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,353.0,0.0,0.008499,0.008499,5.869297,0.222179,1.0,353.0,2.0,49.0,Transferred into expanded access study.,Final Follow-up,FG000,cardiovascular disease,INDUSTRY,0.01108299,0.011079399353839264,3.590646160735525e-06
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Transferred into expanded access study.,Final Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
2.0,353.0,0.0,0.005666,0.005666,5.869297,0.222179,1.0,353.0,2.0,49.0,Transferred into RevAssist Program,Final Follow-up,FG000,cardiovascular disease,INDUSTRY,0.00738866,0.007432017059226207,4.3357059226207216e-05
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Transferred into RevAssist Program,Final Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,353.0,0.0,0.002833,0.002833,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Final Follow-up,FG000,cardiovascular disease,INDUSTRY,0.00369433,0.003685514008511914,8.815991488086202e-06
0.0,353.0,0.0,0.0,0.0,5.869297,0.222179,1.0,353.0,2.0,49.0,Adverse Event,Final Follow-up,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
40.0,224.0,155.0,0.178571,0.178571,5.4161,0.233646,1.0,224.0,3.0,39.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.22597287,0.2587463543509225,0.03277348435092253
10.0,224.0,155.0,0.044643,0.044643,5.4161,0.233646,1.0,224.0,3.0,39.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.05649353,0.05767087764859128,0.00117734764859128
6.0,224.0,155.0,0.026786,0.026786,5.4161,0.233646,1.0,224.0,3.0,39.0,Not compliant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.03389637,0.033786918386488105,0.00010945161351189753
1.0,224.0,155.0,0.004464,0.004464,5.4161,0.233646,1.0,224.0,3.0,39.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00564897,0.005706964961577379,5.7994961577378934e-05
1.0,224.0,155.0,0.004464,0.004464,5.4161,0.233646,1.0,224.0,3.0,39.0,Addition of other PAH therapeutic agent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00564897,0.00569548936904762,4.651936904762066e-05
3.0,224.0,155.0,0.013393,0.013393,5.4161,0.233646,1.0,224.0,3.0,39.0,Lung transplant,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01694819,0.017406542410313842,0.0004583524103138441
2.0,224.0,155.0,0.008929,0.008929,5.4161,0.233646,1.0,224.0,3.0,39.0,Physician Decision,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01129921,0.011462725821388891,0.00016351582138889043
1.0,224.0,155.0,0.004464,0.004464,5.4161,0.233646,1.0,224.0,3.0,39.0,Partipant moved away,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00564897,0.00569548936904762,4.651936904762066e-05
5.0,224.0,155.0,0.022321,0.022321,5.4161,0.233646,1.0,224.0,3.0,39.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02824613,0.0288672046200397,0.0006210746200396994
60.0,556.0,452.0,0.107914,0.107914,6.322565,0.212734,1.0,556.0,8.0,8.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.14514706,0.15051701819146834,0.005369958191468349
7.0,556.0,452.0,0.01259,0.01259,6.322565,0.212734,1.0,556.0,8.0,8.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01693387,0.016886930167252002,4.6939832747998345e-05
1.0,556.0,452.0,0.001799,0.001799,6.322565,0.212734,1.0,556.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.0024197,0.002461994345654768,4.2294345654768275e-05
2.0,556.0,452.0,0.003597,0.003597,6.322565,0.212734,1.0,556.0,8.0,8.0,Unsatisfactory therapeutic effect,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00483806,0.004855269401011896,1.7209401011896233e-05
2.0,556.0,452.0,0.003597,0.003597,6.322565,0.212734,1.0,556.0,8.0,8.0,Condition no longer requires study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00483806,0.0048492995703968145,1.1239570396814544e-05
0.0,556.0,452.0,0.0,0.0,6.322565,0.212734,1.0,556.0,8.0,8.0,Condition no longer requires study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
8.0,556.0,452.0,0.014388,0.014388,6.322565,0.212734,1.0,556.0,8.0,8.0,Protocol Deviation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01935222,0.019333228971350102,1.899102864989788e-05
0.0,556.0,452.0,0.0,0.0,6.322565,0.212734,1.0,556.0,8.0,8.0,Protocol Deviation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
12.0,556.0,452.0,0.021583,0.021583,6.322565,0.212734,1.0,556.0,8.0,8.0,Patient withdrew consent,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02902968,0.028990194409513878,3.948559048612063e-05
1.0,556.0,452.0,0.001799,0.001799,6.322565,0.212734,1.0,556.0,8.0,8.0,Patient withdrew consent,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0024197,0.0024591611651587357,3.946116515873583e-05
6.0,556.0,452.0,0.010791,0.010791,6.322565,0.212734,1.0,556.0,8.0,8.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01451417,0.014471891819513893,4.227818048610672e-05
3.0,556.0,452.0,0.005396,0.005396,6.322565,0.212734,1.0,556.0,8.0,8.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.00725776,0.007191007148085322,6.675285191467834e-05
2.0,556.0,452.0,0.003597,0.003597,6.322565,0.212734,1.0,556.0,8.0,8.0,Administrative problems,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00483806,0.0048492995703968145,1.1239570396814544e-05
0.0,556.0,452.0,0.0,0.0,6.322565,0.212734,1.0,556.0,8.0,8.0,Administrative problems,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
35.0,242.0,83.0,0.144628,0.144628,5.493061,0.371096,1.0,242.0,1.0,15.0,Adverse Event,Controlled Treatment Period (CTP),FG000,cardiovascular disease,INDUSTRY,0.29481712,0.29813102338810527,0.003313903388105277
0.0,242.0,83.0,0.0,0.0,5.493061,0.371096,1.0,242.0,1.0,15.0,Adverse Event,Controlled Treatment Period (CTP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
32.0,242.0,83.0,0.132231,0.132231,5.493061,0.371096,1.0,242.0,1.0,15.0,Wk 16 Efficacy and BP Criteria,Controlled Treatment Period (CTP),FG000,cardiovascular disease,INDUSTRY,0.26954645,0.27371009148659753,0.004163641486597536
0.0,242.0,83.0,0.0,0.0,5.493061,0.371096,1.0,242.0,1.0,15.0,Wk 16 Efficacy and BP Criteria,Controlled Treatment Period (CTP),FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
9.0,242.0,83.0,0.03719,0.03719,5.493061,0.371096,1.0,242.0,1.0,15.0,Lost to Follow-up,Controlled Treatment Period (CTP),FG000,cardiovascular disease,INDUSTRY,0.07581,0.07620627228199417,0.0003962722819941672
5.0,242.0,83.0,0.020661,0.020661,5.493061,0.371096,1.0,242.0,1.0,15.0,Lost to Follow-up,Controlled Treatment Period (CTP),FG001,cardiovascular disease,INDUSTRY,0.04211644,0.042391285768045545,0.00027484576804554656
6.0,242.0,83.0,0.024793,0.024793,5.493061,0.371096,1.0,242.0,1.0,15.0,"Withdrawal of Consent,Protocol Deviation",Controlled Treatment Period (CTP),FG000,cardiovascular disease,INDUSTRY,0.05053932,0.051281331604404796,0.0007420116044047978
2.0,242.0,83.0,0.008264,0.008264,5.493061,0.371096,1.0,242.0,1.0,15.0,"Withdrawal of Consent,Protocol Deviation",Controlled Treatment Period (CTP),FG001,cardiovascular disease,INDUSTRY,0.01684576,0.01682859801407736,1.7161985922640316e-05
2.0,242.0,83.0,0.008264,0.008264,5.493061,0.371096,1.0,242.0,1.0,15.0,Adverse Event,Uncontrolled Treatment Period (UTP),FG000,cardiovascular disease,INDUSTRY,0.01684576,0.016808022744642836,3.773725535716546e-05
13.0,242.0,83.0,0.053719,0.053719,5.493061,0.371096,1.0,242.0,1.0,15.0,Adverse Event,Uncontrolled Treatment Period (UTP),FG001,cardiovascular disease,INDUSTRY,0.10950356,0.10849236288889885,0.0010111971111011475
0.0,242.0,83.0,0.0,0.0,5.493061,0.371096,1.0,242.0,1.0,15.0,Wk 42 Efficacy and BP Criteria,Uncontrolled Treatment Period (UTP),FG000,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
26.0,242.0,83.0,0.107438,0.107438,5.493061,0.371096,1.0,242.0,1.0,15.0,Wk 42 Efficacy and BP Criteria,Uncontrolled Treatment Period (UTP),FG001,cardiovascular disease,INDUSTRY,0.21900712,0.23414743424003956,0.01514031424003956
9.0,242.0,83.0,0.03719,0.03719,5.493061,0.371096,1.0,242.0,1.0,15.0,Lost to Follow-up,Uncontrolled Treatment Period (UTP),FG000,cardiovascular disease,INDUSTRY,0.07581,0.07621877645866088,0.00040877645866087275
9.0,242.0,83.0,0.03719,0.03719,5.493061,0.371096,1.0,242.0,1.0,15.0,Lost to Follow-up,Uncontrolled Treatment Period (UTP),FG001,cardiovascular disease,INDUSTRY,0.07581,0.07594574867247036,0.00013574867247036215
5.0,242.0,83.0,0.020661,0.020661,5.493061,0.371096,1.0,242.0,1.0,15.0,"Withdrawal of Consent,Protocol Deviation",Uncontrolled Treatment Period (UTP),FG000,cardiovascular disease,INDUSTRY,0.04211644,0.042353811447668546,0.00023737144766854817
5.0,242.0,83.0,0.020661,0.020661,5.493061,0.371096,1.0,242.0,1.0,15.0,"Withdrawal of Consent,Protocol Deviation",Uncontrolled Treatment Period (UTP),FG001,cardiovascular disease,INDUSTRY,0.04211644,0.04236812489471216,0.00025168489471216055
1.0,865.0,861.0,0.001156,0.001156,6.763885,0.7371,1.0,865.0,1.0,3.0,Intraoperative exclusion criteria,Overall Study,FG000,cardiovascular disease,OTHER,0.00576342,0.005776648960148829,1.3228960148829044e-05
1.0,865.0,861.0,0.001156,0.001156,6.763885,0.7371,1.0,865.0,1.0,3.0,Intraoperative exclusion criteria,Overall Study,FG001,cardiovascular disease,OTHER,0.00576342,0.005783216875466288,1.9796875466287882e-05
1.0,865.0,861.0,0.001156,0.001156,6.763885,0.7371,1.0,865.0,1.0,3.0,Intraoperative exclusion criteria,Overall Study,FG000,cardiovascular disease,OTHER,0.00576342,0.005776648960148829,1.3228960148829044e-05
1.0,865.0,861.0,0.001156,0.001156,6.763885,0.7371,1.0,865.0,1.0,3.0,Intraoperative exclusion criteria,Overall Study,FG001,cardiovascular disease,OTHER,0.00576342,0.005783216875466288,1.9796875466287882e-05
66.0,984.0,681.0,0.067073,0.067073,6.892642,0.588565,1.0,984.0,1.0,164.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.27209963,0.2836736044293456,0.011573974429345602
69.0,984.0,681.0,0.070122,0.070122,6.892642,0.588565,1.0,984.0,1.0,164.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.28446872,0.2930195156021928,0.008550795602192796
81.0,984.0,681.0,0.082317,0.082317,6.892642,0.588565,1.0,984.0,1.0,164.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.33394101,0.34253505222672637,0.008594042226726384
77.0,984.0,681.0,0.078252,0.078252,6.892642,0.588565,1.0,984.0,1.0,164.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.31745025,0.31932101771330396,0.0018707677133039669
4.0,984.0,681.0,0.004065,0.004065,6.892642,0.588565,1.0,984.0,1.0,164.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01649076,0.016551388930505964,6.062893050596402e-05
6.0,984.0,681.0,0.006098,0.006098,6.892642,0.588565,1.0,984.0,1.0,164.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02473817,0.024893642192946427,0.00015547219294642645
2.0,396.0,244.0,0.005051,0.005051,5.983936,0.57068,1.0,396.0,27.0,99.0,Other,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01724872,0.017248606429196553,1.1357080344567838e-07
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Other,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Other,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
1.0,396.0,244.0,0.002525,0.002525,5.983936,0.57068,1.0,396.0,27.0,99.0,Missing,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00862265,0.008623129889226182,4.798892261816817e-07
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Missing,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Missing,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
40.0,396.0,244.0,0.10101,0.10101,5.983936,0.57068,1.0,396.0,27.0,99.0,Death,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.34494022,0.34585560672186494,0.0009153867218649192
23.0,396.0,244.0,0.058081,0.058081,5.983936,0.57068,1.0,396.0,27.0,99.0,Death,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.19834148,0.19145429322008933,0.006887186779910653
6.0,396.0,244.0,0.015152,0.015152,5.983936,0.57068,1.0,396.0,27.0,99.0,Death,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05174274,0.05172769047715277,1.5049522847233876e-05
12.0,396.0,244.0,0.030303,0.030303,5.983936,0.57068,1.0,396.0,27.0,99.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.10348207,0.10622850356493052,0.0027464335649305255
5.0,396.0,244.0,0.012626,0.012626,5.983936,0.57068,1.0,396.0,27.0,99.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.04311667,0.04246461619591267,0.0006520538040873311
2.0,396.0,244.0,0.005051,0.005051,5.983936,0.57068,1.0,396.0,27.0,99.0,Withdrawal by Subject,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.01724872,0.01723174883098224,1.6971169017759163e-05
2.0,396.0,244.0,0.005051,0.005051,5.983936,0.57068,1.0,396.0,27.0,99.0,Protocol Violation,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01724872,0.017248606429196553,1.1357080344567838e-07
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Protocol Violation,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Protocol Violation,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,396.0,244.0,0.007576,0.007576,5.983936,0.57068,1.0,396.0,27.0,99.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.02587137,0.02564222961458338,0.00022914038541662143
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,396.0,244.0,0.007576,0.007576,5.983936,0.57068,1.0,396.0,27.0,99.0,Lost to Follow-up,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.02587137,0.025637954813333374,0.0002334151866666273
28.0,396.0,244.0,0.070707,0.070707,5.983936,0.57068,1.0,396.0,27.0,99.0,Adverse Event,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.24145816,0.24570714001764898,0.004248980017648979
10.0,396.0,244.0,0.025253,0.025253,5.983936,0.57068,1.0,396.0,27.0,99.0,Adverse Event,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.08623676,0.0858878808389583,0.00034887916104169026
6.0,396.0,244.0,0.015152,0.015152,5.983936,0.57068,1.0,396.0,27.0,99.0,Adverse Event,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.05174274,0.05165843819256943,8.430180743057569e-05
2.0,396.0,244.0,0.005051,0.005051,5.983936,0.57068,1.0,396.0,27.0,99.0,Lack of Efficacy,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.01724872,0.017251490680238225,2.77068023822602e-06
2.0,396.0,244.0,0.005051,0.005051,5.983936,0.57068,1.0,396.0,27.0,99.0,Lack of Efficacy,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.01724872,0.0172497112347391,9.912347391019538e-07
1.0,396.0,244.0,0.002525,0.002525,5.983936,0.57068,1.0,396.0,27.0,99.0,Lack of Efficacy,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.00862265,0.008609363630297611,1.3286369702389736e-05
1.0,396.0,244.0,0.002525,0.002525,5.983936,0.57068,1.0,396.0,27.0,99.0,Non-compliance with study drug,Overall Study,FG000,cardiovascular disease,INDUSTRY,0.00862265,0.008623129889226182,4.798892261816817e-07
3.0,396.0,244.0,0.007576,0.007576,5.983936,0.57068,1.0,396.0,27.0,99.0,Non-compliance with study drug,Overall Study,FG001,cardiovascular disease,INDUSTRY,0.02587137,0.02569133398982147,0.00018003601017852963
0.0,396.0,244.0,0.0,0.0,5.983936,0.57068,1.0,396.0,27.0,99.0,Non-compliance with study drug,Overall Study,FG002,cardiovascular disease,INDUSTRY,0.0,0.0,0.0
3.0,523.0,491.0,0.005736,0.005736,6.261492,0.404683,1.0,523.0,2.0,23.0,Death,Overall Study,FG000,cardiovascular disease,OTHER,0.01453455,0.014614863419980154,8.031341998015334e-05
2.0,523.0,491.0,0.003824,0.003824,6.261492,0.404683,1.0,523.0,2.0,23.0,Death,Overall Study,FG001,cardiovascular disease,OTHER,0.0096897,0.00979350355494047,0.00010380355494046985
10.0,523.0,491.0,0.01912,0.01912,6.261492,0.404683,1.0,523.0,2.0,23.0,Withdrawal by Subject,Overall Study,FG000,cardiovascular disease,OTHER,0.0484485,0.04769284278707346,0.0007556572129265374
9.0,523.0,491.0,0.017208,0.017208,6.261492,0.404683,1.0,523.0,2.0,23.0,Withdrawal by Subject,Overall Study,FG001,cardiovascular disease,OTHER,0.04360365,0.04413205679924601,0.0005284067992460117
4.0,523.0,491.0,0.007648,0.007648,6.261492,0.404683,1.0,523.0,2.0,23.0,Lost to Follow-up,Overall Study,FG000,cardiovascular disease,OTHER,0.0193794,0.019422652232470264,4.325223247026236e-05
4.0,523.0,491.0,0.007648,0.007648,6.261492,0.404683,1.0,523.0,2.0,23.0,Lost to Follow-up,Overall Study,FG001,cardiovascular disease,OTHER,0.0193794,0.019424745993482172,4.534599348217025e-05
503.0,6505.0,5315.0,0.077325,0.077325,8.78048,0.252985,1.0,6505.0,2.0,2.0,Death,Overall Study,FG000,heart failure,OTHER,0.17176427,0.16314315424492537,0.008621115755074626
553.0,6505.0,5315.0,0.085012,0.085012,8.78048,0.252985,1.0,6505.0,2.0,2.0,Death,Overall Study,FG001,heart failure,OTHER,0.18883962,0.1694506665005602,0.01938895349943981
73.0,6505.0,5315.0,0.011222,0.011222,8.78048,0.252985,1.0,6505.0,2.0,2.0,Withdrawal by Subject,Overall Study,FG000,heart failure,OTHER,0.02492775,0.023692668338035697,0.0012350816619643018
58.0,6505.0,5315.0,0.008916,0.008916,8.78048,0.252985,1.0,6505.0,2.0,2.0,Withdrawal by Subject,Overall Study,FG001,heart failure,OTHER,0.01980537,0.018851070055347224,0.0009542999446527749
2.0,6505.0,5315.0,0.000307,0.000307,8.78048,0.252985,1.0,6505.0,2.0,2.0,Lost to Follow-up,Overall Study,FG000,heart failure,OTHER,0.00068195,0.0006704577614682552,1.1492238531744803e-05
1.0,6505.0,5315.0,0.000154,0.000154,8.78048,0.252985,1.0,6505.0,2.0,2.0,Lost to Follow-up,Overall Study,FG001,heart failure,OTHER,0.00034208,0.0003572145949702383,1.5134594970238314e-05
8.0,6545.0,6528.0,0.001222,0.001222,8.786609,0.457741,1.0,6600.0,35.0,540.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.00491487,0.004714993170029759,0.00019987682997024084
7.0,6545.0,6528.0,0.00107,0.00107,8.786609,0.457741,1.0,6600.0,35.0,540.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.00430353,0.004342976532609129,3.944653260912895e-05
0.0,6545.0,6528.0,0.0,0.0,8.786609,0.457741,1.0,6600.0,35.0,540.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,6545.0,6528.0,0.000306,0.000306,8.786609,0.457741,1.0,6600.0,35.0,540.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.00123073,0.0012489182326091278,1.818823260912785e-05
1.0,313.0,302.0,0.003195,0.003195,5.749393,0.598569,1.0,313.0,9.0,76.0,Adverse Event,Overall Study,FG000,heart failure,INDUSTRY,0.0109953,0.011018376471408737,2.3076471408737045e-05
2.0,313.0,302.0,0.00639,0.00639,5.749393,0.598569,1.0,313.0,9.0,76.0,Adverse Event,Overall Study,FG001,heart failure,INDUSTRY,0.02199059,0.02222189218083336,0.0002313021808333579
3.0,313.0,302.0,0.009585,0.009585,5.749393,0.598569,1.0,313.0,9.0,76.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.03298589,0.03284218735433531,0.00014370264566468394
2.0,313.0,302.0,0.00639,0.00639,5.749393,0.598569,1.0,313.0,9.0,76.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.02199059,0.022204844882916696,0.00021425488291669514
1.0,313.0,302.0,0.003195,0.003195,5.749393,0.598569,1.0,313.0,9.0,76.0,Physician Decision,Overall Study,FG000,heart failure,INDUSTRY,0.0109953,0.011013327580575405,1.802758057540578e-05
0.0,313.0,302.0,0.0,0.0,5.749393,0.598569,1.0,313.0,9.0,76.0,Physician Decision,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,313.0,302.0,0.0,0.0,5.749393,0.598569,1.0,313.0,9.0,76.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,313.0,302.0,0.00639,0.00639,5.749393,0.598569,1.0,313.0,9.0,76.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.02199059,0.022253345244196462,0.0002627552441964616
1.0,731.0,663.0,0.001368,0.001368,6.595781,0.870551,1.0,731.0,10.0,146.0,Adverse Event,Overall Study,FG000,heart failure,INDUSTRY,0.007855,0.007877078888720239,2.207888872023979e-05
0.0,731.0,663.0,0.0,0.0,6.595781,0.870551,1.0,731.0,10.0,146.0,Adverse Event,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
19.0,731.0,663.0,0.025992,0.025992,6.595781,0.870551,1.0,731.0,10.0,146.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.14924504,0.15044133909072782,0.001196299090727826
15.0,731.0,663.0,0.02052,0.02052,6.595781,0.870551,1.0,731.0,10.0,146.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.11782503,0.11890911720077373,0.0010840872007737284
3.0,731.0,663.0,0.004104,0.004104,6.595781,0.870551,1.0,731.0,10.0,146.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.02356501,0.023344639035863084,0.00022037096413691712
6.0,731.0,663.0,0.008208,0.008208,6.595781,0.870551,1.0,731.0,10.0,146.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.04713001,0.04846751688492157,0.0013375068849215688
1.0,731.0,663.0,0.001368,0.001368,6.595781,0.870551,1.0,731.0,10.0,146.0,Physician Decision,Overall Study,FG000,heart failure,INDUSTRY,0.007855,0.007877290065803571,2.2290065803572123e-05
0.0,731.0,663.0,0.0,0.0,6.595781,0.870551,1.0,731.0,10.0,146.0,Physician Decision,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,731.0,663.0,0.0,0.0,6.595781,0.870551,1.0,731.0,10.0,146.0,Protocol Violation,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,731.0,663.0,0.001368,0.001368,6.595781,0.870551,1.0,731.0,10.0,146.0,Protocol Violation,Overall Study,FG001,heart failure,INDUSTRY,0.007855,0.007867824456220236,1.2824456220236757e-05
8.0,731.0,663.0,0.010944,0.010944,6.595781,0.870551,1.0,731.0,10.0,146.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.06284002,0.062013260052460294,0.0008267599475397028
14.0,731.0,663.0,0.019152,0.019152,6.595781,0.870551,1.0,731.0,10.0,146.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.10997003,0.11432681392802577,0.00435678392802577
372.0,6105.0,5219.0,0.060934,0.060934,8.717027,0.916786,1.0,6106.0,36.0,519.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.48696332,0.46155118286093255,0.025412137139067426
434.0,6105.0,5219.0,0.071089,0.071089,8.717027,0.916786,1.0,6106.0,36.0,519.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.56811854,0.5101176802207736,0.05800085977922631
13.0,6105.0,5219.0,0.002129,0.002129,8.717027,0.916786,1.0,6106.0,36.0,519.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.01701423,0.016785776018752693,0.0002284539812473091
16.0,6105.0,5219.0,0.002621,0.002621,8.717027,0.916786,1.0,6106.0,36.0,519.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.02094612,0.02077059844701389,0.0001755215529861097
0.0,6105.0,5219.0,0.0,0.0,8.717027,0.916786,1.0,6106.0,36.0,519.0,Physician Decision,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,6105.0,5219.0,0.000328,0.000328,8.717027,0.916786,1.0,6106.0,36.0,519.0,Physician Decision,Overall Study,FG001,heart failure,INDUSTRY,0.00262126,0.0023443523312896833,0.00027690766871031657
1.0,6105.0,5219.0,0.000164,0.000164,8.717027,0.916786,1.0,6106.0,36.0,519.0,Sponsor Decision,Overall Study,FG000,heart failure,INDUSTRY,0.00131063,0.0010469908894444441,0.0002636391105555558
3.0,6105.0,5219.0,0.000491,0.000491,8.717027,0.916786,1.0,6106.0,36.0,519.0,Sponsor Decision,Overall Study,FG001,heart failure,INDUSTRY,0.0039239,0.0035141545931231914,0.0004097454068768087
1.0,6105.0,5219.0,0.000164,0.000164,8.717027,0.916786,1.0,6106.0,36.0,519.0,Withdrawal by Guardian,Overall Study,FG000,heart failure,INDUSTRY,0.00131063,0.0010469908894444441,0.0002636391105555558
1.0,6105.0,5219.0,0.000164,0.000164,8.717027,0.916786,1.0,6106.0,36.0,519.0,Withdrawal by Guardian,Overall Study,FG001,heart failure,INDUSTRY,0.00131063,0.001037667321944444,0.000272962678055556
18.0,6105.0,5219.0,0.002948,0.002948,8.717027,0.916786,1.0,6106.0,36.0,519.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.02355939,0.02258140312368054,0.000977986876319458
25.0,6105.0,5219.0,0.004095,0.004095,8.717027,0.916786,1.0,6106.0,36.0,519.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.03272581,0.03176310741937499,0.0009627025806250092
4.0,467.0,41.0,0.008565,0.008565,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Double-Blind,FG000,heart failure,INDUSTRY,0.04008095,0.040310704626747816,0.000229754626747819
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Double-Blind,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Double-Blind,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
18.0,467.0,41.0,0.038544,0.038544,6.148468,0.761103,1.0,467.0,2.0,97.0,Death,Double-Blind,FG000,heart failure,INDUSTRY,0.18037128,0.1809319439425992,0.0005606639425992099
26.0,467.0,41.0,0.055675,0.055675,6.148468,0.761103,1.0,467.0,2.0,97.0,Death,Double-Blind,FG001,heart failure,INDUSTRY,0.26053785,0.25610875984855164,0.004429090151448378
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Death,Double-Blind,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
6.0,467.0,41.0,0.012848,0.012848,6.148468,0.761103,1.0,467.0,2.0,97.0,Lost to Follow-up,Double-Blind,FG000,heart failure,INDUSTRY,0.06012376,0.060489625187242095,0.00036586518724209677
7.0,467.0,41.0,0.014989,0.014989,6.148468,0.761103,1.0,467.0,2.0,97.0,Lost to Follow-up,Double-Blind,FG001,heart failure,INDUSTRY,0.07014283,0.06566240715907744,0.0044804228409225655
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Lost to Follow-up,Double-Blind,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
9.0,467.0,41.0,0.019272,0.019272,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Double-Blind,FG000,heart failure,INDUSTRY,0.09018564,0.09018406463926584,1.5753607341545406e-06
5.0,467.0,41.0,0.010707,0.010707,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Double-Blind,FG001,heart failure,INDUSTRY,0.05010469,0.05038257543574131,0.00027788543574130964
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Double-Blind,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
24.0,467.0,41.0,0.051392,0.051392,6.148468,0.761103,1.0,467.0,2.0,97.0,Subject decision,Double-Blind,FG000,heart failure,INDUSTRY,0.24049504,0.2377143330174999,0.002780706982500103
13.0,467.0,41.0,0.027837,0.027837,6.148468,0.761103,1.0,467.0,2.0,97.0,Subject decision,Double-Blind,FG001,heart failure,INDUSTRY,0.13026659,0.12890664742339275,0.001359942576607237
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Subject decision,Double-Blind,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Open-Label,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Open-Label,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
7.0,467.0,41.0,0.014989,0.014989,6.148468,0.761103,1.0,467.0,2.0,97.0,Adverse Event,Open-Label,FG002,heart failure,INDUSTRY,0.07014283,0.0653710274305457,0.004771802569454309
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Open-Label,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Open-Label,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,467.0,41.0,0.002141,0.002141,6.148468,0.761103,1.0,467.0,2.0,97.0,Physician Decision,Open-Label,FG002,heart failure,INDUSTRY,0.01001907,0.010042513884404731,2.344388440473147e-05
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Technical problems,Open-Label,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,467.0,41.0,0.0,0.0,6.148468,0.761103,1.0,467.0,2.0,97.0,Technical problems,Open-Label,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,467.0,41.0,0.002141,0.002141,6.148468,0.761103,1.0,467.0,2.0,97.0,Technical problems,Open-Label,FG002,heart failure,INDUSTRY,0.01001907,0.010063717779999972,4.4647779999972687e-05
2.0,529.0,510.0,0.003781,0.003781,6.272877,0.784026,1.0,529.0,13.0,146.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.01859532,0.018507842563382976,8.747743661702279e-05
1.0,529.0,510.0,0.00189,0.00189,6.272877,0.784026,1.0,529.0,13.0,146.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.0092952,0.009192760557589288,0.00010243944241071154
2.0,529.0,510.0,0.003781,0.003781,6.272877,0.784026,1.0,529.0,13.0,146.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.01859532,0.01856458362177583,3.073637822416722e-05
7.0,529.0,510.0,0.013233,0.013233,6.272877,0.784026,1.0,529.0,13.0,146.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.06508116,0.06467000442763887,0.0004111555723611271
3.0,529.0,510.0,0.005671,0.005671,6.272877,0.784026,1.0,529.0,13.0,146.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.02789052,0.028373816432172586,0.000483296432172587
4.0,529.0,510.0,0.007561,0.007561,6.272877,0.784026,1.0,529.0,13.0,146.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.03718572,0.03676477217811056,0.00042094782188943636
1.0,17.0,333.0,0.058824,0.058824,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 1 Open Label Epoch- Period 1,FG000,heart failure,INDUSTRY,0.11922986,0.12757336042515838,0.008343500425158384
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 1 Open Label Epoch- Period 1,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 1 Open Label Epoch- Period 1,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 1 Open Label Epoch- Period 1,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 1 Open Label Epoch- Period 1,FG004,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,17.0,333.0,0.058824,0.058824,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 1 Open Label Epoch- Period 1,FG000,heart failure,INDUSTRY,0.11922986,0.1281790802909918,0.008949220290991794
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 1 Open Label Epoch- Period 1,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 1 Open Label Epoch- Period 1,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 1 Open Label Epoch- Period 1,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 1 Open Label Epoch- Period 1,FG004,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,17.0,333.0,0.058824,0.058824,2.890372,0.701256,1.0,393.0,29.0,98.0,Physician Decision,Part 1 Open Label Epoch- Period 1,FG000,heart failure,INDUSTRY,0.11922986,0.12815357276390843,0.008923712763908437
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Physician Decision,Part 1 Open Label Epoch- Period 1,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Physician Decision,Part 1 Open Label Epoch- Period 1,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Physician Decision,Part 1 Open Label Epoch- Period 1,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Physician Decision,Part 1 Open Label Epoch- Period 1,FG004,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 2 Double Blind Epoch,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 2 Double Blind Epoch,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 2 Double Blind Epoch,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,17.0,333.0,0.058824,0.058824,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 2 Double Blind Epoch,FG003,heart failure,INDUSTRY,0.11922986,0.12909868835462263,0.009868828354622633
2.0,17.0,333.0,0.117647,0.117647,2.890372,0.701256,1.0,393.0,29.0,98.0,Adverse Event,Part 2 Double Blind Epoch,FG004,heart failure,INDUSTRY,0.23845769,0.3120386002932948,0.07358091029329478
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Death,Part 2 Double Blind Epoch,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Death,Part 2 Double Blind Epoch,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Death,Part 2 Double Blind Epoch,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
8.0,17.0,333.0,0.470588,0.470588,2.890372,0.701256,1.0,393.0,29.0,98.0,Death,Part 2 Double Blind Epoch,FG003,heart failure,INDUSTRY,0.95383075,1.3498389663311616,0.3960082163311617
12.0,17.0,333.0,0.705882,0.705882,2.890372,0.701256,1.0,393.0,29.0,98.0,Death,Part 2 Double Blind Epoch,FG004,heart failure,INDUSTRY,1.43074613,1.4589699746440488,0.028223844644048812
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Technical Problems,Part 2 Double Blind Epoch,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Technical Problems,Part 2 Double Blind Epoch,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Technical Problems,Part 2 Double Blind Epoch,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
4.0,17.0,333.0,0.235294,0.235294,2.890372,0.701256,1.0,393.0,29.0,98.0,Technical Problems,Part 2 Double Blind Epoch,FG003,heart failure,INDUSTRY,0.47691538,0.6724847471733937,0.19556936717339368
2.0,17.0,333.0,0.117647,0.117647,2.890372,0.701256,1.0,393.0,29.0,98.0,Technical Problems,Part 2 Double Blind Epoch,FG004,heart failure,INDUSTRY,0.23845769,0.3121214665849615,0.07366377658496148
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 2 Double Blind Epoch,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 2 Double Blind Epoch,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 2 Double Blind Epoch,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 2 Double Blind Epoch,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,17.0,333.0,0.117647,0.117647,2.890372,0.701256,1.0,393.0,29.0,98.0,Lost to Follow-up,Part 2 Double Blind Epoch,FG004,heart failure,INDUSTRY,0.23845769,0.3121214665849615,0.07366377658496148
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Subject/guardian Decision,Part 2 Double Blind Epoch,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Subject/guardian Decision,Part 2 Double Blind Epoch,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,17.0,333.0,0.0,0.0,2.890372,0.701256,1.0,393.0,29.0,98.0,Subject/guardian Decision,Part 2 Double Blind Epoch,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
5.0,17.0,333.0,0.294118,0.294118,2.890372,0.701256,1.0,393.0,29.0,98.0,Subject/guardian Decision,Part 2 Double Blind Epoch,FG003,heart failure,INDUSTRY,0.59614523,0.811707310017569,0.21556208001756905
6.0,17.0,333.0,0.352941,0.352941,2.890372,0.701256,1.0,393.0,29.0,98.0,Subject/guardian Decision,Part 2 Double Blind Epoch,FG004,heart failure,INDUSTRY,0.71537306,1.2495041269131055,0.5341310669131055
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,Core Part of Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,225.0,124.0,0.004444,0.004444,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,Core Part of Study,FG001,heart failure,INDUSTRY,0.01566053,0.01601369681356327,0.0003531668135632708
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,Core Part of Study,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,Core Part of Study,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
20.0,225.0,124.0,0.088889,0.088889,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,Core Part of Study,FG000,heart failure,INDUSTRY,0.31324233,0.3221005351018548,0.00885820510185481
17.0,225.0,124.0,0.075556,0.075556,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,Core Part of Study,FG001,heart failure,INDUSTRY,0.26625721,0.26879540479743036,0.0025381947974303376
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,Core Part of Study,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,Core Part of Study,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,225.0,124.0,0.004444,0.004444,5.420535,0.650115,1.0,225.0,1.0,49.0,Technical Problems,Core Part of Study,FG000,heart failure,INDUSTRY,0.01566053,0.016136722266063275,0.00047619226606327586
1.0,225.0,124.0,0.004444,0.004444,5.420535,0.650115,1.0,225.0,1.0,49.0,Technical Problems,Core Part of Study,FG001,heart failure,INDUSTRY,0.01566053,0.016026267656479937,0.0003657376564799378
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Technical Problems,Core Part of Study,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Technical Problems,Core Part of Study,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,OLE Part of Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,OLE Part of Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
4.0,225.0,124.0,0.017778,0.017778,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,OLE Part of Study,FG002,heart failure,INDUSTRY,0.06264917,0.06358643946892861,0.0009372694689286087
5.0,225.0,124.0,0.022222,0.022222,5.420535,0.650115,1.0,225.0,1.0,49.0,Adverse Event,OLE Part of Study,FG003,heart failure,INDUSTRY,0.0783097,0.07875500455144821,0.000445304551448214
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,OLE Part of Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,OLE Part of Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
4.0,225.0,124.0,0.017778,0.017778,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,OLE Part of Study,FG002,heart failure,INDUSTRY,0.06264917,0.06357335398825403,0.0009241839882540293
2.0,225.0,124.0,0.008889,0.008889,5.420535,0.650115,1.0,225.0,1.0,49.0,Death,OLE Part of Study,FG003,heart failure,INDUSTRY,0.03132459,0.03241418295997023,0.0010895929599702286
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Physician Decision,OLE Part of Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Physician Decision,OLE Part of Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
4.0,225.0,124.0,0.017778,0.017778,5.420535,0.650115,1.0,225.0,1.0,49.0,Physician Decision,OLE Part of Study,FG002,heart failure,INDUSTRY,0.06264917,0.06352624791783737,0.0008770779178373656
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Physician Decision,OLE Part of Study,FG003,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Subject/Guardian decision,OLE Part of Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,225.0,124.0,0.0,0.0,5.420535,0.650115,1.0,225.0,1.0,49.0,Subject/Guardian decision,OLE Part of Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,225.0,124.0,0.008889,0.008889,5.420535,0.650115,1.0,225.0,1.0,49.0,Subject/Guardian decision,OLE Part of Study,FG002,heart failure,INDUSTRY,0.03132459,0.0325045308981845,0.0011799408981845033
5.0,225.0,124.0,0.022222,0.022222,5.420535,0.650115,1.0,225.0,1.0,49.0,Subject/Guardian decision,OLE Part of Study,FG003,heart failure,INDUSTRY,0.0783097,0.07886054017061488,0.0005508401706148802
3.0,504.0,491.0,0.005952,0.005952,6.224558,0.61645,1.0,504.0,12.0,101.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.02283858,0.02257290566516685,0.00026567433483315125
2.0,504.0,491.0,0.003968,0.003968,6.224558,0.61645,1.0,504.0,12.0,101.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.01522572,0.014899855926607124,0.00032586407339287547
1.0,504.0,491.0,0.001984,0.001984,6.224558,0.61645,1.0,504.0,12.0,101.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.00761286,0.007613281644216286,4.2164421628580057e-07
6.0,504.0,491.0,0.011905,0.011905,6.224558,0.61645,1.0,504.0,12.0,101.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.04568099,0.04593101802793652,0.0002500280279365205
1.0,504.0,491.0,0.001984,0.001984,6.224558,0.61645,1.0,504.0,12.0,101.0,"Participant is alive, just unable to come for visits",Overall Study,FG000,heart failure,INDUSTRY,0.00761286,0.007605108283799619,7.751716200380537e-06
0.0,504.0,491.0,0.0,0.0,6.224558,0.61645,1.0,504.0,12.0,101.0,"Participant is alive, just unable to come for visits",Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
12.0,276.0,249.0,0.043478,0.043478,5.624018,0.701756,1.0,276.0,9.0,81.0,Adverse Event,Overall Study,FG000,heart failure,INDUSTRY,0.17159407,0.16293900038484313,0.008655069615156857
4.0,276.0,249.0,0.014493,0.014493,5.624018,0.701756,1.0,276.0,9.0,81.0,Adverse Event,Overall Study,FG001,heart failure,INDUSTRY,0.05719934,0.05761666277876986,0.00041732277876985885
2.0,276.0,249.0,0.007246,0.007246,5.624018,0.701756,1.0,276.0,9.0,81.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.0285977,0.02885992497747025,0.000262224977470249
1.0,276.0,249.0,0.003623,0.003623,5.624018,0.701756,1.0,276.0,9.0,81.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.01429885,0.014272170280396845,2.667971960315478e-05
2.0,276.0,249.0,0.007246,0.007246,5.624018,0.701756,1.0,276.0,9.0,81.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.0285977,0.028833248086755973,0.00023554808675597255
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,276.0,249.0,0.007246,0.007246,5.624018,0.701756,1.0,276.0,9.0,81.0,Protocol Violation,Overall Study,FG000,heart failure,INDUSTRY,0.0285977,0.02882559527669646,0.00022789527669645968
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,Protocol Violation,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,Physician Decision,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,276.0,249.0,0.003623,0.003623,5.624018,0.701756,1.0,276.0,9.0,81.0,Physician Decision,Overall Study,FG001,heart failure,INDUSTRY,0.01429885,0.014262012540158752,3.6837459841248046e-05
1.0,276.0,249.0,0.003623,0.003623,5.624018,0.701756,1.0,276.0,9.0,81.0,Consistently forgot to bring study drug kits to site visits (for compliance check),Overall Study,FG000,heart failure,INDUSTRY,0.01429885,0.014276465853908753,2.238414609124703e-05
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,Consistently forgot to bring study drug kits to site visits (for compliance check),Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,276.0,249.0,0.003623,0.003623,5.624018,0.701756,1.0,276.0,9.0,81.0,No longer able to take medicines,Overall Study,FG000,heart failure,INDUSTRY,0.01429885,0.014276465853908753,2.238414609124703e-05
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,No longer able to take medicines,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
1.0,276.0,249.0,0.003623,0.003623,5.624018,0.701756,1.0,276.0,9.0,81.0,Stopped taking study drug,Overall Study,FG000,heart failure,INDUSTRY,0.01429885,0.014276465853908753,2.238414609124703e-05
0.0,276.0,249.0,0.0,0.0,5.624018,0.701756,1.0,276.0,9.0,81.0,Stopped taking study drug,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,6263.0,6242.0,0.000319,0.000319,8.742574,0.71521,1.0,6263.0,20.0,348.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.00199464,0.00202180795049603,2.716795049602979e-05
1.0,6263.0,6242.0,0.00016,0.00016,8.742574,0.71521,1.0,6263.0,20.0,348.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.00100044,0.000993707045238095,6.732954761904915e-06
8.0,6263.0,6242.0,0.001277,0.001277,8.742574,0.71521,1.0,6263.0,20.0,348.0,Withdrawal by Subject,Overall Study,FG000,heart failure,INDUSTRY,0.00798479,0.007508057584801588,0.00047673241519841265
10.0,6263.0,6242.0,0.001597,0.001597,8.742574,0.71521,1.0,6263.0,20.0,348.0,Withdrawal by Subject,Overall Study,FG001,heart failure,INDUSTRY,0.00998568,0.009190560907142866,0.0007951190928571338
3.0,225.0,203.0,0.013333,0.013333,5.420535,0.426176,1.0,225.0,1.0,17.0,Death,Overall Study,FG000,heart failure,OTHER,0.03080057,0.030915948406309565,0.00011537840630956517
1.0,225.0,203.0,0.004444,0.004444,5.420535,0.426176,1.0,225.0,1.0,17.0,Death,Overall Study,FG001,heart failure,OTHER,0.01026609,0.010477015728353172,0.00021092572835317187
1.0,225.0,203.0,0.004444,0.004444,5.420535,0.426176,1.0,225.0,1.0,17.0,Lost to Follow-up,Overall Study,FG000,heart failure,OTHER,0.01026609,0.010463203791713565,0.000197113791713565
0.0,225.0,203.0,0.0,0.0,5.420535,0.426176,1.0,225.0,1.0,17.0,Lost to Follow-up,Overall Study,FG001,heart failure,OTHER,0.0,0.0,0.0
3.0,225.0,203.0,0.013333,0.013333,5.420535,0.426176,1.0,225.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG000,heart failure,OTHER,0.03080057,0.030910084355059566,0.00010951435505956661
9.0,225.0,203.0,0.04,0.04,5.420535,0.426176,1.0,225.0,1.0,17.0,Withdrawal by Subject,Overall Study,FG001,heart failure,OTHER,0.09240403,0.09305974521288686,0.0006557152128868621
2.0,225.0,203.0,0.008889,0.008889,5.420535,0.426176,1.0,225.0,1.0,17.0,Physician Decision,Overall Study,FG000,heart failure,OTHER,0.02053449,0.021085319188303538,0.0005508291883035386
3.0,225.0,203.0,0.013333,0.013333,5.420535,0.426176,1.0,225.0,1.0,17.0,Physician Decision,Overall Study,FG001,heart failure,OTHER,0.03080057,0.030888548643452425,8.797864345242573e-05
713.0,7064.0,4630.0,0.100934,0.100934,8.862908,0.407575,1.0,7064.0,44.0,806.0,Death,Overall Study,FG000,heart failure,INDUSTRY,0.36460375,0.3666747054416667,0.0020709554416666887
768.0,7064.0,4630.0,0.10872,0.10872,8.862908,0.407575,1.0,7064.0,44.0,806.0,Death,Overall Study,FG001,heart failure,INDUSTRY,0.39272911,0.38132731835559547,0.011401791644404524
753.0,7064.0,4630.0,0.106597,0.106597,8.862908,0.407575,1.0,7064.0,44.0,806.0,Death,Overall Study,FG002,heart failure,INDUSTRY,0.3850602,0.3782587676278574,0.006801432372142646
11.0,7064.0,4630.0,0.001557,0.001557,8.862908,0.407575,1.0,7064.0,44.0,806.0,Lost to Follow-up,Overall Study,FG000,heart failure,INDUSTRY,0.00562435,0.005564284235575394,6.006576442460585e-05
6.0,7064.0,4630.0,0.000849,0.000849,8.862908,0.407575,1.0,7064.0,44.0,806.0,Lost to Follow-up,Overall Study,FG001,heart failure,INDUSTRY,0.00306684,0.0030198147451758633,4.7025254824136636e-05
11.0,7064.0,4630.0,0.001557,0.001557,8.862908,0.407575,1.0,7064.0,44.0,806.0,Lost to Follow-up,Overall Study,FG002,heart failure,INDUSTRY,0.00562435,0.0056011188149503975,2.323118504960267e-05
26.0,7064.0,4630.0,0.003681,0.003681,8.862908,0.407575,1.0,7064.0,44.0,806.0,H.A. Request,Overall Study,FG000,heart failure,INDUSTRY,0.01329687,0.013414017814851194,0.0001171478148511932
23.0,7064.0,4630.0,0.003256,0.003256,8.862908,0.407575,1.0,7064.0,44.0,806.0,H.A. Request,Overall Study,FG001,heart failure,INDUSTRY,0.01176164,0.011522638148017681,0.00023900185198231887
19.0,7064.0,4630.0,0.00269,0.00269,8.862908,0.407575,1.0,7064.0,44.0,806.0,H.A. Request,Overall Study,FG002,heart failure,INDUSTRY,0.00971708,0.009876600591460137,0.0001595205914601376
0.0,7064.0,4630.0,0.0,0.0,8.862908,0.407575,1.0,7064.0,44.0,806.0,IRB request,Overall Study,FG000,heart failure,INDUSTRY,0.0,0.0,0.0
0.0,7064.0,4630.0,0.0,0.0,8.862908,0.407575,1.0,7064.0,44.0,806.0,IRB request,Overall Study,FG001,heart failure,INDUSTRY,0.0,0.0,0.0
2.0,7064.0,4630.0,0.000283,0.000283,8.862908,0.407575,1.0,7064.0,44.0,806.0,IRB request,Overall Study,FG002,heart failure,INDUSTRY,0.00102228,0.0010218177395238102,4.622604761897811e-07
2.0,7064.0,4630.0,0.000283,0.000283,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status known (alive) at study end,Overall Study,FG000,heart failure,INDUSTRY,0.00102228,0.001023201452738096,9.214527380960093e-07
3.0,7064.0,4630.0,0.000425,0.000425,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status known (alive) at study end,Overall Study,FG001,heart failure,INDUSTRY,0.00153523,0.0015291605706250011,6.06942937499892e-06
3.0,7064.0,4630.0,0.000425,0.000425,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status known (alive) at study end,Overall Study,FG002,heart failure,INDUSTRY,0.00153523,0.0015311120072916678,4.1179927083323e-06
1.0,7064.0,4630.0,0.000142,0.000142,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status unknown at study end,Overall Study,FG000,heart failure,INDUSTRY,0.00051295,0.0005065733030303029,6.37669696969712e-06
1.0,7064.0,4630.0,0.000142,0.000142,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status unknown at study end,Overall Study,FG001,heart failure,INDUSTRY,0.00051295,0.0005078133979816011,5.136602018398877e-06
0.0,7064.0,4630.0,0.0,0.0,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status unknown at study end,Overall Study,FG002,heart failure,INDUSTRY,0.0,0.0,0.0
8.0,7064.0,4630.0,0.001133,0.001133,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status at study end N/A,Overall Study,FG000,heart failure,INDUSTRY,0.00409273,0.0041345062329464265,4.177623294642635e-05
10.0,7064.0,4630.0,0.001416,0.001416,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status at study end N/A,Overall Study,FG001,heart failure,INDUSTRY,0.00511501,0.005102590746875004,1.2419253124995415e-05
10.0,7064.0,4630.0,0.001416,0.001416,8.862908,0.407575,1.0,7064.0,44.0,806.0,Vital Status at study end N/A,Overall Study,FG002,heart failure,INDUSTRY,0.00511501,0.005096917660238098,1.8092339761901707e-05
21.0,7064.0,4630.0,0.002973,0.002973,8.862908,0.407575,1.0,7064.0,44.0,806.0,Patient's request,Overall Study,FG000,heart failure,INDUSTRY,0.01073936,0.01075918762606331,1.9827626063310608e-05
17.0,7064.0,4630.0,0.002407,0.002407,8.862908,0.407575,1.0,7064.0,44.0,806.0,Patient's request,Overall Study,FG001,heart failure,INDUSTRY,0.0086948,0.008764996864609487,7.019686460948624e-05
11.0,7064.0,4630.0,0.001557,0.001557,8.862908,0.407575,1.0,7064.0,44.0,806.0,Patient's request,Overall Study,FG002,heart failure,INDUSTRY,0.00562435,0.005602656603144843,2.1693396855156956e-05
5.0,7064.0,4630.0,0.000708,0.000708,8.862908,0.407575,1.0,7064.0,44.0,806.0,Missing study completion information,Overall Study,FG000,heart failure,INDUSTRY,0.00255751,0.0025211266987500013,3.6383301249998546e-05
4.0,7064.0,4630.0,0.000566,0.000566,8.862908,0.407575,1.0,7064.0,44.0,806.0,Missing study completion information,Overall Study,FG001,heart failure,INDUSTRY,0.00204456,0.0021034942298313554,5.8934229831355406e-05
6.0,7064.0,4630.0,0.000849,0.000849,8.862908,0.407575,1.0,7064.0,44.0,806.0,Missing study completion information,Overall Study,FG002,heart failure,INDUSTRY,0.00306684,0.0029902657224080056,7.657427759199436e-05
8.0,406.0,364.0,0.019704,0.019704,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Period 1,FG000,dyslipidemia,INDUSTRY,0.03562856,0.035452469230327424,0.00017609076967257248
4.0,406.0,364.0,0.009852,0.009852,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Period 1,FG001,dyslipidemia,INDUSTRY,0.01781428,0.01778412773841265,3.0152261587347573e-05
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Lost to Follow-up,Period 1,FG000,dyslipidemia,INDUSTRY,0.00890714,0.008905210919027729,1.929080972270028e-06
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Lost to Follow-up,Period 1,FG001,dyslipidemia,INDUSTRY,0.00890714,0.008895046629861073,1.2093370138925932e-05
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Protocol Violation,Period 1,FG000,dyslipidemia,INDUSTRY,0.00890714,0.008911918970694398,4.778970694398546e-06
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Protocol Violation,Period 1,FG001,dyslipidemia,INDUSTRY,0.00890714,0.008901930400277742,5.209599722257041e-06
4.0,406.0,364.0,0.009852,0.009852,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Period 1,FG000,dyslipidemia,INDUSTRY,0.01781428,0.017779889903531708,3.4390096468290415e-05
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Period 1,FG001,dyslipidemia,INDUSTRY,0.00890714,0.008901425149761869,5.7148502381303146e-06
0.0,406.0,364.0,0.0,0.0,6.008813,0.300923,1.0,406.0,0.0,0.0,Could not access randomization system,Period 1,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Could not access randomization system,Period 1,FG001,dyslipidemia,INDUSTRY,0.00445357,0.0044516068680654506,1.9631319345490145e-06
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Crossover Washout Period,FG000,dyslipidemia,INDUSTRY,0.00445357,0.004455089473958307,1.5194739583076697e-06
4.0,406.0,364.0,0.009852,0.009852,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Crossover Washout Period,FG001,dyslipidemia,INDUSTRY,0.01781428,0.017781170730912663,3.310926908733566e-05
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Lost to Follow-up,Crossover Washout Period,FG000,dyslipidemia,INDUSTRY,0.00890714,0.008908406900932496,1.2669009324967756e-06
0.0,406.0,364.0,0.0,0.0,6.008813,0.300923,1.0,406.0,0.0,0.0,Lost to Follow-up,Crossover Washout Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Non-compliance with Study Drug,Crossover Washout Period,FG000,dyslipidemia,INDUSTRY,0.00445357,0.004454574352232119,1.0043522321191017e-06
0.0,406.0,364.0,0.0,0.0,6.008813,0.300923,1.0,406.0,0.0,0.0,Non-compliance with Study Drug,Crossover Washout Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Crossover Washout Period,FG000,dyslipidemia,INDUSTRY,0.00890714,0.008914575979166624,7.435979166624598e-06
2.0,406.0,364.0,0.004926,0.004926,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Crossover Washout Period,FG001,dyslipidemia,INDUSTRY,0.00890714,0.008904691219166636,2.4487808333636257e-06
0.0,406.0,364.0,0.0,0.0,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Period 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Adverse Event,Period 2,FG001,dyslipidemia,INDUSTRY,0.00445357,0.004452005962708304,1.5640372916956788e-06
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Period 2,FG000,dyslipidemia,INDUSTRY,0.00445357,0.004455152206815449,1.5822068154492872e-06
1.0,406.0,364.0,0.002463,0.002463,6.008813,0.300923,1.0,406.0,0.0,0.0,Withdrawal by Subject,Period 2,FG001,dyslipidemia,INDUSTRY,0.00445357,0.00445184225139878,1.7277486012191867e-06
2.0,803.0,653.0,0.002491,0.002491,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00650302,0.006507633498068162,4.6134980681619e-06
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00325021,0.003241527065535727,8.682934464272762e-06
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00325021,0.003250708710714299,4.987107142992962e-07
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,803.0,653.0,0.003736,0.003736,6.689599,0.390249,1.0,803.0,8.0,83.0,Participant moved,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00975323,0.009736027609662667,1.7202390337332785e-05
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,803.0,653.0,0.002491,0.002491,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00650302,0.006503520180538403,5.00180538403304e-07
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00325021,0.0032314928973809663,1.8717102619033622e-05
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00325021,0.003241006108392872,9.203891607127701e-06
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Physician Decision,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,803.0,653.0,0.002491,0.002491,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00650302,0.006507633498068162,4.6134980681619e-06
3.0,803.0,653.0,0.003736,0.003736,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00975323,0.009731964898710288,2.1265101289712207e-05
5.0,803.0,653.0,0.006227,0.006227,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01625625,0.01627663499622022,2.0384996220219193e-05
12.0,803.0,653.0,0.014944,0.014944,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG003,dyslipidemia,INDUSTRY,0.03901292,0.03849025001364088,0.0005226699863591228
4.0,803.0,653.0,0.004981,0.004981,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01300344,0.013016252328660724,1.281232866072457e-05
11.0,803.0,653.0,0.013699,0.013699,6.689599,0.390249,1.0,803.0,8.0,83.0,Other than specified,Overall Study,FG005,dyslipidemia,INDUSTRY,0.03576271,0.03612075024533731,0.00035804024533730994
13.0,803.0,653.0,0.016189,0.016189,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04226312,0.04224197016721231,2.114983278769106e-05
4.0,803.0,653.0,0.004981,0.004981,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01300344,0.012996460502202392,6.979497797607662e-06
17.0,803.0,653.0,0.021171,0.021171,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.05526917,0.056796753520565485,0.0015275835205654856
4.0,803.0,653.0,0.004981,0.004981,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01300344,0.012997734720119065,5.705279880934347e-06
3.0,803.0,653.0,0.003736,0.003736,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00975323,0.009757002050793622,3.7720507936218894e-06
14.0,803.0,653.0,0.017435,0.017435,6.689599,0.390249,1.0,803.0,8.0,83.0,Adverse Event,Overall Study,FG005,dyslipidemia,INDUSTRY,0.04551594,0.04651856149749009,0.001002621497490093
5.0,803.0,653.0,0.006227,0.006227,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01625625,0.016278285246517837,2.2035246517837503e-05
3.0,803.0,653.0,0.003736,0.003736,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00975323,0.009720486051091238,3.274394890876234e-05
8.0,803.0,653.0,0.009963,0.009963,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02600948,0.02617950632603627,0.00017002632603626763
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00325021,0.0032489264377976307,1.2835622023692206e-06
6.0,803.0,653.0,0.007472,0.007472,6.689599,0.390249,1.0,803.0,8.0,83.0,Poor compliance to protocol,Overall Study,FG005,dyslipidemia,INDUSTRY,0.01950646,0.019197845585119045,0.0003086144148809547
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00325021,0.0032500756398809653,1.3436011903457737e-07
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Randomized and not treated,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,803.0,653.0,0.007472,0.007472,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01950646,0.019180410397380956,0.00032604960261904334
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00325021,0.0032521460522023926,1.9360522023927074e-06
8.0,803.0,653.0,0.009963,0.009963,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02600948,0.026163635353119604,0.00015415535311960257
1.0,803.0,653.0,0.001245,0.001245,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00325021,0.0032502664898809656,5.6489880965668315e-08
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,803.0,653.0,0.006227,0.006227,6.689599,0.390249,1.0,803.0,8.0,83.0,Withdrawal by Subject,Overall Study,FG005,dyslipidemia,INDUSTRY,0.01625625,0.016296543985624985,4.029398562498468e-05
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,803.0,653.0,0.0,0.0,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,803.0,653.0,0.002491,0.002491,6.689599,0.390249,1.0,803.0,8.0,83.0,Related to study drug administration,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00650302,0.006503795806163403,7.758061634031282e-07
7.0,315.0,241.0,0.022222,0.022222,5.755742,0.323595,1.0,315.0,5.0,15.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0413891,0.04135989090912704,2.9209090872957255e-05
3.0,315.0,241.0,0.009524,0.009524,5.755742,0.323595,1.0,315.0,5.0,15.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01773872,0.017703083001845213,3.56369981547866e-05
56.0,315.0,241.0,0.177778,0.177778,5.755742,0.323595,1.0,315.0,5.0,15.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.33111653,0.37007099291659723,0.03895446291659721
0.0,315.0,241.0,0.0,0.0,5.755742,0.323595,1.0,315.0,5.0,15.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,315.0,241.0,0.006349,0.006349,5.755742,0.323595,1.0,315.0,5.0,15.0,Provided in CRF for specific reasons,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01182519,0.012223080825843273,0.0003978908258432737
3.0,315.0,241.0,0.009524,0.009524,5.755742,0.323595,1.0,315.0,5.0,15.0,Provided in CRF for specific reasons,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01773872,0.01769842950470236,4.029049529763809e-05
3.0,315.0,241.0,0.009524,0.009524,5.755742,0.323595,1.0,315.0,5.0,15.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01773872,0.017701244943690454,3.747505630954592e-05
0.0,315.0,241.0,0.0,0.0,5.755742,0.323595,1.0,315.0,5.0,15.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,350.0,334.0,0.014286,0.014286,5.860786,0.868074,1.0,350.0,5.0,42.0,Subject decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.07268142,0.07336530956452388,0.0006838895645238791
2.0,350.0,334.0,0.005714,0.005714,5.860786,0.868074,1.0,350.0,5.0,42.0,Subject decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02907053,0.029786452241250025,0.0007159222412500242
1.0,350.0,334.0,0.002857,0.002857,5.860786,0.868074,1.0,350.0,5.0,42.0,Subject decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01453527,0.014739570860654735,0.000204300860654736
4.0,350.0,334.0,0.011429,0.011429,5.860786,0.868074,1.0,350.0,5.0,42.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.05814616,0.05797971375809894,0.00016644624190106233
1.0,350.0,334.0,0.002857,0.002857,5.860786,0.868074,1.0,350.0,5.0,42.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01453527,0.014764916379910691,0.00022964637991069146
2.0,350.0,334.0,0.005714,0.005714,5.860786,0.868074,1.0,350.0,5.0,42.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02907053,0.029763446088869067,0.0006929160888690666
1.0,350.0,334.0,0.002857,0.002857,5.860786,0.868074,1.0,350.0,5.0,42.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01453527,0.014743115293273785,0.00020784529327378537
0.0,350.0,334.0,0.0,0.0,5.860786,0.868074,1.0,350.0,5.0,42.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,350.0,334.0,0.0,0.0,5.860786,0.868074,1.0,350.0,5.0,42.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
7.0,702.0,663.0,0.009972,0.009972,6.555357,0.272045,1.0,702.0,1.0,80.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01778359,0.017871362557033733,8.777255703373496e-05
8.0,702.0,663.0,0.011396,0.011396,6.555357,0.272045,1.0,702.0,1.0,80.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02032309,0.02039491973226191,7.182973226190978e-05
5.0,702.0,663.0,0.007123,0.007123,6.555357,0.272045,1.0,702.0,1.0,80.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01270282,0.012779604898074488,7.678489807448792e-05
6.0,702.0,663.0,0.008547,0.008547,6.555357,0.272045,1.0,702.0,1.0,80.0,Withdrew Consent,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01524232,0.015280530559434527,3.821055943452681e-05
2.0,702.0,663.0,0.002849,0.002849,6.555357,0.272045,1.0,702.0,1.0,80.0,Withdrew Consent,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00508077,0.005016863635396824,6.39063646031765e-05
4.0,702.0,663.0,0.005698,0.005698,6.555357,0.272045,1.0,702.0,1.0,80.0,Withdrew Consent,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01016154,0.010315224821081328,0.00015368482108132735
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00254128,0.0025494258923511853,8.145892351185333e-06
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00254128,0.0025488950836011857,7.615083601185749e-06
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Triglycerides >800 mg/dL,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00254128,0.002549388721696421,8.1087216964211e-06
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Triglycerides >800 mg/dL,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Triglycerides >800 mg/dL,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00254128,0.002549144196696421,7.864196696421091e-06
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Other discontinuation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00254128,0.0025480914941964196,6.811494196419694e-06
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Other discontinuation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Other discontinuation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00254128,0.002544668959196421,3.3889591964210777e-06
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Investigator judgement,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,702.0,663.0,0.0,0.0,6.555357,0.272045,1.0,702.0,1.0,80.0,Investigator judgement,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,702.0,663.0,0.001425,0.001425,6.555357,0.272045,1.0,702.0,1.0,80.0,Investigator judgement,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00254128,0.002545966186696423,4.686186696422918e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG001,dyslipidemia,INDUSTRY,0.00440203,0.004389177038095247,1.2852961904753595e-05
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG002,dyslipidemia,INDUSTRY,0.00440203,0.004398035391666676,3.994608333324039e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG005,dyslipidemia,INDUSTRY,0.00440203,0.004399648667261915,2.381332738085433e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period1 to End Period1 (Week 1-6),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG005,dyslipidemia,INDUSTRY,0.00440203,0.004401739421428581,2.9057857141908533e-07
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period1 to End Period1 (Week 1-6),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG003,dyslipidemia,INDUSTRY,0.00440203,0.0043938088711309616,8.2211288690388e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period1 to End Period1 (Week 1-6),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG002,dyslipidemia,INDUSTRY,0.00440203,0.004400787695833342,1.2423041666582632e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG004,dyslipidemia,INDUSTRY,0.00440203,0.004401863646428581,1.663535714197667e-07
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period1 to End Period1 (Week 1-6),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,248.0,222.0,0.008065,0.008065,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG002,dyslipidemia,INDUSTRY,0.00880515,0.009014604269682529,0.00020945426968252932
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Adverse Event,Start Period2 to End Period2 (Week 7-33),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,248.0,222.0,0.012097,0.012097,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG002,dyslipidemia,INDUSTRY,0.01320718,0.013680870591359123,0.00047369059135912196
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG005,dyslipidemia,INDUSTRY,0.00440203,0.0043986461130952476,3.383886904752796e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Laboratory Adverse Event,Start Period2 to End Period2 (Week 7-33),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG002,dyslipidemia,INDUSTRY,0.00440203,0.004398022108333343,4.007891666657493e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period2 to End Period2 (Week 7-33),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG002,dyslipidemia,INDUSTRY,0.00440203,0.004398197275000009,3.832724999991086e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,248.0,222.0,0.012097,0.012097,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG005,dyslipidemia,INDUSTRY,0.01320718,0.013665479666150795,0.0004582996661507948
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period2 to End Period2 (Week 7-33),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG002,dyslipidemia,INDUSTRY,0.00440203,0.00439043492470239,1.159507529761069e-05
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG005,dyslipidemia,INDUSTRY,0.00440203,0.004391253879464294,1.0776120535706084e-05
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period2 to End Period2 (Week 7-33),FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Lost to Follow-up,Start Period3 to End Period3(Week 34-53),FG006,dyslipidemia,INDUSTRY,0.00440203,0.004397042106011914,4.987893988086384e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,248.0,222.0,0.012097,0.012097,5.517453,0.197876,1.0,248.0,0.0,0.0,Withdrawal by Subject,Start Period3 to End Period3(Week 34-53),FG006,dyslipidemia,INDUSTRY,0.01320718,0.013665479666150795,0.0004582996661507948
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Subject moved,Start Period3 to End Period3(Week 34-53),FG006,dyslipidemia,INDUSTRY,0.00440203,0.004396847156011914,5.182843988086293e-06
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,248.0,222.0,0.0,0.0,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,248.0,222.0,0.004032,0.004032,5.517453,0.197876,1.0,248.0,0.0,0.0,Protocol Violation,Start Period3 to End Period3(Week 34-53),FG006,dyslipidemia,INDUSTRY,0.00440203,0.004389552397380961,1.2477602619039192e-05
1.0,307.0,290.0,0.003257,0.003257,5.7301,0.346738,1.0,307.0,14.0,58.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00647115,0.006473749207023811,2.599207023811119e-06
1.0,307.0,290.0,0.003257,0.003257,5.7301,0.346738,1.0,307.0,14.0,58.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00647115,0.0064740570674404795,2.907067440479326e-06
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,307.0,290.0,0.003257,0.003257,5.7301,0.346738,1.0,307.0,14.0,58.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00647115,0.006470375233690479,7.747663095213075e-07
5.0,307.0,290.0,0.016287,0.016287,5.7301,0.346738,1.0,307.0,14.0,58.0,Decision by sponsor,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03235972,0.03238358324330355,2.3863243303549886e-05
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Decision by sponsor,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
8.0,307.0,290.0,0.026059,0.026059,5.7301,0.346738,1.0,307.0,14.0,58.0,Decision by sponsor,Overall Study,FG002,dyslipidemia,INDUSTRY,0.05177515,0.05343961087635914,0.0016644608763591376
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Decision by sponsor,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,307.0,290.0,0.003257,0.003257,5.7301,0.346738,1.0,307.0,14.0,58.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00647115,0.006486110797440479,1.4960797440478728e-05
0.0,307.0,290.0,0.0,0.0,5.7301,0.346738,1.0,307.0,14.0,58.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
16.0,1053.0,1010.0,0.015195,0.015195,6.960348,0.222179,1.0,1053.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02349821,0.023369674033928554,0.00012853596607144413
9.0,1053.0,1010.0,0.008547,0.008547,6.960348,0.222179,1.0,1053.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01321745,0.013203915983769845,1.3534016230155183e-05
0.0,1053.0,1010.0,0.0,0.0,6.960348,0.222179,1.0,1053.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1053.0,1010.0,0.00095,0.00095,6.960348,0.222179,1.0,1053.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00146912,0.0014697976433594878,6.776433594877888e-07
4.0,1053.0,1010.0,0.003799,0.003799,6.960348,0.222179,1.0,1053.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00587494,0.0057457269791765875,0.00012921302082341286
3.0,1053.0,1010.0,0.002849,0.002849,6.960348,0.222179,1.0,1053.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00440582,0.004365338301236455,4.048169876354549e-05
3.0,1053.0,1010.0,0.002849,0.002849,6.960348,0.222179,1.0,1053.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00440582,0.004365216277218598,4.0603722781402604e-05
7.0,1053.0,1010.0,0.006648,0.006648,6.960348,0.222179,1.0,1053.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01028075,0.010171682083422623,0.00010906791657737738
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,454.0,416.0,0.002203,0.002203,6.120297,0.656629,1.0,454.0,1.0,30.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00885334,0.009166176140605156,0.00031283614060515635
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Death,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,454.0,416.0,0.004405,0.004405,6.120297,0.656629,1.0,454.0,1.0,30.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01770266,0.017714560351706373,1.1900351706374546e-05
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,454.0,416.0,0.0,0.0,6.120297,0.656629,1.0,454.0,1.0,30.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,454.0,416.0,0.006608,0.006608,6.120297,0.656629,1.0,454.0,1.0,30.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.026556,0.026889092876498023,0.0003330928764980236
2.0,454.0,416.0,0.004405,0.004405,6.120297,0.656629,1.0,454.0,1.0,30.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01770266,0.017631469265813528,7.119073418647079e-05
4.0,454.0,416.0,0.008811,0.008811,6.120297,0.656629,1.0,454.0,1.0,30.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.03540934,0.03546237900970229,5.3039009702292306e-05
4.0,454.0,416.0,0.008811,0.008811,6.120297,0.656629,1.0,454.0,1.0,30.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.03540934,0.03536286994595229,4.6470054047710596e-05
7.0,454.0,416.0,0.015419,0.015419,6.120297,0.656629,1.0,454.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.06196535,0.06272776680171639,0.0007624168017163896
2.0,454.0,416.0,0.004405,0.004405,6.120297,0.656629,1.0,454.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01770266,0.017627404967480192,7.525503251980606e-05
6.0,454.0,416.0,0.013216,0.013216,6.120297,0.656629,1.0,454.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.05311201,0.0539869835262798,0.0008749735262797986
7.0,454.0,416.0,0.015419,0.015419,6.120297,0.656629,1.0,454.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.06196535,0.06276703228632949,0.0008016822863294859
0.0,162.0,156.0,0.0,0.0,5.09375,0.381185,1.0,379.0,7.0,40.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,162.0,156.0,0.012346,0.012346,5.09375,0.381185,1.0,379.0,7.0,40.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02397172,0.024729801803115098,0.0007580818031150995
0.0,162.0,156.0,0.0,0.0,5.09375,0.381185,1.0,379.0,7.0,40.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,162.0,156.0,0.012346,0.012346,5.09375,0.381185,1.0,379.0,7.0,40.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02397172,0.024739936484781767,0.0007682164847817689
1.0,162.0,156.0,0.006173,0.006173,5.09375,0.381185,1.0,379.0,7.0,40.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01198586,0.012867332972192471,0.0008814729721924718
1.0,162.0,156.0,0.006173,0.006173,5.09375,0.381185,1.0,379.0,7.0,40.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01198586,0.012837142527192475,0.0008512825271924755
10.0,1196.0,1154.0,0.008361,0.008361,7.087574,0.775143,1.0,1196.0,1.0,1.0,Screen failure or other uncategorised,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04593435,0.04538420260126982,0.0005501473987301816
4.0,1196.0,1154.0,0.003344,0.003344,7.087574,0.775143,1.0,1196.0,1.0,1.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01837154,0.018455191846671187,8.365184667118858e-05
9.0,1196.0,1154.0,0.007525,0.007525,7.087574,0.775143,1.0,1196.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04134147,0.04160442459180555,0.00026295459180555175
18.0,1196.0,1154.0,0.01505,0.01505,7.087574,0.775143,1.0,1196.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.08268293,0.08131006363808531,0.001372866361914693
1.0,1196.0,1154.0,0.000836,0.000836,7.087574,0.775143,1.0,1196.0,1.0,1.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00459289,0.0047991483888690485,0.0002062583888690489
3.0,354.0,336.0,0.008475,0.008475,5.872118,0.863348,1.0,354.0,10.0,96.0,Withdrawal of Consent,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04296554,0.04330918451151526,0.0003436445115152578
3.0,354.0,336.0,0.008475,0.008475,5.872118,0.863348,1.0,354.0,10.0,96.0,Withdrawal of Consent,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04296554,0.04328712775252718,0.00032158775252717764
2.0,354.0,336.0,0.00565,0.00565,5.872118,0.863348,1.0,354.0,10.0,96.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02864369,0.02890574054244585,0.0002620505424458519
3.0,354.0,336.0,0.008475,0.008475,5.872118,0.863348,1.0,354.0,10.0,96.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04296554,0.04334647496294385,0.0003809349629438491
1.0,354.0,336.0,0.002825,0.002825,5.872118,0.863348,1.0,354.0,10.0,96.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01432185,0.014382632333065453,6.07823330654525e-05
2.0,354.0,336.0,0.00565,0.00565,5.872118,0.863348,1.0,354.0,10.0,96.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02864369,0.028916519312445845,0.0002728293124458457
0.0,354.0,336.0,0.0,0.0,5.872118,0.863348,1.0,354.0,10.0,96.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,354.0,336.0,0.002825,0.002825,5.872118,0.863348,1.0,354.0,10.0,96.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01432185,0.014346346994583306,2.449699458330519e-05
0.0,354.0,336.0,0.0,0.0,5.872118,0.863348,1.0,354.0,10.0,96.0,Did not return for end of study visit,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,354.0,336.0,0.002825,0.002825,5.872118,0.863348,1.0,354.0,10.0,96.0,Did not return for end of study visit,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01432185,0.014342963350595213,2.111335059521227e-05
1.0,354.0,336.0,0.002825,0.002825,5.872118,0.863348,1.0,354.0,10.0,96.0,End of study visit completed by phone,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01432185,0.014344892080089265,2.304208008926424e-05
0.0,354.0,336.0,0.0,0.0,5.872118,0.863348,1.0,354.0,10.0,96.0,End of study visit completed by phone,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,354.0,336.0,0.002825,0.002825,5.872118,0.863348,1.0,354.0,10.0,96.0,Subject decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01432185,0.014344892080089265,2.304208008926424e-05
0.0,354.0,336.0,0.0,0.0,5.872118,0.863348,1.0,354.0,10.0,96.0,Subject decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00276631,0.002767059536493517,7.495364935166879e-07
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00138447,0.0013870749040178648,2.604904017864708e-06
4.0,1899.0,1826.0,0.002106,0.002106,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00553262,0.005526869782138351,5.7502178616494065e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,1899.0,1826.0,0.00158,0.00158,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00415078,0.004184184101071434,3.340410107143411e-05
4.0,1899.0,1826.0,0.002106,0.002106,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00553262,0.00552506364838835,7.5563516116500945e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG007,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG008,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG009,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG010,dyslipidemia,INDUSTRY,0.00276631,0.0027677908573268527,1.4808573268526234e-06
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG011,dyslipidemia,INDUSTRY,0.00276631,0.0027677908573268527,1.4808573268526234e-06
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG012,dyslipidemia,INDUSTRY,0.00276631,0.0027677908573268527,1.4808573268526234e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG013,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,1899.0,1826.0,0.00316,0.00316,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG014,dyslipidemia,INDUSTRY,0.00830155,0.00828855782074406,1.2992179255939817e-05
3.0,1899.0,1826.0,0.00158,0.00158,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG015,dyslipidemia,INDUSTRY,0.00415078,0.004184563593571434,3.3783593571434095e-05
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG016,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG017,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG018,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG019,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG020,dyslipidemia,INDUSTRY,0.00276631,0.0027677908573268527,1.4808573268526234e-06
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG021,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG022,dyslipidemia,INDUSTRY,0.00276631,0.0027677908573268527,1.4808573268526234e-06
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Withdrawal by Subject,Overall Study,FG023,dyslipidemia,INDUSTRY,0.00138447,0.0013844791797321511,9.179732151070458e-09
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00138447,0.001384398193422627,7.180657737295912e-08
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00276631,0.0027690120138149465,2.7020138149464086e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00276631,0.0027690120138149465,2.7020138149464086e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG007,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG008,dyslipidemia,INDUSTRY,0.00276631,0.0027690120138149465,2.7020138149464086e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG009,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,1899.0,1826.0,0.00316,0.00316,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG010,dyslipidemia,INDUSTRY,0.00830155,0.008279693625327392,2.185637467260783e-05
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG011,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG012,dyslipidemia,INDUSTRY,0.00138447,0.0013842264184226272,2.4358157737288007e-07
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG013,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,1899.0,1826.0,0.002633,0.002633,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG014,dyslipidemia,INDUSTRY,0.00691709,0.007210116651904761,0.0002930266519047611
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG015,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG016,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG017,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,1899.0,1826.0,0.002106,0.002106,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG018,dyslipidemia,INDUSTRY,0.00553262,0.005525691590114541,6.92840988545957e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG019,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1899.0,1826.0,0.001053,0.001053,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG020,dyslipidemia,INDUSTRY,0.00276631,0.0027690120138149465,2.7020138149464086e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG021,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG022,dyslipidemia,INDUSTRY,0.00138447,0.0013842264184226272,2.4358157737288007e-07
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Decision by sponsor,Overall Study,FG023,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00138447,0.0013823649112698496,2.105088730150473e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG007,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG008,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG009,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG010,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG011,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG012,dyslipidemia,INDUSTRY,0.00138447,0.0013823649112698496,2.105088730150473e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG013,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG014,dyslipidemia,INDUSTRY,0.00138447,0.0013823649112698496,2.105088730150473e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG015,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG016,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG017,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG018,dyslipidemia,INDUSTRY,0.00138447,0.0013823649112698496,2.105088730150473e-06
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG019,dyslipidemia,INDUSTRY,0.00138447,0.0013823649112698496,2.105088730150473e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG020,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG021,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG022,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Lost to Follow-up,Overall Study,FG023,dyslipidemia,INDUSTRY,0.00138447,0.001382353019603183,2.1169803968170385e-06
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG007,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG008,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG009,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG010,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG011,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG012,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG013,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG014,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG015,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1899.0,1826.0,0.000527,0.000527,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG016,dyslipidemia,INDUSTRY,0.00138447,0.0013836891148511982,7.808851488018322e-07
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG017,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG018,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG019,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG020,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG021,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG022,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1899.0,1826.0,0.0,0.0,7.549609,0.347975,1.0,2067.0,21.0,244.0,Death,Overall Study,FG023,dyslipidemia,INDUSTRY,0.0,0.0,0.0
41.0,309.0,116.0,0.132686,0.132686,5.736572,0.416277,1.0,309.0,30.0,113.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.31685473,0.32140806391971233,0.004553333919712355
15.0,309.0,116.0,0.048544,0.048544,5.736572,0.416277,1.0,309.0,30.0,113.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.11592328,0.11586028703292653,6.299296707347468e-05
27.0,309.0,116.0,0.087379,0.087379,5.736572,0.416277,1.0,309.0,30.0,113.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.20866142,0.2194226466962497,0.01076122669624971
11.0,309.0,116.0,0.035599,0.035599,5.736572,0.416277,1.0,309.0,30.0,113.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.08501056,0.08476437936274822,0.00024618063725177775
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00772758,0.007713065709761928,1.4514290238072484e-05
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00772758,0.007717092967916697,1.0487032083303024e-05
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Death,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Lack of Efficacy,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Lack of Efficacy,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Lack of Efficacy,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00772758,0.007717774078333361,9.805921666639593e-06
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Lack of Efficacy,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,309.0,116.0,0.009709,0.009709,5.736572,0.416277,1.0,309.0,30.0,113.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02318513,0.023151036749623013,3.4093250376988904e-05
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00772758,0.0077156317557738364,1.1948244226163938e-05
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Non-compliance with Study Drug,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00772758,0.007713065709761928,1.4514290238072484e-05
2.0,309.0,116.0,0.006472,0.006472,5.736572,0.416277,1.0,309.0,30.0,113.0,Non-compliance with Study Drug,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01545516,0.01562322659,0.00016806658999999995
4.0,309.0,116.0,0.012945,0.012945,5.736572,0.416277,1.0,309.0,30.0,113.0,Non-compliance with Study Drug,Overall Study,FG002,dyslipidemia,INDUSTRY,0.03091271,0.031055541953005937,0.00014283195300593757
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Non-compliance with Study Drug,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Other: Not available,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Other: Not available,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,309.0,116.0,0.006472,0.006472,5.736572,0.416277,1.0,309.0,30.0,113.0,Other: Not available,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01545516,0.015618796892619045,0.00016363689261904464
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Other: Not available,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00772758,0.007713065709761928,1.4514290238072484e-05
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,116.0,0.003236,0.003236,5.736572,0.416277,1.0,309.0,30.0,113.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00772758,0.007718216230178596,9.363769821404619e-06
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,116.0,0.0,0.0,5.736572,0.416277,1.0,309.0,30.0,113.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
8.0,309.0,116.0,0.02589,0.02589,5.736572,0.416277,1.0,309.0,30.0,113.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.06182543,0.06011989326133927,0.0017055367386607304
3.0,309.0,116.0,0.009709,0.009709,5.736572,0.416277,1.0,309.0,30.0,113.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02318513,0.023120307915277763,6.482208472223874e-05
11.0,309.0,116.0,0.035599,0.035599,5.736572,0.416277,1.0,309.0,30.0,113.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.08501056,0.08529924689364096,0.0002886868936409631
7.0,309.0,116.0,0.022654,0.022654,5.736572,0.416277,1.0,309.0,30.0,113.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.05409785,0.05427112618889882,0.00017327618889882018
15.0,309.0,116.0,0.048544,0.048544,5.736572,0.416277,1.0,309.0,30.0,113.0,Did not enter OLC,Overall Study,FG000,dyslipidemia,INDUSTRY,0.11592328,0.11671759760453361,0.0007943176045336064
11.0,309.0,116.0,0.035599,0.035599,5.736572,0.416277,1.0,309.0,30.0,113.0,Did not enter OLC,Overall Study,FG001,dyslipidemia,INDUSTRY,0.08501056,0.08504327736679583,3.271736679583137e-05
15.0,309.0,116.0,0.048544,0.048544,5.736572,0.416277,1.0,309.0,30.0,113.0,Did not enter OLC,Overall Study,FG002,dyslipidemia,INDUSTRY,0.11592328,0.11605225562875984,0.00012897562875983926
11.0,309.0,116.0,0.035599,0.035599,5.736572,0.416277,1.0,309.0,30.0,113.0,Did not enter OLC,Overall Study,FG003,dyslipidemia,INDUSTRY,0.08501056,0.0851234407567959,0.00011288075679589948
3.0,1143.0,1096.0,0.002625,0.002625,7.042286,0.217379,1.0,1143.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00401848,0.003996530163084431,2.194983691556837e-05
4.0,1143.0,1096.0,0.0035,0.0035,7.042286,0.217379,1.0,1143.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00535797,0.005259072061547624,9.889793845237627e-05
4.0,1143.0,1096.0,0.0035,0.0035,7.042286,0.217379,1.0,1143.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00535797,0.005249321872023812,0.00010864812797618806
2.0,1143.0,1096.0,0.00175,0.00175,7.042286,0.217379,1.0,1143.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00267898,0.0026807438547916647,1.7638547916646458e-06
6.0,1143.0,1096.0,0.005249,0.005249,7.042286,0.217379,1.0,1143.0,0.0,0.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00803542,0.00802385447479166,1.15655252083402e-05
6.0,1143.0,1096.0,0.005249,0.005249,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00803542,0.007990628395029762,4.479160497023772e-05
1.0,1143.0,1096.0,0.000875,0.000875,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00133949,0.0013386551994940476,8.34800505952445e-07
2.0,1143.0,1096.0,0.00175,0.00175,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00267898,0.002681386838482141,2.40683848214086e-06
3.0,1143.0,1096.0,0.002625,0.002625,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00401848,0.003992700483977291,2.5779516022709018e-05
1.0,1143.0,1096.0,0.000875,0.000875,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00133949,0.0013364511141369048,3.038885863095248e-06
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1143.0,1096.0,0.00175,0.00175,7.042286,0.217379,1.0,1143.0,0.0,0.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00267898,0.0026803253568749986,1.3453568749985552e-06
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1143.0,1096.0,0.00175,0.00175,7.042286,0.217379,1.0,1143.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00267898,0.0026818277369345224,2.847736934522352e-06
3.0,1143.0,1096.0,0.002625,0.002625,7.042286,0.217379,1.0,1143.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00401848,0.003999096869572529,1.938313042747046e-05
3.0,1143.0,1096.0,0.002625,0.002625,7.042286,0.217379,1.0,1143.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00401848,0.003995829729155862,2.2650270844137843e-05
1.0,1143.0,1096.0,0.000875,0.000875,7.042286,0.217379,1.0,1143.0,0.0,0.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00133949,0.0013362286366369047,3.2613633630953175e-06
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1143.0,1096.0,0.00175,0.00175,7.042286,0.217379,1.0,1143.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00267898,0.0026809889743749983,2.0089743749981785e-06
1.0,1143.0,1096.0,0.000875,0.000875,7.042286,0.217379,1.0,1143.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00133949,0.0013366552766369048,2.8347233630952873e-06
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lack of Eligibility,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lack of Eligibility,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lack of Eligibility,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1143.0,1096.0,0.0,0.0,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lack of Eligibility,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1143.0,1096.0,0.000875,0.000875,7.042286,0.217379,1.0,1143.0,0.0,0.0,Lack of Eligibility,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00133949,0.0013366552766369048,2.8347233630952873e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,297.0,0.003236,0.003236,5.736572,0.431674,1.0,309.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0080134,0.008015917428392829,2.5174283928286467e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,297.0,0.003236,0.003236,5.736572,0.431674,1.0,309.0,0.0,0.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0080134,0.00801119802767854,2.201972321459744e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,309.0,297.0,0.006472,0.006472,5.736572,0.431674,1.0,309.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0160268,0.01613917774740075,0.00011237774740074924
2.0,309.0,297.0,0.006472,0.006472,5.736572,0.431674,1.0,309.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0160268,0.016140931617341227,0.0001141316173412267
1.0,309.0,297.0,0.003236,0.003236,5.736572,0.431674,1.0,309.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0080134,0.008005428262083301,7.971737916698945e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,309.0,297.0,0.009709,0.009709,5.736572,0.431674,1.0,309.0,0.0,0.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.02404267,0.024577612115880224,0.0005349421158802256
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Participant moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Participant moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Participant moved,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,297.0,0.003236,0.003236,5.736572,0.431674,1.0,309.0,0.0,0.0,Participant moved,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0080134,0.008010753198511873,2.646801488127848e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Participant moved,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,309.0,297.0,0.003236,0.003236,5.736572,0.431674,1.0,309.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0080134,0.008009045650297588,4.354349702412677e-06
0.0,309.0,297.0,0.0,0.0,5.736572,0.431674,1.0,309.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,328.0,284.0,0.015244,0.015244,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Period 1,FG000,dyslipidemia,INDUSTRY,0.02677809,0.02680653428190475,2.8444281904748542e-05
3.0,328.0,284.0,0.009146,0.009146,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Period 1,FG001,dyslipidemia,INDUSTRY,0.01606615,0.016182906336686495,0.00011675633668649377
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Period 1,FG000,dyslipidemia,INDUSTRY,0.01071194,0.010736294491488139,2.435449148813912e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Period 1,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Protocol Violation,Period 1,FG000,dyslipidemia,INDUSTRY,0.01071194,0.01072578163047623,1.3841630476230798e-05
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Protocol Violation,Period 1,FG001,dyslipidemia,INDUSTRY,0.01071194,0.010718698172559564,6.758172559564665e-06
5.0,328.0,284.0,0.015244,0.015244,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Period 1,FG000,dyslipidemia,INDUSTRY,0.02677809,0.02676087943068452,1.7210569315480317e-05
5.0,328.0,284.0,0.015244,0.015244,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Period 1,FG001,dyslipidemia,INDUSTRY,0.02677809,0.026776129912827372,1.9600871726289937e-06
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Crossover Washout,FG000,dyslipidemia,INDUSTRY,0.01071194,0.010723453122619082,1.1513122619082744e-05
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Crossover Washout,FG001,dyslipidemia,INDUSTRY,0.00535597,0.005390150674421009,3.4180674421009465e-05
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Crossover Washout,FG000,dyslipidemia,INDUSTRY,0.01071194,0.010736591031071479,2.4651031071479257e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Crossover Washout,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Protocol Violation,Crossover Washout,FG000,dyslipidemia,INDUSTRY,0.00535597,0.005384809069301959,2.8839069301959258e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Protocol Violation,Crossover Washout,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,328.0,284.0,0.012195,0.012195,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Crossover Washout,FG000,dyslipidemia,INDUSTRY,0.02142212,0.021566022871180607,0.00014390287118060813
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Crossover Washout,FG001,dyslipidemia,INDUSTRY,0.00535597,0.005386322978587674,3.035297858767442e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Non-compliance with Study Drug,Crossover Washout,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,328.0,284.0,0.006098,0.006098,5.796058,0.303074,1.0,328.0,0.0,0.0,Non-compliance with Study Drug,Crossover Washout,FG001,dyslipidemia,INDUSTRY,0.01071194,0.010716882353809569,4.942353809569283e-06
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Period 2,FG000,dyslipidemia,INDUSTRY,0.00535597,0.00538327647525434,2.73064752543406e-05
4.0,328.0,284.0,0.012195,0.012195,5.796058,0.303074,1.0,328.0,0.0,0.0,Adverse Event,Period 2,FG001,dyslipidemia,INDUSTRY,0.02142212,0.02149048468999013,6.836468999013232e-05
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Period 2,FG000,dyslipidemia,INDUSTRY,0.00535597,0.005383039925671007,2.7069925671007085e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Lost to Follow-up,Period 2,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,328.0,284.0,0.003049,0.003049,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Period 2,FG000,dyslipidemia,INDUSTRY,0.00535597,0.005379503904421008,2.3533904421007765e-05
0.0,328.0,284.0,0.0,0.0,5.796058,0.303074,1.0,328.0,0.0,0.0,Withdrawal by Subject,Period 2,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,310.0,287.0,0.019355,0.019355,5.739793,0.22382,1.0,310.0,1.0,1.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02486499,0.025146283512450376,0.0002812935124503757
1.0,310.0,287.0,0.003226,0.003226,5.739793,0.22382,1.0,310.0,1.0,1.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00414438,0.004144886829487736,5.068294877362545e-07
2.0,310.0,287.0,0.006452,0.006452,5.739793,0.22382,1.0,310.0,1.0,1.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00828876,0.008364226171567467,7.546617156746829e-05
3.0,310.0,287.0,0.009677,0.009677,5.739793,0.22382,1.0,310.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01243185,0.01246913233823411,3.728233823411045e-05
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,310.0,287.0,0.009677,0.009677,5.739793,0.22382,1.0,310.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01243185,0.012461288696626969,2.9438696626969338e-05
2.0,310.0,287.0,0.006452,0.006452,5.739793,0.22382,1.0,310.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00828876,0.008439280839801597,0.00015052083980159753
2.0,310.0,287.0,0.006452,0.006452,5.739793,0.22382,1.0,310.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00828876,0.00837077786710318,8.201786710318112e-05
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,310.0,287.0,0.003226,0.003226,5.739793,0.22382,1.0,310.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00414438,0.004145574992821069,1.1949928210696487e-06
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Lack of Efficacy,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Investigator Discretion,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,310.0,287.0,0.003226,0.003226,5.739793,0.22382,1.0,310.0,1.0,1.0,Investigator Discretion,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00414438,0.004145574992821069,1.1949928210696487e-06
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Investigator Discretion,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Patient Request,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,310.0,287.0,0.003226,0.003226,5.739793,0.22382,1.0,310.0,1.0,1.0,Patient Request,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00414438,0.004145574992821069,1.1949928210696487e-06
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Patient Request,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Use of Prohibited Medication,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,310.0,287.0,0.0,0.0,5.739793,0.22382,1.0,310.0,1.0,1.0,Use of Prohibited Medication,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,310.0,287.0,0.003226,0.003226,5.739793,0.22382,1.0,310.0,1.0,1.0,Use of Prohibited Medication,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00414438,0.004145237525410355,8.575254103557889e-07
4.0,436.0,56.0,0.009174,0.009174,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Randomised Treatment Period,FG000,dyslipidemia,INDUSTRY,0.01322223,0.013193606572529756,2.862342747024342e-05
1.0,436.0,56.0,0.002294,0.002294,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Randomised Treatment Period,FG001,dyslipidemia,INDUSTRY,0.00330628,0.003319834230297634,1.3554230297634084e-05
2.0,436.0,56.0,0.004587,0.004587,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Randomised Treatment Period,FG002,dyslipidemia,INDUSTRY,0.00661112,0.006643401023759942,3.2281023759942254e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Randomised Treatment Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,436.0,56.0,0.002294,0.002294,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Randomised Treatment Period,FG001,dyslipidemia,INDUSTRY,0.00330628,0.0033213511544643,1.507115446430004e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Randomised Treatment Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,436.0,56.0,0.004587,0.004587,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Randomised Treatment Period,FG000,dyslipidemia,INDUSTRY,0.00661112,0.0066346067250694675,2.3486725069467654e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Randomised Treatment Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,436.0,56.0,0.004587,0.004587,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Randomised Treatment Period,FG002,dyslipidemia,INDUSTRY,0.00661112,0.006642351302926611,3.1231302926611366e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Reason not provided,Randomised Treatment Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Reason not provided,Randomised Treatment Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,436.0,56.0,0.004587,0.004587,6.079933,0.237054,1.0,934.0,1.0,6.0,Reason not provided,Randomised Treatment Period,FG002,dyslipidemia,INDUSTRY,0.00661112,0.006643401023759942,3.2281023759942254e-05
1.0,436.0,56.0,0.002294,0.002294,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Extension Treatment Period,FG000,dyslipidemia,INDUSTRY,0.00330628,0.003317429878630967,1.1149878630966822e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Extension Treatment Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Withdrawal by Subject,Extension Treatment Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,436.0,56.0,0.002294,0.002294,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Extension Treatment Period,FG000,dyslipidemia,INDUSTRY,0.00330628,0.003317219797083348,1.093979708334785e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Extension Treatment Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Adverse Event,Extension Treatment Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,436.0,56.0,0.002294,0.002294,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Extension Treatment Period,FG000,dyslipidemia,INDUSTRY,0.00330628,0.003318865398630967,1.2585398630967064e-05
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Extension Treatment Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,436.0,56.0,0.0,0.0,6.079933,0.237054,1.0,934.0,1.0,6.0,Protocol Violation,Extension Treatment Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
11.0,271.0,227.0,0.04059,0.04059,5.605802,0.215837,1.0,276.0,1.0,40.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04911143,0.05054011536229172,0.0014286853622917234
8.0,271.0,227.0,0.02952,0.02952,5.605802,0.215837,1.0,276.0,1.0,40.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0357174,0.03571654139458333,8.586054166745405e-07
7.0,271.0,227.0,0.02583,0.02583,5.605802,0.215837,1.0,276.0,1.0,40.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.03125273,0.03192482310705359,0.0006720931070535938
3.0,271.0,227.0,0.01107,0.01107,5.605802,0.215837,1.0,276.0,1.0,40.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01339403,0.013421095036022714,2.7065036022714054e-05
4.0,271.0,227.0,0.01476,0.01476,5.605802,0.215837,1.0,276.0,1.0,40.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0178587,0.018163571423150265,0.00030487142315026305
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,271.0,227.0,0.00738,0.00738,5.605802,0.215837,1.0,276.0,1.0,40.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00892935,0.0089255333997619,3.8166002381007785e-06
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,271.0,227.0,0.00738,0.00738,5.605802,0.215837,1.0,276.0,1.0,40.0,Noncompliance,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00892935,0.008918721074226185,1.062892577381562e-05
3.0,271.0,227.0,0.01107,0.01107,5.605802,0.215837,1.0,276.0,1.0,40.0,Noncompliance,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01339403,0.013493402917440462,9.937291744046249e-05
1.0,271.0,227.0,0.00369,0.00369,5.605802,0.215837,1.0,276.0,1.0,40.0,Noncompliance,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00446468,0.004468762563750031,4.082563750030903e-06
1.0,271.0,227.0,0.00369,0.00369,5.605802,0.215837,1.0,276.0,1.0,40.0,Protocol violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00446468,0.0044713612333333605,6.681233333360147e-06
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Protocol violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,271.0,227.0,0.00369,0.00369,5.605802,0.215837,1.0,276.0,1.0,40.0,Protocol violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00446468,0.004468970887500033,4.290887500032342e-06
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Personal reasons,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,271.0,227.0,0.0,0.0,5.605802,0.215837,1.0,276.0,1.0,40.0,Personal reasons,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,271.0,227.0,0.00369,0.00369,5.605802,0.215837,1.0,276.0,1.0,40.0,Personal reasons,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00446468,0.004468736563750031,4.05656375003071e-06
2.0,392.0,364.0,0.005102,0.005102,5.97381,0.188165,1.0,392.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00573496,0.005723417012232141,1.1542987767858628e-05
1.0,392.0,364.0,0.002551,0.002551,5.97381,0.188165,1.0,392.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00286748,0.0028743708938690432,6.890893869043301e-06
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,392.0,364.0,0.002551,0.002551,5.97381,0.188165,1.0,392.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00286748,0.0028676314470833307,1.5144708333074408e-07
2.0,392.0,364.0,0.005102,0.005102,5.97381,0.188165,1.0,392.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00573496,0.00571846215360119,1.649784639881028e-05
1.0,392.0,364.0,0.002551,0.002551,5.97381,0.188165,1.0,392.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00286748,0.002854362265535712,1.3117734464287989e-05
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,392.0,364.0,0.010204,0.010204,5.97381,0.188165,1.0,392.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01146991,0.011648353012916675,0.00017844301291667503
5.0,392.0,364.0,0.012755,0.012755,5.97381,0.188165,1.0,392.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01433739,0.014373138121670266,3.574812167026625e-05
7.0,392.0,364.0,0.017857,0.017857,5.97381,0.188165,1.0,392.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02007235,0.02015953698477185,8.718698477185038e-05
2.0,392.0,364.0,0.005102,0.005102,5.97381,0.188165,1.0,392.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00573496,0.005731467920446428,3.492079553571968e-06
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,392.0,364.0,0.005102,0.005102,5.97381,0.188165,1.0,392.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00573496,0.005733481453690472,1.478546309528067e-06
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Other,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,392.0,364.0,0.0,0.0,5.97381,0.188165,1.0,392.0,0.0,0.0,Other,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,392.0,364.0,0.002551,0.002551,5.97381,0.188165,1.0,392.0,0.0,0.0,Other,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00286748,0.002869010101369045,1.5301013690451233e-06
20.0,3681.0,3275.0,0.005433,0.005433,8.211211,0.513472,1.0,3681.0,25.0,363.0,Withdrawal by Subject,SOC-controlled Period (Year 1),FG000,dyslipidemia,INDUSTRY,0.02290674,0.022650140635257946,0.00025659936474205225
49.0,3681.0,3275.0,0.013312,0.013312,8.211211,0.513472,1.0,3681.0,25.0,363.0,Withdrawal by Subject,SOC-controlled Period (Year 1),FG001,dyslipidemia,INDUSTRY,0.05612636,0.054334089231309515,0.0017922707686904849
2.0,3681.0,3275.0,0.000543,0.000543,8.211211,0.513472,1.0,3681.0,25.0,363.0,Decision by Sponsor,SOC-controlled Period (Year 1),FG000,dyslipidemia,INDUSTRY,0.00228941,0.0023648645436408744,7.545454364087448e-05
1.0,3681.0,3275.0,0.000272,0.000272,8.211211,0.513472,1.0,3681.0,25.0,363.0,Decision by Sponsor,SOC-controlled Period (Year 1),FG001,dyslipidemia,INDUSTRY,0.00114681,0.0011695593482440477,2.2749348244047608e-05
3.0,3681.0,3275.0,0.000815,0.000815,8.211211,0.513472,1.0,3681.0,25.0,363.0,Lost to Follow-up,SOC-controlled Period (Year 1),FG000,dyslipidemia,INDUSTRY,0.00343622,0.0035200985769444403,8.387857694444048e-05
8.0,3681.0,3275.0,0.002173,0.002173,8.211211,0.513472,1.0,3681.0,25.0,363.0,Lost to Follow-up,SOC-controlled Period (Year 1),FG001,dyslipidemia,INDUSTRY,0.00916185,0.009170274988571418,8.4249885714191e-06
5.0,3681.0,3275.0,0.001358,0.001358,8.211211,0.513472,1.0,3681.0,25.0,363.0,Death,SOC-controlled Period (Year 1),FG000,dyslipidemia,INDUSTRY,0.00572563,0.0058753135831250015,0.0001496835831250017
5.0,3681.0,3275.0,0.001358,0.001358,8.211211,0.513472,1.0,3681.0,25.0,363.0,Death,SOC-controlled Period (Year 1),FG001,dyslipidemia,INDUSTRY,0.00572563,0.005897722057886907,0.0001720920578869075
78.0,3681.0,3275.0,0.02119,0.02119,8.211211,0.513472,1.0,3681.0,25.0,363.0,Withdrawal by Subject,All-IP Period (Years 2 and 3),FG000,dyslipidemia,INDUSTRY,0.08934177,0.08589638700207351,0.0034453829979264883
117.0,3681.0,3275.0,0.031785,0.031785,8.211211,0.513472,1.0,3681.0,25.0,363.0,Withdrawal by Subject,All-IP Period (Years 2 and 3),FG001,dyslipidemia,INDUSTRY,0.13401265,0.13433051955109124,0.0003178695510912266
8.0,3681.0,3275.0,0.002173,0.002173,8.211211,0.513472,1.0,3681.0,25.0,363.0,Decision by Sponsor,All-IP Period (Years 2 and 3),FG000,dyslipidemia,INDUSTRY,0.00916185,0.009204449916755942,4.2599916755942796e-05
11.0,3681.0,3275.0,0.002988,0.002988,8.211211,0.513472,1.0,3681.0,25.0,363.0,Decision by Sponsor,All-IP Period (Years 2 and 3),FG001,dyslipidemia,INDUSTRY,0.01259807,0.01247691657107143,0.00012115342892856859
27.0,3681.0,3275.0,0.007335,0.007335,8.211211,0.513472,1.0,3681.0,25.0,363.0,Lost to Follow-up,All-IP Period (Years 2 and 3),FG000,dyslipidemia,INDUSTRY,0.030926,0.029837452157301603,0.001088547842698396
51.0,3681.0,3275.0,0.013855,0.013855,8.211211,0.513472,1.0,3681.0,25.0,363.0,Lost to Follow-up,All-IP Period (Years 2 and 3),FG001,dyslipidemia,INDUSTRY,0.05841577,0.05784783959017857,0.000567930409821428
5.0,3681.0,3275.0,0.001358,0.001358,8.211211,0.513472,1.0,3681.0,25.0,363.0,Death,All-IP Period (Years 2 and 3),FG000,dyslipidemia,INDUSTRY,0.00572563,0.0058753135831250015,0.0001496835831250017
16.0,3681.0,3275.0,0.004347,0.004347,8.211211,0.513472,1.0,3681.0,25.0,363.0,Death,All-IP Period (Years 2 and 3),FG001,dyslipidemia,INDUSTRY,0.01832792,0.017852941448492064,0.00047497855150793744
0.0,486.0,376.0,0.0,0.0,6.188264,0.379199,1.0,486.0,14.0,91.0,Randomized but not treated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,486.0,376.0,0.002058,0.002058,6.188264,0.379199,1.0,486.0,14.0,91.0,Randomized but not treated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00482927,0.0048503145917559816,2.1044591755981466e-05
1.0,486.0,376.0,0.002058,0.002058,6.188264,0.379199,1.0,486.0,14.0,91.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00482927,0.004847419562668681,1.8149562668681035e-05
0.0,486.0,376.0,0.0,0.0,6.188264,0.379199,1.0,486.0,14.0,91.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,486.0,376.0,0.002058,0.002058,6.188264,0.379199,1.0,486.0,14.0,91.0,Participants moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00482927,0.004847066137668682,1.779613766868162e-05
5.0,486.0,376.0,0.010288,0.010288,6.188264,0.379199,1.0,486.0,14.0,91.0,Participants moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02414166,0.024166412436994054,2.4752436994054938e-05
10.0,486.0,376.0,0.020576,0.020576,6.188264,0.379199,1.0,486.0,14.0,91.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04828331,0.04843071652516864,0.00014740652516864045
13.0,486.0,376.0,0.026749,0.026749,6.188264,0.379199,1.0,486.0,14.0,91.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.06276878,0.06164448398003966,0.0011242960199603358
4.0,486.0,376.0,0.00823,0.00823,6.188264,0.379199,1.0,486.0,14.0,91.0,Poor compliance to protocol,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01931239,0.019267655625773775,4.473437422622406e-05
10.0,486.0,376.0,0.020576,0.020576,6.188264,0.379199,1.0,486.0,14.0,91.0,Poor compliance to protocol,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04828331,0.048442308031597214,0.00015899803159721143
2.0,486.0,376.0,0.004115,0.004115,6.188264,0.379199,1.0,486.0,14.0,91.0,Consent withdrawn by participant,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00965619,0.009696232862261898,4.004286226189785e-05
6.0,486.0,376.0,0.012346,0.012346,6.188264,0.379199,1.0,486.0,14.0,91.0,Consent withdrawn by participant,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02897093,0.028297563350625037,0.0006733666493749617
0.0,486.0,376.0,0.0,0.0,6.188264,0.379199,1.0,486.0,14.0,91.0,Related to study drug administration,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,486.0,376.0,0.004115,0.004115,6.188264,0.379199,1.0,486.0,14.0,91.0,Related to study drug administration,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00965619,0.009686377543869041,3.0187543869041045e-05
14.0,486.0,376.0,0.028807,0.028807,6.188264,0.379199,1.0,486.0,14.0,91.0,Last visit outside protocol visit window,Overall Study,FG000,dyslipidemia,INDUSTRY,0.06759805,0.06734113958473209,0.00025691041526791636
26.0,486.0,376.0,0.053498,0.053498,6.188264,0.379199,1.0,486.0,14.0,91.0,Last visit outside protocol visit window,Overall Study,FG001,dyslipidemia,INDUSTRY,0.12553756,0.128226119027887,0.0026885590278870053
1.0,486.0,376.0,0.002058,0.002058,6.188264,0.379199,1.0,486.0,14.0,91.0,Site closure,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00482927,0.004847066137668682,1.779613766868162e-05
7.0,486.0,376.0,0.014403,0.014403,6.188264,0.379199,1.0,486.0,14.0,91.0,Site closure,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03379785,0.03385477273215821,5.6922732158209977e-05
0.0,486.0,376.0,0.0,0.0,6.188264,0.379199,1.0,486.0,14.0,91.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,486.0,376.0,0.00823,0.00823,6.188264,0.379199,1.0,486.0,14.0,91.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01931239,0.019275955420059488,3.6434579940510664e-05
0.0,486.0,376.0,0.0,0.0,6.188264,0.379199,1.0,486.0,14.0,91.0,Other than specified above,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,486.0,376.0,0.006173,0.006173,6.188264,0.379199,1.0,486.0,14.0,91.0,Other than specified above,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01448546,0.014296474053125001,0.00018898594687499944
48.0,1311.0,1014.0,0.036613,0.036613,7.179308,0.379199,1.0,1311.0,1.0,37.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.09967476,0.10069010293214298,0.0010153429321429763
2.0,1311.0,1014.0,0.001526,0.001526,7.179308,0.379199,1.0,1311.0,1.0,37.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00415436,0.00414645568876984,7.904311230160117e-06
4.0,1311.0,1014.0,0.003051,0.003051,7.179308,0.379199,1.0,1311.0,1.0,37.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.008306,0.008162947742896812,0.00014305225710318711
88.0,1311.0,1014.0,0.067124,0.067124,7.179308,0.379199,1.0,1311.0,1.0,37.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.18273751,0.18245152489999017,0.00028598510000982236
87.0,1311.0,1014.0,0.066362,0.066362,7.179308,0.379199,1.0,1311.0,1.0,37.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.18066305,0.17970792043135922,0.0009551295686407724
1.0,1311.0,1014.0,0.000763,0.000763,7.179308,0.379199,1.0,1311.0,1.0,37.0,Pregnancy,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00207718,0.002080730828373024,3.550828373023989e-06
1.0,1311.0,1014.0,0.000763,0.000763,7.179308,0.379199,1.0,1311.0,1.0,37.0,No Longer Meets Eligibility Criteria,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00207718,0.002080730828373024,3.550828373023989e-06
55.0,1311.0,1014.0,0.041953,0.041953,7.179308,0.379199,1.0,1311.0,1.0,37.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.1142123,0.1166604624125299,0.002448162412529903
1.0,1311.0,1014.0,0.000763,0.000763,7.179308,0.379199,1.0,1311.0,1.0,37.0,Investigator Discretion,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00207718,0.002080730828373024,3.550828373023989e-06
9.0,1311.0,1014.0,0.006865,0.006865,7.179308,0.379199,1.0,1311.0,1.0,37.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01868919,0.018306698944434523,0.000382491055565478
1.0,1311.0,1014.0,0.000763,0.000763,7.179308,0.379199,1.0,1311.0,1.0,37.0,Did not meet eligibility criteria,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00207718,0.002080730828373024,3.550828373023989e-06
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00596479,0.005965756791636916,9.667916369155566e-07
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Randomized but not treated,Overall Study,FG006,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00596479,0.005976985734255964,1.2195734255963757e-05
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Subject moved,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00596479,0.005966352698779772,1.5626987797719843e-06
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00596479,0.005966564166636915,1.77416663691473e-06
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Physician Decision,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00596479,0.005967160073779771,2.3700737797711577e-06
7.0,355.0,286.0,0.019718,0.019718,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04175141,0.041490141080049635,0.0002612689199503679
8.0,355.0,286.0,0.022535,0.022535,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0477162,0.04707690052165672,0.0006392994783432776
5.0,355.0,286.0,0.014085,0.014085,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02982395,0.02986336978407198,3.9419784071983294e-05
5.0,355.0,286.0,0.014085,0.014085,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG003,dyslipidemia,INDUSTRY,0.02982395,0.029859354696571982,3.540469657198342e-05
5.0,355.0,286.0,0.014085,0.014085,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG004,dyslipidemia,INDUSTRY,0.02982395,0.029861537471571976,3.758747157197803e-05
4.0,355.0,286.0,0.011268,0.011268,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG005,dyslipidemia,INDUSTRY,0.02385916,0.023870602716795683,1.1442716795682234e-05
4.0,355.0,286.0,0.011268,0.011268,5.874931,0.360417,1.0,355.0,9.0,97.0,Other than specified,Overall Study,FG006,dyslipidemia,INDUSTRY,0.02385916,0.023870602716795683,1.1442716795682234e-05
4.0,355.0,286.0,0.011268,0.011268,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02385916,0.02387536789477186,1.6207894771858022e-05
3.0,355.0,286.0,0.008451,0.008451,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01789437,0.017856383052248938,3.798694775106193e-05
5.0,355.0,286.0,0.014085,0.014085,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02982395,0.02988630360948864,6.235360948864122e-05
3.0,355.0,286.0,0.008451,0.008451,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01789437,0.01783574711433227,5.8622885667731356e-05
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00596479,0.005970103944196439,5.313944196438762e-06
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00596479,0.005974228670386915,9.438670386914885e-06
2.0,355.0,286.0,0.005634,0.005634,5.874931,0.360417,1.0,355.0,9.0,97.0,Adverse Event,Overall Study,FG006,dyslipidemia,INDUSTRY,0.01192958,0.012062098082281753,0.00013251808228175246
2.0,355.0,286.0,0.005634,0.005634,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01192958,0.01205551203954366,0.00012593203954365875
4.0,355.0,286.0,0.011268,0.011268,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02385916,0.023844152652986145,1.500734701385606e-05
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,355.0,286.0,0.0,0.0,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,355.0,286.0,0.002817,0.002817,5.874931,0.360417,1.0,355.0,9.0,97.0,Poor compliance to protocol,Overall Study,FG006,dyslipidemia,INDUSTRY,0.00596479,0.005966352698779772,1.5626987797719843e-06
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0024589,0.00245966648368057,7.664836805701229e-07
7.0,642.0,410.0,0.010903,0.010903,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01720755,0.01724310002931551,3.55500293155106e-05
7.0,642.0,410.0,0.010903,0.010903,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01720755,0.01723488203630956,2.7332036309560964e-05
8.0,642.0,410.0,0.012461,0.012461,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01966645,0.019832236946282472,0.00016578694628247362
13.0,642.0,410.0,0.020249,0.020249,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.03195779,0.03241407539647907,0.0004562853964790725
4.0,642.0,410.0,0.006231,0.006231,6.466145,0.244077,1.0,642.0,8.0,73.0,Adverse Event,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00983401,0.009831562342500022,2.4476574999789807e-06
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0024589,0.0024579936980492567,9.063019507432254e-07
2.0,642.0,410.0,0.003115,0.003115,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00491622,0.004916874435952364,6.544359523645918e-07
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0024589,0.0024575874063825897,1.3125936174102765e-06
2.0,642.0,410.0,0.003115,0.003115,6.466145,0.244077,1.0,642.0,8.0,73.0,Death,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00491622,0.004913205212083316,3.0147879166841224e-06
32.0,642.0,410.0,0.049844,0.049844,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0786658,0.07766939100992061,0.0009964089900793838
12.0,642.0,410.0,0.018692,0.018692,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02950047,0.029237794881212097,0.00026267511878790353
10.0,642.0,410.0,0.015576,0.015576,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02458267,0.024542420445595185,4.024955440481634e-05
13.0,642.0,410.0,0.020249,0.020249,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG003,dyslipidemia,INDUSTRY,0.03195779,0.0323879922585624,0.00043020225856239824
7.0,642.0,410.0,0.010903,0.010903,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01720755,0.01723272901366077,2.5179013660770605e-05
31.0,642.0,410.0,0.048287,0.048287,6.466145,0.244077,1.0,642.0,8.0,73.0,Lack of Efficacy,Overall Study,FG005,dyslipidemia,INDUSTRY,0.07620848,0.07581674742197418,0.0003917325780258135
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0024589,0.00245980735868057,9.07358680570132e-07
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0024589,0.00245344285909092,5.457140909079922e-06
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Physician Decision,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0024589,0.0024585332934659236,3.6670653407637824e-07
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,642.0,410.0,0.0,0.0,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,642.0,410.0,0.006231,0.006231,6.466145,0.244077,1.0,642.0,8.0,73.0,Protocol Violation,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00983401,0.009831659159583353,2.3508404166476538e-06
5.0,642.0,410.0,0.007788,0.007788,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01229133,0.012233433906279756,5.789609372024336e-05
8.0,642.0,410.0,0.012461,0.012461,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01966645,0.019811833708149353,0.00014538370814935406
10.0,642.0,410.0,0.015576,0.015576,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02458267,0.02454388617428567,3.878382571433081e-05
11.0,642.0,410.0,0.017134,0.017134,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.02704157,0.027484971198333326,0.000443401198333325
15.0,642.0,410.0,0.023364,0.023364,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.036874,0.0367935564414583,8.044355854169849e-05
7.0,642.0,410.0,0.010903,0.010903,6.466145,0.244077,1.0,642.0,8.0,73.0,Withdrawal by Subject,Overall Study,FG005,dyslipidemia,INDUSTRY,0.01720755,0.01721864016008934,1.1090160089342882e-05
4.0,642.0,410.0,0.006231,0.006231,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00983401,0.009834099312281769,8.931228176814465e-08
1.0,642.0,410.0,0.001558,0.001558,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0024589,0.0024560961955492557,2.8038044507443065e-06
4.0,642.0,410.0,0.006231,0.006231,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00983401,0.009833877523333359,1.3247666664183144e-07
3.0,642.0,410.0,0.004673,0.004673,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00737512,0.0074252906786210346,5.017067862103479e-05
4.0,642.0,410.0,0.006231,0.006231,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00983401,0.009833275593333359,7.34406666641832e-07
2.0,642.0,410.0,0.003115,0.003115,6.466145,0.244077,1.0,642.0,8.0,73.0,Other Reasons,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00491622,0.004914718978333316,1.5010216666841783e-06
2.0,331.0,312.0,0.006042,0.006042,5.805135,0.349216,1.0,331.0,14.0,39.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01224862,0.012291778486190473,4.3158486190473036e-05
1.0,331.0,312.0,0.003021,0.003021,5.805135,0.349216,1.0,331.0,14.0,39.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00612431,0.006135582781875001,1.1272781875001046e-05
1.0,331.0,312.0,0.003021,0.003021,5.805135,0.349216,1.0,331.0,14.0,39.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00612431,0.006135083117291667,1.077311729166721e-05
2.0,331.0,312.0,0.006042,0.006042,5.805135,0.349216,1.0,331.0,14.0,39.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01224862,0.012303730713511903,5.5110713511902915e-05
4.0,331.0,312.0,0.012085,0.012085,5.805135,0.349216,1.0,331.0,14.0,39.0,Sponsor Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02449927,0.02467289169369047,0.00017362169369046845
0.0,331.0,312.0,0.0,0.0,5.805135,0.349216,1.0,331.0,14.0,39.0,Sponsor Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
9.0,331.0,312.0,0.02719,0.02719,5.805135,0.349216,1.0,331.0,14.0,39.0,Sponsor Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.05512083,0.05562724592844246,0.000506415928442458
0.0,331.0,312.0,0.0,0.0,5.805135,0.349216,1.0,331.0,14.0,39.0,Sponsor Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
7.0,474.0,443.0,0.014768,0.014768,6.163315,0.235372,1.0,474.0,1.0,129.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02142351,0.021383194648789662,4.031535121033769e-05
6.0,474.0,443.0,0.012658,0.012658,6.163315,0.235372,1.0,474.0,1.0,129.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01836259,0.018336624843511923,2.596515648807876e-05
3.0,474.0,443.0,0.006329,0.006329,6.163315,0.235372,1.0,474.0,1.0,129.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0091813,0.009154433287331341,2.686671266865885e-05
4.0,474.0,443.0,0.008439,0.008439,6.163315,0.235372,1.0,474.0,1.0,129.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01224221,0.012138148625975825,0.00010406137402417526
2.0,474.0,443.0,0.004219,0.004219,6.163315,0.235372,1.0,474.0,1.0,129.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00612038,0.0061168948148611095,3.4851851388904495e-06
1.0,474.0,443.0,0.00211,0.00211,6.163315,0.235372,1.0,474.0,1.0,129.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00306092,0.003048272097311516,1.2647902688484036e-05
1.0,474.0,443.0,0.00211,0.00211,6.163315,0.235372,1.0,474.0,1.0,129.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00306092,0.0030503396568948484,1.0580343105151546e-05
2.0,474.0,443.0,0.004219,0.004219,6.163315,0.235372,1.0,474.0,1.0,129.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00612038,0.006123803789444445,3.423789444445373e-06
1.0,474.0,443.0,0.00211,0.00211,6.163315,0.235372,1.0,474.0,1.0,129.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00306092,0.003048351090704372,1.256890929562807e-05
0.0,474.0,443.0,0.0,0.0,6.163315,0.235372,1.0,474.0,1.0,129.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,474.0,443.0,0.00211,0.00211,6.163315,0.235372,1.0,474.0,1.0,129.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00306092,0.0030508093423710393,1.0110657628960643e-05
2.0,474.0,443.0,0.004219,0.004219,6.163315,0.235372,1.0,474.0,1.0,129.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00612038,0.006124261647777778,3.881647777778316e-06
0.0,474.0,443.0,0.0,0.0,6.163315,0.235372,1.0,474.0,1.0,129.0,randomized in error,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,474.0,443.0,0.0,0.0,6.163315,0.235372,1.0,474.0,1.0,129.0,randomized in error,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,474.0,443.0,0.00211,0.00211,6.163315,0.235372,1.0,474.0,1.0,129.0,randomized in error,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00306092,0.0030494298773710393,1.1490122628960656e-05
0.0,474.0,443.0,0.0,0.0,6.163315,0.235372,1.0,474.0,1.0,129.0,randomized in error,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
13.0,857.0,802.0,0.015169,0.015169,6.754604,0.186785,1.0,857.0,5.0,42.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01913812,0.020060264443244047,0.0009221444432440454
2.0,857.0,802.0,0.002334,0.002334,6.754604,0.186785,1.0,857.0,5.0,42.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00294471,0.003120890781904752,0.00017618078190475206
8.0,857.0,802.0,0.009335,0.009335,6.754604,0.186785,1.0,857.0,5.0,42.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0117776,0.01207488892553572,0.0002972889255357207
1.0,857.0,802.0,0.001167,0.001167,6.754604,0.186785,1.0,857.0,5.0,42.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00147236,0.0014929903630357102,2.0630363035710215e-05
4.0,857.0,802.0,0.004667,0.004667,6.754604,0.186785,1.0,857.0,5.0,42.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00588817,0.006251934877351191,0.00036376487735119076
1.0,857.0,802.0,0.001167,0.001167,6.754604,0.186785,1.0,857.0,5.0,42.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00147236,0.0014938865172023767,2.152651720237664e-05
3.0,857.0,802.0,0.003501,0.003501,6.754604,0.186785,1.0,857.0,5.0,42.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00441707,0.004737343713214291,0.00032027371321429084
1.0,857.0,802.0,0.001167,0.001167,6.754604,0.186785,1.0,857.0,5.0,42.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00147236,0.0014896016276190432,1.7241627619043196e-05
6.0,857.0,802.0,0.007001,0.007001,6.754604,0.186785,1.0,857.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00883288,0.009084501525635813,0.00025162152563581314
5.0,857.0,802.0,0.005834,0.005834,6.754604,0.186785,1.0,857.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00736052,0.007822508434890876,0.0004619884348908759
7.0,857.0,802.0,0.008168,0.008168,6.754604,0.186785,1.0,857.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01030524,0.010743957043363096,0.000438717043363096
2.0,857.0,802.0,0.002334,0.002334,6.754604,0.186785,1.0,857.0,5.0,42.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00294471,0.0031203173245238,0.0001756073245237997
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,857.0,802.0,0.001167,0.001167,6.754604,0.186785,1.0,857.0,5.0,42.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00147236,0.0015028007715773767,3.044077157737671e-05
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,857.0,802.0,0.001167,0.001167,6.754604,0.186785,1.0,857.0,5.0,42.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00147236,0.0014973216609523768,2.4961660952376808e-05
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,857.0,802.0,0.0,0.0,6.754604,0.186785,1.0,857.0,5.0,42.0,Death,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
9.0,770.0,745.0,0.011688,0.011688,6.647688,0.503454,1.0,770.0,29.0,126.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03911745,0.03895428407673611,0.0001631659232638888
14.0,770.0,745.0,0.018182,0.018182,6.647688,0.503454,1.0,770.0,29.0,126.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0608516,0.06088099678973214,2.939678973214177e-05
2.0,770.0,745.0,0.002597,0.002597,6.647688,0.503454,1.0,770.0,29.0,126.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00869165,0.008538853399255957,0.00015279660074404323
7.0,786.0,752.0,0.008906,0.008906,6.668228,0.215837,1.0,786.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01281796,0.01315954149113096,0.0003415814911309611
5.0,786.0,752.0,0.006361,0.006361,6.668228,0.215837,1.0,786.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00915507,0.009251454498750013,9.638449875001322e-05
9.0,786.0,752.0,0.01145,0.01145,6.668228,0.215837,1.0,786.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01647941,0.01638127901408729,9.813098591271094e-05
0.0,786.0,752.0,0.0,0.0,6.668228,0.215837,1.0,786.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,786.0,752.0,0.002545,0.002545,6.668228,0.215837,1.0,786.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00366289,0.003676780394851192,1.3890394851192017e-05
1.0,786.0,752.0,0.001272,0.001272,6.668228,0.215837,1.0,786.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00183073,0.0018326872555357162,1.9572555357161986e-06
3.0,786.0,752.0,0.003817,0.003817,6.668228,0.215837,1.0,786.0,0.0,0.0,Withdrew consent,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00549362,0.00549655371646825,2.9337164682494143e-06
3.0,786.0,752.0,0.003817,0.003817,6.668228,0.215837,1.0,786.0,0.0,0.0,Withdrew consent,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00549362,0.005494505604325391,8.85604325390893e-07
0.0,786.0,752.0,0.0,0.0,6.668228,0.215837,1.0,786.0,0.0,0.0,Withdrew consent,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,786.0,752.0,0.001272,0.001272,6.668228,0.215837,1.0,786.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00183073,0.0018332039013690495,2.4739013690495103e-06
1.0,786.0,752.0,0.001272,0.001272,6.668228,0.215837,1.0,786.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00183073,0.0018334006494940495,2.6706494940494444e-06
1.0,786.0,752.0,0.001272,0.001272,6.668228,0.215837,1.0,786.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00183073,0.0018327907382440498,2.060738244049785e-06
1.0,786.0,752.0,0.001272,0.001272,6.668228,0.215837,1.0,786.0,0.0,0.0,Discontinued after 41 days Rx,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00183073,0.0018336090469940496,2.879046994049613e-06
0.0,786.0,752.0,0.0,0.0,6.668228,0.215837,1.0,786.0,0.0,0.0,Discontinued after 41 days Rx,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,786.0,752.0,0.0,0.0,6.668228,0.215837,1.0,786.0,0.0,0.0,Discontinued after 41 days Rx,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
13.0,280.0,251.0,0.046429,0.046429,5.638355,0.275882,1.0,280.0,2.0,114.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.07222127,0.07176444100868055,0.00045682899131944954
7.0,280.0,251.0,0.025,0.025,5.638355,0.275882,1.0,280.0,2.0,114.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03888802,0.039289198475565515,0.0004011784755655126
2.0,280.0,251.0,0.007143,0.007143,5.638355,0.275882,1.0,280.0,2.0,114.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01111108,0.011302519916498032,0.00019143991649803183
5.0,280.0,251.0,0.017857,0.017857,5.638355,0.275882,1.0,280.0,2.0,114.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02777693,0.028307242176349178,0.0005303121763491798
2.0,280.0,251.0,0.007143,0.007143,5.638355,0.275882,1.0,280.0,2.0,114.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01111108,0.01131027120661708,0.00019919120661707895
0.0,280.0,251.0,0.0,0.0,5.638355,0.275882,1.0,280.0,2.0,114.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.02220703,0.022142802943868996,6.422705613100266e-05
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.02220703,0.02219774881955351,9.281180446487486e-06
5.0,233.0,178.0,0.021459,0.021459,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.05551498,0.0589768873680953,0.0034619073680953044
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.02220703,0.022199246528303504,7.783471696495153e-06
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.01110351,0.011105196633363047,1.68663336304678e-06
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Physician Decision,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Physician Decision,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.01110351,0.011095507568095192,8.002431904808802e-06
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Physician Decision,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Consent withdrawn by participant,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.01110351,0.011102421565952335,1.0884340476656484e-06
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Consent withdrawn by participant,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Consent withdrawn by participant,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.01110351,0.011105252294613049,1.7422946130482564e-06
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Randomized but not treated,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Randomized but not treated,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.01110351,0.011094905093095192,8.604906904808793e-06
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Randomized but not treated,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.01110351,0.011103929681279713,4.196812797129662e-07
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Period 1: 24-Week Double-blind Treatment,FG000,dyslipidemia,INDUSTRY,0.01110351,0.011099178224285666,4.33177571433456e-06
3.0,233.0,178.0,0.012876,0.012876,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Period 1: 24-Week Double-blind Treatment,FG001,dyslipidemia,INDUSTRY,0.03331054,0.03426217622349204,0.0009516362234920431
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Period 1: 24-Week Double-blind Treatment,FG002,dyslipidemia,INDUSTRY,0.01110351,0.011101904236279714,1.6057637202866737e-06
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Extension Open Label Treatment,FG000,dyslipidemia,INDUSTRY,0.01110351,0.011091263525357099,1.224647464290185e-05
7.0,233.0,178.0,0.030043,0.030043,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Extension Open Label Treatment,FG001,dyslipidemia,INDUSTRY,0.07772201,0.07851794420424586,0.0007959342042458684
3.0,233.0,178.0,0.012876,0.012876,5.455321,0.474221,1.0,233.0,8.0,43.0,Adverse Event,Extension Open Label Treatment,FG002,dyslipidemia,INDUSTRY,0.03331054,0.03421458591113094,0.0009040459111309407
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Extension Open Label Treatment,FG000,dyslipidemia,INDUSTRY,0.01110351,0.011096825483452335,6.684516547665609e-06
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Extension Open Label Treatment,FG001,dyslipidemia,INDUSTRY,0.01110351,0.01108973287351186,1.3777126488140681e-05
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Poor compliance to protocol,Extension Open Label Treatment,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,233.0,178.0,0.004292,0.004292,5.455321,0.474221,1.0,233.0,8.0,43.0,Participant moved,Extension Open Label Treatment,FG000,dyslipidemia,INDUSTRY,0.01110351,0.011094292950119,9.217049881000972e-06
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Participant moved,Extension Open Label Treatment,FG001,dyslipidemia,INDUSTRY,0.02220703,0.022198493052886854,8.536947113144816e-06
0.0,233.0,178.0,0.0,0.0,5.455321,0.474221,1.0,233.0,8.0,43.0,Participant moved,Extension Open Label Treatment,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Extension Open Label Treatment,FG000,dyslipidemia,INDUSTRY,0.02220703,0.02214667669470234,6.035330529765778e-05
7.0,233.0,178.0,0.030043,0.030043,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Extension Open Label Treatment,FG001,dyslipidemia,INDUSTRY,0.07772201,0.07860032250303554,0.0008783125030355499
2.0,233.0,178.0,0.008584,0.008584,5.455321,0.474221,1.0,233.0,8.0,43.0,Other than specified above,Extension Open Label Treatment,FG002,dyslipidemia,INDUSTRY,0.02220703,0.022207170970386856,1.4097038685684238e-07
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,321.0,314.0,0.006231,0.006231,5.774552,0.456222,1.0,321.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01641543,0.01729622458646443,0.0008807945864644298
2.0,321.0,314.0,0.006231,0.006231,5.774552,0.456222,1.0,321.0,0.0,0.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01641543,0.01729622458646443,0.0008807945864644298
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,321.0,314.0,0.003115,0.003115,5.774552,0.456222,1.0,321.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0082064,0.008231330588511918,2.4930588511917415e-05
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,321.0,314.0,0.003115,0.003115,5.774552,0.456222,1.0,321.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0082064,0.008219142385000013,1.2742385000012388e-05
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,321.0,314.0,0.003115,0.003115,5.774552,0.456222,1.0,321.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0082064,0.008216739343333345,1.0339343333344228e-05
0.0,321.0,314.0,0.0,0.0,5.774552,0.456222,1.0,321.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00800418,0.008016028447023774,1.1848447023773967e-05
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00800418,0.008040523416369022,3.634341636902204e-05
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00800418,0.008026353546785683,2.2173546785683035e-05
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00800418,0.00802819105142854,2.401105142854111e-05
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,299.0,289.0,0.006689,0.006689,5.703782,0.419651,1.0,299.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01601076,0.016195935967916672,0.00018517596791667312
2.0,299.0,289.0,0.006689,0.006689,5.703782,0.419651,1.0,299.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01601076,0.01619137270916667,0.00018061270916666997
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00800418,0.008013442142559488,9.262142559487985e-06
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Relocated Out of State,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Relocated Out of State,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,299.0,289.0,0.0,0.0,5.703782,0.419651,1.0,299.0,1.0,30.0,Relocated Out of State,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,299.0,289.0,0.003344,0.003344,5.703782,0.419651,1.0,299.0,1.0,30.0,Relocated Out of State,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00800418,0.008015485615773773,1.1305615773773633e-05
35.0,1152.0,882.0,0.030382,0.030382,7.050123,0.270051,1.0,1152.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.05784397,0.05768765437566467,0.00015631562433533058
54.0,1152.0,882.0,0.046875,0.046875,7.050123,0.270051,1.0,1152.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.08924482,0.08960274361150786,0.00035792361150785434
13.0,1152.0,882.0,0.011285,0.011285,7.050123,0.270051,1.0,1152.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02148539,0.02147087527080359,1.451472919640831e-05
29.0,1152.0,882.0,0.025174,0.025174,7.050123,0.270051,1.0,1152.0,0.0,0.0,Flushing Symptoms,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04792851,0.04785113738172618,7.737261827382019e-05
46.0,1152.0,882.0,0.039931,0.039931,7.050123,0.270051,1.0,1152.0,0.0,0.0,Flushing Symptoms,Overall Study,FG001,dyslipidemia,INDUSTRY,0.07602421,0.07601849803833599,5.711961664003895e-06
3.0,1152.0,882.0,0.002604,0.002604,7.050123,0.270051,1.0,1152.0,0.0,0.0,Flushing Symptoms,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00495773,0.004886265967797612,7.146403220238771e-05
2.0,1152.0,882.0,0.001736,0.001736,7.050123,0.270051,1.0,1152.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00330515,0.0033333973410714286,2.8247341071428386e-05
3.0,1152.0,882.0,0.002604,0.002604,7.050123,0.270051,1.0,1152.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00495773,0.0048964546188690426,6.127538113095705e-05
1.0,1152.0,882.0,0.000868,0.000868,7.050123,0.270051,1.0,1152.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00165258,0.0016734953559920645,2.0915355992064425e-05
3.0,1152.0,882.0,0.002604,0.002604,7.050123,0.270051,1.0,1152.0,0.0,0.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00495773,0.004879758709285707,7.797129071429251e-05
1.0,1152.0,882.0,0.000868,0.000868,7.050123,0.270051,1.0,1152.0,0.0,0.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00165258,0.001670403735773811,1.7823735773810946e-05
1.0,1152.0,882.0,0.000868,0.000868,7.050123,0.270051,1.0,1152.0,0.0,0.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00165258,0.0016700331524404784,1.7453152440478382e-05
9.0,1152.0,882.0,0.007812,0.007812,7.050123,0.270051,1.0,1152.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01487318,0.015202739292827389,0.0003295592928273892
5.0,1152.0,882.0,0.00434,0.00434,7.050123,0.270051,1.0,1152.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00826288,0.008244126564226194,1.8753435773805754e-05
1.0,1152.0,882.0,0.000868,0.000868,7.050123,0.270051,1.0,1152.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00165258,0.001675788512242064,2.320851224206391e-05
29.0,1152.0,882.0,0.025174,0.025174,7.050123,0.270051,1.0,1152.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04792851,0.04785256197440474,7.594802559526131e-05
22.0,1152.0,882.0,0.019097,0.019097,7.050123,0.270051,1.0,1152.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03635858,0.03582759984723213,0.0005309801527678681
13.0,1152.0,882.0,0.011285,0.011285,7.050123,0.270051,1.0,1152.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02148539,0.021444005832232174,4.1384167767825886e-05
6.0,1289.0,1190.0,0.004655,0.004655,7.162397,0.230287,1.0,1289.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.007678,0.007671821402003962,6.178597996038017e-06
8.0,1289.0,1190.0,0.006206,0.006206,7.162397,0.230287,1.0,1289.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01023623,0.010254226756074116,1.79967560741158e-05
3.0,1289.0,1190.0,0.002327,0.002327,7.162397,0.230287,1.0,1289.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00383818,0.0038393934935416806,1.2134935416805229e-06
8.0,1289.0,1190.0,0.006206,0.006206,7.162397,0.230287,1.0,1289.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01023623,0.010268478333514595,3.224833351459476e-05
6.0,1289.0,1190.0,0.004655,0.004655,7.162397,0.230287,1.0,1289.0,0.0,0.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.007678,0.007677401781617056,5.982183829437646e-07
1.0,1289.0,1190.0,0.000776,0.000776,7.162397,0.230287,1.0,1289.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00127994,0.0012801073478571356,1.6734785713559339e-07
3.0,1289.0,1190.0,0.002327,0.002327,7.162397,0.230287,1.0,1289.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00383818,0.0038408540804166793,2.6740804166792108e-06
3.0,1289.0,1190.0,0.002327,0.002327,7.162397,0.230287,1.0,1289.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00383818,0.003839339297708347,1.1592977083468327e-06
2.0,1289.0,1190.0,0.001552,0.001552,7.162397,0.230287,1.0,1289.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00255988,0.002562509291567447,2.6292915674469217e-06
1.0,1289.0,1190.0,0.000776,0.000776,7.162397,0.230287,1.0,1289.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00127994,0.0012798220678571356,1.1793214286441416e-07
3.0,1289.0,1190.0,0.002327,0.002327,7.162397,0.230287,1.0,1289.0,0.0,0.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00383818,0.003848947021875013,1.076702187501272e-05
2.0,1289.0,1190.0,0.001552,0.001552,7.162397,0.230287,1.0,1289.0,0.0,0.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00255988,0.002564850553353162,4.970553353161877e-06
0.0,1289.0,1190.0,0.0,0.0,7.162397,0.230287,1.0,1289.0,0.0,0.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1289.0,1190.0,0.000776,0.000776,7.162397,0.230287,1.0,1289.0,0.0,0.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00127994,0.0012798071999404691,1.3280005953090514e-07
1.0,1289.0,1190.0,0.000776,0.000776,7.162397,0.230287,1.0,1289.0,0.0,0.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00127994,0.0012801857811904696,2.457811904695798e-07
2.0,1289.0,1190.0,0.001552,0.001552,7.162397,0.230287,1.0,1289.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00255988,0.002562936184484114,3.056184484114162e-06
2.0,1289.0,1190.0,0.001552,0.001552,7.162397,0.230287,1.0,1289.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00255988,0.0025632449262698274,3.3649262698273903e-06
2.0,1289.0,1190.0,0.001552,0.001552,7.162397,0.230287,1.0,1289.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00255988,0.0025611656732341137,1.2856732341135976e-06
1.0,1289.0,1190.0,0.000776,0.000776,7.162397,0.230287,1.0,1289.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00127994,0.0012791483891071355,7.916108928644923e-07
0.0,1289.0,1190.0,0.0,0.0,7.162397,0.230287,1.0,1289.0,0.0,0.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,1289.0,1190.0,0.003879,0.003879,7.162397,0.230287,1.0,1289.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00639806,0.006409956613492053,1.189661349205312e-05
11.0,1289.0,1190.0,0.008534,0.008534,7.162397,0.230287,1.0,1289.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01407606,0.014003573422033743,7.248657796625653e-05
10.0,1289.0,1190.0,0.007758,0.007758,7.162397,0.230287,1.0,1289.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01279612,0.012765745908184517,3.037409181548198e-05
10.0,1289.0,1190.0,0.007758,0.007758,7.162397,0.230287,1.0,1289.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01279612,0.012760769602351184,3.535039764881488e-05
8.0,1289.0,1190.0,0.006206,0.006206,7.162397,0.230287,1.0,1289.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01023623,0.010259074023445149,2.2844023445147896e-05
3.0,440.0,428.0,0.006818,0.006818,6.089045,0.254793,1.0,440.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01057776,0.010770726175376978,0.00019296617537697784
0.0,440.0,428.0,0.0,0.0,6.089045,0.254793,1.0,440.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,440.0,428.0,0.004545,0.004545,6.089045,0.254793,1.0,440.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00705132,0.007095090641671999,4.377064167199879e-05
1.0,440.0,428.0,0.002273,0.002273,6.089045,0.254793,1.0,440.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00352644,0.0035317070552083225,5.267055208322494e-06
1.0,440.0,428.0,0.002273,0.002273,6.089045,0.254793,1.0,440.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00352644,0.0035317669227083216,5.326922708321583e-06
1.0,440.0,428.0,0.002273,0.002273,6.089045,0.254793,1.0,440.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00352644,0.0035331255148511793,6.685514851179249e-06
0.0,440.0,428.0,0.0,0.0,6.089045,0.254793,1.0,440.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,440.0,428.0,0.0,0.0,6.089045,0.254793,1.0,440.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,440.0,428.0,0.0,0.0,6.089045,0.254793,1.0,440.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,440.0,428.0,0.002273,0.002273,6.089045,0.254793,1.0,440.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00352644,0.0035320592452678452,5.619245267845206e-06
1.0,440.0,428.0,0.002273,0.002273,6.089045,0.254793,1.0,440.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00352644,0.0035326019658333224,6.161965833322361e-06
2.0,440.0,428.0,0.004545,0.004545,6.089045,0.254793,1.0,440.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00705132,0.00709249918875533,4.1179188755330505e-05
9.0,905.0,855.0,0.009945,0.009945,6.809039,0.343788,1.0,905.0,9.0,96.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02327988,0.023275077824915207,4.802175084792082e-06
11.0,905.0,855.0,0.012155,0.012155,6.809039,0.343788,1.0,905.0,9.0,96.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02845319,0.02825870924056277,0.00019448075943722873
0.0,905.0,855.0,0.0,0.0,6.809039,0.343788,1.0,905.0,9.0,96.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,905.0,855.0,0.00221,0.00221,6.809039,0.343788,1.0,905.0,9.0,96.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00517331,0.005311191579349134,0.0001378815793491332
2.0,905.0,855.0,0.00221,0.00221,6.809039,0.343788,1.0,905.0,9.0,96.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00517331,0.005280272793396747,0.00010696279339674625
11.0,905.0,855.0,0.012155,0.012155,6.809039,0.343788,1.0,905.0,9.0,96.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02845319,0.028316809037586568,0.00013638096241343212
5.0,905.0,855.0,0.005525,0.005525,6.809039,0.343788,1.0,905.0,9.0,96.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01293327,0.012674768086576495,0.00025850191342350476
10.0,905.0,855.0,0.01105,0.01105,6.809039,0.343788,1.0,905.0,9.0,96.0,Other,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02586653,0.025646713858958333,0.0002198161410416656
90.0,1216.0,1011.0,0.074013,0.074013,7.104144,0.222179,1.0,1216.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.11682151,0.11657474028439484,0.00024676971560516625
45.0,1216.0,1011.0,0.037007,0.037007,7.104144,0.222179,1.0,1216.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.05841155,0.0604321430770138,0.002020593077013799
0.0,1216.0,1011.0,0.0,0.0,7.104144,0.222179,1.0,1216.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1216.0,1011.0,0.001645,0.001645,7.104144,0.222179,1.0,1216.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00259645,0.0025991738520634894,2.723852063489258e-06
10.0,1216.0,1011.0,0.008224,0.008224,7.104144,0.222179,1.0,1216.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01298069,0.01292400117851192,5.668882148807987e-05
9.0,1216.0,1011.0,0.007401,0.007401,7.104144,0.222179,1.0,1216.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01168168,0.011611217025327372,7.046297467262763e-05
32.0,1216.0,1011.0,0.026316,0.026316,7.104144,0.222179,1.0,1216.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04153696,0.04157668886331348,3.9728863313479024e-05
17.0,1216.0,1011.0,0.01398,0.01398,7.104144,0.222179,1.0,1216.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02206592,0.02205964369317458,6.276306825418743e-06
27.0,646.0,535.0,0.041796,0.041796,6.472346,0.211174,1.0,646.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.05712652,0.05677135492751985,0.0003551650724801514
4.0,646.0,535.0,0.006192,0.006192,6.472346,0.211174,1.0,646.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00846319,0.008504441656785725,4.125165678572386e-05
11.0,646.0,535.0,0.017028,0.017028,6.472346,0.211174,1.0,646.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02327377,0.023429386343581354,0.00015561634358135512
8.0,646.0,535.0,0.012384,0.012384,6.472346,0.211174,1.0,646.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01692637,0.017012883749573424,8.651374957342403e-05
4.0,646.0,535.0,0.006192,0.006192,6.472346,0.211174,1.0,646.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00846319,0.008532449610178587,6.925961017858681e-05
5.0,646.0,535.0,0.00774,0.00774,6.472346,0.211174,1.0,646.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01057898,0.01079356632666666,0.00021458632666665999
16.0,646.0,535.0,0.024768,0.024768,6.472346,0.211174,1.0,646.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03385275,0.034115813347578496,0.00026306334757849464
9.0,646.0,535.0,0.013932,0.013932,6.472346,0.211174,1.0,646.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01904217,0.019183959816488988,0.00014178981648898734
20.0,646.0,535.0,0.03096,0.03096,6.472346,0.211174,1.0,646.0,0.0,0.0,Flushing with Product,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04231594,0.04213176702678571,0.00018417297321429021
0.0,646.0,535.0,0.0,0.0,6.472346,0.211174,1.0,646.0,0.0,0.0,Flushing with Product,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,646.0,535.0,0.003096,0.003096,6.472346,0.211174,1.0,646.0,0.0,0.0,Laboratory Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00423159,0.004253636725505957,2.204672550595692e-05
1.0,646.0,535.0,0.001548,0.001548,6.472346,0.211174,1.0,646.0,0.0,0.0,Laboratory Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0021158,0.0021356891704635617,1.98891704635616e-05
2.0,646.0,535.0,0.003096,0.003096,6.472346,0.211174,1.0,646.0,0.0,0.0,Patient Discontinued for Other Reasons,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00423159,0.004253636725505957,2.204672550595692e-05
2.0,646.0,535.0,0.003096,0.003096,6.472346,0.211174,1.0,646.0,0.0,0.0,Patient Discontinued for Other Reasons,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00423159,0.0042599880512202435,2.8398051220243116e-05
3.0,218.0,208.0,0.013761,0.013761,5.389072,0.490711,1.0,511.0,13.0,58.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03639064,0.03812767169086307,0.0017370316908630681
5.0,218.0,208.0,0.022936,0.022936,5.389072,0.490711,1.0,511.0,13.0,58.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.06065371,0.0652297002795635,0.004575990279563499
0.0,218.0,208.0,0.0,0.0,5.389072,0.490711,1.0,511.0,13.0,58.0,Sponsor Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,218.0,208.0,0.004587,0.004587,5.389072,0.490711,1.0,511.0,13.0,58.0,Sponsor Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01213021,0.012195170403142132,6.496040314213185e-05
0.0,218.0,208.0,0.0,0.0,5.389072,0.490711,1.0,511.0,13.0,58.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,218.0,208.0,0.004587,0.004587,5.389072,0.490711,1.0,511.0,13.0,58.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01213021,0.012198154706892133,6.794470689213197e-05
2.0,467.0,451.0,0.004283,0.004283,6.148468,0.592912,1.0,467.0,15.0,78.0,Withdrawal by Subject,Double-Blind Period,FG000,dyslipidemia,INDUSTRY,0.01561368,0.015665139196339325,5.145919633932523e-05
3.0,467.0,451.0,0.006424,0.006424,6.148468,0.592912,1.0,467.0,15.0,78.0,Withdrawal by Subject,Double-Blind Period,FG001,dyslipidemia,INDUSTRY,0.0234187,0.023222178490029756,0.0001965215099702447
0.0,467.0,451.0,0.0,0.0,6.148468,0.592912,1.0,467.0,15.0,78.0,Protocol Violation,Double-Blind Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,467.0,451.0,0.008565,0.008565,6.148468,0.592912,1.0,467.0,15.0,78.0,Protocol Violation,Double-Blind Period,FG001,dyslipidemia,INDUSTRY,0.03122372,0.03121742597180559,6.2940281944090515e-06
0.0,467.0,451.0,0.0,0.0,6.148468,0.592912,1.0,467.0,15.0,78.0,Death,Open-Label Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,467.0,451.0,0.004283,0.004283,6.148468,0.592912,1.0,467.0,15.0,78.0,Death,Open-Label Period,FG001,dyslipidemia,INDUSTRY,0.01561368,0.015654683490367097,4.100349036709715e-05
1.0,467.0,451.0,0.002141,0.002141,6.148468,0.592912,1.0,467.0,15.0,78.0,Lost to Follow-up,Open-Label Period,FG000,dyslipidemia,INDUSTRY,0.00780502,0.00815042458374008,0.00034540458374008026
0.0,467.0,451.0,0.0,0.0,6.148468,0.592912,1.0,467.0,15.0,78.0,Lost to Follow-up,Open-Label Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,467.0,451.0,0.002141,0.002141,6.148468,0.592912,1.0,467.0,15.0,78.0,Withdrawal by Subject,Open-Label Period,FG000,dyslipidemia,INDUSTRY,0.00780502,0.00816326556499008,0.00035824556499008
0.0,467.0,451.0,0.0,0.0,6.148468,0.592912,1.0,467.0,15.0,78.0,Withdrawal by Subject,Open-Label Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,383.0,349.0,0.007833,0.007833,5.950643,0.461888,1.0,383.0,1.0,26.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02152926,0.021484777538392823,4.448246160717803e-05
5.0,383.0,349.0,0.013055,0.013055,5.950643,0.461888,1.0,383.0,1.0,26.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0358821,0.036006242252648826,0.00012414225264882617
1.0,383.0,349.0,0.002611,0.002611,5.950643,0.461888,1.0,383.0,1.0,26.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00717642,0.007188171183720212,1.1751183720211736e-05
1.0,383.0,349.0,0.002611,0.002611,5.950643,0.461888,1.0,383.0,1.0,26.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00717642,0.007187808396101166,1.1388396101165953e-05
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Death,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,383.0,349.0,0.002611,0.002611,5.950643,0.461888,1.0,383.0,1.0,26.0,Eligibility criteria not fulfilled,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00717642,0.007191142828601166,1.4722828601165978e-05
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Eligibility criteria not fulfilled,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Eligibility criteria not fulfilled,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
7.0,383.0,349.0,0.018277,0.018277,5.950643,0.461888,1.0,383.0,1.0,26.0,Reason not specified,Overall Study,FG000,dyslipidemia,INDUSTRY,0.05023494,0.05149370264439394,0.0012587626443939445
9.0,383.0,349.0,0.023499,0.023499,5.950643,0.461888,1.0,383.0,1.0,26.0,Reason not specified,Overall Study,FG001,dyslipidemia,INDUSTRY,0.06458778,0.06445409329491068,0.00013368670508931424
4.0,383.0,349.0,0.010444,0.010444,5.950643,0.461888,1.0,383.0,1.0,26.0,Reason not specified,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02870568,0.0293874067166369,0.0006817267166368997
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,383.0,349.0,0.005222,0.005222,5.950643,0.461888,1.0,383.0,1.0,26.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01435284,0.014540512877518747,0.00018767287751874674
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,383.0,349.0,0.0,0.0,5.950643,0.461888,1.0,383.0,1.0,26.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,383.0,349.0,0.002611,0.002611,5.950643,0.461888,1.0,383.0,1.0,26.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00717642,0.007189045580922593,1.2625580922592632e-05
28.0,2340.0,1954.0,0.011966,0.011966,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02420498,0.02394383859931548,0.00026114140068451974
40.0,2340.0,1954.0,0.017094,0.017094,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03457797,0.034903884138769846,0.0003259141387698464
13.0,2340.0,1954.0,0.005556,0.005556,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01123875,0.011255642082708328,1.689208270832729e-05
19.0,2340.0,1954.0,0.00812,0.00812,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01642524,0.01634200416580358,8.323583419642122e-05
20.0,2340.0,1954.0,0.008547,0.008547,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01728899,0.017008574704702382,0.00028041529529761883
33.0,2340.0,1954.0,0.014103,0.014103,7.758333,0.260728,1.0,2340.0,0.0,0.0,Adverse Event,Overall Study,FG005,dyslipidemia,INDUSTRY,0.02852774,0.027683574112628954,0.0008441658873710456
7.0,2340.0,1954.0,0.002991,0.002991,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00605023,0.005985540793005961,6.468920699403882e-05
7.0,2340.0,1954.0,0.002991,0.002991,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00605023,0.005981300494285724,6.892950571427657e-05
8.0,2340.0,1954.0,0.003419,0.003419,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.006916,0.006920786600188462,4.786600188461977e-06
8.0,2340.0,1954.0,0.003419,0.003419,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.006916,0.006922362789771801,6.362789771801117e-06
4.0,2340.0,1954.0,0.001709,0.001709,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00345699,0.00339651001302489,6.047998697511015e-05
8.0,2340.0,1954.0,0.003419,0.003419,7.758333,0.260728,1.0,2340.0,0.0,0.0,Lost to Follow-up,Overall Study,FG005,dyslipidemia,INDUSTRY,0.006916,0.006924861627271801,8.861627271801106e-06
18.0,2340.0,1954.0,0.007692,0.007692,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01555948,0.01554224793110121,1.7232068898790157e-05
42.0,2340.0,1954.0,0.017949,0.017949,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03630748,0.03607070628667658,0.00023677371332342378
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00086374,0.0008648542260416679,1.11422604166789e-06
2.0,2340.0,1954.0,0.000855,0.000855,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00172951,0.0017114708289926012,1.8039171007398856e-05
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,2340.0,1954.0,0.001709,0.001709,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant had flushing,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00345699,0.003400831126477272,5.615887352272827e-05
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,2340.0,1954.0,0.002137,0.002137,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00432275,0.00412752278228175,0.00019522721771825062
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00086374,0.0008651306006845251,1.390600684525109e-06
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Other,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00086374,0.0008652114449702393,1.4714449702393252e-06
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00086374,0.0008651160631845252,1.3760631845251932e-06
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00086374,0.0008651160631845252,1.3760631845251932e-06
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Participant moved,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00086374,0.0008651160631845252,1.3760631845251932e-06
10.0,2340.0,1954.0,0.004274,0.004274,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0086455,0.008408899135912699,0.00023660086408730172
21.0,2340.0,1954.0,0.008974,0.008974,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01815273,0.017744772626279767,0.0004079573737202323
8.0,2340.0,1954.0,0.003419,0.003419,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.006916,0.006924788115198385,8.78811519838471e-06
18.0,2340.0,1954.0,0.007692,0.007692,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01555948,0.015514025500744067,4.54544992559338e-05
12.0,2340.0,1954.0,0.005128,0.005128,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01037299,0.009907803151081343,0.00046518684891865697
11.0,2340.0,1954.0,0.004701,0.004701,7.758333,0.260728,1.0,2340.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00950925,0.009361267389593255,0.0001479826104067456
3.0,2340.0,1954.0,0.001282,0.001282,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00259325,0.002534235240089286,5.9014759910714244e-05
9.0,2340.0,1954.0,0.003846,0.003846,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00777974,0.007608596785505952,0.00017114321449404786
2.0,2340.0,1954.0,0.000855,0.000855,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00172951,0.0017129091007242027,1.6600899275797353e-05
6.0,2340.0,1954.0,0.002564,0.002564,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00518649,0.005000354736011903,0.00018613526398809747
7.0,2340.0,1954.0,0.002991,0.002991,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00605023,0.005993470705089294,5.6759294910706075e-05
4.0,2340.0,1954.0,0.001709,0.001709,7.758333,0.260728,1.0,2340.0,0.0,0.0,Protocol Violation,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00345699,0.0034002453827272714,5.6744617272728656e-05
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00086374,0.0008651794330952394,1.4394330952393567e-06
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00086374,0.000864801339166668,1.0613391666679586e-06
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,site terminated,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,2340.0,1954.0,0.000427,0.000427,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00086374,0.0008651318436011918,1.3918436011918327e-06
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2340.0,1954.0,0.0,0.0,7.758333,0.260728,1.0,2340.0,0.0,0.0,Not treated,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,986.0,968.0,0.006085,0.006085,6.89467,0.492461,1.0,986.0,10.0,110.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02066075,0.020541442625185785,0.00011930737481421344
1.0,986.0,968.0,0.001014,0.001014,6.89467,0.492461,1.0,986.0,10.0,110.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00344289,0.003494489445218257,5.1599445218257056e-05
6.0,986.0,968.0,0.006085,0.006085,6.89467,0.492461,1.0,986.0,10.0,110.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02066075,0.020559671787864348,0.0001010782121356503
4.0,986.0,968.0,0.004057,0.004057,6.89467,0.492461,1.0,986.0,10.0,110.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.01377497,0.013836187971944452,6.121797194445257e-05
1.0,986.0,968.0,0.001014,0.001014,6.89467,0.492461,1.0,986.0,10.0,110.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00344289,0.003492100733194447,4.921073319444705e-05
0.0,986.0,968.0,0.0,0.0,6.89467,0.492461,1.0,986.0,10.0,110.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,986.0,968.0,0.0,0.0,6.89467,0.492461,1.0,986.0,10.0,110.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,986.0,968.0,0.0,0.0,6.89467,0.492461,1.0,986.0,10.0,110.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,579.0,557.0,0.006908,0.006908,6.363028,0.211174,1.0,579.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00928234,0.009293539749792568,1.1199749792568242e-05
7.0,579.0,557.0,0.01209,0.01209,6.363028,0.211174,1.0,579.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01624544,0.016446192650049617,0.0002007526500496168
1.0,579.0,557.0,0.001727,0.001727,6.363028,0.211174,1.0,579.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00232058,0.0023261205289583408,5.540528958340729e-06
1.0,579.0,557.0,0.001727,0.001727,6.363028,0.211174,1.0,579.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00232058,0.0023116454115178642,8.93458848213579e-06
0.0,579.0,557.0,0.0,0.0,6.363028,0.211174,1.0,579.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,579.0,557.0,0.001727,0.001727,6.363028,0.211174,1.0,579.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00232058,0.0023143693347321497,6.21066526785034e-06
4.0,579.0,557.0,0.006908,0.006908,6.363028,0.211174,1.0,579.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00928234,0.009285059199524713,2.7191995247127093e-06
3.0,579.0,557.0,0.005181,0.005181,6.363028,0.211174,1.0,579.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00696175,0.006953325414325403,8.424585674597293e-06
0.0,579.0,557.0,0.0,0.0,6.363028,0.211174,1.0,579.0,0.0,0.0,Could not take time off work,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,579.0,557.0,0.001727,0.001727,6.363028,0.211174,1.0,579.0,0.0,0.0,Could not take time off work,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00232058,0.00231377387973215,6.806120267850192e-06
4.0,503.0,460.0,0.007952,0.007952,6.222576,0.270051,1.0,503.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01336262,0.013466067773055559,0.00010344777305555837
9.0,503.0,460.0,0.017893,0.017893,6.222576,0.270051,1.0,503.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03006758,0.030632674776478182,0.0005650947764781825
10.0,503.0,460.0,0.019881,0.019881,6.222576,0.270051,1.0,503.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.03340823,0.033608268702549585,0.00020003870254958755
3.0,503.0,460.0,0.005964,0.005964,6.222576,0.270051,1.0,503.0,0.0,0.0,Voluntary withdrawal,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01002197,0.010191412408060067,0.0001694424080600672
4.0,503.0,460.0,0.007952,0.007952,6.222576,0.270051,1.0,503.0,0.0,0.0,Voluntary withdrawal,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01336262,0.01348044819073413,0.00011782819073413026
6.0,503.0,460.0,0.011928,0.011928,6.222576,0.270051,1.0,503.0,0.0,0.0,Voluntary withdrawal,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02004393,0.01999720606940477,4.672393059523133e-05
1.0,503.0,460.0,0.001988,0.001988,6.222576,0.270051,1.0,503.0,0.0,0.0,Difficulty Making it to Study Visit,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00334066,0.0034092328278868987,6.857282788689861e-05
1.0,503.0,460.0,0.001988,0.001988,6.222576,0.270051,1.0,503.0,0.0,0.0,Difficulty Making it to Study Visit,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00334066,0.0034043277614980117,6.366776149801167e-05
5.0,503.0,460.0,0.00994,0.00994,6.222576,0.270051,1.0,503.0,0.0,0.0,Difficulty Making it to Study Visit,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01670328,0.016825616344295642,0.00012233634429564127
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 1-8 / 10 mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.004579177536428546,1.6875364285458966e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 1-8 / 10 mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.004580580811428547,3.0908114285466137e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Lost to Follow-up,Weeks 1-8 / 10 mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.0045786148733333075,1.1248733333074981e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Lost to Follow-up,Weeks 1-8 / 10 mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.004579231594166641,1.7415941666407836e-06
2.0,245.0,219.0,0.008163,0.008163,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 1-8 / 10 mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00915386,0.009200853392232141,4.6993392232141246e-05
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 1-8 / 10 mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.0045804104614285465,2.9204614285464198e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Family Crisis - could not participate,Weeks 1-8 / 10 mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.004579177536428546,1.6875364285458966e-06
0.0,245.0,219.0,0.0,0.0,5.505332,0.203691,1.0,245.0,0.0,0.0,Family Crisis - could not participate,Weeks 1-8 / 10 mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,245.0,219.0,0.0,0.0,5.505332,0.203691,1.0,245.0,0.0,0.0,Requirement for Excluded Medications,Weeks 1-8 / 10 mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Requirement for Excluded Medications,Weeks 1-8 / 10 mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.004580580811428547,3.0908114285466137e-06
4.0,245.0,219.0,0.016327,0.016327,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 9-12 / 20mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.01830885,0.018763230755079355,0.00045438075507935397
3.0,245.0,219.0,0.012245,0.012245,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 9-12 / 20mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.01373136,0.014083570517142853,0.0003522105171428532
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Lost to Follow-up,Weeks 9-12 / 20mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.004583064272142833,5.574272142832952e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Lost to Follow-up,Weeks 9-12 / 20mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.004584587902976166,7.097902976166241e-06
0.0,245.0,219.0,0.0,0.0,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 9-12 / 20mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 9-12 / 20mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00457749,0.004587494786904738,1.000478690473764e-05
3.0,245.0,219.0,0.012245,0.012245,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 13-16 / 40mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.01373136,0.01413238374863095,0.000401023748630951
2.0,245.0,219.0,0.008163,0.008163,5.505332,0.203691,1.0,245.0,0.0,0.0,Adverse Event,Weeks 13-16 / 40mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.00915386,0.009144259878869042,9.600121130957928e-06
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 13-16 / 40mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.004584728636904738,7.23863690473784e-06
0.0,245.0,219.0,0.0,0.0,5.505332,0.203691,1.0,245.0,0.0,0.0,Withdrawal by Subject,Weeks 13-16 / 40mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,245.0,219.0,0.004082,0.004082,5.505332,0.203691,1.0,245.0,0.0,0.0,Per Sponsors Request,Weeks 13-16 / 40mg Dose Level,FG000,dyslipidemia,INDUSTRY,0.00457749,0.004584898986904738,7.408986904738034e-06
0.0,245.0,219.0,0.0,0.0,5.505332,0.203691,1.0,245.0,0.0,0.0,Per Sponsors Request,Weeks 13-16 / 40mg Dose Level,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,986.0,899.0,0.001014,0.001014,6.89467,0.474221,1.0,986.0,24.0,177.0,Enrolled but not treated,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00331537,0.0033721999794047606,5.682997940476041e-05
0.0,986.0,899.0,0.0,0.0,6.89467,0.474221,1.0,986.0,24.0,177.0,Enrolled but not treated,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
10.0,986.0,899.0,0.010142,0.010142,6.89467,0.474221,1.0,986.0,24.0,177.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03316023,0.03349069332916667,0.0003304633291666692
23.0,986.0,899.0,0.023327,0.023327,6.89467,0.474221,1.0,986.0,24.0,177.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.07626983,0.07573065769557547,0.0005391723044245317
7.0,986.0,899.0,0.007099,0.007099,6.89467,0.474221,1.0,986.0,24.0,177.0,Poor compliance to protocol,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02321085,0.023220691358658025,9.841358658023436e-06
7.0,986.0,899.0,0.007099,0.007099,6.89467,0.474221,1.0,986.0,24.0,177.0,Poor compliance to protocol,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02321085,0.023214345633869055,3.4956338690536604e-06
0.0,986.0,899.0,0.0,0.0,6.89467,0.474221,1.0,986.0,24.0,177.0,Participant Moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,986.0,899.0,0.004057,0.004057,6.89467,0.474221,1.0,986.0,24.0,177.0,Participant Moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01326474,0.013418316590803572,0.00015357659080357175
2.0,986.0,899.0,0.002028,0.002028,6.89467,0.474221,1.0,986.0,24.0,177.0,Related to Study Drug administration,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00663074,0.006656196414176577,2.5456414176576805e-05
2.0,986.0,899.0,0.002028,0.002028,6.89467,0.474221,1.0,986.0,24.0,177.0,Related to Study Drug administration,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00663074,0.006628471243402768,2.2687565972324963e-06
10.0,986.0,899.0,0.010142,0.010142,6.89467,0.474221,1.0,986.0,24.0,177.0,Other than specified above,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03316023,0.03348282297375001,0.00032259297375000773
21.0,986.0,899.0,0.021298,0.021298,6.89467,0.474221,1.0,986.0,24.0,177.0,Other than specified above,Overall Study,FG001,dyslipidemia,INDUSTRY,0.06963582,0.07109831767810516,0.0014624976781051624
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00360339,0.0036051222875595423,1.7322875595420992e-06
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,615.0,598.0,0.003252,0.003252,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00720679,0.0071866350244047805,2.015497559521972e-05
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Withdrawal by Subject,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,615.0,598.0,0.003252,0.003252,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00720679,0.0072001428344047776,6.64716559522268e-06
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,615.0,598.0,0.004878,0.004878,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01081018,0.010980996144285717,0.00017081614428571604
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,615.0,598.0,0.003252,0.003252,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00720679,0.007201912206071447,4.877793928553462e-06
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Decision by sponsor,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00360339,0.0036075744058333527,4.184405833352559e-06
0.0,615.0,598.0,0.0,0.0,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00360339,0.0036096571492857314,6.267149285731251e-06
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00360339,0.003608136316369066,4.746316369065844e-06
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00360339,0.0036124073138690655,9.01731386906534e-06
2.0,615.0,598.0,0.003252,0.003252,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG004,dyslipidemia,INDUSTRY,0.00720679,0.007202309881488111,4.480118511888953e-06
1.0,615.0,598.0,0.001626,0.001626,6.423247,0.345014,1.0,615.0,10.0,83.0,Lost to Follow-up,Overall Study,FG005,dyslipidemia,INDUSTRY,0.00360339,0.0036084339663095427,5.0439663095425136e-06
14.0,300.0,252.0,0.046667,0.046667,5.70711,0.51104,1.0,300.0,18.0,44.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.13610706,0.14507494003535715,0.008967880035357145
4.0,300.0,252.0,0.013333,0.013333,5.70711,0.51104,1.0,300.0,18.0,44.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03888648,0.03901534944855159,0.00012886944855158844
3.0,300.0,252.0,0.01,0.01,5.70711,0.51104,1.0,300.0,18.0,44.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02916559,0.029636883881686494,0.0004712938816864923
6.0,300.0,252.0,0.02,0.02,5.70711,0.51104,1.0,300.0,18.0,44.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.05833118,0.05996610456944444,0.001634924569444439
12.0,300.0,252.0,0.04,0.04,5.70711,0.51104,1.0,300.0,18.0,44.0,Study Closure,Overall Study,FG000,dyslipidemia,INDUSTRY,0.11666236,0.12137090110620935,0.0047085411062093435
6.0,300.0,252.0,0.02,0.02,5.70711,0.51104,1.0,300.0,18.0,44.0,Study Closure,Overall Study,FG001,dyslipidemia,INDUSTRY,0.05833118,0.059951719988194443,0.0016205399881944402
2.0,300.0,252.0,0.006667,0.006667,5.70711,0.51104,1.0,300.0,18.0,44.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0194447,0.01967632868641954,0.00023162868641954035
0.0,300.0,252.0,0.0,0.0,5.70711,0.51104,1.0,300.0,18.0,44.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,300.0,252.0,0.003333,0.003333,5.70711,0.51104,1.0,300.0,18.0,44.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00972089,0.009873316757619049,0.00015242675761904974
0.0,300.0,252.0,0.0,0.0,5.70711,0.51104,1.0,300.0,18.0,44.0,Other,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,229.0,215.0,0.0131,0.0131,5.438079,0.281906,1.0,229.0,11.0,60.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02008268,0.02042950944585317,0.00034682944585317024
1.0,229.0,215.0,0.004367,0.004367,5.438079,0.281906,1.0,229.0,11.0,60.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00669474,0.006708705981954332,1.3965981954331547e-05
0.0,229.0,215.0,0.0,0.0,5.438079,0.281906,1.0,229.0,11.0,60.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,229.0,215.0,0.004367,0.004367,5.438079,0.281906,1.0,229.0,11.0,60.0,Withdrew Consent,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00669474,0.0066901752879265615,4.564712073438712e-06
4.0,229.0,215.0,0.017467,0.017467,5.438079,0.281906,1.0,229.0,11.0,60.0,Withdrew Consent,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02677742,0.02706374647898808,0.0002863264789880818
2.0,229.0,215.0,0.008734,0.008734,5.438079,0.281906,1.0,229.0,11.0,60.0,Withdrew Consent,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01338947,0.013742093509037696,0.0003526235090376955
0.0,229.0,215.0,0.0,0.0,5.438079,0.281906,1.0,229.0,11.0,60.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,229.0,215.0,0.004367,0.004367,5.438079,0.281906,1.0,229.0,11.0,60.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00669474,0.00670681117016862,1.207117016861943e-05
0.0,229.0,215.0,0.0,0.0,5.438079,0.281906,1.0,229.0,11.0,60.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,229.0,215.0,0.004367,0.004367,5.438079,0.281906,1.0,229.0,11.0,60.0,Triglycerides >2000 mg/dL,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00669474,0.0066901752879265615,4.564712073438712e-06
0.0,229.0,215.0,0.0,0.0,5.438079,0.281906,1.0,229.0,11.0,60.0,Triglycerides >2000 mg/dL,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,229.0,215.0,0.004367,0.004367,5.438079,0.281906,1.0,229.0,11.0,60.0,Triglycerides >2000 mg/dL,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00669474,0.006705462266835283,1.0722266835282504e-05
96.0,2414.0,1733.0,0.039768,0.039768,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.06709852,0.06677669530146822,0.0003218246985317724
99.0,2414.0,1733.0,0.041011,0.041011,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.06919577,0.06977346289875004,0.0005776928987500374
98.0,2414.0,1733.0,0.040597,0.040597,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.06849725,0.06880581854666666,0.00030856854666666544
87.0,2414.0,1733.0,0.03604,0.03604,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.06080846,0.06181143141464282,0.0010029714146428184
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,2414.0,1733.0,0.001657,0.001657,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.00279577,0.0027921486894642803,3.6213105357196275e-06
4.0,2414.0,1733.0,0.001657,0.001657,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.00279577,0.002791892552380947,3.877447619053155e-06
4.0,2414.0,1733.0,0.001657,0.001657,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.00279577,0.00279350557898809,2.264421011909882e-06
12.0,2414.0,1733.0,0.004971,0.004971,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.00838732,0.008363436375595272,2.388362440472816e-05
9.0,2414.0,1733.0,0.003728,0.003728,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.00629006,0.006333989415208324,4.392941520832416e-05
9.0,2414.0,1733.0,0.003728,0.003728,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.00629006,0.0063126122628273705,2.2552262827370446e-05
11.0,2414.0,1733.0,0.004557,0.004557,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.00768879,0.007704664858273812,1.5874858273812187e-05
4.0,2414.0,1733.0,0.001657,0.001657,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.00279577,0.0027895329457142837,6.237054285716196e-06
6.0,2414.0,1733.0,0.002486,0.002486,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.0041945,0.004221211191359129,2.671119135912864e-05
9.0,2414.0,1733.0,0.003728,0.003728,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.00629006,0.006318422191994038,2.8362191994037514e-05
5.0,2414.0,1733.0,0.002071,0.002071,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.00349429,0.003504633185357139,1.0343185357138823e-05
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
4.0,2414.0,1733.0,0.001657,0.001657,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.00279577,0.002794019211547617,1.7507884523828253e-06
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.00139873,0.0013955560955952418,3.1739044047580933e-06
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.00069852,0.0007075134900595251,8.993490059525078e-06
24.0,2414.0,1733.0,0.009942,0.009942,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.01677463,0.01703498720502975,0.00026035720502975285
33.0,2414.0,1733.0,0.01367,0.01367,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.0230647,0.023767965814464272,0.0007032658144642719
30.0,2414.0,1733.0,0.012428,0.012428,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.02096913,0.021534183711835318,0.0005650537118353192
25.0,2414.0,1733.0,0.010356,0.010356,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.01747315,0.01767438610842261,0.00020123610842261164
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Precrossover: Periods I/II (Weeks 1-12),FG000,dyslipidemia,INDUSTRY,0.00139873,0.0013953426276190509,3.387372380949088e-06
7.0,2414.0,1733.0,0.0029,0.0029,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Precrossover: Periods I/II (Weeks 1-12),FG001,dyslipidemia,INDUSTRY,0.00489302,0.004924019012182532,3.09990121825322e-05
5.0,2414.0,1733.0,0.002071,0.002071,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Precrossover: Periods I/II (Weeks 1-12),FG002,dyslipidemia,INDUSTRY,0.00349429,0.0035069111532738044,1.2621153273804225e-05
7.0,2414.0,1733.0,0.0029,0.0029,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Precrossover: Periods I/II (Weeks 1-12),FG003,dyslipidemia,INDUSTRY,0.00489302,0.0049176478117658635,2.4627811765863886e-05
12.0,2414.0,1733.0,0.004971,0.004971,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00838732,0.008390226193988133,2.906193988133285e-06
13.0,2414.0,1733.0,0.005385,0.005385,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.00908584,0.008971694829345253,0.0001141451706547468
12.0,2414.0,1733.0,0.004971,0.004971,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00838732,0.008394726235714318,7.406235714317588e-06
10.0,2414.0,1733.0,0.004143,0.004143,7.789455,0.216607,1.0,2414.0,0.0,0.0,Clinical Adverse Event,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.00699027,0.006982529625624996,7.740374375004092e-06
3.0,2414.0,1733.0,0.001243,0.001243,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00209725,0.0021127194646825506,1.546946468255041e-05
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.00069852,0.0007039080677380961,5.3880677380961075e-06
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00139873,0.00139851679226191,2.1320773808996066e-07
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Laboratory Adverse Event,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.00139873,0.0013978609242857188,8.690757142811121e-07
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00069852,0.0007004083683928576,1.8883683928575803e-06
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.00139873,0.0013981244284523844,6.055715476155354e-07
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00069852,0.0006997153748015877,1.1953748015877197e-06
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Lost to Follow-up,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.00069852,0.0007000770746428578,1.5570746428577708e-06
5.0,2414.0,1733.0,0.002071,0.002071,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00349429,0.0034957340995238058,1.4440995238056142e-06
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00139873,0.001398901901428576,1.7190142857607948e-07
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Other,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.00139873,0.0013982783209523853,4.516790476146327e-07
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00069852,0.0007001950121428578,1.6750121428578185e-06
2.0,2414.0,1733.0,0.000829,0.000829,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.00139873,0.0013985793847023848,1.5061529761513544e-07
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00069852,0.0006995020185515878,9.820185515878495e-07
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Participant moved,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,2414.0,1733.0,0.001243,0.001243,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.00209725,0.0021056739001587433,8.423900158743142e-06
3.0,2414.0,1733.0,0.001243,0.001243,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.00209725,0.00210170877807541,4.45877807540981e-06
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00069852,0.0006998014789682545,1.281478968254493e-06
3.0,2414.0,1733.0,0.001243,0.001243,7.789455,0.216607,1.0,2414.0,0.0,0.0,Withdrawal by Subject,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.00209725,0.002105061084742077,7.811084742077e-06
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Crossover: Period III (Weeks 13-20),FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Crossover: Period III (Weeks 13-20),FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,2414.0,1733.0,0.000414,0.000414,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Crossover: Period III (Weeks 13-20),FG002,dyslipidemia,INDUSTRY,0.00069852,0.0007004001023015877,1.8801023015876678e-06
0.0,2414.0,1733.0,0.0,0.0,7.789455,0.216607,1.0,2414.0,0.0,0.0,Protocol Violation,Crossover: Period III (Weeks 13-20),FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG002,dyslipidemia,INDUSTRY,0.00445428,0.004449891287797638,4.388712202361457e-06
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG004,dyslipidemia,INDUSTRY,0.00445428,0.004449891175297639,4.388824702360357e-06
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Run-in Period,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG001,dyslipidemia,INDUSTRY,0.00445428,0.00445345948750002,8.205124999794214e-07
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG002,dyslipidemia,INDUSTRY,0.00445428,0.004454280112500019,1.1250001971663259e-10
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG003,dyslipidemia,INDUSTRY,0.00445428,0.0044542800000000205,2.0816681711721685e-17
3.0,267.0,219.0,0.011236,0.011236,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG004,dyslipidemia,INDUSTRY,0.01336403,0.013360001526826284,4.028473173716893e-06
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Run-in Period,FG005,dyslipidemia,INDUSTRY,0.00445428,0.0044542800000000205,2.0816681711721685e-17
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG000,dyslipidemia,INDUSTRY,0.00445428,0.00445655764986113,2.277649861130368e-06
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG002,dyslipidemia,INDUSTRY,0.00445428,0.004454327779166686,4.777916668644716e-08
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Noncompliance,Run-in Period,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,267.0,219.0,0.011236,0.011236,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG000,dyslipidemia,INDUSTRY,0.01336403,0.01337760154354165,1.3571543541649606e-05
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG001,dyslipidemia,INDUSTRY,0.00445428,0.00444929346279764,4.986537202360079e-06
7.0,267.0,219.0,0.026217,0.026217,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG002,dyslipidemia,INDUSTRY,0.03118233,0.031560015321428575,0.00037768532142857386
4.0,267.0,219.0,0.014981,0.014981,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG003,dyslipidemia,INDUSTRY,0.01781831,0.017858527265689927,4.0217265689927034e-05
3.0,267.0,219.0,0.011236,0.011236,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG004,dyslipidemia,INDUSTRY,0.01336403,0.013386784015863075,2.2754015863074573e-05
4.0,267.0,219.0,0.014981,0.014981,5.590987,0.212734,1.0,277.0,1.0,26.0,Adverse Event,Coadministration Period,FG005,dyslipidemia,INDUSTRY,0.01781831,0.01785538290318993,3.70729031899282e-05
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG000,dyslipidemia,INDUSTRY,0.00445428,0.004456509983194464,2.229983194464505e-06
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG001,dyslipidemia,INDUSTRY,0.00445428,0.004453695287500021,5.847124999788095e-07
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG003,dyslipidemia,INDUSTRY,0.00445428,0.0044542800000000205,2.0816681711721685e-17
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Withdrawal by Subject,Coadministration Period,FG005,dyslipidemia,INDUSTRY,0.00445428,0.0044542800000000205,2.0816681711721685e-17
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG001,dyslipidemia,INDUSTRY,0.00445428,0.0044541060208333535,1.7397916664621538e-07
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG003,dyslipidemia,INDUSTRY,0.00445428,0.004454690733333353,4.107333333534108e-07
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG004,dyslipidemia,INDUSTRY,0.00445428,0.004454690733333353,4.107333333534108e-07
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Protocol Violation,Coadministration Period,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,267.0,219.0,0.0,0.0,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,267.0,219.0,0.007491,0.007491,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG001,dyslipidemia,INDUSTRY,0.00890975,0.008935623443005955,2.5873443005955746e-05
3.0,267.0,219.0,0.011236,0.011236,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG002,dyslipidemia,INDUSTRY,0.01336403,0.01338306946068451,1.9039460684509846e-05
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG003,dyslipidemia,INDUSTRY,0.00445428,0.004456451013333354,2.1710133333539827e-06
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG004,dyslipidemia,INDUSTRY,0.00445428,0.004456451013333354,2.1710133333539827e-06
1.0,267.0,219.0,0.003745,0.003745,5.590987,0.212734,1.0,277.0,1.0,26.0,Other,Coadministration Period,FG005,dyslipidemia,INDUSTRY,0.00445428,0.004456451013333354,2.1710133333539827e-06
4.0,611.0,589.0,0.006547,0.006547,6.416732,0.268071,1.0,611.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01126174,0.01104194414210318,0.00021979585789681962
7.0,611.0,589.0,0.011457,0.011457,6.416732,0.268071,1.0,611.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01970761,0.019744020074851168,3.641007485116754e-05
7.0,611.0,589.0,0.011457,0.011457,6.416732,0.268071,1.0,611.0,0.0,0.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01970761,0.019720471974851175,1.2861974851174907e-05
2.0,611.0,589.0,0.003273,0.003273,6.416732,0.268071,1.0,611.0,0.0,0.0,Voluntary Withdrawal,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00563001,0.005498423532678578,0.0001315864673214224
1.0,611.0,589.0,0.001637,0.001637,6.416732,0.268071,1.0,611.0,0.0,0.0,Voluntary Withdrawal,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00281586,0.0029483716964448046,0.0001325116964448047
1.0,611.0,589.0,0.001637,0.001637,6.416732,0.268071,1.0,611.0,0.0,0.0,Voluntary Withdrawal,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00281586,0.0029448601931114714,0.00012900019311147147
14.0,260.0,215.0,0.053846,0.053846,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG000,dyslipidemia,INDUSTRY,0.0752454,0.07648089092706704,0.00123549092706704
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
9.0,260.0,215.0,0.034615,0.034615,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG003,dyslipidemia,INDUSTRY,0.04837164,0.04949345311336313,0.0011218131133631307
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Adverse Event,Active Comparison Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG000,dyslipidemia,INDUSTRY,0.00537447,0.005374253550297634,2.1644970236642247e-07
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG003,dyslipidemia,INDUSTRY,0.00537447,0.005374082643333349,3.873566666512049e-07
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Active Comparison Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG000,dyslipidemia,INDUSTRY,0.00537447,0.005376144893630967,1.6748936309670878e-06
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG003,dyslipidemia,INDUSTRY,0.00537447,0.0053760114600000155,1.541460000015378e-06
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Physician Decision,Active Comparison Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
7.0,260.0,215.0,0.026923,0.026923,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG000,dyslipidemia,INDUSTRY,0.0376227,0.03790301886816469,0.0002803188681646876
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,260.0,215.0,0.023077,0.023077,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG003,dyslipidemia,INDUSTRY,0.03224823,0.032375045551369046,0.00012681555136904304
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Active Comparison Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG000,dyslipidemia,INDUSTRY,0.00537447,0.005374531739880967,6.173988096724176e-08
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG003,dyslipidemia,INDUSTRY,0.00537447,0.0053744074662500155,6.25337499846404e-08
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Other Reasons,Active Comparison Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG002,dyslipidemia,INDUSTRY,0.00537447,0.005380049210773823,5.579210773823222e-06
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG004,dyslipidemia,INDUSTRY,0.00537447,0.005378836160773824,4.366160773823513e-06
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Death,Placebo-controlled Withdrawal Phase,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,260.0,215.0,0.0,0.0,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,260.0,215.0,0.003846,0.003846,5.56452,0.25113,1.0,260.0,13.0,39.0,Withdrawal by Subject,Placebo-controlled Withdrawal Phase,FG005,dyslipidemia,INDUSTRY,0.00537447,0.0053793107169047725,4.840716904772405e-06
21.0,758.0,663.0,0.027704,0.027704,6.632002,0.209726,1.0,760.0,1.0,168.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03853352,0.0395235983937888,0.0009900783937887986
18.0,758.0,663.0,0.023747,0.023747,6.632002,0.209726,1.0,760.0,1.0,168.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.03302973,0.03399070550764424,0.0009609755076442419
11.0,758.0,663.0,0.014512,0.014512,6.632002,0.209726,1.0,760.0,1.0,168.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02018476,0.02010840758892858,7.635241107141824e-05
11.0,758.0,663.0,0.014512,0.014512,6.632002,0.209726,1.0,760.0,1.0,168.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02018476,0.020177984576547625,6.775423452374391e-06
11.0,758.0,663.0,0.014512,0.014512,6.632002,0.209726,1.0,760.0,1.0,168.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02018476,0.020205526123988106,2.0766123988106427e-05
5.0,758.0,663.0,0.006596,0.006596,6.632002,0.209726,1.0,760.0,1.0,168.0,Withdrawal by Subject,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00917438,0.009362512961508841,0.00018813296150884187
2.0,758.0,663.0,0.002639,0.002639,6.632002,0.209726,1.0,760.0,1.0,168.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00367059,0.003702336524791674,3.1746524791674124e-05
2.0,758.0,663.0,0.002639,0.002639,6.632002,0.209726,1.0,760.0,1.0,168.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00367059,0.003699207913125008,2.8617913125007777e-05
3.0,758.0,663.0,0.003958,0.003958,6.632002,0.209726,1.0,760.0,1.0,168.0,Lost to Follow-up,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00550519,0.00557439594338293,6.920594338293007e-05
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject noncompliance,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0018346,0.0018350376593452495,4.376593452494557e-07
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject noncompliance,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0018346,0.0018350847131250105,4.847131250104632e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject noncompliance,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject moved out of town,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0018346,0.001835103568511916,5.035685119159344e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject moved out of town,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Subject moved out of town,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0018346,0.001835144172291677,5.441722916769108e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Sponsor request,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Sponsor request,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0018346,0.001835144172291677,5.441722916769108e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Sponsor request,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,758.0,663.0,0.002639,0.002639,6.632002,0.209726,1.0,760.0,1.0,168.0,Exclusion criteria violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00367059,0.003704005869791673,3.3415869791672895e-05
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Exclusion criteria violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Exclusion criteria violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Coordinator error,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0018346,0.001835103568511916,5.035685119159344e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Coordinator error,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Coordinator error,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Patient randomized in error,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0018346,0.001835103568511916,5.035685119159344e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Patient randomized in error,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Patient randomized in error,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Participation in another ABT-335 trial,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0018346,0.001835103568511916,5.035685119159344e-07
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Participation in another ABT-335 trial,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Participation in another ABT-335 trial,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,758.0,663.0,0.0,0.0,6.632002,0.209726,1.0,760.0,1.0,168.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,758.0,663.0,0.001319,0.001319,6.632002,0.209726,1.0,760.0,1.0,168.0,Protocol Violation,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0018346,0.001834977121845249,3.7712184524892403e-07
4.0,271.0,206.0,0.01476,0.01476,5.605802,0.342728,1.0,272.0,15.0,40.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0283579,0.028204925368749897,0.00015297463125010097
3.0,271.0,206.0,0.01107,0.01107,5.605802,0.342728,1.0,272.0,15.0,40.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.02126842,0.02145023559669187,0.00018181559669187136
3.0,271.0,206.0,0.01107,0.01107,5.605802,0.342728,1.0,272.0,15.0,40.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.02126842,0.021413267193775197,0.0001448471937751973
1.0,271.0,206.0,0.00369,0.00369,5.605802,0.342728,1.0,272.0,15.0,40.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00708947,0.007193618845559168,0.00010414884555916878
7.0,271.0,206.0,0.02583,0.02583,5.605802,0.342728,1.0,272.0,15.0,40.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04962632,0.05042853924975194,0.0008022192497519412
6.0,271.0,206.0,0.02214,0.02214,5.605802,0.342728,1.0,272.0,15.0,40.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04253684,0.04269248500996033,0.00015564500996033404
0.0,271.0,206.0,0.0,0.0,5.605802,0.342728,1.0,272.0,15.0,40.0,Pregnancy,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,271.0,206.0,0.00369,0.00369,5.605802,0.342728,1.0,272.0,15.0,40.0,Pregnancy,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00708947,0.00719383929794012,0.00010436929794012048
5.0,271.0,206.0,0.01845,0.01845,5.605802,0.342728,1.0,272.0,15.0,40.0,Other,Overall Study,FG000,dyslipidemia,INDUSTRY,0.03544737,0.035610477024908896,0.000163107024908897
13.0,271.0,206.0,0.04797,0.04797,5.605802,0.342728,1.0,272.0,15.0,40.0,Other,Overall Study,FG001,dyslipidemia,INDUSTRY,0.09216316,0.09883873754202382,0.006675577542023831
4.0,271.0,206.0,0.01476,0.01476,5.605802,0.342728,1.0,272.0,15.0,40.0,LDL below 2.59 mmol/L,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0283579,0.028206523102083228,0.0001513768979167704
12.0,271.0,206.0,0.04428,0.04428,5.605802,0.342728,1.0,272.0,15.0,40.0,LDL below 2.59 mmol/L,Overall Study,FG001,dyslipidemia,INDUSTRY,0.08507369,0.08758520984525521,0.0025115198452552168
4.0,271.0,206.0,0.01476,0.01476,5.605802,0.342728,1.0,272.0,15.0,40.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0283579,0.02821246025505944,0.00014543974494055784
2.0,271.0,206.0,0.00738,0.00738,5.605802,0.342728,1.0,272.0,15.0,40.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01417895,0.014499767920560049,0.00032081792056004935
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,305.0,245.0,0.003279,0.003279,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG002,dyslipidemia,INDUSTRY,0.00681252,0.0068199759796130875,7.4559796130876585e-06
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Participant moved,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG002,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,305.0,245.0,0.003279,0.003279,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG003,dyslipidemia,INDUSTRY,0.00681252,0.006818656288363089,6.1362883630889514e-06
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Physician Decision,Overall Study,FG005,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01362296,0.013616794305426646,6.165694573354377e-06
6.0,305.0,245.0,0.019672,0.019672,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04087097,0.040756299602609174,0.00011467039739082585
3.0,305.0,245.0,0.009836,0.009836,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG002,dyslipidemia,INDUSTRY,0.02043548,0.02052340818204362,8.792818204362077e-05
3.0,305.0,245.0,0.009836,0.009836,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG003,dyslipidemia,INDUSTRY,0.02043548,0.020511930787043622,7.645078704362346e-05
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG004,dyslipidemia,INDUSTRY,0.01362296,0.01362179527274808,1.1647272519198226e-06
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Adverse Event,Overall Study,FG005,dyslipidemia,INDUSTRY,0.01362296,0.01362179527274808,1.1647272519198226e-06
1.0,305.0,245.0,0.003279,0.003279,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00681252,0.006821381067440472,8.861067440472242e-06
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01362296,0.01361258719209333,1.0372807906670195e-05
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG002,dyslipidemia,INDUSTRY,0.01362296,0.0136104309557243,1.2529044275700132e-05
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG003,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,305.0,245.0,0.0,0.0,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG004,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Poor compliance to protocol,Overall Study,FG005,dyslipidemia,INDUSTRY,0.01362296,0.013606393378938587,1.656662106141321e-05
2.0,305.0,245.0,0.006557,0.006557,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01362296,0.013606618103819518,1.6341896180481832e-05
6.0,305.0,245.0,0.019672,0.019672,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04087097,0.040895378849335355,2.4408849335355587e-05
5.0,305.0,245.0,0.016393,0.016393,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG002,dyslipidemia,INDUSTRY,0.03405845,0.034006919592053535,5.153040794646235e-05
4.0,305.0,245.0,0.013115,0.013115,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG003,dyslipidemia,INDUSTRY,0.027248,0.027341153638521822,9.315363852182082e-05
7.0,305.0,245.0,0.022951,0.022951,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG004,dyslipidemia,INDUSTRY,0.04768349,0.04786241988722215,0.0001789298872221512
9.0,305.0,245.0,0.029508,0.029508,5.723585,0.362993,1.0,305.0,9.0,93.0,Other than specified,Overall Study,FG005,dyslipidemia,INDUSTRY,0.06130645,0.0622212917030654,0.0009148417030654041
14.0,970.0,934.0,0.014433,0.014433,6.878326,0.437866,1.0,970.0,32.0,226.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04346911,0.04406865601194352,0.000599546011943522
8.0,970.0,934.0,0.008247,0.008247,6.878326,0.437866,1.0,970.0,32.0,226.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0248382,0.025276896562857164,0.0004386965628571625
2.0,970.0,934.0,0.002062,0.002062,6.878326,0.437866,1.0,970.0,32.0,226.0,Death,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0062103,0.006189620550932517,2.0679449067482862e-05
3.0,970.0,934.0,0.003093,0.003093,6.878326,0.437866,1.0,970.0,32.0,226.0,Death,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00931545,0.009179293227767863,0.000136156772232136
2.0,970.0,934.0,0.002062,0.002062,6.878326,0.437866,1.0,970.0,32.0,226.0,Sponsor Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0062103,0.006192655901765851,1.7644098234148933e-05
1.0,970.0,934.0,0.001031,0.001031,6.878326,0.437866,1.0,970.0,32.0,226.0,Sponsor Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00310515,0.0031924910817757927,8.734108177579263e-05
2.0,970.0,934.0,0.002062,0.002062,6.878326,0.437866,1.0,970.0,32.0,226.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0062103,0.006186171660515857,2.412833948414305e-05
4.0,970.0,934.0,0.004124,0.004124,6.878326,0.437866,1.0,970.0,32.0,226.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01242061,0.012462149838313494,4.1539838313493435e-05
4.0,256.0,245.0,0.015625,0.015625,5.549076,0.218985,1.0,256.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.01898695,0.01932450921940568,0.0003375592194056823
3.0,256.0,245.0,0.011719,0.011719,5.549076,0.218985,1.0,256.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.01424051,0.014303317989722232,6.280798972223278e-05
2.0,256.0,245.0,0.007812,0.007812,5.549076,0.218985,1.0,256.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00949287,0.00959274551579365,9.987551579365012e-05
2.0,256.0,245.0,0.007812,0.007812,5.549076,0.218985,1.0,256.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00949287,0.009588361678571423,9.549167857142264e-05
68.0,1220.0,635.0,0.055738,0.055738,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 1,FG000,dyslipidemia,INDUSTRY,0.0830836,0.08453376636041816,0.0014501663604181703
25.0,1220.0,635.0,0.020492,0.020492,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 1,FG001,dyslipidemia,INDUSTRY,0.03054557,0.030875725029940463,0.00033015502994046195
156.0,1220.0,635.0,0.127869,0.127869,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 1,FG002,dyslipidemia,INDUSTRY,0.19060275,0.1949474335991468,0.004344683599146804
6.0,1220.0,635.0,0.004918,0.004918,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 1,FG000,dyslipidemia,INDUSTRY,0.00733082,0.007318605784087282,1.2214215912718235e-05
8.0,1220.0,635.0,0.006557,0.006557,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 1,FG001,dyslipidemia,INDUSTRY,0.00977393,0.009734495843789673,3.943415621032731e-05
24.0,1220.0,635.0,0.019672,0.019672,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 1,FG002,dyslipidemia,INDUSTRY,0.02932327,0.02954835819999009,0.00022508819999009222
5.0,1220.0,635.0,0.004098,0.004098,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 1,FG000,dyslipidemia,INDUSTRY,0.00610852,0.006099247569434526,9.272430565474173e-06
4.0,1220.0,635.0,0.003279,0.003279,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 1,FG001,dyslipidemia,INDUSTRY,0.00488771,0.004896407220803573,8.697220803572693e-06
7.0,1220.0,635.0,0.005738,0.005738,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 1,FG002,dyslipidemia,INDUSTRY,0.00855312,0.008751235236577382,0.0001981152365773814
3.0,1220.0,635.0,0.002459,0.002459,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 1,FG000,dyslipidemia,INDUSTRY,0.00366541,0.003660685173988091,4.724826011908833e-06
1.0,1220.0,635.0,0.00082,0.00082,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 1,FG001,dyslipidemia,INDUSTRY,0.0012223,0.0012316008637599232,9.300863759923242e-06
5.0,1220.0,635.0,0.004098,0.004098,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 1,FG002,dyslipidemia,INDUSTRY,0.00610852,0.006108622480634924,1.0248063492430959e-07
23.0,1220.0,635.0,0.018852,0.018852,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 1,FG000,dyslipidemia,INDUSTRY,0.02810097,0.02844119560993052,0.0003402256099305223
17.0,1220.0,635.0,0.013934,0.013934,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 1,FG001,dyslipidemia,INDUSTRY,0.02077015,0.020848726152648798,7.857615264879672e-05
45.0,1220.0,635.0,0.036885,0.036885,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 1,FG002,dyslipidemia,INDUSTRY,0.05498113,0.05683674426630955,0.0018556142663095493
1.0,1220.0,635.0,0.00082,0.00082,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 1,FG000,dyslipidemia,INDUSTRY,0.0012223,0.001233797384593255,1.1497384593255099e-05
4.0,1220.0,635.0,0.003279,0.003279,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 1,FG001,dyslipidemia,INDUSTRY,0.00488771,0.004894440642261906,6.730642261905916e-06
48.0,1220.0,635.0,0.039344,0.039344,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 1,FG002,dyslipidemia,INDUSTRY,0.05864654,0.059564038044702415,0.0009174980447024181
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
17.0,1220.0,635.0,0.013934,0.013934,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 2,FG001,dyslipidemia,INDUSTRY,0.02077015,0.020794959792053556,2.4809792053555324e-05
33.0,1220.0,635.0,0.027049,0.027049,7.107425,0.209726,1.0,1220.0,0.0,0.0,Adverse Event,Part 2,FG002,dyslipidemia,INDUSTRY,0.0403195,0.04071262288652779,0.00039312288652779137
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lack of Efficacy,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,1220.0,635.0,0.00082,0.00082,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lack of Efficacy,Part 2,FG001,dyslipidemia,INDUSTRY,0.0012223,0.0012314597845932563,9.15978459325637e-06
6.0,1220.0,635.0,0.004918,0.004918,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lack of Efficacy,Part 2,FG002,dyslipidemia,INDUSTRY,0.00733082,0.0073305789586110915,2.4104138890857635e-07
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
6.0,1220.0,635.0,0.004918,0.004918,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 2,FG001,dyslipidemia,INDUSTRY,0.00733082,0.007329574444087283,1.2455559127173138e-06
18.0,1220.0,635.0,0.014754,0.014754,7.107425,0.209726,1.0,1220.0,0.0,0.0,Lost to Follow-up,Part 2,FG002,dyslipidemia,INDUSTRY,0.02199245,0.02165887880728173,0.0003335711927182697
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,1220.0,635.0,0.002459,0.002459,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 2,FG001,dyslipidemia,INDUSTRY,0.00366541,0.003661339256934519,4.070743065481223e-06
5.0,1220.0,635.0,0.004098,0.004098,7.107425,0.209726,1.0,1220.0,0.0,0.0,Protocol Violation,Part 2,FG002,dyslipidemia,INDUSTRY,0.00610852,0.006086262656527777,2.225734347222324e-05
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 2,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,1220.0,635.0,0.004098,0.004098,7.107425,0.209726,1.0,1220.0,0.0,0.0,Patient Moved,Part 2,FG002,dyslipidemia,INDUSTRY,0.00610852,0.006108668897301591,1.488973015908307e-07
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,1220.0,635.0,0.001639,0.001639,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 2,FG001,dyslipidemia,INDUSTRY,0.00244311,0.002460799925494228,1.7689925494228115e-05
13.0,1220.0,635.0,0.010656,0.010656,7.107425,0.209726,1.0,1220.0,0.0,0.0,Withdrawal by Subject,Part 2,FG002,dyslipidemia,INDUSTRY,0.01588394,0.01589257487791665,8.63487791664952e-06
0.0,1220.0,635.0,0.0,0.0,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 2,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
3.0,1220.0,635.0,0.002459,0.002459,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 2,FG001,dyslipidemia,INDUSTRY,0.00366541,0.0036606800496428527,4.729950357147336e-06
4.0,1220.0,635.0,0.003279,0.003279,7.107425,0.209726,1.0,1220.0,0.0,0.0,LDL < 50 mg/dL,Part 2,FG002,dyslipidemia,INDUSTRY,0.00488771,0.00488632175622024,1.388243779760004e-06
0.0,306.0,262.0,0.0,0.0,5.726848,0.534109,1.0,306.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,dyslipidemia,INDUSTRY,0.0,0.0,0.0
1.0,306.0,262.0,0.003268,0.003268,5.726848,0.534109,1.0,306.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00999603,0.01003609341494046,4.006341494046037e-05
1.0,306.0,262.0,0.003268,0.003268,5.726848,0.534109,1.0,306.0,0.0,0.0,Physician Decision,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00999603,0.010027652954404744,3.162295440474472e-05
0.0,306.0,262.0,0.0,0.0,5.726848,0.534109,1.0,306.0,0.0,0.0,Physician Decision,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
5.0,306.0,262.0,0.01634,0.01634,5.726848,0.534109,1.0,306.0,0.0,0.0,Protocol Violation,Overall Study,FG000,dyslipidemia,INDUSTRY,0.04998013,0.04977200905973216,0.00020812094026783495
1.0,306.0,262.0,0.003268,0.003268,5.726848,0.534109,1.0,306.0,0.0,0.0,Protocol Violation,Overall Study,FG001,dyslipidemia,INDUSTRY,0.00999603,0.010042376661190455,4.6346661190455746e-05
11.0,306.0,262.0,0.035948,0.035948,5.726848,0.534109,1.0,306.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,dyslipidemia,INDUSTRY,0.10995629,0.11076964387483043,0.0008133538748304331
7.0,306.0,262.0,0.022876,0.022876,5.726848,0.534109,1.0,306.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,dyslipidemia,INDUSTRY,0.06997218,0.06868965075325406,0.0012825292467459337
12.0,306.0,262.0,0.039216,0.039216,5.726848,0.534109,1.0,306.0,0.0,0.0,Adverse Event,Overall Study,FG000,dyslipidemia,INDUSTRY,0.11995232,0.12078454193615974,0.000832221936159741
5.0,306.0,262.0,0.01634,0.01634,5.726848,0.534109,1.0,306.0,0.0,0.0,Adverse Event,Overall Study,FG001,dyslipidemia,INDUSTRY,0.04998013,0.049787504071121064,0.00019262592887893393
1.0,306.0,262.0,0.003268,0.003268,5.726848,0.534109,1.0,306.0,0.0,0.0,Did not take study medication,Overall Study,FG000,dyslipidemia,INDUSTRY,0.00999603,0.010029142979404744,3.311297940474488e-05
0.0,306.0,262.0,0.0,0.0,5.726848,0.534109,1.0,306.0,0.0,0.0,Did not take study medication,Overall Study,FG001,dyslipidemia,INDUSTRY,0.0,0.0,0.0
2.0,245.0,238.0,0.008163,0.008163,5.505332,0.675603,1.0,245.0,1.0,1.0,Adverse Event,Study Completion,FG000,hypertension,INDUSTRY,0.03036159,0.03140426929634382,0.0010426792963438222
3.0,245.0,238.0,0.012245,0.012245,5.505332,0.675603,1.0,245.0,1.0,1.0,Adverse Event,Study Completion,FG001,hypertension,INDUSTRY,0.04554425,0.04849041433607141,0.002946164336071408
2.0,245.0,238.0,0.008163,0.008163,5.505332,0.675603,1.0,245.0,1.0,1.0,Withdrawal by Subject,Study Completion,FG000,hypertension,INDUSTRY,0.03036159,0.031373336329558105,0.001011746329558104
0.0,245.0,238.0,0.0,0.0,5.505332,0.675603,1.0,245.0,1.0,1.0,Withdrawal by Subject,Study Completion,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
17.0,750.0,685.0,0.022667,0.022667,6.621406,0.460793,1.0,750.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.06915928,0.06896200648116965,0.0001972735188303515
15.0,750.0,685.0,0.02,0.02,6.621406,0.460793,1.0,750.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.06102199,0.06024648975165671,0.0007755002483432888
5.0,750.0,685.0,0.006667,0.006667,6.621406,0.460793,1.0,750.0,1.0,1.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.02034168,0.020411666733898767,6.998673389876572e-05
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.00406712,0.004067315513045623,1.9551304562305527e-07
5.0,750.0,685.0,0.006667,0.006667,6.621406,0.460793,1.0,750.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.02034168,0.020414670891190437,7.299089119043589e-05
4.0,750.0,685.0,0.005333,0.005333,6.621406,0.460793,1.0,750.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.01627151,0.01628392711450653,1.2417114506529936e-05
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,No-compliant subject,Overall Study,FG000,hypertension,INDUSTRY,0.00406712,0.004067324104712288,2.0410471228849564e-07
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,No-compliant subject,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,No-compliant subject,Overall Study,FG002,hypertension,INDUSTRY,0.00406712,0.004071874085267845,4.7540852678457785e-06
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00406712,0.004070664653878956,3.544653878956479e-06
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,750.0,685.0,0.002667,0.002667,6.621406,0.460793,1.0,750.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.00813728,0.00812989406472224,7.385935277760131e-06
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,750.0,685.0,0.004,0.004,6.621406,0.460793,1.0,750.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,hypertension,INDUSTRY,0.0122044,0.011911941580615076,0.000292458419384925
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Lack of Efficacy,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,750.0,685.0,0.002667,0.002667,6.621406,0.460793,1.0,750.0,1.0,1.0,Disallowed Concurrent Medication,Overall Study,FG000,hypertension,INDUSTRY,0.00813728,0.008117446900436524,1.983309956347587e-05
2.0,750.0,685.0,0.002667,0.002667,6.621406,0.460793,1.0,750.0,1.0,1.0,Disallowed Concurrent Medication,Overall Study,FG001,hypertension,INDUSTRY,0.00813728,0.008117201739682554,2.007826031744618e-05
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Disallowed Concurrent Medication,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.00406712,0.004062964605545623,4.155394454376758e-06
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.00406712,0.004069449929831339,2.329929831339228e-06
2.0,750.0,685.0,0.002667,0.002667,6.621406,0.460793,1.0,750.0,1.0,1.0,Protocol Violation,Overall Study,FG002,hypertension,INDUSTRY,0.00813728,0.008124446603710334,1.2833396289666302e-05
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.00406712,0.004074062280486101,6.942280486101592e-06
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Death,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,750.0,685.0,0.001333,0.001333,6.621406,0.460793,1.0,750.0,1.0,1.0,Subject missed V6.2,Overall Study,FG000,hypertension,INDUSTRY,0.00406712,0.0040662041547122885,9.158452877111242e-07
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Subject missed V6.2,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,750.0,685.0,0.0,0.0,6.621406,0.460793,1.0,750.0,1.0,1.0,Subject missed V6.2,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
63.0,470.0,272.0,0.134043,0.134043,6.154858,0.677691,1.0,471.0,23.0,153.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.55910533,0.6144840904837505,0.055378760483750566
69.0,470.0,272.0,0.146809,0.146809,6.154858,0.677691,1.0,471.0,23.0,153.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.61235346,0.6302296495783436,0.017876189578343582
8.0,470.0,272.0,0.017021,0.017021,6.154858,0.677691,1.0,471.0,23.0,153.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.07099611,0.07252054979239089,0.0015244397923908914
8.0,470.0,272.0,0.017021,0.017021,6.154858,0.677691,1.0,471.0,23.0,153.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.07099611,0.07250937982655756,0.0015132698265575562
24.0,470.0,272.0,0.051064,0.051064,6.154858,0.677691,1.0,471.0,23.0,153.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.21299251,0.20949752296064492,0.0034949870393550797
20.0,470.0,272.0,0.042553,0.042553,6.154858,0.677691,1.0,471.0,23.0,153.0,Progressive Disease,Overall Study,FG000,hypertension,INDUSTRY,0.17749237,0.1784129405382341,0.0009205705382340779
6.0,470.0,272.0,0.012766,0.012766,6.154858,0.677691,1.0,471.0,23.0,153.0,Other Reason Not Specified,Overall Study,FG000,hypertension,INDUSTRY,0.05324813,0.05378656304047616,0.000538433040476162
3.0,402.0,392.0,0.007463,0.007463,5.998937,0.268071,1.0,404.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.01200154,0.012121236076696422,0.00011969607669642252
1.0,402.0,392.0,0.002488,0.002488,5.998937,0.268071,1.0,404.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00400105,0.003999991894156754,1.058105843245588e-06
1.0,402.0,392.0,0.002488,0.002488,5.998937,0.268071,1.0,404.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00400105,0.00399991808299604,1.1319170039603144e-06
0.0,402.0,392.0,0.0,0.0,5.998937,0.268071,1.0,404.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,402.0,392.0,0.002488,0.002488,5.998937,0.268071,1.0,404.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.00400105,0.003999936395912705,1.1136040872945785e-06
0.0,402.0,392.0,0.0,0.0,5.998937,0.268071,1.0,404.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,402.0,392.0,0.0,0.0,5.998937,0.268071,1.0,404.0,1.0,1.0,use of commercial drug instead of study,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,402.0,392.0,0.002488,0.002488,5.998937,0.268071,1.0,404.0,1.0,1.0,use of commercial drug instead of study,Overall Study,FG001,hypertension,INDUSTRY,0.00400105,0.003999941820823421,1.1081791765786206e-06
2.0,402.0,392.0,0.004975,0.004975,5.998937,0.268071,1.0,404.0,1.0,1.0,Non respect of one of inclusion criteria,Overall Study,FG000,hypertension,INDUSTRY,0.00800049,0.008014385590595257,1.3895590595256607e-05
1.0,402.0,392.0,0.002488,0.002488,5.998937,0.268071,1.0,404.0,1.0,1.0,Non respect of one of inclusion criteria,Overall Study,FG001,hypertension,INDUSTRY,0.00400105,0.003999941820823421,1.1081791765786206e-06
12.0,726.0,670.0,0.016529,0.016529,6.588926,0.233646,1.0,726.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.02544602,0.02566541404748017,0.00021939404748017033
10.0,726.0,670.0,0.013774,0.013774,6.588926,0.233646,1.0,726.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.02120476,0.021121091163759913,8.366883624008614e-05
1.0,726.0,670.0,0.001377,0.001377,6.588926,0.233646,1.0,726.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00211986,0.002108833646810961,1.1026353189038697e-05
4.0,726.0,670.0,0.00551,0.00551,6.588926,0.233646,1.0,726.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.00848252,0.008559141325882938,7.662132588293763e-05
0.0,726.0,670.0,0.0,0.0,6.588926,0.233646,1.0,726.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
9.0,726.0,670.0,0.012397,0.012397,6.588926,0.233646,1.0,726.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0190849,0.019224763770942465,0.0001398637709424666
6.0,726.0,670.0,0.008264,0.008264,6.588926,0.233646,1.0,726.0,0.0,0.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.01272224,0.012651510063968259,7.072993603174024e-05
7.0,726.0,670.0,0.009642,0.009642,6.588926,0.233646,1.0,726.0,0.0,0.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.01484364,0.014968312784642881,0.0001246727846428812
1.0,726.0,670.0,0.001377,0.001377,6.588926,0.233646,1.0,726.0,0.0,0.0,Noncompliance,Overall Study,FG000,hypertension,INDUSTRY,0.00211986,0.0021080248968109614,1.1835103189038448e-05
2.0,726.0,670.0,0.002755,0.002755,6.588926,0.233646,1.0,726.0,0.0,0.0,Noncompliance,Overall Study,FG001,hypertension,INDUSTRY,0.00424126,0.004240487644742063,7.723552579372295e-07
1.0,726.0,670.0,0.001377,0.001377,6.588926,0.233646,1.0,726.0,0.0,0.0,Other not specified,Overall Study,FG000,hypertension,INDUSTRY,0.00211986,0.0021080248968109614,1.1835103189038448e-05
3.0,726.0,670.0,0.004132,0.004132,6.588926,0.233646,1.0,726.0,0.0,0.0,Other not specified,Overall Study,FG001,hypertension,INDUSTRY,0.00636112,0.006372309705565473,1.1189705565473225e-05
155.0,1156.0,541.0,0.134083,0.134083,7.053586,0.373748,1.0,1156.0,39.0,182.0,Morbidity or Mortality primary endpoint,Overall Study,FG000,hypertension,INDUSTRY,0.35347794,0.33137940044179587,0.022098539558204122
242.0,1156.0,541.0,0.209343,0.209343,7.053586,0.373748,1.0,1156.0,39.0,182.0,Morbidity or Mortality primary endpoint,Overall Study,FG001,hypertension,INDUSTRY,0.55188302,0.5861719335337794,0.034288913533779386
78.0,1156.0,541.0,0.067474,0.067474,7.053586,0.373748,1.0,1156.0,39.0,182.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.17787915,0.18647628582645837,0.008597135826458352
42.0,1156.0,541.0,0.036332,0.036332,7.053586,0.373748,1.0,1156.0,39.0,182.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.09578068,0.09550304985430566,0.0002776301456943464
43.0,1156.0,541.0,0.037197,0.037197,7.053586,0.373748,1.0,1156.0,39.0,182.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.09806104,0.0974318954272521,0.0006291445727479028
37.0,1156.0,541.0,0.032007,0.032007,7.053586,0.373748,1.0,1156.0,39.0,182.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.08437884,0.08545821590778768,0.0010793759077876858
7.0,1156.0,541.0,0.006055,0.006055,7.053586,0.373748,1.0,1156.0,39.0,182.0,Administrative reason,Overall Study,FG000,hypertension,INDUSTRY,0.01596257,0.015514348352718256,0.0004482216472817425
6.0,1156.0,541.0,0.00519,0.00519,7.053586,0.373748,1.0,1156.0,39.0,182.0,Administrative reason,Overall Study,FG001,hypertension,INDUSTRY,0.0136822,0.013201774171547604,0.00048042582845239656
2.0,1156.0,541.0,0.00173,0.00173,7.053586,0.373748,1.0,1156.0,39.0,182.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00456073,0.004453784697580268,0.0001069453024197314
3.0,1156.0,541.0,0.002595,0.002595,7.053586,0.373748,1.0,1156.0,39.0,182.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0068411,0.00679334053785715,4.7759462142850546e-05
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.01468871,0.014726455219216235,3.7745219216234194e-05
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.01468871,0.014709128411537669,2.0418411537668005e-05
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.00734436,0.007339280754553546,5.079245446454675e-06
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.01468871,0.014707974454672588,1.9264454672587514e-05
3.0,528.0,444.0,0.005682,0.005682,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.02203307,0.02207426569315479,4.1195693154791324e-05
5.0,528.0,444.0,0.00947,0.00947,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.03672178,0.03614846353066468,0.0005733164693353249
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.00734436,0.007341979340386879,2.3806596131216787e-06
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.00734436,0.00733169930187497,1.2660698125030283e-05
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Randomized but not Treated,Treatment Period 1 (Day 1 to Week 15),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Randomized but not Treated,Treatment Period 1 (Day 1 to Week 15),FG001,hypertension,INDUSTRY,0.00734436,0.007344248517886874,1.1148211312601852e-07
3.0,528.0,444.0,0.005682,0.005682,6.270988,0.618355,1.0,528.0,15.0,113.0,Randomized but not Treated,Treatment Period 1 (Day 1 to Week 15),FG002,hypertension,INDUSTRY,0.02203307,0.022112421410131703,7.935141013170471e-05
4.0,528.0,444.0,0.007576,0.007576,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 2 (Week 16 to Week 31),FG000,hypertension,INDUSTRY,0.02937742,0.029266751960238077,0.00011066803976192419
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 2 (Week 16 to Week 31),FG001,hypertension,INDUSTRY,0.00734436,0.0073436518924702085,7.081075297918002e-07
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 2 (Week 16 to Week 31),FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 2 (Week 16 to Week 31),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 2 (Week 16 to Week 31),FG001,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,528.0,444.0,0.005682,0.005682,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 2 (Week 16 to Week 31),FG002,hypertension,INDUSTRY,0.02203307,0.02206959503665947,3.6525036659473126e-05
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 2 (Week 16 to Week 31),FG000,hypertension,INDUSTRY,0.01468871,0.014705197851517825,1.648785151782406e-05
3.0,528.0,444.0,0.005682,0.005682,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 2 (Week 16 to Week 31),FG001,hypertension,INDUSTRY,0.02203307,0.02205150895926589,1.8438959265891508e-05
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 2 (Week 16 to Week 31),FG002,hypertension,INDUSTRY,0.01468871,0.014708296785297588,1.958678529758763e-05
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 2 (Week 16 to Week 31),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 2 (Week 16 to Week 31),FG001,hypertension,INDUSTRY,0.00734436,0.007341625432886875,2.7345671131254537e-06
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Protocol Deviation,Treatment Period 2 (Week 16 to Week 31),FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 2 (Week 16 to Week 31),FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 2 (Week 16 to Week 31),FG001,hypertension,INDUSTRY,0.00734436,0.007341859808303541,2.500191696458952e-06
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 2 (Week 16 to Week 31),FG002,hypertension,INDUSTRY,0.0,0.0,0.0
4.0,528.0,444.0,0.007576,0.007576,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 3 (Week 32 to Week 52),FG000,hypertension,INDUSTRY,0.02937742,0.029266751960238077,0.00011066803976192419
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 3 (Week 32 to Week 52),FG001,hypertension,INDUSTRY,0.00734436,0.007346590662321398,2.2306623213980137e-06
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Adverse Event,Treatment Period 3 (Week 32 to Week 52),FG002,hypertension,INDUSTRY,0.00734436,0.007334110596249971,1.0249403750029439e-05
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 3 (Week 32 to Week 52),FG000,hypertension,INDUSTRY,0.00734436,0.0073411586239285455,3.2013760714547784e-06
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 3 (Week 32 to Week 52),FG001,hypertension,INDUSTRY,0.01468871,0.014725401299960274,3.669129996027379e-05
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Lost to Follow-up,Treatment Period 3 (Week 32 to Week 52),FG002,hypertension,INDUSTRY,0.00734436,0.007327915871666637,1.644412833336304e-05
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 3 (Week 32 to Week 52),FG000,hypertension,INDUSTRY,0.01468871,0.01469629290967258,7.582909672579352e-06
0.0,528.0,444.0,0.0,0.0,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 3 (Week 32 to Week 52),FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Personal Reasons,Treatment Period 3 (Week 32 to Week 52),FG002,hypertension,INDUSTRY,0.01468871,0.014699217553869008,1.0507553869007827e-05
2.0,528.0,444.0,0.003788,0.003788,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 3 (Week 32 to Week 52),FG000,hypertension,INDUSTRY,0.01468871,0.014692809302132901,4.099302132900759e-06
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 3 (Week 32 to Week 52),FG001,hypertension,INDUSTRY,0.00734436,0.0073453856906547325,1.025690654732174e-06
1.0,528.0,444.0,0.001894,0.001894,6.270988,0.618355,1.0,528.0,15.0,113.0,Reason not Specified,Treatment Period 3 (Week 32 to Week 52),FG002,hypertension,INDUSTRY,0.00734436,0.007333156969166638,1.1203030833362333e-05
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Did not receive allocated intervention,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Did not receive allocated intervention,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,489.0,484.0,0.002045,0.002045,6.194405,1.0,1.0,489.0,1.0,1.0,Did not receive allocated intervention,Overall Study,FG002,hypertension,INDUSTRY,0.01266756,0.012574422415810771,9.313758418922832e-05
1.0,489.0,484.0,0.002045,0.002045,6.194405,1.0,1.0,489.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.01266756,0.01257514201027505,9.241798972494872e-05
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,489.0,484.0,0.002045,0.002045,6.194405,1.0,1.0,489.0,1.0,1.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.01266756,0.012574577445275056,9.29825547249432e-05
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Physician Decision,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,489.0,484.0,0.002045,0.002045,6.194405,1.0,1.0,489.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.01266756,0.012584809594441722,8.275040555827742e-05
1.0,489.0,484.0,0.002045,0.002045,6.194405,1.0,1.0,489.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.01266756,0.012584015754441725,8.354424555827474e-05
0.0,489.0,484.0,0.0,0.0,6.194405,1.0,1.0,489.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
44.0,742.0,587.0,0.059299,0.059299,6.610696,0.300923,1.0,742.0,38.0,153.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.11796408,0.11983917930011902,0.001875099300119018
47.0,742.0,587.0,0.063342,0.063342,6.610696,0.300923,1.0,742.0,38.0,153.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.12600686,0.12750874700541362,0.0015018870054136213
34.0,742.0,587.0,0.045822,0.045822,6.610696,0.300923,1.0,742.0,38.0,153.0,Death,Overall Study,FG002,hypertension,INDUSTRY,0.09115415,0.09244491461206734,0.001290764612067341
4.0,742.0,587.0,0.005391,0.005391,6.610696,0.300923,1.0,742.0,38.0,153.0,Withdrawal of consent,Overall Study,FG000,hypertension,INDUSTRY,0.01072437,0.010722550797876993,1.8192021230076932e-06
6.0,742.0,587.0,0.008086,0.008086,6.610696,0.300923,1.0,742.0,38.0,153.0,Withdrawal of consent,Overall Study,FG001,hypertension,INDUSTRY,0.01608556,0.01590246059747025,0.00018309940252974818
4.0,742.0,587.0,0.005391,0.005391,6.610696,0.300923,1.0,742.0,38.0,153.0,Withdrawal of consent,Overall Study,FG002,hypertension,INDUSTRY,0.01072437,0.010714989879662708,9.38012033729202e-06
7.0,742.0,587.0,0.009434,0.009434,6.610696,0.300923,1.0,742.0,38.0,153.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.01876715,0.018418803985962327,0.0003483460140376732
5.0,742.0,587.0,0.006739,0.006739,6.610696,0.300923,1.0,742.0,38.0,153.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.01340596,0.013430977168600287,2.501716860028695e-05
2.0,742.0,587.0,0.002695,0.002695,6.610696,0.300923,1.0,742.0,38.0,153.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.00536119,0.0053204351444841235,4.075485551587651e-05
0.0,742.0,587.0,0.0,0.0,6.610696,0.300923,1.0,742.0,38.0,153.0,Administrative reason,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,742.0,587.0,0.0,0.0,6.610696,0.300923,1.0,742.0,38.0,153.0,Administrative reason,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,742.0,587.0,0.001348,0.001348,6.610696,0.300923,1.0,742.0,38.0,153.0,Administrative reason,Overall Study,FG002,hypertension,INDUSTRY,0.00268159,0.002712224198244048,3.063419824404778e-05
1.0,742.0,587.0,0.001348,0.001348,6.610696,0.300923,1.0,742.0,38.0,153.0,Incorrect randomization,Overall Study,FG000,hypertension,INDUSTRY,0.00268159,0.002715813028720238,3.4223028720237886e-05
0.0,742.0,587.0,0.0,0.0,6.610696,0.300923,1.0,742.0,38.0,153.0,Incorrect randomization,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,742.0,587.0,0.0,0.0,6.610696,0.300923,1.0,742.0,38.0,153.0,Incorrect randomization,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
8.0,273.0,120.0,0.029304,0.029304,5.613128,0.546679,1.0,273.0,2.0,75.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.08992173,0.09120741054501989,0.0012856805450198877
12.0,273.0,120.0,0.043956,0.043956,5.613128,0.546679,1.0,273.0,2.0,75.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.13488259,0.1376498655369938,0.0027672755369937962
2.0,273.0,120.0,0.007326,0.007326,5.613128,0.546679,1.0,273.0,2.0,75.0,Lack of Efficacy,Overall Study,FG000,hypertension,INDUSTRY,0.02248043,0.022633826003650756,0.00015339600365075687
2.0,273.0,120.0,0.007326,0.007326,5.613128,0.546679,1.0,273.0,2.0,75.0,Lack of Efficacy,Overall Study,FG001,hypertension,INDUSTRY,0.02248043,0.02265987923781743,0.0001794492378174306
2.0,273.0,120.0,0.007326,0.007326,5.613128,0.546679,1.0,273.0,2.0,75.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.02248043,0.022692105658908696,0.0002116756589086964
4.0,273.0,120.0,0.014652,0.014652,5.613128,0.546679,1.0,273.0,2.0,75.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.04496086,0.04469013065916665,0.000270729340833345
8.0,273.0,120.0,0.029304,0.029304,5.613128,0.546679,1.0,273.0,2.0,75.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.08992173,0.09104972626095244,0.0011279962609524324
8.0,273.0,120.0,0.029304,0.029304,5.613128,0.546679,1.0,273.0,2.0,75.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.08992173,0.09101887333904765,0.001097143339047646
15.0,273.0,120.0,0.054945,0.054945,5.613128,0.546679,1.0,273.0,2.0,75.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.16860323,0.16342027818107152,0.005182951818928472
10.0,273.0,120.0,0.03663,0.03663,5.613128,0.546679,1.0,273.0,2.0,75.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.11240216,0.11346952859793578,0.0010673685979357833
0.0,273.0,120.0,0.0,0.0,5.613128,0.546679,1.0,273.0,2.0,75.0,Pregnancy,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,273.0,120.0,0.003663,0.003663,5.613128,0.546679,1.0,273.0,2.0,75.0,Pregnancy,Overall Study,FG001,hypertension,INDUSTRY,0.01124022,0.011407765847005496,0.0001675458470054951
1.0,273.0,120.0,0.003663,0.003663,5.613128,0.546679,1.0,273.0,2.0,75.0,Randomized in Error,Overall Study,FG000,hypertension,INDUSTRY,0.01124022,0.011417681729267406,0.00017746172926740543
0.0,273.0,120.0,0.0,0.0,5.613128,0.546679,1.0,273.0,2.0,75.0,Randomized in Error,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
9.0,273.0,120.0,0.032967,0.032967,5.613128,0.546679,1.0,273.0,2.0,75.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.10116194,0.1025781506728671,0.0014162106728670965
12.0,273.0,120.0,0.043956,0.043956,5.613128,0.546679,1.0,273.0,2.0,75.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.13488259,0.13783811629720213,0.002955526297202138
30.0,273.0,120.0,0.10989,0.10989,5.613128,0.546679,1.0,273.0,2.0,75.0,Progressive Disease,Overall Study,FG000,hypertension,INDUSTRY,0.33720647,0.345220766929365,0.008014296929365006
29.0,273.0,120.0,0.106227,0.106227,5.613128,0.546679,1.0,273.0,2.0,75.0,Progressive Disease,Overall Study,FG001,hypertension,INDUSTRY,0.32596625,0.32852071275383926,0.0025544627538392484
40.0,430.0,362.0,0.093023,0.093023,6.066108,0.634262,1.0,436.0,11.0,68.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.35790613,0.36891933766851204,0.011013207668512048
4.0,430.0,362.0,0.009302,0.009302,6.066108,0.634262,1.0,436.0,11.0,68.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.03578946,0.03554608711227187,0.0002433728877281327
5.0,430.0,362.0,0.011628,0.011628,6.066108,0.634262,1.0,436.0,11.0,68.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.04473875,0.04416835248975197,0.0005703975102480316
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.00894929,0.008951057490257926,1.7674902579260104e-06
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00894929,0.008951456219047606,2.166219047606069e-06
0.0,430.0,362.0,0.0,0.0,6.066108,0.634262,1.0,436.0,11.0,68.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Lack of Efficacy,Overall Study,FG000,hypertension,INDUSTRY,0.00894929,0.008952111303869036,2.82130386903591e-06
0.0,430.0,362.0,0.0,0.0,6.066108,0.634262,1.0,436.0,11.0,68.0,Lack of Efficacy,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Disallowed Concurrent Medication,Overall Study,FG000,hypertension,INDUSTRY,0.00894929,0.00895239323690475,3.1032369047501174e-06
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Disallowed Concurrent Medication,Overall Study,FG001,hypertension,INDUSTRY,0.00894929,0.008950963094960306,1.6730949603058903e-06
3.0,430.0,362.0,0.006977,0.006977,6.066108,0.634262,1.0,436.0,11.0,68.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.02684402,0.026839977952738202,4.042047261797882e-06
3.0,430.0,362.0,0.006977,0.006977,6.066108,0.634262,1.0,436.0,11.0,68.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.02684402,0.02690750674231163,6.348674231163032e-05
0.0,430.0,362.0,0.0,0.0,6.066108,0.634262,1.0,436.0,11.0,68.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,430.0,362.0,0.002326,0.002326,6.066108,0.634262,1.0,436.0,11.0,68.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.00894929,0.008951055000257929,1.7650002579281537e-06
4.0,430.0,362.0,0.009302,0.009302,6.066108,0.634262,1.0,436.0,11.0,68.0,Other - Reason not reported in CSR,Overall Study,FG000,hypertension,INDUSTRY,0.03578946,0.03554612028063496,0.0002433397193650419
3.0,430.0,362.0,0.006977,0.006977,6.066108,0.634262,1.0,436.0,11.0,68.0,Other - Reason not reported in CSR,Overall Study,FG001,hypertension,INDUSTRY,0.02684402,0.026902223360853267,5.820336085326713e-05
3.0,240.0,201.0,0.0125,0.0125,5.484797,0.792069,1.0,240.0,12.0,95.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.05430424,0.05571191255639879,0.0014076725563987938
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.03620138,0.03607497836867047,0.00012640163132952853
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.03620138,0.03610077083101169,0.00010060916898831096
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,Adverse Event,Overall Study,FG003,hypertension,INDUSTRY,0.03620138,0.03606457831089267,0.00013680168910732565
1.0,240.0,201.0,0.004167,0.004167,5.484797,0.792069,1.0,240.0,12.0,95.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.01810286,0.018236302306488098,0.00013344230648809977
4.0,240.0,201.0,0.016667,0.016667,5.484797,0.792069,1.0,240.0,12.0,95.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.07240711,0.07431114163698495,0.0019040316369849514
6.0,240.0,201.0,0.025,0.025,5.484797,0.792069,1.0,240.0,12.0,95.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.10860849,0.11014943512305547,0.0015409451230554705
6.0,240.0,201.0,0.025,0.025,5.484797,0.792069,1.0,240.0,12.0,95.0,Withdrawal by Subject,Overall Study,FG003,hypertension,INDUSTRY,0.10860849,0.11049666269936505,0.0018881726993650455
1.0,240.0,201.0,0.004167,0.004167,5.484797,0.792069,1.0,240.0,12.0,95.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.01810286,0.018229805851071434,0.00012694585107143538
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,Protocol Violation,Overall Study,FG002,hypertension,INDUSTRY,0.03620138,0.036235770534744825,3.4390534744827006e-05
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Protocol Violation,Overall Study,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.03620138,0.03623248125661984,3.110125661984209e-05
1.0,240.0,201.0,0.004167,0.004167,5.484797,0.792069,1.0,240.0,12.0,95.0,Lost to Follow-up,Overall Study,FG003,hypertension,INDUSTRY,0.01810286,0.018255403349047624,0.00015254334904762565
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Screen Failure,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Screen Failure,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,240.0,201.0,0.004167,0.004167,5.484797,0.792069,1.0,240.0,12.0,95.0,Screen Failure,Overall Study,FG002,hypertension,INDUSTRY,0.01810286,0.018244388677500004,0.0001415286775000059
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,Screen Failure,Overall Study,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,"Other, Not Specified",Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,240.0,201.0,0.0,0.0,5.484797,0.792069,1.0,240.0,12.0,95.0,"Other, Not Specified",Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,240.0,201.0,0.008333,0.008333,5.484797,0.792069,1.0,240.0,12.0,95.0,"Other, Not Specified",Overall Study,FG002,hypertension,INDUSTRY,0.03620138,0.03622213893891149,2.0758938911492886e-05
4.0,240.0,201.0,0.016667,0.016667,5.484797,0.792069,1.0,240.0,12.0,95.0,"Other, Not Specified",Overall Study,FG003,hypertension,INDUSTRY,0.07240711,0.07421271156580439,0.0018056015658043933
20.0,411.0,367.0,0.048662,0.048662,6.021023,0.387388,1.0,411.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.11350262,0.11522478115223216,0.0017221611522321573
4.0,411.0,367.0,0.009732,0.009732,6.021023,0.387388,1.0,411.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.02269959,0.022864178831249995,0.00016458883124999615
3.0,411.0,367.0,0.007299,0.007299,6.021023,0.387388,1.0,411.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.01702469,0.017056631142222237,3.194114222223807e-05
2.0,411.0,367.0,0.004866,0.004866,6.021023,0.387388,1.0,411.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0113498,0.011329145865654765,2.0654134345234748e-05
0.0,411.0,367.0,0.0,0.0,6.021023,0.387388,1.0,411.0,1.0,1.0,Non-compliant,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,411.0,367.0,0.002433,0.002433,6.021023,0.387388,1.0,411.0,1.0,1.0,Non-compliant,Overall Study,FG001,hypertension,INDUSTRY,0.0056749,0.005752856352402595,7.795635240259464e-05
0.0,411.0,367.0,0.0,0.0,6.021023,0.387388,1.0,411.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,411.0,367.0,0.002433,0.002433,6.021023,0.387388,1.0,411.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0056749,0.005746708118235926,7.180811823592585e-05
3.0,411.0,367.0,0.007299,0.007299,6.021023,0.387388,1.0,411.0,1.0,1.0,Lack of Efficacy,Overall Study,FG000,hypertension,INDUSTRY,0.01702469,0.017065229007638905,4.053900763890603e-05
0.0,411.0,367.0,0.0,0.0,6.021023,0.387388,1.0,411.0,1.0,1.0,Lack of Efficacy,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,411.0,367.0,0.004866,0.004866,6.021023,0.387388,1.0,411.0,1.0,1.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0113498,0.011332558099851191,1.7241900148809094e-05
0.0,411.0,367.0,0.0,0.0,6.021023,0.387388,1.0,411.0,1.0,1.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,411.0,367.0,0.007299,0.007299,6.021023,0.387388,1.0,411.0,1.0,1.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.01702469,0.017068716428472238,4.402642847223942e-05
5.0,411.0,367.0,0.012165,0.012165,6.021023,0.387388,1.0,411.0,1.0,1.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.02837449,0.02828986868122025,8.462131877974913e-05
7.0,474.0,451.0,0.014768,0.014768,6.163315,0.210474,1.0,474.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.01915729,0.01918581205754058,2.8522057540579515e-05
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00273713,0.002744251685476185,7.121685476185052e-06
6.0,474.0,451.0,0.012658,0.012658,6.163315,0.210474,1.0,474.0,0.0,0.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.01642016,0.016221990797232137,0.00019816920276786304
0.0,474.0,451.0,0.0,0.0,6.163315,0.210474,1.0,474.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,474.0,451.0,0.0,0.0,6.163315,0.210474,1.0,474.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,hypertension,INDUSTRY,0.00273713,0.002745428997142853,8.298997142852996e-06
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.00273713,0.002746029795833329,8.899795833329071e-06
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.00273713,0.00274336892166666,6.238921666660083e-06
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Protocol Violation,Overall Study,FG002,hypertension,INDUSTRY,0.00273713,0.0027414658971428524,4.335897142852471e-06
0.0,474.0,451.0,0.0,0.0,6.163315,0.210474,1.0,474.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.00273713,0.0027422423475595183,5.112347559518317e-06
0.0,474.0,451.0,0.0,0.0,6.163315,0.210474,1.0,474.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,474.0,451.0,0.004219,0.004219,6.163315,0.210474,1.0,474.0,0.0,0.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.00547295,0.005474032675297612,1.0826752976124399e-06
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.00273713,0.0027417947442261847,4.664744226184729e-06
1.0,474.0,451.0,0.00211,0.00211,6.163315,0.210474,1.0,474.0,0.0,0.0,Physician Decision,Overall Study,FG002,hypertension,INDUSTRY,0.00273713,0.0027430397417261857,5.909741726185802e-06
2.0,371.0,360.0,0.005391,0.005391,5.918894,0.247637,1.0,371.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0079018,0.007932026550416658,3.022655041665795e-05
2.0,371.0,360.0,0.005391,0.005391,5.918894,0.247637,1.0,371.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.0079018,0.007918998905773798,1.71989057737975e-05
0.0,371.0,360.0,0.0,0.0,5.918894,0.247637,1.0,371.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,371.0,360.0,0.002695,0.002695,5.918894,0.247637,1.0,371.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.00395017,0.003952427279871018,2.2572798710181544e-06
0.0,371.0,360.0,0.0,0.0,5.918894,0.247637,1.0,371.0,0.0,0.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,371.0,360.0,0.002695,0.002695,5.918894,0.247637,1.0,371.0,0.0,0.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.00395017,0.0039486339393948276,1.5360606051726886e-06
1.0,371.0,360.0,0.002695,0.002695,5.918894,0.247637,1.0,371.0,0.0,0.0,Noncompliance,Overall Study,FG000,hypertension,INDUSTRY,0.00395017,0.0039558386917360995,5.668691736099296e-06
0.0,371.0,360.0,0.0,0.0,5.918894,0.247637,1.0,371.0,0.0,0.0,Noncompliance,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,371.0,360.0,0.002695,0.002695,5.918894,0.247637,1.0,371.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG000,hypertension,INDUSTRY,0.00395017,0.003953178154236099,3.008154236098376e-06
1.0,371.0,360.0,0.002695,0.002695,5.918894,0.247637,1.0,371.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG001,hypertension,INDUSTRY,0.00395017,0.003952293523621018,2.123523621017781e-06
0.0,371.0,360.0,0.0,0.0,5.918894,0.247637,1.0,371.0,0.0,0.0,Patient Moved,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,371.0,360.0,0.005391,0.005391,5.918894,0.247637,1.0,371.0,0.0,0.0,Patient Moved,Overall Study,FG001,hypertension,INDUSTRY,0.0079018,0.00792344185573051,2.1641855730510084e-05
4.0,560.0,0.0,0.007143,0.007143,6.329721,0.867868,1.0,560.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0392391,0.03925560532001984,1.650532001984395e-05
0.0,560.0,0.0,0.0,0.0,6.329721,0.867868,1.0,560.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.00981115,0.009812935980833324,1.7859808333249572e-06
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.00981115,0.009837403310654748,2.625331065474884e-05
0.0,560.0,0.0,0.0,0.0,6.329721,0.867868,1.0,560.0,1.0,1.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Physician Decision,Overall Study,FG002,hypertension,INDUSTRY,0.00981115,0.009813558430833326,2.4084308333262305e-06
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00981115,0.00983665059065475,2.5500590654750285e-05
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.00981115,0.0098120306395238,8.80639523800214e-07
2.0,560.0,0.0,0.003571,0.003571,6.329721,0.867868,1.0,560.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.0196168,0.01949415585386272,0.00012264414613728097
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.00981115,0.009823334262738083,1.218426273808318e-05
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.00981115,0.0098003502320238,1.0799767976198832e-05
2.0,560.0,0.0,0.003571,0.003571,6.329721,0.867868,1.0,560.0,1.0,1.0,Death,Overall Study,FG002,hypertension,INDUSTRY,0.0196168,0.019460433128207954,0.00015636687179204634
0.0,560.0,0.0,0.0,0.0,6.329721,0.867868,1.0,560.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,560.0,0.0,0.0,0.0,6.329721,0.867868,1.0,560.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,560.0,0.0,0.005357,0.005357,6.329721,0.867868,1.0,560.0,1.0,1.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.02942795,0.029494849301761387,6.689930176138545e-05
2.0,560.0,0.0,0.003571,0.003571,6.329721,0.867868,1.0,560.0,1.0,1.0,Explanted,Overall Study,FG000,hypertension,INDUSTRY,0.0196168,0.01942631962177939,0.0001904803782206109
1.0,560.0,0.0,0.001786,0.001786,6.329721,0.867868,1.0,560.0,1.0,1.0,Explanted,Overall Study,FG001,hypertension,INDUSTRY,0.00981115,0.009811282759523799,1.327595237996665e-07
0.0,560.0,0.0,0.0,0.0,6.329721,0.867868,1.0,560.0,1.0,1.0,Explanted,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
176.0,560.0,0.0,0.314286,0.314286,6.329721,0.867868,1.0,560.0,1.0,1.0,Ongoing in study,Overall Study,FG000,hypertension,INDUSTRY,1.72648733,1.7553928354607138,0.028905505460713687
180.0,560.0,0.0,0.321429,0.321429,6.329721,0.867868,1.0,560.0,1.0,1.0,Ongoing in study,Overall Study,FG001,hypertension,INDUSTRY,1.76572643,1.763070721333839,0.0026557086661609386
183.0,560.0,0.0,0.326786,0.326786,6.329721,0.867868,1.0,560.0,1.0,1.0,Ongoing in study,Overall Study,FG002,hypertension,INDUSTRY,1.79515438,1.799511959447143,0.004357579447142879
1.0,335.0,328.0,0.002985,0.002985,5.817111,0.382,1.0,335.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.00663307,0.006619561076567428,1.3508923432571478e-05
1.0,335.0,328.0,0.002985,0.002985,5.817111,0.382,1.0,335.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00663307,0.006625027428888857,8.042571111142524e-06
1.0,335.0,328.0,0.002985,0.002985,5.817111,0.382,1.0,335.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.00663307,0.006612149431626956,2.0920568373043735e-05
0.0,335.0,328.0,0.0,0.0,5.817111,0.382,1.0,335.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,335.0,328.0,0.0,0.0,5.817111,0.382,1.0,335.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,335.0,328.0,0.008955,0.008955,5.817111,0.382,1.0,335.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.01989922,0.019542735564722212,0.0003564844352777867
1.0,335.0,328.0,0.002985,0.002985,5.817111,0.382,1.0,335.0,1.0,1.0,Ran out of IP and decided to discontinue,Overall Study,FG000,hypertension,INDUSTRY,0.00663307,0.006609474458293622,2.359554170637719e-05
0.0,335.0,328.0,0.0,0.0,5.817111,0.382,1.0,335.0,1.0,1.0,Ran out of IP and decided to discontinue,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
51.0,335.0,269.0,0.152239,0.152239,5.817111,0.410585,1.0,284.0,1.0,81.0,"Other, 2 PAH-SYMPACT cycles not complete",Screening Period,FG000,hypertension,INDUSTRY,0.36361061,0.3807642804080655,0.01715367040806548
16.0,335.0,269.0,0.047761,0.047761,5.817111,0.410585,1.0,284.0,1.0,81.0,Adverse Event,Treatment Period,FG000,hypertension,INDUSTRY,0.11407331,0.11404497068788698,2.833931211301821e-05
1.0,335.0,269.0,0.002985,0.002985,5.817111,0.410585,1.0,284.0,1.0,81.0,Death,Treatment Period,FG000,hypertension,INDUSTRY,0.00712943,0.007118352267837302,1.1077732162697619e-05
7.0,335.0,269.0,0.020896,0.020896,5.817111,0.410585,1.0,284.0,1.0,81.0,Withdrawal by Subject,Treatment Period,FG000,hypertension,INDUSTRY,0.04990842,0.049473508844632905,0.0004349111553670973
1.0,335.0,269.0,0.002985,0.002985,5.817111,0.410585,1.0,284.0,1.0,81.0,Lost to Follow-up,Treatment Period,FG000,hypertension,INDUSTRY,0.00712943,0.007114058963134924,1.537103686507623e-05
2.0,335.0,269.0,0.00597,0.00597,5.817111,0.410585,1.0,284.0,1.0,81.0,Physician Decision,Treatment Period,FG000,hypertension,INDUSTRY,0.01425886,0.014442569718452387,0.00018370971845238677
5.0,335.0,269.0,0.014925,0.014925,5.817111,0.410585,1.0,284.0,1.0,81.0,"Other, including non-compliance",Treatment Period,FG000,hypertension,INDUSTRY,0.03564716,0.035176486752827384,0.00047067324717261355
1.0,335.0,269.0,0.002985,0.002985,5.817111,0.410585,1.0,284.0,1.0,81.0,Death,Post-Treatment Safety Follow-Up Period,FG000,hypertension,INDUSTRY,0.00712943,0.007117552496170637,1.1877503829363194e-05
7.0,335.0,269.0,0.020896,0.020896,5.817111,0.410585,1.0,284.0,1.0,81.0,Withdrawal by Subject,Post-Treatment Safety Follow-Up Period,FG000,hypertension,INDUSTRY,0.04990842,0.049488090207132907,0.00042032979286709543
6.0,335.0,269.0,0.01791,0.01791,5.817111,0.410585,1.0,284.0,1.0,81.0,Lost to Follow-up,Post-Treatment Safety Follow-Up Period,FG000,hypertension,INDUSTRY,0.04277659,0.042339039736011885,0.0004375502639881179
1.0,335.0,269.0,0.002985,0.002985,5.817111,0.410585,1.0,284.0,1.0,81.0,"Other, administrative error",Post-Treatment Safety Follow-Up Period,FG000,hypertension,INDUSTRY,0.00712943,0.007113986028611114,1.5443971388886396e-05
39.0,2464.0,2301.0,0.015828,0.015828,7.809947,0.441414,1.0,2464.0,5.0,72.0,Withdrew consent,Overall Study,FG000,hypertension,OTHER,0.05456581,0.05312403163230158,0.001441778367698418
47.0,2464.0,2301.0,0.019075,0.019075,7.809947,0.441414,1.0,2464.0,5.0,72.0,Withdrew consent,Overall Study,FG001,hypertension,OTHER,0.06575959,0.06310522696926767,0.00265436303073234
17.0,2464.0,2301.0,0.006899,0.006899,7.809947,0.441414,1.0,2464.0,5.0,72.0,No primary outcome data,Overall Study,FG000,hypertension,OTHER,0.02378377,0.02278490178081348,0.0009988682191865196
11.0,2464.0,2301.0,0.004464,0.004464,7.809947,0.441414,1.0,2464.0,5.0,72.0,No primary outcome data,Overall Study,FG001,hypertension,OTHER,0.0153893,0.01534821771233136,4.108228766864022e-05
22.0,2464.0,2301.0,0.008929,0.008929,7.809947,0.441414,1.0,2464.0,5.0,72.0,Spontaneous abortion (<20 weeks),Overall Study,FG000,hypertension,OTHER,0.03078204,0.03091830674955354,0.00013626674955354023
15.0,2464.0,2301.0,0.006088,0.006088,7.809947,0.441414,1.0,2464.0,5.0,72.0,Spontaneous abortion (<20 weeks),Overall Study,FG001,hypertension,OTHER,0.02098791,0.020046021323115063,0.0009418886768849354
6.0,2464.0,2301.0,0.002435,0.002435,7.809947,0.441414,1.0,2464.0,5.0,72.0,Early intrauterine fetal death,Overall Study,FG000,hypertension,OTHER,0.00839447,0.008402401500773801,7.93150077380185e-06
6.0,2464.0,2301.0,0.002435,0.002435,7.809947,0.441414,1.0,2464.0,5.0,72.0,Early intrauterine fetal death,Overall Study,FG001,hypertension,OTHER,0.00839447,0.008429503810515864,3.503381051586478e-05
6.0,730.0,577.0,0.008219,0.008219,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG000,hypertension,INDUSTRY,0.03903177,0.038869799943759914,0.00016197005624008637
5.0,730.0,577.0,0.006849,0.006849,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG001,hypertension,INDUSTRY,0.03252569,0.03245546843108133,7.022156891867137e-05
2.0,730.0,577.0,0.00274,0.00274,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG002,hypertension,INDUSTRY,0.01301217,0.01301252643981149,3.564398114892786e-07
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 1 Double-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,730.0,577.0,0.00274,0.00274,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG000,hypertension,INDUSTRY,0.01301217,0.013019100952609108,6.930952609108393e-06
2.0,730.0,577.0,0.00274,0.00274,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG001,hypertension,INDUSTRY,0.01301217,0.013032476342192446,2.0306342192445703e-05
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG002,hypertension,INDUSTRY,0.00650609,0.006506471264226163,3.8126422616333727e-07
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 1 Double-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,730.0,577.0,0.00411,0.00411,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG000,hypertension,INDUSTRY,0.01951826,0.019554771562361104,3.651156236110509e-05
2.0,730.0,577.0,0.00274,0.00274,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG001,hypertension,INDUSTRY,0.01301217,0.01303359299100197,2.142299100196983e-05
3.0,730.0,577.0,0.00411,0.00411,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG002,hypertension,INDUSTRY,0.01951826,0.019547771441349213,2.9511441349213546e-05
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 1 Double-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
25.0,730.0,577.0,0.034247,0.034247,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.16263793,0.16464664608961305,0.002008716089613033
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.00650609,0.006505235691249971,8.54308750028801e-07
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lack of Efficacy,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
19.0,730.0,577.0,0.026027,0.026027,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.1236014,0.11840998101612905,0.005191418983870946
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
8.0,730.0,577.0,0.010959,0.010959,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.05204395,0.0518851656644048,0.00015878433559519955
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
5.0,730.0,577.0,0.006849,0.006849,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.03252569,0.032459054681646816,6.663531835318648e-05
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Death,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.00650609,0.00650541134124997,6.786587500298355e-07
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Pregnancy,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
32.0,730.0,577.0,0.043836,0.043836,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG003,hypertension,INDUSTRY,0.20817579,0.20720585300975106,0.000969936990248943
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 2 Single-Blind,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
8.0,730.0,577.0,0.010959,0.010959,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG004,hypertension,INDUSTRY,0.05204395,0.05187717131579369,0.00016677868420630904
7.0,730.0,577.0,0.009589,0.009589,6.594413,0.72015,1.0,730.0,20.0,159.0,Adverse Event,Part 3 Double-Blind Withdrawal,FG005,hypertension,INDUSTRY,0.04553786,0.04436245725278767,0.0011754027472123327
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG004,hypertension,INDUSTRY,0.00650609,0.006509902989642828,3.8129896428283627e-06
4.0,730.0,577.0,0.005479,0.005479,6.594413,0.72015,1.0,730.0,20.0,159.0,Withdrawal by Subject,Part 3 Double-Blind Withdrawal,FG005,hypertension,INDUSTRY,0.0260196,0.02631230497517857,0.0002927049751785711
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,Lost to Follow-up,Part 3 Double-Blind Withdrawal,FG005,hypertension,INDUSTRY,0.00650609,0.006497554683333304,8.535316666695957e-06
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
9.0,730.0,577.0,0.012329,0.012329,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG004,hypertension,INDUSTRY,0.05855003,0.060017081053363126,0.0014670510533631234
6.0,730.0,577.0,0.008219,0.008219,6.594413,0.72015,1.0,730.0,20.0,159.0,Other reasons,Part 3 Double-Blind Withdrawal,FG005,hypertension,INDUSTRY,0.03903177,0.038988805657827356,4.296434217264389e-05
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,730.0,577.0,0.00137,0.00137,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG004,hypertension,INDUSTRY,0.00650609,0.006502586982499971,3.50301750002939e-06
0.0,730.0,577.0,0.0,0.0,6.594413,0.72015,1.0,730.0,20.0,159.0,"Re-randomized in part 3, however no drug dispensed",Part 3 Double-Blind Withdrawal,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,328.0,309.0,0.003049,0.003049,5.796058,0.321222,1.0,328.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0056767,0.005686746397979785,1.0046397979785078e-05
1.0,328.0,309.0,0.003049,0.003049,5.796058,0.321222,1.0,328.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.0056767,0.005691761444487721,1.5061444487721176e-05
4.0,328.0,309.0,0.012195,0.012195,5.796058,0.321222,1.0,328.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.02270493,0.023014463911222034,0.0003095339112220326
3.0,328.0,309.0,0.009146,0.009146,5.796058,0.321222,1.0,328.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.01702823,0.017031017236408763,2.787236408764715e-06
0.0,328.0,309.0,0.0,0.0,5.796058,0.321222,1.0,328.0,0.0,0.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,328.0,309.0,0.006098,0.006098,5.796058,0.321222,1.0,328.0,0.0,0.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.0113534,0.011630773030982124,0.000277373030982124
1.0,328.0,309.0,0.003049,0.003049,5.796058,0.321222,1.0,328.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG000,hypertension,INDUSTRY,0.0056767,0.005688211766313119,1.151176631311937e-05
2.0,328.0,309.0,0.006098,0.006098,5.796058,0.321222,1.0,328.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG001,hypertension,INDUSTRY,0.0113534,0.011629346285982122,0.00027594628598212254
3.0,328.0,309.0,0.009146,0.009146,5.796058,0.321222,1.0,328.0,0.0,0.0,Decision Unrelated to Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.01702823,0.017040195448313523,1.196544831352439e-05
1.0,328.0,309.0,0.003049,0.003049,5.796058,0.321222,1.0,328.0,0.0,0.0,Decision Unrelated to Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.0056767,0.005693226812821055,1.652681282105547e-05
1.0,328.0,309.0,0.003049,0.003049,5.796058,0.321222,1.0,328.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0056767,0.005687796847146452,1.1096847146452316e-05
0.0,328.0,309.0,0.0,0.0,5.796058,0.321222,1.0,328.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
42.0,690.0,548.0,0.06087,0.06087,6.53814,0.305312,1.0,1062.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.12150702,0.12088321697008929,0.000623803029910705
10.0,690.0,548.0,0.014493,0.014493,6.53814,0.305312,1.0,1062.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.02893053,0.0282630565601885,0.000667473439811498
38.0,690.0,548.0,0.055072,0.055072,6.53814,0.305312,1.0,1062.0,0.0,0.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.10993321,0.11307348051250984,0.0031402705125098407
6.0,690.0,548.0,0.008696,0.008696,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Decision Unrelated to AE,Overall Study,FG000,hypertension,INDUSTRY,0.01735872,0.016974961242728175,0.0003837587572718265
5.0,690.0,548.0,0.007246,0.007246,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Decision Unrelated to AE,Overall Study,FG001,hypertension,INDUSTRY,0.01446427,0.014202750147936488,0.00026151985206351175
2.0,690.0,548.0,0.002899,0.002899,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Decision Unrelated to AE,Overall Study,FG002,hypertension,INDUSTRY,0.0057869,0.005730768747172621,5.613125282737889e-05
1.0,690.0,548.0,0.001449,0.001449,6.53814,0.305312,1.0,1062.0,0.0,0.0,Noncompliance,Overall Study,FG000,hypertension,INDUSTRY,0.00289245,0.0029060508382981677,1.3600838298167758e-05
0.0,690.0,548.0,0.0,0.0,6.53814,0.305312,1.0,1062.0,0.0,0.0,Noncompliance,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,690.0,548.0,0.0,0.0,6.53814,0.305312,1.0,1062.0,0.0,0.0,Noncompliance,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,690.0,548.0,0.001449,0.001449,6.53814,0.305312,1.0,1062.0,0.0,0.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.00289245,0.0029067628607981665,1.431286079816652e-05
3.0,690.0,548.0,0.004348,0.004348,6.53814,0.305312,1.0,1062.0,0.0,0.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.00867936,0.008656222401676602,2.313759832339897e-05
0.0,690.0,548.0,0.0,0.0,6.53814,0.305312,1.0,1062.0,0.0,0.0,Protocol Violation,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
7.0,690.0,548.0,0.010145,0.010145,6.53814,0.305312,1.0,1062.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG000,hypertension,INDUSTRY,0.02025117,0.020273925195813506,2.2755195813507073e-05
9.0,690.0,548.0,0.013043,0.013043,6.53814,0.305312,1.0,1062.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG001,hypertension,INDUSTRY,0.02603608,0.025645951025416655,0.0003901289745833446
17.0,690.0,548.0,0.024638,0.024638,6.53814,0.305312,1.0,1062.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG002,hypertension,INDUSTRY,0.0491817,0.0496573829364015,0.0004756829364014961
1.0,690.0,548.0,0.001449,0.001449,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Did Not Meet Entrance Criteria,Overall Study,FG000,hypertension,INDUSTRY,0.00289245,0.0029067979857981675,1.4347985798167547e-05
0.0,690.0,548.0,0.0,0.0,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Did Not Meet Entrance Criteria,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,690.0,548.0,0.0,0.0,6.53814,0.305312,1.0,1062.0,0.0,0.0,Patient Did Not Meet Entrance Criteria,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,691.0,657.0,0.004342,0.004342,6.539586,0.745192,1.0,691.0,1.0,1.0,Due to adaptive design,Overall Study,FG000,hypertension,INDUSTRY,0.02115965,0.021156237849821454,3.4121501785444597e-06
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Due to adaptive design,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Due to adaptive design,Overall Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,691.0,657.0,0.001447,0.001447,6.539586,0.745192,1.0,691.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.00705159,0.007043078077643447,8.511922356553223e-06
4.0,691.0,657.0,0.005789,0.005789,6.539586,0.745192,1.0,691.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.02821124,0.028331728964216284,0.00012048896421628513
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Sponsor or IRB Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,691.0,657.0,0.001447,0.001447,6.539586,0.745192,1.0,691.0,1.0,1.0,Sponsor or IRB Decision,Overall Study,FG001,hypertension,INDUSTRY,0.00705159,0.00704212385097678,9.46614902321962e-06
2.0,691.0,657.0,0.002894,0.002894,6.539586,0.745192,1.0,691.0,1.0,1.0,Sponsor or IRB Decision,Overall Study,FG002,hypertension,INDUSTRY,0.01410319,0.01337912601502976,0.0007240639849702395
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,691.0,657.0,0.004342,0.004342,6.539586,0.745192,1.0,691.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.02115965,0.021179279466011926,1.9629466011927138e-05
3.0,691.0,657.0,0.004342,0.004342,6.539586,0.745192,1.0,691.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,hypertension,INDUSTRY,0.02115965,0.021155663396428593,3.9866035714056225e-06
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
8.0,691.0,657.0,0.011577,0.011577,6.539586,0.745192,1.0,691.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.05641761,0.05543587216221227,0.0009817378377877314
6.0,691.0,657.0,0.008683,0.008683,6.539586,0.745192,1.0,691.0,1.0,1.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.04231443,0.04253312595547621,0.00021869595547620996
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Other Reason,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,691.0,657.0,0.001447,0.001447,6.539586,0.745192,1.0,691.0,1.0,1.0,Other Reason,Overall Study,FG001,hypertension,INDUSTRY,0.00705159,0.007045085106780354,6.504893219645876e-06
1.0,691.0,657.0,0.001447,0.001447,6.539586,0.745192,1.0,691.0,1.0,1.0,Other Reason,Overall Study,FG002,hypertension,INDUSTRY,0.00705159,0.007048591518417259,2.998481582741283e-06
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,691.0,657.0,0.0,0.0,6.539586,0.745192,1.0,691.0,1.0,1.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,691.0,657.0,0.001447,0.001447,6.539586,0.745192,1.0,691.0,1.0,1.0,Protocol Violation,Overall Study,FG002,hypertension,INDUSTRY,0.00705159,0.0070452758459470174,6.314154052982496e-06
174.0,894.0,208.0,0.194631,0.194631,6.796824,0.595168,1.0,894.0,20.0,135.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.78733198,0.8020578580307636,0.014725878030763528
163.0,894.0,208.0,0.182327,0.182327,6.796824,0.595168,1.0,894.0,20.0,135.0,Progressive Disease,Overall Study,FG000,hypertension,INDUSTRY,0.73755917,0.756251650593403,0.018692480593403005
172.0,894.0,208.0,0.192394,0.192394,6.796824,0.595168,1.0,894.0,20.0,135.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.77828275,0.7815587936626684,0.0032760436626684264
113.0,894.0,208.0,0.126398,0.126398,6.796824,0.595168,1.0,894.0,20.0,135.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.51131211,0.60269354732634,0.09138143732633996
17.0,894.0,208.0,0.019016,0.019016,6.796824,0.595168,1.0,894.0,20.0,135.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.07692456,0.07857522599338294,0.001650665993382941
13.0,894.0,208.0,0.014541,0.014541,6.796824,0.595168,1.0,894.0,20.0,135.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.05882205,0.05797653956672618,0.0008455104332738203
8.0,894.0,208.0,0.008949,0.008949,6.796824,0.595168,1.0,894.0,20.0,135.0,PI Decision,Overall Study,FG000,hypertension,INDUSTRY,0.03620098,0.03650419686388891,0.00030321686388890684
7.0,894.0,208.0,0.00783,0.00783,6.796824,0.595168,1.0,894.0,20.0,135.0,Limited Study Drug Effectiveness,Overall Study,FG000,hypertension,INDUSTRY,0.03167434,0.0325849744953968,0.0009106344953968004
7.0,894.0,208.0,0.00783,0.00783,6.796824,0.595168,1.0,894.0,20.0,135.0,Non-compliance with Study Procedures,Overall Study,FG000,hypertension,INDUSTRY,0.03167434,0.0325849744953968,0.0009106344953968004
5.0,894.0,208.0,0.005593,0.005593,6.796824,0.595168,1.0,894.0,20.0,135.0,Lung Transplant,Overall Study,FG000,hypertension,INDUSTRY,0.02262511,0.023143516356095784,0.0005184063560957838
2.0,894.0,208.0,0.002237,0.002237,6.796824,0.595168,1.0,894.0,20.0,135.0,Unable to Tolerate Study Drug,Overall Study,FG000,hypertension,INDUSTRY,0.00904923,0.008922899915664674,0.00012633008433532607
2.0,894.0,208.0,0.002237,0.002237,6.796824,0.595168,1.0,894.0,20.0,135.0,Use of Excluded Medication,Overall Study,FG000,hypertension,INDUSTRY,0.00904923,0.008922899915664674,0.00012633008433532607
1.0,894.0,208.0,0.001119,0.001119,6.796824,0.595168,1.0,894.0,20.0,135.0,Patient Self-discontinuation,Overall Study,FG000,hypertension,INDUSTRY,0.00452664,0.0045176940740773615,8.945925922638695e-06
1.0,894.0,208.0,0.001119,0.001119,6.796824,0.595168,1.0,894.0,20.0,135.0,Pregnancy,Overall Study,FG000,hypertension,INDUSTRY,0.00452664,0.0045176940740773615,8.945925922638695e-06
1.0,894.0,208.0,0.001119,0.001119,6.796824,0.595168,1.0,894.0,20.0,135.0,Surgery,Overall Study,FG000,hypertension,INDUSTRY,0.00452664,0.0045176940740773615,8.945925922638695e-06
3.0,864.0,840.0,0.003472,0.003472,6.76273,0.309765,1.0,1099.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.00727335,0.007329453795625004,5.61037956250043e-05
4.0,864.0,840.0,0.00463,0.00463,6.76273,0.309765,1.0,1099.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00969919,0.00975599232389882,5.680232389882085e-05
2.0,864.0,840.0,0.002315,0.002315,6.76273,0.309765,1.0,1099.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0048496,0.004936084097974389,8.64840979743894e-05
1.0,864.0,840.0,0.001157,0.001157,6.76273,0.309765,1.0,1099.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.00242375,0.0024262099554761764,2.459955476176272e-06
3.0,864.0,840.0,0.003472,0.003472,6.76273,0.309765,1.0,1099.0,0.0,0.0,Patient Decision Unrel to Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.00727335,0.007333410903779765,6.006090377976524e-05
3.0,864.0,840.0,0.003472,0.003472,6.76273,0.309765,1.0,1099.0,0.0,0.0,Patient Decision Unrel to Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00727335,0.007324524833303574,5.1174833303574765e-05
1.0,864.0,840.0,0.001157,0.001157,6.76273,0.309765,1.0,1099.0,0.0,0.0,Noncompliance,Overall Study,FG000,hypertension,INDUSTRY,0.00242375,0.002428405825773794,4.655825773794073e-06
0.0,864.0,840.0,0.0,0.0,6.76273,0.309765,1.0,1099.0,0.0,0.0,Noncompliance,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,864.0,840.0,0.001157,0.001157,6.76273,0.309765,1.0,1099.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG000,hypertension,INDUSTRY,0.00242375,0.002428405825773794,4.655825773794073e-06
5.0,864.0,840.0,0.005787,0.005787,6.76273,0.309765,1.0,1099.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG001,hypertension,INDUSTRY,0.01212294,0.012213532185119053,9.059218511905248e-05
0.0,864.0,840.0,0.0,0.0,6.76273,0.309765,1.0,1099.0,0.0,0.0,Other,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,864.0,840.0,0.001157,0.001157,6.76273,0.309765,1.0,1099.0,0.0,0.0,Other,Overall Study,FG001,hypertension,INDUSTRY,0.00242375,0.002428695587499986,4.945587499985849e-06
4.0,247.0,196.0,0.016194,0.016194,5.513429,0.604853,1.0,247.0,15.0,58.0,Death,Overall Study,FG000,hypertension,INDUSTRY,0.05400402,0.05508534436527778,0.0010813243652777818
12.0,247.0,196.0,0.048583,0.048583,5.513429,0.604853,1.0,247.0,15.0,58.0,Death,Overall Study,FG001,hypertension,INDUSTRY,0.16201538,0.15774686403178595,0.004268515968214037
7.0,247.0,196.0,0.02834,0.02834,5.513429,0.604853,1.0,247.0,15.0,58.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0945087,0.09480787615140862,0.00029917615140861997
4.0,247.0,196.0,0.016194,0.016194,5.513429,0.604853,1.0,247.0,15.0,58.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.05400402,0.05517419569843254,0.0011701756984325434
7.0,247.0,196.0,0.02834,0.02834,5.513429,0.604853,1.0,247.0,15.0,58.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0945087,0.09507807261390859,0.0005693726139085892
4.0,247.0,196.0,0.016194,0.016194,5.513429,0.604853,1.0,247.0,15.0,58.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.05400402,0.05513133060968254,0.00112731060968254
7.0,247.0,196.0,0.02834,0.02834,5.513429,0.604853,1.0,247.0,15.0,58.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0945087,0.09475284909623002,0.000244149096230023
5.0,247.0,196.0,0.020243,0.020243,5.513429,0.604853,1.0,247.0,15.0,58.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.06750669,0.06794300926306553,0.00043631926306553215
0.0,247.0,196.0,0.0,0.0,5.513429,0.604853,1.0,247.0,15.0,58.0,Sponsor Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,247.0,196.0,0.004049,0.004049,5.513429,0.604853,1.0,247.0,15.0,58.0,Sponsor Decision,Overall Study,FG001,hypertension,INDUSTRY,0.01350267,0.013842298609751984,0.0003396286097519848
23.0,560.0,483.0,0.041071,0.041071,6.329721,0.321222,1.0,771.0,0.0,0.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0835075,0.08305936657614087,0.0004481334238591317
1.0,560.0,483.0,0.001786,0.001786,6.329721,0.321222,1.0,771.0,0.0,0.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00363138,0.0036404432526190578,9.063252619057743e-06
15.0,560.0,483.0,0.026786,0.026786,6.329721,0.321222,1.0,771.0,0.0,0.0,Adverse Event,Overall Study,FG002,hypertension,INDUSTRY,0.05446256,0.054354252856561106,0.00010830714343889464
0.0,560.0,483.0,0.0,0.0,6.329721,0.321222,1.0,771.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
4.0,560.0,483.0,0.007143,0.007143,6.329721,0.321222,1.0,771.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.01452349,0.014504879238660711,1.861076133928899e-05
1.0,560.0,483.0,0.001786,0.001786,6.329721,0.321222,1.0,771.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,hypertension,INDUSTRY,0.00363138,0.003645428786964294,1.404878696429409e-05
1.0,560.0,483.0,0.001786,0.001786,6.329721,0.321222,1.0,771.0,0.0,0.0,Patient's Decision Unrelated to AE,Overall Study,FG000,hypertension,INDUSTRY,0.00363138,0.0036387827698809616,7.402769880961602e-06
1.0,560.0,483.0,0.001786,0.001786,6.329721,0.321222,1.0,771.0,0.0,0.0,Patient's Decision Unrelated to AE,Overall Study,FG001,hypertension,INDUSTRY,0.00363138,0.003641033052619058,9.653052619058074e-06
2.0,560.0,483.0,0.003571,0.003571,6.329721,0.321222,1.0,771.0,0.0,0.0,Patient's Decision Unrelated to AE,Overall Study,FG002,hypertension,INDUSTRY,0.00726073,0.00723086420531747,2.9865794682530297e-05
5.0,560.0,483.0,0.008929,0.008929,6.329721,0.321222,1.0,771.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG000,hypertension,INDUSTRY,0.01815487,0.018426887989097224,0.00027201798909722366
7.0,560.0,483.0,0.0125,0.0125,6.329721,0.321222,1.0,771.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG001,hypertension,INDUSTRY,0.02541559,0.02570776765769839,0.0002921776576983934
10.0,560.0,483.0,0.017857,0.017857,6.329721,0.321222,1.0,771.0,0.0,0.0,Inadequate Control of IOP,Overall Study,FG002,hypertension,INDUSTRY,0.0363077,0.03656822041279763,0.0002605204127976296
4.0,560.0,483.0,0.007143,0.007143,6.329721,0.321222,1.0,771.0,0.0,0.0,Other,Overall Study,FG000,hypertension,INDUSTRY,0.01452349,0.01449878921038691,2.470078961308922e-05
1.0,560.0,483.0,0.001786,0.001786,6.329721,0.321222,1.0,771.0,0.0,0.0,Other,Overall Study,FG001,hypertension,INDUSTRY,0.00363138,0.003640188290119058,8.808290119058024e-06
2.0,560.0,483.0,0.003571,0.003571,6.329721,0.321222,1.0,771.0,0.0,0.0,Other,Overall Study,FG002,hypertension,INDUSTRY,0.00726073,0.00723038537031747,3.0344629682529933e-05
1.0,237.0,229.0,0.004219,0.004219,5.472271,0.387388,1.0,237.0,1.0,1.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.00894381,0.009063397912470237,0.00011958791247023738
2.0,237.0,229.0,0.008439,0.008439,5.472271,0.387388,1.0,237.0,1.0,1.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.01788975,0.01805772706634924,0.00016797706634924178
0.0,237.0,229.0,0.0,0.0,5.472271,0.387388,1.0,237.0,1.0,1.0,Physician Decision,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,237.0,229.0,0.004219,0.004219,5.472271,0.387388,1.0,237.0,1.0,1.0,Physician Decision,Overall Study,FG001,hypertension,INDUSTRY,0.00894381,0.00908027956794643,0.00013646956794642964
2.0,237.0,229.0,0.008439,0.008439,5.472271,0.387388,1.0,237.0,1.0,1.0,Protocol Violation,Overall Study,FG000,hypertension,INDUSTRY,0.01788975,0.018053408744742105,0.00016365874474210534
0.0,237.0,229.0,0.0,0.0,5.472271,0.387388,1.0,237.0,1.0,1.0,Protocol Violation,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,237.0,229.0,0.008439,0.008439,5.472271,0.387388,1.0,237.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.01788975,0.01805888394015877,0.00016913394015877214
0.0,237.0,229.0,0.0,0.0,5.472271,0.387388,1.0,237.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
5.0,289.0,282.0,0.017301,0.017301,5.669881,0.203691,1.0,300.0,1.0,54.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.01998096,0.020272621236478185,0.00029166123647818634
1.0,289.0,282.0,0.00346,0.00346,5.669881,0.203691,1.0,300.0,1.0,54.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.00399596,0.00403473063190477,3.87706319047703e-05
0.0,289.0,282.0,0.0,0.0,5.669881,0.203691,1.0,300.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,289.0,282.0,0.00346,0.00346,5.669881,0.203691,1.0,300.0,1.0,54.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.00399596,0.004034661498571436,3.870149857143623e-05
0.0,973.0,925.0,0.0,0.0,6.881411,0.428712,1.0,973.0,1.0,10.0,Adverse Event,Overall Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
4.0,973.0,925.0,0.004111,0.004111,6.881411,0.428712,1.0,973.0,1.0,10.0,Adverse Event,Overall Study,FG001,hypertension,INDUSTRY,0.01212805,0.012216225481448415,8.817548144841522e-05
6.0,973.0,925.0,0.006166,0.006166,6.881411,0.428712,1.0,973.0,1.0,10.0,Withdrawal by Subject,Overall Study,FG000,hypertension,INDUSTRY,0.0181906,0.018098226700823398,9.237329917660339e-05
6.0,973.0,925.0,0.006166,0.006166,6.881411,0.428712,1.0,973.0,1.0,10.0,Withdrawal by Subject,Overall Study,FG001,hypertension,INDUSTRY,0.0181906,0.018133860347222207,5.673965277779372e-05
1.0,973.0,925.0,0.001028,0.001028,6.881411,0.428712,1.0,973.0,1.0,10.0,Non-compliance with study drug,Overall Study,FG000,hypertension,INDUSTRY,0.00303275,0.003169669671684222,0.00013691967168422223
2.0,973.0,925.0,0.002055,0.002055,6.881411,0.428712,1.0,973.0,1.0,10.0,Non-compliance with study drug,Overall Study,FG001,hypertension,INDUSTRY,0.00606255,0.006061376118124993,1.1738818750071933e-06
5.0,973.0,925.0,0.005139,0.005139,6.881411,0.428712,1.0,973.0,1.0,10.0,Lost to Follow-up,Overall Study,FG000,hypertension,INDUSTRY,0.0151608,0.015205503120876816,4.4703120876815605e-05
2.0,973.0,925.0,0.002055,0.002055,6.881411,0.428712,1.0,973.0,1.0,10.0,Lost to Follow-up,Overall Study,FG001,hypertension,INDUSTRY,0.00606255,0.006056466362708333,6.083637291666964e-06
11.0,973.0,925.0,0.011305,0.011305,6.881411,0.428712,1.0,973.0,1.0,10.0,Other,Overall Study,FG000,hypertension,INDUSTRY,0.03335141,0.03312440065770833,0.00022700934229166747
11.0,973.0,925.0,0.011305,0.011305,6.881411,0.428712,1.0,973.0,1.0,10.0,Other,Overall Study,FG001,hypertension,INDUSTRY,0.03335141,0.03316975588785716,0.00018165411214284
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
2.0,306.0,109.0,0.006536,0.006536,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.01025074,0.010274806868005968,2.4066868005968856e-05
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.00512537,0.005126786666666681,1.4166666666816721e-06
2.0,306.0,109.0,0.006536,0.006536,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.01025074,0.010279320671755967,2.8580671755967096e-05
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.00512537,0.0051255412057738215,1.7120577382179203e-07
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.00512537,0.005119844027261919,5.525972738080337e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.00512537,0.0051297619076785825,4.39190767858276e-06
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.00512537,0.005115380656488109,9.989343511890986e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.00512537,0.005124568550000014,8.014499999859856e-07
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,306.0,109.0,0.009804,0.009804,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.01537611,0.015278772250228176,9.733774977182391e-05
2.0,306.0,109.0,0.006536,0.006536,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.01025074,0.010285199063422632,3.44590634226323e-05
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.00512537,0.005131129649702392,5.759649702391859e-06
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.00512537,0.005116550424345251,8.819575654748883e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG003,hypertension,INDUSTRY,0.00512537,0.005124568550000014,8.014499999859856e-07
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Double Blind Base Study,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
11.0,306.0,109.0,0.035948,0.035948,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG004,hypertension,INDUSTRY,0.05637907,0.05666017715181549,0.00028110715181548646
8.0,306.0,109.0,0.026144,0.026144,5.726848,0.273859,1.0,306.0,0.0,0.0,Adverse Event,Open Label Extension,FG005,hypertension,INDUSTRY,0.04100296,0.04124958361363093,0.00024662361363093216
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG004,hypertension,INDUSTRY,0.00512537,0.0051243090027976316,1.0609972023681996e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Protocol Violation,Open Label Extension,FG005,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
6.0,306.0,109.0,0.019608,0.019608,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG004,hypertension,INDUSTRY,0.03075222,0.030789916284335365,3.769628433536454e-05
11.0,306.0,109.0,0.035948,0.035948,5.726848,0.273859,1.0,306.0,0.0,0.0,Lost to Follow-up,Open Label Extension,FG005,hypertension,INDUSTRY,0.05637907,0.056694073103482144,0.0003150031034821407
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
9.0,306.0,109.0,0.029412,0.029412,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG004,hypertension,INDUSTRY,0.04612833,0.046335087465962335,0.00020675746596233308
8.0,306.0,109.0,0.026144,0.026144,5.726848,0.273859,1.0,306.0,0.0,0.0,Physician Decision,Open Label Extension,FG005,hypertension,INDUSTRY,0.04100296,0.04127277148829363,0.0002698114882936295
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG004,hypertension,INDUSTRY,0.0,0.0,0.0
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Pregnancy,Open Label Extension,FG005,hypertension,INDUSTRY,0.00512537,0.005123533848630965,1.8361513690343459e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
3.0,306.0,109.0,0.009804,0.009804,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG004,hypertension,INDUSTRY,0.01537611,0.015262436118144844,0.0001136738818551565
1.0,306.0,109.0,0.003268,0.003268,5.726848,0.273859,1.0,306.0,0.0,0.0,Progressive Disease,Open Label Extension,FG005,hypertension,INDUSTRY,0.00512537,0.005123533848630965,1.8361513690343459e-06
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
45.0,306.0,109.0,0.147059,0.147059,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG004,hypertension,INDUSTRY,0.23064007,0.2269385961962599,0.003701473803740113
47.0,306.0,109.0,0.153595,0.153595,5.726848,0.273859,1.0,306.0,0.0,0.0,Termination of Trial,Open Label Extension,FG005,hypertension,INDUSTRY,0.24089081,0.23121373930536693,0.009677070694633083
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG000,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG001,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG002,hypertension,INDUSTRY,0.0,0.0,0.0
0.0,306.0,109.0,0.0,0.0,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG003,hypertension,INDUSTRY,0.0,0.0,0.0
4.0,306.0,109.0,0.013072,0.013072,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG004,hypertension,INDUSTRY,0.02050148,0.020596441779196444,9.496177919644452e-05
4.0,306.0,109.0,0.013072,0.013072,5.726848,0.273859,1.0,306.0,0.0,0.0,Withdrawal by Subject,Open Label Extension,FG005,hypertension,INDUSTRY,0.02050148,0.02059656593336311,9.508593336311072e-05
17.0,620.0,141.0,0.027419,0.027419,6.431331,0.948892,1.0,620.0,1.0,1.0,Pregnancy,Overall Study,FG000,obesity,OTHER,0.16732816,0.16255790648036708,0.004770253519632922
25.0,620.0,141.0,0.040323,0.040323,6.431331,0.948892,1.0,620.0,1.0,1.0,Pregnancy,Overall Study,FG001,obesity,OTHER,0.24607657,0.2334170315449799,0.012659538455020103
60.0,620.0,141.0,0.096774,0.096774,6.431331,0.948892,1.0,620.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,obesity,OTHER,0.59057645,0.5695457722811704,0.021030677718829605
54.0,620.0,141.0,0.087097,0.087097,6.431331,0.948892,1.0,620.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,obesity,OTHER,0.53152125,0.5229982292687101,0.008523020731289854
2.0,620.0,141.0,0.003226,0.003226,6.431331,0.948892,1.0,620.0,1.0,1.0,Protocol Violation,Overall Study,FG000,obesity,OTHER,0.0196871,0.018993850442380934,0.0006932495576190655
0.0,620.0,141.0,0.0,0.0,6.431331,0.948892,1.0,620.0,1.0,1.0,Protocol Violation,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
8.0,620.0,141.0,0.012903,0.012903,6.431331,0.948892,1.0,620.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,obesity,OTHER,0.07874231,0.07758714884648814,0.0011551611535118578
2.0,620.0,141.0,0.003226,0.003226,6.431331,0.948892,1.0,620.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,obesity,OTHER,0.0196871,0.01904010278898807,0.00064699721101193
183.0,620.0,141.0,0.295161,0.295161,6.431331,0.948892,1.0,620.0,1.0,1.0,Providers not included in the primary outcome.,Overall Study,FG000,obesity,OTHER,1.80126,1.5262867685919932,0.2749732314080069
128.0,620.0,141.0,0.206452,0.206452,6.431331,0.948892,1.0,620.0,1.0,1.0,Providers not included in the primary outcome.,Overall Study,FG001,obesity,OTHER,1.25990131,1.1079945178224704,0.15190679217752967
2.0,793.0,732.0,0.002522,0.002522,6.677083,0.410293,1.0,793.0,1.0,35.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.00690917,0.0068837016059226245,2.546839407737561e-05
3.0,793.0,732.0,0.003783,0.003783,6.677083,0.410293,1.0,793.0,1.0,35.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.01036375,0.010312727100922616,5.102289907738325e-05
5.0,793.0,732.0,0.006305,0.006305,6.677083,0.410293,1.0,793.0,1.0,35.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.01727292,0.016928591117827362,0.0003443288821726384
0.0,793.0,732.0,0.0,0.0,6.677083,0.410293,1.0,793.0,1.0,35.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
4.0,793.0,732.0,0.005044,0.005044,6.677083,0.410293,1.0,793.0,1.0,35.0,Non-compliance,Overall Study,FG000,obesity,INDUSTRY,0.01381834,0.013641285007777755,0.00017705499222224474
4.0,793.0,732.0,0.005044,0.005044,6.677083,0.410293,1.0,793.0,1.0,35.0,Non-compliance,Overall Study,FG001,obesity,INDUSTRY,0.01381834,0.01363324722736109,0.00018509277263891073
6.0,793.0,732.0,0.007566,0.007566,6.677083,0.410293,1.0,793.0,1.0,35.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.02072751,0.020249745238482157,0.0004777647615178439
10.0,793.0,732.0,0.01261,0.01261,6.677083,0.410293,1.0,793.0,1.0,35.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.03454585,0.034014020784285705,0.0005318292157142981
2.0,793.0,732.0,0.002522,0.002522,6.677083,0.410293,1.0,793.0,1.0,35.0,Sponsor Decision,Overall Study,FG000,obesity,INDUSTRY,0.00690917,0.006881117272172625,2.805272782737539e-05
1.0,793.0,732.0,0.001261,0.001261,6.677083,0.410293,1.0,793.0,1.0,35.0,Sponsor Decision,Overall Study,FG001,obesity,INDUSTRY,0.00345458,0.003622167424067459,0.00016758742406745896
1.0,793.0,732.0,0.001261,0.001261,6.677083,0.410293,1.0,793.0,1.0,35.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00345458,0.00361877491362103,0.00016419491362102984
0.0,793.0,732.0,0.0,0.0,6.677083,0.410293,1.0,793.0,1.0,35.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
7.0,793.0,732.0,0.008827,0.008827,6.677083,0.410293,1.0,793.0,1.0,35.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.02418209,0.02277493996063494,0.0014071500393650592
16.0,793.0,732.0,0.020177,0.020177,6.677083,0.410293,1.0,793.0,1.0,35.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.0552761,0.055096031782132876,0.00018006821786712562
7.0,267.0,192.0,0.026217,0.026217,5.590987,0.796595,1.0,267.0,1.0,18.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.11676398,0.11576997284551582,0.0009940071544841805
8.0,267.0,192.0,0.029963,0.029963,5.590987,0.796595,1.0,267.0,1.0,18.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.13344773,0.13641424850010894,0.0029665185001089556
5.0,267.0,192.0,0.018727,0.018727,5.590987,0.796595,1.0,267.0,1.0,18.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.08340539,0.08479250059404755,0.001387110594047558
0.0,267.0,192.0,0.0,0.0,5.590987,0.796595,1.0,267.0,1.0,18.0,Physician Decision,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,267.0,192.0,0.003745,0.003745,5.590987,0.796595,1.0,267.0,1.0,18.0,Physician Decision,Overall Study,FG001,obesity,INDUSTRY,0.0166793,0.01692262357048612,0.0002433235704861203
0.0,267.0,192.0,0.0,0.0,5.590987,0.796595,1.0,267.0,1.0,18.0,Physician Decision,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
6.0,267.0,192.0,0.022472,0.022472,5.590987,0.796595,1.0,267.0,1.0,18.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.10008468,0.10441249553922613,0.004327815539226135
3.0,267.0,192.0,0.011236,0.011236,5.590987,0.796595,1.0,267.0,1.0,18.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.05004234,0.05036220139141409,0.00031986139141409325
3.0,267.0,192.0,0.011236,0.011236,5.590987,0.796595,1.0,267.0,1.0,18.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.05004234,0.050317738138221435,0.0002753981382214374
15.0,267.0,192.0,0.05618,0.05618,5.590987,0.796595,1.0,267.0,1.0,18.0,Participants Excluded Due to GCP Compliance Issue,Overall Study,FG000,obesity,INDUSTRY,0.25021171,0.2505717343670634,0.00036002436706344954
13.0,267.0,192.0,0.048689,0.048689,5.590987,0.796595,1.0,267.0,1.0,18.0,Participants Excluded Due to GCP Compliance Issue,Overall Study,FG001,obesity,INDUSTRY,0.21684867,0.22535845010940464,0.008509780109404647
14.0,267.0,192.0,0.052434,0.052434,5.590987,0.796595,1.0,267.0,1.0,18.0,Participants Excluded Due to GCP Compliance Issue,Overall Study,FG002,obesity,INDUSTRY,0.23352796,0.23422847601857125,0.00070051601857124
12.0,282.0,217.0,0.042553,0.042553,5.645447,0.515793,1.0,282.0,1.0,10.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.12390922,0.13102883914922595,0.007119619149225945
6.0,282.0,217.0,0.021277,0.021277,5.645447,0.515793,1.0,282.0,1.0,10.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.06195607,0.06347603273997032,0.0015199627399703208
2.0,282.0,217.0,0.007092,0.007092,5.645447,0.515793,1.0,282.0,1.0,10.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.02065105,0.020741253890486994,9.020389048699368e-05
1.0,282.0,217.0,0.003546,0.003546,5.645447,0.515793,1.0,282.0,1.0,10.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.01032553,0.010411548668204353,8.601866820435317e-05
0.0,282.0,217.0,0.0,0.0,5.645447,0.515793,1.0,282.0,1.0,10.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
2.0,282.0,217.0,0.007092,0.007092,5.645447,0.515793,1.0,282.0,1.0,10.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.02065105,0.020745476393353154,9.442639335315375e-05
1.0,282.0,217.0,0.003546,0.003546,5.645447,0.515793,1.0,282.0,1.0,10.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.01032553,0.010376117039394834,5.0587039394834124e-05
6.0,282.0,217.0,0.021277,0.021277,5.645447,0.515793,1.0,282.0,1.0,10.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.06195607,0.06419028314494053,0.0022342131449405306
13.0,282.0,217.0,0.046099,0.046099,5.645447,0.515793,1.0,282.0,1.0,10.0,Unclassified,Overall Study,FG000,obesity,INDUSTRY,0.13423475,0.138824892077351,0.004590142077350978
22.0,282.0,217.0,0.078014,0.078014,5.645447,0.515793,1.0,282.0,1.0,10.0,Unclassified,Overall Study,FG001,obesity,INDUSTRY,0.22716739,0.23312111876610128,0.005953728766101285
2.0,338.0,319.0,0.005917,0.005917,5.826,0.662894,1.0,338.0,1.0,19.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.02285156,0.024825354284474223,0.001973794284474223
4.0,338.0,319.0,0.011834,0.011834,5.826,0.662894,1.0,338.0,1.0,19.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.04570313,0.045854262392529724,0.00015113239252972227
1.0,338.0,319.0,0.002959,0.002959,5.826,0.662894,1.0,338.0,1.0,19.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.01142771,0.011704339782817453,0.00027662978281745194
4.0,338.0,319.0,0.011834,0.011834,5.826,0.662894,1.0,338.0,1.0,19.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.04570313,0.0459393941913176,0.00023626419131760057
5.0,338.0,319.0,0.014793,0.014793,5.826,0.662894,1.0,338.0,1.0,19.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.05713084,0.05659694624909726,0.0005338937509027433
3.0,338.0,319.0,0.008876,0.008876,5.826,0.662894,1.0,338.0,1.0,19.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.03427928,0.034997930140089235,0.0007186501400892331
1.0,302.0,275.0,0.003311,0.003311,5.713733,0.279906,1.0,302.0,1.0,1.0,Not ready to exercise,Initial 3 Month Counseling,FG000,obesity,FED,0.00529531,0.005310725480089278,1.5415480089277754e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Not ready to exercise,Initial 3 Month Counseling,FG001,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Not ready to exercise,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
3.0,302.0,275.0,0.009934,0.009934,5.713733,0.279906,1.0,302.0,1.0,1.0,Lack of Interest,Initial 3 Month Counseling,FG000,obesity,FED,0.01588752,0.01593290353576387,4.53835357638703e-05
3.0,302.0,275.0,0.009934,0.009934,5.713733,0.279906,1.0,302.0,1.0,1.0,Lack of Interest,Initial 3 Month Counseling,FG001,obesity,FED,0.01588752,0.015931581846240054,4.4061846240055214e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Lack of Interest,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
2.0,302.0,275.0,0.006623,0.006623,5.713733,0.279906,1.0,302.0,1.0,1.0,Personal issues,Initial 3 Month Counseling,FG000,obesity,FED,0.01059221,0.010740401133551594,0.00014819113355159404
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Personal issues,Initial 3 Month Counseling,FG001,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Personal issues,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
7.0,302.0,275.0,0.023179,0.023179,5.713733,0.279906,1.0,302.0,1.0,1.0,Too busy,Initial 3 Month Counseling,FG000,obesity,FED,0.03707035,0.03670143922693185,0.00036891077306815123
1.0,302.0,275.0,0.003311,0.003311,5.713733,0.279906,1.0,302.0,1.0,1.0,Too busy,Initial 3 Month Counseling,FG001,obesity,FED,0.00529531,0.005307531358333328,1.2221358333328047e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Too busy,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
2.0,302.0,275.0,0.006623,0.006623,5.713733,0.279906,1.0,302.0,1.0,1.0,Pain,Initial 3 Month Counseling,FG000,obesity,FED,0.01059221,0.010740401133551594,0.00014819113355159404
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Pain,Initial 3 Month Counseling,FG001,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Pain,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
1.0,302.0,275.0,0.003311,0.003311,5.713733,0.279906,1.0,302.0,1.0,1.0,Moved,Initial 3 Month Counseling,FG000,obesity,FED,0.00529531,0.005310725480089278,1.5415480089277754e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Moved,Initial 3 Month Counseling,FG001,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Moved,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
1.0,302.0,275.0,0.003311,0.003311,5.713733,0.279906,1.0,302.0,1.0,1.0,Family illness,Initial 3 Month Counseling,FG000,obesity,FED,0.00529531,0.005310725480089278,1.5415480089277754e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Family illness,Initial 3 Month Counseling,FG001,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Family illness,Initial 3 Month Counseling,FG002,obesity,FED,0.0,0.0,0.0
2.0,302.0,275.0,0.006623,0.006623,5.713733,0.279906,1.0,302.0,1.0,1.0,Death,Rerandomization Arm 1 Only,FG000,obesity,FED,0.01059221,0.010749491895218259,0.00015728189521825933
1.0,302.0,275.0,0.003311,0.003311,5.713733,0.279906,1.0,302.0,1.0,1.0,Death,Rerandomization Arm 1 Only,FG001,obesity,FED,0.00529531,0.005311855823511901,1.6545823511900787e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Death,Rerandomization Arm 1 Only,FG002,obesity,FED,0.0,0.0,0.0
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Withdrawal by Subject,Rerandomization Arm 1 Only,FG000,obesity,FED,0.0,0.0,0.0
3.0,302.0,275.0,0.009934,0.009934,5.713733,0.279906,1.0,302.0,1.0,1.0,Withdrawal by Subject,Rerandomization Arm 1 Only,FG001,obesity,FED,0.01588752,0.015920381699216245,3.2861699216246015e-05
0.0,302.0,275.0,0.0,0.0,5.713733,0.279906,1.0,302.0,1.0,1.0,Withdrawal by Subject,Rerandomization Arm 1 Only,FG002,obesity,FED,0.0,0.0,0.0
3.0,304.0,282.0,0.009868,0.009868,5.720312,0.655228,1.0,304.0,5.0,41.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.03698632,0.037430841492023754,0.0004445214920237514
14.0,304.0,282.0,0.046053,0.046053,5.720312,0.655228,1.0,304.0,5.0,41.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.17261159,0.16937409938726206,0.0032374906127379532
1.0,304.0,282.0,0.003289,0.003289,5.720312,0.655228,1.0,304.0,5.0,41.0,Death,Overall Study,FG000,obesity,INDUSTRY,0.01232753,0.012409772563253964,8.224256325396403e-05
0.0,304.0,282.0,0.0,0.0,5.720312,0.655228,1.0,304.0,5.0,41.0,Death,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,304.0,282.0,0.0,0.0,5.720312,0.655228,1.0,304.0,5.0,41.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
4.0,304.0,282.0,0.013158,0.013158,5.720312,0.655228,1.0,304.0,5.0,41.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.0493176,0.052731105316904815,0.003413505316904812
26.0,1961.0,1849.0,0.013259,0.013259,7.58172,0.652434,1.0,1961.0,17.0,128.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0655866,0.06547599190892853,0.00011060809107146796
17.0,1961.0,1849.0,0.008669,0.008669,7.58172,0.652434,1.0,1961.0,17.0,128.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.04288184,0.04298854323771825,0.00010670323771825446
39.0,1961.0,1849.0,0.019888,0.019888,7.58172,0.652434,1.0,1961.0,17.0,128.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.09837743,0.10017746128410074,0.0018000312841007365
28.0,1961.0,1849.0,0.014278,0.014278,7.58172,0.652434,1.0,1961.0,17.0,128.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.07062716,0.06992553589441462,0.0007016241055853717
1.0,1961.0,1849.0,0.00051,0.00051,7.58172,0.652434,1.0,1961.0,17.0,128.0,Death,Overall Study,FG000,obesity,INDUSTRY,0.00252275,0.0025257115450396856,2.9615450396858027e-06
1.0,1961.0,1849.0,0.00051,0.00051,7.58172,0.652434,1.0,1961.0,17.0,128.0,Death,Overall Study,FG001,obesity,INDUSTRY,0.00252275,0.0025242427543452424,1.4927543452425938e-06
92.0,1267.0,759.0,0.072612,0.072612,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.12122193,0.12089881070138889,0.00032311929861111865
31.0,1267.0,759.0,0.024467,0.024467,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.04084638,0.040968953249424594,0.0001225732494245929
63.0,1267.0,759.0,0.049724,0.049724,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.08301162,0.08401717888071332,0.0010055588807133253
16.0,1267.0,759.0,0.012628,0.012628,7.145196,0.233646,1.0,1267.0,1.0,5.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.02108179,0.020972498206299622,0.0001092917937003772
16.0,1267.0,759.0,0.012628,0.012628,7.145196,0.233646,1.0,1267.0,1.0,5.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.02108179,0.02095606862568454,0.00012572137431545935
36.0,1267.0,759.0,0.028414,0.028414,7.145196,0.233646,1.0,1267.0,1.0,5.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.04743569,0.04787131654667655,0.00043562654667654577
92.0,1267.0,759.0,0.072612,0.072612,7.145196,0.233646,1.0,1267.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.12122193,0.1210378189812103,0.0001841110187897066
31.0,1267.0,759.0,0.024467,0.024467,7.145196,0.233646,1.0,1267.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.04084638,0.04083867794330356,7.70205669644447e-06
43.0,1267.0,759.0,0.033938,0.033938,7.145196,0.233646,1.0,1267.0,1.0,5.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.05665772,0.057245316039425426,0.000587596039425424
10.0,1267.0,759.0,0.007893,0.007893,7.145196,0.233646,1.0,1267.0,1.0,5.0,Non compliance,Overall Study,FG000,obesity,INDUSTRY,0.01317695,0.012997409015922617,0.00017954098407738268
4.0,1267.0,759.0,0.003157,0.003157,7.145196,0.233646,1.0,1267.0,1.0,5.0,Non compliance,Overall Study,FG001,obesity,INDUSTRY,0.00527045,0.005269000687638891,1.4493123611089218e-06
5.0,1267.0,759.0,0.003946,0.003946,7.145196,0.233646,1.0,1267.0,1.0,5.0,Non compliance,Overall Study,FG002,obesity,INDUSTRY,0.00658764,0.006577806919017856,9.833080982143624e-06
2.0,1267.0,759.0,0.001579,0.001579,7.145196,0.233646,1.0,1267.0,1.0,5.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00263606,0.0026222473523511893,1.3812647648810648e-05
1.0,1267.0,759.0,0.000789,0.000789,7.145196,0.233646,1.0,1267.0,1.0,5.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.00131719,0.001315099853601195,2.090146398804919e-06
14.0,1267.0,759.0,0.01105,0.01105,7.145196,0.233646,1.0,1267.0,1.0,5.0,Pregnancy,Overall Study,FG002,obesity,INDUSTRY,0.0184474,0.018238238856259952,0.00020916114374004702
3.0,1267.0,759.0,0.002368,0.002368,7.145196,0.233646,1.0,1267.0,1.0,5.0,Restricted med,Overall Study,FG000,obesity,INDUSTRY,0.00395325,0.00393422295600198,1.902704399802009e-05
1.0,1267.0,759.0,0.000789,0.000789,7.145196,0.233646,1.0,1267.0,1.0,5.0,Restricted med,Overall Study,FG001,obesity,INDUSTRY,0.00131719,0.0013161155552678624,1.0744447321376152e-06
1.0,1267.0,759.0,0.000789,0.000789,7.145196,0.233646,1.0,1267.0,1.0,5.0,Restricted med,Overall Study,FG002,obesity,INDUSTRY,0.00131719,0.0013161380430654825,1.0519569345174805e-06
12.0,1267.0,759.0,0.009471,0.009471,7.145196,0.233646,1.0,1267.0,1.0,5.0,Other,Overall Study,FG000,obesity,INDUSTRY,0.01581134,0.015406707521359132,0.0004046324786408685
7.0,1267.0,759.0,0.005525,0.005525,7.145196,0.233646,1.0,1267.0,1.0,5.0,Other,Overall Study,FG001,obesity,INDUSTRY,0.0092237,0.009189937675069444,3.37623249305561e-05
10.0,1267.0,759.0,0.007893,0.007893,7.145196,0.233646,1.0,1267.0,1.0,5.0,Other,Overall Study,FG002,obesity,INDUSTRY,0.01317695,0.012968864465059524,0.0002080855349404758
15.0,1267.0,759.0,0.011839,0.011839,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.01976459,0.019526530532896828,0.0002380594671031709
3.0,1267.0,759.0,0.002368,0.002368,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.00395325,0.003932999841835313,2.025015816468738e-05
0.0,1267.0,759.0,0.0,0.0,7.145196,0.233646,1.0,1267.0,1.0,5.0,Lack of Efficacy,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
3.0,242.0,204.0,0.012397,0.012397,5.493061,0.395941,1.0,242.0,1.0,1.0,Did not Receive Intervention,Overall Study,FG000,obesity,OTHER,0.02696256,0.026972959332242044,1.0399332242044118e-05
2.0,242.0,204.0,0.008264,0.008264,5.493061,0.395941,1.0,242.0,1.0,1.0,Did not Receive Intervention,Overall Study,FG001,obesity,OTHER,0.01797359,0.017987364270912798,1.3774270912796788e-05
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Did not Receive Intervention,Overall Study,FG002,obesity,OTHER,0.0089868,0.008978120945267896,8.67905473210355e-06
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Did not Receive Intervention,Overall Study,FG003,obesity,OTHER,0.0089868,0.008984166453164731,2.6335468352681884e-06
2.0,242.0,204.0,0.008264,0.008264,5.493061,0.395941,1.0,242.0,1.0,1.0,Did not Receive Intervention,Overall Study,FG004,obesity,OTHER,0.01797359,0.01797232957275804,1.260427241960016e-06
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,obesity,OTHER,0.0089868,0.009002740356299624,1.594035629962423e-05
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,obesity,OTHER,0.0089868,0.008979851625873054,6.9483741269461136e-06
3.0,242.0,204.0,0.012397,0.012397,5.493061,0.395941,1.0,242.0,1.0,1.0,Lost to Follow-up,Overall Study,FG004,obesity,OTHER,0.02696256,0.026991507640575386,2.894764057538579e-05
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Available for the 8 Week Visit,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
3.0,242.0,204.0,0.012397,0.012397,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Available for the 8 Week Visit,Overall Study,FG001,obesity,OTHER,0.02696256,0.026966314764682545,3.7547646825446257e-06
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Available for the 8 Week Visit,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Available for the 8 Week Visit,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Available for the 8 Week Visit,Overall Study,FG004,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Participant Developed a Rash,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Participant Developed a Rash,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
2.0,242.0,204.0,0.008264,0.008264,5.493061,0.395941,1.0,242.0,1.0,1.0,Participant Developed a Rash,Overall Study,FG002,obesity,OTHER,0.01797359,0.01797232638716278,1.2636128372198185e-06
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Participant Developed a Rash,Overall Study,FG003,obesity,OTHER,0.0089868,0.008979851625873054,6.9483741269461136e-06
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Participant Developed a Rash,Overall Study,FG004,obesity,OTHER,0.0089868,0.008980949555803613,5.850444196386223e-06
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Non-compliant with Medication,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Non-compliant with Medication,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Non-compliant with Medication,Overall Study,FG002,obesity,OTHER,0.0089868,0.00897380611797622,1.299388202377974e-05
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Non-compliant with Medication,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Non-compliant with Medication,Overall Study,FG004,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Adverse Event,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Adverse Event,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
3.0,242.0,204.0,0.012397,0.012397,5.493061,0.395941,1.0,242.0,1.0,1.0,Adverse Event,Overall Study,FG002,obesity,OTHER,0.02696256,0.026990464476408717,2.7904476408716766e-05
6.0,242.0,204.0,0.024793,0.024793,5.493061,0.395941,1.0,242.0,1.0,1.0,Adverse Event,Overall Study,FG003,obesity,OTHER,0.05392295,0.054457765309632956,0.0005348153096329591
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Adverse Event,Overall Study,FG004,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Compliant with Study Procedures,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Compliant with Study Procedures,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Compliant with Study Procedures,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
4.0,242.0,204.0,0.016529,0.016529,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Compliant with Study Procedures,Overall Study,FG003,obesity,OTHER,0.03594936,0.03635303687961307,0.00040367687961306853
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Not Compliant with Study Procedures,Overall Study,FG004,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Pregnancy,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Pregnancy,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Pregnancy,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Pregnancy,Overall Study,FG003,obesity,OTHER,0.0089868,0.008996009769206385,9.209769206385693e-06
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Pregnancy,Overall Study,FG004,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Started an Exclusionary Medication,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Started an Exclusionary Medication,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Started an Exclusionary Medication,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Started an Exclusionary Medication,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Started an Exclusionary Medication,Overall Study,FG004,obesity,OTHER,0.0089868,0.008980949555803613,5.850444196386223e-06
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Withdrew due to Health Condition,Overall Study,FG000,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Withdrew due to Health Condition,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Withdrew due to Health Condition,Overall Study,FG002,obesity,OTHER,0.0,0.0,0.0
0.0,242.0,204.0,0.0,0.0,5.493061,0.395941,1.0,242.0,1.0,1.0,Withdrew due to Health Condition,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
1.0,242.0,204.0,0.004132,0.004132,5.493061,0.395941,1.0,242.0,1.0,1.0,Withdrew due to Health Condition,Overall Study,FG004,obesity,OTHER,0.0089868,0.008980949555803613,5.850444196386223e-06
26.0,1502.0,1419.0,0.01731,0.01731,7.315218,0.262342,1.0,1502.0,1.0,43.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.03321943,0.03326737075073416,4.7940750734158655e-05
47.0,1502.0,1419.0,0.031292,0.031292,7.315218,0.262342,1.0,1502.0,1.0,43.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.06005213,0.059654872616636864,0.00039725738336313793
10.0,1502.0,1419.0,0.006658,0.006658,7.315218,0.262342,1.0,1502.0,1.0,43.0,Randomized but not treated,Overall Study,FG000,obesity,INDUSTRY,0.01277729,0.012660719546091263,0.00011657045390873685
0.0,1502.0,1419.0,0.0,0.0,7.315218,0.262342,1.0,1502.0,1.0,43.0,Randomized but not treated,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,obesity,OTHER,0.0108991,0.010885070817971066,1.4029182028934065e-05
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,obesity,OTHER,0.0108991,0.010911069832613904,1.1969832613903733e-05
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,obesity,OTHER,0.0108991,0.010898289795947253,8.102040527473153e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG004,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG005,obesity,OTHER,0.01634712,0.0163526796436078,5.559643607801201e-06
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG006,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG007,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG008,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG009,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG010,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG011,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG012,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG013,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG014,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG015,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG016,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG017,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG018,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG019,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG020,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG021,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG022,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG023,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
4.0,562.0,474.0,0.007117,0.007117,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG024,obesity,OTHER,0.02179514,0.021721452159951308,7.368784004869317e-05
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG025,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG026,obesity,OTHER,0.00544802,0.005448632450499342,6.124504993423527e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG027,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG028,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG029,obesity,OTHER,0.01634712,0.016352544845797283,5.424845797283306e-06
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG030,obesity,OTHER,0.0108991,0.010898961904280587,1.380957194135196e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Lost to Follow-up,Overall Study,FG031,obesity,OTHER,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,obesity,OTHER,0.0108991,0.010886310564276566,1.2789435723433926e-05
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,obesity,OTHER,0.0,0.0,0.0
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,obesity,OTHER,0.00544802,0.005448529737439657,5.097374396571819e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,obesity,OTHER,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG004,obesity,OTHER,0.0108991,0.010900189806836089,1.0898068360885166e-06
3.0,562.0,474.0,0.005338,0.005338,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG005,obesity,OTHER,0.01634712,0.01639444498319803,4.73249831980313e-05
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG006,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG007,obesity,OTHER,0.0,0.0,0.0
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG008,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG009,obesity,OTHER,0.0108991,0.010900189806836089,1.0898068360885166e-06
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG010,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG011,obesity,OTHER,0.0,0.0,0.0
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG012,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG013,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG014,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG015,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG016,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG017,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG018,obesity,OTHER,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG019,obesity,OTHER,0.0108991,0.010900189806836089,1.0898068360885166e-06
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG020,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG021,obesity,OTHER,0.0,0.0,0.0
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG022,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG023,obesity,OTHER,0.0,0.0,0.0
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG024,obesity,OTHER,0.0108991,0.010900189806836089,1.0898068360885166e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG025,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG026,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
2.0,562.0,474.0,0.003559,0.003559,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG027,obesity,OTHER,0.0108991,0.010900189806836089,1.0898068360885166e-06
1.0,562.0,474.0,0.001779,0.001779,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG028,obesity,OTHER,0.00544802,0.005447120818689656,8.991813103438606e-07
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG029,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG030,obesity,OTHER,0.0,0.0,0.0
0.0,562.0,474.0,0.0,0.0,6.33328,0.483542,1.0,562.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG031,obesity,OTHER,0.0,0.0,0.0
18.0,422.0,294.0,0.042654,0.042654,6.047372,0.262342,1.0,422.0,2.0,37.0,Adverse Event,Main Trial Period Through Week 56,FG000,obesity,INDUSTRY,0.0676697,0.06725146811691463,0.00041823188308537373
18.0,422.0,294.0,0.042654,0.042654,6.047372,0.262342,1.0,422.0,2.0,37.0,Adverse Event,Main Trial Period Through Week 56,FG001,obesity,INDUSTRY,0.0676697,0.0673319114520932,0.0003377885479067949
0.0,422.0,294.0,0.0,0.0,6.047372,0.262342,1.0,422.0,2.0,37.0,Lack of Efficacy,Main Trial Period Through Week 56,FG000,obesity,INDUSTRY,0.0,0.0,0.0
2.0,422.0,294.0,0.004739,0.004739,6.047372,0.262342,1.0,422.0,2.0,37.0,Lack of Efficacy,Main Trial Period Through Week 56,FG001,obesity,INDUSTRY,0.00751833,0.007556491658536257,3.816165853625687e-05
8.0,422.0,294.0,0.018957,0.018957,6.047372,0.262342,1.0,422.0,2.0,37.0,Protocol Violation,Main Trial Period Through Week 56,FG000,obesity,INDUSTRY,0.03007489,0.029997527629206357,7.736237079364328e-05
5.0,422.0,294.0,0.011848,0.011848,6.047372,0.262342,1.0,422.0,2.0,37.0,Protocol Violation,Main Trial Period Through Week 56,FG001,obesity,INDUSTRY,0.01879661,0.018623894742331337,0.00017271525766866108
17.0,422.0,294.0,0.040284,0.040284,6.047372,0.262342,1.0,422.0,2.0,37.0,Withdrawal by Subject,Main Trial Period Through Week 56,FG000,obesity,INDUSTRY,0.06390974,0.06358225382919641,0.0003274861708035953
24.0,422.0,294.0,0.056872,0.056872,6.047372,0.262342,1.0,422.0,2.0,37.0,Withdrawal by Subject,Main Trial Period Through Week 56,FG001,obesity,INDUSTRY,0.09022626,0.089522162994881,0.0007040970051190032
10.0,422.0,294.0,0.023697,0.023697,6.047372,0.262342,1.0,422.0,2.0,37.0,Unclassified,Main Trial Period Through Week 56,FG000,obesity,INDUSTRY,0.03759481,0.03713026862928297,0.00046454137071703233
15.0,422.0,294.0,0.035545,0.035545,6.047372,0.262342,1.0,422.0,2.0,37.0,Unclassified,Main Trial Period Through Week 56,FG001,obesity,INDUSTRY,0.05639142,0.05597557768545635,0.0004158423145436477
1.0,422.0,294.0,0.00237,0.00237,6.047372,0.262342,1.0,422.0,2.0,37.0,Protocol Violation,Follow up Period (Week 56-68),FG000,obesity,INDUSTRY,0.00375996,0.003815023908749997,5.5063908749996855e-05
1.0,422.0,294.0,0.00237,0.00237,6.047372,0.262342,1.0,422.0,2.0,37.0,Protocol Violation,Follow up Period (Week 56-68),FG001,obesity,INDUSTRY,0.00375996,0.0038165430989285706,5.658309892857044e-05
5.0,422.0,294.0,0.011848,0.011848,6.047372,0.262342,1.0,422.0,2.0,37.0,Unclassified,Follow up Period (Week 56-68),FG000,obesity,INDUSTRY,0.01879661,0.01861193546316467,0.00018467453683532892
4.0,422.0,294.0,0.009479,0.009479,6.047372,0.262342,1.0,422.0,2.0,37.0,Unclassified,Follow up Period (Week 56-68),FG001,obesity,INDUSTRY,0.01503824,0.014925840309196435,0.00011239969080356453
241.0,1496.0,805.0,0.161096,0.161096,7.311218,0.235372,1.0,1496.0,1.0,36.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.27722286,0.27703146122044625,0.00019139877955376416
68.0,1496.0,805.0,0.045455,0.045455,7.311218,0.235372,1.0,1496.0,1.0,36.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.07822146,0.07764415586752879,0.0005773041324712153
77.0,1496.0,805.0,0.051471,0.051471,7.311218,0.235372,1.0,1496.0,1.0,36.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.08857413,0.08790188472350202,0.0006722452764979792
48.0,1496.0,805.0,0.032086,0.032086,7.311218,0.235372,1.0,1496.0,1.0,36.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.05521535,0.055771658978363024,0.000556308978363021
75.0,1496.0,805.0,0.050134,0.050134,7.311218,0.235372,1.0,1496.0,1.0,36.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.08627334,0.08634830037434524,7.496037434523428e-05
56.0,1496.0,805.0,0.037433,0.037433,7.311218,0.235372,1.0,1496.0,1.0,36.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.06441677,0.06405183671008924,0.0003649332899107599
19.0,1496.0,805.0,0.012701,0.012701,7.311218,0.235372,1.0,1496.0,1.0,36.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.02185658,0.021821900561210302,3.4679438789698286e-05
33.0,1496.0,805.0,0.022059,0.022059,7.311218,0.235372,1.0,1496.0,1.0,36.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.03796034,0.03869496737217257,0.0007346273721725652
20.0,1496.0,805.0,0.013369,0.013369,7.311218,0.235372,1.0,1496.0,1.0,36.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.02300611,0.02313683065347221,0.0001307206534722112
8.0,1496.0,805.0,0.005348,0.005348,7.311218,0.235372,1.0,1496.0,1.0,36.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.00920313,0.009009000305942457,0.00019412969405754356
6.0,1496.0,805.0,0.004011,0.004011,7.311218,0.235372,1.0,1496.0,1.0,36.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00690235,0.006776761187708328,0.0001255888122916717
0.0,1496.0,805.0,0.0,0.0,7.311218,0.235372,1.0,1496.0,1.0,36.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
25.0,1496.0,805.0,0.016711,0.016711,7.311218,0.235372,1.0,1496.0,1.0,36.0,"Drug noncompliance,moved,other",Overall Study,FG000,obesity,INDUSTRY,0.02875721,0.029148646949464285,0.0003914369494642869
15.0,1496.0,805.0,0.010027,0.010027,7.311218,0.235372,1.0,1496.0,1.0,36.0,"Drug noncompliance,moved,other",Overall Study,FG001,obesity,INDUSTRY,0.01725501,0.017024842830634917,0.00023016716936508433
6.0,205.0,89.0,0.029268,0.029268,5.327876,0.910929,1.0,205.0,8.0,27.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.14204692,0.1464561996139977,0.004409279613997702
18.0,205.0,89.0,0.087805,0.087805,5.327876,0.910929,1.0,205.0,8.0,27.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.42614562,0.4366898157913095,0.010544195791309496
5.0,205.0,89.0,0.02439,0.02439,5.327876,0.910929,1.0,205.0,8.0,27.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.11837244,0.1266955863066469,0.008323146306646906
4.0,205.0,89.0,0.019512,0.019512,5.327876,0.910929,1.0,205.0,8.0,27.0,Non-Compliance with Study Drug,Overall Study,FG000,obesity,INDUSTRY,0.09469795,0.10806348392255959,0.013365533922559583
6.0,205.0,89.0,0.029268,0.029268,5.327876,0.910929,1.0,205.0,8.0,27.0,Physician Decision,Overall Study,FG000,obesity,INDUSTRY,0.14204692,0.14581740724962272,0.003770487249622728
1.0,205.0,89.0,0.004878,0.004878,5.327876,0.910929,1.0,205.0,8.0,27.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.02367449,0.023637283093571416,3.720690642858293e-05
40.0,205.0,89.0,0.195122,0.195122,5.327876,0.910929,1.0,205.0,8.0,27.0,Discontinued by Sponsor,Overall Study,FG000,obesity,INDUSTRY,0.94698919,0.9510837694282543,0.004094579428254308
6.0,205.0,89.0,0.029268,0.029268,5.327876,0.910929,1.0,205.0,8.0,27.0,Withdrawal by Parent/Guardian,Overall Study,FG000,obesity,INDUSTRY,0.14204692,0.14581740724962272,0.003770487249622728
24.0,205.0,89.0,0.117073,0.117073,5.327876,0.910929,1.0,205.0,8.0,27.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.56819254,0.5476186026677289,0.020573937332271086
6.0,205.0,89.0,0.029268,0.029268,5.327876,0.910929,1.0,205.0,8.0,27.0,Miscellaneous,Overall Study,FG000,obesity,INDUSTRY,0.14204692,0.14581740724962272,0.003770487249622728
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,obesity,OTHER,0.07345082,0.07348435466139289,3.353466139288663e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,obesity,OTHER,0.04896878,0.048948085701881874,2.0694298118129062e-05
2.0,384.0,253.0,0.005208,0.005208,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,obesity,OTHER,0.02448204,0.024475208827797613,6.831172202386576e-06
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,obesity,OTHER,0.03672306,0.03674983777712997,2.677777712997015e-05
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG004,obesity,OTHER,0.07345082,0.07340725629285129,4.356370714871105e-05
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG005,obesity,OTHER,0.07345082,0.07340725629285129,4.356370714871105e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG006,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG007,obesity,OTHER,0.07345082,0.07340725629285129,4.356370714871105e-05
1.0,384.0,253.0,0.002604,0.002604,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG008,obesity,OTHER,0.01224102,0.012249163171815463,8.143171815463285e-06
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG009,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG010,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
2.0,384.0,253.0,0.005208,0.005208,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG011,obesity,OTHER,0.02448204,0.024475208827797613,6.831172202386576e-06
5.0,384.0,253.0,0.013021,0.013021,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG012,obesity,OTHER,0.0612098,0.06113449046813499,7.530953186501294e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG013,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG014,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG015,obesity,OTHER,0.07345082,0.07340725629285129,4.356370714871105e-05
6.0,384.0,253.0,0.015625,0.015625,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG016,obesity,OTHER,0.07345082,0.07340725629285129,4.356370714871105e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG017,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG018,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG019,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
7.0,384.0,253.0,0.018229,0.018229,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG020,obesity,OTHER,0.08569184,0.08486371020924595,0.0008281297907540563
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG021,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG022,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
8.0,384.0,253.0,0.020833,0.020833,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG023,obesity,OTHER,0.09793286,0.09771472872437506,0.00021813127562493595
5.0,384.0,253.0,0.013021,0.013021,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG024,obesity,OTHER,0.0612098,0.06113449046813499,7.530953186501294e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG025,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG026,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG027,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
3.0,384.0,253.0,0.007812,0.007812,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG028,obesity,OTHER,0.03672306,0.036757798437963306,3.473843796330395e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG029,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG030,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
4.0,384.0,253.0,0.010417,0.010417,5.953243,0.789629,1.0,384.0,1.0,1.0,Lost to Follow-up,Overall Study,FG031,obesity,OTHER,0.04896878,0.048950197028738776,1.858297126122732e-05
0.0,207.0,192.0,0.0,0.0,5.337538,0.800386,1.0,207.0,5.0,43.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
2.0,207.0,192.0,0.009662,0.009662,5.337538,0.800386,1.0,207.0,5.0,43.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.04127692,0.04246237700136903,0.0011854570013690308
8.0,207.0,192.0,0.038647,0.038647,5.337538,0.800386,1.0,207.0,5.0,43.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.16510341,0.17402324448155748,0.008919834481557476
3.0,207.0,192.0,0.014493,0.014493,5.337538,0.800386,1.0,207.0,5.0,43.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.06191538,0.06313505020895842,0.001219670208958419
2.0,207.0,192.0,0.009662,0.009662,5.337538,0.800386,1.0,207.0,5.0,43.0,Death,Overall Study,FG000,obesity,INDUSTRY,0.04127692,0.042530814809464274,0.0012538948094642718
0.0,207.0,192.0,0.0,0.0,5.337538,0.800386,1.0,207.0,5.0,43.0,Death,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
2.0,469.0,389.0,0.004264,0.004264,6.152733,0.851138,1.0,469.0,10.0,58.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.02232983,0.02256661849289686,0.0002367884928968604
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.01116492,0.011188869102648817,2.394910264881707e-05
5.0,469.0,389.0,0.010661,0.010661,6.152733,0.851138,1.0,469.0,10.0,58.0,Adverse Event,Overall Study,FG003,obesity,INDUSTRY,0.05582982,0.05571773674192825,0.0001120832580717504
5.0,469.0,389.0,0.010661,0.010661,6.152733,0.851138,1.0,469.0,10.0,58.0,Assigned Treatment by Mistake,Overall Study,FG000,obesity,INDUSTRY,0.05582982,0.056335020775836984,0.0005052007758369823
10.0,469.0,389.0,0.021322,0.021322,6.152733,0.851138,1.0,469.0,10.0,58.0,Assigned Treatment by Mistake,Overall Study,FG001,obesity,INDUSTRY,0.11165963,0.1128061531558037,0.0011465231558036998
2.0,469.0,389.0,0.004264,0.004264,6.152733,0.851138,1.0,469.0,10.0,58.0,Assigned Treatment by Mistake,Overall Study,FG002,obesity,INDUSTRY,0.02232983,0.02252743965807543,0.00019760965807543232
5.0,469.0,389.0,0.010661,0.010661,6.152733,0.851138,1.0,469.0,10.0,58.0,Assigned Treatment by Mistake,Overall Study,FG003,obesity,INDUSTRY,0.05582982,0.055713685091511575,0.00011613490848842722
3.0,469.0,389.0,0.006397,0.006397,6.152733,0.851138,1.0,469.0,10.0,58.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.03349999,0.03274201442265873,0.000757975577341273
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Lost to Follow-up,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Patient could not travel to site,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Patient could not travel to site,Overall Study,FG001,obesity,INDUSTRY,0.01116492,0.011189295756934536,2.4375756934535975e-05
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Patient could not travel to site,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Patient could not travel to site,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Physician Decision,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Physician Decision,Overall Study,FG001,obesity,INDUSTRY,0.01116492,0.011196233422351203,3.131342235120245e-05
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Physician Decision,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Physician Decision,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.01116492,0.011189295756934536,2.4375756934535975e-05
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Pregnancy,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Pregnancy,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.01116492,0.011193094763482157,2.817476348215657e-05
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Protocol Violation,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Protocol Violation,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
4.0,469.0,389.0,0.008529,0.008529,6.152733,0.851138,1.0,469.0,10.0,58.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0446649,0.044716377216249964,5.147721624996354e-05
19.0,469.0,389.0,0.040512,0.040512,6.152733,0.851138,1.0,469.0,10.0,58.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.21215435,0.21555238305472238,0.003398033054722388
4.0,469.0,389.0,0.008529,0.008529,6.152733,0.851138,1.0,469.0,10.0,58.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.0446649,0.04480359380779759,0.000138693807797588
14.0,469.0,389.0,0.029851,0.029851,6.152733,0.851138,1.0,469.0,10.0,58.0,Withdrawal by Subject,Overall Study,FG003,obesity,INDUSTRY,0.15632454,0.15732111980143224,0.0009965798014322236
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Screen Failure,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Screen Failure,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,Screen Failure,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,Screen Failure,Overall Study,FG003,obesity,INDUSTRY,0.01116492,0.011191322621815486,2.6402621815486277e-05
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,The participant quit treatment and study due to their schedule and the final V801 was done remotely,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,The participant quit treatment and study due to their schedule and the final V801 was done remotely,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,469.0,389.0,0.0,0.0,6.152733,0.851138,1.0,469.0,10.0,58.0,The participant quit treatment and study due to their schedule and the final V801 was done remotely,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
1.0,469.0,389.0,0.002132,0.002132,6.152733,0.851138,1.0,469.0,10.0,58.0,The participant quit treatment and study due to their schedule and the final V801 was done remotely,Overall Study,FG003,obesity,INDUSTRY,0.01116492,0.011191322621815486,2.6402621815486277e-05
3.0,251.0,215.0,0.011952,0.011952,5.529429,0.569192,1.0,251.0,5.0,33.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.03761659,0.038077634717232155,0.00046104471723215634
6.0,251.0,215.0,0.023904,0.023904,5.529429,0.569192,1.0,251.0,5.0,33.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.07523317,0.07562294321366081,0.0003897732136608073
5.0,251.0,215.0,0.01992,0.01992,5.529429,0.569192,1.0,251.0,5.0,33.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.06269431,0.06364145072945449,0.000947140729454482
15.0,251.0,215.0,0.059761,0.059761,5.529429,0.569192,1.0,251.0,5.0,33.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.18808607,0.1873269341273212,0.0007591358726787845
2.0,251.0,215.0,0.007968,0.007968,5.529429,0.569192,1.0,251.0,5.0,33.0,Withdrawal by parent/guardian,Overall Study,FG000,obesity,INDUSTRY,0.02507772,0.025479693320138906,0.0004019733201389049
1.0,251.0,215.0,0.003984,0.003984,5.529429,0.569192,1.0,251.0,5.0,33.0,Withdrawal by parent/guardian,Overall Study,FG001,obesity,INDUSTRY,0.01253886,0.012590864857686696,5.200485768669556e-05
3.0,251.0,215.0,0.011952,0.011952,5.529429,0.569192,1.0,251.0,5.0,33.0,Other,Overall Study,FG000,obesity,INDUSTRY,0.03761659,0.038073586142232156,0.0004569961422321578
1.0,251.0,215.0,0.003984,0.003984,5.529429,0.569192,1.0,251.0,5.0,33.0,Other,Overall Study,FG001,obesity,INDUSTRY,0.01253886,0.012589599682686697,5.07396826866964e-05
26.0,611.0,505.0,0.042553,0.042553,6.416732,0.606003,1.0,611.0,1.0,41.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.1654699,0.16318702816209496,0.0022828718379050428
6.0,611.0,505.0,0.00982,0.00982,6.416732,0.606003,1.0,611.0,1.0,41.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.03818566,0.03823238545611722,4.6725456117217845e-05
0.0,611.0,505.0,0.0,0.0,6.416732,0.606003,1.0,611.0,1.0,41.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,611.0,505.0,0.001637,0.001637,6.416732,0.606003,1.0,611.0,1.0,41.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.00636557,0.006384001232251977,1.8431232251976508e-05
1.0,611.0,505.0,0.001637,0.001637,6.416732,0.606003,1.0,611.0,1.0,41.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00636557,0.006361508938918644,4.061061081355767e-06
2.0,611.0,505.0,0.003273,0.003273,6.416732,0.606003,1.0,611.0,1.0,41.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.01272726,0.012537781245029776,0.0001894787549702251
0.0,611.0,505.0,0.0,0.0,6.416732,0.606003,1.0,611.0,1.0,41.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,611.0,505.0,0.001637,0.001637,6.416732,0.606003,1.0,611.0,1.0,41.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.00636557,0.006383066407251976,1.7496407251975724e-05
1.0,611.0,505.0,0.001637,0.001637,6.416732,0.606003,1.0,611.0,1.0,41.0,At the discretion of the investigator,Overall Study,FG000,obesity,INDUSTRY,0.00636557,0.006361508938918644,4.061061081355767e-06
0.0,611.0,505.0,0.0,0.0,6.416732,0.606003,1.0,611.0,1.0,41.0,At the discretion of the investigator,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,611.0,505.0,0.001637,0.001637,6.416732,0.606003,1.0,611.0,1.0,41.0,Safety concern as judged by the investigator,Overall Study,FG000,obesity,INDUSTRY,0.00636557,0.006361508938918644,4.061061081355767e-06
2.0,611.0,505.0,0.003273,0.003273,6.416732,0.606003,1.0,611.0,1.0,41.0,Safety concern as judged by the investigator,Overall Study,FG001,obesity,INDUSTRY,0.01272726,0.012537781245029776,0.0001894787549702251
4.0,611.0,505.0,0.006547,0.006547,6.416732,0.606003,1.0,611.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0254584,0.025529653765416667,7.125376541666784e-05
3.0,611.0,505.0,0.00491,0.00491,6.416732,0.606003,1.0,611.0,1.0,41.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.01909283,0.018542278944107135,0.0005505510558928665
18.0,611.0,505.0,0.02946,0.02946,6.416732,0.606003,1.0,611.0,1.0,41.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.11455698,0.11343112325864085,0.0011258567413591491
7.0,611.0,505.0,0.011457,0.011457,6.416732,0.606003,1.0,611.0,1.0,41.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.04455123,0.044530484338551564,2.0745661448433317e-05
17.0,611.0,505.0,0.027823,0.027823,6.416732,0.606003,1.0,611.0,1.0,41.0,other,Overall Study,FG000,obesity,INDUSTRY,0.10819141,0.10565936046694455,0.0025320495330554554
16.0,611.0,505.0,0.026187,0.026187,6.416732,0.606003,1.0,611.0,1.0,41.0,other,Overall Study,FG001,obesity,INDUSTRY,0.10182972,0.10086415291479163,0.0009655670852083686
150.0,793.0,460.0,0.189155,0.189155,6.677083,0.22542,1.0,793.0,1.0,9.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.28470581,0.309961204811339,0.025255394811338983
25.0,793.0,460.0,0.031526,0.031526,6.677083,0.22542,1.0,793.0,1.0,9.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.04745122,0.04608908352839286,0.0013621364716071421
43.0,793.0,460.0,0.054224,0.054224,6.677083,0.22542,1.0,793.0,1.0,9.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.08161501,0.08288300151064483,0.001267991510644828
24.0,793.0,460.0,0.030265,0.030265,6.677083,0.22542,1.0,793.0,1.0,9.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.04555323,0.04441660746123015,0.001136622538769852
22.0,793.0,460.0,0.027743,0.027743,6.677083,0.22542,1.0,793.0,1.0,9.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.04175725,0.04161411208494049,0.00014313791505951579
17.0,793.0,460.0,0.021438,0.021438,6.677083,0.22542,1.0,793.0,1.0,9.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.03226731,0.03216102859250989,0.00010628140749011084
3.0,793.0,460.0,0.003783,0.003783,6.677083,0.22542,1.0,793.0,1.0,9.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.00569397,0.005736144452787695,4.2174452787695216e-05
6.0,793.0,460.0,0.007566,0.007566,6.677083,0.22542,1.0,793.0,1.0,9.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.01138793,0.011383068713462306,4.86128653769298e-06
4.0,793.0,460.0,0.005044,0.005044,6.677083,0.22542,1.0,793.0,1.0,9.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.00759195,0.007649147482390873,5.719748239087306e-05
0.0,793.0,460.0,0.0,0.0,6.677083,0.22542,1.0,793.0,1.0,9.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,793.0,460.0,0.001261,0.001261,6.677083,0.22542,1.0,793.0,1.0,9.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00189799,0.0019057742085317483,7.784208531748339e-06
1.0,793.0,460.0,0.001261,0.001261,6.677083,0.22542,1.0,793.0,1.0,9.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.00189799,0.0019038287409127014,5.838740912701397e-06
26.0,793.0,460.0,0.032787,0.032787,6.677083,0.22542,1.0,793.0,1.0,9.0,"Drug non-compliance, moved, other",Overall Study,FG000,obesity,INDUSTRY,0.04934921,0.048847906718958375,0.0005013032810416221
11.0,793.0,460.0,0.013871,0.013871,6.677083,0.22542,1.0,793.0,1.0,9.0,"Drug non-compliance, moved, other",Overall Study,FG001,obesity,INDUSTRY,0.02087787,0.020777574201091265,0.00010029579890873455
20.0,359.0,276.0,0.05571,0.05571,5.886104,0.334212,1.0,359.0,2.0,42.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.10959309,0.11013897207441994,0.00054588207441994
6.0,359.0,276.0,0.016713,0.016713,5.886104,0.334212,1.0,359.0,2.0,42.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.03287793,0.033216299177539675,0.0003383691775396755
2.0,359.0,276.0,0.005571,0.005571,5.886104,0.334212,1.0,359.0,2.0,42.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.01095931,0.011031303101636903,7.199310163690312e-05
1.0,359.0,276.0,0.002786,0.002786,5.886104,0.334212,1.0,359.0,2.0,42.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.00548064,0.005478556499583345,2.0835004166551083e-06
8.0,359.0,276.0,0.022284,0.022284,5.886104,0.334212,1.0,359.0,2.0,42.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.04383724,0.04323302754086221,0.0006042124591377901
5.0,359.0,276.0,0.013928,0.013928,5.886104,0.334212,1.0,359.0,2.0,42.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.02739926,0.02760368245785708,0.00020442245785707788
12.0,359.0,276.0,0.033426,0.033426,5.886104,0.334212,1.0,359.0,2.0,42.0,Withdrawn consent,Overall Study,FG000,obesity,INDUSTRY,0.06575586,0.06698641953580363,0.0012305595358036298
20.0,359.0,276.0,0.05571,0.05571,5.886104,0.334212,1.0,359.0,2.0,42.0,Withdrawn consent,Overall Study,FG001,obesity,INDUSTRY,0.10959309,0.10974553445356677,0.00015244445356676906
1.0,359.0,276.0,0.002786,0.002786,5.886104,0.334212,1.0,359.0,2.0,42.0,Target dose not tolerated,Overall Study,FG000,obesity,INDUSTRY,0.00548064,0.00548322743264882,2.5874326488196236e-06
0.0,359.0,276.0,0.0,0.0,5.886104,0.334212,1.0,359.0,2.0,42.0,Target dose not tolerated,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,359.0,276.0,0.002786,0.002786,5.886104,0.334212,1.0,359.0,2.0,42.0,Psychiatric disorder,Overall Study,FG000,obesity,INDUSTRY,0.00548064,0.00548322743264882,2.5874326488196236e-06
0.0,359.0,276.0,0.0,0.0,5.886104,0.334212,1.0,359.0,2.0,42.0,Psychiatric disorder,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
2.0,359.0,276.0,0.005571,0.005571,5.886104,0.334212,1.0,359.0,2.0,42.0,Unclassified,Overall Study,FG000,obesity,INDUSTRY,0.01095931,0.011037029228720236,7.771922872023586e-05
5.0,359.0,276.0,0.013928,0.013928,5.886104,0.334212,1.0,359.0,2.0,42.0,Unclassified,Overall Study,FG001,obesity,INDUSTRY,0.02739926,0.027580482598690413,0.00018122259869041146
86.0,3731.0,1110.0,0.02305,0.02305,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG000,obesity,INDUSTRY,0.0734581,0.07153351653119049,0.0019245834688095126
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG002,obesity,INDUSTRY,0.0,0.0,0.0
16.0,3731.0,1110.0,0.004288,0.004288,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG003,obesity,INDUSTRY,0.01366544,0.013590191527301598,7.524847269840124e-05
152.0,3731.0,1110.0,0.04074,0.04074,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG004,obesity,INDUSTRY,0.1298344,0.12833164349876,0.001502756501239988
29.0,3731.0,1110.0,0.007773,0.007773,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main Period: Week 0 to Week 56,FG005,obesity,INDUSTRY,0.02477179,0.024914499141041664,0.00014270914104166574
11.0,3731.0,1110.0,0.002948,0.002948,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG000,obesity,INDUSTRY,0.00939499,0.009419846910992059,2.4856910992058015e-05
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG002,obesity,INDUSTRY,0.0,0.0,0.0
14.0,3731.0,1110.0,0.003752,0.003752,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG003,obesity,INDUSTRY,0.01195726,0.01205818078801587,0.0001009207880158687
12.0,3731.0,1110.0,0.003216,0.003216,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG004,obesity,INDUSTRY,0.01024908,0.010006195857529765,0.00024288414247023576
22.0,3731.0,1110.0,0.005897,0.005897,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main Period: Week 0 to Week 56,FG005,obesity,INDUSTRY,0.01879316,0.018335422036547623,0.00045773796345237663
25.0,3731.0,1110.0,0.006701,0.006701,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG000,obesity,INDUSTRY,0.02135543,0.019481186158988098,0.0018742438410119036
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG002,obesity,INDUSTRY,0.0,0.0,0.0
18.0,3731.0,1110.0,0.004824,0.004824,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG003,obesity,INDUSTRY,0.01537362,0.015030336228581343,0.00034328377141865617
40.0,3731.0,1110.0,0.010721,0.010721,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG004,obesity,INDUSTRY,0.03416678,0.03405260109732143,0.00011417890267857028
20.0,3731.0,1110.0,0.00536,0.00536,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main Period: Week 0 to Week 56,FG005,obesity,INDUSTRY,0.0170818,0.01694983882749999,0.0001319611725000107
122.0,3731.0,1110.0,0.032699,0.032699,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG000,obesity,INDUSTRY,0.10420852,0.10725788618633926,0.0030493661863392613
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG002,obesity,INDUSTRY,0.0,0.0,0.0
114.0,3731.0,1110.0,0.030555,0.030555,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG003,obesity,INDUSTRY,0.0973758,0.09881693743146819,0.0014411374314681896
172.0,3731.0,1110.0,0.0461,0.0461,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG004,obesity,INDUSTRY,0.14691619,0.14654123832147817,0.0003749516785218343
147.0,3731.0,1110.0,0.0394,0.0394,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main Period: Week 0 to Week 56,FG005,obesity,INDUSTRY,0.12556395,0.1242548907933235,0.0013090592066765105
36.0,3731.0,1110.0,0.009649,0.009649,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG000,obesity,INDUSTRY,0.03075042,0.030373798323859173,0.00037662167614082795
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG002,obesity,INDUSTRY,0.0,0.0,0.0
29.0,3731.0,1110.0,0.007773,0.007773,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG003,obesity,INDUSTRY,0.02477179,0.024871630762291663,9.984076229166416e-05
42.0,3731.0,1110.0,0.011257,0.011257,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG004,obesity,INDUSTRY,0.03587496,0.03516843906304562,0.0007065209369543773
34.0,3731.0,1110.0,0.009113,0.009113,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main Period: Week 0 to Week 56,FG005,obesity,INDUSTRY,0.02904224,0.028013175758750015,0.001029064241249985
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG001,obesity,INDUSTRY,0.00085409,0.0008611110070238053,7.021007023805324e-06
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG002,obesity,INDUSTRY,0.00085409,0.0008631543894047574,9.064389404757497e-06
2.0,3731.0,1110.0,0.000536,0.000536,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG003,obesity,INDUSTRY,0.00170818,0.001711092861934525,2.9128619345251527e-06
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Re-randomised Period: Week 56 to Week 68,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG002,obesity,INDUSTRY,0.0,0.0,0.0
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG003,obesity,INDUSTRY,0.00085409,0.0008668249756547575,1.2734975654757536e-05
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Re-randomised Period: Week 56 to Week 68,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG001,obesity,INDUSTRY,0.00085409,0.0008635529707738052,9.462970773805213e-06
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG002,obesity,INDUSTRY,0.0,0.0,0.0
3.0,3731.0,1110.0,0.000804,0.000804,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG003,obesity,INDUSTRY,0.00256227,0.002460089401557539,0.00010218059844246128
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Re-randomised Period: Week 56 to Week 68,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG000,obesity,INDUSTRY,0.0,0.0,0.0
6.0,3731.0,1110.0,0.001608,0.001608,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG001,obesity,INDUSTRY,0.00512454,0.0050135339289682605,0.00011100607103173982
4.0,3731.0,1110.0,0.001072,0.001072,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG002,obesity,INDUSTRY,0.00341636,0.0034213276963095257,4.967696309525916e-06
7.0,3731.0,1110.0,0.001876,0.001876,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG003,obesity,INDUSTRY,0.00597863,0.006005347637291674,2.6717637291673313e-05
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Re-randomised Period: Week 56 to Week 68,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG001,obesity,INDUSTRY,0.00085409,0.0008650041020238053,1.0914102023805309e-05
2.0,3731.0,1110.0,0.000536,0.000536,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG002,obesity,INDUSTRY,0.00170818,0.0017104607265178587,2.280726517858798e-06
2.0,3731.0,1110.0,0.000536,0.000536,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG003,obesity,INDUSTRY,0.00170818,0.0017109540619345254,2.774061934525526e-06
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Re-randomised Period: Week 56 to Week 68,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
191.0,3731.0,1110.0,0.051193,0.051193,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.16314709,0.1593992831234525,0.0037478068765474937
43.0,3731.0,1110.0,0.011525,0.011525,8.2247,0.387479,1.0,3731.0,29.0,226.0,Adverse Event,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.03672905,0.03584334644764878,0.0008857035523512219
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
29.0,3731.0,1110.0,0.007773,0.007773,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.02477179,0.024881525356041666,0.00010973535604166806
36.0,3731.0,1110.0,0.009649,0.009649,8.2247,0.387479,1.0,3731.0,29.0,226.0,Lack of Efficacy,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.03075042,0.030495291412073477,0.00025512858792652374
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
76.0,3731.0,1110.0,0.02037,0.02037,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.0649172,0.06558338073883933,0.0006661807388393393
36.0,3731.0,1110.0,0.009649,0.009649,8.2247,0.387479,1.0,3731.0,29.0,226.0,Protocol Violation,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.03075042,0.03050762317596236,0.0002427968240376402
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
364.0,3731.0,1110.0,0.097561,0.097561,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.31091737,0.31123436286851225,0.0003169928685122225
256.0,3731.0,1110.0,0.068614,0.068614,8.2247,0.387479,1.0,3731.0,29.0,226.0,Withdrawal criteria,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.21866611,0.21627526186011914,0.002390848139880858
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
1.0,3731.0,1110.0,0.000268,0.000268,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.00085409,0.000890775084841266,3.668508484126602e-05
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Missing reason,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG001,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG002,obesity,INDUSTRY,0.0,0.0,0.0
0.0,3731.0,1110.0,0.0,0.0,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG003,obesity,INDUSTRY,0.0,0.0,0.0
61.0,3731.0,1110.0,0.01635,0.01635,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG004,obesity,INDUSTRY,0.05210585,0.05145231146382939,0.00065353853617061
51.0,3731.0,1110.0,0.013669,0.013669,8.2247,0.387479,1.0,3731.0,29.0,226.0,Unclassified,Main + Extension Period: Week 0-172,FG005,obesity,INDUSTRY,0.04356177,0.044181274117132956,0.000619504117132956
6.0,676.0,574.0,0.008876,0.008876,6.517671,0.258509,1.0,676.0,0.0,0.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.01495498,0.01481406450398811,0.00014091549601188968
4.0,676.0,574.0,0.005917,0.005917,6.517671,0.258509,1.0,676.0,0.0,0.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.00996942,0.009944691869732144,2.4728130267855433e-05
7.0,676.0,574.0,0.010355,0.010355,6.517671,0.258509,1.0,676.0,0.0,0.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.01744691,0.017361614125297617,8.529587470238256e-05
5.0,676.0,574.0,0.007396,0.007396,6.517671,0.258509,1.0,676.0,0.0,0.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.01246136,0.012340474782420627,0.00012088521757937232
4.0,676.0,574.0,0.005917,0.005917,6.517671,0.258509,1.0,676.0,0.0,0.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.00996942,0.009933309430565475,3.6110569434524495e-05
21.0,676.0,574.0,0.031065,0.031065,6.517671,0.258509,1.0,676.0,0.0,0.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.05234074,0.05235262368997019,1.1883689970196287e-05
9.0,676.0,574.0,0.013314,0.013314,6.517671,0.258509,1.0,676.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.02243247,0.02165398956660533,0.0007784804333946689
11.0,676.0,574.0,0.016272,0.016272,6.517671,0.258509,1.0,676.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.02741634,0.02676761138689662,0.0006487286131033818
12.0,676.0,574.0,0.017751,0.017751,6.517671,0.258509,1.0,676.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.02990827,0.029610710302648783,0.00029755969735121776
2.0,676.0,574.0,0.002959,0.002959,6.517671,0.258509,1.0,676.0,0.0,0.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.00498555,0.004983655509556282,1.8944904437183038e-06
1.0,676.0,574.0,0.001479,0.001479,6.517671,0.258509,1.0,676.0,0.0,0.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.00249193,0.00249248228708334,5.522870833401909e-07
0.0,676.0,574.0,0.0,0.0,6.517671,0.258509,1.0,676.0,0.0,0.0,Lack of Efficacy,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
3.0,676.0,574.0,0.004438,0.004438,6.517671,0.258509,1.0,676.0,0.0,0.0,non compliance,Overall Study,FG000,obesity,INDUSTRY,0.00747749,0.007464241463095244,1.3248536904755456e-05
1.0,676.0,574.0,0.001479,0.001479,6.517671,0.258509,1.0,676.0,0.0,0.0,non compliance,Overall Study,FG001,obesity,INDUSTRY,0.00249193,0.002493091714166675,1.1617141666749736e-06
1.0,676.0,574.0,0.001479,0.001479,6.517671,0.258509,1.0,676.0,0.0,0.0,non compliance,Overall Study,FG002,obesity,INDUSTRY,0.00249193,0.002492649369047627,7.193690476272468e-07
1.0,676.0,574.0,0.001479,0.001479,6.517671,0.258509,1.0,676.0,0.0,0.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00249193,0.002493993804464293,2.0638044642929884e-06
0.0,676.0,574.0,0.0,0.0,6.517671,0.258509,1.0,676.0,0.0,0.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,676.0,574.0,0.001479,0.001479,6.517671,0.258509,1.0,676.0,0.0,0.0,Pregnancy,Overall Study,FG002,obesity,INDUSTRY,0.00249193,0.0024926137740476266,6.837740476267964e-07
2.0,676.0,574.0,0.002959,0.002959,6.517671,0.258509,1.0,676.0,0.0,0.0,Requirement for restricted medication,Overall Study,FG000,obesity,INDUSTRY,0.00498555,0.004983628698722948,1.9213012770521315e-06
0.0,676.0,574.0,0.0,0.0,6.517671,0.258509,1.0,676.0,0.0,0.0,Requirement for restricted medication,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
2.0,676.0,574.0,0.002959,0.002959,6.517671,0.258509,1.0,676.0,0.0,0.0,Requirement for restricted medication,Overall Study,FG002,obesity,INDUSTRY,0.00498555,0.004981320306758662,4.2296932413381574e-06
2.0,676.0,574.0,0.002959,0.002959,6.517671,0.258509,1.0,676.0,0.0,0.0,other,Overall Study,FG000,obesity,INDUSTRY,0.00498555,0.004983252098722948,2.2979012770521848e-06
4.0,676.0,574.0,0.005917,0.005917,6.517671,0.258509,1.0,676.0,0.0,0.0,other,Overall Study,FG001,obesity,INDUSTRY,0.00996942,0.009934875574315473,3.454442568452676e-05
3.0,676.0,574.0,0.004438,0.004438,6.517671,0.258509,1.0,676.0,0.0,0.0,other,Overall Study,FG002,obesity,INDUSTRY,0.00747749,0.007460483007053583,1.7006992946416895e-05
2.0,401.0,395.0,0.004988,0.004988,5.996452,0.636373,1.0,401.0,2.0,28.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.01903412,0.018745394366282486,0.00028872563371751606
4.0,401.0,395.0,0.009975,0.009975,5.996452,0.636373,1.0,401.0,2.0,28.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.03806442,0.03762864969348214,0.0004357703065178617
0.0,401.0,395.0,0.0,0.0,5.996452,0.636373,1.0,401.0,2.0,28.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
122.0,1742.0,870.0,0.070034,0.070034,7.463363,0.233646,1.0,1742.0,1.0,34.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.12212432,0.12132319748297621,0.0008011225170237862
112.0,1742.0,870.0,0.064294,0.064294,7.463363,0.233646,1.0,1742.0,1.0,34.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.11211499,0.11121472893573413,0.0009002610642658698
56.0,1742.0,870.0,0.032147,0.032147,7.463363,0.233646,1.0,1742.0,1.0,34.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.05605749,0.056798494200665524,0.0007410042006655224
76.0,1742.0,870.0,0.043628,0.043628,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.0760779,0.07572878336974202,0.00034911663025798123
65.0,1742.0,870.0,0.037313,0.037313,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.06506589,0.0647863362644525,0.00027955373554749974
66.0,1742.0,870.0,0.037887,0.037887,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.06606683,0.06526393061027778,0.0008028993897222086
63.0,1742.0,870.0,0.036165,0.036165,7.463363,0.233646,1.0,1742.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.06306403,0.06333469490315471,0.00027066490315472147
60.0,1742.0,870.0,0.034443,0.034443,7.463363,0.233646,1.0,1742.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.06006123,0.05935716367394923,0.0007040663260507729
90.0,1742.0,870.0,0.051665,0.051665,7.463363,0.233646,1.0,1742.0,1.0,34.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.09009271,0.08900644264146744,0.0010862673585325666
12.0,1742.0,870.0,0.006889,0.006889,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lack of Efficacy,Overall Study,FG000,obesity,INDUSTRY,0.01201294,0.011670236251994053,0.00034270374800594687
12.0,1742.0,870.0,0.006889,0.006889,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lack of Efficacy,Overall Study,FG001,obesity,INDUSTRY,0.01201294,0.011665697816994051,0.0003472421830059483
40.0,1742.0,870.0,0.022962,0.022962,7.463363,0.233646,1.0,1742.0,1.0,34.0,Lack of Efficacy,Overall Study,FG002,obesity,INDUSTRY,0.04004082,0.03981386576039681,0.00022695423960318595
5.0,1742.0,870.0,0.00287,0.00287,7.463363,0.233646,1.0,1742.0,1.0,34.0,Protocol Violation,Overall Study,FG000,obesity,INDUSTRY,0.00500467,0.00499553182074404,9.13817925596045e-06
9.0,1742.0,870.0,0.005166,0.005166,7.463363,0.233646,1.0,1742.0,1.0,34.0,Protocol Violation,Overall Study,FG001,obesity,INDUSTRY,0.0090084,0.008871900134097225,0.00013649986590277483
7.0,1742.0,870.0,0.004018,0.004018,7.463363,0.233646,1.0,1742.0,1.0,34.0,Protocol Violation,Overall Study,FG002,obesity,INDUSTRY,0.00700653,0.006930271255654763,7.625874434523741e-05
2.0,1742.0,870.0,0.001148,0.001148,7.463363,0.233646,1.0,1742.0,1.0,34.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00200187,0.001954714665945168,4.715533405483209e-05
5.0,1742.0,870.0,0.00287,0.00287,7.463363,0.233646,1.0,1742.0,1.0,34.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.00500467,0.0049942496078273745,1.0420392172625671e-05
3.0,1742.0,870.0,0.001722,0.001722,7.463363,0.233646,1.0,1742.0,1.0,34.0,Pregnancy,Overall Study,FG002,obesity,INDUSTRY,0.0030028,0.0028985765590872977,0.00010422344091270226
0.0,1742.0,870.0,0.0,0.0,7.463363,0.233646,1.0,1742.0,1.0,34.0,Death,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,1742.0,870.0,0.000574,0.000574,7.463363,0.233646,1.0,1742.0,1.0,34.0,Death,Overall Study,FG001,obesity,INDUSTRY,0.00100093,0.001044110791855158,4.3180791855158135e-05
0.0,1742.0,870.0,0.0,0.0,7.463363,0.233646,1.0,1742.0,1.0,34.0,Death,Overall Study,FG002,obesity,INDUSTRY,0.0,0.0,0.0
14.0,1742.0,870.0,0.008037,0.008037,7.463363,0.233646,1.0,1742.0,1.0,34.0,"Drug noncompliance, moved, other",Overall Study,FG000,obesity,INDUSTRY,0.01401481,0.014124470938908727,0.00010966093890872608
23.0,1742.0,870.0,0.013203,0.013203,7.463363,0.233646,1.0,1742.0,1.0,34.0,"Drug noncompliance, moved, other",Overall Study,FG001,obesity,INDUSTRY,0.02302321,0.02325895609992064,0.0002357460999206397
29.0,1742.0,870.0,0.016648,0.016648,7.463363,0.233646,1.0,1742.0,1.0,34.0,"Drug noncompliance, moved, other",Overall Study,FG002,obesity,INDUSTRY,0.02903055,0.02946629278226192,0.0004357427822619213
7.0,407.0,368.0,0.017199,0.017199,6.011267,0.811096,1.0,407.0,11.0,122.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.08385745,0.08351192028311502,0.00034552971688497913
8.0,407.0,368.0,0.019656,0.019656,6.011267,0.811096,1.0,407.0,11.0,122.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.09583709,0.09471807548368069,0.0011190145163193083
7.0,407.0,368.0,0.017199,0.017199,6.011267,0.811096,1.0,407.0,11.0,122.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.08385745,0.08336659200703371,0.0004908579929662898
2.0,407.0,368.0,0.004914,0.004914,6.011267,0.811096,1.0,407.0,11.0,122.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.02395927,0.02368519090479166,0.0002740790952083412
2.0,407.0,368.0,0.004914,0.004914,6.011267,0.811096,1.0,407.0,11.0,122.0,Physician Decision,Overall Study,FG000,obesity,INDUSTRY,0.02395927,0.023661857617619044,0.00029741238238095713
1.0,407.0,368.0,0.002457,0.002457,6.011267,0.811096,1.0,407.0,11.0,122.0,Physician Decision,Overall Study,FG001,obesity,INDUSTRY,0.01197964,0.012138664741755918,0.00015902474175591777
2.0,407.0,368.0,0.004914,0.004914,6.011267,0.811096,1.0,407.0,11.0,122.0,Failing to Meet Randomization Requirements,Overall Study,FG000,obesity,INDUSTRY,0.02395927,0.02364905397267857,0.0003102160273214319
1.0,407.0,368.0,0.002457,0.002457,6.011267,0.811096,1.0,407.0,11.0,122.0,Failing to Meet Randomization Requirements,Overall Study,FG001,obesity,INDUSTRY,0.01197964,0.012139693381755922,0.0001600533817559223
7.0,407.0,368.0,0.017199,0.017199,6.011267,0.811096,1.0,407.0,11.0,122.0,Site Closure,Overall Study,FG000,obesity,INDUSTRY,0.08385745,0.08353710438701384,0.0003203456129861615
2.0,407.0,368.0,0.004914,0.004914,6.011267,0.811096,1.0,407.0,11.0,122.0,Site Closure,Overall Study,FG001,obesity,INDUSTRY,0.02395927,0.023642986032470236,0.0003162839675297652
1.0,201.0,196.0,0.004975,0.004975,5.308268,0.71538,1.0,201.0,8.0,51.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0188922,0.019029565571805535,0.00013736557180553388
2.0,201.0,196.0,0.00995,0.00995,5.308268,0.71538,1.0,201.0,8.0,51.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.03778439,0.039137106669523795,0.0013527166695237944
0.0,201.0,196.0,0.0,0.0,5.308268,0.71538,1.0,201.0,8.0,51.0,Withdrawal by parent/guardian,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,201.0,196.0,0.004975,0.004975,5.308268,0.71538,1.0,201.0,8.0,51.0,Withdrawal by parent/guardian,Overall Study,FG001,obesity,INDUSTRY,0.0188922,0.019024949681150774,0.00013274968115077265
1.0,201.0,196.0,0.004975,0.004975,5.308268,0.71538,1.0,201.0,8.0,51.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.0188922,0.019055366507222202,0.00016316650722220105
0.0,201.0,196.0,0.0,0.0,5.308268,0.71538,1.0,201.0,8.0,51.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
6.0,751.0,638.0,0.007989,0.007989,6.622736,0.898687,1.0,751.0,2.0,32.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.04754866,0.04816919023974215,0.0006205302397421508
6.0,751.0,638.0,0.007989,0.007989,6.622736,0.898687,1.0,751.0,2.0,32.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.04754866,0.048048093432242124,0.0004994334322421246
5.0,751.0,638.0,0.006658,0.006658,6.622736,0.898687,1.0,751.0,2.0,32.0,Assigned Treatment by Mistake,Overall Study,FG000,obesity,INDUSTRY,0.03962686,0.03767095274907735,0.0019559072509226505
3.0,751.0,638.0,0.003995,0.003995,6.622736,0.898687,1.0,751.0,2.0,32.0,Assigned Treatment by Mistake,Overall Study,FG001,obesity,INDUSTRY,0.02377731,0.023019616972341245,0.000757693027658754
16.0,751.0,638.0,0.021305,0.021305,6.622736,0.898687,1.0,751.0,2.0,32.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.12680238,0.13106126374268842,0.00425888374268843
18.0,751.0,638.0,0.023968,0.023968,6.622736,0.898687,1.0,751.0,2.0,32.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.14265193,0.14255095688457342,0.00010097311542658916
1.0,751.0,638.0,0.001332,0.001332,6.622736,0.898687,1.0,751.0,2.0,32.0,Non-Compliance With Study Drug,Overall Study,FG000,obesity,INDUSTRY,0.00792775,0.007923430006279715,4.31999372028577e-06
1.0,751.0,638.0,0.001332,0.001332,6.622736,0.898687,1.0,751.0,2.0,32.0,Non-Compliance With Study Drug,Overall Study,FG001,obesity,INDUSTRY,0.00792775,0.007925940084672577,1.809915327423417e-06
0.0,751.0,638.0,0.0,0.0,6.622736,0.898687,1.0,751.0,2.0,32.0,Participant was Out of the Country,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
1.0,751.0,638.0,0.001332,0.001332,6.622736,0.898687,1.0,751.0,2.0,32.0,Participant was Out of the Country,Overall Study,FG001,obesity,INDUSTRY,0.00792775,0.007926291901755917,1.4580982440840634e-06
1.0,751.0,638.0,0.001332,0.001332,6.622736,0.898687,1.0,751.0,2.0,32.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00792775,0.007923781823363056,3.968176636944681e-06
2.0,751.0,638.0,0.002663,0.002663,6.622736,0.898687,1.0,751.0,2.0,32.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.01584955,0.015558413081924592,0.00029113691807540823
27.0,751.0,638.0,0.035952,0.035952,6.622736,0.898687,1.0,751.0,2.0,32.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.21397789,0.21134849950688483,0.002629390493115169
26.0,751.0,638.0,0.034621,0.034621,6.622736,0.898687,1.0,751.0,2.0,32.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.20605609,0.205293996774732,0.0007620932252679902
9.0,902.0,741.0,0.009978,0.009978,6.805723,0.600419,1.0,902.0,10.0,72.0,Other,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.04077294,0.04137212101174601,0.0005991810117460111
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Other,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
8.0,902.0,741.0,0.008869,0.008869,6.805723,0.600419,1.0,902.0,10.0,72.0,Lost to Follow-up,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.03624125,0.03727353424921628,0.001032284249216274
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Lost to Follow-up,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
11.0,902.0,741.0,0.012195,0.012195,6.805723,0.600419,1.0,902.0,10.0,72.0,Withdrawal by Subject,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.04983223,0.050383680632896895,0.0005514506328968966
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Withdrawal by Subject,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
2.0,902.0,741.0,0.002217,0.002217,6.805723,0.600419,1.0,902.0,10.0,72.0,Safety concern as judged by investigator,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.00905929,0.008997095963601208,6.219403639879176e-05
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Safety concern as judged by investigator,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
19.0,902.0,741.0,0.021064,0.021064,6.805723,0.600419,1.0,902.0,10.0,72.0,Run-in failure,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.08607348,0.08665437894615076,0.0005808989461507652
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Run-in failure,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Pregnancy,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.00453169,0.004536476016517869,4.786016517869217e-06
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Pregnancy,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Protocol Violation,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.00453169,0.004533591221279775,1.9012212797752184e-06
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Protocol Violation,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
48.0,902.0,741.0,0.053215,0.053215,6.805723,0.600419,1.0,902.0,10.0,72.0,Adverse Event,Run-in Period (Week 0 to Week 20),FG000,obesity,INDUSTRY,0.2174516,0.20063217046022003,0.016819429539779968
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Adverse Event,Run-in Period (Week 0 to Week 20),FG001,obesity,INDUSTRY,0.0,0.0,0.0
12.0,902.0,741.0,0.013304,0.013304,6.805723,0.600419,1.0,902.0,10.0,72.0,other,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.05436392,0.054777712760248065,0.00041379276024806205
23.0,902.0,741.0,0.025499,0.025499,6.805723,0.600419,1.0,902.0,10.0,72.0,other,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.10419615,0.10442766077926123,0.0002315107792612292
2.0,902.0,741.0,0.002217,0.002217,6.805723,0.600419,1.0,902.0,10.0,72.0,Lost to Follow-up,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.00905929,0.008983348675337326,7.594132466267299e-05
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Lost to Follow-up,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.00453169,0.004534211612886922,2.5216128869218896e-06
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Withdrawal by Subject,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.00453169,0.004540349081577402,8.659081577402222e-06
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Withdrawal by Subject,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.00453169,0.00453891937342264,7.2293734226401216e-06
2.0,902.0,741.0,0.002217,0.002217,6.805723,0.600419,1.0,902.0,10.0,72.0,Pregnancy,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.00905929,0.008996823409712328,6.246659028767178e-05
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Pregnancy,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,902.0,741.0,0.001109,0.001109,6.805723,0.600419,1.0,902.0,10.0,72.0,Protocol Violation,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.00453169,0.004534276102470257,2.5861024702577076e-06
0.0,902.0,741.0,0.0,0.0,6.805723,0.600419,1.0,902.0,10.0,72.0,Protocol Violation,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.0,0.0,0.0
13.0,902.0,741.0,0.014412,0.014412,6.805723,0.600419,1.0,902.0,10.0,72.0,Adverse Event,Maintenance Period (Week 20 to Week 68),FG000,obesity,INDUSTRY,0.05889152,0.057562387219146804,0.0013291327808531983
6.0,902.0,741.0,0.006652,0.006652,6.805723,0.600419,1.0,902.0,10.0,72.0,Adverse Event,Maintenance Period (Week 20 to Week 68),FG001,obesity,INDUSTRY,0.02718196,0.027154461587172638,2.7498412827363372e-05
14.0,756.0,541.0,0.018519,0.018519,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG000,obesity,INDUSTRY,0.02708318,0.026914676462619035,0.00016850353738096305
14.0,756.0,541.0,0.018519,0.018519,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG001,obesity,INDUSTRY,0.02708318,0.0269262673436607,0.00015691265633929752
12.0,756.0,541.0,0.015873,0.015873,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG002,obesity,INDUSTRY,0.02321353,0.023265786598065493,5.225659806549349e-05
6.0,756.0,541.0,0.007937,0.007937,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG003,obesity,INDUSTRY,0.01160749,0.011611684432559522,4.1944325595219545e-06
9.0,756.0,541.0,0.011905,0.011905,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG004,obesity,INDUSTRY,0.01741051,0.017416193718432598,5.683718432597518e-06
8.0,756.0,541.0,0.010582,0.010582,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG005,obesity,INDUSTRY,0.01547568,0.015564312321269853,8.863232126985268e-05
9.0,756.0,541.0,0.011905,0.011905,6.629363,0.220602,1.0,756.0,1.0,2.0,Lost to Follow-up,Overall Study,FG006,obesity,INDUSTRY,0.01741051,0.017416193718432598,5.683718432597518e-06
3.0,756.0,541.0,0.003968,0.003968,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG000,obesity,INDUSTRY,0.00580302,0.005791907799295649,1.1112200704350463e-05
4.0,756.0,541.0,0.005291,0.005291,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG001,obesity,INDUSTRY,0.00773784,0.007759702046626975,2.1862046626974947e-05
5.0,756.0,541.0,0.006614,0.006614,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG002,obesity,INDUSTRY,0.00967267,0.00964411566894843,2.8554331051569917e-05
9.0,756.0,541.0,0.011905,0.011905,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG003,obesity,INDUSTRY,0.01741051,0.01740129385753973,9.216142460272136e-06
6.0,756.0,541.0,0.007937,0.007937,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG004,obesity,INDUSTRY,0.01160749,0.011606246849523811,1.2431504761885315e-06
10.0,756.0,541.0,0.013228,0.013228,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG005,obesity,INDUSTRY,0.01934534,0.019281988466041663,6.335153395833557e-05
17.0,756.0,541.0,0.022487,0.022487,6.629363,0.220602,1.0,756.0,1.0,2.0,Adverse Event,Overall Study,FG006,obesity,INDUSTRY,0.03288619,0.03245309133502517,0.00043309866497483196
11.0,756.0,541.0,0.01455,0.01455,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG000,obesity,INDUSTRY,0.0212787,0.021123454194196412,0.00015524580580358882
6.0,756.0,541.0,0.007937,0.007937,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG001,obesity,INDUSTRY,0.01160749,0.01160191903244047,5.57096755953064e-06
5.0,756.0,541.0,0.006614,0.006614,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG002,obesity,INDUSTRY,0.00967267,0.00966673293049605,5.937069503948733e-06
7.0,756.0,541.0,0.009259,0.009259,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG003,obesity,INDUSTRY,0.01354086,0.013547098053184513,6.2380531845127735e-06
8.0,756.0,541.0,0.010582,0.010582,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG004,obesity,INDUSTRY,0.01547568,0.015566916526269849,9.123652626984863e-05
5.0,756.0,541.0,0.006614,0.006614,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG005,obesity,INDUSTRY,0.00967267,0.009672309490317478,3.6050968252147875e-07
4.0,756.0,541.0,0.005291,0.005291,6.629363,0.220602,1.0,756.0,1.0,2.0,Withdrawal by Subject,Overall Study,FG006,obesity,INDUSTRY,0.00773784,0.007737967148888886,1.2714888888553516e-07
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG000,obesity,INDUSTRY,0.00193483,0.0019387867837500148,3.956783750014813e-06
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG001,obesity,INDUSTRY,0.00193483,0.0019402745479762055,5.444547976205492e-06
2.0,756.0,541.0,0.002646,0.002646,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG002,obesity,INDUSTRY,0.00386965,0.003876686806775787,7.036806775786997e-06
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG003,obesity,INDUSTRY,0.00193483,0.0019380225246428734,3.192524642873368e-06
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG004,obesity,INDUSTRY,0.0,0.0,0.0
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG005,obesity,INDUSTRY,0.00193483,0.0019387163546428735,3.886354642873482e-06
3.0,756.0,541.0,0.003968,0.003968,6.629363,0.220602,1.0,756.0,1.0,2.0,protocol non-compliance,Overall Study,FG006,obesity,INDUSTRY,0.00580302,0.005793612344950412,9.407655049587828e-06
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG000,obesity,INDUSTRY,0.00193483,0.0019371882196428714,2.3582196428714296e-06
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG002,obesity,INDUSTRY,0.00193483,0.0019376638863690628,2.833886369062828e-06
2.0,756.0,541.0,0.002646,0.002646,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG003,obesity,INDUSTRY,0.00386965,0.0038751610878868968,5.511087886896689e-06
1.0,756.0,541.0,0.001323,0.001323,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG004,obesity,INDUSTRY,0.00193483,0.00193706400303573,2.2340030357299173e-06
2.0,756.0,541.0,0.002646,0.002646,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG005,obesity,INDUSTRY,0.00386965,0.0038771671113392784,7.517111339278362e-06
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,Pregnancy,Overall Study,FG006,obesity,INDUSTRY,0.0,0.0,0.0
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG000,obesity,INDUSTRY,0.0,0.0,0.0
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG001,obesity,INDUSTRY,0.0,0.0,0.0
2.0,756.0,541.0,0.002646,0.002646,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG002,obesity,INDUSTRY,0.00386965,0.003876686806775787,7.036806775786997e-06
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG003,obesity,INDUSTRY,0.0,0.0,0.0
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG004,obesity,INDUSTRY,0.0,0.0,0.0
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG005,obesity,INDUSTRY,0.0,0.0,0.0
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,requirement for restricted medication,Overall Study,FG006,obesity,INDUSTRY,0.0,0.0,0.0
5.0,756.0,541.0,0.006614,0.006614,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG000,obesity,INDUSTRY,0.00967267,0.009665331866091292,7.3381339087078695e-06
5.0,756.0,541.0,0.006614,0.006614,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG001,obesity,INDUSTRY,0.00967267,0.009679286131686522,6.616131686522017e-06
3.0,756.0,541.0,0.003968,0.003968,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG002,obesity,INDUSTRY,0.00580302,0.00578994655370041,1.3073446299589897e-05
4.0,756.0,541.0,0.005291,0.005291,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG003,obesity,INDUSTRY,0.00773784,0.007739312697847215,1.4726978472146685e-06
4.0,756.0,541.0,0.005291,0.005291,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG004,obesity,INDUSTRY,0.00773784,0.007747508323740072,9.66832374007208e-06
4.0,756.0,541.0,0.005291,0.005291,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG005,obesity,INDUSTRY,0.00773784,0.007737968622847215,1.286228472150569e-07
0.0,756.0,541.0,0.0,0.0,6.629363,0.220602,1.0,756.0,1.0,2.0,Other,Overall Study,FG006,obesity,INDUSTRY,0.0,0.0,0.0
3.0,700.0,595.0,0.004286,0.004286,6.552508,0.376508,1.0,700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG000,metabolic syndrome,OTHER,0.01057388,0.010459975052440458,0.00011390494755954272
3.0,700.0,595.0,0.004286,0.004286,6.552508,0.376508,1.0,700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG001,metabolic syndrome,OTHER,0.01057388,0.010460813496488072,0.00011306650351192854
7.0,700.0,595.0,0.01,0.01,6.552508,0.376508,1.0,700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG002,metabolic syndrome,OTHER,0.02467073,0.024802570777242062,0.0001318407772420635
10.0,700.0,595.0,0.014286,0.014286,6.552508,0.376508,1.0,700.0,1.0,1.0,Lost to Follow-up,Overall Study,FG003,metabolic syndrome,OTHER,0.03524461,0.03510683429408729,0.00013777570591270993
1.0,700.0,595.0,0.001429,0.001429,6.552508,0.376508,1.0,700.0,1.0,1.0,Death,Overall Study,FG000,metabolic syndrome,OTHER,0.00352545,0.0035470231413392795,2.157314133927968e-05
2.0,700.0,595.0,0.002857,0.002857,6.552508,0.376508,1.0,700.0,1.0,1.0,Death,Overall Study,FG001,metabolic syndrome,OTHER,0.00704843,0.0069855008328111425,6.292916718885714e-05
1.0,700.0,595.0,0.001429,0.001429,6.552508,0.376508,1.0,700.0,1.0,1.0,Death,Overall Study,FG002,metabolic syndrome,OTHER,0.00352545,0.003547442052886899,2.1992052886899045e-05
0.0,700.0,595.0,0.0,0.0,6.552508,0.376508,1.0,700.0,1.0,1.0,Death,Overall Study,FG003,metabolic syndrome,OTHER,0.0,0.0,0.0
17.0,700.0,595.0,0.024286,0.024286,6.552508,0.376508,1.0,700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG000,metabolic syndrome,OTHER,0.05991534,0.059945516807182575,3.0176807182577536e-05
20.0,700.0,595.0,0.028571,0.028571,6.552508,0.376508,1.0,700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG001,metabolic syndrome,OTHER,0.07048675,0.06892299323488546,0.0015637567651145406
26.0,700.0,595.0,0.037143,0.037143,6.552508,0.376508,1.0,700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG002,metabolic syndrome,OTHER,0.09163451,0.0922579928122223,0.000623482812222298
14.0,700.0,595.0,0.02,0.02,6.552508,0.376508,1.0,700.0,1.0,1.0,Withdrawal by Subject,Overall Study,FG003,metabolic syndrome,OTHER,0.04934147,0.0495189060772619,0.0001774360772619013
1.0,700.0,595.0,0.001429,0.001429,6.552508,0.376508,1.0,700.0,1.0,1.0,Physician Decision,Overall Study,FG000,metabolic syndrome,OTHER,0.00352545,0.003547447528005947,2.1997528005947287e-05
0.0,700.0,595.0,0.0,0.0,6.552508,0.376508,1.0,700.0,1.0,1.0,Physician Decision,Overall Study,FG001,metabolic syndrome,OTHER,0.0,0.0,0.0
0.0,700.0,595.0,0.0,0.0,6.552508,0.376508,1.0,700.0,1.0,1.0,Physician Decision,Overall Study,FG002,metabolic syndrome,OTHER,0.0,0.0,0.0
0.0,700.0,595.0,0.0,0.0,6.552508,0.376508,1.0,700.0,1.0,1.0,Physician Decision,Overall Study,FG003,metabolic syndrome,OTHER,0.0,0.0,0.0
1.0,205.0,200.0,0.004878,0.004878,5.327876,0.597433,1.0,205.0,1.0,13.0,Protocol Violation,Overall Study,FG000,metabolic syndrome,OTHER,0.01552692,0.015516657140892884,1.0262859107115774e-05
3.0,205.0,200.0,0.014634,0.014634,5.327876,0.597433,1.0,205.0,1.0,13.0,Protocol Violation,Overall Study,FG001,metabolic syndrome,OTHER,0.04658076,0.04835435656031747,0.0017735965603174683
1.0,205.0,200.0,0.004878,0.004878,5.327876,0.597433,1.0,205.0,1.0,13.0,Death,Overall Study,FG000,metabolic syndrome,OTHER,0.01552692,0.015508469595892875,1.8450404107124216e-05
0.0,205.0,200.0,0.0,0.0,5.327876,0.597433,1.0,205.0,1.0,13.0,Death,Overall Study,FG001,metabolic syndrome,OTHER,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Receive Study Drug,Treatment Period I (Week 1 to Week 12),FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,326.0,209.0,0.003067,0.003067,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Receive Study Drug,Treatment Period I (Week 1 to Week 12),FG001,metabolic syndrome,INDUSTRY,0.00303944,0.003078452021517858,3.901202151785797e-05
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Receive Study Drug,Treatment Period I (Week 1 to Week 12),FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Receive Study Drug,Treatment Period I (Week 1 to Week 12),FG003,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Receive Study Drug,Treatment Period I (Week 1 to Week 12),FG004,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
2.0,326.0,209.0,0.006135,0.006135,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Without Post-Baseline Assessmen,Treatment Period I (Week 1 to Week 12),FG000,metabolic syndrome,INDUSTRY,0.00607987,0.006423733833774357,0.00034386383377435666
1.0,326.0,209.0,0.003067,0.003067,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Without Post-Baseline Assessmen,Treatment Period I (Week 1 to Week 12),FG001,metabolic syndrome,INDUSTRY,0.00303944,0.003078452021517858,3.901202151785797e-05
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Without Post-Baseline Assessmen,Treatment Period I (Week 1 to Week 12),FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Without Post-Baseline Assessmen,Treatment Period I (Week 1 to Week 12),FG003,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Without Post-Baseline Assessmen,Treatment Period I (Week 1 to Week 12),FG004,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
5.0,326.0,209.0,0.015337,0.015337,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 12,Treatment Period I (Week 1 to Week 12),FG000,metabolic syndrome,INDUSTRY,0.01519919,0.01588070553745222,0.0006815155374522205
43.0,326.0,209.0,0.131902,0.131902,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 12,Treatment Period I (Week 1 to Week 12),FG001,metabolic syndrome,INDUSTRY,0.1307168,0.17818788544093267,0.047471085440932675
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 12,Treatment Period I (Week 1 to Week 12),FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 12,Treatment Period I (Week 1 to Week 12),FG003,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 12,Treatment Period I (Week 1 to Week 12),FG004,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,326.0,209.0,0.003067,0.003067,5.78996,0.171161,1.0,326.0,2.0,31.0,Did not continue to Period II,Treatment Period I (Week 1 to Week 12),FG000,metabolic syndrome,INDUSTRY,0.00303944,0.0030929339759424622,5.3493975942462205e-05
15.0,326.0,209.0,0.046012,0.046012,5.78996,0.171161,1.0,326.0,2.0,31.0,Did not continue to Period II,Treatment Period I (Week 1 to Week 12),FG001,metabolic syndrome,INDUSTRY,0.04559856,0.04735750225751982,0.0017589422575198174
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Did not continue to Period II,Treatment Period I (Week 1 to Week 12),FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Did not continue to Period II,Treatment Period I (Week 1 to Week 12),FG003,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Did not continue to Period II,Treatment Period I (Week 1 to Week 12),FG004,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Lost to Follow-up,Treatment Period II: Week 12 to Week 36,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Lost to Follow-up,Treatment Period II: Week 12 to Week 36,FG001,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Lost to Follow-up,Treatment Period II: Week 12 to Week 36,FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Lost to Follow-up,Treatment Period II: Week 12 to Week 36,FG003,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,326.0,209.0,0.003067,0.003067,5.78996,0.171161,1.0,326.0,2.0,31.0,Lost to Follow-up,Treatment Period II: Week 12 to Week 36,FG004,metabolic syndrome,INDUSTRY,0.00303944,0.0030809064698710327,4.146646987103269e-05
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Withdrawal by Subject,Treatment Period II: Week 12 to Week 36,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Withdrawal by Subject,Treatment Period II: Week 12 to Week 36,FG001,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Withdrawal by Subject,Treatment Period II: Week 12 to Week 36,FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,326.0,209.0,0.003067,0.003067,5.78996,0.171161,1.0,326.0,2.0,31.0,Withdrawal by Subject,Treatment Period II: Week 12 to Week 36,FG003,metabolic syndrome,INDUSTRY,0.00303944,0.003078696741418652,3.925674141865183e-05
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Withdrawal by Subject,Treatment Period II: Week 12 to Week 36,FG004,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 36,Treatment Period II: Week 12 to Week 36,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
0.0,326.0,209.0,0.0,0.0,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 36,Treatment Period II: Week 12 to Week 36,FG001,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
15.0,326.0,209.0,0.046012,0.046012,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 36,Treatment Period II: Week 12 to Week 36,FG002,metabolic syndrome,INDUSTRY,0.04559856,0.04724836700757933,0.0016498070075793292
15.0,326.0,209.0,0.046012,0.046012,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 36,Treatment Period II: Week 12 to Week 36,FG003,metabolic syndrome,INDUSTRY,0.04559856,0.04720369613674601,0.0016051361367460035
17.0,326.0,209.0,0.052147,0.052147,5.78996,0.171161,1.0,326.0,2.0,31.0,Subjects Did Not Complete Week 36,Treatment Period II: Week 12 to Week 36,FG004,metabolic syndrome,INDUSTRY,0.05167843,0.053578249731478136,0.001899819731478139
8.0,263.0,215.0,0.030418,0.030418,5.575949,0.222179,1.0,263.0,6.0,47.0,Withdrawal by Subject,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.03768361,0.038055718866339246,0.00037210886633924634
10.0,263.0,215.0,0.038023,0.038023,5.575949,0.222179,1.0,263.0,6.0,47.0,Withdrawal by Subject,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.04710513,0.049007012582509904,0.001901882582509902
7.0,263.0,215.0,0.026616,0.026616,5.575949,0.222179,1.0,263.0,6.0,47.0,Withdrawal by Subject,Overall Study,FG002,metabolic syndrome,INDUSTRY,0.03297347,0.03349938802049604,0.0005259180204960426
1.0,263.0,215.0,0.003802,0.003802,5.575949,0.222179,1.0,263.0,6.0,47.0,Adverse Event,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.00471014,0.004722065717817474,1.1925717817474167e-05
4.0,263.0,215.0,0.015209,0.015209,5.575949,0.222179,1.0,263.0,6.0,47.0,Adverse Event,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.01884181,0.019030798458314423,0.00018898845831442218
5.0,263.0,215.0,0.019011,0.019011,5.575949,0.222179,1.0,263.0,6.0,47.0,Adverse Event,Overall Study,FG002,metabolic syndrome,INDUSTRY,0.02355195,0.023794501322291665,0.00024255132229166615
2.0,263.0,215.0,0.007605,0.007605,5.575949,0.222179,1.0,263.0,6.0,47.0,Lost to Follow-up,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.00942152,0.009436280155376998,1.476015537699854e-05
2.0,263.0,215.0,0.007605,0.007605,5.575949,0.222179,1.0,263.0,6.0,47.0,Lost to Follow-up,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.00942152,0.009447550982341284,2.603098234128451e-05
1.0,263.0,215.0,0.003802,0.003802,5.575949,0.222179,1.0,263.0,6.0,47.0,Lost to Follow-up,Overall Study,FG002,metabolic syndrome,INDUSTRY,0.00471014,0.004719640851626997,9.500851626997181e-06
1.0,263.0,215.0,0.003802,0.003802,5.575949,0.222179,1.0,263.0,6.0,47.0,Protocol Violation,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.00471014,0.004719361544067473,9.221544067473594e-06
3.0,263.0,215.0,0.011407,0.011407,5.575949,0.222179,1.0,263.0,6.0,47.0,Protocol Violation,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.01413166,0.014076724345575409,5.4935654424591654e-05
1.0,263.0,215.0,0.003802,0.003802,5.575949,0.222179,1.0,263.0,6.0,47.0,Protocol Violation,Overall Study,FG002,metabolic syndrome,INDUSTRY,0.00471014,0.004716736892876996,6.596892876996503e-06
0.0,263.0,215.0,0.0,0.0,5.575949,0.222179,1.0,263.0,6.0,47.0,Unknown reason,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
3.0,263.0,215.0,0.011407,0.011407,5.575949,0.222179,1.0,263.0,6.0,47.0,Unknown reason,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.01413166,0.014062027770277789,6.963222972221177e-05
0.0,263.0,215.0,0.0,0.0,5.575949,0.222179,1.0,263.0,6.0,47.0,Unknown reason,Overall Study,FG002,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,242.0,228.0,0.004132,0.004132,5.493061,0.30466,1.0,242.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.00691498,0.006902544642539635,1.2435357460365004e-05
4.0,242.0,228.0,0.016529,0.016529,5.493061,0.30466,1.0,242.0,0.0,0.0,Withdrawal by Subject,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.02766159,0.02793462020318451,0.0002730302031845114
0.0,242.0,228.0,0.0,0.0,5.493061,0.30466,1.0,242.0,0.0,0.0,Adverse Event,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
3.0,242.0,228.0,0.012397,0.012397,5.493061,0.30466,1.0,242.0,0.0,0.0,Adverse Event,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.02074661,0.02129665143990081,0.0005500414399008113
2.0,242.0,228.0,0.008264,0.008264,5.493061,0.30466,1.0,242.0,0.0,0.0,Ineligibility determined,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.01382996,0.01409095449626351,0.00026099449626350996
1.0,242.0,228.0,0.004132,0.004132,5.493061,0.30466,1.0,242.0,0.0,0.0,Ineligibility determined,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.00691498,0.006900302891289633,1.4677108710367363e-05
1.0,242.0,228.0,0.004132,0.004132,5.493061,0.30466,1.0,242.0,0.0,0.0,Death,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.00691498,0.0069020598879563,1.2920112043700305e-05
1.0,242.0,228.0,0.004132,0.004132,5.493061,0.30466,1.0,242.0,0.0,0.0,Death,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.00691498,0.006901467432956299,1.3512567043701303e-05
0.0,242.0,228.0,0.0,0.0,5.493061,0.30466,1.0,242.0,0.0,0.0,Other,Overall Study,FG000,metabolic syndrome,INDUSTRY,0.0,0.0,0.0
1.0,242.0,228.0,0.004132,0.004132,5.493061,0.30466,1.0,242.0,0.0,0.0,Other,Overall Study,FG001,metabolic syndrome,INDUSTRY,0.00691498,0.006902608928789632,1.2371071210368068e-05
9.0,1358.0,1059.0,0.006627,0.006627,7.214504,0.537671,1.0,1358.0,1.0,47.0,Lost to Follow-up,Screened Vitamin D Deficient,FG000,metabolic syndrome,OTHER,0.02570631,0.02488823504524802,0.0008180749547519808
12.0,1358.0,1059.0,0.008837,0.008837,7.214504,0.537671,1.0,1358.0,1.0,47.0,Lost to Follow-up,Screened Vitamin D Deficient,FG001,metabolic syndrome,OTHER,0.03427896,0.03387039961523812,0.0004085603847618774
